PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	RUDENKO, G; BLUNDELL, PA; DIRKSMULDER, A; KIEFT, R; BORST, P				RUDENKO, G; BLUNDELL, PA; DIRKSMULDER, A; KIEFT, R; BORST, P			A RIBOSOMAL DNA PROMOTER REPLACING THE PROMOTER OF A TELOMERIC VSG GENE-EXPRESSION SITE CAN BE EFFICIENTLY SWITCHED ON AND OFF IN TRYPANOSOMA-BRUCEI	CELL			English	Article							VARIANT SURFACE GLYCOPROTEIN; RNA POLYMERASE-I; PROTOZOAN TRYPANOSOMA-BRUCEI; BLOOD-STREAM-FORM; ANTIGENIC VARIATION; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION UNITS; INACTIVATION; SEQUENCES; PROTEIN	Trypanosoma brucei survives in the mammalian bloodstream by regularly changing its variant surface glycoprotein (VSG) coat. The active VSG gene is located in a telomeric expression site, and coat switching occurs either by replacing the transcribed VSG gene or by changing the expression site that is active, To determine whether VSG expression site control requires promoter-specific sequences, we replaced the active VSG expression site promoter in bloodstream-form T. brucei with a ribosomal DNA (rDNA) promoter. These transformants were fully infective in laboratory animals, and the rDNA promoter, which is normally constitutively active, was efficiently inactivated and reactivated in the context of the VSG gene expression site. As there is no sequence similarity between the VSG expression site promoter and the rDNA promoter, VSG expression site control does not involve sequences specific to the VSG expression site promoter. We conclude that an epigenetic mechanism, such as telomeric silencing, is involved in VSG expression site control in bloodstream-form T. brucei.			RUDENKO, G (corresponding author), NETHERLANDS CANC INST,DEPT BIOL MOLEC,PLESMANLAAN 121,1066 CX AMSTERDAM,NETHERLANDS.							ALARCON CM, 1994, MOL CELL BIOL, V14, P5579, DOI 10.1128/MCB.14.8.5579; BERNARDS A, 1984, NUCLEIC ACIDS RES, V12, P4153, DOI 10.1093/nar/12.10.4153; BERNARDS A, 1984, CELL, V36, P163, DOI 10.1016/0092-8674(84)90085-0; CARRUTHERS VB, 1992, P NATL ACAD SCI USA, V89, P8818, DOI 10.1073/pnas.89.18.8818; CARRUTHERS VB, 1993, NUCLEIC ACIDS RES, V21, P2537, DOI 10.1093/nar/21.10.2537; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; CULLY DF, 1985, CELL, V42, P173, DOI 10.1016/S0092-8674(85)80113-6; GOMMERSAMPT JH, 1993, CELL, V75, P1129, DOI 10.1016/0092-8674(93)90322-H; GOTTESDIENER K, 1990, MOL CELL BIOL, V10, P6079, DOI 10.1128/MCB.10.11.6079; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; GRITZ L, 1983, GENE, V25, P179, DOI 10.1016/0378-1119(83)90223-8; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; JANZ L, 1994, MOL CELL BIOL, V14, P5804, DOI 10.1128/MCB.14.9.5804; JEFFERIES D, 1991, MOL CELL BIOL, V11, P338, DOI 10.1128/MCB.11.1.338; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; JOHNSON PJ, 1987, CELL, V51, P273, DOI 10.1016/0092-8674(87)90154-1; KOOTER JM, 1987, CELL, V51, P261, DOI 10.1016/0092-8674(87)90153-X; LAMONT GS, 1986, PARASITOLOGY, V92, P355, DOI 10.1017/S003118200006412X; LENARDO MJ, 1986, MOL CELL BIOL, V6, P1991, DOI 10.1128/MCB.6.6.1991; LIGTENBERG MJL, 1994, EMBO J, V13, P2565, DOI 10.1002/j.1460-2075.1994.tb06546.x; MICHELS PAM, 1984, EMBO J, V3, P1345, DOI 10.1002/j.1460-2075.1984.tb01975.x; PALLADINO F, 1994, CURR OPIN CELL BIOL, V6, P373, DOI 10.1016/0955-0674(94)90029-9; PAYS E, 1989, CELL, V57, P835, DOI 10.1016/0092-8674(89)90798-8; PAYS E, 1994, ANNU REV MICROBIOL, V48, P25, DOI 10.1146/annurev.mi.48.100194.000325; PAYS E, 1984, NUCLEIC ACIDS RES, V12, P5235, DOI 10.1093/nar/12.13.5235; PAYS E, 1989, MOL CELL BIOL, V9, P4018, DOI 10.1128/MCB.9.9.4018; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; RICEFICHT AC, 1981, NATURE, V294, P53, DOI 10.1038/294053a0; RUDENKO G, 1991, EMBO J, V10, P3387, DOI 10.1002/j.1460-2075.1991.tb04903.x; RUDENKO G, 1992, NUCLEIC ACIDS RES, V20, P303, DOI 10.1093/nar/20.2.303; RUDENKO G, 1994, EMBO J, V13, P5470, DOI 10.1002/j.1460-2075.1994.tb06882.x; Sambrook J., 1989, MOL CLONING LAB MANU; SCHNAPP A, 1990, EMBO J, V9, P2857, DOI 10.1002/j.1460-2075.1990.tb07475.x; THOMASHOW LS, 1983, CELL, V32, P35, DOI 10.1016/0092-8674(83)90494-4; VANDERPLOEG LHT, 1991, NEW BIOL, V3, P324; WHITE TC, 1986, NUCLEIC ACIDS RES, V14, P9471, DOI 10.1093/nar/14.23.9471; ZOMERDIJK JCBM, 1991, NUCLEIC ACIDS RES, V19, P5153, DOI 10.1093/nar/19.19.5153; ZOMERDIJK JCBM, 1991, NATURE, V353, P772, DOI 10.1038/353772a0; ZOMERDIJK JCBM, 1990, EMBO J, V9, P2791, DOI 10.1002/j.1460-2075.1990.tb07467.x; ZOMERDIJK JCBM, 1991, NUCLEIC ACIDS RES, V19, P1359, DOI 10.1093/nar/19.7.1359	41	124	125	0	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 17	1995	83	4					547	553		10.1016/0092-8674(95)90094-2	http://dx.doi.org/10.1016/0092-8674(95)90094-2			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TF248	7585957	Bronze			2022-12-24	WOS:A1995TF24800007
J	NELSON, MT; CHENG, H; RUBART, M; SANTANA, LF; BONEV, AD; KNOT, HJ; LEDERER, WJ				NELSON, MT; CHENG, H; RUBART, M; SANTANA, LF; BONEV, AD; KNOT, HJ; LEDERER, WJ			RELAXATION OF ARTERIAL SMOOTH-MUSCLE BY CALCIUM SPARKS	SCIENCE			English	Article							TRANSIENT OUTWARD CURRENTS; SIZED CEREBRAL-ARTERIES; RABBIT PORTAL-VEIN; SARCOPLASMIC-RETICULUM; POTASSIUM CHANNELS; K+ CURRENTS; CELLS; RELEASE; THAPSIGARGIN; CONTRACTION	Local increases in intracellular calcium ion concentration ([Ca2+](i)) resulting from activation of the ryanodine-sensitive calcium-release channel in the sarcoplasmic reticulum (SR) of smooth muscle cause arterial dilation. Ryanodine-sensitive, spontaneous local increases in [Ca2+](i) (Ca2+ sparks) from the SR were observed just under the surface membrane of single smooth muscle cells from myogenic cerebral arteries. Ryanodine and thapsigargin inhibited Ca2+ sparks and Ca2+-dependent potassium (K-Ca), currents, suggesting that Ca2+ sparks activate K-Ca channels. Furthermore, K-Ca channels activated by Ca2+ sparks appeared to hyperpolarize and dilate pressurized myogenic arteries because ryanodine and thapsigargin depolarized and constricted these arteries to an extent similar to that produced by blockers of K-Ca channels. Ca2+ sparks indirectly cause vasodilation through activation of K-Ca channels, but have little direct effect on spatially averaged [Ca2+](i), which regulates contraction.	UNIV MARYLAND,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,CTR MED BIOTECHNOL,BALTIMORE,MD 21201; UNIV VERMONT,DEPT PHARMACOL,COLCHESTER,VT 05446; INDIANA UNIV,SCH MED,KRANNERT INST CARDIOL,INDIANAPOLIS,IN 46202	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University of Vermont; Indiana University System; Indiana University-Purdue University Indianapolis			Santana, Luis/AAF-9298-2019; Heping, Cheng/AAE-2680-2019; Lederer, William/B-1285-2010	Santana, Luis/0000-0002-4297-8029; Heping, Cheng/0000-0002-9604-6702; Nelson, Mark/0000-0002-6608-8784	NHLBI NIH HHS [HL25675, HL51728, HL44455] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051728, R01HL044455, R01HL025675] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bayliss WM, 1902, J PHYSIOL-LONDON, V28, P220; BENHAM CD, 1986, J PHYSIOL-LONDON, V381, P385, DOI 10.1113/jphysiol.1986.sp016333; BOLTON TB, 1989, J PHYSIOL-LONDON, V409, P385, DOI 10.1113/jphysiol.1989.sp017504; BOND M, 1984, J PHYSIOL-LONDON, V357, P185, DOI 10.1113/jphysiol.1984.sp015496; BRAYDEN JE, 1989, J CEREBR BLOOD F MET, V9, P256, DOI 10.1038/jcbfm.1989.42; BRAYDEN JE, 1992, SCIENCE, V256, P532, DOI 10.1126/science.1373909; CANNELL MB, 1995, SCIENCE, V268, P1045, DOI 10.1126/science.7754384; CANNELL MB, 1994, BIOPHYS J, V67, P1942, DOI 10.1016/S0006-3495(94)80677-0; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; DEVINE CE, 1972, J CELL BIOL, V52, P690, DOI 10.1083/jcb.52.3.690; FFLEISCHMANN BK, 1994, P NATL ACAD SCI USA, V91, P11914; FLEISCHMANN BK, P NATL ACAD SCI USA, V91, P11914; GANITKEVICH V, 1990, CIRC RES, V67, P525, DOI 10.1161/01.RES.67.2.525; GANITKEVICH VY, 1995, J PHYSIOL-LONDON, V484, P287, DOI 10.1113/jphysiol.1995.sp020665; GELBAND CH, 1993, CIRC RES, V73, P24, DOI 10.1161/01.RES.73.1.24; GLANGIACOMO KM, 1992, BIOCHEMISTRY-US, V31, P6719; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARDER DR, 1984, CIRC RES, V55, P197, DOI 10.1161/01.RES.55.2.197; HERRMANNFRANK A, 1991, PFLUG ARCH EUR J PHY, V418, P353, DOI 10.1007/BF00550873; HOGG RC, 1993, PFLUG ARCH EUR J PHY, V425, P233, DOI 10.1007/BF00374172; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; HUME JR, 1989, J PHYSIOL-LONDON, V413, P49, DOI 10.1113/jphysiol.1989.sp017641; IKEMOTO N, 1989, BIOCHEMISTRY-US, V28, P6764, DOI 10.1021/bi00442a033; IKEMOTO N, 1991, BIOCHEMISTRY-US, V30, P5230, DOI 10.1021/bi00235a017; KAPICKA CL, 1994, AM J PHYSIOL, V266, pC601, DOI 10.1152/ajpcell.1994.266.3.C601; KIRBY MS, 1992, J BIOL CHEM, V267, P12545; KNOT HJ, 1995, AM J PHYSIOL-HEART C, V269, pH348, DOI 10.1152/ajpheart.1995.269.1.H348; LANGTONPD, 1991, AM J PHYSIOL, V260, pH927; LU X, 1994, P NATL ACAD SCI USA, V91, P3294; MATSUYAMA S, 1993, LIFE SCI, V53, P681, DOI 10.1016/0024-3205(93)90244-W; MEININGER GA, 1992, AM J PHYSIOL, V263, pH647, DOI 10.1152/ajpheart.1992.263.3.H647; MEININGERGA, 1991, AM J PHYSL, V261, pH950; MOORE EDW, 1993, NATURE, V365, P657, DOI 10.1038/365657a0; MORITOKI H, 1994, BRIT J PHARMACOL, V111, P655, DOI 10.1111/j.1476-5381.1994.tb14788.x; NELSON MT, 1990, AM J PHYSIOL, V259, pC3; NELSON MT, 1995, AM J PHYSIOL-CELL PH, V268, pC799, DOI 10.1152/ajpcell.1995.268.4.C799; NILSSON H, 1994, J VASC RES, V31, P314, DOI 10.1159/000159059; QUAYLE JM, 1993, AM J PHYSIOL, V264, pH470, DOI 10.1152/ajpheart.1993.264.2.H470; QUAYLE JM, 1993, AM J PHYSIOL, V265, pC1363, DOI 10.1152/ajpcell.1993.265.5.C1363; QUAYLE JM, 1994, J PHYSIOL-LONDON, V475, P9, DOI 10.1113/jphysiol.1994.sp020045; SAGARA Y, 1992, J BIOL CHEM, V267, P12606; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; STEHNOBITTEL L, 1992, J PHYSIOL-LONDON, V451, P49, DOI 10.1113/jphysiol.1992.sp019153; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TRIPATHY A, 1994, BIOPHYS J, V66, pA416; TTHEDFORD SE, 1994, BIOPHYS J, V66, pA20; WATANABE J, 1993, CIRC RES, V73, P465, DOI 10.1161/01.RES.73.3.465; YAGI S, 1988, P NATL ACAD SCI USA, V85, P4109, DOI 10.1073/pnas.85.11.4109	48	1143	1174	1	36	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 27	1995	270	5236					633	637		10.1126/science.270.5236.633	http://dx.doi.org/10.1126/science.270.5236.633			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TB557	7570021				2022-12-24	WOS:A1995TB55700040
J	CARNEY, AS; WEIR, J; BALDWIN, DL				CARNEY, AS; WEIR, J; BALDWIN, DL			CONTAMINATION WITH BLOOD DURING MANAGEMENT OF EPISTAXIS	BRITISH MEDICAL JOURNAL			English	Article									SOUTHMEAD GEN HOSP,DEPT OTOLARYNGOL,BRISTOL BS10 5NB,AVON,ENGLAND	Southmead Hospital			Carney, A/W-8202-2019	Carney, A/0000-0001-7507-7983				BOON D, 1994, J ACCID EMERG MED, V11, P175; BREARLY S, 1989, BRIT MED J, V299, P131; LITTLECHILD P, 1992, BRIT MED J, V305, P156, DOI 10.1136/bmj.305.6846.156; STEEDMAN DJ, 1994, J ACCID EMERG MED, V11, P17; 1990, GUIDANCE CLIN HLTH W	5	10	10	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 21	1995	311	7012					1064	1064		10.1136/bmj.311.7012.1064	http://dx.doi.org/10.1136/bmj.311.7012.1064			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB354	7580665	Green Published			2022-12-24	WOS:A1995TB35400024
J	HUPP, TR; SPARKS, A; LANE, DP				HUPP, TR; SPARKS, A; LANE, DP			SMALL PEPTIDES ACTIVATE THE LATENT SEQUENCE-SPECIFIC DNA-BINDING FUNCTION OF P53	CELL			English	Article							WILD-TYPE P53; MONOCLONAL-ANTIBODIES; GROWTH ARREST; MOUSE CELLS; PROTEIN; FORMS; UV; IRRADIATION; APOPTOSIS; RADIATION	Normal cells contain p53 protein in a latent state that can be activated for sequence-specific transcription by low levels of UV radiation without an increase in protein levels. Microinjection of cells with an antibody specific to the C-terminal negative regulatory domain can activate the function of p53 as a specific transcription factor in the absence of irradiation damage, suggesting that posttranslational modification of a negative regulatory domain in vivo is a rate-limiting step for p53 activation. Small peptides derived from the negative regulatory domain of p53 have been used as biochemical tools to distinguish between allosteric and steric mechanisms of negative regulation of p53 tetramer activity. Presented is the development of a highly specific peptide activation system that is consistent with an allosteric mechanism of negative regulation and that forms a precedent for the synthesis of novel low molecular mass modifiers of the p53 response.	UNIV DUNDEE, DEPT BIOCHEM, CANC RES CAMPAIGN LABS, DUNDEE DD1 4HN, SCOTLAND	University of Dundee			Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DELPHIN C, 1994, J BIOL CHEM, V269, P29579; DEPPERT W, 1990, ONCOGENE, V5, P1701; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALL PA, 1993, ONCOGENE, V8, P203; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; ISHLOKA C, 1995, ONCOGENE, V10, P1485; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; JUPP TR, 1994, COLD SPRING HARB SYM, V59, P195; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KULESZMARTIN MF, 1994, MOL CELL BIOL, V14, P1698, DOI 10.1128/MCB.14.3.1698; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MERRITT AJ, 1994, CANCER RES, V54, P614; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; NIEWOLIK D, 1995, ONCOGENE, V10, P881; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; TARUNINA M, 1993, ONCOGENE, V8, P3165; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; YONISH RE, 1991, NATURE, V353, P345; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	38	439	471	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 20	1995	83	2					237	245		10.1016/0092-8674(95)90165-5	http://dx.doi.org/10.1016/0092-8674(95)90165-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TA965	7585941	Green Submitted, Bronze			2022-12-24	WOS:A1995TA96500010
J	KERREBROCK, AW; MOORE, DP; WU, JS; ORRWEAVER, TL				KERREBROCK, AW; MOORE, DP; WU, JS; ORRWEAVER, TL			MEI-S332, A DROSOPHILA PROTEIN REQUIRED FOR SISTER-CHROMATID COHESION, CAN LOCALIZE TO MEIOTIC CENTROMERE REGIONS	CELL			English	Article							DNA TOPOISOMERASE-II; GCN4 LEUCINE-ZIPPER; CHROMOSOME ORIENTATION; INNER CENTROMERE; CELL-DIVISION; COILED COILS; MELANOGASTER; SEPARATION; ANAPHASE; MITOSIS	Mutations in the Drosophila mei-S332 gene cause premature separation of the sister chromatids in late anaphase of meiosis I. Therefore, the mei-S332 protein was postulated to hold the centromere regions of sister chromatids together until anaphase II. The mei-3332 gene encodes a novel 44 kDa protein. Mutations in mei-S332 that differentially affect function in males or females map to distinct domains of the protein. a fusion of mei-S332 to the green fluorescent protein (GFP) is fully functional and localizes specifically to the centromere region of meiotic chromosomes. When sister chromatids separate at anaphase II, mei-S332-GFP disappears from the chromosomes, suggesting that the destruction or release of this protein is required for sister-chromatid separation.	MIT, DEPT BIOL, CAMBRIDGE, MA 02142 USA	Massachusetts Institute of Technology (MIT)	KERREBROCK, AW (corresponding author), MIT, WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA.		Wu, JIm S/AAQ-3416-2021					ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ASHBURNER M, 1989, DROSOPHILA LABORATOR; BAKER BS, 1978, GENETICS, V90, P531; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHURCHILL MEA, 1989, EMBO J, V8, P4189, DOI 10.1002/j.1460-2075.1989.tb08604.x; CLAYBERG CD, 1959, GENETICS, V44, P1335; COOKE CA, 1987, J CELL BIOL, V105, P2053, DOI 10.1083/jcb.105.5.2053; DAVIS BK, 1971, MOL GEN GENET, V113, P251, DOI 10.1007/BF00339546; DAVIS BK, 1977, DROS INFO SERV, V52, P100; DOBSON MJ, 1994, J CELL SCI, V107, P2749; DOMBRADI V, 1989, EUR J BIOCHEM, V183, P603, DOI 10.1111/j.1432-1033.1989.tb21089.x; EARNSHAW WC, 1991, J CELL SCI, V98, P443; GATTI M, 1991, METHOD CELL BIOL, V35, P543; GERMAN J, 1979, CLIN GENET, V16, P441; GOLDSTEIN LSB, 1980, CHROMOSOMA, V78, P79, DOI 10.1007/BF00291909; GOLDSTEIN LSB, 1981, CELL, V25, P591, DOI 10.1016/0092-8674(81)90167-7; GONZALEZ C, 1991, EXP CELL RES, V192, P10, DOI 10.1016/0014-4827(91)90150-S; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; HOLM C, 1989, MOL CELL BIOL, V9, P159, DOI 10.1128/MCB.9.1.159; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; KERREBROCK AW, 1992, GENETICS, V130, P827; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; KOSHLAND D, 1987, SCIENCE, V238, P1713, DOI 10.1126/science.3317838; LEVIS R, 1985, SCIENCE, V229, P558, DOI 10.1126/science.2992080; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LUMB KJ, 1995, BIOCHEMISTRY-US, V34, P8642, DOI 10.1021/bi00027a013; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MACKAY AM, 1993, J CELL BIOL, V123, P373, DOI 10.1083/jcb.123.2.373; MASON JM, 1976, GENETICS, V84, P545; MIYAZAKI WY, 1994, ANNU REV GENET, V28, P167, DOI 10.1146/annurev.ge.28.120194.001123; MIYAZAKI WY, 1992, GENETICS, V132, P1047; MULLINS MC, 1989, GENE DEV, V3, P729, DOI 10.1101/gad.3.5.729; MURRAY AW, 1985, ANNU REV CELL BIOL, V1, P289, DOI 10.1146/annurev.cellbio.1.1.289; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; ORRWEAVER TL, 1995, IN PRESS P NATL ACAD; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; RATTNER JB, 1988, CHROMOSOMA, V96, P360, DOI 10.1007/BF00330702; RECHSTEINER M, 1988, ADV ENZYME REGUL, V27, P135; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Sambrook J., 1989, MOL CLONING LAB MANU; SANDLER L, 1968, GENETICS, V60, P525; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; STEPANOVA NG, 1985, HISTOCHEM J, V17, P131, DOI 10.1007/BF01003213; SUMNER AT, 1991, CHROMOSOMA, V100, P410, DOI 10.1007/BF00337519; SUNDIN O, 1980, CELL, V21, P103, DOI 10.1016/0092-8674(80)90118-X; SUZUKI M, 1989, EMBO J, V8, P797, DOI 10.1002/j.1460-2075.1989.tb03440.x; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; THEURKAUF WE, 1992, J CELL BIOL, V116, P1167, DOI 10.1083/jcb.116.5.1167; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; WANG SX, 1994, NATURE, V369, P400, DOI 10.1038/369400a0	57	215	220	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 20	1995	83	2					247	256		10.1016/0092-8674(95)90166-3	http://dx.doi.org/10.1016/0092-8674(95)90166-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TA965	7585942	Bronze			2022-12-24	WOS:A1995TA96500011
J	SHANNON, RV; ZENG, FG; KAMATH, V; WYGONSKI, J; EKELID, M				SHANNON, RV; ZENG, FG; KAMATH, V; WYGONSKI, J; EKELID, M			SPEECH RECOGNITION WITH PRIMARILY TEMPORAL CUES	SCIENCE			English	Article							INERAID COCHLEAR IMPLANT; CONSONANT RECOGNITION; ENVELOPE CUES; STIMULATION; PERCEPTION	Nearly perfect speech recognition was observed under conditions of greatly reduced spectral information. Temporal envelopes of speech were extracted from broad frequency bands and were used to modulate noises of the same bandwidths. This manipulation preserved temporal envelope cues in each band but restricted the listener to severely degraded information on the distribution of spectral energy. The identification of consonants, vowels, and words in simple sentences improved markedly as the number of bands increased; high speech recognition performance was obtained with only three bands of modulated noise. Thus, the presentation of a dynamic temporal pattern in only a few broad spectral regions is sufficient for the recognition of speech.			SHANNON, RV (corresponding author), HOUSE EAR RES INST,2100 W 3RD ST,LOS ANGELES,CA 90057, USA.		Zeng, Fan-Gang/G-4875-2012		NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC001526] Funding Source: NIH RePORTER; NIDCD NIH HHS [R01 DCO1526] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Allen JB, 1994, IEEE T SPEECH AUDI P, V2, P567, DOI 10.1109/89.326615; DORMAN M, 1989, EAR HEARING, V10, P288, DOI 10.1097/00003446-198910000-00003; DORMAN M, 1988, J ACOUST SOC AM, V84, P5011; DORMAN MF, 1990, J ACOUST SOC AM, V88, P2074, DOI 10.1121/1.400104; DORMAN MF, 1992, J ACOUST SOC AM, V92, P3428, DOI 10.1121/1.404193; EDDINGTON DK, 1980, J ACOUST SOC AM, V68, P885, DOI 10.1121/1.384827; FREYMAN RL, 1991, J SPEECH HEAR RES, V34, P415, DOI 10.1044/jshr.3402.415; HILL FJ, 1968, J ACOUST SOC AM, V44, P13, DOI 10.1121/1.1911047; Licklider J.C.R., 1951, HDB EXPT PSYCHOL EDI, P1040; LICKLIDER JCR, 1948, J ACOUST SOC AM, V20, P42, DOI 10.1121/1.1906346; MILLER GA, 1955, J ACOUST SOC AM, V27, P338, DOI 10.1121/1.1907526; REMEZ RE, 1981, SCIENCE, V212, P947, DOI 10.1126/science.7233191; ROSEN S, 1989, J SPEECH HEAR RES, V32, P93, DOI 10.1044/jshr.3201.93; ROSEN S, 1992, PHILOS T ROY SOC B, V336, P367, DOI 10.1098/rstb.1992.0070; ROSEN SM, 1981, NATURE, V291, P150, DOI 10.1038/291150a0; SCHROEDE.MR, 1966, PR INST ELECTR ELECT, V54, P720, DOI 10.1109/PROC.1966.4841; SHANNON RV, 1989, J ACOUST SOC AM, V85, P2587, DOI 10.1121/1.397753; SHANNON RV, 1983, HEARING RES, V11, P157, DOI 10.1016/0378-5955(83)90077-1; SHANNON RV, 1992, J ACOUST SOC AM, V91, P1974; SHANNON RV, 1992, AUDITORY PROCESSING, P263; Stevens KN., 1981, PERSPECTIVES STUDY S, P1; TALLAL P, 1993, ANN NY ACAD SCI, V682; VANTASELL DJ, 1987, J ACOUST SOC AM, V82, P1152, DOI 10.1121/1.395251; VANTASSELL DJ, 1992, J ACOUST SOC AM, V92, P1247, DOI 10.1121/1.403920; WILSON B S, 1990, P339; WILSON BS, 1991, NATURE, V352, P236, DOI 10.1038/352236a0	26	2041	2088	9	178	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 13	1995	270	5234					303	304		10.1126/science.270.5234.303	http://dx.doi.org/10.1126/science.270.5234.303			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ342	7569981				2022-12-24	WOS:A1995RZ34200040
J	BRUGAROLAS, J; CHANDRASEKARAN, C; GORDON, JI; BEACH, D; JACKS, T; HANNON, GJ				BRUGAROLAS, J; CHANDRASEKARAN, C; GORDON, JI; BEACH, D; JACKS, T; HANNON, GJ			RADIATION-INDUCED CELL-CYCLE ARREST COMPROMISED BY P21 DEFICIENCY	NATURE			English	Article							DEPENDENT KINASES; SUBUNIT; MOUSE; P53	THE protein p21 is a dual inhibitor of cyclin-dependent kinases(1-3) and proliferating-cell nuclear antigen (PCNA)(4), both of which are required for passage through the cell cycle. The p21 gene is under the transcriptional control of p53 (ref. 5), suggesting that p21 might promote p53-dependent cell cycle arrest or apoptosis. p21 has also been implicated in cell senescence(6) and in cell-cycle withdrawal upon termination differentiation(7-9). Here we investigate the role of p21 in these processes using chimaeric mice composed partly of p21(-/-) and partly of p21(+/+) cells. Immunohistochemical studies of the p21(+/+) and p21(-/-) components of adult small intestine indicated that deletion of p21 had no detectable effect on the migration-associated differentiation of the four principal intestinal epithelial cell lineages or on p53-dependent apoptosis following irradiation. However, p21(-/-) mouse embryo fibroblasts are impaired in their ability to undergo G1 arrest following DNA damage.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110; COLD SPRING HARBOR LAB,HOWARD HUGHES MED INST,COLD SPRING HARBOR,NY 11724	Washington University (WUSTL); Cold Spring Harbor Laboratory; Howard Hughes Medical Institute	BRUGAROLAS, J (corresponding author), MIT,CTR CANC RES,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139, USA.		Hannon, Gregory/AAB-3568-2019					Bradley A, 1987, TERATOCARCINOMAS EMB, P113; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CLARKE AR, 1994, ONCOGENE, V9, P1767; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GORDON JI, 1994, CURR OPIN CELL BIOL, V6, P795, DOI 10.1016/0955-0674(94)90047-7; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; LI YJ, 1994, ONCOGENE, V10, P599; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MERRITT AJ, 1994, CANCER RES, V54, P614; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; POTTEN CS, 1990, INT J RADIAT BIOL, V58, P925, DOI 10.1080/09553009014552281; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P710	23	1155	1174	1	77	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 12	1995	377	6549					552	557		10.1038/377552a0	http://dx.doi.org/10.1038/377552a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ336	7566157				2022-12-24	WOS:A1995RZ33600069
J	CHEN, RH; MIETTINEN, PJ; MARUOKA, EM; CHOY, L; DERYNCK, R				CHEN, RH; MIETTINEN, PJ; MARUOKA, EM; CHOY, L; DERYNCK, R			A WD-DOMAIN PROTEIN THAT IS ASSOCIATED WITH AND PHOSPHORYLATED BY THE TYPE-II TGF-BETA RECEPTOR	NATURE			English	Article							CLONING; EXPRESSION; BINDING; COMPLEX; KINASES; ACTIVIN; CELLS; ACID	TRANSFORMING growth factor-beta (TGF-beta) is tbe prototype for a family of extracellular polypeptides that affect cell proliferation and differentiation, and tissue morphogenesis(1). TGF-beta signalling is mediated by two types of serine/threonine kinase receptors, the type I and II receptors, which are able to form a heteromeric complex(2). No cytoplasmic proteins that associate with these receptors in vivo, or are their kinase targets, have yet been described. We have now identified a WD-domain-containiag protein, TRIP-1, which specifically associates with the type II TGF-beta receptor in a kinase-dependent way. TRIP-1 does not interact with the type II activin or type I receptors, but associates with the heteromeric TGF-beta receptor complex, TRIP-1 is phosphorylated on serine and threonine by the receptor kinase, strongly suggesting that it has a role in TGF-beta signalling. This is supported by coexpression of TRIP-1 and type II receptor during development. The existence of TRIP-1 homologues in plant and yeast suggests a conserved function in all eukaryotes.	UNIV CALIF SAN FRANCISCO,DEPT ANAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CELL BIOL PROGRAM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,PROGRAM DEV BIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	CHEN, RH (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT GROWTH & DEV,SAN FRANCISCO,CA 94143, USA.		Chen, Ruey-Hwa/G-6121-2019	Chen, Ruey-Hwa/0000-0001-8124-5832				CHEN RH, 1995, J BIOL CHEM, V270, P12235, DOI 10.1074/jbc.270.20.12235; CHEN RH, 1994, J BIOL CHEM, V269, P22868; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; Derynck R, 1994, CYTOKINE HDB, P319; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GAZIT D, 1993, MOL ENDOCRINOL, V7, P189, DOI 10.1210/me.7.2.189; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GRAYCAR JL, 1989, MOL ENDOCRINOL, V3, P1977, DOI 10.1210/mend-3-12-1977; HARPER JW, 1993, CELL, V75, P805; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATZUK MM, 1992, BIOCHIM BIOPHYS ACTA, V1130, P105, DOI 10.1016/0167-4781(92)90472-C; MIETTINEN PJ, 1989, PEDIATR RES, V26, P25, DOI 10.1203/00006450-198907000-00009; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Sambrook J., 1989, MOL CLONING LAB MANU; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172	29	174	196	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 12	1995	377	6549					548	552		10.1038/377548a0	http://dx.doi.org/10.1038/377548a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ336	7566156				2022-12-24	WOS:A1995RZ33600068
J	WEIGEL, D; NILSSON, O				WEIGEL, D; NILSSON, O			A DEVELOPMENTAL SWITCH SUFFICIENT FOR FLOWER INITIATION IN DIVERSE PLANTS	NATURE			English	Article							ARABIDOPSIS FLORAL DEVELOPMENT; INFLORESCENCE DEVELOPMENT; HOMEOTIC GENES; THALIANA; LEAFY; APETALA1; PROMOTER	We have generated transgenic plants in which the flower-meristem-identity gene LEAFY of Arabidopsis is constitutively expressed. LEAFY is sufficient to determine floral fate in lateral shoot meristems of both Arabidopsis and the heterologous species aspen, with the consequence that flower development is induced precociously. Our results also suggest a new level of regulation during flower development, as indicated by the competence of the main shoot to respond to LEAFY activity.	SWEDISH UNIV AGR SCI,S-90183 UMEA,SWEDEN	Swedish University of Agricultural Sciences	WEIGEL, D (corresponding author), SALK INST BIOL STUDIES,10010 N TORREY PINES RD,LA JOLLA,CA 92037, USA.		Weigel, Detlef/GSJ-0799-2022; Weigel, Detlef/C-1418-2008; Weigel, Detlef/AAR-3312-2021	Weigel, Detlef/0000-0002-2114-7963; Weigel, Detlef/0000-0002-2114-7963; Nilsson, Ove/0000-0002-1033-1909				ALVAREZ J, 1992, PLANT J, V2, P103, DOI 10.1111/j.1365-313X.1992.00103.x; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BOWMAN JL, 1993, DEVELOPMENT, V119, P721; HUALA E, 1992, PLANT CELL, V4, P901, DOI 10.1105/tpc.4.8.901; IRISH VF, 1990, PLANT CELL, V2, P741, DOI 10.1105/tpc.2.8.741; JACK T, 1994, CELL, V76, P703, DOI 10.1016/0092-8674(94)90509-6; JOFUKU KD, 1994, PLANT CELL, V6, P1211, DOI 10.1105/tpc.6.9.1211; JOHNSON E, 1994, PLANT PHYSIOL, V105, P141, DOI 10.1104/pp.105.1.141; KELLY AJ, 1995, PLANT CELL, V7, P225, DOI 10.1105/tpc.7.2.225; KEMPIN SA, 1994, SCIENCE, V267, P522; LAMB CJ, 1992, BIO-TECHNOL, V10, P1436, DOI 10.1038/nbt1192-1436; LEVIN JZ, 1995, PLANT CELL, V7, P529, DOI 10.1105/tpc.7.5.529; MANDEL MA, 1992, NATURE, V360, P273, DOI 10.1038/360273a0; Martinez-Zapater JM, 1994, ARABIDOPSIS, P403; MCDANIEL CN, 1992, DEV BIOL, V153, P59, DOI 10.1016/0012-1606(92)90091-T; NILSSON O, 1995, THESIS SWEDISH U AGR; Nilsson Ove, 1992, Transgenic Research, V1, P209, DOI 10.1007/BF02524751; ODELL JT, 1985, NATURE, V313, P810, DOI 10.1038/313810a0; REED JW, 1994, PLANT PHYSIOL, V104, P1139, DOI 10.1104/pp.104.4.1139; Schreiner E. J., 1974, USDA AGR HDB, P645; SCHULTZ EA, 1993, DEVELOPMENT, V119, P745; SCHULTZ EA, 1991, PLANT CELL, V3, P771, DOI 10.1105/tpc.3.8.771; SHANNON S, 1991, PLANT CELL, V3, P877, DOI 10.1105/tpc.3.9.877; SHANNON S, 1993, PLANT CELL, V5, P639, DOI 10.1105/tpc.5.6.639; SINGER SR, 1992, PLANTA, V188, P546, DOI 10.1007/BF00197047; STRAUSS SH, 1995, MOL BREEDING, V1, P5, DOI 10.1007/BF01682086; TANKSLEY SD, 1989, BIO-TECHNOL, V7, P257, DOI 10.1038/nbt0389-257; Telfer A, 1994, ARABIDOPSIS, P379, DOI DOI 10.1083/JCB.201205114; WEIGEL D, 1993, SCIENCE, V261, P1723, DOI 10.1126/science.261.5129.1723; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; WEIGEL DA, 1995, REV GENET, V29, P19	31	609	757	4	64	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 12	1995	377	6549					495	500		10.1038/377495a0	http://dx.doi.org/10.1038/377495a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ336	7566146				2022-12-24	WOS:A1995RZ33600051
J	CUNDELL, DR; GERARD, NP; GERARD, C; IDANPAANHEIKKILA, I; TUOMANEN, EI				CUNDELL, DR; GERARD, NP; GERARD, C; IDANPAANHEIKKILA, I; TUOMANEN, EI			STREPTOCOCCUS-PNEUMONIAE ANCHOR TO ACTIVATED HUMAN-CELLS BY THE RECEPTOR FOR PLATELET-ACTIVATING-FACTOR	NATURE			English	Article							HUMAN ENDOTHELIAL-CELLS; INFLAMMATION; LUNG; EXPRESSION; INDUCTION; CLONING; WALL	THE Gram-positive bacterium Streptococcus pneumoniae is a major cause of pneumonia, sepsis and meningitis(1). Although the invasive disease is severe, some 40% of individuals harbour the pneumococcus in the nasopharynx asymptomatically(2). Here we investigate the molecular elements of the encounter between host and pathogen that distinguish these different outcomes. We show that inflammatory activation of human cells shifts the targeting of the pneumococcos to a new receptor, that for the G-protein-coupled platelet-activating factor (PAF). Only virulent pneumococci engage the PAF receptor. Attachment of the bacterial phosphorylcholine to the PAF receptor enhanced adherence, which was coupled to invasion of endothelial, epithelial and PAF-receptor-transfected cells. This progression could be arrested in vitro and in vivo by PAF-receptor-specific antagonists, suggesting a possible approach to therapy.	ROCKEFELLER UNIV,MOLEC INFECT DIS LAB,NEW YORK,NY 10021; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,CHILDRENS HOSP,SCH MED,INA SUE PERLMUTTER CYST FIBROSIS LAB,BOSTON,MA 02115	Rockefeller University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School			Tuomanen, Elaine I/N-3081-2018	Tuomanen, Elaine I/0000-0003-0349-8716; Cundell, Diana/0000-0003-3119-180X				AMATRUDA TT, 1993, J BIOL CHEM, V268, P10139; AUSTRIAN R, 1986, J ANTIMICROB CHEMOTH, V18, P35, DOI 10.1093/jac/18.Supplement_A.35; BKAILY G, 1993, BRIT J PHARMACOL, V110, P519, DOI 10.1111/j.1476-5381.1993.tb13841.x; BUSSOLINO F, 1994, J BIOL CHEM, V269, P2877; CABELLOS C, 1992, J CLIN INVEST, V90, P612, DOI 10.1172/JCI115900; CHAO W, 1993, BIOCHEM J, V292, P617, DOI 10.1042/bj2920617; CUNDELL D, 1934, MICROB PATHOG, V17, P361; ELIAS JA, 1990, AM J RESP CELL MOL, V3, P13, DOI 10.1165/ajrcmb/3.1.13; GARDNER CR, 1993, J LEUKOCYTE BIOL, V53, P190, DOI 10.1002/jlb.53.2.190; GEELEN S, 1993, INFECT IMMUN, V61, P1538, DOI 10.1128/IAI.61.4.1538-1543.1993; GEELEN S, 1992, INFECT IMMUN, V60, P4179, DOI 10.1128/IAI.60.10.4179-4183.1992; GERARD NP, 1994, J IMMUNOL, V152, P793; HELLER R, 1992, J IMMUNOL, V149, P3682; HENSON PM, 1992, AM REV RESPIR DIS, V145, P726, DOI 10.1164/ajrccm/145.3.726; HEUMANN D, 1994, INFECT IMMUN, V62, P2715, DOI 10.1128/IAI.62.7.2715-2721.1994; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; ISBERG RR, 1991, SCIENCE, V252, P934, DOI 10.1126/science.1674624; KRIVAN HC, 1988, P NATL ACAD SCI USA, V85, P6157, DOI 10.1073/pnas.85.16.6157; KUNZ D, 1992, J BIOL CHEM, V267, P9101; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LINDER TE, 1994, MICROB PATHOGENESIS, V16, P435, DOI 10.1006/mpat.1994.1043; SHIRASAKI H, 1994, AM J RESP CELL MOL, V10, P533, DOI 10.1165/ajrcmb.10.5.8179916; STOLL LL, 1994, J BIOL CHEM, V269, P4254; SUN DX, 1992, ACTA PHARMACOL SIN, V13, P326; TUOMANEN E, 1985, J INFECT DIS, V151, P859, DOI 10.1093/infdis/151.5.859; TUOMANEN EI, 1995, NEW ENGL J MED, V332, P1280, DOI 10.1056/NEJM199505113321907; WEISER JN, 1994, INFECT IMMUN, V62, P2582, DOI 10.1128/IAI.62.6.2582-2589.1994; WINDKELSTEIN J, 1978, J IMMUNOL, V120, P174; WISSNER A, 1986, J MED CHEM, V29, P328, DOI 10.1021/jm00153a005; ZIMMERMAN GA, 1992, IMMUNOL TODAY, V13, P93, DOI 10.1016/0167-5699(92)90149-2	30	557	583	10	54	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 5	1995	377	6548					435	438		10.1038/377435a0	http://dx.doi.org/10.1038/377435a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY190	7566121				2022-12-24	WOS:A1995RY19000051
J	KAUPPILA, LI				KAUPPILA, LI			CAN LOW-BACK-PAIN BE DUE TO LUMBAR-ARTERY DISEASE	LANCET			English	Note									HELSINKI UNIV,DEPT FORENS MED,SF-00014 HELSINKI,FINLAND	University of Helsinki								CHIRAS J, 1979, J NEURORADIOLOGY, V6, P169; CLUROE AD, 1992, PATHOLOGY, V24, P140, DOI 10.3109/00313029209063161; Crock H.V., 1977, BLOOD SUPPLY VERTEBR; EDWARDS EA, 1955, SURGERY, V38, P950; Kauppila L I, 1993, Duodecim, V109, P1929; KAUPPILA LI, 1995, J BONE JOINT SURG AM, V77A, P26, DOI 10.2106/00004623-199501000-00004; KAUPPILA LI, 1994, ACTA RADIOL, V35, P541; KAUPPILA LI, 1993, J SPINAL DISORD, V6, P124; KAUPPILA LI, 1994, SPINE, V19, P923, DOI 10.1097/00007632-199404150-00010; VIHERT AM, 1976, B WORLD HEALTH ORGAN, V53, P501; WALTER BJ, 1979, GEN PATHOLOGY, P509	11	45	47	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 30	1995	346	8979					888	889		10.1016/S0140-6736(95)92714-X	http://dx.doi.org/10.1016/S0140-6736(95)92714-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX196	7564676				2022-12-24	WOS:A1995RX19600014
J	HASHIMOTO, K; HIRAI, M; KUROSAWA, Y				HASHIMOTO, K; HIRAI, M; KUROSAWA, Y			A GENE OUTSIDE THE HUMAN MHC RELATED TO CLASSICAL HLA CLASS-I GENES	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; ANTIGENS; SEQUENCE; ASSIGNMENT; CDNA; ZN-ALPHA-2-GLYCOPROTEIN; EXPRESSION; XENOPUS; CLONING; FAMILY	By presenting antigenic peptides to T lymphocytes, major histocompatibility complex (MHC) class I molecules play important roles in the human immune system. Knowledge is limited on the evolutionary history of human MHC class I-related molecules. An expressed class I gene, MRI, has now been identified on human chromosome 1q25, outside the MHC. In contrast to other known human divergent class I genes, MR1 encodes peptide-binding domains similar to those encoded by human leukocyte antigen (HLA) class I genes on chromosome 6 and by nonmammalian classical MHC class I genes. This gene may thus contribute to understanding the evolution of the MHC.	UNIV TOKYO,GRAD SCH SCI,DEPT BIOL SCI,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo	HASHIMOTO, K (corresponding author), FUJITA HLTH UNIV,INST COMPREHENS MED SCI,TOYOAKE,AICHI 47011,JAPAN.							ALBERTSON DG, 1988, EMBO J, V7, P2801, DOI 10.1002/j.1460-2075.1988.tb03135.x; ARAKI T, 1988, P NATL ACAD SCI USA, V85, P679, DOI 10.1073/pnas.85.3.679; ARUFFO A, 1989, J IMMUNOL, V143, P1723; BAHRAM S, 1994, P NATL ACAD SCI USA, V91, P6259, DOI 10.1073/pnas.91.14.6259; BRILES WE, 1993, IMMUNOGENETICS, V37, P408, DOI 10.1007/BF00222464; BRUNS GA, 1991, CYTOGENET CELL GENET, V58, P103, DOI 10.1159/000133161; CALABI F, 1986, NATURE, V323, P540, DOI 10.1038/323540a0; CAMPBELL RD, 1993, IMMUNOL TODAY, V14, P349, DOI 10.1016/0167-5699(93)90234-C; ELLIS SA, 1990, J IMMUNOL, V144, P731; FLAJNIK MF, 1993, EMBO J, V12, P4385, DOI 10.1002/j.1460-2075.1993.tb06123.x; GRIMHOLT U, 1993, IMMUNOGENETICS, V37, P469, DOI 10.1007/BF00222473; GROSSBERGER D, 1992, IMMUNOGENETICS, V36, P166, DOI 10.1007/BF00661093; GUILD BC, 1983, P NATL ACAD SCI-BIOL, V80, P2894, DOI 10.1073/pnas.80.10.2894; GUILLEMOT F, 1988, EMBO J, V7, P2775, DOI 10.1002/j.1460-2075.1988.tb03132.x; HASHIMOTO K, 1992, P NATL ACAD SCI USA, V89, P2209, DOI 10.1073/pnas.89.6.2209; HASHIMOTO K, 1990, P NATL ACAD SCI USA, V87, P6863, DOI 10.1073/pnas.87.17.6863; HASHIMOTO K, 1991, MOL EVOLUTION MAJOR, P103; ICHIHARA Y, 1992, IMMUNOL LETT, V33, P277, DOI 10.1016/0165-2478(92)90073-W; KOVATS S, 1990, SCIENCE, V248, P220, DOI 10.1126/science.2326636; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MILLER MM, 1994, P NATL ACAD SCI USA, V91, P4397, DOI 10.1073/pnas.91.10.4397; OKAMURA K, 1993, J IMMUNOL, V151, P188; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING LAB MANU; SHUM BP, 1993, J IMMUNOL, V151, P5376; SIMISTER NE, 1989, NATURE, V337, P184, DOI 10.1038/337184a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; UEYAMA H, 1991, BIOCHEM BIOPH RES CO, V177, P696, DOI 10.1016/0006-291X(91)91844-3; WATKINS DI, 1990, NATURE, V346, P60, DOI 10.1038/346060a0; WATTS S, 1989, IMMUNOGENETICS, V30, P390, DOI 10.1007/BF02425281; WEI XH, 1990, HUM IMMUNOL, V29, P131, DOI 10.1016/0198-8859(90)90076-2; ZEMMOUR J, 1991, IMMUNOGENETICS, V33, P310, DOI 10.1007/BF00216690	32	147	148	2	10	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 4	1995	269	5224					693	695		10.1126/science.7624800	http://dx.doi.org/10.1126/science.7624800			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM702	7624800				2022-12-24	WOS:A1995RM70200035
J	MATSUMOTO, Y; KIM, K				MATSUMOTO, Y; KIM, K			EXCISION OF DEOXYRIBOSE PHOSPHATE RESIDUES BY DNA-POLYMERASE-BETA DURING DNA-REPAIR	SCIENCE			English	Article							SULFATE-POLYACRYLAMIDE GELS; SODIUM DODECYL-SULFATE; ESCHERICHIA-COLI; HUMAN-CELLS; NOVIKOFF HEPATOMA; MESSENGER-RNA; DAMAGED DNA; IDENTIFICATION; ACID; DOMAIN	Eukaryotic DNA polymerase beta (pol beta) can catalyze DNA synthesis during base excision DNA repair. It is shown here that pol beta also catalyzes release of 5'-terminal deoxyribose phosphate (dRP) residues from incised apurinic-apyrimidinic sites, which are common intermediate products in base excision repair. The catalytic domain for this activity resides within an amino-terminal 8-kilodalton fragment of pol beta, which comprises a distinct structural domain of the enzyme. Magnesium is required for the release of dRP from double-stranded DNA but not from a single-stranded oligonucleotide. Analysis of the released products indicates that the excision reaction occurs by beta-elimination rather than hydrolysis.			MATSUMOTO, Y (corresponding author), FOX CHASE CANC CTR,DEPT RADIAT ONCOL,PHILADELPHIA,PA 19111, USA.			Matsumoto, Yoshihiro/0000-0001-6580-7188	NCI NIH HHS [CA06927, CA63154] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA063154, P30CA006927, R01CA063154] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBOTTS J, 1988, BIOCHEMISTRY-US, V27, P901, DOI 10.1021/bi00403a010; BAILLY V, 1988, BIOCHEM J, V253, P553, DOI 10.1042/bj2530553; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; DIANOV G, 1994, NUCLEIC ACIDS RES, V22, P993, DOI 10.1093/nar/22.6.993; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; DIANOV G, 1994, CURR BIOL, V4, P1069, DOI 10.1016/S0960-9822(00)00245-1; FORNACE AJ, 1989, MOL CELL BIOL, V9, P851, DOI 10.1128/MCB.9.2.851; FRANKLIN WA, 1988, EMBO J, V7, P3617, DOI 10.1002/j.1460-2075.1988.tb03240.x; GRAVES RJ, 1992, J BIOL CHEM, V267, P14429; HADI SM, 1971, BIOCHEMISTRY-US, V10, P4986, DOI 10.1021/bi00802a024; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; KUMAR A, 1990, J BIOL CHEM, V265, P2124; KUMAR A, 1990, BIOCHEMISTRY-US, V29, P7156, DOI 10.1021/bi00483a002; LEE C, 1987, ANAL BIOCHEM, V166, P308, DOI 10.1016/0003-2697(87)90579-3; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LOVETT ST, 1989, P NATL ACAD SCI USA, V86, P2627, DOI 10.1073/pnas.86.8.2627; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; Matsumoto Y., UNPUB; MILLICAN TA, 1984, NUCLEIC ACIDS RES, V12, P7435, DOI 10.1093/nar/12.19.7435; MOSBAUGH DW, 1980, J BIOL CHEM, V255, P239; MOSBAUGH DW, 1983, J BIOL CHEM, V258, P108; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; PRASAD R, 1993, J BIOL CHEM, V268, P22746; PRASAD R, 1993, NUCLEIC ACIDS RES, V21, P5301, DOI 10.1093/nar/21.23.5301; PRASAD R, 1994, J BIOL CHEM, V269, P18096; PRICE A, 1991, BIOCHEMISTRY-US, V30, P8631, DOI 10.1021/bi00099a020; SAWAYA MR, 1994, SCIENCE, V264, P1930, DOI 10.1126/science.7516581; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; TAKESHITA M, 1987, J BIOL CHEM, V262, P10171; THOMAS DC, 1982, BIOCHEMISTRY-US, V21, P5060, DOI 10.1021/bi00263a033; WANG TSF, 1980, BIOCHEMISTRY-US, V19, P1782, DOI 10.1021/bi00550a009; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; ZMUDZKA BZ, 1988, NUCLEIC ACIDS RES, V16, P9587, DOI 10.1093/nar/16.20.9587	34	616	629	0	32	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 4	1995	269	5224					699	702		10.1126/science.7624801	http://dx.doi.org/10.1126/science.7624801			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM702	7624801				2022-12-24	WOS:A1995RM70200037
J	DAVIDSON, PT				DAVIDSON, PT			MANAGING TUBERCULOSIS DURING PREGNANCY	LANCET			English	Editorial Material									UNIV SO CALIF,SCH MED,LOS ANGELES,CA	University of Southern California	DAVIDSON, PT (corresponding author), TB CONTROL PROGRAM LOS ANGELES CTY,LOS ANGELES,CA, USA.		Addis, Antonio/K-1865-2019	Addis, Antonio/0000-0003-0962-9959				CARTER EJ, 1994, CHEST, V106, P1466, DOI 10.1378/chest.106.5.1466; DAUTZENBERG B, 1988, REV MAL RESPIR, V5, P279; DEMARCH P, 1974, CHEST, V68, P800; FRANKS AL, 1989, PUBLIC HEALTH REP, V104, P151; GOOD JT, 1981, AM J OBSTET GYNECOL, V140, P492, DOI 10.1016/0002-9378(81)90222-2; HAMADEH MA, 1992, CHEST, V101, P1114, DOI 10.1378/chest.101.4.1114; JANA N, 1994, INT J GYNECOL OBSTET, V44, P119, DOI 10.1016/0020-7292(94)90064-7; MARGONO F, 1994, OBSTET GYNECOL, V83, P911, DOI 10.1097/00006250-199406000-00001; SCHAEFER G, 1975, OBSTET GYNECOL, V46, P706; SNIDER DE, 1980, AM REV RESPIR DIS, V122, P65; 1994, AM J RESP CRIT CARE, V149, P1359; 1994, REPORTED TUBERCULOSI, P1	12	17	17	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 22	1995	346	8969					199	200		10.1016/S0140-6736(95)91263-0	http://dx.doi.org/10.1016/S0140-6736(95)91263-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK419	7616796				2022-12-24	WOS:A1995RK41900005
J	ZHOU, JS; NOCEK, JM; DEVAN, ML; HOFFMAN, BM				ZHOU, JS; NOCEK, JM; DEVAN, ML; HOFFMAN, BM			INHIBITOR-ENHANCED ELECTRON-TRANSFER - COPPER CYTOCHROME-C AS A REDOX-INERT PROBE OF TERNARY COMPLEXES	SCIENCE			English	Article							CRYSTAL-STRUCTURE; EMISSION-SPECTRA; PEROXIDASE; BINDING; PROTEINS; PLASTOCYANIN; ABSORPTION	Copper-substituted cytochrome c (CuCc) has been used as a structurally faithful, redox-inert inhibitor to probe the mechanism of electron transfer (ET) between Cc molecules and cytochrome c peroxidase (CcP). This inhibitor enhances photoinduced ET quenching of the triplet excited state of a zinc-substituted protein (ZnCcP or ZnCc) by its iron(lll) partner (Fe(3+)Cc or Fe(3+)CcP). These results show that CcP and Cc form a ternary complex in which one Cc molecule binds tightly at a surface domain of CcP having low ET reactivity, whereas the second Cc molecule binds weakly to the 1:1 complex at a second domain I with markedly greater (similar to 10(3)) reactivity. These results also rule out the possibility that Cc bound at the second domain cooperatively enhances ET to Cc at the first domain. The multiphasic kinetics observed for the photoproduced ET intermediate do not reflect electron self-exchange between two Cc molecules within the ternary complex.	NORTHWESTERN UNIV, DEPT CHEM, EVANSTON, IL 60208 USA	Northwestern University			Nocek, Judith/D-1254-2010		NHLBI NIH HHS [HL13531] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL013531, R37HL013531] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANNI H, 1995, BIOCHEMISTRY-US, V34, P5744, DOI 10.1021/bi00017a006; BERATAN DN, 1992, SCIENCE, V258, P1740, DOI 10.1126/science.1334572; CHANG IJ, 1991, J AM CHEM SOC, V113, P7056, DOI 10.1021/ja00018a064; CHURCH WB, 1986, J BIOL CHEM, V261, P234; CLARKE MJ, 1991, STRUCT BONDING BERLI, V75; DIXON DW, 1989, BIOPHYS J, V56, P339, DOI 10.1016/S0006-3495(89)82680-3; ENGESETH HR, 1984, J BIOL CHEM, V259, P4822; FINDLAY MC, 1977, J AM CHEM SOC, V99, P5168, DOI 10.1021/ja00457a043; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.bi.54.070185.005055; HOFFMAN BM, 1991, STRUCT BOND, V75, P85; HOFFMAN BM, 1987, J AM CHEM SOC, V109, P6237, DOI 10.1021/ja00255a003; KANG CH, 1977, J BIOL CHEM, V252, P919; LIU RQ, 1995, BIOCHEMISTRY-US, V34, P973, DOI 10.1021/bi00003a032; MAUK MR, 1994, BIOCHEMISTRY-US, V33, P12609, DOI 10.1021/bi00208a011; MCLENDON G, 1993, J AM CHEM SOC, V115, P3665, DOI 10.1021/ja00062a035; MOORE GR, 1980, J INORG BIOCHEM, V12, P1, DOI 10.1016/S0162-0134(00)80039-2; MOSER CC, 1988, BIOCHEMISTRY-US, V27, P2450, DOI 10.1021/bi00407a031; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; NOCEK JM, 1991, J AM CHEM SOC, V113, P6822, DOI 10.1021/ja00018a017; PELLETIER H, 1992, SCIENCE, V258, P1748, DOI 10.1126/science.1334573; QIN L, 1993, BIOCHEMISTRY-US, V32, P6073, DOI 10.1021/bi00074a019; Sigel H., 1991, METAL IONS BIOL SYST, V27; SILVERMAN RB, 1988, MECHANISM BASED ENZY; STEMP EDA, 1993, BIOCHEMISTRY-US, V32, P10848, DOI 10.1021/bi00091a041; UTSCHIG LM, 1993, METHOD ENZYMOL, V226, P71, DOI 10.1016/0076-6879(93)26006-U; VANDERKOOI JM, 1975, EUR J BIOCHEM, V60, P199, DOI 10.1111/j.1432-1033.1975.tb20992.x; VANDERKOOI JM, 1976, EUR J BIOCHEM, V64, P381, DOI 10.1111/j.1432-1033.1976.tb10312.x; WALLIN SA, 1991, J AM CHEM SOC, V113, P1842, DOI 10.1021/ja00005a065; ZHANG QP, 1991, MOL CRYST LIQ CRYST, V194, P343, DOI 10.1080/00268949108041186; Zhou J.-S., UNPUB; ZHOU JS, 1993, J AM CHEM SOC, V115, P10796, DOI 10.1021/ja00076a042; ZHOU JS, 1993, J AM CHEM SOC, V115, P11008, DOI 10.1021/ja00076a076; ZHOU JS, 1994, SCIENCE, V265, P1693, DOI 10.1126/science.8085152	33	56	57	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 14	1995	269	5221					204	207		10.1126/science.7618081	http://dx.doi.org/10.1126/science.7618081			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ029	7618081				2022-12-24	WOS:A1995RJ02900033
J	RAHME, LG; STEVENS, EJ; WOLFORT, SF; SHAO, J; TOMPKINS, RG; AUSUBEL, FM				RAHME, LG; STEVENS, EJ; WOLFORT, SF; SHAO, J; TOMPKINS, RG; AUSUBEL, FM			COMMON VIRULENCE FACTORS FOR BACTERIAL PATHOGENICITY IN PLANTS AND ANIMALS	SCIENCE			English	Article							PSEUDOMONAS-AERUGINOSA; ARABIDOPSIS-THALIANA; ESCHERICHIA-COLI; IDENTIFICATION; DETERMINANTS; RESISTANCE; SECRETION; CLONING; REGION; GENES	A Pseudomonas aeruginosa strain (UCBPP-PA14) is infectious both in an Arabidopsis thaliana leaf infiltration model and in a mouse full-thickness skin burn model. UCBPP-PA14 exhibits ecotype specificity for Arabidqosis, causing a range of symptoms from none to severe in four different ecotypes. In the mouse model, UCBPP-PA14 is as lethal as other well-studied P. aeruginosa strains. Mutations in the UCBPP-PA14 toxA, plcS, and gacA genes resulted in a significant reduction in pathogenicity in both hosts, indicating that these genes encode virulence factors required for the full expression of pathogenicity in both plants and animals.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,SHRINERS BURNS INST,BOSTON,MA 02114; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT SURG,BOSTON,MA 02114	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital								BERKA RM, 1982, J BACTERIOL, V152, P239; BODEY GP, 1983, REV INFECT DIS, V5, P279; BURKHOLDER WALTER H., 1950, PHYTOPATH, V40, P115; CHO JJ, 1974, PHYTOPATHOLOGY, V65, P425; Crute I, 1994, ARABIDOPSIS, P705; DAVIS KR, 1991, MOL PLANT MICROBE IN, V4, P477, DOI 10.1094/MPMI-4-477; DEBENER T, 1991, PLANT J, V1, P289, DOI 10.1046/j.1365-313X.1991.t01-7-00999.x; DONG XN, 1991, PLANT CELL, V3, P61, DOI 10.1105/tpc.3.1.61; ELROD RP, 1942, J BACTERIOL, V46, P633; FENSELAU S, 1992, MOL PLANT MICROBE IN, V5, P390, DOI 10.1094/MPMI-5-390; GAFFNEY TD, 1994, MOL PLANT MICROBE IN, V7, P455, DOI 10.1094/MPMI-7-0455; GOUGH CL, 1992, MOL PLANT MICROBE IN, V5, P384, DOI 10.1094/MPMI-5-384; HOHN B, 1980, GENE, V11, P291, DOI 10.1016/0378-1119(80)90069-4; HOLLOWAY BW, 1955, J GEN MICROBIOL, V13, P572, DOI 10.1099/00221287-13-3-572; HUANG HC, 1992, J BACTERIOL, V174, P6878, DOI 10.1128/JB.174.21.6878-6885.1992; HUANG HC, 1993, MOL PLANT MICROBE IN, V6, P515, DOI 10.1094/MPMI-6-515; IGLEWSKI BH, 1975, P NATL ACAD SCI USA, V72, P2284, DOI 10.1073/pnas.72.6.2284; ISHIMOTO KS, 1989, P NATL ACAD SCI USA, V86, P1954, DOI 10.1073/pnas.86.6.1954; KOMINOS SD, 1972, APPL MICROBIOL, V24, P567, DOI 10.1128/AEM.24.4.567-570.1972; LAVILLE J, 1992, P NATL ACAD SCI USA, V89, P1562, DOI 10.1073/pnas.89.5.1562; LONG SR, 1993, CELL, V73, P921, DOI 10.1016/0092-8674(93)90271-Q; LORY S, 1983, GENE, V22, P95, DOI 10.1016/0378-1119(83)90068-9; LORY S, 1988, J BACTERIOL, V170, P714, DOI 10.1128/jb.170.2.714-719.1988; MEYERS BR, 1972, ANN INTERN MED, V76, P9, DOI 10.7326/0003-4819-76-1-9; OHMAN DE, 1980, INFECT IMMUN, V28, P899; OSTROFF RM, 1987, J BACTERIOL, V169, P4597, DOI 10.1128/jb.169.10.4597-4601.1987; OSTROFF RM, 1989, INFECT IMMUN, V57, P1369, DOI 10.1128/IAI.57.5.1369-1373.1989; RAHME LG, 1991, J BACTERIOL, V170, P575; RICH JJ, 1994, J BACTERIOL, V176, P7468, DOI 10.1128/JB.176.24.7468-7475.1994; ROBERTS RC, 1990, J BACTERIOL, V172, P6204, DOI 10.1128/jb.172.11.6204-6216.1990; RUBIN RA, 1987, PLASMID, V18, P84, DOI 10.1016/0147-619X(87)90081-3; Stevens Emily J., 1994, Journal of Burn Care and Rehabilitation, V15, P232, DOI 10.1097/00004630-199405000-00005; Young, 1977, PSEUDOMONAS AERUGINO, P1	33	961	998	7	140	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 30	1995	268	5219					1899	1902		10.1126/science.7604262	http://dx.doi.org/10.1126/science.7604262			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF990	7604262				2022-12-24	WOS:A1995RF99000038
J	GALLAY, P; SWINGLER, S; SONG, JP; BUSHMAN, F; TRONO, D				GALLAY, P; SWINGLER, S; SONG, JP; BUSHMAN, F; TRONO, D			HIV NUCLEAR IMPORT IS GOVERNED BY THE PHOSPHOTYROSINE-MEDIATED BINDING OF MATRIX TO THE CORE DOMAIN OF INTEGRASE	CELL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PLASMA-MEMBRANE; CELL-CYCLE; PROTEIN; INFECTION; DNA; REGION; RNA	The karyophilic properties of the viral matrix (MA) protein govern HIV nuclear import in nondividing cells such as macrophages. A critical regulator of this process is the C-terminal tyrosine phosphorylation of MA during virus maturation. Here, we reveal the mechanism of this phenomenon, by demonstrating that tyrosine phosphorylation induces the binding of MA to integrase (IN). This leads to the incorporation of MA molecules into virus cores, and subsequently into uncoated viral nucleoprotein complexes. A direct interaction between tyrosine-phosphorylated MA and the central domain of IN can be demonstrated in vitro. It is blocked by phosphotyrosine, indicating that IN recognizes the phosphorylated C-terminal residue of MA. These results explain how the karyophilic potential of MA is conferred to the HIV nucleoprotein complex.			GALLAY, P (corresponding author), SALK INST BIOL STUDIES,INFECT DIS LAB,10010 N TORREY PINES RD,LA JOLLA,CA 92037, USA.				NIAID NIH HHS [AI34786, AI37510] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037510, R01AI034786] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; AIKEN C, 1995, J VIROL, V69, P5048, DOI 10.1128/JVI.69.8.5048-5056.1995; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; BUSHMAN FD, 1993, P NATL ACAD SCI USA, V90, P3428, DOI 10.1073/pnas.90.8.3428; CHARNEAU P, 1994, J MOL BIOL, V241, P651, DOI 10.1006/jmbi.1994.1542; FARNET CM, 1991, J VIROL, V65, P1910, DOI 10.1128/JVI.65.4.1910-1915.1991; GALLAY P, 1995, CELL, V80, P379, DOI 10.1016/0092-8674(95)90488-3; GOFF S, 1981, J VIROL, V38, P239, DOI 10.1128/JVI.38.1.239-248.1981; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; HUMPHRIES EH, 1972, J VIROL, V10, P82, DOI 10.1128/JVI.10.1.82-87.1972; HUMPHRIES EH, 1974, J VIROL, V14, P531, DOI 10.1128/JVI.14.3.531-546.1974; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KIM SY, 1989, J VIROL, V63, P3708, DOI 10.1128/JVI.63.9.3708-3713.1989; LEWIS P, 1992, EMBO J, V11, P3053, DOI 10.1002/j.1460-2075.1992.tb05376.x; LEWIS PF, 1994, J VIROL, V68, P510, DOI 10.1128/JVI.68.1.510-516.1994; Meltzer M S, 1992, Curr Top Microbiol Immunol, V181, P239; MILLER MD, 1995, J VIROL, V69, P3938, DOI 10.1128/JVI.69.6.3938-3944.1995; MYERS G, 1992, HUMAN RETROVIRUSES A; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; ROE TY, 1993, EMBO J, V12, P2099, DOI 10.1002/j.1460-2075.1993.tb05858.x; SHAROVA N, 1991, AIDS RES HUM RETROV, V7, P303, DOI 10.1089/aid.1991.7.303; SPEARMAN P, 1994, J VIROL, V68, P3232, DOI 10.1128/JVI.68.5.3232-3242.1994; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; TRONO D, 1992, J VIROL, V66, P4893, DOI 10.1128/JVI.66.8.4893-4900.1992; VARMUS H, 1984, RNA TUMOR VIRUSES, P369; VINK C, 1993, NUCLEIC ACIDS RES, V21, P1419, DOI 10.1093/nar/21.6.1419; VONSCHWEDLER U, 1994, P NATL ACAD SCI USA, V91, P6992, DOI 10.1073/pnas.91.15.6992; WALKER F, 1993, J BIOL CHEM, V268, P19552; WEINBERG JB, 1991, J EXP MED, V174, P1477, DOI 10.1084/jem.174.6.1477; YUAN X, 1993, J VIROL, V67, P6387, DOI 10.1128/JVI.67.11.6387-6394.1993; ZHOU WJ, 1994, J VIROL, V68, P2556, DOI 10.1128/JVI.68.4.2556-2569.1994	33	319	323	0	7	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 17	1995	83	4					569	576		10.1016/0092-8674(95)90097-7	http://dx.doi.org/10.1016/0092-8674(95)90097-7			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TF248	7585960	Bronze			2022-12-24	WOS:A1995TF24800010
J	LIN, RL; THOMPSON, S; PRIESS, JR				LIN, RL; THOMPSON, S; PRIESS, JR			POP-1 ENCODES AN HMG BOX PROTEIN REQUIRED FOR THE SPECIFICATION OF A MESODERM PRECURSOR IN EARLY C-ELEGANS EMBRYOS	CELL			English	Article							SEX-DETERMINING REGION; DNA-BINDING MOTIF; CAENORHABDITIS-ELEGANS; CELLULAR INTERACTIONS; TRANSCRIPTION FACTOR; ALPHA-ENHANCER; MESSENGER-RNA; GENE; GUT; EXPRESSION	In C. elegans embryogenesis, the MS blastomere produces predominantly mesodermal cell types, while its sister E generates only endodermal tissue. We show that a maternal gene, pop-1, is essential for the specification of MS fate and that a mutation in pop-1 results in MS adopting an E fate. Previous studies have shown that the maternal gene skn-1 is required for both MS and E development and that skn-1 encodes a transcription factor. We show here that the pop-1 gene encodes a protein with an HMG box similar to the HMG boxes in the vertebrate lymphoid-specific transcriptional regulators TCF-1 and LEF-1. We propose that POP-1 and SKN-1 function together in the early embryo to allow MS-specific differentiation.			LIN, RL (corresponding author), HOWARD HUGHES MED INST,FRED HUTCHINSON CANC RES CTR,DIV BASIC SCI,SEATTLE,WA 98109, USA.							AAMODT EJ, 1991, SCIENCE, V252, P579, DOI 10.1126/science.2020855; ALBERTSON DG, 1984, DEV BIOL, V101, P61, DOI 10.1016/0012-1606(84)90117-9; ARTAVANISTSAKON.S, 1995, SCIENCE, V268, P225; AVERY L, 1989, NEURON, V3, P473, DOI 10.1016/0896-6273(89)90206-7; BLACKWELL TK, 1994, SCIENCE, V266, P621, DOI 10.1126/science.7939715; BOWERMAN B, 1992, CELL, V68, P1061, DOI 10.1016/0092-8674(92)90078-Q; BOWERMAN B, 1993, CELL, V74, P443, DOI 10.1016/0092-8674(93)80046-H; BRENNER S, 1974, GENETICS, V77, P71; CHEN BPC, 1994, GENE, V139, P73, DOI 10.1016/0378-1119(94)90525-8; CHEN L, 1992, SCIENCE, V256, P240, DOI 10.1126/science.1314423; DENNY P, 1992, EMBO J, V11, P3705, DOI 10.1002/j.1460-2075.1992.tb05455.x; EDGAR LG, 1986, DEV BIOL, V114, P109, DOI 10.1016/0012-1606(86)90387-8; EPSTEIN HF, 1982, MUSCLE DEV MOL CELLU, P7; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GOLDSTEIN B, 1993, DEVELOPMENT, V118, P1267; GOLDSTEIN B, 1995, DEVELOPMENT, V121, P1227; GOLDSTEIN B, 1992, NATURE, V357, P255, DOI 10.1038/357255a0; GRANATO M, 1994, DEVELOPMENT, V120, P3005; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; HO IC, 1990, MOL CELL BIOL, V10, P4720, DOI 10.1128/MCB.10.9.4720; HUTTER H, 1994, DEVELOPMENT, V120, P2051; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; JUNKERSDORF B, 1992, ROUX ARCH DEV BIOL, V202, P17, DOI 10.1007/BF00364593; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; KRAUSE M, 1990, CELL, V63, P907, DOI 10.1016/0092-8674(90)90494-Y; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LAUDET V, 1993, NUCLEIC ACIDS RES, V21, P2493, DOI 10.1093/nar/21.10.2493; MANGO SE, 1994, DEVELOPMENT, V120, P3019; MANGO SE, 1994, DEVELOPMENT, V120, P2305; MELLO CC, 1992, CELL, V70, P163, DOI 10.1016/0092-8674(92)90542-K; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MELLO CC, 1994, CELL, V77, P95, DOI 10.1016/0092-8674(94)90238-0; OKKEMA PG, 1994, DEVELOPMENT, V120, P2175; PRIESS JR, 1987, CELL, V48, P241, DOI 10.1016/0092-8674(87)90427-2; PRIESS JR, 1987, CELL, V51, P601, DOI 10.1016/0092-8674(87)90129-2; ROBINSON PA, 1988, J IMMUNOL METHODS, V108, P115, DOI 10.1016/0022-1759(88)90409-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIERENBERG E, 1987, DEV BIOL, V122, P452, DOI 10.1016/0012-1606(87)90309-5; SCHNABEL H, 1990, SCIENCE, V250, P686, DOI 10.1126/science.250.4981.686; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SPIETH J, 1993, CELL, V73, P521, DOI 10.1016/0092-8674(93)90139-H; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; WATERMAN M L, 1990, New Biologist, V2, P621; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656; WOOD WB, 1994, TRENDS GENET, V10, P49, DOI 10.1016/0168-9525(94)90148-1; XIE W, 1991, BIOTECHNIQUES, V11, P325; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4	51	255	261	1	10	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 17	1995	83	4					599	609		10.1016/0092-8674(95)90100-0	http://dx.doi.org/10.1016/0092-8674(95)90100-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TF248	7585963	Bronze			2022-12-24	WOS:A1995TF24800013
J	MUTHUSAMY, N; BARTON, K; LEIDEN, JM				MUTHUSAMY, N; BARTON, K; LEIDEN, JM			DEFECTIVE ACTIVATION AND SURVIVAL OF T-CELLS LACKING THE ETS-1 TRANSCRIPTION FACTOR	NATURE			English	Article							GENE PROMOTER; EXPRESSION; BINDING; PROTOONCOGENE; PROTEINS; ONCOGENE; FAMILY; DOMAIN; MICE	THE Ets-1 proto-oncogene(1) is a member of the Ets family of eukaryotic transcription factors(2-7). Members of this family play important roles in regulating gene expression in response to multiple developmental and mitogenic signals(4,5,8,9) Ets-1 is preferentially expressed at high levels in B and T cells of adult mice(10,11) and is regulated during both thymocyte development(11) and T-cell activation(12,13), To study the role of Ets-1 in T-cell development and function we have used the RAG-2(-/-) complementation system(14) and murine embryonic stem (ES) cells containing homozygous deletions in the Ets-1 gene (Ets-1(-/-)). Ets-1(-/-)-RAG-2(-/-) chimaeric mice displayed markedly decreased numbers of mature thymocytes and peripheral T cells. Ets-1(-/-) T cells expressed normal levels of CD3 and T-cell antigen receptor (TCR)-alpha/beta. However, they displayed a severe proliferative defect in response to multiple activational signals and demonstrated increased rates of spontaneous apoptosis in vitro. These findings demonstrate that Ets-1 is required for the normal survival and activation of murine T cells.	UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV CHICAGO,DEPT PATHOL,CHICAGO,IL 60637	University of Chicago; University of Chicago			Muthusamy, Natarajan/A-6915-2009					BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BHAT NK, 1989, J IMMUNOL, V142, P672; CHEN JH, 1985, MOL CELL BIOL, V5, P2993, DOI 10.1128/MCB.5.11.2993; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEUNG S, 1993, ONCOGENE, V8, P989; LI X, 1995, CYTOMETRY, V20, P172, DOI 10.1002/cyto.990200210; LIN JX, 1993, MOL CELL BIOL, V13, P6201, DOI 10.1128/MCB.13.10.6201; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; RABAULT B, 1994, J BIOL CHEM, V269, P28143; SALMON P, 1993, P NATL ACAD SCI USA, V90, P7739, DOI 10.1073/pnas.90.16.7739; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WOTTON D, 1993, LEUKEMIA, V7, pS55	25	282	286	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 19	1995	377	6550					639	642		10.1038/377639a0	http://dx.doi.org/10.1038/377639a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA275	7566177				2022-12-24	WOS:A1995TA27500055
J	GARRED, P; MADSEN, HO; HOFMANN, B; SVEJGAARD, A				GARRED, P; MADSEN, HO; HOFMANN, B; SVEJGAARD, A			INCREASED FREQUENCY OF HOMOZYGOSITY OF ABNORMAL MANNAN-BINDING-PROTEIN ALLELES IN PATIENTS WITH SUSPECTED IMMUNODEFICIENCY	LANCET			English	Note							CHILDREN; GENE	A low plasma concentration of mannan-binding protein (MBP) impairs opsonisation and phagocytosis. Three different mutations in the MBP gene have a dominant effect on MBP concentration. We investigated the frequency of the abnormal MBP alleles in 228 unrelated patients suspected of various non-HIV-related immunodeficiencies. The frequency of heterozygotes for the abnormal alleles was not different from that in the background population (36.0% and 37.4%, respectively). By contrast, the frequency of homozygotes for the abnormal alleles was significantly increased (8.3% and 0.8%, respectively; p=0.0017). This finding implies that homozygotes for abnormal MBP alleles are predisposed to recurrent infections.			GARRED, P (corresponding author), RIGSHOSP,DEPT CLIN IMMUNOL,TISSUE TYPING LAB,DK-2200 COPENHAGEN,DENMARK.		Madsen, Hans O/Q-2035-2015	Madsen, Hans O/0000-0001-5551-4787; Garred, Peter/0000-0002-2876-8586				GARRED P, 1992, CLIN EXP IMMUNOL, V90, P517; GARRED P, 1993, CLIN EXP IMMUNOL, V94, P99; GARRED P, 1994, EUR J IMMUNOGENET, V21, P125, DOI 10.1111/j.1744-313X.1994.tb00183.x; GARRED P, 1992, EUR J IMMUNOGENET, V19, P403, DOI 10.1111/j.1744-313X.1992.tb00083.x; Lipscombe R. J., 1992, Human Molecular Genetics, V1, P709, DOI 10.1093/hmg/1.9.709; LIPSCOMBE RJ, 1995, IMMUNOLOGY, V85, P660; MADSEN HO, 1995, J IMMUNOL, V155, P3013; MADSEN HO, 1994, IMMUNOGENETICS, V40, P37, DOI 10.1007/BF00163962; SUMIYA M, 1991, LANCET, V337, P1569, DOI 10.1016/0140-6736(91)93263-9; SUMMERFIELD JA, 1995, LANCET, V345, P886, DOI 10.1016/S0140-6736(95)90009-8	10	223	243	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 7	1995	346	8980					941	943		10.1016/S0140-6736(95)91559-1	http://dx.doi.org/10.1016/S0140-6736(95)91559-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY808	7564730				2022-12-24	WOS:A1995RY80800011
J	MARTIN, A; HAXBY, JV; LALONDE, FM; WIGGS, CL; UNGERLEIDER, LG				MARTIN, A; HAXBY, JV; LALONDE, FM; WIGGS, CL; UNGERLEIDER, LG			DISCRETE CORTICAL REGIONS ASSOCIATED WITH KNOWLEDGE OF COLOR AND KNOWLEDGE OF ACTION	SCIENCE			English	Article							VISUAL-CORTEX; PET IMAGES; VERBS; RETRIEVAL; SYSTEMS; NOUNS; BRAIN; COMPREHENSION; ACHROMATOPSIA; ORGANIZATION	The areas of the brain that mediate knowledge about objects were investigated by measuring changes in regional cerebral blood flow (rCBF) using positron emission tomography (PET). Subjects generated words denoting colors and actions associated with static, achromatic line drawings of objects in one experiment, and with the written names of objects in a second experiment. In both studies, generation of color words selectively activated a region in the ventral temporal lobe just anterior to the area involved in the perception of color, whereas generation of action words activated a region in the middle temporal gyrus just anterior to the area involved in the perception of motion. These data suggest that object knowledge is organized as a distributed system in which the attributes of an object are stored close to the regions of the cortex that mediate perception of those attributes.			MARTIN, A (corresponding author), NIMH,PSYCHOL & PSYCHOPATHOL LAB,BLDG 10,ROOM 4C110,10 CTR DR,MSC 1366,BETHESDA,MD 20892, USA.		martin, alex/B-6176-2009					ALBERT ML, 1981, CLIN ASPECTS DYSPHAG, P69; Allport D.A., 1985, CURRENT PERSPECTIVES, P32; BATTIG WF, 1969, J EXPT PSYCHOL MON 2, V80; CARAMAZZA A, 1991, NATURE, V349, P788, DOI 10.1038/349788a0; CORBETTA M, 1990, SCIENCE, V248, P1556, DOI 10.1126/science.2360050; DAMASIO A, 1980, NEUROLOGY, V30, P1064, DOI 10.1212/WNL.30.10.1064; DAMASIO AR, 1993, P NATL ACAD SCI USA, V90, P4957, DOI 10.1073/pnas.90.11.4957; DAMASIO AR, 1983, NEUROLOGY, V33, P1573, DOI 10.1212/WNL.33.12.1573; DAMASIO AR, 1989, COGNITION, V33, P25, DOI 10.1016/0010-0277(89)90005-X; Desimone R., 1989, HDB NEUROPSYCHOLOGY, P267; FARAH MJ, 1992, J EXP PSYCHOL HUMAN, V18, P241, DOI 10.1037/0096-1523.18.1.241; FRISTON KJ, 1989, J CEREBR BLOOD F MET, V9, P690, DOI 10.1038/jcbfm.1989.97; FRISTON KJ, 1991, J COMPUT ASSIST TOMO, V15, P634, DOI 10.1097/00004728-199107000-00020; FRISTON KJ, 1990, BLOOD FLOW METAB, V10, P458; GESCHWIND N, 1966, ARCH NEUROL-CHICAGO, V15, P137, DOI 10.1001/archneur.1966.00470140027004; GLASER WR, 1992, COGNITION, V42, P61, DOI 10.1016/0010-0277(92)90040-O; GOLDBERG E, 1989, J CLIN EXP NEUROPSYC, V11, P489, DOI 10.1080/01688638908400909; HAXBY JV, 1994, J NEUROSCI, V14, P6336; HURTIG RR, 1994, J CEREBR BLOOD F MET, V14, P423, DOI 10.1038/jcbfm.1994.53; KOSSLYN SM, 1993, J COGNITIVE NEUROSCI, V5, P263, DOI 10.1162/jocn.1993.5.3.263; KOSSLYN SM, 1994, BRAIN, V117, P15; Kucera H., 1967, COMPUTATIONAL ANAL P; LEE KS, 1991, J CEREB BLOOD FLO S2, V11, pS557; LUZZATTI C, 1994, NEUROPSYCHOLOGIA, V32, P933, DOI 10.1016/0028-3932(94)90044-2; MCCARTHY R, 1985, NEUROPSYCHOLOGIA, V23, P709, DOI 10.1016/0028-3932(85)90079-X; MESULAM MM, 1990, ANN NEUROL, V28, P597, DOI 10.1002/ana.410280502; MICELI G, 1984, CORTEX, V20, P207, DOI 10.1016/S0010-9452(84)80038-6; Milner B., 1964, FRONTAL GRANULAR COR, P313; Neely J. H., 1991, BASIC PROCESSES READ, P264; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.neuro.13.1.25; RAICHLE ME, 1994, CEREB CORTEX, V4, P8, DOI 10.1093/cercor/4.1.8; SERGENT J, 1992, BRAIN, V115, P15, DOI 10.1093/brain/115.1.15; SNODGRASS JG, 1980, J EXP PSYCHOL-HUM L, V6, P174, DOI 10.1037/0278-7393.6.2.174; Talairach J., 1988, COPLANAR STEREOTAXIC; Ungerleider LG., 1982, ANAL VISUAL BEHAV, P549; Vaina L., 1994, CEREB CORTEX, V5, P555; VANESSEN DC, 1992, SCIENCE, V255, P419, DOI 10.1126/science.1734518; WARRINGTON EK, 1984, BRAIN, V107, P829, DOI 10.1093/brain/107.3.829; WISE R, 1991, BRAIN, V114, P1803, DOI 10.1093/brain/114.4.1803; ZEKI S, 1991, J NEUROSCI, V11, P641; ZEKI S, 1990, BRAIN, V113, P1721, DOI 10.1093/brain/113.6.1721; ZEKI S, 1991, BRAIN, V114, P1721; ZIHL J, 1991, BRAIN, V114, P2235, DOI 10.1093/brain/114.5.2235; ZINGESER LB, 1990, BRAIN LANG, V39, P14, DOI 10.1016/0093-934X(90)90002-X	45	811	828	2	33	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 6	1995	270	5233					102	105		10.1126/science.270.5233.102	http://dx.doi.org/10.1126/science.270.5233.102			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RY302	7569934				2022-12-24	WOS:A1995RY30200043
J	MENDILLO, M; BAUMGARDNER, J				MENDILLO, M; BAUMGARDNER, J			CONSTRAINTS ON THE ORIGIN OF THE MOONS ATMOSPHERE FROM OBSERVATION DURING A LUNAR ECLIPSE	NATURE			English	Article							EXTENDED SODIUM ATMOSPHERE; POTASSIUM	THE properties of the Moon's rarefied atmosphere, which can be traced through observations of sodium and potassium(1-4), provide important insights into the formation and maintenance of atmospheres on other primitive Solar System bodies(5-7). The lunar atmosphere is believed to be composed of atoms from the surface rocks and soil, which might have been sputtered by micrometeorites(8), by ions in the solar wind(9), or by photons(10,11). It might also form by the evaporation of atoms from the hot, illuminated surface(10,11) Here we report the detection of sodium emission from the Moon's atmosphere during a total lunar eclipse (which occurs when the Moon is full). The sodium atmosphere is considerably more extended at full Moon than expected--it extends to at least nine lunar radii--and its brightness distribution is incompatible with sources involving either solar-wind or micrometeorite sputtering. This leaves photon sputtering or thermal desorption as the preferred explanations for the lunar atmosphere, and suggests that sunlight might also be responsible for the transient atmospheres of other primitive bodies (such as Mercury).	BOSTON UNIV,DEPT ASTRON,BOSTON,MA 02215	Boston University	MENDILLO, M (corresponding author), BOSTON UNIV,CTR SPACE PHYS,BOSTON,MA 02215, USA.		Mendillo, Michael/H-4397-2014					AHEARN MF, 1992, ICARUS, V98, P54, DOI 10.1016/0019-1035(92)90206-M; ELFORD WG, 1964, 9 HARV U RES REP; FLYNN B, 1993, SCIENCE, V261, P184, DOI 10.1126/science.261.5118.184; FLYNN B, IN PRESS J GEOPHYS R; HALL DT, 1995, NATURE, V373, P677, DOI 10.1038/373677a0; IP WH, 1991, GEOPHYS RES LETT, V18, P2093, DOI 10.1029/91GL02549; KOZLOWSKI RWH, 1990, GEOPHYS RES LETT, V17, P2253, DOI 10.1029/GL017i012p02253; MENDILLO M, 1991, GEOPHYS RES LETT, V18, P2097, DOI 10.1029/91GL02622; MENDILLO M, 1993, ADV SPACE RES, V13, P313; MORGAN T, 1991, EOS, V72, P225; MORGAN TH, 1991, J GEOPHYS RES-SPACE, V96, P1351, DOI 10.1029/90JA02127; PAPAGLANNIS MD, 1972, SPACE PHYSICS ASTROP, P94; POTTER AE, 1988, SCIENCE, V241, P675, DOI 10.1126/science.241.4866.675; POTTER AE, 1988, GEOPHYS RES LETT, V15, P1515, DOI 10.1029/GL015i013p01515; POTTER AE, 1994, GEOPHYS RES LETT, V21, P2263, DOI 10.1029/94GL01702; SMYTH WH, 1995, ASTROPHYS J, V441, P839, DOI 10.1086/175407; SMYTH WH, 1995, ASTROPHYS J, V443, P371, DOI 10.1086/175532; SPRAGUE AL, 1990, ICARUS, V84, P93, DOI 10.1016/0019-1035(90)90160-B; SPRAGUE AL, 1992, ICARUS, V96, P27, DOI 10.1016/0019-1035(92)90004-Q; SPRAGUE AL, 1990, THESIS U ARIZONA; STERN SA, 1995, ASTRON J, V109, P835, DOI 10.1086/117327; TYLER AL, 1988, GEOPHYS RES LETT, V15, P1141, DOI 10.1029/GL015i010p01141	22	42	42	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 5	1995	377	6548					404	406		10.1038/377404a0	http://dx.doi.org/10.1038/377404a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY190	7566115				2022-12-24	WOS:A1995RY19000040
J	ZHENG, LX; FISHER, G; MILLER, RE; PESCHON, J; LYNCH, DH; LENARDO, MJ				ZHENG, LX; FISHER, G; MILLER, RE; PESCHON, J; LYNCH, DH; LENARDO, MJ			INDUCTION OF APOPTOSIS IN MATURE T-CELLS BY TUMOR-NECROSIS-FACTOR	NATURE			English	Article							FACTOR-ALPHA; MICE	T-CELL receptor-induced apoptosis regulates immune responses and can result from interactions between Fas (Apo1/CD95) and Fas ligand (FasL)(1-12). Mutations in the genes for Fas and FasL cause disorders resembling human autoimmune diseases in lpr and gld mice, respectively(13,14). However, peripheral T-cell deletion takes place in lpr mice, acid autoimmune syndromes occur in mouse strains without Fas or FasL defects(15,16). Here we show that tumour necrosis factor (TNF) can mediate mature T-cell receptor-induced apoptosis through the p75 TNF receptor. Blockage of both TNF and Fast is required to abrogate T-cell death and TNF mediates the death of most CD8(+) T cells, whereas FasL mediates the death of most CD4(+) T cells. Our results suggest that autoregulatory apoptosis of the mature T cells can occur by two distinct molecular mechanisms.	NIAID, IMMUNOL LAB, BETHESDA, MD 20892 USA; IMMUNEX RES & DEV CORP, DEPT IMMUNOBIOL, SEATTLE, WA 98101 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								ALDERSON MR, 1995, J EXP MED, V181, P71, DOI 10.1084/jem.181.1.71; BIGDA J, 1994, J EXP MED, V180, P445, DOI 10.1084/jem.180.2.445; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CLEMENT MV, 1994, J EXP MED, V180, P557, DOI 10.1084/jem.180.2.557; CRITCHFIELD JM, 1994, SCIENCE, V263, P1139, DOI 10.1126/science.7509084; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; GILLETTEFERGUSON I, 1994, EUR J IMMUNOL, V24, P1181, DOI 10.1002/eji.1830240526; JACOB CO, 1988, NATURE, V331, P356, DOI 10.1038/331356a0; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; LYNCH DH, 1994, IMMUNITY, V1, P131, DOI 10.1016/1074-7613(94)90106-6; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARIANI SM, 1994, EUR J IMMUNOL, V24, P3119, DOI 10.1002/eji.1830241231; MOSKOPHIDIS D, 1993, NATURE, V362, P758, DOI 10.1038/362758a0; Nagata S, 1994, Semin Immunol, V6, P3, DOI 10.1006/smim.1994.1002; RAMSDELL F, 1994, INT IMMUNOL, V6, P1545, DOI 10.1093/intimm/6.10.1545; RAZVI ES, 1995, AM J PATHOL, V147, P79; ROCHA B, 1991, SCIENCE, V251, P1225, DOI 10.1126/science.1900951; RUSSELL JH, 1993, P NATL ACAD SCI USA, V90, P4409, DOI 10.1073/pnas.90.10.4409; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; SCOTT DE, 1993, J IMMUNOL, V150, P664; SHEEHAN KCF, 1995, J EXP MED, V181, P607, DOI 10.1084/jem.181.2.607; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SMITH MR, 1990, J IMMUNOL, V144, P162; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; THEOFILOPOULOS AN, 1989, ADV IMMUNOL, V46, P61, DOI 10.1016/S0065-2776(08)60651-3; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J	29	1025	1061	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 28	1995	377	6547					348	351		10.1038/377348a0	http://dx.doi.org/10.1038/377348a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX111	7566090				2022-12-24	WOS:A1995RX11100059
J	HILL, MR; JAMES, AL; FAUX, JA; RYAN, G; HOPKIN, JM; LESOUEF, P; MUSK, AW; COOKSON, WOCM				HILL, MR; JAMES, AL; FAUX, JA; RYAN, G; HOPKIN, JM; LESOUEF, P; MUSK, AW; COOKSON, WOCM			FC-EPSILON-RI-BETA POLYMORPHISM AND RISK OF ATOPY IN A GENERAL-POPULATION SAMPLE	BRITISH MEDICAL JOURNAL			English	Article							SINGLE AMINO-ACID; BRONCHIAL HYPERRESPONSIVENESS; SERUM IGE; RESPONSES; ASTHMA; CHROMOSOME-11Q13; LINKAGE; ALLERGY; INFANCY; ADULTS	Objective-To establish the prevalence of Fc epsilon RI-beta polymorphisms Leu181 and Leu181/Leu183 on chromosome 11q13 in the general population and to examine whether when maternally inherited they confer a risk of atopy. Design-A population based survey for measures of atopy (skin prick test reactions, specific IgE titres, total serum IgE concentration), bronchial hyperresponsiveness, and carriage of Fc epsilon RI-beta Leu181 and Leu181/Leu183. Setting-The rural coastal town of Busselton, Western Australia. Subjects-1004 members of 230 two generation families identified through adults aged under 55. Results-Fc epsilon RI-beta Leu181/Leu183 was identified in 45 subjects (4.5%). All 13 children who had inherited the variant maternally were atopic. Six had asthma and nine rhinitis. The odds ratio of a positive Skin prick test reaction to house dust mite or grass pollen in these children compared with the other 523 children was 7.37 (95% confidence interval 1.62 to 33.60). The 95% confidence interval for the odds ratio of a positive specific IgE response (radio-allergosorbent test) was 3.00 to infinity and the odds ratio for bronchial hyperresponsiveness was 3.70 (1.21 to 11.60). By contrast, the eight children mho had derived the variant paternally had negative skin prick and radioallergosorbent test results and did not have increased bronchial responsiveness. Conclusion-Fc epsilon R triple prime beta Leu181/Leu183 when inherited maternally identifies a genetic risk factor for atopy and bronchial hyperresponsiveness.	UNIV OXFORD,JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN MED,OXFORD OX3 9DU,ENGLAND; QUEEN ELIZABETH II MED CTR,DEPT RESP MED,PERTH,WA 6009,AUSTRALIA; CHURCHILL HOSP,OSLER CHEST UNIT,OXFORD OX3 7LJ,ENGLAND; UNIV WESTERN AUSTRALIA,PRINCESS MARGARET HOSP,DEPT PAEDIAT,PERTH,WA,AUSTRALIA	University of Oxford; University of Western Australia; University of Oxford; University of Western Australia			Hill, Michael/C-4861-2008; Cookson, William/HHC-1790-2022; Le Souef, Peter N/H-5256-2014		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABERG N, 1994, CLIN EXP ALLERGY, V23, P829; ARSHAD SH, 1992, LANCET, V339, P1493, DOI 10.1016/0140-6736(92)91260-F; BEINBORN M, 1993, NATURE, V362, P348, DOI 10.1038/362348a0; CLINE MG, 1989, THORAX, V44, P425, DOI 10.1136/thx.44.5.425; COLLEE JM, 1993, LANCET, V342, P936, DOI 10.1016/0140-6736(93)91988-X; COOKSON WOCM, 1991, CLIN EXP ALLERGY, V21, P473, DOI 10.1111/j.1365-2222.1991.tb01688.x; COOKSON WOCM, 1992, LANCET, V340, P381, DOI 10.1016/0140-6736(92)91468-N; COOKSON WOCM, 1989, LANCET, V1, P1292; HALONEN M, 1992, AM REV RESPIR DIS, V146, P866, DOI 10.1164/ajrccm/146.4.866; HOLFORDSTREVENS V, 1984, J ALLERGY CLIN IMMUN, V73, P516, DOI 10.1016/0091-6749(84)90363-4; HOLT PG, 1990, PEDIATR ALLERGY IMMU, V1, P3; KUEHR J, 1993, CLIN EXP ALLERGY, V23, P600, DOI 10.1111/j.1365-2222.1993.tb00900.x; MAGNUSSON CGM, 1988, ALLERGY, V43, P241, DOI 10.1111/j.1398-9995.1988.tb00896.x; MARSH DG, 1992, NAT GENET, V2, P252, DOI 10.1038/ng1292-252; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MOFFATT F, 1994, LANCET, V343, P1597, DOI 10.1016/S0140-6736(94)93057-0; NEWTON CR, 1989, NUCLEIC ACIDS RES, V17, P2503, DOI 10.1093/nar/17.7.2503; OKSENBERG D, 1992, NATURE, V360, P161, DOI 10.1038/360161a0; SANDFORD AJ, 1993, LANCET, V341, P332, DOI 10.1016/0140-6736(93)90136-5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIRAKAWA T, 1994, CLIN GENET, V46, P228; SHIRAKAWA T, 1994, NAT GENET, V7, P125, DOI 10.1038/ng0694-125; WOOLCOCK AJ, 1987, THORAX, V42, P361, DOI 10.1136/thx.42.5.361; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760; YOUNG RP, 1992, J MED GENET, V29, P236, DOI 10.1136/jmg.29.4.236	25	132	135	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 23	1995	311	7008					776	779		10.1136/bmj.311.7008.776	http://dx.doi.org/10.1136/bmj.311.7008.776			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX107	7580438	Green Published			2022-12-24	WOS:A1995RX10700019
J	IMRIE, KR; KOVACS, MJ; SELBY, D; LIPTON, J; PATTERSON, BJ; PANTALONY, D; POLDRE, P; NGAN, BY; KEATING, A				IMRIE, KR; KOVACS, MJ; SELBY, D; LIPTON, J; PATTERSON, BJ; PANTALONY, D; POLDRE, P; NGAN, BY; KEATING, A			ISOLATED CHLOROMA - THE EFFECT OF EARLY ANTILEUKEMIC THERAPY	ANNALS OF INTERNAL MEDICINE			English	Note							GRANULOCYTIC SARCOMA; LEUKEMIA; TRANSLOCATION	Objective: To evaluate the effect of antileukemic chemotherapy administered at diagnosis on the survival of patients with isolated chloroma. Design: Retrospective review of locally identified patients and analysis of cases from the medical literature. Patients: The records of all patients with isolated chloroma identified at three teaching hospitals in Toronto between 1980 and 1994 were reviewed. A MEDLINE search was done to identify all cases of isolated chloroma reported in the English-language medical literature. Patients with a previous known hematologic disorder were excluded. Measurements: The effect of therapy on 1) the interval between diagnosis of chloroma and diagnosis of acute myeloid leukemia and 2) survival was determined. Results: 7 local patients and 83 published cases were identified, for a total of 90 evaluable patients. For the entire group, the median time to the diagnosis of acute myeloid leukemia was 9 months, and median survival was 22 months. Chemotherapy was administered to 49 patients (54%) at diagnosis of chloroma. Significantly fewer patients treated with chemotherapy subsequently developed acute myeloid leukemia (41% compared with 71%; P = 0.001). Survival was longer in patients treated with chemotherapy (>50% alive with a median follow-up of 25 months compared with a median survival of 13 months for those initially untreated; P = 0.001). Multivariate analysis showed that neither local radiotherapy nor surgery had an effect on survival. Conclusions: Administration of antileukemic chemotherapy at diagnosis of chloroma is associated with a significantly lower probability of developing acute myeloid leukemia and with longer survival.	TORONTO GEN HOSP, TORONTO, ON M5G 2C4, CANADA; PRINCESS MARGARET HOSP, TORONTO, ON, CANADA; VICTORIA HOSP, LONDON, ON, CANADA; SUNNYBROOK HLTH SCI CTR, N YORK, ON, CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Victoria; Western University (University of Western Ontario); University of Toronto; University Toronto Affiliates; Sunnybrook Health Science Center			Kovacs, Michael/G-3315-2011					ABE R, 1986, CANCER, V58, P1260, DOI 10.1002/1097-0142(19860915)58:6<1260::AID-CNCR2820580614>3.0.CO;2-O; Dock G., 1893, AM J MED SCI, V106, P152, DOI DOI 10.1097/00000441-189308000-00003; ESHGHABADI M, 1986, J CLIN ONCOL, V4, P912, DOI 10.1200/JCO.1986.4.6.912; HESTON JF, 1986, 45 YEARS CANCER INCI; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KRAUSE JR, 1979, CANCER-AM CANCER SOC, V44, P1017, DOI 10.1002/1097-0142(197909)44:3<1017::AID-CNCR2820440333>3.0.CO;2-I; MEIS JM, 1986, CANCER-AM CANCER SOC, V58, P2697, DOI 10.1002/1097-0142(19861215)58:12<2697::AID-CNCR2820581225>3.0.CO;2-R; NEIMAN RS, 1981, CANCER-AM CANCER SOC, V48, P1426, DOI 10.1002/1097-0142(19810915)48:6<1426::AID-CNCR2820480626>3.0.CO;2-G; SWIRSKY DM, 1984, BRIT J HAEMATOL, V56, P199, DOI 10.1111/j.1365-2141.1984.tb03948.x; WIERNIK PH, 1970, BLOOD-J HEMATOL, V35, P361, DOI 10.1182/blood.V35.3.361.361; YATES J, 1982, BLOOD, V60, P454	11	167	172	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1995	123	5					351	353		10.7326/0003-4819-123-5-199509010-00005	http://dx.doi.org/10.7326/0003-4819-123-5-199509010-00005			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ988	7625623				2022-12-24	WOS:A1995RQ98800005
J	GRUBB, NR; ELTON, RA; FOX, KAA				GRUBB, NR; ELTON, RA; FOX, KAA			IN-HOSPITAL MORTALITY AFTER OUT-OF-HOSPITAL CARDIAC-ARREST	LANCET			English	Article							AMERICAN-HEART-ASSOCIATION; CARDIOPULMONARY RESUSCITATION; HEALTH-PROFESSIONALS; UTSTEIN STYLE; SURVIVAL; DEFIBRILLATION; EMERGENCY; EXPERIENCE; STATEMENT; SCOTLAND	In-hospital management of out-of-hospital cardiac arrest is complicated by uncertainty about prognosis and the need to identify markers of adverse outcome in individuals surviving initial resuscitation. We sought to identify factors that predict in-hospital death among patients who initially survive out-of-hospital cardiac arrest. We investigated 346 consecutive cases of out-of-hospital cardiac arrest received by a single centre in Edinburgh, UK (270 cases examined retrospectively, 76 prospectively). Of the retrospective cohort, 246 cases were thought to be of cardiac origin. There were associations between in-hospital mortality and pre-arrest variables, resuscitation variables, and factors measured during admission. Crew-witnessed arrests were associated with low mortality; arrest rhythm (p<0.001), resuscitation by a health professional (p<0.05), conscious level on admission (p<0.001), and requirement for ventilaton (p<0.05) independently predicted in-hospital mortality. A weighted prognostic scoring system based on three of these variables accurately predicted the likelihood of in-hospital death in the prospective test group. Further assessment of conscious level during admission with the Glasgow coma score predicted mortality rates in the study population, but coma did not predict a hopeless prognosis in individual cases unless it persisted for 72 h or more. Accurate prognostic assessment of out-of-hospital cardiac arrest survivors can be made from information available on admission. Of factors that independently predicted outcome, the skill of the resuscitator is most readily modified. This suggests that public training in resuscitation may reduce mortality rates.	UNIV EDINBURGH,ROYAL INFIRM EDINBURGH,MED STAT UNIT,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND	Royal Infirmary of Edinburgh; University of Edinburgh	GRUBB, NR (corresponding author), UNIV EDINBURGH,ROYAL INFIRM EDINBURGH,CARDIOVASC RES UNIT,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND.		Fox, keith A A/I-3742-2013	Fox, Keith/0000-0002-0140-2752				AARONS EJ, 1991, BRIT MED J, V303, P1504, DOI 10.1136/bmj.303.6816.1504; BOSSAERT L, 1989, RESUSCITATION, V17, pS57; COBB LA, 1982, ANN NY ACAD SCI, V382, P330, DOI 10.1111/j.1749-6632.1982.tb55228.x; COBB LA, 1992, CIRCULATION, V85, P98; COBBE SM, 1991, BRIT MED J, V302, P1517, DOI 10.1136/bmj.302.6791.1517; CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; CUMMINS RO, 1991, CIRCULATION, V83, P1832, DOI 10.1161/01.CIR.83.5.1832; CUSACK S, 1992, ARCH EMERG MED, V9, P203; DICKEY W, 1992, BRIT HEART J, V67, P334; EARNEST MP, 1979, NEUROLOGY, V29, P56, DOI 10.1212/WNL.29.1.56; EDGREN E, 1994, LANCET, V343, P1055, DOI 10.1016/S0140-6736(94)90179-1; EISENBERG MS, 1980, NEW ENGL J MED, V302, P1379, DOI 10.1056/NEJM198006193022502; GUZY PM, 1983, AM J PUBLIC HEALTH, V73, P766, DOI 10.2105/AJPH.73.7.766; HAMER DW, 1993, RESUSCITATION, V26, P31, DOI 10.1016/0300-9572(93)90160-R; JENNETT B, 1975, LANCET, V1, P480; JUCHEMS R, 1993, RESUSCITATION, V26, P23, DOI 10.1016/0300-9572(93)90159-N; ROWLEY JM, 1990, BRIT HEART J, V64, P309; SEDGWICK ML, 1993, RESUSCITATION, V26, P75, DOI 10.1016/0300-9572(93)90166-N; TORPPEDERSEN C, 1991, RESUSCITATION, V21, P283, DOI 10.1016/0300-9572(91)90053-2; WEAVER WD, 1986, J AM COLL CARDIOL, V7, P752, DOI 10.1016/S0735-1097(86)80332-1; WIK L, 1994, RESUSCITATION, V28, P195, DOI 10.1016/0300-9572(94)90064-7; ZIPES DP, 1992, CIRCULATION, V85, P160	22	94	96	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 12	1995	346	8972					417	421		10.1016/S0140-6736(95)92784-0	http://dx.doi.org/10.1016/S0140-6736(95)92784-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN656	7623574				2022-12-24	WOS:A1995RN65600013
J	SHAW, GM; LAMMER, EJ; WASSERMAN, CR; OMALLEY, CD; TOLAROVA, MM				SHAW, GM; LAMMER, EJ; WASSERMAN, CR; OMALLEY, CD; TOLAROVA, MM			RISKS OF OROFACIAL CLEFTS IN CHILDREN BORN TO WOMEN USING MULTIVITAMINS CONTAINING FOLIC-ACID PERICONCEPTIONALLY	LANCET			English	Article							NEURAL-TUBE DEFECTS; VITAMIN SUPPLEMENTATION; PREVENT RECURRENCE; WESTERN-AUSTRALIA; DIETARY-FOLATE; ORAL CLEFTS; PREGNANCY; LIP; SMOKING; PALATE	Women are advised to take folic acid before they conceive as a precaution against neural-tube defects. However, the use of folic acid in preventing orofacial clefts is unknown. We investigated whether a woman's periconceptional use of multivitamins containing folic acid was associated with a reduced risk of orofacial clefts. We derived data from a population-based case-control study of fetuses and liveborn infants with orofacial anomalies among a 1987-89 cohort of births in California. We interviewed 731 (84.7%) of eligible mothers with orofacial cleft case infants and 734 (78.2%) mothers with non-malformed control infants. We found a reduced risk of orofacial clefts if the mother had used multivitamins containing folic acid during the period from one month before through two months after conception. The odds ratios ranged from 0.50-0.73 depending on cleft phenotype. Controlling for the potential influence of other variables did not substantially alter the results. Maternal daily consumption of cereal containing folic acid was also associated with a reduced risk of orofacial clefts. Women who used multivitamins containing folic acid periconceptionally had a 25-50% reduction in risk for offspring with orofacial clefts compared to women who did not use such vitamins. However, this association may not be attributable to folic acid specifically, but may be a consequence of other multivitamin supplement components, or behaviours, that are highly correlated with the use of multivitamins containing folic acid.	CHILDRENS HOSP,DEPT MED GENET,OAKLAND,CA	Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute	SHAW, GM (corresponding author), MARCH DIMES BIRTH DEFECTS FDN,CALIF BIRTH DEFECTS MONITORING PROGRAM,EMERYVILLE,CA, USA.			Shaw, Gary/0000-0001-7438-4914				BOWER C, 1989, MED J AUSTRALIA, V150, P613, DOI 10.5694/j.1326-5377.1989.tb136723.x; BOWER C, 1992, AM J MED GENET, V44, P647, DOI 10.1002/ajmg.1320440524; Briggs R M, 1976, Clin Plast Surg, V3, P647; CONWAY H, 1958, Plast Reconstr Surg Transplant Bull, V22, P450, DOI 10.1097/00006534-195811000-00003; Croen L A, 1991, Paediatr Perinat Epidemiol, V5, P423, DOI 10.1111/j.1365-3016.1991.tb00728.x; CZEIZEL AE, 1993, BRIT MED J, V306, P1645, DOI 10.1136/bmj.306.6893.1645; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; DANSKY LV, 1987, ANN NEUROL, V21, P176, DOI 10.1002/ana.410210210; DOUGLAS B, 1958, Plast Reconstr Surg Transplant Bull, V22, P94, DOI 10.1097/00006534-195808000-00002; HILL L, 1988, J EPIDEMIOL COMMUN H, V42, P1, DOI 10.1136/jech.42.1.1; JORDAN RL, 1977, TERATOLOGY, V15, P73, DOI 10.1002/tera.1420150110; KHOURY MJ, 1989, AM J DIS CHILD, V143, P333, DOI 10.1001/archpedi.1989.02150150091023; LAURENCE KM, 1981, BRIT MED J, V282, P1509, DOI 10.1136/bmj.282.6275.1509; MILUNSKY A, 1989, JAMA-J AM MED ASSOC, V262, P2847, DOI 10.1001/jama.262.20.2847; MULINARE J, 1988, JAMA-J AM MED ASSOC, V260, P3141, DOI 10.1001/jama.260.21.3141; NELSON MM, 1960, CIBA F S CONGENITAL, P134; PEER LA, 1964, PLAST RECONSTR SURG, V34, P358; PEER LA, 1958, PLAST RECONSTR SURG, V22, P422; SAXEN I, 1975, INT J EPIDEMIOL, V4, P37, DOI 10.1093/ije/4.1.37; SHAW GM, 1995, EPIDEMIOLOGY, V6, P219, DOI 10.1097/00001648-199505000-00005; SMITHELLS RW, 1983, LANCET, V1, P1027; TOLAROVA M, 1982, LANCET, V2, P217; TOLAROVA M, 1987, SCAND J PLAST RECONS, V21, P19, DOI 10.3109/02844318709083574; WAITZMAN NJ, 1994, INQUIRY-J HEALTH CAR, V31, P188; WEGNER C, 1992, NEUROLOGY, V42, P17; WERLER MM, 1993, JAMA-J AM MED ASSOC, V269, P1257, DOI 10.1001/jama.269.10.1257; WITTER FR, 1982, AM J OBSTET GYNECOL, V144, P857, DOI 10.1016/0002-9378(82)90369-6; 1991, STATISTICS EPIIDEMIO; 1991, LANCET, V338, P131; 1989, HLTH HABITS HIST QUE	30	373	387	0	14	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 12	1995	346	8972					393	396		10.1016/S0140-6736(95)92778-6	http://dx.doi.org/10.1016/S0140-6736(95)92778-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN656	7623568				2022-12-24	WOS:A1995RN65600007
J	BAI, YW; SOSNICK, TR; MAYNE, L; ENGLANDER, SW				BAI, YW; SOSNICK, TR; MAYNE, L; ENGLANDER, SW			PROTEIN-FOLDING INTERMEDIATES - NATIVE-STATE HYDROGEN-EXCHANGE	SCIENCE			English	Article							CYTOCHROME-C; GUANIDINIUM CHLORIDE; FERROCYTOCHROME-C; FREE-ENERGY; HEMOGLOBIN; RESOLUTION; FRAGMENT; COMPLEX; MODEL; CORE	The hydrogen exchange behavior of native cytochrome c in low concentrations of denaturant reveals a sequence of metastable, partially unfolded forms that occupy free energy levels reaching up to the fully unfolded state. The step from one form to another is accomplished by the unfolding of one or more cooperative units of structure. The cooperative units are entire omega loops or mutually stabilizing pairs of whole helices and loops. The partially unfolded forms detected by hydrogen exchange appear to represent the major intermediates in the reversible, dynamic unfolding reactions that occur even at native conditions and thus may define the major pathway for cytochrome c folding.	UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,JOHNSON RES FDN,PHILADELPHIA,PA 19104	University of Pennsylvania			Freed, Karl F/J-7764-2018	Freed, Karl F/0000-0001-6240-2599	NIGMS NIH HHS [R01 GM031847, GM31847] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031847] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAI Y, 1994, THESIS U PENNSYLVANI; BAI YW, 1993, PROTEINS, V17, P75, DOI 10.1002/prot.340170110; BAI YW, 1994, PROTEINS, V20, P4, DOI 10.1002/prot.340200103; BREMS DN, 1983, J BIOL CHEM, V258, P3655; BRYNGELSON JD, 1995, PROTEINS, V21, P167, DOI 10.1002/prot.340210302; BUSHNELL GW, 1990, J MOL BIOL, V214, P585, DOI 10.1016/0022-2836(90)90200-6; CONNELLY GP, 1993, PROTEINS, V17, P87, DOI 10.1002/prot.340170111; ELOVE GA, 1994, BIOCHEMISTRY-US, V33, P10271; ENGLANDER SW, 1992, SCIENCE, V256, P1684, DOI 10.1126/science.256.5064.1684; ENGLANDER SW, 1975, ANN NY ACAD SCI, V244, P10, DOI 10.1111/j.1749-6632.1975.tb41518.x; ENGLANDER SW, 1984, Q REV BIOPHYS, V15, P521; FERSHT AR, 1994, CURR OPIN STRUC BIOL, V4, P67, DOI 10.1016/S0959-440X(94)90061-2; FISHER A, 1992, ARCH BIOCHEM BIOPHYS, V296, P1, DOI 10.1016/0003-9861(92)90538-8; HVIDT AASE, 1966, ADVANCE PROTEIN CHEM, V21, P287, DOI 10.1016/S0065-3233(08)60129-1; JENG MF, 1992, J MOL BIOL, V221, P1045; KIM KS, 1993, BIOCHEMISTRY-US, V32, P9609, DOI 10.1021/bi00088a013; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KURODA Y, 1993, BIOCHEMISTRY-US, V32, P1219, DOI 10.1021/bi00056a004; LESZCZYNSKI JF, 1986, SCIENCE, V234, P849, DOI 10.1126/science.3775366; LEVINTHAL C, 1968, J CHIM PHYS PCB, V65, P44, DOI 10.1051/jcp/1968650044; LINDERSTROMLANG KU, 1955, CHEM SOC SPEC PUBL, V2, P1; MAKHATADZE GI, 1992, J MOL BIOL, V226, P491, DOI 10.1016/0022-2836(92)90963-K; MATTHEWS CR, 1993, ANNU REV BIOCHEM, V62, P653, DOI 10.1146/annurev.bi.62.070193.003253; MAYO SL, 1993, SCIENCE, V262, P873, DOI 10.1126/science.8235609; MOLDAY RS, 1972, BIOCHEMISTRY-US, V11, P150, DOI 10.1021/bi00752a003; NALL BT, 1986, BIOCHEMISTRY-US, V25, P2974, DOI 10.1021/bi00358a036; Pace C N, 1986, Methods Enzymol, V131, P266; PTITSYN OB, 1975, BIOPHYS CHEM, V3, P1, DOI 10.1016/0301-4622(75)80033-0; PTITSYN OB, 1994, PROTEIN ENG, V7, P593, DOI 10.1093/protein/7.5.593; QIAN H, 1994, BIOCHEMISTRY-US, V33, P8167, DOI 10.1021/bi00193a001; RIDGE JA, 1981, BIOCHEMISTRY-US, V20, P1662; RODER H, 1988, NATURE, V335, P700, DOI 10.1038/335700a0; ROSENBERG A, 1968, J BIOL CHEM, V243, P5193; SALI A, 1994, NATURE, V369, P248, DOI 10.1038/369248a0; Schechter E, 1967, BIOPOLYMERS, V5, P788; SCHELLMAN JA, 1987, BIOPOLYMERS, V26, P549, DOI 10.1002/bip.360260408; SOSNICK TR, 1994, NAT STRUCT BIOL, V1, P149, DOI 10.1038/nsb0394-149; TAKANO T, 1981, J MOL BIOL, V153, P79, DOI 10.1016/0022-2836(81)90528-3; WAND AJ, 1989, BIOCHEMISTRY-US, V28, P186, DOI 10.1021/bi00427a026; WOLYNES PG, 1995, SCIENCE, V267, P1619, DOI 10.1126/science.7886447; WOODWARD C, 1993, TRENDS BIOCHEM SCI, V18, P359, DOI 10.1016/0968-0004(93)90086-3; WU LC, 1993, BIOCHEMISTRY-US, V32, P10271, DOI 10.1021/bi00089a050	43	1000	1009	4	85	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 14	1995	269	5221					192	197		10.1126/science.7618079	http://dx.doi.org/10.1126/science.7618079			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ029	7618079	Green Accepted			2022-12-24	WOS:A1995RJ02900030
J	HUNINK, MGM; WONG, JB; DONALDSON, MC; MEYEROVITZ, MF; DEVRIES, J; HARRINGTON, DP				HUNINK, MGM; WONG, JB; DONALDSON, MC; MEYEROVITZ, MF; DEVRIES, J; HARRINGTON, DP			REVASCULARIZATION FOR FEMOROPOPLITEAL DISEASE - A DECISION AND COST-EFFECTIVENESS ANALYSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRANS-LUMINAL ANGIOPLASTY; PERIPHERAL VASCULAR-DISEASE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; LOWER-EXTREMITY ISCHEMIA; LOWER-LIMB ISCHEMIA; SAPHENOUS-VEIN; POLYTETRAFLUOROETHYLENE GRAFTS; BALLOON ANGIOPLASTY; INTERMITTENT CLAUDICATION; ARTERIAL RECONSTRUCTIONS	Objective.-To evaluate the relative benefits and cost-effectiveness of revascularization for femoropopliteal disease using percutaneous transluminal angioplasty or bypass surgery. Design.-Decision analysis using a multistate transition simulation model (Markov process) and cost-effectiveness analysis from the perspective of the health care system. Setting.-Based on mortality, morbidity, patency, and cost data from a literature review. Patients.-Hypothetical cohort of patients with chronic femoropopliteal disease who desire revascularization. Subgroup analysis for patients defined by age, sex, indication, lesion type, and graft type. Interventions.-Percutaneous transluminal angioplasty, bypass surgery, and a strategies combining the two treatments. Main Outcome Measures.-Five-year patency results, quality-adjusted life expectancy, lifetime costs, and incremental cost-effectiveness ratios. Results.-For 65-year-old men with disabling claudication and a femoropoptiteal stenosis or occlusion and for 65-year-old men with chronic critical ischemia and a femoropopliteal stenosis, initial angioplasty increased quality-adjusted life expectancy by 2 to 13 months and resulted in decreased lifetime expenditures compared with bypass surgery. For patients with chronic critical ischemia and a femoropopliteal occlusion, initial bypass surgery increased quality-adjusted life expectancy by 1 to 4 months and resulted in decreased lifetime expenditures compared with angioplasty. Sensitivity analysis demonstrated that angioplasty would always be the preferred initial treatment if the angioplasty 5-year patency rate exceeds 30%. Conclusion.-Angioplasty is the preferred initial treatment in patients with disabling claudication and a femoropopliteal stenosis or occlusion and in those with chronic critical ischemia and a stenosis. Bypass surgery is the preferred initial treatment in patients with chronic critical ischemia and a femoropopliteal occlusion.	UNIV GRONINGEN HOSP, OFF MED TECHNOL ASSESSMENT, GRONINGEN, NETHERLANDS; HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, BOSTON, MA 02115 USA; TUFTS UNIV, NEW ENGLAND MED CTR,SCH MED,DEPT MED, DIV CLIN DECIS MAKING, BOSTON, MA 02111 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DIV VASC SURG, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DEPT RADIOL, BOSTON, MA 02115 USA; SUNY STONY BROOK, DEPT RADIOL, STONY BROOK, NY 11794 USA	University of Groningen; Harvard University; Harvard T.H. Chan School of Public Health; Tufts Medical Center; Tufts University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	HUNINK, MGM (corresponding author), UNIV GRONINGEN, FAC MED, DEPT HLTH SCI, ANT DEUSINGLAAN 1, 9713 AV GRONINGEN, NETHERLANDS.			Wong, John/0000-0003-4203-9010	AHRQ HHS [HS-06503, HS-06665] Funding Source: Medline; NLM NIH HHS [LM04493] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS006665] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [R01LM004493] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BECKER GJ, 1989, RADIOLOGY, V170, P921, DOI 10.1148/radiology.170.3.2521745; BELLI AM, 1990, CLIN RADIOL, V41, P380, DOI 10.1016/S0009-9260(05)80595-1; BERGAMINI TM, 1991, J VASC SURG, V13, P137, DOI 10.1016/0741-5214(91)90021-L; CALLOW AD, 1988, INT SURG, V73, P237; CAPEK P, 1991, CIRCULATION, V83, P70; CHESHIRE NJW, 1992, J VASC SURG, V15, P167, DOI 10.1016/0741-5214(92)70025-G; COFFMAN JD, 1991, NEW ENGL J MED, V325, P577, DOI 10.1056/NEJM199108223250810; CRIQUI MH, 1992, NEW ENGL J MED, V326, P381, DOI 10.1056/NEJM199202063260605; Donaldson M C, 1991, Adv Surg, V24, P69; DONALDSON MC, 1991, ANN SURG, V213, P457, DOI 10.1097/00000658-199105000-00011; DOUBILET P, 1984, NEW ENGL J MED, V310, P95, DOI 10.1056/NEJM198401123100206; DRUMMOND MF, 1987, METHODS EX EVALUATIO; Fowkes F G, 1988, Eur J Vasc Surg, V2, P283, DOI 10.1016/S0950-821X(88)80002-1; GILLUM RF, 1990, AM HEART J, V120, P1414, DOI 10.1016/0002-8703(90)90257-X; GOLDMAN L, 1992, CIRCULATION, V85, P1960, DOI 10.1161/01.CIR.85.5.1960; Gupta S K, 1988, Eur J Vasc Surg, V2, P151, DOI 10.1016/S0950-821X(88)80067-7; GUPTA SK, 1990, J VASC SURG, V11, P348, DOI 10.1067/mva.1990.16967; GUPTA SK, 1991, J VASC SURG, V13, P162; HASSON JE, 1990, SURGERY, V108, P748; HENRIKSEN LO, 1988, ACTA CHIR SCAND, V154, P573; HOBSON RW, 1985, J VASC SURG, V2, P174, DOI 10.1067/mva.1985.avs0020174; Holm J, 1991, Eur J Vasc Surg, V5, P517, DOI 10.1016/S0950-821X(05)80338-X; HOWELL MA, 1989, J VASC SURG, V9, P691, DOI 10.1067/mva.1989.vs0090691; HUNINK MGM, 1994, J VASC SURG, V19, P632, DOI 10.1016/S0741-5214(94)70036-2; HUNINK MGM, 1994, MED DECIS MAKING, V14, P71, DOI 10.1177/0272989X9401400109; HUNINK MGM, 1994, MED DECIS MAKING, V14, P59, DOI 10.1177/0272989X9401400108; HUNINK MGM, 1993, J VASC SURG, V17, P183; JEANS WD, 1990, RADIOLOGY, V177, P559, DOI 10.1148/radiology.177.2.2145608; JOHNSTON KW, 1987, ANN SURG, V206, P403, DOI 10.1097/00000658-198710000-00002; JOHNSTON KW, 1992, RADIOLOGY, V183, P767, DOI 10.1148/radiology.183.3.1294068; JONES BA, 1985, CAN J SURG, V28, P150; JORGENSEN B, 1988, ACTA CHIR SCAND, V154, P647; KENT KC, 1988, ARCH SURG-CHICAGO, V123, P1196; KINNISON ML, 1985, AM J ROENTGENOL, V145, P1241, DOI 10.2214/ajr.145.6.1241; KRAM HB, 1991, J VASC SURG, V14, P386, DOI 10.1016/0741-5214(91)90092-9; LEATHER RP, 1988, ANN SURG, V208, P435, DOI 10.1097/00000658-198810000-00005; MACKEY WC, 1986, SURGERY, V99, P26; MARTIN EC, 1991, CIRCULATION, V83, P1; McDaniel M D, 1989, Ann Vasc Surg, V3, P273, DOI 10.1016/S0890-5096(07)60040-5; MILFORD MA, 1988, J VASC SURG, V8, P292, DOI 10.1067/mva.1988.avs0080292; MILLER N, 1991, J VASC SURG, V13, P705, DOI 10.1016/0741-5214(91)90357-Z; MORSE MH, 1991, BRIT J RADIOL, V64, P5, DOI 10.1259/0007-1285-64-757-5; PENTECOST MJ, 1994, CIRCULATION, V89, P511, DOI 10.1161/01.CIR.89.1.511; PLECHA FR, 1985, J VASC SURG, V2, P769, DOI 10.1067/mva.1985.avs0020769; QUINONESBALDRICH WJ, 1988, J VASC SURG, V8, P219, DOI 10.1067/mva.1988.avs0080219; RAVIOLA CA, 1988, ARCH SURG-CHICAGO, V123, P495; RUTHERFORD RB, 1991, RADIOLOGY, V181, P277, DOI 10.1148/radiology.181.1.1887047; RUTHERFORD RB, 1986, J VASC SURG, V4, P80; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P170; TAYLOR LM, 1990, J VASC SURG, V11, P193, DOI 10.1067/mva.1990.17235; TUNIS SR, 1991, NEW ENGL J MED, V325, P556, DOI 10.1056/NEJM199108223250806; VEITH FJ, 1986, J VASC SURG, V3, P104; WALDEN R, 1986, J VASC SURG, V3, P583, DOI 10.1067/mva.1986.avs0030583; WEIBULL H, 1987, J VASC SURG, V5, P681, DOI 10.1067/mva.1987.avs0050681; Weinstein MC, 1980, CLIN DECISION ANAL; WEISS GN, 1990, J AM GERIATR SOC, V38, P877, DOI 10.1111/j.1532-5415.1990.tb05703.x; WHITTEMORE AD, 1989, J VASC SURG, V10, P299, DOI 10.1067/mva.1989.14116; WITTELS EH, 1990, AM J CARDIOL, V65, P432, DOI 10.1016/0002-9149(90)90806-C; Wolf G L, 1993, J Vasc Interv Radiol, V4, P639, DOI 10.1016/S1051-0443(93)71939-9; WOLF GL, 1984, SEMIN INTERVENT RAD, V1, P237; WONG JB, 1990, ANN INTERN MED, V113, P852, DOI 10.7326/0003-4819-113-11-852; 1991, VITAL STATISTICS U A, V2; 1992, VITAL HLTH STAT 13, V113	65	190	200	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 12	1995	274	2					165	171		10.1001/jama.274.2.165	http://dx.doi.org/10.1001/jama.274.2.165			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH222	7596006				2022-12-24	WOS:A1995RH22200031
J	SHALABY, F; ROSSANT, J; YAMAGUCHI, TP; GERTSENSTEIN, M; WU, XF; BREITMAN, ML; SCHUH, AC				SHALABY, F; ROSSANT, J; YAMAGUCHI, TP; GERTSENSTEIN, M; WU, XF; BREITMAN, ML; SCHUH, AC			FAILURE OF BLOOD-ISLAND FORMATION AND VASCULOGENESIS IN FLK-1-DEFICIENT MICE	NATURE			English	Article							ENDOTHELIAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; STEM-CELLS; MOUSE; PRECURSORS; EXPRESSION; GENE; DIFFERENTIATION; COMMITMENT; PROTEIN	THE receptor tyrosine kinase Flk-1 (ref. 1) is believed to play a pivotal role in endothelial development. Expression of the Flk-1 receptor is restricted to endothelial cells and their embryonic precursors(2-5), and is complementary to that of its ligand, vascular endothelial growth factor (VEGF)(2,3), which, is aa endothelial-specific mitogen. Highest levels of flk-1 expression are observed during embryonic vasculogenesis and angiogenesis(2-5), and dating pathological processes associated with neovascularization, such its tumour angiogenesis(7,8). Because flk-1 expression can be detected in presumptive mesodermal yolk-sac blood-island progenitors as early as 7.0 days postcoitum, Flk-1 may mark the putative common embryonic endothelial and haematopoietic precursor, the haemangioblast, and thus may also be involved in early haematopoiesis(4). Here rye report the generation of mice deficient in Flk-1 by disruption of the gene using homologous recombination in embryonic stem (ES) cells. Embryos homozygous for this mutation die in utero between 8.5 and 9.5 days post-coitum, as a result of an early defect in the development of haematopoietic and endothelial cells. Yolk-sac blood islands were absent at 7.5 days, organized blood vessels could not be observed in the embryo or yolk sac at any stage, acid haematopoietic progenitors were severely reduced. These results indicate that Flk-1 is essential for yolk-sac Mood-island formation and vasculogenesis in the mouse embryo.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,TORONTO,ON M5G 1X5,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,DEPT MED,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,INST MED SCI,TORONTO,ON M5S 1A8,CANADA; TORONTO HOSP,DIV HAEMATOL ONCOL,TORONTO,ON M5G 2C4,CANADA; CANADIAN RED CROSS SOC,TORONTO BLOOD CTR,TORONTO,ON M5G 2M1,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto								BROTHERTON TW, 1979, P NATL ACAD SCI USA, V76, P2853, DOI 10.1073/pnas.76.6.2853; DORHONEN J, 1994, ONCOGENE, V9, P395; DUMONT DJ, 1992, ONCOGENE, V7, P1471; DUMONT DJ, 1995, DEV DYNAM, V203, P80, DOI 10.1002/aja.1002030109; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; GODIN IE, 1993, NATURE, V364, P67, DOI 10.1038/364067a0; IWAMA A, 1993, BIOCHEM BIOPH RES CO, V195, P301, DOI 10.1006/bbrc.1993.2045; KAIPAINEN A, IN PRESS P NATN ACAD; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; MATHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026; MCCLANAHAN T, 1993, BLOOD, V81, P2903; MEDVINSKY AL, 1993, NATURE, V364, P64, DOI 10.1038/364064a0; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MILLAUER B, 1993, CELL, V72, P1; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NODEN DM, 1989, AM REV RESPIR DIS, V140, P1097, DOI 10.1164/ajrccm/140.4.1097; OELRICHS RB, 1993, ONCOGENE, V8, P11; PLATE KH, 1993, CANCER RES, V53, P5822; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Sambrook J., 1989, MOL CLONING LAB MANU; SHIBUYA M, 1990, ONCOGENE, V5, P519; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WAGNER RC, 1980, ADV MICROCIRCULAT, V9, P45; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; WONG PMC, 1986, P NATL ACAD SCI USA, V83, P3851, DOI 10.1073/pnas.83.11.3851; Wurst W., 1993, Gene targeting: a practical approach., P33; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489; YOUNG PE, 1995, BLOOD, V85, P96, DOI 10.1182/blood.V85.1.96.bloodjournal85196; ZIPORI D, 1988, BLOOD, V71, P586	31	3103	3258	3	101	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 6	1995	376	6535					62	66		10.1038/376062a0	http://dx.doi.org/10.1038/376062a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH111	7596435				2022-12-24	WOS:A1995RH11100062
J	HILL, CS; WYNNE, J; TREISMAN, R				HILL, CS; WYNNE, J; TREISMAN, R			THE RHO-FAMILY GTPASES RHOA, RAC1, AND CDC42HS REGULATE TRANSCRIPTIONAL ACTIVATION BY SRF	CELL			English	Article							SERUM RESPONSE ELEMENT; C-FOS; PHOSPHATIDYLINOSITOL 3-KINASE; BINDING-SITE; YEAST; ACTIN; GTP; IDENTIFICATION; EXPRESSION; PROMOTER	The c-fos serum response element (SRE) forms a ternary complex with the transcription factors SRF (serum response factor) and TCF (ternary complex factor). By itself, SRF can mediate transcriptional activation induced by serum, lysophosphatidic acid, or intracellular activation of heterotrimeric G proteins. Activated forms of the Rho family GTPases RhoA, Rad, and CDC42Hs also activate transcription via SRF and act synergistically at the SRE with signals that activate TCF. Functional Rho is required for signaling to SRF by several stimuli, but not by activated CDC42Hs or Rac1. Activation of the SRF-linked signaling pathway does not correlate with activation of the MAP kinases ERK, SAPK/JNK, or MPK2/p38. Functional Rho is required for regulated activity of the c-fos promoter. These results establish SRF as a nuclear target of a novel Rho-mediated signaling pathway.	IMPERIAL CANC RES FUND,TRANSCRIPT LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK				Treisman, Richard/0000-0002-9658-0067; Hill, Caroline/0000-0002-8632-0480				AMMERER G, 1990, GENE DEV, V4, P299, DOI 10.1101/gad.4.2.299; BANNISTER AJ, 1993, NUCLEIC ACIDS RES, V21, P1289, DOI 10.1093/nar/21.5.1289; BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014-5793(85)80004-1; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BRUHN L, 1994, MOL CELL BIOL, V14, P2534, DOI 10.1128/MCB.14.4.2534; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; COOPER JA, 1994, CURR BIOL, V4, P1118, DOI 10.1016/S0960-9822(00)00251-7; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HILL CS, 1994, EMBO J, V13, P5421, DOI 10.1002/j.1460-2075.1994.tb06877.x; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; JALINK K, 1994, BBA-REV CANCER, V1198, P185, DOI 10.1016/0304-419X(94)90013-2; JOHANSEN FE, 1993, MOL CELL BIOL, V13, P4640, DOI 10.1128/MCB.13.8.4640; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MOHUN T, 1987, EMBO J, V6, P667, DOI 10.1002/j.1460-2075.1987.tb04806.x; MOOLENAAR WH, 1995, CURR OPIN CELL BIOL, V7, P203, DOI 10.1016/0955-0674(95)80029-8; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SCHULTZ J, 1995, CURR OPIN GENET DEV, V5, P31, DOI 10.1016/S0959-437X(95)90050-0; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; TAN S, 1990, CELL, V62, P367, DOI 10.1016/0092-8674(90)90373-M; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; Treisman R, 1990, Semin Cancer Biol, V1, P47; TREISMAN R, 1983, P NATL ACAD SCI-BIOL, V80, P7428, DOI 10.1073/pnas.80.24.7428; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; YUAN YLO, 1993, GENE DEV, V7, P1584, DOI 10.1101/gad.7.8.1584; ZAMBETTI G, 1991, EXP CELL RES, V192, P93, DOI 10.1016/0014-4827(91)90162-N	49	1191	1210	0	28	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 30	1995	81	7					1159	1170		10.1016/S0092-8674(05)80020-0	http://dx.doi.org/10.1016/S0092-8674(05)80020-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RG910	7600583	Bronze			2022-12-24	WOS:A1995RG91000020
J	OGG, SC; WALTER, P				OGG, SC; WALTER, P			SRP SAMPLES NASCENT CHAINS FOR THE PRESENCE OF SIGNAL SEQUENCES BY INTERACTING WITH RIBOSOMES AT A DISCRETE STEP DURING TRANSLATION ELONGATION	CELL			English	Article							PREPRO-ALPHA-FACTOR; RECOGNITION PARTICLE; SACCHAROMYCES-CEREVISIAE; PROTEIN TRANSLOCATION; ESCHERICHIA-COLI; ENDOPLASMIC-RETICULUM; CELL-GROWTH; YEAST; GENE; RNA	The signal recognition particle (SRP) binds to ribosomes that synthesize nascent chains bearing signal sequences and catalyzes their targeting to the endoplasmic reticulum membrane. In S. cerevisiae, a temperature-sensitive mutation in the SEC65 gene, encoding an SRP subunit, results in lowered levels of SRP. Growth and protein translocation defects induced by this mutation can be suppressed specifically by sublethal doses of cycloheximide but not anisomycin, each inhibitors of different steps of translation elongation. Cycloheximide also suppresses protein translocation defects caused by depletion of a different SRP subunit. We propose that reduced elongation rates in the presence of cycloheximide allow otherwise insufficient SRP to interact efficiently with ribosomes. These results are consistent with a sampling model in which SRP cycles on and off of translating ribosomes at specific steps during the elongation cycle to inspect ah nascent chains for the presence of signal sequences.			OGG, SC (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.			Ogg, Stephen/0000-0003-4157-1654				ARNOLD CE, 1994, J BIOL CHEM, V269, P30412; BROWN JD, 1994, EMBO J, V13, P4390, DOI 10.1002/j.1460-2075.1994.tb06759.x; BROWN S, 1989, J MOL BIOL, V209, P79, DOI 10.1016/0022-2836(89)90171-X; BROWN S, 1984, J MOL BIOL, V178, P533, DOI 10.1016/0022-2836(84)90237-7; BROWN S, 1987, CELL, V49, P825, DOI 10.1016/0092-8674(87)90620-9; CONNOLLY T, 1991, SCIENCE, V252, P1171, DOI 10.1126/science.252.5009.1171; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; FELICI F, 1989, MOL CELL BIOL, V9, P3260, DOI 10.1128/MCB.9.8.3260; Gale E.F., 1981, MOL BASIS ANTIBIOTIC, Vsecond; HANN BC, 1992, NATURE, V356, P532, DOI 10.1038/356532a0; HANN BC, 1989, J CELL BIOL, V109, P3223, DOI 10.1083/jcb.109.6.3223; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HANSEN W, 1986, CELL, V45, P397, DOI 10.1016/0092-8674(86)90325-9; JENSEN CG, 1994, J BACTERIOL, V176, P7148, DOI 10.1128/JB.176.23.7148-7154.1994; MILLER JD, 1993, NATURE, V366, P351, DOI 10.1038/366351a0; MOAZED D, 1989, NATURE, V342, P142, DOI 10.1038/342142a0; OGG SC, 1992, MOL BIOL CELL, V3, P895, DOI 10.1091/mbc.3.8.895; ORRWEAVER TL, 1988, MOL CELL BIOL, V8, P5292, DOI 10.1128/MCB.8.12.5292; PHILLIPS GJ, 1992, NATURE, V359, P744, DOI 10.1038/359744a0; ROTHBLATT JA, 1986, EMBO J, V5, P1031; SIEGEL V, 1988, EMBO J, V7, P1769, DOI 10.1002/j.1460-2075.1988.tb03007.x; SIKORSKI RS, 1989, GENETICS, V122, P19; STIRLING CJ, 1992, NATURE, V356, P534, DOI 10.1038/356534a0; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; STOCKLEIN W, 1980, CURR GENET, V1, P177, DOI 10.1007/BF00390941; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WATERS MG, 1986, J CELL BIOL, V102, P1543, DOI 10.1083/jcb.102.5.1543; WOLIN SL, 1989, J CELL BIOL, V109, P2617, DOI 10.1083/jcb.109.6.2617; WOLIN SL, 1994, CELL, V77, P787, DOI 10.1016/0092-8674(94)90124-4	30	87	88	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 30	1995	81	7					1075	1084		10.1016/S0092-8674(05)80012-1	http://dx.doi.org/10.1016/S0092-8674(05)80012-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RG910	7600575	Bronze			2022-12-24	WOS:A1995RG91000012
J	BENNICKE, K; CONRAD, C; SABROE, S; SORENSEN, HT				BENNICKE, K; CONRAD, C; SABROE, S; SORENSEN, HT			CIGARETTE-SMOKING AND BREAST-CANCER	BRITISH MEDICAL JOURNAL			English	Article								Objective-To investigate cigarette smoking in relation to the risk of breast cancer. Design-interviews with women referred for mammography. Setting-Hjorring District Hospital, a public, population based hospital in Denmark. Subjects-3240 women aged 15-99 years referred for mammography during 1 June 1989 to 1 November 1991. Main outcome measures-Smoking, parity, age, reason for referral, breast cancer. Results-In a multiple logistic regression analysis adjusted for six variables a pronounced increased risk of breast cancer was found in women who had smoked for over 20 years, and this was significant in women who had smoked for over 30 years (odds ratio 1.6, 95% confidence interval 1.1 to 2.3). The median age of women with breast cancer was 59 (range 31-81) years for smokers and 67 (38-92) years for nonsmokers. The difference of eight years between the median ages was significant (P<0.01). Conclusion-Smoking may increase the risk of breast cancer after 30 years of smoking.	HJORRING DIST HOSP,DEPT RADIOL,DK-9800 HJORRING,DENMARK; AARHUS UNIV,DEPT EPIDEMIOL & SOCIAL MED,DK-8000 AARHUS C,DENMARK; AARHUS UNIV,STENO INST PUBL HLTH,DANISH EPIDEMIOL SCI CTR,AARHUS,DENMARK	Aarhus University; Aarhus University			Sorensen, Henrik Toft/Z-6181-2019	Sorensen, Henrik Toft/0000-0003-4299-7040				BARON JA, 1990, AM J OBSTET GYNECOL, V162, P502, DOI 10.1016/0002-9378(90)90420-C; HIATT RA, 1986, JNCI-J NATL CANCER I, V76, P833; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; HUNTER DJ, 1993, EPIDEMIOL REV, V15, P110, DOI 10.1093/oxfordjournals.epirev.a036096; KRALL EA, 1989, AM J PUBLIC HEALTH, V79, P200, DOI 10.2105/AJPH.79.2.200; MACMAHON B, 1982, NEW ENGL J MED, V307, P1062, DOI 10.1056/NEJM198210213071707; MALONE KE, 1993, EPIDEMIOL REV, V15, P80, DOI 10.1093/oxfordjournals.epirev.a036119; Osler M, 1992, DANSKERNES RYGEVANER; PALMER JR, 1993, EPIDEMIOL REV, V5, P145; PETRAKIS NL, 1980, CANCER RES, V40, P188; ROTH HD, 1994, J CLIN EPIDEMIOL, V47, P207, DOI 10.1016/0895-4356(94)90026-4; VOGT TM, 1977, AM J PUBLIC HEALTH, V67, P545, DOI 10.2105/AJPH.67.6.545	12	40	40	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 3	1995	310	6992					1431	1433		10.1136/bmj.310.6992.1431	http://dx.doi.org/10.1136/bmj.310.6992.1431			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC105	7613275	Green Published			2022-12-24	WOS:A1995RC10500015
J	BERGLUND, J; EITREM, R; ORNSTEIN, K; LINDBERG, A; RINGNER, A; ELMRUD, H; CARLSSON, M; RUNEHAGEN, A; SVANBORG, C; NORRBY, R				BERGLUND, J; EITREM, R; ORNSTEIN, K; LINDBERG, A; RINGNER, A; ELMRUD, H; CARLSSON, M; RUNEHAGEN, A; SVANBORG, C; NORRBY, R			AN EPIDEMIOLOGIC-STUDY OF LYME-DISEASE IN SOUTHERN SWEDEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LATE CUTANEOUS MANIFESTATIONS; TICK-BORNE ENCEPHALITIS; CENTRAL-NERVOUS-SYSTEM; BORRELIA-BURGDORFERI; FORESTRY WORKERS; PREVALENCE; SERODIAGNOSIS; ANTIBODIES; POPULATION; ARTHRITIS	Background. Lyme disease is the most common vector-borne infection in some temperate regions of the Northern Hemisphere, However, for most areas of endemic disease reliable epidemiologic data are sparse. Methods. Over a one-year period, we conducted a prospective, population-based survey of cases of Lyme disease in southern Sweden. The diagnosis was made on the basis of the presence of erythema migrans at least 5 cm in diameter or characteristic clinical manifestations such as arthritis, neuroborreliosis, and carditis. Results. We identified 1471 patients with Lyme disease, for an overall annual incidence of 69 cases per 100,000 inhabitants. The incidence varied markedly according to geographic region, and there were several areas where disease was widely prevalent. The incidence varied according to age, with the highest rates among people 5 to 9 and 60 to 74 years of age, but not according to sex. The most frequent clinical manifestation was erythema migrans (seen in 77 percent of all cases), followed by neuroborreliosis (16 percent) and arthritis (7 percent). Carditis was rare. A preceding tick bite was reported by 79 percent of the patients. Bites in the head and neck region were more common among children than among adults and were associated with an increased risk of neuroborreliosis. Conclusions. Lyme disease is very common in southern Sweden, with a relatively high frequency of neurologic complications and arthritis. With the exception of the low incidence of carditis, the pattern of disease we found in Sweden was similar to that reported in the United States.	LUND UNIV, DEPT COMMUNITY HLTH SCI, LUND, SWEDEN; LUND UNIV, DEPT INFECT DIS, LUND, SWEDEN; LUND UNIV, DEPT MED MICROBIOL, LUND, SWEDEN; DEPT INFECT DIS CONTROL BLEKINGE CTY, KARLSKRONA, SWEDEN; DEPT INFECT DIS CONTROL HALLAND CTY, HALMSTAD, SWEDEN; DEPT INFECT DIS CONTROL KALMAR CTY, KALMAR, SWEDEN; DEPT INFECT DIS CONTROL KRISTIANSTAD CTY, KRISTIANSTAD, SWEDEN; DEPT INFECT DIS CONTROL JONKOPING CTY, JONKOPING, SWEDEN; DEPT INFECT DIS CONTROL KRONOBERG CTY, VAXJO, SWEDEN	Lund University; Lund University; Lund University			Sanmartin Berglund, Johan/HGB-0471-2022					AESCHLIMANN A, 1986, Zentralblatt fuer Bakteriologie Mikrobiologie und Hygiene Series A, V263, P450; AGUEROROSENFELD ME, 1993, J CLIN MICROBIOL, V31, P3090, DOI 10.1128/JCM.31.12.3090-3095.1993; AGUEROROSENFELD ME, 1994, J CLIN MICROBIOL, V32, P860; ANANJEVA LP, 1995, ARTHRITIS RHHEUM, V22, P689; ASBRINK E, 1988, ANN NY ACAD SCI, V539, P4, DOI 10.1111/j.1749-6632.1988.tb31833.x; ASBRINK E, 1984, ACTA DERM-VENEREOL, V64, P506; BERGLUND J, 1993, SCAND J INFECT DIS, V25, P67, DOI 10.3109/00365549309169672; BERGLUND J, 1995, J RHEUMATOL, V22, P695; BLAAUW I, 1991, J RHEUMATOL, V18, P1819; CANICA MM, 1993, SCAND J INFECT DIS, V25, P441, DOI 10.3109/00365549309008525; CHRISTEN HJ, 1993, ACTA PAEDIATR, V82, P1, DOI 10.1111/j.1651-2227.1993.tb18082.x; DEKONENKO EJ, 1988, J INFECT DIS, V158, P748, DOI 10.1093/infdis/158.4.748; DENNIS DT, 1993, LYME DISEASE, V27, P37; DRESSLER F, 1994, CLIN EXP RHEUMATOL, V12, pS49; DRESSLER F, 1993, J INFECT DIS, V167, P392, DOI 10.1093/infdis/167.2.392; FAHRER H, 1991, J INFECT DIS, V163, P305, DOI 10.1093/infdis/163.2.305; GARCIAMONCO JC, 1990, J INFECT DIS, V161, P1187, DOI 10.1093/infdis/161.6.1187; GUSTAFSON R, 1993, SCAND J INFECT DIS, V25, P605, DOI 10.3109/00365549309008549; Gustafson R, 1994, Scand J Infect Dis Suppl, V92, P1; HAMMERSBERGGREN S, 1993, STROKE, V24, P1393, DOI 10.1161/01.STR.24.9.1393; HANRAHAN JP, 1984, J INFECT DIS, V150, P489, DOI 10.1093/infdis/150.4.489; HANSEN K, 1988, J CLIN MICROBIOL, V26, P338, DOI 10.1128/JCM.26.2.338-346.1988; HORST H, 1990, NIEDERSACHSISCH ARZT, V63, P32; KRYGER P, 1990, SCAND J RHEUMATOL, V19, P77, DOI 10.3109/03009749009092625; KUIPER H, 1993, EUR J CLIN MICROBIOL, V12, P413, DOI 10.1007/BF01967434; LEY C, 1994, WESTERN J MED, V160, P534; Linde M. R. van der, 1993, Aspects of Lyme borreliosis., P131; LUFT BJ, 1992, JAMA-J AM MED ASSOC, V267, P1364, DOI 10.1001/jama.267.10.1364; LUFT BJ, 1992, JAMA-J AM MED ASSOC, V268, P873, DOI 10.1001/jama.1992.03490070050034; MITCHELL PD, 1994, J CLIN MICROBIOL, V32, P1958, DOI 10.1128/JCM.32.8.1958-1962.1994; MITCHELL PD, 1994, J CLIN MICROBIOL, V32, P2343; NADAL D, 1989, EUR J CLIN MICROBIOL, V8, P992, DOI 10.1007/BF01967572; SCHMID GP, 1985, REV INFECT DIS, V7, P41; SCHMUTZHARD E, 1988, INFECTION, V16, P269, DOI 10.1007/BF01645068; SCHWARTZ BS, 1994, AM J EPIDEMIOL, V139, P504, DOI 10.1093/oxfordjournals.aje.a117033; STANEK G, 1988, ANN NY ACAD SCI, V539, P274, DOI 10.1111/j.1749-6632.1988.tb31861.x; STEERE AC, 1980, ANN INTERN MED, V93, P8, DOI 10.7326/0003-4819-93-1-8; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1986, J INFECT DIS, V154, P295, DOI 10.1093/infdis/154.2.295; WILSKE B, 1988, ANN NY ACAD SCI, V539, P126, DOI 10.1111/j.1749-6632.1988.tb31846.x; 1990, MMWR-MORBID MORTAL W, V39, P19; 1995, MMWR MORTAL WKLY REP, V44, P459; 1994, MMWR MORTAL WKLY REP, V43, P564	43	294	302	1	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 16	1995	333	20					1319	1324		10.1056/NEJM199511163332004	http://dx.doi.org/10.1056/NEJM199511163332004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE365	7566023				2022-12-24	WOS:A1995TE36500004
J	BERN, C; PHILEN, RM; FREDMAN, D; BOWMAN, BA; NEWMAN, NJ; GERR, F; RIDEL, GM; PENA, EZ; MALILAY, J; MILLER, DT; SOWELL, AL; MILLER, MA; FLANDERS, WD; FALTER, KH; OLSON, DR; KILBOURNE, EM; SINKS, T; ING, R; STAEHLING, N; BOYD, M; GUNTER, EW; PASCHAL, DC; MUELLER, PW; SPIERTO, FW; NEEDHAM, LL; HILL, RH; ASHLEY, DL; HANNON, WH; MARQUEZ, AR; FERNANDEZ, JRD; HADAD, JH; MILORD, DR; CRISTIA, RP; PEREZ, MAH; VERDURA, CS; ALBA, MAM; HODELIN, MT; GORBEA, MB; DIAZ, ED; HIORTLORENZEN, CLC; CLUA, AM; GUTIERREZ, PM; ACOSTA, SJ; CABRERA, A; FERNANDEZ, MM; FREIXAS, RS; ESTRADA, R; ARIAS, L; MESTRE, PF; PLA, E; ROMERO, MC; FERRET, AC; LLANOS, G; JIMENEZ, JS; ROMAN, GC; OBERMEYER, W; CASTRO, MD; RUIZ, CAP; RICO, NS; BETANCOURT, IP; FUENTES, BEE; CABRERA, AP; CALDELLICEHIO, LET; MEDINA, AG; GOMEZ, N; MOJARRIETA, MS; VARA, JAC; PORTALES, JMR; HERNANDEZ, GR; GINALY, SM; GARCIA, PP; GARCIA, M; HERNANDEZ, CS; DIAZ, EI; RECIO, EM; GARCIA, SH; SANCHEZ, AL; VALDES, P; RODRIGUEZ, OM; OLIVA, NB; DIAZ, D; PEREZ, MC; HERNANDEZ, MCR; GONEZ, JMR; AMADO, SN; DELLLANO, AC; BREIJO, DH; ACOSTA, AC; GONZALEZ, MM; ROMERO, RM; CHAVEZ, OC; VALDES, MH; OTERO, GR; CABALLERO, MM; VALDES, AG; OLIVERA, BR; BENITEZ, EE; BEADE, C; LEON, LS; MARIMON, FD; ROMAN, AS; RODRIGUEZ, R; RODRIGUEZ, FD; ALVAREZ, MR; COLUMBE, MS; MARRERO, A; ZULUETA, D; GARCIA, CR; SANTOS, JPA; PEDROSO, F; RODRIGUEZ, HM; VALDES, NM; ACOSTA, MS; CHOBEL, ER; GODOY, MM; LUGO, MM; LOPEZ, LL; DIAZ, EM; MARTINEZ, JCB; DELGADO, NA; VALDES, MT; MORENO, ARD; SANCHEZ, SH; HERNANDEZ, LEP; VALDES, OM; MARTINEZ, AO; DOMINGUEZ, I; DEARMAS, MR; IGLESIAS, OR; CASTELL, OR; TRUJILLO, OG; BEUNE, MDM; RODRIGUEZ, FM; MEDINA, RM; RUIZCALDERON, JC; FERNANDEZ, B; BARROSO, EV; MACHIN, JL; ARMENTEROS, LR; MENDEZ, CV; PEREZ, JH; CAMPOS, AC; DIAZ, NA; PEREZ, AO; MILIAN, J; LEON, OH; CAPOTE, BR; LEZCANOS, MR; EZMORIZ, LP; MOYA, O; VITRIAGO, A; MURGUIA, AU				BERN, C; PHILEN, RM; FREDMAN, D; BOWMAN, BA; NEWMAN, NJ; GERR, F; RIDEL, GM; PENA, EZ; MALILAY, J; MILLER, DT; SOWELL, AL; MILLER, MA; FLANDERS, WD; FALTER, KH; OLSON, DR; KILBOURNE, EM; SINKS, T; ING, R; STAEHLING, N; BOYD, M; GUNTER, EW; PASCHAL, DC; MUELLER, PW; SPIERTO, FW; NEEDHAM, LL; HILL, RH; ASHLEY, DL; HANNON, WH; MARQUEZ, AR; FERNANDEZ, JRD; HADAD, JH; MILORD, DR; CRISTIA, RP; PEREZ, MAH; VERDURA, CS; ALBA, MAM; HODELIN, MT; GORBEA, MB; DIAZ, ED; HIORTLORENZEN, CLC; CLUA, AM; GUTIERREZ, PM; ACOSTA, SJ; CABRERA, A; FERNANDEZ, MM; FREIXAS, RS; ESTRADA, R; ARIAS, L; MESTRE, PF; PLA, E; ROMERO, MC; FERRET, AC; LLANOS, G; JIMENEZ, JS; ROMAN, GC; OBERMEYER, W; CASTRO, MD; RUIZ, CAP; RICO, NS; BETANCOURT, IP; FUENTES, BEE; CABRERA, AP; CALDELLICEHIO, LET; MEDINA, AG; GOMEZ, N; MOJARRIETA, MS; VARA, JAC; PORTALES, JMR; HERNANDEZ, GR; GINALY, SM; GARCIA, PP; GARCIA, M; HERNANDEZ, CS; DIAZ, EI; RECIO, EM; GARCIA, SH; SANCHEZ, AL; VALDES, P; RODRIGUEZ, OM; OLIVA, NB; DIAZ, D; PEREZ, MC; HERNANDEZ, MCR; GONEZ, JMR; AMADO, SN; DELLLANO, AC; BREIJO, DH; ACOSTA, AC; GONZALEZ, MM; ROMERO, RM; CHAVEZ, OC; VALDES, MH; OTERO, GR; CABALLERO, MM; VALDES, AG; OLIVERA, BR; BENITEZ, EE; BEADE, C; LEON, LS; MARIMON, FD; ROMAN, AS; RODRIGUEZ, R; RODRIGUEZ, FD; ALVAREZ, MR; COLUMBE, MS; MARRERO, A; ZULUETA, D; GARCIA, CR; SANTOS, JPA; PEDROSO, F; RODRIGUEZ, HM; VALDES, NM; ACOSTA, MS; CHOBEL, ER; GODOY, MM; LUGO, MM; LOPEZ, LL; DIAZ, EM; MARTINEZ, JCB; DELGADO, NA; VALDES, MT; MORENO, ARD; SANCHEZ, SH; HERNANDEZ, LEP; VALDES, OM; MARTINEZ, AO; DOMINGUEZ, I; DEARMAS, MR; IGLESIAS, OR; CASTELL, OR; TRUJILLO, OG; BEUNE, MDM; RODRIGUEZ, FM; MEDINA, RM; RUIZCALDERON, JC; FERNANDEZ, B; BARROSO, EV; MACHIN, JL; ARMENTEROS, LR; MENDEZ, CV; PEREZ, JH; CAMPOS, AC; DIAZ, NA; PEREZ, AO; MILIAN, J; LEON, OH; CAPOTE, BR; LEZCANOS, MR; EZMORIZ, LP; MOYA, O; VITRIAGO, A; MURGUIA, AU			EPIDEMIC OPTIC NEUROPATHY IN CUBA - CLINICAL CHARACTERIZATION AND RISK-FACTORS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AMBLYOPIA	Background. From 1991 to 1993, epidemic optic and peripheral neuropathy affected more than 50,000 people in Cuba. The number of new cases decreased after the initiation of vitamin supplementation in the population. In September 1993, Cuban and U.S. investigators conducted a study to characterize and identify risk factors for the optic form of the syndrome. Methods. We conducted ophthalmologic and neurologic examinations, assessed exposure to potential toxins, administered a semiquantitative food-frequency questionnaire, and assessed serum measures of nutritional status in 123 patients with severe optic neuropathy, matched for sex and age to randomly chosen normal subjects. Results. In the case patients, prominent clinical features were subacute loss of visual acuity with field defects, diminished color vision, optic-nerve pallor, and decreased sensitivity to vibration and temperature in the legs. Tobacco use, particularly cigar smoking, was associated with an increased risk of optic neuropathy. The risk was reduced among subjects with higher dietary intakes of methionine, vitamin B-12, riboflavin, and niacin and higher serum concentrations of antioxidant carotenoids, The risk was also reduced among subjects who raised chickens at home or had relatives living overseas - factors that may be indirect measures of increased food availability. Conclusions. The epidemic of optic and peripheral neuropathy in Cuba between 1991 and 1993 appears to be linked to reduced nutrient intake caused by the country's deteriorating economic situation and the high prevalence of tobacco use.	CTR DIS CONTROL & PREVENT, ATLANTA, GA 30341 USA; EMORY UNIV, ATLANTA, GA 30322 USA; MINIST PUBL HLTH CUBA, HAVANA, CUBA; PAN AMER HLTH ORG, WASHINGTON, DC USA; NIH, BETHESDA, MD 20892 USA; US FDA, ROCKVILLE, MD 20857 USA	Centers for Disease Control & Prevention - USA; Emory University; Pan American Health Organization; National Institutes of Health (NIH) - USA; US Food & Drug Administration (FDA)			Needham, Larry/E-4930-2011; Hernandez-Triana, Manuel T/B-4513-2015; Newman, Nancy/AAB-2532-2021	Hernandez-Triana, Manuel T/0000-0002-2752-2592; Santos Hernandez, Carmen/0000-0002-8433-554X				BOVE FJ, 1989, J OCCUP ENVIRON MED, V31, P320; Breslow NE, 1980, IARC SCI PUBL, V32, P248; BROWN CC, 1994, AM J EPIDEMIOL, V139, P323, DOI 10.1093/oxfordjournals.aje.a117000; Costagliola C, 1990, Metab Pediatr Syst Ophthalmol (1985), V13, P96; DANG CV, 1981, MED HYPOTHESES, V7, P1317, DOI 10.1016/0306-9877(81)90122-5; DI MASCIO P, 1989, ARCH BIOCHEM BIOPHYS, V274, P532, DOI 10.1016/0003-9861(89)90467-0; DIXON ZR, 1994, FREE RADICAL BIO MED, V17, P537, DOI 10.1016/0891-5849(94)90093-0; Gay John, 1994, Boletin de la Oficina Sanitaria Panamericana, V117, P389; GERR F, 1990, ARCH ENVIRON HEALTH, V45, P148, DOI 10.1080/00039896.1990.9936708; Hernandez Teresa, 1995, Natural Toxins, V3, P114, DOI 10.1002/nt.2620030210; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; KNOX DL, 1982, RETINA-J RET VIT DIS, V2, P288, DOI 10.1097/00006982-198202040-00014; LANNAN S, 1994, AM J PHYSIOL, V266, pL92, DOI 10.1152/ajplung.1994.266.1.L92; LESSELL S, 1971, ARCH OPHTHALMOL-CHIC, V86, P194; LETZ R, 1994, NEUROTOXICOLOGY, V15, P603; LINCOFF NS, 1994, JAMA-J AM MED ASSOC, V271, P664; LINCOFF NS, 1993, JAMA-J AM MED ASSOC, V270, P511, DOI 10.1001/jama.270.4.511; MADAN D, 1898, CRONICA MED QUIRURGI, V24, P81; MATHIOWETZ V, 1985, ARCH PHYS MED REHAB, V66, P69; MCCORMICK DB, 1994, MODERN NUTR HLTH DIS, P366; MILLER NR, 1982, WALSH HOYTS CLIN NEU, P289; NEWMAN NJ, 1993, ARCH NEUROL-CHICAGO, V50, P540, DOI 10.1001/archneur.1993.00540050082021; NEWMAN NJ, 1994, AM J OPHTHALMOL, V118, P158, DOI 10.1016/S0002-9394(14)72895-8; PASCHAL DC, 1986, ATOM SPECTROSC, V7, P75; Pennington JA, 1994, BOWES CHURCHS FOOD V; RIZZO JF, 1993, AM J OPHTHALMOL, V116, P84, DOI 10.1016/S0002-9394(14)71749-0; RODRIGUEZ A, 1992, NUTRISIS VERSIION 4; Schaumburg H. H., 1992, DISORDERS PERIPHERAL; SOWELL AL, 1994, CLIN CHEM, V40, P411; SPILLANE JD, 1947, NUTRITIONAL DISORDER; TOPPING MD, 1986, CLIN CHEM, V32, P1863; TORRONI A, 1995, HUM MUTAT, V5, P310, DOI 10.1002/humu.1380050407; WALL M, 1986, ARCH OPHTHALMOL-CHIC, V104, P520, DOI 10.1001/archopht.1986.01050160076015; WILLETT W, 1990, MONOGRAPHS EPIDEMIOL, V15, P245; 1984, B WORLD HEALTH ORGAN, V62, P477; 1993, EPIDEMIC NEUROPATHY; 1994, MMWR-MORBID MORTAL W, V43, P183; 1986, AGR HDB SERIES DEP A, V8	38	113	116	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 2	1995	333	18					1176	1182						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB560	7565972				2022-12-24	WOS:A1995TB56000003
J	SANDLER, RS; NYREN, O; EKBOM, A; EISEN, GM; YUEN, J; JOSEFSSON, S				SANDLER, RS; NYREN, O; EKBOM, A; EISEN, GM; YUEN, J; JOSEFSSON, S			THE RISK OF ESOPHAGEAL CANCER IN PATIENTS WITH ACHALASIA - A POPULATION-BASED STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARCINOMA	Objective.-To determine more precise and accurate cancer risk estimates for achalasia that could be used to plan surveillance. Design.-Cohort. Setting.-Swedish population. Participants.--All patients with achalasia listed in the population-based Swedish Inpatient Register from 1964 through 1989. Main Outcome Measures.-The observed number of cancers in the cohort was compared with expected numbers of cancers (standardized incidence ratio [SIR]) for each 5-year age group and calendar year of observation, calculated using data from the Swedish Cancer Registry. Results.-A total of 1062 patients with achalasia accumulated 9864 years of follow-up. The mean age at entry was 57.2 years, and the mean age at cancer diagnosis was 71.0 years. Esophageal cancer occurred in 24 patients, The risk of esophageal cancer in the first year after achalasia diagnosis was extremely high (SIR, 126.3; 95% confidence interval [CI], 63.0 to 226.1) as a consequence of prevalent cancers leading to distal esophageal obstruction simulating achalasia. During years 1 to 24, the risk was increased more than 16-fold (SIR, 16.6; 95% CI, 8.8 to 28.3). Annual surveillance after the first year would require 406 endoscopic examinations in men and 2220 in women to detect one cancer. Conclusions.-Patients with achalasia are at markedly increased risk of developing esophageal cancer. A substantial number of surveillance examinations might be required to screen for cancers, especially in women. It is not known whether surveillance will result in improved survival.	UNIV N CAROLINA,CTR GASTROINTESTINAL BIOL & DIS,CHAPEL HILL,NC 27599; UPPSALA UNIV,DEPT EPIDEMIOL,UPPSALA,SWEDEN; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115	University of North Carolina; University of North Carolina Chapel Hill; Uppsala University; Harvard University; Harvard T.H. Chan School of Public Health	SANDLER, RS (corresponding author), UNIV N CAROLINA,DEPT MED,DIV DIGEST DIS & NUTR,CB 7080,423A BURNETT WOMACK BLDG,CHAPEL HILL,NC 27599, USA.		Yuen, Jonathan/AAI-2035-2021	Yuen, Jonathan/0000-0003-2944-9226	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP085636] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007634, P30DK034987] Funding Source: NIH RePORTER; NCI NIH HHS [CP85636] Funding Source: Medline; NIDDK NIH HHS [T32 DK 07634, P30 DK34987] Funding Source: Medline	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGGESTRUP S, 1992, CHEST, V102, P1013, DOI 10.1378/chest.102.4.1013; Bolivar J C, 1970, Ann Thorac Surg, V10, P81; CAMARALOPES LH, 1981, AM J DIG DIS, V6, P742; CARTER R, 1975, AM J SURG, V130, P114, DOI 10.1016/0002-9610(75)90358-X; CHUONG JJH, 1984, DIGEST DIS SCI, V29, P1105, DOI 10.1007/BF01317084; CODINI RT, 1981, PRACTICAL GASTRO NOV, P6; DENT TL, 1989, SURG CLIN N AM, V69, P1205; FAGGE CH, 1872, GUYS HOSP REP, V17, P43; FRANK MS, 1979, AM J GASTROENTEROL, V71, P206; HANKINS JR, 1975, J THORAC CARDIOV SUR, V69, P355; HEISS FW, 1984, DIGEST DIS SCI, V29, P1066, DOI 10.1007/BF01311263; JUSTVIERA JO, 1976, SURG GYNECOL OBSTET, V128, P1081; LORTATJA.JL, 1969, SURGERY, V66, P969; LUNDE AS, 1985, DHHS PHS801358 PUBL; MEIJSSEN MAC, 1992, GUT, V33, P155, DOI 10.1136/gut.33.2.155; NAESSEN T, 1989, AM J EPIDEMIOL, V130, P289, DOI 10.1093/oxfordjournals.aje.a115335; PERACCHIA A, 1991, HEPATO-GASTROENTEROL, V38, P514; PIERCE WS, 1970, J THORAC CARDIOV SUR, V59, P335, DOI 10.1016/S0022-5223(19)42467-7; SELIGER G, 1972, AM J GASTROENTEROL, V57, P20; SONNENBERG A, 1993, DIGEST DIS SCI, V38, P233, DOI 10.1007/BF01307540; TUCKER HJ, 1978, ANN INTERN MED, V89, P315, DOI 10.7326/0003-4819-89-3-315; WYCHULIS AR, 1971, J AMER MED ASSOC, V215, P1638, DOI 10.1001/jama.215.10.1638; 1965, CAUSES DEATH SWEDEN; 1988, GASTROINTEST ENDOS S, V34, pS18; 1960, 1960 1988 SWED BOARD; 1991, PATIENT REGISTER INP, P20	26	114	119	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 1	1995	274	17					1359	1362		10.1001/jama.274.17.1359	http://dx.doi.org/10.1001/jama.274.17.1359			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB278	7563560				2022-12-24	WOS:A1995TB27800026
J	ASSCHER, AW; PARR, GD; WHITMARSH, VB				ASSCHER, AW; PARR, GD; WHITMARSH, VB			TOWARDS THE SAFER USE OF MEDICINES	BRITISH MEDICAL JOURNAL			English	Article							ADVERSE DRUG-REACTIONS; GENERAL-PRACTICE; DISEASE; RISKS	In Britain the tools are now available to provide better information on safety of medicines in both hospital and community settings, and this could be done at relatively modest cost. The needs of patients, doctors, and pharmacists are changing; although more research is needed, such information as is presently available must be both better and more widely publicised and understood. Universities, government, the pharmaceutical industry, and educated journalism all have an important part to play in this process.	MED BENEFIT RISK FDN,PHARMACOEPIDEMIOL GRP,LONDON W1M 8AE,ENGLAND									ABRAMSON NS, 1980, JAMA-J AM MED ASSOC, V244, P1582, DOI 10.1001/jama.244.14.1582; BRADLEY CP, 1992, BRIT MED J, V304, P294, DOI 10.1136/bmj.304.6822.294; BROWN PJ, PERCEPTION MANAGEMEN, P149; BURKHOLDER DF, 1979, DRUG INTEL CLIN PHAR, V13, P421, DOI 10.1177/106002807901300708; CARTWRIGHT A, 1988, OLDER PEOPLE THEIR M; CONI N, 1988, LECTURE NOTES GERIAT; DEVRIES TPGM, 1993, BRIT J CLIN PHARMACO, V35, P591; DODDSSMITH I, 1995, 2ND P S, P1; DRURY VVM, 1986, DOCTOR MONITORING DR, P651; EVANS JG, 1993, HLTH FUNCTION 3RD AG; FERNER RE, 1992, BRIT J CLIN PHARMACO, V33, P125, DOI 10.1111/j.1365-2125.1992.tb04013.x; FERNER RE, 1994, J ROY SOC MED, V87, P145; GEORGE CF, 1983, BRIT MED J, V287, P1193, DOI 10.1136/bmj.287.6400.1193; GIBBS S, 1987, Pharmaceutical Medicine (London), V2, P23; HAYES A, 1990, PHARM J, V245, pR36; HURWITZ N, 1969, BMJ-BRIT MED J, V1, P531, DOI 10.1136/bmj.1.5643.531; JICK H, 1974, NEW ENGL J MED, V291, P824, DOI 10.1056/NEJM197410172911605; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; JICK H, 1984, J ALLERGY CLIN IMMUN, V74, P555, DOI 10.1016/0091-6749(84)90106-4; Jick H., 1992, PHARMACOEPIDEM DR S, V1, P347, DOI DOI 10.1002/PDS.2630010607; Keeney R.L., 1976, DECISIONS MULTIPLE O, P96; KNIGHT R, 1987, J ROY COLL GEN PRACT, V37, P19; LAWSON DH, 1978, SCOTTISH MED J, V24, P127; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; LIVINGSTONE C, 1993, PHARM J S, V251, pR6; MACDONALD TM, 1994, PHARMACOEPIDEM DR S, P245; MARTYS CR, 1979, BMJ-BRIT MED J, V2, P1194, DOI 10.1136/bmj.2.6199.1194; MILLER RR, 1974, ARCH INTERN MED, V43, P219; MULROY R, 1973, BRIT MED J, V2, P407, DOI 10.1136/bmj.2.5863.407; OBRIEN BJ, 1990, J EPIDEMIOL COMMUN H, V44, P249, DOI 10.1136/jech.44.3.249; OBRIEN BJ, 1990, J RHEUMATOL, V17, P503; OGILVIE RI, 1967, CAN MED ASSOC J, V97, P1450; PECKHAM M, 1991, LANCET, V338, P367, DOI 10.1016/0140-6736(91)90494-A; RAWLINS MD, 1988, BRIT J CLIN PHARMACO, V26, P1; RAWLINS MD, 1988, BRIT J CLIN PHARMACO, V26, P7, DOI 10.1111/j.1365-2125.1988.tb03357.x; RAWLINS MD, 1989, RISK AND CONSENT TO RISK IN MEDICINE, P193; RAWLINS MD, 1991, BRIT MED J, V302, P322; RIDOUT S, 1986, BRIT J CLIN PHARMACO, V21, P701, DOI 10.1111/j.1365-2125.1986.tb05236.x; ROBERTS K, 1986, BR J PHARM PRACT, V8, P387; SLOVIC P, 1981, P ROY SOC LOND A MAT, V376, P17, DOI 10.1098/rspa.1981.0073; Slovic P, 1989, PERCEPTION MANAGEMEN; VINCENT C, 1993, MED ACCIDENTS; WILKIE A, 1994, J ROY SOC MED, V87, P594; 1995, WAY HLTH         JUN, P80; 1982, RISK ANAL PERCEPTION; 1994, OBSERVER        0529, P26; 1991, CONSUMER EXPECTATION; 1992, PHARM CARE FUTURE CO; 1993, CHEAPER THAN PRESCRI	49	24	25	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 14	1995	311	7011					1003	1006						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA079	7580589				2022-12-24	WOS:A1995TA07900031
J	AUPHAN, N; DIDONATO, JA; ROSETTE, C; HELMBERG, A; KARIN, M				AUPHAN, N; DIDONATO, JA; ROSETTE, C; HELMBERG, A; KARIN, M			IMMUNOSUPPRESSION BY GLUCOCORTICOIDS - INHIBITION OF NF-KAPPA-B ACTIVITY THROUGH INDUCTION OF I-KAPPA-B SYNTHESIS	SCIENCE			English	Article							TRANSCRIPTION FACTOR; NEGATIVE REGULATION; GENE-EXPRESSION; LYMPHOCYTES-T; DNA-BINDING; ACTIVATION; CELLS; ALPHA; PROTEINS; HORMONES	Glucocorticoids are among the most potent anti-inflammatory and immunosuppressive agents. They inhibit synthesis of almost all known cytokines and of several cell surface molecules required for immune function, but the mechanism underlying this activity has been unclear. Here it is shown that glucocorticoids are potent inhibitors of nuclear factor kappa B (NF-kappa B) activation in mice and cultured cells, This inhibition is mediated by induction of the I kappa B alpha inhibitory protein, which traps activated NF-kappa B in inactive cytoplasmic complexes. Because NF-kappa B activates many immunoregulatory genes in response to pro-inflammatory stimuli, the inhibition of its activity can be a major component of the anti-inflammatory activity of glucocorticoids.	UNIV CALIF SAN DIEGO,SCH MED,CTR GENET MOLEC,DEPT PHARMACOL,PROGRAM BIOMED SCI,LA JOLLA,CA 92093	University of California System; University of California San Diego			AUPHAN-ANEZIN, Nathalie/E-7790-2018; Hazen, Stanley L/ABD-5845-2021	AUPHAN-ANEZIN, Nathalie/0000-0002-1967-5206; 				AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; ALLERGE ML, 1991, J IMMUNOL, V146, P1184; ARYA SK, 1984, J IMMUNOL, V133, P273; AUPHAN N, UNPUB; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; COCKERILL PN, 1993, P NATL ACAD SCI USA, V90, P2466, DOI 10.1073/pnas.90.6.2466; COHEN JJ, 1989, ANTIINFLAMMATORY STE, P111; COLLART MA, 1987, J IMMUNOL, V139, P949; CRESSMAN DE, 1993, ONCOGENE, V8, P2567; CULPEPPER JA, 1985, J IMMUNOL, V135, P3191; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; DIDONATO JA, UNPUB; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOEBERITZ MV, 1990, EUR J IMMUNOL, V20, P35, DOI 10.1002/eji.1830200106; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GAUGLER B, 1991, EUR J IMMUNOL, V21, P2581, DOI 10.1002/eji.1830211040; GODOWSKI PJ, 1989, UCLA S MOL CELLULAR, V95; GONZALO JA, 1993, J EXP MED, V177, P1239, DOI 10.1084/jem.177.5.1239; GRILLI M, 1993, INT REV CYTOL, V143, P1; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KNUDSEN PJ, 1987, J IMMUNOL, V139, P4129; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; NORTHROP JP, 1992, J EXP MED, V175, P1235, DOI 10.1084/jem.175.5.1235; Parillo J E, 1979, ANN REV PHARMACOL TO, V19, P179; PARK JH, 1993, J BIOL CHEM, V268, P6299; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; ROSETTE C, UNPUB; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SERFLING E, 1989, EMBO J, V8, P465, DOI 10.1002/j.1460-2075.1989.tb03399.x; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; VACCA A, 1989, MOL ENDOCRINOL, V3, P1659, DOI 10.1210/mend-3-10-1659; WANG Y, 1993, J STEROID BIOCHEM, V44, P203, DOI 10.1016/0960-0760(93)90080-G; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x; ZANKER B, 1990, TRANSPLANTATION, V49, P183, DOI 10.1097/00007890-199001000-00040	57	2009	2092	1	76	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 13	1995	270	5234					286	290		10.1126/science.270.5234.286	http://dx.doi.org/10.1126/science.270.5234.286			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ342	7569976				2022-12-24	WOS:A1995RZ34200035
J	ALLAART, CF; ROSENDAAL, FR; NOTEBOOM, WMP; VANDENBROUCKE, JP; BRIET, E				ALLAART, CF; ROSENDAAL, FR; NOTEBOOM, WMP; VANDENBROUCKE, JP; BRIET, E			SURVIVAL IN FAMILIES WITH HEREDITARY PROTEIN-C DEFICIENCY, 1820 TO 1993	BRITISH MEDICAL JOURNAL			English	Article							THROMBOTIC DISEASE; VENOUS THROMBOSIS; FACTOR-V; INACTIVATION; MORTALITY; NEWBORN	Objectives-To establish the survival of individuals heterozygous for hereditary protein C deficiency, who have an increased risk of venous thrombotic events, and to compare it with the survival of the general population. Design-Retrospective study in pedigrees of 23 families with hereditary protein C deficiency for period 1820 and 1993. Setting-23 completed family trees of 24 probands from various parts of the Netherlands with symptoms of protein C deficiency. Subjects-All 736 members of the 23 families with a 50% or 100%, probability of being (or having been) heterozygous for the genetic defect on the basis of DNA analysis or their place in the pedigrees, following mendelian rules. Main outcome measures-Observed mortality compared with the mortality of the general Dutch population; the standardised mortality ratio was calculated by dividing the observed mortality by the expected mortality. Results-No excess mortality was found in the 206 proved heterozygous individuals and ''obligatory transmitters'' (those who have definitely passed on the deficiency) (standardised mortality ratio 0.95 (95% confidence interval 0.5 to 1.2)) or in the 530 family members with a 50%, genetic probability of heterozygosity (1.10 (0.9 to 1.3)). Conclusion-Heterozygous individuals with hereditary protein C deficiency type I have normal survival compared with the general population. Prophylactic anticoagulant treatment may prevent thrombotic events in heterozygous individuals but may not be expected to improve their survival.	UNIV LEIDEN HOSP,DEPT CLIN EPIDEMIOL,LEIDEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC)	ALLAART, CF (corresponding author), UNIV LEIDEN HOSP,HAEMOSTASIS & THROMBOSIS RES CTR,DEPT HAEMATOL,BLDG 1,C2-R,POB 9600,2300 RC LEIDEN,NETHERLANDS.		Vandenbroucke, Jan/AAM-3928-2020	Vandenbroucke, Jan/0000-0001-5668-6716				ALLAART CF, 1993, LANCET, V341, P134, DOI 10.1016/0140-6736(93)90003-Y; BERTINA RM, 1982, THROMB HAEMOSTASIS, V48, P1; BRANSON HE, 1983, LANCET, V2, P1165; BROEKMANS AW, 1983, NEW ENGL J MED, V309, P340, DOI 10.1056/NEJM198308113090604; FULCHER CA, 1984, BLOOD, V63, P486; GRIFFIN JH, 1981, J CLIN INVEST, V68, P1370, DOI 10.1172/JCI110385; MARLAR RA, 1989, J PEDIATR-US, V114, P528, DOI 10.1016/S0022-3476(89)80688-2; ROSENDAAL FR, 1991, LANCET, V337, P260, DOI 10.1016/0140-6736(91)90867-O; SELIGSOHN U, 1984, NEW ENGL J MED, V310, P559, DOI 10.1056/NEJM198403013100904; SUZUKI K, 1983, J BIOL CHEM, V258, P1914; VANDENBROUCKE JP, 1982, AM J EPIDEMIOL, V115, P303, DOI 10.1093/oxfordjournals.aje.a113306; VANDERMEER FJM, 1993, ARCH INTERN MED, V153, P1157	12	19	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 7	1995	311	7010					910	913						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ237	7580547				2022-12-24	WOS:A1995RZ23700018
J	ASPINALL, RL; GOODMAN, NW				ASPINALL, RL; GOODMAN, NW			DENIAL OF EFFECTIVE TREATMENT AND POOR QUALITY OF CLINICAL INFORMATION IN PLACEBO-CONTROLLED TRIALS OF ONDANSETRON FOR POSTOPERATIVE NAUSEA AND VOMITING - A REVIEW OF PUBLISHED TRIALS	BRITISH MEDICAL JOURNAL			English	Article							DOUBLE-BLIND; INTRAVENOUS ONDANSETRON; PREVENTION; SURGERY; METOCLOPRAMIDE; ANESTHESIA; EFFICACY	Objective-To determine how many patients were deprived of treatment by being given placebo as comparator in trials of ondansetron for postoperative nausea and vomiting. Design-Review of published trials of ondansetron during 1991 to July 1994. Setting-Medline search in a university department of anaesthesia. Subjects-8806 patients who had been included in 18 indexed placebo controlled trials of ondansetron as prophylaxis against or treatment of postoperative nausea and vomiting. Results-Five studies (1236 patients) had been published by July 1992. All were placebo controlled trials. By July 1994, 8806 patients had been included in 18 indexed placebo controlled studies of prophylaxis or treatment. Only 462 patients had been in studies that compared ondansetron with other drugs, and there were no indexed comparative trials of treatment of nausea and vomiting. Roughly 2180 patients had been given placebo as prophylaxis and 440 had been given placebo when already experiencing postoperative nausea or vomiting. Conclusions-Around 2620 patients in the reviewed studies were denied existing drugs, which, though not completely effective or without side effects, do bring some relief from postoperative nausea and vomiting. Drug regulatory bodies should collaborate with drug companies to ensure better comparison of new with established drugs. This would avoid placebos being given to more than the fewest patients necessary to confirm effect and would allow doctors to be informed more quickly about relative efficacies.	SOUTHMEAD GEN HOSP,MED SCH UNIT,UNIV DEPT ANAESTHESIA,BRISTOL BS10 5NB,AVON,ENGLAND	Southmead Hospital								ALON E, 1992, ANESTH ANALG, V75, P561; ALTMAN DG, 1991, PRACTICAL STAT MED R, P450; [Anonymous], 1993, LANCET, V341, P1507; BERO LA, 1994, JAMA-J AM MED ASSOC, V271, P612, DOI 10.1001/jama.271.8.612; BERO LA, 1992, NEW ENGL J MED, V327, P1135, DOI 10.1056/NEJM199210153271606; BODNER M, 1991, ANESTH ANALG, V73, P250; Bohrer H, 1994, Anaesthesiol Reanim, V19, P11; BOULY A, 1992, ANN FR ANESTH, V11, P496, DOI 10.1016/S0750-7658(05)80754-3; CHALMERS J, 1993, DRUG COSTS TREATMENT, P14; CLAYBON L, 1994, ANAESTHESIA, V49, P24, DOI 10.1111/j.1365-2044.1994.tb03579.x; DERSHWITZ M, 1992, CLIN PHARMACOL THER, V52, P96, DOI 10.1038/clpt.1992.107; Du Pen S, 1992, Eur J Anaesthesiol Suppl, V6, P55; DUPEYRON JP, 1993, ANAESTHESIA, V48, P214, DOI 10.1111/j.1365-2044.1993.tb06904.x; GAN TJ, 1994, BRIT J ANAESTH, V72, P544, DOI 10.1093/bja/72.5.544; HELMERS JH, 1992, EUROPEAN J ANAEST S6, V9, P49; HELMERS JHJH, 1993, CAN J ANAESTH, V40, P1155; HERXHEIMER A, 1990, BRIT MED J, V300, P307, DOI 10.1136/bmj.300.6720.307; HERXHEIMER A, 1993, J MED ETHICS, V19, P211, DOI 10.1136/jme.19.4.211; HERXHEIMER A, 1993, J MED ETHICS, V19, P218; ISAL JP, 1992, EUR J ANAESTH     S6, V9, P33; JOSLYN AF, 1994, ANAESTHESIA, V49, P34, DOI 10.1111/j.1365-2044.1994.tb03581.x; KAUFMANN MA, 1994, ANESTH ANALG, V78, P988; KENNY GNC, 1992, BRIT J ANAESTH, V68, P466, DOI 10.1093/bja/68.5.466; Kovac A, 1992, Eur J Anaesthesiol Suppl, V6, P37; LARIJANI GE, 1991, ANESTH ANALG, V73, P246; LEESER J, 1991, ANESTH ANALG, V72, P751; LITMAN RS, 1994, ANESTH ANALG, V78, P478; MALINS AF, 1994, BRIT J ANAESTH, V72, P231, DOI 10.1093/bja/72.2.231; MCKENZIE R, 1993, J CLIN ANESTH, V5, P30, DOI 10.1016/0952-8180(93)90084-R; MCKENZIE R, 1993, ANESTHESIOLOGY, V78, P21, DOI 10.1097/00000542-199301000-00005; PEARMAN MH, 1994, ANAESTHESIA, V49, P11, DOI 10.1111/j.1365-2044.1994.tb03577.x; RAPHAEL JH, 1993, BRIT J ANAESTH, V71, P845, DOI 10.1093/bja/71.6.845; ROCHON PA, 1994, JAMA-J AM MED ASSOC, V272, P108, DOI 10.1001/jama.272.2.108; ROSEN M, 1994, ANAESTHESIA, V49, P1, DOI 10.1111/j.1365-2044.1994.tb03574.x; ROTHMAN KJ, 1994, NEW ENGL J MED, V331, P394, DOI 10.1056/NEJM199408113310611; RUSSELL D, 1992, BRIT J ANAESTH, V69, pS63, DOI 10.1093/bja/69.supplement_1.63S; RUST M, 1994, ANAESTHESIA, V49, P16, DOI 10.1111/j.1365-2044.1994.tb03578.x; SCUDERI P, 1993, ANESTHESIOLOGY, V78, P15, DOI 10.1097/00000542-199301000-00004; SUNG YF, 1993, J CLIN ANESTH, V5, P22, DOI 10.1016/0952-8180(93)90083-Q; 1994, 2ND DEP HLTH REP	40	66	67	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 30	1995	311	7009					844	846		10.1136/bmj.311.7009.844	http://dx.doi.org/10.1136/bmj.311.7009.844			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY191	7580491	Green Published			2022-12-24	WOS:A1995RY19100022
J	MUTHUPILLAI, R; LOMAS, DJ; ROSSMAN, PJ; GREENLEAF, JF; MANDUCA, A; EHMAN, RL				MUTHUPILLAI, R; LOMAS, DJ; ROSSMAN, PJ; GREENLEAF, JF; MANDUCA, A; EHMAN, RL			MAGNETIC-RESONANCE ELASTOGRAPHY BY DIRECT VISUALIZATION OF PROPAGATING ACOUSTIC STRAIN WAVES	SCIENCE			English	Article							BLOOD-FLOW; TISSUES	A nuclear magnetic resonance imaging (MRI) method is presented for quantitatively mapping the physical response of a material to harmonic mechanical excitation. The resulting images allow calculation of regional mechanical properties. Measurements of shear modulus obtained with the MRI technique in gel materials correlate with independent measurements of static shear modulus. The results indicate that displacement patterns corresponding to cyclic displacements smaller than 200 nanometers can be measured. The findings suggest the feasibility of a medical imaging technique for delineating elasticity and other mechanical properties of tissue.	MAYO CLIN & MAYO FDN, ROCHESTER, MN 55905 USA; ADDENBROOKES HOSP, DEPT RADIOL, CAMBRIDGE, ENGLAND	Mayo Clinic; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge			Muthupillai, Raja/D-6544-2017	Muthupillai, Raja/0000-0001-5041-2562; LOMAS, David/0000-0003-2904-8617	NCI NIH HHS [CA51124] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051124] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRYANT DJ, 1984, J COMPUT ASSIST TOMO, V8, P588, DOI 10.1097/00004728-198408000-00002; BURLEW MM, 1980, RADIOLOGY, V134, P517, DOI 10.1148/radiology.134.2.7352242; DUMOULIN CL, 1986, RADIOLOGY, V161, P717, DOI 10.1148/radiology.161.3.3786721; FUNG YC, 1981, BIOMECHANICS MECHANI, P35; HAHN EL, 1960, J GEOPHYS RES, V65, P776, DOI 10.1029/JZ065i002p00776; HUANG SR, 1990, THESIS U ROCHESTER R; KNUTSSON H, 1994, IEEE IMAGE PROC, P36, DOI 10.1109/ICIP.1994.413270; KOLSKY H, 1963, STRESS WAVES SOLIDS, P131; KUMAR A, 1975, J MAGN RESON, V18, P69, DOI 10.1016/0022-2364(75)90224-3; LEWA CJ, 1995, JMRI-J MAGN RESON IM, V5, P242, DOI 10.1002/jmri.1880050221; MADSEN EL, 1983, J ACOUST SOC AM, V74, P1346, DOI 10.1121/1.390158; MORAN P R, 1982, Magnetic Resonance Imaging, V1, P197; OPHIR J, 1991, ULTRASONIC IMAGING, V13, P111, DOI 10.1016/0161-7346(91)90079-W; PARKER KJ, 1990, ULTRASOUND MED BIOL, V16, P241, DOI 10.1016/0301-5629(90)90003-U; PELC LR, 1992, RADIOLOGY, V185, P809, DOI 10.1148/radiology.185.3.1438767; PELC NJ, 1991, JMRI-J MAGN RESON IM, V1, P405, DOI 10.1002/jmri.1880010404; PLEWES DB, 1994, P SOC MAGN RESON, V1, P410; VANDIJK P, 1984, J COMPUT ASSIST TOMO, V8, P429, DOI 10.1097/00004728-198406000-00012	18	1501	1555	1	129	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 29	1995	269	5232					1854	1857		10.1126/science.7569924	http://dx.doi.org/10.1126/science.7569924			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX194	7569924				2022-12-24	WOS:A1995RX19400032
J	TAUBES, G				TAUBES, G			CANCER BIOLOGY - ANOTHER BLOW WEAKENS EMF-CANCER LINK	SCIENCE			English	Editorial Material																			0	9	9	0	0	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 29	1995	269	5232					1816	1817		10.1126/science.269.5232.1816-a	http://dx.doi.org/10.1126/science.269.5232.1816-a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX194	7569913				2022-12-24	WOS:A1995RX19400020
J	LEVITAN, D; GREENWALD, I				LEVITAN, D; GREENWALD, I			FACILITATION OF LIN-12-MEDIATED SIGNALING BY SEL-12, A CAENORHABDITIS-ELEGANS S182 ALZHEIMERS-DISEASE GENE	NATURE			English	Article							SPECIFIES CELL FATES; C-ELEGANS; VULVAL INDUCTION; LIN-12; GLP-1; AUTONOMY; DECISION; PROTEIN; LET-60; LOCUS	THE lin-12 and glp-1 genes of Caenorhabditis elegans are members of the lin-12/Notch family of receptors for intercellular signals that specify cell fate(1,2). By screening for suppressors of a lin-12 gain-of-function mutation, we identified a new gene, sel-12, which appears to function in receiving cells to facilitate signalling mediated by lin-12 and glp-1. The sel-12 gene encodes a protein with multiple transmembrane domains, and is similar to S182, which has been implicated in early-onset familial Alzheimer's disease(3). The high degree of sequence conservation suggests that the function of the SEL-12 and S182 proteins may also be conserved.	COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032; PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544	Columbia University; Howard Hughes Medical Institute; Columbia University; Princeton University								ARTAVANISTSAKON.S, 1995, SCIENCE, V268, P225; AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BRENNER S, 1974, GENETICS, V77, P71; COULSON A, 1988, NATURE, V235, P184; FERGUSON EL, 1985, NATURE, V110, P259; GREENWALD I, 1990, NATURE, V346, P197, DOI 10.1038/346197a0; GREENWALD I, 1994, CURR OPIN GENET DEV, V4, P556, DOI 10.1016/0959-437X(94)90072-B; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; KHAN AS, 1992, NAT GENET, V2, P180, DOI 10.1038/ng1192-180; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LAMBIE EJ, 1991, DEVELOPMENT, V112, P231; LHERNAULT SW, 1992, J CELL BIOL, V119, P55, DOI 10.1083/jcb.119.1.55; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; OHARA O, 1989, P NATL ACAD SCI USA, V86, P5673, DOI 10.1073/pnas.86.15.5673; PRIESS JR, 1987, CELL, V51, P601, DOI 10.1016/0092-8674(87)90129-2; SEYDOUX G, 1989, CELL, V57, P1237, DOI 10.1016/0092-8674(89)90060-3; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SIMSKE JS, 1995, NATURE, V375, P142, DOI 10.1038/375142a0; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; STERNBERG PW, 1989, CELL, V58, P679, DOI 10.1016/0092-8674(89)90103-7; STERNBERG PW, 1988, NATURE, V335, P551, DOI 10.1038/335551a0; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; SUNDARAM M, 1993, GENETICS, V135, P755; TUCK S, 1995, GENE DEV, V9, P341, DOI 10.1101/gad.9.3.341	29	640	676	1	21	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 28	1995	377	6547					351	354		10.1038/377351a0	http://dx.doi.org/10.1038/377351a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX111	7566091				2022-12-24	WOS:A1995RX11100060
J	DWYER, JH				DWYER, JH			GENES, BLOOD-PRESSURE, AND AFRICAN HERITAGE	LANCET			English	Editorial Material							URBAN				DWYER, JH (corresponding author), UNIV SO CALIF,SCH MED,DEPT PREVENT MED,LOS ANGELES,CA 90033, USA.							COOPER R, 1994, J HYPERTENS, V12, P215; GILES WH, 1994, AM J MED SCI, V308, P271, DOI 10.1097/00000441-199411000-00003; MBUYAMBAKABANGU JR, 1986, AM J EPIDEMIOL, V124, P957, DOI 10.1093/oxfordjournals.aje.a114485; POULTER NR, 1990, BMJ-BRIT MED J, V300, P967, DOI 10.1136/bmj.300.6730.967; SEEDAT YK, 1982, J EPIDEMIOL COMMUN H, V36, P256, DOI 10.1136/jech.36.4.256; ZARATE AO, 1994, INT MORTALITY CHARTB	6	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 12	1995	346	8972					392	392		10.1016/S0140-6736(95)92777-8	http://dx.doi.org/10.1016/S0140-6736(95)92777-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN656	7623567				2022-12-24	WOS:A1995RN65600006
J	SALVARANI, C; GABRIEL, SE; OFALLON, WM; HUNDER, GG				SALVARANI, C; GABRIEL, SE; OFALLON, WM; HUNDER, GG			THE INCIDENCE OF GIANT-CELL ARTERITIS IN OLMSTED COUNTY, MINNESOTA - APPARENT FLUCTUATIONS IN A CYCLIC PATTERN	ANNALS OF INTERNAL MEDICINE			English	Note							POLYMYALGIA-RHEUMATICA; TEMPORAL ARTERITIS; INTERMEDIATE FILAMENTS; EPIDEMIOLOGY; ANTIBODIES; 10-YEAR; VIRUS	Objective: To investigate trends in the incidence of giant cell arteritis over Design: Population-based incidence study. Setting: Olmsted County, Minnesota. Methods: All incidence cases of giant cell arteritis first diagnosed between 1950 and 1991 were identified using the unified record system at Mayo Clinic. Age- and sex-specific incidence rates were calculated using the number of incidence cases as the numerator and population estimates as the denominator. Overall rates were age- and sex-adjusted to the 1980 United States. white population. The annual incidence rates were graphically illustrated using a 3-year centered moving average. Results: Between 1950 and 1998, 125 Olmsted County residents (103 women and 22 men) were diagnosed with giant cell arteritis. The age- and sex-adjusted incidence per 100 000 persons 50 years of age or older was 17.8 (95% CI, 14.1 to 21.0); incidence was significantly higher in women (24.2 [CI, 19.5 to 28.9]) than in men (8.2 [CI, 4.8 to 11.6]). Age-specific incidence rates increased with age (P < 0.0001). The annual incidence rates increased significantly over the study period (P = 0.002) and appear to have clustered in five peak periods, which occurred about every 7 years. A significant calendar-time effect was identified; it predicted an increase in incidence of 2.6% (CI, 0.9% to 4.3%) every 5 years. Conclusions: Our observation of a regular cyclic pattern in incidence rates over time supports the hypothesis of an infectious cause for giant cell arteritis. Similar studies in other populations are needed to confirm our findings.	MAYO CLIN & MAYO FDN, DEPT HLTH SCI RES, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DIV RHEUMATOL, ROCHESTER, MN 55905 USA	Mayo Clinic; Mayo Clinic			Salvarani, Carlo/K-2431-2018	Salvarani, Carlo/0000-0001-5426-5133	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 30582] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Anderson DW, 1991, NEUROEPIDEMIOLOGY TR, P239; BARRIER JH, 1988, J RHEUMATOL, V15, P383; BENGTSSON BA, 1982, ACTA MED SCAND, P1; BOESEN P, 1987, ARTHRITIS RHEUM, V30, P294, DOI 10.1002/art.1780300308; CHUANG TY, 1982, ANN INTERN MED, V97, P672, DOI 10.7326/0003-4819-97-5-672; CIMMINO MA, 1993, CLIN EXP RHEUMATOL, V11, P309; DASGUPTA B, 1987, ANN RHEUM DIS, V46, P746, DOI 10.1136/ard.46.10.746; ELLING H, 1980, ANN RHEUM DIS, V39, P511, DOI 10.1136/ard.39.5.511; FESSEL WJ, 1969, LANCET, V2, P1249; FRANZEN P, 1992, J RHEUMATOL, V19, P273; FRIEDMAN G, 1982, ISRAEL J MED SCI, V18, P241; GONZALEZGAY MA, 1992, J RHEUMATOL, V19, P277; HICKSTEIN DD, 1981, ARTHRITIS RHEUM, V24, P1448, DOI 10.1002/art.1780241122; HUNDER GG, 1990, ARTHRITIS RHEUM, V33, P1122; HUSTON KA, 1978, ANN INTERN MED, V88, P162, DOI 10.7326/0003-4819-88-2-162; KURLAND LT, 1981, SCI AM, V245, P54, DOI 10.1038/scientificamerican1081-54; MACHADO EBV, 1988, ARTHRITIS RHEUM, V31, P745, DOI 10.1002/art.1780310607; MATHEWSON JA, 1986, J RHEUMATOL, V13, P190; McCullagh P., 1989, GENERALIZED LINEAR M, DOI DOI 10.1007/978-1-4899-3242-6; NORDBORG E, 1990, J INTERN MED, V227, P233, DOI 10.1111/j.1365-2796.1990.tb00150.x; OBRIEN JP, 1992, ARTHRITIS RHEUM, V35, P794, DOI 10.1002/art.1780350713; SALVARANI C, 1991, ARTHRITIS RHEUM, V34, P351, DOI 10.1002/art.1780340313; SMITH CA, 1983, ARTHRITIS RHEUM, V26, P1214, DOI 10.1002/art.1780261007; TOH BH, 1979, CLIN EXP IMMUNOL, V37, P76	24	246	249	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1995	123	3					192	194		10.7326/0003-4819-123-3-199508010-00006	http://dx.doi.org/10.7326/0003-4819-123-3-199508010-00006			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL104	7598301				2022-12-24	WOS:A1995RL10400006
J	EKLAND, EH; SZOSTAK, JW; BARTEL, DP				EKLAND, EH; SZOSTAK, JW; BARTEL, DP			STRUCTURALLY COMPLEX AND HIGHLY-ACTIVE RNA LIGASES DERIVED FROM RANDOM RNA SEQUENCES	SCIENCE			English	Article							RIBOZYMES; SUBSTRATE	Seven families of RNA ligases, previously isolated from random RNA sequences, fall into three classes on the basis of secondary structure and regiospecificity of ligation. Two of the three classes of ribozymes have been engineered to act as true enzymes, catalyzing the multiple-turnover transformation of substrates into products. The most complex of these ribozymes has a minimal catalytic domain of 93 nucleotides. An optimized version of this ribozyme has a k(cat), exceeding one per second, a value far greater than that of most natural RNA catalysts and approaching that of comparable protein enzymes. The fact that such a large and complex ligase emerged from avery limited sampling of sequence space implies the existence of a large number of distinct RNA structures of equivalent complexity and activity.	MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital	EKLAND, EH (corresponding author), WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142, USA.							AXELROD VD, 1985, BIOCHEMISTRY-US, V24, P5716, DOI 10.1021/bi00342a005; BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155; BARTEL DP, UNPUB; CHAPMAN KB, 1995, CHEM BIOL, V2, P325, DOI 10.1016/1074-5521(95)90051-9; Ekland E. H., UNPUB; EKLAND EH, IN PRESS NUCLEIC ACI; HARADA K, 1993, NUCLEIC ACIDS RES, V21, P2287, DOI 10.1093/nar/21.10.2287; HARRIS ME, 1994, EMBO J, V13, P3953, DOI 10.1002/j.1460-2075.1994.tb06711.x; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10172, DOI 10.1021/bi00496a004; LLANGASEKARE M, 1995, SCIENCE, V267, P643; LOHMANN R, 1977, J MOL BIOL, V113, P193; LOHRMANN R, 1978, TETRAHEDRON, V34, P853, DOI 10.1016/0040-4020(78)88129-0; LORSCH JR, 1994, NATURE, V371, P31, DOI 10.1038/371031a0; LUCIA J S JR, 1990, Biochemistry, V29, P8813; MODRICH P, 1973, J BIOL CHEM, V21, P7502; PAN T, 1992, NATURE, V358, P560, DOI 10.1038/358560a0; PLEY HW, 1994, NATURE, V372, P68, DOI 10.1038/372068a0; PRUDENT JR, 1994, SCIENCE, V264, P1924; PYLE AM, 1993, SCIENCE, V261, P709, DOI 10.1126/science.7688142; ROHATGI R, UNPUB; TUERK C, 1988, P NATL ACAD SCI USA, V85, P1364, DOI 10.1073/pnas.85.5.1364; TURNER DH, 1988, ANNU REV BIOPHYS BIO, V17, P167; WILSON C, 1995, NATURE, V374, P777, DOI 10.1038/374777a0	23	278	292	1	22	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 21	1995	269	5222					364	370		10.1126/science.7618102	http://dx.doi.org/10.1126/science.7618102			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK427	7618102				2022-12-24	WOS:A1995RK42700038
J	HIROSE, K; LOCKHART, A; CROSS, RA; AMOS, LA				HIROSE, K; LOCKHART, A; CROSS, RA; AMOS, LA			NUCLEOTIDE-DEPENDENT ANGULAR CHANGE IN KINESIN MOTOR DOMAIN BOUND TO TUBULIN	NATURE			English	Article							MICROTUBULES; MICROSCOPY; IMAGES	KINESIN is a 'motor' molecule, consisting of two head domains, an alpha-helical coiled coil rod, and a tail part that binds to its cargo(1,2). When expressed in a bacterial system, the head domain is functional(3), and can bind to microtubules with the stoichiometry of one head per tubulin dimer. Kinesin moves along microtubules by means of a cyclic process of nucleotide binding, hydrolysis and product release(4,5). We have used negative-stain electron microscopy and image analysis to study the structures of microtubules and tubulin sheets decorated with the motor domain (bead) of kinesin in three states: in the presence of an unhydrolysable ATP analogue, 5'-adenylylimidodiphosphate (AMP-PNP); without nucleotides; and with adenosine 5'-diphosphate (ADP). A single kinesin head bound to a microtubule has a pear-shaped structure, with the broader end towards the 'plus' end of the microtubule under all conditions; the reverse motor, ncd, is similarly oriented. Three-dimensional maps reveal that kinesin heads have a spike that is assumed to form the attachment to the tail of a complete kinesin molecule. This spike is perpendicular to the microtubule axis in the presence of ADP, but points towards the plus end (similar to 45 degrees) in the presence of AMP-PNP or absence of nucleotides. Our results provide direct evidence for a conformational change of the kinesin motor domain during the ATPase cycle.	MRC, MOLEC BIOL LAB, CAMBRIDGE CB2 2QH, ENGLAND; MARIE CURIE INST, OXTED RH8 0TL, SURREY, ENGLAND	MRC Laboratory Molecular Biology			Cross, Robert A/F-1798-2011; Hirose, Keiko/M-5429-2018	Cross, Robert A/0000-0002-0004-7832; Amos, Linda/0000-0001-8305-5346; Hirose, Keiko/0000-0003-4587-8346				AMOS LA, 1975, J MOL BIOL, V99, P51, DOI 10.1016/S0022-2836(75)80158-6; DALLAI R, 1990, J STRUCT BIOL, V103, P164, DOI 10.1016/1047-8477(90)90020-D; DEROSIER DJ, 1970, J MOL BIOL, V52, P355, DOI 10.1016/0022-2836(70)90036-7; EGELMAN EH, 1986, ULTRAMICROSCOPY, V19, P367, DOI 10.1016/0304-3991(86)90096-3; ENDOW SA, 1991, TRENDS BIOCHEM SCI, V16, P221, DOI 10.1016/0968-0004(91)90089-E; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; Goldstein L S, 1991, Trends Cell Biol, V1, P93, DOI 10.1016/0962-8924(91)90036-9; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; HIROSE K, IN PRESS J MOL BIOL; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HUANG TG, 1994, J BIOL CHEM, V269, P16502; KUO SC, 1991, J CELL SCI, P135; LANZAVECCHIA S, 1994, J STRUCT BIOL, V113, P225, DOI 10.1006/jsbi.1994.1057; LOCKHART A, 1995, J MOL BIOL, V249, P763, DOI 10.1006/jmbi.1995.0335; LOCKHART A, 1994, EMBO J, V13, P751, DOI 10.1002/j.1460-2075.1994.tb06317.x; MIKKAWA M, 1994, J CELL BIOL, V127, P1965; ROMBERG L, 1993, NATURE, V361, P168, DOI 10.1038/361168a0; SCHNAPP BJ, 1990, P NATL ACAD SCI USA, V87, P10053, DOI 10.1073/pnas.87.24.10053; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; SONG YH, 1995, J CELL BIOL, V128, P81, DOI 10.1083/jcb.128.1.81; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; VIGERS GPA, 1986, EMBO J, V5, P529, DOI 10.1002/j.1460-2075.1986.tb04242.x; WADE RH, 1993, J STRUCT BIOL, V110, P1, DOI 10.1006/jsbi.1993.1001; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332	25	110	111	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 20	1995	376	6537					277	279		10.1038/376277a0	http://dx.doi.org/10.1038/376277a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK331	7617042				2022-12-24	WOS:A1995RK33100053
J	LIU, D; BIENKOWSKA, J; PETOSA, C; COLLIER, RJ; FU, H; LIDDINGTON, R				LIU, D; BIENKOWSKA, J; PETOSA, C; COLLIER, RJ; FU, H; LIDDINGTON, R			CRYSTAL-STRUCTURE OF THE ZETA-ISOFORM OF THE 14-3-3 PROTEIN	NATURE			English	Article								THE 14-3-3 family of proteins have recently been identified as regulatory elements in intracellular signalling pathways(1): 14-3-3 proteins bind to oncogene and proto-oncogene products, including c-Raf-1 (refs 2-5), c-Bcr (ref. 6) and polyomavirus middle-T antigen(7); overexpression of 14-3-3 activates Raf kinase in yeast(2,3) and induces meiotic maturation in Xenopus oocytes(5). Here we report the crystal structure of the major isoform of mammalian 14-3-3 proteins at 2.9 Angstrom resolution. Each subunit of the dimeric protein consists of a bundle of nine antiparallel helices that form a palisade around an amphipathic groove. The groove is large enough to accommodate a tenth helix, and we propose that binding to an amphipathic helix represents a general mechanism for the interaction of 14-3-3 with diverse cellular proteins. The residues in the dimer interface and the putative ligand-binding surface are invariant among vertebrates, yeast and plants, suggesting a conservation of structure and function throughout the 14-3-3 family.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115; EMORY UNIV,SCH MED,DEPT PHARMACOL,ATLANTA,GA 30322	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Emory University	LIU, D (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,44 BINNEY ST,BOSTON,MA 02115, USA.			Collier, R John/0000-0002-2427-4239; Petosa, Carlo/0000-0002-9975-1167				ADAM R, 1994, J BIOCHEM-TOKYO, V116, P416; AITKEN A, 1995, J BIOL CHEM, V270, P5706, DOI 10.1074/jbc.270.11.5706; BOSTON PF, 1982, J NEUROCHEM, V38, P1466, DOI 10.1111/j.1471-4159.1982.tb07927.x; BRUNGER AT, 1992, XPLOR VERSION 31 SYS; BURBELO PD, 1995, CURR BIOL, V5, P95, DOI 10.1016/S0960-9822(95)00022-4; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FINN BE, 1995, STRUCTURE, V3, P7, DOI 10.1016/S0969-2126(01)00130-7; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; FURUKAWA Y, 1993, BIOCHEM BIOPH RES CO, V194, P144, DOI 10.1006/bbrc.1993.1796; HARRISON CJ, 1994, SCIENCE, V263, P224, DOI 10.1126/science.8284672; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; JONES DHA, 1995, J MOL BIOL, V245, P375, DOI 10.1006/jmbi.1994.0031; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0	21	430	449	0	30	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 13	1995	376	6536					191	194		10.1038/376191a0	http://dx.doi.org/10.1038/376191a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ028	7603574				2022-12-24	WOS:A1995RJ02800066
J	HEDGES, LV; NOWELL, A				HEDGES, LV; NOWELL, A			SEX-DIFFERENCES IN MENTAL TEST-SCORES, VARIABILITY, AND NUMBERS OF HIGH-SCORING INDIVIDUALS	SCIENCE			English	Article							COGNITIVE GENDER DIFFERENCES; META-ANALYSIS; INTELLECTUAL ABILITIES; METAANALYSIS; MATHEMATICS	Sex differences in central tendency, variability, and numbers of high scores on mental tests have been extensively studied. Research has not always seemed to yield consistent results, partly because most studies have not used representative samples of national populations. An analysis of mental test scores from six studies that used national probability samples provided evidence that although average sex differences have been generally small and stable over time, the test scores of males consistently have larger variance. Except in tests of reading comprehension, perceptual speed, and associative memory, males typically outnumber females substantially among high-scoring individuals.			HEDGES, LV (corresponding author), UNIV CHICAGO,DEPT EDUC,5835 S KIMBARK AVE,CHICAGO,IL 60637, USA.			Hedges, Larry/0000-0002-7531-0631				BECKER BJ, 1988, BEHAV BRAIN SCI, V11, P183; BECKER BJ, 1984, J EDUC PSYCHOL, V76, P583, DOI 10.1037/0022-0663.76.4.583; BENBOW CP, 1988, BEHAV BRAIN SCI, V11, P169, DOI 10.1017/S0140525X00049244; BOCK RD, 1986, ADVANTAGE DISADVANTA; Cochran W. G., 1963, SAMPLING TECHNIQUES, DOI [10.1002/bimj.19650070312, DOI 10.1002/BIMJ.19650070312]; COHEN J, 1977, STATISTICAL POWER AN; ELLIS H, 1984, MAN WOMAN STUDY HUMA; FEINGOLD A, 1988, AM PSYCHOL, V43, P95, DOI 10.1037/0003-066X.43.2.95; FEINGOLD A, 1992, REV EDUC RES, V62, P61, DOI 10.3102/00346543062001061; Flanagan J. C., 1962, DESIGN STUDY AM YOUT; FRIEDMAN L, 1989, REV EDUC RES, V59, P185; Hansen M.H., 1953, SAMPLE SURVEY METHOD; HEDGES LV, 1993, REV EDUC RES, V63, P94, DOI 10.3102/00346543063001094; HOLLINGWORTH LS, 1914, AM J SOCIOL, V22, P19; HYDE JS, 1990, PSYCHOL BULL, V107, P139, DOI 10.1037/0033-2909.107.2.139; HYDE JS, 1988, PSYCHOL BULL, V104, P53, DOI 10.1037/0033-2909.104.1.53; HYDE JS, 1981, AM PSYCHOL, V36, P892, DOI 10.1037/0003-066X.36.8.892; Jensen A, 1971, INTELLIGENCE GENETIC, P107; Kish L, 1965, SURVEY SAMPLING; LAZEAR EP, 1990, J LABOR ECON, V8, pS106, DOI 10.1086/298246; LEWIS C, 1995, ETS RR9513 ED TEST S; Maccoby E.E., 1978, PSYCHOL SEX DIFFEREN, V2; Maccoby E.E., 1966, DEV SEX DIFFERENCES; MICCERI T, 1989, PSYCHOL BULL, V105, P156, DOI 10.1037/0033-2909.105.1.156; MULLIS IVS, 1991, TRENDS ACADEMIC PROG; PAGLIN M, 1990, J LABOR ECON, V8, P123, DOI 10.1086/298239; PEARSON K, 1897, CHANCES DEATH, V1, pCH8; ROCK DA, 1985, PSYCHOMETRIC ANAL NL; ROSEN S, 1981, AM ECON REV, V71, P845; SHAYCROFT MF, 1963, STUDIES COMPLETE AGE; SHIELDS SA, 1975, AM PSYCHOL, V30, P739, DOI 10.1037/h0076948; Stanley J. C., 1992, TALENT DEV, P42; Terman L. M., 1925, GENETIC STUDIES GENI, VI; TERMAN LM, 1954, MANUAL CHILD PSYCHOL, P1064; Thorndike E. L., 1910, ED PSYCHOL; WISE LL, 1979, ORIGINS CAREER CONSE	36	615	624	3	101	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 7	1995	269	5220					41	45		10.1126/science.7604277	http://dx.doi.org/10.1126/science.7604277			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RG980	7604277				2022-12-24	WOS:A1995RG98000025
J	BUDRENE, EO; BERG, HC				BUDRENE, EO; BERG, HC			DYNAMICS OF FORMATION OF SYMMETRICAL PATTERNS BY CHEMOTACTIC BACTERIA	NATURE			English	Article							ESCHERICHIA-COLI	MOTILE cells of Escherichia coli aggregate to form stable patterns of remarkable regularity when grown from a single point on certain substrates. Central to this self-organization is chemotaxis, the motion of bacteria along gradients of a chemical attractant that the cells themselves excrete(1). Here we show how these complex patterns develop. The long-range spatial order arises from interactions between two multicellular aggregate structures: a 'swarm ring' that expands radially, and focal aggregates that have lower mobility. Patterning occurs through alternating domination by these two sources of excreted attractant (which we identify here as aspartate). The pattern geometries vary in a systematic way, depending on how long an aggregate remains active; this depends, in turn, on the initial concentration of substrate (here, succinate).	ROWLAND INST SCI INC,CAMBRIDGE,MA 02142		BUDRENE, EO (corresponding author), HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,16 DIVIN AVE,CAMBRIDGE,MA 02138, USA.		Ladoux, Benoit/A-9879-2013					ADLER J, 1967, J GEN MICROBIOL, V46, P175, DOI 10.1099/00221287-46-2-175; ADLER J, 1966, SCIENCE, V153, P708, DOI 10.1126/science.153.3737.708; BARINAGA M, 1994, SCIENCE, V266, P561, DOI 10.1126/science.7939701; BENJACOB E, 1995, NATURE, V373, P566, DOI 10.1038/373566a0; BLAT Y, 1995, J BACTERIOL, V177, P1683, DOI 10.1128/jb.177.7.1683-1691.1995; BRUNN SD, 1992, ANN ASSOC AM GEOGR, V82, P1; BUDRENE EO, 1991, NATURE, V349, P630, DOI 10.1038/349630a0; GUTNICK D, 1969, J BACTERIOL, V100, P215, DOI 10.1128/JB.100.1.215-219.1969; MARCUS M, 1969, BIOCHIM BIOPHYS ACTA, V177, P314, DOI 10.1016/0304-4165(69)90141-X; Miller J.H., 1972, EXPT MOL GENETICS; NEIDHARDT C, 1990, PHSYL BACTERIAL CELL, P208; NOSSAL R, 1972, EXP CELL RES, V75, P183; PARKINSON JS, 1978, J BACTERIOL, V135, P45, DOI 10.1128/JB.135.1.45-53.1978; PARKINSON JS, 1987, GENETICS, V116, P499; WOLFE AJ, 1987, J BACTERIOL, V169, P1878, DOI 10.1128/jb.169.5.1878-1885.1987; WOODWARD DE, 1995, BIOPHYS J, V68, P2181	16	376	376	1	63	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 6	1995	376	6535					49	53		10.1038/376049a0	http://dx.doi.org/10.1038/376049a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH111	7596432				2022-12-24	WOS:A1995RH11100058
J	TRIGWELL, P; HATCHER, S; JOHNSON, M; STANLEY, P; HOUSE, A				TRIGWELL, P; HATCHER, S; JOHNSON, M; STANLEY, P; HOUSE, A			ABNORMAL ILLNESS BEHAVIOR IN CHRONIC FATIGUE SYNDROME AND MULTIPLE-SCLEROSIS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							POSTVIRAL FATIGUE; GUIDELINES; HEALTH	Objective-To investigate the presence of abnormal illness behaviour in patients with a diagnosis of chronic fatigue syndrome. Design-A cross sectional descriptive study using the illness behaviour questionnaire to compare illness behaviour scores and illness behaviour profiles of patients with chronic fatigue syndrome and patients with multiple sclerosis. Setting-A multidisciplinary fatigue clinic and a teaching hospital neurology outpatient clinic. Subjects-98 patients satisfying the Oxford criteria for chronic fatigue syndrome and 78 patients with a diagnosis of multiple sclerosis. Main outcome measure-Responses to the 62 item illness behaviour questionnaire. Results-90 (92%) patients in the chronic fatigue syndrome group and 70 (90%) in the multiple sclerosis group completed the illness behaviour questionnaire. Both groups had significantly high scores on the general hypochondriasis and disease conviction subscales and significantly low scores on the psychological versus somatic concern subscale, as measured in relation to normative data. There were, however, no significant differences in the subscale scores between the two groups and the two groups had identical illness behaviour profiles. Conclusion-Scores on the illness behaviour questionnaire cannot be taken as evidence that chronic fatigue syndrome is a variety of abnormal illness behaviour, because the same profile occurs in multiple sclerosis. Neither can they be taken as evidence that chronic fatigue and multiple sclerosis share an aetiology. More needs to be known about the origins of illness beliefs in chronic fatigue syndrome, especially as they are important in determining outcome.	UNIV LEEDS, LEEDS LS2 9LT, W YORKSHIRE, ENGLAND; ST JAMES UNIV HOSP, LEEDS LS9 7TF, W YORKSHIRE, ENGLAND; SEACROFT HOSP, LEEDS LS14 6UH, W YORKSHIRE, ENGLAND; GEN INFIRM, LEEDS LS1 3EX, W YORKSHIRE, ENGLAND	University of Leeds; Saint James's University Hospital; Leeds General Infirmary	TRIGWELL, P (corresponding author), HIGH ROYDS HOSP, LEEDS LS29 6AQ, W YORKSHIRE, ENGLAND.			House, Allan/0000-0001-8721-8026				CONFAVREUX C, 1980, BRAIN, V103, P281, DOI 10.1093/brain/103.2.281; DAVID AS, 1988, BRIT MED J, V296, P696, DOI 10.1136/bmj.296.6623.696; FREAL JE, 1984, ARCH PHYS MED REHAB, V65, P135; HICKIE I, 1990, BRIT J PSYCHIAT, V156, P534, DOI 10.1192/bjp.156.4.534; Kleinman Arthur, 1985, CULTURE DEPRESSION S, P429; KRUPP LB, 1988, ARCH NEUROL-CHICAGO, V45, P435, DOI 10.1001/archneur.1988.00520280085020; MANU P, 1988, ARCH INTERN MED, V148, P2213, DOI 10.1001/archinte.148.10.2213; Matthews WB, 1991, MCALPINES MULTIPLE S, P139; MCEVEDY CP, 1970, BRIT MED J, V1, P11, DOI 10.1136/bmj.1.5687.11; MECHANIC D, 1962, J CHRON DIS, V15, P189, DOI 10.1016/0021-9681(62)90068-1; MURRAY M, 1991, CURRENT DEV HLTH PSY, P63; PARSONS T, 1952, SOCIALSYSTEM; PEMBERTON S, IN PRESS BRIT J OCCU; PILOWSKY I, 1969, BRIT J MED PSYCHOL, V42, P347, DOI 10.1111/j.2044-8341.1969.tb02089.x; Pilowsky I., 1983, MANUAL ILLNESS BEHAV; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; POSER S, 1979, J NEUROL SCI, V40, P159, DOI 10.1016/0022-510X(79)90201-6; SCHWEITZER R, 1994, J PSYCHOSOM RES, V38, P41, DOI 10.1016/0022-3999(94)90007-8; SHARPE MC, 1991, J ROY SOC MED, V84, P118, DOI 10.1177/014107689108400224; SMITH GR, 1986, ARCH INTERN MED, V146, P69, DOI 10.1001/archinte.146.1.69; WESSELY S, 1989, J NEUROL NEUROSUR PS, V52, P940, DOI 10.1136/jnnp.52.8.940; WESSELY S, 1990, RECENT ADV NEUROLOGY, V6; WILSON A, 1994, BRIT MED J, V308, P756, DOI 10.1136/bmj.308.6931.756; ZONDERMAN AB, 1985, HEALTH PSYCHOL, V4, P425, DOI 10.1037/0278-6133.4.5.425; 1987, DIAGNOSTIC STATISTIC	25	30	30	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 1	1995	311	6996					15	18		10.1136/bmj.311.6996.15	http://dx.doi.org/10.1136/bmj.311.6996.15			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RG975	7613314	Green Published			2022-12-24	WOS:A1995RG97500018
J	DAS, A; GILBERT, CD				DAS, A; GILBERT, CD			LONG-RANGE HORIZONTAL CONNECTIONS AND THEIR ROLE IN CORTICAL REORGANIZATION REVEALED BY OPTICAL-RECORDING OF CAT PRIMARY VISUAL-CORTEX	NATURE			English	Article							MONKEY STRIATE CORTEX; FUNCTIONAL ARCHITECTURE; INTRINSIC SIGNALS; ORGANIZATION; NEURONS; PROJECTIONS; LESIONS; MAPS	THE cortical 'point spread' (PS) is the area of cortex activated by a minimal visual stimulus(1). Here we use the PS to explore the functional role of lateral connectivity in normal cat primary visual cortex (V1) and its involvement in topographic reorganization of cortex following retinal lesions. We compared the distributions of PSs measured with optical recording, which reflects both spiking and subthreshold activity, with those measured with extracellular electrodes, which reveal spiking activity alone. The spiking PS represented only 5% of the area of activation shown in the optical PS, indicating that the remaining 95% was probably generated by subthreshold activation. The orientation dependence of the pattern of the subthreshold activation and its close match with orientation columns suggests that long-range horizontal connections radiating from the locus of spiking activity were responsible for the observed activation. The spike PS showed anisotropies and inhomogeneities that were related to the pattern of orientation columns and indicated distortions in the representation of visual space on the cortical surface. In the reorganized cortex the spike PS expanded, approximating the extent of the optical PS seen in normal cortex, and suggesting that reorganization was mediated by an unmasking of normally subthreshold activation to suprathreshold levels. The orientation map of the reorganized cortex showed a close match to that obtained before placing the lesion, despite the large shift in topography, supporting the idea that intrinsic horizontal connections were responsible for the remapping.			DAS, A (corresponding author), ROCKEFELLER UNIV,NEW YORK,NY 10021, USA.							BISHOP PO, 1971, J PHYSIOL-LONDON, V219, P659, DOI 10.1113/jphysiol.1971.sp009682; BLASDEL GG, 1986, NATURE, V321, P579, DOI 10.1038/321579a0; BONHOEFFER T, 1991, NATURE, V353, P429, DOI 10.1038/353429a0; DARIANSMITH C, 1995, J NEUROSCI, V15, P1631, DOI 10.1523/JNEUROSCI.15-03-01631.1995; DARIANSMITH C, 1994, NATURE, V368, P737, DOI 10.1038/368737a0; DURBIN R, 1990, NATURE, V343, P644, DOI 10.1038/343644a0; FROSTIG RD, 1990, P NATL ACAD SCI USA, V87, P6082, DOI 10.1073/pnas.87.16.6082; GILBERT CD, 1989, J NEUROSCI, V9, P2432; GILBERT CD, 1990, COLD SPRING HARB SYM, V55, P663; GILBERT CD, 1979, NATURE, V280, P120, DOI 10.1038/280120a0; GILBERT CD, 1992, NATURE, V356, P150, DOI 10.1038/356150a0; GILBERT CD, 1983, J NEUROSCI, V3, P1116; GRINVALD A, 1994, J NEUROSCI, V14, P2545; GRINVALD A, 1986, NATURE, V324, P361, DOI 10.1038/324361a0; HEINEN SJ, 1991, EXP BRAIN RES, V83, P670; HUBEL DH, 1974, J COMP NEUROL, V158, P295, DOI 10.1002/cne.901580305; HUBEL DH, 1977, PROC R SOC SER B-BIO, V198, P1, DOI 10.1098/rspb.1977.0085; KAAS JH, 1990, SCIENCE, V248, P229, DOI 10.1126/science.2326637; MARTIN KAC, 1984, J PHYSIOL-LONDON, V353, P463, DOI 10.1113/jphysiol.1984.sp015347; MCILWAIN JT, 1975, J NEUROPHYSIOL, V38, P219, DOI 10.1152/jn.1975.38.2.219; ROCKLAND KS, 1983, J COMP NEUROL, V216, P303, DOI 10.1002/cne.902160307; TOOTELL RBH, 1982, SCIENCE, V218, P902, DOI 10.1126/science.7134981; TSO DY, 1986, J NEUROSCI, V6, P1160; TSO DY, 1990, SCIENCE, V249, P417, DOI 10.1126/science.2165630	24	339	344	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 29	1995	375	6534					780	784		10.1038/375780a0	http://dx.doi.org/10.1038/375780a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF989	7596409				2022-12-24	WOS:A1995RF98900076
J	RIGBY, R				RIGBY, R			OUT OF CONTROL	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 3	1995	310	6992					1475	1475		10.1136/bmj.310.6992.1475	http://dx.doi.org/10.1136/bmj.310.6992.1475			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC105	7613305	Green Published			2022-12-24	WOS:A1995RC10500073
J	ZIMMERLY, S; GUO, HT; ESKES, R; YANG, J; PERLMAN, PS; LAMBOWITZ, AM				ZIMMERLY, S; GUO, HT; ESKES, R; YANG, J; PERLMAN, PS; LAMBOWITZ, AM			A GROUP-II INTRON RNA IS A CATALYTIC COMPONENT OF A DNA ENDONUCLEASE INVOLVED IN INTRON MOBILITY	CELL			English	Article							YEAST MITOCHONDRIA; INVITRO; TRANSPOSITION; PROTEINS	The mobility (homing) of the yeast mitochondrial DNA group II intron al2 occurs via target DNA-primed reverse transcription at a double-strand break in the recipient DNA. Here, we show that the site-specific DNA endonuclease that makes the double-strand break is a ribonucleoprotein complex containing the al2-encoded reverse transcriptase protein and excised al2 RNA. Remarkably, the al2 RNA catalyzes cleavage of the sense strand of the recipient DNA, while the al2 protein appears to cleave the antisense strand. The RNA-catalyzed sense strand cleavage occurs via a partial reverse splicing reaction in which the protein component stabilizes the active intron structure and appears to confer preference for DNA substrates. Our results demonstrate a biologically relevant ribozyme reaction with a substrate other than RNA.	OHIO STATE UNIV,DEPT BIOCHEM,COLUMBUS,OH 43210; OHIO STATE UNIV,DEPT MED BIOCHEM,COLUMBUS,OH 43210; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	ZIMMERLY, S (corresponding author), OHIO STATE UNIV,DEPT MOLEC GENET,COLUMBUS,OH 43210, USA.				NIGMS NIH HHS [GM37949, GM31480] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031480, R01GM037949] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELFORT M, 1993, SCIENCE, V262, P1009, DOI 10.1126/science.7694364; GORBALENYA AE, 1994, PROTEIN SCI, V3, P1117, DOI 10.1002/pro.5560030716; HEBBAR SK, 1992, NUCLEIC ACIDS RES, V20, P1747, DOI 10.1093/nar/20.7.1747; KENNELL JC, 1993, CELL, V73, P133, DOI 10.1016/0092-8674(93)90166-N; LAMBOWITZ AM, 1990, TRENDS BIOCHEM SCI, V15, P440, DOI 10.1016/0968-0004(90)90283-H; LAMBOWITZ AM, 1993, ANNU REV BIOCHEM, V62, P587, DOI 10.1146/annurev.bi.62.070193.003103; LAZOWSKA J, 1994, EMBO J, V13, P4963, DOI 10.1002/j.1460-2075.1994.tb06823.x; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; Meunier B, 1990, STRUCTURE FUNCTION B, P169; MICHEL F, 1995, ANNU REV BIOCHEM, V64, P435, DOI 10.1146/annurev.bi.64.070195.002251; MOHR G, 1993, NUCLEIC ACIDS RES, V21, P4991, DOI 10.1093/nar/21.22.4991; MORAN JV, 1994, NUCLEIC ACIDS RES, V22, P2057, DOI 10.1093/nar/22.11.2057; MORAN JV, 1995, MOL CELL BIOL, V15, P2828; MORL M, 1990, NUCLEIC ACIDS RES, V18, P6545, DOI 10.1093/nar/18.22.6545; MORL M, 1992, CELL, V70, P803, DOI 10.1016/0092-8674(92)90313-2; MORL M, 1990, CELL, V60, P629, DOI 10.1016/0092-8674(90)90666-3; MUELLER MW, 1993, NATURE, V366, P174, DOI 10.1038/366174a0; SALDANHA R, 1993, FASEB J, V7, P15, DOI 10.1096/fasebj.7.1.8422962; Sambrook J., 1989, MOL CLONING LAB MANU; SCHMIDT WM, 1994, J MOL BIOL, V243, P157, DOI 10.1006/jmbi.1994.1642; SELLEM CH, 1993, NATURE, V366, P176, DOI 10.1038/366176a0; SHUB DA, 1994, TRENDS BIOCHEM SCI, V19, P402, DOI 10.1016/0968-0004(94)90086-8; ZIMMERLY S, 1995, CELL, V82, P545, DOI 10.1016/0092-8674(95)90027-6	23	156	179	0	9	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 17	1995	83	4					529	538		10.1016/0092-8674(95)90092-6	http://dx.doi.org/10.1016/0092-8674(95)90092-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TF248	7585955	Bronze			2022-12-24	WOS:A1995TF24800005
J	DOLL, DC				DOLL, DC			SPUR CELLS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											DOLL, DC (corresponding author), HARRY S TRUMAN VET AFFAIRS MED CTR,COLUMBIA,MO 65201, USA.								0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 2	1995	333	18					1183	1183		10.1056/NEJM199511023331804	http://dx.doi.org/10.1056/NEJM199511023331804			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB560	7565973				2022-12-24	WOS:A1995TB56000004
J	BUMP, NJ; HACKETT, M; HUGUNIN, M; SESHAGIRI, S; BRADY, K; CHEN, P; FERENZ, C; FRANKLIN, S; GHAYUR, T; LI, P; LICARI, P; MANKOVICH, J; SHI, LF; GREENBERG, AH; MILLER, LK; WONG, WW				BUMP, NJ; HACKETT, M; HUGUNIN, M; SESHAGIRI, S; BRADY, K; CHEN, P; FERENZ, C; FRANKLIN, S; GHAYUR, T; LI, P; LICARI, P; MANKOVICH, J; SHI, LF; GREENBERG, AH; MILLER, LK; WONG, WW			INHIBITION OF ICE FAMILY PROTEASES BY BACULOVIRUS ANTIAPOPTOTIC PROTEIN P35	SCIENCE			English	Article							CELL-DEATH; APOPTOSIS; GENE; EXPRESSION; ENZYME	The baculovirus antiapoptotic protein p35 inhibited the proteolytic activity of human interleukin-1 beta converting enzyme (ICD) and three of its homologs in enzymatic assays. Coexpression of p35 prevented the autoproteolytic activation on ICE from its precursor form and blocked ICE-induced apoptosis, Inhibition of enzymatic activity correlated with the cleavage of p35 and the formation of a stable ICE-p35 complex. The ability of p35 to block apoptosis in different pathways and in distantly related organisms suggests a central and conserved role for ICE-like proteases in the induction of apoptosis.	BASF BIORES CORP,WORCESTER,MA 01605; UNIV GEORGIA,DEPT ENTOMOL,ATHENS,GA 30602; UNIV GEORGIA,DEPT GENET,ATHENS,GA 30602; UNIV MANITOBA,MANITOBA INST CELL BIOL,WINNIPEG,MB R3E 0V9,CANADA	BASF; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; University of Manitoba				Seshagiri, Somasekar/0000-0003-4272-6443	NIAID NIH HHS [AI 38262] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038262] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BUMP N, UNPUB; CARTIER JL, 1994, J VIROL, V68, P7728, DOI 10.1128/JVI.68.12.7728-7737.1994; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMR.T, 1994, J BIOL CHEM, V269, P30761; HAY BA, 1994, DEVELOPMENT, V120, P2121; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MORRIS TD, 1992, J VIROL, V66, P7397, DOI 10.1128/JVI.66.12.7397-7405.1992; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; QUAN LT, 1995, J BIOL CHEM, V270, P10377, DOI 10.1074/jbc.270.18.10377; RABIZADEH S, 1993, J NEUROCHEM, V61, P2318, DOI 10.1111/j.1471-4159.1993.tb07477.x; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; SESHAGIRI S, UNPUB; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; SUGIMOTO A, 1994, EMBO J, V13, P2023, DOI 10.1002/j.1460-2075.1994.tb06475.x; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0	27	584	606	0	17	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 29	1995	269	5232					1885	1888		10.1126/science.7569933	http://dx.doi.org/10.1126/science.7569933			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX194	7569933				2022-12-24	WOS:A1995RX19400043
J	KOLB, FC; BRAUN, J				KOLB, FC; BRAUN, J			BLINDSIGHT IN NORMAL OBSERVERS	NATURE			English	Article							UNCONSCIOUS PERCEPTION; TEXTURE-DISCRIMINATION; VISUAL-STIMULI; LOCALIZATION; AWARENESS; VISION	SOME patients with lesions in visual cortex lack conscious visual experience but, when tested, exhibit a significant ability, termed 'blindsight', to discriminate visual stimuli(1-3,27). Here we report two different visual displays that induce blindsight in normal observers. Using an objective measure, we show that conscious experience remains defective at presentation times much longer (1 s) than the onset of visual sensitivity (similar to 60 ms). To obtain this effect, we generate a contrast between visual textures and then conceal the contrast by superimposing 'complementary' textures. Complementarity can involve either opposite motion or binocular rivalry and orthogonal orientation. In both cases, observers locate the texture contrast reliably but do not, by either subjective or objective measures, consciously experience it. Taken together with present knowledge of the visual cortical site(s) at which opposite motion and rivalrous orientation interact(4-7), this observation bears upon the functional anatomy of conscious visual experience.	CALTECH, PASADENA, CA 91125 USA	California Institute of Technology			Braun, Jochen/F-1370-2013	Braun, Jochen/0000-0002-8886-078X				ADAMS JK, 1957, PSYCHOL BULL, V54, P383, DOI 10.1037/h0043350; CRICK F, 1995, NATURE, V375, P121, DOI 10.1038/375121a0; DOBBINS A, 1994, J SOC NEUR ABSTR, V20, P624; FARAH MJ, 1991, NEUROPSYCHOLOGIA, V29, P949, DOI 10.1016/0028-3932(91)90059-H; Fox R, 1991, BINOCULAR VISION, V9, P93; GRAVES RE, 1992, COGN NEUROPSYCHOL, V9, P487, DOI 10.1080/02643299208252069; GREEN DM, 1967, SIGNAL DETECTION THE; GREENWALD AG, 1992, AM PSYCHOL, V47, P766, DOI 10.1037/0003-066X.47.6.766; KARNI A, 1993, SOC NEUR ABSTR, V19, P1503; KNIERIM JJ, 1992, J NEUROPHYSIOL, V67, P961, DOI 10.1152/jn.1992.67.4.961; LEOPOLD DA, 1995, INVEST OPHTH VIS SCI, V36, pS813; LOGOTHETIS NK, 1989, SCIENCE, V245, P761, DOI 10.1126/science.2772635; MALACH R, 1993, P NATL ACAD SCI USA, V90, P10469, DOI 10.1073/pnas.90.22.10469; MALIK J, 1990, J OPT SOC AM A, V7, P923, DOI 10.1364/JOSAA.7.000923; MARCEL AJ, 1983, COGNITIVE PSYCHOL, V15, P197, DOI 10.1016/0010-0285(83)90009-9; MEERES SL, 1990, NEUROPSYCHOLOGIA, V28, P1231, DOI 10.1016/0028-3932(90)90039-Q; MERIKLE PM, 1992, AM PSYCHOL, V47, P792, DOI 10.1037/0003-066X.47.6.792; POPPEL E, 1973, NATURE, V243, P295, DOI 10.1038/243295a0; Press W. A., 1994, Society for Neuroscience Abstracts, V20, P838; QIAN N, 1994, J NEUROSCI, V14, P7367; QIAN N, 1994, J NEUROSCI, V14, P7357; RUBENSTEIN BS, 1990, J OPT SOC AM A, V7, P1632, DOI 10.1364/JOSAA.7.001632; SCHACTER DL, 1992, P NATL ACAD SCI USA, V89, P11113, DOI 10.1073/pnas.89.23.11113; Sidis B., 1898, PSYCHOL SUGGESTION; STOREIG P, 1993, PROGR BRAIN RES, V95, P445; WEISKRANTZ L, 1974, BRAIN, V97, P709, DOI 10.1093/brain/97.1.709; WEISKRANTZ L, 1995, P NATL ACAD SCI USA, V92, P6122, DOI 10.1073/pnas.92.13.6122	27	150	151	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 28	1995	377	6547					336	338		10.1038/377336a0	http://dx.doi.org/10.1038/377336a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RX111	7566086				2022-12-24	WOS:A1995RX11100055
J	HAUSKNECHT, RU				HAUSKNECHT, RU			METHOTREXATE AND MISOPROSTOL TO TERMINATE EARLY-PREGNANCY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ILLEGAL ABORTION; INJECTION; BRAZIL	Background. Although medical termination of pregnancy is available in Europe and China as an alternative to surgical termination, political and social factors have blocked medical approaches to pregnancy termination in the United States, Methotrexate, which is toxic to trophoblastic tissue, has been used safely to treat unruptured ectopic pregnancies, This report describes the use of a single low dose of methotrexate followed by intravaginal misoprostol for the medical termination of early pregnancy. Methods. Women seeking termination of pregnancy were selected for this study on the basis of their good general health, emotional stability, and a pregnancy of 63 days or less in duration, Each woman received an intramuscular dose of methotrexate (50 mg per square meter of body-surface area). Five to seven days later, 800 mu g of misoprostol was administered intravaginally. If abortion did not occur after seven days, the woman was offered a second dose of misoprostol or vacuum aspiration. Successful abortion was defined as a complete termination of pregnancy within seven days after the first or second administration of misoprostol. Results. A total of 171 of the 178 women enrolled in the study (96 percent) had successful medical abortions. Twenty-five women (14 percent) did not have an abortion after the first dose of misoprostol and received a second dose. Eighteen subsequently had complete abortions, but seven required suction curettage. In all seven women who required suction curettage, there was histologic evidence of disruption in the conceptus, No important side effects or complications were noted. Conclusions. The combination of methotrexate and misoprostol represents a safe and effective alternative to invasive methods for the termination of early pregnancy.	MT SINAI SCH MED,DEPT OBSTET GYNECOL & REPROD SCI,NEW YORK,NY	Icahn School of Medicine at Mount Sinai								BARBOSA RM, 1993, STUD FAMILY PLANN, V24, P236, DOI 10.2307/2939191; BOND GR, 1994, AM J OBSTET GYNECOL, V171, P561, DOI 10.1016/0002-9378(94)90302-6; BUCKSHEE K, 1992, INT J GYNECOL OBSTET, V37, P297, DOI 10.1016/0020-7292(92)90334-F; COELHO HLL, 1993, LANCET, V341, P1261, DOI 10.1016/0140-6736(93)91157-H; COELHO HLL, 1993, LANCET, V341, P1486; COOK RJ, 1992, FAM PLANN PERSPECT, V24, P39, DOI 10.2307/2135726; COSTA SH, 1993, LANCET, V341, P1258, DOI 10.1016/0140-6736(93)91156-G; CREININ MD, 1994, JAMA-J AM MED ASSOC, V272, P1190, DOI 10.1001/jama.272.15.1190; CREININ MD, 1993, CONTRACEPTION, V48, P519, DOI 10.1016/0010-7824(93)90114-M; ELREFAEY H, 1995, NEW ENGL J MED, V332, P983, DOI 10.1056/NEJM199504133321502; FERNANDEZ H, 1993, FERTIL STERIL, V59, P773; FLETCHER HM, 1993, BRIT J OBSTET GYNAEC, V100, P641, DOI 10.1111/j.1471-0528.1993.tb14230.x; GOLDSTEIN SR, 1991, AM J OBSTET GYNECOL, V165, P497, DOI 10.1016/0002-9378(91)90274-U; GONZALEZ CH, 1993, AM J MED GENET, V47, P59, DOI 10.1002/ajmg.1320470113; HENSHAW R, 1994, ACTA OBSTET GYN SCAN, V73, P812, DOI 10.3109/00016349409072511; HOLE H, 1975, GEBURTSH FRAUENHEILK, V35, P538; ICHINOE K, 1987, AM J OBSTET GYNECOL, V156, P484, DOI 10.1016/0002-9378(87)90315-2; MILUNSKY A, 1968, J PEDIATR-US, V72, P790, DOI 10.1016/S0022-3476(68)80430-5; NESKET M, 1976, CANCER S, V37, P1048; ONEILL E, 1976, CANCER, V38, P984, DOI 10.1002/1097-0142(197608)38:2<984::AID-CNCR2820380249>3.0.CO;2-Q; Reich E W, 1978, Birth Defects Orig Artic Ser, V14, P139; ROSENFIELD A, 1992, AM J PUBLIC HEALTH, V82, P1325, DOI 10.2105/AJPH.82.10.1325; ROSS GT, 1976, CANCER, V37, P1043, DOI 10.1002/1097-0142(197602)37:2+<1043::AID-CNCR2820370809>3.0.CO;2-N; STOVALL TG, 1993, AM J OBSTET GYNECOL, V168, P1759, DOI 10.1016/0002-9378(93)90687-E; STROHMER H, 1992, HUM REPROD, V7, P1027, DOI 10.1093/oxfordjournals.humrep.a137763; THONG KJ, 1992, CONTRACEPTION, V46, P435, DOI 10.1016/0010-7824(92)90147-L; WILSON J, 1970, ANAT REC, V166, P39	27	120	124	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 31	1995	333	9					537	540		10.1056/NEJM199508313330901	http://dx.doi.org/10.1056/NEJM199508313330901			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ751	7623901	Bronze			2022-12-24	WOS:A1995RQ75100001
J	HUMPEL, C; LINDQVIST, E; SODERSTROM, S; KYLBERG, A; EBENDAL, T; OLSON, L				HUMPEL, C; LINDQVIST, E; SODERSTROM, S; KYLBERG, A; EBENDAL, T; OLSON, L			MONITORING RELEASE OF NEUROTROPHIC ACTIVITY IN THE BRAINS OF AWAKE RATS	SCIENCE			English	Article							NERVE GROWTH-FACTOR; EXPRESSION; ANTIBODIES	Intracerebral microdialysis of awake rats was used to monitor the possible release of neurotrophic factors from brain cells in response to injury and excitation. Perfusates were tested with ganglia bioassays and enzyme immunoassay. Trophic activity was released after implantation of the microdialysis probe into the hippocampus but not into the striatum, as assessed by increased nerve fiber outgrowth from Remak's ganglion. Kainic acid treatment significantly increased the release of trophic activity from hippocampal sites. These findings suggest that the brain responds to mechanical injury as well as to certain excitatory stimuli by regional extracellular release of neurotrophic activity that is not identical to the actions of known neurotrophic factors.	KAROLINSKA INST, DEPT NEUROSCI, S-17177 STOCKHOLM, SWEDEN; UNIV INNSBRUCK, DEPT PSYCHIAT, NEUROCHEM UNIT, A-6020 INNSBRUCK, AUSTRIA; UNIV UPPSALA, CTR BIOMED, DEPT DEV NEUROSCI, S-75123 UPPSALA, SWEDEN	Karolinska Institutet; University of Innsbruck; Uppsala University								AYERLELIEVRE C, 1988, SCIENCE, V240, P1339, DOI 10.1126/science.2897715; BARDE Y-A, 1990, Progress in Growth Factor Research, V2, P237, DOI 10.1016/0955-2235(90)90021-B; EBENDAL T, 1978, ZOON, V6, P235; EBENDAL T, 1995, J NEUROSCI RES, V40, P276, DOI 10.1002/jnr.490400217; EBENDAL T, 1992, J NEUROSCI RES, V32, P461, DOI 10.1002/jnr.490320402; EBENDAL T, 1989, NERVE GROWTH FACTORS, P81; EBENDAL T, UNPUB; ERNFORS P, 1990, NEURON, V5, P511, DOI 10.1016/0896-6273(90)90090-3; GALL CM, 1992, TRENDS PHARMACOL SCI, V13, P401, DOI 10.1016/0165-6147(92)90123-N; Lapchak P A, 1992, Rev Neurosci, V3, P109, DOI [10.1515/REVNEURO.1992.3.1.1, 10.1515/REVNEURO.1992.3.2.109]; Levi-Montalcini R, 1990, PROG NEUROENDOCRINOL, V3, P1; LEVIMONTALCINI R, 1987, BIOSCIENCE REP, V7, P681, DOI 10.1007/BF01116861; LEVIMONTALCINI R, 1968, PHYSIOL REV, V48, P534, DOI 10.1152/physrev.1968.48.3.534; WETMORE C, 1991, P NATL ACAD SCI USA, V88, P9843, DOI 10.1073/pnas.88.21.9843; WETMORE CJ, 1993, J HISTOCHEM CYTOCHEM, V41, P521, DOI 10.1177/41.4.8450192	15	19	19	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 28	1995	269	5223					552	554		10.1126/science.7624780	http://dx.doi.org/10.1126/science.7624780			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL495	7624780				2022-12-24	WOS:A1995RL49500032
J	SLADE, J; BERO, LA; HANAUER, P; BARNES, DE; GLANTZ, SA				SLADE, J; BERO, LA; HANAUER, P; BARNES, DE; GLANTZ, SA			NICOTINE AND ADDICTION - THE BROWN-AND-WILLIAMSON DOCUMENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CIGARETTES; BLOCKING; VENTS	Objective.-To learn how nicotine has been regarded by a major tobacco company. Data Sources.-Documents from Brown and Williamson Tobacco Corporation (B&W), the British American Tobacco Company (BAT), and other tobacco interests provided by an anonymous source, obtained from Congress, and received from the private papers of a former BAT officer. Study Selection.-All available materials, including confidential reports regarding research and internal memoranda exchanged between tobacco industry lawyers. Conclusions.-During a period of 22 years (1962 to 1984), employees of B&W and BAT conducted research and commented on the pharmacology of nicotine. They consistently regarded nicotine as the pharmacological agent that explained tobacco use, In the early part of the period under study, officials of the companies wrote about nicotine addiction explicitly. Inhalation of cigarette smoke by the consumer was recognized throughout the period as necessary for the normal function of a cigarette. The documents contain little indication that research was conducted on either the taste or the flavor of nicotine, The documents reveal an intention on the part of B&W and its corporate parent to affect the function of the body with nicotine.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,ST PETERS MED CTR,DEPT MED,NEW BRUNSWICK,NJ; UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,DEPT MED,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO,DIV CLIN PHARM,SAN FRANCISCO,CA	Rutgers State University New Brunswick; Rutgers State University Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NCI NIH HHS [CA-61021] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061021] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1962, SMOKING HLTH REPORT; BENOWITZ NL, 1994, NEW ENGL J MED, V331, P123, DOI 10.1056/NEJM199407143310212; Ellis C., 1966, US Patent, Patent No. [3 258 015, 3258015]; Ellis Charles, 1967, US Patent, Patent No. [3 356 094, 3356094]; GLANTZ SA, 1995, JAMA-J AM MED ASSOC, V274, P219, DOI 10.1001/jama.274.3.219; GRUNBERG NE, 1982, ADDICT BEHAV, V7, P317, DOI 10.1016/0306-4603(82)90001-6; HANAUER P, 1995, JAMA-J AM MED ASSOC, V274, P234; HENNINGFIELD JE, 1992, J CONSULT CLIN PSYCH, V61, P743; JOHNSON R, 1990, Patent No. 4955397; Kessler David A., 1994, TOB CONTROL, V3, P150, DOI DOI 10.1136/TC.3.2.148; KOZLOWSKI LT, 1988, AM J PUBLIC HEALTH, V78, P694, DOI 10.2105/AJPH.78.6.694; KOZLOWSKI LT, 1989, PHARMACOL BIOCHEM BE, V33, P815, DOI 10.1016/0091-3057(89)90476-0; LITZINGER E, 1990, Patent No. 4924886; MARTINI L, 1966, NEUROENDOCRINOLOGY; MEDVEI V, 1992, HIST CLIN ENDOCRINOL; OCKENE J, 1982, PREV MED, V10, P476; PORENSKI H, 1994, Patent No. 5327915; SLADE J, 1993, NICOTINE ADDICTION P, P3; 1988, DHHS CDC888406 US DE; 1989, DHHS CDC898411 US DE; 1964, US DHEW PHS1103 PUBL, V1103; 1980, BRIT MED J, V280, P972	22	85	86	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 19	1995	274	3					225	233		10.1001/jama.274.3.225	http://dx.doi.org/10.1001/jama.274.3.225			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RH937	7609231				2022-12-24	WOS:A1995RH93700028
J	WANNAMETHEE, SG; SHAPER, AG; WHINCUP, PH; WALKER, M				WANNAMETHEE, SG; SHAPER, AG; WHINCUP, PH; WALKER, M			SMOKING CESSATION AND THE RISK OF STROKE IN MIDDLE-AGED MEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ISCHEMIC-HEART-DISEASE; CIGARETTE-SMOKING; BRITISH MEN; WOMEN; INFARCTION; SMOKERS	Objective.-To examine the effects of giving up smoking, years since quitting smoking and the quantity of cigarettes smoked, and primary pipe or cigar smoking on the risk of stroke. Design, Subjects, and Setting.-A prospective study of cardiovascular disease and its risk factors in 7735 men aged 40 through 59 years drawn at random from the age-sex registers of one general practice in each of 24 British towns from 1978 through 1980 (the British Regional Heart Study). Main Outcome Measure.-Incidence of fatal and nonfatal major stroke events (strokes) during an average follow-up period of 12.75 years. Results.-During the 12.75 years of follow-up, there were 167 major stroke events (43 fatal and 124 nonfatal) in the 7264 men with no recall of previous ischemic heart disease or stroke. After full adjustment for other risk factors, current smokers had a nearly fourfold relative risk (RR) of stroke compared with never smokers (RR, 3.7; 95% confidence interval [CI], 2.0 to 6.9). Ex-cigarette smokers showed lower risk than current smokers but showed excess risk compared with never smokers (RR, 1.7, 95% CI, 0.9 to 3.3; P=.11); those who switched to pipe or cigar smoking showed a significantly increased risk (RR, 3.3; 95% CI, 1.6 to 7.1) similar to that of current light smokers. Primary pipe or cigar smokers also showed increased risk (RR, 2.2; 95% CI, 0.6 to 8.0), but the number of subjects involved was small. The benefit of giving up smoking completely was seen within 5 years of quitting, with no further consistent decline in risk thereafter, but this was dependent on the amount of tobacco smoked. Light smokers (<20 cigarettes/d) reverted to the risk level of those who had never smoked. Heavy smokers retained a more than twofold risk compared with never smokers (RR, 2.2; 95% CI, 1.1 to 4.3). The age-adjusted RR of stroke in those who quit smoking during the first 5 years of follow-up (recent quitters) was reduced compared with continuing smokers (RR, 1.8; 95% CI, 0.7 to 4.6 vs RR, 4.3; 95% CI, 2.1 to 8.8). The benefit of quitting smoking was observed in both normotensive and hypertensive men, but the absolute benefit was greater in hypertensive subjects. Conclusion.-Smoking cessation is associated with a considerable and rapid benefit in decreasing the risk of stroke, particularly in light smokers (<20 cigarettes/d); a complete loss of risk is not seen in heavy smokers. Switching to pipe or cigar smoking confers little benefit, emphasizing the need for complete cessation of smoking. The absolute benefit of quitting smoking on risk of stroke is most marked in hypertensive subjects.			WANNAMETHEE, SG (corresponding author), ROYAL FREE HOSP,SCH MED,DEPT PUBL HLTH,ROWLAND HILL ST,LONDON NW3 2PF,ENGLAND.		Lennon, Lucy/ABB-9433-2020	Lennon, Lucy/0000-0002-1738-1351; Whincup, Peter/0000-0002-5589-4107; Wannamethee, Sasiwarang/0000-0001-9484-9977				ABBOTT RD, 1986, NEW ENGL J MED, V315, P717, DOI 10.1056/NEJM198609183151201; BONITA R, 1986, BRIT MED J, V293, P6, DOI 10.1136/bmj.293.6538.6; BRUCE NG, 1988, J HYPERTENS, V6, P375; COLDITZ GA, 1988, NEW ENGL J MED, V318, P937, DOI 10.1056/NEJM198804143181501; COOK DG, 1986, LANCET, V2, P1376; COOK DG, 1989, INT J EPIDEMIOL, V18, P607, DOI 10.1093/ije/18.3.607; COOK DG, 1990, J SMOKING RELATED DI, V1, P45; COX DR, 1972, J R STAT SOC B, V34, P187; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; KAUFMAN DW, 1987, BRIT MED J, V294, P1315, DOI 10.1136/bmj.294.6583.1315; KAWACHI I, 1993, JAMA-J AM MED ASSOC, V269, P232, DOI 10.1001/jama.269.2.232; MEADE TW, 1987, LANCET, V2, P986; POCOCK SJ, 1988, HUM TOXICOL, V7, P95, DOI 10.1177/096032718800700201; POCOCK SJ, 1987, LANCET, V2, P197; ROBBINS AS, 1994, ANN INTERN MED, V120, P458, DOI 10.7326/0003-4819-120-6-199403150-00002; ROGERS RL, 1983, JAMA-J AM MED ASSOC, V250, P2796, DOI 10.1001/jama.250.20.2796; ROGERS RL, 1985, JAMA-J AM MED ASSOC, V253, P2970, DOI 10.1001/jama.253.20.2970; SANDERCOCK PAG, 1989, BRIT MED J, V298, P75, DOI 10.1136/bmj.298.6666.75; SHAPER AG, 1991, BRIT HEART J, V66, P384; SHAPER AG, 1981, BRIT MED J, V283, P179, DOI 10.1136/bmj.283.6285.179; SHAPER AG, 1991, BRIT MED J, V302, P1111, DOI 10.1136/bmj.302.6785.1111; SHINTON R, 1989, BMJ-BRIT MED J, V298, P789, DOI 10.1136/bmj.298.6676.789; Tang J, 1992, J SMOKING RELATED DI, V3, P203; WALKER M, 1984, J ROY COLL GEN PRACT, V34, P365; WANNAMETHEE G, 1994, THROMB HAEMOSTASIS, V72, P58; Wannamethee G, 1994, J Cardiovasc Risk, V1, P223; WANNAMETHEE G, 1994, J INTERN MED, V235, P164; WOLF PA, 1988, JAMA-J AM MED ASSOC, V259, P1025, DOI 10.1001/jama.259.7.1025; YARNELL JWG, 1987, J CLIN PATHOL, V40, P909, DOI 10.1136/jcp.40.8.909; 1991, SAS R217 SAS I TECHN; [No title captured]; 1990, CDC908416 US DEP HLT	32	192	202	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 12	1995	274	2					155	160						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH222	7596004				2022-12-24	WOS:A1995RH22200029
J	SHORT, RV				SHORT, RV			PERCUSSION AS A WAY OF LIFE	LANCET			English	Editorial Material											SHORT, RV (corresponding author), MONASH UNIV,DEPT PHYSIOL,CLAYTON,VIC,AUSTRALIA.							FEISTNER ATC, 1994, FOLIA PRIMATOL, P62	1	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 8	1995	346	8967					67	68		10.1016/S0140-6736(95)92108-7	http://dx.doi.org/10.1016/S0140-6736(95)92108-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH220	7603213	Bronze			2022-12-24	WOS:A1995RH22000006
J	TRUDEAU, MC; WARMKE, JW; GANETZKY, B; ROBERTSON, GA				TRUDEAU, MC; WARMKE, JW; GANETZKY, B; ROBERTSON, GA			HERG, A HUMAN INWARD RECTIFIER IN THE VOLTAGE-GATED POTASSIUM CHANNEL FAMILY	SCIENCE			English	Article							MAMMALIAN K+ CHANNEL; FUNCTIONAL EXPRESSION; DROSOPHILA; SHAKER; INACTIVATION; RECTIFICATION; BLOCKING; CLONING; REGION; LOCUS	In contrast to other members of the Eag family of voltage-gated, outwardly rectifying potassium channels, the human eag-related gene (HERG) has now been shown to encode an inwardly rectifying potassium channel. The properties of HERG channels are consistent with the gating properties of Eag-related and other outwardly rectifying, S4-containing potassium channels, but with the addition of an inactivation mechanism that attenuates potassium efflux during depolarization. Because mutations in HERG cause a form of long-QT syndrome, these properties of HERG channel function may be critical to the maintenance of normal cardiac rhythmicity.	UNIV WISCONSIN,SCH MED,DEPT PHYSIOL,MADISON,WI 53706; UNIV WISCONSIN,GENET LAB,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison				Robertson, Gail/0000-0003-4694-5790				ARMSTRON.CM, 1969, J GEN PHYSIOL, V54, P553, DOI 10.1085/jgp.54.5.553; ARMSTRONG CM, 1965, J GEN PHYSIOL, V48, P859, DOI 10.1085/jgp.48.5.859; ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; BRUGGEMANN A, 1993, NATURE, V365, P445, DOI 10.1038/365445a0; BUCHANAN LV, 1993, J CARDIOVASC PHARM, V22, P540; CRANEFIELD PF, 1988, CARDIAC ARRHYTHMIAS, P553; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; DIFRANCESCO D, 1985, PHILOS T ROY SOC B, V307, P353, DOI 10.1098/rstb.1985.0001; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; Ganetzky B, 1983, J NEUROGENET, V1, P17, DOI 10.3109/01677068309107069; HAGIWARA S, 1978, J PHYSIOL-LONDON, V279, P167, DOI 10.1113/jphysiol.1978.sp012338; HAGIWARA S, 1976, J GEN PHYSIOL, V67, P612; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; KAPLAN WD, 1969, GENETICS, V61, P399; KAPLAN WD, 1995, TRENDS GENETICS GUID; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; LIMAN ER, 1991, NATURE, V353, P752, DOI 10.1038/353752a0; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; LUDWIG J, 1994, EMBO J, V13, P4451, DOI 10.1002/j.1460-2075.1994.tb06767.x; MAKHINA EN, 1994, J BIOL CHEM, V269, P20468; MATSUDA H, 1987, NATURE, V325, P156, DOI 10.1038/325156a0; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PERIER F, 1994, P NATL ACAD SCI USA, V91, P6240, DOI 10.1073/pnas.91.13.6240; ROBERTSON GA, 1993, BIOPHYS J, V64, pA340; Robertson Gail A., 1995, Biophysical Journal, V68, pA363; RUDY B, 1992, METHOD ENZYMOL, V207, P225; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; SANGUINETTI MC, 1990, J GEN PHYSIOL, V96, P195, DOI 10.1085/jgp.96.1.195; SCHACHTMAN DP, 1992, SCIENCE, V258, P1654, DOI 10.1126/science.8966547; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; Trudeau Matthew C., 1995, Biophysical Journal, V68, pA32; TSENG GN, 1995, CARDIAC ELECTROPHYSI, P260; VANDENBERG CA, 1987, P NATL ACAD SCI USA, V84, P2560, DOI 10.1073/pnas.84.8.2560; WARMKE J, 1991, SCIENCE, V252, P1560, DOI 10.1126/science.1840699; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; Zei Paul C., 1995, Biophysical Journal, V68, pA32	41	1050	1082	0	50	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 7	1995	269	5220					92	95		10.1126/science.7604285	http://dx.doi.org/10.1126/science.7604285			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RG980	7604285				2022-12-24	WOS:A1995RG98000042
J	GARATTINI, S				GARATTINI, S			CULTURAL SHIFT IN ITALY DRUG POLICY	LANCET			English	Editorial Material											GARATTINI, S (corresponding author), IST RIC FARMACOL MARIO NEGRI,MILAN,ITALY.		Garattini, Silvio/AAA-6390-2020	Garattini, Silvio/0000-0003-0647-9297				GARATTINI L, 1994, PHARMACOECONOMICS, V6, P417, DOI 10.2165/00019053-199406050-00003; GARATTINI S, 1993, LANCET, V342, P1191, DOI 10.1016/0140-6736(93)92181-R	2	17	17	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 1	1995	346	8966					5	6		10.1016/S0140-6736(95)92647-X	http://dx.doi.org/10.1016/S0140-6736(95)92647-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RF985	7603156				2022-12-24	WOS:A1995RF98500005
J	BOSMA, PJ; CHOWDHURY, JR; BAKKER, C; GANTLA, S; DEBOER, A; OOSTRA, BA; LINDHOUT, D; TYTGAT, GNJ; JANSEN, PLM; ELFERINK, RPJO; CHOWDHURY, NR				BOSMA, PJ; CHOWDHURY, JR; BAKKER, C; GANTLA, S; DEBOER, A; OOSTRA, BA; LINDHOUT, D; TYTGAT, GNJ; JANSEN, PLM; ELFERINK, RPJO; CHOWDHURY, NR			THE GENETIC-BASIS OF THE REDUCED EXPRESSION OF BILIRUBIN UDP-GLUCURONOSYLTRANSFERASE-1 IN GILBERTS-SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CRIGLER-NAJJAR SYNDROME; RNA POLYMERASE-II; BETA-GLOBIN GENE; COMPLEX LOCUS; MUTATION; IDENTIFICATION; TRANSCRIPTION; PATIENT; HYPERBILIRUBINEMIA; DISEASE	Background. People with Gilbert's syndrome have mild, chronic unconjugated hyperbilirubinemia in the absence of liver disease or overt hemolysis. Hepatic glucuronidating activity, essential for efficient biliary excretion of bilirubin, is reduced to about 30 percent of normal. Methods. We sequenced the coding and promoter regions of the gene for bilirubin UDP-glucuronosyltransferase 1 (bilirubin/uridine diphosphoglucuronate-glucuronosyltransferase 1) - the only enzyme that contributes substantially to bi[irubin glucuronidation - in 10 unrelated patients with Gilbert's syndrome, 16 members of a kindred with a history of Crigler-Najjar syndrome type II, and 55 normal subjects. Results. The coding region of the gene for the enzyme was normal in the 10 patients with Gilbert's syndrome. These patients were homozygous for two extra bases (TA) in the TATAA element of the 5' promoter region of the gene (A(TA)(7)TAA rather than the normal A(TA)(6)TAA). The presence of the. longer TATAA element resulted in the reduced expression of a reporter gene, encoding firefly luciferase, in a human hepatoma cell line. The frequency of the abnormal allele was 40 percent among the normal subjects. The 3 men in the control group who were homozygous for the longer TATAA element had significantly higher serum bilirubin levels than the other 52 normal subjects (P = 0.009). Among the kindred with a history of Crigler-Najjar syndrome type II, only the six heterozygous carriers who had a longer TATAA element on the structurally normal allele had mild hyperbilirubinemia, characteristic of Gilbert's syndrome. Conclusions. Reduced expression of bilirubin UDP-glucuronosyltransferase 1 due to an abnormality in the promoter region of the gene for this enzyme appears to be necessary for Gilbert's syndrome but not sufficient for the complete manifestation of the syndrome.	ALBERT EINSTEIN COLL MED,MARION BESSIN LIVER RES CTR,DEPT MED,DIV GASTROENTEROL & LIVER DIS,BRONX,NY; ALBERT EINSTEIN COLL MED,DEPT MOLEC GENET,BRONX,NY; ERASMUS UNIV ROTTERDAM,DEPT CLIN GENET,3000 DR ROTTERDAM,NETHERLANDS; ACAD HOSP GRONINGEN,DEPT GASTROENTEROL & HEPATOL,GRONINGEN,NETHERLANDS	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Erasmus University Rotterdam; University of Groningen	BOSMA, PJ (corresponding author), UNIV AMSTERDAM,ACAD MED CTR,DEPT GASTROENTEROL & HEPATOL,FO-116,MEIBERGDREEF 9,1105 AZ AMSTERDAM,NETHERLANDS.		Lindhout, Dick/AAH-5765-2019; Jansen, Peter LM/I-4509-2013	Lindhout, Dick/0000-0001-9580-624X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039137, R01DK046057, P30DK041296] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK46057, R01-DK39137, P30-DK41296] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altman DG, 1991, PRACTICAL STATISTICS; ARIAS IM, 1969, AM J MED, V47, P395, DOI 10.1016/0002-9343(69)90224-1; ARIAS IM, 1957, SCIENCE, V126, P563, DOI 10.1126/science.126.3273.563; BAILEY A, 1977, LANCET, V1, P931; BENSINGER TA, 1973, P SOC EXP BIOL MED, V144, P417, DOI 10.3181/00379727-144-37603; BERK PD, 1972, ANN INTERN MED, V77, P527, DOI 10.7326/0003-4819-77-4-527; BERK PD, 1972, GASTROENTEROLOGY, V63, P472; BILLING BH, 1964, CLIN SCI, V27, P245; BLACK M, 1969, NEW ENGL J MED, V280, P1266, DOI 10.1056/NEJM196906052802303; BOSMA PJ, 1993, GASTROENTEROLOGY, V105, P216, DOI 10.1016/0016-5085(93)90029-C; BOSMA PJ, 1992, FASEB J, V6, P2859, DOI 10.1096/fasebj.6.10.1634050; BOSMA PJ, 1994, J BIOL CHEM, V269, P17960; BOSMA PJ, 1992, HEPATOLOGY, V15, P941, DOI 10.1002/hep.1840150531; BOSMA PJ, 1994, J BIOL CHEM, V269, P2542; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chowdhury Jayanta Roy, 1994, P471; DIERKS P, 1983, CELL, V32, P695, DOI 10.1016/0092-8674(83)90055-7; ERPS LT, 1994, J CLIN INVEST, V93, P564, DOI 10.1172/JCI117008; FELSHER BF, 1979, J LAB CLIN MED, V93, P414; FEVERY J, 1977, J CLIN INVEST, V60, P970, DOI 10.1172/JCI108877; Gilbert A., 1901, SEMAINE MEDICALE, V21, P241; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; GROSVELD GC, 1982, NATURE, V295, P120, DOI 10.1038/295120a0; HUNTER JO, 1973, GUT, V14, P46, DOI 10.1136/gut.14.1.46; Jendrassik L, 1938, BIOCHEM Z, V297, P81; LABRUNE P, 1993, HEPATOLOGY, V18, pA126, DOI 10.1016/0270-9139(93)92034-W; LUNDH B, 1972, SCAND J CLIN LAB INV, V30, P421, DOI 10.3109/00365517209080280; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MARTIN JF, 1976, GASTROENTEROLOGY, V70, P385; MOGHRABI N, 1993, GENOMICS, V18, P171, DOI 10.1006/geno.1993.1451; MOGHRABI N, 1993, AM J HUM GENET, V53, P722; MURACA M, 1984, GASTROENTEROLOGY, V87, P308; OWENS D, 1975, J MED GENET, V12, P152, DOI 10.1136/jmg.12.2.152; OWENS IS, 1992, PHARMACOGENETICS, V2, P93, DOI 10.1097/00008571-199206000-00001; PLATT T, 1972, EXPT MOL GENETICS, P352; POWELL LW, 1967, NEW ENGL J MED, V277, P1108, DOI 10.1056/NEJM196711232772102; RITTER JK, 1992, J CLIN INVEST, V90, P150, DOI 10.1172/JCI115829; RITTER JK, 1993, J BIOL CHEM, V268, P23573; RITTER JK, 1992, J BIOL CHEM, V267, P3257; RITTER JK, 1991, J BIOL CHEM, V266, P1043; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; SEPPEN J, 1994, J CLIN INVEST, V94, P2385, DOI 10.1172/JCI117604; SIEG A, 1987, DEUT MED WOCHENSCHR, V112, P1206, DOI 10.1055/s-2008-1068222; SPIVAK W, 1985, BIOCHEM J, V225, P787, DOI 10.1042/bj2250787; Thompson R.P.H., 1981, FAMILIAL HYPERBILIRU, P91	45	1125	1173	1	30	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 2	1995	333	18					1171	1175		10.1056/NEJM199511023331802	http://dx.doi.org/10.1056/NEJM199511023331802			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB560	7565971				2022-12-24	WOS:A1995TB56000002
J	CROSS, SS; HARRISON, RF; KENNEDY, RL				CROSS, SS; HARRISON, RF; KENNEDY, RL			INTRODUCTION TO NEURAL NETWORKS	LANCET			English	Note									UNIV SHEFFIELD,DEPT AUTOMAT CONTROL & SYST ENGN,SHEFFIELD,S YORKSHIRE,ENGLAND; UNIV EDINBURGH,DEPT MED,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND	University of Sheffield; University of Edinburgh	CROSS, SS (corresponding author), UNIV SHEFFIELD,SCH MED,DEPT PATHOL,BEECH HILL RD,SHEFFIELD S10 2UL,S YORKSHIRE,ENGLAND.		Harrison, Robert/B-9034-2008					Ash T., 1989, Connection Science, V1, P365, DOI 10.1080/09540098908915647; BRAHAMS D, 1989, LANCET, V1, P632; CARPENTER GA, 1991, NEURAL NETWORKS, V4, P565, DOI 10.1016/0893-6080(91)90012-T; CARPENTER GA, 1987, COMPUT VISION GRAPH, V37, P54, DOI 10.1016/S0734-189X(87)80014-2; CARPENTER GA, 1993, P WORLD C NEURAL NET, V1, P501; Cybenko G., 1989, Mathematics of Control, Signals, and Systems, V2, P303, DOI 10.1007/BF02551274; Fausett L., 1994, FUNDAMENTALS NEURAL; GOLDMAN L, 1988, NEW ENGL J MED, V318, P797, DOI 10.1056/NEJM198803313181301; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Harrison R. F., 1994, Journal of Artificial Neural Networks, V1, P183; HART A, 1990, MED INFORM, V15, P229, DOI 10.3109/14639239009025270; JOHNSTON ME, 1994, ANN INTERN MED, V120, P135, DOI 10.7326/0003-4819-120-2-199401150-00007; Kohonen Teuvo, 1984, SELF ORG ASS MEMORY; McCulloch Warren S., 1943, BULL MATH BIOPHYS, V5, P115, DOI 10.1007/BF02478259; Moody J, 1989, NEURAL COMPUT, V1, P281, DOI 10.1162/neco.1989.1.2.281; Mozer M. C., 1989, Connection Science, V1, P3, DOI 10.1080/09540098908915626; RUMELHART DE, 1986, NATURE, V323, P533, DOI 10.1038/323533a0; STEEN PM, 1994, ANN THORAC SURG, V58, P1836, DOI 10.1016/0003-4975(94)91723-X; WYATT J, 1991, 15TH P ANN S COMP AP, P3	19	378	383	1	30	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 21	1995	346	8982					1075	1079		10.1016/S0140-6736(95)91746-2	http://dx.doi.org/10.1016/S0140-6736(95)91746-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA697	7564791				2022-12-24	WOS:A1995TA69700015
J	HERNANDEZRODRIGUEZ, NA; CAMBREY, AD; HARRISON, NK; CHAMBERS, RC; GRAY, AJ; SOUTHCOTT, AM; DUBOIS, RM; BLACK, CM; SCULLY, MF; MCANULTY, RJ; LAURENT, GJ				HERNANDEZRODRIGUEZ, NA; CAMBREY, AD; HARRISON, NK; CHAMBERS, RC; GRAY, AJ; SOUTHCOTT, AM; DUBOIS, RM; BLACK, CM; SCULLY, MF; MCANULTY, RJ; LAURENT, GJ			ROLE OF THROMBIN IN PULMONARY FIBROSIS	LANCET			English	Note							GROWTH-FACTORS	Pulmonary fibrosis commonly develops in systemic sclerosis. We assessed the role of thrombin in promoting fibroblast proliferation in the lungs in this disorder. Bronchoalveolar lavage fluid (BALF) thrombin concentrations were higher in ten patients with systemic sclerosis than in 12 healthy controls (14.6 vs 3.6 nmol/L, p<0.02), but values in patients with cryptogenic fibrosing alveolitis (n=10) or sarcoidosis (n=10) were not increased. BALF from all patients induced fibroblast proliferation. This proliferation was attenuated by thrombin inhibitors for BALF from systemic sclerosis patients only. We suggest thrombin contributes to lung fibroblast proliferation in this disorder.	UNIV LONDON UNIV COLL,SCH MED,CTR CARDIOPULM BIOCHEM & RESP MED,LONDON WC1E 6JJ,ENGLAND; MORRISTON HOSP,RESP UNIT,SWANSEA,W GLAM,WALES; NATL HEART & LUNG INST,INTERSTITIAL LUNG DIS UNIT,LONDON,ENGLAND; ROYAL FREE HOSP,DEPT RHEUMATOL,LONDON,ENGLAND; THROMBOSIS RES INST,LONDON SW3 6LR,ENGLAND	University of London; University College London; UCL Medical School; Morriston Hospital; Imperial College London; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Thrombosis Research Institute			McAnulty, Robin J/C-2502-2008	McAnulty, Robin J/0000-0003-1936-4245; Chambers, Rachel/0000-0003-1370-9417				ANTONIADES HN, 1990, J CLIN INVEST, V86, P1055, DOI 10.1172/JCI114808; CAMBREY AD, 1994, AM J RESP CELL MOL, V11, P439, DOI 10.1165/ajrcmb.11.4.7917311; DAWES KE, 1993, EUR J CELL BIOL, V61, P126; GRAY AJ, 1990, J CELL SCI, V96, P271; HARRISON NK, 1991, AM REV RESPIR DIS, V144, P706, DOI 10.1164/ajrccm/144.3_Pt_1.706; HARRISON NK, 1994, CLIN SCI, V86, P141, DOI 10.1042/cs0860141; HARRISON NK, 1993, RESP MED, P190; IDELL S, 1987, AM REV RESPIR DIS, V136, P1466, DOI 10.1164/ajrccm/136.6.1466; LEROY EC, 1988, TXB MED, P1211; OLIVER MH, 1989, J CELL SCI, V92, P513	10	117	118	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 21	1995	346	8982					1071	1073		10.1016/S0140-6736(95)91744-6	http://dx.doi.org/10.1016/S0140-6736(95)91744-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA697	7564789				2022-12-24	WOS:A1995TA69700013
J	PEET, SM; CASTLEDEN, CM; MCGROTHER, CW				PEET, SM; CASTLEDEN, CM; MCGROTHER, CW			PREVALENCE OF URINARY AND FECAL INCONTINENCE IN HOSPITALS AND RESIDENTIAL AND NURSING-HOMES FOR OLDER-PEOPLE	BRITISH MEDICAL JOURNAL			English	Article									UNIV LEICESTER,LEICESTER ROYAL INFIRM,DEPT EPIDEMIOL & PUBL HLTH,LEICESTER LE2 7LX,LEICS,ENGLAND	University of Leicester	PEET, SM (corresponding author), UNIV LEICESTER,LEICESTER GEN HOSP,DIV MED ELEDRLY,LEICESTER LE5 4PW,LEICS,ENGLAND.							Clarke M, 1979, HLTH TRENDS, V11, P17; Donaldson L J, 1983, Health Trends, V15, P58; MCGROTHER CW, 1987, AGE AGEING, V16, P105, DOI 10.1093/ageing/16.2.105; STERN MC, 1993, BRIT MED J, V306, P827, DOI 10.1136/bmj.306.6881.827; TOBIN GW, 1986, AGE AGEING, V15, P292, DOI 10.1093/ageing/15.5.292	5	75	75	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 21	1995	311	7012					1063	1064		10.1136/bmj.311.7012.1063	http://dx.doi.org/10.1136/bmj.311.7012.1063			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB354	7580664	Green Published			2022-12-24	WOS:A1995TB35400023
J	LLOYD, DCEF; HARRIS, CM; ROBERTS, DJ				LLOYD, DCEF; HARRIS, CM; ROBERTS, DJ			SPECIFIC THERAPEUTIC GROUP AGE-SEX RELATED PRESCRIBING UNITS (STAR-PUS) - WEIGHTINGS FOR ANALYZING GENERAL PRACTICES PRESCRIBING IN ENGLAND	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To derive cost comparators for prescribing by English general practitioners in eight specific therapeutic groups, based on age-sex related weightings, and to confirm, from a new dataset, earlier age-sex weightings for overall prescribing (ASTRO-PUs). Design-Calculations based on one year's prescribing data from selected practices using AAH Meditel software, held on MediPlus by Intercontinental Medical Statistics (IMS, UK and Ireland), and research practices using VAMP software, held on the General Practice Research Database. Setting-112 English practices with 739 672 patients and 510 British practices with 3 126 570 patients. Main outcome measures-Cost based weightings for 18 age-sex groups and for temporary residents for eight leading specific therapeutic groups and for prescribing overall. Results-The two datasets were similar in age distribution and in the way that prescription numbers were distributed by age-sex band in each therapeutic group. The cost based weightings for specific therapeutic groups showed great variation in the use of these groups for patients in different age-sex groups. When these weightings were applied to the prescribing of practices in two family health services authorities they differed in their power to predict prescribing costs: for cardiovascular and gastrointestinal drugs predictive power was particularly high; for drugs for infections it was particularly low, since these are widely used at all ages and for both sexes. Cost based weightings for overall prescribing derived from the IMS data were similar to those of the ASTRO-PU system even though they were derived by different methods from different datasets. Conclusions-The weightings (STAR-PUs) offer a sound basis for cost comparisons at the therapeutic group level. Cost-based weightings for overall prescribing derived from the UMS data were reassuringly similar to those of the existing ASTRO-PU system.	UNIV LEEDS,RES SCH MED,PRESCRIBING RES UNIT,LEEDS LS2 9NZ,W YORKSHIRE,ENGLAND	University of Leeds								BOGLE SM, 1994, BRIT MED J, V308, P637, DOI 10.1136/bmj.308.6929.637; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; Jick H., 1992, PHARMACOEPIDEM DR S, V1, P347, DOI DOI 10.1002/PDS.2630010607; ROBERTS SJ, 1993, BRIT MED J, V307, P485, DOI 10.1136/bmj.307.6902.485; SLEATOR DJD, 1993, BRIT J GEN PRACT, V43, P102	5	53	57	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 14	1995	311	7011					991	994						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA079	7580642				2022-12-24	WOS:A1995TA07900027
J	MEUNIER, JC; MOLLEREAU, C; TOLL, L; SUAUDEAU, C; MOISAND, C; ALVINERIE, P; BUTOUR, JL; GUILLEMOT, JC; FERRARA, P; MONSARRAT, B; MAZARGUIL, H; VASSART, G; PARMENTIER, M; COSTENTIN, J				MEUNIER, JC; MOLLEREAU, C; TOLL, L; SUAUDEAU, C; MOISAND, C; ALVINERIE, P; BUTOUR, JL; GUILLEMOT, JC; FERRARA, P; MONSARRAT, B; MAZARGUIL, H; VASSART, G; PARMENTIER, M; COSTENTIN, J			ISOLATION AND STRUCTURE OF THE ENDOGENOUS AGONIST OF OPIOID RECEPTOR-LIKE ORL(1) RECEPTOR	NATURE			English	Article							PITUITARY; DYNORPHIN	THE ORL(1) receptor, an orphan receptor whose human(1) and murine(2-8) complementary DNAs have recently been characterized, structurally resembles opioid receptors and is negatively coupled with adenylate cyclase(1). ORL(1) transcripts are particularly abundant in the central nervous system. Here we report the isolation, on the basis of its ability to inhibit the cyclase in a stable recombinant CHO(ORL(1)(+)) cell line, of a neuropeptide that resembles dynorphin A(9) and whose amino acid sequence is Phe-Gly-Gly-Phe-Thr-Gly-Ala-Arg-Lys-Ser-Ala-Arg-Lys-Leu-Ala-Asn- Gln. A rat-brain cDNA encodes the peptide flanked by Lys-Arg proteolytic cleavage motifs. The synthetic heptadecapeptide potently inhibits adenylate cyclase in CHO(ORL(1)(+)) cells in culture and induces hyperalgesia when administered intracerebroventricularly to mice. Taken together, these data indicate that the newly discovered heptadecapeptide is an endogenous agonist of the ORL(1) receptor and that it may be endowed with pro-nociceptive properties.	FAC MED & PHARM ST ETIENNE ROUVRAY, IFRMP,CNRS,UNITE NEUROPSYCHOPHARMACOL EXPTL, URA 1969, F-76803 ST ETIENNE DU ROUVRAY, FRANCE; SANOFI RECH, UNITE BIOCHIM PROT, F-31676 LABEGE, FRANCE; FREE UNIV BRUSSELS, CAMPUS HOSP ERASME, IRIBHN, B-1070 BRUSSELS, BELGIUM; SRI INT, MENLO PK, CA 94025 USA	Centre National de la Recherche Scientifique (CNRS); Sanofi-Aventis; Sanofi France; Universite Libre de Bruxelles; Vrije Universiteit Brussel; SRI International	MEUNIER, JC (corresponding author), CNRS, UPR 8221, PHARMACOL & TOXICOL FONDAMENTALES LAB, 205 ROUTE NARBONNE, F-31077 TOULOUSE, FRANCE.		hu, jenny/AAK-8712-2020	Mollereau, Catherine/0000-0003-1543-5624				ALVAREZ R, 1992, ANAL BIOCHEM, V203, P76, DOI 10.1016/0003-2697(92)90045-9; BUNZOW JR, 1994, FEBS LETT, V347, P284, DOI 10.1016/0014-5793(94)00561-3; CHAVKIN C, 1981, P NATL ACAD SCI-BIOL, V78, P6543, DOI 10.1073/pnas.78.10.6543; CHEN Y, 1994, FEBS LETT, V347, P279, DOI 10.1016/0014-5793(94)00560-5; EDDY NB, 1953, J PHARMACOL EXP THER, V107, P385; EVANS CJ, 1988, OPIATE RECEPTORS, P23; FUKUDA K, 1994, FEBS LETT, V343, P42, DOI 10.1016/0014-5793(94)80603-9; GOLDSTEIN A, 1981, P NATL ACAD SCI-BIOL, V78, P7219, DOI 10.1073/pnas.78.11.7219; LACHOWICZ JE, 1995, J NEUROCHEM, V64, P34; MOLLEREAU C, 1994, FEBS LETT, V341, P33, DOI 10.1016/0014-5793(94)80235-1; NISHI M, 1994, BIOCHEM BIOPH RES CO, V205, P1353, DOI 10.1006/bbrc.1994.2814; TESCHEMACHER H, 1975, LIFE SCI, V16, P1771, DOI 10.1016/0024-3205(75)90271-4; WAHLESTEDT C, 1994, TRENDS PHARMACOL SCI, V15, P42, DOI 10.1016/0165-6147(94)90107-4; WANG JB, 1994, J BIOL CHEM, V269, P25966; WANG JB, 1994, FEBS LETT, V348, P75, DOI 10.1016/0014-5793(94)00557-5; WICK MJ, 1994, MOL BRAIN RES, V27, P37, DOI 10.1016/0169-328X(94)90181-3; XUE JC, 1994, J BIOL CHEM, V269, P30195	17	1736	1832	0	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 12	1995	377	6549					532	535		10.1038/377532a0	http://dx.doi.org/10.1038/377532a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ336	7566152				2022-12-24	WOS:A1995RZ33600064
J	CHRYSTIE, IL; WOLFE, CDA; KENNEDY, J; ZANDER, L; TILZEY, A; BANATVALA, JE				CHRYSTIE, IL; WOLFE, CDA; KENNEDY, J; ZANDER, L; TILZEY, A; BANATVALA, JE			VOLUNTARY, NAMED TESTING FOR HIV IN A COMMUNITY-BASED ANTENATAL CLINIC - A PILOT-STUDY	BRITISH MEDICAL JOURNAL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TRANSMISSION; WOMEN; RISK	Despite the increasing advantages of identifying HIV infection in pregnant women, only some 12% of HIV positive women attending antenatal clinics in London have been identified by named testing. As virtually all antenatal care will be community based within the next two to three years, we assessed the problems of introducing named HIV testing during pregnancy into the primary care setting. Planning the service took a considerable time and required the production of educational material for both staff and pregnant women and some reorganisation of procedures. Over a one year period an uptake of 44% was noted. Several problems were encountered including an average of 21 minutes needed to give information on AIDS and HIV, an adverse effect on the midwife-mother relationship, and anxiety (affecting both women and midwives). Possible solutions to this difficult problem are discussed.	UNITED MED & DENT SCH,ST THOMAS HOSP,DEPT VIROL,LONDON SE1 7EH,ENGLAND; UNITED MED & DENT SCH,ST THOMAS HOSP,DEPT PUBL HLTH MED,LONDON SE1 7EH,ENGLAND; UNITED MED & DENT SCH,DIRECTORATE OBSTET & GYNAECOL,LONDON SE1 7EH,ENGLAND; UNITED MED & DENT SCH,DEPT GEN PRACTICE,LONDON SE1 7EH,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of London; King's College London; University of London; King's College London				Wolfe, Charles/0000-0001-8264-0981				ADES AE, 1992, AIDS, V6, P1031, DOI 10.1097/00002030-199209000-00018; BANATVALA JE, 1994, LANCET, V343, P1113, DOI 10.1016/S0140-6736(94)90230-5; BANATVALA JE, 1991, LANCET, V337, P1218, DOI 10.1016/0140-6736(91)92885-6; BARBACCI M, 1991, LANCET, V337, P709, DOI 10.1016/0140-6736(91)90286-X; BOYER PJ, 1994, JAMA-J AM MED ASSOC, V271, P1925, DOI 10.1001/jama.271.24.1925; Chrystie I, 1992, Health Trends, V24, P13; CHRYSTIE IL, 1995, AIDS CARE, V7, P135, DOI 10.1080/09540129550126650; CHRYSTIE IL, 1992, LANCET, V339, P364, DOI 10.1016/0140-6736(92)91682-X; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; COZEN W, 1993, J ACQ IMMUN DEF SYND, V6, P95; DELAMOTHE T, 1995, BRIT MED J, V310, P213, DOI 10.1136/bmj.310.6974.213; DESMOND N, 1994, BRIT MED J, V309, P877, DOI 10.1136/bmj.309.6958.877a; DUNN DT, 1992, LANCET, V340, P585, DOI 10.1016/0140-6736(92)92115-V; Flesch R, 1948, J APPL PSYCHOL, V32, P221, DOI 10.1037/h0057532; Holland F J, 1994, J Med Screen, V1, P176; HOWARD LC, 1989, BRIT J OBSTET GYNAEC, V96, P135, DOI 10.1111/j.1471-0528.1989.tb01651.x; MEADOWS J, 1994, INT J STD AIDS, V5, P400, DOI 10.1177/095646249400500604; MEADOWS J, 1992, LANCET, V339, P622; NICOLL A, 1994, BRIT MED J, V309, P376, DOI 10.1136/bmj.309.6951.376a; 1993, CHANGING CHILDBIRTH; 1994, GUIDELINES OFFERING; 1995, UNLINKED ANONYMOUS H; 1994, LANCET, V343, P1464; 1992, GUIDELINES OFFERING	24	22	22	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 7	1995	311	7010					928	931						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ237	7580555	Green Published			2022-12-24	WOS:A1995RZ23700026
J	JAYARAMAN, V; RODGERS, KR; MUKERJI, I; SPIRO, TG				JAYARAMAN, V; RODGERS, KR; MUKERJI, I; SPIRO, TG			HEMOGLOBIN ALLOSTERY - RESONANCE RAMAN-SPECTROSCOPY OF KINETIC INTERMEDIATES	SCIENCE			English	Article							HISTIDINE LINKAGE; PHOTOLYSIS; DYNAMICS; COOPERATIVITY; RELAXATION; BINDING	The end states, R and T, of the allosteric transition in hemoglobin (Hb) are structurally well characterized, but there is little information on intermediate structures along the allosteric pathway. These intermediates were examined by means of time-resolved resonance Raman spectroscopy in the nanosecond-to-microsecond interval after HbCO photolysis. Complementary spectra of the heme group and of the tyrosine and tryptophan residues were recorded during laser excitation at 436 and 230 nanometers. These spectra reveal a sequence of interleaved tertiary and quaternary motions during the photocycle, motions involving the proximal and distal helices, and the alpha(1) beta(2) subunit interface. This sequence leads to a modified form of the T state, in which the alpha(1) beta(2) interface is deformed as a result of two carbon monoxide molecules binding to the same dimer within the tetramer.	PRINCETON UNIV,DEPT CHEM,PRINCETON,NJ 08544; N DAKOTA STATE UNIV,DEPT CHEM,FARGO,ND 58105; WESLEYAN UNIV,DEPT BIOCHEM & MOLEC BIOL,MIDDLETOWN,CT 06457	Princeton University; North Dakota State University Fargo; Wesleyan University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025158] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 25158] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERS GK, 1990, BIOPHYS CHEM, V37, P371, DOI 10.1016/0301-4622(90)88036-R; ACKERS GK, 1992, SCIENCE, V255, P54, DOI 10.1126/science.1553532; ANFINRUD PA, 1989, P NATL ACAD SCI USA, V86, P8387, DOI 10.1073/pnas.86.21.8387; BALDWIN J, 1979, J MOL BIOL, V129, P175, DOI 10.1016/0022-2836(79)90277-8; BANGCHAROENPAUR.O, 1984, J AM CHEM SOC, V106, P5688; DASGUPTA S, 1986, BIOCHEMISTRY-US, V25, P5941, DOI 10.1021/bi00368a016; FRIEDMAN JM, 1983, J BIOL CHEM, V258, P564; FRIEDMAN JM, 1982, SCIENCE, V218, P1244, DOI 10.1126/science.7146910; FRIEDMAN JM, 1980, NATURE, V284, P570, DOI 10.1038/284570a0; GELLIN BR, 1983, J MOL BIOL, V171, P489; HOFRICHTER J, 1983, P NATL ACAD SCI-BIOL, V80, P2235, DOI 10.1073/pnas.80.8.2235; JAYARAMAN V, 1995, BIOCHEMISTRY-US, V34, P4511, DOI 10.1021/bi00014a002; JAYARAMAN V, 1993, BIOCHEMISTRY-US, V32, P4547, DOI 10.1021/bi00068a009; KAMINAKA S, 1990, J AM CHEM SOC, V112, P23, DOI 10.1021/ja00157a006; KAMINAKA S, 1992, J AM CHEM SOC, V114, P3256, DOI 10.1021/ja00035a015; KERR EA, 1987, BIOL APPLICATIONS RA, V3, P39; LIM M, 1995, SCIENCE, V269, P962, DOI 10.1126/science.7638619; LOCKE B, 1991, CHEM PHYS, V158, P409, DOI 10.1016/0301-0104(91)87080-F; MIURA S, 1982, BIOCHEMISTRY-US, V21, P6280, DOI 10.1021/bi00267a037; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; MUKERJI I, 1994, BIOCHEMISTRY-US, V33, P13132, DOI 10.1021/bi00248a024; ORMOS P, 1988, P NATL ACAD SCI USA, V85, P8492, DOI 10.1073/pnas.85.22.8492; PERUTZ MF, 1990, MECHANISMS COOPERATI; PIN S, 1986, CHEM PHYS LETT, V128, P79, DOI 10.1016/0009-2614(86)80149-X; RODGERS KR, 1992, J AM CHEM SOC, V114, P3697, DOI 10.1021/ja00036a019; RODGERS KR, 1994, SCIENCE, V265, P1697, DOI 10.1126/science.8085153; ROUSSEAU DL, 1987, BIOL APPLICATIONS RA, V3, P133; SAWICKI CA, 1976, J BIOL CHEM, V251, P1533; SCHLICHTING I, 1994, NATURE, V371, P808, DOI 10.1038/371808a0; SCHUMACHER MA, 1995, NATURE, V375, P84, DOI 10.1038/375084a0; SCOTT TW, 1984, J AM CHEM SOC, V106, P5677, DOI 10.1021/ja00331a044; Spiro T.G., 1983, IRON PORPHYRINS P2, P89; TENG TY, 1994, NAT STRUCT BIOL, V1, P701, DOI 10.1038/nsb1094-701	33	171	172	2	37	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 29	1995	269	5232					1843	1848		10.1126/science.7569921	http://dx.doi.org/10.1126/science.7569921			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX194	7569921				2022-12-24	WOS:A1995RX19400029
J	PETERSEN, JM; SKALICKY, JJ; DONALDSON, LW; MCINTOSH, LP; ALBER, T; GRAVES, BJ				PETERSEN, JM; SKALICKY, JJ; DONALDSON, LW; MCINTOSH, LP; ALBER, T; GRAVES, BJ			MODULATION OF TRANSCRIPTION FACTOR ETS-1 DNA-BINDING - DNA-INDUCED UNFOLDING OF AN ALPHA-HELIX	SCIENCE			English	Article							INDUCED CONFORMATIONAL CHANGE; CRYSTAL-STRUCTURE; PROTEIN-KINASES; BASIC REGION; DOMAIN; SEQUENCE; FAMILY; GCN4; REPRESSOR; SUBUNITS	Conformational changes, including local protein folding, play important roles in protein-DNA interactions. Here, studies of the transcription factor Ets-1 provided evidence that local protein unfolding also can accompany DNA binding. Circular dichroism and partial proteolysis showed that the secondary structure of the Ets-1 DNA-binding domain is unchanged in the presence of DNA. In contrast, DNA allosterically induced the unfolding of an cr helix that lies within a flanking region involved in the negative regulation of DNA binding. These findings suggest a structural basis for the intramolecular inhibition of DNA binding and a mechanism for the cooperative partnerships that are common features of many eukaryotic transcription factors.	UNIV UTAH,SCH MED,DEPT ONCOL SCI,DIV MOLEC BIOL & GENET,SALT LAKE CITY,UT 84132; UNIV UTAH,SCH MED,HUNTSMAN CANC INST,SALT LAKE CITY,UT 84132; UNIV BRITISH COLUMBIA,DEPT CHEM,VANCOUVER,BC V6T 1Z3,CANADA; UNIV BRITISH COLUMBIA,DEPT BIOCHEM & MOLEC BIOL,VANCOUVER,BC V6T 1Z3,CANADA; UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; University of British Columbia; University of British Columbia; University of California System; University of California Berkeley					NCI NIH HHS [CA 42014] Funding Source: Medline; NIGMS NIH HHS [GM38663, R01 GM038663, GM 48958] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038663, R01GM048958, R29GM038663] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CLARKE ND, 1991, SCIENCE, V254, P267, DOI 10.1126/science.1833818; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DONALDSON LW, 1994, BIOCHEMISTRY-US, V33, P13509, DOI 10.1021/bi00250a001; DONALDSON LW, UNPUB; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FISHER RJ, 1994, PROTEIN SCI, V3, P257; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JANKNECHT R, 1994, ONCOGENE, V9, P1273; JONSEN MD, UNPUB; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; KUDDUS R, 1993, NUCLEIC ACIDS RES, V21, P1789, DOI 10.1093/nar/21.8.1789; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LEFSTIN JA, 1994, GENE DEV, V8, P2842, DOI 10.1101/gad.8.23.2842; LIANG H, 1994, NAT STRUCT BIOL, V1, P871, DOI 10.1038/nsb1294-871; LIEBERMAN PM, 1991, MOL CELL BIOL, V11, P63, DOI 10.1128/MCB.11.1.63; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MUKHERJI S, 1994, J BIOL CHEM, V269, P20733; NEWMAN M, 1995, SCIENCE, V269, P656, DOI 10.1126/science.7624794; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PETERSEN JH, UNPUB; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SANCHEZGARCIA I, 1993, EMBO J, V12, P4243, DOI 10.1002/j.1460-2075.1993.tb06108.x; SAUDEK V, 1991, BIOCHEMISTRY-US, V30, P1310, DOI 10.1021/bi00219a022; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHUMAN JD, 1990, SCIENCE, V249, P771, DOI 10.1126/science.2202050; SKALICKY JJ, UNPUB; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; TAN S, 1990, CELL, V62, P367, DOI 10.1016/0092-8674(90)90373-M; von Hippel P H, 1974, Proc Natl Acad Sci U S A, V71, P4808; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; Xu Q., UNPUB; ZHAO D, 1993, J MOL BIOL, V229, P735, DOI 10.1006/jmbi.1993.1076	47	175	175	0	7	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 29	1995	269	5232					1866	1869		10.1126/science.7569926	http://dx.doi.org/10.1126/science.7569926			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX194	7569926				2022-12-24	WOS:A1995RX19400036
J	COLLINS, JE; COLE, CG; SMINK, LJ; GARRETT, CL; LEVERSHA, MA; SODERLUND, CA; MASLEN, GL; EVERETT, LA; RICE, KM; COFFEY, AJ; GREGORY, SG; GWILLIAM, R; DUNHAM, A; DAVIES, AF; HASSOCK, S; TODD, CM; LEHRACH, H; HULSEBOS, JM; WEISSENBACH, J; MORROW, B; KUCHERLAPATI, RS; WADEY, R; SCAMBLER, PJ; KIM, UJ; SIMON, MI; PEYRARD, M; XIE, YG; CARTER, NP; DURBIN, R; DUMANSKI, JP; BENTLEY, DR; DUNHAM, I				COLLINS, JE; COLE, CG; SMINK, LJ; GARRETT, CL; LEVERSHA, MA; SODERLUND, CA; MASLEN, GL; EVERETT, LA; RICE, KM; COFFEY, AJ; GREGORY, SG; GWILLIAM, R; DUNHAM, A; DAVIES, AF; HASSOCK, S; TODD, CM; LEHRACH, H; HULSEBOS, JM; WEISSENBACH, J; MORROW, B; KUCHERLAPATI, RS; WADEY, R; SCAMBLER, PJ; KIM, UJ; SIMON, MI; PEYRARD, M; XIE, YG; CARTER, NP; DURBIN, R; DUMANSKI, JP; BENTLEY, DR; DUNHAM, I			A HIGH-DENSITY YAC CONTIG MAP OF HUMAN-CHROMOSOME-22	NATURE			English	Article							YEAST ARTIFICIAL CHROMOSOMES; SEQUENCE TAGGED SITES; HUMAN GENOME; HUMAN DNA; CLONES; LIBRARY; REGION; CLONING; GENES; TRANSPEPTIDASE	We have constructed a high-resolution clone map of human chromosome 22 which integrates the available physical and genetic information, establishing a single consensus. The map consists of all classes of DNA landmarks ordered on 705 yeast artificial chromosomes (YACs) at an average landmark density of more than one per 70 kilobases. This map represents the practical limits of currently available YAC resources and provides the basis for determination of the entire gene content and genomic DNA sequence of human chromosome 22.	SANGER CTR,CAMBRIDGE,ENGLAND; UNITED MED & DENT SCH,GUYS HOSP,DIV MED & MOLEC GENET,LONDON SE1 9RT,ENGLAND; MAX PLANCK INST MOLEC GENET,D-14195 BERLIN,GERMANY; UNIV AMSTERDAM,ACAD MED CTR,INST HUMAN GENET,1105 AZ AMSTERDAM,NETHERLANDS; GENETHON SA,CNRS,URA 1922,F-91002 EVRY,FRANCE; YESHIVA UNIV ALBERT EINSTEIN COLL MED,BRONX,NY 10461; INST CHILD HLTH,DIV BIOCHEM & GENET,MOLEC MED UNIT,LONDON WC1N 1EH,ENGLAND; CALTECH,DIV BIOL,PASADENA,CA 91125; KAROLINSKA HOSP,DEPT MOLEC GENET,CLIN GENET UNIT,S-17176 STOCKHOLM,SWEDEN	Wellcome Trust Sanger Institute; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Max Planck Society; University of Amsterdam; Academic Medical Center Amsterdam; Centre National de la Recherche Scientifique (CNRS); Yeshiva University; Albert Einstein College of Medicine; University of London; University College London; California Institute of Technology; Karolinska Institutet; Karolinska University Hospital			Kucherlapati, Raju/ABC-8807-2021; Scambler, Peter J/C-4998-2008; Durbin, Richard/AAE-7178-2019; Scambler, Peter/AAZ-6026-2020	Scambler, Peter J/0000-0002-1487-4628; Durbin, Richard/0000-0002-9130-1006; Scambler, Peter/0000-0002-1487-4628; Maslen, Gareth/0000-0001-7318-3678; Dunham, Ian/0000-0003-2525-5598	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; ANAND R, 1990, NUCLEIC ACIDS RES, V18, P1951, DOI 10.1093/nar/18.8.1951; BAUER TR, 1993, IMMUNOGENETICS, V38, P387, DOI 10.1007/BF00184519; BELL CJ, 1995, HUM MOL GENET, V4, P59; BENTLEY DR, 1995, CURR OPIN GENET DEV, V5, P328, DOI 10.1016/0959-437X(95)80047-6; BENTLEY DR, 1992, GENOMICS, V12, P534, DOI 10.1016/0888-7543(92)90445-X; BROWNSTEIN BH, 1989, SCIENCE, V244, P1348, DOI 10.1126/science.2544027; BUETOW KH, 1993, GENOMICS, V18, P329, DOI 10.1006/geno.1993.1473; BUETOW KH, 1994, NAT GENET, V6, P391, DOI 10.1038/ng0494-391; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; CHUMAKOV I, 1992, NATURE, V359, P380, DOI 10.1038/359380a0; CHUMAKOV IM, 1992, NAT GENET, V1, P222, DOI 10.1038/ng0692-222; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; COLE CG, 1991, GENOMICS, V10, P816, DOI 10.1016/0888-7543(91)90468-T; COLE CG, 1992, GENOMICS, V14, P931, DOI 10.1016/S0888-7543(05)80114-4; COLLINS JE, 1992, GENOMICS, V14, P1098, DOI 10.1016/S0888-7543(05)80137-5; CRAIG JM, 1994, NAT GENET, V7, P376, DOI 10.1038/ng0794-376; DELATTRE O, 1991, GENOMICS, V9, P721, DOI 10.1016/0888-7543(91)90366-M; DUMANSKI JP, 1990, HUM GENET, V84, P219, DOI 10.1007/BF00200562; DUMANSKI JP, 1991, GENOMICS, V11, P709, DOI 10.1016/0888-7543(91)90079-T; DUNHAM I, 1994, GUIDE HUMAN GENOME C, P111; FIGLEWICZ DA, 1993, GENOMICS, V17, P299, DOI 10.1006/geno.1993.1325; FOOTE S, 1992, SCIENCE, V258, P60, DOI 10.1126/science.1359640; FRAZER KA, 1992, GENOMICS, V14, P574, DOI 10.1016/S0888-7543(05)80154-5; GREEN ED, 1991, GENOMICS, V11, P658, DOI 10.1016/0888-7543(91)90073-N; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HALFORD S, 1993, HUM MOL GENET, V2, P191, DOI 10.1093/hmg/2.2.191; HODGSON CP, 1987, NUCLEIC ACIDS RES, V15, P6295, DOI 10.1093/nar/15.15.6295; HUDSON TJ, 1994, GENOMICS, V24, P588, DOI 10.1006/geno.1994.1671; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; KOUPRINA N, 1994, GENOMICS, V21, P7, DOI 10.1006/geno.1994.1218; LARIN Z, 1991, P NATL ACAD SCI USA, V88, P4123, DOI 10.1073/pnas.88.10.4123; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LORONOV V, 1994, NUCLEIC ACIDS RES, V22, P4154; MACCOLLIN M, 1993, GENOMICS, V15, P680, DOI 10.1006/geno.1993.1125; MCDERMID HE, 1993, GENOMICS, V18, P308, DOI 10.1006/geno.1993.1470; MORROW B, 1995, AM J HUM GENET, V56, P1391; MURAKAWA K, 1994, GENOMICS, V23, P379, DOI 10.1006/geno.1994.1514; MURRAY JC, 1994, SCIENCE, V265, P2049, DOI 10.1126/science.8091227; NEIL DL, 1990, NUCLEIC ACIDS RES, V18, P1421, DOI 10.1093/nar/18.6.1421; PAWLAK A, 1988, J BIOL CHEM, V263, P9913; PORTER JC, 1993, GENOMICS, V156, P57; Riley B P, 1994, Eur J Hum Genet, V2, P246; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; RUTTLEDGE MH, 1994, GENOMICS, V19, P52, DOI 10.1006/geno.1994.1012; SACCONE S, 1992, P NATL ACAD SCI USA, V89, P4913, DOI 10.1073/pnas.89.11.4913; Sambrook J., 1989, MOL CLONING LAB MANU; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; VALLADA HP, 1994, HUM GENET, V93, P688; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; XIE YG, 1994, HUM GENET, V94, P339; XIE YG, 1993, HUM MOL GENET, V2, P1361; 1992, NIH CEPH COLLABORATI, V258, P67	53	95	96	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 28	1995	377			S			367	379						13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA343	7566101				2022-12-24	WOS:A1995TA34300007
J	GEMMILL, RM; CHUMAKOV, I; SCOTT, P; WAGGONER, B; RIGAULT, P; CYPSER, J; CHEN, Q; WEISSENBACH, J; GARDINER, K; WANG, H; PEKARSKY, Y; LEGALL, I; LEPASLIER, D; GUILLOU, S; LI, E; ROBINSON, L; HAHNER, L; TODD, S; COHEN, D; DRABKIN, HA				GEMMILL, RM; CHUMAKOV, I; SCOTT, P; WAGGONER, B; RIGAULT, P; CYPSER, J; CHEN, Q; WEISSENBACH, J; GARDINER, K; WANG, H; PEKARSKY, Y; LEGALL, I; LEPASLIER, D; GUILLOU, S; LI, E; ROBINSON, L; HAHNER, L; TODD, S; COHEN, D; DRABKIN, HA			A 2ND-GENERATION YAC CONTIG MAP OF HUMAN-CHROMOSOME-3	NATURE			English	Article							YEAST ARTIFICIAL CHROMOSOMES; CYSTIC-FIBROSIS GENE; HUMAN GENOME PROJECT; HUMAN DNA; CLONING; LIBRARY; CLONES; IDENTIFICATION; FRAGMENTS	A map of human chromosome 3 which integrates both physical and genetic data has been developed from the fusion of two large collections of markers and corresponding yeast artificial chromosome (YAC) clones. The map contains 972 megabase-sized YACs identified with 593 primary markers, of which 162 are highly polymorphic sequence-tagged sites (STSs) and form a closely spaced genetic linkage map; the remaining markers are hybridization-based. Chromosome 3 is now represented by 24 large YAC contigs whose order and orientation is largely known. The map generated by fusion of these hybridization- and STS-based datasets covers about 80% (over 160 megabases) of the chromosome and will provide the foundation necessary for vapid development of a detailed genetic understanding for this large autosome.	FDN JEAN DAUSSET,CEPH,F-75010 PARIS,FRANCE; GENETHON SA,F-91002 EVRY,FRANCE; UNIV COLORADO,HLTH SCI CTR,DENVER,CO 80262	Foundation Jean Dausset-CEPH; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	GEMMILL, RM (corresponding author), ELEANOR ROOSEVELT INST CANC RES,1899 GAYLORD ST,DENVER,CO 80206, USA.			Le Paslier, Denis/0000-0003-4335-9956				ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; BELLANNECHANTEL.C, 1992, CELL, V70, P1059; BROWNSTEIN BH, 1989, SCIENCE, V244, P1348, DOI 10.1126/science.2544027; CHUMAKOV I, 1992, NATURE, V359, P380, DOI 10.1038/359380a0; CHUMAKOV IM, 1992, NAT GENET, V1, P222, DOI 10.1038/ng0692-222; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; COLLINS F, 1993, SCIENCE, V262, P43, DOI 10.1126/science.8211127; DAUSSET J, 1992, Behring Institute Mitteilungen, P13; DRABKIN H, 1990, GENOMICS, V8, P435, DOI 10.1016/0888-7543(90)90029-T; FOOTE S, 1992, SCIENCE, V258, P60, DOI 10.1126/science.1359640; GORDEN J, 1991, CELL, V66, P589; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; ICANNOU PA, 1994, NAT GENET, V6, P84; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NAYLOR SL, 1992, SCIENCE, V258, P67; OLSON MV, 1993, P NATL ACAD SCI USA, V90, P4338, DOI 10.1073/pnas.90.10.4338; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; STERNBERG N, 1990, P NATL ACAD SCI USA, V87, P103, DOI 10.1073/pnas.87.1.103; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0	22	71	73	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 28	1995	377			S			299	319						21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA343	7566097				2022-12-24	WOS:A1995TA34300004
J	SAMAHA, RR; GREEN, R; NOLLER, HF				SAMAHA, RR; GREEN, R; NOLLER, HF			A BASE-PAIR BETWEEN TRANSFER-RNA AND 23S RIBOSOMAL-RNA IN THE PEPTIDYL TRANSFERASE CENTER OF THE RIBOSOME	NATURE			English	Article							ESCHERICHIA-COLI; TRANSFER-RNA; P-SITES; COMPLEX; IDENTIFICATION; NUCLEOTIDES; PROTEIN; END	Interaction of the conserved CCA terminus of tRNA with rRNA in the peptidyl transferase P site has been studied by in vitro genetics. A Watson-Crick G-C pair between G2252 in a conserved hairpin loop of 235 rRNA and C74 at the acceptor end of tRNA is required for proper functional interaction of the CCA end of tRNA with the ribosomal P site. These findings establish a direct role for 23S rRNA in protein synthesis.	UNIV CALIF SANTA CRUZ, SINSHEIMER LABS, CTR MOLEC BIOL RNA, SANTA CRUZ, CA 95064 USA	University of California System; University of California Santa Cruz								AAGAARD C, 1991, BIOCHIMIE, V73, P1439, DOI 10.1016/0300-9084(91)90176-2; BARTA A, 1984, P NATL ACAD SCI-BIOL, V81, P3607, DOI 10.1073/pnas.81.12.3607; BREITMEYER JB, 1976, J MOL BIOL, V101, P297, DOI 10.1016/0022-2836(76)90149-2; CANNON M, 1963, J MOL BIOL, V7, P360, DOI 10.1016/S0022-2836(63)80030-3; DORING T, 1994, EMBO J, V13, P2677, DOI 10.1002/j.1460-2075.1994.tb06558.x; DOUTHWAITE S, 1983, EUR J BIOCHEM, V131, P261, DOI 10.1111/j.1432-1033.1983.tb07258.x; Evnin L B, 1988, Ann N Y Acad Sci, V542, P61, DOI 10.1111/j.1749-6632.1988.tb25808.x; GRAJEVSKAJA RA, 1973, FEBS LETT, V33, P11, DOI 10.1016/0014-5793(73)80147-4; GREGORY ST, 1994, NUCLEIC ACIDS RES, V22, P279, DOI 10.1093/nar/22.3.279; GUREVICH VV, 1991, ANAL BIOCHEM, V195, P207, DOI 10.1016/0003-2697(91)90318-N; KAJI H, 1966, J BIOL CHEM, V241, P1251; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIEBERMAN KR, 1994, J BIOL CHEM, V269, P16163; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MITCHELL P, 1993, NUCLEIC ACIDS RES, V21, P887, DOI 10.1093/nar/21.4.887; MOAZED D, 1991, P NATL ACAD SCI USA, V88, P3725, DOI 10.1073/pnas.88.9.3725; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; MOAZED D, 1986, CELL, V47, P985, DOI 10.1016/0092-8674(86)90813-5; MONRO RE, 1968, P NATL ACAD SCI USA, V61, P1042, DOI 10.1073/pnas.61.3.1042; MONRO RE, 1969, NATURE, V222, P356, DOI 10.1038/222356a0; Nierhaus K., 1990, RIBOSOMES PROTEIN SY, P161; NIERHAUS KH, 1974, P NATL ACAD SCI USA, V71, P4713, DOI 10.1073/pnas.71.12.4713; NIRENBERG MW, 1964, SCIENCE, V145, P1399, DOI 10.1126/science.145.3639.1399; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; NOLLER HF, 1993, FASEB J, V7, P87, DOI 10.1096/fasebj.7.1.8422979; NOLLER HF, 1993, J BACTERIOL, V175, P5297, DOI 10.1128/JB.175.17.5297-5300.1993; NOLLER HF, 1981, NUCLEIC ACIDS RES, V8, P2275; PEATTIE DA, 1981, P NATL ACAD SCI-BIOL, V78, P2273, DOI 10.1073/pnas.78.4.2273; POWERS T, 1991, EMBO J, V10, P2203, DOI 10.1002/j.1460-2075.1991.tb07756.x; POWERS T, 1993, GENE, V123, P75, DOI 10.1016/0378-1119(93)90542-B; PRINCE JB, 1982, P NATL ACAD SCI-BIOL, V79, P5450, DOI 10.1073/pnas.79.18.5450; SAMPSON JR, 1989, SCIENCE, V243, P1363; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STERN S, 1988, METHOD ENZYMOL, V164, P481; TAPPRICH WE, 1986, P NATL ACAD SCI USA, V83, P556, DOI 10.1073/pnas.83.3.556; TRIMAN K, 1989, J MOL BIOL, V209, P645, DOI 10.1016/0022-2836(89)92000-7; VONAHSEN U, 1995, SCIENCE, V267, P234, DOI 10.1126/science.7528943; WOWER J, 1989, P NATL ACAD SCI USA, V86, P5232, DOI 10.1073/pnas.86.14.5232	39	216	218	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 28	1995	377	6547					309	314		10.1038/377309a0	http://dx.doi.org/10.1038/377309a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX111	7566085				2022-12-24	WOS:A1995RX11100046
J	TSIRKA, SE; GUALANDRIS, A; AMARAL, DG; STRICKLAND, S				TSIRKA, SE; GUALANDRIS, A; AMARAL, DG; STRICKLAND, S			EXCITOTOXIN-INDUCED NEURONAL DEGENERATION AND SEIZURE ARE MEDIATED BY TISSUE-PLASMINOGEN ACTIVATOR	NATURE			English	Article							BRAIN	NEURONAL degeneration in the hippocampus, a region of the brain important for acquisition of memory in humans, occurs in various pathological conditions, including Alzheimer's disease, brain ischaemia and epilepsy. When neuronal activity is stimulated in the adult rat and mouse hippocampus, tissue plasminogen activator (tPA), a serine protease that converts inactive plasminogen to the active protease plasmin, is transcriptionally induced(1,2). The activity of tPA in neural tissue is correlated with neurite outgrowth(3), regeneration(4) and migration(5), suggesting that it might be involved in neuronal plasticity. Here we show that tPA is produced primarily by microglia in the hippocampus. Using excitotoxins to induce neuronal cell loss, we demonstrate that tPA-deficient mice are resistant to neuronal degeneration. These mice are also less susceptible to pharmacologically induced seizures than wild-type mice. These findings identify a role for tPA in neuronal degeneration and seizure.	SUNY STONY BROOK,MED CTR,PROGRAM GENET,STONY BROOK,NY 11794; SUNY STONY BROOK,CTR BEHAV NEUROSCI,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	TSIRKA, SE (corresponding author), SUNY STONY BROOK,MED CTR,DEPT PHARMACOL,STONY BROOK,NY 11794, USA.		Tsirka, Stella/AAD-4018-2019	Gualandris, anna/0000-0002-2889-4080; Strickland, Sidney/0000-0002-3072-9244				ANDERSSON PB, 1991, NEUROSCIENCE, V42, P201, DOI 10.1016/0306-4522(91)90159-L; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CARROLL PM, 1994, DEVELOPMENT, V120, P3173; GOLARAI G, 1992, BRAIN RES, V593, P257, DOI 10.1016/0006-8993(92)91316-7; Kandel E.R., 1991, PRINC NEUROSCI; KINGSTON IB, 1995, NAT MED, V1, P138; KRYSTOSEK A, 1981, P NATL ACAD SCI-BIOL, V78, P7810, DOI 10.1073/pnas.78.12.7810; KRYSTOSEK A, 1981, SCIENCE, V213, P1532, DOI 10.1126/science.7197054; LAWSON LJ, 1990, NEUROSCIENCE, V39, P151, DOI 10.1016/0306-4522(90)90229-W; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; POLLARD H, 1994, NEUROSCIENCE, V63, P7, DOI 10.1016/0306-4522(94)90003-5; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; SALLES FJ, 1990, EMBO J, V9, P2471, DOI 10.1002/j.1460-2075.1990.tb07425.x; SAPPINO AP, 1993, J CLIN INVEST, V92, P679, DOI 10.1172/JCI116637; SMEYNE R, 1992, NEURON, V6, P13; STREIT WJ, 1993, J CHEM NEUROANAT, V6, P261, DOI 10.1016/0891-0618(93)90047-8; THANOS S, 1991, EUR J NEUROSCI, V3, P1189, DOI 10.1111/j.1460-9568.1991.tb00054.x	17	574	592	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 28	1995	377	6547					340	344		10.1038/377340a0	http://dx.doi.org/10.1038/377340a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX111	7566088				2022-12-24	WOS:A1995RX11100057
J	REZZA, G; PEZZOTTI, P; AIUTI, F				REZZA, G; PEZZOTTI, P; AIUTI, F			ACQUIRED IMMUNODEFICIENCY WITHOUT HIV-INFECTION - EPIDEMIOLOGY AND CLINICAL OUTCOME IN ITALY	BRITISH MEDICAL JOURNAL			English	Article							CD4+ T-LYMPHOCYTOPENIA		UNIV ROMA LA SAPIENZA,CATTEDRA ALLERGOL & IMMUNOL CLIN,I-00162 ROME,ITALY	Sapienza University Rome	REZZA, G (corresponding author), IST SUPER SANITA,CTR OPERAT AIDS,I-00161 ROME,ITALY.		PEZZOTTI, PATRIZIO/C-6480-2016; rezza, giovanni/D-4393-2016	PEZZOTTI, PATRIZIO/0000-0002-0805-2927; rezza, giovanni/0000-0003-0268-6790				ABENI DD, 1993, GIORNALE ITALIANO AI, V4, P16; HO DD, 1993, NEW ENGL J MED, V328, P380, DOI 10.1056/NEJM199302113280602; MCNULTY A, 1994, BRIT MED J, V308, P825, DOI 10.1136/bmj.308.6932.825; MONTELLA F, 1994, AIDS, V8, P390, DOI 10.1097/00002030-199403000-00018; SMITH DK, 1993, NEW ENGL J MED, V328, P373, DOI 10.1056/NEJM199302113280601	5	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 23	1995	311	7008					785	786		10.1136/bmj.311.7008.785	http://dx.doi.org/10.1136/bmj.311.7008.785			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX107	7580441	Green Published			2022-12-24	WOS:A1995RX10700022
J	WIDEN, E; LEHTO, M; KANNINEN, T; WALSTON, J; SHULDINER, AR; GROOP, LC				WIDEN, E; LEHTO, M; KANNINEN, T; WALSTON, J; SHULDINER, AR; GROOP, LC			ASSOCIATION OF A POLYMORPHISM IN THE BETA(3)-ADRENERGIC-RECEPTOR GENE WITH FEATURES OF THE INSULIN-RESISTANCE SYNDROME IN FINNS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BETA-3-ADRENERGIC RECEPTOR; DIABETES-MELLITUS; MUSCLE; OBESITY; GLUCOSE; TISSUE; MEN	Background, Because visceral obesity predicts insulin resistance, we studied whether alterations in the gene encoding for the beta(3)-adrenergic receptor in visceral fat are associated with insulin resistance. Methods. We studied the frequency of a cytosine-to-thymidine mutation that results in the replacement of tryptophan by arginine at position 64 (Trp64Arg) of the beta(3)-adrenergic receptor by restriction-enzyme digestion with BstOl in 335 subjects from western Finland, 207 of whom were nondiabetic and 128 of whom had non-insulin-dependent diabetes mellitus (NIDDM). We also determined the frequency of the mutation in 156 subjects from southern Finland. Sensitivity to insulin was measured by the hyperinsulinemic-euglycemic clamp technique in 66 randomly selected nondiabetic subjects. Results. In the subjects from western Finland, the frequency of the mutated allele was similar in the nondiabetic subjects and the subjects with NIDDM (12 vs, 11 percent), The mean age of the subjects at the onset of diabetes was lower among those with the mutation than those without it (56 vs. 61 years, P = 0,04). Among the nondiabetic subjects, those with the mutation had a higher ratio of waist to hip circumference (P = 0.02), a greater increase in the serum insulin response after the oral administration of glucose (P = 0.05), a higher diastolic blood pressure (82 vs. 78 mm Hg, P = 0.01), and a lower rate of glucose disposal during the clamp study (5.3 vs, 6.5 mg [29 vs. 36 mu mol] per kilogram of body weight per minute; P = 0.04) than the subjects without the mutated allele. In an analysis of sibling pairs, the siblings with the mutation generally had higher waist:hip ratios (P = 0.05) and higher responses of blood glucose and serum insulin after the oral administration of glucose than their siblings without the mutation (P = 0.02 and P = 0.005, respectively). Conclusions. The Trp64Arg allele of the beta(3)-adrenergic receptor is associated with abdominal obesity acid resistance to insulin and may contribute to the early onset of NIDDM.	LUND UNIV,DEPT ENDOCRINOL,LUND,SWEDEN; HELSINKI UNIV HOSP,DEPT MED 4,SF-00170 HELSINKI,FINLAND; JOHNS HOPKINS UNIV,SCH MED,DIV GERIATR MED & GERONTOL,BALTIMORE,MD	Lund University; University of Helsinki; Helsinki University Central Hospital; Johns Hopkins University				Shuldiner, Alan/0000-0001-9921-4305				BORKMAN M, 1993, NEW ENGL J MED, V328, P238, DOI 10.1056/NEJM199301283280404; CARO JF, 1991, J CLIN ENDOCR METAB, V73, P691, DOI 10.1210/jcem-73-4-691; COLBERG SR, 1995, J CLIN INVEST, V95, P1846, DOI 10.1172/JCI117864; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; EMORINE LJ, 1989, SCIENCE, V245, P1118, DOI 10.1126/science.2570461; ERIKSSON J, 1989, NEW ENGL J MED, V321, P337, DOI 10.1056/NEJM198908103210601; FERRANNINI E, 1991, DIABETOLOGIA, V34, P416, DOI 10.1007/BF00403180; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; KRIEF S, 1993, J CLIN INVEST, V91, P344, DOI 10.1172/JCI116191; LONNQVIST F, 1995, J CLIN INVEST, V95, P1109, DOI 10.1172/JCI117758; MARIN P, 1992, METABOLISM, V41, P1242, DOI 10.1016/0026-0495(92)90016-4; MARTIN BC, 1992, LANCET, V340, P925, DOI 10.1016/0140-6736(92)92814-V; POULIOT MC, 1992, DIABETES, V41, P826, DOI 10.2337/diabetes.41.7.826; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; STORLIEN LH, 1991, DIABETES, V40, P280, DOI 10.2337/diabetes.40.2.280; WALSTON J, 1995, NEW ENGL J MED, V333, P343, DOI 10.1056/NEJM199508103330603; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	17	539	564	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 10	1995	333	6					348	351		10.1056/NEJM199508103330604	http://dx.doi.org/10.1056/NEJM199508103330604			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN082	7609751				2022-12-24	WOS:A1995RN08200004
J	HANKS, M; WURST, W; ANSONCARTWRIGHT, L; AUERBACH, AB; JOYNER, AL				HANKS, M; WURST, W; ANSONCARTWRIGHT, L; AUERBACH, AB; JOYNER, AL			RESCUE OF THE EN-1 MUTANT PHENOTYPE BY REPLACEMENT OF EN-1 WITH EN-2	SCIENCE			English	Article							HOMEO BOX; MOUSE; EXPRESSION; MICE; SEQUENCE; GENES; RECOMBINATION; VERTEBRAE; DELETION; CHICKEN	The related mouse Engrailed genes En-1 and En-2 are expressed from the one- and approximately five-somite stages, respectively, in a similar presumptive mid-hindbrain domain. However, mutations in En-1 and En-2 produce different phenotypes. En-1 mutant mice die at birth with a large mid-hindbrain deletion, whereas En-2 mutants are viable, with cerebellar defects. To determine whether these contrasting phenotypes reflect differences in temporal expression or biochemical activity of the En proteins, En-1 coding sequences were replaced with En-2 sequences by gene targeting. This rescued all En-1 mutant defects, demonstrating that the difference between En-1 and En-2 stems from their divergent expression patterns.	MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, TORONTO, ON M5G 1X5, CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute				Wurst, Wolfgang/0000-0003-4422-7410				CHARITE J, 1994, CELL, V78, P589, DOI 10.1016/0092-8674(94)90524-X; CONLON RA, 1992, DEVELOPMENT, V116, P357; DAVIDSON D, 1988, DEVELOPMENT, V104, P305; DAVIS CA, 1988, GENE DEV, V2, P1736, DOI 10.1101/gad.2.12b.1736; DAVIS CA, 1991, DEVELOPMENT, V111, P287; DAVIS CA, 1988, GENE DEV, V2, P361, DOI 10.1101/gad.2.3.361; HANKS M, UNPUB; HOESS RH, 1982, P NATL ACAD SCI-BIOL, V79, P3398, DOI 10.1073/pnas.79.11.3398; JOYNER AL, 1987, GENE DEV, V1, P29, DOI 10.1101/gad.1.1.29; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; Joyner Alexandra L., 1991, Seminars in Developmental Biology, V2, P435; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; LI XL, 1994, NATURE, V367, P83, DOI 10.1038/367083a0; LOGAN C, 1992, DEV GENET, V13, P345, DOI 10.1002/dvg.1020130505; LOGAN C, 1993, DEVELOPMENT, V117, P905; MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092-8674(92)90222-X; MILLEN KJ, 1994, DEVELOPMENT, V120, P695; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nagy A., 1993, Gene targeting: a practical approach., P147; ORBAN PC, 1992, P NATL ACAD SCI USA, V89, P6861, DOI 10.1073/pnas.89.15.6861; SHAM MH, 1993, CELL, V72, P183, DOI 10.1016/0092-8674(93)90659-E; WURST W, 1994, DEVELOPMENT, V120, P2065; Wurst W., 1993, Gene targeting: a practical approach., P33; ZHANG MB, 1994, DEVELOPMENT, V120, P2431	24	343	361	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 4	1995	269	5224					679	682		10.1126/science.7624797	http://dx.doi.org/10.1126/science.7624797			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM702	7624797				2022-12-24	WOS:A1995RM70200030
J	JACKMAN, RJ; WILBUR, JL; WHITESIDES, GM				JACKMAN, RJ; WILBUR, JL; WHITESIDES, GM			FABRICATION OF SUBMICROMETER FEATURES ON CURVED SUBSTRATES BY MICROCONTACT PRINTING	SCIENCE			English	Article							SELF-ASSEMBLED MONOLAYERS; GOLD	Microcontact printing (mu CP) has been used to produce patterned self-assembled monolayers (SAMs) with submicrometer features on curved substrates with radii of curvature as small as 25 micrometers. Wet-chemical etching that uses the patterned SAMs as resists transfers the patterns formed by mu CP into gold. At present, there is no comparable method for microfabrication on curved surfaces.	HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138	Harvard University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM016511] Funding Source: NIH RePORTER; NIGMS NIH HHS [1-F32 GM16511-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Feely W. E., 1988, 1988 Solid State Sensor and Actuator Workshop. Technical Digest (Cat. No.88TH0215-4), P13, DOI 10.1109/SOLSEN.1988.26421; JACOBSEN SC, 1991, IEEE MICRO ELECTRO MECHANICAL SYSTEMS, P45; JACOBSEN SC, 1989, 1989 IEEE INT C ROBA, V3, P1536; JACOBSEN SC, 1989, FEB P IEEE MICR EL M, P17; KIM E, 1995, J ELECTROCHEM SOC, V142, P628, DOI 10.1149/1.2044112; KUMAR A, 1992, J AM CHEM SOC, V114, P9188, DOI 10.1021/ja00049a061; KUMAR A, 1994, LANGMUIR, V10, P1498, DOI 10.1021/la00017a030; KUMAR A, 1993, APPL PHYS LETT, V63, P2002, DOI 10.1063/1.110628; LOPEZ GP, 1993, LANGMUIR, V9, P1513, DOI 10.1021/la00030a015; Puddephatt R.J., 1978, CHEM GOLD; WILBUR JL, 1994, ADV MATER, V6, P600, DOI 10.1002/adma.19940060719; WILBUR JL, IN PRESS ADV MAT; XIA Y, UNPUB; XIA Y, 1994, J AM CHEM SOC, V117, P3274; XIA YN, 1995, ADV MATER, V7, P471, DOI 10.1002/adma.19950070513	15	364	410	3	93	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 4	1995	269	5224					664	666		10.1126/science.7624795	http://dx.doi.org/10.1126/science.7624795			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM702	7624795				2022-12-24	WOS:A1995RM70200024
J	BOICE, JD; MANDEL, JS; DOODY, MM				BOICE, JD; MANDEL, JS; DOODY, MM			BREAST-CANCER AMONG RADIOLOGIC TECHNOLOGISTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FOLLOW-UP; RISK; RADIATION; THERAPY; MORTALITY; WORKERS; TUBERCULOSIS; EPIDEMIOLOGY; RADIOTHERAPY; CHILDHOOD	Objective.-To evaluate the risk of breast cancer among women occupationally ex Design.-Case-control study. Participants.-A health survey of 105 385 women radiologic technologists certified by the American Registry of Radiologic Technologists since 1926. Among 79016 respondents, 600 breast cancer cases were identified. Each of 528 eligible subjects with breast cancer was matched to five control subjects based on age, year of certification, and follow-up time. Main Outcome Measures.-Relative risk (RR) estimated as the relative odds ratio for breast cancer over categories of years worked as a radiologic technologist and according to personal and occupational exposure characteristics. Results.-Study subjects had been certified for a mean of 29 years; 63.8% of cases and 62.6% of controls worked as radiologic technologists for 10 years or more. Significant increased risks for breast cancer were associated with early age at menarche (for <11 years of age: RR=1.79; 95% confidence interval [CI], 1.09 to 2.94), nulliparity (RR=1.36; 95% CI, 1.04 to 1.78), first-degree relative with history of breast cancer(RR=2.07; 95% CI, 1.56 to 2.74), prior breast biopsy (RR=1.53; 95% CI, 1.17 to 2.00), alcohol consumption (for >14 alcoholic drinks per week: RR=2.12; 95% CI, 1.06 to 4.27), thyroid cancer (RR=5.36; 95% CI, 1.64 to 17.5), hyperthyroidism (RR=1.66; 95% CI, 1.02 to 2.71), and residence in the northeastern United States (RR=1.66; 95% CI, 1.19 to 2.30). Jobs involving radiotherapy, radioisotopes, or fluoroscopic equipment, however, were not linked to breast cancer risk, nor were personal exposures to fluoroscopy or multifilm procedures. Use of birth control pills, postmenopausal estrogens, or permanent hair dyes also were not risk factors. Based on dosimetry records for 35% of study subjects, cumulative exposures appeared low. Among women who worked more than 20 years, the RR for breast cancer was 1.13 (95% CI, 0.79 to 1.64). Conclusions.-More than 50% of the reported breast cancers could be explained by established risk factors. Employment as a radiologic technologist, however, was not found to increase the risk of breast cancer. The contribution of prolonged exposure to relatively low doses of ionizing radiation to breast cancer risk was too small to be detectable at this time.	UNIV MINNESOTA, SCH PUBL HLTH, DIV ENVIRONM & OCCUPAT HLTH, MINNEAPOLIS, MN USA	University of Minnesota System; University of Minnesota Twin Cities	BOICE, JD (corresponding author), NCI, RADIAT EPIDEMIOL BRANCH, 6130 EXECUT BLVD, EPN ROOM 408, BETHESDA, MD 20892 USA.				DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP005609, N01CP085604, N01CP095614] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CP9-5614, N01-CP8-5604, N01-CP0-5609] Funding Source: Medline	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1994, SOURCES EFFECTS IONI; BAVERSTOCK KF, 1989, BIR REPORT, P72; BOICE JD, 1992, NEW ENGL J MED, V326, P781, DOI 10.1056/NEJM199203193261201; BOICE JD, 1992, CANCER, V69, P586, DOI 10.1002/1097-0142(19920115)69:2<586::AID-CNCR2820690251>3.0.CO;2-3; BOICE JD, 1989, INT J CANCER, V44, P7, DOI 10.1002/ijc.2910440103; BOICE JD, 1991, RADIAT RES, V125, P214, DOI 10.2307/3577890; BRINTON LA, 1993, EPIDEMIOL REV, V15, P66, DOI 10.1093/oxfordjournals.epirev.a036117; BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; COLDITZ GA, 1992, CANCER CAUSE CONTROL, V3, P433, DOI 10.1007/BF00051356; FURST CJ, 1988, JNCI-J NATL CANCER I, V80, P1387, DOI 10.1093/jnci/80.17.1387; GILBERT ES, 1993, RADIAT RES, V136, P408, DOI 10.2307/3578555; GREEN A, 1987, JNCI-J NATL CANCER I, V79, P253; HANCOCK SL, 1993, J NATL CANCER I, V85, P25, DOI 10.1093/jnci/85.1.25; Harvey E B, 1985, Natl Cancer Inst Monogr, V68, P99; HIDRETH NG, 1989, NEW ENGL J MED, V321, P1281; HOFFMAN DA, 1989, J NATL CANCER I, V81, P1307, DOI 10.1093/jnci/81.17.1307; HOLM LE, 1991, JNCI-J NATL CANCER I, V83, P1072, DOI 10.1093/jnci/83.15.1072; HUNTER DJ, 1993, EPIDEMIOL REV, V15, P110, DOI 10.1093/oxfordjournals.epirev.a036096; KELSEY JL, 1993, EPIDEMIOL REV, V15, P256, DOI 10.1093/oxfordjournals.epirev.a036112; KELSEY JL, 1993, EPIDEMIOL REV, V15, P7, DOI 10.1093/oxfordjournals.epirev.a036118; KENDALL GM, 1992, BRIT MED J, V304, P220, DOI 10.1136/bmj.304.6821.220; KEREIAKES JG, 1980, HDB RAD DOSES NUCLEA; LI FP, 1983, CANCER, V51, P521, DOI 10.1002/1097-0142(19830201)51:3<521::AID-CNCR2820510325>3.0.CO;2-U; LONDON S J, 1989, Journal of the American Medical Association, V262, P2853, DOI 10.1001/jama.262.20.2853; LUBIN JH, 1981, COMPUT BIOMED RES, V14, P138, DOI 10.1016/0010-4809(81)90031-8; LUCAS JN, 1992, INT J RADIAT BIOL, V62, P53, DOI 10.1080/09553009214551821; MACKENZI.I, 1965, BRIT J CANCER, V19, P1, DOI 10.1038/bjc.1965.1; MALONE KE, 1993, EPIDEMIOL REV, V15, P80, DOI 10.1093/oxfordjournals.epirev.a036119; MATTSSON A, 1993, J NATL CANCER I, V85, P1679, DOI 10.1093/jnci/85.20.1679; MCLAUGHLIN JR, 1993, INT J EPIDEMIOL, V22, P584, DOI 10.1093/ije/22.4.584; MILLER AB, 1989, NEW ENGL J MED, V321, P1285, DOI 10.1056/NEJM198911093211902; PALMER JR, 1993, EPIDEMIOL REV, V15, P145, DOI 10.1093/oxfordjournals.epirev.a036098; ROSENBERG L, 1993, EPIDEMIOL REV, V15, P133, DOI 10.1093/oxfordjournals.epirev.a036097; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SHORE RE, 1986, J NATL CANCER I, V77, P689, DOI 10.1093/jnci/77.3.689; STEBBINGS JH, 1984, AM J IND MED, V5, P435, DOI 10.1002/ajim.4700050604; STRAUME T, 1992, HEALTH PHYS, V62, P122, DOI 10.1097/00004032-199202000-00001; TOKUNAGA M, 1994, RADIAT RES, V138, P209, DOI 10.2307/3578591; WANEBO CK, 1968, NEW ENGL J MED, V279, P667, DOI 10.1056/NEJM196809262791301; WANG JX, 1990, INT J CANCER, V45, P889, DOI 10.1002/ijc.2910450519; WEISS HA, 1994, INT J CANCER, V59, P327, DOI 10.1002/ijc.2910590307; WHITE E, 1994, JNCI-J NATL CANCER I, V86, P505, DOI 10.1093/jnci/86.7.505	42	52	52	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 2	1995	274	5					394	401		10.1001/jama.274.5.394	http://dx.doi.org/10.1001/jama.274.5.394			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL416	7616635				2022-12-24	WOS:A1995RL41600025
J	JAMES, JA; LAING, GJ; LOGAN, S				JAMES, JA; LAING, GJ; LOGAN, S			CHANGING PATTERNS OF IRON-DEFICIENCY ANEMIA IN THE 2ND YEAR OF LIFE	BRITISH MEDICAL JOURNAL			English	Article									ST LEONARDS HOSP,DEPT COMMUNITY CHILD HLTH,LONDON N1 5LZ,ENGLAND; INST CHILD HLTH,DEPT EPIDEMIOL & BIOSTAT,LONDON WC1 1EH,ENGLAND	University of London; University College London	JAMES, JA (corresponding author), MONTPELIER HLTH CTR,BATH BLDG,BRISTOL BS6 5PT,AVON,ENGLAND.			Logan, Stuart/0000-0002-9279-261X				AUKETT MA, 1986, ARCH DIS CHILD, V61, P849, DOI 10.1136/adc.61.9.849; HALL DMB, 1991, HLTH ALL CHILDREN PR; IDRADINATA P, 1993, LANCET, V341, P1; JAMES J, 1989, BRIT MED J, V299, P838, DOI 10.1136/bmj.299.6703.838; LOZOFF B, 1994, J PEDIATR-US, V125, P577	5	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 22	1995	311	6999					230	230		10.1136/bmj.311.6999.230	http://dx.doi.org/10.1136/bmj.311.6999.230			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL441	7627036	Green Published			2022-12-24	WOS:A1995RL44100019
J	DUYAO, MP; AUERBACH, AB; RYAN, A; PERSICHETTI, F; BARNES, GT; MCNEIL, SM; GE, P; VONSATTEL, JP; GUSELLA, JF; JOYNER, AL; MACDONALD, ME				DUYAO, MP; AUERBACH, AB; RYAN, A; PERSICHETTI, F; BARNES, GT; MCNEIL, SM; GE, P; VONSATTEL, JP; GUSELLA, JF; JOYNER, AL; MACDONALD, ME			INACTIVATION OF THE MOUSE HUNTINGTONS-DISEASE GENE HOMOLOG HDH	SCIENCE			English	Article							FRAGILE-X-SYNDROME; EXPRESSION; FMR-1; CELLS; MICE	Huntington's disease (HD) is a dominant neurodegenerative disorder caused by expansion of a CAG repeat in the gene encoding huntingtin, a protein of unknown function. To distinguish between ''loss of function'' and ''gain of function'' models of HD, the murine HD homolog Hdh was inactivated by gene targeting. Mice heterozygous for Hdh inactivation were phenotypically normal, whereas homozygosity resulted in embryonic death. Homozygotes displayed abnormal gastrulation at embryonic day 7.5 and were resorbing by day 8.5. Thus, huntingtin is critical early in embryonic development, before the emergence of the nervous system. That Hdh inactivation does not mimic adult HD neuropathology suggests that the human disease involves a gain of function.	MASSACHUSETTS GEN HOSP,MOLEC NEUROGENET UNIT,BOSTON,MA 02129; MT SINAI HOSP,DIV MOLEC & DEV BIOL,TORONTO,ON M5G 1X5,CANADA; MASSACHUSETTS GEN HOSP,MOLEC NEUROPATHOL LAB,BOSTON,MA 02129	Harvard University; Massachusetts General Hospital; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Harvard University; Massachusetts General Hospital				Persichetti, Francesca/0000-0002-9804-644X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS016367, P01NS016367, R01NS032765] Funding Source: NIH RePORTER; NINDS NIH HHS [NS32765, NS16367] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMBROSE CM, 1994, SOMAT CELL MOLEC GEN, V20, P27, DOI 10.1007/BF02257483; [Anonymous], 1994, CELL, V78, P23; BARNES GT, 1994, SOMAT CELL MOLEC GEN, V20, P87, DOI 10.1007/BF02290678; BLUM M, 1992, CELL, V69, P1097, DOI 10.1016/0092-8674(92)90632-M; CONLON RA, 1993, METHOD ENZYMOL, V225, P373; COPP AJ, 1995, TRENDS GENET, V11, P87, DOI 10.1016/S0168-9525(00)89008-3; DIFIGLIA M, 1995, NEURON, V14, P1075, DOI 10.1016/0896-6273(95)90346-1; FOLSTEIN SE, 1989, HUNTINGTONS DISEASE; GUSELLA JF, 1995, SEMIN CELL BIOL, V6, P21, DOI 10.1016/1043-4682(95)90011-X; GUSELLA JF, 1993, ARCH NEUROL-CHICAGO, V50, P1157, DOI 10.1001/archneur.1993.00540110037003; HERRMANN BG, 1991, DEVELOPMENT, V113, P913; JOU YS, 1995, HUM MOL GENET, V4, P465, DOI 10.1093/hmg/4.3.465; Joyner AL, 1993, GENE TARGETING PRACT; LIN BY, 1994, HUM MOL GENET, V3, P85, DOI 10.1093/hmg/3.1.85; MARTIN JB, 1986, NEW ENGL J MED, V315, P1267; MONAGHAN AP, 1993, DEVELOPMENT, V119, P567; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nagy A., 1993, Gene targeting: a practical approach., P147; NASIR J, 1995, CELL, V81, P811, DOI 10.1016/0092-8674(95)90542-1; PERSICHETTI F, 1995, MOL MED, V1, P374, DOI 10.1007/BF03401575; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; SHARP AH, 1995, NEURON, V14, P1065, DOI 10.1016/0896-6273(95)90345-3; Sutcliffe James S., 1992, Human Molecular Genetics, V1, P397, DOI 10.1093/hmg/1.6.397; TROTTIER Y, 1995, NAT GENET, V10, P104, DOI 10.1038/ng0595-104; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VONSATTEL JP, 1985, J NEUROPATH EXP NEUR, V44, P559, DOI 10.1097/00005072-198511000-00003; WILLEMS PJ, 1994, NAT GENET, V8, P213, DOI 10.1038/ng1194-213; WURST W, 1993, GENE TARGETING PRACT, P31; 1993, CELL, V72, P971	31	514	531	0	23	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 21	1995	269	5222					407	410		10.1126/science.7618107	http://dx.doi.org/10.1126/science.7618107			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK427	7618107				2022-12-24	WOS:A1995RK42700050
J	KORN, SJ; IKEDA, SR				KORN, SJ; IKEDA, SR			PERMEATION SELECTIVITY BY COMPETITION IN A DELAYED RECTIFIER POTASSIUM CHANNEL	SCIENCE			English	Article							CALCIUM CHANNELS; ION CONDUCTANCE; K+ CHANNEL; NEURONS; MUSCLE; CELLS	Permeation selectivity was studied in two human potassium channels, Kv2.1 and Kv1.5, expressed in a mouse cell line. With normal concentrations of potassium and sodium, both channels were highly selective for potassium. On removal of potassium, Kv2.1 displayed a large sodium conductance that was inhibited by low concentrations of potassium. The channel showed a competition mechanism of selectivity similar to that of calcium channels. In contrast, Kv1.5 displayed a negligible sodium conductance on removal of potassium. The observation that structurally similar potassium channels show different abilities to conduct sodium provides a basis for understanding the structural determinants of potassium channel selectivity.	MED COLL GEORGIA,DEPT PHARMACOL & TOXICOL,AUGUSTA,GA 30912	University System of Georgia; Augusta University	KORN, SJ (corresponding author), UNIV CONNECTICUT,DEPT PHYSIOL & NEUROBIOL,BOX U-156,STORRS,CT 06269, USA.			Ikeda, Stephen/0000-0002-4088-9508				ALMERS W, 1984, J PHYSIOL-LONDON, V353, P585, DOI 10.1113/jphysiol.1984.sp015352; BEZANILLA F, 1972, J GEN PHYSIOL, V60, P588, DOI 10.1085/jgp.60.5.588; BLATZ AL, 1984, J GEN PHYSIOL, V84, P1, DOI 10.1085/jgp.84.1.1; CALLAHAN MJ, 1994, J GEN PHYSIOL, V104, P747, DOI 10.1085/jgp.104.4.747; HAMILL OP, 1981, PFLUGERS ARCH, V381, P85; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; HEGINBOTHAM L, 1993, BIOPHYS J, V65, P2089, DOI 10.1016/S0006-3495(93)81244-X; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; HILLE B, 1973, J GEN PHYSIOL, V61, P669, DOI 10.1085/jgp.61.6.669; HILLE B, 1978, J GEN PHYSIOL, V72, P409, DOI 10.1085/jgp.72.4.409; HODGKIN AL, 1955, J PHYSIOL-LONDON, V128, P61, DOI 10.1113/jphysiol.1955.sp005291; IKEDA SR, 1992, PFLUG ARCH EUR J PHY, V422, P201, DOI 10.1007/BF00370422; IKEDA SR, 1995, J PHYSIOL-LONDON, V486, P267, DOI 10.1113/jphysiol.1995.sp020809; KORN SJ, UNPUB; LEVITT DG, 1978, BIOPHYS J, V22, P209, DOI 10.1016/S0006-3495(78)85485-X; REUTER H, 1980, J MEMBRANE BIOL, V57, P103, DOI 10.1007/BF01868997; YELLEN G, 1984, J GEN PHYSIOL, V84, P157, DOI 10.1085/jgp.84.2.157; ZHU Y, 1993, J PHYSIOL-LONDON, V468, P441, DOI 10.1113/jphysiol.1993.sp019781	18	83	85	0	5	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 21	1995	269	5222					410	412		10.1126/science.7618108	http://dx.doi.org/10.1126/science.7618108			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK427	7618108				2022-12-24	WOS:A1995RK42700051
J	WEISSKOPF, MG; NICOLL, RA				WEISSKOPF, MG; NICOLL, RA			PRESYNAPTIC CHANGES DURING MOSSY FIBER LTP REVEALED BY NMDA RECEPTOR-MEDIATED SYNAPTIC RESPONSES	NATURE			English	Article							LONG-TERM POTENTIATION; GUINEA-PIG HIPPOCAMPUS; RAT HIPPOCAMPUS; MECHANISMS; PROBABILITY; NEURONS; RELEASE; SLICES; FORMS; BRAIN	ACTIVITY-DEPENDENT changes in synaptic strength are important for learning and memory. Long-term potentiation (LTP) of glutamatergic excitatory synapses following brief repetitive stimulation provides a compelling cellular model for such plasticity(1-4). In the CA1 region of the hippocampus, anatomical studies have revealed large numbers of NMDA (N-methyl-D-aspartate) receptor sites at excitatory synapses(5,6), which express primarily an NMDA receptor-dependent form of LTP(7). In contrast, these studies(5,6) have suggested that messy fibre synapses activate primarily or exclusively alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors and, indeed, these synapses express a form of LTP that is entirely independent of NMDA receptors(8,9). Here we present physiological data demonstrating that messy fibres activate a substantial NMDA receptor synaptic component that expresses LTP. The presence of an NMDA receptor response allowed us to use the open-channel NMDA receptor antagonist MK-801 to establish directly that the probability of transmitter release is enhanced during the expression of messy fibre LTP.	UNIV CALIF SAN FRANCISCO,DEPT MOLEC & CELLULAR PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco								BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CASTILLO PE, 1994, NEURON, V12, P261, DOI 10.1016/0896-6273(94)90269-0; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; GUSTAFSSON B, 1991, SEMIN NEUROSCI, V2, P321; HARRIS EW, 1986, NEUROSCI LETT, V70, P132, DOI 10.1016/0304-3940(86)90451-9; HESSLER NA, 1993, NATURE, V366, P569, DOI 10.1038/366569a0; ISAACSON JS, 1990, SOC NEUR ABSTR, V20, P468; ISHIZUKA N, 1990, J COMP NEUROL, V295, P580, DOI 10.1002/cne.902950407; JONAS P, 1993, J PHYSIOL-LONDON, V472, P615, DOI 10.1113/jphysiol.1993.sp019965; KATSUKI H, 1991, NEUROSCI RES, V12, P393, DOI 10.1016/0168-0102(91)90070-F; KULLMANN DM, 1994, NEURON, V12, P1111, DOI 10.1016/0896-6273(94)90318-2; LANTHORN TH, 1984, BRAIN RES, V290, P174, DOI 10.1016/0006-8993(84)90750-9; LI XG, 1994, J COMP NEUROL, V339, P181, DOI 10.1002/cne.903390204; LISMAN J, 1994, TRENDS NEUROSCI, V17, P406, DOI 10.1016/0166-2236(94)90014-0; MALENKA RC, 1993, TRENDS NEUROSCI, V16, P521, DOI 10.1016/0166-2236(93)90197-T; MANABE T, 1994, SCIENCE, V265, P1888, DOI 10.1126/science.7916483; MONAGHAN DT, 1985, J NEUROSCI, V5, P2909; NELSON S, 1994, SCIENCE, V265, P774, DOI 10.1126/science.8047882; NICOLL RA, 1981, J NEUROSCI METH, V4, P153, DOI 10.1016/0165-0270(81)90049-2; ROSENMUND C, 1993, SCIENCE, V262, P754, DOI 10.1126/science.7901909; SCHARFMAN HE, 1994, NEUROPHYSIOL, V72, P2167; SIEGEL SJ, 1994, P NATL ACAD SCI USA, V91, P564, DOI 10.1073/pnas.91.2.564; STAUBLI U, 1990, SYNAPSE, V5, P333, DOI 10.1002/syn.890050410; XIANG ZX, 1994, J NEUROPHYSIOL, V71, P2552, DOI 10.1152/jn.1994.71.6.2552; YAMAMOTO C, 1983, EXP BRAIN RES, V51, P128; YAMAMOTO C, 1992, NEUROSCI LETT, V138, P111, DOI 10.1016/0304-3940(92)90484-O; ZALUTSKY RA, 1990, SCIENCE, V248, P1619, DOI 10.1126/science.2114039	27	153	155	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 20	1995	376	6537					256	259		10.1038/376256a0	http://dx.doi.org/10.1038/376256a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK331	7617037				2022-12-24	WOS:A1995RK33100047
J	BARNES, DE; HANAUER, P; SLADE, J; BERO, LA; GLANTZ, SA				BARNES, DE; HANAUER, P; SLADE, J; BERO, LA; GLANTZ, SA			ENVIRONMENTAL TOBACCO-SMOKE - THE BROWN-AND-WILLIAMSON DOCUMENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PASSIVE SMOKING; LUNG-CANCER; HEART-DISEASE	Objective.-To examine the tobacco industry's public and private responses to rising concern over the health effects of environmental tobacco smoke (ETS). Data Sources.-Documents from Brown and Williamson Tobacco Corporation (B&W), the British American Tobacco Company (BAT), and other tobacco interests provided by an anonymous source, obtained from Congress, and received from the private papers of a former BAT officer. Study Selection.-All available materials, including confidential reports regarding research and internal memoranda exchanged between tobacco industry lawyers. Conclusions.-Privately, B&W and BAT began conducting research related to ETS in the mid 1970s. BAT researchers appear to have determined that sidestream smoke produces irritation, that it contains toxic substances including N-nitrosamines, and that it is ''biologically active'' (eg, carcinogenic) in laboratory tests. During the 1980s, the primary purpose of BAT's research related to ETS was to develop a new cigarette that emitted less irritating and less biologically active sidestream smoke. Publicly, the tobacco industry has denied that exposure to ETS has been proven dangerous to health. It has criticized the methodology of published research on ETS, even when some of its own consultants have privately acknowledged that the research was valid, In addition, the industry has funded scientific research with the stated purpose of anticipating and refuting the evidence against ETS. The tobacco industry's strategy regarding passive smoking has been remarkarbly similar to its strategy regarding active smoking. it has privately conducted internal research, at least some of which has supported the conclusion that passive smoking is dangerous to health, while it has publicly denied that the hazards have been proven.	UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DIV CLIN PHARM,SAN FRANCISCO,CA 94143; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,ST PETERS MED CTR,DEPT MED,NEW BRUNSWICK,NJ	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Rutgers State University New Brunswick; Rutgers State University Medical Center					NATIONAL CANCER INSTITUTE [R01CA061021] Funding Source: NIH RePORTER; NCI NIH HHS [CA-61021] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTMAN L, 1977, NY TIMES        0918, P29; [Anonymous], 1986, ENV TOBACCO SMOKE ME; BECKER CG, 1979, AM J PATHOL, V96, P249; BECKER CG, 1977, J EXP MED, V146, P457, DOI 10.1084/jem.146.2.457; BECKER CG, 1976, P NATL ACAD SCI USA, V73, P1712, DOI 10.1073/pnas.73.5.1712; BERO L, 1995, JAMA-J AM MED ASSOC, V274, P241, DOI 10.1001/jama.274.3.241; Brunnemann K D, 1978, IARC Sci Publ, P343; BRUNNEMANN KD, 1977, CANCER RES, V37, P3218; CUDDEBACK JE, 1976, AM IND HYG ASSOC J, V37, P263, DOI 10.1080/0002889768507453; FONTHAM ETH, 1994, JAMA-J AM MED ASSOC, V271, P1752, DOI 10.1001/jama.271.22.1752; FRIEDMAN A, 1993, WALL STREET J   0211, pA1; GARFINKEL L, 1981, JNCI-J NATL CANCER I, V66, P1061, DOI 10.1093/jnci/66.6.1061; GIDDING SS, 1994, CIRCULATION, V90, P2582; GLANTZ SA, 1995, JAMA-J AM MED ASSOC, V273, P1047, DOI 10.1001/jama.273.13.1047; GLANTZ SA, 1992, J CLIN EPIDEMIOL, V45, P815, DOI 10.1016/0895-4356(92)90063-S; GLANTZ SA, 1991, CIRCULATION, V83, P1, DOI 10.1161/01.CIR.83.1.1; GLANTZ SA, 1995, JAMA-J AM MED ASSOC, V274, P219, DOI 10.1001/jama.274.3.219; GLANTZ SA, 1983, 12TH P WORLD C TOB H, P287; HANAUER P, 1995, JAMA-J AM MED ASSOC, V274, P234; HIRAYAMA T, 1981, BRIT MED J, V282, P183, DOI 10.1136/bmj.282.6259.183; HOFFMANN D, 1994, J TOXICOL ENV HEALTH, V41, P1, DOI 10.1080/15287399409531825; Levin M, 1993, NATION          0809, P168; LEVY D, 1994, USA TODAY       0621, pD1; RUSSELL MAH, 1973, LANCET, V1, P576; Taylor Peter, 1984, SMOKE RING TOBACCO M; TRICHOPOULOS D, 1981, INT J CANCER, V27, P1, DOI 10.1002/ijc.2910270102; TURNER S, 1992, ENVIRON INT, V18, P19, DOI 10.1016/0160-4120(92)90207-K; 1992, EPA600690006F; 1993, ANN REV SUMMARY FINA; 1981, BRIT MED J, V283, P914; 1994, ENV TOBACCO SMOKE IN; 1994, OVERSIGHT HEARING TO; 1986, PHS CDC878398 US DEP; 1986, TOBACCO SMOKE NONSMO	34	65	65	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 19	1995	274	3					248	253		10.1001/jama.274.3.248	http://dx.doi.org/10.1001/jama.274.3.248			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH937	7609234				2022-12-24	WOS:A1995RH93700031
J	BERO, L; BARNES, DE; HANAUER, P; SLADE, J; GLANTZ, SA				BERO, L; BARNES, DE; HANAUER, P; SLADE, J; GLANTZ, SA			LAWYER CONTROL OF THE TOBACCO INDUSTRYS EXTERNAL RESEARCH-PROGRAM - THE BROWN-AND-WILLIAMSON DOCUMENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To examine the involvement of tobacco industry lawyers in the selection of tobacco industry scientific research projects and to examine how the research was used to influence public policy. Data Sources.-Documents from Brown and Williamson Tobacco Corporation, the British American Tobacco Company (BAT), and other tobacco interests provided by an anonymous source, obtained from Congress, and received from the private papers of a former BAT officer. Study Selection.-All available materials, including confidential reports regarding research and internal memoranda exchanged between tobacco industry lawyers. Conclusions.-The involvement of tobacco industry lawyers in the selection of scientific projects to be funded is in sharp contrast to the industry's public statements about its review process for its external research program. Scientific merit played little role in the selection of external research projects, The results of the projects were used to generate good publicity for the industry, to deflect attention away from tobacco use as a health danger, and to attempt, sometimes surreptitiously, to influence policymakers.	UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DIV CLIN PHARM,SAN FRANCISCO,CA 94143; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,ST PETERS MED CTR,DEPT MED,NEW BRUNSWICK,NJ	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Rutgers State University New Brunswick; Rutgers State University Medical Center					NATIONAL CANCER INSTITUTE [R01CA061021] Funding Source: NIH RePORTER; NCI NIH HHS [CA-61021] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARNES DE, 1995, JAMA-J AM MED ASSOC, V274, P248, DOI 10.1001/jama.274.3.248; BECKER CG, 1977, J EXP MED, V146, P457, DOI 10.1084/jem.146.2.457; BERO LA, 1994, JAMA-J AM MED ASSOC, V271, P612, DOI 10.1001/jama.271.8.612; BERO LA, 1992, NEW ENGL J MED, V327, P1135, DOI 10.1056/NEJM199210153271606; BERO LA, 1993, TOB CONTROL, V2, P103; DURBIN R, 1993, TOB CONTROL, V2, P8; FRIEDMAN GD, 1979, NEW ENGL J MED, V300, P213, DOI 10.1056/NEJM197902013000501; GLANTZ SA, 1995, JAMA-J AM MED ASSOC, V274, P219, DOI 10.1001/jama.274.3.219; SAMUELS B, 1991, JAMA-J AM MED ASSOC, V266, P2110, DOI 10.1001/jama.266.15.2110; SLADE J, 1995, JAMA-J AM MED ASSOC, V274, P225, DOI 10.1001/jama.274.3.225; 1992, EPA600690006F; 1964, US DHEW PHS PUBLICAT, V1103; 1992, 1992 COUNC TOB RES R	13	76	76	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 19	1995	274	3					241	247		10.1001/jama.274.3.241	http://dx.doi.org/10.1001/jama.274.3.241			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH937	7609233				2022-12-24	WOS:A1995RH93700030
J	KNAUS, UG; MORRIS, S; DONG, HJ; CHERNOFF, J; BOKOCH, GM				KNAUS, UG; MORRIS, S; DONG, HJ; CHERNOFF, J; BOKOCH, GM			REGULATION OF HUMAN-LEUKOCYTE P21-ACTIVATED KINASES THROUGH G-PROTEIN-COUPLED RECEPTORS	SCIENCE			English	Article							NEUTROPHIL NADPH OXIDASE; ACTIVATION; PHOSPHORYLATION; GTP; TRANSLOCATION; STIMULATION; REQUIREMENT; COMPONENTS	The Rac guanosine 5'-triphosphate (GTP)-binding proteins regulate oxidant production by phagocytic leukocytes. Two Ste20-related p21-activated kinases (PAKs) were identified as targets of Rac in human neutrophils. Activity of the similar to 65- and similar to 68-kilodalton PAKs was rapidly stimulated by chemoattractants acting through pertussis toxin-sensitive heterotrimeric GTP-binding proteins (G proteins). Native and recombinant PAKs phos phorylated the p47(phox) reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase component in a Rac-GTP-dependent manner. The action of PAKs during phagocyte activation by G protein-coupled pathways may contribute to regulation of NADPH oxidase activity.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; FOX CHASE CANC CTR, PHILADELPHIA, PA 19111 USA	Scripps Research Institute; Fox Chase Cancer Center	KNAUS, UG (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Chernoff, Jonathan/I-7631-2014	Chernoff, Jonathan/0000-0002-4803-7836	NHLBI NIH HHS [HL48008] Funding Source: Medline; NIAID NIH HHS [AI35947] Funding Source: Medline; NIAMS NIH HHS [P60 AR40770] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035947] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR040770] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ABO A, 1994, BIOCHEM J, V298, P585, DOI 10.1042/bj2980585; BOKOCH GM, 1984, CELL, V39, P301, DOI 10.1016/0092-8674(84)90008-4; BOKOCH GM, 1995, TRENDS CELL BIOL, V5, P109, DOI 10.1016/S0962-8924(00)88960-6; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; BOKOCH GM, 1991, CURRENT TOPICS MEMBR, V35, P65; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; DING JB, 1995, J BIOL CHEM, V270, P11684, DOI 10.1074/jbc.270.19.11684; DING JB, 1993, J BIOL CHEM, V268, P17326; DORSEUIL O, IN PRESS J LEUKOCYTE; DUSI S, 1993, BIOCHEM J, V296, P367, DOI 10.1042/bj2960367; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; GRINSTEIN S, 1993, J BIOL CHEM, V268, P20223; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P261, DOI 10.1091/mbc.4.3.261; HEYWORTH PG, 1990, J BIOENERG BIOMEMBR, V22, P1, DOI 10.1007/BF00762842; HUANG CK, 1988, J BIOL CHEM, V263, P13144; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KNAUS UG, UNPUB; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LIANG L, 1995, J LEUKOCYTE BIOL, V57, P326, DOI 10.1002/jlb.57.2.326; MANSER E, 1992, J BIOL CHEM, V267, P16025; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; NAUSEEF WM, 1990, BLOOD, V76, P2622; PEVERI P, 1992, P NATL ACAD SCI USA, V89, P2494, DOI 10.1073/pnas.89.6.2494; QUINN MT, 1993, J BIOL CHEM, V268, P20983; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; SELLS MA, UNPUB; TRILIVAS I, 1991, J BIOL CHEM, V266, P8431; VONCKEN JW, 1995, CELL, V80, P719, DOI 10.1016/0092-8674(95)90350-X; XU XM, 1994, J BIOL CHEM, V269, P23569	31	357	366	1	10	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 14	1995	269	5221					221	223		10.1126/science.7618083	http://dx.doi.org/10.1126/science.7618083			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ029	7618083				2022-12-24	WOS:A1995RJ02900039
J	SHEN, XT; YU, LL; WEIR, JW; GOROVSKY, MA				SHEN, XT; YU, LL; WEIR, JW; GOROVSKY, MA			LINKER HISTONES ARE NOT ESSENTIAL AND AFFECT CHROMATIN CONDENSATION IN-VIVO	CELL			English	Article							TETRAHYMENA-THERMOPHILA; CELL-CYCLE; SEQUENCE; PHOSPHORYLATION; TRANSFORMATION; GENE; H1; HYBRIDIZATION; MICRONUCLEI; MACRONUCLEI	We have (separately) disrupted all of the expressed macronuclear copies of the HHO gene encoding macronuclear histone H1 and of the micronuclear linker histone (MLH) gene encoding the protein MicLH in Tetrahymena thermophila. These disruptions are shown to eliminate completely the expression of each protein. Strains without either linker histone grow at normal rates and reach near-normal cell densities, demonstrating that linker histones are not essential for cell survival. Histone H1 knockout (Delta H1) cells have enlarged DAPI-stained macronuclei and normal-sized micronuclei, while MicLH knockout (Delta MicLH) cells have enlarged micronuclei and normal-sized macronuclei. Delta MicLH cells undergo mitosis normally. However, the micronuclear mitotic chromosome structure is less condensed. These studies provide evidence that linker histones are nonessential and are involved in chromatin packaging and condensation in vivo.			SHEN, XT (corresponding author), UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14627, USA.			Shen, Xuetong/0000-0002-4267-5298	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026973] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26973] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAN J, 1981, J CELL BIOL, V90, P279, DOI 10.1083/jcb.90.2.279; ALLAN J, 1980, NATURE, V288, P675, DOI 10.1038/288675a0; ALLIS CD, 1984, J CELL BIOL, V99, P1669, DOI 10.1083/jcb.99.5.1669; ALLIS CD, 1982, DEV BIOL, V93, P519, DOI 10.1016/0012-1606(82)90139-7; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BANNON GA, 1983, NUCLEIC ACIDS RES, V11, P3903, DOI 10.1093/nar/11.12.3903; BRADBURY EM, 1992, BIOESSAYS, V14, P9; CHICOINE LG, 1985, DEV BIOL, V109, P1, DOI 10.1016/0012-1606(85)90339-2; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARK DJ, 1990, J MOL BIOL, V211, P883, DOI 10.1016/0022-2836(90)90081-V; DASSO M, 1994, P NATL ACAD SCI USA, V91, P12477, DOI 10.1073/pnas.91.26.12477; ELLIOTT AM, 1963, CELL MITOSIS, P107; GAERTIG J, 1994, P NATL ACAD SCI USA, V91, P4549, DOI 10.1073/pnas.91.10.4549; GAERTIG J, 1994, NUCLEIC ACIDS RES, V22, P5391, DOI 10.1093/nar/22.24.5391; GAERTIG J, 1992, P NATL ACAD SCI USA, V89, P9196, DOI 10.1073/pnas.89.19.9196; GARRARD WT, 1991, BIOESSAYS, V13, P87, DOI 10.1002/bies.950130208; GLOVER CVC, 1981, CELL, V23, P73, DOI 10.1016/0092-8674(81)90271-3; Gorovsky M A, 1975, Methods Cell Biol, V9, P311, DOI 10.1016/S0091-679X(08)60080-1; Gorovsky M.A., 1986, P227; GOROVSKY MA, 1974, J CELL BIOL, V61, P134, DOI 10.1083/jcb.61.1.134; GOROVSKY MA, 1973, J PROTOZOOL, V20, P19, DOI 10.1111/j.1550-7408.1973.tb05995.x; GOROVSKY MA, 1980, ANNU REV GENET, V14, P203, DOI 10.1146/annurev.ge.14.120180.001223; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; HAYASHI T, 1987, J BIOCHEM-TOKYO, V102, P369, DOI 10.1093/oxfordjournals.jbchem.a122063; HIRANO T, 1993, J CELL BIOL, V120, P601, DOI 10.1083/jcb.120.3.601; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; HOHMANN P, 1983, MOL CELL BIOCHEM, V57, P81; IWAMURA Y, 1979, BIOCHEMISTRY-US, V18, P5289, DOI 10.1021/bi00591a004; JOHMANN CA, 1976, J CELL BIOL, V71, P89, DOI 10.1083/jcb.71.1.89; JUAN LJ, 1994, EMBO J, V13, P6031, DOI 10.1002/j.1460-2075.1994.tb06949.x; KAHN RW, 1993, P NATL ACAD SCI USA, V90, P9295, DOI 10.1073/pnas.90.20.9295; KHOCHBIN S, 1994, EUR J BIOCHEM, V225, P501, DOI 10.1111/j.1432-1033.1994.00501.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LICHTER P, 1988, HUM GENET, V80, P224, DOI 10.1007/BF01790090; LILLEY DMJ, 1992, NATURE, V357, P282, DOI 10.1038/357282a0; Maniatis T., 1982, MOL CLONING; Nanney D.L., 1980, EXPT CILIATOLOGY; NER S S, 1992, Current Biology, V2, P208, DOI 10.1016/0960-9822(92)90541-H; NER SS, 1994, EMBO J, V13, P1817, DOI 10.1002/j.1460-2075.1994.tb06450.x; OHSUMI K, 1993, SCIENCE, V262, P2033, DOI 10.1126/science.8266099; Orias E., 1986, P45; PETERSON CL, 1994, CELL, V79, P389, DOI 10.1016/0092-8674(94)90247-X; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; ROTH SY, 1991, EMBO J, V10, P2069, DOI 10.1002/j.1460-2075.1991.tb07738.x; ROTH SY, 1992, TRENDS BIOCHEM SCI, V17, P93, DOI 10.1016/0968-0004(92)90243-3; STAYNOV DZ, 1988, EMBO J, V7, P3685, DOI 10.1002/j.1460-2075.1988.tb03250.x; SWEET MT, 1993, CHROMOSOMA, V102, P637, DOI 10.1007/BF00352312; THATCHER TH, 1994, NUCLEIC ACIDS RES, V22, P180, DOI 10.1093/nar/22.2.180; THATCHER TH, 1994, NUCLEIC ACIDS RES, V22, P174, DOI 10.1093/nar/22.2.174; THOMA F, 1979, J CELL BIOL, V83, P407; TONDRAVI MM, 1986, P NATL ACAD SCI USA, V83, P4369, DOI 10.1073/pnas.83.12.4369; TRASK BJ, 1991, TRENDS GENET, V7, P149, DOI 10.1016/0168-9525(91)90378-4; van Holde KE., 1989, SPRINGER SERIES MOL; VANDENENGH G, 1992, SCIENCE, V257, P1410, DOI 10.1126/science.1388286; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3; WHITE EM, 1988, NUCLEIC ACIDS RES, V16, P179, DOI 10.1093/nar/16.1.179; WOLFFE AP, 1994, SCIENCE, V264, P1100, DOI 10.1126/science.8178167; WU M, 1988, P NATL ACAD SCI USA, V85, P2205, DOI 10.1073/pnas.85.7.2205; WU M, 1994, MOL CELL BIOL, V14, P10, DOI 10.1128/MCB.14.1.10; WU M, 1986, P NATL ACAD SCI USA, V83, P8674, DOI 10.1073/pnas.83.22.8674; WU M, 1989, THESIS U ROCHESTER R; YAO MC, 1991, P NATL ACAD SCI USA, V88, P9493, DOI 10.1073/pnas.88.21.9493; ZLATANOVA J, 1992, J CELL SCI, V103, P889	63	247	256	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 14	1995	82	1					47	56		10.1016/0092-8674(95)90051-9	http://dx.doi.org/10.1016/0092-8674(95)90051-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RK424	7606784	Bronze			2022-12-24	WOS:A1995RK42400008
J	MASTERS, GA; GOLOMB, HM				MASTERS, GA; GOLOMB, HM			MANAGEMENT OF PULMONARY METASTASES	LANCET			English	Editorial Material							SARCOMA; LUNG				MASTERS, GA (corresponding author), UNIV CHICAGO,MED CTR,CHEST ONCOL PROGRAM,CHICAGO,IL 60637, USA.							CASSON AG, 1992, CANCER, V69, P662, DOI 10.1002/1097-0142(19920201)69:3<662::AID-CNCR2820690311>3.0.CO;2-I; CROW J, 1981, CANCER, V47, P2595, DOI 10.1002/1097-0142(19810601)47:11<2595::AID-CNCR2820471114>3.0.CO;2-Q; GIRARD P, 1994, AM J RESP CRIT CARE, V149, P469, DOI 10.1164/ajrccm.149.2.8306048; GIRARD P, 1994, CANCER, V74, P2791, DOI 10.1002/1097-0142(19941115)74:10<2791::AID-CNCR2820741008>3.0.CO;2-Q; HARPOLE DH, 1992, J THORAC CARDIOV SUR, V103, P743; HELLMAN S, 1995, J CLIN ONCOL, V113, P8; MATTHAY RA, 1993, AM REV RESPIR DIS, V148, P1691, DOI 10.1164/ajrccm/148.6_Pt_1.1691; MENTZER SJ, 1993, J SURG ONCOL, V53, P54, DOI 10.1002/jso.2930530114; MOUNTAIN CF, 1984, ANN THORAC SURG, V38, P323, DOI 10.1016/S0003-4975(10)62280-1; TODD TR, 1993, CHEST, V103, pS401, DOI 10.1378/chest.103.4_Supplement.401S	10	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 8	1995	346	8967					68	68		10.1016/S0140-6736(95)92109-5	http://dx.doi.org/10.1016/S0140-6736(95)92109-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH220	7603214				2022-12-24	WOS:A1995RH22000007
J	DENT, P; JELINEK, T; MORRISON, DK; WEBER, MJ; STURGILL, TW				DENT, P; JELINEK, T; MORRISON, DK; WEBER, MJ; STURGILL, TW			REVERSAL OF RAF-1 ACTIVATION BY PURIFIED AND MEMBRANE-ASSOCIATED PROTEIN PHOSPHATASES	SCIENCE			English	Article							KINASE-ACTIVITY; PHOSPHORYLATION; CELLS; MECHANISM	The Raf-1 protein kinase participates in transduction of mitogenic signals, but its mechanisms of activation are incompletely understood. Treatment of human Raf-1 purified from insect Sf9 cells co-expressing c-H-Ras and Src(Y527F) (in which phenylalanine replaces tyrosine at residue 527) with either serine-threonine or tyrosine phosphatases resulted in enzymatic inactivation of Raf-1. Inactivation of purified Raf-1 was blocked by addition of either the 14-3-3 zeta protein or heat shock protein 90, Loading of plasma membranes from transformed cells with guanosine triphosphate (GTP) resulted in inactivation of endogenous or exogenous Raf-1; inactivation was blocked by inclusion of protein phosphatase inhibitors. These results suggest the existence of protein phosphatases in the cell membrane that are regulated by GTP and are responsible for Raf-1 inactivation.	UNIV VIRGINIA,HOWARD HUGHES MED INST,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,MARKEY CTR CELL SIGNALING,DEPT MED,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,MARKEY CTR CELL SIGNALING,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908; NCI,FREDERICK CANC RES & DEV CTR,ADV BIOSCI LABS INC,BASIC RES PROGRAM,FREDERICK,MD 21702	Howard Hughes Medical Institute; University of Virginia; University of Virginia; University of Virginia; University of Virginia; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041077] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO046000] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-46000] Funding Source: Medline; NIDDK NIH HHS [DK41077] Funding Source: Medline; NIGMS NIH HHS [GM47322] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BALLOU LM, 1986, ENZYMES, V27, P311; BARFORD D, 1994, J MOL BIOL, V239, P726, DOI 10.1006/jmbi.1994.1409; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BRAUTIGAN DL, 1989, ARCH BIOCHEM BIOPHYS, V275, P44, DOI 10.1016/0003-9861(89)90348-2; CHEN FS, 1994, FEBS LETT, V347, P128, DOI 10.1016/0014-5793(94)00520-6; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1994, P NATL ACAD SCI USA, V91, P9544, DOI 10.1073/pnas.91.20.9544; DENT P, 1994, BIOCHEM J, V303, P105, DOI 10.1042/bj3030105; DENT P, UNPUB; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FORCE T, 1994, P NATL ACAD SCI USA, V91, P1270, DOI 10.1073/pnas.91.4.1270; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; FURUKAWA Y, 1993, BIOCHEM BIOPH RES CO, V194, P144, DOI 10.1006/bbrc.1993.1796; HALL A, 1986, J BIOL CHEM, V261, P963; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; JELINEK T, UNPUB; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; MORRISON D, UNPUB; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; PAN MG, 1992, SCIENCE, V256, P1215, DOI 10.1126/science.256.5060.1215; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SHIMIZU K, 1994, J BIOL CHEM, V269, P22917; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TRAVERSE S, 1993, ONCOGENE, V8, P3175; TRAVERSE S, 1994, FEBS LETT, V350, P13, DOI 10.1016/0014-5793(94)00723-3; TURNER BC, 1993, P NATL ACAD SCI USA, V90, P5544, DOI 10.1073/pnas.90.12.5544; USUI H, 1983, J BIOL CHEM, V258, P455; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WHITEHURST CE, 1995, J BIOL CHEM, V270, P5594, DOI 10.1074/jbc.270.10.5594; WILLIAMS NG, 1994, CANCER METAST REV, V13, P105, DOI 10.1007/BF00690421	39	186	189	0	2	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 30	1995	268	5219					1902	1906		10.1126/science.7604263	http://dx.doi.org/10.1126/science.7604263			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF990	7604263				2022-12-24	WOS:A1995RF99000039
J	DAVIS, AP; WITTE, DP; HSIEHLI, HM; POTTER, SS; CAPECCHI, MR				DAVIS, AP; WITTE, DP; HSIEHLI, HM; POTTER, SS; CAPECCHI, MR			ABSENCE OF RADIUS AND ULNA IN MICE LACKING HOXA-11 AND HOXD-11	NATURE			English	Article							VERTEBRATE LIMB; HOMEOTIC TRANSFORMATIONS; PATTERN-FORMATION; HOX-4 GENES; EXPRESSION; EVOLUTION	MICE with targeted disruptions(1) in Hox genes have been generated to evaluate the role of the Hox complex in determining the mammalian body plan. This complex of 38 genes encodes transcription factors that specify regional information along the embryonic axes. Early in vertebrate evolution an ancestral complex shared with invertebrates was duplicated twice to give rise to the four linkage groups (Hox A, B, C and D)(2,3). As a consequence, corresponding genes on the separate linkage groups, called paralogues, are most closely related to each other. Based on sequence similarities, the Hox genes have been subdivided into 13 paralogous groups. The five most 5' groups (Hox 9-13) pattern the posterior region of the vertebrate embryo and the appendicular skeleton(4-18). Mice with individual mutations in the paralogous genes hoxa-11 and hoxd-11 have been described(15-18). By breeding these two strains together we have generated double mutants which have dramatic phenotypes not apparent in mice homozygous for the individual mutations. The radius and the ulna of the forelimb are almost entirely eliminated, the axial skeleton shows homeotic transformations, and there are severe kidney defects not present in either single mutant. The limb and axial phenotypes are quantitative: as more mutant alleles are added to the genotype, the phenotype becomes progressively more severe. The appendicular skeleton defects suggest that paralogous Hox genes function together to specify limb outgrowth and patterning along the proximodistal axis.	UNIV UTAH,SCH MED,HOWARD HUGHES MED INST,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112; UNIV CINCINNATI,COLL MED,DEPT PEDIAT,CINCINNATI,OH 45229; UNIV CINCINNATI,COLL MED,CHILDRENS HOSP RES FDN,DIV BASIC SCI RES & PATHOL,CINCINNATI,OH 45229	Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati								CAPECCHI MR, 1994, SCI AM, V270, P54; COHN MJ, 1995, CELL, V80, P739, DOI 10.1016/0092-8674(95)90352-6; CONDIE BG, 1994, NATURE, V370, P304, DOI 10.1038/370304a0; DAVIS AP, 1994, DEVELOPMENT, V120, P2187; DOLLE P, 1991, GENE DEV, V5, P1767, DOI 10.1101/gad.5.10.1767; DOLLE P, 1993, CELL, V75, P431, DOI 10.1016/0092-8674(93)90378-4; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; DUBOULE D, 1992, BIOESSAYS, V14, P375, DOI 10.1002/bies.950140606; DUBOULE D, 1994, SCIENCE, V268, P575; Duboule D, 1991, CURR OPIN GENET DEV, V1, P211, DOI 10.1016/S0959-437X(05)80072-3; FALLON JF, 1994, SCIENCE, V264, P104, DOI 10.1126/science.7908145; FAVIER B, 1994, P NATL ACAD SCI USA, V92, P310; HAACK H, 1993, DEV BIOL, V157, P410, DOI 10.1006/dbio.1993.1145; HOLLAND PWH, 1994, DEVELOPMENT, P125; IZPISUABELMONTE JC, 1992, DEV BIOL, V152, P26, DOI 10.1016/0012-1606(92)90153-8; IZPISUABELMONTE JC, 1991, EMBO J, V10, P2279, DOI 10.1002/j.1460-2075.1991.tb07764.x; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; LI HMH, 1995, DEVELOPMENT, V121, P1373; MORGAN BA, 1992, NATURE, V358, P236, DOI 10.1038/358236a0; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; OSTER GF, 1988, EVOLUTION, V42, P862, DOI 10.1111/j.1558-5646.1988.tb02508.x; PETERSON RL, 1994, MECH DEVELOP, V47, P253, DOI 10.1016/0925-4773(94)90043-4; RANCOURT DE, 1995, GENE DEV, V9, P108, DOI 10.1101/gad.9.1.108; RUDDLE FH, 1994, ANNU REV GENET, V28, P423, DOI 10.1146/annurev.ge.28.120194.002231; SHUBIN NH, 1986, EVOL BIOL, V20, P319; SMALL KM, 1993, GENE DEV, V7, P2318, DOI 10.1101/gad.7.12a.2318; TABIN C, 1995, CELL, V80, P671, DOI 10.1016/0092-8674(95)90343-7; YOKOUCHI Y, 1991, NATURE, V353, P443, DOI 10.1038/353443a0	29	478	490	0	21	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 29	1995	375	6534					791	795		10.1038/375791a0	http://dx.doi.org/10.1038/375791a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF989	7596412				2022-12-24	WOS:A1995RF98900079
J	MCNICHOLL, BP; LEE, J				MCNICHOLL, BP; LEE, J			PATIENTS WITH MAJOR TRAUMA WHO DO NOT USE EMERGENCY AMBULANCES	BRITISH MEDICAL JOURNAL			English	Article							FIELD TRIAGE				MCNICHOLL, BP (corresponding author), ROYAL VICTORIA HOSP,DEPT ACCID & EMERGENCY,BELFAST BT12 6BA,ANTRIM,NORTH IRELAND.							KNUDSON P, 1988, J TRAUMA, V28, P602, DOI 10.1097/00005373-198805000-00006; MACKENZIE EJ, 1990, J TRAUMA, V30, P681, DOI 10.1097/00005373-199006000-00005; WEST JG, 1986, J TRAUMA, V26, P655	3	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 3	1995	310	6992					1442	1442		10.1136/bmj.310.6992.1442	http://dx.doi.org/10.1136/bmj.310.6992.1442			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC105	7613278	Green Published			2022-12-24	WOS:A1995RC10500019
J	WEISSMAN, JS; HOHL, CM; KOVALENKO, O; KASHI, Y; CHEN, SX; BRAIG, K; SAIBIL, HR; FENTON, WA; HORWICH, AL				WEISSMAN, JS; HOHL, CM; KOVALENKO, O; KASHI, Y; CHEN, SX; BRAIG, K; SAIBIL, HR; FENTON, WA; HORWICH, AL			MECHANISM OF GROEL ACTION - PRODUCTIVE RELEASE OF POLYPEPTIDE FROM A SEQUESTERED POSITION UNDER GROES	CELL			English	Article							ESCHERICHIA-COLI; ORNITHINE TRANSCARBAMYLASE; MOLECULAR CHAPERONE; CENTRAL CAVITY; COOPERATIVITY; HYDROLYSIS; SURFACE; BINDING; CYCLE	The chaperonin GroEL is a large, double-ring structure that, together with ATP and the cochaperonin GroES, assists protein folding in vivo. GroES forms an asymmetric complex with GroEL in which a single GroES ring binds one end of the GroEL cylinder. Cross-linking studies reveal that polypeptide binding occurs exclusively to the GroEL ring not occupied by GroES (trans). During the folding reaction, however, released GroES can rebind to the GroEL ring containing polypeptide (cis). The polypeptide is held tightly in a proteolytically protected environment in cis complexes, in the presence of ADP. Single turnover experiments with ornithine transcarbamylase reveal that polypeptide is productively released from the cis but not the trans complex. These observations suggest a two-step mechanism for GroEL-mediated folding. First, GroES displaces the polypeptide from its initial binding sites, sequestering it in the GroEL central cavity. Second, ATP hydrolysis induces release of GroES and productive release of polypeptide.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; UNIV LONDON BIRKBECK COLL,DEPT CRYSTALLOG,LONDON WC1E 7HX,ENGLAND	Howard Hughes Medical Institute; Yale University; University of London; Birkbeck University London	WEISSMAN, JS (corresponding author), YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510, USA.		Kashi, Yechezkel/D-5433-2013					AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P25672; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BURSTON SG, 1995, J MOL BIOL, V249, P138, DOI 10.1006/jmbi.1995.0285; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; CORRALES FJ, 1995, P NATL ACAD SCI USA, V92, P5326, DOI 10.1073/pnas.92.12.5326; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GORDON CL, 1994, J BIOL CHEM, V269, P27941; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; GRIMM R, 1993, J BIOL CHEM, V268, P5220; HLODAN R, 1995, NAT STRUCT BIOL, V2, P587, DOI 10.1038/nsb0795-587; HOOGENRAAD NJ, 1980, ANAL BIOCHEM, V101, P97, DOI 10.1016/0003-2697(80)90045-7; ISHII N, 1992, FEBS LETT, V299, P169, DOI 10.1016/0014-5793(92)80240-H; ISHII N, 1994, J MOL BIOL, V236, P691, DOI 10.1006/jmbi.1994.1181; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; LANDRY SJ, 1994, ANNU REV BIOPH BIOM, V23, P645, DOI 10.1146/annurev.bb.23.060194.003241; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LLORCA O, 1994, FEBS LETT, V345, P181, DOI 10.1016/0014-5793(94)00432-3; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MIZOBATA T, 1992, J BIOL CHEM, V267, P17773; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT; PERALTA D, 1994, FEBS LETT, V339, P45, DOI 10.1016/0014-5793(94)80381-1; RANSON NA, 1995, J MOL BIOL, V250, P581, DOI 10.1006/jmbi.1995.0399; SAIBIL H, 1991, NATURE, V353, P25, DOI 10.1038/353025b0; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; SCHMIDT M, 1994, J BIOL CHEM, V14, P10304; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; TIAN GL, 1995, NATURE, V375, P250, DOI 10.1038/375250a0; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1995, J BIOL CHEM, V270, P5388, DOI 10.1074/jbc.270.10.5388; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; ZHENG XX, 1993, J BIOL CHEM, V268, P7489	43	372	376	0	19	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 17	1995	83	4					577	587		10.1016/0092-8674(95)90098-5	http://dx.doi.org/10.1016/0092-8674(95)90098-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TF248	7585961	hybrid			2022-12-24	WOS:A1995TF24800011
J	GORE, SM; BIRD, AG; ROSS, AJ				GORE, SM; BIRD, AG; ROSS, AJ			PRISON RITES - STARTING TO INJECT INSIDE	BRITISH MEDICAL JOURNAL			English	Article									CHURCHILL HOSP,DEPT IMMUNOL,OXFORD OX3 7LJ,ENGLAND; BIAS,MRC,CTR HIV RES,EDINBURGH EH9 3JN,MIDLOTHIAN,SCOTLAND	University of Oxford; University of Edinburgh	GORE, SM (corresponding author), MRC,BIOSTAT UNIT,CAMBRIDGE CB2 2SR,ENGLAND.							BIRD AG, 1994, AIDS, V8, P1345, DOI 10.1097/00002030-199409000-00021; BIRD AG, 1995, IN PRESS AIDS; GORE SM, 1995, BRIT MED J, V310, P293, DOI 10.1136/bmj.310.6975.293; STRANG J, 1989, BRIT MED J, V298, P1310, DOI 10.1136/bmj.298.6683.1310; TAYLOR A, 1995, BRIT MED J, V310, P289, DOI 10.1136/bmj.310.6975.289	5	27	27	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 28	1995	311	7013					1135	1136		10.1136/bmj.311.7013.1135	http://dx.doi.org/10.1136/bmj.311.7013.1135			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC466	7580709	Green Published			2022-12-24	WOS:A1995TC46600018
J	HWANG, J; TAMM, LK; BOHM, C; RAMALINGAM, TS; BETZIG, E; EDIDIN, M				HWANG, J; TAMM, LK; BOHM, C; RAMALINGAM, TS; BETZIG, E; EDIDIN, M			NANOSCALE COMPLEXITY OF PHOSPHOLIPID MONOLAYERS INVESTIGATED BY NEAR-FIELD SCANNING OPTICAL MICROSCOPY	SCIENCE			English	Article							LANGMUIR-BLODGETT-FILMS; ATOMIC-FORCE MICROSCOPY; DIMYRISTOYLPHOSPHATIDIC ACID; LIPID MONOLAYERS; INTERFACE; TRANSITIONS; RESOLUTION; DIFFUSION; BILAYERS; SYSTEM	Near-field scanning optical microscopy of phospholipid monolayers doped with fluorescent lipid analogs reveals previously undescribed features in various phases, including a concentration gradient at the liquid-expanded/liquid-condensed domain boundary and weblike structures in the solid-condensed phase. Presumably, the web structures are grain boundaries between crystalline solid lipid. These structures are strongly modulated by the addition of low concentrations of cholesterol and ganglioside G(M1) in the monolayer.	UNIV VIRGINIA,DEPT MOLEC PHYSIOL & BIOL PHYS,CHARLOTTESVILLE,VA 22908; AT&T BELL LABS,MURRAY HILL,NJ 07974	University of Virginia; AT&T; Nokia Corporation; Nokia Bell Labs	HWANG, J (corresponding author), JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218, USA.				NIAID NIH HHS [AI14584, R37 AI030557, AI30557] Funding Source: Medline; NIDDK NIH HHS [DK44375] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030557, R01AI014584, R37AI030557, R37AI014584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK044375] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BETZIG E, 1992, SCIENCE, V257, P189, DOI 10.1126/science.257.5067.189; BETZIG E, 1993, SCIENCE, V262, P1422, DOI 10.1126/science.262.5138.1422; BOHM C, 1993, BIOPHYS J, V64, P553, DOI 10.1016/S0006-3495(93)81386-9; CHI LF, 1993, SCIENCE, V259, P213, DOI 10.1126/science.259.5092.213; Fischer A., 1984, Journal de Physique Lettres, V45, P785, DOI 10.1051/jphyslet:019840045016078500; FISHER A, 1984, J PHYSIQUE, V45, P517; GARNAES J, 1992, NATURE, V357, P54, DOI 10.1038/357054a0; HECKL WM, 1988, LANGMUIR, V4, P1352, DOI 10.1021/la00084a026; HICKEL W, 1990, J APPL PHYS, V67, P3572, DOI 10.1063/1.345307; HINTERDORFER P, 1994, J BIOL CHEM, V269, P20360; HWANG JS, 1994, BIOPHYS J, V66, pA277; LEE KYC, 1994, SCIENCE, V263, P655, DOI 10.1126/science.8303272; LOSCHE M, 1983, BER BUNSEN PHYS CHEM, V87, P848, DOI 10.1002/bbpc.19830871004; MCCONNELL HM, 1991, ANNU REV PHYS CHEM, V42, P171, DOI 10.1146/annurev.physchem.42.1.171; MCCONNELL HM, 1984, P NATL ACAD SCI USA, V81, P3249, DOI 10.1073/pnas.81.10.3249; MCCONNELL HM, 1986, BIOCHIM BIOPHYS ACTA, V864, P95, DOI 10.1016/0304-4157(86)90016-X; MIKRUT JM, 1993, PHYS REV B, V48, P14479, DOI 10.1103/PhysRevB.48.14479; MOERS MHP, 1994, LANGMUIR, V10, P2774, DOI 10.1021/la00020a044; MOHWALD H, 1990, ANNU REV PHYS CHEM, V41, P441, DOI 10.1146/annurev.pc.41.100190.002301; PAGANO RE, 1991, J CELL BIOL, V113, P1267, DOI 10.1083/jcb.113.6.1267; PETERS R, 1983, P NATL ACAD SCI-BIOL, V80, P7183, DOI 10.1073/pnas.80.23.7183; SEUL M, 1985, J PHYS CHEM-US, V89, P3592, DOI 10.1021/j100263a003; TAMM LK, 1988, BIOCHEMISTRY-US, V27, P1450, DOI 10.1021/bi00405a009; WEIS RM, 1984, NATURE, V310, P47, DOI 10.1038/310047a0; WEIS RM, 1985, J PHYS CHEM-US, V89, P4453, DOI 10.1021/j100267a011; WEISENHORN AL, 1991, LANGMUIR, V7, P8, DOI 10.1021/la00049a003; YANG J, 1993, J MICROSC-OXFORD, V171, P183, DOI 10.1111/j.1365-2818.1993.tb03375.x	27	135	135	0	27	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 27	1995	270	5236					610	614		10.1126/science.270.5236.610	http://dx.doi.org/10.1126/science.270.5236.610			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TB557	7570018				2022-12-24	WOS:A1995TB55700032
J	SMITH, J; CHANNER, KS				SMITH, J; CHANNER, KS			INCREASING PRESCRIPTION OF DRUGS FOR SECONDARY PREVENTION AFTER MYOCARDIAL-INFARCTION	BRITISH MEDICAL JOURNAL			English	Article							TRIALS		ROYAL HALLAMSHIRE HOSP,DEPT CARDIOL,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND	University of Sheffield								ECCLES M, 1991, BMJ-BRIT MED J, V302, P91, DOI 10.1136/bmj.302.6768.91; KETLEY D, 1993, LANCET, V342, P891, DOI 10.1016/0140-6736(93)91945-I; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; LAWSONMATTHEW PJ, 1994, J ROY COLL PHYS LOND, V28, P49; 1990, DRUG THER B, V28, P47	5	16	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 7	1995	311	7010					917	918						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ237	7580549				2022-12-24	WOS:A1995RZ23700020
J	DEMENOCAL, PB				DEMENOCAL, PB			PLIOPLEISTOCENE AFRICAN CLIMATE	SCIENCE			English	Article							SEA-SURFACE TEMPERATURE; EQUATORIAL ATLANTIC; TROPICAL ATLANTIC; LAST GLACIATION; NORTH-ATLANTIC; 2.4 MYR; DROUGHT; CIRCULATION; ETHIOPIA; SAHEL	Marine records of African climate variability document a shift toward more arid conditions after 2.8 million years ago (Ma), evidently resulting from remote forcing by cold North Atlantic sea-surface temperatures associated with the onset of Northern Hemisphere glacial cycles. African climate before 2.8 Ma was regulated by low-latitude insolation forcing of monsoonal climate due to Earth orbital precession. Major steps in the evolution of African hominids and other vertebrates are coincident with shifts to more arid, open conditions near 2.8 Ma, 1.7 Ma, and 1.0 Ma, suggesting that some Pliocene (Plio)-Pleistocene speciation events may have been climatically mediated.			DEMENOCAL, PB (corresponding author), LAMONT DOHERTY EARTH OBSERV,PALISADES,NY 10964, USA.		demenocal, peter/B-1386-2013	demenocal, peter/0000-0002-7191-717X				ASFAW B, 1992, NATURE, V362, P732; BERGER A, 1991, QUATERNARY SCI REV, V10, P297, DOI 10.1016/0277-3791(91)90033-Q; Blackman R.B., 1958, MEASUREMENT POWER SP, P1; BLOEMENDAL J, 1989, NATURE, V342, P897, DOI 10.1038/342897a0; BONNEFILLE R, 1983, NATURE, V303, P487, DOI 10.1038/303487a0; BONNEFILLE R, 1987, PALAEOGEOGR PALAEOCL, V60, P249, DOI 10.1016/0031-0182(87)90035-6; BONNEFILLE R, 1990, NATURE, V345, P347; BRAIN CK, 1981, ANN GEOL SOC S AFR, V84, P1; BROECKER WS, 1989, GEOCHIM COSMOCHIM AC, V53, P2465, DOI 10.1016/0016-7037(89)90123-3; Brown F.H., 1992, QUATERN INT, V13-14, P55, DOI DOI 10.1016/1040-6182(92)90010-Y; CANE MA, 1994, NATURE, V370, P204, DOI 10.1038/370204a0; CERLING TE, 1992, NATURE, V97, P241; Clark J.D., 1980, HUMAN ECOLOGY SAVANN, P41; CLEMENS SC, 1991, P OCEAN DRILLING PRO, V0117; DAVIES TD, 1985, J CLIMATOL, V5, P17, DOI 10.1002/joc.3370050103; DEMENOCAL PB, 1993, J GEOPHYS RES-ATMOS, V98, P7265, DOI 10.1029/92JD02924; DEMENOCAL PB, 1993, PALEOCEANOGRAPHY, V8, P209, DOI 10.1029/93PA02688; DEMENOCAL PB, IN PRESS PALEOCLIMAT; DRUYAN LM, 1989, INT J CLIMATOL, V9, P77, DOI 10.1002/joc.3370090107; DUPONT LM, 1989, ACTA BOT NEERL, V38, P405, DOI 10.1111/j.1438-8677.1989.tb01372.x; FEIBEL CS, 1989, AM J PHYS ANTHROPOL, V78, P595, DOI 10.1002/ajpa.1330780412; FOLLAND CK, 1986, NATURE, V320, P602, DOI 10.1038/320602a0; GASSE F, 1994, EARTH PLANET SC LETT, V126, P435, DOI 10.1016/0012-821X(94)90123-6; GASSE F, 1990, NATURE, V346, P141, DOI 10.1038/346141a0; GASSE F, 1989, NATURE, V342, P57, DOI 10.1038/342057a0; GRINE FE, 1986, S AFR J SCI, V82, P87; GUILDERSON TP, 1994, SCIENCE, V263, P663, DOI 10.1126/science.263.5147.663; Hamilton A. C., 1982, ENV HIST E AFRICA; HARRIS JWK, 1983, AFRICAN ACHAEOLOGICA, P3; HASTENRATH S, 1985, CLIMATE CIRCULATION; Hilgen FJ, 1989, TERRA NOVA, V1, P409, DOI 10.1111/j.1365-3121.1989.tb00401.x; HILL A, 1992, NATURE, V355, P719, DOI 10.1038/355719a0; IMBRIE J, 1993, PALEOCEANOGRAPHY, V8, P699, DOI 10.1029/93PA02751; JANSEN E, 1991, NATURE, V349, P600, DOI 10.1038/349600a0; KIMBEL W, IN PRESS PALEOCLIMAT; KLEIN RG, 1988, EVOLUTION HIST ROBUS; LAMB PJ, 1978, MON WEATHER REV, V106, P482, DOI 10.1175/1520-0493(1978)106<0482:CSOTAS>2.0.CO;2; LEROY S, 1994, NATURE, V109, P295; McIntyre A, 1989, PALEOCEANOGRAPHY, V4, P19, DOI 10.1029/PA004i001p00019; MIDDLETON NJ, 1985, NATURE, V316, P431, DOI 10.1038/316431a0; MOLFINO B, 1990, SCIENCE, V249, P766, DOI 10.1126/science.249.4970.766; NAIR RR, 1989, NATURE, V338, P749, DOI 10.1038/338749a0; NEWELL RE, 1984, J CLIMATOL, V4, P27, DOI 10.1002/joc.3370040103; NICHOLSON SE, LIMNOLOGY CLIMATOLOG; POKRAS EM, 1985, QUATERNARY RES, V24, P137, DOI 10.1016/0033-5894(85)90001-8; PRELL WL, 1987, J GEOPHYS RES-ATMOS, V92, P8411, DOI 10.1029/JD092iD07p08411; PROSPERO JM, 1986, NATURE, V320, P735, DOI 10.1038/320735a0; PROSPERO JM, 1977, SCIENCE, V196, P1196, DOI 10.1126/science.196.4295.1196; Pye K., 1987, AEOLIAN DUST DUST DE; RAYMO ME, 1990, EARTH PLANET SC LETT, V97, P353, DOI 10.1016/0012-821X(90)90051-X; REA DK, 1994, REV GEOPHYS, V32, P159, DOI 10.1029/93RG03257; RIND D, 1985, QUATERNARY RES, V24, P1, DOI 10.1016/0033-5894(85)90080-8; Rossignol-Strick M., 1983, NATURE, V303, P46; Ruddiman WF, 1989, PALEOCEANOGRAPHY, V4, P353, DOI 10.1029/PA004i004p00353; RUDDIMAN WF, 1989, P OCEAN DRILLING PRO, V0108; Sama-Wojcicki A. M., 1985, NATURE, V313, P306; SARNTHEIN M, 1981, NATURE, V293, P193, DOI 10.1038/293193a0; SCHRENK F, 1993, NATURE, V365, P833, DOI 10.1038/365833a0; SHACKLETON NJ, 1984, NATURE, V307, P620, DOI 10.1038/307620a0; SHACKLETON NJ, 1990, T ROY SOC EDIN-EARTH, V81, P251, DOI 10.1017/S0263593300020782; SHACKLETON NJ, IN PRESS P OCEAN DRI; SIROCKO F, 1991, QUATERNARY RES, V36, P72, DOI 10.1016/0033-5894(91)90018-Z; SIROCKO F, 1989, NATO ASI SER C-MATH, P401; STREETPERROTT FA, 1990, NATURE, V343, P607, DOI 10.1038/343607a0; SWISHER CC, 1994, SCIENCE, V263, P1118, DOI 10.1126/science.8108729; TIEDEMANN R, 1994, PALEOCEANOGRAPHY, V9, P619, DOI 10.1029/94PA00208; VRBA ES, 1989, OSSA, V14, P127; VRBA ES, IN PRESS PALEOCLIMAT; WEBB R, 1994, EOS, V75, P381; WEBSTER PJ, 1978, QUATERNARY RES, V10, P279, DOI 10.1016/0033-5894(78)90024-8; WESSELMAN HB, 1985, S AFR J SCI, V81, P260; WOLDEGABRIEL G, 1994, NATURE, V371, P330, DOI 10.1038/371330a0; WOOD B, 1992, NATURE, V355, P783, DOI 10.1038/355783a0; YEMANE K, 1985, NATURE, V318, P653, DOI 10.1038/318653a0; 1981, GEOL SOC AM MAP CHAR, V36; [No title captured]	76	841	877	7	142	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 6	1995	270	5233					53	59		10.1126/science.270.5233.53	http://dx.doi.org/10.1126/science.270.5233.53			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY302	7569951				2022-12-24	WOS:A1995RY30200030
J	JOHNSON, CH; KNIGHT, MR; KONDO, T; MASSON, P; SEDBROOK, J; HALEY, A; TREWAVAS, A				JOHNSON, CH; KNIGHT, MR; KONDO, T; MASSON, P; SEDBROOK, J; HALEY, A; TREWAVAS, A			CIRCADIAN OSCILLATIONS OF CYTOSOLIC AND CHLOROPLASTIC FREE CALCIUM IN PLANTS	SCIENCE			English	Article							SIGNAL-TRANSDUCTION; CYTOPLASMIC CALCIUM; GENE-EXPRESSION; PROTEIN-KINASE; TRANSFORMATION; PHYTOCHROME; ARABIDOPSIS; CHANNELS; CELLS; PROTOPLASTS	Tobacco and Arabidopsis plants, expressing a transgene for the calcium-sensitive luminescent protein apoaequorin, revealed circadian oscillations in free cytosolic calcium that can be phase-shifted by light-dark signals. When apoaequorin was targeted to the chloroplast, circadian chloroplast calcium rhythms were likewise observed after transfer of the seedlings to constant darkness. Circadian oscillations in free calcium concentrations can be expected to control many calcium-dependent enzymes and processes accounting for circadian outputs. Regulation of calcium flux is therefore fundamental to the organization of circadian systems.	UNIV OXFORD,DEPT PLANT SCI,OXFORD OX1 3RB,ENGLAND; NAGOYA UNIV,FAC SCI,DEPT BIOL,NAGOYA,AICHI 46401,JAPAN; UNIV WISCONSIN,GENET LAB,MADISON,WI 53706; UNIV EDINBURGH,INST CELL & MOLEC BIOL,EDINBURGH EH9 3JH,MIDLOTHIAN,SCOTLAND	University of Oxford; Nagoya University; University of Wisconsin System; University of Wisconsin Madison; University of Edinburgh	JOHNSON, CH (corresponding author), VANDERBILT UNIV,DEPT BIOL,NASHVILLE,TN 37235, USA.		Johnson, Carl H/I-4655-2014	Knight, Marc/0000-0002-4830-8608	NIGMS NIH HHS [GM48053] Funding Source: Medline; NIMH NIH HHS [MH43836, MH01179] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH043836, K02MH001179, R29MH043836] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AMON DI, 1949, PLANT PHYSIOL, V24, P1; ANDERSON S, 1986, BIOCHEM J, V240, P709, DOI 10.1042/bj2400709; BRUSSLAN JA, 1992, P NATL ACAD SCI USA, V89, P7791, DOI 10.1073/pnas.89.16.7791; Campbell A.K, 1983, INTRACELLULAR CALCIU; COBBOLD PH, 1987, BIOCHEM J, V248, P313, DOI 10.1042/bj2480313; DING JM, 1994, SCIENCE, V266, P1713, DOI 10.1126/science.7527589; Edmunds LN, 1988, CELLULAR MOL BASES B; GILROY S, 1990, NATURE, V346, P769, DOI 10.1038/346769a0; GOMEZ LA, 1995, PHOTOCHEM PHOTOBIOL, V61, P210, DOI 10.1111/j.1751-1097.1995.tb03963.x; GOTO K, 1985, SCIENCE, V228, P1284, DOI 10.1126/science.2988128; GUESZ ME, 1994, NEUROSCI BIOBEHAV RE, V18, P555; HEPLER PK, 1994, CELL CALCIUM, V16, P322, DOI 10.1016/0143-4160(94)90096-5; HETHERINGTON A, 1982, FEBS LETT, V145, P67, DOI 10.1016/0014-5793(82)81208-8; HORWITZ BA, 1978, PLANT SCI LETT, V13, P9, DOI 10.1016/0304-4211(78)90058-5; JOHANNES E, 1991, BIOESSAYS, V13, P331, DOI 10.1002/bies.950130704; Johnson Carl Hirschie, 1994, Seminars in Cell Biology, V5, P355, DOI 10.1006/scel.1994.1042; KIM HY, 1993, SCIENCE, V260, P960, DOI 10.1126/science.260.5110.960; KNIGHT MR, 1992, P NATL ACAD SCI USA, V89, P4967, DOI 10.1073/pnas.89.11.4967; KNIGHT MR, 1991, NATURE, V352, P524, DOI 10.1038/352524a0; KNIGHT MR, 1993, J CELL BIOL, V121, P83, DOI 10.1083/jcb.121.1.83; KONDO T, 1993, P NATL ACAD SCI USA, V90, P5672, DOI 10.1073/pnas.90.12.5672; LI HM, 1991, PLANT PHYSIOL, V96, P720, DOI 10.1104/pp.96.3.720; LUMSDEN PJ, 1991, ANNU REV PLANT PHYS, V42, P351, DOI 10.1146/annurev.pp.42.060191.002031; MALHO R, 1993, PLANT J, V5, P331; MELKONIAN B, 1990, CURR T PL B, V9, P38; MILLAR AJ, 1992, PLANT CELL, V4, P1075, DOI 10.1105/tpc.4.9.1075; MILLAR AJ, 1995, SCIENCE, V267, P1163, DOI 10.1126/science.7855596; MILLAR AJ, 1994, ANNU REV GENET, V28, P325, DOI 10.1146/annurev.ge.28.120194.001545; MILLER AJ, 1987, NATURE, V326, P397, DOI 10.1038/326397a0; MOURIOUX G, 1981, PLANT PHYSIOL, V67, P470, DOI 10.1104/pp.67.3.470; NAKASHIMA H, 1984, PLANT PHYSIOL, V74, P268, DOI 10.1104/pp.74.2.268; NEGRUTIU I, 1987, PLANT MOL BIOL, V8, P363, DOI 10.1007/BF00015814; NEUHAUS G, 1993, CELL, V73, P937, DOI 10.1016/0092-8674(93)90272-R; OKAZAKI Y, 1990, J MEMBRANE BIOL, V114, P189, DOI 10.1007/BF01869213; PIERSON ES, 1994, PLANT CELL, V6, P1815, DOI 10.1105/tpc.6.12.1815; PIETRZAK M, 1986, NUCLEIC ACIDS RES, V14, P5857, DOI 10.1093/nar/14.14.5857; ROENNEBERG T, 1993, NATURE, V362, P362, DOI 10.1038/362362a0; Roux Stanley J., 1994, P187; SATTER RL, 1981, ANNU REV PLANT PHYS, V32, P83, DOI 10.1146/annurev.pp.32.060181.000503; SCHROEDER JI, 1989, NATURE, V338, P427, DOI 10.1038/338427a0; SHACKLOCK PS, 1992, NATURE, V358, P753, DOI 10.1038/358753a0; SHEEN J, 1990, PLANT CELL, V2, P1027, DOI 10.1105/tpc.2.10.1027; SHIMOMURA O, 1993, BIOCHEM J, V296, P549, DOI 10.1042/bj2960549; Sweeney BM., 1987, RHYTHMIC PHENOMENA P; TSUKAYA H, 1991, PLANT PHYSIOL, V97, P1414, DOI 10.1104/pp.97.4.1414; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536	46	271	289	0	33	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 29	1995	269	5232					1863	1865		10.1126/science.7569925	http://dx.doi.org/10.1126/science.7569925			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX194	7569925				2022-12-24	WOS:A1995RX19400035
J	HOFMANN, J; CETRON, M; FARLEY, MM; BAUGHMAN, WS; FACKLAM, RR; ELLIOTT, JA; DEAVER, KA; BREIMAN, RF				HOFMANN, J; CETRON, M; FARLEY, MM; BAUGHMAN, WS; FACKLAM, RR; ELLIOTT, JA; DEAVER, KA; BREIMAN, RF			THE PREVALENCE OF DRUG-RESISTANT STREPTOCOCCUS-PNEUMONIAE IN ATLANTA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DAY-CARE-CENTER; UNITED-STATES; ANTIMICROBIAL RESISTANCE; PNEUMOCOCCAL INFECTIONS; PENICILLIN; CHILDREN; DISEASE; VACCINE; MENINGITIS; EFFICACY	Background. Streptococcus pneumoniae is a major cause of illness, and the emergence of drug-resistant strains threatens to complicate the management of pneumococcal infections. We conducted a laboratory-based surveillance for drug-resistant S. pneumoniae among patients with invasive pneumococcal infections in Atlanta. Methods. From January through October 1994, pneumococcal isolates from 431 patients with invasive disease in metropolitan Atlanta were serotyped and tested to determine their susceptibility to various antimicrobial agents. Susceptibility to the antimicrobial agents was defined according to guidelines established by the National Committee for Clinical Laboratory Standards. Results. The annual incidence of invasive pneumococcal infection was 30 cases per 100,000 population, Isolates from 25 percent of the patients were resistant to penicillin (7 percent were highly resistant), and isolates from 26 percent were resistant to trimethoprim-sulfamethoxazole (7 percent highly resistant). Fifteen percent of the isolates were resistant to erythromycin, 9 percent to cefotaxime (4 percent were highly resistant), and 25 percent to multiple drugs. Drug-resistant pneumococci were found in bath children and adults. Children under six years of age were more likely than older children and adults to have isolates resistant to multiple drugs or cefotaxime, Whites were more likely than blacks to have invasive pneumococcal infections caused by drug-resistant organisms. Among white children younger than six years, 41 percent of the S. pneumoniae isolates were resistant to penicillin. Conclusions. Drug-resistant strains of S. pneumoniae are common among both children and adults in Atlanta, Although blacks had a higher incidence of invasive pneumococcal infections than whites, whites were more likely to be infected with a drug-resistant isolate. Control of drug-resistant pneumococci will require more judicious use of antimicrobial agents and wider use of the pneumococcal polysaccharide vaccine.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,CHILDHOOD & RESP DIS BRANCH,ATLANTA,GA 30333; EMORY UNIV,SCH MED,DEPT MED,DIV INFECT DIS,ATLANTA,GA; VET AFFAIRS MED CTR,ATLANTA,GA 30033	Centers for Disease Control & Prevention - USA; Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System								AMITAI Y, 1985, ISRAEL J MED SCI, V21, P340; [Anonymous], 1993, M7A3 NAT COMM CLIN L; BREIMAN RF, 1994, JAMA-J AM MED ASSOC, V271, P1831, DOI 10.1001/jama.271.23.1831; BUTLER JC, 1993, JAMA-J AM MED ASSOC, V270, P1826, DOI 10.1001/jama.270.15.1826; BUTLER JC, 1995, J INFECT DIS, V171, P885, DOI 10.1093/infdis/171.4.885; CHESNEY PJ, 1992, AM J DIS CHILD, V146, P912, DOI 10.1001/archpedi.1992.02160200034022; Facklam RR, 1991, MANUAL CLIN MICROBIO, P238; FORD KL, 1991, J PEDIATR-US, V119, P941, DOI 10.1016/S0022-3476(05)83050-1; FRIEDLAND IR, 1993, PEDIATR INFECT DIS J, V12, P196, DOI 10.1097/00006454-199303000-00004; FRIEDLAND IR, 1994, NEW ENGL J MED, V331, P337; GABLE CB, 1990, JAMA-J AM MED ASSOC, V264, P2910, DOI 10.1001/jama.264.22.2910; GARCIALEONI ME, 1992, CLIN INFECT DIS, V14, P427, DOI 10.1093/clinids/14.2.427; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; HAGLUND LA, 1993, J INFECT DIS, V168, P1532, DOI 10.1093/infdis/168.6.1532; HENDERSON FW, 1988, J INFECT DIS, V157, P256, DOI 10.1093/infdis/157.2.256; JACKSON MA, 1984, PEDIATR INFECT DIS J, V3, P129, DOI 10.1097/00006454-198403000-00010; JACOBS MR, 1978, NEW ENGL J MED, V299, P735, DOI 10.1056/NEJM197810052991402; KLUGMAN KP, 1990, CLIN MICROBIOL REV, V3, P171, DOI 10.1128/CMR.3.2.171-196.1990; LEGGIADRO RJ, 1994, PEDIATR INFECT DIS J, V13, P320; LEGGIADRO RJ, 1994, PEDIATRICS, V93, P500; MASON EO, 1992, ANTIMICROB AGENTS CH, V36, P1703, DOI 10.1128/AAC.36.8.1703; MCCAIG LF, 1995, JAMA-J AM MED ASSOC, V273, P214, DOI 10.1001/jama.273.3.214; MELNICK SL, 1992, ANN PHARMACOTHER, V26, P1292, DOI 10.1177/106002809202601020; MUFSON MA, 1982, JAMA-J AM MED ASSOC, V248, P1486, DOI 10.1001/jama.248.12.1486; NAVA JM, 1994, CLIN INFECT DIS, V19, P884, DOI 10.1093/clinids/19.5.884; ORANGE M, 1993, PEDIATR INFECT DIS J, V12, P244, DOI 10.1097/00006454-199303000-00015; PALLARES R, 1987, NEW ENGL J MED, V317, P18, DOI 10.1056/NEJM198707023170104; PARIS MM, 1994, ANTIMICROB AGENTS CH, V38, P1320, DOI 10.1128/AAC.38.6.1320; QUICK RE, 1993, AM J MED, V94, P149, DOI 10.1016/0002-9343(93)90176-P; RADETSKY MS, 1981, LANCET, V2, P771; RAUCH AM, 1990, AM J DIS CHILD, V144, P923, DOI 10.1001/archpedi.1990.02150320087033; REICHLER MR, 1992, J INFECT DIS, V166, P1346, DOI 10.1093/infdis/166.6.1346; ROBINSBROWNE RM, 1984, J HYG-CAMBRIDGE, V93, P9, DOI 10.1017/S0022172400060873; SIBER GR, 1994, SCIENCE, V265, P1385, DOI 10.1126/science.8073278; SIMBERKOFF MS, 1986, J INFECT DIS, V153, P78, DOI 10.1093/infdis/153.1.78; SPIKA JS, 1991, J INFECT DIS, V163, P1273, DOI 10.1093/infdis/163.6.1273; STOOL SE, 1989, PEDIATR INFECT DIS J, V8, pS11; TAN TQ, 1993, PEDIATRICS, V92, P761; TAN TQ, 1992, PEDIATRICS, V90, P928; THOMPSON JW, 1994, PEDIATR INFECT DIS J, V13, P408, DOI 10.1097/00006454-199405000-00013; VILADRICH PF, 1991, ANTIMICROB AGENTS CH, V35, P2467, DOI 10.1128/AAC.35.12.2467; WELBY PL, 1994, PEDIATR INFECT DIS J, V13, P281, DOI 10.1097/00006454-199404000-00007; WENGER JD, 1991, LANCET, V338, P395; 1994, MMWR-MORBID MORTAL W, V43, P31; 1994, MMWR-MORBID MORTAL W, V43, P216; 1992, CP112 BUR CENS DEP C; 1994, MMWR-MORBID MORTAL W, V43, P23; 1994, M7A3 NAT COMM CLIN L	48	413	435	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 24	1995	333	8					481	486		10.1056/NEJM199508243330803	http://dx.doi.org/10.1056/NEJM199508243330803			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP759	7623880				2022-12-24	WOS:A1995RP75900003
J	CLAUSEN, JO; HANSEN, T; BJORBAEK, C; ECHWALD, SM; URHAMMER, SA; RASMUSSEN, S; ANDERSEN, CB; HANSEN, L; ALMIND, K; WINTHER, K; HARALDSDOTTIR, J; BORCHJOHNSEN, K; PEDERSEN, O				CLAUSEN, JO; HANSEN, T; BJORBAEK, C; ECHWALD, SM; URHAMMER, SA; RASMUSSEN, S; ANDERSEN, CB; HANSEN, L; ALMIND, K; WINTHER, K; HARALDSDOTTIR, J; BORCHJOHNSEN, K; PEDERSEN, O			INSULIN-RESISTANCE - INTERACTIONS BETWEEN OBESITY AND A COMMON VARIANT OF INSULIN-RECEPTOR SUBSTRATE-1	LANCET			English	Article							DEPENDENT DIABETES-MELLITUS; SENSITIVITY; GLUCOSE; POLYMORPHISMS; PLASMA	We previously discovered two aminoacid polymorphisms in codons 513 and 972 of the protein insulin receptor substrate-1 (IRS-1), which is important in cellular insulin action. We have investigated whether these polymorphisms are associated with changes in insulin sensitivity in a random sample of young healthy adults. Insulin sensitivity and secretion were measured during a combined intravenous glucose and tolbutamide tolerance test in 380 unrelated white subjects aged 18-32. IRS-1 polymorphisms were examined conformation polymorphism and enzyme digestion. No homozygous carrier of the codon-513 variant was identified, but one non-obese man had the codon-972 mutation on both alleles. He had low fasting-serum insulin and C-peptide concentrations and low insulin sensitivity and glucose effectiveness. During a 24 h dexamethasone test, he developed transient diabetes. In their heterozygous forms the codon-513 and codon-972 variants of IRS-1 were found in 3% and 9% of the subjects. Non-obese carriers of either polymorphism had similar insulin sensitivity and pancreatic beta-cell function to non-obese wild-type subjects (no known variants of IRS-1). Analysis of variance showed, however, a significant interaction between obesity (body-mass index greater than or equal to 25 kg/m(2)) and the heterozygous form of the codon-972 variant (p<0.003); obese polymorphism carriers had lower insulin sensitivity than obese non-carriers (mean 6.0 [SD 3.3] vs 12.3 [9.5] x 10(-5) L min(-1) pmol(-1)). The obese carriers of the codon-972 variant were also characterised by a clustering of metabolic cardiovascular risk factors, with raised fasting concentrations of plasma glucose, serum triglyceride, and plasma tissue-plasminogen-activator and its fast-acting inhibitor. With adjustment for known modulators of insulin sensitivity, multivariate analyses showed that the combination of obesity and the codon-972 variant was associated with a 50% reduction in insulin sensitivity (p=0.0008). Our results suggest that the codon-972 IRS-1 gene variant may interact with obesity in the pathogenesis of common insulin-resistant disorders.	STENO DIABET CTR, DK-2820 GENTOFTE, DENMARK; HAGEDORN RES INST, COPENHAGEN, DENMARK; GLOSTRUP POPULAT STUDIES, MED DEPT C, COPENHAGEN, DENMARK; UNIV COPENHAGEN, GLOSTRUP HOSP, DEPT CLIN CHEM, COPENHAGEN, DENMARK; ROYAL VET & AGR UNIV, RES DEPT HUMAN NUTR, COPENHAGEN, DENMARK	Steno Diabetes Center; Novo Nordisk; Hagedorn Research Institute; University of Copenhagen; University of Copenhagen			Pedersen, Oluf/AAG-8015-2020; Bjorbaek, Christian/S-4727-2019					ALMIND K, 1993, LANCET, V342, P828, DOI 10.1016/0140-6736(93)92694-O; ANDERSEN L, 1993, CLIN CHEM, V39, P578; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; ASTRAND PO, 1954, J APPL PHYSIOL, V7, P218, DOI 10.1152/jappl.1954.7.2.218; BEARD JC, 1986, DIABETES, V35, P362, DOI 10.2337/diabetes.35.3.362; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; BORKMAN M, 1993, NEW ENGL J MED, V328, P238, DOI 10.1056/NEJM199301283280404; CERASI E, 1972, DIABETES, V21, P224, DOI 10.2337/diab.21.4.224; ECHWALD SM, 1995, DIABETES, V44, P347, DOI 10.2337/diabetes.44.3.347; HAGER J, 1993, LANCET, V342, P1430, DOI 10.1016/0140-6736(93)92793-S; HAMSTEN A, 1985, NEW ENGL J MED, V313, P1557, DOI 10.1056/NEJM198512193132501; HEDING LG, 1975, DIABETOLOGIA, V11, P541, DOI 10.1007/BF01222104; HITMAN GA, 1995, DIABETOLOGIA, V38, P481, DOI 10.1007/s001250050309; HITMAN GA, 1991, BAILLIERE CLIN ENDOC, V5, P455, DOI 10.1016/S0950-351X(05)80142-9; HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271; IBSEN KK, 1981, ACTA PAEDIATR SCAND, V70, P27, DOI 10.1111/j.1651-2227.1981.tb07168.x; IMAI Y, 1994, J CLIN ENDOCR METAB, V79, P1655, DOI 10.1210/jc.79.6.1655; LAAKSO M, 1994, J CLIN INVEST, V94, P1141, DOI 10.1172/JCI117429; LILLIOJA S, 1993, NEW ENGL J MED, V329, P1988, DOI 10.1056/NEJM199312303292703; LUNDBAEK K, 1962, BRIT MED J, P1507, DOI 10.1136/bmj.1.5291.1507; MARTIN BC, 1992, LANCET, V340, P925, DOI 10.1016/0140-6736(92)92814-V; OKADA T, 1994, J BIOL CHEM, V269, P3568; PACINI G, 1986, COMPUT METH PROG BIO, V23, P113, DOI 10.1016/0169-2607(86)90106-9; RANBY M, 1986, CLIN CHEM, V32, P2160; SHIMOKAWA K, 1994, BIOCHEM BIOPH RES CO, V202, P463, DOI 10.1006/bbrc.1994.1951; STEIL GM, 1993, DIABETES, V42, P250, DOI 10.2337/diabetes.42.2.250; STUNKARD AJ, 1986, NEW ENGL J MED, V314, P193, DOI 10.1056/NEJM198601233140401; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; VAAG A, 1992, J CLIN INVEST, V89, P782, DOI 10.1172/JCI115656; WHITE MF, 1994, J BIOL CHEM, V269, P1	30	197	206	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 12	1995	346	8972					397	402		10.1016/S0140-6736(95)92779-4	http://dx.doi.org/10.1016/S0140-6736(95)92779-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN656	7623569				2022-12-24	WOS:A1995RN65600008
J	RUWENDE, C; KHOO, SC; SNOW, AW; YATES, SNR; KWIATKOWSKI, D; GUPTA, S; WARN, P; ALLSOPP, CEM; GILBERT, SC; PESCHU, N; NEWBOLD, CI; GREENWOOD, BM; MARSH, K; HILL, AVS				RUWENDE, C; KHOO, SC; SNOW, AW; YATES, SNR; KWIATKOWSKI, D; GUPTA, S; WARN, P; ALLSOPP, CEM; GILBERT, SC; PESCHU, N; NEWBOLD, CI; GREENWOOD, BM; MARSH, K; HILL, AVS			NATURAL-SELECTION OF HEMIZYGOTES AND HETEROZYGOTES FOR G6PD DEFICIENCY IN AFRICA BY RESISTANCE TO SEVERE MALARIA	NATURE			English	Article							PLASMODIUM-FALCIPARUM; GLUCOSE-6-PHOSPHATE-DEHYDROGENASE DEFICIENCY; VARIANT; DEHYDROGENASE; SEQUENCE; CHILDREN; ENZYME	GLUCOSE-6-PHOSPHATE dehydrogenase (G6PD) deficiency, the most common enzymopathy of humans, affects over 400 million people(1). The geographical correlation of its distribution with the historical endemicity of malaria suggests that this disorder has risen in frequency through natural selection by malaria(2.3). However, attempts to confirm that G6PD deficiency is protective in case-control studies of malaria have yielded conflicting results(4-8). Hence, for this X-linked disorder, it is unclear whether both male hemizygotes and female heterozygotes are protected or, as frequently suggested, only females(1,5-11). Furthermore, how much protection may be afforded is unknown. Here we report that, in two large case-control studies of over 2,000 African children, the common African form of G6PD deficiency (G6PD A-) is associated with a 46-58% reduction in risk of severe malaria for both female heterozygotes and male hemizygotes. A mathematical model incorporating the measured selective advantage against malaria suggests that a counterbalancing selective disadvantage, associated with this enzyme deficiency, has retarded its rise in frequency in malaria-endemic regions. Although G6PD deficiency is now regarded as a generally benign disorder, in earlier environmental conditions it could have been significantly disadvantageous.	UNIV OXFORD, WELLCOME TRUST CTR HUMAN GENET, OXFORD OX3 7BN, ENGLAND; UNIV OXFORD, JOHN RADCLIFFE HOSP, INST MOLEC MED, OXFORD OX3 9DU, ENGLAND; KEMRI, CLIN RES CTR, KILIFI UNIT, KILIFI, KENYA; MRC LABS, BANJUL, GAMBIA; UNIV OXFORD, DEPT ZOOL, OXFORD OX1 3PS, ENGLAND	University of Oxford; Wellcome Centre for Human Genetics; University of Oxford; MRC Laboratory Molecular Biology; University of Oxford			Gilbert, Sarah C./H-2857-2019; HILL, Adrian V>S>/C-1306-2008	Gilbert, Sarah C./0000-0002-6823-9750; Kwiatkowski, Dominic/0000-0002-5023-0176; Snow, Robert/0000-0003-3725-6088	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLISON AC, 1960, NATURE, V186, P531, DOI 10.1038/186531a0; BEUTLER E, 1989, BLOOD, V74, P2550; BEUTLER E, 1990, SEMIN HEMATOL, V27, P137; BIENZLE U, 1972, LANCET, V1, P107; Bruce-Chwatt L. J., 1988, Malaria: principles and practice of malariology. Volume 1., P1; GILLES HM, 1967, LANCET, V1, P138; GREENBERG DR, 1993, SOLID STATE ELECTRON, V36, P53, DOI 10.1016/0038-1101(93)90068-2; GREENWOOD B, 1991, PARASITOL TODAY, V7, P277, DOI 10.1016/0169-4758(91)90096-7; GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2; HELLER P, 1979, NEW ENGL J MED, V300, P1001, DOI 10.1056/NEJM197905033001801; HILL AVS, 1992, T ROY SOC TROP MED H, V86, P225, DOI 10.1016/0035-9203(92)90282-H; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; HIRONO A, 1988, P NATL ACAD SCI USA, V85, P3951, DOI 10.1073/pnas.85.11.3951; KURDIHAIDAR B, 1990, MOL BIOCHEM PARASIT, V41, P83, DOI 10.1016/0166-6851(90)90099-8; LING IT, 1988, MOL BIOCHEM PARASIT, V31, P47, DOI 10.1016/0166-6851(88)90144-2; Livingstone F. B., 1985, FREQUENCIES HEMOGLOB; Luzzato L, 1989, METABOLIC BASIS INHE, P2237; LUZZATTO L, 1979, LANCET, V1, P1183; LUZZATTO L, 1985, ADV HUM GENET, V14, P217; MARSH K, 1992, PARASITOLOGY, V104, pS53, DOI 10.1017/S0031182000075247; MARTIN SK, 1979, LANCET, V1, P524; MARTIN SK, 1994, PARASITOL TODAY, V10, P251, DOI 10.1016/0169-4758(94)90133-3; MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0; MILLER LH, 1988, MALARIA PRINCIPLES P, P493; MOTULSKY AG, 1961, LANCET, V1, P1168; MOTULSKY ARNO G., 1960, HUMAN BIOL, V32, P28; ROTH EF, 1983, P NATL ACAD SCI-BIOL, V80, P298, DOI 10.1073/pnas.80.1.298; USANGA EA, 1985, NATURE, V313, P793, DOI 10.1038/313793a0; VULLIAMY TJ, 1991, P NATL ACAD SCI USA, V88, P8568, DOI 10.1073/pnas.88.19.8568	29	409	426	2	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 20	1995	376	6537					246	249		10.1038/376246a0	http://dx.doi.org/10.1038/376246a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK331	7617034				2022-12-24	WOS:A1995RK33100044
J	BERTHOZ, A; ISRAEL, I; GEORGESFRANCOIS, P; GRASSO, R; TSUZUKU, T				BERTHOZ, A; ISRAEL, I; GEORGESFRANCOIS, P; GRASSO, R; TSUZUKU, T			SPATIAL MEMORY OF BODY LINEAR DISPLACEMENT - WHAT IS BEING STORED	SCIENCE			English	Article							GUIDED SACCADES; HUMANS; NAVIGATION; ROTATION; OTOLITHS	The ability to evaluate traveled distance is common to most animal species. Head trajectory in space is measured on the basis of the converging signals of the visual, vestibular, and somatosensory systems, together with efferent copies of motor commands. Recent evidence from human studies has shown that head trajectory in space can be stored in spatial memory. A fundamental question, however, remains unanswered: How is movement stored? In this study, humans who were asked to reproduce passive linear whole-body displacement distances while blindfolded were also able to reproduce velocity profiles. This finding suggests that a spatiotemporal dynamic pattern of motion is stored and can be retrieved with the use of vestibular and somesthetic cues.	COLL FRANCE, PHYSIOL PERCEPT & ACT LAB, CNRS, F-75006 PARIS, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; College de France								BERITOFF JS, 1965, NEURAL MECHANISMS HI, P107; BERTHOZ A, 1987, NEUROSCI LETT, V82, P285, DOI 10.1016/0304-3940(87)90270-9; Berthoz A, 1988, Adv Otorhinolaryngol, V41, P76; BLOOMBERG J, 1991, EXP BRAIN RES, V84, P47; BLOOMBERG J, 1988, ADV OTORHINOLARYNGOL, V40, P71; ETIENNE AS, 1986, ANIM BEHAV, V34, P696, DOI 10.1016/S0003-3472(86)80054-9; ETIENNE AS, 1988, BEHAVIOUR, V106, P81, DOI 10.1163/156853988X00106; GLASAUER S, 1994, EXP BRAIN RES, V98, P323; GUEDRY FE, 1963, LABYRINTHINE FUNCTIO; GUILFORD T, 1993, NATURE, V363, P112, DOI 10.1038/363112a0; ISRAEL I, 1993, J NEUROPHYSIOL, V70, P1270, DOI 10.1152/jn.1993.70.3.1270; ISRAEL I, 1989, J NEUROPHYSIOL, V62, P247, DOI 10.1152/jn.1989.62.1.247; ISRAEL I, 1992, ANN NY ACAD SCI, V656, P472, DOI 10.1111/j.1749-6632.1992.tb25229.x; ISRAEL I, 1995, ACTA OTO-LARYNGOL, V115, P3, DOI 10.3109/00016489509133338; ISRAEL I, 1991, NATO ADV SCI I D-BEH, V62, P599; ISRAEL I, 1993, EXP BRAIN RES, V96, P335; ISRAEL I, IN PRESS BRAIN; ISRAEL I, 1992, TUTORIALS MOTOR BEHA, V2, P195; LICHTENBERG BK, 1982, EXP BRAIN RES, V48, P127; MATTHEWS GVT, 1951, J EXP BIOL, V28, P508; MCCLOSKEY DI, 1981, HDB PHYSL NERVOUS SY, V2, P1391; MCNAUGHTON BL, 1991, J COGNITIVE NEUROSCI, V3, P192, DOI 10.1162/jocn.1991.3.2.190; MCNAUGHTON BL, 1983, EXP BRAIN RES, V52, P41; METCALFE T, 1992, ANN NY ACAD SCI, V656, P695; MILLER S, 1983, PHYSIOL PSYCHOL, V11, P1; Mittelstaedt H., 1982, P290; MITTELSTAEDT ML, 1991, ZOOL JAHRB ALLG ZOOL, V95, P427; MITTELSTAEDT ML, 1980, NATURWISSENSCHAFTEN, V67, P566, DOI 10.1007/BF00450672; OMARA SM, 1994, J NEUROSCI, V14, P6511; PIERROTDESEILLIGNY C, 1993, EXP BRAIN RES, V95, P166; Potegal M, 1982, SPATIAL ABILITIES DE, P361; Poulton E. C., 1981, HDB PHYSL NERVOUS SY, V2, P1337; SHARP PE, 1995, J NEUROSCI, V15, P173; Shelhamer M, 1994, J Vestib Res, V4, P1; STEVENS SS, 1960, AM SCI, V48, P226; WIENER SI, 1989, J NEUROSCI, V9, P2737; Wiener SI, 1993, MULTISENSORY CONTROL, P427, DOI [10.1093/acprof:oso/9780198547853.003.0208, DOI 10.1093/ACPROF:OSO/9780198547853.003.0208]; Young L.R, 1984, HDB PHYSL NERVOUS SY, P978; YOUNG LR, 1968, AEROSPACE MED, V39, P606	39	178	180	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 7	1995	269	5220					95	98		10.1126/science.7604286	http://dx.doi.org/10.1126/science.7604286			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RG980	7604286				2022-12-24	WOS:A1995RG98000043
J	SLOAN, VS; CAMERON, P; PORTER, G; GAMMON, M; AMAYA, M; MELLINS, E; ZALLER, DM				SLOAN, VS; CAMERON, P; PORTER, G; GAMMON, M; AMAYA, M; MELLINS, E; ZALLER, DM			MEDIATION BY HLA-DM OF DISSOCIATION OF PEPTIDES FROM HLA-DR	NATURE			English	Article							ANTIGEN-PROCESSING MUTANT; MAJOR HISTOCOMPATIBILITY COMPLEX; INVARIANT CHAIN PEPTIDES; CLASS-II MOLECULES; GENES; CELLS	HUMAN leukocyte antigen (HLA)-DM is an unconventional major histocompatibility complex (MHC) class II heterodimer that is important for B-cell-mediated antigen processing and presentation to MHC class II-restricted T cells(1-12). HLA-DM is encoded by two genes, DMA and DMB, which map to the MHC class II region(1), and shares some homology with MHC class I and class II proteins(2,3). Here we define the biochemical role of HLA-DM. Recombinant soluble HLA-DM heterodimers have been purified from culture supernatants of insect cell transformants. At pH 5.0, they induce the dissociation of a subset of peptides bound to HLA-DR, including a nested set of class-II-associated invariant chain peptides (CLIP). This process liberates HLA-DR and leads to the enhanced binding of exogenous peptides.	MERCK & CO INC,RES LABS,DEPT MOLEC IMMUNOL,RAHWAY,NJ 07065; MERCK & CO INC,RES LABS,DEPT AUTOIMMUNE DIS RES,RAHWAY,NJ 07065; MERCK & CO INC,RES LABS,DEPT MOLEC DESIGN & DIVERS,RAHWAY,NJ 07065; CHILDRENS HOSP PHILADELPHIA,PHILADELPHIA,PA 19104	Merck & Company; Merck & Company; Merck & Company; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia				Mellins, Elizabeth/0000-0003-2577-139X				AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; BUUS S, 1986, CELL, V47, P1071, DOI 10.1016/0092-8674(86)90822-6; CEMAN S, 1992, J IMMUNOL, V149, P754; DENZIN LK, 1994, IMMUNITY, V2, P595; FLING SP, 1994, NATURE, V368, P554, DOI 10.1038/368554a0; GERMAIN RN, 1993, NATURE, V363, P725, DOI 10.1038/363725a0; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; KARLSSON L, 1994, SCIENCE, V266, P1569, DOI 10.1126/science.7985028; KELLY AP, 1991, NATURE, V353, P571, DOI 10.1038/353571a0; LANZAVECCHIA A, 1992, NATURE, V357, P249, DOI 10.1038/357249a0; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; MELLINS E, 1991, J EXP MED, V174, P1607, DOI 10.1084/jem.174.6.1607; MELLINS E, 1994, J EXP MED, V179, P541, DOI 10.1084/jem.179.2.541; MELLINS E, 1990, NATURE, V343, P71, DOI 10.1038/343071a0; MONJI T, 1994, J IMMUNOL, V153, P4468; MORRIS P, 1994, NATURE, V368, P551, DOI 10.1038/368551a0; NELSON CA, 1993, P NATL ACAD SCI USA, V90, P1227, DOI 10.1073/pnas.90.4.1227; NELSON CA, 1994, NATURE, V371, P250, DOI 10.1038/371250a0; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; QUI Y, 1994, J CELL BIOL, V125, P595, DOI DOI 10.1083/JCB.125.3.595; RIBERDY JM, 1992, J IMMUNOL, V148, P2586; RIBERDY JM, 1992, NATURE, V360, P474, DOI 10.1038/360474a0; SANDERSON F, 1994, SCIENCE, V266, P1566, DOI 10.1126/science.7985027; SERCARZ EE, 1993, ANNU REV IMMUNOL, V11, P729, DOI 10.1146/annurev.iy.11.040193.003501; SETTE A, 1992, SCIENCE, V258, P1801, DOI 10.1126/science.1465617; STELLER H, 1985, EMBO J, V4, P167, DOI 10.1002/j.1460-2075.1985.tb02332.x; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; TULP A, 1994, NATURE, V369, P120, DOI 10.1038/369120a0; WEST MA, 1994, NATURE, V369, P147, DOI 10.1038/369147a0	30	497	501	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 29	1995	375	6534					802	806		10.1038/375802a0	http://dx.doi.org/10.1038/375802a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF989	7596415				2022-12-24	WOS:A1995RF98900082
J	WEINTRAUB, SJ; CHOW, KNB; LUO, RX; ZHANG, SH; HE, S; DEAN, DC				WEINTRAUB, SJ; CHOW, KNB; LUO, RX; ZHANG, SH; HE, S; DEAN, DC			MECHANISM OF ACTIVE TRANSCRIPTIONAL REPRESSION BY THE RETINOBLASTOMA PROTEIN	NATURE			English	Article							LARGE T-ANTIGEN; GENE-PRODUCT; BINDING PROTEIN; CELL-CYCLE; C-MYC; DOMAIN; TRANSACTIVATION; PHOSPHORYLATION; EXPRESSION; PROMOTER	THE retinoblastoma tumour-suppressor protein (Rb) belongs to a family that share a motif known as the pocket. The pocket was originally identified as the region of Rb required for binding to oncoproteins from DNA tumour viruses(1,2), which disrupt the binding of Rb to the E2F family of cell-cycle transcription factors (referred to collectively here as E2F)(3). Rb switches E2F sites from positive to negative elements(4), suggesting that Rb-E2F is an active complex that blocks transcription. Here we report that Rb is selectively recruited to promoters through E2F, where it in turn inactivates surrounding transcription factors by blocking their interaction with the basal transcription complex. We suggest that this repressor activity is essential for inhibiting promoters that contain enhancers in addition to E2F sites.	WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)								BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HAGEMEIER C, 1993, NUCLEIC ACIDS RES, V21, P4998, DOI 10.1093/nar/21.22.4998; HATEBOER G, 1993, P NATL ACAD SCI USA, V90, P8489, DOI 10.1073/pnas.90.18.8489; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KASHANCHI F, 1994, NATURE, V367, P295, DOI 10.1038/367295a0; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0	29	451	456	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 29	1995	375	6534					812	815		10.1038/375812a0	http://dx.doi.org/10.1038/375812a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF989	7596417				2022-12-24	WOS:A1995RF98900085
J	FERMO, I; DANGELO, SV; PARONI, R; MAZZOLA, G; CALORI, G; DANGELO, A				FERMO, I; DANGELO, SV; PARONI, R; MAZZOLA, G; CALORI, G; DANGELO, A			PREVALENCE OF MODERATE HYPERHOMOCYSTEINEMIA IN PATIENTS WITH EARLY-ONSET VENOUS AND ARTERIAL OCCLUSIVE DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article						HYPERHOMOCYSTEINEMIA; HOMOCYSTEINE; ARTERIAL OCCLUSIVE DISEASES; THROMBOPHLEBITIS; THROMBOEMBOLISM	POOR ANTICOAGULANT RESPONSE; PROTEIN-C ACTIVATION; PLASMA HOMOCYSTEINE; ENDOTHELIAL-CELLS; VASCULAR-DISEASE; ORAL ANTICOAGULATION; THROMBOGENIC AGENT; RISK FACTOR; THROMBOSIS; HOMOCYST(E)INE	Objective: To evaluate the prevalence of moderate hyperhomocysteinemia and inherited thrombophilia disorders (congenital defects of the natural anticoagulant or fibrinolytic mechanisms) in patients with early-onset venous or arterial thromboembolic disease. Design: Cross-sectional e-year evaluation of consecutive unrelated patients with a history of venous or arterial occlusive disease occurring before the age of 45 years or at unusual sites, in the absence of local predisposing factors. Setting: Thrombosis research unit of a community hospital. Patients: 107 patients with venous thromboembolism (mean age at event, 32.9 +/- 11.9 years) and 50 patients with arterial occlusive disease (mean age at event, 31.1 +/- 10 years) who did not have acquired coagulation defects, overt cancer, or acquired conditions affecting methionine metabolism. Measurements: Total plasma homocysteine (fasting levels), antithrombin III, protein C, protein S, activated protein C resistance, plasminogen, and heparin cofactor II were measured at least 3 months after the event. In 87 patients, total plasma homocysteine levels were also measured 8 hours after an oral methionine load was administered (L-methionine, 0.1 g/kg body weight). Ninety-fifth percentiles of the distribution of these variables were established in 60 apparently healthy persons; sex-specific ranges were used for protein S and total plasma homocysteine. Relatives of patients with laboratory abnormalities were studied to confirm inheritance of the defects. Results: Moderate hyperhomocysteinemia was detected in 13.1% (95% Cl, 7.6% to 21.3%) and in 19.2% (CI, 9.0% to 31.9%) of patients with venous or arterial occlusive disease. The prevalence of hyperhomocysteinemia was almost twice as high when based on homocysteine measurements done after oral methionine load as when based on fasting levels. The remaining defects were detected only in patients with venous occlusive disease (activated protein C resistance in 11.2% of patients, protein S or C deficiency in 6.6%, and plasminogen deficiency in 0.9%), with an overall prevalence of 18.7% (Cl, 12.1% to 27.6%). Inheritance of hyperhomocysteinemia and of the other defects was confirmed in 26 of the 30 families studied. Event-free survival analysis showed that the relative risk for occlusive disease in patients with moderate hyperhomocysteinemia and other defects was 1.70 times (Cl, 1.19 to 2.42; P < 0.01) greater than in patients without defects. After adjustment for the presence of predisposing factors (for example, use of contraceptive drugs, pregnancy, surgery, prolonged bedrest, smoking, mild hypertension or dyslipidemia) and a family history of thrombosis, the age at first event of patients with moderate hyperhomocysteinemia was similar to that of patients with the other defects (26.4 +/- 11.2 years compared with 25.2 +/- 10.6 years), and the 43 patients with defects were significantly younger at first event than the 114 patients without defects (25.5 +/- 11.1 years compared with 31.0 +/- 12.3; P < 0.005). Patients with mild hyperhomocysteineria had a higher rate of recurrence than those without defects (52% compared with 25%; P = 0.01); among the 56 patients who had their first event more than 1 year before observation, the recurrence rate was higher (80% [Cl, 51% to 95%]) in patients with defects than in patients without defects (41% [Cl, 26% to 57%] P = 0.01). Conclusions: Moderate hyperhomocysteinemia may have pathogenic significance in premature venous and arterial occlusive disease and should be included among the (inherited) disorders of venous and arterial thrombophilia.			FERMO, I (corresponding author), IRCCS, IST SCI HS RAFFAELE, ANAL LAB, VIA OLGETTINA 60, I-20132 MILAN, ITALY.		D'Angelo, Armando/K-2583-2018; fermo, isabella/AAN-3999-2020; PARONI, RITA/C-2955-2012; PARONI, RITA/AAC-6265-2020	D'Angelo, Armando/0000-0002-9857-4509; fermo, isabella/0000-0003-2947-1933; PARONI, RITA/0000-0002-3186-8860; PARONI, RITA/0000-0002-3186-8860				BANDELLO F, 1994, THROMB HAEMOSTASIS, V72, P39; BERTINA RM, 1994, NATURE, V64, P369; BLANN AD, 1992, ATHEROSCLEROSIS, V94, P89, DOI 10.1016/0021-9150(92)90192-J; BRATTSTROM L, 1991, HAEMOSTASIS, V21, P51; CADROY Y, 1994, BLOOD, V83, P2008; CHRISTENSEN E, 1987, HEPATOLOGY, V7, P1346, DOI 10.1002/hep.1840070628; CUSHMAN M, 1994, THROMB HAEMOSTASIS, V72, P647; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; DAHLBACK B, 1995, BLOOD, V85, P607, DOI 10.1182/blood.V85.3.607.bloodjournal853607; DANGELO A, 1988, J CLIN INVEST, V81, P1445, DOI 10.1172/JCI113475; DANGELO SV, 1986, J CLIN INVEST, V77, P416, DOI 10.1172/JCI112319; DANGELO SV, 1992, THROMB HAEMOSTASIS, V67, P631; DANGELO SV, 1995, THROMB RES, V77, P375; DENHEIJER M, 1995, LANCET, V345, P882, DOI 10.1016/S0140-6736(95)90008-X; FALCON CR, 1994, ARTERIOSCLER THROMB, V14, P1080, DOI 10.1161/01.ATV.14.7.1080; FERMO I, 1992, J CHROMATOGR, V593, P171, DOI 10.1016/0021-9673(92)80283-Z; FERMO I, 1993, AMINO ACIDS, V5, P17, DOI 10.1007/BF00806188; FRANKEN DG, 1994, ARTERIOSCLER THROMB, V14, P465, DOI 10.1161/01.ATV.14.3.465; FRYER RH, 1993, ARTERIOSCLER THROMB, V13, P1327, DOI 10.1161/01.ATV.13.9.1327; GENEST JJ, 1990, J AM COLL CARDIOL, V16, P1114, DOI 10.1016/0735-1097(90)90542-W; GRIFFIN JH, 1993, BLOOD, V82, P1989; HAJJAR KA, 1993, J CLIN INVEST, V91, P2873, DOI 10.1172/JCI116532; HARPEL PC, 1992, P NATL ACAD SCI USA, V89, P10193, DOI 10.1073/pnas.89.21.10193; HEIJBOER H, 1990, NEW ENGL J MED, V323, P1512, DOI 10.1056/NEJM199011293232202; HIRSH J, 1994, HEMOSTASIS THROMBOSI, P1543; JACOBSEN DW, 1994, CLIN CHEM, V40, P873; KANG SS, 1992, ANNU REV NUTR, V12, P279, DOI 10.1146/annurev.nu.12.070192.001431; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; LENTZ SR, 1991, J CLIN INVEST, V88, P1906, DOI 10.1172/JCI115514; MALINOW MR, 1989, CIRCULATION, V79, P1180, DOI 10.1161/01.CIR.79.6.1180; MALINOW MR, 1994, J INTERN MED, V236, P603, DOI 10.1111/j.1365-2796.1994.tb00854.x; MANSOOR MA, 1992, CLIN CHEM, V38, P1316; MUDD SH, 1985, AM J HUM GENET, V37, P1; MUDD SH, 1983, METABOLIC BASIS INHE, P522; NISHINAGA M, 1993, J CLIN INVEST, V92, P1381, DOI 10.1172/JCI116712; OLSZEWSKI AJ, 1988, ATHEROSCLEROSIS, V69, P109, DOI 10.1016/0021-9150(88)90003-2; PATHASARATHY S, 1987, BIOCHIM BIOPHYS ACTA, V917, P337; REES MM, 1993, THROMB RES, V71, P337, DOI 10.1016/0049-3848(93)90160-P; RODGERS GM, 1986, J CLIN INVEST, V77, P1909, DOI 10.1172/JCI112519; RODGERS GM, 1990, BLOOD, V75, P895; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; STAMLER JS, 1993, J CLIN INVEST, V91, P308, DOI 10.1172/JCI116187; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; TAYLOR LM, 1991, J VASC SURG, V13, P128, DOI 10.1016/0741-5214(91)90020-U; UELAND PM, 1989, J LAB CLIN MED, V114, P473; WANG J, 1993, THROMB HAEMOSTASIS, V70, P1047	46	217	222	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1995	123	10					747	+		10.7326/0003-4819-123-10-199511150-00002	http://dx.doi.org/10.7326/0003-4819-123-10-199511150-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE172	7574192				2022-12-24	WOS:A1995TE17200002
J	POLVIKOSKI, T; SULKAVA, R; HALTIA, M; KAINULAINEN, K; VUORIO, A; VERKKONIEMI, A; NIINISTO, L; HALONEN, P; KONTULA, K				POLVIKOSKI, T; SULKAVA, R; HALTIA, M; KAINULAINEN, K; VUORIO, A; VERKKONIEMI, A; NIINISTO, L; HALONEN, P; KONTULA, K			APOLIPOPROTEIN-E, DEMENTIA, AND CORTICAL DEPOSITION OF BETA-AMYLOID PROTEIN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SPORADIC ALZHEIMERS-DISEASE; SENILE PLAQUES; E POLYMORPHISM; TYPE-4 ALLELE; E GENOTYPE; BINDING; METHENAMINE; DIAGNOSIS; PEPTIDE; HEALTH	Background. The epsilon 4 allele of apolipoprotein E has been associated with an increased risk of late-onset Alzheimer's disease. In a cohort of elderly subjects we prospectively investigated the relation between the apolipoprotein E genotype, dementia, and the accumulation of beta-amyloid protein in the cerebral cortex. Methods. Autopsy involving neuropathological analysis and DNA analysis of frozen blood samples was performed in 92 of 271 persons who were at least 85 years of age, who had been living in Vantaa, Finland, on April 1, 1991, and who had died between that time and the end of 1993. All subjects had been tested for dementia, Apolipoprotein E genotyping was done with a solid-phase minisequencing technique. The percentage of the cortex occupied by methenamine silver-stained plaques was used as an estimate of the extent of beta-amyloid protein deposition. Results. The frequency of the epsilon 4 allele was significantly higher in the subjects with Alzheimer's disease than in the subjects without dementia (30 percent vs, 8 percent, P<0.001), There was a greater accumulation of beta-amyloid protein in the brain and more neurofibrillary tangles in the subjects with the epsilon 4 allele than in those without it (P<0.001), The deposition of beta-amyloid protein varied according to the genotype in both the subjects with dementia and those without dementia: it was lowest in those with the epsilon 2/epsilon 3 genotype, intermediate in those with the epsilon 3/epsilon 3 genotype, and highest in those with the epsilon 3/epsilon 4 genotype. A single subject had the epsilon 4/epsilon 4 genotype and had dementia. Conclusions. The epsilon 4 allele of apolipoprotein E is significantly associated with Alzheimer's disease. Even in elderly subjects without dementia, the apolipoprotein E genotype is related to the degree of deposition of beta-amyloid protein in the cerebral cortex.	HELSINKI UNIV,DEPT NEUROL,HELSINKI,FINLAND; KUOPIO UNIV,DEPT COMMUNITY HLTH & GEN PRACTICE,KUOPIO,FINLAND; KATARIINA GERIATR HOSP,VANTAA,FINLAND	University of Helsinki; University of Eastern Finland	POLVIKOSKI, T (corresponding author), HELSINKI UNIV,DEPT PATHOL,POB 21,HAARTMANINKATU 3,SF-00014 HELSINKI,FINLAND.		Vuorio, Alpo/I-3116-2019					ALLSOP D, 1989, NEUROPATH APPL NEURO, V15, P531, DOI 10.1111/j.1365-2990.1989.tb01252.x; AMOUYEL P, 1993, LANCET, V342, P1309; ANWAR N, 1993, LANCET, V342, P1308, DOI 10.1016/0140-6736(93)92404-H; BORGAONKAR DS, 1993, LANCET, V342, P625, DOI 10.1016/0140-6736(93)91458-X; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; GUNDERSEN HJG, 1988, APMIS, V96, P379, DOI 10.1111/j.1699-0463.1988.tb05320.x; HOULDEN H, 1994, NEUROSCI LETT, V174, P222, DOI 10.1016/0304-3940(94)90026-4; KONDOH H, 1993, BIOTECH HISTOCHEM, V68, P113, DOI 10.3109/10520299309104677; KUUSISTO J, 1994, BRIT MED J, V309, P636, DOI 10.1136/bmj.309.6955.636; LADU MJ, 1994, J BIOL CHEM, V269, P23403; LOUHIJA J, 1994, ARTERIOSCLER THROMB, V14, P1084, DOI 10.1161/01.ATV.14.7.1084; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MIETTINEN HE, 1994, HUM GENET, V94, P189; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; NOGUCHI S, 1993, LANCET, V342, P737, DOI 10.1016/0140-6736(93)91728-5; PAYAMI H, 1994, JAMA-J AM MED ASSOC, V271, P1316, DOI 10.1001/jama.271.17.1316; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; REBECK GW, 1993, NEURON, V11, P575; RICHEY PL, 1995, BIOCHEM BIOPH RES CO, V208, P657, DOI 10.1006/bbrc.1995.1389; ROMAN GC, 1993, NEUROLOGY, V43, P250, DOI 10.1212/WNL.43.2.250; ROSES AD, 1994, LANCET, V343, P1564, DOI 10.1016/S0140-6736(94)92960-2; SAUNDERS AM, 1993, LANCET, V342, P710, DOI 10.1016/0140-6736(93)91709-U; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SOBEL E, 1995, NEUROLOGY, V45, P903, DOI 10.1212/WNL.45.5.903; STGEORGEHYSLOP P, 1994, SCIENCE, V263, P904; STGEORGEHYSLOP P, 1994, SCIENCE, V263, P537, DOI 10.1126/science.8290965; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; STRITTMATTER WJ, 1994, EXP NEUROL, V125, P163, DOI 10.1006/exnr.1994.1019; SYVANEN AC, 1993, AM J HUM GENET, V52, P46; TALBOT C, 1994, LANCET, V343, P1432, DOI 10.1016/S0140-6736(94)92557-7; UTERMANN G, 1987, AM HEART J, V113, P433, DOI 10.1016/0002-8703(87)90610-7; VAN BROECKHOVEN C, 1994, NEUROSCI LETT, V169, P179, DOI 10.1016/0304-3940(94)90385-9; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C; WISNIEWSKI T, 1993, BIOCHEM BIOPH RES CO, V192, P359, DOI 10.1006/bbrc.1993.1423; YAMAGUCHI H, 1990, ACTA NEUROPATHOL, V79, P569, DOI 10.1007/BF00296119; 1987, DIAGNOSTIC STATISTIC	41	423	435	1	25	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 9	1995	333	19					1242	1247		10.1056/NEJM199511093331902	http://dx.doi.org/10.1056/NEJM199511093331902			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC715	7566000				2022-12-24	WOS:A1995TC71500002
J	SLOAND, EM; PITT, E; KLEIN, HG				SLOAND, EM; PITT, E; KLEIN, HG			SAFETY OF THE BLOOD-SUPPLY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; HEPATITIS-C VIRUS; T-CELL LEUKEMIA; HTLV-II INFECTION; NON-B HEPATITIS; TRANSFUSION-ASSOCIATED HEPATITIS; POLYMERASE CHAIN-REACTION; INTRAVENOUS-DRUG-USERS; LYMPHOTROPIC VIRUS; TRYPANOSOMA-CRUZI		NIH, WARREN GRANT MAGNUSON CLIN CTR, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA	SLOAND, EM (corresponding author), NHLBI, 31 CTR DR, MSC 2490, BLDG 31, ROOM 4A11, BETHESDA, MD 20892 USA.							AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901; Aach RD, 1978, VIRAL HEPATITIS, P383; ADLER SP, 1989, TRANSFUSION, V29, P667, DOI 10.1046/j.1537-2995.1989.29890020436.x; ALI AM, 1987, BLOOD S, V70, pA325; ALTER HJ, 1990, NEW ENGL J MED, V323, P1312, DOI 10.1056/NEJM199011083231905; ALTER HJ, 1966, BLOOD-J HEMATOL, V27, P297, DOI 10.1182/blood.V27.3.297.297; ALTER HJ, 1975, LANCET, V2, P838, DOI 10.1016/S0140-6736(75)90234-2; ALTER HJ, 1991, TRANSFUSION, V31, P771, DOI 10.1046/j.1537-2995.1991.31892023507.x; Alter HJ, 1987, TRANSFUSION TRANSMIT, P53; [Anonymous], 1995, JAMA, V274, P1374; [Anonymous], 1991, MMWR Recomm Rep, V40, P1; APPLEMAN MD, 1993, TRANSFUSION, V33, P61, DOI 10.1046/j.1537-2995.1993.33193142312.x; BACKER U, 1988, 4TH P INT C AIDS STO, V2, P364; BARRETT BB, 1993, TRANSFUSION, V33, P228, DOI 10.1046/j.1537-2995.1993.33393174449.x; BLOCH M, 1982, REV I INVEST MED, V11, P148; BOWDEN R, 1990, TRANSFUSION, V30, P762, DOI 10.1046/j.1537-2995.1990.30891020340.x; BOWDEN RA, 1992, BLOOD SAFETY CURRENT, P201; BRAINE HG, 1986, TRANSFUSION, V26, P391, DOI 10.1046/j.1537-2995.1986.26486262752.x; BRECHOT C, 1985, NEW ENGL J MED, V312, P270, DOI 10.1056/NEJM198501313120503; BRYSON YJ, 1995, NEW ENGL J MED, V332, P833, DOI 10.1056/NEJM199503303321301; BUCHHOLZ DH, 1992, TRANSFUSION, V32, P667, DOI 10.1046/j.1537-2995.1992.32792391043.x; BUCHHOLZ DH, 1971, NEW ENGL J MED, V285, P429, DOI 10.1056/NEJM197108192850803; BUSCH M, 1994, SEP FOOD DRUG ADM C; BUSCH MP, 1990, NEW ENGL J MED, V323, P1308, DOI 10.1056/NEJM199011083231904; BUSCH MP, 1991, NEW ENGL J MED, V325, P1, DOI 10.1056/NEJM199107043250101; BUSCH MP, 1991, TRANSFUSION, V31, P4, DOI 10.1046/j.1537-2995.1991.31191096183.x; CARVALHO MR, 1993, TRANSFUSION, V33, P830, DOI 10.1046/j.1537-2995.1993.331094054620.x; CUMMING PD, 1989, NEW ENGL J MED, V321, P941, DOI 10.1056/NEJM198910053211405; DESCHRYVER A, 1990, TRANSFUSION, V30, P844; DODD RY, 1992, NEW ENGL J MED, V327, P419, DOI 10.1056/NEJM199208063270610; DODD RY, 1988, INFECT CONT HOSP EP, V9, P357; DOLL LS, 1991, TRANSFUSION, V31, P704, DOI 10.1046/j.1537-2995.1991.31892023494.x; DONAHUE JG, 1992, NEW ENGL J MED, V327, P369, DOI 10.1056/NEJM199208063270601; DONAHUE JG, 1990, NEW ENGL J MED, V323, P1709; DONDERO TJ, 1994, LANCET, V343, P1376, DOI 10.1016/S0140-6736(94)92517-8; DONEGAN E, 1990, ANN INTERN MED, V113, P733, DOI 10.7326/0003-4819-113-10-733; DONEGAN E, 1990, TRANSFUSION, V30, P851, DOI 10.1046/j.1537-2995.1990.30991048798.x; ESTEBAN JI, 1985, LANCET, V2, P1083; ESTEBAN JI, 1990, NEW ENGL J MED, V323, P1107, DOI 10.1056/NEJM199010183231605; ESTEBAN JI, 1991, ANN INTERN MED, V115, P443, DOI 10.7326/0003-4819-115-6-443; FARCI P, 1991, NEW ENGL J MED, V325, P98, DOI 10.1056/NEJM199107113250205; FARZADEGAN H, 1988, ANN INTERN MED, V108, P785, DOI 10.7326/0003-4819-108-6-785; FEIGAL E, 1991, J INFECT DIS, V164, P36, DOI 10.1093/infdis/164.1.36; GILBERT GL, 1989, LANCET, V1, P1228, DOI 10.1016/S0140-6736(89)92330-1; GOLDMAN M, 1991, Transfusion Medicine Reviews, V5, P73, DOI 10.1016/S0887-7963(91)70194-6; GRANT IH, 1989, ANN INTERN MED, V111, P849, DOI 10.7326/0003-4819-111-10-849; HJELLE B, 1992, LANCET, V339, P645, DOI 10.1016/0140-6736(92)90797-7; HOOFNAGLE JH, 1990, TRANSFUSION, V30, P384, DOI 10.1046/j.1537-2995.1990.30590296367.x; HORSBURGH CR, 1989, LANCET, V2, P637; JACOBSON MA, 1988, ANN INTERN MED, V108, P585, DOI 10.7326/0003-4819-108-4-585; KALYANARAMAN VS, 1982, P NATL ACAD SCI-BIOL, V79, P1653, DOI 10.1073/pnas.79.5.1653; KERNDT PR, 1991, TRANSFUSION, V31, P814, DOI 10.1046/j.1537-2995.1991.31992094668.x; KHABBAZ RF, 1992, NEW ENGL J MED, V326, P375, DOI 10.1056/NEJM199202063260604; KHABBAZ RF, 1993, ANN INTERN MED, V118, P448; KIM DM, 1992, TRANSFUSION, V32, P221, DOI 10.1046/j.1537-2995.1992.32392213804.x; KLEINMAN S, 1991, Transfusion (Bethesda), V31, p41S; KORELITZ JJ, 1994, TRANSFUSION, V34, P870, DOI 10.1046/j.1537-2995.1994.341095026972.x; KOZIOL DE, 1986, ANN INTERN MED, V104, P488, DOI 10.7326/0003-4819-104-4-488; KRECH U, 1973, B WORLD HEALTH ORGAN, V49, P103; LANDER JJ, 1978, VOX SANG, V34, P77, DOI 10.1111/j.1423-0410.1978.tb03726.x; LEE H, 1989, SCIENCE, V244, P471, DOI 10.1126/science.2655084; LEFRERE JJ, 1990, LANCET, V335, P1400, DOI 10.1016/0140-6736(90)91277-H; LEITMAN SF, 1989, NEW ENGL J MED, V321, P917, DOI 10.1056/NEJM198910053211401; LINDEN JV, 1992, TRANSFUSION, V32, P601, DOI 10.1046/j.1537-2995.1992.32792391030.x; LOIACONO BR, 1989, TRANSFUSION, V29, P823, DOI 10.1046/j.1537-2995.1989.29990070189.x; MACKINNON S, 1988, J CLIN PATHOL, V41, P948, DOI 10.1136/jcp.41.9.948; MANEZ R, 1993, TRANSFUSION, V33, P594, DOI 10.1046/j.1537-2995.1993.33793325057.x; MANNS A, 1992, INT J CANCER, V51, P886, DOI 10.1002/ijc.2910510609; MAURICE J, 1987, TROPICAL DISEASE RES, P89; MORDUCHOWICZ G, 1991, REV INFECT DIS, V13, P307; MORROW JF, 1991, JAMA-J AM MED ASSOC, V266, P555; MURPHY EL, 1993, LANCET, V341, P757, DOI 10.1016/0140-6736(93)90529-P; MURPHY EL, 1989, INT J CANCER, V43, P250, DOI 10.1002/ijc.2910430214; NELSON KE, 1992, ANN INTERN MED, V117, P554, DOI 10.7326/0003-4819-117-7-554; NICKERSON P, 1989, ANN INTERN MED, V111, P851, DOI 10.7326/0003-4819-111-10-851; OKOCHI K, 1984, VOX SANG, V46, P245, DOI 10.1111/j.1423-0410.1984.tb00083.x; PETERSEN LR, 1991, TRANSFUSION, V31, P698, DOI 10.1046/j.1537-2995.1991.31892023493.x; PETERSEN LR, 1994, TRANSFUSION, V34, P865, DOI 10.1046/j.1537-2995.1994.341095026971.x; PETERSEN LR, 1994, TRANSFUSION, V34, P283, DOI 10.1046/j.1537-2995.1994.34494233574.x; PINDYCK J, 1985, TRANSFUSION, V25, P3, DOI 10.1046/j.1537-2995.1985.25185116497.x; ROBERTGUROFF M, 1982, SCIENCE, V215, P975, DOI 10.1126/science.6760397; ROY MJ, 1993, JAMA-J AM MED ASSOC, V269, P2876, DOI 10.1001/jama.269.22.2876; SARIN PS, 1989, P NATL ACAD SCI USA, V86, P2021, DOI 10.1073/pnas.86.6.2021; SAYERS MH, 1992, ANN INTERN MED, V116, P55, DOI 10.7326/0003-4819-116-1-55; SCHMIDT PJ, 1994, ARCH PATHOL LAB MED, V118, P454; SCHMUNIS GA, 1991, TRANSFUSION, V31, P547, DOI 10.1046/j.1537-2995.1991.31691306255.x; SCHOECHETMAN G, 1994, SEP FOOD DRUG ADM C; Selbie FR, 1943, BRIT J EXP PATHOL, V24, P150; SELIK RM, 1993, TRANSFUSION, V33, P890, DOI 10.1046/j.1537-2995.1993.331194082377.x; SHIH LN, 1990, J MED VIROL, V32, P257, DOI 10.1002/jmv.1890320412; SILVER H, 1970, Transfusion (Bethesda), V10, P315; SIMONS JN, 1995, P NATL ACAD SCI USA, V92, P3401, DOI 10.1073/pnas.92.8.3401; STARKEY JM, 1989, JAMA-J AM MED ASSOC, V262, P3452, DOI 10.1001/jama.262.24.3452; STEVENS CE, 1984, ANN INTERN MED, V101, P733, DOI 10.7326/0003-4819-101-6-733; SULLIVAN MT, 1991, ARCH INTERN MED, V151, P2043, DOI 10.1001/archinte.151.10.2043; TAYLOR PE, 1990, TRANSFUSION, V30, P783, DOI 10.1046/j.1537-2995.1990.30991048782.x; THIERS V, 1988, LANCET, V2, P1273; THOMPSON KS, 1992, TRANSFUSION, V32, pS65; TIPPLE MA, 1990, TRANSFUSION, V30, P207, DOI 10.1046/j.1537-2995.1990.30390194338.x; VISCIDI RP, 1991, J ACQ IMMUN DEF SYND, V4, P1190; WARD JW, 1988, NEW ENGL J MED, V318, P473, DOI 10.1056/NEJM198802253180803; WIKTOR SZ, 1991, LANCET, V338, P512, DOI 10.1016/0140-6736(91)90585-D; WRENN HE, 1974, TRANSFUSION, V14, P171, DOI 10.1111/j.1537-2995.1974.tb04512.x; ZIERDT CH, 1983, J CLIN MICROBIOL, V17, P628, DOI 10.1128/JCM.17.4.628-630.1983; 1993, ATTITUDES US ADULTS; 1991, MMWR-MORBID MORTAL W, V40, P176; 1991, TRANSFUSION S8S, V31, pS41	107	69	73	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 1	1995	274	17					1368	1373		10.1001/jama.274.17.1368	http://dx.doi.org/10.1001/jama.274.17.1368			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB278	7563562				2022-12-24	WOS:A1995TB27800028
J	FISHERHOCH, SP; TOMORI, O; NASIDI, A; PEREZORONOZ, GI; FAKILE, Y; HUTWAGNER, L; MCCORMICK, JB				FISHERHOCH, SP; TOMORI, O; NASIDI, A; PEREZORONOZ, GI; FAKILE, Y; HUTWAGNER, L; MCCORMICK, JB			REVIEW OF CASES OF NOSOCOMIAL LASSA FEVER IN NIGERIA - THE HIGH PRICE OF POOR MEDICAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article								Objective-To investigate two hospital outbreaks of Lassa fever in southern central Nigeria. Setting-Hospitals and clinics in urban and rural areas of Imo State, Nigeria. Design-Medical records were reviewed in hospitals and clinics in both areas. Patients with presumed and laboratory confirmed Lassa fever were identified and contracts traced. Hospital staff, patients, and local residents were questioned, records were carefully reviewed, and serum samples were taken. Serum samples were assayed for antibody specific to Lassa virus, and isolates of Lassa virus were obtained. Results-Among 34 patients with Lassa fever, including 20 patients, six nurses, two surgeons, one physician, and the son of a patient, there were 22 deaths (65% fatality rate). Eleven cases were laboratory confirmed, five by isolation of virus. Most patients had been exposed in hospitals (attack rate in patients in one hospital 55%). Both outbreak hospitals were inadequately equipped and staffed, with poor medical practice. Compelling, indirect evidence revealed that parenteral drug rounds with sharing of syringes, conducted by minimally educated and supervised staff, fuelled the epidemic among patients. Staff were subsequently infected during emergency surgery and while caring for nosocomially infected patients. Conclusion-This outbreak illustrates the high price exacted by the practice of modern medicine, particularly use of parenteral injections and surgery, without due attention to good medical practice. High priority must be given to education of medical staff in developing countries and to guidelines for safe operation of clinics and hospitals. Failure to do so will have far reaching, costly, and ultimately devastating consequences.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV VIRAL & RICKETTSIAL DIS,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV BACTERIAL & MYCOT DIS,BIOSTAT BRANCH,ATLANTA,GA 30333; UNIV IBADAN,COLL MED,DEPT VIROL,IBADAN,NIGERIA; FED MINIST HLTH,FED EPIDEMIOL DIV,LAGOS,NIGERIA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; University of Ibadan			TOMORI, OYEWALE/GWQ-4419-2022; TOMORI, OYEWALE/X-3021-2019; Fakile, Yetunde F/AAL-7938-2020	TOMORI, OYEWALE/0000-0002-6959-5749; Fakile, Yetunde F/0000-0002-6439-8981; McCormick, Joseph/0000-0002-5844-8102				ALTER MJ, 1991, HEPATOLOGY, V14, P389, DOI 10.1016/0270-9139(91)91431-Y; [Anonymous], 1978, Bull World Health Organ, V56, P271; BOWEN GS, 1975, B WORLD HEALTH ORGAN, V52, P599; CAREY DE, 1972, T ROY SOC TROP MED H, V66, P402, DOI 10.1016/0035-9203(72)90271-4; FABIYI A, 1979, NIGERIAN MED J, V9, P23; FRAME JD, 1970, AM J TROP MED HYG, V19, P670, DOI 10.4269/ajtmh.1970.19.670; HERSH BS, 1991, LANCET, V338, P645, DOI 10.1016/0140-6736(91)91230-R; JOHNSON KM, 1987, J INFECT DIS, V155, P456, DOI 10.1093/infdis/155.3.456; MCCORMICK JB, 1987, J INFECT DIS, V155, P437, DOI 10.1093/infdis/155.3.437; MCCORMICK JB, 1987, J INFECT DIS, V155, P445, DOI 10.1093/infdis/155.3.445; TOMORI O, 1988, AM J TROP MED HYG, V38, P407, DOI 10.4269/ajtmh.1988.38.407	11	225	235	1	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 30	1995	311	7009					857	859		10.1136/bmj.311.7009.857	http://dx.doi.org/10.1136/bmj.311.7009.857			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY191	7580496	Green Published			2022-12-24	WOS:A1995RY19100029
J	STEMMLER, M; USHER, M; NIEBUR, E				STEMMLER, M; USHER, M; NIEBUR, E			LATERAL INTERACTIONS IN PRIMARY VISUAL-CORTEX - A MODEL BRIDGING PHYSIOLOGY AND PSYCHOPHYSICS	SCIENCE			English	Article							EXCITATORY POSTSYNAPTIC POTENTIALS; INTRINSIC CONNECTIONS; MACAQUE MONKEY; STRIATE CORTEX; FACILITATION; SUPPRESSION; NEOCORTEX; PATTERNS	Recent physiological studies show that the spatial context of visual stimuli enhances the response of cells in primary visual cortex to weak stimuli and suppresses the response to strong stimuli. A model of orientation-tuned neurons was constructed to explore the role of lateral cortical connections in this dual effect. The differential effect of excitatory and inhibitory current and noise conveyed by the lateral connections explains the physiological results as well as the psychophysics of pop-out and contour completion. Exploiting the model's property of stochastic resonance, the visual context changes the model's intrinsic input variability to enhance the detection of weak signals.	UNIV PITTSBURGH,DEPT PSYCHIAT,PITTSBURGH,PA 15260; CARNEGIE MELLON UNIV,DEPT PSYCHOL,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Carnegie Mellon University	STEMMLER, M (corresponding author), CALTECH,COMPUTAT & NEURAL SYST PROGRAM,139-74,PASADENA,CA 91125, USA.				NIMH NIH HHS [MH47566, MH45156] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH047566, P50MH045156] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BERGEN JR, 1983, IEEE T SYST MAN CYB, V13, P857, DOI 10.1109/TSMC.1983.6313080; BERNANDER O, 1994, J NEUROPHYSIOL, V72, P2743, DOI 10.1152/jn.1994.72.6.2743; BLASDEL GG, 1992, J NEUROSCI, V12, P3139, DOI 10.1523/JNEUROSCI.12-08-03139.1992; CANNON MW, 1993, VISION RES, V33, P1685, DOI 10.1016/0042-6989(93)90034-T; CAULLER LJ, 1992, SINGLE NEURON COMPUT, P19; DOUGLAS RJ, 1991, J PHYSIOL-LONDON, V440, P735, DOI 10.1113/jphysiol.1991.sp018733; DOUGLAS RJ, 1995, SCIENCE, V269, P981, DOI 10.1126/science.7638624; GILBERT CD, 1992, NEURON, V9, P1, DOI 10.1016/0896-6273(92)90215-Y; GILBERT CD, 1983, J NEUROSCI, V3, P1116; GRINVALD A, 1994, J NEUROSCI, V14, P2545; HIRSCH JA, 1991, J NEUROSCI, V11, P1800; HUBEL DH, 1959, J PHYSIOL-LONDON, V148, P574, DOI 10.1113/jphysiol.1959.sp006308; KNIERIM JJ, 1992, J NEUROPHYSIOL, V67, P961, DOI 10.1152/jn.1992.67.4.961; LUND JS, 1993, CEREB CORTEX, V3, P148, DOI 10.1093/cercor/3.2.148; MAINEN ZF, 1995, SCIENCE, V268, P1503, DOI 10.1126/science.7770778; MALACH R, 1993, P NATL ACAD SCI USA, V90, P10469, DOI 10.1073/pnas.90.22.10469; MCCORMICK DA, 1985, J NEUROPHYSIOL, V54, P782, DOI 10.1152/jn.1985.54.4.782; MOUNTCASTLE VB, 1957, J NEUROPHYSIOL, V20, P408, DOI 10.1152/jn.1957.20.4.408; POLAT U, 1993, VISION RES, V33, P993, DOI 10.1016/0042-6989(93)90081-7; POLAT U, UNPUB VISION RES; Somers D., 1994, Society for Neuroscience Abstracts, V20, P1577; SOMERS DC, 1995, J NEUROSCI, V15, P5448; SOMERS DC, IN PRESS LATERAL INT; THOMSON AM, 1993, NEUROSCIENCE, V54, P347, DOI 10.1016/0306-4522(93)90257-G; THOMSON AM, 1993, NEUROSCIENCE, V54, P329, DOI 10.1016/0306-4522(93)90256-F; WIESENFELD K, 1995, NATURE, V373, P33, DOI 10.1038/373033a0; WORGOTTER F, 1991, J NEUROPHYSIOL, V66, P444, DOI 10.1152/jn.1991.66.2.444	27	174	175	0	5	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 29	1995	269	5232					1877	1880		10.1126/science.7569930	http://dx.doi.org/10.1126/science.7569930			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX194	7569930				2022-12-24	WOS:A1995RX19400040
J	GONG, XH; DUBOIS, DH; MILLER, DJ; SHUR, BD				GONG, XH; DUBOIS, DH; MILLER, DJ; SHUR, BD			ACTIVATION OF A G-PROTEIN COMPLEX BY AGGREGATION OF BETA-1,4-GALACTOSYLTRANSFERASE ON THE SURFACE OF SPERM	SCIENCE			English	Article							NUCLEOTIDE REGULATORY PROTEIN; PERTUSSIS TOXIN; MOUSE SPERM; ACROSOME REACTION; ZONA-PELLUCIDA; RAT HEPATOCYTES; BINDING; RECEPTOR; ZP3; MEMBRANES	Fertilization is initialed by the species-specific binding of sperm to the extracellular coat of the egg. One sperm receptor for the mouse egg is beta-1,4-galactosyltransferase (GalTase), which binds O-linked oligosaccharides on the egg coat glycoprotein ZP3. ZP3 binding induces acrosomal exocytosis through the activation of a pertussis toxin-sensitive heterotrimeric guanine nucleotide-binding protein (G protein). The cytoplasmic domain of sperm surface GalTase bound to and activated a heterotrimeric G protein complex that contained the G(i alpha) subunit. Aggregation of GalTase by multivalent ligands elicited G protein activation. Sperm from transgenic mice that overexpressed GalTase had higher rates of G protein activation than did wild-type sperm, which rendered transgenic sperm hypersensitive to their ZP3 ligand. Thus, the cytoplasmic domain of cell surface GalTase appears to enable it to function as a signal-transducing receptor for extracellular oligosaccharide ligands.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NICHD NIH HHS [T32 HD07324, R01 HD23479, R01 HD22590] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007324, R01HD022590, R01HD023479] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		CHENG A, 1994, J CELL BIOL, V125, P867, DOI 10.1083/jcb.125.4.867; ENDO Y, 1987, DEV BIOL, V119, P210, DOI 10.1016/0012-1606(87)90222-3; ENDO Y, 1988, DEV BIOL, V129, P12, DOI 10.1016/0012-1606(88)90157-1; EVANS SC, 1995, BIOESSAYS, V17, P261, DOI 10.1002/bies.950170313; FLORMAN HM, 1994, DEV BIOL, V165, P152, DOI 10.1006/dbio.1994.1242; GONG X, UNPUB; HUANG CL, 1989, J BIOL CHEM, V264, P4391; IMAMURA K, 1988, J BIOL CHEM, V263, P14093; KALAB P, 1994, J BIOL CHEM, V269, P3810; KORNER C, 1995, J BIOL CHEM, V270, P287, DOI 10.1074/jbc.270.1.287; LEYTON L, 1989, J CELL BIOL, V108, P2163, DOI 10.1083/jcb.108.6.2163; LEYTON L, 1989, CELL, V57, P1123, DOI 10.1016/0092-8674(89)90049-4; LIANG M, 1991, J BIOL CHEM, V266, P13342; LOPEZ LC, 1991, J BIOL CHEM, V266, P15984; LUTTRELL L, 1990, J BIOL CHEM, V265, P16873; MACEK MB, 1991, DEV BIOL, V147, P440, DOI 10.1016/0012-1606(91)90301-I; Miller David J., 1994, Seminars in Developmental Biology, V5, P255, DOI 10.1006/sedb.1994.1033; MILLER DJ, 1992, NATURE, V357, P589, DOI 10.1038/357589a0; NGUYEN TTM, 1994, J BIOL CHEM, V269, P28000; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; OKAJIMA F, 1985, J BIOL CHEM, V260, P6761; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; OKAMOTO T, 1991, BIOCHEM BIOPH RES CO, V179, P10, DOI 10.1016/0006-291X(91)91326-8; OKAMOTO T, 1995, J BIOL CHEM, V270, P4205, DOI 10.1074/jbc.270.9.4205; PRATT SA, 1993, DEV BIOL, V156, P80, DOI 10.1006/dbio.1993.1060; ROLDAN ERS, 1994, SCIENCE, V266, P1578, DOI 10.1126/science.7985030; SHAPER NL, 1988, J BIOL CHEM, V263, P10420; STROUS GJ, 1987, EUR J BIOCHEM, V169, P307, DOI 10.1111/j.1432-1033.1987.tb13613.x; SUN H, 1995, P NATL ACAD SCI USA, V92, P2229, DOI 10.1073/pnas.92.6.2229; WARD CR, 1992, J BIOL CHEM, V267, P14061; YANG LJ, 1991, J BIOL CHEM, V266, P22451; YOUAKIM A, 1994, J CELL BIOL, V126, P1573, DOI 10.1083/jcb.126.6.1573	32	152	157	0	2	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 22	1995	269	5231					1718	1721		10.1126/science.7569899	http://dx.doi.org/10.1126/science.7569899			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV948	7569899				2022-12-24	WOS:A1995RV94800037
J	KRONTIRIS, TG				KRONTIRIS, TG			MINISATELLITES AND HUMAN-DISEASE	SCIENCE			English	Editorial Material							HUMAN INSULIN GENE; HRAS1 MINISATELLITE; DNA-SEQUENCE; LOCUS; MUTATION; ALLELES; ACTIVATION; REGION; CANCER		TUFTS UNIV,SCH MED,GENET PROGRAM,BOSTON,MA 02111; TUFTS UNIV NEW ENGLAND MED CTR,BOSTON,MA 02111	Tufts University; Tufts Medical Center	KRONTIRIS, TG (corresponding author), TUFTS UNIV,SCH MED,DEPT MED,BOSTON,MA 02111, USA.							BELL GI, 1982, NATURE, V295, P31, DOI 10.1038/295031a0; BELL GI, 1984, DIABETES, V33, P176, DOI 10.2337/diabetes.33.2.176; BENNETT ST, 1995, NAT GENET, V9, P284, DOI 10.1038/ng0395-284; BUARD J, 1994, EMBO J, V13, P3203, DOI 10.1002/j.1460-2075.1994.tb06619.x; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CASKEY CT, 1992, SCIENCE, V256, P784, DOI 10.1126/science.1589758; DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; GREEN M, 1993, GENOMICS, V17, P429, DOI 10.1006/geno.1993.1343; JEFFREYS AJ, 1994, NAT GENET, V6, P136, DOI 10.1038/ng0294-136; JEFFREYS AJ, 1988, NATURE, V332, P278, DOI 10.1038/332278a0; JEFFREYS AJ, 1990, CELL, V60, P473, DOI 10.1016/0092-8674(90)90598-9; JEFFREYS AJ, 1985, NATURE, V316, P76, DOI 10.1038/316076a0; KASPERCZYK A, 1990, AM J HUM GENET, V47, P854; KELLY R, 1989, GENOMICS, V5, P844, DOI 10.1016/0888-7543(89)90126-2; KENNEDY GC, 1995, NAT GENET, V9, P293, DOI 10.1038/ng0395-293; KRONTIRIS TG, 1993, NEW ENGL J MED, V329, P517, DOI 10.1056/NEJM199308193290801; KRONTIRIS TG, 1985, NATURE, V313, P369, DOI 10.1038/313369a0; MONCKTON DG, 1994, NAT GENET, V8, P162, DOI 10.1038/ng1094-162; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; OWERBACH D, 1994, AM J HUM GENET, V54, P909; OWERBACH D, 1993, DIABETES, V42, P1708, DOI 10.2337/diabetes.42.12.1708; Phelan C., 1994, American Journal of Human Genetics, V55, pA67; TREPICCHIO WL, 1992, NUCLEIC ACIDS RES, V20, P2427, DOI 10.1093/nar/20.10.2427; TREPICCHIO WL, 1993, NUCLEIC ACIDS RES, V21, P977, DOI 10.1093/nar/21.4.977; Warren S T, 1993, Curr Opin Neurobiol, V3, P752, DOI 10.1016/0959-4388(93)90149-S; WOLFF RK, 1989, GENOMICS, V5, P382, DOI 10.1016/0888-7543(89)90076-1; WOLFF RK, 1988, GENOMICS, V3, P347, DOI 10.1016/0888-7543(88)90126-7	27	64	64	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 22	1995	269	5231					1682	1683		10.1126/science.7569893	http://dx.doi.org/10.1126/science.7569893			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV948	7569893				2022-12-24	WOS:A1995RV94800026
J	PAPPAS, PG; KAUFFMAN, CA; PERFECT, J; JOHNSON, PC; MCKINSEY, DS; BAMBERGER, DM; HAMILL, R; SHARKEY, PK; CHAPMAN, SW; SOBEL, JD				PAPPAS, PG; KAUFFMAN, CA; PERFECT, J; JOHNSON, PC; MCKINSEY, DS; BAMBERGER, DM; HAMILL, R; SHARKEY, PK; CHAPMAN, SW; SOBEL, JD			ALOPECIA ASSOCIATED WITH FLUCONAZOLE THERAPY	ANNALS OF INTERNAL MEDICINE			English	Note							HIGH-DOSE KETOCONAZOLE; FUNGAL-INFECTIONS; PROPHYLAXIS; MENINGITIS; TRIAL	Objective: To describe the association between fluconazole and reversible alopecia. Design: A retrospective survey of 1) patients enrolled in NIAID Mycoses Study Group (MSG) protocols involving the long-term use of fluconazole for treatment of endemic mycoses and 2) patients treated with fluconazole outside of a protocol setting but by the MSG investigators who were MSG members. Setting: 26 MSG sites in the United States. Patients: 33 patients with various deep and superficial mycoses who developed alopecia while receiving fluconazole. Results: 11 of 26 investigators reported a total of 33 patients with substantial alopecia related to fluconazole therapy, Underlying mycoses included blastomycosis, sporotrichosis, histoplasmosis, cryptococcosis, coccidioidomycosis, and mucosal candidiasis. In separate MSG studies, 17 of 136 (12.5%) and 8 of 40 (20%) patients had substantial reversible alopecia associated with fluconazole therapy. Eight patients who were not in the protocol had similar adverse effects. Twenty-nine of 33 patients (88%) received at least 400 mg of fluconazole daily for a mean of 7. 1 months. Alopecia developed a median of 3 months after initiation of fluconazole therapy and involved the scalp in all patients. Other sites were involved in about one third of patients. Three patients required wigs because of extensive hair loss. Alopecia resolved within 6 months of discontinuation of fluconazole therapy or reduction of the daily dose by at least 50%. Conclusions: Alopecia appears to be a common adverse event associated with higher-dose (400 mg/d) fluconazole given for 2 months or longer. This effect may be severe but is reversed by discontinuing fluconazole therapy or substantially reducing the daily dose.	UNIV MICHIGAN, ANN ARBOR, MI USA; DUKE UNIV, MED CTR, DURHAM, NC USA; UNIV TEXAS, MED CTR, HOUSTON, TX USA; BAYLOR COLL MED, HOUSTON, TX USA; MED RES CTR, KANSAS CITY, MO USA; UNIV MISSOURI, KANSAS CITY, MO USA; UNIV TEXAS, SAN ANTONIO MED CTR, SAN ANTONIO, TX USA; UNIV MISSISSIPPI, JACKSON, MS USA; WAYNE STATE MED SCH, DETROIT, MI USA	University of Michigan System; University of Michigan; Duke University; University of Texas System; Baylor College of Medicine; University of Missouri System; University of Missouri Kansas City; University of Texas System; University of Mississippi; Wayne State University	PAPPAS, PG (corresponding author), UNIV ALABAMA, DEPT MED, DIV INFECT DIS, 1900 UNIV BLVD, 229 TINSLEY HARRISON TOWER, BIRMINGHAM, AL 35294 USA.		MOORE-MILLAR, KARENA/A-9015-2012; Bamberger, David/GYV-3403-2022		NIAID NIH HHS [N01-AI-15082] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI015082] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		GALGIANI JN, 1993, ANN INTERN MED, V119, P28, DOI 10.7326/0003-4819-119-1-199307010-00005; GALGIANI JN, 1990, ANN INTERN MED, V113, P177, DOI 10.7326/0003-4819-113-3-177; GOODMAN JL, 1992, NEW ENGL J MED, V326, P845, DOI 10.1056/NEJM199203263261301; GRANT SM, 1990, DRUGS, V39, P877, DOI 10.2165/00003495-199039060-00006; Hay R J, 1988, Ann N Y Acad Sci, V544, P580, DOI 10.1111/j.1749-6632.1988.tb40456.x; JUSTNUBLING G, 1991, EUR J CLIN MICROBIOL, V10, P917, DOI 10.1007/BF02005444; PAPPAS PG, 1995, CLIN INFECT DIS, V20, P267, DOI 10.1093/clinids/20.2.267; PAPPAS PG, 1994, FLUCONAZOLE TREATMEN; PONT A, 1984, ARCH INTERN MED, V144, P2150, DOI 10.1001/archinte.144.11.2150; REX JH, 1994, NEW ENGL J MED, V331, P1325, DOI 10.1056/NEJM199411173312001; SAAG MS, 1992, NEW ENGL J MED, V326, P83, DOI 10.1056/NEJM199201093260202; SUGAR AM, 1987, ANTIMICROB AGENTS CH, V31, P1874, DOI 10.1128/AAC.31.12.1874; VANCAUTEREN H, 1987, REV INFECT DIS, V9, pS43; WEINROTH SE, 1993, ANN INTERN MED, V119, P637, DOI 10.7326/0003-4819-119-7_Part_1-199310010-00029; WINSTON DJ, 1993, ANN INTERN MED, V118, P495, DOI 10.7326/0003-4819-118-7-199304010-00003	15	46	46	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1995	123	5					354	357		10.7326/0003-4819-123-5-199509010-00006	http://dx.doi.org/10.7326/0003-4819-123-5-199509010-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ988	7625624				2022-12-24	WOS:A1995RQ98800006
J	GUADAGNOLI, E; HAUPTMAN, PJ; AYANIAN, JZ; PASHOS, CL; MCNEIL, BJ; CLEARY, PD				GUADAGNOLI, E; HAUPTMAN, PJ; AYANIAN, JZ; PASHOS, CL; MCNEIL, BJ; CLEARY, PD			VARIATION IN THE USE OF CARDIAC PROCEDURES AFTER ACUTE MYOCARDIAL-INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							Q-WAVE; PROGNOSTIC-SIGNIFICANCE; MEDICARE POPULATION; PATIENT POPULATION; SAMPLE SELECTION; UNITED-STATES; VALIDITY; ISCHEMIA; CARE; RELIABILITY	Background. There are large geographic differences in the frequency with which coronary angiography and revascularization are performed. We attempted to assess whether differences in case mix or in the treatment of specific groups of patients may explain this variability. We also assessed the consequences of various patterns of treatment. Methods. We studied patients covered by Medicare who were 65 to 79 years of age and were admitted to 478 hospitals with acute myocardial infarctions during 1990 in New York (1852 patients), where the rate of use of cardiac procedures is low, and in Texas (1837 patients), where the rate of use of such procedures is high. We compared the patterns of treatment of clinically similar groups of patients in the two states. We also compared mortality rates and measures of the health-related quality of life. Results. Coronary angiography was performed more often in Texas than in New York (45 percent vs. 30 percent, P<0.001). The frequency of use in Texas was significantly higher than that in New York for all the clinical subgroups of patients analyzed except those at greatest risk for reinfarction. Over a two-year period, the adjusted likelihood of death was lower in New York than in Texas (hazard ratio, 0.87; 95 percent confidence interval, 0.78 to 0.98). Patients from Texas were 41 percent more likely to report angina (P = 0.002) and 62 percent more likely to say they could not perform activities requiring energy expenditure of 5 or more metabolic equivalents than patients from New York approximately two years after infarction (P<0.001). Conclusions. Physicians in Texas were more likely to perform angiography than physicians in New York for patients whose conditions allowed more discretion in the use of cardiac procedures. On average, there appears to be no advantage with respect to mortality or health-related quality of life to performing the procedures at the higher rate used in Texas.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV CARDIOVASC,BOSTON,MA; BRIGHAM & WOMENS HOSP,DEPT MED,DIV GEN MED,HLTH SERV & POLICY RES SECT,BOSTON,MA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	GUADAGNOLI, E (corresponding author), HARVARD UNIV,SCH MED,DEPT HLTH CARE POLICY,25 SHATTUCK ST,PARCEL B,1ST FLOOR,BOSTON,MA 02115, USA.		Cleary, Paul/AAF-7048-2019		AHRQ HHS [HS06341] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ANDERSON GM, 1993, JAMA-J AM MED ASSOC, V269, P1661; AYANIAN JZ, 1994, NEW ENGL J MED, V331, P1136, DOI 10.1056/NEJM199410273311707; BENHORIN J, 1990, J AM COLL CARDIOL, V15, P253, DOI 10.1016/S0735-1097(10)80043-9; BODEN WE, 1989, AM J CARDIOL, V64, P799, DOI 10.1016/0002-9149(89)90768-6; BOSCH X, 1987, CIRCULATION, V75, P988, DOI 10.1161/01.CIR.75.5.988; BRAUNWALD E, 1992, HEART DISEASE TXB CA; CHASSIN MR, 1986, NEW ENGL J MED, V314, P285, DOI 10.1056/NEJM198601303140505; CLEARY PD, 1991, MED CARE, V29, P939, DOI 10.1097/00005650-199110000-00001; CLEARY PD, 1991, CONTROL CLIN TRIALS, V12, pS189, DOI 10.1016/S0197-2456(05)80023-6; CLEARY PD, 1992, MED CARE, V30, P76; GATSONIS CA, 1995, MED CARE, V33, P625, DOI 10.1097/00005650-199506000-00005; GOLDBERG KC, 1992, JAMA-J AM MED ASSOC, V267, P1473, DOI 10.1001/jama.267.11.1473; GOLDMAN L, 1981, CIRCULATION, V64, P1227, DOI 10.1161/01.CIR.64.6.1227; GROTZINGER KM, 1994, MED CARE, V32, P989, DOI 10.1097/00005650-199410000-00002; HECKMAN JJ, 1979, ECONOMETRICA, V47, P153, DOI 10.2307/1912352; HECKMAN JJ, 1976, ANN ECON SOC MEAS, V5, P475; HUTTER AM, 1981, AM J CARDIOL, V48, P595, DOI 10.1016/0002-9149(81)90136-3; JETTE AM, 1986, J GEN INTERN MED, V1, P143, DOI 10.1007/BF02602324; JETTE AM, 1986, J GEN INTERN MED, V1, P427; MAISEL AS, 1985, CIRCULATION, V71, P211, DOI 10.1161/01.CIR.71.2.211; MARK DB, 1994, NEW ENGL J MED, V331, P1130, DOI 10.1056/NEJM199410273311706; MARMOR A, 1982, CIRCULATION, V66, P415, DOI 10.1161/01.CIR.66.2.415; NICOD P, 1989, CIRCULATION, V79, P528, DOI 10.1161/01.CIR.79.3.528; PASHOS CL, 1993, JAMA-J AM MED ASSOC, V270, P1832, DOI 10.1001/jama.270.15.1832; PILOTE L, 1994, ARCH INTERN MED, V154, P1090, DOI 10.1001/archinte.154.10.1090; ROSE GA, 1968, WHO MONOGRAPH SERIES, V56; ROULEAU JL, 1993, NEW ENGL J MED, V328, P779, DOI 10.1056/NEJM199303183281108; SCHUSTER EH, 1981, NEW ENGL J MED, V305, P1101, DOI 10.1056/NEJM198111053051901; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530	30	187	198	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 31	1995	333	9					573	578		10.1056/NEJM199508313330908	http://dx.doi.org/10.1056/NEJM199508313330908			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ751	7623908				2022-12-24	WOS:A1995RQ75100008
J	DOODY, GM; JUSTEMENT, LB; DELIBRIAS, CC; MATTHEWS, RJ; LIN, JJ; THOMAS, ML; FEARON, DT				DOODY, GM; JUSTEMENT, LB; DELIBRIAS, CC; MATTHEWS, RJ; LIN, JJ; THOMAS, ML; FEARON, DT			A ROLE IN B-CELL ACTIVATION FOR CD22 AND THE PROTEIN-TYROSINE-PHOSPHATASE SHP	SCIENCE			English	Article							ANTIGEN RECEPTOR; ADHESION MOLECULE; MOTH-EATEN; EXPRESSION; CD40; MICE; LYMPHOCYTES; KINASES; DOMAINS; CD19	CD22 is a membrane immunoglobulin (mlg)-associated protein of B cells. CD22 is tyrosine-phosphorylated when mlg is ligated. Tyrosine-phosphorylated CD22 binds and activates SHP, a protein tyrosine phosphatase known to negatively regulate signaling through mlg. Ligation of CD22 to prevent its coaggregation with mlg lowers the threshold at which mlg activates the B cell by a factor of 100. In secondary lymphoid organs, CD22 may be sequestered away from mlg through interactions with counterreceptors on T cells. Thus, CD22 is a molecular switch for SHP that may bias mlg signaling to anatomic sites rich in T cells.	UNIV CAMBRIDGE,SCH CLIN MED,DEPT MED,WELLCOME TRUST IMMUNOL UNIT,CAMBRIDGE CB2 2SP,ENGLAND; UNIV TEXAS,MED BRANCH,DEPT MICROBIOL & IMMUNOL,GALVESTON,TX 77555; WASHINGTON UNIV,SCH MED,DEPT PATHOL,HOWARD HUGHES MED INST,ST LOUIS,MO 63110	University of Cambridge; University of Texas System; University of Texas Medical Branch Galveston; Howard Hughes Medical Institute; Washington University (WUSTL)			Doody, Gina/AAN-8246-2021	Doody, Gina/0000-0003-0665-6759; Justement, Louis/0000-0001-7058-867X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM046524, R01GM046524] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-46524] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission)		ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; BOUE DR, 1988, J IMMUNOL, V140, P192; BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; CARTER RH, 1992, SCIENCE, V256, P105, DOI 10.1126/science.1373518; CYSTER JG, 1995, IMMUNITY, V2, P13, DOI 10.1016/1074-7613(95)90075-6; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; ENGEL P, 1993, J IMMUNOL, V150, P4719; GOODNOW CC, 1992, ANNU REV IMMUNOL, V10, P489, DOI 10.1146/annurev.iy.10.040192.002421; KELM S, 1994, CURR BIOL, V4, P965, DOI 10.1016/S0960-9822(00)00220-7; KOZLOWSKI M, 1993, J EXP MED, V178, P2157, DOI 10.1084/jem.178.6.2157; LEDERMAN S, 1992, J IMMUNOL, V149, P3817; LEPRINCE C, 1993, P NATL ACAD SCI USA, V90, P3236, DOI 10.1073/pnas.90.8.3236; LIN JJ, 1992, J IMMUNOL, V149, P1548; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; PEAKER CJG, 1993, EUR J IMMUNOL, V23, P1358, DOI 10.1002/eji.1830230626; PEI DH, 1993, P NATL ACAD SCI USA, V90, P1092, DOI 10.1073/pnas.90.3.1092; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; POWELL LD, 1993, J BIOL CHEM, V268, P7019; SCHULTE RJ, 1992, SCIENCE, V258, P1001, DOI 10.1126/science.1279802; SCHWARTZALBIEZ R, 1991, INT IMMUNOL, V3, P623, DOI 10.1093/intimm/3.7.623; SGROI D, 1993, J BIOL CHEM, V268, P7011; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SIDMAN CL, 1986, SCIENCE, V232, P1423, DOI 10.1126/science.3487115; STAMENKOVIC I, 1990, NATURE, V345, P74, DOI 10.1038/345074a0; TORRES RM, 1992, J IMMUNOL, V149, P2641; TOWNLEY R, 1993, BIOCHEMISTRY-US, V32, P13414, DOI 10.1021/bi00212a006; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; WILSON GL, 1991, J EXP MED, V173, P137, DOI 10.1084/jem.173.1.137; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836	32	487	491	0	14	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 14	1995	269	5221					242	244		10.1126/science.7618087	http://dx.doi.org/10.1126/science.7618087			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ029	7618087				2022-12-24	WOS:A1995RJ02900046
J	BOORE, JL; COLLINS, TM; STANTON, D; DAEHLER, LL; BROWN, WM				BOORE, JL; COLLINS, TM; STANTON, D; DAEHLER, LL; BROWN, WM			DEDUCING THE PATTERN OF ARTHROPOD PHYLOGENY FROM MITOCHONDRIAL-DNA REARRANGEMENTS	NATURE			English	Article							RIBOSOMAL-RNA; GENE; EVOLUTION; SEQUENCE; ORIGIN; GENOME	THE origins of arthropods and the phylogenetic relationships among their three major living groups (atdocerates, crustaceans and chelicerates) are vigorously contended. To help resolve this, we determined mitochondrial gene arrangements for a chelicerate, a myriapod, two crustaceans, an onychophoran, a mollusc and an annelid, and compared them with published gene orders of other species. The result strongly supports the monophyly of Arthropoda and of Mandibulata (atelocerates plus crustaceans) and refutes the Uniramia (atelocerates plus onychophorans). Gene arrangement comparisons are emerging as a powerful new tool for resolving ancient phylogenetic relationships.	UNIV MICHIGAN,DEPT BIOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan			Brown, William/GXN-2777-2022					Adoutte Andre, 1993, Experientia Supplementum (Basel), V63, P1; BALLARD JWO, 1992, SCIENCE, V258, P1345, DOI 10.1126/science.1455227; BOORE JL, 1994, GENETICS, V138, P423; BOORE JL, 1994, NAUTILUS, V108, P61; Boudreaux H. B., 1979, ARTHROPOD PHYLOGENY; Brusca R.C., 1990, INVERTEBRATES; CISNE JL, 1974, SCIENCE, V186, P13, DOI 10.1126/science.186.4158.13; CROZIER RH, 1993, GENETICS, V133, P97; FELSENSTEIN J, 1978, SYST ZOOL, V27, P401, DOI 10.2307/2412923; FIELD KG, 1988, SCIENCE, V239, P748, DOI 10.1126/science.3277277; HAUCKE HR, 1988, CURR GENET, V14, P471, DOI 10.1007/BF00521271; HENDRIKS L, 1988, EUR J BIOCHEM, V177, P15, DOI 10.1111/j.1432-1033.1988.tb14339.x; HESSLER R R, 1975, Fossils and Strata, V4, P437; KUKALOVAPECK J, 1992, CAN J ZOOL, V70, P236, DOI 10.1139/z92-037; LAKE JA, 1990, P NATL ACAD SCI USA, V87, P763, DOI 10.1073/pnas.87.2.763; Liu H, 1992, MOL PHYLOGENET EVOL, V1, P41, DOI 10.1016/1055-7903(92)90034-E; Maddison W.P., 1992, ANAL PHYLOGENY CHARA; Manton S. M., 1979, ORIGIN MAJOR INVERTE, P269; MITCHELL SE, 1993, GENOME, V36, P1058, DOI 10.1139/g93-141; PASHLEY DP, 1992, MOL BIOL EVOL, V9, P1061; PATTERSON C, 1993, ANNU REV ECOL SYST, V24, P153; PREUSS K, 1992, J MED ENTOMOL, V29, P644; SANKOFF D, 1992, P NATL ACAD SCI USA, V89, P6575, DOI 10.1073/pnas.89.14.6575; SMITH MJ, 1993, J MOL EVOL, V36, P545, DOI 10.1007/BF00556359; TIEGS OWQ, 1947, J MICROSC SCI, V82, P165; VALENTINE JW, 1989, P NATL ACAD SCI USA, V86, P2272, DOI 10.1073/pnas.86.7.2272; VALVERDE JR, 1994, J MOL EVOL, V39, P400, DOI 10.1007/BF00160272; VAWTER L, 1993, GENETICS, V134, P597; WHEELER WC, 1993, CLADISTICS, V9, P11; WOLSTENHOLME DR, 1992, INT REV CYTOL, V141, P173, DOI 10.1016/S0074-7696(08)62066-5	30	336	350	0	28	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 13	1995	376	6536					163	165		10.1038/376163a0	http://dx.doi.org/10.1038/376163a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ028	7603565	Green Submitted			2022-12-24	WOS:A1995RJ02800057
J	BIZEBARD, T; GIGANT, B; RIGOLET, P; RASMUSSEN, B; DIAT, O; BOSECKE, P; WHARTON, SA; SKEHEL, JJ; KNOSSOW, M				BIZEBARD, T; GIGANT, B; RIGOLET, P; RASMUSSEN, B; DIAT, O; BOSECKE, P; WHARTON, SA; SKEHEL, JJ; KNOSSOW, M			STRUCTURE OF INFLUENZA-VIRUS HEMAGGLUTININ COMPLEXED WITH A NEUTRALIZING ANTIBODY	NATURE			English	Article							HEMAGGLUTININ MEMBRANE GLYCOPROTEIN; FUSION; RECOGNITION; MECHANISM; RECEPTOR; MUTANT; ACID	HAEMAGGLUTININ (HA) is the influenza surface glycoprotein that interacts with infectivity-neutralizing antibodies. As a consequence of this immune pressure it is the variable virus component, which is important in antigenic drift, that results in recurrent epidemics of influenza. We have determined the crystallographic structure of a complex formed between the antigen-binding fragment (Fab) of a neutralizing antibody tend the membrane-distal domain ((HA top') of a HA subunit prepared from HA in its membrane-fusion-active conformation. A dramatic change is seen in the structure of the Fab-combining site on complex formation. Our results indicate that neutralization of infectivity by this antibody involves the inhibition of receptor binding, and demonstrate how influenza virus can maintain its conserved receptor-binding site despite the immune selective pressure for change in this region of the molecule; they also contribute to a complete description of the endosomal pH-induced fusion-active HA structure.	EUROPEAN SYNCHROTRON RADIAT FACIL,F-38043 GRENOBLE,FRANCE; ILL GRENOBLE,EUROPEAN MOLEC BIOL LAB,GRENOBLE OUTSTN,F-38042 GRENOBLE,FRANCE; NATL INST MED RES,MRC,DIV VIROL,LONDON NW7 1AA,ENGLAND	European Synchrotron Radiation Facility (ESRF); European Molecular Biology Laboratory (EMBL); Institut Laue-Langevin (ILL); MRC National Institute for Medical Research	BIZEBARD, T (corresponding author), UNIV PARIS SUD,BIOL STRUCT LAB,CNRS,UMR 9920,BAT 34,F-91198 GIF SUR YVETTE,FRANCE.		diat, olivier PC/B-5985-2016; Rigolet, Pascal/S-8602-2018	diat, olivier PC/0000-0003-3011-8168; Rigolet, Pascal/0000-0001-6868-4953; Gigant, Benoit/0000-0002-5946-6759				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BIZEBARD T, 1994, ACTA CRYSTALLOGR D, V50, P768, DOI 10.1107/S0907444994001903; BIZEBARD T, 1990, J MOL BIOL, V216, P513, DOI 10.1016/0022-2836(90)90378-Y; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CHERFILS J, 1994, PROTEINS, V18, P8, DOI 10.1002/prot.340180104; DANIELS RS, 1983, J GEN VIROL, V64, P1657, DOI 10.1099/0022-1317-64-8-1657; DANIELS RS, 1985, CELL, V40, P431, DOI 10.1016/0092-8674(85)90157-6; DANIELS RS, 1987, EMBO J, V6, P1459, DOI 10.1002/j.1460-2075.1987.tb02387.x; GODLEY L, 1992, CELL, V68, P635, DOI 10.1016/0092-8674(92)90140-8; GRUNGER AT, 1992, XPLOR VERSION 3 1; JANIN J, 1990, J BIOL CHEM, V265, P16027; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KNOSSOW M, 1984, NATURE, V311, P678, DOI 10.1038/311678a0; KRAULIS P, 1991, J APPL CRYSTALLOGR, V24, P924; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1992, CCP4; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; PARRY N, 1990, NATURE, V347, P569, DOI 10.1038/347569a0; RUIGROK RW, 1988, J GEN VIROL, P2785; RUIGROK RWH, 1986, EMBO J, V5, P41, DOI 10.1002/j.1460-2075.1986.tb04175.x; SHRAKE A, 1973, J MOL BIOL, V79, P351, DOI 10.1016/0022-2836(73)90011-9; SKEHEL JJ, 1971, VIROLOGY, V44, P396, DOI 10.1016/0042-6822(71)90270-4; WARD CW, 1981, CURR TOP MICROBIOL, V94-5, P1; WEIS W, 1988, NATURE, V333, P426, DOI 10.1038/333426a0; WHARTON SA, 1988, J BIOL CHEM, V263, P4474; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.biochem.56.1.365; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; WILSON IA, 1994, CURR OPIN STRUC BIOL, V4, P857, DOI 10.1016/0959-440X(94)90267-4; WILSON IA, 1990, ANNU REV IMMUNOL, V8, P737, DOI 10.1146/annurev.immunol.8.1.737; WRIGLEY NG, 1983, VIROLOGY, P308	30	208	220	0	25	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 6	1995	376	6535					92	94		10.1038/376092a0	http://dx.doi.org/10.1038/376092a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH111	7596443				2022-12-24	WOS:A1995RH11100069
J	HOPFIELD, JJ				HOPFIELD, JJ			PATTERN-RECOGNITION COMPUTATION USING ACTION-POTENTIAL TIMING FOR STIMULUS REPRESENTATION	NATURE			English	Article							INFERIOR COLLICULUS; INTERAURAL TIME; VISUAL-CORTEX; DELAY-LINES; BRAIN-STEM; INFORMATION; OSCILLATIONS; CIRCUIT; CELLS; BAT	A computational model is described in which the sizes of variables are represented by the explicit times at which action potentials occur, rather than by the more usual 'firing rate' of neurons. The comparison of patterns over sets of analogue variables is done by a network using different delays for different information paths. This mode of computation explains how one scheme of neuroarchitecture can be used for very different sensory modalities and seemingly different computations. The oscillations and anatomy of the mammalian olfactory systems have a simple interpretation in terms of this representation, and relate to processing in the auditory system. Single-electrode recording would plot detect such neural computing. Recognition 'units' in this style respond more like radial basis function units than elementary sigmoid un its.	CALTECH,DIV BIOL,PASADENA,CA 91125	California Institute of Technology	HOPFIELD, JJ (corresponding author), CALTECH,DIV CHEM & CHEM ENGN,PASADENA,CA 91125, USA.							ADRIAN ED, 1941, J PHYSIOL-LONDON, V100, P459; ALONSO A, 1989, NATURE, V342, P175, DOI 10.1038/342175a0; Aticky JJ, 2011, NETWORK-COMP NEURAL, V22, P4, DOI [10.1088/0954-898X/3/2/009, 10.3109/0954898X.2011.638888]; BIALEK W, 1992, TRENDS NEUROSCI, V15, P428, DOI 10.1016/0166-2236(92)90005-S; BULLOCK TH, 1993, ANNU REV NEUROSCI, V16, P1, DOI 10.1146/annurev.ne.16.030193.000245; Burgess N, 1993, ADV NEURAL INFORMATI, V5, P929; CARR CE, 1988, P NATL ACAD SCI USA, V85, P8311, DOI 10.1073/pnas.85.21.8311; CARR CE, 1990, J NEUROSCI, V10, P3227; DELANEY KR, 1994, P NATL ACAD SCI USA, V91, P669, DOI 10.1073/pnas.91.2.669; ECKHORN R, 1988, BIOL CYBERN, V60, P121, DOI 10.1007/BF00202899; GIROSI F, 1990, BIOL CYBERN, V63, P169, DOI 10.1007/BF00195855; GRAY CM, 1989, P NATL ACAD SCI USA, V86, P1698, DOI 10.1073/pnas.86.5.1698; HABERLY LB, 1985, CHEM SENSES, V10, P219, DOI 10.1093/chemse/10.2.219; HARNISCHFEGER G, 1985, J NEUROPHYSIOL, V53, P89, DOI 10.1152/jn.1985.53.1.89; HEILIGENBERG WF, 1991, NEURAL NETS ELECTRIC, P51; Herz J., 1991, INTRO THEORY NEURAL; HOSSAM O, 1994, NEURAL COMPUTAT, V6, P927; KAUER JS, 1991, TRENDS NEUROSCI, V14, P79, DOI 10.1016/0166-2236(91)90025-P; KUWABARA N, 1993, J NEUROPHYSIOL, V69, P1713, DOI 10.1152/jn.1993.69.5.1713; LAURENT G, 1994, J NEUROSCI, V14, P2993; MCCLURKIN JW, 1991, SCIENCE, V253, P675, DOI 10.1126/science.1908118; Nickell W.T., 1992, SCIENCE OLFACTION, P172; Perkel D.H., 1968, NEUROSCI RES PROGRAM, V6, P221; REICHARDT W, 1957, Z NATURFORSCH PT B, V12, P448, DOI 10.1515/znb-1957-0707; REVIAL MF, 1982, CHEM SENSES, V7, P175, DOI 10.1093/chemse/7.2.175; RODIECK RW, 1973, VERTEBRATE RETINA; Shepherd G, 1979, SYNAPTIC ORG BRAIN, P289; SHEPHERD GM, 1979, BRAIN RES, V175, P377, DOI 10.1016/0006-8993(79)91020-5; SHEPHERD GM, 1979, SYNAPTIC ORG BRAIN, P152; SILVA LR, 1991, SCIENCE, V252, P432; TANK DW, 1987, P NATL ACAD SCI USA, V84, P1896, DOI 10.1073/pnas.84.7.1896; TANK DW, 1994, SCIENCE, V265, P1819, DOI 10.1126/science.265.5180.1819; UNNIKRISHNAN KP, 1991, IEEE T SIGNAL PROCES, V39, P698, DOI 10.1109/78.80888	33	812	846	1	66	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 6	1995	376	6535					33	36		10.1038/376033a0	http://dx.doi.org/10.1038/376033a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH111	7596429				2022-12-24	WOS:A1995RH11100054
J	PARK, HW; KIM, ST; SANCAR, A; DEISENHOFER, J				PARK, HW; KIM, ST; SANCAR, A; DEISENHOFER, J			CRYSTAL-STRUCTURE OF DNA PHOTOLYASE FROM ESCHERICHIA-COLI	SCIENCE			English	Article							T4 ENDONUCLEASE-V; X-RAY-DIFFRACTION; THYMINE PHOTODIMER; ANACYSTIS-NIDULANS; ELECTRON-TRANSFER; MACROMOLECULAR CRYSTALLOGRAPHY; PYRIMIDINE DIMERS; ENERGY-TRANSFER; ACTIVE FORM; BINDING	Photolyase repairs ultraviolet (UV) damage to DNA by splitting the cyclobutane ring of the major UV photoproduct, the cis,syn-cyclobutane pyrimidine dimer (Pyr >$($) over bar Pyr). The reaction is initiated by blue light and proceeds through long-range energy transfer, single electron transfer, and enzyme catalysis by a radical mechanism. The three-dimensional crystallographic structure of DNA photolyase from Escherichia coli is presented and the atomic model was refined to an R value of 0.172 at 2.3 Angstrom resolution. The polypeptide chain of 471 amino acids is folded into an amino-terminal alpha/beta domain resembling dinucleotide binding domains and a carboxyl-terminal helical domain; a loop of 72 residues connects the domains. The light-harvesting cofactor 5,10-methenyltetrahydrofolylpolyglutamate (MTHF) binds in a cleft between the two domains. Energy transfer from MTHF to the catalytic cofactor flavin adenine dinucleotide (FAD) occurs over a distance of 16.8 Angstrom. The FAD adopts a U-shaped conformation between two helix clusters in the center of the helical domain and is accessible through a hole in the surface of this domain. Dimensions and polarity of the hole match those of a Pyr >$($) over bar Pyr dinucleotide, suggesting that the Pyr >$($) over bar Pyr ''flips out'' of the helix to fit into this hole, and that electron transfer between the flavin and the Pyr >$($) over bar Pyr occurs over van der Waals contact distance.	UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV N CAROLINA,SCH MED,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	PARK, HW (corresponding author), UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235, USA.				NIGMS NIH HHS [GM31082] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM031082, R01GM031082] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; BAER ME, 1993, J BIOL CHEM, V268, P16717; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CHEN P, 1992, J MOL BIOL, V227, P283, DOI 10.1016/0022-2836(92)90698-J; COLONNACESARI F, 1986, J BIOL CHEM, V261, P5273; DEISENHOFER J, 1991, ANNU REV CELL BIOL, V7, P1; Forster T, 1959, DISCUSS FARADAY SOC, V27, P7, DOI DOI 10.1039/DF9592700007; FOX ME, 1994, MOL CELL BIOL, V14, P8071, DOI 10.1128/MCB.14.12.8071; HAMMALVAREZ S, 1989, J BIOL CHEM, V264, P9649; HAMMALVAREZ S, 1990, J BIOL CHEM, V265, P18656; Harm W, 1980, BIOL EFFECTS ULTRAVI; HAYES FN, 1971, J AM CHEM SOC, V93, P4940, DOI 10.1021/ja00748a065; HEELIS PF, 1990, BIOCHEMISTRY-US, V29, P5694, DOI 10.1021/bi00476a008; HUSAIN I, 1987, J BIOL CHEM, V262, P13188; HUSAIN I, 1987, NUCLEIC ACIDS RES, V15, P1109; HUSAIN I, 1988, P NATL ACAD SCI USA, V85, P2558, DOI 10.1073/pnas.85.8.2558; INAOKA T, 1989, J BIOL CHEM, V264, P2609; ISHIDA M, 1990, BIOCHEMISTRY-US, V29, P3817, DOI 10.1021/bi00468a002; JANIN J, 1990, J BIOL CHEM, V265, P16027; JOHNSON JL, 1988, P NATL ACAD SCI USA, V85, P2046, DOI 10.1073/pnas.85.7.2046; JONES TA, 1990, CRYSTALLOGRAPHIC MOD, P189; JORNS MS, 1985, BIOCHEMISTRY-US, V24, P1856, DOI 10.1021/bi00329a008; JORNS MS, 1990, BIOCHEMISTRY-US, V29, P552, DOI 10.1021/bi00454a032; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KATO T, 1994, NUCLEIC ACIDS RES, V22, P4119, DOI 10.1093/nar/22.20.4119; KE HM, 1988, J MOL BIOL, V204, P725, DOI 10.1016/0022-2836(88)90365-8; KEMMINK J, 1987, NUCLEIC ACIDS RES, V15, P4645, DOI 10.1093/nar/15.11.4645; Kim S.O., UNPUB; KIM ST, 1991, BIOCHEMISTRY-US, V30, P11262, DOI 10.1021/bi00111a011; KIM ST, 1991, BIOCHEMISTRY-US, V30, P8623, DOI 10.1021/bi00099a019; KIM ST, 1992, P NATL ACAD SCI USA, V89, P900, DOI 10.1073/pnas.89.3.900; KIM ST, 1993, P NATL ACAD SCI USA, V90, P8023, DOI 10.1073/pnas.90.17.8023; KIM ST, 1993, PHOTOCHEM PHOTOBIOL, V57, P895, DOI 10.1111/j.1751-1097.1993.tb09232.x; KIM ST, 1992, BIOCHEMISTRY-US, V31, P11244, DOI 10.1021/bi00160a040; KIM ST, 1994, J AM CHEM SOC, V116, P3115, DOI 10.1021/ja00086a048; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; Kleywegt G. J., UNPUB; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE BJ, 1994, BIOCHEMISTRY-US, V33, P57, DOI 10.1021/bi00167a008; LI YF, 1990, BIOCHEMISTRY-US, V29, P5698, DOI 10.1021/bi00476a009; LI YF, 1990, BIOCHEMISTRY-US, V30, P6322; MALHOTRA K, 1992, J BIOL CHEM, V267, P15406; MALHOTRA K, 1994, BIOCHEMISTRY-US, V33, P8712, DOI 10.1021/bi00195a012; MALHOTRA K, 1995, BIOCHEMISTRY-US, V34, P6892, DOI 10.1021/bi00020a037; MALHOTRA K, UNPUB; MATSUURA Y, 1982, J MOL BIOL, V156, P389, DOI 10.1016/0022-2836(82)90335-7; MIKI K, 1993, J MOL BIOL, V233, P167, DOI 10.1006/jmbi.1993.1492; MOFFAT K, 1989, ANNU REV BIOPHYS BIO, V18, P309, DOI 10.1146/annurev.bb.18.060189.001521; MORIKAWA K, 1992, SCIENCE, V256, P523, DOI 10.1126/science.1575827; Nicholls A., 1992, GRASP GRAPHICAL REPR; OKAMURA T, 1991, J AM CHEM SOC, V113, P3143, DOI 10.1021/ja00008a050; OKAMURA T, 1994, J AM CHEM SOC, V116, P3115; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; PARK HW, 1993, J MOL BIOL, V231, P1122, DOI 10.1006/jmbi.1993.1356; PAYNE G, 1990, BIOCHEMISTRY-US, V29, P7715, DOI 10.1021/bi00485a021; PAYNE G, 1987, BIOCHEMISTRY-US, V26, P7121, DOI 10.1021/bi00396a038; PAYNE G, 1990, BIOCHEMISTRY-US, V29, P5706, DOI 10.1021/bi00476a010; PEARLMAN DA, 1985, SCIENCE, V227, P1304, DOI 10.1126/science.3975615; RAO SN, 1984, NUCLEIC ACIDS RES, V12, P4789, DOI 10.1093/nar/12.11.4789; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; REARDON JT, UNPUB; RECINOS A, 1988, BIOCHEMISTRY-US, V27, P1832, DOI 10.1021/bi00406a006; REMINGTON S, 1982, J MOL BIOL, V158, P111, DOI 10.1016/0022-2836(82)90452-1; RUPERT CS, 1958, J GEN PHYSIOL, V41, P451, DOI 10.1085/jgp.41.3.451; SANCAR A, 1994, BIOCHEMISTRY-US, V33, P2, DOI 10.1021/bi00167a001; SANCAR GB, 1985, BIOCHEMISTRY-US, V24, P1849, DOI 10.1021/bi00329a007; SANCAR GB, 1990, MUTAT RES, V236, P147, DOI 10.1016/0921-8777(90)90002-M; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; SEAWELL PC, 1980, BIOCHEMISTRY-US, V19, P1685, DOI 10.1021/bi00549a026; SHERMAN SE, 1985, SCIENCE, V230, P412, DOI 10.1126/science.4048939; STELGEMANN W, 1992, PROGRAM SYSTEM CRYST; STOLARSKI R, 1992, SCIENCE, V256, P342, DOI 10.1126/science.256.5055.342; STUMP DG, 1988, BIOCHEMISTRY-US, V27, P1839, DOI 10.1021/bi00406a007; SVOBODA DL, 1993, J BIOL CHEM, V268, P10694; TAYLOR JS, 1990, BIOCHEMISTRY-US, V29, P8858, DOI 10.1021/bi00489a049; TODO T, 1994, MUTAT RES-DNA REPAIR, V315, P213, DOI 10.1016/0921-8777(94)90033-7; VOLBEDA A, 1989, J MOL BIOL, V209, P249, DOI 10.1016/0022-2836(89)90276-3; VRIEND G, 1991, PROTEINS, V11, P52, DOI 10.1002/prot.340110107; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WANG CI, 1991, P NATL ACAD SCI USA, V88, P9072, DOI 10.1073/pnas.88.20.9072; WILSON KP, 1992, P NATL ACAD SCI USA, V89, P9257, DOI 10.1073/pnas.89.19.9257; YAJIMA H, 1991, NUCLEIC ACIDS RES, V19, P5359, DOI 10.1093/nar/19.19.5359; YASUHIRA S, 1992, J BIOL CHEM, V267, P25644	88	473	487	2	67	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 30	1995	268	5219					1866	1872		10.1126/science.7604260	http://dx.doi.org/10.1126/science.7604260			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF990	7604260				2022-12-24	WOS:A1995RF99000029
J	HOHFELD, J; MINAMI, Y; HARTL, FU				HOHFELD, J; MINAMI, Y; HARTL, FU			HIP, A NOVEL COCHAPERONE INVOLVED IN THE EUKARYOTIC HSC70/HSP40 REACTION CYCLE	CELL			English	Article							HEAT-SHOCK PROTEINS; BINDING-SPECIFICITY; ATPASE; CLONING; HSP90; HSP70; DNAK; IDENTIFICATION; EXPRESSION; FRAGMENT	The Hsc70-interacting protein Hip, a tetratricopeptide repeat protein, participates in the regulation of the eukaryotic 70 kDa heat shock cognate Hsc70. One Hip oligomer binds the ATPase domains of at least two Hsc70 molecules dependent on activation of the Hsc70 ATPase by Hsp40. While hydrolysis remains the rate-limiting step in the ATPase cycle, Hip stabilizes the ADP state of Hsc70 that has a high affinity for substrate protein. Through its own chaperone activity, Hip may contribute to the interaction of Hsc70 with various target proteins. We propose a mechanism for the regulation of eukaryotic Hsc70 that is distinct from that of bacterial Hsp70. The Hsc70/Hsp40/Hip system is apparently independent of a GrpE-like nucleotide exchange factor.	HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, CELLULAR BIOCHEM & BIOPHYS PROGRAM, NEW YORK, NY 10021 USA	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center			Hartl, F. Ulrich/Y-8206-2019		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048742] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 48742] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ausubel F, 1989, MOL REPROD DEV, V1, P146; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; Bohen SP., 1994, BIOL HEAT SHOCK PROT, V26, P313; BOORSTEIN WR, 1994, J MOL EVOL, V38, P1; BUCHBERGER A, 1994, NAT STRUCT BIOL, V1, P95, DOI 10.1038/nsb0294-95; CHANG HCJ, 1994, J BIOL CHEM, V269, P24983; CHAPPEL TG, 1987, J BIOL CHEM, V252, P746; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; HARLOW W, 1988, ANTIBODIES LABORATOR; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HOHFELD J, 1994, CURR OPIN CELL BIOL, V6, P499, DOI 10.1016/0955-0674(94)90068-X; HONORE B, 1992, J BIOL CHEM, V267, P8485; HUTCHISON KA, 1992, J BIOL CHEM, V267, P2902; KIMURA Y, 1995, SCIENCE, V268, P1362, DOI 10.1126/science.7761857; KOZAK M, 1984, NATURE, V308, P241, DOI 10.1038/308241a0; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LEWIN B, 1990, GENES, V4, P120; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; NICOLET CM, 1989, MOL CELL BIOL, V9, P3638, DOI 10.1128/MCB.9.9.3638; OHTSUKA K, 1993, BIOCHEM BIOPH RES CO, V197, P235, DOI 10.1006/bbrc.1993.2466; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; RUTHERFORD SL, 1994, CELL, V79, P1129, DOI 10.1016/0092-8674(94)90003-5; SADIS S, 1992, BIOCHEMISTRY-US, V31, P9407; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SHI YG, 1992, MOL CELL BIOL, V12, P2186, DOI 10.1128/MCB.12.5.2186; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SORGER PK, 1987, EMBO J, V6, P993, DOI 10.1002/j.1460-2075.1987.tb04850.x; STUART RA, 1994, TRENDS BIOCHEM SCI, V19, P87, DOI 10.1016/0968-0004(94)90041-8; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; UPARANUKRAW P, 1993, MOL BIOCHEM PARASIT, V33, P101; WANG TF, 1993, J BIOL CHEM, V268, P26049; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; ZIEGELHOFFER T, 1995, J BIOL CHEM, V270, P10412, DOI 10.1074/jbc.270.18.10412; [No title captured]	46	352	365	0	16	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 17	1995	83	4					589	598						10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TF248	7585962				2022-12-24	WOS:A1995TF24800012
J	KINOSHITA, N; MINSHULL, J; KIRSCHNER, MW				KINOSHITA, N; MINSHULL, J; KIRSCHNER, MW			THE IDENTIFICATION OF 2 NOVEL LIGANDS OF THE FGF RECEPTOR BY A YEAST SCREENING METHOD AND THEIR ACTIVITY IN XENOPUS DEVELOPMENT	CELL			English	Article							FIBROBLAST GROWTH-FACTOR; AMINO-ACID SEQUENCE; SACCHAROMYCES-CEREVISIAE; PANCREATIC RIBONUCLEASE; MIDBLASTULA TRANSITION; MESODERM INDUCTION; BINDING-PROTEIN; FACTOR-II; GENE; EXPRESSION	We have developed a functional screen in yeast to identify ligands for receptor tyrosine kinases, Using this method, we cloned two Xenopus genes that activate the fibroblast growth factor (FGF) receptor. These encode novel secreted proteins, designated FRL1 and FRL2, distantly related to the epidermal growth factor and angiogenin/ribonuclease families, respectively. Both genes activate the FGF receptor in Xenopus oocytes as well as in yeast. Overexpression induces mesoderm and neural-specific genes in Xenopus explants; induction Is blocked by a dominant negative inhibitor of the FGF receptor. FRL1 is broadly expressed during gastrulation and neurulation, while FRL2 is expressed principally in the axial mesoderm and brain at later stages. Our results indicate that despite their lack of similarity with FGF, FRL1 and FRL2 are ligands for the FGF receptor that play distinct roles in development.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	KINOSHITA, N (corresponding author), HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115, USA.			Kinoshita, Noriyuki/0000-0002-1362-4045				AMAYA E, 1993, DEVELOPMENT, V118, P477; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BASSEZ T, 1990, DEVELOPMENT, V110, P955; BEINTEMA JJ, 1988, PROG BIOPHYS MOL BIO, V51, P165, DOI 10.1016/0079-6107(88)90001-6; BOND MD, 1993, BIOCHIM BIOPHYS ACTA, V1162, P177, DOI 10.1016/0167-4838(93)90145-H; BOND MD, 1990, BIOCHEM BIOPH RES CO, V171, P988, DOI 10.1016/0006-291X(90)90781-H; BRANDLI AW, 1995, DEV DYNAM, V203, P119; BYERS S, 1992, DEV BIOL, V152, P411, DOI 10.1016/0012-1606(92)90149-B; CARLSON M, 1983, MOL CELL BIOL, V3, P439, DOI 10.1128/MCB.3.3.439; CARSANA A, 1988, NUCLEIC ACIDS RES, V16, P5491, DOI 10.1093/nar/16.12.5491; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CICCODICOLA A, 1989, EMBO J, V8, P1987, DOI 10.1002/j.1460-2075.1989.tb03605.x; CORNELL RA, 1994, DEVELOPMENT, V120, P453; DONO R, 1993, DEVELOPMENT, V118, P1157; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; Faber J., 1994, NORMAL TABLE XENOPUS, P2; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GAL S, 1988, BIOCHEM J, V253, P303, DOI 10.1042/bj2530303; GALLWITZ D, 1981, NUCLEIC ACIDS RES, V9, P6339, DOI 10.1093/nar/9.23.6339; HAO QL, 1989, MOL CELL BIOL, V9, P1587, DOI 10.1128/MCB.9.4.1587; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HEMMATI-BRIVANLOUA, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; HEMMATIBRIVANLO.A, 1994, CELL, V77, P273; HOPP TP, 1986, BIOTECHNOLOGY, V6, P1205; ISAACS HV, 1992, DEVELOPMENT, V114, P711; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JOSEPH LJ, 1988, J CLIN INVEST, V81, P1621, DOI 10.1172/JCI113497; KAY BK, 1990, P NATL ACAD SCI USA, V87, P1367, DOI 10.1073/pnas.87.4.1367; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; KIM YJ, 1993, MOL CELL BIOL, V13, P174, DOI 10.1128/MCB.13.1.174; KIMELMAN D, 1989, CELL, V59, P687, DOI 10.1016/0092-8674(89)90015-9; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; KURACHI K, 1985, BIOCHEMISTRY-US, V24, P5494, DOI 10.1021/bi00341a032; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LABONNE C, 1994, DEVELOPMENT, V120, P463; LUSTIG KD, 1995, P NATL ACAD SCI USA, V92, P6234, DOI 10.1073/pnas.92.14.6234; LYMAN SD, 1993, CELL, V75, P1157, DOI 10.1016/0092-8674(93)90325-K; LYONS S, 1984, P NATL ACAD SCI-BIOL, V81, P7426, DOI 10.1073/pnas.81.23.7426; MAES P, 1988, FEBS LETT, V241, P41, DOI 10.1016/0014-5793(88)81027-5; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; MUSCI TJ, 1990, P NATL ACAD SCI USA, V87, P8365, DOI 10.1073/pnas.87.21.8365; RECHLER MM, 1980, ENDOCRINOLOGY, V107, P1451, DOI 10.1210/endo-107-5-1451; RISAU W, 1990, Progress in Growth Factor Research, V2, P71, DOI 10.1016/0955-2235(90)90010-H; RUPP RAW, 1991, CELL, V65, P927, DOI 10.1016/0092-8674(91)90545-A; SCHULLER C, 1990, MOL BIOL EVOL, V7, P29; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SMYTH DG, 1963, J BIOL CHEM, V238, P227; TITANI K, 1987, BIOCHEMISTRY-US, V26, P2189, DOI 10.1021/bi00382a018; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; WESTERMARK B, 1991, CANCER RES, V51, P2087; WILSON PA, 1994, CURR BIOL, V4, P676, DOI 10.1016/S0960-9822(00)00152-4; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	56	131	133	0	4	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 17	1995	83	4					621	630		10.1016/0092-8674(95)90102-7	http://dx.doi.org/10.1016/0092-8674(95)90102-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TF248	7585965	Bronze			2022-12-24	WOS:A1995TF24800015
J	HIRATA, J; NAKAGOSHI, H; NABESHIMA, Y; MATSUZAKI, F				HIRATA, J; NAKAGOSHI, H; NABESHIMA, Y; MATSUZAKI, F			ASYMMETRIC SEGREGATION OF THE HOMEODOMAIN PROTEIN PROSPERO DURING DROSOPHILA DEVELOPMENT	NATURE			English	Article							GENE; TRANSFORMATION; EMBRYOS; CELLS	ASYMMETRIC divisions that produce two distinct cells play fundamental roles in generating different cell types during development(1,2). In the Drosophila central nervous system, neural stem cells called neuroblasts divide unequally into another neuroblast and a ganglion mother cell which is Subsequently cleaved into neurons. Correct gene expression of ganglion mother tells requires the transcription factor Prospero(3-5). Here we demonstrate the asymmetric segregation of Prospero on neuroblast division, Prospero synthesized in neuroblasts is retained in the cytoplasm and at mitosis is exclusively partitioned to ganglion mother cells, in which it is translocated to the nucleus, Differential segregation of Prospero was also found in the endoderm. We have identified a region in Prospero that is responsible for this event, The region shares a common motif with Numb(6), which also shows unequal segregation(7). We propose that asymmetric segregation of transcription factors is an intrinsic mechanism for establishing asymmetry in gene expression between sibling cells.	UNIV TOKYO,FAC MED,DEPT PHARMACOL,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo	HIRATA, J (corresponding author), NATL CTR NEUROL & PSYCHIAT,NATL INST NEUROSCI,DEPT MOLEC GENET,4-1-1 OGAWAHIGASHI,KODAIRA,TOKYO 187,JAPAN.		NAKAGOSHI, Hideki/B-2145-2011	NAKAGOSHI, Hideki/0000-0003-0850-1814				BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; DOE CQ, 1991, CELL, V65, P451, DOI 10.1016/0092-8674(91)90463-9; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; EVANS TC, 1994, CELL, V77, P183, DOI 10.1016/0092-8674(94)90311-5; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; GAVIS ER, 1992, CELL, V71, P301, DOI 10.1016/0092-8674(92)90358-J; GAVIS ER, 1994, NATURE, V369, P315, DOI 10.1038/369315a0; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; LAWRENCE PA, 1994, CELL, V78, P181, DOI 10.1016/0092-8674(94)90289-5; MATSUZAKI F, 1992, BIOCHEM BIOPH RES CO, V182, P1326, DOI 10.1016/0006-291X(92)91878-T; PRATT WB, 1989, CANCER RES, V49, pS2222; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; Skaer Helen, 1993, P941; SPANA EP, IN PRESS DEVELOPMENT; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; TEPASS U, 1995, DEVELOPMENT, V121, P393; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; UEMURA T, 1989, CELL, V58, P349, DOI 10.1016/0092-8674(89)90849-0; VAESSIN H, 1991, CELL, V67, P941, DOI 10.1016/0092-8674(91)90367-8; WARTON RP, 1991, CELL, V67, P955; ZINMAN M, 1993, MOL BIOL CELL, V4, P1307	27	300	300	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 19	1995	377	6550					627	630		10.1038/377627a0	http://dx.doi.org/10.1038/377627a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA275	7566173				2022-12-24	WOS:A1995TA27500051
J	BRODIE, MJ; PELLOCK, JM				BRODIE, MJ; PELLOCK, JM			TAMING THE BRAIN STORMS - FELBAMATE UPDATED	LANCET			English	Editorial Material									VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,RICHMOND,VA 23298	Virginia Commonwealth University	BRODIE, MJ (corresponding author), WESTERN INFIRM & ASSOCIATED HOSP,DEPT MED & THERAPEUT,EPILEPSY RES UNIT,GLASGOW,LANARK,SCOTLAND.							BRODIE MJ, 1993, LANCET, V341, P1445, DOI 10.1016/0140-6736(93)90888-N; LEPPIK IE, 1995, EPILEPSIA, V36, pS66, DOI 10.1111/j.1528-1157.1995.tb06000.x; MCCABE RT, 1993, J PHARMACOL EXP THER, V264, P1248	3	26	26	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 7	1995	346	8980					918	919		10.1016/S0140-6736(95)91550-8	http://dx.doi.org/10.1016/S0140-6736(95)91550-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY808	7564721				2022-12-24	WOS:A1995RY80800002
J	COLETURNER, R				COLETURNER, R			RELIGION AND GENE PATENTING	SCIENCE			English	Editorial Material											COLETURNER, R (corresponding author), MEMPHIS THEOL SEMINARY,168 E PKWY S,MEMPHIS,TN 38104, USA.							Cole-Turner Ronald, 1993, NEW GENESIS THEOLOGY; Holifield EB, 1986, HLTH MED METHODIST T; STONE R, 1995, SCIENCE, V268, P1126, DOI 10.1126/science.7761825; 1995, MAY F EC TRENDS GEN; 1995, US TODAY        0519, pA12	5	12	12	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 6	1995	270	5233					52	52		10.1126/science.270.5233.52	http://dx.doi.org/10.1126/science.270.5233.52			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	Science & Technology - Other Topics	RY302	7569950				2022-12-24	WOS:A1995RY30200029
J	POON, RYC; HUNTER, T				POON, RYC; HUNTER, T			DEPHOSPHORYLATION OF CDK2 THR(160) BY THE CYCLIN-DEPENDENT KINASE-INTERACTING PHOSPHATASE KAP IN THE ABSENCE OF CYCLIN	SCIENCE			English	Article							GENE	The activation of cyclin-dependent kinases (CDKs) requires the phosphorylation of a conserved threonine (Thr(160) in Cdk2) by CDK-activating kinase (CAK). Human KAP (also called Cdl1), a CDK-associated phosphatase, was shown to dephosphorylate Thr(160) in human Cdk2. KAP was unable to dephosphorylate Tyr(15) and only dephosphorylated Thr(160) in native monomeric Cdk2. The binding of cyclin A to Cdk2 inhibited the dephosphorylation of Thr(160) by KAP but did not preclude the binding of KAP to the cyclin A-Cdk2 complex. Moreover, the dephosphorylation of Thr(160) bit KAP prevented Cdk2 kinase activity upon subsequent association with cyclin A. These results suggest that KAP binds to Cdk2 and dephosphorylates Thr(160) when the associated cyclin subunit is degraded or dissociates.			POON, RYC (corresponding author), SALK INST BIOL STUDIES,MOLEC BIOL & VIROL LAB,10100 N TORREY PINES RD,LA JOLLA,CA 92037, USA.			Poon, Randy/0000-0001-5571-6231	NATIONAL CANCER INSTITUTE [P30CA014195, R35CA039780] Funding Source: NIH RePORTER; NCI NIH HHS [CA39780, CA14195] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HANNON GJ, 1994, P NATL ACAD SCI USA, V91, P1731, DOI 10.1073/pnas.91.5.1731; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; IGARASHI M, 1991, NATURE, V353, P80, DOI 10.1038/353080a0; KAKIZUKA A, 1992, GENE DEV, V6, P578, DOI 10.1101/gad.6.4.578; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; POON RYC, 1994, ANAL BIOCHEM, V218, P26, DOI 10.1006/abio.1994.1137; POON RYC, 1994, J CELL SCI, V107, P2789; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; POON RYC, UNPUB; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x	24	149	154	0	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 6	1995	270	5233					90	93		10.1126/science.270.5233.90	http://dx.doi.org/10.1126/science.270.5233.90			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY302	7569954				2022-12-24	WOS:A1995RY30200039
J	JOUAVILLE, LS; ICHAS, F; HOLMUHAMEDOV, EL; CAMACHO, P; LECHLEITER, JD				JOUAVILLE, LS; ICHAS, F; HOLMUHAMEDOV, EL; CAMACHO, P; LECHLEITER, JD			SYNCHRONIZATION OF CALCIUM WAVES BY MITOCHONDRIAL SUBSTRATES IN XENOPUS-LAEVIS OOCYTES	NATURE			English	Article							INOSITOL TRISPHOSPHATE; ACINAR-CELLS; PROPAGATION; MECHANISMS; CHANNELS; RECEPTOR; PROTEIN	IN Xenopus oocytes, as well as other cells, inositol-1,4,5-trisphosphate (Ins(1,4,5)P-3)-induced Ca2+ release(1-4) is an excitable process that generates propagating Ca2+ waves(5-7) that annihilate upon collision(8-12). The fundamental property responsible for excitability appears to be the Ca2+ dependency of the Ins(1,4,5)P-3 receptor(9). Here we report that Ins(1,4,5)P-3-induced Ca2+ were activity is strengthened by oxidizable substrates that energize mitochrondria, increasing Ca2+ wave amplitude, velocity and interwave period. The effects of pyruvate/malate are blocked by ruthenium red at the Ca2+ uniporter, by rotenone at complex I, and by antimycin A at complex III, and are subsequently rescued at complex IV by ascorbate tetramethylphenylenediamine (TMPD)(14). Our data reveal that potential-driven mitochondrial Ca2+ uptake is a major factor in the regulation of Ins(1,4,5)P-3-induced Ca2+ release and clearly demonstrate a physiological role of mitrochondria in intracellular Ca2+ signalling.			JOUAVILLE, LS (corresponding author), UNIV VIRGINIA,DEPT NEUROSCI,CHARLOTTESVILLE,VA 22908, USA.		Holmuhamedov, Ekhson L/P-5228-2016; Ichas, François/ABD-8277-2020	Holmuhamedov, Ekhson L/0000-0002-0809-350X; Ichas, François/0000-0001-8184-5248				BEMENT WM, 1989, CELL TISSUE RES, V255, P183; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1993, NEURON, V10, P1175, DOI 10.1016/0896-6273(93)90065-Y; BIRD GS, 1992, J BIOL CHEM, V267, P18382; BOITANO S, 1992, SCIENCE, V258, P292, DOI 10.1126/science.1411526; CAHCON E, 1994, BIOPHYS J, V66, P942; CAMACHO P, 1993, SCIENCE, V260, P226, DOI 10.1126/science.8385800; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; DELISLE S, 1992, J BIOL CHEM, V267, P7963; FRIEL DD, 1994, J NEUROSCI, V14, P4007; GOLDSTONE TP, 1987, BIOCHEMISTRY-US, V26, P246, DOI 10.1021/bi00375a034; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; MAEDA N, 1989, DEV BIOL, V133, P67, DOI 10.1016/0012-1606(89)90297-2; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; Nicholls D.G., 1992, BIOENERGETICS, V2, P22; PARKER I, 1991, P ROY SOC B-BIOL SCI, V246, P269, DOI 10.1098/rspb.1991.0154; PARYS JB, 1992, J BIOL CHEM, V267, P18776; PETERSEN OH, 1994, REV PHYSL, V56, P297; POZAN T, 1994, PHYSIOL REV, V74, P595; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; SPEKSNIJDER JE, 1993, J CELL BIOL, V120, P1337, DOI 10.1083/jcb.120.6.1337; TOESCU EC, 1993, BIOCHEM BIOPH RES CO, V192, P854, DOI 10.1006/bbrc.1993.1493; WERTH JL, 1994, J NEUROSCI, V14, P348; WINFREE AT, 1980, GEOMETRY BIOL TIME, P246	30	356	362	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 5	1995	377	6548					438	441		10.1038/377438a0	http://dx.doi.org/10.1038/377438a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY190	7566122				2022-12-24	WOS:A1995RY19000052
J	NIELSEN, FC; OSTERGAARD, L; NIELSEN, J; CHRISTIANSEN, J				NIELSEN, FC; OSTERGAARD, L; NIELSEN, J; CHRISTIANSEN, J			GROWTH-DEPENDENT TRANSLATION OF IGF-II MESSENGER-RNA BY A RAPAMYCIN-SENSITIVE PATHWAY	NATURE			English	Article							RIBOSOMAL PROTEIN-S6; INSULIN; KINASE; CELLS; DNA	INSULIN-LIKE growth factor (IGF)-II is important for fetal growth and development(1). The human IGF-II gene generates multiple mature transcripts with different 5' untranslated regions (5'UTRs) but identical coding regions and 3'UTRs(2). We have previously shown that a minor 4.8-kilobase messenger RNA was engaged in the synthesis of preproIGF-II, and a major 6.0-kb mRNA was untranslated and stored in a 100S ribonucleoprotein particle(3). Here we demonstrate that the 6.0-kb mRNA is selectively mobilized and translated in dispersed exponentially growing cells. Translational activation is prevented by rapamycin and mimicked by anisomycin, which suggests that translation of the 6.0-kb mRNA is regulated by the p70(S6k)/85(S6k) kinase signalling pathway. Therefore, the minor 4.8-kb mRNA generates a constitutive production of preproIGF-II, whereas the major 6.0-kb mRNA provides a post-transcriptionally regulated species.	UNIV COPENHAGEN,INST MOLEC BIOL,DK-1307 COPENHAGEN K,DENMARK; RIGSHOSP,DEPT CLIN BIOCHEM,DK-2100 COPENHAGEN 0,DENMARK	University of Copenhagen; Rigshospitalet; University of Copenhagen			Ostergaard, Lars/AAA-3020-2020; Christiansen, Jan/L-3312-2014; Nielsen, Finn Cilius/AAA-4926-2020	Ostergaard, Lars/0000-0003-2459-0511; Christiansen, Jan/0000-0001-8624-4601; Ostergaard, Lars/0000-0002-7619-605X; Nielsen, Jacob/0000-0001-9842-2276				AN GH, 1982, MOL CELL BIOL, V2, P1628, DOI 10.1128/MCB.2.12.1628; AVNI D, 1994, MOL CELL BIOL, V14, P3822, DOI 10.1128/MCB.14.6.3822; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; DEMOOR CH, 1995, BIOCHEM J, V307, P225, DOI 10.1042/bj3070225; DILLING MB, 1994, CANCER RES, V54, P903; ELBADRY OM, 1990, CELL GROWTH DIFFER, V1, P325; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HOLTHUIZEN P, 1990, BIOCHIM BIOPHYS ACTA, V1087, P341, DOI 10.1016/0167-4781(90)90010-Y; JEFFERIES HBJ, 1994, J BIOL CHEM, V269, P4367; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; JENO P, 1989, J BIOL CHEM, V264, P1293; KARDALINOU E, 1994, MOL CELL BIOL, V14, P1066, DOI 10.1128/MCB.14.2.1066; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAHADEVAN LC, 1991, NATURE, V349, P747, DOI 10.1038/349747c0; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; MYERS MG, 1994, J BIOL CHEM, V269, P28783; NEWELL S, 1994, MOL REPROD DEV, V39, P249, DOI 10.1002/mrd.1080390302; NIELSEN FC, 1992, J BIOL CHEM, V267, P19404; NIELSEN FC, 1990, J BIOL CHEM, V265, P13431; Nielsen Finn Cilius, 1992, Progress in Growth Factor Research, V4, P257, DOI 10.1016/0955-2235(92)90023-B; OHLSSON R, 1989, EMBO J, V8, P1993, DOI 10.1002/j.1460-2075.1989.tb03606.x; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; SIEGMANN M, 1987, METHOD ENZYMOL, V146, P362; Sussenbach J S, 1989, Prog Growth Factor Res, V1, P33, DOI 10.1016/0955-2235(89)90040-9; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; THOMAS G, 1982, CELL, V30, P235, DOI 10.1016/0092-8674(82)90029-0	29	155	156	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 28	1995	377	6547					358	362		10.1038/377358a0	http://dx.doi.org/10.1038/377358a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX111	7566093				2022-12-24	WOS:A1995RX11100062
J	SHORT, N				SHORT, N			ON FIRST LOOKING INTO THE HUMAN GENOME - FOREWORD	NATURE			English	Editorial Material																			0	2	2	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 28	1995	377			S			1	1						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA343	7566095				2022-12-24	WOS:A1995TA34300001
J	PAUL, REL; PACKER, MJ; WALMSLEY, M; LAGOG, M; RANFORDCARTWRIGHT, LC; PARU, R; DAY, KP				PAUL, REL; PACKER, MJ; WALMSLEY, M; LAGOG, M; RANFORDCARTWRIGHT, LC; PARU, R; DAY, KP			MATING PATTERNS IN MALARIA PARASITE POPULATIONS OF PAPUA-NEW-GUINEA	SCIENCE			English	Article							ANOPHELES-PUNCTULATUS COMPLEX; PLASMODIUM-FALCIPARUM; GENETIC DIVERSITY; SPOROZOITE RATES; TRANSMISSION; EPIDEMIOLOGY; RESISTANCE; MADANG; AREA	Description of the genetic structure of malaria parasite populations is central to an understanding of the spread of multiple-locus drug and vaccine resistance. The Plasmodium falciparum mating patterns from Madang, Papua New Guinea, where intense transmission of malaria occurs, are described here. A high degree of inbreeding occurs in the absence of detectable linkage disequilibrium. This contrasts with other studies, indicating that the genetic structure of malaria parasite populations is neither clonal nor panmictic but will vary according to the transmission characteristics of the region.	UNIV OXFORD, DEPT ZOOL, WELLCOME CTR EPIDEMIOL INFECT DIS, OXFORD OX1 3PS, ENGLAND; PAPUA NEW GUINEA INST MED RES, MADANG, PAPUA N GUINEA; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, DEPT BIOL, LONDON SW7 2BB, ENGLAND; UNIV EDINBURGH, INST CELL ANIM & POPULAT BIOL, DIV BIOL SCI, EDINBURGH EH9 3JT, MIDLOTHIAN, SCOTLAND	University of Oxford; PNG Institute Of Medical Research; Imperial College London; University of Edinburgh			Day, Karen/F-3697-2015; Ranford-Cartwright, Lisa C/H-4701-2013	Day, Karen/0000-0002-6115-6135; Ranford-Cartwright, Lisa C/0000-0003-1992-3940	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AITKIN M, 1989, STATISTICAL MODELLIN; BABIKER H, 1994, T ROY SOC TROP MED H, V88, P328, DOI 10.1016/0035-9203(94)90103-1; BABIKER HA, 1994, PARASITOLOGY, V109, P413, DOI 10.1017/S0031182000080665; BORRE MB, 1991, MOL BIOCHEM PARASIT, V49, P119, DOI 10.1016/0166-6851(91)90135-S; BURKOT TR, 1989, AM J TROP MED HYG, V40, P229, DOI 10.4269/ajtmh.1989.40.229; BURKOT TR, 1988, AM J TROP MED HYG, V39, P135, DOI 10.4269/ajtmh.1988.39.135; CARTER R, 1975, T ROY SOC TROP MED H, V69, P371, DOI 10.1016/0035-9203(75)90191-1; CATTANI JA, 1986, AM J TROP MED HYG, V35, P3, DOI 10.4269/ajtmh.1986.35.3; CATTANI JA, 1986, PAPUA NEW GUINEA MED, V29, P11; CAUGANT DA, 1981, GENETICS, V98, P467; CONWAY DJ, 1991, T ROY SOC TROP MED H, V85, P454, DOI 10.1016/0035-9203(91)90217-M; CONWAY DJ, 1991, PARASITOLOGY, V103, P7, DOI 10.1017/S0031182000059229; Crawley M.J., 1993, GLIM ECOLOGISTS; CURTIS CF, 1986, T ROY SOC TROP MED H, V80, P889, DOI 10.1016/0035-9203(86)90248-8; DAY KP, 1992, PARASITOLOGY, V104, pS35, DOI 10.1017/S0031182000075235; DYE C, 1992, MODELLING VECTOR BOR, P165; GUPTA S, 1994, PARASITOL TODAY, V10, P476, DOI 10.1016/0169-4758(94)90160-0; HAMILTON WD, 1967, SCIENCE, V156, P477, DOI 10.1126/science.156.3774.477; Hartl D. L., 1989, PRINCIPLES POPULATIO; Hartl DL, 1992, CURR OPIN GENET DEV, V2, P937, DOI 10.1016/S0959-437X(05)80119-4; HILL WG, 1995, GENET RES, V65, P53, DOI 10.1017/S0016672300033000; KEMP DJ, 1990, ADV PARASIT, V29, P75; KOELLA JC, 1990, T ROY SOC TROP MED H, V84, P662, DOI 10.1016/0035-9203(90)90135-2; LENSKI RE, 1993, P NATL ACAD SCI USA, V90, P4334, DOI 10.1073/pnas.90.10.4334; MARSHALL VM, 1993, PROTOCOLS MOL PARASI, V21, P223; MAYNARDSMITH J, 1993, P NATIONAL ACADEMY S, V90, P4384; RANFORDCARTWRIGHT LC, 1991, MOL BIOCHEM PARASIT, V49, P239, DOI 10.1016/0166-6851(91)90067-G; RANFORDCARTWRIGHT LC, 1993, PARASITOLOGY, V107, P11, DOI 10.1017/S003118200007935X; READ AF, 1992, PARASITOLOGY, V104, P387, DOI 10.1017/S0031182000063630; ROSENBERG R, 1990, T ROY SOC TROP MED H, V84, P209, DOI 10.1016/0035-9203(90)90258-G; TIBAYRENC M, 1991, P NATL ACAD SCI USA, V88, P5129, DOI 10.1073/pnas.88.12.5129; TIBAYRENC M, 1991, PARASITOL TODAY, V7, P228, DOI 10.1016/0169-4758(91)90234-F; TRIGLIA T, 1992, PARASITOL TODAY, V8, P225, DOI 10.1016/0169-4758(92)90118-L; VIRIYAKOSOL S, 1995, B WORLD HEALTH ORGAN, V73, P85; WALLIKER D, 1991, PARASITOL TODAY, V7, P232, DOI 10.1016/0169-4758(91)90235-G; WALLIKER D, 1989, EXP PARASITOL, V69, P303, DOI 10.1016/0014-4894(89)90078-7; WEIR BS, 1984, EVOLUTION, V38, P1358, DOI [10.2307/2408641, 10.1111/j.1558-5646.1984.tb05657.x]; Wright S., 1969, THEORY GENE FREQUENC, V2, P520	38	267	274	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 22	1995	269	5231					1709	1711		10.1126/science.7569897	http://dx.doi.org/10.1126/science.7569897			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV948	7569897				2022-12-24	WOS:A1995RV94800034
J	SIVILOTTI, L; COLQUHOUN, D				SIVILOTTI, L; COLQUHOUN, D			ACETYLCHOLINE-RECEPTORS - TOO MANY CHANNELS, TOO FEW FUNCTIONS	SCIENCE			English	Editorial Material							RAT HIPPOCAMPAL-NEURONS; CURRENTS; PERMEABILITY; SUBTYPES; SUBUNIT; CORTEX; BRAIN		UCL, WELLCOME LAB MOLEC PHARMACOL, LONDON WC1E 6BT, ENGLAND	University of London; University College London	SIVILOTTI, L (corresponding author), UCL, DEPT PHARMACOL, LONDON WC1E 6BT, ENGLAND.		Colquhoun, David/C-1664-2008; Sivilotti, Lucia/D-8919-2011	Colquhoun, David/0000-0002-4263-017X; Sivilotti, Lucia/0000-0003-2510-8424				ALKONDON M, 1993, J PHARMACOL EXP THER, V265, P1455; BERTRAND D, 1993, P NATL ACAD SCI USA, V90, P6971, DOI 10.1073/pnas.90.15.6971; BOULTER J, 1986, NATURE, V319, P368, DOI 10.1038/319368a0; CLARKE PBS, 1992, TRENDS PHARMACOL SCI, V13, P407, DOI 10.1016/0165-6147(92)90125-P; COLQUHOUN D, 1985, J PHYSIOL-LONDON, V369, P501, DOI 10.1113/jphysiol.1985.sp015912; CONNOLLY JG, 1995, J PHYSIOL-LONDON, V484, P87, DOI 10.1113/jphysiol.1995.sp020650; FLORES CM, 1992, MOL PHARMACOL, V41, P31; GALZI JL, 1995, NEUROPHARMACOLOGY, V34, P563, DOI 10.1016/0028-3908(95)00034-4; Hill AV, 1909, J PHYSIOL-LONDON, V39, P361; Hille B., 1992, IONIC CHANNELS EXCIT; LENA C, 1993, J NEUROSCI, V13, P2680, DOI 10.1523/JNEUROSCI.13-06-02680.1993; LENOVERE N, 1995, J MOL EVOL, V40, P155, DOI 10.1007/BF00167110; LESTER RAJ, 1995, J NEUROPHYSIOL, V74, P195, DOI 10.1152/jn.1995.74.1.195; MCGEHEE DS, 1995, SCIENCE, V269, P1692, DOI 10.1126/science.7569895; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; MCMAHON LL, 1994, J NEUROPHYSIOL, V71, P826, DOI 10.1152/jn.1994.71.2.826; NEHER E, 1976, NATURE, V260, P799, DOI 10.1038/260799a0; ORTELLS MO, 1995, TRENDS NEUROSCI, V18, P121, DOI 10.1016/0166-2236(95)93887-4; PATON WDM, 1951, BRIT J PHARM CHEMOTH, V6, P155, DOI 10.1111/j.1476-5381.1951.tb00631.x; PERRY EK, 1995, NEUROSCIENCE, V64, P385, DOI 10.1016/0306-4522(94)00410-7; SANDS SB, 1993, BIOPHYS J, V65, P2614, DOI 10.1016/S0006-3495(93)81296-7; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; SCHOEPFER R, 1988, NEURON, V1, P241, DOI 10.1016/0896-6273(88)90145-6; SUGAYA K, 1990, J NEUROSCI RES, V27, P349, DOI 10.1002/jnr.490270314; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; VIDAL C, 1993, NEUROSCIENCE, V56, P23, DOI 10.1016/0306-4522(93)90558-W; Wonnacott S, 1990, BIOL NICOTINE DEPEND; ZORUMSKI CF, 1992, MOL PHARMACOL, V41, P931	29	49	51	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 22	1995	269	5231					1681	1682		10.1126/science.7569892	http://dx.doi.org/10.1126/science.7569892			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV948	7569892				2022-12-24	WOS:A1995RV94800025
J	LOZANO, P; CONNELL, FA; KOEPSELL, TD				LOZANO, P; CONNELL, FA; KOEPSELL, TD			USE OF HEALTH-SERVICES BY AFRICAN-AMERICAN CHILDREN WITH ASTHMA ON MEDICAID	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHILDHOOD ASTHMA; UNITED-STATES; RACE; HOSPITALIZATIONS; PREVALENCE; MORTALITY; TRENDS; EVENTS; SODIUM	Objective.-To determine whether African-American children with asthma use more emergency department (ED) and inpatient medical services and fewer preventive services than white children with similar insurance coverage and family income. Design.-Historical cohort study using Medicaid claims data, Setting.-Aid to Families With Dependent Children enrollees aged 3 through 17 years in the Seattle-Tacoma, Wash, metropolitan area. Patients.-All 576 African-American children and 1369 white children receiving services for asthma between June 1988 and December 1992. Main Outcome Measures.-Utilization of asthma services (ED, inpatient, office visits, and pharmacy) and well-child services and associated Medicaid reimbursements, Results.-African-American children were more likely than white children to make ED visits or to be hospitalized for asthma; adjusted odds ratios (ORs) were 1.70 (95% confidence interval [CI], 1.34 to 2.15) and 1.42 (95% CI, 1.03 to 1.96), respectively, African-American children were less likely to have made an office visit for asthma; the adjusted OR was 0.48 (95% CI, 0.26 to 0.85). The two groups were similarly likely to have filled a prescription for an asthma medication and to have made a well-child visit. Per capita payments for asthma services were 24% higher for African-American children: $436 vs $350 per child-year. Conclusions.-Higher use of ED and inpatient services for asthma among African-American children using Medicaid (compared with white children) cannot be fully explained by poverty or inadequate health insurance. Furthermore, these children appear to make disproportionately few office visits for asthma, suggesting suboptimal use of preventive services for asthma. In contrast, the comparable use of well-child visits in the two groups suggests the problem may not be in access to care in general, but there may be specific problems in the successful management of chronic diseases such as asthma among African-American children.	UNIV WASHINGTON,SCH MED,DEPT PEDIAT,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,ROBERT WOOD JOHNSON CLIN SCHOLARS PROGRAM,SEATTLE,WA 98195; UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT HLTH SERV,SEATTLE,WA 98195; UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT EPIDEMIOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	LOZANO, P (corresponding author), GRP HLTH COOPERAT PUGET SOUND,CTR HLTH STUDIES,1730 MINOR AVE,SUITE 1600,SEATTLE,WA 98101, USA.		Lozano, Paula Maria/GPP-4090-2022		PHS HHS [MCJ-9043] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BOSCO LA, 1993, CHEST, V104, P1727, DOI 10.1378/chest.104.6.1727; BRIGHT RA, 1989, J CLIN EPIDEMIOL, V42, P937, DOI 10.1016/0895-4356(89)90158-3; CARR W, 1992, AM J PUBLIC HEALTH, V82, P59, DOI 10.2105/AJPH.82.1.59; CARR W, 1989, SOC SCI MED, V29, P705, DOI 10.1016/0277-9536(89)90149-4; COGSWELL JJ, 1985, ARCH DIS CHILD, V60, P736, DOI 10.1136/adc.60.8.736; CONNELL FA, 1987, ANNU REV PUBL HEALTH, V8, P51, DOI 10.1146/annurev.publhealth.8.1.51; DUAN N, 1983, J EC BUSINESS STATIS, V1, P115, DOI DOI 10.2307/1391852; EVANS R, 1987, CHEST, V91, pS65, DOI 10.1378/chest.91.6_Supplement.65S; FINKELSTEIN JA, 1995, PEDIATRICS, V95, P389; FITZPATRICK SB, 1992, J NATL MED ASSOC, V84, P233; FURUKAWA CT, 1984, PEDIATRICS, V74, P453; GERGEN PJ, 1990, JAMA-J AM MED ASSOC, V264, P1688, DOI 10.1001/jama.264.13.1688; GERGEN PJ, 1988, PEDIATRICS, V81, P1; KLEIN R, 1977, PEDIATRICS, V60, P7; MARDER D, 1992, CHEST, V101, pS426, DOI 10.1378/chest.101.6.426S; OSBORNE NG, 1992, JAMA-J AM MED ASSOC, V267, P275, DOI 10.1001/jama.267.2.275; ROBINSON JC, 1991, INQUIRY-J HEALTH CAR, V28, P107; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555, DOI 10.1164/ajrccm/142.3.555; SLY RM, 1988, ANN ALLERGY, V60, P433; TAYLOR WR, 1992, PEDIATRICS, V90, P657; WEISS KB, 1990, JAMA-J AM MED ASSOC, V263, P2323; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304; WEITZMAN M, 1992, JAMA-J AM MED ASSOC, V268, P2673, DOI 10.1001/jama.268.19.2673; WEITZMAN M, 1990, AM J DIS CHILD, V144, P1189, DOI 10.1001/archpedi.1990.02150350021016; WISSOW LS, 1988, AM J PUBLIC HEALTH, V78, P777, DOI 10.2105/AJPH.78.7.777; 1991, NIH PHS913042 NAT HE; 1992, STATE AM CHILDREN 19	27	162	163	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 9	1995	274	6					469	473		10.1001/jama.274.6.469	http://dx.doi.org/10.1001/jama.274.6.469			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RM699	7629955				2022-12-24	WOS:A1995RM69900026
J	DEWIND, N; DEKKER, M; BERNS, A; RADMAN, M; RIELE, HT				DEWIND, N; DEKKER, M; BERNS, A; RADMAN, M; RIELE, HT			INACTIVATION OF THE MOUSE MSH2 GENE RESULTS IN MISMATCH REPAIR DEFICIENCY, METHYLATION TOLERANCE, HYPERRECOMBINATION, AND PREDISPOSITION TO CANCER	CELL			English	Article							NONPOLYPOSIS COLORECTAL-CANCER; BASE-PAIR MISMATCHES; SACCHAROMYCES-CEREVISIAE; MAMMALIAN-CELLS; GENOMIC INSTABILITY; ESCHERICHIA-COLI; DNA-DAMAGE; EXTRACTS; BINDING; MUTATIONS	To investigate the role of the presumed DNA mismatch repair (MMR) gene Msh2 in genome stability and tumorigenesis, we have generated cells and mice that are deficient for the gene. Msh2-deficient cells have lost mismatch binding and have acquired microsatellite instability, a mutator phenotype, and tolerance to methylating agents. Moreover, in these cells, homologous recombination has lost dependence on complete identity between interacting DNA sequences, suggesting that Msh2 is involved in safeguarding the genome from promiscuous recombination. Msh2-deficient mice display no major abnormalities, but a significant fraction develops lymphomas at an early age. Thus, Msh2 is involved in MMR, controlling several aspects of genome stability; loss of MMR-controlled genome stability predisposes to cancer.	NETHERLANDS CANC INST, DIV MOLEC GENET, 1066 CX AMSTERDAM, NETHERLANDS; INST JACQUES MONOD, MUTAGENESIS LAB, F-75251 PARIS 5, FRANCE	Netherlands Cancer Institute; UDICE-French Research Universities; Universite Paris Cite	DEWIND, N (corresponding author), NETHERLANDS CANC INST, DIV MOLEC CARCINOGENESIS, PLESMANLAAN 121, 1066 CX AMSTERDAM, NETHERLANDS.		; Radman, Miroslav/HDM-5955-2022	Radman, Miroslav/0000-0002-7034-4365; Radman, Miroslav/0000-0003-0216-3148				AALTONEN LA, 1994, CANCER RES, V54, P1645; ALANI E, 1995, GENE DEV, V9, P234, DOI 10.1101/gad.9.2.234; ALANI E, 1994, GENETICS, V137, P19; AQUILINA G, 1994, P NATL ACAD SCI USA, V91, P8905, DOI 10.1073/pnas.91.19.8905; AQUILINA G, 1993, CARCINOGENESIS, V14, P2097, DOI 10.1093/carcin/14.10.2097; BEIJERSBERGEN RL, 1995, IN PRESS GENES DEV; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BICKNELL DC, 1994, P NATL ACAD SCI USA, V91, P4751, DOI 10.1073/pnas.91.11.4751; BOUFFLER S, 1993, BIOESSAYS, V15, P409, DOI 10.1002/bies.950150607; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BROSIUS J, 1992, P NATL ACAD SCI USA, V89, P10706, DOI 10.1073/pnas.89.22.10706; CHONG JM, 1994, CANCER RES, V54, P4595; COHEN PR, 1991, AM J MED, V90, P606; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; DOLAN ME, 1990, P NATL ACAD SCI USA, V87, P5368, DOI 10.1073/pnas.87.14.5368; ESHLEMAN JR, 1995, ONCOGENE, V10, P33; FANG WH, 1993, J BIOL CHEM, V268, P11838; FISHEL R, 1994, CANCER RES, V54, P5539; FISHEL R, 1994, SCIENCE, V266, P1403, DOI 10.1126/science.7973733; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GOLDMACHER VS, 1986, J BIOL CHEM, V261, P2462; GRIFFIN S, 1994, BIOCHEMISTRY-US, V33, P4787, DOI 10.1021/bi00182a006; GRIFFIN S, 1993, BIOCHEMISTRY-US, V32, P13032, DOI 10.1021/bi00211a012; HAN HJ, 1993, CANCER RES, V53, P5087; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HEMMINKI A, 1994, NAT GENET, V8, P405, DOI 10.1038/ng1294-405; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; HUGHES MJ, 1992, J BIOL CHEM, V267, P23876; JASS JR, 1994, MUTAT RES-FUND MOL M, V310, P125, DOI 10.1016/0027-5107(94)90016-7; JIRICNY J, 1988, P NATL ACAD SCI USA, V85, P8860, DOI 10.1073/pnas.85.23.8860; JIRICNY J, 1994, TRENDS GENET, V10, P164, DOI 10.1016/0168-9525(94)90093-0; KARRAN P, 1992, NUCLEIC ACIDS RES, V20, P2933, DOI 10.1093/nar/20.12.2933; KARRAN P, 1994, BIOESSAYS, V16, P833, DOI 10.1002/bies.950161110; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; KOI M, 1994, CANCER RES, V54, P4308; KOLODNER RD, 1994, GENOMICS, V24, P516, DOI 10.1006/geno.1994.1661; KOLODNER RD, 1995, CANCER RES, V55, P242; KRAMER B, 1989, MOL CELL BIOL, V9, P4432, DOI 10.1128/MCB.9.10.4432; KRAMER W, 1989, J BACTERIOL, V171, P5339, DOI 10.1128/jb.171.10.5339-5346.1989; LAZAR V, 1994, HUM MOL GENET, V3, P2257, DOI 10.1093/hmg/3.12.2257; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; LIU B, 1994, CANCER RES, V54, P4590; LOEB LA, 1994, CANCER RES, V54, P5059; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; MICHEJDA CJ, 1994, DNA ADDUCTS IDENTIFI, P323; MIRET JJ, 1993, J BIOL CHEM, V268, P3507; MIRONOV NM, 1994, CANCER RES, V54, P41; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; NASSIF N, 1993, P NATL ACAD SCI USA, V90, P1262, DOI 10.1073/pnas.90.4.1262; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; NOWAK R, 1994, SCIENCE, V263, P608, DOI 10.1126/science.7508142; ORTH K, 1994, P NATL ACAD SCI USA, V91, P9495, DOI 10.1073/pnas.91.20.9495; PALOMBO F, 1994, NATURE, V367, P417, DOI 10.1038/367417a0; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PETIT MA, 1991, GENETICS, V129, P327; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; PROLLA TA, 1994, MOL CELL BIOL, V14, P407, DOI 10.1128/MCB.14.1.407; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; REENAN RAG, 1992, GENETICS, V132, P963; REENAN RAG, 1992, GENETICS, V132, P975; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; RISINGER JI, 1993, CANCER RES, V53, P5100; Sambrook J., 1989, MOL CLONING LAB MANU; SELVA EM, 1995, GENETICS, V139, P1175; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; STEPHENSON C, 1989, J BIOL CHEM, V264, P21177; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; SUZUKI H, 1994, CANCER RES, V54, P4841; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; UMAR A, 1994, J BIOL CHEM, V269, P14367; UMAR A, 1994, SCIENCE, V266, P814, DOI 10.1126/science.7973637; VARLET I, 1994, NUCLEIC ACIDS RES, V22, P5723, DOI 10.1093/nar/22.25.5723; VARLET I, 1990, P NATL ACAD SCI USA, V87, P7883, DOI 10.1073/pnas.87.20.7883; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WADA C, 1994, BLOOD, V83, P3449, DOI 10.1182/blood.V83.12.3449.bloodjournal83123449; WALDMAN AS, 1988, MOL CELL BIOL, V8, P5350, DOI 10.1128/MCB.8.12.5350; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152; WORTH L, 1994, P NATL ACAD SCI USA, V91, P3238, DOI 10.1073/pnas.91.8.3238; YOUNG J, 1993, HUM MUTAT, V2, P351, DOI 10.1002/humu.1380020505	88	693	720	0	34	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 28	1995	82	2					321	330		10.1016/0092-8674(95)90319-4	http://dx.doi.org/10.1016/0092-8674(95)90319-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RL760	7628020	Bronze			2022-12-24	WOS:A1995RL76000019
J	KATZ, WS; HILL, RJ; CLANDININ, TR; STERNBERG, PW				KATZ, WS; HILL, RJ; CLANDININ, TR; STERNBERG, PW			DIFFERENT LEVELS OF THE C-ELEGANS GROWTH-FACTOR LIN-3 PROMOTE DISTINCT VULVAR PRECURSOR FATES	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; POST-EMBRYONIC DEVELOPMENT; CELL LINEAGES; EXPRESSION; INDUCTION; AUTONOMY; ENCODES; MUTANTS; PATTERN; SIGNAL	An invariant spatial pattern of three cell fates (3 degrees-3 degrees 2 degrees-1 degrees-2 degrees-3 degrees) is generated from a field of multipotent precursor cells during C. elegans vulval development. We demonstrate that the epidermal growth factor-like domain of the LIN-3 protein can induce either of two distinct vulval cell fates: a high dose of LIN-3 induces a 1 degrees fate; a lower dose of LIN-3 induces a 2 degrees fate. A high dose of LIN-3 can also induce adjacent vulval precursor cells to assume 1 degrees fates; thus, high levels of LIN-3 can override the lateral signaling that normally inhibits formation of adjacent 1 degrees fates. We propose that the invariant pattern of vulval cell fates is generated by a graded distribution of LIN-3 that promotes different vulval fates according to local concentration and by a lateral signal that reinforces this initial bias.	CALTECH,DIV BIOL,PASADENA,CA 91125	California Institute of Technology	KATZ, WS (corresponding author), CALTECH,HOWARD HUGHES MED INST,PASADENA,CA 91125, USA.			Sternberg, Paul/0000-0002-7699-0173; Katz, Wendy/0000-0003-3038-6314	NICHD NIH HHS [HD23690] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD023690] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AVERY L, 1987, CELL, V51, P1071, DOI 10.1016/0092-8674(87)90593-9; BRENNER S, 1974, GENETICS, V77, P71; CARPENTER G, 1990, PEPTIDE GROWTH FACTO, P69; CRICK F, 1970, NATURE, V225, P420, DOI 10.1038/225420a0; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FERGUSON EL, 1987, NATURE, V326, P259, DOI 10.1038/326259a0; FERGUSON EL, 1985, GENETICS, V110, P17; FIRE A, 1992, GENET ANAL-BIOMOL E, V9, P151, DOI 10.1016/1050-3862(92)90042-4; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; FREYD G, 1991, THESIS MIT CAMBRIDGE; GREEN JBA, 1991, TRENDS GENET, V7, P245, DOI 10.1016/0168-9525(91)90323-I; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; HAN M, 1990, GENETICS, V126, P899; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; HORVITZ HR, 1980, GENETICS, V96, P435; JAN YN, 1994, ANNU REV GENET, V28, P373, DOI 10.1146/annurev.ge.28.120194.002105; JONGEWARD GD, 1995, GENETICS, V139, P1553; KAYNE PS, 1995, CURR OPIN GENET DEV, V5, P38, DOI 10.1016/S0959-437X(95)90051-9; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; KOGA M, 1995, IN PRESS DEVELOPMENT; KUNISCH M, 1994, P NATL ACAD SCI USA, V91, P10139, DOI 10.1073/pnas.91.21.10139; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MELLO CC, 1995, METHODS CELL BIOL C; PEIFER M, 1994, SCIENCE, V266, P192; PERRY MD, 1993, GENE DEV, V7, P216, DOI 10.1101/gad.7.2.216; Sambrook J., 1989, MOL CLONING LAB MANU; SEYDOUX G, 1989, CELL, V57, P1237, DOI 10.1016/0092-8674(89)90060-3; SIMSKE JS, 1995, NATURE, V375, P142, DOI 10.1038/375142a0; SIVE HL, 1993, GENE DEV, V7, P1, DOI 10.1101/gad.7.1.1; Slack J. M. W, 1991, EGG EMBRYON REGIONAL; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; STERNBERG PW, 1989, CELL, V58, P679, DOI 10.1016/0092-8674(89)90103-7; STERNBERG PW, 1988, NATURE, V335, P551, DOI 10.1038/335551a0; STJOHNSTON D, 1992, CELL, V68, P201; STRATHMANN M, 1991, P NATL ACAD SCI USA, V88, P1247, DOI 10.1073/pnas.88.4.1247; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; SULSTON JE, 1976, PHILOS T ROY SOC B, V275, P287, DOI 10.1098/rstb.1976.0084; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1981, DEV BIOL, V82, P41, DOI 10.1016/0012-1606(81)90427-9; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; THOMAS JH, 1990, CELL, V62, P1041, DOI 10.1016/0092-8674(90)90382-O; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WAY JC, 1991, GENE DEV, V5, P2199, DOI 10.1101/gad.5.12a.2199; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	49	167	177	0	7	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 28	1995	82	2					297	307		10.1016/0092-8674(95)90317-8	http://dx.doi.org/10.1016/0092-8674(95)90317-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RL760	7628018	Bronze			2022-12-24	WOS:A1995RL76000017
J	MOHRIG, JR; MOERKE, KA; CLOUTIER, DL; LANE, BD; PERSON, EC; ONASCH, TB				MOHRIG, JR; MOERKE, KA; CLOUTIER, DL; LANE, BD; PERSON, EC; ONASCH, TB			IMPORTANCE OF HISTORICAL CONTINGENCY IN THE STEREOCHEMISTRY OF HYDRATASE-DEHYDRATASE ENZYMES	SCIENCE			English	Article							STEREOSPECIFICITY; ANALOGS; EVOLUTION; FUMARASE	There are two stereochemical classes of hydratase-dehydratase enzymes. Those that catalyze the addition of water to alpha,beta-unsaturated thioesters give syn addition-elimination stereochemistry, whereas those that catalyze the addition of water to conjugated carboxylate substrates give anti stereochemistry. This dichotomy could reflect different adaptive advantages or contingencies of separate evolutionary histories. Determination of the nonenzymatic stereochemistry of deuterium oxide addition to fumarate and to S-crotonyl N-acetylcysteamine has provided direct evidence for the importance of the contingencies of evolutionary history, rather than chemical efficiency, in the pathways of these hydratase-dehydratase enzymes.			MOHRIG, JR (corresponding author), CARLETON COLL, DEPT CHEM, NORTHFIELD, MN 55057 USA.		Onasch, Tim/AAY-4998-2020; MOHRIG, JERRY/V-8908-2019	Onasch, Tim/0000-0001-7796-7840; 				AMYES TL, 1992, J AM CHEM SOC, V114, P10297, DOI 10.1021/ja00052a028; ANDERSON SR, 1994, BIOCHEMISTRY-US, V33, P10545, DOI 10.1021/bi00200a041; ANDERSON VE, 1984, BIOCHEMISTRY-US, V23, P2779, DOI 10.1021/bi00307a038; BAHNSON BJ, 1991, BIOCHEMISTRY-US, V30, P5894, DOI 10.1021/bi00238a013; BAHNSON BJ, 1989, BIOCHEMISTRY-US, V28, P4173, DOI 10.1021/bi00436a008; BENNER SA, 1989, CHEM REV, V89, P789, DOI 10.1021/cr00094a004; BENNER SA, 1989, TOP STEREOCHEM, V19, P127; BLANCHARD JS, 1980, BIOCHEMISTRY-US, V19, P4506, DOI 10.1021/bi00560a019; CLELAND WW, 1975, ACCOUNTS CHEM RES, V8, P145, DOI 10.1021/ar50089a001; CREIGHTON DJ, 1990, ENZYMES, V19, pCH7; DORDINE RL, 1994, BIOCHEMISTRY-US, V33, P14733, DOI 10.1021/bi00253a011; DORIT RL, 1990, SCIENCE, V250, P1377, DOI 10.1126/science.2255907; ERICKSON LE, 1959, J PHYS CHEM-US, V63, P705, DOI 10.1021/j150575a014; GAWRON O, 1961, J AM CHEM SOC, V83, P3634, DOI 10.1021/ja01478a021; GERIT JA, 1992, J AM CHEM SOC, V114, P5928; GERIT JA, 1993, BIOCHEMISTRY-US, V32, P11943; GETZOFF ED, 1992, NATURE, V358, P347, DOI 10.1038/358347a0; GLASFELD A, 1990, J BIOL CHEM, V265, P11692; HANSON KR, 1975, ACCOUNTS CHEM RES, V8, P1, DOI 10.1021/ar50085a001; KNOWLES JR, 1977, ACCOUNTS CHEM RES, V10, P105, DOI 10.1021/ar50112a001; LYNEN F, 1969, METHOD ENZYMOL, V14, P17; MOHRIG JR, 1990, J AM CHEM SOC, V112, P3665, DOI 10.1021/ja00165a065; MOHRIG JR, 1981, J ORG CHEM, V46, P4655, DOI 10.1021/jo00336a003; PORTER DJT, 1980, J BIOL CHEM, V255, P4772; SAUNDERS WH, 1973, MECHANISMS ELIMINATI, pCH3; SCHLOSS JV, 1980, BIOCHEMISTRY-US, V19, P2358, DOI 10.1021/bi00552a012; SCHWAB JM, 1986, J AM CHEM SOC, V108, P5304, DOI 10.1021/ja00277a040; SPEIR TW, 1971, BIOCHEM J, V125, P267, DOI 10.1042/bj1250267	28	54	54	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 28	1995	269	5223					527	529						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	RL495	7624773				2022-12-24	WOS:A1995RL49500023
J	MEHTA, M; SCHILLER, JH				MEHTA, M; SCHILLER, JH			PROGNOSIS WITH ASYMPTOMATIC PULMONARY NODULES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											MEHTA, M (corresponding author), UNIV WISCONSIN,MADISON,WI 53706, USA.							BERLIN NI, 1984, AM REV RESPIR DIS, V30, P565; EDDY DM, 1989, ANN INTERN MED, V111, P232, DOI 10.7326/0003-4819-111-3-232; GINSBERG RJ, 1993, CANCER PRINCIPLES PR; HARVEY JC, 1993, SEMIN SURG ONCOL, V9, P32; SAAD R, 1989, REV ASSOC MED BRAS, V35, P23; STEELE JD, 1964, SOLITARY PULMONARY N	6	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 26	1995	274	4					358	358						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ898	7609270				2022-12-24	WOS:A1995RJ89800044
J	KIKKAWA, M; ISHIKAWA, T; WAKABAYASHI, T; HIROKAWA, N				KIKKAWA, M; ISHIKAWA, T; WAKABAYASHI, T; HIROKAWA, N			3-DIMENSIONAL STRUCTURE OF THE KINESIN HEAD-MICROTUBULE COMPLEX	NATURE			English	Article							CRYO-ELECTRON MICROSCOPY; SURFACE LATTICE; RECONSTRUCTION; DECORATION; TUBULIN; SYSTEM; IMAGES	KINESIN is a microtubule (MT)-associated 'motor' molecule fundamental to organelle transport(1,2). Recently, various kinesin superfamily members (KIFs) have also been identified and suggested as being responsible for the transport of specific organelles(3-5). Kinesin is a heterotetramer composed of two heavy chains and two light chains. The heavy chains form two globular heads, a rod and a fan-like tail completed by the light chains(6,7). The globular head, which is composed of approximately 340 amino-terminal residues of the heavy chain, includes both ATP-binding and MT-binding domains, and its recombinant protein also has these properties(8). To improve the understanding of the mechanism of force generation by an MT-based molecular motor, kinesin, we report here the three-dimensional structure of the complex of a recombinant kinesin head and MTs, as revealed by helical reconstruction from cryoelectron micrographs. A kinesin head is a globular teardrop-like structure binding to the ridge of one protofilament of MTs. We have determined the polarity of the structure of the complex of MTs and the kinesin head in relation to MT polarity.	UNIV TOKYO, FAC MED, DEPT ANAT & CELL BIOL, BUNKYO KU, TOKYO 113, JAPAN; UNIV TOKYO, FAC SCI, DEPT PHYS, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo; University of Tokyo			Ishikawa, Takashi/E-5023-2017; Kikkawa, Masahide/A-6692-2010	Ishikawa, Takashi/0000-0002-1976-7477; Kikkawa, Masahide/0000-0001-7656-8194				AMOS LA, 1975, J MOL BIOL, V99, P51, DOI 10.1016/S0022-2836(75)80158-6; BEESE L, 1987, J MOL BIOL, V194, P257, DOI 10.1016/0022-2836(87)90373-1; BERLINER E, 1995, NATURE, V373, P718, DOI 10.1038/373718a0; BRADY ST, 1991, NEURON, V7, P521, DOI 10.1016/0896-6273(91)90365-7; CHRETIEN D, 1991, BIOL CELL, V71, P161, DOI 10.1016/0248-4900(91)90062-R; DEROSIER DJ, 1970, J MOL BIOL, V52, P355, DOI 10.1016/0022-2836(70)90036-7; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; EGELMAN EH, 1986, ULTRAMICROSCOPY, V19, P367, DOI 10.1016/0304-3991(86)90096-3; HARRISON BC, 1993, NATURE, V362, P73, DOI 10.1038/362073a0; HERZOG W, 1978, EUR J BIOCHEM, V92, P1, DOI 10.1111/j.1432-1033.1978.tb12716.x; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; HIROKAWA N, 1982, J CELL BIOL, V94, P129, DOI 10.1083/jcb.94.1.129; Hirokawa Nobutaka, 1993, Current Opinion in Neurobiology, V3, P724, DOI 10.1016/0959-4388(93)90144-N; ISHIKAWA T, 1994, BIOCHEM BIOPH RES CO, V203, P951, DOI 10.1006/bbrc.1994.2274; KATO K, 1990, EUR J NEUROSCI, V2, P704, DOI 10.1111/j.1460-9568.1990.tb00460.x; KIKKAWA M, 1994, J CELL BIOL, V127, P1965, DOI 10.1083/jcb.127.6.1965; MANDELKOW EM, 1986, J CELL BIOL, V102, P1067, DOI 10.1083/jcb.102.3.1067; MANDELKOW EM, 1985, J MOL BIOL, V181, P123, DOI 10.1016/0022-2836(85)90330-4; NANGAKU M, 1994, CELL, V79, P1209, DOI 10.1016/0092-8674(94)90012-4; OKADA Y, 1995, CELL, V81, P769, DOI 10.1016/0092-8674(95)90538-3; RAY S, 1993, J CELL BIOL, V121, P1083, DOI 10.1083/jcb.121.5.1083; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; SONG YH, 1995, J CELL BIOL, V128, P81, DOI 10.1083/jcb.128.1.81; SONG YH, 1993, P NATL ACAD SCI USA, V90, P1671, DOI 10.1073/pnas.90.5.1671; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; Vale Ronald D., 1993, P175; WAKABAYASHI T, 1975, J MOL BIOL, V93, P477, DOI 10.1016/0022-2836(75)90241-7; WITMAN GB, 1986, METHOD ENZYMOL, V134, P280; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332	30	88	88	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 20	1995	376	6537					274	277		10.1038/376274a0	http://dx.doi.org/10.1038/376274a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK331	7617041				2022-12-24	WOS:A1995RK33100052
J	MIGONE, TS; LIN, JX; CERESETO, A; MULLOY, JC; O'SHEA, JJ; FRANCHINI, G; LEONARD, WJ				MIGONE, TS; LIN, JX; CERESETO, A; MULLOY, JC; O'SHEA, JJ; FRANCHINI, G; LEONARD, WJ			CONSTITUTIVELY ACTIVATED JAK-STAT PATHWAY IN T-CELLS TRANSFORMED WITH HTLV-I	SCIENCE			English	Article							VIRUS TYPE-I; RECEPTOR GAMMA-CHAIN; LEUKEMIA-LYMPHOMA; FUNCTIONAL COMPONENT; INFECTED-CELLS; IL-2 RECEPTOR; PROTEINS; LEUKOCYTES; EXPRESSION; GROWTH	Human T cell lymphotropic virus I (HTLV-I) is the etiological agent for adult T cell leukemia and tropical spastic paraparesis (also termed HTLV-I-associated myelopathy). HTLV-I-infected peripheral blood T cells exhibit an initial phase of interleukin-2 (IL-2)-dependent growth; over time, by an un known mechanism, the cells become IL-2-independent. Whereas the Jak kinases Jak1 and Jak3 and the signal transducer and activator of transcription proteins Stat3 and Stat5 are activated in normal T cells in response to IL-2, this signaling pathway was constitutively activated in HTLV-I-transformed cells. In HTLV-I-infected cord blood lymphocytes, the transition from IL-2-dependent to IL-2-independent growth correlated with the acquisition of a constitutively activated Jak-STAT pathway, which suggests that this pathway participates in HTLV-I-mediated T cell transformation.	NHLBI, MOLEC IMMUNOL LAB, BETHESDA, MD 20892 USA; NCI, TUMOR CELL BIOL LAB, BETHESDA, MD 20892 USA; NIAMSD, ARTHRITIS & RHEUMATISM BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)			Leonard, Warren/AAA-1397-2022	Cereseto, Anna/0000-0003-4453-2597				ARYA SK, 1984, SCIENCE, V223, P1086, DOI 10.1126/science.6320374; BAMFORD RN, 1994, P NATL ACAD SCI USA, V91, P4940, DOI 10.1073/pnas.91.11.4940; BEADLING C, 1994, EMBO J, V13, P5605, DOI 10.1002/j.1460-2075.1994.tb06898.x; BERNEMAN ZN, 1992, P NATL ACAD SCI USA, V89, P3005, DOI 10.1073/pnas.89.7.3005; BOUSSIOTIS VA, 1994, SCIENCE, V266, P1039, DOI 10.1126/science.7973657; BURTON JD, 1994, P NATL ACAD SCI USA, V91, P4935, DOI 10.1073/pnas.91.11.4935; CIMINALE V, 1992, J VIROL, V66, P1737, DOI 10.1128/JVI.66.3.1737-1745.1992; DANIAL PB, IN PRESS SCIENCE; FRANCHINI G, 1993, J VIROL, V67, P7701, DOI 10.1128/JVI.67.12.7701-7704.1993; Franklin Audrey A., 1995, Journal of Biomedical Science, V2, P17, DOI 10.1007/BF02257921; FRIEDMANN M, UNPUB; GALLO RC, 1986, SCI AM, V255, P88, DOI 10.1038/scientificamerican1286-88; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; HOLLSBERG P, 1992, J IMMUNOL, V148, P3256; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KAWAMURA M, 1994, P NATL ACAD SCI USA, V91, P6374, DOI 10.1073/pnas.91.14.6374; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KORALNIK IJ, 1993, J VIROL, V67, P2360, DOI 10.1128/JVI.67.4.2360-2366.1993; KORALNIK IJ, 1992, P NATL ACAD SCI USA, V89, P8813, DOI 10.1073/pnas.89.18.8813; LEONARD WJ, 1994, IMMUNOL REV, V138, P61, DOI 10.1111/j.1600-065X.1994.tb00847.x; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; MAEDA M, 1987, BLOOD, V70, P1407; MIGONE TS, UNPUB; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; MULLOY JC, UNPUB; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; POPOVIC M, 1983, P NATL ACAD SCI-BIOL, V80, P5402, DOI 10.1073/pnas.80.17.5402; ROHWER F, 1994, INT J ONCOL, V5, P1163; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; TSUDO M, 1989, P NATL ACAD SCI USA, V86, P1982, DOI 10.1073/pnas.86.6.1982; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; YAMAMOTO N, 1982, SCIENCE, V217, P737, DOI 10.1126/science.6980467; YODOI J, 1992, IMMUNOL TODAY, V13, P4; YOSHIDA M, 1987, ANNU REV IMMUNOL, V5, P541, DOI 10.1146/annurev.iy.05.040187.002545; YSSEL H, 1989, J IMMUNOL, V142, P2279	43	501	518	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 7	1995	269	5220					79	81		10.1126/science.7604283	http://dx.doi.org/10.1126/science.7604283			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RG980	7604283				2022-12-24	WOS:A1995RG98000037
J	PEARCE, MC; SHERIDAN, JW; JONES, DM; LAWRENCE, GW; MURPHY, DM; MASUTTI, B; MCCOSKER, C; DOUGLAS, V; GEORGE, D; OKEEFE, A; YOUNG, F; THOMSON, M; GORMAN, B; HANSMAN, D; HILL, PS				PEARCE, MC; SHERIDAN, JW; JONES, DM; LAWRENCE, GW; MURPHY, DM; MASUTTI, B; MCCOSKER, C; DOUGLAS, V; GEORGE, D; OKEEFE, A; YOUNG, F; THOMSON, M; GORMAN, B; HANSMAN, D; HILL, PS			CONTROL OF GROUP-C MENINGOCOCCAL DISEASE IN AUSTRALIAN ABORIGINAL CHILDREN BY MASS RIFAMPICIN CHEMOPROPHYLAXIS AND VACCINATION	LANCET			English	Article							POPULATION; CARRIAGE; VACCINES; INFANTS	An outbreak of 12 cases of meningitis, 11 caused by Neisseria meningitidis serogroup C, occurred at Doomadgee from September, 1990, to April, 1991. The incidence of meningitis was 17.55/10(3) person-years. Only children aged 1-10 years were affected. In October, 1990, or shortly thereafter, 473/509 children aged between 1 and 15 years inclusive had one dose of Mencevax AC. From the time of vaccination until April, 1991, a further eight cases occurred, six in vaccinated children. Vaccine efficacy in 1-15 year olds was calculated as 77%. Despite this, in April, 1991, the prevalence of antibody to group C polysaccharide in vaccinated children (78%) was not significantly different from that in unvaccinated children and adults. 45 nonresponders were revaccinated, and, in February, 1992, 78% had antibodies to group C polysaccharide. In April, 1991, an estimated 3.0% of the population had group C organisms, carriage being directly related to household crowding. In June, 1991, 2 months after mass prophylaxis with rifampicin, none of these individuals were carriers. In October, 1991, the carriage rate of group C organisms was 0.64%. There have been no further cases caused by the epidemic strain. Although uncrowded housing is a basic need, mass chemoprophylaxis and two doses of vaccine for children should be used in similar outbreaks.	QUEENSLAND HLTH,COMMUNICABLE DIS BRANCH,BRISBANE,QLD 4001,AUSTRALIA; AUSTRALIAN NATL UNIV,NATL CTR EPIDEMIOL & POPULAT HLTH,CANBERRA,ACT,AUSTRALIA; WITHINGTON HOSP,PUBL HLTH LAB,MANCHESTER M20 8LR,LANCS,ENGLAND; QUEENSLAND INST MED RES,HERSTON,QLD,AUSTRALIA; STATE HLTH LAB SERV,BRISBANE,QLD,AUSTRALIA; DOOMADGEE HOSP,ABORIGINAL HLTH PROGRAMME,DOOMADGEE,QLD,AUSTRALIA; MT ISA HOSP,MT ISA,QLD,AUSTRALIA; ADELAIDE CHILDRENS HOSP INC,DEPT MICROBIOL,ADELAIDE,SA,AUSTRALIA; UNIV QUEENSLAND,SCH MED,TROP HLTH PROGRAM,HERSTON,QLD,AUSTRALIA	Queensland Health; Australian National University; QIMR Berghofer Medical Research Institute; University of Queensland			Hill, Peter/F-2768-2010; Hill, Peter Stewart/AAL-8053-2020	Hill, Peter/0000-0001-7091-5108; Hill, Peter Stewart/0000-0001-7091-5108				ARTENSTEIN MS, 1969, NEW ENGL J MED, V281, P678, DOI 10.1056/NEJM196909182811210; BLAKEBROUGH IS, 1983, ANN TROP MED PARASIT, V77, P175, DOI 10.1080/00034983.1983.11811694; BUTCHER R, 1986, SAMPLING ERRORS MANU; GOLD R, 1979, J INFECT DIS, V140, P690, DOI 10.1093/infdis/140.5.690; GREENFIELD S, 1971, J INFECT DIS, V123, P67, DOI 10.1093/infdis/123.1.67; GREENWOOD BM, 1980, T ROY SOC TROP MED H, V74, P340, DOI 10.1016/0035-9203(80)90095-4; HOGUE CJR, 1983, AM J EPIDEMIOL, V118, P396, DOI 10.1093/oxfordjournals.aje.a113646; JONES DM, 1989, BRIT MED J, V298, P542, DOI 10.1136/bmj.298.6673.542; KAISER AB, 1974, J INFECT DIS, V130, P217, DOI 10.1093/infdis/130.3.217; Levy P, 1980, SAMPLING HLTH PROFES; MUMFORD RS, 1974, LANCET, V1, P1275; PELTOLA H, 1985, PEDIATRICS, V76, P91; Pizzi M, 1944, AM J PUBLIC HEALTH N, V34, P231, DOI 10.2105/AJPH.34.3.231; RAKE G, 1934, J EXP MED, V59, P533; STUART JM, 1989, BRIT MED J, V298, P569, DOI 10.1136/bmj.298.6673.569; WEIDMER CE, 1971, J INFECT DIS, V124, P172, DOI 10.1093/infdis/124.2.172	16	18	20	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 1	1995	346	8966					20	23		10.1016/S0140-6736(95)92651-8	http://dx.doi.org/10.1016/S0140-6736(95)92651-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RF985	7603139				2022-12-24	WOS:A1995RF98500009
J	COSO, OA; CHIARIELLO, M; YU, JC; TERAMOTO, H; CRESPO, P; XU, NG; MIKI, T; GUTKIND, JS				COSO, OA; CHIARIELLO, M; YU, JC; TERAMOTO, H; CRESPO, P; XU, NG; MIKI, T; GUTKIND, JS			THE SMALL GTP-BINDING PROTEINS RAC1 AND CDC42 REGULATE THE ACTIVITY OF THE JNK/SAPK SIGNALING PATHWAY	CELL			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; SERINE THREONINE KINASE; DBL-ONCOGENE PRODUCT; MOLECULAR-CLONING; ACTIVATING PROTEINS; CELL-PROLIFERATION; PROTO-ONCOGENE; RAS; RHO; PHOSPHORYLATES	c-Jun amino-terminal kinases (JNKs) and mitogen-activated protein kinases (MAPKs) are closely related; however, they are independently regulated by a variety of environmental stimuli. Although molecules linking growth factor receptors to MAPKs have been recently identified, little is known about pathways controlling JNK activation. Here, we show that in COS-7 cells, activated Rac1 effectively stimulates MAPK but poorly induces JNK activity. In contrast, mutationally activated Rac1. and Cdc42 GTPases potently activate JNK without affecting MAPK, and oncogenic guanine nucleotide exchange factors for these Rho-like proteins selectively stimulate JNK activity. Furthermore, expression of inhibitory molecules for Rho-related GTPases and dominant negative mutants of Rac1 and Cdc42 block JNK activation by oncogenic exchange factors or after induction by inflammatory cytokines and growth factors. Taken together, these findings strongly support a critical role for Rac1 and Cdc42 in controlling the JNK signaling pathway.	NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	COSO, OA (corresponding author), NIDR,CELLULAR DEV & ONCOL LAB,MOLEC SIGNALING UNIT,BETHESDA,MD 20892, USA.		Gutkind, J. Silvio/A-1053-2009; Chiariello, Mario/O-3642-2014; Gutkind, J. Silvio/J-1201-2016; Crespo, Piero/M-3273-2014	Chiariello, Mario/0000-0001-8434-5177; Gutkind, J. Silvio/0000-0002-5150-4482; Crespo, Piero/0000-0003-2825-7783				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BARDWELL L, 1994, DEV BIOL, V166, P363, DOI 10.1006/dbio.1994.1323; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; EVA A, 1988, P NATL ACAD SCI USA, V85, P2061, DOI 10.1073/pnas.85.7.2061; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCCORMICK F, 1991, COLD SH Q B, V56, P237; McCormick Frank, 1994, Trends in Cell Biology, V4, P347, DOI 10.1016/0962-8924(94)90075-2; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SASAKI T, 1993, J BIOL CHEM, V268, P23959; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; UEDA T, 1990, J BIOL CHEM, V265, P9373; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YAN MH, 1994, NATURE, V372, P798	52	1560	1576	2	36	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 30	1995	81	7					1137	1146		10.1016/S0092-8674(05)80018-2	http://dx.doi.org/10.1016/S0092-8674(05)80018-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RG910	7600581	Bronze			2022-12-24	WOS:A1995RG91000018
J	BANFIELD, DK; LEWIS, MJ; PELHAM, HRB				BANFIELD, DK; LEWIS, MJ; PELHAM, HRB			A SNARE-LIKE PROTEIN REQUIRED FOR TRAFFIC THROUGH THE GOLGI-COMPLEX	NATURE			English	Article							INTEGRAL MEMBRANE-PROTEIN; VESICULAR TRANSPORT; ENDOPLASMIC-RETICULUM; SECRETORY PATHWAY; YEAST GENES; APPARATUS; ER; GLYCOPROTEIN; RECEPTORS; RETRIEVAL	THE secretory pathway of eukaryotic cells comprises several distinct membrane-bound compartments which are interconnected by transport vesicles that pinch off from one membrane and fuse with the next. Targeting of these vesicles is mediated in part by interactions between integral membrane proteins on the vesicles and target organelles (soluble NSF attachment protein receptors (SNAREs)), termed v-SNAREs and t-SNAREs, respectively(1-4). SNAREs required for endoplasmic reticulum (ER)-Golgi transport and for fusion of vesicles with the plasma membrane are already known. Here we identify two yeast membrane proteins that show genetic interactions with Sed5p, which is the t-SNARE for ER-Golgi traffic(3,4). One of these membrane proteins, Sft1p, is structurally similar to the known v-SNAREs and is required for transport from an early to a later Golgi compartment. Our results indicate that a single t-SNARE can control more than one transport step, and provide the first candidate for a SNARE involved in intra-Golgi traffic.	MRC, MOLEC BIOL LAB, CAMBRIDGE CB2 2QH, ENGLAND	MRC Laboratory Molecular Biology								BANFIELD DK, 1994, J CELL BIOL, V127, P357, DOI 10.1083/jcb.127.2.357; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; DEAN N, 1990, J CELL BIOL, V111, P369, DOI 10.1083/jcb.111.2.369; FRANZUSOFF A, 1989, EMBO J, V8, P2695, DOI 10.1002/j.1460-2075.1989.tb08410.x; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; HARDWICK KG, 1990, EMBO J, V9, P623, DOI 10.1002/j.1460-2075.1990.tb08154.x; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; PELHAM HRB, 1993, CELL, V73, P425, DOI 10.1016/0092-8674(93)90128-D; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SWEET DJ, 1992, EMBO J, V11, P423, DOI 10.1002/j.1460-2075.1992.tb05071.x	20	130	133	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 29	1995	375	6534					806	809		10.1038/375806a0	http://dx.doi.org/10.1038/375806a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF989	7596416				2022-12-24	WOS:A1995RF98900083
J	QIAN, XQ; JEON, CJ; YOON, HS; AGARWAL, K; WEISS, MA				QIAN, XQ; JEON, CJ; YOON, HS; AGARWAL, K; WEISS, MA			STRUCTURE OF A NEW NUCLEIC-ACID-BINDING MOTIF IN EUKARYOTIC TRANSCRIPTIONAL ELONGATION-FACTOR TFIIS	NATURE			English	Article							RNA POLYMERASE-II; ZINC FINGER; CRYSTAL-STRUCTURE; GLUCOCORTICOID RECEPTOR; DNA RECOGNITION; DOMAINS; PROTEIN; COMPLEX; SUBUNIT; BLOCK	TRANSCRIPTIONAL elongation involves dynamic interactions among RNA polymerase and single-stranded and double-stranded nucleic acids in the ternary complex1-4. In prokaryotes its regulation provides an important mechanism of genetic control1. Analogous eukaryotic mechanisms are not well understood5, but may control expression of proto-oncogenes6,7 and viruses, including the human immunodeficiency virus HIV-1 (ref. 8). The highly conserved eukaryotic transcriptional elongation factor TFIIS9 enables RNA polymerase II (RNAPII) to read though pause or termination sites, nucleosomes and sequence-specific DNA-binding proteins10-14 . Two distinct domains of human TFIIS, which bind RNAPII and nucleic acids, regulate read-through10 and possibly nascent transcript cleavage11-15. Here we describe the three-dimensional NMR16 structure of a Cys4 nucleic-acid-binding domain from human TFIIS9,10. Unlike previously characterized zinc modules17-21, which contain an alpha-helix, this structure consists of a three-stranded beta-sheet. Analogous Cys4, structural motifs may occur in other proteins involved in DNA or RNA transactions22-24, including RNAPII itself25. This new structure, designated the Zn ribbon, extends the repertoire of Zn-mediated peptide architectures26 and highlights the growing recognition of the beta-sheet as a motif of nucleic-acid recognition27,28.	UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT CHEM,CHICAGO,IL 60637; MASSACHUSETTS GEN HOSP,DEPT MED,BOSTON,MA 02114	University of Chicago; University of Chicago; Harvard University; Massachusetts General Hospital	QIAN, XQ (corresponding author), HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115, USA.		Yoon, Ho Sup/A-2193-2011	Yoon, Ho Sup/0000-0002-8243-3904				AGARWAL K, 1991, BIOCHEMISTRY-US, V30, P7842, DOI 10.1021/bi00245a026; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; CLORE GM, 1991, PROG NUCL MAG RES SP, V23, P43, DOI 10.1016/0079-6565(91)80002-J; DAUBE SS, 1992, SCIENCE, V258, P1320, DOI 10.1126/science.1280856; DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; FEINBERG MB, 1991, P NATL ACAD SCI USA, V88, P4045, DOI 10.1073/pnas.88.9.4045; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; KASSAVETIS GA, 1993, SCIENCE, V259, P944, DOI 10.1126/science.7679800; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MAMORSTEIN R, 1992, NATURE, V356, P408; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; OHKUMA Y, 1991, NATURE, V354, P398, DOI 10.1038/354398a0; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; QIAN X, IN PRESS BIOCHEMISTR; QIAN XQ, 1992, BIOCHEMISTRY-US, V31, P7463, DOI 10.1021/bi00148a006; REINES D, 1989, J BIOL CHEM, V264, P10799; REINES D, 1993, P NATL ACAD SCI USA, V90, P1917, DOI 10.1073/pnas.90.5.1917; RENIES D, 1992, J BIOL CHEM, V267, P3795; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; SOMERS WS, 1992, NATURE, V359, P387, DOI 10.1038/359387a0; VALLEE BL, 1991, P NATL ACAD SCI USA, V88, P999, DOI 10.1073/pnas.88.3.999; VONHIPPEL PH, 1992, SCIENCE, V255, P809, DOI 10.1126/science.1536005; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843; WOYCHIK NA, 1991, J BIOL CHEM, V266, P19053; YANOFSKY C, 1988, J BIOL CHEM, V263, P609; YOO OJ, 1991, NUCLEIC ACIDS RES, V19, P1073, DOI 10.1093/nar/19.5.1073	30	111	118	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 16	1993	365	6443					277	279		10.1038/365277a0	http://dx.doi.org/10.1038/365277a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LX471	7626141	Green Accepted			2022-12-24	WOS:A1993LX47100062
J	YAGAMIHIROMASA, T; SATO, T; KURISAKI, T; KAMIJO, K; NABESHIMA, Y; FUJISAWASEHARA, A				YAGAMIHIROMASA, T; SATO, T; KURISAKI, T; KAMIJO, K; NABESHIMA, Y; FUJISAWASEHARA, A			A METALLOPROTEASE-DISINTEGRIN PARTICIPATING IN MYOBLAST FUSION	NATURE			English	Article							PLATELET-AGGREGATION INHIBITOR; CELL-ADHESION MOLECULE; SPERM-EGG FUSION; HEMORRHAGIC PROTEIN; N-CADHERIN; MYOGENESIS; INTEGRIN; SEQUENCE; VENOM; PURIFICATION	SKELETAL muscle development involves the formation of multinucleated myotubes. This is thought to proceed by the induction of differentiation (acquisition of fusion competence) of myoblast cells, their aggregation, and union of their plasma membranes(1-3) Various membrane proteins including N-(4,5) and M-cadherins(6), N-(5,7-9) and V-CAMs(10) and integrins(10,11) participate in myotube formation, but the molecular mechanisms of muscle cell fusion are poorly understood. Here we report the identification of three new, myoblast-expressed gene products, mcltrin-alpha, beta and gamma, with homology to both viper haemorrhagic factors(12,13) and fertilin (PH-30)(14,15), a membrane protein involved in egg-sperm fusion. Meltrin-alpha, a member of the metalloproteinase/disintegrin protein family, appears to be required for myotube formation. Involvement of a fertilin-related protein in myogenesis suggests that there are common mechanisms in gamete and myoblast fusion.	NATL CTR NEUROL & PSYCHIAT,NATL INST NEUROSCI,DIV MOLEC GENET,KODAIRA,TOKYO 187,JAPAN; CHIBA UNIV,FAC SCI,DEPT BIOL,CHIBA 260,JAPAN	National Center for Neurology & Psychiatry - Japan; Chiba University								AU LC, 1991, BIOCHEM BIOPH RES CO, V181, P585, DOI 10.1016/0006-291X(91)91230-A; BLOBEL CP, 1990, J CELL BIOL, V111, P69, DOI 10.1083/jcb.111.1.69; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; COUCH CB, 1983, CELL, V32, P257, DOI 10.1016/0092-8674(83)90516-0; DICKSON G, 1990, NATURE, V344, P348, DOI 10.1038/344348a0; DONALIES M, 1991, P NATL ACAD SCI USA, V88, P8024, DOI 10.1073/pnas.88.18.8024; EMI M, 1993, NAT GENET, V5, P151, DOI 10.1038/ng1093-151; GOULD RJ, 1990, P SOC EXP BIOL MED, V195, P168, DOI 10.3181/00379727-195-43129B; KNUDSEN KA, 1990, DEV BIOL, V138, P159, DOI 10.1016/0012-1606(90)90185-L; KNUDSEN KA, 1990, EXP CELL RES, V188, P175, DOI 10.1016/0014-4827(90)90157-6; KNUDSEN KA, 1992, MEMBRANE FUSION, P601; LAMB RA, 1993, VIROLOGY, V197, P1, DOI 10.1006/viro.1993.1561; MEGE RM, 1992, J CELL SCI, V103, P897; MENKO AS, 1987, CELL, V51, P51, DOI 10.1016/0092-8674(87)90009-2; MINTZ B, 1967, P NATL ACAD SCI USA, V58, P592, DOI 10.1073/pnas.58.2.592; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MORRISON TG, 1988, VIRUS RES, V10, P113, DOI 10.1016/0168-1702(88)90010-X; MYLES DG, 1994, P NATL ACAD SCI USA, V91, P4195, DOI 10.1073/pnas.91.10.4195; NEEPER MP, 1990, NUCLEIC ACIDS RES, V18, P4255, DOI 10.1093/nar/18.14.4255; PAINE MJI, 1992, J BIOL CHEM, V267, P22869; PECK D, 1993, J CELL BIOL, V123, P1587, DOI 10.1083/jcb.123.6.1587; PERRY ACF, 1992, BIOCHEM J, V286, P671, DOI 10.1042/bj2860671; PRIMAKOFF P, 1987, J CELL BIOL, V104, P141, DOI 10.1083/jcb.104.1.141; ROSEN GD, 1992, CELL, V69, P1107, DOI 10.1016/0092-8674(92)90633-N; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAKEYA H, 1990, J BIOL CHEM, V265, P16068; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YAFFE D, 1965, DEV BIOL, V11, P300, DOI 10.1016/0012-1606(65)90062-X; YOSHIDA S, 1990, INT IMMUNOL, V2, P585, DOI 10.1093/intimm/2.6.585	30	418	439	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 19	1995	377	6550					652	656		10.1038/377652a0	http://dx.doi.org/10.1038/377652a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA275	7566181				2022-12-24	WOS:A1995TA27500059
J	CHIN, DP; HOPEWELL, PC				CHIN, DP; HOPEWELL, PC			HOW TO TREAT BACTEREMIC MYCOBACTERIUM-AVIUM COMPLEX DISEASE	LANCET			English	Editorial Material							INFECTION; AIDS; CIPROFLOXACIN; ETHAMBUTOL; RIFAMPIN		UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	CHIN, DP (corresponding author), SAN FRANCISCO GEN HOSP,DIV PULM & CRIT CARE MED,SAN FRANCISCO,CA 94110, USA.							CHAISSON RE, 1994, ANN INTERN MED, V121, P905, DOI 10.7326/0003-4819-121-12-199412150-00001; CHIN DP, 1994, J INFECT DIS, V170, P578, DOI 10.1093/infdis/170.3.578; CHIU J, 1990, ANN INTERN MED, V113, P358, DOI 10.7326/0003-4819-113-5-358; DAUTZENBERG B, 1991, AM REV RESPIR DIS, V144, P564, DOI 10.1164/ajrccm/144.3_Pt_1.564; GORDON SM, 1993, J INFECT DIS, V168, P1559, DOI 10.1093/infdis/168.6.1559; HORSBURGH CR, 1991, NEW ENGL J MED, V324, P1332, DOI 10.1056/NEJM199105093241906; ISEMAN MD, 1991, AM REV RESPIR DIS, V143, P697, DOI 10.1164/ajrccm/143.4_Pt_1.697; KEMPER CA, 1994, J INFECT DIS, V170, P157, DOI 10.1093/infdis/170.1.157; KEMPER CA, 1992, ANN INTERN MED, V116, P466, DOI 10.7326/0003-4819-116-6-466; MASUR H, 1993, NEW ENGL J MED, V329, P898, DOI 10.1056/NEJM199309163291228; SHAFRAN SD, 1994, NEW ENGL J MED, V330, P438, DOI 10.1056/NEJM199402103300616; WALLACE RJ, 1995, J INFECT DIS, V171, P747, DOI 10.1093/infdis/171.3.747; YOUNG LS, 1991, LANCET, V338, P1107, DOI 10.1016/0140-6736(91)91965-W	13	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 7	1995	346	8980					920	921		10.1016/S0140-6736(95)91552-4	http://dx.doi.org/10.1016/S0140-6736(95)91552-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY808	7564723				2022-12-24	WOS:A1995RY80800004
J	RYLANCE, G; BOWEN, C; RYLANCE, J				RYLANCE, G; BOWEN, C; RYLANCE, J			MEASLES AND RUBELLA IMMUNIZATION - INFORMATION AND CONSENT IN CHILDREN	BRITISH MEDICAL JOURNAL			English	Article									KING EDWARD VI CAMP HILL SCH GIRLS,BIRMINGHAM B14 7QJ,W MIDLANDS,ENGLAND; KING EDWARD VI CAMP HILL SCH BOYS,BIRMINGHAM B14 7QJ,W MIDLANDS,ENGLAND		RYLANCE, G (corresponding author), CHILDRENS HOSP,LADYWOOD MIDDLEWAY,BIRMINGHAM B16 8ET,W MIDLANDS,ENGLAND.		Rylance, Jamie/ABD-9314-2021	Rylance, Jamie/0000-0002-2323-3611				Alderson P., 1993, CHILDRENS CONSENT SU; 1994, DOH PL CNO9412 DEP H; 1994, DOH1525 95M994 DEP H; 1994, 9000M894 DEP HLTH HL	4	8	8	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 7	1995	311	7010					923	924						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ237	7580552	Green Published			2022-12-24	WOS:A1995RZ23700023
J	CRANE, BR; SIEGEL, LM; GETZOFF, ED				CRANE, BR; SIEGEL, LM; GETZOFF, ED			SULFITE REDUCTASE STRUCTURE AT 1.6 ANGSTROM - EVOLUTION AND CATALYSIS FOR REDUCTION OF INORGANIC ANIONS	SCIENCE			English	Article							ESCHERICHIA-COLI HEMOFLAVOPROTEIN; ELECTRON-PARAMAGNETIC-RES; SPINACH NITRITE REDUCTASE; PROSTHETIC GROUPS; HEMOPROTEIN SUBUNIT; MACROMOLECULAR CRYSTALLOGRAPHY; DESULFOVIBRIO-VULGARIS; SALMONELLA-TYPHIMURIUM; ANOMALOUS DIFFRACTION; SYNCHROTRON RADIATION	Fundamental chemical transformations for biogeochemical cycling of sulfur and nitrogen are catalyzed by sulfite and nitrite reductases. The crystallographic structure of Escherichia coli sulfite reductase hemoprotein (SiRHP), which catalyzes the concerted six-electron reductions of sulfite to sulfide and nitrite to ammonia, was solved with multiwavelength anomalous diffraction (MAD) of the native siroheme and Fe4S4 cluster cofactors, multiple isomorphous replacement, and selenomethionine sequence markers. Twofold symmetry within the 84-kilodalton polypeptide generates a distinctive three-domain alpha/beta fold that controls cofactor assembly and reactivity. Homology regions conserved between the symmetry-related halves of SiRHP and among other sulfite and nitrite reductases revealed key residues for stability and function, and identified a sulfite or nitrite reductase repeat (SNiRR) common to a redox-enzyme superfamily. The saddle-shaped siroheme shares a cysteine thiolate ligand with the Fe4S4 cluster and ligates an unexpected phosphate anion. In the substrate complex, sulfite displaces phosphate and binds to siroheme iron through sulfur. An extensive hydrogen-bonding network of positive side chains, water molecules, and siroheme carboxylates activates S-O bonds for reductive cleavage.	Scripps Res Inst, RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	Scripps Research Institute; Duke University					NIGMS NIH HHS [GM37684, GM212226] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; ARGOS P, 1988, PROTEIN ENG, V2, P101, DOI 10.1093/protein/2.2.101; BACK E, 1988, MOL GEN GENET, V212, P20, DOI 10.1007/BF00322440; BOMINAAR EL, 1995, J AM CHEM SOC, V117, P6976, DOI 10.1021/ja00131a021; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; CAMERON EM, 1982, NATURE, V296, P145, DOI 10.1038/296145a0; CAMPBELL WH, 1990, TRENDS BIOCHEM SCI, V15, P315, DOI 10.1016/0968-0004(90)90021-3; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHANG CK, 1981, P NATL ACAD SCI USA, V78, P2652, DOI 10.1073/pnas.78.5.2652; CHRISTNER JA, 1983, J BIOL CHEM, V258, P1147; CLINE JF, 1985, BIOCHEMISTRY-US, V25, P7942; COLE JA, 1988, 42ND S SOC GEN MICR; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; CRANE BR, UNPUB; CRAWFORD NM, 1988, P NATL ACAD SCI USA, V85, P5006, DOI 10.1073/pnas.85.14.5006; DAHL C, 1993, J GEN MICROBIOL, V139, P1817, DOI 10.1099/00221287-139-8-1817; DAY EP, 1988, BIOCHEMISTRY-US, V27, P2126, DOI 10.1021/bi00406a046; FUREY W, 1990, P AM CRYSTALLOGRAPHI, P73; GARRETT RM, 1994, J BIOL CHEM, V269, P272; GILSON MK, 1985, J MOL BIOL, V183, P503; GISSELMANN G, 1993, BIOCHIM BIOPHYS ACTA, V1144, P102, DOI 10.1016/0005-2728(93)90037-G; HAN SW, 1989, BIOCHEMISTRY-US, V28, P5461, DOI 10.1021/bi00439a022; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HENDRICKSON WA, 1988, PROTEINS, V4, P77, DOI 10.1002/prot.340040202; HENDRICKSON WA, 1989, P NATL ACAD SCI USA, V86, P2190, DOI 10.1073/pnas.86.7.2190; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; HUYNH BH, 1984, J BIOL CHEM, V259, P5373; JANICK PA, 1982, BIOCHEMISTRY-US, V21, P3538, DOI 10.1021/bi00258a003; JANICK PA, 1983, BIOCHEMISTRY-US, V22, P396, DOI 10.1021/bi00271a025; JOHNSTONE IL, 1990, GENE, V90, P181, DOI 10.1016/0378-1119(90)90178-T; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KAUFMAN J, 1993, BIOCHEMISTRY-US, V32, P2853, DOI 10.1021/bi00062a017; Kinghorn J. R., 1989, Molecular and genetic aspects of nitrate assimilation., P385; KRUEGER RJ, 1982, BIOCHEMISTRY-US, V21, P2892, DOI 10.1021/bi00541a014; LEE J, 1973, J BACTERIOL, V259, P15373; LESLIE AGW, 1986, CCP4 NEWSLETTER, V18, P33; LIDE DR, 1990, HDB CHEM PHYSICS; LUQUE I, 1993, PLANT MOL BIOL, V21, P1201, DOI 10.1007/BF00023618; MADDEN JF, 1989, BIOCHEMISTRY-US, V28, P5471, DOI 10.1021/bi00439a023; MCREE DE, 1986, J BIOL CHEM, V261, P277; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; MOURA I, 1988, J AM CHEM SOC, V110, P1075, DOI 10.1021/ja00212a013; MOURA I, 1986, BIOCHEM BIOPH RES CO, V141, P1032, DOI 10.1016/S0006-291X(86)80148-6; MURPHY MJ, 1973, J BIOL CHEM, V248, P6911; OSTROWSKI J, 1989, J BIOL CHEM, V264, P15726; OSTROWSKI J, 1989, J BIOL CHEM, V264, P15796; PAHLER A, 1990, ACTA CRYSTALLOGR A, V46, P537, DOI 10.1107/S0108767390002379; PECK HD, 1988, S SOC GEN MICROBIOL, V42, P99; Postgate J.R, 1979, SULPHATE REDUCING BA; Price C. C., 1962, SULFUR BONDING; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RUTTEN M, 1972, ORIGIN LIFE NATURAL; SCHEIDT WR, 1981, CHEM REV, V81, P543, DOI 10.1021/cr00046a002; Schidlowski M., 1983, P149; SEKI Y, 1979, J BIOCHEM-TOKYO, V86, P273; SEKI Y, 1981, J BIOCHEM-TOKYO, V90, P1487, DOI 10.1093/oxfordjournals.jbchem.a133615; SIEGEL LM, 1982, J BIOL CHEM, V257, P6343; SIEGEL LM, 1974, J BIOL CHEM, V249, P1587; SIEGEL LM, 1973, J BIOL CHEM, V248, P251; SIEGEL LM, 1974, J BIOL CHEM, V249, P1572; SIEGEL LM, 1975, METABOLIC PATHWAYS, V7, P217; Singleton Jr R., 1993, SULFATE REDUCING BAC; SORIANO A, 1995, J AM CHEM SOC, V117, P4724, DOI 10.1021/ja00121a038; TAN J, 1991, BIOCHEMISTRY-US, V30, P9900, DOI 10.1021/bi00105a013; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; UPSON C, 1989, IEEE COMPUT GRAPH, V9, P30, DOI 10.1109/38.31462; Wray J.L., 1989, MOL GENETIC ASPECTS; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648; YOUNG LJ, 1988, BIOCHEMISTRY-US, V27, P2790, DOI 10.1021/bi00408a020	74	281	287	2	49	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 6	1995	270	5233					59	67		10.1126/science.270.5233.59	http://dx.doi.org/10.1126/science.270.5233.59			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY302	7569952				2022-12-24	WOS:A1995RY30200031
J	ADAMS, MD; KERLAVAGE, AR; FLEISCHMANN, RD; FULDNER, RA; BULT, CJ; LEE, NH; KIRKNESS, EF; WEINSTOCK, KG; GOCAYNE, JD; WHITE, O; SUTTON, G; BLAKE, JA; BRANDON, RG; CHIU, MW; CLAYTON, RA; CLINE, RT; COTTON, MD; EARLEHUGHES, J; FINE, LD; FITZGERALD, LM; FITZHUGH, WM; FRITCHMAN, JL; GEOGHAGEN, NSM; GLODEK, A; GNEHM, CL; HANNA, MC; HEDBLOM, E; HINKLE, PS; KELLEY, JM; KLIMEK, KM; KELLEY, JC; LIU, LI; MARMAROS, SM; MERRICK, JM; MORENOPALANQUES, RF; MCDONALD, LA; NGUYEN, DT; PELLEGRINO, SM; PHILLIPS, CA; RYDER, SE; SCOTT, JL; SAUDEK, DM; SHIRLEY, R; SMALL, KV; SPRIGGS, TA; UTTERBACK, TR; WELDMAN, JF; LI, Y; BARTHLOW, R; BEDNARIK, DP; CAO, LA; CEPEDA, MA; COLEMAN, TA; COLLINS, EJ; DIMKE, D; FENG, P; FERRIE, A; FISCHER, C; HASTINGS, GA; HE, WW; HU, JS; HUDDLESTON, KA; GREENE, JM; GRUBER, J; HUDSON, P; KIM, A; KOZAK, DL; KUNSCH, C; JI, HJ; LI, HD; MEISSNER, PS; OLSEN, H; RAYMOND, L; WEI, YF; WING, J; XU, C; YU, GL; RUBEN, SM; DILLON, PJ; FANNON, MR; ROSEN, CA; HASELTINE, WA; FIELDS, C; FRASER, CM; VENTER, JC				ADAMS, MD; KERLAVAGE, AR; FLEISCHMANN, RD; FULDNER, RA; BULT, CJ; LEE, NH; KIRKNESS, EF; WEINSTOCK, KG; GOCAYNE, JD; WHITE, O; SUTTON, G; BLAKE, JA; BRANDON, RG; CHIU, MW; CLAYTON, RA; CLINE, RT; COTTON, MD; EARLEHUGHES, J; FINE, LD; FITZGERALD, LM; FITZHUGH, WM; FRITCHMAN, JL; GEOGHAGEN, NSM; GLODEK, A; GNEHM, CL; HANNA, MC; HEDBLOM, E; HINKLE, PS; KELLEY, JM; KLIMEK, KM; KELLEY, JC; LIU, LI; MARMAROS, SM; MERRICK, JM; MORENOPALANQUES, RF; MCDONALD, LA; NGUYEN, DT; PELLEGRINO, SM; PHILLIPS, CA; RYDER, SE; SCOTT, JL; SAUDEK, DM; SHIRLEY, R; SMALL, KV; SPRIGGS, TA; UTTERBACK, TR; WELDMAN, JF; LI, Y; BARTHLOW, R; BEDNARIK, DP; CAO, LA; CEPEDA, MA; COLEMAN, TA; COLLINS, EJ; DIMKE, D; FENG, P; FERRIE, A; FISCHER, C; HASTINGS, GA; HE, WW; HU, JS; HUDDLESTON, KA; GREENE, JM; GRUBER, J; HUDSON, P; KIM, A; KOZAK, DL; KUNSCH, C; JI, HJ; LI, HD; MEISSNER, PS; OLSEN, H; RAYMOND, L; WEI, YF; WING, J; XU, C; YU, GL; RUBEN, SM; DILLON, PJ; FANNON, MR; ROSEN, CA; HASELTINE, WA; FIELDS, C; FRASER, CM; VENTER, JC			INITIAL ASSESSMENT OF HUMAN GENE DIVERSITY AND EXPRESSION PATTERNS BASED UPON 83-MILLION NUCLEOTIDES OF CDNA SEQUENCE	NATURE			English	Article							CAENORHABDITIS-ELEGANS; HUMAN BRAIN; TAGS; DNA; LIBRARY; IDENTIFICATION; CLONES; EFFICIENT; INVENTORY; ALGORITHM	In an effort to identify new genes and analyse their expression patterns, 174,472 partial complementary DNA sequences (expressed sequence tags (ESTs)), totalling more than 52 million nucleotides of human DNA sequence, have been generated from 300 cDNA libraries constructed from 37 distinct organs and tissues. These ESTs have been combined with an additional 118,406 ESTs from the database dbEST, for a total of 83 million nucleotides, and treated as a shotgun sequence assembly project. The assembly process yielded 29,599 distinct tentative human consensus (THC) sequences and 58,384 non-overlapping ESTs. Of these 87,983 distinct sequences, 10,214 further characterize previously known genes based on statistically significant similarity to sequences in the available databases; the remainder identify previously unknown genes. Thirty tissues were sampled by over 1,000 ESTs each; only eight genes were matched by ESTs from all 30 tissues, and 227 genes were represented in 20 or more of the tissues sampled with more than 1,000 ESTs. Approximately 40% of identified human genes appear to be associated with basic energy metabolism, cell structure, homeostasis and cell division, 22% with RNA and protein synthesis and processing, and 12% with cell signalling and communication.	INST GENOM RES, ROCKVILLE, MD 20850 USA; HUMAN GENOME SCI INC, ROCKVILLE, MD 20850 USA	J. Craig Venter Institute; GlaxoSmithKline; Human Genome Sciences Inc			Bednarik, Daniel/GRN-7985-2022	Fredrikson, Karin/0000-0001-7360-4276; Fraser, Claire/0000-0003-1462-2428; Blake, Judith/0000-0001-8522-334X; Fields, Chris/0000-0002-4812-0744; Kerlavage, Anthony/0000-0002-3954-9653				ADAMS MD, 1993, NAT GENET, V4, P256, DOI 10.1038/ng0793-256; ADAMS MD, 1993, NAT GENET, V4, P373, DOI 10.1038/ng0893-373; ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ADAMS MD, 1994, NATURE, V368, P474, DOI 10.1038/368474a0; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; AFFARA NA, 1994, GENOMICS, V22, P205, DOI 10.1006/geno.1994.1363; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AUFFRAY C, 1995, CR ACAD SCI III-VIE, V318, P263; BENSON D, 1993, NUCLEIC ACIDS RES, V21, P2963, DOI 10.1093/nar/21.13.2963; BOGUSKI MS, 1995, NAT GENET, V10, P369, DOI 10.1038/ng0895-369; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; BRUTLAG DL, 1993, COMPUT CHEM, V17, P203, DOI 10.1016/0097-8485(93)85011-Z; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAVERIE JM, 1992, GENOMICS, V12, P838, DOI 10.1016/0888-7543(92)90321-I; CLAVERIE JM, 1994, AUTOMATED DNA SEQUEN; COHEN D, 1995, NATURE, V377, P321; COLLET C, 1994, BIOCHEM GENET, V32, P181, DOI 10.1007/BF00554621; CUTICCHIA AJ, 1993, NUCLEIC ACIDS RES, V21, P3003, DOI 10.1093/nar/21.13.3003; DUBNICK M, 1992, COMPUT APPL BIOSCI, V8, P601; DURKIN AS, 1994, CYTOGENET CELL GENET, V65, P86, DOI 10.1159/000133606; FIELDS C, 1994, NAT GENET, V7, P345, DOI 10.1038/ng0794-345; FIELDS C, 1994, BIOCHEM BIOPH RES CO, V198, P288, DOI 10.1006/bbrc.1994.1040; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; GIESER L, 1992, GENOMICS, V13, P873, DOI 10.1016/0888-7543(92)90173-P; GREEN P, 1993, SCIENCE, V259, P1711, DOI 10.1126/science.8456298; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HAY B, 1992, STRATEGIES, V5, P16; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; HOFTE H, 1993, PLANT J, V4, P1051, DOI 10.1046/j.1365-313X.1993.04061051.x; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; HOOG C, 1991, NUCLEIC ACIDS RES, V19, P6123, DOI 10.1093/nar/19.22.6123; HORNES E, 1990, GENET ANAL-BIOMOL E, V7, P145, DOI 10.1016/0735-0651(90)90028-E; KEITH CS, 1993, PLANT PHYSIOL, V101, P329, DOI 10.1104/pp.101.1.329; KERLAVAGE AR, IN PRESS ENG MED BIO, V14; KHAN AS, 1992, NAT GENET, V2, P180, DOI 10.1038/ng1192-180; KHAN WN, 1992, GENOMICS, V12, P780, DOI 10.1016/0888-7543(92)90309-G; KIM CW, 1993, J MOL BIOL, V231, P960, DOI 10.1006/jmbi.1993.1345; KRAUSE M, 1989, J MOL BIOL, V208, P381, DOI 10.1016/0022-2836(89)90503-2; LEE NH, INPRESS P NATN ACAD; LIEW CC, 1993, J MOL CELL CARDIOL, V25, P891, DOI 10.1006/jmcc.1993.1101; LIEW CC, 1994, P NATL ACAD SCI USA, V91, P10645, DOI 10.1073/pnas.91.22.10645; MATSUBARA K, 1993, GENE, V135, P265, DOI 10.1016/0378-1119(93)90076-F; MCCOMBIE WR, 1992, NAT GENET, V1, P124, DOI 10.1038/ng0592-124; MCCOMBIE WR, 1993, DNA SEQ DNA SEQ MAP, V2, P289; NEWMAN T, 1994, PLANT PHYSIOL, V106, P1241, DOI 10.1104/pp.106.4.1241; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; OKUBO K, 1992, NAT GENET, V2, P173, DOI 10.1038/ng1192-173; Okubo K, 1994, DNA Res, V1, P37, DOI 10.1093/dnares/1.1.37; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARK YS, 1993, PLANT PHYSIOL, V103, P359, DOI 10.1104/pp.103.2.359; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POLYMEROPOULOS MH, 1993, NAT GENET, V4, P381, DOI 10.1038/ng0893-381; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SLIGHTOM JL, 1980, CELL, V21, P627, DOI 10.1016/0092-8674(80)90426-2; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; SOARES MB, 1994, P NATL ACAD SCI USA, V91, P9228, DOI 10.1073/pnas.91.20.9228; SUTTON GG, IN PRESS GENOME SCI; TAKEDA J, 1993, HUM MOL GENET, V2, P1793, DOI 10.1093/hmg/2.11.1793; TSAI JY, 1994, NAT GENET, V8, P321, DOI 10.1038/ng1294-321; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; UCHIMIYA H, 1992, PLANT J, V2, P1005, DOI 10.1111/j.1365-313X.1992.01005.x; UTTERBACK T, IN PRESS GENOME SCI; VIGILANT L, 1991, SCIENCE, V253, P1503, DOI 10.1126/science.1840702; WARD CJ, 1994, CELL, V77, P881; WATERSTON R, 1992, NAT GENET, V1, P114, DOI 10.1038/ng0592-114; Watson J. D., 1987, MOL BIOL GENE; WHITE O, 1993, NUCLEIC ACIDS RES, V21, P3829, DOI 10.1093/nar/21.16.3829; WILKIE TM, 1992, NAT GENET, V1, P85, DOI 10.1038/ng0592-85	68	727	868	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 28	1995	377			S			3	+						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA343	7566098				2022-12-24	WOS:A1995TA34300002
J	HENRARD, DR; PHILLIPS, JF; MUENZ, LR; BLATTNER, WA; WIESNER, D; EYSTER, ME; GOEDERT, JJ				HENRARD, DR; PHILLIPS, JF; MUENZ, LR; BLATTNER, WA; WIESNER, D; EYSTER, ME; GOEDERT, JJ			NATURAL-HISTORY OF HIV-1 CELL-FREE VIREMIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; POLYMERASE CHAIN-REACTION; HOMOSEXUAL MEN; VIRAL BURDEN; INFECTION; AIDS; PLASMA; TYPE-1; BLOOD	Objective.-To characterize the natural history of viremia with human immunodeficiency virus type 1 (HIV-1) and its association with disease progression from infection to acquired immunodeficiency syndrome (AIDS). Design.-Prospective cohort study. Annual specimens were tested for quantitative virion-associated HIV-1 RNA, p24 antigen, and CD4(+) lymphocyte levels. Participants.-A total of 42 homosexual men who seroconverted to HIV-1 between 1982 and 1985. Main Outcome Measures.-Trends over time in serum HIV-1 RNA level, correlations between serum HIV-1 RNA and other markers, and prediction of AIDS using these markers. ResuIts.-HIV-1 RNA levels were stable overtime, increasing by 10-fold or more in only six (14%) of the 42 subjects during 3 to 11 years of follow-up. Mean HIV-1 RNA levels were 10(3.8) copies/mL if AIDS occurred in less than 4 years, 10(3.07) copies/mL if AIDS developed within 4 through 9 years, and 10(2.27) copies/mL if AIDS did not develop within 6 through 11 years. In both univariate and multivariate models, initial and subsequent HIV-1 RNA levels, p24 antigenemia, and percentage of CD4(+) lymphocytes were independently predictive of AIDS. Conclusions.-The stability of virion-associated HIV-1 RNA levels suggests that an equilibrium between HIV-1 replication rate and efficacy of immunologic response is established shortly after infection and persists throughout the asymptomatic period of the disease. Thus, defective immunologic control of HIV-1 infection may be as important as the viral replication rate for determining AIDS-free survival. Because individual steady-state levels of viremia were established soon after infection, HIV-1 RNA levels may be useful markers for predicting clinical outcome.	ABBOTT LABS, DEPT MED RES, N CHICAGO, IL 60064 USA; NCI, VIRAL EPIDEMIOL BRANCH, BETHESDA, MD 20892 USA; PENN STATE UNIV, MILTON S HERSHEY MED CTR, DEPT MED, DIV HEMATOL, HERSHEY, PA 17033 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health				, M. Elaine Eyster/0000-0001-8248-6793	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP095612] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CP-33060, N01-CP-40521, N01-CP-95612] Funding Source: Medline	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AOKISEI S, 1992, AIDS RES HUM RETROV, V8, P1263, DOI 10.1089/aid.1992.8.1263; BOURINBAIAR AS, 1991, NATURE, V349, P111, DOI 10.1038/349111b0; COOMBS RW, 1993, J CLIN MICROBIOL, V31, P1980, DOI 10.1128/JCM.31.8.1980-1986.1993; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; DEWOLF F, 1987, BMJ-BRIT MED J, V295, P569, DOI 10.1136/bmj.295.6598.569; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; FARZADEGAN H, 1993, 1ST P NAT C HUM RETR; FAUCI AS, 1991, ANN INTERN MED, V114, P678, DOI 10.7326/0003-4819-114-8-678; GARRY RF, 1993, NATURE, V365, P301, DOI 10.1038/365301b0; GOEDERT JJ, 1987, JAMA-J AM MED ASSOC, V257, P331, DOI 10.1001/jama.257.3.331; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; JOLLERJEMELKA HI, 1994, J HEPATOL, V21, P269, DOI 10.1016/S0168-8278(05)80407-6; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KARIM MR, SAS MACRO GENERALIZE; KOJIMA E, 1994, 10TH P INT C AIDS; KRONER BL, 1995, AIDS, V9, P275, DOI 10.1097/00002030-199509030-00009; LEE TH, 1994, J ACQ IMMUN DEF SYND, V7, P381; LIN HJ, 1994, J INFECT DIS, V170, P553, DOI 10.1093/infdis/170.3.553; LOVEDAY C, 1995, LANCET, V345, P820, DOI 10.1016/S0140-6736(95)92963-0; MCLEAN A, 1993, NATURE, V365, P301, DOI 10.1038/365301a0; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PETRICCIANI JC, 1992, AIDS RES HUM RETROV, V8, P1527, DOI 10.1089/aid.1992.8.1527; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; PRESTON DL, 1990, EPICURE RISK REGRESS; ROSENBERG PS, 1994, AIDS, V8, P803, DOI 10.1097/00002030-199406000-00013; SCHNITTMAN SM, 1990, ANN INTERN MED, V113, P438, DOI 10.7326/0003-4819-113-6-438; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; THOMAS DG, 1977, COMPUT BIOMED RES, V10, P373, DOI 10.1016/0010-4809(77)90006-4; WAINHOBSON S, 1993, NATURE, V366, P22, DOI 10.1038/366022b0; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	34	200	202	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 16	1995	274	7					554	558						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN466	7629984				2022-12-24	WOS:A1995RN46600026
J	DOPPMAN, JL; CHANG, R; FRAKER, DL; NORTON, JA; ALEXANDER, HR; MILLER, DL; COLLIER, E; SKARULIS, MC; GORDEN, P				DOPPMAN, JL; CHANG, R; FRAKER, DL; NORTON, JA; ALEXANDER, HR; MILLER, DL; COLLIER, E; SKARULIS, MC; GORDEN, P			LOCALIZATION OF INSULINOMAS TO REGIONS OF THE PANCREAS BY INTRAARTERIAL STIMULATION WITH CALCIUM	ANNALS OF INTERNAL MEDICINE			English	Article						INSULINOMA; CALCIUM; HEPATIC VEINS; ANGIOGRAPHY; PANCREAS	SELECTIVE INTRAARTERIAL INJECTION; ZOLLINGER-ELLISON SYNDROME; INTRAOPERATIVE ULTRASONOGRAPHY; INFUSION; GASTRINOMAS; SECRETION; RELEASE	Objective: To determine the sensitivity of calcium injected into pancreatic arteries in localizing insulin-secreting tumors to regions of the pancreas. Design and Patients: To stimulate the release of insulin, 25 patients with surgically proven insulinomas (average diameter, 15 mm) had calcium gluconate (0.025 mEq Ca++/kg body weight) injected before surgery into the arteries supplying the pancreatic head (gastroduodenal and superior mesenteric arteries) and the body and tail (splenic artery) of the pancreas. Setting: Tertiary referral hospital. Measurements: Insulin levels were measured in samples taken from the right and left hepatic veins before and 30, 60, and 120 seconds after calcium injection. A twofold increase in insulin level in the sample taken from the right hepatic vein 30 or 60 seconds after injection localized the insulinoma to the segment of the pancreas supplied by the selectively injected artery. Localization done using calcium stimulation was compared with localization done using transcutaneous ultrasonography (n = 22), computed tomography (n = 23), magnetic resonance imaging (n = 21), arteriography (n = 25), and portal venous sampling (n = 9) Results: Calcium stimulation localized 22 of 25 insulinomas (sensitivity, 88% [95% CI, 68% to 97%]) to the correct region of the pancreas. The sensitivities of the other imaging methods were 9% for ultrasonography (CI, 1% to 23%), 17% for computed tomography (CI, 5% to 39%), 43% for magnetic resonance imaging (CI, 22% to 66%), 36% for arteriography (CI, 18% to 57%), and 67% for portal venous sampling (CI, 30% to 93%). Calcium stimulation added only a few minutes to the time needed for pancreatic arteriography and caused no morbid conditions. Conclusion: Intra-arterial calcium stimulation with right hepatic vein sampling for insulin gradients is the most sensitive preoperative test for localizing insulinomas.	NATL NAVAL MED CTR, BETHESDA, MD 20889 USA; WASHINGTON UNIV, ST LOUIS, MO USA	Walter Reed National Military Medical Center; Washington University (WUSTL)	DOPPMAN, JL (corresponding author), NIH, CTR CLIN,DEPT DIAGNOST RADIOL,BLDG 10,ROOM 1C660, 10 CTR DR, MSC 1182, BETHESDA, MD 20892 USA.							BRUNT LM, 1986, J CLIN ENDOCR METAB, V62, P210, DOI 10.1210/jcem-62-1-210; DEPALO C, 1981, J CLIN ENDOCR METAB, V52, P804, DOI 10.1210/jcem-52-4-804; DOHERTY GM, 1991, SURGERY, V110, P989; DOPPMAN JL, 1990, RADIOLOGY, V174, P25, DOI 10.1148/radiology.174.1.2294556; DOPPMAN JL, 1993, WORLD J SURG, V17, P439, DOI 10.1007/BF01655101; DOPPMAN JL, 1991, RADIOLOGY, V178, P237, DOI 10.1148/radiology.178.1.1984311; GAEKE RF, 1975, METABOLISM, V24, P1029, DOI 10.1016/0026-0495(75)90096-7; GALIBER AK, 1988, RADIOLOGY, V166, P405, DOI 10.1148/radiology.166.2.2827232; GRANT CS, 1988, ARCH SURG-CHICAGO, V123, P843; HARRISON TS, 1981, MIL MED, V146, P103; IMAMURA M, 1987, ANN SURG, V205, P230, DOI 10.1097/00000658-198703000-00003; KAKITA K, 1981, HORM METAB RES, V13, P237, DOI 10.1055/s-2007-1019231; KAPLAN EL, 1979, ANN SURG, V190, P501, DOI 10.1097/00000658-197910000-00009; KING CMP, 1994, CLIN RADIOL, V49, P295, DOI 10.1016/S0009-9260(05)81790-8; MILLER DL, 1992, RADIOLOGY, V182, P235, DOI 10.1148/radiology.182.1.1727289; MILLER JL, 1981, NEW ENGL J MED, V304, P1430; NORTON JA, 1990, ANN SURG, V212, P615, DOI 10.1097/00000658-199011000-00009; POINTEL JP, 1978, HORM METAB RES, V10, P572, DOI 10.1055/s-0028-1096158; ROY BK, 1979, METABOLISM, V28, P246, DOI 10.1016/0026-0495(79)90071-4; THOM AK, 1992, SURGERY, V112, P1002	20	207	216	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1995	123	4					269	273		10.7326/0003-4819-123-4-199508150-00004	http://dx.doi.org/10.7326/0003-4819-123-4-199508150-00004			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN665	7611592				2022-12-24	WOS:A1995RN66500004
J	GILSDORF, JR				GILSDORF, JR			BRAD MISSED THE MIRACLE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 9	1995	274	6					443	443						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM699	7629936				2022-12-24	WOS:A1995RM69900002
J	CHEN, JJ; REID, CE; BAND, V; ANDROPHY, EJ				CHEN, JJ; REID, CE; BAND, V; ANDROPHY, EJ			INTERACTION OF PAPILLOMAVIRUS E6 ONCOPROTEINS WITH A PUTATIVE CALCIUM-BINDING PROTEIN	SCIENCE			English	Article							MAMMARY EPITHELIAL-CELLS; BOVINE PAPILLOMAVIRUS; CERVICAL-CARCINOMA; HUMAN KERATINOCYTES; P53 PROTEIN; HPV-16 E6; TYPE-16; DEGRADATION; DNA; TRANSACTIVATION	Human papillomaviruses (HPVs) are associated with the majority of cervical cancers and encode a transforming protein, E6, that interacts with the tumor suppressor protein p53. Because E6 has p53-independent transforming activity, the yeast two-hybrid system was used to search for other EG-binding proteins. One such protein, E6BP, interacted with cancer-associated HPV E6 and with bovine papillomavirus type 1 (BPV-1) E6. The transforming activity of BPV-1 E6 mutants correlated with their E6BP-binding ability. E6BP is identical to a putative calcium-binding protein, ERC-55, that appears to be localized in the endoplasmic reticulum.	TUFTS UNIV NEW ENGLAND MED CTR, DEPT DERMATOL, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, BOSTON, MA 02111 USA; TUFTS UNIV NEW ENGLAND MED CTR, DEPT RADIAT ONCOL, BOSTON, MA 02111 USA; TUFTS UNIV NEW ENGLAND MED CTR, DEPT BIOCHEM, BOSTON, MA 02111 USA; TUFTS UNIV NEW ENGLAND MED CTR, DEPT MOLEC BIOL & MICROBIOL, BOSTON, MA 02111 USA	Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts Medical Center; Tufts Medical Center				Androphy, Elliot/0000-0002-8104-0703	NATIONAL CANCER INSTITUTE [R29CA056803, R01CA044174] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA44174, R29CA56803] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; ANDROPHY EJ, 1985, SCIENCE, V230, P442, DOI 10.1126/science.2996134; BAND V, 1993, EMBO J, V12, P1847, DOI 10.1002/j.1460-2075.1993.tb05833.x; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; Chen J., UNPUB; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DOSHI N, UNPUB; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; GROSSMAN SR, 1989, J VIROL, V63, P366, DOI 10.1128/JVI.63.1.366-374.1989; HUBBERT NL, 1992, J VIROL, V66, P6237, DOI 10.1128/JVI.66.10.6237-6241.1992; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; KEEN N, 1994, ONCOGENE, V9, P1493; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KIYONO T, 1994, J VIROL, V68, P4656, DOI 10.1128/JVI.68.7.4656-4661.1994; LECHNER MS, 1994, J VIROL, V68, P4262, DOI 10.1128/JVI.68.7.4262-4273.1994; LIANG XH, 1993, ONCOGENE, V8, P2645; MANSUR CP, 1995, ONCOGENE, V10, P457; MANSUR CP, 1993, BIOCHIM BIOPHYS ACTA, V1155, P323, DOI 10.1016/0304-419X(93)90013-3; MCCANCE DJ, 1988, P NATL ACAD SCI USA, V85, P7169, DOI 10.1073/pnas.85.19.7169; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PIM D, 1994, ONCOGENE, V9, P1869; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHILLER JT, 1984, P NATL ACAD SCI-BIOL, V81, P7880, DOI 10.1073/pnas.81.24.7880; SCHILLER JT, 1986, DNA TUMOR VIRUSES CO, P571; SCHLEGEL R, 1988, EMBO J, V7, P3181, DOI 10.1002/j.1460-2075.1988.tb03185.x; SCHMITT A, 1994, ONCOGENE, V68, P7051; SEDMAN SA, 1992, J VIROL, V66, P4201, DOI 10.1128/JVI.66.7.4201-4208.1992; STEGER G, 1992, ARCH VIROL, V125, P355, DOI 10.1007/BF01309654; TUFTY RM, 1975, SCIENCE, V187, P167, DOI 10.1126/science.1111094; VOUSDEN KH, 1989, J VIROL, V63, P2340, DOI 10.1128/JVI.63.5.2340-2342.1989; WEIS K, 1994, J BIOL CHEM, V269, P19142; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286	40	245	255	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 28	1995	269	5223					529	531		10.1126/science.7624774	http://dx.doi.org/10.1126/science.7624774			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL495	7624774				2022-12-24	WOS:A1995RL49500024
J	FOSTER, S; BUVE, A				FOSTER, S; BUVE, A			BENEFITS OF HIV SCREENING OF BLOOD-TRANSFUSIONS IN ZAMBIA	LANCET			English	Article								Blood transfusion continues to be an important route of transmission of HIV in developing countries, especially for young children following the perinatal period, Testing for HIV is costly and reliable donor support for the purchase of test kits is often essential, yet difficult to secure. The costs of screening of transfusions for HIV and the financial benefits in terms of savings on treatment costs averted were calculated for a district hospital in Zambia where seroprevalence among donors was 15.9%. Financial benefits exceed costs by a factor of 2.7-3.5. In 1991, 1073 transfusions were given and an estimated 150 cases of transfusion-related AIDS were prevented by screening, of which 59% were in children aged 5 years or under and 31% were in women. The total cost of HIV screening was pound 3061 ($4745), and the cost per case of HIV infection prevented was pound 20.40 ($31.62); the cost of this protection for the population served by the hospital was pound 0.02 ($0.03) per person. An estimated 3625 undiscounted healthy years of life were saved, of which nearly 69% were in children under 6, at a cost of pound 0.85 ($1.32) per year of life saved. It is essential that financial and political support for HIV screening of blood for transfusion is maintained,	INST TROP MED,B-2000 ANTWERP,BELGIUM	Institute of Tropical Medicine (ITM)	FOSTER, S (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,LONDON WC1E 7HT,ENGLAND.							BEAL R, 1992, SAFE BLOOD DEV COUNT; BUVE A, 1993, 9TH C AIDS BERL; EISENSTAEDT RS, 1988, AM J PUBLIC HEALTH, V78, P450, DOI 10.2105/AJPH.78.4.450; Gibbs WN, 1992, GUIDELINES ORG BLOOD; GUMODOKA B, 1993, AIDS, V7, P387, DOI 10.1097/00002030-199303000-00013; HIRA SK, 1989, BRIT MED J, V299, P1250, DOI 10.1136/bmj.299.6710.1250; KASLOW RA, 1989, EPIDEMIOLOGY AIDS; MILLS A, 1993, COSTS HIV AIDS PREVE; OVER M, 1988, GLOBAL IMPACT AIDS; SAVARIT D, 1992, BRIT MED J, V305, P498, DOI 10.1136/bmj.305.6852.498; SODERLUND N, 1993, B WORLD HEALTH ORGAN, V71, P595	11	37	37	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 22	1995	346	8969					225	227		10.1016/S0140-6736(95)91272-X	http://dx.doi.org/10.1016/S0140-6736(95)91272-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK419	7616804				2022-12-24	WOS:A1995RK41900014
J	WHITMARSH, AJ; SHORE, P; SHARROCKS, AD; DAVIS, RJ				WHITMARSH, AJ; SHORE, P; SHARROCKS, AD; DAVIS, RJ			INTEGRATION OF MAP KINASE SIGNAL-TRANSDUCTION PATHWAYS AT THE SERUM RESPONSE ELEMENT	SCIENCE			English	Article							ACTIVATED PROTEIN-KINASE; ETS-RELATED PROTEIN; FACTOR P62TCF; DNA-BINDING; ELK-1; PHOSPHORYLATION; EXPRESSION; GENE	The ternary complex factor (TCF) subfamily of ETS-domain transcription factors bind with serum response factor (SRF) to the serum response element (SRE) and mediate increased gene expression. The TCF protein Elk-1 is phosphorylated by the JNK and ERK groups of mitogen-activated protein (MAP) kinases causing increased DNA binding, ternary complex formation, and transcriptional activation. Activated SRE-dependent gene expression is induced by JNK in cells treated with interleukin-1 and by ERK after treatment with phorbol ester. The Elk-1 transcription factor therefore integrates MAP kinase signaling pathways in vivo to coordinate biological responses to different extracellular stimuli.	UNIV MASSACHUSETTS,SCH MED,HOWARD HUGHES MED INST,WORCESTER,MA 01605; UNIV MASSACHUSETTS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,PROGRAM MOLEC MED,WORCESTER,MA 01605; UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT BIOCHEM & GENET,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Newcastle University - UK				Whitmarsh, Alan/0000-0003-1184-6610; Shore, Paul/0000-0002-1832-5976				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BUSCHER M, 1988, ONCOGENE, V3, P301; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DERLJARD B, 1994, CELL, V76, P1025; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JANKNECHT R, 1992, NUCLEIC ACIDS RES, V20, P3317, DOI 10.1093/nar/20.13.3317; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; RAO VN, 1992, ONCOGENE, V7, P65; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SEGER R, 1994, J BIOL CHEM, V269, P25699; SETH A, 1992, J BIOL CHEM, V267, P24796; SHARROCKS AD, 1993, MOL CELL BIOL, V13, P123, DOI 10.1128/MCB.13.1.123; SHARROCKS AD, IN PRESS FEBS LETT; SHORE P, 1994, MOL CELL BIOL, V14, P3283, DOI 10.1128/MCB.14.5.3283; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WHITMARSH AJ, UNPUB; YAN MH, 1994, NATURE, V372, P798	43	887	904	0	16	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 21	1995	269	5222					403	407		10.1126/science.7618106	http://dx.doi.org/10.1126/science.7618106			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK427	7618106				2022-12-24	WOS:A1995RK42700049
J	THOMAS, SM; SORIANO, P; IMAMOTO, A				THOMAS, SM; SORIANO, P; IMAMOTO, A			SPECIFIC AND REDUNDANT ROLES OF SRC AND FYN IN ORGANIZING THE CYTOSKELETON	NATURE			English	Article							TYROSINE PHOSPHORYLATION; CELLS; GENE; MICE; KINASES; IDENTIFICATION; OSTEOPETROSIS; DISRUPTION; SUBSTRATE; ENCODES	MOUSE embryos lacking Csk, a negative regulator of Src family kinases, exhibit defects in neurulation and die at mid-gestation(1,2). To determine the role of activated Src family kinases in the csk(-) phenotype, we have introduced mutations in the src and fyn genes(3,4) into the csk(-) mutant background. Genetic analysis reveals that src, but not fyn, is partly epistatic to the csk gene. Biochemical analysis indicates that several cytoskeletal proteins are hyperphosphorylated an tyrosine residues in csk(-) cells. Regulation of cortactin and tensin hyperphosphorylation is Src-dependent, whereas focal adhesion kinase and paxillin hyperphosphorylation is partly dependent on both Src and Fyn. Furthermore, the src(-) mutation can restore the normal distribution of cortactin and partly correct filamentous actin organization in csk(-) cells. Thus, Src family kinases have both specific and overlapping functions in regulation of the cytoskeleton. The disturbance of these functions may be a molecular basis for the phenotype exhibited by csk(-) mutants.			THOMAS, SM (corresponding author), FRED HUTCHINSON CANC RES CTR, DIV MOLEC MED, 1124 COLUMBIA ST, SEATTLE, WA 98104 USA.		Soriano, Philippe M/E-5797-2015	Soriano, Philippe M/0000-0002-0427-926X				BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BRAUNINGER A, 1992, GENE, V110, P205, DOI 10.1016/0378-1119(92)90649-A; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HANAFUSA H, 1977, COMPREHENSIVE VIROLO, V10, P401; HOWELL BW, 1994, MOL CELL BIOL, V14, P5402, DOI 10.1128/MCB.14.8.5402; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; IMAMOTO A, 1994, CURR OPIN GENET DEV, V4, P40, DOI 10.1016/0959-437X(94)90089-2; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; LO SH, 1994, J CELL BIOL, V125, P1067, DOI 10.1083/jcb.125.5.1067; LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485; LOWELL CA, 1994, GENE DEV, V8, P387, DOI 10.1101/gad.8.4.387; NADA S, 1994, ONCOGENE, V9, P3571; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; PARTANEN J, 1991, ONCOGENE, V6, P2013; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; ROHRSCHNEIDER LR, 1980, P NATL ACAD SCI-BIOL, V77, P3514, DOI 10.1073/pnas.77.6.3514; SCHALLER MD, 1993, PROG NUCLEIC ACID RE, V44, P205, DOI 10.1016/S0079-6603(08)60221-4; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEIN PL, 1994, GENE DEV, V8, P1999, DOI 10.1101/gad.8.17.1999; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; TURNER CE, 1994, J CELL SCI, V107, P1583; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; YAGI T, 1994, ONCOGENE, V9, P2433; YANG JT, 1993, DEVELOPMENT, V119, P1093	30	301	302	1	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUL 20	1995	376	6537					267	271		10.1038/376267a0	http://dx.doi.org/10.1038/376267a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK331	7617039				2022-12-24	WOS:A1995RK33100050
J	YELAMOS, J; KLIX, N; GOYENECHEA, B; LOZANO, F; CHUI, YL; FERNANDEZ, AG; PANNELL, R; NEUBERGER, MS; MILSTEIN, C				YELAMOS, J; KLIX, N; GOYENECHEA, B; LOZANO, F; CHUI, YL; FERNANDEZ, AG; PANNELL, R; NEUBERGER, MS; MILSTEIN, C			TARGETING OF NON-LG SEQUENCES IN-PLACE OF THE V-SEGMENT BY SOMATIC HYPERMUTATION	NATURE			English	Article							GERMINAL-CENTERS; IMMUNE-RESPONSE; IMMUNOGLOBULIN GENES; PASSENGER TRANSGENES; AFFINITY MATURATION; MUTATION; KAPPA; MUTAGENESIS; MECHANISM; PROMOTER	Affinity maturation of antibodies is characterized by localized hypermutation of the DNA around the V segment. Here we show, using mice containing single or multiple transgene constructs, that an immunoglobulin V-kappa segment can be replaced by human beta-globin or prokaryotic neo or gpt genes without affecting the rate of hypermutation; the V gene itself is not necessary for recruiting hypermutation. The ability to target hypermutation to heterologous genes in vivo could find more general applications in biology.			YELAMOS, J (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.		Yelamos, Jose/N-2842-2016; González-Fernández, África/E-2641-2012	González-Fernández, África/0000-0002-9226-4825; LOZANO, FRANCISCO/0000-0003-1119-4368; Yelamos, Jose/0000-0003-1195-1496; Chui, Yiu-Loon/0000-0002-3441-9729				AZUMA T, 1993, INT IMMUNOL, V5, P121, DOI 10.1093/intimm/5.2.121; BEREK C, 1991, CELL, V67, P1121, DOI 10.1016/0092-8674(91)90289-B; BEREK C, 1987, IMMUNOL REV, V96, P23, DOI 10.1111/j.1600-065X.1987.tb00507.x; BETZ AG, 1994, CELL, V77, P239, DOI 10.1016/0092-8674(94)90316-6; BETZ AG, 1993, IMMUNOL TODAY, V14, P405, DOI 10.1016/0167-5699(93)90144-A; BETZ AG, 1993, P NATL ACAD SCI USA, V90, P2385, DOI 10.1073/pnas.90.6.2385; BOTH GW, 1990, MOL CELL BIOL, V10, P5187, DOI 10.1128/MCB.10.10.5187; CHUI YL, 1995, J MOL BIOL, V249, P555, DOI 10.1006/jmbi.1995.0318; CLACKSON T, 1989, NUCLEIC ACIDS RES, V17, P10163, DOI 10.1093/nar/17.24.10163; Galfre G, 1981, Methods Enzymol, V73, P3; GEARHART PJ, 1983, P NATL ACAD SCI-BIOL, V80, P3439, DOI 10.1073/pnas.80.11.3439; GONZALEZFERNAND.A, 1994, P NATL ACAD SCI USA, V91, P12614; GONZALEZFERNANDEZ, 1993, P NATL ACAD SCI USA, V90, P9862; GRIFFITHS GM, 1984, NATURE, V312, P271, DOI 10.1038/312271a0; HACKETT J, 1992, J EXP MED, V176, P225, DOI 10.1084/jem.176.1.225; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; KEPLER TB, 1993, IMMUNOL TODAY, V14, P412, DOI 10.1016/0167-5699(93)90145-B; KOCKS C, 1988, P NATL ACAD SCI USA, V85, P8206, DOI 10.1073/pnas.85.21.8206; KUPPERS R, 1993, EMBO J, V12, P4955, DOI 10.1002/j.1460-2075.1993.tb06189.x; LEBECQUE SG, 1990, J EXP MED, V172, P1717, DOI 10.1084/jem.172.6.1717; LOZANO F, 1993, NATURE, V363, P271, DOI 10.1038/363271a0; LOZANO F, 1994, EMBO J, V13, P4617, DOI 10.1002/j.1460-2075.1994.tb06783.x; MACLENNAN ICM, 1992, IMMUNOL REV, V126, P143, DOI 10.1111/j.1600-065X.1992.tb00635.x; MANSER T, 1990, SOMATIC HYPERMUTATIO, P20; MOTOYAMA N, 1991, P NATL ACAD SCI USA, V88, P7933, DOI 10.1073/pnas.88.18.7933; NEUBERGER MS, 1995, CURR OPIN IMMUNOL, V7, P248, DOI 10.1016/0952-7915(95)80010-7; OBRIEN RL, 1987, NATURE, V326, P405, DOI 10.1038/326405a0; PASCUAL V, 1994, J EXP MED, V180, P329, DOI 10.1084/jem.180.1.329; Pettersson S, 1989, Int Immunol, V1, P509, DOI 10.1093/intimm/1.5.509; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; RADA C, 1994, EUR J IMMUNOL, V24, P1453, DOI 10.1002/eji.1830240632; ROGERSON B, 1991, EMBO J, V10, P4331, DOI 10.1002/j.1460-2075.1991.tb05011.x; ROGOZIN IB, 1992, BIOCHIM BIOPHYS ACTA, V1171, P11, DOI 10.1016/0167-4781(92)90134-L; ROTHENFLUH HS, 1993, EUR J IMMUNOL, V23, P2152, DOI 10.1002/eji.1830230916; SHARPE MJ, 1991, EMBO J, V10, P2139, DOI 10.1002/j.1460-2075.1991.tb07748.x; STEELE EJ, 1992, IMMUNOL CELL BIOL, V70, P129, DOI 10.1038/icb.1992.18; UMAR A, 1991, P NATL ACAD SCI USA, V88, P4902, DOI 10.1073/pnas.88.11.4902; WEBER JS, 1991, J IMMUNOL, V146, P3652; WEBER JS, 1994, J IMMUNOL, V153, P3594; WEIGERT M, 1986, PROG IMMUNOL, V6, P139	40	208	247	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 20	1995	376	6537					225	229						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK331	7617031				2022-12-24	WOS:A1995RK33100038
J	THREADGILL, DW; DLUGOSZ, AA; HANSEN, LA; TENNENBAUM, T; LICHTI, U; YEE, D; LAMANTIA, C; MOURTON, T; HERRUP, K; HARRIS, RC; BARNARD, JA; YUSPA, SH; COFFEY, RJ; MAGNUSON, T				THREADGILL, DW; DLUGOSZ, AA; HANSEN, LA; TENNENBAUM, T; LICHTI, U; YEE, D; LAMANTIA, C; MOURTON, T; HERRUP, K; HARRIS, RC; BARNARD, JA; YUSPA, SH; COFFEY, RJ; MAGNUSON, T			TARGETED DISRUPTION OF MOUSE EGF RECEPTOR - EFFECT OF GENETIC BACKGROUND ON MUTANT PHENOTYPE	SCIENCE			English	Article							EPIDERMAL GROWTH-FACTOR; HAIR FOLLICLE; EXPRESSION; DIFFERENTIATION; ALPHA; SKIN; IMPLANTATION; ANTIBODIES; EMBRYOS; INVITRO	Gene targeting was used to create a null allele at the epidermal growth factor receptor locus (Egfr). The phenotype was dependent on genetic background. EGFR deficiency on a CF-1 background resulted in peri-implantation death due to degeneration of the inner cell mass. On a 129/Sv background, homozygous mutants died at mid-gestation due to placental defects; on a CD-1 background, the mutants lived for up to 3 weeks and showed abnormalities in skin, kidney, brain, liver, and gastrointestinal tract. The multiple abnormalities associated with EGFR deficiency indicate that the receptor is involved in a wide range of cellular activities.	CASE WESTERN RESERVE UNIV,DEPT GENET,CLEVELAND,OH 44106; NCI,CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB,BETHESDA,MD 20892; CASE WESTERN RESERVE UNIV,DEPT NEUROL,ALZHEIMER RES LAB,CLEVELAND,OH 44106; VANDERBILT UNIV,DEPT MED,NASHVILLE,TN 37232; VANDERBILT UNIV,DEPT PEDIAT,NASHVILLE,TN 37232; VANDERBILT UNIV,DEPT CELL BIOL,NASHVILLE,TN 37232	Case Western Reserve University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Case Western Reserve University; Vanderbilt University; Vanderbilt University; Vanderbilt University			Threadgill, David W/N-4425-2013; Herrup, Karl/C-5313-2014	Threadgill, David W/0000-0003-3538-1635; Herrup, Karl/0000-0001-7786-5844	NICHD NIH HHS [HD26722, HD07104] Funding Source: Medline; NIGMS NIH HHS [GM14630] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014630] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMSON ED, 1990, MOL REPROD DEV, V27, P16, DOI 10.1002/mrd.1080270106; AVNER ED, 1990, PEDIATR NEPHROL, V4, P372, DOI 10.1007/BF00862522; BARNARD JA, 1995, GASTROENTEROLOGY, V108, P564, DOI 10.1016/0016-5085(95)90087-X; BRICE EC, 1993, DEV GENET, V14, P174, DOI 10.1002/dvg.1020140304; CAREY TE, 1992, MONOGR NATL CANCER I, V20, P75; CHEN JD, 1993, EXP CELL RES, V209, P216, DOI 10.1006/excr.1993.1304; DARDIK A, 1992, DEV BIOL, V154, P396, DOI 10.1016/0012-1606(92)90078-U; DONALDSON RW, 1992, P NATL ACAD SCI USA, V89, P8477, DOI 10.1073/pnas.89.18.8477; FOWLER KJ, 1995, P NATL ACAD SCI USA, V92, P1465, DOI 10.1073/pnas.92.5.1465; GLICK AB, 1993, P NATL ACAD SCI USA, V90, P6076, DOI 10.1073/pnas.90.13.6076; LUETTEKE NC, 1993, CELL, V73, P263, DOI 10.1016/0092-8674(93)90228-I; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; MANN GB, 1993, CELL, V73, P249, DOI 10.1016/0092-8674(93)90227-H; PARIA BC, 1993, P NATL ACAD SCI USA, V90, P55, DOI 10.1073/pnas.90.1.55; PARIA BC, 1990, P NATL ACAD SCI USA, V87, P4756, DOI 10.1073/pnas.87.12.4756; POIRIER F, 1991, DEVELOPMENT, V113, P1105; ROOP DR, 1987, DIFFERENTIATION, V35, P143, DOI 10.1111/j.1432-0436.1987.tb00162.x; SASSOON D, 1993, GUIDE TECHNIQUES MOU, P384; TENHAVEOPBROEK AAW, 1988, ANAT REC, V221, P846, DOI 10.1002/ar.1092210409; TENNENBAUM T, 1992, CANCER RES, V52, P2966; THREADGILL DW, UNPUB; WEINBERG WC, 1990, DIFFERENTIATION, V45, P168, DOI 10.1111/j.1432-0436.1990.tb00470.x; WILEY LM, 1992, DEV BIOL, V149, P247, DOI 10.1016/0012-1606(92)90282-L; WOOD SA, 1989, J REPROD FERTIL, V85, P575, DOI 10.1530/jrf.0.0850575; ZELLER R, 1989, CUR PROT MOL BIOL	25	1194	1217	1	30	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 14	1995	269	5221					230	234		10.1126/science.7618084	http://dx.doi.org/10.1126/science.7618084			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ029	7618084				2022-12-24	WOS:A1995RJ02900042
J	WODARZ, A; HINZ, U; ENGELBERT, M; KNUST, E				WODARZ, A; HINZ, U; ENGELBERT, M; KNUST, E			EXPRESSION OF CRUMBS CONFERS APICAL CHARACTER ON PLASMA-MEMBRANE DOMAINS OF ECTODERMAL EPITHELIA OF DROSOPHILA	CELL			English	Article							ADHESION MOLECULE UVOMORULIN; CELL-SURFACE POLARITY; FASCICLIN-III; ORGANIZATION; MELANOGASTER; PROTEIN; PATHWAYS; RECEPTOR; PRODUCT; ENCODES	The crumbs protein of Drosophila is an integral membrane protein, with 30 EGF-like and 4 laminin A G domain-like repeats in its extracellular segment, which is expressed on the apical plasma membrane of all ectodermally derived epithelia. Here, we present evidence to show that the insertion of crumbs into the plasma membrane is necessary and sufficient to confer apical character on a membrane domain. Overexpression of crumbs results in an enormous expansion of the apical plasma membrane and the concomitant reduction of the basolateral domain. This is followed by the redistribution of beta(Heavy)-spectrin, a component of the membrane cytoskeleton, and by the ectopic deposition of cuticle and other apical components into these areas. Strikingly, overexpression of the membrane-bound cytoplasmic portion of crumbs alone is sufficient to produce this dominant phenotype. Our results suggest that crumbs plays a key role in specifying the apical plasma membrane domain of ectodermal epithelial cells of Drosophila.	UNIV COLOGNE,INST ENTWICKLUNGSBIOL,D-50923 COLOGNE,GERMANY	University of Cologne			Wodarz, Andreas/D-4642-2013; Knust, Elisabeth/B-4338-2017	Wodarz, Andreas/0000-0002-0007-6289; 				BRAND AH, 1993, DEVELOPMENT, V118, P401; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; DUBREUIL RR, 1990, J CELL BIOL, V111, P1849, DOI 10.1083/jcb.111.5.1849; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fleming Tom P., 1992, P111; Foe Victoria E., 1993, P149; GILBERT T, 1991, J CELL BIOL, V113, P275, DOI 10.1083/jcb.113.2.275; HINZ U, 1994, CELL, V76, P77, DOI 10.1016/0092-8674(94)90174-0; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; KNUST E, 1994, TRENDS GENET, V10, P275, DOI 10.1016/0168-9525(90)90010-4; KNUST E, 1993, DEVELOPMENT S, V119, P261; KORNEZOS A, 1992, MOL GEN GENET, V235, P397, DOI 10.1007/BF00279386; LAFONT F, 1994, NATURE, V372, P801; LARUE L, 1994, P NATL ACAD SCI USA, V91, P8263, DOI 10.1073/pnas.91.17.8263; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MAYS RW, 1994, CURR OPIN CELL BIOL, V6, P16, DOI 10.1016/0955-0674(94)90111-2; MCNEILL H, 1990, CELL, V62, P309, DOI 10.1016/0092-8674(90)90368-O; McNeill Helen, 1992, P53; NELSON WJ, 1992, SCIENCE, V258, P948, DOI 10.1126/science.1439806; NELSON WJ, 1990, J CELL BIOL, V110, P349, DOI 10.1083/jcb.110.2.349; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; PATTHY L, 1991, FEBS LETT, V289, P99, DOI 10.1016/0014-5793(91)80917-R; Poodry C.A., 1980, Genetics and Biology of Drosophila, V2d, P443; RIETHMACHER D, 1995, P NATL ACAD SCI USA, V92, P855, DOI 10.1073/pnas.92.3.855; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; SCHONBAUM CP, 1992, DEV BIOL, V151, P431, DOI 10.1016/0012-1606(92)90183-H; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SNOW PM, 1989, CELL, V59, P313, DOI 10.1016/0092-8674(89)90293-6; SPEICHER SA, 1994, DEVELOPMENT, V120, P535; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; TEPASS U, 1994, DEV BIOL, V161, P563, DOI 10.1006/dbio.1994.1054; TEPASS U, 1993, DEV BIOL, V159, P311, DOI 10.1006/dbio.1993.1243; TEPASS U, 1990, ROUX ARCH DEV BIOL, V199, P189, DOI 10.1007/BF01682078; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; THOMAS GH, 1994, DEVELOPMENT, V120, P2039; WARN RM, 1992, EPITHELIAL ORG DEV, P136; Wieschaus E., 1986, P199; WILEY LM, 1990, BIOESSAYS, V12, P67, DOI 10.1002/bies.950120204; WODARZ A, 1993, MECH DEVELOP, V44, P175, DOI 10.1016/0925-4773(93)90066-7	41	548	551	0	12	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 14	1995	82	1					67	76		10.1016/0092-8674(95)90053-5	http://dx.doi.org/10.1016/0092-8674(95)90053-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RK424	7606787	Bronze			2022-12-24	WOS:A1995RK42400010
J	FRASER, RC; FAROOQI, A; SORRIE, R				FRASER, RC; FAROOQI, A; SORRIE, R			USE OF VITAMIN-B-12 IN LEICESTERSHIRE PRACTICES - A SINGLE TOPIC AUDIT LED BY A MEDICAL AUDIT ADVISORY GROUP	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE	Objectives-To encourage active participation of Leicestershire general practitioners and their staff in audit; to examine the use of vitamin B-12 injections and to achieve a more appropriate use. Design-Implementation of an agreed audit protocol, with central analysis and feedback of anonymous and aggregated data by a medical audit advisory group. Setting-All 147 Leicestershire practices. Main outcome measures-Participation in the complete audit cycle, comparison of actual use of vitamin B-12 injections with agreed criteria of use, and assessment of improvement in use. Results-264 general practitioners (55% of all doctors from 49% of all Leicestershire practices) completed both phases of the audit cycle, and 321 (67%) completed phase 1 only. Twenty four (16%) practices failed to participate from the outset, and a further 58 (35%) dropped out at various stages. Only 10 of the 37 singlehanded practices completed the audit, although 34 initially agreed to participate. If singlehanded practices were excluded, 56% (61) of practices completed both phases of the audit cycle. In total 1714 patients received B-12 injections. Appropriate use increased from 62% in phase 1 to 72% in phase 2 of the audit; there was a 32% reduction in the number of patients inappropriately receiving B-12 (521 to 352), and the proportion of patients receiving B-12 at the correct frequency rose from 58% to 72%. The proportion of patients in whom all the diagnostic criteria for pernicious anaemia were established before treatment with B-12 was 27% in phase 1 and 28% in phase 2. Conclusion-Our study suggests that single topic audits organised by a medical audit advisory group can encourage large numbers of general practitioners to participate and can bring about changes in behaviour resulting in improvements in standards of care. Nevertheless, advisory groups will need to devise strategies to encourage even higher levels of involvement, most particularly from singlehanded practices.			FRASER, RC (corresponding author), UNIV LEICESTER,LEICESTER GEN HOSP,DEPT GEN PRACTICE,LEICESTERSHIRE MED AUDIT ADVISORY GRP,LEICESTER LE5 4PW,LEICS,ENGLAND.		Farooqi, Ammad Ahmad/AAF-5325-2021; Farooqi, Ammad A/H-1610-2016					BAKER R, 1995, BRIT MED J, V311, P31, DOI 10.1136/bmj.311.6996.31; COCHRANE AL, 1971, BRIT J PREV SOC MED, V25, P147; DERRY J, 1991, BRIT MED J, V303, P1247, DOI 10.1136/bmj.303.6812.1247; ELLIS FR, 1970, PRACTITIONER, V204, P838; FRASER RC, 1983, BRIT MED J, V287, P729, DOI 10.1136/bmj.287.6394.729; HOLDEN JD, 1994, FAM PRACT, V11, P358, DOI 10.1093/fampra/11.4.358; MIDDLETON J, 1985, BRIT MED J, V290, P1254, DOI 10.1136/bmj.290.6477.1254; WEBB SJ, 1991, BRIT MED J, V302, P390, DOI 10.1136/bmj.302.6773.390; WILSON A, 1994, AUDIT TRENDS, V2, P97; 1990, DOH HCFP908 DEP HLTH	10	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 1	1995	311	6996					28	30		10.1136/bmj.311.6996.28	http://dx.doi.org/10.1136/bmj.311.6996.28			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG975	7613320	Green Published			2022-12-24	WOS:A1995RG97500023
J	OREOPOULOS, DG				OREOPOULOS, DG			WITHDRAWAL FROM DIALYSIS - WHEN LETTING DIE IS BETTER THAN HELPING TO LIVE	LANCET			English	Editorial Material							ATTITUDES; DECISIONS				OREOPOULOS, DG (corresponding author), TORONTO HOSP, DIV NEPHROL, WESTERN DIV, TORONTO, ON, CANADA.							AGODOA LY, 1995, AM J KIDNEY DIS, V25, P119, DOI 10.1016/0272-6386(95)90638-X; COHEN LM, 1995, ARCH INTERN MED, V155, P42, DOI 10.1001/archinte.155.1.42; COHEN LM, 1993, PSYCHOSOMATICS, V34, P395, DOI 10.1016/S0033-3182(93)71842-3; DISNEY APS, 1994, ANZDATA REPORT; KJELLSTRAND C, 1993, DEV NEPHROL, V34, P563; MOSS AH, 1993, J AM SOC NEPHROL, V4, P229; NELSON CB, 1994, J AM SOC NEPHROL, V4, P1608; OREOPOULOS DG, 1994, PERITON DIALYSIS INT, V14, P205; SCHNEIDERMAN LJ, 1994, AM J MED, V96, P110, DOI 10.1016/0002-9343(94)90130-9; SINGER PA, 1992, J AM SOC NEPHROL, V2, P1235; 1993, CANADIAN ORGAN REPLA; 1995, USRDS 1995 ANN DATA, P87	12	11	12	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 1	1995	346	8966					3	4		10.1016/S0140-6736(95)92645-3	http://dx.doi.org/10.1016/S0140-6736(95)92645-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RF985	7603145				2022-12-24	WOS:A1995RF98500003
J	POUND, P; BURY, M; GOMPERTZ, P; EBRAHIM, S				POUND, P; BURY, M; GOMPERTZ, P; EBRAHIM, S			STROKE PATIENTS VIEWS ON THEIR ADMISSION TO HOSPITAL	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HOME	Objective-To explore which components of care were valued by patients admitted to hospital following a stroke. Design-Qualitative study using in depth interviews 10 months after the stroke. Setting-Two adjacent districts in North Thames Regional Health Authority. Subjects-82 survivors of stroke taken consecutively from a stroke register, 40 of whom agreed to be interviewed. Results-Patients reported that during the acute stage of the stroke they wanted to put their faith in experienced and trusted experts who would help them make sense of the event, take all the actions necessary to ensure survival, and provide comfort and human warmth during the crisis. In addition to being reassured by the clinical tests and practical nursing help they received, patients valued feeling cared about by the staff, In most cases patients reported that their needs were met; however, the institutional nature of the hospital sometimes obstructed the fulfilment of their needs. Conclusion-Patients have important psychosocial needs during the acute stage of the stroke, which are often met by hospital admission. Patients gained benefits from their admission over and above those measurable in terms of morbidity or function. They used a combination of criteria to evaluate their care, focusing on the process as well as the outcome of care. Researchers and clinicians should do likewise.	UNIV LONDON, ROYAL HOLLOWAY & BEDFORD NEW COLL, DEPT SOCIAL POLICY & SOCIAL SCI, EGHAM TW20 0EX, SURREY, ENGLAND	University of London; Royal Holloway University London	POUND, P (corresponding author), ROYAL FREE HOSP, SCH MED, DEPT PUBL HLTH, LONDON NW3 2PF, ENGLAND.							Anderson R., 1992, AFTERMATH STROKE EXP; BAMFORD J, 1986, BRIT MED J, V292, P1369, DOI 10.1136/bmj.292.6532.1369; BENSIRA Z, 1980, J HEALTH SOC BEHAV, V21, P170, DOI 10.2307/2136736; BROCKLEHURST J C, 1978, Age and Ageing, V7, P100, DOI 10.1093/ageing/7.2.100; Bury M, 1994, Health Care Anal, V2, P240, DOI 10.1007/BF02251026; CHRISTIE D, 1978, SOC SCI MED, V12, P49; Fitzpatrick R, 1994, Qual Health Care, V3, P107; GOMPERTZ P, 1995, AGE AGEING, V24, P137, DOI 10.1093/ageing/24.2.137; HOFFMANN JE, 1974, URBAN LIFE CULT, V3, P50, DOI 10.1177/089124167400300103; Hunt SM, 1986, MEASURING HLTH STATU; ISAACS B, 1978, BRIT MED J, V2, P1640, DOI 10.1136/bmj.2.6152.1640; KAUFMAN SR, 1988, QUALITATIVE GERONTOL, P82; LUM O, 1982, CLIN GERONTOL, V1, P37; MAHONEY F I, 1965, Md State Med J, V14, P61; McKeown Thomas, 1979, ROLE MED; MULLEY G, 1978, BRIT MED J, V2, P1321, DOI 10.1136/bmj.2.6148.1321; Nouri F., 1987, CLIN REHABIL, V1, P301, DOI [DOI 10.1177/026921558700100409, 10.1177/026921558700100409]; Parker R., 1981, NEW LOOK PERSONAL SO, P17; Pound P, 1994, Qual Health Care, V3, P69, DOI 10.1136/qshc.3.2.69; POUND P, 1994, CLIN REHABIL, V8, P7, DOI DOI 10.1177/026921559400800102; WADE DT, 1987, BRIT J HOSP MED, V37, P200; WADE DT, 1985, LANCET, V1, P323; WADE DT, 1983, LANCET, V1, P807; WADE DT, 1985, J EPIDEMIOL COMMUN H, V39, P347, DOI 10.1136/jech.39.4.347; WILLIAMS SJ, 1991, SOC SCI MED, V33, P707, DOI 10.1016/0277-9536(91)90025-8; YOUNG J, 1994, BRIT MED J, V309, P1356, DOI 10.1136/bmj.309.6965.1356	26	54	55	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 1	1995	311	6996					18	22		10.1136/bmj.311.6996.18	http://dx.doi.org/10.1136/bmj.311.6996.18			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG975	7613315	Green Published			2022-12-24	WOS:A1995RG97500019
J	KAUFMAN, PD; KOBAYASHI, R; KESSLER, N; STILLMAN, B				KAUFMAN, PD; KOBAYASHI, R; KESSLER, N; STILLMAN, B			THE P150 AND P60 SUBUNITS OF CHROMATIN ASSEMBLY FACTOR-I - A MOLECULAR LINK BETWEEN NEWLY SYNTHESIZED HISTONES AND DNA-REPLICATION	CELL			English	Article							CELL-FREE SYSTEM; ACETYLATION; INVITRO; TRANSCRIPTION; TETRAHYMENA; PURIFICATION; COMPLEXES; MECHANISM; EXISTENCE; EXTRACTS	Chromatin assembly factor I (CAF-I) from human cell nuclei is a three-subunit protein complex that assembles histone octamers onto replicating DNA in a cell-free system. Sequences of cDNAs encoding the two largest CAF-I subunits reveal that the p150 protein contains large clusters of charged residues, whereas p60 contains WD repeats. p150 and p60 directly interact and are both required for DNA replication-dependent assembly of nucleosomes. Deletion of the p60-binding domain from the p150 protein prevents chromatin assembly. p150 and p60 form complexes with newly synthesized histones H3 and acetylated H4 in human cell extracts, suggesting that such complexes are intermediates between histone synthesis and assembly onto replicating DNA.			KAUFMAN, PD (corresponding author), COLD SPRING HARBOR LAB, POB 100, COLD SPRING HARBOR, NY 11724 USA.			Stillman, Bruce/0000-0002-9453-4091; Kaufman, Paul/0000-0003-3089-313X	NCI NIH HHS [CA13106] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLIS CD, 1985, P NATL ACAD SCI USA, V82, P8048, DOI 10.1073/pnas.82.23.8048; BECKER PB, 1992, MOL CELL BIOL, V12, P2241, DOI 10.1128/MCB.12.5.2241; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; CHICOINE LG, 1986, J BIOL CHEM, V261, P1071; CSORDAS A, 1990, BIOCHEM J, V265, P23, DOI 10.1042/bj2650023; DILWORTH SM, 1987, CELL, V51, P1009, DOI 10.1016/0092-8674(87)90587-3; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; GLIKIN GC, 1984, CELL, V37, P33, DOI 10.1016/0092-8674(84)90298-8; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HANSEN JC, 1991, J BIOL CHEM, V266, P4276; HARLOW E, 1988, ANTIBODIES LABORATOR; JACKSON V, 1976, J MOL BIOL, V104, P471, DOI 10.1016/0022-2836(76)90282-5; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; KLEINSCHMIDT JA, 1985, J BIOL CHEM, V260, P1166; KOMACHI K, 1994, GENE DEV, V8, P2857, DOI 10.1101/gad.8.23.2857; KRUDE T, 1993, J BIOL CHEM, V268, P14432; LASKEY RA, 1977, CELL, V10, P237, DOI 10.1016/0092-8674(77)90217-3; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LEVY A, 1978, CELL, V14, P259, DOI 10.1016/0092-8674(78)90112-5; LIN R, 1989, J CELL BIOL, V108, P1577, DOI 10.1083/jcb.108.5.1577; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; PERRY CA, 1993, BIOCHEMISTRY-US, V32, P13605, DOI 10.1021/bi00212a028; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RUIZCARRILLO A, 1975, SCIENCE, V190, P117, DOI 10.1126/science.1166303; Sambrook J., 1989, MOL CLONING; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; SMITH PA, 1984, BIOCHEMISTRY-US, V23, P1576, DOI 10.1021/bi00302a036; SMITH S, 1991, EMBO J, V10, P971, DOI 10.1002/j.1460-2075.1991.tb08031.x; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; SMITH S, 1991, J BIOL CHEM, V266, P12041; SOBEL RE, 1994, J BIOL CHEM, V269, P18576; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; STILLMAN B, 1986, CELL, V45, P555, DOI 10.1016/0092-8674(86)90287-4; THOMAS JO, 1989, METHOD ENZYMOL, V170, P549; TURNER BM, 1991, J CELL SCI, V99, P13; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; van Holde KE., 1989, SPRINGER SERIES MOL; WOLFFE A, 1992, CHROMATIN STRUCTURE; WORCEL A, 1978, CELL, V15, P969, DOI 10.1016/0092-8674(78)90280-5; WU RS, 1981, CELL, V27, P321, DOI 10.1016/0092-8674(81)90415-3	42	325	329	2	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 30	1995	81	7					1105	1114		10.1016/S0092-8674(05)80015-7	http://dx.doi.org/10.1016/S0092-8674(05)80015-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RG910	7600578	Bronze			2022-12-24	WOS:A1995RG91000015
J	ARIGONI, F; POGLIANO, K; WEBB, CD; STRAGIER, P; LOSICK, R				ARIGONI, F; POGLIANO, K; WEBB, CD; STRAGIER, P; LOSICK, R			LOCALIZATION OF PROTEIN IMPLICATED IN ESTABLISHMENT OF CELL-TYPE TO SITES OF ASYMMETRIC DIVISION	SCIENCE			English	Article							ANTI-SIGMA FACTOR; BACILLUS-SUBTILIS; GENE-EXPRESSION; TRANSCRIPTION FACTOR; SPORULATION; MORPHOGENESIS	Asymmetric division in Bacillus subtilis generates progeny cells with dissimilar fates. SpoIIE, a membrane protein required for the establishment of cell type, was shown to localize near sites of potential polar division. SpoIIE initially localizes in a bipolar pattern, coalescing at marks in the cell envelope at which asymmetric division can take place. Then, during division, SpoIIE becomes restricted to the polar septum and is lost from the distal pole. Thus, when division is complete, SpoIIE sits at the boundary between the progeny from which it dictates cell fate by the activation of a cell-specific transcription factor.	HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,BIOL LABS,CAMBRIDGE,MA 02138; INST BIOL PHYSICOCHIM,F-75005 PARIS,FRANCE	Harvard University				Pogliano, Kit/0000-0002-7868-3345; STRAGIER, Patrick/0000-0003-0849-3025	NIGMS NIH HHS [GM18568] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018568, R37GM018568] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALPER S, 1994, CELL, V77, P195, DOI 10.1016/0092-8674(94)90312-3; ARIGONI F, UNPUB; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; DIEDERICH B, 1994, GENE DEV, V8, P2653, DOI 10.1101/gad.8.21.2653; DNCAN L, 1995, SCIENCE, V270, P641; DUNCAN L, 1993, P NATL ACAD SCI USA, V90, P2325, DOI 10.1073/pnas.90.6.2325; ERRINGTON J, 1993, MICROBIOL REV, V57, P1; GUZMAN P, 1988, J BACTERIOL, V170, P1598, DOI 10.1128/jb.170.4.1598-1609.1988; HARRY EJ, 1995, J BACTERIOL, V177, P3386, DOI 10.1128/jb.177.12.3386-3393.1995; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; ILLING N, 1991, J BACTERIOL, V173, P3159, DOI 10.1128/JB.173.10.3159-3169.1991; LEWIS PJ, 1994, P NATL ACAD SCI USA, V91, P3849, DOI 10.1073/pnas.91.9.3849; LOSICK R, 1992, NATURE, V355, P601, DOI 10.1038/355601a0; MARGOLIS P, 1991, SCIENCE, V254, P562, DOI 10.1126/science.1948031; MIN KT, 1993, CELL, V74, P735, DOI 10.1016/0092-8674(93)90520-Z; Ogasawara N, 1994, DNA Res, V1, P1, DOI 10.1093/dnares/1.1.1; PIGGOT PJ, 1976, BACTERIOL REV, V40, P908, DOI 10.1128/MMBR.40.4.908-962.1976; POGLIANO K, IN PRESS MOL MICROBI; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; SALAMITOU S, 1994, J BACTERIOL, V176, P2828, DOI 10.1128/JB.176.10.2828-2834.1994; SETLOW B, 1991, J BACTERIOL, V173, P6270, DOI 10.1128/jb.173.19.6270-6278.1991; SPRINGER M, 1986, P NATL ACAD SCI USA, V83, P4384, DOI 10.1073/pnas.83.12.4384; STERLINI JM, 1969, BIOCHEM J, V113, P29, DOI 10.1042/bj1130029; STRAGIER P, 1988, CELL, V52, P697, DOI 10.1016/0092-8674(88)90407-2; STUDIER FW, 1986, J MOL BIOL, V189, P116; SUN DX, 1991, J BACTERIOL, V173, P7867, DOI 10.1128/jb.173.24.7867-7874.1991; WEBB CD, IN PRESS J BACTERIOL; WU LJ, 1995, GENE DEV, V9, P1316, DOI 10.1101/gad.9.11.1316; WU LJ, 1994, SCIENCE, V264, P572, DOI 10.1126/science.8160014	29	153	153	0	5	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 27	1995	270	5236					637	640		10.1126/science.270.5236.637	http://dx.doi.org/10.1126/science.270.5236.637			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TB557	7570022				2022-12-24	WOS:A1995TB55700041
J	DUNCAN, L; ALPER, S; ARIGONI, F; LOSICK, R; STRAGIER, P				DUNCAN, L; ALPER, S; ARIGONI, F; LOSICK, R; STRAGIER, P			ACTIVATION OF CELL-SPECIFIC TRANSCRIPTION BY A SERINE PHOSPHATASE AT THE SITE OF ASYMMETRIC DIVISION	SCIENCE			English	Article							ANTI-SIGMA FACTOR; BACILLUS-SUBTILIS; EXPRESSION; SPOIIAB	Cell fate is determined by cell-specific activation of transcription factor sigma(F) after asym metric division during sporulation by Bacillus subtilis. The activity of sigma(F) is governed by SpoIIAA, SpoIIAB, and SpoIIE, a membrane protein localized at the polar septum. SpoIIAB binds to and inhibits of, and SpoIIAA inhibits SpoIIAB, which prevents SpoIIAB from binding to sigma(F). SpoIIAB is also a serine kinase that inactivates SpoIIAA. Here, it is demonstrated that SpoIIE dephosphorylates SpoIIAA-P and overcomes SpoIIAB-mediated inhibition of sigma(F). The finding that SpoIIE is a serine phosphatase links asymmetric division to the pathway governing cell-specific gene transcription.	HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,BIOL LABS,CAMBRIDGE,MA 02138; INST BIOL PHYSICOCHIM,F-75005 PARIS,FRANCE	Harvard University				STRAGIER, Patrick/0000-0003-0849-3025	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018568, R01GM018568] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM18568] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALPER S, 1994, CELL, V77, P195, DOI 10.1016/0092-8674(94)90312-3; ARIGONI F, 1995, SCIENCE, V270, P637, DOI 10.1126/science.270.5236.637; ARIGONI F, UNPUB; BARTON GJ, 1994, EUR J BIOCHEM, V220, P225, DOI 10.1111/j.1432-1033.1994.tb18618.x; BENSON AK, 1993, P NATL ACAD SCI USA, V90, P2330, DOI 10.1073/pnas.90.6.2330; BENSON AK, 1992, J BACTERIOL, V174, P749, DOI 10.1128/jb.174.3.749-757.1992; BOYLAN SA, 1992, J BACTERIOL, V174, P3695, DOI 10.1128/JB.174.11.3695-3706.1992; DIEDERICH B, 1994, GENE DEV, V8, P2653, DOI 10.1101/gad.8.21.2653; DUFOUR A, 1994, J BACTERIOL, V176, P1813, DOI 10.1128/jb.176.7.1813-1820.1994; DUNCAN L, 1993, P NATL ACAD SCI USA, V90, P2325, DOI 10.1073/pnas.90.6.2325; DUNCAN LL, UNPUB; ERINGTON J, 1993, MICROBIOL REV, V57, P1; HARRY EJ, 1995, J BACTERIOL, V177, P3386, DOI 10.1128/jb.177.12.3386-3393.1995; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; KAIMAN S, 1990, J BACTERIOL, V172, P5575; LOSICK R, 1992, NATURE, V355, P601, DOI 10.1038/355601a0; MARGOLIS P, 1991, SCIENCE, V254, P562, DOI 10.1126/science.1948031; MIN KT, 1993, CELL, V74, P735, DOI 10.1016/0092-8674(93)90520-Z; NAJAFI SMA, 1995, J BACTERIOL, V177, P2912, DOI 10.1128/jb.177.10.2912-2913.1995; Ogasawara N, 1994, DNA Res, V1, P1, DOI 10.1093/dnares/1.1.1; SCHMIDT R, 1990, P NATL ACAD SCI USA, V87, P9221, DOI 10.1073/pnas.87.23.9221; SUN DX, 1991, J BACTERIOL, V173, P7867, DOI 10.1128/jb.173.24.7867-7874.1991; VOELKER U, 1995, J BACTERIOL, V177, P114, DOI 10.1128/jb.177.1.114-122.1995; WISE AA, 1995, J BACTERIOL, V177, P123, DOI 10.1128/jb.177.1.123-133.1995	24	204	209	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 27	1995	270	5236					641	644		10.1126/science.270.5236.641	http://dx.doi.org/10.1126/science.270.5236.641			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TB557	7570023				2022-12-24	WOS:A1995TB55700042
J	RAO, JK; ALLEN, NB; FEUSSNER, JR; WEINBERGER, M				RAO, JK; ALLEN, NB; FEUSSNER, JR; WEINBERGER, M			A PROSPECTIVE-STUDY OF ANTINEUTROPHIL CYTOPLASMIC ANTIBODY (C-ANCA) AND CLINICAL-CRITERIA IN DIAGNOSING WEGENERS GRANULOMATOSIS	LANCET			English	Article							ANTICYTOPLASMIC AUTOANTIBODIES; TEMPORAL ARTERITIS; GLOMERULONEPHRITIS; CLASSIFICATION; DISEASE; TESTS; BIAS	Antineutrophil cytoplasmic antibody (c-ANCA) has a reported sensitivity and specificity greater than 90% for active Wegener's granulomatosis in selected patients with previously-defined disease. Because of these reports, some clinicians believe that a positive c-ANCA result provides strong circumstantial evidence for the diagnosis of Wegener's granulomatosis in patients with compatible clinical symptoms. However, this approach has not been examined prospectively. We prospectively studied 346 consecutive patients suspected of having vasculitis; those with previously established Wegener's granulomatosis (n=29) or receiving immunosuppressives other than corticosteroids (n=65) at baseline were excluded. Measures included a baseline cANCA, blinded chart reviews to record symptoms, physical findings, and corticosteroid use at baseline, and 2 to 8 months later to record final diagnoses and biopsy results. Wegener's granulomatosis was defined using the 1990 American College of Rheumatology (ACR) criteria, which does not require a biopsy. Follow-up information was available for 212 (84%) of the 252 patients eligible for this study (no corticosteroids: n=174; corticosteroids: n=78). 25 patients with compatible symptoms were classified with Wegener's granulomatosis by ACR criteria; only 6 of the 25 had biopsy-proven disease. 14 of these 212 patients had positive c-ANCA results. The overall sensitivity of c-ANCA for ACR-defined Wegener's granulomatosis were 28% (95% CI, 10%-46%) and 96% respectively. The positive and negative and 0.91. The specificity regardless of baseline corticosteroid use or disease activity; however, the sensitivity and positive predictive value remained poor. For Wegener's granulomatosis defined by biopsy criteria and compatible clinical symptoms, the sensitivity was 83% (53%-100%); however, the positive predictive value was 36%. These results raise serious questions about the use of positive c-ANCA tests in diagnosing Wegener's granulomatosis in patients with clinical symptoms alone.	VET AFFAIRS MED CTR,CTR HLTH SERV RES PRIMARY CARE,DURHAM,NC 27705; DUKE UNIV,MED CTR,DIV RHEUMATOL & IMMUNOL,DURHAM,NC; DUKE UNIV,MED CTR,DIV GEN INTERNAL MED,DURHAM,NC 27710	US Department of Veterans Affairs; Veterans Health Administration (VHA); Duke University; Duke University	RAO, JK (corresponding author), RICHARD L ROUDEBUSH VET AFFAIRS MED CTR,1481 W 10TH ST,INDIANAPOLIS,IN 46208, USA.							ANDRASSY K, 1989, CLIN NEPHROL, V32, P159; AYMARD B, 1990, DIS COLON RECTUM, V33, P427, DOI 10.1007/BF02156272; BEGG CB, 1988, RADIOLOGY, V167, P565, DOI 10.1148/radiology.167.2.3357976; BRAY VJ, 1991, AM J KIDNEY DIS, V17, P578, DOI 10.1016/S0272-6386(12)80500-2; COHENTERVAERT JW, 1991, AM J MED, V91, P59; DAVENPORT A, 1992, CLIN NEPHROL, V37, P124; DAVIES DJ, 1982, BMJ-BRIT MED J, V285, P606, DOI 10.1136/bmj.285.6342.606; DEREMEE RA, 1976, MAYO CLIN PROC, V51, P777; FAUCI AS, 1983, ANN INTERN MED, V98, P76, DOI 10.7326/0003-4819-98-1-76; GROSS WL, 1986, LANCET, V1, P806; HAYNES BF, 1986, MED CLIN N AM, V70, P355, DOI 10.1016/S0025-7125(16)30958-0; HERREROBEAUMONT G, 1991, BRIT J RHEUMATOL, V30, P382; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; JENNETTE J C, 1992, Current Opinion in Rheumatology, V4, P9; LEAVITT RY, 1990, ARTHRITIS RHEUM, V33, P1101, DOI 10.1002/art.1780330807; LICHTENSTEIN MJ, 1988, J GEN INTERN MED, V3, P435, DOI 10.1007/BF02595919; MAINS B, 1989, J LARYNGOL OTOL, V103, P524, DOI 10.1017/S0022215100156774; MANDELL BF, 1994, RHEUM DIS CLIN N AM, V20, P409; MUSTONEN J, 1990, AM J NEPHROL, V10, P482, DOI 10.1159/000168173; NOLLE B, 1989, ANN INTERN MED, V111, P28, DOI 10.7326/0003-4819-111-1-28; ONEIL KM, 1992, DIGEST DIS SCI, V37, P702, DOI 10.1007/BF01296425; PALAIC M, 1991, NEUROLOGY, V41, P1694, DOI 10.1212/WNL.41.10.1694-a; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; SHMERLING RH, 1992, ARCH INTERN MED, V152, P2417, DOI 10.1001/archinte.152.12.2417; SMALL P, 1991, ARTHRITIS RHEUM, V34, P220, DOI 10.1002/art.1780340215; SPECKS U, 1989, MAYO CLIN PROC, V64, P28, DOI 10.1016/S0025-6196(12)65300-2; VANDERWOUDE FJ, 1985, LANCET, V1, P425; VANDERWOUDE FJ, 1985, LANCET, V2, P48; 1989, APMIS S, V97, P5	29	94	98	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 7	1995	346	8980					926	931		10.1016/S0140-6736(95)91555-9	http://dx.doi.org/10.1016/S0140-6736(95)91555-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY808	7564726				2022-12-24	WOS:A1995RY80800007
J	MELE, A; STROFFOLINI, T; CATAPANO, R; PALUMBO, F; MOIRAGHI, A; NOVACO, F				MELE, A; STROFFOLINI, T; CATAPANO, R; PALUMBO, F; MOIRAGHI, A; NOVACO, F			INCIDENCE OF TRANSFUSION-ASSOCIATED BHEPATITIS AND NON-AHEPATITIS, NON-B-HEPATITIS IN ITALY	BRITISH MEDICAL JOURNAL			English	Article									IST SUPER SANITA,EPIDEMIOL & BIOSTAT LAB,I-00161 ROME,ITALY; UNIV ROMA TOR VERGATA,DIPARTIMENTO SANITA PUBBL,ROME,ITALY; ASSESSORATO SANITA REG CAMPANIA,NAPLES,ITALY; UNIV TURIN,DIPARTIMENTO SANITA PUBBL,TURIN,ITALY; REG EMILIA ROMAGNA,ASSESSORATO SANITA,BOLOGNA,ITALY	Istituto Superiore di Sanita (ISS); University of Rome Tor Vergata; University of Turin								CAMPS J, 1994, HEPATOLOGY, V20, pA200; DONAHUE JG, 1992, NEW ENGL J MED, V327, P369, DOI 10.1056/NEJM199208063270601; MELE A, 1986, European Journal of Epidemiology, V2, P300, DOI 10.1007/BF00419494; THIERS V, 1988, LANCET, V2, P1273; 1991, LANCET, V338, P1040	5	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 30	1995	311	7009					846	847		10.1136/bmj.311.7009.846	http://dx.doi.org/10.1136/bmj.311.7009.846			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY191	7580492	Green Published			2022-12-24	WOS:A1995RY19100023
J	WOLPERT, DM; GHAHRAMANI, Z; JORDAN, MI				WOLPERT, DM; GHAHRAMANI, Z; JORDAN, MI			AN INTERNAL MODEL FOR SENSORIMOTOR INTEGRATION	SCIENCE			English	Article								On the basis of computational studies it has been proposed that the central nervous system internally simulates the dynamic behavior of the motor system in planning, control, acid learning; the existence and use of such an internal model is still under debate. A sensorimotor integration task was investigated in which participants estimated the location of one of their hands at the end of movements made in the dark and under externally imposed forces. The temporal propagation of errors in this task was analyzed within the theoretical framework of optimal state estimation. These results provide direct support for the existence of an internal model.	MIT,DEPT BRAIN & COGNIT SCI,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)			Jordan, Michael I/C-5253-2013	Wolpert, Daniel/0000-0003-2011-2790				Craig J. J, 1986, INTRO ROBOTICS; GALLISTEL C, 1990, ORG LEARNING, pCH4; Gallistel C.R., 1980, ORG ACTION; Goodwin GC, 1984, ADAPTIVE FILTERING P; Hastie T.J., 1990, GEN ADDITIVE MODELS; Ito M, 1984, CEREBELLUM NEURAL CO; JORDAN MI, 1992, COGNITIVE SCI, V16, P307, DOI 10.1207/s15516709cog1603_1; JORDAN MI, 1995, HDB PERCEPTION ACTIO; Kalman R. E., 1961, J BASIC ENG, V83, P95, DOI [10.1115/1.3658902, DOI 10.1115/1.3658902]; Kawato M., 1987, BIOL CYBERN, V56, P1; MIALL RC, 1993, J MOTOR BEHAV, V25, P203, DOI 10.1080/00222895.1993.9942050; ROBINSON DA, 1986, BIOL CYBERN, V55, P43, DOI 10.1007/BF00363977; SOECHTING JF, 1989, J NEUROPHYSIOL, V62, P582, DOI 10.1152/jn.1989.62.2.582; SUTTON RS, 1981, PSYCHOL REV, V88, P135, DOI 10.1037/0033-295X.88.2.135; WOLPERT DM, 1995, EXP BRAIN RES, V103, P460	15	2151	2161	7	155	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 29	1995	269	5232					1880	1882		10.1126/science.7569931	http://dx.doi.org/10.1126/science.7569931			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RX194	7569931				2022-12-24	WOS:A1995RX19400041
J	VAUGHAN, PS; AZIZ, F; VANWIJNEN, AJ; WU, SJ; HARADA, H; TANIGUCHI, T; SOPRANO, KJ; STEIN, JL; STEIN, GS				VAUGHAN, PS; AZIZ, F; VANWIJNEN, AJ; WU, SJ; HARADA, H; TANIGUCHI, T; SOPRANO, KJ; STEIN, JL; STEIN, GS			ACTIVATION OF A CELL-CYCLE-REGULATED HISTONE GENE BY THE ONCOGENIC TRANSCRIPTION FACTOR IRF-2	NATURE			English	Article							PROTEIN-DNA INTERACTIONS; FACTOR-I; MESSENGER-RNAS; EXPRESSION; PURIFICATION; PROMOTERS; INDUCTION; COMPLEX; GROWTH; BINDS	THE human histone H4 gene FO108 is regulated during the cell cycle with a peak in transcription during early S phase(1,2). The cell-cycle element (CCE) required for H4 histone activation is a sequence of 11 base pairs that binds a protein factor in electrophoretic mobility shift assays that has been designated histone nuclear factor M (HiNF-M)(2,3). Here we report the purification of HiNF-M, and show it to be a protein of relative molecular mass (M(r)) 48K that is identical to interferon (IFN) regulatory factor 2 (IRF-2), a negative transcriptional regulator of the IFN response(4). Recombinant IRF-2 (as well as the related protein IRF-1 (ref. 5)) binds the CCE specifically and activates transcription of this H4 histone gene, IRF-2 has been shown to have oncogenic potential(6), and our results demonstrate a link between IRF-2 and a gene that is functionally coupled to DNA replication and cell-cycle progression at the G1/S phase transition.	TEMPLE UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140; UNIV TOKYO,FAC MED,DEPT IMMUNOL,BUNKYO KU,TOKYO 113,JAPAN	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Tokyo	VAUGHAN, PS (corresponding author), UNIV MASSACHUSETTS,MED CTR,DEPT CELL BIOL,CTR CANC,55 LAKE AVE N,WORCESTER,MA 01655, USA.		van Wijnen, Andre J./AAG-3578-2019	van Wijnen, Andre J./0000-0002-4458-0946				ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; Ausubel FM, 1994, CURRENT PROTOCOLS MO; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; FRAPPIER L, 1991, J BIOL CHEM, V266, P7819; FUJITA T, 1989, P NATL ACAD SCI USA, V86, P9936, DOI 10.1073/pnas.86.24.9936; HAHN S, 1992, Current Biology, V2, P152, DOI 10.1016/0960-9822(92)90268-F; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1989, CELL, V56, P729; ITOH S, 1989, NUCLEIC ACIDS RES, V17, P8372, DOI 10.1093/nar/17.20.8372; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; PALOMBELLA VJ, 1992, MOL CELL BIOL, V12, P3325, DOI 10.1128/MCB.12.8.3325; PAULI U, 1987, SCIENCE, V236, P1308, DOI 10.1126/science.3035717; PENA A, 1993, J BIOL CHEM, V268, P27277; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; PLUMB M, 1983, NUCLEIC ACIDS RES, V11, P2391, DOI 10.1093/nar/11.8.2391; RAMSEYEWING A, 1994, P NATL ACAD SCI USA, V91, P4475, DOI 10.1073/pnas.91.10.4475; SHAKOORI R, IN PRESS J CELL BIOC; SUSSEL L, 1991, P NATL ACAD SCI USA, V88, P7749, DOI 10.1073/pnas.88.17.7749; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; VANWIJNEN AJ, 1992, MOL CELL BIOL, V12, P3273, DOI 10.1128/MCB.12.7.3273; VANWIJNEN AJ, 1994, P NATL ACAD SCI USA, V91, P12882, DOI 10.1073/pnas.91.26.12882; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; YAMAMOTO H, 1994, ONCOGENE, V9, P1423	29	167	170	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 28	1995	377	6547					362	365		10.1038/377362a0	http://dx.doi.org/10.1038/377362a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX111	7566094				2022-12-24	WOS:A1995RX11100063
J	CORTI, MC; GURALNIK, JM; SALIVE, ME; HARRIS, T; FIELD, TS; WALLACE, RB; BERKMAN, LF; SEEMAN, TE; GLYNN, RJ; HENNEKENS, CH; HAVLIK, RJ				CORTI, MC; GURALNIK, JM; SALIVE, ME; HARRIS, T; FIELD, TS; WALLACE, RB; BERKMAN, LF; SEEMAN, TE; GLYNN, RJ; HENNEKENS, CH; HAVLIK, RJ			HDL CHOLESTEROL PREDICTS CORONARY HEART-DISEASE MORTALITY IN OLDER PERSONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIGH-DENSITY LIPOPROTEIN; HIGH BLOOD CHOLESTEROL; UNITED-STATES ADULTS; CARDIOVASCULAR-DISEASE; SERUM-CHOLESTEROL; RISK-FACTORS; FOLLOW-UP; FRAMINGHAM; PREVALENCE; HEALTH	Objectives.-To examine the relationship of total cholesterol and high-density lipoprotein cholesterol (HDL-C) with coronary heart disease (CHD) mortality and with occurrence of new CHD events in persons aged 71 years and older. Design.-Prospective cohort study with a median of 4.4 years of follow-up. Setting.-East Boston, Mass; New Haven, Conn; and Iowa and Washington counties, Iowa. Participants.-A total of 2527 women and 1377 men who completed an interview, had serum lipid determinations, and survived at least 1 year. New CHD events were evaluated in persons with no CHD history or hospitalization. Main Outcome Measures.-Death due to CHD (ICD-9 codes 410 through 414 as underlying cause of death); new occurrence of CHD events (fatal CHD or hospitalization with CHD [ICD-9 codes 410 through 414]). Results.-After adjustment for established CHD risk factors, the relative risk (RR) of death due to CHD for those with low HDL-C (<0.90 mmol/L [<35 mg/dL]) compared with the reference group (HDL-C greater than or equal to 1.55 mmol/L [greater than or equal to 60 mg/dL]) was 2.5 (95% confidence interval [Cl], 1.6 to 4.0). Elevated risk was present in subgroups aged 71 through 80 years (RR, 4.1; 95% Cl, 1.9 to 8.8) and over 80 years (RR, 1.8; 95% Cl, 0.99 to 3.4), and in men and women. Low HDL-C predicted an increased risk of occurrence of new CHD events (RR, 1.4, 95% Cl, 1.1 to 2.0), with similar but nonsignificant results in subgroups of men and women. Total cholesterol was less consistently associated with CHD mortality than HDL-C. When we compared individuals with total cholesterol of at least 6.20 mmol/L (240 mg/dL) with the reference group with total cholesterol of 4.16 to 5.19 mmol/L (161 to 199 mg/dL), a significant risk of CHD mortality was seen for women (RR, 1.8; 95% Cl, 1.03 to 3.0) but not for men (RR, 1.0; 95% Cl, 0.5 to 2.0). In the total population, for each 1-unit increase in the total cholesterol/HDL-C ratio there was a 17% increase in the risk of CHD death that was statistically significant. Conclusions.-Low HDL-C predicts CHD mortality and occurrence of new CHD events in persons older than 70 years. Elevated total cholesterol was not found to be associated with CHD mortality in older men, but may be a risk factor for CHD in older women.	HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED, DIV PREVENT MED, BOSTON, MA 02115 USA; UNIV IOWA, DEPT PREVENT MED & ENVIRONM HLTH, IOWA CITY, IA 52242 USA; YALE UNIV, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, NEW HAVEN, CT 06510 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Iowa; Yale University; Harvard University; Harvard T.H. Chan School of Public Health	CORTI, MC (corresponding author), NIA, EPIDEMIOL DEMOG & BIOMETRY PROGRAM, 7201 WISCONSIN AVE, ROOM 3C309, BETHESDA, MD 20892 USA.				NATIONAL INSTITUTE ON AGING [N01AG002105, N01AG002107, N01AG002106] Funding Source: NIH RePORTER; NIA NIH HHS [N01-AG-02105, N01-AG-02106, N01-AG-02107] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AGNER E, 1983, ACTA MED SCAND, V214, P33; ANDERSON KM, 1987, JAMA-J AM MED ASSOC, V257, P2176, DOI 10.1001/jama.257.16.2176; [Anonymous], 1994, CIRCULATION, V89, P1329; Barrett-Connor E, 1992, Ann Epidemiol, V2, P77, DOI 10.1016/1047-2797(92)90040-W; BARRETTCONNOR E, 1984, J CHRON DIS, V37, P903, DOI 10.1016/0021-9681(84)90066-3; BENFANTE RJ, 1989, J CLIN EPIDEMIOL, V42, P95, DOI 10.1016/0895-4356(89)90082-6; BRAY GA, 1978, INT J OBESITY, V2, P99; CORNONIHUNTLEY J, 1993, AGING-CLIN EXP RES, V5, P27; CORTI MC, 1994, JAMA-J AM MED ASSOC, V272, P1036, DOI 10.1001/jama.272.13.1036; DAVIS CE, 1990, JAMA-J AM MED ASSOC, V264, P3044, DOI 10.1001/jama.264.23.3044; FISHER ES, 1992, AM J PUBLIC HEALTH, V82, P243, DOI 10.2105/AJPH.82.2.243; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; HARRIS T, 1988, J AM GERIATR SOC, V36, P1023, DOI 10.1111/j.1532-5415.1988.tb04370.x; HULLEY SB, 1994, JAMA-J AM MED ASSOC, V272, P1372, DOI 10.1001/jama.272.17.1372; JACKSON R, 1988, NEW ZEAL MED J, V101, P658; JACOBS D, 1992, CIRCULATION, V86, P1046, DOI 10.1161/01.CIR.86.3.1046; JACOBS DR, 1990, AM J EPIDEMIOL, V131, P32, DOI 10.1093/oxfordjournals.aje.a115483; JOHNSON CL, 1993, JAMA-J AM MED ASSOC, V269, P3002, DOI 10.1001/jama.269.23.3002; JOLLIS JG, 1993, ANN INTERN MED, V119, P844, DOI 10.7326/0003-4819-119-8-199310150-00011; KRONMAL RA, 1993, ARCH INTERN MED, V153, P1065, DOI 10.1001/archinte.153.9.1065; KRUMHOLZ HM, 1994, JAMA-J AM MED ASSOC, V272, P1335, DOI 10.1001/jama.272.17.1335; LACROIX AZ, 1991, NEW ENGL J MED, V325, P1586; MALENKA DJ, 1988, ARCH INTERN MED, V148, P2247, DOI 10.1001/archinte.148.10.2247; MANOLIO TA, 1992, ANN INTERN MED, V116, P641, DOI 10.7326/0003-4819-116-8-641; MILLERBASS K, 1993, ARCH INTERN MED, V153, P2209; PEDERSEN TR, 1994, LANCET, V344, P1383; PEKKANEN J, 1994, AM J EPIDEMIOL, V139, P155, DOI 10.1093/oxfordjournals.aje.a116977; Reed D, 1992, Ann Epidemiol, V2, P29, DOI 10.1016/1047-2797(92)90034-N; RUBIN SM, 1990, ANN INTERN MED, V113, P916, DOI 10.7326/0003-4819-113-12-916; SEMPOS CT, 1993, JAMA-J AM MED ASSOC, V269, P3009, DOI 10.1001/jama.269.23.3009; SHURTLEFF D, 1974, US DHEW NIH74599 PUB; Sorkin J D, 1992, Ann Epidemiol, V2, P59, DOI 10.1016/1047-2797(92)90038-R; STAESSEN J, 1990, J HYPERTENS, V8, P755, DOI 10.1097/00004872-199008000-00010; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; Wallace R B, 1992, Ann Epidemiol, V2, P15, DOI 10.1016/1047-2797(92)90032-L; WILSON PWF, 1988, ARTERIOSCLEROSIS, V8, P737, DOI 10.1161/01.ATV.8.6.737; ZIMETBAUM P, 1992, ARTERIOSCLER THROMB, V12, P416, DOI 10.1161/01.ATV.12.4.416; 1991, P217 SAS I INC TECHN; [No title captured]; 1977, JAMA-J AM MED ASSOC, V237, P2385	42	210	214	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 16	1995	274	7					539	544		10.1001/jama.274.7.539	http://dx.doi.org/10.1001/jama.274.7.539			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN466	7629981				2022-12-24	WOS:A1995RN46600023
J	DEBERG, JC; PATTYNAMA, PMT; OBERMANN, WR; BODE, PJ; VIELVOYE, GJ; TAMINIAU, AHM				DEBERG, JC; PATTYNAMA, PMT; OBERMANN, WR; BODE, PJ; VIELVOYE, GJ; TAMINIAU, AHM			PERCUTANEOUS COMPUTED-TOMOGRAPHY-GUIDED THERMOCOAGULATION FOR OSTEOID OSTEOMAS	LANCET			English	Note							ELECTRODE	Current treatment for osteoid osteomas is usually surgical excision of the nidus. We treated 18 patients with osteoid osteoma by percutaneous thermocoagulation of the nidus under computed-tomography guidance. The procedure was technically successful in all cases and there were no complications. Patients were discharged on the following morning and resumed normal activities immediately. Air patients but one remained pain free during follow-up (range 3-15 months). A second thermocoagulation treatment relieved the recurrent symptoms in this patient. Percutaneous thermocoagulation appears to be effective for osteoid osteomas, and is a minimally invasive alternative to surgical resection.	UNIV LEIDEN HOSP,DEPT ORTHOPAED SURG,2333 AA LEIDEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC)	DEBERG, JC (corresponding author), UNIV LEIDEN HOSP,DEPT RADIOL,2333 AA LEIDEN,NETHERLANDS.							MARCOVE RC, 1991, CLIN ORTHOP RELAT R, V267, P197; MAZOYER JF, 1991, RADIOLOGY, V181, P269, DOI 10.1148/radiology.181.1.1887046; MULDER JD, 1993, RADIOLOGIC ATLAS BON, P385; NORMAN A, 1975, CLIN ORTHOP RELAT R, V110, P233; Picci P, 1989, BONE TUMORS CLIN RAD, P226; ROSENTHAL DI, 1992, RADIOLOGY, V183, P29, DOI 10.1148/radiology.183.1.1549690; TILLOTSON CL, 1989, INVEST RADIOL, V24, P888, DOI 10.1097/00004424-198911000-00009	7	103	107	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 5	1995	346	8971					350	351		10.1016/S0140-6736(95)92228-8	http://dx.doi.org/10.1016/S0140-6736(95)92228-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM713	7623534				2022-12-24	WOS:A1995RM71300011
J	BINDMAN, AB; GRUMBACH, K; OSMOND, D; KOMAROMY, M; VRANIZAN, K; LURIE, N; BILLINGS, J; STEWART, A				BINDMAN, AB; GRUMBACH, K; OSMOND, D; KOMAROMY, M; VRANIZAN, K; LURIE, N; BILLINGS, J; STEWART, A			PREVENTABLE HOSPITALIZATIONS AND ACCESS TO HEALTH-CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICAL-CARE; CITY; POOR	Objective. To examine whether the higher hospital admission rates for chronic medical conditions such as asthma, hypertension, congestive heart failure, chronic obstructive pulmonary disease, and diabetes in low-income communities resulted from community differences in access to care, prevalence of the diseases, propensity to seek care, or physician admitting style. Design.-Analysis of California hospital discharge data. We calculated the hospitalization rates for these five chronic conditions for the 250 ZIP code clusters that define urban California. We performed a random-digit telephone survey among adults residing in a random sample of 41 of these urban ZIP code clusters stratified by admission rates and a mailed survey of generalist and emergency physicians who practiced in the same 41 areas. Setting.-Community based. Participants.-A total of 6674 English- and Spanish-speaking adults aged 18 through 64 years residing in the 41 areas were asked about their access to care, their chronic medical conditions, and their propensity to seek health care. Physician admitting style was measured with written clinical vignettes among 723 generalist and emergency physicians practicing in the same communities. Main Outcome Measures.-We compared respondents' reports of access to medical care in an area with the area's cumulative admission rate for these five chronic conditions. We then tested whether access to medical care remained independently associated with preventable hospitalization rates after controlling for the prevalence of the conditions, health care seeking, and physician practice style. Results.-Access to care was inversely associated with the hospitalization rates for the five chronic medical conditions (R(2)=0.50; P<.001). In a multivariate analysis that included a measure of access, the prevalence of conditions, health care seeking, and physician practice style to predict cumulative hospitalization rates for chronic medical conditions, both self-rated access to care (P<.002) and the prevalence of the conditions (P<.03) remained independent predictors. Conclusion.-Communities where people perceive poor access to medical care have higher rates of hospitalization for chronic diseases. Improving access to care is more likely than changing patients' propensity to seek health care or eliminating variation in physician practice style to reduce hospitalization rates for chronic conditions.	SAN FRANCISCO GEN HOSP,DIV GEN INTERNAL MED,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO,DEPT FAMILY & COMMUNITY MED,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO,DIV GEN INTERNAL MED,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO,INST HLTH & AGING,SAN FRANCISCO,CA 94143; UNIV MINNESOTA,SCH MED,HENNEPIN CTY MED CTR,DEPT MED,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH PUBL HLTH,MINNEAPOLIS,MN 55455; NYU,ROBERT F WAGNER GRAD SCH PUBL SERV,NEW YORK,NY 10003	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Hennepin County Medical Center; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; New York University	BINDMAN, AB (corresponding author), SAN FRANCISCO GEN HOSP,PRIMARY CARE RES CTR,WARD 95,1001 POTRERO AVE,SAN FRANCISCO,CA 94110, USA.		Grumbach, Kevin/L-9222-2016		AHRQ HHS [HSO7373] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BILLINGS J, 1993, HEALTH AFFAIR, V12, P162, DOI 10.1377/hlthaff.12.1.162; CAPER P, 1993, HEALTH AFFAIR, V12, P174, DOI 10.1377/hlthaff.12.1.174; DIEHR P, 1990, HEALTH SERV RES, V24, P741; FREEMAN HE, 1987, HEALTH AFFAIR, V6, P6, DOI 10.1377/hlthaff.6.1.6; GRISWOLD PR, 1992, HLTH CARE COSTS MASS; GRUMBACH K, 1995, CALIFORNIA POLICY SE; HAFNEREATON C, 1993, JAMA-J AM MED ASSOC, V269, P787, DOI 10.1001/jama.269.6.787; KLEINMAN JC, 1981, MED CARE, V19, P1011, DOI 10.1097/00005650-198110000-00004; Komaromy Miriam, 1995, JGIM, V10, P70; MEUX E, 1994, HEALTH SERV RES, V29, P247; MEUX EF, 1990, REPORT RESULTS OSHPD; NEWACHECK PW, 1988, HEALTH SERV RES, V23, P401; SHAPIRO MF, 1986, ANN INTERN MED, V104, P246, DOI 10.7326/0003-4819-104-2-246; SHEA S, 1992, NEW ENGL J MED, V327, P776, DOI 10.1056/NEJM199209103271107; SMELOFF EA, 1981, PUBLIC HEALTH REP, V96, P310; WEISSMAN JS, 1992, JAMA-J AM MED ASSOC, V268, P2388, DOI 10.1001/jama.268.17.2388; 1993, CD ROM SERIES 10, V4; 1990, STATISTICAL ANAL SAM; 1992, US DEPT HLTH HUMA 10, V4; 1992, 1990 CALIFORNIA HOSP	20	687	692	0	54	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 26	1995	274	4					305	311		10.1001/jama.274.4.305	http://dx.doi.org/10.1001/jama.274.4.305			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RJ898	7609259				2022-12-24	WOS:A1995RJ89800032
J	BEREK, JS				BEREK, JS			OVARIAN-CANCER SPREAD - IS LAPAROSCOPY TO BLAME	LANCET			English	Editorial Material							TUMORS				BEREK, JS (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT OBSTET & GYNAECOL,LOS ANGELES,CA 90024, USA.							CHILDERS JM, 1994, OBSTET GYNECOL, V84, P765; DEMBO AJ, 1990, OBSTET GYNECOL, V75, P263; GLEESON NC, 1993, AM J OBSTET GYNECOL, V169, P522, DOI 10.1016/0002-9378(93)90611-L; GRANBERG S, 1990, GYNECOL ONCOL, V37, P224, DOI 10.1016/0090-8258(90)90337-K; HERRMANN UJ, 1987, OBSTET GYNECOL, V69, P777; HULKA J, 1992, J REPROD MED, V7, P599; MAIMAN M, 1991, OBSTET GYNECOL, V77, P563; PARKER WH, 1990, AM J OBSTET GYNECOL, V163, P1574, DOI 10.1016/0002-9378(90)90630-P; PARKER WH, 1994, J AM COLL SURGEONS, V179, P733; SEVELDA P, 1989, GYNECOL ONCOL, V35, P321, DOI 10.1016/0090-8258(89)90071-1; SJOVALL K, 1994, INT J GYNECOL CANCER, V4, P333, DOI 10.1046/j.1525-1438.1994.04050333.x; WEBB MJ, 1973, AM J OBSTET GYNECOL, V116, P222, DOI 10.1016/0002-9378(73)91054-5	12	18	18	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 22	1995	346	8969					200	200		10.1016/S0140-6736(95)91264-9	http://dx.doi.org/10.1016/S0140-6736(95)91264-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK419	7616797				2022-12-24	WOS:A1995RK41900006
J	HOLLEY, SA; JACKSON, PD; SASAI, Y; LU, B; DEROBERTIS, EM; HOFFMANN, FM; FERGUSON, EL				HOLLEY, SA; JACKSON, PD; SASAI, Y; LU, B; DEROBERTIS, EM; HOFFMANN, FM; FERGUSON, EL			A CONSERVED SYSTEM FOR DORSAL-VENTRAL PATTERNING IN INSECTS AND VERTEBRATES INVOLVING SOG AND CHORDIN	NATURE			English	Article							DROSOPHILA EMBRYO; XENOPUS; GRADIENT; POLARITY; DOMINANT; GENES; TOLL	DORSAL-VENTRAL patterning within the ectoderm of the Drosophila embryo requires seven zygotic genes, including short gastrulation (sog)(1). Here we demonstrate that sog, which is expressed in the ventrolateral region of the embryo that gives rise to the nerve cord(2), is functionally homologous to the chordin gene of Xenopus, which is expressed in the dorsal blastopore lip of the embryo and in dorsal mesoderm, in particular the notochord(3). We show by injections of messenger RNA that both sog and chordin can promote ventral development in Drosophila, and that sog, like chordin(3), can promote dorsal development in Xenopus. In Drosophila, sog antagonizes the dorsalizing effects of decapentaplegic (dpp)(1,2,4), member of the transforming growth factor-beta family. One of the dpp homologues in vertebrates, bmp-4, is expressed ventrally in Xenopus(5) and promotes ventral development(6,7). We show that dpp can promote ventral fates in Xenopus, and that injection of sog mRNA counteracts the ventralizing effects of dpp. These results suggest the molecular conservation of dorsoventral patterning mechanisms during evolution.	UNIV WISCONSIN,SCH MED,MCARDLE LAB CANC RES,MADISON,WI 53706; UNIV WISCONSIN,SCH MED,GENET LAB,MADISON,WI 53706; UNIV CALIF LOS ANGELES,DEPT BIOL CHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,LOS ANGELES,CA 90024	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles	HOLLEY, SA (corresponding author), UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,920 E 58TH ST,CHICAGO,IL 60637, USA.			Ferguson, Edwin/0000-0003-4125-4253; Hoffmann, F. Michael/0000-0002-2770-9656				AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; ARENDT D, 1994, NATURE, V371, P26, DOI 10.1038/371026a0; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; DALE L, 1992, DEVELOPMENT, V115, P573; FAINSOD A, 1994, EMBO J, V13, P5015, DOI 10.1002/j.1460-2075.1994.tb06830.x; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FRANCOIS V, 1995, CELL, V80, P19, DOI 10.1016/0092-8674(95)90446-8; FRANCOIS V, 1994, GENE DEV, V8, P2602, DOI 10.1101/gad.8.21.2602; Geoffroy Saint-Hilaire E., 1822, MEMOIRES DU MUSEUM D, V9, P89; JONES CM, 1992, DEVELOPMENT, V115, P39; LACALLI TC, 1995, NATURE, V373, P110, DOI 10.1038/373110c0; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; PETERSON KJ, 1995, NATURE, V373, P112; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; STEWART RM, 1991, ROUX ARCH DEV BIOL, V199, P341, DOI 10.1007/BF01705927; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; WHARTON KA, 1993, DEVELOPMENT, V117, P807; ZUSMAN SB, 1988, DEV BIOL, V129, P417, DOI 10.1016/0012-1606(88)90389-2	24	363	371	0	22	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 20	1995	376	6537					249	253		10.1038/376249a0	http://dx.doi.org/10.1038/376249a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK331	7617035				2022-12-24	WOS:A1995RK33100045
J	BAUER, TM; RITZ, R; HABERTHUR, C; HA, HR; HUNKELER, W; SLEIGHT, AJ; SCOLLOLAVIZZARI, G; HAEFELI, WE				BAUER, TM; RITZ, R; HABERTHUR, C; HA, HR; HUNKELER, W; SLEIGHT, AJ; SCOLLOLAVIZZARI, G; HAEFELI, WE			PROLONGED SEDATION DUE TO ACCUMULATION OF CONJUGATED METABOLITES OF MIDAZOLAM	LANCET			English	Article							MORPHINE-6-GLUCURONIDE; PLASMA	Midazolam is a short-acting benzodiazepine routinely used in intensive-care medicine. Conjugates of its main metabolite, alpha-hydroxymidazolam, have been shown to accumulate in renal failure but have not previously been related to the prolonged sedative effects commonly observed in critically ill patients. We report five patients with severe renal failure who had prolonged sedation after administration of midazolam. In all five patients, the comatose state was immediately reversed by the benzodiazepine-receptor antagonist flumazenil. Serum concentration monitoring showed high concentrations of conjugated alpha-hydroxymidazolam when concentrations of the unconjugated metabolite and the parent drug were below the therapeutic range. In-vitro binding studies showed that the affinity of binding to the cerebral benzodiazepine receptor of glucuronidated alpha-hydroxymidazolam was only about ten times weaker (affinity constant 16 nmol/L) than that of midazolam (1 . 4 nmol/L) or unconjugated alpha-hydroxymidazolam (2 . 2 nmol/L). Conjugated metabolites of midazolam have substantial pharmacological activity. Physicians should be aware that these metabolites can accumulate in patients with renal failure.	UNIV BASEL HOSP,DEPT INTERNAL MED,DIV CLIN PHARMACOL,CH-4031 BASEL,SWITZERLAND; UNIV BASEL HOSP,DEPT INTERNAL MED,DIV INTENS CARE,CH-4031 BASEL,SWITZERLAND; UNIV BASEL HOSP,DEPT NEUROL,CH-4031 BASEL,SWITZERLAND; UNIV ZURICH HOSP,CARDIOVASC THERAPY RES UNIT,CH-8091 ZURICH,SWITZERLAND; F HOFFMANN LA ROCHE & CO LTD,CH-4002 BASEL,SWITZERLAND	University of Basel; University of Basel; University of Basel; University of Zurich; University Zurich Hospital; Roche Holding			Haefeli, Walter Emil/AAJ-3024-2020	Haefeli, Walter Emil/0000-0003-0672-6876				BYATT CM, 1984, BRIT MED J, V289, P799, DOI 10.1136/bmj.289.6448.799; DREISSEN JJ, 1991, ACTA ANAESTH BELG, V42, P149; HA HR, 1993, THER DRUG MONIT, V15, P338, DOI 10.1097/00007691-199308000-00013; HAND CW, 1987, LANCET, V2, P1207; HEISMANN P, 1983, BR J CLIN PHARM, V16, pS43; KROEMER HK, 1992, CLIN PHARMACOKINET, V23, P292, DOI 10.2165/00003088-199223040-00005; MOHLER H, 1981, NATURE, V294, P763, DOI 10.1038/294763a0; MOHLER H, 1981, J NEUROCHEM, V37, P714; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OLDENHOF H, 1988, CLIN PHARMACOL THER, V43, P263, DOI 10.1038/clpt.1988.31; OSBORNE R, 1988, LANCET, V1, P828; PERSSON MP, 1988, CLIN PHARMACOL THER, V43, P324; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; SCOLLOLAVIZZARI G, 1987, EUR NEUROL, V26, P161, DOI 10.1159/000116329	14	208	225	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 15	1995	346	8968					145	147		10.1016/S0140-6736(95)91209-6	http://dx.doi.org/10.1016/S0140-6736(95)91209-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ031	7603229				2022-12-24	WOS:A1995RJ03100009
J	PEISACH, E; CASEBIER, D; GALLION, SL; FURTH, P; PETSKO, GA; HOGAN, JC; RINGE, D				PEISACH, E; CASEBIER, D; GALLION, SL; FURTH, P; PETSKO, GA; HOGAN, JC; RINGE, D			INTERACTION OF A PEPTIDOMIMETIC AMINIMIDE INHIBITOR WITH ELASTASE	SCIENCE			English	Article							LIBRARY; LIGANDS; BINDING	The crystal structure of an aminimide analog of a dipeptide inhibitor of porcine pancreatic elastase bound to its target serine protease has been solved. The peptidomimetic molecule binds in the same fashion as the class of dipeptides from which it was derived, making similar interactions with the subsites on the elastase surface. Because aminimides are readily synthesized from a wide variety of starting materials, they form the basis for a combinatorial chemistry approach to rational drug design.	BRANDEIS UNIV,DEPT BIOCHEM,WALTHAM,MA 02254; BRANDEIS UNIV,DEPT CHEM,WALTHAM,MA 02254; BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,WALTHAM,MA 02254; BRANDEIS UNIV,PROGRAM BIOPHYS,WALTHAM,MA 02254	Brandeis University; Brandeis University; Brandeis University; Brandeis University			Petsko, Gregory/AAO-7962-2020	Peisach, Ezra/0000-0002-7905-6327	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007596] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32GMO7596] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMOUR A, 1994, INT J PEPT PROT RES, V43, P297; AUBURY A, 1994, INT J PEPT PROT RES, V43, P305; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BODE W, 1986, EMBO J, V5, P2453, DOI 10.1002/j.1460-2075.1986.tb04521.x; BRUNGER AT, 1989, ACTA CRYSTALLOGR A, V45, P50, DOI 10.1107/S0108767388009195; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DELASIERRA IL, 1990, J MOL RECOG, V0003; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; GALLOP MA, 1994, J MED CHEM, V37, P1233, DOI 10.1021/jm00035a001; GEYSEN HM, 1986, CIBA F S, V119; HUGHES DL, 1982, J MOL BIOL, V162, P645, DOI 10.1016/0022-2836(82)90393-X; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAVIE A, COMMUNICATION; MATTOS C, 1994, NAT STRUCT BIOL, V1, P55, DOI 10.1038/nsb0194-55; MATTOS C, 1995, BIOCHEMISTRY-US, V34, P3193, DOI 10.1021/bi00010a008; MATTOS C, 1993, QSAR DRUG DESIGN THE, P226; RENAUD A, 1983, J BIOL CHEM, V258, P8312; RINGE D, 1995, NEW PERSPECTIVES IN DRUG DESIGN, P89; RINGE D, UNPUB; SAWYER L, 1978, J MOL BIOL, V118, P137, DOI 10.1016/0022-2836(78)90412-6; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SHOTTON D M, 1970, Nature (London), V225, P811, DOI 10.1038/225811a0	23	43	47	0	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 7	1995	269	5220					66	69		10.1126/science.7604279	http://dx.doi.org/10.1126/science.7604279			4	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RG980	7604279				2022-12-24	WOS:A1995RG98000033
J	STARGELL, LA; STRUHL, K				STARGELL, LA; STRUHL, K			THE TBP-TFIIA INTERACTION IN THE RESPONSE TO ACIDIC ACTIVATORS IN-VIVO	SCIENCE			English	Article							TATA-BINDING PROTEIN; RNA POLYMERASE-II; GENERAL TRANSCRIPTION FACTOR; YEAST; INITIATION; PROMOTERS; CLONING; MUTANTS; DOMAIN; VP16	A yeast TBP mutant (N2-1) is described here that is defective specifically in responding to acidic activators in vivo. N2-1 does not support activation by Gal4, Ace1, and Gcn4, but appears unaffected for constitutive transcription, repression by the Cyc8-Tup1 and Not complexes, and transcription by polymerase I (Pol) and Pol III. In vitro, N2-1 fails to interact with TFIIA, but it associates normally with a TATA element, an acidic activation domain, and TFIIB. Fusion of the small subunit of TFIIA to N2-1 restores activation function in vivo. Thus, an efficient interaction between TBP and TFIIA is required for transcriptional activation in vivo.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Harvard Medical School			Stargell, Laurie/GWC-7423-2022		NIGMS NIH HHS [GM30186] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030186, R01GM030186] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; BURATOWSKI S, 1992, SCIENCE, V255, P1130, DOI 10.1126/science.1546314; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; BUTLER G, 1991, MOL CELL BIOL, V11, P476, DOI 10.1128/MCB.11.1.476; CHATTERJEE S, 1995, NATURE, V374, P820, DOI 10.1038/374820a0; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; COLGAN J, 1992, GENE DEV, V6, P304, DOI 10.1101/gad.6.2.304; COLLART MA, 1994, GENE DEV, V8, P525, DOI 10.1101/gad.8.5.525; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CORMACK BP, 1993, SCIENCE, V262, P244, DOI 10.1126/science.8211143; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; FURST P, 1988, CELL, V55, P705, DOI 10.1016/0092-8674(88)90229-2; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HAHN S, 1989, EMBO J, V8, P3379, DOI 10.1002/j.1460-2075.1989.tb08501.x; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; INOSTROZA JA, 1992, CELL, V70, P477; KANG JJ, 1995, MOL CELL BIOL, V15, P1234; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KIM K, 1994, J BIOL CHEM, V269, P4891; KIM TK, 1994, NATURE, V369, P252, DOI 10.1038/369252a0; KLAGES N, 1995, NATURE, V374, P822, DOI 10.1038/374822a0; KLEIN C, 1994, MOL CELL BIOL, V14, P1920, DOI 10.1128/MCB.14.3.1920; KLEIN C, 1994, SCIENCE, V266, P280, DOI 10.1126/science.7939664; LEE DK, 1992, MOL CELL BIOL, V12, P5189, DOI 10.1128/MCB.12.11.5189; LIEBERMAN PM, 1994, GENE DEV, V8, P995, DOI 10.1101/gad.8.9.995; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; OZER J, 1994, GENE DEV, V8, P2324, DOI 10.1101/gad.8.19.2324; RANISH JA, 1992, SCIENCE, V255, P1127, DOI 10.1126/science.1546313; SINGER VL, 1990, GENE DEV, V4, P636, DOI 10.1101/gad.4.4.636; STARGELL LA, 1994, MOL CELL BIOL, V14, P723, DOI 10.1128/MCB.14.1.723; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STRUHL K, 1986, MOL CELL BIOL, V6, P3847, DOI 10.1128/MCB.6.11.3847; TAMAI KT, 1994, MOL CELL BIOL, V14, P8155, DOI 10.1128/MCB.14.12.8155; TANSEY WP, 1994, GENE DEV, V8, P2756, DOI 10.1101/gad.8.22.2756; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TZAMARIAS D, 1995, GENE DEV, V9, P821, DOI 10.1101/gad.9.7.821; TZAMARIAS D, 1994, NATURE, V369, P758, DOI 10.1038/369758a0; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; YOKOMORI K, 1994, GENE DEV, V8, P2313, DOI 10.1101/gad.8.19.2313; YOKOMORI K, 1994, GENE DEV, V8, P2336; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	50	103	103	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 7	1995	269	5220					75	78		10.1126/science.7604282	http://dx.doi.org/10.1126/science.7604282			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RG980	7604282				2022-12-24	WOS:A1995RG98000036
J	BERTHOLD, J; BAUER, MF; SCHNEIDER, HC; KLAUS, C; DIETMEIER, K; NEUPERT, W; BRUNNER, M				BERTHOLD, J; BAUER, MF; SCHNEIDER, HC; KLAUS, C; DIETMEIER, K; NEUPERT, W; BRUNNER, M			THE MIM COMPLEX MEDIATES PREPROTEIN TRANSLOCATION ACROSS THE MITOCHONDRIAL INNER MEMBRANE AND COUPLES IT TO THE MT-HSP70/ATP DRIVING SYSTEM	CELL			English	Article							PROTEIN IMPORT MACHINERY; YEAST MITOCHONDRIA; OUTER-MEMBRANE; CONTACT SITES; IDENTIFICATION; PRECURSOR; CROSS; COMPONENT; LINKING; MPI1	We have identified a complex in mitochondria that functions as a part of the preprotein import machinery of the inner membrane (MIM complex). Two known components, MIM23 and MIM17, and two novel components, MIM33 and MIM14, were found as constituents of this complex. In the presence of a translocating chain, the outer membrane import machinery (MOM complex) and the MINI complex form translocation contact sites. On the matrix side, the MIM complex is associated with the mt-Hsp70-MIM44 system. We propose a structure of the import machinery in which the MIM complex constitutes a proteinaceous channel that accepts preproteins from the MOM complex, facilitates their reversible transmembrane movement, and mediates unidirectional transport by linkage to the ATP-dependent mt-Hsp70-MIM44 system.			BERTHOLD, J (corresponding author), UNIV MUNICH, INST PHYSIOL CHEM, GOETHESTR 33, D-80336 MUNICH, GERMANY.			Brunner, Michael/0000-0001-9798-3047				ARRETZ M, 1994, J BIOL CHEM, V269, P4959; BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; BLOM J, 1993, MOL CELL BIOL, V13, P7364, DOI 10.1128/MCB.13.12.7364; BROACH JR, 1983, EXPT MANIPULATION GE, P85; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; DAUM G, 1982, J BIOL CHEM, V257, P3075; DEKKER PJT, 1993, FEBS LETT, V330, P66, DOI 10.1016/0014-5793(93)80921-G; EMTAGE JLT, 1993, J CELL BIOL, V122, P1003, DOI 10.1083/jcb.122.5.1003; Glick B, 1991, Trends Cell Biol, V1, P99, DOI 10.1016/0962-8924(91)90037-A; GLICK BS, 1995, CELL, V80, P11, DOI 10.1016/0092-8674(95)90444-1; GRUHLER A, 1995, EMBO J, V14, P1349, DOI 10.1002/j.1460-2075.1995.tb07121.x; HARLOW E, 1988, LABORATORY MANUAL; HIGH S, 1993, J BIOL CHEM, V268, P26745; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; HOCHULI E, 1989, CHEM IND, V12, P69; HOVLAND P, 1989, GENE, V83, P57, DOI 10.1016/0378-1119(89)90403-4; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; KRONIDOU NG, 1994, P NATL ACAD SCI USA, V91, P12818, DOI 10.1073/pnas.91.26.12818; KUBRICH M, 1994, FEBS LETT, V349, P222, DOI 10.1016/0014-5793(94)00670-9; MAARSE AC, 1992, EMBO J, V11, P3619, DOI 10.1002/j.1460-2075.1992.tb05446.x; MAARSE AC, 1994, FEBS LETT, V349, P215, DOI 10.1016/0014-5793(94)00669-5; MAYER A, 1995, CELL, V80, P127, DOI 10.1016/0092-8674(95)90457-3; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; NICCHITTA CV, 1991, CELL, V65, P587, DOI 10.1016/0092-8674(91)90091-C; PFANNER N, 1995, CURR BIOL, V5, P132; PFANNER N, 1992, CELL, V68, P999, DOI 10.1016/0092-8674(92)90069-O; RASSOW J, 1990, FEBS LETT, V275, P190, DOI 10.1016/0014-5793(90)81469-5; RASSOW J, 1989, J CELL BIOL, V109, P1421, DOI 10.1083/jcb.109.4.1421; RASSOW J, 1994, J CELL BIOL, V127, P1547, DOI 10.1083/jcb.127.6.1547; RYAN KR, 1994, MOL BIOL CELL, V5, P529, DOI 10.1091/mbc.5.5.529; RYAN KR, 1993, J BIOL CHEM, V268, P23743; SCHERER PE, 1992, P NATL ACAD SCI USA, V89, P11930, DOI 10.1073/pnas.89.24.11930; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; SEQUIREAL B, 1993, EMBO J, V12, P2211, DOI 10.1002/j.1460-2075.1993.tb05869.x; Sherman F., 1986, METHODS YEAST GENETI; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; UNGERMANN C, 1994, SCIENCE, V266, P1250, DOI 10.1126/science.7973708; VALE RD, 1994, CELL, V78, P733, DOI 10.1016/S0092-8674(94)90402-2	41	153	153	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 30	1995	81	7					1085	1093		10.1016/S0092-8674(05)80013-3	http://dx.doi.org/10.1016/S0092-8674(05)80013-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RG910	7600576	Bronze			2022-12-24	WOS:A1995RG91000013
J	COUCOUVANIS, E; MARTIN, GR				COUCOUVANIS, E; MARTIN, GR			SIGNALS FOR DEATH AND SURVIVAL - A 2-STEP MECHANISM FOR CAVITATION IN THE VERTEBRATE EMBRYO	CELL			English	Article							PROGRAMMED CELL-DEATH; MOUSE EMBRYOS; NERVOUS-SYSTEM; CARCINOMA-CELLS; APOPTOSIS; DIFFERENTIATION; TERATOCARCINOMA; FIBROBLASTS; BLASTOCYST; INDUCTION	Conversion of a solid primordium to a hollow tube of cells is a morphogenetic process used frequently during vertebrate embryogenesis. In the early mouse embryo, this process of cavitation transforms the solid embryonic ectoderm into a columnar epithelium surrounding a cavity. Using both established cell lines and normal embryos, we provide evidence that cavitation in the early mouse embryo is the result of the interplay of two signals, one from an outer layer of endoderm cells that acts over short distances to create a cavity by inducing apoptosis of the inner ectodermal cells, and the other a rescue signal mediated by contact with the basement membrane that is required for the survival of the columnar cells that line the cavity. This simple model provides a paradigm for investigating tube morphogenesis in diverse developmental settings.	UNIV CALIF SAN FRANCISCO,SCH MED,PROGRAM DEV BIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	COUCOUVANIS, E (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT ANAT,SAN FRANCISCO,CA 94143, USA.				NICHD NIH HHS [R01 HD22731] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022731] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALBELDA SM, 1989, J CLIN INVEST, V83, P1992, DOI 10.1172/JCI114109; ARENDS MJ, 1990, AM J PATHOL, V136, P593; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; BORGHESE E, 1955, J ANAT, V84, P287; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BROKS PC, 1994, CELL, V79, P1157; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; CROSBY WM, 1962, OBSTET GYNECOL, V20, P507; ELLIOTT B, 1992, J CELL PHYSIOL, V152, P292, DOI 10.1002/jcp.1041520210; ELSHERSH.AM, 1974, J EMBRYOL EXP MORPH, V31, P643; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; FERGUSON MWJ, 1988, DEVELOPMENT, V103, P41; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; GARCIAMARTINEZ V, 1993, J CELL SCI, V106, P201; GLUCKSMANN A, 1951, BIOL REV, V26, P59, DOI 10.1111/j.1469-185X.1951.tb00774.x; HAMBURGER V, 1949, J EXP ZOOL, V111, P451; HEBERT JM, 1994, CELL, V78, P1017, DOI 10.1016/0092-8674(94)90276-3; HINCHLIFFE JR, 1981, CELL DEATH BIOL PATH, P35; Hogan B., 1986, MANIPULATING MOUSE E, P17; HOGAN BLM, 1981, J EMBRYOL EXP MORPH, V62, P379; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KOFF ARTHUR K., 1933, CARNEGIE INST WASHINGTON [PUBL 443] CONTR TO EMBR, V24, P61; LANG RA, 1993, CELL, V74, P453, DOI 10.1016/0092-8674(93)80047-I; LEHMAN JM, 1974, J CELL PHYSIOL, V84, P13, DOI 10.1002/jcp.1040840103; MARTIN GR, 1977, DEV BIOL, V61, P230, DOI 10.1016/0012-1606(77)90294-9; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; MARTIN GR, 1980, SCIENCE, V209, P768, DOI 10.1126/science.6250214; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; MUMMERY CL, 1991, DIFFERENTIATION, V46, P51, DOI 10.1111/j.1432-0436.1991.tb00865.x; MUMMERY CL, 1985, DEV BIOL, V108, P402; Nagy A., 1993, Gene targeting: a practical approach., P147; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; PRATT RM, 1976, DEV BIOL, V54, P135, DOI 10.1016/0012-1606(76)90292-X; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SAUNDERS JW, 1966, SCIENCE, V154, P604, DOI 10.1126/science.154.3749.604; SHERWOOD SW, 1994, EXP CELL RES, V215, P373, DOI 10.1006/excr.1994.1354; Snow M.H.L., 1987, P202; SNOW MHL, 1977, J EMBRYOL EXP MORPH, V42, P293; SOLTER D, 1975, P NATL ACAD SCI USA, V72, P5099, DOI 10.1073/pnas.72.12.5099; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Wyllie A H, 1980, Int Rev Cytol, V68, P251	48	484	498	1	18	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 20	1995	83	2					279	287		10.1016/0092-8674(95)90169-8	http://dx.doi.org/10.1016/0092-8674(95)90169-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TA965	7585945	Bronze			2022-12-24	WOS:A1995TA96500014
J	ELIEZER, D; JENNINGS, PA; WRIGHT, PE; DONIACH, S; HODGSON, KO; TSURUTA, H				ELIEZER, D; JENNINGS, PA; WRIGHT, PE; DONIACH, S; HODGSON, KO; TSURUTA, H			THE RADIUS OF GYRATION OF AN APOMYOGLOBIN FOLDING INTERMEDIATE	SCIENCE			English	Article							PATHWAY		STANFORD UNIV, DEPT APPL PHYS, STANFORD, CA 94305 USA; STANFORD UNIV, STANFORD SYNCHROTRON RADIAT LAB, STANFORD, CA 94305 USA; STANFORD UNIV, DEPT CHEM, STANFORD, CA 94305 USA	Stanford University; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory; Stanford University	ELIEZER, D (corresponding author), SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA.		Eliezer, David/GRS-5702-2022	Wright, Peter/0000-0002-1368-0223	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001209] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034909, R37DK034909] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014541] Funding Source: NIH RePORTER; NCRR NIH HHS [RR01209] Funding Source: Medline; NIDDK NIH HHS [DK34909] Funding Source: Medline; NIGMS NIH HHS [GM14541] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ELIEZER D, 1993, BIOPHYS J, V65, P912, DOI 10.1016/S0006-3495(93)81124-X; ELIEZER D, 1994, EUR BIOPHYS J, V23, P297; GRIKO YV, 1988, J MOL BIOL, V202, P127, DOI 10.1016/0022-2836(88)90525-6; HUGHSON FM, 1990, SCIENCE, V249, P1544, DOI 10.1126/science.2218495; JENNINGS PA, 1993, SCIENCE, V262, P892, DOI 10.1126/science.8235610; JENNINGS PA, 1994, STATISTICAL MECHANIC; NISHII I, 1994, BIOCHEMISTRY-US, V33, P4903, DOI 10.1021/bi00182a019	7	131	131	1	11	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 20	1995	270	5235					487	488		10.1126/science.270.5235.487	http://dx.doi.org/10.1126/science.270.5235.487			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA374	7570004				2022-12-24	WOS:A1995TA37400046
J	WINANDY, S; WU, P; GEORGOPOULOS, K				WINANDY, S; WU, P; GEORGOPOULOS, K			A DOMINANT MUTATION IN THE IKAROS GENE LEADS TO RAPID DEVELOPMENT OF LEUKEMIA AND LYMPHOMA	CELL			English	Article							MATURE T-CELLS; RETINOBLASTOMA; MICE; LYMPHOCYTES; SELECTION; GLD; REARRANGEMENT; AUTOIMMUNITY; COMMITMENT; SUICIDE	The Ikaros gene is essential for lymphoid lineage specification. As previously reported, mice homozygous fora mutation in the Ikaros DNA-binding domain fail to generate mature lymphocytes as well as their earliest described progenitors. In addition, our studies with mice heterozygous for this mutation establish the Ikaros gene as an essential regulator of T cell proliferation. Thymocytes display augmented TCR-mediated proliferative responses, and peripheral T cells are autoproliferative. A general lymphoproliferation precedes the T cell leukemia and lymphoma that rapidly develop in all heterozygotes. The first step toward leukemic transformation occurs within the maturing thymocyte population and is demarcated by clonal expansions and loss of the single Ikaros wild-type allele. From these studies, we propose that within developing and mature T lymphocytes, distinct thresholds of Ikaros activity are required to regulate proliferation. A decrease in Ikaros activity below the first threshold causes the rapid accumulation of T lymphoblasts, whereas a further decrease leads to neoplastic transformation.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,CUTANEOUS BIOL RES CTR,BOSTON,MA 02129	Harvard University; Harvard Medical School; Massachusetts General Hospital					NIAID NIH HHS [R01-AI33062-02] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033062] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON SJ, 1995, IMMUNOL TODAY, V16, P99, DOI 10.1016/0167-5699(95)80096-4; ANDERSON SJ, 1992, EMBO J, V11, P4877, DOI 10.1002/j.1460-2075.1992.tb05594.x; ANDREWS BS, 1978, J EXP MED, V148, P1198, DOI 10.1084/jem.148.5.1198; ASHTONRICKARDT PG, 1993, CELL, V73, P1041, DOI 10.1016/0092-8674(93)90281-T; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHAN SH, 1993, CELL, V73, P225, DOI 10.1016/0092-8674(93)90225-F; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; DAVIS CB, 1993, CELL, V73, P237, DOI 10.1016/0092-8674(93)90226-G; DRYJA TP, 1986, P NATL ACAD SCI USA, V83, P7391, DOI 10.1073/pnas.83.19.7391; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GEORGOPOULOS K, 1992, SCIENCE, V258, P808, DOI 10.1126/science.1439790; GEORGOPOULOS K, 1994, CELL, V78, P143; GODFREY DI, 1994, J IMMUNOL, V152, P4783; GOOTENBERG JE, 1981, J EXP MED, V154, P1403, DOI 10.1084/jem.154.5.1403; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; JANEWAY CA, 1994, IMMUNITY, V1, P3, DOI 10.1016/1074-7613(94)90003-5; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; MADRENAS J, 1995, SCIENCE, V267, P515, DOI 10.1126/science.7824949; MOLNAR A, 1994, MOL CELL BIOL, V14, P8292, DOI 10.1128/MCB.14.12.8292; MOLNAR A, 1995, IN PRESS J IMMUNOL; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; RODEWALD HR, 1994, EMBO J, V13, P7229; ROTHS JB, 1984, J EXP MED, V159, P1, DOI 10.1084/jem.159.1.1; RUSSELL JH, 1993, P NATL ACAD SCI USA, V90, P4409, DOI 10.1073/pnas.90.10.4409; RUSSELL JH, 1993, EUR J IMMUNOL, V23, P2379, DOI 10.1002/eji.1830230951; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; TAKAHAMA Y, 1994, NATURE, V371, P67, DOI 10.1038/371067a0; VASQUEZ NJ, 1994, IMMUNITY, V1, P45, DOI 10.1016/1074-7613(94)90008-6; VONBOEHMER H, 1993, CELL, V73, P207, DOI 10.1016/0092-8674(93)90220-K; WAYNE J, 1994, IMMUNITY, V1, P95, DOI 10.1016/1074-7613(94)90103-1	35	349	364	0	8	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 20	1995	83	2					289	299		10.1016/0092-8674(95)90170-1	http://dx.doi.org/10.1016/0092-8674(95)90170-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TA965	7585946	Bronze			2022-12-24	WOS:A1995TA96500015
J	KNOBLICH, JA; JAN, LY; JAN, YN				KNOBLICH, JA; JAN, LY; JAN, YN			ASYMMETRIC SEGREGATION OF NUMB AND PROSPERO DURING CELL-DIVISION	NATURE			English	Article							CENTRAL-NERVOUS-SYSTEM; C-ELEGANS EMBRYOS; CAENORHABDITIS-ELEGANS; DROSOPHILA EMBRYOS; GENE; EMBRYOGENESIS; VISUALIZATION; CYTOKINESIS; PATTERNS; GRANULES	A CELL can divide asymmetrically by specifically segregating a determinant into one of its daughter cells(1). The Numb protein is a candidate for such a determinant in the asymmetric cell divisions of the developing Drosophila nervous system(2,3). Numb is a membrane-associated protein that localizes asymmetrically during cell division and segregates into one daughter cell, where it is required for the specification of the correct cell fate(3-5). Here we show that a nuclear protein, Prospero(6,7), translocates to the membrane at the beginning of cell division and colocalizes with Numb throughout mitosis, suggesting a common mechanism for asymmetric segregation. Numb and Prospero localization is coupled to mitosis and tightly correlated with the position of one of the two centrosomes. In contrast to centrosome positioning, however, Numb and Prospero localization is independent of microtubules. Cytochalasin D treatment suggests that the process is also independent of actin, We propose that there is an organizer of asymmetric cell division which provides positional information for both the orientation of the mitotic spindle and asymmetric localization of Numb and Prospero.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	KNOBLICH, JA (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143, USA.		Knoblich, Juergen A/C-2974-2015	Knoblich, Juergen A/0000-0002-6751-3404; Jan, Lily/0000-0003-3938-8498; Jan, Yuh Nung/0000-0003-1367-6299				BODMER R, 1989, NEURON, V3, P21, DOI 10.1016/0896-6273(89)90112-8; CHANT J, 1994, TRENDS GENET, V10, P328, DOI 10.1016/0168-9525(94)90036-1; DOE CQ, 1991, CELL, V65, P451, DOI 10.1016/0092-8674(91)90463-9; DOE CQ, 1992, DEVELOPMENT, V116, P855; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; HARTENSTEIN V, 1994, DEV BIOL, V165, P480, DOI 10.1006/dbio.1994.1269; HIME G, 1992, DEVELOPMENT, V114, P165; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; HYMAN AA, 1987, J CELL BIOL, V105, P2123, DOI 10.1083/jcb.105.5.2123; HYMAN AA, 1989, J CELL BIOL, V109, P1185, DOI 10.1083/jcb.109.3.1185; JARMAN AP, 1995, DEVELOPMENT, V121, P2019; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; KIRBY C, 1990, DEV BIOL, V142, P203, DOI 10.1016/0012-1606(90)90164-E; LEHNER CF, 1992, J CELL SCI, V103, P1021; ORSULIC S, 1994, BIOTECHNIQUES, V16, P441; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; SPANA EP, IN PRESS DEVELOPMENT; STROME S, 1982, P NATL ACAD SCI-BIOL, V79, P1558, DOI 10.1073/pnas.79.5.1558; STROME S, 1986, J CELL BIOL, V103, P2241, DOI 10.1083/jcb.103.6.2241; STROME S, 1983, CELL, V35, P15, DOI 10.1016/0092-8674(83)90203-9; STROME S, 1993, CELL, V72, P3, DOI 10.1016/0092-8674(93)90041-N; TEPASS U, 1995, DEVELOPMENT, V121, P393; UEMURA T, 1989, CELL, V58, P349, DOI 10.1016/0092-8674(89)90849-0; VAESSIN H, 1991, CELL, V67, P941, DOI 10.1016/0092-8674(91)90367-8	26	409	417	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 19	1995	377	6550					624	627		10.1038/377624a0	http://dx.doi.org/10.1038/377624a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA275	7566172				2022-12-24	WOS:A1995TA27500050
J	TAKAHARA, PM; ROSENZWEIG, AC; FREDERICK, CA; LIPPARD, SJ				TAKAHARA, PM; ROSENZWEIG, AC; FREDERICK, CA; LIPPARD, SJ			CRYSTAL-STRUCTURE OF DOUBLE-STRANDED DNA CONTAINING THE MAJOR ADDUCT OF THE ANTICANCER DRUG CISPLATIN	NATURE			English	Article							MOLECULAR-STRUCTURE; A-DNA; CIS-DIAMMINEDICHLOROPLATINUM(II); PLATINUM; CIS-<PT(NH3)2(D(PGPG))>; PROTEIN; SINGLE; DUPLEX; GROOVE	THE success of cisplatin in cancer chemotherapy derives from its ability to crosslink DNA and alter the structure, Most cisplatin-DNA adducts are intrastrand d(GpG) and d(ApG) crosslinks(1), which unwind and bend the duplex to facilitate the binding of proteins that contain one or more high-mobility-group (HMG) domains(2). When HMG-domain proteins such as HMG1, IXR (intrastrand-crosslink recognition) protein from yeast, or human upstream-binding factor (hUBF) bind cisplatin intrastrand crosslinks, they can be diverted from their natural binding sites on the genome and shield the adducts from excision repair(3-5). These activities sensitize cells to cisplatin and contribute to its cytotoxic properties, Crystallographic information about the structure of cisplatin-DNA adducts has been limited to short single-stranded deoxyoligonucleotides such as Cis-[Pt(NH3)(2){d(pGpG)}](6-8). Here we describe the X-ray structure at 2.6 Angstrom resolution of a double-stranded DNA dodecamer containing this adduct. Our information provides, to our knowledge, the first crystallographic look at a platinated DNA duplex and should help the design of new platinum and other metal crosslinking antitumour drug candidates. Moreover, the structure reveals a unique fusion of A- and B-type DNA segments that could be of more general importance.	HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	TAKAHARA, PM (corresponding author), MIT, DEPT CHEM, CAMBRIDGE, MA 02139 USA.							ADMIRAAL G, 1987, J AM CHEM SOC, V109, P592, DOI 10.1021/ja00236a053; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BELLON SF, 1990, BIOPHYS CHEM, V35, P179, DOI 10.1016/0301-4622(90)80007-T; BELLON SF, 1991, BIOCHEMISTRY-US, V30, P8026, DOI 10.1021/bi00246a021; BROWN SJ, 1993, SCIENCE, V261, P603, DOI 10.1126/science.8342024; BRUHN SL, 1990, PROG INORG CHEM, V38, P477; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CHOW CS, 1994, BIOCHEMISTRY-US, V33, P15124, DOI 10.1021/bi00254a023; DENHARTOG JHJ, 1985, J BIOMOL STRUCT DYN, V2, P1137, DOI 10.1080/07391102.1985.10507629; FICHTINGERSCHEPMAN AMJ, 1985, BIOCHEMISTRY-US, V24, P707, DOI 10.1021/bi00324a025; FREDERICK CA, 1989, EUR J BIOCHEM, V181, P295, DOI 10.1111/j.1432-1033.1989.tb14724.x; HERMAN F, 1990, EUR J BIOCHEM, V194, P119, DOI 10.1111/j.1432-1033.1990.tb19435.x; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P10394, DOI 10.1073/pnas.91.22.10394; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KING CY, 1993, P NATL ACAD SCI USA, V90, P11990, DOI 10.1073/pnas.90.24.11990; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; RICE JA, 1988, P NATL ACAD SCI USA, V85, P4158, DOI 10.1073/pnas.85.12.4158; SAENGER W, 1984, PRINCIPLES NUCLEIC A, P226; SHERMAN SE, 1987, CHEM REV, V87, P1153, DOI 10.1021/cr00081a013; SHERMAN SE, 1988, J AM CHEM SOC, V110, P7368, DOI 10.1021/ja00230a017; SHERMAN SE, 1985, SCIENCE, V230, P412, DOI 10.1126/science.4048939; TREIBER DK, 1994, P NATL ACAD SCI USA, V91, P5672, DOI 10.1073/pnas.91.12.5672; WANG AHJ, 1982, P NATL ACAD SCI-BIOL, V79, P3968, DOI 10.1073/pnas.79.13.3968; WANG AHJ, 1988, J CRYST GROWTH, V90, P295, DOI 10.1016/0022-0248(88)90325-9; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; WHITEHEAD JP, METAL IONS BIOL SYST	27	699	717	1	125	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 19	1995	377	6550					649	652		10.1038/377649a0	http://dx.doi.org/10.1038/377649a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA275	7566180				2022-12-24	WOS:A1995TA27500058
J	DARMON, AJ; NICHOLSON, DW; BLEACKLEY, RC				DARMON, AJ; NICHOLSON, DW; BLEACKLEY, RC			ACTIVATION OF THE APOPTOTIC PROTEASE CPP32 BY CYTOTOXIC T-CELL-DERIVED GRANZYME-B	NATURE			English	Article							SERINE PROTEASES; LYMPHOCYTES-T; PURIFICATION; INHIBITION; POLYMERASE	CYTOTOXIC T lymphocyte (CTL)-mediated cytotoxicity represents the body's major defence against virus-infected and tumorigenic cells, and contributes to transplant rejection and autoimmune disease. During killing, CTL granules are exocytosed, releasing their contents into the intercellular space between the target cell and the effector. Perforin facilitates the entry of cytotoxic cell serine proteases, the granzymes, into the target cell, where they induce apoptotic death by an unknown pathway(1). Granzyme B is essential for the induction of DNA fragmentation and apoptosis in target cells(2-5), yet its substrate is unknown. Identification of the intracellular substrate far granzyme B is therefore the key to understanding the mechanism of CTL-mediated killing. Here we show that granzyme B cleaves and activates CPP32, the precursor of the protease responsible for cleavage of poly(ADP-ribose) polymerase.	UNIV ALBERTA,DEPT BIOCHEM,EDMONTON,AB T6G 2H7,CANADA; MERCK FROSST CTR THERAPEUT RES,DEPT BIOCHEM & MOLEC BIOL,POINTE CLAIRE,PQ H9R 4P8,CANADA	University of Alberta; Merck & Company								BERKE G, 1995, CELL, V81, P9, DOI 10.1016/0092-8674(95)90365-8; CAPUTO A, 1994, NAT STRUCT BIOL, V1, P364, DOI 10.1038/nsb0694-364; CAPUTO A, 1993, J BIOL CHEM, V268, P17672; DARMON AJ, 1994, J BIOL CHEM, V269, P32043; DING RC, 1994, CANCER RES, V54, P4627; GARNER R, 1994, J IMMUNOL, V153, P5413; HANNA WL, 1993, PROTEIN EXPRES PURIF, V4, P398, DOI 10.1006/prep.1993.1052; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; MURPHY MEP, 1988, PROTEINS, V4, P190, DOI 10.1002/prot.340040306; NICHOLSON DW, 1994, NATURE, V376, P37; ODAKE S, 1991, BIOCHEMISTRY-US, V30, P2217, DOI 10.1021/bi00222a027; REDEGELD FA, 1992, J IMMUNOL, V149, P3509; SHI LF, 1992, J EXP MED, V175, P553, DOI 10.1084/jem.175.2.553; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; SMULSON M, 1994, BIOCHEMISTRY-US, V33, P6186, DOI 10.1021/bi00186a018; SU B, 1994, EUR J IMMUNOL, V24, P2073, DOI 10.1002/eji.1830240921; TANAKA Y, 1984, J BIOL CHEM, V259, P6579; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509	23	616	633	1	19	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 5	1995	377	6548					446	448		10.1038/377446a0	http://dx.doi.org/10.1038/377446a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY190	7566124				2022-12-24	WOS:A1995RY19000054
J	BRITTO, J; NADEL, S; MACONOCHIE, I; LEVIN, M; HABIBI, P				BRITTO, J; NADEL, S; MACONOCHIE, I; LEVIN, M; HABIBI, P			MORBIDITY AND SEVERITY OF ILLNESS DURING INTERHOSPITAL TRANSFER - IMPACT OF A SPECIALIZED PEDIATRIC RETRIEVAL TEAM	BRITISH MEDICAL JOURNAL			English	Article							AIRWAY MANAGEMENT; TRANSPORT; STABILIZATION	Objective-To evaluate the morbidity and severity of illness during interhospital transfer of critically ill children by a specialised paediatric retrieval team. Design-Prospective, descriptive study. Setting-Hospitals without paediatric intensive care facilities in and around the London area, and a paediatric intensive care unit at a tertiary centre. Subjects-51 critically ill children transferred to the paediatric intensive care unit. Main outcome measures-Adverse events related to equipment and physiological deterioration during transfer. Paediatric risk of mortality score before and after retrieval. Therapeutic intervention score before and after arrival of retrieval team. Results-Two (4%) patients had preventable physiological deterioration during transport. There were no adverse events related to equipment. Severity of illness decreased during stabilisation and transport by the retrieval team, suggested by the difference between risk of mortality scores before and after retrieval (P < 0.001). The median (range) difference between the two scores was 3.0 (-6 to 17). Interventions during stabilisation by the retrieval team increased, demonstrated by the difference between intervention scores before and after retrieval, median (range) difference between the two scores being 6 (-8 to 38) (P < 0.001). Conclusions-Our study indicates that a specialised paediatric retrieval team can rapidly deliver intensive care to critically iu children awaiting transfer. Such children can be transferred to a paediatric intensive care unit with minimal morbidity and mortality related to transport. There was no deterioration in the clinical condition of most patients during transfer.			BRITTO, J (corresponding author), ST MARYS HOSP,DEPT PAEDIAT,PRAED ST,LONDON W2 1NY,ENGLAND.			Levin, Michael/0000-0003-2767-6919; Maconochie, Ian/0000-0001-6319-8550				BARRY PW, 1994, ARCH DIS CHILD, V71, P8, DOI 10.1136/adc.71.1.8; BLACK RE, 1982, NEW ENGL J MED, V307, P1465, DOI 10.1056/NEJM198212023072342; EDGE WE, 1994, CRIT CARE MED, V22, P1186, DOI 10.1097/00003246-199407000-00023; FULLER J, 1991, CAN J ANAESTH, V38, P252, DOI 10.1007/BF03008156; HENNING R, 1992, MED J AUSTRALIA, V156, P117; KANTER RK, 1989, PEDIATRICS, V84, P43; KANTER RK, 1993, CRIT CARE MED, V21, pS265; KEENE AR, 1983, CRIT CARE MED, V11, P1, DOI 10.1097/00003246-198301000-00001; MACNAB AJ, 1991, J TRAUMA, V31, P205, DOI 10.1097/00005373-199131020-00009; MCCLOSKEY K A, 1991, Emergency Medicine Clinics of North America, V9, P475; MCDONALD TB, 1993, PEDIATR CLIN N AM, V40, P381; ORR RA, 1994, CRIT CARE MED, V22, P101, DOI 10.1097/00003246-199401000-00020; ORR RA, 1992, TXB PEDIATRIC INTENS, P1571; POLLACK MM, 1991, CRIT CARE MED, V19, P150, DOI 10.1097/00003246-199102000-00007; POLLACK MM, 1988, CRIT CARE MED, V16, P1110, DOI 10.1097/00003246-198811000-00006; ROBB HM, 1992, BRIT J INTENSIVE CAR, V2, P371; WETZEL RC, 1992, TXB PEDIATRIC INTENS, P563; WHITFIELD JM, 1993, PEDIATR EMERG CARE, V9, P69, DOI 10.1097/00006565-199304000-00002; 1995, CRD1 NHS CTR REV DIS; 1993, CARE CRITICALLY ILL	20	96	98	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 30	1995	311	7009					836	839		10.1136/bmj.311.7009.836	http://dx.doi.org/10.1136/bmj.311.7009.836			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY191	7580489	Green Published			2022-12-24	WOS:A1995RY19100019
J	JARRIAULT, S; BROU, C; LOGEAT, F; SCHROETER, EH; KOPAN, R; ISRAEL, A				JARRIAULT, S; BROU, C; LOGEAT, F; SCHROETER, EH; KOPAN, R; ISRAEL, A			SIGNALING DOWNSTREAM OF ACTIVATED MAMMALIAN NOTCH	NATURE			English	Article							BINDING-PROTEIN; CELL-FATE; DROSOPHILA; EXPRESSION; GENE; DIFFERENTIATION; ENHANCER; SEQUENCE; RECEPTOR; HOMOLOG	NOTCH belongs to a family of transmembrane proteins that are widely conserved from flies to vertebrates and are thought to be involved in cell-fate decisions. In Drosophila, the Suppressor of hairless (Su(H)) gene(1,2) and genes of the Enhancer of split (E(Spl)) complex, which encode proteins of the basic helix-loop-helix type(3,4) have been implicated in the Notch signalling pathway. Mammalian homologues of E(Spl), such as the mouse Hairy enhancer of split (HES-1)(5), have been isolated. Both HES-1 and the intracellular domain of murine Notch (mNotch) are able to block MyoD-induced myogenesis(5-7). Here we show that activated forms of mNotch associate with the human analogue of Su(H), KBF2/RBP-J kappa (refs 8,9) and act as transcriptional activators through the KBF2-binding sites of the HES-1 promoter.	WASHINGTON UNIV, DIV DERMATOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, DEPT MOLEC BIOL & PHARMACOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	JARRIAULT, S (corresponding author), INST PASTEUR, CNRS, URA 1149, UNITE BIOL MOLEC EXPRESS GENET, 28 RUE DR ROUX, F-75724 PARIS 15, FRANCE.		Kopan, Raphael/AFG-3275-2022; Kopan, Raphael/AAF-1357-2022	Kopan, Raphael/0000-0002-0350-2730				BROU C, 1994, GENE DEV, V8, P2491, DOI 10.1101/gad.8.20.2491; COFFMAN CR, 1993, CELL, V73, P659, DOI 10.1016/0092-8674(93)90247-N; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; FURUKAWA T, 1991, J BIOL CHEM, V266, P23334; GROSSMAN SR, 1994, P NATL ACAD SCI USA, V91, P7568, DOI 10.1073/pnas.91.16.7568; HENKEL T, 1994, SCIENCE, V265, P92, DOI 10.1126/science.8016657; ISRAEL A, 1989, NUCLEIC ACIDS RES, V17, P5245, DOI 10.1093/nar/17.13.5245; JENNINGS B, 1994, DEVELOPMENT, V120, P3537; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; KOOH PJ, 1993, DEVELOPMENT, V117, P493; KOPAN R, 1994, DEVELOPMENT, V120, P2385; NYE JS, 1994, DEVELOPMENT, V120, P2421; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; SCHWEISGUTH F, 1995, DEVELOPMENT, V121, P1875; SCHWEISGUTH F, 1992, CELL, V69, P1199, DOI 10.1016/0092-8674(92)90641-O; TAKEBAYASHI K, 1994, J BIOL CHEM, V269, P5150; TATA F, 1993, DEVELOPMENT, P139; TUN T, 1994, NUCLEIC ACIDS RES, V22, P965, DOI 10.1093/nar/22.6.965; WALTZER L, 1994, EMBO J, V13, P5633, DOI 10.1002/j.1460-2075.1994.tb06901.x; ZIMBERSTROBL U, 1994, EMBO J, V13, P4973, DOI 10.1002/j.1460-2075.1994.tb06824.x	24	1197	1246	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 28	1995	377	6547					355	358		10.1038/377355a0	http://dx.doi.org/10.1038/377355a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX111	7566092				2022-12-24	WOS:A1995RX11100061
J	BACON, KB; PREMACK, BA; GARDNER, P; SCHALL, TJ				BACON, KB; PREMACK, BA; GARDNER, P; SCHALL, TJ			ACTIVATION OF DUAL T-CELL SIGNALING PATHWAYS BY THE CHEMOKINE RANTES	SCIENCE			English	Article							LYMPHOCYTES-T; TYROSINE PHOSPHORYLATION; COUPLED RECEPTORS; CALCIUM CURRENT; G-PROTEIN; INTERLEUKIN-8; FLUORESCENCE; DEPLETION; STORES	The chemokine RANTES induced biphasic mobilization of Ca2+ in T cells. The initial peak, a transient increase in cytosolic Ca2+ mediated by a heterotrimeric guanine nucleotide-binding protein (G protein)-coupled pathway, was associated predominantly with chemotaxis. The second peak, Ca2+ release and sustained influx dependent on protein tyrosine kinases, was associated with a spectrum of cellular responses--Ca2+ channel opening, interleukin-2 receptor expression, cytokine release, and T cell proliferation-characteristic of T cell receptor activation. Other chemokines did not produce these responses. Thus, in addition to inducing chemotaxis, RANTES can act as an antigenin-dependent activator of T cells in vitro.	STANFORD UNIV,SCH MED,DEPT MOLEC PHARMACOL,STANFORD,CA 94305	Stanford University	BACON, KB (corresponding author), DNAX RES INST MOLEC & CELLULAR BIOL INC,DEPT IMMUNOL,901 CALIF AVE,PALO ALTO,CA 94304, USA.				NIGMS NIH HHS [GM07065] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACON KB, 1995, J IMMUNOL, V154, P3654; BACON KB, 1988, BRIT J PHARMACOL, V95, P966, DOI 10.1111/j.1476-5381.1988.tb11727.x; BACON KB, 1993, BLOOD, V81, P430; BACON KB, 1990, BIOCHEM BIOPH RES CO, V169, P1099, DOI 10.1016/0006-291X(90)92008-N; BISCHOFF SC, 1993, EUR J IMMUNOL, V23, P761, DOI 10.1002/eji.1830230329; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; GRAHAM GJ, 1994, J BIOL CHEM, V269, P4974; GRAY LS, 1989, J IMMUNOL, V142, P1631; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; JUNE CH, 1990, J IMMUNOL, V144, P1591; MCDONALD TV, 1993, J BIOL CHEM, V268, P3889; MODESTO J, 1991, CELL SIGNAL, V3, P25, DOI 10.1016/0898-6568(91)90004-E; MUSTELIN T, 1994, IMMUNITY, V1, P351, DOI 10.1016/1074-7613(94)90065-5; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; POENIE M, 1990, CELL CALCIUM, V11, P85, DOI 10.1016/0143-4160(90)90062-Y; PREMACK BA, 1994, ADV EXP MED BIOL, V365, P91; PREMACK BA, 1994, J IMMUNOL, V152, P5226; PREMACK BA, 1992, AM J PHYSIOL, V263, pC1115; RAJARATHNAM K, 1994, SCIENCE, V264, P90, DOI 10.1126/science.8140420; RONCAROLO MG, 1989, J EXP MED, V168, P2139; SCHALL TJ, 1994, CURR OPIN IMMUNOL, V6, P865, DOI 10.1016/0952-7915(94)90006-X; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHALL TJ, 1994, CYTOKINE HDB, P419; SKELTON NJ, 1995, BIOCHEMISTRY-US, V34, P5329, DOI 10.1021/bi00016a004; SOZZANI S, 1994, J IMMUNOL, V152, P3615; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; VANRIPER G, 1993, J EXP MED, V177, P851, DOI 10.1084/jem.177.3.851; WEBB LMC, 1993, P NATL ACAD SCI USA, V90, P7158, DOI 10.1073/pnas.90.15.7158; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WITT DP, 1994, CURR BIOL, V4, P394, DOI 10.1016/S0960-9822(00)00088-9; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	35	396	409	0	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 22	1995	269	5231					1727	1730		10.1126/science.7569902	http://dx.doi.org/10.1126/science.7569902			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV948	7569902				2022-12-24	WOS:A1995RV94800040
J	FENDRICK, AM; CHERNEW, ME; HIRTH, RA; BLOOM, BS				FENDRICK, AM; CHERNEW, ME; HIRTH, RA; BLOOM, BS			ALTERNATIVE MANAGEMENT STRATEGIES FOR PATIENTS WITH SUSPECTED PEPTIC-ULCER DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article						PEPTIC ULCER; COST-BENEFIT ANALYSIS; HELICOBACTER PYLORI; HELICOBACTER INFECTIONS; ENDOSCOPY	HELICOBACTER-PYLORI INFECTION; DOUBLE-BLIND TRIAL; DUODENAL-ULCER; CAMPYLOBACTER-PYLORI; NONULCER DYSPEPSIA; BREATH TEST; GASTRIC-CARCINOMA; TRIPLE THERAPY; FOLLOW-UP; H-2-RECEPTOR ANTAGONISTS	Objective: To estimate the clinical and economic effects of available invasive and noninvasive management strategies for peptic ulcer and Helicobacter pylori in persons with symptoms suggesting peptic ulcer disease. Design: Cost-effectiveness analysis using a decision analytic model. Intervention: 2 immediate endoscopy and 3 noninvasive diagnostic and treatment strategies were evaluated: 1) immediate endoscopy for peptic ulcer and biopsy for H. pylori; 2) immediate endoscopy without biopsy; 3) serologic test for H. pylori; 4) empiric treatment with antisecretory therapy; and 5) empiric treatment with antisecretory therapy and antibiotic agents to eradicate H. pylori. Measurements: Cost per ulcer cured and cost per patient treated. Results: The estimated costs per ulcer cured by strategy were as follows: 1) endoscopy and biopsy for H. pylori, $8045; 2) endoscopy without biopsy, $6984; 3) serologic test for H. pylori, $4541; 4) empiric antisecretory therapy, $4835; and 5) empiric antisecretory and antibiotic therapy, $4155. The predicted costs per patient treated were as follows: 1) endoscopy and biopsy for H. pylori, $1584; 2) endoscopy without biopsy, $1375; 3) serologic test for H. pylori, $894; 4) empiric antisecretory therapy, $952; and 5) empiric antisecretory and antibiotic therapy, $818. The cost-effectiveness advantage of the noninvasive strategies diminished as the cost of endoscopy decreased or as the probability of recurrent symptoms increased in patients initially managed without endoscopy. Conclusion: Endoscopy, although costly, precisely guided diagnosis and treatment and thus potentially reduced the number of patients inappropriately treated. However, the safety and effectiveness of less expensive, less invasive diagnostic and treatment strategies strongly support initial noninvasive care of symptomatic persons thought to have peptic ulcer disease.	UNIV MICHIGAN, SCH MED, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH PUBL HLTH, ANN ARBOR, MI 48109 USA; UNIV PENN, PHILADELPHIA, PA 19104 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Pennsylvania	FENDRICK, AM (corresponding author), UNIV MICHIGAN, MED CTR, DIV GEN MED, 3116 TAUBMAN CTR, ANN ARBOR, MI 48109 USA.							ARCHAMBAULT AP, 1988, GASTROENTEROLOGY, V94, P1130, DOI 10.1016/0016-5085(88)90003-0; BAMBERG P, 1992, J GASTROEN HEPATOL, V7, P577, DOI 10.1111/j.1440-1746.1992.tb01489.x; BANK S, 1992, AM J GASTROENTEROL, V87, P1365; BARDHAN KD, 1989, J CLIN GASTROENTEROL, V21, P408; BARNES RJ, 1974, BRIT MED J, V4, P214, DOI 10.1136/bmj.4.5938.214; BAYERDORFFER E, 1993, SCAND J GASTROENTERO, V28, P19, DOI 10.3109/00365529309098337; BAYERDORFFER E, 1995, GASTROENTEROLOGY, V108, P1412, DOI 10.1016/0016-5085(95)90689-4; BELL GD, 1987, LANCET, V1, P1367; BELL GD, 1992, ALIMENT PHARM THERAP, V6, P427; BLASER MJ, 1992, GASTROENTEROLOGY, V102, P720, DOI 10.1016/0016-5085(92)90126-J; BLASER MJ, 1993, INT J CANCER, V55, P799, DOI 10.1002/ijc.2910550518; BLOOM BS, 1989, J CLIN GASTROENTEROL, V11, P615, DOI 10.1097/00004836-198912000-00003; BLOOM BS, 1990, J CLIN GASTROENTEROL, V12, P100, DOI 10.1097/00004836-199002000-00026; BONNEVIE O, 1985, DIGEST DIS SCI, V30, pS8, DOI 10.1007/BF01309380; BORODY TJ, 1989, MED J AUSTRALIA, V151, P431, DOI 10.5694/j.1326-5377.1989.tb101251.x; BURETTE A, 1993, GASTROENTEROLOGY S, V4, pA49; BYTZER P, 1994, LANCET, V343, P811, DOI 10.1016/S0140-6736(94)92023-0; CADY B, 1977, AM J SURG, V133, P423, DOI 10.1016/0002-9610(77)90126-X; CHIBA N, 1992, AM J GASTROENTEROL, V87, P1716; COELHO LGV, 1991, AM J GASTROENTEROL, V86, P971; COGHLAN JG, 1987, LANCET, V2, P1109; COLINJONES DG, 1986, LANCET, V1, P1022; CORREA P, 1990, CANCER-AM CANCER SOC, V66, P2569, DOI 10.1002/1097-0142(19901215)66:12<2569::AID-CNCR2820661220>3.0.CO;2-I; CUTLER AF, 1993, AM J GASTROENTEROL, V88, P1359; DOBRILLA G, 1988, GUT, V29, P181, DOI 10.1136/gut.29.2.181; DOOLEY CP, 1989, NEW ENGL J MED, V321, P1562, DOI 10.1056/NEJM198912073212302; DUPONT JB, 1978, CANCER-AM CANCER SOC, V41, P941, DOI 10.1002/1097-0142(197803)41:3<941::AID-CNCR2820410323>3.0.CO;2-M; ELASHOFF JD, 1983, J CLIN GASTROENTEROL, V5, P509, DOI 10.1097/00004836-198312000-00008; EVANS DJ, 1989, GASTROENTEROLOGY, V96, P1004, DOI 10.1016/0016-5085(89)91616-8; FARUP PG, 1992, ALIMENT PHARM THERAP, V6, P179; FISHER JA, 1977, BRIT MED J, V2, P1199, DOI 10.1136/bmj.2.6096.1199; FORBES GM, 1994, LANCET, V343, P258, DOI 10.1016/S0140-6736(94)91111-8; FORMAN D, 1993, LANCET, V341, P1359; GEAR MWL, 1980, BRIT MED J, V280, P1136, DOI 10.1136/bmj.280.6223.1136; GLISE H, 1987, AM J MED, V83, P105, DOI 10.1016/0002-9343(87)90838-2; GLUPCZYNSKI Y, 1988, AM J GASTROENTEROL, V83, P365; GOH KL, 1991, SCAND J GASTROENTERO, V26, P1123, DOI 10.3109/00365529108998603; GRAHAM DY, 1992, GASTROENTEROLOGY, V102, P1289; GRAHAM DY, 1991, GASTROENTEROLOGY, V100, P1495, DOI 10.1016/0016-5085(91)90644-Z; GRAHAM DY, 1993, GASTROENTEROLOGY, V105, P279, DOI 10.1016/0016-5085(93)90038-E; GRAHAM DY, 1990, DIGEST DIS SCI, V35, P66, DOI 10.1007/BF01537225; GREENBERG RE, 1990, ARCH INTERN MED, V150, P2053, DOI 10.1001/archinte.150.10.2053; HANSSON LE, 1993, GASTROENTEROLOGY, V105, P1098, DOI 10.1016/0016-5085(93)90954-B; HENTSCHEL E, 1993, NEW ENGL J MED, V328, P308, DOI 10.1056/NEJM199302043280503; HOLCOMBE C, 1992, ALIMENT PHARM THERAP, V6, P119; HORROCKS JC, 1978, GUT, V19, P19, DOI 10.1136/gut.19.1.19; HOSKING SW, 1992, BRIT MED J, V305, P502, DOI 10.1136/bmj.305.6852.502; HOSKING SW, 1994, LANCET, V343, P508, DOI 10.1016/S0140-6736(94)91460-5; JENSEN DM, 1986, AM J MED, V81, P42, DOI 10.1016/0002-9343(86)90599-1; JONES DM, 1986, J MED MICROBIOL, V22, P57, DOI 10.1099/00222615-22-1-57; JONES R, 1989, BRIT MED J, V298, P30, DOI 10.1136/bmj.298.6665.30; KAGEVI I, 1989, SCAND J GASTROENTERO, V24, P145, DOI 10.3109/00365528909093029; KAHN KL, 1986, J CLIN GASTROENTEROL, V8, P346, DOI 10.1097/00004836-198606002-00005; KASSIRER JP, 1989, NEW ENGL J MED, V320, P1489, DOI 10.1056/NEJM198906013202211; KERRIGAN DD, 1990, BRIT MED J, V300, P374, DOI 10.1136/bmj.300.6721.374; KLEIN PD, 1993, AM J GASTROENTEROL, V88, P1865; LABENZ J, 1993, AM J GASTROENTEROL, V88, P491; LABENZ J, 1993, GUT, V34, P1167, DOI 10.1136/gut.34.9.1167; LAMBERT JR, 1993, GASTROENTEROL CLIN N, V22, P141; LANE MR, 1988, LANCET, V1, P1147; LINDBERG G, 1987, SCAND J GASTROENTERO, V22, P190, DOI 10.3109/00365528709090990; LOGAN RPH, 1992, LANCET, V340, P239, DOI 10.1016/0140-6736(92)90502-T; MALATY HM, 1992, GASTROENTEROLOGY, V103, P813, DOI 10.1016/0016-5085(92)90011-M; MALFERTHEINER P, 1993, SCAND J GASTROENTERO, V28, P34, DOI 10.3109/00365529309098341; MANSI C, 1990, DIGEST DIS SCI, V35, P1452, DOI 10.1007/BF01540561; MANSI C, 1993, J CLIN GASTROENTEROL, V16, P149, DOI 10.1097/00004836-199303000-00015; MARSHALL BJ, 1988, J NUCL MED, V29, P11; MARSHALL BJ, 1988, LANCET, V2, P1437; MARSHALL BJ, 1984, LANCET, V1, P1311; MARSHALL BJ, 1991, AM J GASTROENTEROL, V86, P438; MARSHALL RJ, 1985, MED J AUSTRALIA, V82, P192; MCNULTY CAM, 1989, GUT, V30, P1058, DOI 10.1136/gut.30.8.1058; MEGRAUD F, 1989, J CLIN MICROBIOL, V27, P1870; MOLLMANN KM, 1975, SCAND J GASTROENTERO, V10, P805; MORRISSEY JF, 1988, ANN INTERN MED, V109, P605, DOI 10.7326/0003-4819-109-8-605; MORRISSEY JF, 1976, GASTROINTEST ENDOSC, V23, P13, DOI 10.1016/S0016-5107(76)73567-3; NOMURA A, 1991, NEW ENGL J MED, V325, P1132, DOI 10.1056/NEJM199110173251604; NOMURA A, 1994, ANN INTERN MED, V120, P977, DOI 10.7326/0003-4819-120-12-199406150-00001; OLEARCHYK AS, 1978, AM J GASTROENTEROL, V70, P25; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; PATCHETT S, 1991, BMJ-BRIT MED J, V303, P1238, DOI 10.1136/bmj.303.6812.1238; PETERSON WL, 1993, AM J GASTROENTEROL, V88, P1860; RAUTELIN H, 1992, ANTIMICROB AGENTS CH, V36, P163, DOI 10.1128/AAC.36.1.163; RAUWS EAJ, 1989, GUT, V30, P798, DOI 10.1136/gut.30.6.798; RAUWS EAJ, 1990, LANCET, V335, P1233, DOI 10.1016/0140-6736(90)91301-P; SIPPONEN P, 1991, SCAND J GASTROENTERO, V26, P6, DOI 10.3109/00365529109103980; SIPPONEN P, 1990, SCAND J GASTROENTERO, V25, P966, DOI 10.3109/00365529008997621; TALLEY NJ, 1993, GASTROENTEROLOGY, V105, P1378, DOI 10.1016/0016-5085(93)90142-Y; TALLEY NJ, 1993, GASTROENTEROL CLIN N, V22, P153; TALLEY NJ, 1992, J CLIN MICROBIOL, V30, P3146, DOI 10.1128/JCM.30.12.3146-3150.1992; TAYLOR DN, 1991, EPIDEMIOL REV, V13, P42, DOI 10.1093/oxfordjournals.epirev.a036078; THIJS JC, 1993, SCAND J GASTROENTERO, V28, P934, DOI 10.3109/00365529309098287; VANDEVENTER GM, 1989, NEW ENGL J MED, V320, P1113, DOI 10.1056/NEJM198904273201704; WHITE LJ, 1985, ANN INTERN MED, V102, P266, DOI 10.7326/0003-4819-102-2-266; YAMADA T, 1994, JAMA-J AM MED ASSOC, V272, P65, DOI 10.1001/jama.272.1.65	96	183	183	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1995	123	4					260	268		10.7326/0003-4819-123-4-199508150-00003	http://dx.doi.org/10.7326/0003-4819-123-4-199508150-00003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN665	7611591				2022-12-24	WOS:A1995RN66500003
J	WALSTON, J; SILVER, K; BOGARDUS, C; KNOWLER, WC; CELI, FS; AUSTIN, S; MANNING, B; STROSBERG, AD; STERN, MP; RABEN, N; SORKIN, JD; ROTH, J; SHULDINER, AR				WALSTON, J; SILVER, K; BOGARDUS, C; KNOWLER, WC; CELI, FS; AUSTIN, S; MANNING, B; STROSBERG, AD; STERN, MP; RABEN, N; SORKIN, JD; ROTH, J; SHULDINER, AR			TIME OF ONSET OF NON-INSULIN-DEPENDENT DIABETES-MELLITUS AND GENETIC-VARIATION IN THE BETA(3)-ADRENERGIC-RECEPTOR GENE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BROWN ADIPOSE-TISSUE; BETA-3-ADRENERGIC RECEPTOR; GLUCOSE-TOLERANCE; METABOLIC-RATE; OBESITY; THERMOGENESIS; MUTATIONS; CHAIN; RISK	Background. The beta(3)-adrenergic receptor is expressed in visceral adipose tissue and is thought to contribute to the regulation of the resting metabolic rate and lipolysis. Methods. To investigate whether mutations in the gene for the beta(3)-adrenergic receptor predispose patients to obesity and non-insulin-dependent diabetes mellitus (NIDDM), we studied this gene in 10 Pima Indians by analysis of single-stranded conformational polymorphisms and dideoxy sequence analysis. Association studies were performed in 642 Pima subjects (390 with NIDDM and 252 without NIDDM). Results. A missense mutation was identified in the gene for the beta(3)-adrenergic receptor that results in the replacement of tryptophan by arginine (Trp64Arg) in the first intracellular loop of the receptor. This mutation was detected with allelic frequencies of 0.31 in Pima Indians, 0.13 in 62 Mexican Americans, 0.12 in 49 blacks, and 0.08 in 48 whites in the United States. Among Pimas, the frequency of the Trp64Arg mutation was similar in nondiabetic and diabetic subjects. However, in subjects homozygous for the mutation the mean (+/-SD) age at the onset of NIDDM was significantly lower (36+/-10 years) than in Trp64Arg heterozygotes (40+/-10 years) or normal homozygotes (41 +/- 11 years; P = 0.02). Furthermore, subjects with the mutation tended to have a lower adjusted resting metabolic rate (P = 0.14 by analysis of covariance). Conclusions. Pima subjects homozygous for the Trp64Arg beta(3)-adrenergic-receptor mutation have an earlier onset of NIDDM and tend to have a lower resting metabolic rate. This mutation may accelerate the onset of NIDDM by altering the balance of energy metabolism invisceral adipose tissue.	JOHNS HOPKINS UNIV, SCH MED, DIV GERIATR MED & GERONTOL, BALTIMORE, MD 21224 USA; JOHNS HOPKINS UNIV, SCH MED, DIV ENDOCRINOL & METAB, BALTIMORE, MD USA; NIDDKD, CLIN DIABET & NUTR SECT, PHOENIX, AZ 85016 USA; NIDDKD, DIABET & ARTHRITIS EPIDEMIOL SECT, PHOENIX, AZ 85016 USA; NIA, CLIN PHYSIOL LAB, BALTIMORE, MD 21224 USA; NIAMSD, ARTHRITIS & RHEUMATISM BRANCH, BETHESDA, MD 20892 USA; INST COCHIN GENET MOLEC, IMMUNOPHARMACOL MOLEC LAB, F-75014 PARIS, FRANCE; UNIV TEXAS, HLTH SCI CTR, DEPT MED, DIV CLIN EPIDEMIOL, SAN ANTONIO, TX 78284 USA	Johns Hopkins University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Institut National de la Sante et de la Recherche Medicale (Inserm); University of Texas System; University of Texas Health San Antonio				Shuldiner, Alan/0000-0001-9921-4305	NATIONAL INSTITUTE ON AGING [T32AG000120] Funding Source: NIH RePORTER; NIA NIH HHS [5T32AG00120] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARRETTCONNOR E, 1989, EPIDEMIOL REV, V11, P172, DOI 10.1093/oxfordjournals.epirev.a036035; BOGARDUS C, 1986, NEW ENGL J MED, V315, P96, DOI 10.1056/NEJM198607103150205; BOUCHARD C, 1989, METABOLISM, V38, P364, DOI 10.1016/0026-0495(89)90126-1; BOUCHARD C, 1993, WORLD REV NUTR DIET, V72, P68; CASSARD AM, 1990, J CELL BIOCHEM, V43, P255, DOI 10.1002/jcb.240430306; CIEMENT K, 1995, NEW ENGL J MED, V333, P352; COLLINS S, 1994, MOL ENDOCRINOL, V8, P518, DOI 10.1210/me.8.4.518; CONNACHER AA, 1992, AM J CLIN NUTR, V55, P258; ELBEIN SC, 1994, DIABETES CARE, V17, P1523, DOI 10.2337/diacare.17.12.1523; EMORINE LJ, 1989, SCIENCE, V245, P1118, DOI 10.1126/science.2570461; GRIFFITHS M, 1990, LANCET, V336, P76, DOI 10.1016/0140-6736(90)91592-X; HARRIS MI, 1987, DIABETES, V36, P523, DOI 10.2337/diabetes.36.4.523; HIMMSHAGEN J, 1994, AM J PHYSIOL, V266, pR1371, DOI 10.1152/ajpregu.1994.266.4.R1371; KNOWLER WC, 1991, AM J CLIN NUTR, V53, pS1543, DOI 10.1093/ajcn/53.6.1543S; KRIEF S, 1993, J CLIN INVEST, V91, P344, DOI 10.1172/JCI116191; LIGGETT SB, 1992, DNA SEQUENCE, V2, P61; LYONS J, 1990, PCR PROTOCOLS GUIDE; MITCHELL BD, 1994, DIABETES CARE, V17, P567, DOI 10.2337/diacare.17.6.567; MITCHELL TH, 1989, INT J OBESITY, V13, P757; MUZZIN P, 1991, J BIOL CHEM, V266, P24053; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; OSTROWSKI J, 1992, ANNU REV PHARMACOL, V32, P167, DOI 10.1146/annurev.pharmtox.32.1.167; PROCHAZKA M, 1993, DIABETES, V42, P514, DOI 10.2337/diabetes.42.4.514; RAVUSSIN E, 1988, NEW ENGL J MED, V318, P467, DOI 10.1056/NEJM198802253180802; ROTHWELL NJ, 1979, NATURE, V281, P31, DOI 10.1038/281031a0; ROTTER JI, 1990, ELLENBERG RIFKINS DI, P378; SHULDINER AR, 1993, HDB ENDOCRINE RES TE, P457; STUNKARD AJ, 1986, NEW ENGL J MED, V314, P193, DOI 10.1056/NEJM198601233140401; SUNG CH, 1993, J BIOL CHEM, V268, P26645; SUSULIC S, 1995, 77TH ANN M END SOC B, P36; TRAYHURN P, 1986, BIOCHEM SOC T, V14, P236, DOI 10.1042/bst0140236; TURNER RC, 1995, DIABETES, V44, P1, DOI 10.2337/diabetes.44.1.1; VANSPRONSEN A, 1993, EUR J BIOCHEM, V213, P1117, DOI 10.1111/j.1432-1033.1993.tb17861.x; WIDEN E, 1995, NEW ENGL J MED, V333, P348, DOI 10.1056/NEJM199508103330604; 1985, WHO TECH REP SER, V727, P7	35	566	594	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 10	1995	333	6					343	347		10.1056/NEJM199508103330603	http://dx.doi.org/10.1056/NEJM199508103330603			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN082	7609750				2022-12-24	WOS:A1995RN08200003
J	FRYATT, RJ				FRYATT, RJ			FOREIGN-AID AND TB CONTROL POLICY IN NEPAL	LANCET			English	Editorial Material											FRYATT, RJ (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,HLTH POLICY UNIT,LONDON,ENGLAND.							Chan S. L., 1994, P141; 1995, STOP TB SOURCE WHO R; 1994, NATIONAL TUBERCULOSI; 1993, WORLD HLTH, V4, P2	4	7	7	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 5	1995	346	8971					328	328		10.1016/S0140-6736(95)92223-7	http://dx.doi.org/10.1016/S0140-6736(95)92223-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM713	7623529				2022-12-24	WOS:A1995RM71300006
J	WALTER, MR; WINDSOR, W; NAGABHUSHAN, TL; LUNDELL, DJ; LUNN, CA; ZAUODNY, PJ; NARULA, SK				WALTER, MR; WINDSOR, W; NAGABHUSHAN, TL; LUNDELL, DJ; LUNN, CA; ZAUODNY, PJ; NARULA, SK			CRYSTAL-STRUCTURE OF A COMPLEX BETWEEN INTERFERON-GAMMA AND ITS SOLUBLE HIGH-AFFINITY RECEPTOR	NATURE			English	Article							EXTRACELLULAR DOMAIN; ACCESSORY FACTOR; C-TERMINUS; HUMAN CD4; PROTEIN; EXPRESSION; RESOLUTION; FRAGMENT; CLONING	The crystal structure of interferon-gamma bound to the extracellular fragment of its high-affinity cell-surface receptor reveals the first view of a class-2 cytokine receptor-ligand complex. In the complex, one interferon-gamma homodimer binds two receptor molecules. Unlike the class-1 growth hormone receptor complex, the two interferon-gamma receptors do not interact with one another and are separated by 27 Angstrom. Upon receptor binding, the flexible As loop of interferon-gamma undergoes a conformational change that includes the formation of a 3(10) helix.	UNIV ALABAMA, CTR MACROMOLEC CRYSTALLOG, BIRMINGHAM, AL 35294 USA; SCHERING PLOUGH CORP, RES INST, KENILWORTH, NJ 07033 USA	University of Alabama System; University of Alabama Birmingham; Merck & Company; Schering Plough Corporation	WALTER, MR (corresponding author), UNIV ALABAMA, DEPT PHARMACOL, BIRMINGHAM, AL 35294 USA.							AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CONNOLLY ML, 1993, J MOL GRAPH MODEL, V11, P139, DOI 10.1016/0263-7855(93)87010-3; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; EALICK SE, 1991, SCIENCE, V252, P698, DOI 10.1126/science.1902591; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; GRIGGS ND, 1992, J IMMUNOL, V149, P517; GRZESIEK S, 1992, BIOCHEMISTRY-US, V31, P8180, DOI 10.1021/bi00150a009; HARLOS K, 1994, NATURE, V370, P662, DOI 10.1038/370662a0; HEMMI S, 1994, CELL, V76, P803, DOI 10.1016/0092-8674(94)90355-7; HIBINO Y, 1992, J BIOL CHEM, V267, P3741; HO ASY, 1993, P NATL ACAD SCI USA, V90, P11267, DOI 10.1073/pnas.90.23.11267; HOLMGREN A, 1989, NATURE, V342, P248, DOI 10.1038/342248a0; JARPE MA, 1993, J INTERFERON RES, V13, P99, DOI 10.1089/jir.1993.13.99; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; JUNG V, 1987, P NATL ACAD SCI USA, V84, P4151, DOI 10.1073/pnas.84.12.4151; KOSSIAKOFF AA, 1994, PROTEIN SCI, V3, P1697, DOI 10.1002/pro.5560031008; LUNDELL D, 1994, J BIOL CHEM, V269, P16159; LUNDELL D, 1991, PROTEIN ENG, V4, P335, DOI 10.1093/protein/4.3.335; LUNN CA, 1992, J BIOL CHEM, V267, P17920; LUNN CA, 1992, PROTEIN ENG, V5, P253, DOI 10.1093/protein/5.3.253; MANNEBERG M, 1994, PROTEIN SCI, V3, P30; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER YA, 1994, BIOCHEMISTRY-US, V33, P10864, DOI 10.1021/bi00202a003; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RINDERKNECHT E, 1984, J BIOL CHEM, V259, P6790; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SOH J, 1993, P NATL ACAD SCI USA, V90, P8737, DOI 10.1073/pnas.90.18.8737; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WETZEL R, 1990, PROTEIN ENG, V3, P611, DOI 10.1093/protein/3.7.611; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158	49	337	353	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 20	1995	376	6537					230	235		10.1038/376230a0	http://dx.doi.org/10.1038/376230a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK331	7617032				2022-12-24	WOS:A1995RK33100039
J	ASHAR, HR; FEJZO, MS; TKACHENKO, A; ZHOU, X; FLETCHER, JA; WEREMOWICZ, S; MORTON, CC; CHADA, K				ASHAR, HR; FEJZO, MS; TKACHENKO, A; ZHOU, X; FLETCHER, JA; WEREMOWICZ, S; MORTON, CC; CHADA, K			DISRUPTION OF THE ARCHITECTURAL FACTOR HMGI-C - DNA-BINDING AT HOOK MOTIFS FUSED IN LIPOMAS TO DISTINCT TRANSCRIPTIONAL REGULATORY DOMAINS	CELL			English	Article							PULMONARY CHONDROID HAMARTOMA; NF-KAPPA-B; DIAGNOSTIC RELEVANCE; DROSOPHILA-TRITHORAX; ACUTE LEUKEMIAS; INSULIN GENE; ALL-1 GENE; PROTEINS; TRANSLOCATION; TUMORS	Lipomas are one of the most common mesenchymal neoplasms in humans. They are characterized by consistent cytogenetic aberrations involving chromosome 12 in bands q14-15. Interestingly, this region is also the site of rearrangement for other mesenchymally derived tumors. This study demonstrates that HMGI-C, an architectural factor that functions in transcriptional regulation, has been disrupted by rearrangement at the 12q14-15 chromosomal breakpoint in lipomas. Chimeric transcripts were isolated from two lipomas in which HMGI-C DNA-binding domains (AT hook motifs) are fused to either a LIM or an acidic transactivation domain. These results, identifying a gene rearranged in a benign neoplastic process that does not proceed to a malignancy, suggest a role for HMGI-C in adipogenesis and mesenchyme differentiation.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV PEDIAT ONCOL,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	ASHAR, HR (corresponding author), UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854, USA.			Fejzo, Marlena/0000-0001-6800-687X	NCI NIH HHS [1K11 CA 01498] Funding Source: Medline; NICHD NIH HHS [HD30498] Funding Source: Medline; NIGMS NIH HHS [GM38731] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD030498] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [K11CA001498] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038731] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BENSON KF, 1994, GENET RES, V64, P27, DOI 10.1017/S0016672300032511; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; BRIDGE JA, 1995, GENE CHROMOSOME CANC, V12, P70, DOI 10.1002/gcc.2870120113; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; DALCIN P, 1993, GENE CHROMOSOME CANC, V8, P131; DARMIENTO J, 1992, CELL, V71, P955, DOI 10.1016/0092-8674(92)90391-O; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; FEJZO MS, 1995, GENOMICS, V26, P265, DOI 10.1016/0888-7543(95)80210-D; FEUERSTEIN R, 1994, P NATL ACAD SCI USA, V91, P10655, DOI 10.1073/pnas.91.22.10655; FLETCHER JA, 1993, GENE CHROMOSOME CANC, V6, P24, DOI 10.1002/gcc.2870060106; FLETCHER JA, 1992, CANCER RES, V52, P6224; FLETCHER JA, 1990, CANCER RES, V50, P4092; FLETCHER JA, 1991, NEW ENGL J MED, V324, P436, DOI 10.1056/NEJM199102143240702; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; FRIEDMANN M, 1993, NUCLEIC ACIDS RES, V21, P4259, DOI 10.1093/nar/21.18.4259; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; GIANCOTTI V, 1989, EXP CELL RES, V184, P538, DOI 10.1016/0014-4827(89)90352-2; GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x; GREEN ED, 1990, P NATL ACAD SCI USA, V87, P1213, DOI 10.1073/pnas.87.3.1213; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P218; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; JENKINS RB, 1989, CYTOGENET CELL GENET, V51, P1019; JUSTICE MJ, 1990, GENETICS, V125, P855; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; MacArthur JW, 1944, AM NAT, V78, P142, DOI 10.1086/281181; MANDAHL N, 1993, CANCER, V71, P3009, DOI 10.1002/1097-0142(19930515)71:10<3009::AID-CNCR2820711020>3.0.CO;2-Y; MANDAHL N, 1988, HUM GENET, V79, P203, DOI 10.1007/BF00366238; MANDAHL N, 1989, CANCER, V65, P242; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NILBERT M, 1990, GENE CHROMOSOME CANC, V2, P3, DOI 10.1002/gcc.2870020103; NOGUERA R, 1989, VIRCHOWS ARCH A, V415, P377, DOI 10.1007/BF00718640; PATEL UA, 1994, BIOCHEM BIOPH RES CO, V201, P63, DOI 10.1006/bbrc.1994.1669; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PRASAD R, 1994, P NATL ACAD SCI USA, V91, P8107, DOI 10.1073/pnas.91.17.8107; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; REEVES R, 1990, J BIOL CHEM, V265, P8573; ROGERS P, 1980, BRIT J NUTR, V43, P83, DOI 10.1079/BJN19800066; ROHEN C, 1993, CANCER GENET CYTOGEN, V69, P68, DOI 10.1016/0165-4608(93)90117-5; ROTHER RP, 1992, BIOTECHNIQUES, V13, P524; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SAITOH Y, 1994, CELL, V75, P609; Sambrook J., 1989, MOL CLONING LAB MANU; SANCHEZGARCIA I, 1993, SEMIN CANCER BIOL, V4, P349; SANCHEZGARCIA I, 1993, EMBO J, V12, P4243, DOI 10.1002/j.1460-2075.1993.tb06108.x; SANDROS J, 1990, CANCER GENET CYTOGEN, V44, P153, DOI 10.1016/0165-4608(90)90042-9; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SREEKANTAIAH C, 1991, CANCER RES, V51, P422; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; VANNI R, 1993, CANCER GENET CYTOGEN, V68, P32, DOI 10.1016/0165-4608(93)90070-3; VARTIAINEN E, 1988, FEBS LETT, V228, P45, DOI 10.1016/0014-5793(88)80581-7; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WOLFFE AP, 1994, SCIENCE, V264, P1100, DOI 10.1126/science.8178167; XIANG X, 1990, SCIENCE, V247, P967, DOI 10.1126/science.2305264; XU Y, 1993, P NATL ACAD SCI USA, V90, P227, DOI 10.1073/pnas.90.1.227; YUSPA SH, 1989, GENETIC MECHANISMS C, P115	69	395	408	0	7	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 14	1995	82	1					57	65						9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RK424	7606786				2022-12-24	WOS:A1995RK42400009
J	STANFORD, JL; WEISS, NS; VOIGT, LF; DALING, JR; HABEL, LA; ROSSING, MA				STANFORD, JL; WEISS, NS; VOIGT, LF; DALING, JR; HABEL, LA; ROSSING, MA			COMBINED ESTROGEN AND PROGESTIN HORMONE REPLACEMENT THERAPY IN RELATION TO RISK OF BREAST-CANCER IN MIDDLE-AGED WOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROLIFERATION; SURVEILLANCE; PREVENTION; MODELS	Objective.-To determine the risk of breast cancer in relation to the use of combined estrogen and progestin hormone replacement therapy (HRT). Design.-A population-based case-control study. Setting.-The general female population of King County in western Washington State. Participants.-Middle-aged (50 to 64 years) women, including 537 patients with incident primary breast cancer diagnosed between January 1, 1988, and June 30, 1990, who were ascertained through the Seattle-Puget Sound Surveillance, Epidemiology, and End Results cancer registry and 492 randomly selected control women without a history of breast cancer. Main Outcome Measure,-Breast cancer risk in relation to use of menopausal hormones. Results.-Menopausal hormones of some type had been used by 57.6% of breast cancer cases and 61.0% of comparison women. The women who had ever taken combined estrogen-progestin HRT, representing 21.5% of cases and 21.3% of controls, were not at increased risk of breast cancer (relative odds [RO]=0.9; 95% confidence interval [CI], 0.7 to 1.3). Compared with nonusers of menopausal hormones, those who used estrogen-progestin HRT for 8 or more years had, if anything, a reduced risk of breast cancer (RO=0.4; 95% CI, 0.2 to 1.0). Conclusions.-On the whole, the use of estrogen with progestin HRT does not appear to be associated with an increased risk of breast cancer in middle-aged women. Nonetheless, since the use of combined estrogen-progestin HRT has only recently become prevalent, future investigations must assess whether breast cancer incidence is altered many years after estrogen-progestin HRT has been initiated, particularly among long-term users.	UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT EPIDEMIOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	STANFORD, JL (corresponding author), FRED HUTCHINSON CANC RES CTR,DIV PUBL HLTH SCI,1124 COLUMBIA ST,MP-474,SEATTLE,WA 98104, USA.			Habel, Laurel/0000-0002-7230-587X	NCI NIH HHS [N01-CN-05230, R35-CA39779, K07-CA01364] Funding Source: Medline; DIVISION OF CANCER PREVENTION AND CONTROL [N01CN005230] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [K07CA001364, R35CA039779] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON TJ, 1989, HUM PATHOL, V20, P1139, DOI 10.1016/S0046-8177(89)80003-6; BARRETTCONNOR E, 1991, ANN INTERN MED, V115, P455, DOI 10.7326/0003-4819-115-6-455; BERGKVIST L, 1990, NEW ENGL J MED, V322, P204; BERGKVIST L, 1989, NEW ENGL J MED, V321, P293, DOI 10.1056/NEJM198908033210505; Breslow NE, 1980, ANAL CASE CONTROL ST; Breslow NE Day NE, 1987, DESIGN ANAL COHORT S; BRINTON LA, 1993, EPIDEMIOL REV, V15, P66, DOI 10.1093/oxfordjournals.epirev.a036117; BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; CAULEY JA, 1990, AM J OBSTET GYNECOL, V163, P1438, DOI 10.1016/0002-9378(90)90602-4; CLARKE CL, 1990, ENDOCR REV, V11, P266, DOI 10.1210/edrv-11-2-266; COLDITZ GA, 1992, CANCER CAUSE CONTROL, V3, P433, DOI 10.1007/BF00051356; COX DR, 1972, J R STAT SOC B, V34, P187; CUTLER WB, 1990, NEW ENGL J MED, V322, P202; EWERTZ M, 1988, INT J CANCER, V42, P832, DOI 10.1002/ijc.2910420606; GAMBRELL RD, 1986, MATURITAS, V8, P169, DOI 10.1016/0378-5122(86)90023-X; GENALO MA, 1988, P SECTION SURVEY RES; GINSBURG KA, 1988, FERTIL STERIL, V49, pS16; GOING JJ, 1988, AM J PATHOL, V130, P193; HARLOW BL, 1988, AM J EPIDEMIOL, V127, P857, DOI 10.1093/oxfordjournals.aje.a114869; HARRIS RB, 1990, AM J PUBLIC HEALTH, V80, P1266, DOI 10.2105/AJPH.80.10.1266; HEMMINKI E, 1988, American Journal of Public Health, V78, P1479, DOI 10.2105/AJPH.78.11.1479; HUNT K, 1987, BRIT J OBSTET GYNAEC, V94, P620, DOI 10.1111/j.1471-0528.1987.tb03166.x; JORDAN VC, 1993, CANCER, V71, P1501, DOI 10.1002/cncr.2820710415; KAUFMAN DW, 1991, AM J EPIDEMIOL, V134, P1375, DOI 10.1093/oxfordjournals.aje.a116041; NACHTIGALL LE, 1979, OBSTET GYNECOL, V54, P74, DOI 10.1097/00006250-197907000-00017; PALMER JR, 1991, AM J EPIDEMIOL, V134, P1386, DOI 10.1093/oxfordjournals.aje.a116042; POTTEN CS, 1988, BRIT J CANCER, V58, P163, DOI 10.1038/bjc.1988.185; PRENTICE RL, 1978, BIOMETRIKA, V65, P153, DOI 10.2307/2335290; RISCH HA, 1994, AM J EPIDEMIOL, V139, P670, DOI 10.1093/oxfordjournals.aje.a117057; SCHAIRER C, 1994, CANCER CAUSE CONTROL, V5, P491, DOI 10.1007/BF01831376; SEBOLD J, 1988, TELEPHONE SURVEY MET; STANFORD JL, 1993, EPIDEMIOL REV, V15, P98, DOI 10.1093/oxfordjournals.epirev.a036120; VOIGT LF, 1992, AM J EPIDEMIOL, V136, P1393, DOI 10.1093/oxfordjournals.aje.a116452; WAKSBERG J, 1978, J AM STAT ASSOC, V73, P40, DOI 10.2307/2286513; YANG CP, 1992, CANCER CAUSE CONTROL, V3, P475, DOI 10.1007/BF00051360	35	310	314	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 12	1995	274	2					137	142		10.1001/jama.274.2.137	http://dx.doi.org/10.1001/jama.274.2.137			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH222	7596001				2022-12-24	WOS:A1995RH22200026
J	STACHELHAUS, T; SCHNEIDER, A; MARAHIEL, MA				STACHELHAUS, T; SCHNEIDER, A; MARAHIEL, MA			RATIONAL DESIGN OF PEPTIDE ANTIBIOTICS BY TARGETED REPLACEMENT OF BACTERIAL AND FUNGAL DOMAINS	SCIENCE			English	Article							OPEN READING FRAME; BACILLUS-SUBTILIS; GENE; BIOSYNTHESIS; SURFACTIN; SEQUENCE; ENZYMES; BREVIS; GRSB	Peptide synthetases involved in the nonribosomal synthesis of peptide secondary metabolites possess a highly conserved domain structure. The arrangement of these domains within the multifunctional enzymes determines the number and order of the amino acid constituents of the peptide product. A general approach has been developed for targeted substitution of amino acid-activating domains within the srfA operon, which encodes the protein templates for the synthesis of the lipopeptide antibiotic surfactin in Bacillus subtilis. Exchange of domain-coding regions of bacterial and fungal origin led to the construction of hybrid genes that encoded peptide synthetases with altered amino acid specificities and the production of peptides with modified amino acid sequences.	UNIV MARBURG,FACHBEREICH CHEM,D-35032 MARBURG,GERMANY	Philipps University Marburg								ANTONIEWSKI C, 1990, J BACTERIOL, V172, P86, DOI 10.1128/JB.172.1.86-93.1990; BORCHERT S, 1994, J BACTERIOL, V176, P2458, DOI 10.1128/JB.176.8.2458-2462.1994; COOPER DG, 1986, MICROBIOL SCI, V3, P145; COSMINA P, 1993, MOL MICROBIOL, V8, P821, DOI 10.1111/j.1365-2958.1993.tb01629.x; CUTTING SM, 1990, MOL BIOL METHODS BAC; DSOUZA C, 1994, P NATL ACAD SCI USA, V91, P9397, DOI 10.1073/pnas.91.20.9397; FUMA S, 1993, NUCLEIC ACIDS RES, V21, P93, DOI 10.1093/nar/21.1.93; HAESE A, 1993, MOL MICROBIOL, V7, P905, DOI 10.1111/j.1365-2958.1993.tb01181.x; HAMOEN LW, 1994, MOL MICROBIOL, V15, P55; ITAYA M, 1990, MOL GEN GENET, V223, P268, DOI 10.1007/BF00265063; KRATZSCHMAR J, 1989, J BACTERIOL, V171, P5422; KRAUSE M, 1985, J BACTERIOL, V162, P1120, DOI 10.1128/JB.162.3.1120-1125.1985; LAEMMLI UK, 1970, NATURE, V227, P491; Lipmann F, 1980, Adv Microb Physiol, V21, P227; MARAHIEL MA, 1992, FEBS LETT, V307, P40, DOI 10.1016/0014-5793(92)80898-Q; NAKANO MM, 1992, MOL GEN GENET, V232, P313, DOI 10.1007/BF00280011; NAKANO MM, 1988, J BACTERIOL, V170, P5662, DOI 10.1128/jb.170.12.5662-5668.1988; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTTCRAIG JS, 1992, J BIOL CHEM, V267, P26044; SMITH DJ, 1990, EMBO J, V9, P2743, DOI 10.1002/j.1460-2075.1990.tb07461.x; STACHELHAUS T, 1995, J BIOL CHEM, V270, P6163, DOI 10.1074/jbc.270.11.6163; STACHELHAUS T, 1995, FEMS MICROBIOL LETT, V125, P3, DOI 10.1016/0378-1097(94)00459-5; STACHELHAUS T, UNPUB; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURGAY K, 1994, PEPTIDE RES, V7, P238; TURGAY K, 1992, MOL MICROBIOL, V6, P529, DOI 10.1111/j.1365-2958.1992.tb01498.x; WEBER G, 1994, CURR GENET, V26, P120, DOI 10.1007/BF00313798; Zuber Peter, 1993, P897	29	243	264	1	41	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 7	1995	269	5220					69	72		10.1126/science.7604280	http://dx.doi.org/10.1126/science.7604280			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RG980	7604280				2022-12-24	WOS:A1995RG98000034
J	CHITNIS, A; HENRIQUE, D; LEWIS, J; ISHHOROWICZ, D; KINTNER, C				CHITNIS, A; HENRIQUE, D; LEWIS, J; ISHHOROWICZ, D; KINTNER, C			PRIMARY NEUROGENESIS IN XENOPUS EMBRYOS REGULATED BY A HOMOLOG OF THE DROSOPHILA NEUROGENIC GENE-DELTA	NATURE			English	Article							CELL FATE; NERVOUS-SYSTEM; MOUSE NOTCH; SPINAL-CORD; EXPRESSION; PATTERN; MELANOGASTER; SERRATE; PROTEIN; XOTCH	X-Delta-1, a Xenopus homologue of the Drosophila Delta gene, is expressed in the early embryonic nervous system in scattered cells that appear to be the prospective primary neurons. Ectopic X-Delta-1 activity inhibits production of primary neurons and interference with endogenous X-Delta-1 activity results in overproduction of primary neurons. These results indicate that the X-Delta-1 protein mediates lateral inhibition delivered by prospective neurons to adjacent cells, and that commitment to a neural fate in vertebrates is regulated by Delta-Notch signalling as in Drosophila.	UNIV OXFORD, DEPT ZOOL,IMPERIAL CANC RES FUND, DEV GENET & ORGANOGENESIS LABS,DEV BIOL UNIT, OXFORD OX1 3PS, ENGLAND	University of Oxford	CHITNIS, A (corresponding author), SALK INST BIOL STUDIES, POB 85800, SAN DIEGO, CA 92186 USA.		Lewis, Julian H/E-8733-2010; Henrique, Domingos M/E-5460-2010	Henrique, Domingos M/0000-0001-8869-1894; Ish-Horowicz, David/0000-0001-5684-7129				ALRDELLI M, 1994, MECH DEVELOP, V46, P123; ARTAVANISTSAKONAS S, 1991, TRENDS GENET, V7, P403, DOI 10.1016/0168-9525(91)90264-Q; BIERKAMP C, 1993, MECH DEVELOP, V43, P87, DOI 10.1016/0925-4773(93)90027-U; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CAMPOSORTEGA JA, 1993, J NEUROBIOL, V24, P1305, DOI 10.1002/neu.480241005; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; COFFMAN CR, 1993, CELL, V73, P659, DOI 10.1016/0092-8674(93)90247-N; CONLON RA, 1995, DEVELOPMENT, V121, P1533; COUSO JP, 1994, CELL, V79, P259, DOI 10.1016/0092-8674(94)90195-3; DOE CQ, 1992, DEVELOPMENT, V116, P855; DOE CQ, 1985, DEV BIOL, V111, P206, DOI 10.1016/0012-1606(85)90446-4; FORTINI ME, 1993, CELL, V75, P1245, DOI 10.1016/0092-8674(93)90611-S; GORIELY A, 1991, DEVELOPMENT, V113, P1395; GREENWALD I, 1994, CURR OPIN GENET DEV, V4, P556, DOI 10.1016/0959-437X(94)90072-B; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HARTENSTEIN V, 1989, NEURON, V3, P399, DOI 10.1016/0896-6273(89)90200-6; HARTENSTEIN V, 1993, J COMP NEUROL, V328, P213, DOI 10.1002/cne.903280205; HARTENSTEIN V, 1984, ROUX ARCH DEV BIOL, V193, P308, DOI 10.1007/BF00848159; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; HENDERSON ST, 1994, DEVELOPMENT, V120, P2913; HENRIQUE D, 1995, NATURE, V375, P787, DOI 10.1038/375787a0; KOPAN R, 1993, J CELL BIOL, V121, P631, DOI 10.1083/jcb.121.3.631; KOPAN R, 1994, DEVELOPMENT, V120, P2385; KORZH V, 1993, DEVELOPMENT, V118, P417; LARDELLI M, 1993, EXP CELL RES, V204, P364, DOI 10.1006/excr.1993.1044; LEHMANN R, 1981, ROUX ARCH DEV BIOL, V190, P226, DOI 10.1007/BF00848307; LEHMANN R, 1983, ROUX ARCH DEV BIOL, V192, P62, DOI 10.1007/BF00848482; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; MUSKAVITCH MAT, 1994, DEV BIOL, V166, P415, DOI 10.1006/dbio.1994.1326; NYE JS, 1994, DEVELOPMENT, V120, P2421; OSCHWALD R, 1991, International Journal of Developmental Biology, V35, P399; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; RICHTER K, 1988, P NATL ACAD SCI USA, V85, P8086, DOI 10.1073/pnas.85.21.8086; ROBERTS A, 1982, PHILOS T R SOC B, V296, P195, DOI 10.1098/rstb.1982.0002; ROEHL H, 1993, NATURE, V364, P632, DOI 10.1038/364632a0; SIMPSON P, 1992, COLD SPRING HARB SYM, V57, P391, DOI 10.1101/SQB.1992.057.01.044; SKEATH JB, 1994, FASEB J, V8, P714, DOI 10.1096/fasebj.8.10.8050670; STERNBERG PW, 1993, CURR BIOL, V3, P763, DOI 10.1016/0960-9822(93)90025-J; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; TAX FE, 1994, NATURE, V368, P150, DOI 10.1038/368150a0; THOMAS U, 1991, DEVELOPMENT, V111, P749; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; WEINMASTER G, 1991, DEVELOPMENT, V113, P199; WEINMASTER G, 1992, DEVELOPMENT, V116, P931; WILKINSON HA, 1994, CELL, V79, P1187, DOI 10.1016/0092-8674(94)90010-8	46	622	636	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 29	1995	375	6534					761	766		10.1038/375761a0	http://dx.doi.org/10.1038/375761a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF989	7596407				2022-12-24	WOS:A1995RF98900070
J	HENRIQUE, D; ADAM, J; MYAT, A; CHITNIS, A; LEWIS, J; ISHHOROWICZ, D				HENRIQUE, D; ADAM, J; MYAT, A; CHITNIS, A; LEWIS, J; ISHHOROWICZ, D			EXPRESSION OF A DELTA-HOMOLOG IN PROSPECTIVE NEURONS IN THE CHICK	NATURE			English	Article							NEUROGENIC GENE-DELTA; DROSOPHILA-MELANOGASTER; TRANSMEMBRANE PROTEIN; CELL-INTERACTIONS; SERRATE ENCODES; NOTCH; COMPLEX; PATTERN; FATE; RNA	THE product of the Delta gene, acting as ligand, and that of the Notch gene, acting as receptor, are key components in a lateral-inhibition signalling pathway that regulates the detailed patterning of many different tissues in Drosophila(1-8). During neurogenesis in particular, neural precursors, by expressing Delta, inhibit neighbouring Notch-expressing cells from becoming committed to a neural fate(5,9,10). Vertebrates are known to have several Notch genes(11-14), but their functions are unclear and their ligands hitherto unidentified. Here we identify and describe a chick Delta homologue, C-Delta-1. We show that C-Delta-1 is expressed in prospective neurons during neurogenesis, as new cells are being born and their fates decided. Our data from the chick, combined with parallel evidence from Xenopus(15), suggest that both the Delta/Notch signalling mechanism and its role in neurogenesis have been conserved in vertebrates.	UNIV OXFORD,DEPT ZOOL,IMPERIAL CANC RES FUND,ORGANOGENESIS LAB,BIOL UNIT,OXFORD OX1 3PS,ENGLAND; SALK INST BIOL STUDIES,SAN DIEGO,CA 92186	University of Oxford; Salk Institute	HENRIQUE, D (corresponding author), UNIV OXFORD,DEV GENET LAB,S PARKS RD,OXFORD OX1 3PS,ENGLAND.		Lewis, Julian H/E-8733-2010; Henrique, Domingos M/E-5460-2010	Henrique, Domingos M/0000-0001-8869-1894; Ish-Horowicz, David/0000-0001-5684-7129; Adam, Julie/0000-0002-7980-7151				ARTAVANISTSAKON.S, 1991, TRENDS GENET, V7, P403; BIFFO S, 1992, J HISTOCHEM CYTOCHEM, V40, P535, DOI 10.1177/40.4.1552187; Campos-Ortega Jose A., 1993, P1091; CHITNIS A, 1995, NATURE, V375, P761, DOI 10.1038/375761a0; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FLEMING RJ, 1990, GENE DEV, V4, P2188, DOI 10.1101/gad.4.12a.2188; FORTINI ME, 1993, CELL, V75, P1245, DOI 10.1016/0092-8674(93)90611-S; FUJITA S, 1963, J COMP NEUROL, V120, P37, DOI 10.1002/cne.901200104; GHYSEN A, 1993, GENE DEV, V7, P723, DOI 10.1101/gad.7.5.723; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; HAENLIN M, 1990, DEVELOPMENT, V110, P905; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; HENDERSON ST, 1994, DEVELOPMENT, V120, P2913; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KOOH PJ, 1993, DEVELOPMENT, V117, P493; KOPCZYNSKI CC, 1988, GENE DEV, V2, P1723, DOI 10.1101/gad.2.12b.1723; LARDELLI M, 1993, EXP CELL RES, V204, P364, DOI 10.1006/excr.1993.1044; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; MARTIN AH, 1965, J EMBRYOL EXP MORPH, V14, P23; MELLO CC, 1994, CELL, V77, P95, DOI 10.1016/0092-8674(94)90238-0; MUSKAVITCH MAT, 1994, DEV BIOL, V166, P415, DOI 10.1006/dbio.1994.1326; SECHRIST J, 1991, NEURON, V7, P947, DOI 10.1016/0896-6273(91)90340-6; STRAHLE U, 1994, TRENDS GENET, V10, P75, DOI 10.1016/0168-9525(94)90221-6; TAX FE, 1994, NATURE, V368, P150, DOI 10.1038/368150a0; THOMAS U, 1991, DEVELOPMENT, V111, P749; VASSIN H, 1987, EMBO J, V6, P3431, DOI 10.1002/j.1460-2075.1987.tb02666.x; WEINMASTER G, 1991, DEVELOPMENT, V113, P199; WEINMASTER G, 1992, DEVELOPMENT, V116, P931	29	928	946	0	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 29	1995	375	6534					787	790		10.1038/375787a0	http://dx.doi.org/10.1038/375787a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF989	7596411				2022-12-24	WOS:A1995RF98900078
J	CHEN, CC; AKOPIAN, AN; SIVILOTTI, L; COLQUHOUN, D; BURNSTOCK, G; WOOD, JN				CHEN, CC; AKOPIAN, AN; SIVILOTTI, L; COLQUHOUN, D; BURNSTOCK, G; WOOD, JN			A P2X PURINOCEPTOR EXPRESSED BY A SUBSET OF SENSORY NEURONS	NATURE			English	Article							ATP-ACTIVATED CHANNELS; RAT; TRANSCRIPTION; RECEPTORS; INVITRO	ATP is known to depolarize sensory neurons, and may play a role in nociceptor activation when released from damaged tissue(1-10). Here we report the molecular cloning and characterization of a new member of the P2X receptor family(3,11,12), P2X(3), expressed by these cells, The channel transcript was present in a subset of rat dorsal-root-ganglion sensory neurons, some of which express nociceptor-associated markers; it was absent in other tissues that were tested, including sympathetic, enteric and central nervous system neurons. Moreover, when expressed in Xenopus oocytes, the channel showed an ATP-dependent cation flux, P2X(3) is the only ligand-gated channel known to be expressed exclusively by a subset of sensory neurons. The remarkable selectivity of expression of the channel coupled with its sensory neuron-like pharmacology suggests that this channel may transduce ATP-evoked nociceptor activation.	UNIV LONDON UNIV COLL,DEPT PHARMACOL,LONDON WC1E 6BT,ENGLAND	University of London; University College London	CHEN, CC (corresponding author), UNIV LONDON UNIV COLL,DEPT ANAT & DEV BIOL,GOWER ST,LONDON WC1E 6BT,ENGLAND.		Sivilotti, Lucia/D-8919-2011; Chen, Chih-Cheng/AAT-1062-2021; Colquhoun, David/C-1664-2008; Chen, Chih-Cheng/S-7015-2018	Sivilotti, Lucia/0000-0003-2510-8424; Chen, Chih-Cheng/0000-0003-4768-5660; Colquhoun, David/0000-0002-4263-017X; Chen, Chih-Cheng/0000-0003-4768-5660	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABBRACCHIO MP, 1994, PHARMACOL THERAPEUT, V64, P445, DOI 10.1016/0163-7258(94)00048-4; AKOPIAN A, IN PRESS J BIOL CHEM; ANDREWS PW, 1984, LAB INVEST, V50, P147; BEAN BP, 1990, J NEUROSCI, V10, P11; BEAN BP, 1990, J NEUROSCI, V10, P1; BEAN BP, 1990, ION CHANNELS, V2, P163; BLEEHEN T, 1977, PAIN, V3, P367, DOI 10.1016/0304-3959(77)90066-5; BOUVIER MM, 1991, EUR J NEUROSCI, V3, P285, DOI 10.1111/j.1460-9568.1991.tb00090.x; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; BURNSTOCK G, 1993, DRUG DEVELOP RES, V28, P195, DOI 10.1002/ddr.430280303; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; COLQUHOUN D, 1971, LECTURES BIOSTATISTI; ESCURAT M, 1990, J NEUROSCI, V10, P764; HO BT, 1992, ANTI-CANCER DRUG, V2, P91; HOONG K, 1994, NATURE, V367, P470; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; JAHR CE, 1983, NATURE, V304, P730, DOI 10.1038/304730a0; KHAKH BS, 1995, J PHYSIOL-LONDON, V484, P385, DOI 10.1113/jphysiol.1995.sp020672; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KRISHTAL OA, 1988, BRIT J PHARMACOL, V95, P1057, DOI 10.1111/j.1476-5381.1988.tb11739.x; KRISHTAL OA, 1986, BIOMED RES-TOKYO, V7, P79; Lawson SN., 1992, SENSORY NEURONS DIVE, P27; LEBEAU MC, 1991, NUCLEIC ACIDS RES, V19, P1337, DOI 10.1093/nar/19.6.1337; NINKINA NN, 1993, NUCLEIC ACIDS RES, V21, P3175, DOI 10.1093/nar/21.14.3175; ROBERTSON SJ, IN PRESS BR J PHARM; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; WOOD JN, 1988, J NEUROSCI, V8, P3208; WOOD JN, 1990, P ROY SOC B-BIOL SCI, V241, P187, DOI 10.1098/rspb.1990.0084	29	883	947	1	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 5	1995	377	6548					428	431		10.1038/377428a0	http://dx.doi.org/10.1038/377428a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY190	7566119				2022-12-24	WOS:A1995RY19000049
J	MOSS, SJ; GORRIE, GH; AMATO, A; SMART, TG				MOSS, SJ; GORRIE, GH; AMATO, A; SMART, TG			MODULATION OF GABA(A) RECEPTORS BY TYROSINE PHOSPHORYLATION	NATURE			English	Article							A RECEPTOR; MOLECULAR-BIOLOGY; TRANSFECTED CELLS; BETA-1-SUBUNIT; PHARMACOLOGY; POTENTIATION; SUBUNIT; KINASE	gamma-AMINOBUTYRIC acid type-A (GABA(A)) receptors are the major sites of fast synaptic inhibition in the brain, They are presumed to be pentameric heteroligomers assembled from four classes of subunits with multiple members: alpha (1-6), beta (1-3), gamma (1-3) and delta (1)(1-5). Here, GABA(A) receptors consisting of alpha 1, beta 1 and gamma 2L subunits, coexpressed in mammalian cells with the tyrosine kinase vSRC (the transforming gene product of the Rous sarcoma virus), were phosphorylated on tyrosine residues within the gamma 2L and beta 1 subunits. Tyrosine phosphorylation enhanced the whole-cell current induced by GABA. Site-specific mutagenesis of two tyrosine residues within the predicted intracellular domain of the gamma 2L subunit abolished tyrosine phosphorylation of this subunit and eliminated receptor modulation. A similar modulation of GABA(A) receptor function was observed in primary neuronal cultures. As GABA(A) receptors are critical in mediating fast synaptic inhibition, such a regulation by tyrosine kinases may therefore have profound effects on the control of neuronal excitation.	UNIV LONDON UNIV COLL,DEPT PHARMACOL,LONDON WC1E 6BT,ENGLAND; UNIV LONDON,SCH PHARM,DEPT PHARMACOL,LONDON WC1N 1AX,ENGLAND	University of London; University College London; University of London; University College London; University of London School of Pharmacy	MOSS, SJ (corresponding author), UNIV LONDON UNIV COLL,MRC,MOLEC CELL BIOL LAB,GORDON ST,LONDON WC1E 6BT,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BURT DR, 1991, FASEB J, V5, P2916, DOI 10.1096/fasebj.5.14.1661244; EVANS GI, 1985, MOL CELL BIOL, V353, P769; HERB A, 1992, P NATL ACAD SCI USA, V89, P1433, DOI 10.1073/pnas.89.4.1433; HERBST R, 1991, J BIOL CHEM, V266, P19908; KANO M, 1992, NATURE, V356, P601, DOI 10.1038/356601a0; KRISHEK BJ, 1994, NEURON, V12, P1081, DOI 10.1016/0896-6273(94)90316-6; MCDONALD BJ, 1994, J BIOL CHEM, V269, P18111; MOSS SJ, 1993, NEUROCHEM RES, V18, P105, DOI 10.1007/BF00966929; MOSS SJ, 1992, J BIOL CHEM, V267, P14470; MOSS SJ, 1992, SCIENCE, V257, P661, DOI 10.1126/science.1323140; MOSS SJ, 1991, NEUROSCI LETT, V123, P265, DOI 10.1016/0304-3940(91)90947-R; NAYEEM N, 1994, J NEUROCHEM, V62, P815; OLSEN RW, 1990, FASEB J, V4, P1469, DOI 10.1096/fasebj.4.5.2155149; PRITCHETT DB, 1988, SCIENCE, V242, P1306, DOI 10.1126/science.2848320; PRITCHETT DB, 1989, SCIENCE, V245, P1389, DOI 10.1126/science.2551039; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; SCHOFIELD PR, 1987, NATURE, V326, P221; SMART TG, 1992, J PHYSIOL-LONDON, V447, P587, DOI 10.1113/jphysiol.1992.sp019020; SONGYANG Z, 1994, NATURE, V373, P536; STELZER A, 1988, SCIENCE, V241, P339, DOI 10.1126/science.2455347; SWOPE SL, 1992, FASEB J, V6, P2514, DOI 10.1096/fasebj.6.8.1375568; VALENZUELA CF, 1995, MOL BRAIN RES, V31, P165, DOI 10.1016/0169-328X(95)00048-W; Wagner K R, 1991, Curr Opin Neurobiol, V1, P65, DOI 10.1016/0959-4388(91)90011-U	23	203	212	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 28	1995	377	6547					344	348		10.1038/377344a0	http://dx.doi.org/10.1038/377344a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX111	7566089				2022-12-24	WOS:A1995RX11100058
J	NEUMANN, H; CAVALIE, A; JENNE, DE; WEKERLE, H				NEUMANN, H; CAVALIE, A; JENNE, DE; WEKERLE, H			INDUCTION OF MHC CLASS-I GENES IN NEURONS	SCIENCE			English	Article							EXPRESSION; ANTIGENS; CELLS	Whether neurons express major histocompatibility complex (MHC) class I genes has not been firmly established. The techniques of confocal laser microscopy, patch clamp electrophysiology, and reverse transcriptase-polymerase chain reaction were combined here to directly examine the inducibility of MHC class I genes in individual cultured rat hippocampal neurons. Transcription of MHC class I genes was very rare in neurons with spontaneous action potentials. In electrically silent neurons, transcription was noted, with expression of beta(2)-microglobulin under tighter control than in class I heavy chain molecules. Surface expression of class I molecules occurred only in electrically silent neurons treated with interferon gamma. Immunosurveillance by cytotoxic T cells may be focused on functionally impaired neurons.	MAX PLANCK INST PSYCHIAT,DEPT NEUROIMMUNOL,D-82152 MARTINSRIED,GERMANY	Max Planck Society			Neumann, Harald/A-9718-2010; Jenne, Dieter Erich/AAP-1414-2020	Neumann, Harald/0000-0002-5071-5202; 				BANKER GA, 1977, BRAIN RES, V126, P397, DOI 10.1016/0006-8993(77)90594-7; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; HAMILL OP, 1991, PFLUEGERS ARCH, V391, P85; JOLY E, 1991, SCIENCE, V253, P1283, DOI 10.1126/science.1891717; KISS JZ, 1994, EMBO J, V13, P5284, DOI 10.1002/j.1460-2075.1994.tb06862.x; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; LAMBOLEZ B, 1992, NEURON, V9, P247, DOI 10.1016/0896-6273(92)90164-9; MASSA PT, 1993, GLIA, V8, P201, DOI 10.1002/glia.440080307; WONG GHW, 1984, NATURE, V310, P688, DOI 10.1038/310688a0; ZAFRA F, 1990, EMBO J, V9, P3545, DOI 10.1002/j.1460-2075.1990.tb07564.x	10	354	360	0	9	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 28	1995	269	5223					549	552		10.1126/science.7624779	http://dx.doi.org/10.1126/science.7624779			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL495	7624779				2022-12-24	WOS:A1995RL49500031
J	NIGHTINGALE, SL				NIGHTINGALE, SL			NEW INFORMATION ADDED TO THEOPHYLLINE LABELING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 26	1995	274	4					292	292						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ898	7609246				2022-12-24	WOS:A1995RJ89800009
J	COHN, M; BLACKBURN, EH				COHN, M; BLACKBURN, EH			TELOMERASE IN YEAST	SCIENCE			English	Article							TERMINAL TRANSFERASE-ACTIVITY; PRIMER SPECIFICITY; DNA-SEQUENCES; TETRAHYMENA; IDENTIFICATION; SENESCENCE; RNA; RIBONUCLEOPROTEIN; CHROMOSOMES; ELONGATION	The ribonucleoprotein enzyme telomerase synthesizes telomeric DNA by copying an internal RNA template sequence. The telomerase activities of the yeasts Saccharomyces castellii and Saccharomyces cerevisiae-with regular and irregular telomeric sequences, respectively-have now been identified and characterized. The S. cerevisiae activity required the telomerase RNA gene TLC1 but not the EST1 gene, both of which are required for normal telomere maintenance in vivo. This activity exhibited low processivity and produced no regularly repeated products. An inherently high stalling frequency of the S. cerevisiae telomerase may account for its in vitro properties and for the irregular telomeric sequences of this yeast.	UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco				Cohn, Marita/0000-0002-3370-2864	NIGMS NIH HHS [GM26259] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026259, R37GM026259] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLACKBURN EH, 1994, CELL, V77, P621, DOI 10.1016/0092-8674(94)90046-9; BLACKBURN EH, 1984, ANNU REV BIOCHEM, V53, P163, DOI 10.1146/annurev.bi.53.070184.001115; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; COHN M, UNPUB; COLLINS K, 1993, GENE DEV, V7, P1364, DOI 10.1101/gad.7.7b.1364; GILLEY D, IN PRESS GENES DEV; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARRINGTON LA, 1991, NATURE, V353, P451, DOI 10.1038/353451a0; LEE MS, 1993, MOL CELL BIOL, V13, P6586, DOI 10.1128/MCB.13.10.6586; LIN JJ, 1995, CELL, V81, P1127, DOI 10.1016/S0092-8674(05)80017-0; LINGNER J, 1994, GENE DEV, V8, P1984, DOI 10.1101/gad.8.16.1984; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; LUNDBLAD V, 1990, CELL, V60, P529; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; MANTELL LL, 1994, EMBO J, V13, P3211, DOI 10.1002/j.1460-2075.1994.tb06620.x; MCEACHERN MJ, IN PRESS NATURE; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; PROWSE KR, 1993, P NATL ACAD SCI USA, V90, P1493, DOI 10.1073/pnas.90.4.1493; SHAMPAY J, 1984, NATURE, V310, P154, DOI 10.1038/310154a0; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; SHIPPENLENTZ D, 1989, MOL CELL BIOL, V9, P2761, DOI 10.1128/MCB.9.6.2761; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; WALMSLEY RM, 1984, NATURE, V310, P157, DOI 10.1038/310157a0; WANG SS, 1990, MOL CELL BIOL, V10, P4415, DOI 10.1128/MCB.10.8.4415; WANG SS, 1990, NATURE, V345, P456, DOI 10.1038/345456a0; YU GL, 1991, CELL, V67, P823, DOI 10.1016/0092-8674(91)90077-C; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; ZAHLER AM, 1988, NUCLEIC ACIDS RES, V16, P6953, DOI 10.1093/nar/16.14.6953	30	251	261	0	20	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 21	1995	269	5222					396	400		10.1126/science.7618104	http://dx.doi.org/10.1126/science.7618104			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK427	7618104				2022-12-24	WOS:A1995RK42700047
J	GRAHAM, T				GRAHAM, T			THE BROWN-AND-WILLIAMSON DOCUMENTS - THE COMPANY RESPONSE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											GRAHAM, T (corresponding author), TRIVALLEY HERALD,4770 WILLOW RD,PLEASANTON,CA 94588, USA.								0	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 19	1995	274	3					254	255						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH937	7609235				2022-12-24	WOS:A1995RH93700032
J	MARSDEN, AK; NG, GA; DALZIEL, K; COBBE, SM				MARSDEN, AK; NG, GA; DALZIEL, K; COBBE, SM			WHEN IS IT FUTILE FOR AMBULANCE PERSONNEL TO INITIATE CARDIOPULMONARY-RESUSCITATION	BRITISH MEDICAL JOURNAL			English	Article							HEARTSTART-SCOTLAND PROJECT; HOSPITAL DEFIBRILLATION; DECISION-MAKING; CARDIAC-ARREST; TECHNICIANS	Objective-To determine whether patients with unexpected prehospital cardiac arrest could be identified in whom ambulance resuscitation attempts would be futile. Design-Review of ambulance and hospital records; detailed review of automated external defibrillator rhythm strips of patients in whom no shock was advised. Setting-Scottish Ambulance Service; all cardiopulmonary resuscitation attempts after cardiorespiratory arrest during 1988-94 included in the Heartstart Scotland database. Subjects-414 cardiorespiratory arrest patients with no pulse or breathing on arrival of ambulance personnel, no bystander cardiopulmonary resuscitation performed, and more than 15 minutes from time of arrest to arrival of ambulance. Patients were stratified into those with ''shockable'' and ''nonshockable'' rhythms. Main outcome measures-Return of spontaneous circulation, or survival to reach hospital alive, or survival to discharge, or all three. Results-No patient with a non-shockable rhythm who met the entry criteria for analysis survived a resuscitation attempt. Review of the defibrillator rhythm strips of these patients failed to find any case in which the tracing was deemed compatible with survival. Conclusions-On the basis that it would be inappropriate to initiate vigorous resuscitation in patients who can be identified as ''dead'' and beyond help an algorithm was prepared to guide ambulance personnel.	ROYAL INFIRM,DEPT MED CARDIOL,GLASGOW G4 0SF,LANARK,SCOTLAND	Royal Infirmary of Edinburgh	MARSDEN, AK (corresponding author), SCOTTISH AMBULANCE SERV,NATL HEADQUARTERS,EDINBURGH EH10 5UU,MIDLOTHIAN,SCOTLAND.			Ng, G. Andre/0000-0001-5965-0671				APRAHAMIAN C, 1986, ANN EMERG MED, V15, P445, DOI 10.1016/S0196-0644(86)80185-8; BONNIN MJ, 1993, JAMA-J AM MED ASSOC, V270, P1457, DOI 10.1001/jama.270.12.1457; COBBE SM, 1991, BRIT MED J, V302, P1517, DOI 10.1136/bmj.302.6791.1517; JOHNSON DR, 1993, AM J EMERG MED, V11, P139, DOI 10.1016/0735-6757(93)90107-M; KELLERMANN AL, 1993, JAMA-J AM MED ASSOC, V270, P1433, DOI 10.1001/jama.270.12.1433; SEDGWICK ML, 1993, RESUSCITATION, V26, P75, DOI 10.1016/0300-9572(93)90166-N; SEDGWICK ML, 1992, RESUSCITATION, V24, P73, DOI 10.1016/0300-9572(92)90175-C; WEAVER WD, 1985, ANN INTERN MED, V102, P53, DOI 10.7326/0003-4819-102-1-53; 1993, JAMA-J AM MED ASSOC, V270, P1471; 1992, JAMA-J AM MED ASSOC, V268, P2171	10	35	35	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 1	1995	311	6996					49	51		10.1136/bmj.311.6996.49	http://dx.doi.org/10.1136/bmj.311.6996.49			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG975	7613330	Green Published			2022-12-24	WOS:A1995RG97500032
J	MOCROFT, AJ; JOHNSON, MA; SABIN, CA; LIPMAN, M; ELFORD, J; EMERY, V; MORCINEK, J; YOULE, M; JANOSSY, G; LEE, CA; PHILLIPS, AN				MOCROFT, AJ; JOHNSON, MA; SABIN, CA; LIPMAN, M; ELFORD, J; EMERY, V; MORCINEK, J; YOULE, M; JANOSSY, G; LEE, CA; PHILLIPS, AN			STAGING SYSTEM FOR CLINICAL AIDS PATIENTS	LANCET			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; NATURAL-HISTORY; SURVIVAL; LYMPHOCYTES; ZIDOVUDINE; DIAGNOSIS; MORTALITY; INFECTION; TRIALS; COHORT	Although there are wide differences in prognosis between patients with AIDS they are often thought of as a single homogeneous group. We think a simple staging system that accounts for important prognostic factors including type and number of AIDS diseases and the CD4 lymphocyte count is required. We followed 363 AIDS patients at the Royal Free Hospital and reported the occurrence of 680 AIDS-defining diseases (ADDs). We measured CD4 counts at approximately monthly intervals. Severity of AIDS diseases was defined a priori on the basis of survival in the AIDS in Europe study of 6578 AIDS patients: mild-oesophageal candidiasis, Kaposis sarcoma (cutaneous), Pneumocystis carinii pneumonia, extrapulmonary tuberculosis; severe-all other ADDs except lymphoma; very severe-lymphoma, The risk of death increased by 15% (p=0.08) for each mild condition experienced, by 89% (p<0.001) for each new severe condition and by 535% (p<0.0001) when a lymphoma developed. Estimates from the Cox model were used to derive a score reflecting the risk of death. Patient experience was divided into three categories. Patients in AIDS Grade I had an average death rate of one per 10.1 years, compared with one per 2.8 years in AIDS Grade II and one per 1.1 years in AIDS Grade III. Similar rates were seen in an independent validation study on 1230 AIDS patients at different hospital. Our grading system should be useful for patient management, clinical trial design, surveillance, and resource management.	ROYAL FREE HOSP,SCH MED,DEPT PUBL HLTH,LONDON,ENGLAND; ROYAL FREE HOSP,SCH MED,DEPT THORAC MED,LONDON,ENGLAND; ROYAL FREE HOSP,SCH MED,DEPT VIROL,LONDON,ENGLAND; ROYAL FREE HOSP,SCH MED,CTR HAEMOPHILIA,DEPT HAEMATOL & IMMUNOL,LONDON,ENGLAND; CHELSEA & WESTMINSTER HEALTHCARE NHS TRUST,ST STEPHENS CLIN,HIV GUM RES UNIT,LONDON,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School			Mocroft, Amanda/G-8748-2011; Sabin, Caroline/C-2464-2008; Phillips, Andrew N/B-4427-2008; Mocroft, Amanda/C-1527-2008; Emery, Vincent/G-8928-2013	Mocroft, Amanda/0000-0001-8316-1122; Sabin, Caroline/0000-0001-5173-2760; Phillips, Andrew N/0000-0003-2384-4807; Emery, Vincent/0000-0001-5893-9756; Lipman, Marc/0000-0001-7501-4448				BACHETTI P, 1988, J INFECT DIS, V157, P1044; BLUM S, 1994, AM J EPIDEMIOL, V139, P351, DOI 10.1093/oxfordjournals.aje.a117007; BOFILL M, 1992, CLIN EXP IMMUNOL, V88, P243, DOI 10.1111/j.1365-2249.1992.tb03068.x; CHANG HGH, 1993, AM J EPIDEMIOL, V138, P341, DOI 10.1093/oxfordjournals.aje.a116864; CHOI SS, 1993, ANN INTERN MED, V118, P674, DOI 10.7326/0003-4819-118-9-199305010-00003; COLFORD JM, 1994, AM J EPIDEMIOL, V139, P206, DOI 10.1093/oxfordjournals.aje.a116982; Darbyshire J, 1991, AIDS, V5 Suppl 2, pS167, DOI 10.1097/00002030-199101001-00024; ELLENBERG SS, 1992, J AM STAT ASSOC, V87, P562, DOI 10.2307/2290291; GONELLA JD, 1994, JAMA-J AM MED ASSOC, V251, P637; HANSON DL, 1993, J ACQ IMMUN DEF SYND, V6, P624; HUGHES MD, 1994, J INFECT DIS, V169, P28, DOI 10.1093/infdis/169.1.28; JUSTICE AC, 1989, NEW ENGL J MED, V320, P1388, DOI 10.1056/NEJM198905253202106; LEE CA, 1989, BRIT J HAEMATOL, V73, P228, DOI 10.1111/j.1365-2141.1989.tb00257.x; LEMP GF, 1990, JAMA-J AM MED ASSOC, V263, P402, DOI 10.1001/jama.263.3.402; LIN DY, 1993, STAT MED, V12, P835, DOI 10.1002/sim.4780120904; LUNDGREN JD, 1994, BMJ-BRIT MED J, V308, P1068, DOI 10.1136/bmj.308.6936.1068; MARASCA G, 1986, BRIT MED J, V292, P1727, DOI 10.1136/bmj.292.6537.1727; MILLS GD, 1993, AIDS, V7, P1383, DOI 10.1097/00002030-199310000-00013; MOORE RD, 1991, NEW ENGL J MED, V324, P1412, DOI 10.1056/NEJM199105163242006; NEATON J, 1993, 9 INT C AIDS BERL; RABENECK L, 1993, ARCH INTERN MED, V153, P2749, DOI 10.1001/archinte.153.24.2749; TURNER BJ, 1991, J ACQ IMMUN DEF SYND, V4, P1059; 1990, SAS USERS GUIDE STAT; 1994, LANCET, V343, P871; 1987, MMWR-MORBID MORTAL W, V36, pS1; 1992, MMWR-MORBID MORTAL W, V41, P1	26	50	51	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 1	1995	346	8966					12	17		10.1016/S0140-6736(95)92649-6	http://dx.doi.org/10.1016/S0140-6736(95)92649-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RF985	7603137				2022-12-24	WOS:A1995RF98500007
J	BRENNAN, JA; MAO, L; HRUBAN, RH; BOYLE, JO; EBY, YJ; KOCH, WM; GOODMAN, SN; SIDRANSKY, D				BRENNAN, JA; MAO, L; HRUBAN, RH; BOYLE, JO; EBY, YJ; KOCH, WM; GOODMAN, SN; SIDRANSKY, D			MOLECULAR ASSESSMENT OF HISTOPATHOLOGICAL STAGING IN SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LYMPH-NODE INVOLVEMENT; PROGNOSTIC FACTORS; ORAL CAVITY; POSITIVE MARGINS; GENE-MUTATIONS; P53 MUTATIONS; CANCER; OROPHARYNX; DISSECTION; TUMORS	Background. Surgical oncologists rely heavily on the histopathological assessment of surgical margins to ensure total excision of the tumor in patients with head and neck cancer. However, current techniques may not detect small numbers of cancer cells at the margins of resection or in cervical lymph nodes. Methods. We used molecular techniques to determine whether clonal populations of infiltrating tumor cells harboring mutations of the p53 gene could be detected in histopathologically negative surgical margins and cervical lymph nodes of patients with squamous-cell carcinoma of the head and neck. Results. We identified 25 patients with primary squamous-cell carcinoma of the head and neck containing a p53 mutation who appeared to have had complete tumor resection on the basis of a negative histopathological assessment. In 13 of these 25 patients, molecular analysis was positive for a p53 mutation in at least one tumor margin. In 5 of 13 patients with positive margins by this method (38 percent), the carcinoma has recurred locally, as compared with none of 12 patients with negative margins (P=0.02 by the log-rank test). Furthermore, molecular analysis identified neoplastic cells in 6 of 28 lymph nodes (21 percent) that were initially negative by histopathological assessment. Conclusions. Among specimens initially believed to be negative on light microscopy, a substantial percentage of the surgical margins and lymph nodes from patients with squamous-cell carcinoma of the head and neck contained p53 mutations specific for the primary tumor. Patients with these positive margins appear to have a substantially increased risk of local recurrence. Molecular analysis of surgical margins and lymph nodes can augment standard histopathological assessment and may improve the prediction of local tumor recurrence.	JOHNS HOPKINS UNIV,SCH MED,DEPT OTOLARYNGOL HEAD & NECK SURG,DIV HEAD & NECK CANC RES,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,CTR ONCOL,DIV BIOSTAT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV HOSP,DEPT PATHOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine			Mao, Li/C-7570-2011	Mao, Li/0000-0001-7263-3358; Goodman, Steven/0000-0002-3872-5723	NCI NIH HHS [CA-58184-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058184] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARANY F, 1991, PCR METH APPL, V1, P5; Beahrs OH, 1988, MANUAL STAGING CANCE, P27; BOYLE JO, 1993, CANCER RES, V53, P4477; BRENNAN CT, 1991, LARYNGOSCOPE, V101, P1175; BUCHMAN GW, 1992, FOCUS, V14, P41; BYERS RM, 1978, AM J SURG, V136, P525, DOI 10.1016/0002-9610(78)90275-1; CHEN TY, 1987, INT J RADIAT ONCOL, V13, P833, DOI 10.1016/0360-3016(87)90095-2; CLOSE LG, 1989, ARCH OTOLARYNGOL, V115, P1304; DAVIDSON TM, 1981, OTOLARYNG HEAD NECK, V89, P244, DOI 10.1177/019459988108900219; DAVIDSON TM, 1984, ARCH OTOLARYNGOL, V110, P193; DAVIDSON TM, 1988, LARYNGOSCOPE, V98, P1078; EIBAND JD, 1989, AM J SURG, V158, P314, DOI 10.1016/0002-9610(89)90123-2; FARRAR WB, 1988, AM J SURG, V156, P173, DOI 10.1016/S0002-9610(88)80058-8; FEINMESSER R, 1992, HEAD NECK-J SCI SPEC, V14, P173, DOI 10.1002/hed.2880140302; FIELDING LP, 1992, CANCER, V70, P2367, DOI 10.1002/1097-0142(19921101)70:9<2367::AID-CNCR2820700927>3.0.CO;2-B; GANDOUREDWARDS RF, 1993, HEAD NECK-J SCI SPEC, V15, P373, DOI 10.1002/hed.2880150502; GHOURI AF, 1993, OTOLARYNG HEAD NECK, V108, P225, DOI 10.1177/019459989310800304; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JESSE RH, 1976, AM J SURG, V132, P435, DOI 10.1016/0002-9610(76)90314-7; JONES KR, 1992, ARCH OTOLARYNGOL, V118, P483; KALNINS IK, 1977, AM J SURG, V134, P450, DOI 10.1016/0002-9610(77)90376-2; KOWALSKI LP, 1993, ARCH OTOLARYNGOL, V119, P958; Lee JG, 1974, T AM ACAD OPHTHALMOL, V78, pORL49; LEEMANS CR, 1993, CANCER, V71, P452, DOI 10.1002/1097-0142(19930115)71:2<452::AID-CNCR2820710228>3.0.CO;2-B; LOOSER KG, 1978, HEAD NECK SURG, V1, P107, DOI 10.1002/hed.2890010203; MAESTRO R, 1992, ONCOGENE, V7, P1159; MAO L, 1994, P NATL ACAD SCI USA, V91, P9871, DOI 10.1073/pnas.91.21.9871; MAO L, 1994, CANCER RES, V54, P1634; NAWROZ H, 1994, CANCER RES, V54, P1152; NEES M, 1993, CANCER RES, V53, P4189; OBRIEN CJ, 1987, CANCER, V59, P994, DOI 10.1002/1097-0142(19870301)59:5<994::AID-CNCR2820590524>3.0.CO;2-E; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; PRADIER R, 1993, CANCER, V71, P2472, DOI 10.1002/1097-0142(19930415)71:8<2472::AID-CNCR2820710808>3.0.CO;2-Y; SCHOLL P, 1986, AM J SURG, V152, P354, DOI 10.1016/0002-9610(86)90304-1; SIDRANSKY D, 1992, SCIENCE, V256, P102, DOI 10.1126/science.1566048; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; SNOW GB, 1982, CLIN OTOLARYNGOL, V7, P185, DOI 10.1111/j.1365-2273.1982.tb01581.x; Snow GB, 1989, CANC HEAD NECK, P17; SNYDERMAN CH, 1992, AM J OTOLARYNG, V13, P373, DOI 10.1016/0196-0709(92)90079-9; SOO KC, 1988, AM J SURG, V156, P281, DOI 10.1016/S0002-9610(88)80292-7; SUAREZ C, 1993, OTOLARYNG HEAD NECK, V109, P3, DOI 10.1177/019459989310900102; TADA M, 1993, CANCER RES, V53, P2472; TOBI M, 1994, J NATL CANCER I, V86, P1007; YOO GH, 1994, CANCER RES, V54, P4603; ZATTERSTROM UK, 1991, HEAD NECK-J SCI SPEC, V13, P477, DOI 10.1002/hed.2880130603; ZIESKE LA, 1986, ARCH OTOLARYNGOL, V112, P863	47	596	623	0	19	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 16	1995	332	7					429	435		10.1056/NEJM199502163320704	http://dx.doi.org/10.1056/NEJM199502163320704			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF770	7619114				2022-12-24	WOS:A1995QF77000004
J	CHABRIAT, H; VAHEDI, K; IBAZIZEN, MT; JOUTEL, A; NIBBIO, A; NAGY, TG; KREBS, MO; JULIEN, J; DUBOIS, B; DUCROCQ, X; LEVASSEUR, M; HOMEYER, P; MAS, JL; LYONCAEN, O; LASSERVE, ET; BOUSSER, MG				CHABRIAT, H; VAHEDI, K; IBAZIZEN, MT; JOUTEL, A; NIBBIO, A; NAGY, TG; KREBS, MO; JULIEN, J; DUBOIS, B; DUCROCQ, X; LEVASSEUR, M; HOMEYER, P; MAS, JL; LYONCAEN, O; LASSERVE, ET; BOUSSER, MG			CLINICAL SPECTRUM OF CADASIL - A STUDY OF 7 FAMILIES	LANCET			English	Article							MULTI-INFARCT DEMENTIA; MIGRAINE; LEUKOENCEPHALOPATHY; DISEASE; HEADACHES; STROKES; BRAIN	Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an inherited arterial disease of the brain recently mapped to chromosome 19. We studied 148 subjects belonging to seven families by magnetic resonance imaging and genetic linkage analysis. 45 family members (23 males and 22 females) were clinically affected. Frequent signs were recurrent subcortical ischaemic events (84%), progressive or stepwise subcortical dementia with pseudobulbar palsy (31%), migraine with aura (22%), and mood disorders with severe depressive episodes (20%). All symptomatic subjects had prominent signal abnormalities on MRI with hyperintense lesions on T2-weighted images in the subcortical white-matter and basal ganglia which were also present in 19 asymptomatic subjects. The age at onset of symptoms was mean 45 (SD [10.6]) years, with attacks of migraine with aura occurring earlier in life (38.1[8.03] years) than ischaemic events (49.3 [10.7] years). The mean age at death was 64.5 (10.6) years. On the basis of MRI data, the penetrance of the disease appears complete between 30 and 40 years of age. Genetic analysis showed strong linkage to the CADASIL locus for all seven families, suggesting genetic homogeneity. CADASIL is a hereditary cause of stroke, migraine with aura, mood disorders and dementia. The diagnosis should be considered not only in patients with recurrent small subcortical infarcts leading to dementia, but also in patients with transient ischaemic attacks, migraine with aura or severe mood disturbances, whenever MRI reveals prominent signal abnormalities in the subcortical white-matter and basal ganglia. Clinical and MRI investigations of family members are then crucial for the diagnosis which can be confirmed by genetic linkage analysis. The disease is probably largely undiagnosed.	HOP ST ANTOINE,SERV NEUROL,PARIS 12,FRANCE; HOP QUINZE VINGTS,SERV NEURORADIOL,PARIS,FRANCE; FAC MED NECKER ENFANTS MALAD,INSERM,U25,PARIS,FRANCE; HOP ST ANNE,SERV PSYCHIAT PR LOO,F-75674 PARIS,FRANCE; CHU BORDEAUX,SERV NEUROL,BORDEAUX,FRANCE; CHU NANCY,SERV NEUROL,NANCY,FRANCE; CHG ORSAY,SERV MED INTERNE,ORSAY,FRANCE; HOP ST ANNE,SERV NEUROL,F-75674 PARIS,FRANCE; HOP LA PITIE SALPETRIERE,FEDERAT NEUROL,PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; CHNO des Quinze-Vingts; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; GHU PARIS Psychiatrie Neurosciences; UDICE-French Research Universities; Universite Paris Cite; CHU Bordeaux; CHU de Nancy; GHU PARIS Psychiatrie Neurosciences; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite			Joutel, Anne/K-5601-2017; Krebs, Marie-Odile/O-2104-2017; Chabriat, Hugues/G-5699-2010	Joutel, Anne/0000-0003-3963-3860; Krebs, Marie-Odile/0000-0002-4715-9890; Chabriat, Hugues/0000-0001-8436-6074				AYLWARD ED, 1994, AM J PSYCHIAT, V5, P687; BABIKIAN V, 1987, STROKE, V18, P2, DOI 10.1161/01.STR.18.1.2; BAUDRIMONT M, 1993, STROKE, V24, P122, DOI 10.1161/01.STR.24.1.122; BHATIA KP, 1994, BRAIN, V117, P859, DOI 10.1093/brain/117.4.859; COLMANT HJ, 1980, PATHOLOGIE, V124, P163; Davous P, 1991, REV NEUROL-FRANCE, V5, P376; De Reuck J, 1972, Acta Neurol Belg, V72, P323; FERBERT A, 1991, STROKE, V22, P1010, DOI 10.1161/01.STR.22.8.1010; GRENBERG SM, 1993, NEUROLOGY, V43, P2073; GUTIERREZMOLINA M, 1994, ACTA NEUROPATHOL, V87, P98; HUGHES GRV, 1993, LANCET, V342, P341, DOI 10.1016/0140-6736(93)91477-4; IGARASHI H, 1991, CEPHALALGIA, V11, P69, DOI 10.1046/j.1468-2982.1991.1102069.x; JOUTEL A, 1993, NAT GENET, V5, P40, DOI 10.1038/ng0993-40; LOPEZ OL, 1994, NEUROLOGY, V44, P1240, DOI 10.1212/WNL.44.7.1240; MAS JL, 1992, NEUROLOGY, V42, P1015, DOI 10.1212/WNL.42.5.1015; MONTAGNA P, 1988, NEUROLOGY, V38, P751, DOI 10.1212/WNL.38.5.751; OSBORN RE, 1991, AM J NEURORADIOL, V12, P521; RASMUSSEN BK, 1992, NEUROLOGY, V42, P1225, DOI 10.1212/WNL.42.6.1225; SALVI F, 1992, ITAL J NEUROL SCI, V13, P135, DOI 10.1007/BF02226962; SCHELTENS P, 1992, BRAIN, V115, P735, DOI 10.1093/brain/115.3.735; SCHYER B, 1990, SCHEDULE AFFECTIVE D; SONNINEN V, 1987, EUR NEUROL, V27, P209, DOI 10.1159/000116158; SOURANDER P, 1977, ACTA NEUROPATHOL, V39, P247, DOI 10.1007/BF00691704; STCLAIR D, 1995, J MED GENET, V32, P57, DOI 10.1136/jmg.32.1.57; STEVENS DL, 1977, LANCET, V2, P1364; TOKUNAGA M, 1994, ANN NEUROL, V35, P413, DOI 10.1002/ana.410350407; TOURNIERLASSERV.E, 1994, AM J HUM GENET, V55, pA205; TOURNIERLASSERV.E, 1993, NAT GENET, V3, P356; TOURNIERLASSERVE E, 1991, STROKE, V22, P1297, DOI 10.1161/01.STR.22.10.1297; VAHEDI K, 1995, ANN NEUROL, V37, P289, DOI 10.1002/ana.410370304; VANBOGAERT L, 1955, MED HELLEN, V24, P961; VERIN M, 1994, NEUROLOGY, V44, P288; WEISSENBACH J, 1992, NATURE, V359, P494; 1987, DIAGNOSTIC STATISTIC; 1988, CEPHALALGIA S, V7, P8	35	523	541	0	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 7	1995	346	8980					934	939		10.1016/S0140-6736(95)91557-5	http://dx.doi.org/10.1016/S0140-6736(95)91557-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY808	7564728				2022-12-24	WOS:A1995RY80800009
J	MUELLER, PR; COLEMAN, TR; KUMAGAI, A; DUNPHY, WG				MUELLER, PR; COLEMAN, TR; KUMAGAI, A; DUNPHY, WG			MYT1 - A MEMBRANE-ASSOCIATED INHIBITORY KINASE THAT PHOSPHORYLATES CDC2 ON BOTH THREONINE-14 AND TYROSINE-15	SCIENCE			English	Article							PROTEIN-KINASE; NEGATIVE REGULATION; WEE1; ACTIVATION; MITOSIS; XENOPUS; GENE	Cdc2 is the cyclin-depefident kinase that controls entry of cells into mitosis. Phosphorylation of Cdc2 on threonine-14 and tyrosine-15 inhibits the activity of the enzyme and prevents premature initiation of mitosis. Although Wee1 has been identified as the kinase that phosphorylates tyrosine-15 in various organisms, the threonine-14-specific kinase has not been isolated. A complementary DNA was cloned from Xenopus that encodes Myt1, a member of the Wee1 family that was discovered io phosphorylate Cdc2 efficiently on both threonine-14 and tyrosine-15. Myt1 is a membrane-associated protein that contains a putative transmembrane segment. Immunodepletion studies suggested that Myt1 is the predominant threonine-14-specific kinase in Xenopus egg extracts, Myt1 activity is highly regulated during the cell cycle, suggesting that this relative of Wee1 plays a role in mitotic control.	CALTECH, HOWARD HUGHES MED INST, DIV BIOL 21676, PASADENA, CA 91125 USA	California Institute of Technology; Howard Hughes Medical Institute			Mueller, Paul/B-6699-2012	Coleman, Thomas/0000-0002-1665-4768				ATHERTONFESSLER S, 1994, MOL BIOL CELL, V5, P989, DOI 10.1091/mbc.5.9.989; BOOHER RN, 1993, EMBO J, V12, P3417, DOI 10.1002/j.1460-2075.1993.tb06016.x; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; COLEMAN TR, 1993, CELL, V72, P919, DOI 10.1016/0092-8674(93)90580-J; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; EDGAR BA, 1994, GENE DEV, V8, P440, DOI 10.1101/gad.8.4.440; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; IGARASHI M, 1991, NATURE, V353, P80, DOI 10.1038/353080a0; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KORNBLUTH S, 1994, MOL BIOL CELL, V5, P273, DOI 10.1091/mbc.5.3.273; KUANG J, 1994, MOL BIOL CELL, V5, P135, DOI 10.1091/mbc.5.2.135; KUMAGAI A, 1995, MOL BIOL CELL, V6, P199, DOI 10.1091/mbc.6.2.199; LEE MS, 1994, J BIOL CHEM, V269, P30530; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MCGOWAN CH, 1995, EMBO J, V14, P2166, DOI 10.1002/j.1460-2075.1995.tb07210.x; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MUELLER PR, 1995, MOL BIOL CELL, V6, P119, DOI 10.1091/mbc.6.1.119; MUELLER PR, UNPUB; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x	26	533	546	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 6	1995	270	5233					86	90		10.1126/science.270.5233.86	http://dx.doi.org/10.1126/science.270.5233.86			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY302	7569953				2022-12-24	WOS:A1995RY30200038
J	WHINCUP, P; COOK, D; PAPACOSTA, O; WALKER, M				WHINCUP, P; COOK, D; PAPACOSTA, O; WALKER, M			BIRTH-WEIGHT AND BLOOD-PRESSURE - CROSS-SECTIONAL AND LONGITUDINAL RELATIONS IN CHILDHOOD	BRITISH MEDICAL JOURNAL			English	Article							HYPERTENSION INUTERO; ADULT LIFE; CHILDREN; INITIATION; MORTALITY; FETAL; SIZE; RISK	Objective-To examine cross sectional and longitudinal relations between birth weight and blood pressure in childhood. Design-Cross sectional study of primary school children aged 9-11 years, with analysis in relation to previous measurements at 5-7 years in a subgroup. Setting-20 primary schools in Guildford and Carlisle. Subjects-1511 children measured at 9-11 years (response rate 79%), including 549 who had been measured at 5-7 years. Main outcome measures-Blood pressure at 9-11 years, change in blood pressure between 5-7 and 9-11 years, birth weight (based on maternal recall), and placental weight (based on birth records). Results-At 9-11 years birth weight was inversely related both to systolic blood pressure (regression coefficient -2.80 mm Hg/kg; 95% confidence interval -3.84 to -1.76) and to diastolic blood pressure (regression coefficient -1.42 mm Hg/kg; -2.14 to -0.70) once current height and body mass index were taken into account. Placental weight was inversely related to blood pressure after adjustment for current height and body mass index but placental ratio (placental weight to birth weight) was unrelated to blood pressure. Between 5-7 and 9-11 years systolic blood pressure rose more rapidly in children of lower birth weight (regression coefficient -1.71 mm Hg/kg; -3.35 to -0.07). This effect seemed to be stronger in girls. Conclusions-Birth weight rather than placental ratio is the early Life factor most importantly related to blood pressure in childhood. The results support the possibility of ''amplification'' of the relation between birth weight and blood pressure, particularly in girls.	UNIV LONDON ST GEORGES HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND; UNIV LONDON,ROYAL FREE HOSP,SCH MED,DEPT PUBL HLTH,LONDON NW3 2PF,ENGLAND	St Georges University London; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School				Papacosta, Olia/0000-0001-8781-6747; Whincup, Peter/0000-0002-5589-4107				BARKER DJP, 1989, BRIT MED J, V298, P564, DOI 10.1136/bmj.298.6673.564; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; Barker DJP, 1992, FETAL INFANT ORIGINS; CARTER J, 1984, LOW BIRTHWEIGHT MED, P191; FROHLICH ED, 1988, CIRCULATION, V77, P502; GENNSER G, 1988, BMJ-BRIT MED J, V296, P1498, DOI 10.1136/bmj.296.6635.1498; LAUNER LJ, 1993, BMJ-BRIT MED J, V307, P1451, DOI 10.1136/bmj.307.6917.1451; LAW CM, 1991, ARCH DIS CHILD, V66, P1291, DOI 10.1136/adc.66.11.1291; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; LUCAS A, 1991, CIBA F SYMP, V156, P38; MACINTYRE S, 1991, J EPIDEMIOL COMMUN H, V45, P143, DOI 10.1136/jech.45.2.143; MATTHES JWA, 1994, BMJ-BRIT MED J, V308, P1074, DOI 10.1136/bmj.308.6936.1074; SEIDMAN DS, 1991, BMJ-BRIT MED J, V302, P1235, DOI 10.1136/bmj.302.6787.1235; WHINCUP P, 1994, J HUM HYPERTENS, V8, P337; WHINCUP PH, 1988, LANCET, V2, P890; WHINCUP PH, 1992, J EPIDEMIOL COMMUN H, V46, P164, DOI 10.1136/jech.46.2.164; WHINCUP PH, 1992, ARCH DIS CHILD, V67, P1423, DOI 10.1136/adc.67.12.1423; WHINCUP PH, 1989, BMJ-BRIT MED J, V299, P587, DOI 10.1136/bmj.299.6699.587; WHINCUP PH, 1989, J HYPERTENS, V7, P845, DOI 10.1097/00004872-198910000-00010; WHINCUP PH, 1993, BRIT MED J, V306, P584, DOI 10.1136/bmj.306.6877.584; WILLIAMS S, 1992, J CLIN EPIDEMIOL, V45, P1257, DOI 10.1016/0895-4356(92)90167-L; 1985, SAS USERS GUIDE BASI	22	141	147	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 23	1995	311	7008					773	776		10.1136/bmj.311.7008.773	http://dx.doi.org/10.1136/bmj.311.7008.773			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX107	7580437	Green Published			2022-12-24	WOS:A1995RX10700018
J	HANAUER, P; SLADE, J; BARNES, DE; BERO, L; GLANTZ, SA				HANAUER, P; SLADE, J; BARNES, DE; BERO, L; GLANTZ, SA			LAWYER CONTROL OF INTERNAL SCIENTIFIC-RESEARCH TO PROTECT AGAINST PRODUCTS-LIABILITY LAWSUITS - THE BROWN-AND-WILLIAMSON DOCUMENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To understand how attorneys for the tobacco industry in general, and Brown and Williamson Tobacco Corporation (B&W) in particular, have responded to the threat of products liability litigation arising from smoking-induced diseases. Data Sources.-Documents from B&W, the British American Tobacco Company (BAT), and other tobacco interests provided by an anonymous source, obtained from Congress, or received from the private papers of a former BAT officer. Study Selection.-All available materials, including confidential reports regarding research and internal memoranda exchanged between tobacco industry lawyers. Conclusions.-She documents demonstrate that the tobacco industry in general, and B&W in particular, were very concerned about the threat of products liability lawsuits, and they illustrate some of the steps taken by lawyers at one company to avoid the discovery of documents that might be useful to a plaintiff in such a lawsuit, These steps included efforts to control the language of scientific discourse on issues related to smoking and health, to bring all potentially damaging internal scientific documents under attorney work product and attorney-client privilege to avoid discovery, to remove ''deadwood'' documents, and to insulate B&W from knowledge of potentially damaging scientific information from other BAT companies.	UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94143; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,ST PETERS MED CTR,DEPT MED,NEW BRUNSWICK,NJ	University of California System; University of California San Francisco; Rutgers State University New Brunswick; Rutgers State University Medical Center					NCI NIH HHS [CA-61021] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061021] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		GLANTZ SA, 1995, JAMA-J AM MED ASSOC, V274, P219, DOI 10.1001/jama.274.3.219; RABIN RL, 1992, STANFORD LAW REV, V44, P853, DOI 10.2307/1229002; Taylor Peter, 1984, SMOKE RING TOBACCO M; WAGNER S, 1971, CIGARETTE COUNTRY TO	4	40	40	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 19	1995	274	3					234	240						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RH937	7609232				2022-12-24	WOS:A1995RH93700029
J	SIBILIA, M; WAGNER, EF				SIBILIA, M; WAGNER, EF			STRAIN-DEPENDENT EPITHELIAL DEFECTS IN MICE LACKING THE EGF RECEPTOR	SCIENCE			English	Article							GROWTH-FACTOR RECEPTOR; EMBRYONIC STEM-CELLS; FACTOR-ALPHA; TGF-ALPHA; MOUSE DEVELOPMENT; NULL MUTATION; SELF-RENEWAL; DIFFERENTIATION; PLACENTA; CULTURE	Mice and cells lacking the epidermal growth factor receptor (EGFR) were generated to examine its physiological role in vivo. Mutant fetuses are retarded in growth and die at mid-gestation in a 129/Sv genetic background, whereas in a 129/Sv x C57BL/6 cross some survive until birth and even to postnatal day 20 in a 129/Sv x C57BL/6 x MF1 background. Death in utero probably results from a defect in the spongiotrophoblast layer of the placenta. Newborn mutant mice have open eyes, rudimentary whiskers, immature lungs, and defects in the epidermis, correlating with the expression pattern of the EGFR as monitored by beta-galactosidase activity, These defects are probably cell-autonomous because chimeric mice generated with EGFR(-/-) embryonic stem cells contribute small amounts of mutant cells to some organs. These results indicate that the EGFR regulates epithelial proliferation and differentiation and that the genetic background influences the resulting phenotype.			SIBILIA, M (corresponding author), INST MOLEC PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA.			Sibilia, Maria/0000-0001-6129-5613; Wagner, Erwin F/0000-0001-7872-0196				Adamson E D, 1990, Curr Top Dev Biol, V24, P1, DOI 10.1016/S0070-2153(08)60082-4; AVIVI A, 1991, ONCOGENE, V6, P673; BEDDINGTON RSP, 1989, DEVELOPMENT, V105, P733; BREIER G, IN PRESS DEV DYNAMIC; CROSS JC, 1994, SCIENCE, V266, P1508, DOI 10.1126/science.7985020; DARDIK A, 1992, DEV BIOL, V154, P396, DOI 10.1016/0012-1606(92)90078-U; DAS SK, 1994, DEVELOPMENT, V120, P1071; DERYNCK R, 1992, ADV CANCER RES, V58, P27, DOI 10.1016/S0065-230X(08)60289-4; DOMINEY AM, 1993, CELL GROWTH DIFFER, V4, P1071; FINNERTY H, 1993, ONCOGENE, V8, P2293; FONDACCI C, 1994, J CLIN INVEST, V93, P1149, DOI 10.1172/JCI117067; FOWLER KJ, 1995, P NATL ACAD SCI USA, V92, P1465, DOI 10.1073/pnas.92.5.1465; GUILLEMOT F, 1994, NATURE, V371, P333, DOI 10.1038/371333a0; HAYMAN MJ, 1993, CELL, V74, P157, DOI 10.1016/0092-8674(93)90303-8; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; KAUFMAN MH, 1992, ATLAS MOUSE DEV, P407; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LESCISIN KR, 1989, GENE DEV, V2, P1639; LUETTEKE NC, 1993, CELL, V73, P263, DOI 10.1016/0092-8674(93)90228-I; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; MANN GB, 1993, CELL, V73, P249, DOI 10.1016/0092-8674(93)90227-H; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MCLAREN A, 1969, NATURE, V224, P238, DOI 10.1038/224238a0; MUNTENER M, 1977, ACTA ANAT, V98, P241; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; PAIN B, 1991, CELL, V65, P37, DOI 10.1016/0092-8674(91)90405-N; Partanen A M, 1990, Curr Top Dev Biol, V24, P31, DOI 10.1016/S0070-2153(08)60083-6; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; ROSSANT J, 1985, J EMBRYOL EXP MORPH, V86, P177; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SIBILIA M, UNPUB; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; VONRUDEN T, 1992, BLOOD, V12, P3145; WILEY LM, 1992, DEV BIOL, V149, P247, DOI 10.1016/0012-1606(92)90282-L; WILKINSON DG, 1987, DEVELOPMENT, V99, P493	41	818	829	0	13	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 14	1995	269	5221					234	238		10.1126/science.7618085	http://dx.doi.org/10.1126/science.7618085			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ029	7618085				2022-12-24	WOS:A1995RJ02900043
J	MACLEOD, RJ; BENNETT, HPJ; HAMILTON, JR				MACLEOD, RJ; BENNETT, HPJ; HAMILTON, JR			INHIBITION OF INTESTINAL SECRETION BY RICE	LANCET			English	Note							LIQUID-CHROMATOGRAPHY	Rates of stool output are reduced when cooked rice is incorporated into oral rehydration solutions. We found that a fraction extracted from rice inhibited the response of intestinal epithelial crypt cells to adenosine 3'5'-cyclic monophosphate, a major intracellular mediator of secretion. This response to rice was seen as an inhibition of cell shrinkage and of chloride efflux in fresh suspended guineapig crypt cells. The active fraction was of low molecular weight (<1.5 kDa), hydrophobic, and not a peptide or glycoprotein. It may be chloride-channel blocker.	MCGILL UNIV,MONTREAL CHILDRENS HOSP,RES INST,MONTREAL,PQ H3H 1P3,CANADA; MCGILL UNIV,DEPT PEDIAT,MONTREAL,PQ H3H 1P3,CANADA; MCGILL UNIV,ROYAL VICTORIA HOSP,DEPT MED,MONTREAL,PQ H3A 1A1,CANADA	McGill University; McGill University; McGill University; Royal Victoria Hospital								BENNETT HPJ, 1981, BIOCHEMISTRY-US, V20, P4530, DOI 10.1021/bi00519a004; BROWNE CA, 1982, ANAL BIOCHEM, V124, P201, DOI 10.1016/0003-2697(82)90238-X; FIELD M, 1993, ANNU REV PHYSIOL, V55, P631, DOI 10.1146/annurev.ph.55.030193.003215; GORE SM, 1992, BMJ-BRIT MED J, V304, P287, DOI 10.1136/bmj.304.6822.287; MACLEOD RJ, 1994, AM J PHYSIOL, V267, pG387, DOI 10.1152/ajpgi.1994.267.3.G387; VENGLARIK CJ, 1990, AM J PHYSIOL, V259, pC358	6	27	27	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 8	1995	346	8967					90	92		10.1016/S0140-6736(95)92115-X	http://dx.doi.org/10.1016/S0140-6736(95)92115-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH220	7603220				2022-12-24	WOS:A1995RH22000013
J	BARKER, DJP; WINTER, PD; OSMOND, C; PHILLIPS, DIW; SULTAN, HY				BARKER, DJP; WINTER, PD; OSMOND, C; PHILLIPS, DIW; SULTAN, HY			WEIGHT-GAIN IN INFANCY AND CANCER OF THE OVARY	LANCET			English	Note								The geographic association between ovarian cancer and tall stature suggests a link with rapid growth in early childhood. Among 5585 women born in Hertfordshire, UK, 41 who died from ovarian cancer had had a high rate of weight in infancy. Whereas their mean birthweight was the same as that of the other women, their mean weight at 1 year was higher (22.3 pounds [10.1 kg] vs 21.4 pounds [9.7 kg], p=0.01). These observations are consistent with the hypothesis that ovarian cancer is linked to altered patterns of gonadotropin release established in utero when the fetal hypothalamus is imprinted.			BARKER, DJP (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND.			Osmond, Clive/0000-0002-9054-4655				ADAMI HO, 1994, LANCET, V344, P1250, DOI 10.1016/S0140-6736(94)90749-8; BALASCH J, 1993, HUM REPROD, V8, P990, DOI 10.1093/oxfordjournals.humrep.a138215; BARKER DJP, 1990, ANN HUM BIOL, V17, P1, DOI 10.1080/03014469000000732; BARRACLOUGH C, 1961, ENDOCRINOLOGY, V68, P68, DOI 10.1210/endo-68-1-68; BERAL V, 1978, LANCET, V1, P1083; CRAMER DW, 1983, JNCI-J NATL CANCER I, V71, P717; OSMOND C, 1993, BRIT MED J, V307, P1519, DOI 10.1136/bmj.307.6918.1519; Pfeiffer CA, 1936, AM J ANAT, V58, P195, DOI 10.1002/aja.1000580112; VONSAAL FS, 1980, SCIENCE, V208, P597; WHITTEMORE AS, 1989, CANCER RES, V49, P4047	10	35	35	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 29	1995	345	8957					1087	1088		10.1016/S0140-6736(95)90821-8	http://dx.doi.org/10.1016/S0140-6736(95)90821-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV411	7619123				2022-12-24	WOS:A1995QV41100013
J	HOCHMAN, DW; BARABAN, SC; OWENS, JWM; SCHWARTZKROIN, PA				HOCHMAN, DW; BARABAN, SC; OWENS, JWM; SCHWARTZKROIN, PA			DISSOCIATION OF SYNCHRONIZATION AND EXCITABILITY IN FUROSEMIDE BLOCKADE OF EPILEPTIFORM ACTIVITY	SCIENCE			English	Article							RAT HIPPOCAMPAL SLICE; EXTRACELLULAR POTASSIUM; WATER-INTOXICATION; CHEMICAL SYNAPSES; TRANSPORT; SEIZURES; NEURONS; CELLS; BRAIN; POTENTIALS	Furosemide, a chloride cotransport inhibitor, reversibly blocked synchronized burst discharges in hippocampal slices without reducing the pyramidal cell response to single electrical stimuli. Images of the intrinsic optical signal acquired during these slice experiments indicated that furosemide coincidentally blocked changes in extracellular space. In urethane-anesthetized rats, systemically injected furosemide blocked kainic acid-induced electrical discharges recorded from cortex. These results suggest that (i) neuronal synchronization involved in epileptiform activity can be dissociated from synaptic excitability; (ii) nonsynaptic mechanisms, possibly associated with furosemide-sensitive cell volume regulation, may be critical for synchronization of neuronal activity; and (iii) agents that affect extracellular volume may have clinical utility as antiepileptic drugs.	UNIV WASHINGTON,DEPT NEUROL SURG,SEATTLE,WA 98195	University of Washington; University of Washington Seattle				Baraban, Scott/0000-0003-1975-9781	NINDS NIH HHS [NS07144, NS15317] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015317] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AGHAJANIAN AK, 1989, SYNAPSE, V31, P331; ANDERSON WW, 1986, BRAIN RES, V398, P215, DOI 10.1016/0006-8993(86)91274-6; BARAN H, 1987, NEUROSCIENCE, V21, P679, DOI 10.1016/0306-4522(87)90029-7; BUCKMASTER PS, 1993, J NEUROPHYSIOL, V70, P1281, DOI 10.1152/jn.1993.70.4.1281; CARTER CH, 1962, EPILEPSIA, V3, P198; DELVA NJ, 1988, BRIT J PSYCHIAT, V152, P242, DOI 10.1192/bjp.152.2.242; DIETZEL I, 1980, EXP BRAIN RES, V40, P432; Dudek F E, 1986, Adv Neurol, V44, P593; DUDEK FE, 1990, NEUROSCI LETT, V120, P267, DOI 10.1016/0304-3940(90)90056-F; FERRIER IN, 1985, BRIT MED J, V291, P1594, DOI 10.1136/bmj.291.6509.1594; FORSYTHE WI, 1981, DEV MED CHILD NEUROL, V23, P761; GALVAN M, 1982, BRAIN RES, V241, P75, DOI 10.1016/0006-8993(82)91230-6; Garland HG, 1943, LANCET, V2, P566; GECK P, 1980, BIOCHIM BIOPHYS ACTA, V600, P432, DOI 10.1016/0005-2736(80)90446-0; GUILLAUME D, 1991, EPILEPSIA, V32, P10, DOI 10.1111/j.1528-1157.1991.tb05603.x; HAMMARLUND MM, 1982, BIOPHARM DRUG DISPOS, V3, P345, DOI 10.1002/bdd.2510030408; JEFFERYS JGR, 1982, NATURE, V200, P448; KIMELBERG HK, 1985, BRAIN RES, V361, P125, DOI 10.1016/0006-8993(85)91282-X; KIMELBERG HK, 1986, ASTROCYTES, V3, P129; KONNERTH A, 1984, EXP BRAIN RES, V51, P153; LANGTON PD, 1993, J PHYSIOL-LONDON, V471, P1; LIPTON P, 1973, J PHYSIOL-LONDON, V231, P365, DOI 10.1113/jphysiol.1973.sp010238; LOTHMAN EW, 1981, NEUROLOGY, V31, P806, DOI 10.1212/WNL.31.7.806; MACVICAR BA, 1991, J NEUROSCI, V11, P1458; MARTIN DL, 1992, GLIA, V5, P81, DOI 10.1002/glia.440050202; MCBAIN CJ, 1990, SCIENCE, V249, P674, DOI 10.1126/science.2382142; MCNAMARA JO, 1994, J NEUROSCI, V14, P3413; MEDANI CR, 1987, SOUTHERN MED J, V80, P421, DOI 10.1097/00007611-198704000-00003; MISGELD U, 1986, SCIENCE, V232, P1413, DOI 10.1126/science.2424084; PAOLETTI P, 1994, NEURON, V13, P645, DOI 10.1016/0896-6273(94)90032-9; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; PEARCE RA, 1993, NEURON, V10, P189, DOI 10.1016/0896-6273(93)90310-N; READ DJ, 1964, J PHARM, V146, P154; RICHARDSON TL, 1984, BRAIN RES, V294, P255, DOI 10.1016/0006-8993(84)91037-0; ROPER SN, 1992, ANN NEUROL, V31, P81, DOI 10.1002/ana.410310115; ROSEN AS, 1990, NEUROSCIENCE, V38, P579, DOI 10.1016/0306-4522(90)90052-6; SCHWARTZKROIN PA, 1980, BRAIN RES, V183, P61, DOI 10.1016/0006-8993(80)90119-5; Schwartzkroin Philip A., 1993, P83; STASHEFF SF, 1985, BRAIN RES, V344, P296, DOI 10.1016/0006-8993(85)90807-8; TANIMUKAI H, 1965, BIOCHEM PHARMACOL, V14, P961; TAYLOR CP, 1982, SCIENCE, V218, P810, DOI 10.1126/science.7134978; THOMPSON SM, 1989, J NEUROPHYSIOL, V61, P512, DOI 10.1152/jn.1989.61.3.512; THOMPSON SM, 1988, J NEUROPHYSIOL, V60, P105, DOI 10.1152/jn.1988.60.1.105; TRAYNELIS SF, 1988, J NEUROPHYSIOL, V59, P259, DOI 10.1152/jn.1988.59.1.259; Van Harreveld A., 1967, Journal of Neurophysiology, V30, P911; VANHARREVELD A, 1971, EXP MOL PATHOL, V15, P61, DOI 10.1016/0014-4800(71)90019-0; WALZ W, 1984, J CEREBR BLOOD F MET, V4, P301, DOI 10.1038/jcbfm.1984.42; White H S, 1986, Adv Neurol, V44, P695; ZHANG CL, 1995, EPILEPSY RES, V20, P105	49	161	173	0	5	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 6	1995	270	5233					99	102		10.1126/science.270.5233.99	http://dx.doi.org/10.1126/science.270.5233.99			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY302	7569957				2022-12-24	WOS:A1995RY30200042
J	BAIK, JH; PICETTI, R; SAIARDI, A; THIRIET, G; DIERICH, A; DEPAULIS, A; LEMEUR, M; BORRELLI, E				BAIK, JH; PICETTI, R; SAIARDI, A; THIRIET, G; DIERICH, A; DEPAULIS, A; LEMEUR, M; BORRELLI, E			PARKINSONIAN-LIKE LOCOMOTOR IMPAIRMENT IN MICE LACKING DOPAMINE D2 RECEPTORS	NATURE			English	Article							BASAL GANGLIA; MESSENGER-RNA; EXPRESSION; NEURONS; GENE; SEQUENCE; ANTAGONISTS; CATALEPSY; SCH-23390; PROTEINS	DOPAMINERGIC neuronal pathways arise from mesencephalic nuclei and project axons to the striatum, cortex, limbic system and hypothalamus(1,2). Through these pathways dopamine affects many physiological functions, such as the control of coordinated movement and hormone secretion(3). Here we have studied the physiological involvement of the dopamine D2 receptors in dopaminergic transmission, using homologous recombination to generate D2-receptor-deficient mice. Absence of D2 receptors leads to animals that are akinetic and bradykinetic in behavioural tests, and which show significantly reduced spontaneous movements. This phenotype presents analogies with symptoms characteristic of Parkinson's disease(4,5). Our study shows that D2 receptors have a key role in the dopaminergic control of nervous function. These mice have therapeutic potential as a model for investigating and correcting dysfunctions of the dopaminergic system.	INST GENET & BIOL MOLEC & CELLULAIRE,F-67404 ILLKIRCH GRAFFENS,FRANCE; FAC MED STRASBOURG,INSERM,U398,F-67085 STRASBOURG,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Depaulis, Antoine/B-6098-2012; Borrelli, Emiliana/M-8994-2018; Picetti, Roberto/B-9944-2011	Depaulis, Antoine/0000-0001-6543-6700; Picetti, Roberto/0000-0003-4756-5271				ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; ALEXANDER GE, 1990, TRENDS NEUROSCI, V13, P266, DOI 10.1016/0166-2236(90)90107-L; BANNON MJ, 1986, J BIOL CHEM, V261, P6640; CASEY DE, 1992, PSYCHOPHARMACOLOGY, V107, P18, DOI 10.1007/BF02244960; CIVELLI O, 1985, P NATL ACAD SCI USA, V82, P4291, DOI 10.1073/pnas.82.12.4291; DOLLE P, 1990, DEVELOPMENT, V110, P1133; DRAGO J, 1994, P NATL ACAD SCI USA, V91, P12564, DOI 10.1073/pnas.91.26.12564; FUXE K, 1987, NEUROENDOCRINOLOGY, V5, P5; GERFEN CR, 1990, SCIENCE, V250, P1429, DOI 10.1126/science.2147780; GINGRICH JA, 1993, ANNU REV NEUROSCI, V16, P299, DOI 10.1146/annurev.ne.16.030193.001503; GRAYBIEL AM, 1990, TRENDS NEUROSCI, V13, P244, DOI 10.1016/0166-2236(90)90104-I; GRIMA B, 1985, P NATL ACAD SCI USA, V82, P617, DOI 10.1073/pnas.82.2.617; GUIRAMAND J, 1995, J BIOL CHEM, V270, P7354, DOI 10.1074/jbc.270.13.7354; HORNYKIEWICZ O, 1966, PHARMACOL REV, V18, P925; JACKSON DM, 1994, PHARMACOL THERAPEUT, V64, P291, DOI 10.1016/0163-7258(94)90041-8; JANSSEN PAJ, 1960, PSYCHOPHARMACOLOGIA, V1, P389, DOI 10.1007/BF00441186; KAUFMAN DL, 1986, SCIENCE, V232, P1138, DOI 10.1126/science.3518061; KITA H, 1988, BRAIN RES, V447, P346, DOI 10.1016/0006-8993(88)91138-9; LEMOINE C, 1991, P NATL ACAD SCI USA, V88, P4205, DOI 10.1073/pnas.88.10.4205; LEVESQUE D, 1992, P NATL ACAD SCI USA, V89, P8155, DOI 10.1073/pnas.89.17.8155; MEYER ME, 1992, PHARMACOL BIOCHEM BE, V41, P507, DOI 10.1016/0091-3057(92)90365-M; MONTMAYEUR JP, 1991, FEBS LETT, V278, P239, DOI 10.1016/0014-5793(91)80125-M; MONTMAYEUR JP, 1993, MOL ENDOCRINOL, V7, P161, DOI 10.1210/me.7.2.161; MORELLI M, 1985, EUR J PHARMACOL, V117, P179, DOI 10.1016/0014-2999(85)90602-8; OGREN SO, 1988, NEUROSCI LETT, V85, P333, DOI 10.1016/0304-3940(88)90588-5; PERTWEE RG, 1972, BRIT J PHARMACOL, V46, P753, DOI 10.1111/j.1476-5381.1972.tb06900.x; SEEMAN P, 1990, FASEB J, V4, P2737, DOI 10.1096/fasebj.4.10.2197154; WOLFFGRAMM J, 1990, PHARM BIOCH BEHAV, V36, P9007; XU M, 1994, CELL, V79, P729, DOI 10.1016/0092-8674(94)90557-6; ZURAWSKI G, 1986, SCIENCE, V232, P772, DOI 10.1126/science.2938259	30	455	466	1	19	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 5	1995	377	6548					424	428		10.1038/377424a0	http://dx.doi.org/10.1038/377424a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY190	7566118				2022-12-24	WOS:A1995RY19000048
J	KRAUTER, K; MONTGOMERY, K; YOON, SJ; LEBLANCSTRACESKI, J; RENAULT, B; MARONDEL, I; HERDMAN, V; CUPELLI, L; BANKS, A; LIEMAN, J; MENNINGER, J; BRAYWARD, P; NADKARNI, P; WEISSENBACH, J; LEPASLIER, D; RIGAULT, P; CHUMAKOV, I; COHEN, D; MILLER, P; WARD, D; KUCHERLAPATI, R				KRAUTER, K; MONTGOMERY, K; YOON, SJ; LEBLANCSTRACESKI, J; RENAULT, B; MARONDEL, I; HERDMAN, V; CUPELLI, L; BANKS, A; LIEMAN, J; MENNINGER, J; BRAYWARD, P; NADKARNI, P; WEISSENBACH, J; LEPASLIER, D; RIGAULT, P; CHUMAKOV, I; COHEN, D; MILLER, P; WARD, D; KUCHERLAPATI, R			A 2ND-GENERATION YAC CONTIG MAP OF HUMAN-CHROMOSOME-12	NATURE			English	Article							YEAST ARTIFICIAL CHROMOSOMES; HUMAN GENOME; LINKAGE MAP; CLONES; SEQUENCES	Human chromosome 12 constitutes approximately 4.5% of the human genome and has an estimated size of 135 million base pairs (Mb). We have started to construct a high-resolution physical map of chromosome 12 as overlapping yeast artificial chromosomes (YACs), using as a foundation the first-generation physical map which contained overlapping clones corresponding to 56 markers. Our second-generation map of this chromosome covers nearly 102 Mb of DNA and includes 426 highly polymorphic, monomorphic and gene-based markers. We also mapped 119 of the YACs, most of which are part of the physical map, by cytogenetic methods. Thus the map integrates genetic, physical and cytogenetic data and provides information about the organization of this chromosome and will help in the localization and cloning of disease-related genes. The strategy used here to generate the chromosome-12 map could be applied for the vapid construction of physical and expression maps for other human chromosomes.	YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,CTR MED INFORMAT,NEW HAVEN,CT 06510; GENETHON SA,F-91002 EVRY,FRANCE; JEAN DAUSSET FDN,F-75010 PARIS,FRANCE	Yale University; Yale University	KRAUTER, K (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT CELL BIOL,1300 MORRIS PK AVE,BRONX,NY 10461, USA.		Kucherlapati, Raju/ABC-8807-2021	Le Paslier, Denis/0000-0003-4335-9956				BASSON CT, 1994, NEW ENGL J MED, V330, P885, DOI 10.1056/NEJM199403313301302; BELLANNECHANTEL.C, 1992, CELL, V70, P1059; BONNET D, 1994, NAT GENET, V6, P405, DOI 10.1038/ng0494-405; CARTER SA, 1994, GENOMICS, V24, P378, DOI 10.1006/geno.1994.1632; CHUMAKOV I, 1992, NATURE, V359, P380, DOI 10.1038/359380a0; CHUMAKOV IM, 1992, NAT GENET, V1, P222, DOI 10.1038/ng0692-222; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; DAWSON E, 1993, GENOMICS, V17, P245, DOI 10.1006/geno.1993.1314; ENGLE EC, 1994, NAT GENET, V7, P69, DOI 10.1038/ng0594-69; FOOTE S, 1992, SCIENCE, V258, P60, DOI 10.1126/science.1359640; GISPERT S, 1993, NAT GENET, V4, P295, DOI 10.1038/ng0793-295; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HOLT M, 1992, SCIENCE, V258, P67; KOBAYASHI H, IN PRESS GENES CHROM; LEBIANCSTRACESK.JM, 1994, GENOMICS, V19, P341; LICHTER JB, 1993, GENOMICS, V16, P320, DOI 10.1006/geno.1993.1192; LUKUO JM, 1994, HUM MOL GENET, V3, P99, DOI 10.1093/hmg/3.1.99; MONTGOMERY KT, 1993, GENOMICS, V17, P682, DOI 10.1006/geno.1993.1390; MORTON NE, 1991, P NATL ACAD SCI USA, V88, P7474, DOI 10.1073/pnas.88.17.7474; MURRAY JC, 1994, SCIENCE, V263, P2049; NELSON DL, 1989, P NATL ACAD SCI USA, V86, P6686, DOI 10.1073/pnas.86.17.6686; RAIMONDI SC, 1986, BLOOD, V68, P69; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; ROUYER F, 1990, EMBO J, V9, P505, DOI 10.1002/j.1460-2075.1990.tb08137.x; STEPHENS JC, 1990, SCIENCE, V250, P237, DOI 10.1126/science.2218527; TAKEDA J, 1993, HUM MOL GENET, V2, P1793, DOI 10.1093/hmg/2.11.1793; TERRETT JA, 1994, NAT GENET, V6, P401, DOI 10.1038/ng0494-401; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WEISSENBACH J, 1993, GENE, V135, P275, DOI 10.1016/0378-1119(93)90077-G	30	118	119	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 28	1995	377			S			321	333						13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA343	7566099				2022-12-24	WOS:A1995TA34300005
J	MANT, J; HICKS, N				MANT, J; HICKS, N			DETECTING DIFFERENCES IN QUALITY OF CARE - THE SENSITIVITY OF MEASURES OF PROCESS AND OUTCOME IN TREATING ACUTE MYOCARDIAL-INFARCTION	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MORTALITY; UNITS	The merits or otherwise of publishing hospital specific death rates are much debated. This article compares the relative sensitivity of measures of process and outcome to differences in quality of care for the hospital treatment of myocardial infarction. Aspects of hospital care that have a proved impact on mortality from myocardial infarction are identified, and the results from meta-analysis and large randomised controlled trials are used to estimate the impact that optimal use of these interventions would have on mortality in a typical district general hospital. Sample size calculations are then performed to determine how many years of data would be needed to detect significant differences between hospitals. A comparison is then made with the amount of data that would be needed to detect significant differences if information about process of care was being collected. Process measures based on the results of randomised controlled trials were found to be able to detect relevant differences between hospitals that would not be identified by comparing hospital specific mortality, which is an insensitive indicator of the quality of care.	OXFORDSHIRE HLTH, HEADINGTON, OXON, ENGLAND		MANT, J (corresponding author), UNIV OXFORD, RADCLIFFE INFIRM, DEPT PUBL HLTH & PRIMARY CARE, OXFORD OX2 6HE, ENGLAND.			Hicks, Nicholas/0000-0002-7214-9678				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, Lancet, V2, P57; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; CLARKE A, 1993, BRIT MED J, V307, P1436, DOI 10.1136/bmj.307.6917.1436; COLLINS R, 1995, LANCET, V345, P669; DEVITA C, 1994, LANCET, V343, P1115; DILLNER L, 1994, BRIT MED J, V309, P1599, DOI 10.1136/bmj.309.6969.1599a; HAINES A, 1994, BMJ-BRIT MED J, V308, P1488, DOI 10.1136/bmj.308.6942.1488; KNAUS WA, 1993, ANN INTERN MED, V118, P753, DOI 10.7326/0003-4819-118-10-199305150-00001; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; MCMURRAY J, 1994, BMJ-BRIT MED J, V309, P1343, DOI 10.1136/bmj.309.6965.1343; Moher M., 1995, EVIDENCE EFFECTIVENE; ORCHARD C, 1994, BRIT MED J, V308, P1493, DOI 10.1136/bmj.308.6942.1493; ROBINSON R, 1995, BRIT MED J, V310, P755, DOI 10.1136/bmj.310.6982.755; ROWAN KM, 1993, BRIT MED J, V307, P977, DOI 10.1136/bmj.307.6910.977; SELKER HP, 1993, ANN INTERN MED, V118, P820, DOI 10.7326/0003-4819-118-10-199305150-00010; Sheldon T A, 1993, Qual Health Care, V2, P149, DOI 10.1136/qshc.2.3.149; 1995, ASSESSING OPTIONS CO; 1992, LANCET, V239, P753; 1993, LANCET, V341, P1183	21	221	222	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 23	1995	311	7008					793	796		10.1136/bmj.311.7008.793	http://dx.doi.org/10.1136/bmj.311.7008.793			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX107	7580444	Green Published			2022-12-24	WOS:A1995RX10700026
J	KORNAU, HC; SCHENKER, LT; KENNEDY, MB; SEEBURG, PH				KORNAU, HC; SCHENKER, LT; KENNEDY, MB; SEEBURG, PH			DOMAIN INTERACTION BETWEEN NMDA RECEPTOR SUBUNITS AND THE POSTSYNAPTIC DENSITY PROTEIN PSD-95	SCIENCE			English	Article							AMINO-ACID RECEPTORS; TUMOR SUPPRESSOR GENE; SPINAL-CORD NEURONS; HIPPOCAMPAL-NEURONS; MOLECULAR-CLONING; DROSOPHILA; SYSTEM; ANTAGONISTS; EXPRESSION; AGONISTS	The N-methyl-D-aspartate (NMDA) receptor subserves synaptic glutamate-induced transmission and plasticity in central neurons. The yeast two-hybrid system was used to show that the cytoplasmic tails of NMDA receptor subunits interact with a prominent postsynaptic density protein PSD-95. The second PDZ domain in PSD-95 binds to the seven-amino acid, COOH-terminal domain containing the terminal tSXV motif (where S is serine, X is any amino acid, and V is valine) common to NR2 subunits and certain NR1 splice forms. Transcripts encoding PSD-95 are expressed in a pattern similar to that of NMDA receptors, and the NR2B subunit co-localizes with PSD-95 in cultured rat hippocampal neurons. The interaction of these proteins may affect the plasticity of excitatory synapses.	UNIV HEIDELBERG,CTR MOLEC BIOL,D-69120 HEIDELBERG,GERMANY; CALTECH,DIV BIOL,PASADENA,CA 91125	Ruprecht Karls University Heidelberg; California Institute of Technology				Kennedy, Mary/0000-0003-1369-0525	NINDS NIH HHS [NS-28710] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028710] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOURNE HR, 1993, CELL, V72, P65, DOI 10.1016/S0092-8674(05)80029-7; BOURNE HR, 1993, NEURON S, V10, P65; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; HOLLMANN M, 1993, NEURON, V10, P943, DOI 10.1016/0896-6273(93)90209-A; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; ISHII T, 1992, J BIOL CHEM, V268, P2836; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; KENNEDY MB, 1994, ANNU REV BIOCHEM, V63, P571, DOI 10.1146/annurev.biochem.63.1.571; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KUTSUWADA T, 1993, NATURE, V358, P36; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURIE DJ, 1994, J NEUROSCI, V14, P3180; LAURIE DJ, UNPUB; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MOON IS, 1994, P NATL ACAD SCI USA, V91, P3954, DOI 10.1073/pnas.91.9.3954; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; MULLER M, 1994, J NEUROSCI, V15, P2354; NOVAK L, 1984, NATURE, V307, P462; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHWARZ TL, 1988, NATURE, V331, P137, DOI 10.1038/331137a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; WATKINS JC, 1987, TRENDS NEUROSCI, V10, P265, DOI 10.1016/0166-2236(87)90171-8; WATKINS JC, 1990, TRENDS PHARMACOL SCI, V11, P25, DOI 10.1016/0165-6147(90)90038-A; WISDEN W, 1991, MOL NEUROBIOLOGY PRA, P205; WO ZG, 1994, P NATL ACAD SCI USA, V91, P7154, DOI 10.1073/pnas.91.15.7154; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X	45	1538	1587	1	79	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 22	1995	269	5231					1737	1740		10.1126/science.7569905	http://dx.doi.org/10.1126/science.7569905			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV948	7569905				2022-12-24	WOS:A1995RV94800043
J	MARON, BJ; POLIAC, LC; KAPLAN, JA; MUELLER, FO				MARON, BJ; POLIAC, LC; KAPLAN, JA; MUELLER, FO			BLUNT IMPACT TO THE CHEST LEADING TO SUDDEN-DEATH FROM CARDIAC-ARREST DURING SPORTS ACTIVITIES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LONG-QT SYNDROME; COMMOTIO-CORDIS; MYOCARDIAL-INFARCTION; YOUNG-ADULTS	Background. Sudden death from cardiac arrest in a young person may occur during sports play after a blunt blow to the chest in the absence of structural cardiovascular disease or traumatic injury (cardiac concussion or commotio cordis). We studied the clinical features of this apparently uncommon but important phenomenon. Methods. We identified cases from the registries of relevant agencies and organizations, as well as news-media accounts, and developed a clinical profile of 25 children and young adults, 3 to 19 years of age. Results. Each victim collapsed with cardiac arrest immediately after an unexpected blow to the chest, which was usually inflicted by a projectile (such as a baseball or hockey puck), Incidents took place during organized competitive sports in 16 cases and in recreational settings at home, at school, or on the playground in 9, in each instance, the impact to the chest was not judged to be extraordinary for the sport involved and did not appear to have sufficient force to cause death. Twelve victims collapsed virtually instantaneously on impact, whereas 13 remained conscious and physically active for a brief time before cardiac arrest. Cardiopulmonary resuscitation was administered within about three minutes to 19 victims, but normal cardiac rhythm could be restored in only 2 (both incurred irreversible brain damage and died shortly thereafter), Seven victims (28 percent) were wearing some form of protective chest padding. Conclusions. We speculate that most sudden deaths related to impact to the chest (not associated with traumatic injury) are due to ventricular dysrhythmia induced by an abrupt, blunt precordial blow, presumably delivered at an electrically vulnerable phase of ventricular excitability. This profile of blunt chest impact leading to cardiac arrest adds to our understanding of the range of causes of sudden death on the athletic field and may help in the development of preventive measures.	DARTMOUTH COLL SCH MED,DEPT PATHOL,LEBANON,NH; OFF NEW HAMPSHIRE STATE MED EXAMINER,LEBANON,NH; NATL CTR CATASTROPH SPORTS INJURY RES,CHAPEL HILL,NC; UNIV N CAROLINA,CHAPEL HILL,NC 27515	Dartmouth College; University of North Carolina; University of North Carolina Chapel Hill	MARON, BJ (corresponding author), MINNEAPOLIS HEART INST FDN,DIV CARDIOVASC RES,920 E 28TH ST,SUITE 40,MINNEAPOLIS,MN 55407, USA.							ABRUNZO TJ, 1991, AM J DIS CHILD, V145, P1279, DOI 10.1001/archpedi.1991.02160110071023; BURKE AP, 1991, AM HEART J, V121, P568, DOI 10.1016/0002-8703(91)90727-Y; CHEITLIN MD, 1974, CIRCULATION, V50, P780, DOI 10.1161/01.CIR.50.4.780; COHN PF, 1977, CIRCULATION, V56, P598, DOI 10.1161/01.CIR.56.4.598; Cooper G J, 1989, J R Army Med Corps, V135, P58; CORRADO D, 1990, AM J MED, V89, P588, DOI 10.1016/0002-9343(90)90176-E; EDLICH R F JR, 1987, Journal of Emergency Medicine, V5, P181, DOI 10.1016/0736-4679(87)90176-4; FERSTLE J, 1978, PHYSICIAN SPORTSMED, V6, P21; FRAZER M, 1984, AM J FOREN MED PATH, V5, P249, DOI 10.1097/00000433-198409000-00015; FURLANELLO F, 1984, ANN NY ACAD SCI, V427, P253, DOI 10.1111/j.1749-6632.1984.tb20789.x; GREEN ED, 1980, ANN EMERG MED, V9, P155, DOI 10.1016/S0196-0644(80)80272-1; GROSSFELD PD, 1993, MED SCI SPORT EXER, V25, P901; JAMES TN, 1967, ANN INTERN MED, V67, P1013, DOI 10.7326/0003-4819-67-5-1013; Janda DH., 1992, CLIN J SPORT MED, V2, P172; KAPLAN JA, 1993, J TRAUMA, V34, P151, DOI 10.1097/00005373-199301000-00030; KING AI, 1986, CPSCC841170 CONS PRO; KULBS F, 1909, MITT GRENZGEB MED CH, V19, P678; LOWN B, 1969, AM J MED, V46, P705, DOI 10.1016/0002-9343(69)90022-9; MARON BJ, 1993, NEW ENGL J MED, V329, P55, DOI 10.1056/NEJM199307013290113; MARON BJ, 1986, J AM COLL CARDIOL, V7, P204, DOI 10.1016/S0735-1097(86)80283-2; MARON BJ, 1980, CIRCULATION, V62, P218, DOI 10.1161/01.CIR.62.2.218; MARON BJ, 1993, CIRCULATION, V88, P50; MOSS AJ, 1985, CIRCULATION, V71, P17, DOI 10.1161/01.CIR.71.1.17; PRINGLE SD, 1987, BRIT HEART J, V57, P375; RAGOSTA M, 1984, MED SCI SPORT EXER, V16, P339; RUTHERFORD G, 1981, OVERVIEW SPORTS RELA; SMIRK FH, 1960, AM J CARDIOL, V6, P620, DOI 10.1016/0002-9149(60)90265-4; SWIFT EM, 1993, SPORTS ILLUSTRA 1206, P66; THIENE G, 1983, HUM PATHOL, V14, P704, DOI 10.1016/S0046-8177(83)80143-9; TOPAZ O, 1985, CHEST, V87, P476, DOI 10.1378/chest.87.4.476; TSUNG SH, 1982, ARCH PATHOL LAB MED, V106, P168; VIANO DC, 1978, J TRAUMA, V18, P452, DOI 10.1097/00005373-197806000-00010; Viano DC, 1992, CLIN J SPORT MED, V2, P166; VIANO DC, 1992, CLIN J SPORT MED, V2, P161; VINCENT GM, 1992, NEW ENGL J MED, V327, P846, DOI 10.1056/NEJM199209173271204; ZOLL PM, 1976, NEW ENGL J MED, V294, P1274, DOI 10.1056/NEJM197606032942307	36	223	231	0	14	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 10	1995	333	6					337	342		10.1056/NEJM199508103330602	http://dx.doi.org/10.1056/NEJM199508103330602			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN082	7609749	Green Submitted			2022-12-24	WOS:A1995RN08200002
J	CHOW, WH; FINKLE, WD; MCLAUGHLIN, JK; FRANKL, H; ZIEL, HK; FRAUMENI, JF				CHOW, WH; FINKLE, WD; MCLAUGHLIN, JK; FRANKL, H; ZIEL, HK; FRAUMENI, JF			THE RELATION OF GASTROESOPHAGEAL REFLUX DISEASE AND ITS TREATMENT TO ADENOCARCINOMAS OF THE ESOPHAGUS AND GASTRIC CARDIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BARRETTS-ESOPHAGUS; CIMETIDINE; CANCER	Objective.-To examine the relationship of gastrointestinal disorders and their treatment to the risk of adenocarcinomas of the esophagus and gastric cardia (AEC). Design.-A medical record-based case-control study, with data collected on a standardized form by a trained abstractor, blind to the case-control status. Setting.-A large prepaid health plan. Subjects.-Case patients were plan members newly diagnosed with histologically confirmed AEC from 1986 to 1992. For each of the 196 eligible case patients, one control was selected who matched for membership at time of diagnosis, sex, year of birth, and duration of membership. Main Outcome Measures.-Association between AEC and history of gastroesophageal conditions and their treatment. Conditional logistic regression procedures were used for calculation of odds ratios (ORs) and corresponding 95% confidence intervals (Cls), with adjustment for race, smoking status, and body mass index. Medications were grouped into H-2 antagonists (cimetidine, ranitidine, famotidine, and nizatidine) and anticholinergics (propantheline bromide, dicyclomine hydrochloride, Donnatal [combination of atropine sulfate, hyoscyamine sulfate, phenobarbital, and scopolamine hydrobromide], and Librax [combination of chlordiazepoxide hydrochloride and clidinium bromide]). Results.-Significant twofold or greater risks of AEC were associated with a history of esophageal reflux, hiatal hernia, esophagitis/esophageal ulcer, and difficulty swallowing. The ORs increased with increasing number of these conditions. Although a fourfold risk was linked to four or more prescriptions for H-2 antagonists, the risk was reduced to 1.5 (95% CI, 0.4 to 5.4) after adjusting for the predisposing conditions. Further analysis revealed that the excess risk was restricted to persons with a history of gastroesophageal reflux and related conditions. No association was observed for overall use of anticholinergics. However, after adjustment for predisposing conditions, ORs decreased with increasing number of prescriptions for anticholinergics (P for trend=.08). Conclusions.-This study provides reassuring findings that use of H-2 antagonists and anticholinergics does not increase AEC risk. It also quantifies the elevated risk of AEC associated with gastroesophageal reflux disease. Further research into reflux disease and the production of premalignant epithelial changes may help elucidate carcinogenic mechanisms and measures aimed at early detection and prevention of AEC.	INT EPIDEMIOL INST,ROCKVILLE,MD 20850; NCI,DIV CANC ETIOL,EPIDEMIOL & BIOSTAT PROGRAM,BETHESDA,MD 20892; SO CALIF PERMANENTE MED GRP,DEPT MED,LOS ANGELES,CA 90027; SO CALIF PERMANENTE MED GRP,DEPT OBSTET & GYNECOL,LOS ANGELES,CA 90027	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Kaiser Permanente; Southern California Permanente Medical Group (SCPMG); Permanente Medical Groups; Kaiser Permanente; Southern California Permanente Medical Group (SCPMG); Permanente Medical Groups					NCI NIH HHS [N01 CP 95680] Funding Source: Medline; DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP095680] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics)		BLOT WJ, 1991, JAMA-J AM MED ASSOC, V265, P1287, DOI 10.1001/jama.265.10.1287; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; BROWN LM, 1994, CANCER CAUSE CONTROL, V5, P333, DOI 10.1007/BF01804984; BROWN LM, 1995, J NATL CANCER I, V87, P104, DOI 10.1093/jnci/87.2.104; COLINJONES DG, 1991, Q J MED, V78, P13; ELDER JB, 1979, LANCET, V1, P1005, DOI 10.1016/S0140-6736(79)92757-0; GAREWAL HS, 1989, PREV MED, V18, P749, DOI 10.1016/0091-7435(89)90046-7; HAMILTON SR, 1988, HUM PATHOL, V19, P942, DOI 10.1016/S0046-8177(88)80010-8; HANSSON LE, 1993, INT J CANCER, V54, P402, DOI 10.1002/ijc.2910540309; Harrison S L, 1992, Eur J Cancer Prev, V1, P271, DOI 10.1097/00008469-199204000-00009; KABAT GC, 1993, CANCER CAUSE CONTROL, V4, P123, DOI 10.1007/BF00053153; LAVECCHIA C, 1992, NUTRITION, V8, P177; MACDONALD WC, 1987, CANCER, V60, P1094, DOI 10.1002/1097-0142(19870901)60:5<1094::AID-CNCR2820600529>3.0.CO;2-4; Moller H, 1992, Eur J Cancer Prev, V1, P159; MOLLER H, 1992, GUT, V33, P1166, DOI 10.1136/gut.33.9.1166; Powell J, 1992, Eur J Cancer Prev, V1, P265, DOI 10.1097/00008469-199204000-00008; REED PI, 1979, LANCET, V1, P1234; REID BJ, 1991, GASTROENTEROL CLIN N, V20, P817; Schumacher M C, 1990, Epidemiology, V1, P251, DOI 10.1097/00001648-199005000-00012; SPECHLER SJ, 1986, NEW ENGL J MED, V315, P362, DOI 10.1056/NEJM198608073150605; VAUGHAN TL, 1995, CANCER EPIDEM BIOMAR, V4, P85; VAUGHAN TL, 1992, RECENT ADV BIOL PREV; WANG HH, 1986, HUM PATHOL, V17, P482, DOI 10.1016/S0046-8177(86)80038-7; WANG HH, 1994, CANCER CAUSE CONTROL, V5, P573, DOI 10.1007/BF01831386; [No title captured]	25	291	297	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 9	1995	274	6					474	477		10.1001/jama.274.6.474	http://dx.doi.org/10.1001/jama.274.6.474			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM699	7629956				2022-12-24	WOS:A1995RM69900027
J	LEAN, MEJ; HAN, TS; MORRISON, CE				LEAN, MEJ; HAN, TS; MORRISON, CE			WAIST CIRCUMFERENCE AS A MEASURE FOR INDICATING NEED FOR WEIGHT MANAGEMENT	BRITISH MEDICAL JOURNAL			English	Article							BODY-FAT DISTRIBUTION; CARDIOVASCULAR-DISEASE; OBESE WOMEN; ADIPOSE-TISSUE; RISK-FACTORS; FOLLOW; PARTICIPANTS; CHOLESTEROL; OVERWEIGHT; REDUCTION	Objective-To test the hypothesis that a single measurement, waist circumference, might be used to identify people at health risk both from being overweight and from having a central fat distribution. Design-A community derived random sample of men and women and a second, validation sample. Setting-North Glasgow. Subjects-904 men and 1014 women (first sample); 86 men and 202 women (validation sample). Main outcome measures-Waist circumference, body mass index, waist:hip ratio. Results-Waist circumference greater than or equal to 94 cm for men and greater than or equal to 80 cm for women identified subjects with high body mass index (greater than or equal to 25 kg/m(2)) and those with lower body mass index but high waist:hip ratio (greater than or equal to 0.95 for men, greater than or equal to 0.80 women) with a sensitivity of > 96% and specificity > 97.5%. Waist circumference greater than or equal to 102 cm for men or greater than or equal to 88 cm for women identified subjects with body mass index greater than or equal to 30 and those with lower body mass index but high waist:hip ratio with a sensitivity of > 96% and specificity > 98%, with only about 2% of the sample being misclassified. Conclusions-Waist circumference could be used in health promotion programmes to identify individuals who should seek and be offered weight management. Men with waist circumference greater than or equal to 94 cm and women with waist circumference greater than or equal to 80 cm should gain no further weight; men with waist circumference greater than or equal to 102 cm and women with waist circumference greater than or equal to 88 cm should reduce their weight.	UNIV GLASGOW,DEPT PUBL HLTH,GLASGOW,LANARK,SCOTLAND	University of Glasgow	LEAN, MEJ (corresponding author), UNIV GLASGOW,ROYAL INFIRM,DEPT HUMAN NUTR,GLASGOW G31 2ER,LANARK,SCOTLAND.			Han, Thang/0000-0003-2570-0938				Bennett N, 1995, HLTH SURVEY ENGLAND; BJORNTORP P, 1987, AM J CLIN NUTR, V45, P1120, DOI 10.1093/ajcn/45.5.1120; CASIMIRRI F, 1989, ANN NUTR METAB, V33, P79, DOI 10.1159/000177524; CHAN JM, 1994, DIABETES CARE, V9, P961; DENBESTEN C, 1988, AM J CLIN NUTR, V47, P840, DOI 10.1093/ajcn/47.5.840; DENNIS KE, 1993, ARTERIOSCLER THROMB, V13, P1487, DOI 10.1161/01.ATV.13.10.1487; FLODMARK CE, 1994, ACTA PAEDIATR, V83, P941, DOI 10.1111/j.1651-2227.1994.tb13177.x; Gregory F., 1990, DIETARY NUTR SURVEY; HANSON P, 1988, RESOURCE MANUAL GUID; Higgins M, 1988, Acta Med Scand Suppl, V723, P23; HOUMARD JA, 1994, INT J OBESITY, V18, P243; KANALEY JA, 1993, AM J CLIN NUTR, V57, P20, DOI 10.1093/ajcn/57.1.20; KHOSLA T, 1967, BRIT J PREV SOC MED, V21, P122; LAPIDUS L, 1984, BMJ-BRIT MED J, V289, P1257, DOI 10.1136/bmj.289.6454.1257; LARSSON B, 1984, BRIT MED J, V288, P1401, DOI 10.1136/bmj.288.6428.1401; MUST A, 1992, NEW ENGL J MED, V327, P1350, DOI 10.1056/NEJM199211053271904; NORUSIS MJ, 1993, BASE SYSTEM USERS GU; POULIOT MC, 1994, AM J CARDIOL, V73, P460, DOI 10.1016/0002-9149(94)90676-9; Rimm E B, 1990, Epidemiology, V1, P466, DOI 10.1097/00001648-199011000-00009; SEIDELL JC, 1989, INFUSIONSTHERAPIE, V16, P276; SMITH GD, 1993, BMJ-BRIT MED J, V306, P1367, DOI 10.1136/bmj.306.6889.1367; SONNICHSEN AC, 1992, METABOLISM, V41, P1035, DOI 10.1016/0026-0495(92)90134-V; VANDERKOOY K, 1993, AM J CLIN NUTR, V58, P853, DOI 10.1093/ajcn/58.6.853; VANGAAL LF, 1990, BODY FAT DISTRIBUTIO; WING RR, 1992, AM J CLIN NUTR, V55, P1086, DOI 10.1093/ajcn/55.6.1086; YUDKIN JS, 1993, BMJ-BRIT MED J, V306, P1313, DOI 10.1136/bmj.306.6888.1313; 1992, SCOTLANDS HLTH CHALL; 1989, WHO UD EURICPNUT125; 1991, OBESITY OVERWEIGHT; 1994, NUTRITIONAL ASPECTS; 1991, CM1583	31	1080	1140	0	41	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 15	1995	311	6998					158	161		10.1136/bmj.311.6998.158	http://dx.doi.org/10.1136/bmj.311.6998.158			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK159	7613427	Green Published			2022-12-24	WOS:A1995RK15900021
J	GU, XN; SPITZER, NC				GU, XN; SPITZER, NC			DISTINCT ASPECTS OF NEURONAL DIFFERENTIATION ENCODED BY FREQUENCY OF SPONTANEOUS CA2+ TRANSIENTS	NATURE			English	Article							C-FOS TRANSCRIPTION; PROTEIN-KINASE-C; SPINAL NEURONS; ELECTRICAL-ACTIVITY; SIGNALING PATHWAYS; SENSORY NEURONS; CALCIUM; MIGRATION; CHANNELS; CULTURE	STIMULATION of transient increases in intracellular calcium (Ca-i(2+)) activates protein kinases(1-3), regulates transcription(4-9) and influences motility and morphology Developing neurons generate spontaneous Ca-i(2+) transients, but their role in directing neuronal differentiation and the way in which they encode information are unknown. Acre we image Ca2+ in spinal neurons throughout an extended period of early development, and find that two types of spontaneous events, spikes and waves, are expressed at distinct frequencies. Neuronal differentiation is altered when they are eliminated by preventing Ca2+ influx. Reimposing different frequency patterns of Ca2+ elevation demonstrates that natural spike activity is sufficient to promote normal neurotransmitter expression and channel maturation, whereas wave activity is sufficient to regulate neurite extension. Suppression of spontaneous Ca2+ elevations by BAPTA loaded intracellularly indicates that they are also necessary for differentiation. Ca2+ transients appear to encode information in their frequency, like action potentials, although they are 10(4) times longer in duration and less frequent, and implement an intrinsic development programme.	UNIV CALIF SAN DIEGO, CTR GENET MOLEC, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego	GU, XN (corresponding author), UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA.			Spitzer, Nicholas/0000-0002-3523-1103				BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BIXBY JL, 1984, DEV BIOL, V106, P89, DOI 10.1016/0012-1606(84)90065-4; BRAHA O, 1993, J NEUROSCI, V13, P1839; CLINE HT, 1991, NEURON, V6, P259, DOI 10.1016/0896-6273(91)90361-3; COHAN CS, 1986, SCIENCE, V232, P1638, DOI 10.1126/science.3715470; Colbran R J, 1990, Curr Top Cell Regul, V31, P181; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DESARMENIEN MG, 1991, NEURON, V7, P797, DOI 10.1016/0896-6273(91)90282-5; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; FATATIS A, 1992, GLIA, V5, P95, DOI 10.1002/glia.440050203; FIELDS RD, 1990, J NEUROSCI, V10, P2950; FLUCHER BE, 1993, CELL MOTIL CYTOSKEL, V25, P143, DOI 10.1002/cm.970250204; GHOSH A, 1994, SCIENCE, V263, P1618, DOI 10.1126/science.7907431; GU XN, 1994, J NEUROSCI, V14, P6325; HOLLIDAY J, 1991, NEURON, V7, P787, DOI 10.1016/0896-6273(91)90281-4; HOLLIDAY J, 1990, DEV BIOL, V141, P13, DOI 10.1016/0012-1606(90)90098-4; KOCSIS JD, 1994, J NEUROBIOL, V25, P252, DOI 10.1002/neu.480250306; KOMURO H, 1992, SCIENCE, V257, P806, DOI 10.1126/science.1323145; KOMURO H, 1993, SCIENCE, V260, P95, DOI 10.1126/science.8096653; LEREA LS, 1993, NEURON, V10, P31, DOI 10.1016/0896-6273(93)90239-N; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.biophys.20.1.153; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; POENIE M, 1985, NATURE, V315, P147, DOI 10.1038/315147a0; RINK TJ, 1989, TRENDS NEUROSCI, V12, P43, DOI 10.1016/0166-2236(89)90133-1; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SHENG HZ, 1993, J NEUROSCI RES, V35, P459, DOI 10.1002/jnr.490350502; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SPITZER NC, 1993, J COMP NEUROL, V337, P168, DOI 10.1002/cne.903370111; TURRIGIANO G, 1994, SCIENCE, V264, P974, DOI 10.1126/science.8178157; YUSTE R, 1992, SCIENCE, V257, P666, DOI 10.1126/science.1496379	30	462	469	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 29	1995	375	6534					784	787		10.1038/375784a0	http://dx.doi.org/10.1038/375784a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF989	7596410				2022-12-24	WOS:A1995RF98900077
J	TAFURI, A; ALFERINK, J; MOLLER, P; HAMMERLING, GJ; ARNOLD, B				TAFURI, A; ALFERINK, J; MOLLER, P; HAMMERLING, GJ; ARNOLD, B			T-CELL AWARENESS OF PATERNAL ALLOANTIGENS DURING PREGNANCY	SCIENCE			English	Article							DIFFERENTIAL EXPRESSION; ALPHA-CHAINS; MICE; TOLERANCE; RECEPTOR; PLACENTA; ANTIGEN; IMMUNE; GRAFT	During pregnancy a semiallogeneic fetus survives despite the presence of maternal T cells specific for paternally inherited histocompatibility antigens. A mouse transgenic for a T cell receptor recognizing the major histocompatibility (MHC) antigen H-2K(b) was used to follow the fate of T cells reactive to paternal alloantigens. In contrast to syngeneic and third-party allogeneic pregnancies, mice bearing a Kb-positive conceptus had reduced numbers of Kb-reactive T cells and accepted K-b-positive tumor grafts. T cell phenotype and responsiveness were restored after delivery. Thus, during pregnancy maternal T cells acquire a transient state of tolerance specific for paternal alloantigens.	DEUTSCH KREBSFORSCHUNGSZENTRUM,TUMOR IMMUNOL PROGRAM,D-69120 HEIDELBERG,GERMANY; UNIV HEIDELBERG,INST PATHOL,D-69120 HEIDELBERG,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg			Tafuri, Agostino/AAC-2186-2019	Tafuri, Agostino/0000-0001-7911-9263; alferink, judith/0000-0002-3251-6584				ABRAMSKY O, 1984, PROG CLIN BIOL RES, V12, P695; ALFERIINK B, 1995, INT IMMUNOL, V7, P331; CHAOUAT G, 1993, IMMUNOLOGY PREGNANCY, P1; CLARK DA, 1991, CRIT REV IMMUNOL, V11, P215; CLARK DA, 1990, J IMMUNOL, V144, P3008; CROSS JC, 1994, SCIENCE, V266, P1508, DOI 10.1126/science.7985020; DELASSUS S, 1994, J IMMUNOL, V152, P2411; FABRIS N, 1977, CLIN EXP IMMUNOL, V28, P306; GILL TJI, 1984, CRIT REV IMMUNOL, V5, P201; GUIMEZANES A, COMMUNICATION; HEATH WR, 1993, J EXP MED, V178, P1807, DOI 10.1084/jem.178.5.1807; HEDLEY ML, 1989, J IMMUNOL, V142, P4046; HERRERAGONZALEZ NE, 1993, DEV COMP IMMUNOL, V17, P1, DOI 10.1016/0145-305X(93)90011-E; HETHERINGTON CM, 1990, IMMUNOLOGY, V71, P449; LIMMER A, UNPUB; NICKLIN S, 1982, CLIN EXP IMMUNOL, V49, P135; OHEARN M, 1981, TRANSPLANTATION, V32, P389, DOI 10.1097/00007890-198111000-00009; PADOVAN E, 1993, SCIENCE, V262, P422, DOI 10.1126/science.8211163; PARVIN M, 1992, MICROBIOL IMMUNOL, V36, P77; PAVIA CS, 1979, J IMMUNOL, V123, P2194; PHILIP PJM, 1982, IMMUNOL LETT, V4, P175, DOI 10.1016/0165-2478(82)90032-3; PRIBYL TM, 1993, P NATL ACAD SCI USA, V90, P10695, DOI 10.1073/pnas.90.22.10695; RAGHUPATHY R, 1981, J IMMUNOL, V127, P2074; RAMSDELL F, 1992, SCIENCE, V257, P1130, DOI 10.1126/science.257.5073.1130; SAD S, 1995, IMMUNITY, V2, P271, DOI 10.1016/1074-7613(95)90051-9; SCHONRICH G, 1992, INT IMMUNOL, V4, P581, DOI 10.1093/intimm/4.5.581; SCHONRICH G, 1991, CELL, V65, P293, DOI 10.1016/0092-8674(91)90163-S; SCOTT B, 1989, NATURE, V338, P591, DOI 10.1038/338591a0; SIMMONS RL, 1962, ANN NY ACAD SCI, V99, P717, DOI 10.1111/j.1749-6632.1962.tb45356.x; VARNER MW, 1991, SEMIN PERINATOL, V15, P238; VOISIN GA, 1994, FOLIA BIOL-PRAGUE, V40, P505; WAITES GT, 1987, CLIN EXP IMMUNOL, V67, P467; WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D	33	443	473	0	14	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 27	1995	270	5236					630	633		10.1126/science.270.5236.630	http://dx.doi.org/10.1126/science.270.5236.630			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TB557	7570020				2022-12-24	WOS:A1995TB55700039
J	FRASER, CM; GOCAYNE, JD; WHITE, O; ADAMS, MD; CLAYTON, RA; FLEISCHMANN, RD; BULT, CJ; KERLAVAGE, AR; SUTTON, G; KELLEY, JM; FRITCHMAN, JL; WEIDMAN, JF; SMALL, KV; SANDUSKY, M; FUHRMANN, J; NGUYEN, D; UTTERBACK, TR; SAUDEK, DM; PHILLIPS, CA; MERRICK, JM; TOMB, JF; DOUGHERTY, BA; BOTT, KF; HU, PC; LUCIER, TS; PETERSON, SN; SMITH, HO; HUTCHISON, CA; VENTER, JC				FRASER, CM; GOCAYNE, JD; WHITE, O; ADAMS, MD; CLAYTON, RA; FLEISCHMANN, RD; BULT, CJ; KERLAVAGE, AR; SUTTON, G; KELLEY, JM; FRITCHMAN, JL; WEIDMAN, JF; SMALL, KV; SANDUSKY, M; FUHRMANN, J; NGUYEN, D; UTTERBACK, TR; SAUDEK, DM; PHILLIPS, CA; MERRICK, JM; TOMB, JF; DOUGHERTY, BA; BOTT, KF; HU, PC; LUCIER, TS; PETERSON, SN; SMITH, HO; HUTCHISON, CA; VENTER, JC			THE MINIMAL GENE COMPLEMENT OF MYCOPLASMA-GENITALIUM	SCIENCE			English	Article							TRANSFER RNA-SYNTHETASE; DNA POLYMERASE-III; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; AMINO-ACIDS; PROTEIN; GENOME; PNEUMONIAE; CAPRICOLUM; SEQUENCE	The complete nucleotide sequence (580,070 base pairs) of the Mycoplasma genitalium genome, the smallest known genome of any free-living organism, has been determined by whole-genome random sequencing and assembly. A total of only 470 predicted coding regions were identified that include genes required for DNA replication, transcription and translation, DNA repair, cellular transport, and energy metabolism. Comparison of this genome to that of Haemophilus influenzae suggests that differences in genome content are reflected as profound differences in physiology and metabolic capacity between these two organisms.	SUNY BUFFALO, DEPT MICROBIOL, BUFFALO, NY 14214 USA; JOHNS HOPKINS UNIV, SCH MED, BALTIMORE, MD 21205 USA; UNIV N CAROLINA, SCH MED, CHAPEL HILL, NC 27599 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Johns Hopkins University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	FRASER, CM (corresponding author), INST GENOM RES, 9712 MED CTR DR, ROCKVILLE, MD 20850 USA.			Fraser, Claire/0000-0003-1462-2428; Kerlavage, Anthony/0000-0002-3954-9653	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL019171] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI008998, R01AI033161, R01AI008998, R21AI008998] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL19171] Funding Source: Medline; NIAID NIH HHS [AI33161, AIO8998] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAILEY CC, 1994, J BACTERIOL, V176, P5814, DOI 10.1128/JB.176.18.5814-5819.1994; BASEMAN JB, 1988, J CLIN MICROBIOL, V26, P2266, DOI 10.1128/JCM.26.11.2266-2269.1988; BORK P, 1995, MOL MICROBIOL, V16, P955, DOI 10.1111/j.1365-2958.1995.tb02321.x; BORODOVSKY M, 1988, METHOD ENZYMOL, V164, P123; BRUTLAG DL, 1993, COMPUT CHEM, V17, P203, DOI 10.1016/0097-8485(93)85011-Z; COLLIER AM, 1992, ZENTRALBL BAKTERIO S, V20, P73; COLLIER DN, 1994, J BACTERIOL, V176, P4937, DOI 10.1128/jb.176.16.4937-4940.1994; COLMAN SD, 1990, MOL MICROBIOL, V4, P683, DOI 10.1111/j.1365-2958.1990.tb00638.x; DALLO SF, 1990, MICROB PATHOGENESIS, V8, P371, DOI 10.1016/0882-4010(90)90096-9; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; GILSON E, 1988, EMBO J, V7, P3971, DOI 10.1002/j.1460-2075.1988.tb03284.x; GUTHRIE B, 1990, J BACTERIOL, V172, P5555, DOI 10.1128/jb.172.10.5555-5562.1990; HAYFLICK L, 1965, TEX REP BIOL MED, VS 23, P285; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; HU PC, 1987, INFECT IMMUN, V55, P1126, DOI 10.1128/IAI.55.5.1126-1131.1987; INAMINE JM, 1989, GENE, V82, P259, DOI 10.1016/0378-1119(89)90051-6; JENSEN JS, 1993, GENITOURIN MED, V69, P265; KLEIN P, 1985, BIOCHIM BIOPHYS ACTA, V815, P468, DOI 10.1016/0005-2736(85)90375-X; KOMBERG A, 1992, DNA REPLICATION; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAPOINTE J, 1986, J BACTERIOL, V165, P88, DOI 10.1128/jb.165.1.88-93.1986; LUCIER TS, 1994, GENE, V150, P27, DOI 10.1016/0378-1119(94)90853-2; LUCIER TS, UNPUB; MAIDAK BL, 1994, NUCLEIC ACIDS RES, V22, P3485, DOI 10.1093/nar/22.17.3485; Maniloff Jack, 1992, P549; MARTIN N, 1976, J MOL BIOL, V101, P285, DOI 10.1016/0022-2836(76)90148-0; MARTIN NC, 1977, BIOCHEMISTRY-US, V16, P4672, DOI 10.1021/bi00640a022; MCGEOCH DJ, 1985, VIRUS RES, V3, P271, DOI 10.1016/0168-1702(85)90051-6; MIYATA M, 1993, NUCLEIC ACIDS RES, V21, P4816, DOI 10.1093/nar/21.20.4816; OGASAWARA N, 1990, BACTERIAL CHROMOSOME, P287; OGASAWARA N, 1992, MOL MICROBIOL, V6, P629, DOI 10.1111/j.1365-2958.1992.tb01510.x; PATERSON SN, 1995, IN PRESS P NATL ACAD; PETERSON SN, 1995, J BACTERIOL, V177, P3199, DOI 10.1128/jb.177.11.3199-3204.1995; PETERSON SN, 1993, J BACTERIOL, V175, P7918, DOI 10.1128/JB.175.24.7918-7930.1993; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; PROULX M, 1983, J BIOL CHEM, V258, P753; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; RAZIN S, 1985, MICROBIOL REV, V49, P419, DOI 10.1128/MMBR.49.4.419-455.1985; RILEY M, 1993, MICROBIOL REV, V57, P862, DOI 10.1128/MMBR.57.4.862-952.1993; ROGERS MJ, 1985, P NATL ACAD SCI USA, V82, P1160, DOI 10.1073/pnas.82.4.1160; ROGERS MJ, 1984, ISRAEL J MED SCI, V20, P768; SANJANWALA B, 1989, P NATL ACAD SCI USA, V86, P4421, DOI 10.1073/pnas.86.12.4421; SANJANWALA B, 1991, MOL GEN GENET, V226, P467, DOI 10.1007/BF00260660; SAWADA M, 1981, MOL GEN GENET, V182, P502, DOI 10.1007/BF00293942; SCHON A, 1988, BIOCHIMIE, V70, P391, DOI 10.1016/0300-9084(88)90212-X; SIMONEAU P, 1993, NUCLEIC ACIDS RES, V21, P4967, DOI 10.1093/nar/21.21.4967; STRAUCH MA, 1988, J BACTERIOL, V170, P916, DOI 10.1128/jb.170.2.916-920.1988; SU CJ, 1990, J BACTERIOL, V172, P4705, DOI 10.1128/jb.172.8.4705-4707.1990; Sutton G. G., 1995, GENOME SCI TECHNOL, V1, P9, DOI [10.1089/gst.1995.1.9, DOI 10.1089/GST.1995.1.9]; TAYLORROBINSON D, 1994, LANCET, V13, P1066; TULLY JG, 1983, INT J SYST BACTERIOL, V33, P387, DOI 10.1099/00207713-33-2-387; UTTERBACK TR, 1995, GENOME SCI TECHNOL, V1, P1; VANDIJL JM, 1992, EMBO J, V11, P2819, DOI 10.1002/j.1460-2075.1992.tb05349.x; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WATERMAN MS, 1988, METHOD ENZYMOL, V164, P765; WEISBURG WG, 1989, J BACTERIOL, V171, P6455, DOI 10.1128/jb.171.12.6455-6467.1989; WILCOX M, 1969, EUR J BIOCHEM, V11, P405, DOI 10.1111/j.1432-1033.1969.tb00788.x; ZHU PP, 1994, PROTEIN SCI, V3, P2115, DOI 10.1002/pro.5560031125; ZHU PP, 1993, J BIOL CHEM, V268, P26531	59	2001	2615	3	165	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 20	1995	270	5235					397	403		10.1126/science.270.5235.397	http://dx.doi.org/10.1126/science.270.5235.397			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA374	7569993				2022-12-24	WOS:A1995TA37400030
J	HIBBS, ML; TARLINTON, DM; ARMES, J; GRAIL, D; HODGSON, G; MAGLITTO, R; STACKER, SA; DUNN, ARR				HIBBS, ML; TARLINTON, DM; ARMES, J; GRAIL, D; HODGSON, G; MAGLITTO, R; STACKER, SA; DUNN, ARR			MULTIPLE DEFECTS IN THE IMMUNE-SYSTEM OF LYN-DEFICIENT MICE, CULMINATING IN AUTOIMMUNE-DISEASE	CELL			English	Article							PROTEIN TYROSINE PHOSPHORYLATION; AFFINITY IGE RECEPTOR; CELL ANTIGEN RECEPTOR; LYMPHOCYTES-B; SRC FAMILY; KINASES; IMMUNOGLOBULIN; STIMULATION; ASSOCIATION; ALPHA	Mice homozygous for a disruption at the Lyn locus display abnormalities associated with the B lymphocyte lineage and in mast cell function, Despite reduced numbers of recirculating B lymphocytes, Lyn(-/-) mice are immunoglobulin M (IgM) hyperglobulinemic. Immune responses to T-independent and T-dependent antigens are affected. Lyn(-/-) mice fail to mediate an allergic response to IgE cross-linking, indicating that activation of LYN plays an indispensable role in Fc epsilon RI signaling. Lyn(-/-) mice have circulating autoreactive antibodies, and many show severe glomerulonephritis caused by the deposition of IgG immune complexes in the kidney, a pathology reminiscent of systemic lupus erythematosus. Collectively, these results implicate LYN as having an indispensable role in immunoglobulin-mediated signaling, particularly in establishing B cell tolerance.	ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,MELBOURNE,VIC 3050,AUSTRALIA; AUSTIN HOSP,DEPT ANAT PATHOL,HEIDELBERG,VIC 3084,AUSTRALIA	Royal Melbourne Hospital; Walter & Eliza Hall Institute; Austin Research Institute; Florey Institute of Neuroscience & Mental Health	HIBBS, ML (corresponding author), ROYAL MELBOURNE HOSP,LUDWIG INST CANC RES,MELBOURNE TUMOUR BIOL BRANCH,MELBOURNE,VIC 3050,AUSTRALIA.		Hibbs, Margaret L/D-7013-2011; Armes, Jane/D-6396-2012	Hibbs, Margaret L/0000-0002-3751-6751; Armes, Jane/0000-0002-2215-0347; Stacker, Steven/0000-0003-4096-9273; Tarlinton, David/0000-0001-9928-686X	PHS HHS [A1-03958] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALLEN D, 1987, IMMUNOL REV, V96, P5, DOI 10.1111/j.1600-065X.1987.tb00506.x; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; BELMONT JW, 1995, TRENDS GENET, V11, P112, DOI 10.1016/S0168-9525(00)89012-5; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; COFFMAN RL, 1993, ADV IMMUNOL, V54, P229, DOI 10.1016/S0065-2776(08)60536-2; CORCORAN LM, 1994, IMMUNITY, V1, P635, DOI 10.1016/1074-7613(94)90035-3; CORCORAN LM, 1993, GENE DEV, V7, P570, DOI 10.1101/gad.7.4.570; COREY SJ, 1994, P NATL ACAD SCI USA, V91, P4683, DOI 10.1073/pnas.91.11.4683; DOMBROWICZ D, 1993, CELL, V75, P969, DOI 10.1016/0092-8674(93)90540-7; DRAKE CG, 1992, CURR OPIN IMMUNOL, V4, P733, DOI 10.1016/0952-7915(92)90054-I; EISEMAN E, 1992, NATURE, V355, P78; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; GOLD MR, 1991, P NATL ACAD SCI USA, V88, P3436, DOI 10.1073/pnas.88.8.3436; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; HANDYSIDE AH, 1989, ROUX ARCH DEV BIOL, V198, P8; HAYAKAWA K, 1983, J EXP MED, V157, P202, DOI 10.1084/jem.157.1.202; HIBBS ML, 1995, GENE, V156, P175, DOI 10.1016/0378-1119(95)00022-X; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; LALOR PA, 1992, EUR J IMMUNOL, V22, P3001, DOI 10.1002/eji.1830221136; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; MANN GB, 1993, CELL, V73, P249, DOI 10.1016/0092-8674(93)90227-H; MOUNTZ J D, 1991, Current Opinion in Rheumatology, V3, P738, DOI 10.1097/00002281-199110000-00004; PLEIMAN CM, 1994, P NATL ACAD SCI USA, V91, P4268, DOI 10.1073/pnas.91.10.4268; PLEIMAN CM, 1994, IMMUNOL TODAY, V15, P393, DOI 10.1016/0167-5699(94)90267-4; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; REN CL, 1994, J EXP MED, V179, P673, DOI 10.1084/jem.179.2.673; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; SIDMAN CL, 1986, SCIENCE, V232, P1423, DOI 10.1126/science.3487115; SMITH KGC, 1994, IMMUNITY, V1, P803, DOI 10.1016/S1074-7613(94)80022-7; STANLEY E, 1991, MOL CELL BIOL, V11, P3399, DOI 10.1128/MCB.11.7.3399; STEFANOVA I, 1993, J BIOL CHEM, V268, P20725; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VARMUS HE, 1994, BLOOD, V83, P5; WECHSLER RJ, 1995, J IMMUNOL, V154, P3234; WERSHIL BK, 1987, J IMMUNOL, V139, P2605; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0	47	597	615	0	9	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 20	1995	83	2					301	311		10.1016/0092-8674(95)90171-X	http://dx.doi.org/10.1016/0092-8674(95)90171-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TA965	7585947	Bronze			2022-12-24	WOS:A1995TA96500016
J	SCHMIDT, R; WEST, J; LOVE, K; LENEHAN, Z; LISTER, C; THOMPSON, H; BOUCHEZ, D; DEAN, C				SCHMIDT, R; WEST, J; LOVE, K; LENEHAN, Z; LISTER, C; THOMPSON, H; BOUCHEZ, D; DEAN, C			PHYSICAL MAP AND ORGANIZATION OF ARABIDOPSIS-THALIANA CHROMOSOME-4	SCIENCE			English	Article							POLYMORPHISM LINKAGE MAP; REPEATED DNA-SEQUENCES; DISEASE RESISTANCE; YEAST; GENOME; GENES; LIBRARY; PROTEIN; CONSTRUCTION; CHROMATIN	A physical map of Arabidopsis thaliana chromosome 4 was constructed in yeast artificial chromosome clones and used to analyze the organization of the chromosome. Mapping of the nucleolar organizing region and the centromere integrated the physical and cytogenetic maps. Detailed comparison of physical with genetic distances showed that the frequency of recombination varied substantially, with relative hot and cold spots occurring along the whole chromosome. Eight repeated DNA sequence families were found in a complex arrangement across the centromeric region and nowhere else on the chromosome.	JOHN INNES CTR PLANT SCI RES, BIOTECHNOL & BIOL SCI RES COUNCIL, DEPT MOLEC GENET, NORWICH NR4 7UH, NORFOLK, ENGLAND; INRA, BIOL CELLULAIRE LAB, F-78026 VERSAILLES, FRANCE	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; INRAE; UDICE-French Research Universities; Universite Paris Saclay			Thompson, Helen L/E-7726-2017; Thompson, Henry J/K-7242-2012; Bouchez, David/B-7463-2019	Thompson, Helen L/0000-0003-4414-8018; Thompson, Henry J/0000-0002-3730-9322; Bouchez, David/0000-0003-3545-4339; Schmidt, Renate/0000-0002-8037-3581				AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; ALBINI SM, 1994, PLANT J, V5, P665, DOI 10.1111/j.1365-313X.1994.00665.x; BAUWENS S, 1991, CHROMOSOMA, V101, P41, DOI 10.1007/BF00360685; BELL CJ, 1994, GENOMICS, V19, P137, DOI 10.1006/geno.1994.1023; BENT AF, 1994, SCIENCE, V265, P1856, DOI 10.1126/science.8091210; CAMPELL BR, 1992, GENE, V112, P225, DOI 10.1016/0378-1119(92)90380-8; CHANG C, 1988, P NATL ACAD SCI USA, V85, P6856, DOI 10.1073/pnas.85.18.6856; COPENHAVER G, COMMUNICATION; COULSON A, 1988, NATURE, V335, P184, DOI 10.1038/335184a0; COUPLAND G, 1994, PLANT CELL, V6, P75; CREUSOT F, IN PRESS PLANT J; DEAN C, 1995, ANNU REV PLANT PHYS, V46, P395, DOI 10.1146/annurev.pp.46.060195.002143; ECKER J R, 1990, Methods (Orlando), V1, P186, DOI 10.1016/S1046-2023(05)80134-3; GANAL MW, 1988, MOL GEN GENET, V213, P262, DOI 10.1007/BF00339590; GOODMAN H, GT148 DEP MOL BIOL; GRILL E, 1991, MOL GEN GENET, V226, P484, DOI 10.1007/BF00260662; HAAF T, 1992, CELL, V70, P681, DOI 10.1016/0092-8674(92)90436-G; HESLOPHARRISON JS, 1991, J CELL SCI, V100, P15; HORN MA, 1994, BBA-PROTEIN STRUCT M, V1208, P65, DOI 10.1016/0167-4838(94)90160-0; HUBEL A, 1994, PLANT MOL BIOL, V26, P353, DOI 10.1007/BF00039545; JOFUKU KD, 1994, PLANT CELL, V6, P1211, DOI 10.1105/tpc.6.9.1211; KEITH B, 1991, P NATL ACAD SCI USA, V88, P8821, DOI 10.1073/pnas.88.19.8821; KIEDROWSKI S, 1992, EMBO J, V11, P4677, DOI 10.1002/j.1460-2075.1992.tb05572.x; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; KORFHAGE U, 1994, PLANT CELL, V6, P695, DOI 10.1105/tpc.6.5.695; Kosambi D. D., 1944, ANN EUGENICS, V12, P172; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; LAST RL, 1991, PLANT CELL, V3, P345, DOI 10.1105/tpc.3.4.345; LEPINIEC L, 1995, FEBS LETT, V364, P103, DOI 10.1016/0014-5793(95)00335-7; LISTER C, 1993, PLANT J, V4, P745, DOI 10.1046/j.1365-313X.1993.04040745.x; LISTER C, UNPUB; Lui Y., UNPUB; MALUSZYNSKA J, 1991, PLANT J, V1, P159, DOI 10.1111/j.1365-313X.1991.00159.x; MARTINEZZAPATER JM, 1986, MOL GEN GENET, V204, P417, DOI 10.1007/BF00331018; MCGRATH JM, 1993, THEOR APPL GENET, V86, P880, DOI 10.1007/BF00212616; Meyerowitz E. M., 1992, Methods in Arabidopsis research., P100; MEYEROWITZ EM, 1994, ARABIDOPSIS; MOORE G, 1991, GENOMICS, V10, P461, DOI 10.1016/0888-7543(91)90333-A; MURPHY TD, 1995, CELL, V82, P599, DOI 10.1016/0092-8674(95)90032-2; NAM HG, 1989, PLANT CELL, V1, P699, DOI 10.1105/tpc.1.7.699; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; PALME K, 1992, PLANT CELL, V4, P193, DOI 10.1105/tpc.4.2.193; PARKER JE, 1993, PLANT J, V4, P821, DOI 10.1046/j.1365-313X.1993.04050821.x; PEPPER A, 1994, CELL, V78, P109, DOI 10.1016/0092-8674(94)90577-0; POLIZZI C, 1991, J CELL BIOL, V112, P191, DOI 10.1083/jcb.112.2.191; PRUITT RE, 1986, J MOL BIOL, V187, P169, DOI 10.1016/0022-2836(86)90226-3; QUAEDVLIEG N, 1995, PLANT CELL, V7, P117, DOI 10.1105/tpc.7.1.117; SCHMIDT R, 1992, AUST J PLANT PHYSIOL, V19, P341, DOI 10.1071/PP9920341; SCHMIDT R, 1994, PLANT J, V5, P735, DOI 10.1111/j.1365-313X.1994.00735.x; SCHMIDT R, UNPUB; Schweizer D, 1987, ARABID INF SERV, V25, P27; SPRINGER PS, 1995, SCIENCE, V268, P877, DOI 10.1126/science.7754372; TANKSLEY SD, 1992, GENETICS, V132, P1141; THOMPSON H, UNPUB; TOURMENTE S, 1994, NUCLEIC ACIDS RES, V22, P3317, DOI 10.1093/nar/22.16.3317; VANLIJSEBETTENS M, 1994, EMBO J, V13, P3378, DOI 10.1002/j.1460-2075.1994.tb06640.x; VONSCHAEWEN A, 1990, EMBO J, V9, P3033, DOI 10.1002/j.1460-2075.1990.tb07499.x; WALKER M, PLM117 U CAMBR DEP P; WARD ER, 1990, PLANT MOL BIOL, V14, P561, DOI 10.1007/BF00027501; WEI N, 1994, CELL, V78, P117, DOI 10.1016/0092-8674(94)90578-9	60	175	188	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 20	1995	270	5235					480	483		10.1126/science.270.5235.480	http://dx.doi.org/10.1126/science.270.5235.480			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA374	7570002				2022-12-24	WOS:A1995TA37400044
J	ERDELYI, M; MICHON, AM; GUICHET, A; GLOTZER, JB; EPHRUSSI, A				ERDELYI, M; MICHON, AM; GUICHET, A; GLOTZER, JB; EPHRUSSI, A			REQUIREMENT FOR DROSOPHILA CYTOPLASMIC TROPOMYOSIN IN OSKAR MESSENGER-RNA LOCALIZATION	NATURE			English	Article							MATERNAL MESSENGER-RNA; XENOPUS OOCYTES; CELL-FORMATION; GENE; MELANOGASTER; MICROTUBULES; ENCODES; DIFFERENTIATION; MICROFILAMENTS; PATTERN	THE localization of oskar (osk) RNA to the posterior pole of the developing fruit fly (Drosophila) oocyte induces the assembly of pole plasm, causing development of tbe abdomen and germ line(1,2). Failure to localize oskar RNA results in embryos that lack abdomen and germ cells. Conversely, mis-targeting of oskar RNA to the anterior of the oocyte causes formation of ectopic abdomen and germ cells at the anterior pole(3). Maternal mutants that have reduced pole plasm activity produce sterile adults with normal abdominal development, suggesting that germ cells are more sensitive than abdomen to defects in pole plasm assembly(4). Thus mutations in genes that reduce oskar RNA localization or activity can be recovered as viable sterile adults. In a screen for mutants defective in germ cell formation, we isolated nine alleles of the tropomyosin II gene(5). Here we show that mutations in tropomyosin II (TmII) virtually abolish oskar RNA localization to the posterior pole, suggesting an involvement of the actin network in oskar RNA localization.	EUROPEAN MOLEC BIOL LAB,D-69117 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Ephrussi, Anne/AAG-4075-2020; Ephrussi, Anne/ABD-4393-2021	Ephrussi, Anne/0000-0002-5061-4620				BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; CHOU TB, 1993, DEVELOPMENT, V119, P1359; CLARK I, 1994, CURR BIOL, V4, P289, DOI 10.1016/S0960-9822(00)00068-3; COOLEY L, 1994, SCIENCE, V266, P590, DOI 10.1126/science.7939713; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; GUTZEIT H, 1986, ROUX ARCH DEV BIOL, V195, P173, DOI 10.1007/BF02439435; HALES KH, 1994, DEV BIOL, V165, P639, DOI 10.1006/dbio.1994.1282; HANKE PD, 1987, J BIOL CHEM, V262, P17370; HANKE PD, 1988, MOL CELL BIOL, V8, P3591, DOI 10.1128/MCB.8.9.3591; KARLIK CC, 1986, MOL CELL BIOL, V6, P1965, DOI 10.1128/MCB.6.6.1965; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; KUZNETSOV SA, 1992, NATURE, V356, P722, DOI 10.1038/356722a0; LANGFORD GM, 1995, CURR OPIN CELL BIOL, V7, P82, DOI 10.1016/0955-0674(95)80048-4; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LI MG, 1994, J CELL BIOL, V126, P1475, DOI 10.1083/jcb.126.6.1475; NEUMANSILBERBER.FS, 1993, CELL, V75, P165; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; PITTENGER MF, 1994, CURR OPIN CELL BIOL, V6, P96, DOI 10.1016/0955-0674(94)90122-8; POKRYWKA NJ, 1994, DEV BIOL, V166, P210, DOI 10.1006/dbio.1994.1308; POKRYWKA NJ, 1995, DEV BIOL, V167, P363, DOI 10.1006/dbio.1995.1030; PONDEL MD, 1988, P NATL ACAD SCI USA, V85, P7612, DOI 10.1073/pnas.85.20.7612; SQUIRE JM, 1983, TRENDS NEUROL SCI, V66, P409; STELZER EHK, 1989, SCANNING IMAGINGS, V1028, P146; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; SUNDELL CL, 1991, SCIENCE, V253, P1275, DOI 10.1126/science.1891715; THEURKAUF WE, 1993, DEVELOPMENT, V118, P1169, DOI 10.1016/0168-9525(93)90134-4; WIESCHAUS E, 1979, DEV BIOL, V68, P29, DOI 10.1016/0012-1606(79)90241-0; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9; YISRAELI JK, 1990, DEVELOPMENT, V108, P289	31	183	184	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 12	1995	377	6549					524	527		10.1038/377524a0	http://dx.doi.org/10.1038/377524a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ336	7566149				2022-12-24	WOS:A1995RZ33600061
J	STEPHENS, TW; BASINSKI, M; BRISTOW, PK; BUEVALLESKEY, JM; BURGETT, SG; CRAFT, L; HALE, J; HOFFMANN, J; HSIUNG, HM; KRIAUCIUNAS, A; MACKELLAR, W; ROSTECK, PR; SCHONER, B; SMITH, D; TINSLEY, FC; ZHANG, XY; HEIMAN, M				STEPHENS, TW; BASINSKI, M; BRISTOW, PK; BUEVALLESKEY, JM; BURGETT, SG; CRAFT, L; HALE, J; HOFFMANN, J; HSIUNG, HM; KRIAUCIUNAS, A; MACKELLAR, W; ROSTECK, PR; SCHONER, B; SMITH, D; TINSLEY, FC; ZHANG, XY; HEIMAN, M			THE ROLE OF NEUROPEPTIDE-Y IN THE ANTIOBESITY ACTION OF THE OBESE GENE-PRODUCT	NATURE			English	Article							AGENT; RATS	RECENTLY Zhang et al.(1) cloned a gene that is expressed only in adipose tissue of tbe mouse. The obese phenotype of the ob/ob mouse is linked to a mutation in the obese gene that results in expression of a truncated inactive protein. Human and rat homologues for this gene are known(1,2). Previous experiments(3,4) predict such a hormone to have a hypothalamic target. Hypothalamic neuropeptide Y stimulates food intake, decreases thermogenesis, and increases plasma insulin and corticosterone levels making it a potential target(5). Here we express the obese protein in Escherichia coli and find that it suppresses food intake and decreases body weight dramatically when administered to normal and ob/ob mice but not db/db (diabetic) mice, which are thought to lack the appropriate receptor. High-affinity binding was detected in the rat hypothalamus. One mechanism by which this protein regulated food intake and metabolism was inhibition of neuropeptide-Y synthesis and release.	ELI LILLY & CO,LILLY RES LABS,DIV TECHNOL CORE,INDIANAPOLIS,IN 46285	Eli Lilly	STEPHENS, TW (corresponding author), ELI LILLY & CO,LILLY RES LABS,DIV ENDOCRINE RES,INDIANAPOLIS,IN 46285, USA.							BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; COLEMAN DL, 1973, DIABETOLOGIA, V9, P294, DOI 10.1007/BF01221857; CORDER R, 1988, LIFE SCI, V43, P1879, DOI 10.1016/S0024-3205(88)80005-5; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HULSEY MG, 1992, PHYSIOL BEHAV, V52, P1141, DOI 10.1016/0031-9384(92)90473-F; KARAKASH C, 1977, AM J PHYSIOL, V232, pE286, DOI 10.1152/ajpendo.1977.232.3.E286; MURAKAMI T, 1995, BIOCHEM BIOPH RES CO, V209, P944, DOI 10.1006/bbrc.1995.1589; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; WILDING JPH, 1993, ENDOCRINOLOGY, V132, P1939, DOI 10.1210/en.132.5.1939; ZARJEVSKI N, 1993, ENDOCRINOLOGY, V133, P1753, DOI 10.1210/en.133.4.1753; [No title captured]	12	1419	1468	2	58	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 12	1995	377	6549					530	532		10.1038/377530a0	http://dx.doi.org/10.1038/377530a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ336	7566151				2022-12-24	WOS:A1995RZ33600063
J	GRIFFITH, LL; SHOCK, EL				GRIFFITH, LL; SHOCK, EL			A GEOCHEMICAL MODEL FOR THE FORMATION OF HYDROTHERMAL CARBONATES ON MARS	NATURE			English	Article							ICELAND; ORIGIN; REYKJANES; DEPOSITS; SYSTEMS	IT IS often argued(1-3) that substantially more carbon dioxide and water were degassed from the martian interior that can be found at present in the atmosphere, polar caps and regolith. Calculations have shown that atmospheric escape cannot account for all of the missing volatiles(4). Suggestions that carbon dioxide is stored as marine or lacustrine deposits(5), are challenged by Earth-based and spacecraft remote-sensing data(6,7). Moreover, recent modelling of the martian atmosphere suggests that rainfall or open bodies of water are in any case unlikely to have persisted for extended periods of time(8,9). Hydrothermal carbonates therefore provide a possible solution to this dilemma. Using an accessible terrestrial system (Iceland) as a guide to the underlying processes, and a host rock composition inferred from the least-altered martian meteorite(10), we present a geochemical model for the formation of carbonates in possible martian hydrothermal systems. Our results suggest that an extensive reservoir of carbonate minerals--equivalent to an atmospheric pressure of carbon dioxide of at least one bar--could have been sequestered beneath the surface by widespread hydrothermal activity in the martian past.			GRIFFITH, LL (corresponding author), WASHINGTON UNIV,MCDONNELL CTR SPACE SCI,DEPT EARTH & PLANETARY SCI,CAMPUS BOX 1169,ST LOUIS,MO 63130, USA.			Shock, Everett/0000-0002-4283-0163				ARNORSSON S, 1983, GEOCHIM COSMOCHIM AC, V47, P547, DOI 10.1016/0016-7037(83)90277-6; BLANEY DL, 1990, J GEOPHYS RES, V94, P10159; CARMICHAEL ISE, 1964, J PETROL, V5, P435, DOI 10.1093/petrology/5.3.435; CARR MH, 1986, ICARUS, V68, P187, DOI 10.1016/0019-1035(86)90019-9; EXLEY RA, 1982, J GEOPHYS RES, V87, P6547, DOI 10.1029/JB087iB08p06547; Fanale F.P., 1992, MARS, P1135; HABERLE RM, 1994, ICARUS, V109, P102, DOI 10.1006/icar.1994.1079; Helgeson HC, 1979, GEOCHEMISTRY HYDROTH, P568; JAKOSKY BM, 1994, ICARUS, V111, P271, DOI 10.1006/icar.1994.1145; JULL AJT, 1995, METEORITICS, V30, P311, DOI 10.1111/j.1945-5100.1995.tb01129.x; KASTING JF, 1991, ICARUS, V94, P1, DOI 10.1016/0019-1035(91)90137-I; LONKER SW, 1993, AM J SCI, V293, P605, DOI 10.2475/ajs.293.7.605; MEHEGAN JM, 1982, J GEOPHYS RES, V87, P6511, DOI 10.1029/JB087iB08p06511; MITTLEFEHLDT DW, 1994, METEORITICS, V29, P214, DOI 10.1111/j.1945-5100.1994.tb00673.x; NEDELL SS, 1987, ICARUS, V70, P409, DOI 10.1016/0019-1035(87)90086-8; NEWSOM HE, 1980, ICARUS, V44, P207, DOI 10.1016/0019-1035(80)90066-4; PALMASON G, 1974, ANNU REV EARTH PL SC, V2, P25, DOI 10.1146/annurev.ea.02.050174.000325; POLLACK JB, 1990, J GEOPHYS RES-SOLID, V95, P14595, DOI 10.1029/JB095iB09p14595; ROMANEK CS, 1994, NATURE, V372, P655, DOI 10.1038/372655a0; SHOCK EL, 1992, ORIGINS LIFE EVOL B, V22, P67, DOI 10.1007/BF01808019; Squyres S. W., 1992, MARS, P523; STOLPER E, 1979, GEOCHIM COSMOCHIM AC, V43, P1475, DOI 10.1016/0016-7037(79)90142-X; SVEINBJORNSDOTT.AE, 1986, CONTRIB MINERAL PET, V94, P99; TREIMAN AH, 1995, METEORITICS, V30, P294, DOI 10.1111/j.1945-5100.1995.tb01127.x; VIERECK LG, 1982, J GEOPHYS RES, V87, P6459, DOI 10.1029/JB087iB08p06459; WALTER MR, 1993, ICARUS, V101, P129, DOI 10.1006/icar.1993.1011; WOLERY TJ, 1986, UCRLMA110662 LAWR LI	27	59	60	0	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 5	1995	377	6548					406	408		10.1038/377406a0	http://dx.doi.org/10.1038/377406a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY190	7566116				2022-12-24	WOS:A1995RY19000041
J	HUA, J; CHANG, C; SUN, Q; MEYEROWITZ, EM				HUA, J; CHANG, C; SUN, Q; MEYEROWITZ, EM			ETHYLENE INSENSITIVITY CONFERRED BY ARABIDOPSIS ERS GENE	SCIENCE			English	Article							2-COMPONENT REGULATORS; PLANT TRANSFORMATION; SIGNAL-TRANSDUCTION; THALIANA; PATHWAY	ERS (ethylene response sensor), a gene in the Arabidopsis thaliana ethylene hormone-response pathway, was uncovered by cross-hybridization with the Arabidopsis ETR1 gene. The deduced ERS protein has sequence similarity with the amino-terminal domain and putative histidine protein kinase domain of ETR1, but it does not have a receiver domain as found in ETR1. A missense mutation identical to the dominant etr1-4 mutation was introduced into the ERS gene. The altered ERS gene conferred dominant ethylene insensitivity to wild-type Arabidopsis. Double-mutant analysis indicates that ERS acts upstream of the CTR1 protein kinase gene in the ethylene-response pathway.	CALTECH,DIV BIOL,PASADENA,CA 91125	California Institute of Technology			Meyerowitz, Elliot M/A-7118-2009					Abeles F, 1992, ETHYLENE PLANT BIOL; BLEECKER AB, 1988, SCIENCE, V241, P1086, DOI 10.1126/science.241.4869.1086; CHANG C, 1988, P NATL ACAD SCI USA, V85, P6856, DOI 10.1073/pnas.85.18.6856; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; FRALEY RT, 1985, BIO-TECHNOL, V3, P629, DOI 10.1038/nbt0785-629; FUNKE G. L., 1938, BIOLOGISCH JAARBOEK, V5, P335; GUZMAN P, 1990, PLANT CELL, V2, P513, DOI 10.1105/tpc.2.6.513; HARPHAM NVJ, 1991, ANN BOT-LONDON, V68, P55, DOI 10.1093/oxfordjournals.aob.a088218; HUA J, UNPUB; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MARTON L, 1991, PLANT CELL REP, V10, P235, DOI 10.1007/BF00232565; MCBRIDE KE, 1990, PLANT MOL BIOL, V14, P269, DOI 10.1007/BF00018567; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; ROMAN G, 1995, GENETICS, V139, P1393; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; SWANSON RV, 1994, TRENDS BIOCHEM SCI, V19, P485, DOI 10.1016/0968-0004(94)90135-X; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; VAN DER STRAETEN D, 1993, PLANT PHYSIOL, V102, P401, DOI 10.1104/pp.102.2.401; VANANDEL OM, 1978, J EXP BOT, V29, P638; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N	22	457	496	1	54	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 22	1995	269	5231					1712	1714		10.1126/science.7569898	http://dx.doi.org/10.1126/science.7569898			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV948	7569898				2022-12-24	WOS:A1995RV94800035
J	ALPERS, A; LO, B				ALPERS, A; LO, B			PHYSICIAN-ASSISTED SUICIDE IN OREGON - A BOLD EXPERIMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PATIENT; LIFE; CARE		UNIV CALIF SAN FRANCISCO,ROBERT WOOD JOHNSON CLIN SCHOLARS PROGRAM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CTR AIDS PREVENT STUDIES,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DIV GEN INTERNAL MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	ALPERS, A (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,PROGRAM MED ETH,521 PARNASSUS AVE,ROOM C 126,SAN FRANCISCO,CA 94143, USA.				NIMH NIH HHS [MH42459] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANNAS GJ, 1993, NEW ENGL J MED, V328, P1573, DOI 10.1056/NEJM199305273282121; BEAUCHAMP TL, 1994, PRINCIPLES BIOMEDICA, P474; BELKIN L, 1993, NY TIMES MAGAZI 1114, P75; BELKIN L, 1993, NY TIMES MAGAZI 1114, P74; BELKIN L, 1993, NY TIMES MAGAZI 1114, P63; Belkin Lisa, 1993, N Y Times Mag, P48; BERNAT JL, 1993, ARCH INTERN MED, V153, P2723, DOI 10.1001/archinte.153.24.2723; BLUMENTHAL SJ, 1988, MED CLIN N AM, V72, P937, DOI 10.1016/S0025-7125(16)30754-4; CHRISTAKIS N, 1993, J GEN INTERN MED, V9, P314; COHEN JS, 1994, NEW ENGL J MED, V331, P89, DOI 10.1056/NEJM199407143310206; CONWELL Y, 1991, NEW ENGL J MED, V325, P1100, DOI 10.1056/NEJM199110103251511; Doyle D, 1993, OXFORD TXB PALLIATIV; EDDY DM, 1994, JAMA-J AM MED ASSOC, V272, P179, DOI 10.1001/jama.272.3.179; LO B, 1995, RESOLVING ETHICAL DI, P168; MILES SH, 1994, JAMA-J AM MED ASSOC, V271, P1786, DOI 10.1001/jama.271.22.1786; MILLER FG, 1994, NEW ENGL J MED, V331, P119, DOI 10.1056/NEJM199407143310211; PIJNENBORG L, 1993, LANCET, V341, P1196, DOI 10.1016/0140-6736(93)91014-D; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; QUILL TE, 1992, NEW ENGL J MED, V327, P1380, DOI 10.1056/NEJM199211053271911; STEINBROOK R, 1992, NEW ENGL J MED, V326, P340, DOI 10.1056/NEJM199201303260511; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; WOLF SM, 1991, NEW ENGL J MED, V325, P1666, DOI 10.1056/NEJM199112053252334	22	55	55	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 9	1995	274	6					483	487		10.1001/jama.274.6.483	http://dx.doi.org/10.1001/jama.274.6.483			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM699	7629958				2022-12-24	WOS:A1995RM69900029
J	ASAI, A; FUKUHARA, S; LO, B				ASAI, A; FUKUHARA, S; LO, B			ATTITUDES OF JAPANESE AND JAPANESE-AMERICAN PHYSICIANS TOWARDS LIFE-SUSTAINING TREATMENT	LANCET			English	Article								Doctors in different countries have different approaches to bioethical problems. We studied how attitudes to life-sustaining treatment for terminally ill patients differ in Japan and the USA by administering a questionnaire to Japanese (136) and Japanese-American (77) physicians. In a series of clinical scenarios the questionnaire asked what life-sustaining interventions the doctors would recommend to a patient with metastatic gastric cancer. Most Japanese physicians would recommend blood for transfusions for gastrointestinal bleeding (74%) total parenteral nutrition for malnutrition (67%) and vasopressors for life-threatening hypotension (61%) when the patient did not know of his diagnosis and outlook. Significantly fewer Japanese physicians would want these interventions for themselves: 29% would want transfusion, 36% would want total parenteral nutrition, and 25% would want vasopressors. 36% of Japanese physicians would override the explicit request of a competent moribund cancer patient to withdraw all life-support. By contrast, among Japanese-American physicians only 42% would recommend blood transfusions, 33% total parenteral nutrition, and 34% vasopressors to a terminally ill cancer patient who did not know of his diagnosis or outlook. Cross-cultural studies in medical ethics can help physicians and the public in different countries to take a fresh took at accepted practices and the ethical reasons behind them.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT GEN INTERNAL MED,PROGRAM MED ETH,SAN FRANCISCO,CA 94143; UNIV TOKYO,FAC MED,DIV INTERNAL HLTH,TOKYO,JAPAN	University of California System; University of California San Francisco; University of Tokyo					NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER; NIMH NIH HHS [MH 42459] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; FRAMPTON MW, 1987, J GEN INTERN MED, V2, P394, DOI 10.1007/BF02596364; HADFIELD P, 1993, LANCET, V341, P1141, DOI 10.1016/0140-6736(93)93144-P; LO B, 1995, RESOLVING ETHICAL DI, P141; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; THOMSEN OO, 1993, LANCET, V341, P473, DOI 10.1016/0140-6736(93)90218-6; 1994, REPORT SURVEY JAPANE	7	81	83	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 5	1995	346	8971					356	359		10.1016/S0140-6736(95)92230-X	http://dx.doi.org/10.1016/S0140-6736(95)92230-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RM713	7623536				2022-12-24	WOS:A1995RM71300013
J	STEEL, KP				STEEL, KP			HAIR-CELL REGENERATION - CURE FOR DEAFNESS	LANCET			English	Editorial Material							ACOUSTIC TRAUMA; INNER-EAR				STEEL, KP (corresponding author), MRC, INST HEARING RES, UNIV PK, NOTTINGHAM, ENGLAND.							CORWIN JT, 1991, CIBA F SYMP, V160, P103; CORWIN JT, 1988, SCIENCE, V240, P1772, DOI 10.1126/science.3381100; FORGE A, 1993, SCIENCE, V259, P1616, DOI 10.1126/science.8456284; KESSLER J, 1995, CIBA F S, V196; LEFEBVRE PP, 1993, SCIENCE, V260, P692, DOI 10.1126/science.8480180; LEWIS J, 1991, CIBA F SYMP, V160, P25, DOI 10.4171/RMI/104; RUBEL EW, 1995, SCIENCE, V267, P701, DOI 10.1126/science.7839150; RYALS BM, 1988, SCIENCE, V240, P1774, DOI 10.1126/science.3381101; STAECKER H, 1995, SCIENCE, V267, P709, DOI 10.1126/science.267.5198.709; WARCHOL ME, 1993, SCIENCE, V259, P1619, DOI 10.1126/science.8456285	10	2	2	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 5	1995	346	8971					325	326		10.1016/S0140-6736(95)92220-2	http://dx.doi.org/10.1016/S0140-6736(95)92220-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM713	7623526				2022-12-24	WOS:A1995RM71300003
J	WATTERS, JK				WATTERS, JK			HIV TEST-RESULTS, PARTNER NOTIFICATION, AND PERSONAL CONDUCT	LANCET			English	Editorial Material							INFECTION		UNIV CALIF SAN FRANCISCO,SCH MED,DEPT FAMILY & COMMUNITY MED,SAN FRANCISCO,CA	University of California System; University of California San Francisco	WATTERS, JK (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94143, USA.							BAYER R, 1992, AM J PUBLIC HEALTH, V82, P1158, DOI 10.2105/AJPH.82.8.1158; GREEN J, 1995, LANCET, V345, P1508; HOFFMAN RE, 1995, J ACQ IMMUN DEF SYND, V8, P406; HOLTGRAVE DR, 1993, ARCH INTERN MED, V153, P1225, DOI 10.1001/archinte.153.10.1225; LANDIS SE, 1992, NEW ENGL J MED, V326, P101, DOI 10.1056/NEJM199201093260205; LEMP GF, 1994, JAMA-J AM MED ASSOC, V272, P449, DOI 10.1001/jama.272.6.449; MASON HRC, 1995, HEALTH PSYCHOL, V14, P6, DOI 10.1037/0278-6133.14.1.6; NORTH RL, 1993, NEW ENGL J MED, V329, P1194, DOI 10.1056/NEJM199310143291612; PAVIA AT, 1993, AM J PUBLIC HEALTH, V83, P1418, DOI 10.2105/AJPH.83.10.1418; SIGNORILE M, 1995, NY TIMES        0226, V15; TEMMERMAN M, 1995, LANCET, V345, P969, DOI 10.1016/S0140-6736(95)90707-6; 1995, MMWR-MORBID MORTAL W, V44, P202; 1994, HIV AIDS SURVEILLANC, V6, P17; 1995, MMWR-MORBID MORTAL W, V44, P401	14	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 5	1995	346	8971					326	327		10.1016/S0140-6736(95)92221-0	http://dx.doi.org/10.1016/S0140-6736(95)92221-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM713	7623527				2022-12-24	WOS:A1995RM71300004
J	STOYANOV, B; VOLINIA, S; HANCK, T; RUBIO, I; LOUBTCHENKOV, M; MALEK, D; STOYANOVA, S; VANHAESEBROECK, B; DHAND, R; NURNBERG, B; GIERSCHIK, P; SEEDORF, K; HSUAN, JJ; WATERFIELD, MD; WETZKER, R				STOYANOV, B; VOLINIA, S; HANCK, T; RUBIO, I; LOUBTCHENKOV, M; MALEK, D; STOYANOVA, S; VANHAESEBROECK, B; DHAND, R; NURNBERG, B; GIERSCHIK, P; SEEDORF, K; HSUAN, JJ; WATERFIELD, MD; WETZKER, R			CLONING AND CHARACTERIZATION OF A G-PROTEIN-ACTIVATED HUMAN PHOSPHOINOSITIDE-3 KINASE	SCIENCE			English	Article							PHOSPHOLIPASE-C ISOZYMES; PHOSPHATIDYLINOSITOL 3-KINASE; STIMULATED ACCUMULATION; BINDING-SITE; YEAST; CELLS	Phosphoinositide-3 kinase activity is implicated in diverse cellular responses triggered by mammalian cell surface receptors and in the regulation of protein sorting in yeast. Receptors with intrinsic and associated tyrosine kinase activity recruit heterodimeric phosphoinositide-3 kinases that consist of p110 catalytic subunits and p85 adaptor molecules containing Src homology 2 (SH2) domains. A phosphoinositide-3 kinase isotype, p110 gamma, was cloned and characterized. The p110 gamma enzyme was activated in vitro by both the alpha and beta gamma subunits of heterotrimeric guanosine triphosphate (GTP)-binding proteins (G proteins) and did not interact with p85. A potential pleckstrin homology domain is located near its amino terminus. The p110 gamma isotype may link signaling through G protein-coupled receptors to the generation of phosphoinositide second messengers phosphorylated in the D-3 position.	LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND; UCL, DEPT BIOCHEM & MOLEC BIOL, LONDON WCE 6BT, ENGLAND; UNIV JENA, FAC MED, MAX PLANCK RES UNIT GROWTH FACTOR SIGNAL TRANSDUC, D-07747 JENA, GERMANY; UNIV ULM, DEPT PHARMACOL & TOXICOL, D-89069 ULM, GERMANY; UNIV JENA, FAC MED, INST BIOCHEM 2, D-07747 JENA, GERMANY; FREE UNIV BERLIN, INST PHARMACOL, D-14195 BERLIN, GERMANY; MAX PLANCK INST BIOCHEM, DEPT MOLEC BIOL, D-82152 MARTINSRIED, GERMANY	Ludwig Institute for Cancer Research; University of London; University College London; Friedrich Schiller University of Jena; Max Planck Society; Ulm University; Friedrich Schiller University of Jena; Free University of Berlin; Max Planck Society			Volinia, Stefano/A-3029-2010; Volinia, Stefano/AAA-9264-2019; Wetzker, Reinhard/AAD-8713-2019; Hsuan, Justin/C-8825-2009	Volinia, Stefano/0000-0003-0910-3893; Volinia, Stefano/0000-0003-0910-3893; Hsuan, Justin/0000-0001-6083-7564; Nurnberg, Bernd/0000-0002-5995-6555				AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014-5793(85)80004-1; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; DAVIES AH, 1993, BIO-TECHNOL, V11, P933, DOI 10.1038/nbt0893-933; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; FLANAGAN CA, 1993, SCIENCE, V262, P1444, DOI 10.1126/science.8248783; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; GIERSCHIK P, 1994, METHOD ENZYMOL, V238, P181; GRUNERT S, 1994, EMBO J, V13, P3618, DOI 10.1002/j.1460-2075.1994.tb06669.x; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; HERMAN PK, 1991, CELL, V64, P425, DOI 10.1016/0092-8674(91)90650-N; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; KING WG, 1991, BIOCHEM J, V278, P475, DOI 10.1042/bj2780475; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; NURNBERG B, 1994, BIOCHEM J, V300, P387; OKADA T, 1994, J BIOL CHEM, V269, P3568; PANAYOTOU G, 1993, BIOESSAYS, V15, P171, DOI 10.1002/bies.950150305; RHEE SG, 1992, J BIOL CHEM, V267, P12393; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; STEPHENS L, 1993, EMBO J, V12, P2265, DOI 10.1002/j.1460-2075.1993.tb05880.x; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; THOMASON PA, 1994, J BIOL CHEM, V269, P16525; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; VOLINIA S, 1994, GENOMICS, V24, P472, DOI 10.1006/geno.1994.1655; VOLINIA S, IN PRESS EMBO J; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; YANO H, 1993, J BIOL CHEM, V268, P25846	32	633	675	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 4	1995	269	5224					690	693		10.1126/science.7624799	http://dx.doi.org/10.1126/science.7624799			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM702	7624799				2022-12-24	WOS:A1995RM70200034
J	SHIGEMATSU, I; MENDELSOHN, ML				SHIGEMATSU, I; MENDELSOHN, ML			THE RADIATION-EFFECTS-RESEARCH-FOUNDATION-OF-HIROSHIMA-AND-NAGASAKI - PAST, PRESENT, AND FUTURE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									RADIAT EFFECTS RES FDN,NAGASAKI,JAPAN	Radiation Effects Research Foundation - Japan	SHIGEMATSU, I (corresponding author), RADIAT EFFECTS RES FDN,MINAMI KU,5-2 HIJIYAMA PK,HIROSHIMA 732,JAPAN.							Neel J V, 1991, CHILDREN ATOMIC BOMB; PUTNAM FW, 1994, PERSPECT BIOL MED, V37, P515; ROESCH WE, 1987, US JAPAN REASSESSMEN, V1; SHIGEMATSU I, 1995, EFFECT A BOMB RAD HU; THOMPSON DE, 1994, RADIAT RES, V137, pS17, DOI 10.2307/3578892; YOSHIMOTO Y, 1994, LANCET, V344, P345, DOI 10.1016/S0140-6736(94)91389-7; 1995, R95096 US DEP EN	7	4	4	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 2	1995	274	5					425	426						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL416	7616640				2022-12-24	WOS:A1995RL41600031
J	WEINBERG, AD; KRIPALANI, S; MCCARTHY, PL; SCHULL, WJ				WEINBERG, AD; KRIPALANI, S; MCCARTHY, PL; SCHULL, WJ			CARING FOR SURVIVORS OF THE CHERNOBYL DISASTER - WHAT THE CLINICIAN SHOULD KNOW	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BONE-MARROW TRANSPLANTATION; A-BOMB SURVIVORS; POST-CHERNOBYL; NUCLEAR ACCIDENTS; INDUCED ABORTIONS; BIRTH-DEFECTS; CANCER; CONSEQUENCES; MORTALITY; RADIATION	The health status of approximately 1 million immigrants in the United States and Israel may have been adversely affected by radiation exposure as a result of the Chernobyl nuclear power plant disaster and cleanup efforts. Many of these immigrants suffer from significant psychological distress, fearing that they have a radiation-induced illness. Based on a review of the literature and our experience from the US National Chernobyl Registry Coordinating Center, we recommend that medical management of these immigrants include routine physical examination, with particular attention to the thyroid gland. Adults should receive regular cancer screening as well as routine blood chemistry tests, thyroid function tests, complete blood cell count, and urinalysis. Children should be examined regularly, with attention to the thyroid and overall body growth. It is reasonable for children to undergo thyroid studies, a complete blood cell count, or neuropsychiatric testing if there is clinical suspicion of a disorder. Given the long latency period for disease induction by radiation exposure, it is still too early to fully assess and draw conclusions concerning the possible health effects of the Chernobyl disaster, and long-term follow-up of all potentially affected individuals is important.	UNIV TEXAS, HLTH SCI CTR, CTR HUMAN GENET, SCH PUBL HLTH, HOUSTON, TX USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health	WEINBERG, AD (corresponding author), BAYLOR COLL MED, CTR CANC CONTROL RES, DEPT MED, 1 BAYLOR PLAZA, ST924, HOUSTON, TX 77030 USA.							ABELIN T, 1994, SOZ PRAVENTIV MED, V39, P189, DOI 10.1007/BF01309218; [Anonymous], 1990, HLTH EFFECTS EXPOSUR; [Anonymous], 1991, INT CHERNOBYL PROJEC; AUVINEN A, 1994, BRIT MED J, V309, P151, DOI 10.1136/bmj.309.6948.151; BARANOV A, 1989, NEW ENGL J MED, V321, P205, DOI 10.1056/NEJM198907273210401; Baverstock K F, 1993, World Health Stat Q, V46, P204; BEHAR A, 1990, Journal of Environmental Pathology Toxicology and Oncology, V10, P281; BERTOLLINI R, 1990, SCAND J WORK ENV HEA, V16, P96, DOI 10.5271/sjweh.1803; BOICE J, 1994, BRIT MED J, V309, P139, DOI 10.1136/bmj.309.6948.139; BOLSHOVA EV, 1993, ACTA ENDOCRINOL-COP, V129, P594, DOI 10.1530/acta.0.1290594; BONTE FJ, 1988, SEMIN NUCL MED, V18, P16, DOI 10.1016/S0001-2998(88)80016-3; BUTTURINI A, 1994, BRIT MED J, V309, P1299; CASTRONOVO FP, 1987, J NUCL MED, V28, P535; CHAMPLIN R, 1987, SEMIN HEMATOL, V24, P1; CHAMPLIN RE, 1988, ANN INTERN MED, V109, P730, DOI 10.7326/0003-4819-109-9-730; DERUIG WG, 1992, ANALYST, V117, P545, DOI 10.1039/an9921700545; DEWALS P, 1988, INT J EPIDEMIOL, V17, P230, DOI 10.1093/ije/17.1.230; EMERIT I, 1994, J CANCER RES CLIN, V120, P558, DOI 10.1007/BF01221035; ERICSON A, 1994, ENVIRON RES, V67, P149, DOI 10.1006/enrs.1994.1070; FURMANCHUK AW, 1992, HISTOPATHOLOGY, V21, P401, DOI 10.1111/j.1365-2559.1992.tb00423.x; GALE RP, 1987, JAMA-J AM MED ASSOC, V258, P625, DOI 10.1001/jama.258.5.625; GEIGER HJ, 1986, JAMA-J AM MED ASSOC, V256, P609, DOI 10.1001/jama.256.5.609; GINZBURG HM, 1993, PUBLIC HEALTH REP, V108, P184; GOLD SJ, 1994, AM JEWISH YB, V94, P3; GUVENC H, 1993, J EPIDEMIOL COMMUN H, V47, P40, DOI 10.1136/jech.47.1.40; HAEUSLER MCH, 1992, AM J OBSTET GYNECOL, V167, P1025, DOI 10.1016/S0002-9378(12)80032-9; HARJULEHTO T, 1989, BRIT MED J, V298, P995, DOI 10.1136/bmj.298.6679.995; HARJULEHTOMERVAALA T, 1992, MUTAT RES, V275, P81, DOI 10.1016/0921-8734(92)90011-D; HJALMARS U, 1994, BRIT MED J, V309, P154, DOI 10.1136/bmj.309.6948.154; HOLOWINSKY IZ, 1993, MENT RETARD, V31, P35; JENSEN RH, 1995, RADIAT RES, V141, P129, DOI 10.2307/3579040; KAMPMANN B, 1994, BRIT MED J, V309, P1299; KATO H, 1982, RADIAT RES, V91, P243, DOI 10.2307/3575833; KATO H, 1982, RADIAT RES, V90, P395, DOI 10.2307/3575716; KNUDSEN LB, 1991, BIOMED PHARMACOTHER, V45, P229, DOI 10.1016/0753-3322(91)90022-L; KUCHUK AA, 1994, TOXICOL LETT, V72, P213, DOI 10.1016/0378-4274(94)90031-0; LIE RT, 1992, AM J EPIDEMIOL, V136, P377, DOI 10.1093/oxfordjournals.aje.a116510; LIKHTAREV IA, 1995, NATURE, V375, P365, DOI 10.1038/375365a0; LIKHTAREV IA, 1994, RADIAT ENVIRON BIOPH, V33, P149, DOI 10.1007/BF01219338; LINNEMANN RE, 1987, JAMA-J AM MED ASSOC, V258, P637; LITTELL FH, 1993, HOLOCAUST GENOCIDE S, V7, P121, DOI 10.1093/hgs/7.1.121; Mettler FA, 1995, MED EFFECTS IONIZING; Mould R F, 1987, Br J Radiol, V60, pB29; Nazarov A. N., 1992, Problemy Endokrinologii, V38, P58; Neel J V, 1991, CHILDREN ATOMIC BOMB; NENOT JC, 1990, INT J RADIAT BIOL, V57, P1073, DOI 10.1080/09553009014551201; NIKIFOROV Y, 1994, CANCER-AM CANCER SOC, V74, P748, DOI 10.1002/1097-0142(19940715)74:2<748::AID-CNCR2820740231>3.0.CO;2-H; PARAZZINI F, 1988, BRIT MED J, V296, P136, DOI 10.1136/bmj.296.6615.136-a; PARKIN DM, 1993, EUR J CANCER, V29A, P87, DOI 10.1016/0959-8049(93)90582-Z; Perry A R, 1990, Radiol Technol, V61, P290; PETER RU, 1994, J AM ACAD DERMATOL, V30, P719, DOI 10.1016/S0190-9622(08)81501-0; PETRIDOU E, 1994, SCAND J SOC MED, V22, P127, DOI 10.1177/140349489402200208; RAYMOND L, 1991, SOZ PRAVENTIV MED, V36, P304, DOI 10.1007/BF01359163; RON E, 1992, NATURE, V360, P113, DOI 10.1038/360113a0; SHIMIZU Y, 1990, RADIAT RES, V121, P120, DOI 10.2307/3577495; SJOBERG L, 1987, MED ONCOL TUMOR PHAR, V4, P259; SOUCHKEVITCH G, 1995, PARTICIPANTS CLEAN U; SPERLING K, 1994, BRIT MED J, V309, P158, DOI 10.1136/bmj.309.6948.158; STOLL C, 1990, AM J MED GENET, P79; TAJTAKOVA M, 1993, HORM METAB RES, V25, P644, DOI 10.1055/s-2007-1002197; TRICHOPOULOS D, 1987, BRIT MED J, V295, P1100, DOI 10.1136/bmj.295.6606.1100; YARILIN AA, 1993, INT J RADIAT BIOL, V63, P519, DOI 10.1080/09553009314550681; 1977, 5 NAT COUNC RAD PROT; 1995, CANCER FACTS FIGURES; 1988, 37TH SESS ANN VIENN; 1985, 35TH SESS UNSCEAR NE; 1988, PAEDIATR PERINAT EP, V2, P253	67	19	19	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 2	1995	274	5					408	412		10.1001/jama.274.5.408	http://dx.doi.org/10.1001/jama.274.5.408			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL416	7616637				2022-12-24	WOS:A1995RL41600027
J	NIGHTINGALE, SL				NIGHTINGALE, SL			NEM RULE TO PROTECT IDENTITIES OF REPORTERS OF ADVERSE EVENTS AND PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 26	1995	274	4					292	292						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ898	7609246				2022-12-24	WOS:A1995RJ89800008
J	RIVERAPOMAR, R; LU, XG; PERRIMON, N; TAUBERT, H; JACKLE, H				RIVERAPOMAR, R; LU, XG; PERRIMON, N; TAUBERT, H; JACKLE, H			ACTIVATION OF POSTERIOR GAP DENE EXPRESSION IN THE DROSOPHILA BLASTODERM	NATURE			English	Article							CAUDAL GENE; PATTERN; PROTEIN; EMBRYO; GRADIENT; RNA; EMBRYOGENESIS; LOCALIZATION	THE process of body prepatterning during Drosophila blastoderm formation relies on the localized activities of zygotic segmentation genes, which are controlled by asymmetrically distributed maternal determinants(1,2). The anterior determinant bicoid, a homeodomain transcription factor(3,4), forms an anterior-to-posterior concentration gradient(1-4). It interacts with the maternal transcription factor hunchback(5) to activate the anterior zygotic patterning genes, including the central gap gene Kruppel (Kr)(6). In contrast, the posterior maternal system(1,2) does not provide such a decisive transcription factor, but rather prevents the repressor hunchback from acting in the posterior half so that the gap genes giant (gt) and knirps (kni) are activated by an as yet unknown transcription factor(2,7). Here we show that caudal, a conserved homeodomain protein that forms a posterior-to-anterior concentration gradient(8,9), and the anterior determinant bicoid cooperate to form a partly redundant activator system in the posterior region of the embryo.	HARVARD UNIV, SCH MED, DEPT GENET, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA; UNIV KANSAS, DEPT BIOCHEM, LAWRENCE, KS 66045 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; University of Kansas	RIVERAPOMAR, R (corresponding author), MAX PLANCK INST BIOPHYS CHEM, MOLEK ENTWICKLUNGSBIOL ABT, POSTFACH 2841, D-37018 GOTTINGEN, GERMANY.			Perrimon, Norbert/0000-0001-7542-472X				BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BLUMBERG B, 1991, SCIENCE, V253, P194, DOI 10.1126/science.1677215; DEAROLF CR, 1989, NATURE, V341, P340, DOI 10.1038/341340a0; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DUPREY P, 1988, GENE DEV, V2, P1647, DOI 10.1101/gad.2.12a.1647; EVANS TC, 1994, CELL, V77, P183, DOI 10.1016/0092-8674(94)90311-5; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; FRUMKIN A, 1991, DEVELOPMENT, V112, P207; HOCH M, 1991, EMBO J, V10, P2267, DOI 10.1002/j.1460-2075.1991.tb07763.x; HOUS XS, 1995, CELL, V81, P63; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; LEHMANN R, 1988, DEVELOPMENT, V104, P17; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; MIODZIK M, 1987, DEVELOPMENT, V101, P421; MLODZIK M, 1987, CELL, V48, P465, DOI 10.1016/0092-8674(87)90197-8; MOSQUERA L, 1993, DEVELOPMENT, V117, P377; Pankratz Michael J., 1993, P467; PANKRATZ MJ, 1992, SCIENCE, V255, P986, DOI 10.1126/science.1546296; PATEL NH, 1994, NATURE, V367, P429, DOI 10.1038/367429a0; PATEL NH, 1992, NATURE, V357, P339, DOI 10.1038/357339a0; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; Sander K., 1976, Advances in insect physiology. Volume 12., P125, DOI 10.1016/S0065-2806(08)60255-6; SIMPSONBROSE M, 1994, CELL, V78, P855, DOI 10.1016/S0092-8674(94)90622-X; SOMMER RJ, 1992, P NATL ACAD SCI USA, V89, P10782, DOI 10.1073/pnas.89.22.10782; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; STJOHNSTON D, 1992, CELL, V68, P201; TULLIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469, DOI 10.1073/pnas.83.15.5469; XU X, 1994, DEVELOPMENT, V120, P277	29	153	153	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 20	1995	376	6537					253	256		10.1038/376253a0	http://dx.doi.org/10.1038/376253a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK331	7617036				2022-12-24	WOS:A1995RK33100046
J	REINISCH, KM; CHEN, L; VERDINE, GL; LIPSCOMB, WN				REINISCH, KM; CHEN, L; VERDINE, GL; LIPSCOMB, WN			THE CRYSTAL-STRUCTURE OF HAEIII METHYLTRANSFERASE COVALENTLY COMPLEXED TO DNA - AN EXTRAHELICAL CYTOSINE AND REARRANGED BASE-PAIRING	CELL			English	Article							TARGET-RECOGNIZING DOMAINS; MACROMOLECULAR CRYSTALLOGRAPHY; CPG ISLAND; FRAGILE-X; PROTEIN; REFINEMENT; MECHANISM; METHYLATION; BINDING; SITE	Many organisms expand the information content of their genome through enzymatic methylation of cytosine residues. Here we report the 2.8 Angstrom crystal structure of a bacterial DNA (cytosine-5)-methyltransferase (DCMtase), M. HaeIII, bound covalently to DNA. In this complex, the substrate cytosine is extruded from the DNA helix and inserted into the active site of the enzyme, as has been observed for another DCMtase, M. HhaI. The DNA is bound in a cleft between the two domains of the protein and is distorted from the characteristic B-form conformation at its recognition sequence. A comparison of structures shows a variation in the mode of DNA recognition: M. HaeIII differs from M. HhaI in that the remaining bases in its recognition sequence undergo an extensive rearrangement in their pairing. In this process, the bases are unstacked, and a gap 8 Angstrom long opens in the DNA.	HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138	Harvard University	REINISCH, KM (corresponding author), HARVARD UNIV,GIBBS CHEM LAB,CAMBRIDGE,MA 02138, USA.		chen, Lin/A-3392-2008	chen, Lin/0000-0003-4798-6199	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044853, R01GM006920, R37GM006920] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 44853, GM06920] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams R. L. P., 1985, MOL BIOL DNA METHYLA; BALGANESH TS, 1987, EMBO J, V6, P3543, DOI 10.1002/j.1460-2075.1987.tb02681.x; BARLOW DP, 1993, SCIENCE, V260, P309, DOI 10.1126/science.8469984; BEHRENS B, 1987, EMBO J, V6, P1137, DOI 10.1002/j.1460-2075.1987.tb04869.x; BELL MV, 1991, CELL, V64, P861, DOI 10.1016/0092-8674(91)90514-Y; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; CHEN L, 1991, BIOCHEMISTRY-US, V30, P11018, DOI 10.1021/bi00110a002; CHEN L, 1993, J AM CHEM SOC, V115, P5318, DOI 10.1021/ja00065a063; CHENG XD, 1993, CELL, V74, P299, DOI 10.1016/0092-8674(93)90421-L; CUNIASSE P, 1989, BIOCHEMISTRY-US, V28, P2018, DOI 10.1021/bi00431a009; CUNIASSE P, 1990, J MOL BIOL, V213, P303, DOI 10.1016/S0022-2836(05)80192-5; EFSTRATIADIS A, 1994, CURR OPIN GENET DEV, V4, P265, DOI 10.1016/S0959-437X(05)80054-1; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GARTLER SM, 1983, ANNU REV GENET, V17, P155, DOI 10.1146/annurev.ge.17.120183.001103; Jones P A, 1990, Adv Cancer Res, V54, P1, DOI 10.1016/S0065-230X(08)60806-4; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1985, METHOD ENZYMOL, V115, P359; JOSHUATOR L, 1992, J MOL BIOL, V225, P397, DOI 10.1016/0022-2836(92)90929-E; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KLIMASAUSKAS S, 1991, NUCLEIC ACIDS RES, V19, P6183, DOI 10.1093/nar/19.22.6183; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KNIGHT SJL, 1993, CELL, V74, P127, DOI 10.1016/0092-8674(93)90300-F; KURIYAN J, 1986, J MOL BIOL, V190, P227, DOI 10.1016/0022-2836(86)90295-0; LABAHN J, 1994, P NATL ACAD SCI USA, V91, P10957, DOI 10.1073/pnas.91.23.10957; LAUSTER R, 1989, J MOL BIOL, V206, P305, DOI 10.1016/0022-2836(89)90480-4; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P801; MATTHEWS DA, 1990, J MOL BIOL, V214, P937, DOI 10.1016/0022-2836(90)90347-O; MI S, 1992, NUCLEIC ACIDS RES, V20, P4811, DOI 10.1093/nar/20.18.4811; MILLER M, 1988, NATURE, V334, P85, DOI 10.1038/334085a0; MOE JG, 1992, BIOCHEMISTRY-US, V31, P8421, DOI 10.1021/bi00151a005; NICHOLIS RD, 1995, SEMIN DEV BIOL, V3, P139; NOLLING J, 1992, J BACTERIOL, V174, P5719; OSTERMAN DG, 1988, BIOCHEMISTRY-US, V27, P5204, DOI 10.1021/bi00414a039; PFEIFER GP, 1990, P NATL ACAD SCI USA, V87, P8252, DOI 10.1073/pnas.87.21.8252; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; REINISCH K, 1995, THESIS HARVARD U CAM; REINISCH KM, 1994, J MOL BIOL, V238, P626, DOI 10.1006/jmbi.1994.1319; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; RODGERS DW, 1994, STRUCTURE, V2, P1135, DOI 10.1016/S0969-2126(94)00116-2; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; SANTI DV, 1983, CELL, V33, P9, DOI 10.1016/0092-8674(83)90327-6; SCHHUMACHER MA, 1994, SCIENCE, V266, P763; SELKER EU, 1988, P NATL ACAD SCI USA, V85, P6870, DOI 10.1073/pnas.85.18.6870; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; SUSSMAN JL, 1985, METHOD ENZYMOL, V115, P271; TENG TY, 1990, J APPL CRYSTALLOGR, V23, P387, DOI 10.1107/S0021889890005568; TIMSIT Y, 1991, NATURE, V354, P167, DOI 10.1038/354167a0; TRAUTNER TA, 1988, NUCLEIC ACIDS RES, V16, P6649, DOI 10.1093/nar/16.14.6649; VERDINE GL, 1994, CELL, V76, P197, DOI 10.1016/0092-8674(94)90326-3; VIDGREN J, 1994, NATURE, V368, P354, DOI 10.1038/368354a0; VINCENT A, 1991, NATURE, V349, P624, DOI 10.1038/349624a0; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; WILKE K, 1988, EMBO J, V7, P2601, DOI 10.1002/j.1460-2075.1988.tb03110.x; WINKLER FK, 1994, STRUCTURE, V2, P79, DOI 10.1016/S0969-2126(00)00009-5; WU JC, 1987, J BIOL CHEM, V262, P4778; YANG W, 1995, IN PRESS CELL, V82	64	366	370	0	4	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 14	1995	82	1					143	153		10.1016/0092-8674(95)90060-8	http://dx.doi.org/10.1016/0092-8674(95)90060-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RK424	7606780	Bronze			2022-12-24	WOS:A1995RK42400017
J	CHEN, YH; INOBE, J; MARKS, R; GONNELLA, P; KUCHROO, VK; WEINER, HL				CHEN, YH; INOBE, J; MARKS, R; GONNELLA, P; KUCHROO, VK; WEINER, HL			PERIPHERAL DELETION OF ANTIGEN-REACTIVE T-CELLS IN ORAL TOLERANCE	NATURE			English	Article							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; COLLAGEN-INDUCED ARTHRITIS; MYELIN BASIC-PROTEIN; II COLLAGEN; SUPPRESSION; INDUCTION; MICE	ORAL administration of antigen is used to induce antigen-specific peripheral immune tolerance(1,2). As well as preventing systemic immune responses to ingested proteins(3), oral tolerance to autoantigens has also been used to suppress autoimmune diseases in animals(4-10) and humans(11,12). Both active suppression and clonal anergy are suggested to be mechanisms of oral tolerance, depending on the dose of antigen fed(13,14). Here we report that oral antigen can delete antigen-reactive T cells in Peyer's patches, in mice transgenic for the ovalbumin-specific T-cell receptor genes, The deletion was mediated by apoptosis, and was dependent on dosage and frequency of feeding. At lower doses deletion was not observed; instead there was induction of antigen-specific cells that produced transforming growth factor (TGF)beta and interleukin (IL)-4 and IL-10 cytokines. At higher doses, both Th1 and Th2 cells were deleted following their initial activation, whereas cells which secrete TGF-beta were resistant to deletion. These findings demonstrate that orally administered antigen can induce tolerance not only by active suppression and clonal anergy	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,CTR NEUROL DIS,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School			Chen, Youhai/AAJ-4031-2021					BITAR DM, 1988, CELL IMMUNOL, V112, P364, DOI 10.1016/0008-8749(88)90305-X; CHASE MW, 1946, P SOC EXP BIOL MED, V61, P257; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; COFFMAN R, 1989, J EXP MED, V144, P3411; FRIEDMAN A, 1994, P NATL ACAD SCI USA, V91, P6688, DOI 10.1073/pnas.91.14.6688; HARDIN JA, 1992, J IMMUNOL METHODS, V154, P99, DOI 10.1016/0022-1759(92)90217-H; HIGGINS PJ, 1988, J IMMUNOL, V140, P440; HUANG L, 1994, INT IMMUNOL, V6, P533, DOI 10.1093/intimm/6.4.533; KAWABE Y, 1991, NATURE, V349, P245, DOI 10.1038/349245a0; MOWAT AM, 1987, IMMUNOL TODAY, V8, P93, DOI 10.1016/0167-5699(87)90853-X; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NAGLERANDERSON C, 1986, P NATL ACAD SCI USA, V83, P7443, DOI 10.1073/pnas.83.19.7443; NOGUCHI PD, 1994, CURRENT PROTOCOLS IM; NUSSENBLATT RB, 1990, J IMMUNOL, V144, P1689; ROCHA B, 1992, SCIENCE, V251, P1225; SANTOS LMB, 1994, CELL IMMUNOL, V157, P439, DOI 10.1006/cimm.1994.1240; THOMPSON HSG, 1986, CLIN EXP IMMUNOL, V64, P581; TRENTHAM DE, 1993, SCIENCE, V261, P1727, DOI 10.1126/science.8378772; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; WEINER HL, 1993, SCIENCE, V259, P1321, DOI 10.1126/science.7680493; WEINER HL, 1994, ANNU REV IMMUNOL, V12, P809, DOI 10.1146/annurev.immunol.12.1.809; Wells HG, 1911, J INFECT DIS, V8, P147; WHITACRE CC, 1991, J IMMUNOL, V147, P2155; XUAMANO JC, 1992, INT IMMUNOL, V4, P433, DOI 10.1093/intimm/4.4.433; ZHANG ZJ, 1991, P NATL ACAD SCI USA, V88, P10252, DOI 10.1073/pnas.88.22.10252	25	698	722	0	18	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 13	1995	376	6536					177	180		10.1038/376177a0	http://dx.doi.org/10.1038/376177a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ028	7603570				2022-12-24	WOS:A1995RJ02800062
J	RATHMELL, JC; COOKE, MP; HO, WY; GREIN, J; TOWNSEND, SE; DAVIS, MM; GOODNOW, CC				RATHMELL, JC; COOKE, MP; HO, WY; GREIN, J; TOWNSEND, SE; DAVIS, MM; GOODNOW, CC			CD95 (FAS) DEPENDENT ELIMINATION OF SELF-REACTIVE B-CELLS UPON INTERACTION WITH CD4(+) T-CELLS	NATURE			English	Article							LYMPHOCYTES-B; LPR/LPR MICE; SYSTEMIC AUTOIMMUNITY; LPR; APOPTOSIS; ANTIGEN; DEFECT; MOUSE; INDUCTION; TOLERANCE	THE recessive mouse mutations lpr and gld create deficiencies in an interacting pair of cell surface molecules, CD95 (Fas/APO-1) and Fas-ligand (FasL), respectively(1-3), resulting in autoantibody production resembling human systemic lupus erythematosus(4). The mechanisms of self-tolerance affected by deficiency in either molecule are not established, but CD95 deficiency both in B cells and in CD4(+) T cells recognizing major histocompatibility complex (MHC) class II molecules is required for autoimmunity in lpr mice(5-8). Here we track the outcome of in vivo interactions between B cells and CD4(+) T cells that recognize a transgene-encoded autoantigen, hen egg lysozyme (HEL), using cells from mice transgenic for immunoglobulin and T-cell receptor (TCR) genes. B cells that had not previously encountered HEL autoantigen (naive cells) were triggered into proliferation and antibody-production upon interaction with antigen and HEL-specific CD4(+) T cells. By contrast, B cells that had been chronically exposed to HEL during their development and carried desensitized surface immunoglobulin (sIg) antigen receptors(9) (anergic cells) did not produce antibody but instead were eliminated in the presence of HEL-specific CD4(+) T cells. CD95-deficient anergic B cells, however, were not eliminated by CD4(+) T cells and were triggered to proliferate. These findings identify a novel regulatory step for eliminating autoreactive B cells that seems unique in its dependence on CD95.	STANFORD UNIV,SCH MED,PROGRAM IMMUNOL,STANFORD,CA 94305; STANFORD UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305	Stanford University; Stanford University	RATHMELL, JC (corresponding author), STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,STANFORD,CA 94305, USA.		Goodnow, Christopher C/V-8108-2018	Goodnow, Christopher C/0000-0001-5296-6155; Davis, Mark/0000-0001-6868-657X				BOSSU P, 1993, J IMMUNOL, V151, P7233; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; COOKE MP, 1994, J EXP MED, V179, P425, DOI 10.1084/jem.179.2.425; CYSTER JG, 1994, NATURE, V371, P389, DOI 10.1038/371389a0; FULCHER DA, 1994, J EXP MED, V179, P125, DOI 10.1084/jem.179.1.125; GILLETTEFERGUSO.I, 1994, EUR J IMMUNOL, V4, P1181; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; GOODNOW CC, 1995, ADV IMMUNOL, V59, P279, DOI 10.1016/S0065-2776(08)60633-1; HARTLEY SB, 1991, NATURE, V353, P765, DOI 10.1038/353765a0; HO WY, 1994, J EXP MED, V179, P1539, DOI 10.1084/jem.179.5.1539; JEVNIKAR AM, 1994, J EXP MED, V179, P1137, DOI 10.1084/jem.179.4.1137; KANOST D, 1994, EUR J IMMUNOL, V24, P1186, DOI 10.1002/eji.1830240527; LYNCH DH, 1994, IMMUNITY, V1, P131, DOI 10.1016/1074-7613(94)90106-6; MATSUZAWA A, 1990, J EXP MED, V171, P519, DOI 10.1084/jem.171.2.519; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NEMAZEE D, 1991, J IMMUNOL, V147, P2536; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; RATHMELL JC, 1994, J IMMUNOL, V153, P2831; ROTHSTEIN TL, 1995, NATURE, V374, P163, DOI 10.1038/374163a0; RUSSELL JH, 1993, P NATL ACAD SCI USA, V90, P4409, DOI 10.1073/pnas.90.10.4409; SINGER GG, 1994, IMMUNITY, V1, P365, DOI 10.1016/1074-7613(94)90067-1; SOBEL ES, 1991, J EXP MED, V173, P1441, DOI 10.1084/jem.173.6.1441; SOBEL ES, 1993, J IMMUNOL, V150, P4160; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WESTON KM, 1988, J IMMUNOL, V141, P1941; ZHOU T, 1991, J IMMUNOL, V147, P466; ZHOU T, 1992, J EXP MED, V176, P1063, DOI 10.1084/jem.176.4.1063	29	411	415	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 13	1995	376	6536					181	184		10.1038/376181a0	http://dx.doi.org/10.1038/376181a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ028	7603571				2022-12-24	WOS:A1995RJ02800063
J	PAPADOPOULOS, N; NICOLAIDES, NC; LIU, B; PARSONS, R; LENGAUER, C; PALOMBO, F; DARRIGO, A; MARKOWITZ, S; WILLSON, JKV; KINZLER, KW; JIRICNY, J; VOGELSTEIN, B				PAPADOPOULOS, N; NICOLAIDES, NC; LIU, B; PARSONS, R; LENGAUER, C; PALOMBO, F; DARRIGO, A; MARKOWITZ, S; WILLSON, JKV; KINZLER, KW; JIRICNY, J; VOGELSTEIN, B			MUTATIONS OF GTBP IN GENETICALLY UNSTABLE CELLS	SCIENCE			English	Article							ADENOMATOUS POLYPOSIS; COLORECTAL-CANCER; CLONES	The molecular defects responsible for tumor cell hypermutability in humans have not yet been fully identified. Here the gene encoding a G/T mismatch-binding protein (GTBP) was localized to within 1 megabase of the related hMSH2 gene on chromosome 2 and was found to be inactivated in three hypermutable cell lines. Unlike cells defective in other mismatch repair genes, which display widespread alterations in mononucleotide, dinucleotide, and other simple repeated sequences, the GTBP-deficient cells showed alterations primarily in mononucleotide tracts. These results suggest that GTBP is important for maintaining the integrity of the human genome and document molecular defects accounting for variation in mutator phenotype.	HOWARD HUGHES MED INST,BALTIMORE,MD 21231; JOHNS HOPKINS ONCOL CTR,BALTIMORE,MD 21231; IST RIC BIOL MOLEC P ANGELETTI,I-00040 POMEZIA,ITALY; UNIV HOSP CLEVELAND,IRELAND CANC CTR,DEPT MED,CLEVELAND,OH; CASE WESTERN RESERVE UNIV,CLEVELAND,OH 44106	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins Medicine; University Hospitals of Cleveland; Case Western Reserve University			Papadopoulos, Nickolas/K-7272-2012	Parsons, Ramon/0000-0002-6656-3514; Palombo, Fabio/0000-0003-0473-4901	NCI NIH HHS [CA62924, CA47527, CA35494] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA062924, R01CA047527, R37CA035494, R01CA035494] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BREUKEL C, 1991, NUCLEIC ACIDS RES, V19, P5804, DOI 10.1093/nar/19.20.5804; DACOSTA LT, 1995, NAT GENET, V9, P10, DOI 10.1038/ng0195-10; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; GOLDMACHER VS, 1986, J BIOL CHEM, V261, P2462; GYAPAY G, 1995, NAT GENET, V7, P246; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; KOLODNER RD, 1994, GENOMICS, V24, P516, DOI 10.1006/geno.1994.1661; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LENGAUER C, 1992, CANCER RES, V52, P2590; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; LIU B, 1994, CANCER RES, V54, P4590; LIU B, 1995, NAT MED, V1, P348, DOI 10.1038/nm0495-348; MARRO G, IN PRESS J NAT CANCE; MERLO A, 1994, CANCER RES, V54, P2098; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PAPADOPOULOS N, UNPUB; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; UMAR A, 1994, J BIOL CHEM, V269, P14367; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152	27	477	497	0	10	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 30	1995	268	5219					1915	1917		10.1126/science.7604266	http://dx.doi.org/10.1126/science.7604266			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF990	7604266				2022-12-24	WOS:A1995RF99000043
J	ROBERTSON, MP; MILLER, SL				ROBERTSON, MP; MILLER, SL			AN EFFICIENT PREBIOTIC SYNTHESIS OF CYTOSINE AND URACIL	NATURE			English	Article							CHEMICAL EVOLUTION; PYRIMIDINES; ACIDS	In contrast to the purines(1-3), the routes that have been proposed for the prebiotic synthesis of pyrimidines from simple precursors give only low yields. Cytosine can be synthesized from cyanoacetylene and cyanate(4,5); the former precursor is produced from a spark discharge in a CH4/N-2 mixture(4,5) and is an abundant interstellar molecule(6). But this reaction requires relatively high concentrations of cyanate (>0.1 M), which are unlikely to occur in aqueous media as cyanate is hydrolysed rapidly to CO2 and NH3. An alternative route that has been explored(7) is the reaction of cyanoacetaldehyde (formed by hydrolysis of cyanoacetylene(8)) with urea. But at low concentrations of urea, this reaction produces no detectable quantities of cytosine(7). Here we show that in concentrated urea solution-such as might have been found in an evaporating lagoon or in pools on drying beaches on the early Earth-cyanoacetaldehyde reacts to form cytosine in yields of 30-50%, from which uracil can be formed by hydrolysis. These reactions provide a plausible route to the pyrimidine bases required in the RNA world(9).			ROBERTSON, MP (corresponding author), UNIV CALIF SAN DIEGO,DEPT CHEM & BIOCHEM,LA JOLLA,CA 92093, USA.							CHITTENDEN GJF, 1976, NATURE, V263, P350, DOI 10.1038/263350a0; CRICK FHC, 1966, J MOL BIOL, V19, P548, DOI 10.1016/S0022-2836(66)80022-0; FERRIS JP, 1974, J MOL EVOL, V3, P301, DOI 10.1007/BF01796045; FERRIS JP, 1968, J MOL BIOL, V33, P693, DOI 10.1016/0022-2836(68)90314-8; FERRIS JP, 1978, J MOL EVOL, V11, P293, DOI 10.1007/BF01733839; FERRIS JP, 1970, J AM CHEM SOC, V92, P6598, DOI 10.1021/ja00725a036; GARRETT ER, 1972, J PHARM SCI, V61, P1052, DOI 10.1002/jps.2600610703; KOLB VM, 1994, J MOL EVOL, V38, P549; LIMBACH PA, 1994, NUCLEIC ACIDS RES, V22, P2183, DOI 10.1093/nar/22.12.2183; LOHRMANN R, 1972, J MOL EVOL, V1, P263, DOI 10.1007/BF01660246; LOWE CU, 1963, NATURE, V199, P219, DOI 10.1038/199219a0; Miller S. L., 1974, ORIGINS LIFE EARTH; MILLER SL, 1955, J AM CHEM SOC, V77, P2351, DOI 10.1021/ja01614a001; ORO J, 1960, BIOCHEM BIOPH RES CO, V2, P407, DOI 10.1016/0006-291X(60)90138-8; PICCIRILLI JA, 1990, NATURE, V343, P33, DOI 10.1038/343033a0; SANCHEZ R, 1966, SCIENCE, V153, P72, DOI 10.1126/science.153.3731.72; SANCHEZ RA, 1966, SCIENCE, V154, P784, DOI 10.1126/science.154.3750.784; SANCHEZ RA, 1968, J MOL BIOL, V38, P121, DOI 10.1016/0022-2836(68)90132-0; SHAPIRO R, 1966, BIOCHEMISTRY-US, V5, P2358, DOI 10.1021/bi00871a026; Shnidman L, 1932, J PHYS CHEM-US, V36, P1232, DOI 10.1021/j150334a013; STOKS PG, 1981, GEOCHIM COSMOCHIM AC, V45, P563, DOI 10.1016/0016-7037(81)90189-7; STOKS PG, 1979, NATURE, V282, P709, DOI 10.1038/282709a0; TESTELAND RF, 1993, RNA WORLD; TURNER BE, 1971, ASTROPHYS J, V163, pL35, DOI 10.1086/180662; WACHTERSHAUSER G, 1988, P NATL ACAD SCI USA, V85, P1134, DOI 10.1073/pnas.85.4.1134	25	186	190	2	59	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 29	1995	375	6534					772	774		10.1038/375772a0	http://dx.doi.org/10.1038/375772a0			3	Multidisciplinary Sciences	Current Chemical Reactions (CCR-EXPANDED); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF989	7596408				2022-12-24	WOS:A1995RF98900073
J	HARDING, SP; BROADBENT, DM; NEOH, C; WHITE, MC; VORA, J				HARDING, SP; BROADBENT, DM; NEOH, C; WHITE, MC; VORA, J			SENSITIVITY AND SPECIFICITY OF PHOTOGRAPHY AND DIRECT OPHTHALMOSCOPY IN SCREENING FOR SIGHT THREATENING EYE DISEASE - THE LIVERPOOL DIABETIC EYE STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MYDRIATIC RETINAL PHOTOGRAPHY; PRIMARY CARE PHYSICIANS; FUNDUS PHOTOGRAPHY; RETINOPATHY; PREVENTION; BLINDNESS; DIAGNOSIS; CAMERA	Objective-To evaluate different methods for community based screening for sight threatening diabetic eye disease. Design-Prospective study. Setting-Mobile screening unit visiting inner city community clinics; hospital assessment clinic (tertiary centre). Subjects Subjects-395 diabetic patients registered with four general practices in an inner city location. Interventions-Community based photography with mydriasis and direct ophthalmoscopy through dilated pupils by an experienced ophthalmologist, both compared with reference standard of slit lamp biomicroscopy by a consultant specialist in medical retinal disease. Main outcome measures-Sensitivity and specificity of screening method and prevalence of sight threatening diabetic eye disease (moderate preproliferative retinopathy, circinate maculopathy, exudate within 1 disc diameter of fixation, other diabetes related eye disease). Results-358 subjects underwent photography, 326 attended hospital clinic for ophthalmoscopy, and six were ungradable on photographs and biomicroscopy, leaving 320 for analysis. Of these 295 (91%) attended clinic within four months of photography. Sensitivity of detection of eye disease by photography was 89% (95% confidence interval 80% to 98%), significantly better than for direct ophthalmoscopy (65% (51% to 79%)). Analysis of patients with false negative results indicated possible improvement of photographic sensitivity to 93% by addition of stereoscopic macular pair photographs. Specificity of detection of sight threatening eye disease was 86% (82% to 90%) for photography and 97% (95% to 99%) for direct ophthalmoscopy. Conclusions-Since high sensitivity is essential for an effective screening programme, a photographic method should be considered as preferred option in national, community based screening programmes. Even in the hands of an experienced ophthalmologist, direct ophthalmoscopy is limited by weaknesses inherent to the instrument.	ROYAL LIVERPOOL UNIV HOSP, DEPT ENDOCRINOL & DIABET, LIVERPOOL L7 8XP, MERSEYSIDE, ENGLAND	Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool	HARDING, SP (corresponding author), ROYAL LIVERPOOL UNIV HOSP, ST PAULS EYE UNIT, LIVERPOOL L7 8XP, MERSEYSIDE, ENGLAND.			Harding, Simon/0000-0003-4676-1158				ALTMAN DG, 1994, BRIT MED J, V308, P1552, DOI 10.1136/bmj.308.6943.1552; [Anonymous], 1987, Int Ophthalmol Clin, V27, P265; [Anonymous], 1991, Ophthalmology, V98, P786; [Anonymous], 1981, OPHTHALMOLOGY, V88, P583; AWH CC, 1993, INVEST OPHTH VIS SCI, V34, P713; BURNSCOX CJ, 1985, BMJ-BRIT MED J, V290, P1052, DOI 10.1136/bmj.290.6474.1052; BUXTON MJ, 1991, DIABETIC MED, V8, P371, DOI 10.1111/j.1464-5491.1991.tb01612.x; DCCT Res Grp, 1987, ARCH OPHTHALMOL-CHIC, V105, P1344; ELLINGFORD A, 1992, Journal of Audiovisual Media in Medicine, V15, P104, DOI 10.3109/17453059209018361; FINLAY R, 1991, HLTH TRENDS, V23, P104; FORREST RD, 1987, DIABETES RES CLIN EX, V5, P39; Foulds W S, 1983, Health Bull (Edinb), V41, P318; GEHRS KM, 1993, INVEST OPHTH VIS SCI, V34, P1182; JACOB J, 1995, DIABETIC MED, V12, P419, DOI 10.1111/j.1464-5491.1995.tb00506.x; JAVITT JC, 1989, OPHTHALMOLOGY, V96, P255; JONES D, 1988, BRIT MED J, V296, P1029, DOI 10.1136/bmj.296.6628.1029; KINYOUN JL, 1992, INVEST OPHTH VIS SCI, V33, P1888; KLEIN R, 1985, OPHTHALMOLOGY, V92, P485; Kleinstein R N, 1987, J Am Optom Assoc, V58, P879; KOHNER EM, 1984, DIABETOLOGIA, V26, P173; KOHNER EM, 1991, BRIT MED J, V302, P176, DOI 10.1136/bmj.302.6769.176; LEE CM, 1991, OPHTHALMOLOGY, V98, P1594; LEESE GP, 1993, BRIT MED J, V306, P187, DOI 10.1136/bmj.306.6871.187; MOHAN R, 1988, BRIT J OPHTHALMOL, V72, P841, DOI 10.1136/bjo.72.11.841; MOSS SE, 1985, OPHTHALMOLOGY, V92, P62; ROGERS D, 1990, DIABETIC MED, V7, P165, DOI 10.1111/j.1464-5491.1990.tb01353.x; ROHAN TE, 1989, BMJ-BRIT MED J, V299, P1198, DOI 10.1136/bmj.299.6709.1198; RYDER REJ, 1985, BRIT MED J, V291, P1256, DOI 10.1136/bmj.291.6504.1256; RYDER REJ, 1985, PRACTICAL DIABETES, V2, P34; RYDER REJ, 1995, BRIT MED J, V311, P207; SAVOLAINEN EA, 1982, DIABETOLOGIA, V23, P138, DOI 10.1007/BF01271176; SCHACHAT AP, 1993, ARCH OPHTHALMOL-CHIC, V111, P1064, DOI 10.1001/archopht.1993.01090080060019; SPARROW JM, 1993, EYE, V7, P158, DOI 10.1038/eye.1993.34; SUSSMAN EJ, 1982, JAMA-J AM MED ASSOC, V247, P3231, DOI 10.1001/jama.247.23.3231; TAYLOR R, 1990, BRIT MED J, V301, P1243, DOI 10.1136/bmj.301.6763.1243; WAREHAM N, 1991, DIABETIC MED, V8, P607, DOI 10.1111/j.1464-5491.1991.tb01665.x; WHO/IDF Europe, 1990, DIABETIC MED, V7, P360; WILLIAMS R, 1986, BRIT MED J, V293, P1140, DOI 10.1136/bmj.293.6555.1140; 1991, BRIT MED J, V302, P174; 1991, DIABETIC MED, V8, P263; 1988, CAUSES BLINDNESS PAR	41	197	202	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 28	1995	311	7013					1131	1135		10.1136/bmj.311.7013.1131	http://dx.doi.org/10.1136/bmj.311.7013.1131			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC466	7580708	Green Published			2022-12-24	WOS:A1995TC46600017
J	FRANK, SA				FRANK, SA			MUTUAL POLICING AND REPRESSION OF COMPETITION IN THE EVOLUTION OF COOPERATIVE GROUPS	NATURE			English	Article							DICTYOSTELIUM	EVOLUTIONARY theory has not explained how competition among lower level units is suppressed in the formation of higher-level evolutionary units(1,2). For example, the key problem of early evolution is how small, individual replicators formed cooperative groups of sufficient complexity to allow accurate copying of the genetic material(3). The puzzle is why parasites did not subvert the formation of cells by obtaining benefits from the group without contributing to shared traits that enhance reproduction(4). These parasites would outcompete other replicators within the cell, disrupting reproductive fairness among subunits and destroying the functional coherence of the group. A similar problem arose at a later evolutionary stage with the orderly mendelian segregation of subunits (chromosomes) within cells, and reproductive fairness continued to be a problem in the evolution of insect(5) and human societies(6). Here I present a simple model to show how reproductive fairness evolves among subunits to create functional coherence and higher-level units. Self-restraint, which evolves according to the kin-selection coefficient of relatedness, is not sufficient: mutual policing and enforcement of reproductive fairness are also required for the evolution of increasing social complexity.			FRANK, SA (corresponding author), UNIV CALIF IRVINE, DEPT ECOL & EVOLUTIONARY BIOL, IRVINE, CA 92717 USA.			Frank, Steven/0000-0001-7348-7794				Alexander R., 2008, ESSAYS PEDAGOGY; BONNER JT, 1967, CELLULAR SLIME MOLDS; BREMERMANN HJ, 1983, J THEOR BIOL, V100, P411, DOI 10.1016/0022-5193(83)90438-1; Eigen M, 1979, THE HYPERCYCLE, P60; FRANK SA, 1994, P ROY SOC B-BIOL SCI, V258, P153, DOI 10.1098/rspb.1994.0156; HAMILTON WD, 1970, NATURE, V228, P1218, DOI 10.1038/2281218a0; HARDIN G, 1968, SCIENCE, V162, P1243, DOI 10.1126/science.162.3859.1243; Hardin G., 1993, LIVING LIMITS ECOLOG; HURST LD, 1994, P ROY SOC B-BIOL SCI, V258, P287, DOI 10.1098/rspb.1994.0175; LLOYD WF, 1833, 2 LECTURES CHECKS PO; Maynard Smith J., 1982, pi; Morrissey J, 1982, DEV DICTYOSTELIUM DI, P411; OZAKI T, 1993, DEVELOPMENT, V117, P1299; PRICE GR, 1970, NATURE, V227, P520, DOI 10.1038/227520a0; RATNIEKS FLW, 1992, J THEOR BIOL, V158, P33, DOI 10.1016/S0022-5193(05)80647-2; RATNIEKS FLW, 1989, NATURE, V342, P796, DOI 10.1038/342796a0; Smith J. M., 1995, MAJOR TRANSITIONS EV; SMITH JM, 1979, NATURE, V280, P445, DOI 10.1038/280445a0; WILLIAMS JG, 1989, CELL, V59, P1157, DOI 10.1016/0092-8674(89)90771-X; WILSON DS, 1994, BEHAV BRAIN SCI, V17, P585, DOI 10.1017/S0140525X00036104; WILSON DS, 1989, J THEOR BIOL, V136, P337, DOI 10.1016/S0022-5193(89)80169-9	21	276	283	1	48	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 12	1995	377	6549					520	522		10.1038/377520a0	http://dx.doi.org/10.1038/377520a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ336	7566147	Green Submitted			2022-12-24	WOS:A1995RZ33600059
J	HORLEIN, AJ; NAAR, AM; HEINZEL, T; TORCHIA, J; GLOSS, B; KUROKAWA, R; RYAN, A; KAMEL, Y; SODERSTROM, M; GLASS, CK; ROSENFELD, MG				HORLEIN, AJ; NAAR, AM; HEINZEL, T; TORCHIA, J; GLOSS, B; KUROKAWA, R; RYAN, A; KAMEL, Y; SODERSTROM, M; GLASS, CK; ROSENFELD, MG			LIGAND-INDEPENDENT REPRESSION BY THE THYROID-HORMONE RECEPTOR-MEDIATED BY A NUCLEAR RECEPTOR CO-REPRESSOR	NATURE			English	Article							RETINOID X-RECEPTOR; V-ERBA; TRANSCRIPTION FACTOR; RXR-BETA; PROTEIN; ACID; BINDING; ACTIVATION; INHIBITION; SILENCER	Thyroid-hormone and retinoic-acid receptors exert their regulatory functions by acting as both activators and repressors of gene expression. A nuclear receptor co-repressor (N-CoR) of relative molecular mass 270K has been identified which mediates ligand-independent inhibition of gene transcription by these receptors, suggesting that the molecular mechanisms of repression by thyroid-hormone and retinoic-acid receptors are analogous to the co-repressor-dependent transcriptional inhibitory mechanisms of yeast and Drosophila.	UNIV CALIF SAN DIEGO, DEPT MED, GRAD PROGRAM MOLEC PATHOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, SCH MED, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	HORLEIN, AJ (corresponding author), UNIV CALIF SAN DIEGO, HOWARD HUGHES MED INST, LA JOLLA, CA 92093 USA.		Glass, Christopher/AAI-3933-2021; Söderström, Mats/C-4005-2009; Heinzel, Thorsten/B-1013-2015	Glass, Christopher/0000-0003-4344-3592; Söderström, Mats/0000-0003-3927-4394; 				AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; BANIAHMAD A, 1992, P NATL ACAD SCI USA, V89, P10633, DOI 10.1073/pnas.89.22.10633; BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BANLAHMAD A, 1992, EMBO J, V11, P1015; BLANCO JCG, 1995, P NATL ACAD SCI USA, V92, P1535, DOI 10.1073/pnas.92.5.1535; BRENT G A, 1989, New Biologist, V1, P329; CASANOVA J, 1994, MOL CELL BIOL, V14, P5756, DOI 10.1128/MCB.14.9.5756; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; DAMM K, 1993, P NATL ACAD SCI USA, V90, P10668, DOI 10.1073/pnas.90.22.10668; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HOLLOWAY JM, 1990, P NATL ACAD SCI USA, V87, P8160, DOI 10.1073/pnas.87.20.8160; ING NH, 1992, J BIOL CHEM, V267, P17617; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; KOMACHI K, 1994, GENE DEV, V8, P2857, DOI 10.1101/gad.8.23.2857; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LAZAR MA, 1989, P NATL ACAD SCI USA, V86, P7771, DOI 10.1073/pnas.86.20.7771; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LICHT JD, 1994, MOL CELL BIOL, V14, P4057, DOI 10.1128/MCB.14.6.4057; MADDEN SL, 1993, ONCOGENE, V8, P1713; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MARTIN B, 1994, NUCLEIC ACIDS RES, V22, P4898, DOI 10.1093/nar/22.23.4898; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; QI JS, 1995, MOL CELL BIOL, V15, P1817; RENKAWITZ R, 1993, ANN NY ACAD SCI, V684, P1, DOI 10.1111/j.1749-6632.1993.tb32266.x; SAHA S, 1993, NATURE, V363, P648, DOI 10.1038/363648a0; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SEOL WG, 1995, MOL ENDOCRINOL, V9, P72, DOI 10.1210/me.9.1.72; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; TZAMARIAS D, 1995, GENE DEV, V9, P821, DOI 10.1101/gad.9.7.821; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	52	1670	1690	2	49	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 5	1995	377	6548					397	404		10.1038/377397a0	http://dx.doi.org/10.1038/377397a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY190	7566114				2022-12-24	WOS:A1995RY19000039
J	JUNGNICKEL, B; RAPOPORT, TA				JUNGNICKEL, B; RAPOPORT, TA			A POSTTARGETING SIGNAL SEQUENCE RECOGNITION EVENT IN THE ENDOPLASMIC-RETICULUM MEMBRANE	CELL			English	Article							PROTEIN TRANSLOCATION; SACCHAROMYCES-CEREVISIAE; NASCENT POLYPEPTIDES; SUPPRESSOR MUTATIONS; MICROSOMAL-MEMBRANES; PARTICLE RECEPTOR; ESCHERICHIA-COLI; ER MEMBRANE; COMPONENTS; PEPTIDES	We have analyzed early phases of the cotranslational transport of the secretory protein preprolactin through the mammalian endoplasmic reticulum (ER) membrane. Following recognition of the signal sequence of the nascent polypeptide chain in the cytosol by the SRP, the chain is transferred into the membrane, where a second signal sequence recognition step takes place for which the presence in the lipid bilayer of the Sec61p complex is essential and sufficient. This step leads to a tight junction between the ribosome-nascent chain complex and the Sec61p complex, and to the productive insertion of the nascent chain into the translocation site, These results show that a translocation substrate is subjected to two recognition events before being allowed to cross the ER membrane.	MAX DELBRUCK CTR MOLEC MED,D-13125 BERLIN,GERMANY	Helmholtz Association; Max Delbruck Center for Molecular Medicine	JUNGNICKEL, B (corresponding author), HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115, USA.							ADELMAN MR, 1973, J CELL BIOL, V56, P206, DOI 10.1083/jcb.56.1.206; BRIGGS MS, 1985, SCIENCE, V228, P1096, DOI 10.1126/science.3158076; CONNOLLY T, 1989, J CELL BIOL, V108, P299, DOI 10.1083/jcb.108.2.299; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; EMR SD, 1981, CELL, V23, P79, DOI 10.1016/0092-8674(81)90272-5; GILMORE R, 1983, CELL, V35, P677, DOI 10.1016/0092-8674(83)90100-9; GILMORE R, 1992, J CELL BIOL, V95, P470; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HARTMANN E, 1994, NATURE, V367, P654, DOI 10.1038/367654a0; HIGH S, 1993, J BIOL CHEM, V268, P26745; JUNGNICKEL B, 1993, FEBS LETT, V329, P268, DOI 10.1016/0014-5793(93)80235-M; KALLES KU, 1994, J CELL BIOL, V126, P925; LAURING B, 1995, P NATL ACAD SCI USA, V92, P5411, DOI 10.1073/pnas.92.12.5411; MARTOGLIO B, 1995, CELL, V81, P207, DOI 10.1016/0092-8674(95)90330-5; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; OGG SC, 1992, MOL BIOL CELL, V3, P895, DOI 10.1091/mbc.3.8.895; OSBORNE RS, 1993, EMBO J, V12, P3391, DOI 10.1002/j.1460-2075.1993.tb06013.x; PREHN S, 1980, EUR J BIOCHEM, V107, P185, DOI 10.1111/j.1432-1033.1980.tb04639.x; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WIEDMANN B, 1994, NATURE, V370, P434, DOI 10.1038/370434a0; WOLIN SL, 1993, J CELL BIOL, V121, P1211, DOI 10.1083/jcb.121.6.1211; [No title captured]	30	232	234	0	10	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 28	1995	82	2					261	270		10.1016/0092-8674(95)90313-5	http://dx.doi.org/10.1016/0092-8674(95)90313-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RL760	7628015	Bronze			2022-12-24	WOS:A1995RL76000013
J	MING, M; EWEN, ME; PEREIRA, MEA				MING, M; EWEN, ME; PEREIRA, MEA			TRYPANOSOME INVASION OF MAMMALIAN-CELLS REQUIRES ACTIVATION OF THE TGF-BETA SIGNALING PATHWAY	CELL			English	Article							TRANSFORMING GROWTH-FACTOR; II RECEPTOR; CRUZI; INHIBITION; PROTEIN; KINASE; TRYPOMASTIGOTES; DIFFERENTIATION; IDENTIFICATION; PROLIFERATION	Trypanosoma cruzi invades most nucleated mammalian cells by as yet unknown mechanisms, We report here that while T. cruzi attaches to epithelial cells lacking signaling transforming growth factor beta (TGF beta) receptor I or II, the adherent parasites cannot penetrate and replicate inside the mutant cells, as they do in parental cells, Invasion of the mutants is restored by transfection with the TGF beta receptor genes, as are biological responses to TGF beta. Similar rescue of both TGF beta antiproliferative response and T. cruzi invasion was demonstrated in a hybrid of TGF beta-resistant bladder and colon carcinoma cells. In addition, T. cruzi did not efficiently invade epithelial cells with dysfunction of the intracellular signaling cascade caused by the constitutive expression of the cyclin-dependent kinase cdk4 or of the oncogene H-ras. Treatment with TGF beta, but not with other antiproliferative agents of nonphagocytic cells, greatly enhances T. cruzi invasion. Moreover, infective, but not noninfective, trypanosomes strongly induce a TGF beta-responsive reporter gene in TGF beta-sensitive, but not in TGF beta-insensitive, cell lines. Thus, T. cruzi itself may directly trigger activation of the TGF beta signaling pathway required for parasite entry into the mammalian cells.	TUFTS UNIV,NEW ENGLAND MED CTR,TUPPER RES INST,DIV GEOG MED & INFECT DIS,TROP DIS RES UNIT,BOSTON,MA 02111; HARVARD UNIV,SCH MED,BOSTON,MA 02115; DANA FARBER CANC INST,BOSTON,MA 02115	Tufts Medical Center; Tufts University; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute								ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; ANDRADE Z, 1983, CYTOPATHOLOGY PARASI, P228; BLISKA JB, 1993, CELL, V73, P903, DOI 10.1016/0092-8674(93)90270-Z; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; BOYNTON AL, 1983, ADV CYCLIC NUCL PROT, V15, P193; Brener Z., 1990, Modern parasite biology: cellular, immunological, and molecular aspects., P247; CAVALLESCO R, 1988, J IMMUNOL, V140, P617; CAZZULO JJ, 1989, MOL BIOCHEM PARASIT, V33, P33, DOI 10.1016/0166-6851(89)90039-X; CHEN F, 1995, P NATL ACAD SCI USA, V92, P1565, DOI 10.1073/pnas.92.5.1565; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; DVORAK JA, 1981, SCIENCE, V214, P1034, DOI 10.1126/science.7029713; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FILMUS J, 1992, ONCOGENE, V7, P521; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GEISER AG, 1992, J BIOL CHEM, V267, P2588; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; GOODING LR, 1992, CELL, V71, P5; HENRIQUEZ D, 1981, MOL BIOCHEM PARASIT, V2, P359, DOI 10.1016/0166-6851(81)90087-6; HERRERA EM, 1994, MOL BIOCHEM PARASIT, V65, P73, DOI 10.1016/0166-6851(94)90116-3; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Koberle F., 1968, Advances in Parasitology, V6, P63, DOI 10.1016/S0065-308X(08)60472-8; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; MASSAGUE J, 1986, P NATL ACAD SCI USA, V83, P8206, DOI 10.1073/pnas.83.21.8206; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MING M, 1993, MOL BIOCHEM PARASIT, V59, P243, DOI 10.1016/0166-6851(93)90222-J; MIYAZONO K, 1989, NATURE, V338, P158, DOI 10.1038/338158a0; MIYAZONO K, 1994, ADV IMMUNOL, V55, P181; MORENO SNJ, 1994, J EXP MED, V180, P1535, DOI 10.1084/jem.180.4.1535; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; OLSHEVSKY U, 1990, J VIROL, V64, P5701, DOI 10.1128/JVI.64.12.5701-5707.1990; ORTEGABARRIA E, 1991, CELL, V67, P411, DOI 10.1016/0092-8674(91)90192-2; Pereira M. E. A., 1990, Modern parasite biology: cellular, immunological, and molecular aspects., P64; PEREIRA MEA, 1983, SCIENCE, V219, P1444, DOI 10.1126/science.6338592; PEREIRA MEA, 1994, BAILLIERE CLIN INF D, V1, P305; PETTI L, 1992, P NATL ACAD SCI USA, V89, P6736, DOI 10.1073/pnas.89.15.6736; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; ROWIN KS, 1983, P NATL ACAD SCI-BIOL, V80, P6390, DOI 10.1073/pnas.80.20.6390; SCHENKMAN S, 1991, INFECT IMMUN, V59, P645, DOI 10.1128/IAI.59.2.645-654.1991; SCHWAB JC, 1994, P NATL ACAD SCI USA, V91, P509, DOI 10.1073/pnas.91.2.509; SCUDDER P, 1993, J BIOL CHEM, V268, P9886; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SILVA JS, 1991, J EXP MED, V174, P539, DOI 10.1084/jem.174.3.539; TARDIEUX I, 1994, J EXP MED, V179, P1017, DOI 10.1084/jem.179.3.1017; TARDIEUX I, 1992, CELL, V71, P1117, DOI 10.1016/S0092-8674(05)80061-3; WAHL SM, 1988, J IMMUNOL, V140, P3026; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; YAKUBU MA, 1994, MOL BIOCHEM PARASIT, V66, P119, DOI 10.1016/0166-6851(94)90042-6	50	128	132	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 28	1995	82	2					287	296		10.1016/0092-8674(95)90316-X	http://dx.doi.org/10.1016/0092-8674(95)90316-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RL760	7628017	Bronze			2022-12-24	WOS:A1995RL76000016
J	PELLEYMOUNTER, MA; CULLEN, MJ; BAKER, MB; HECHT, R; WINTERS, D; BOONE, T; COLLINS, F				PELLEYMOUNTER, MA; CULLEN, MJ; BAKER, MB; HECHT, R; WINTERS, D; BOONE, T; COLLINS, F			EFFECTS OF THE OBESE GENE-PRODUCT ON BODY-WEIGHT REGULATION IN OB/OB MICE	SCIENCE			English	Article								C57BL/6J mice with a mutation in the obese (ob) gene are obese, diabetic, and exhibit reduced activity, metabolism, and body temperature. Daily intraperitoneal injection of these mice with recombinant OB protein lowered their body weight, percent body fat, food intake, and serum concentrations of glucose and insulin. In addition, metabolic rate, body temperature, and activity levels were increased by this treatment. None of these parameters was altered beyond the level observed in lean controls, suggesting that the OB protein normalized the metabolic status of the ob/ob mice. Lean animals injected with OB protein maintained a smaller weight loss throughout the 28-day study and showed no changes in any of the metabolic parameters. These data suggest that the OB protein regulates body weight and fat deposition through effects on metabolism and appetite.	AMGEN INC,DEPT RECOVERY PROC DEV,THOUSAND OAKS,CA 91320	Amgen	PELLEYMOUNTER, MA (corresponding author), AMGEN INC,DEPT NEUROBIOL,1840 DEHAVILLAND DR,THOUSAND OAKS,CA 91320, USA.							BRAY GA, 1979, PHYSIOL REV, V59, P719, DOI 10.1152/physrev.1979.59.3.719; BRITTON DR, 1989, PHARMACOL BIOCHEM BE, V34, P779, DOI 10.1016/0091-3057(89)90274-8; COLEMAN DL, 1973, DIABETOLOGIA, V9, P294, DOI 10.1007/BF01221857; FRIEDMAN JM, 1992, CELL, V69, P217, DOI 10.1016/0092-8674(92)90402-X; LESHNER AI, 1972, PHYSIOL BEHAV, V9, P281, DOI 10.1016/0031-9384(72)90251-X; LU H, 1993, PROTEIN FOLDING IN V, V526, pCH15; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	7	3681	3891	3	239	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 28	1995	269	5223					540	543		10.1126/science.7624776	http://dx.doi.org/10.1126/science.7624776			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL495	7624776				2022-12-24	WOS:A1995RL49500028
J	REILLY, JT; TOH, CH				REILLY, JT; TOH, CH			SHEAR-STRESS AND PLATELET-FUNCTION - A THERAPEUTIC CHALLENGE	LANCET			English	Editorial Material							AGGREGATION				REILLY, JT (corresponding author), NO GEN HOSP,DEPT HAEMATOL,SHEFFIELD S5 7AU,S YORKSHIRE,ENGLAND.							BEURLINGHARBURY C, 1978, BLOOD, V52, P13; CAPPELL MS, 1986, ANN INTERN MED, V105, P54, DOI 10.7326/0003-4819-105-1-54; DARDIK R, 1993, THROMB HAEMOSTASIS, V70, P522; IKEDA Y, 1991, J CLIN INVEST, V87, P1234, DOI 10.1172/JCI115124; MOAKE JL, 1988, BLOOD, V71, P1366; OBRIEN JR, 1992, THROMB RES, V65, P821, DOI 10.1016/0049-3848(92)90121-P; OBRIEN JR, 1995, PLATELETS, V6, P242, DOI 10.3109/09537109509078461; OBRIEN JR, 1994, THROMB RES, V76, P103, DOI 10.1016/0049-3848(94)90212-7; ROTH GJ, 1991, BLOOD, V77, P5	9	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 22	1995	346	8969					196	197		10.1016/S0140-6736(95)91261-4	http://dx.doi.org/10.1016/S0140-6736(95)91261-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK419	7616794				2022-12-24	WOS:A1995RK41900003
J	HENSEL, M; SHEA, JE; GLEESON, C; JONES, MD; DALTON, E; HOLDEN, DW				HENSEL, M; SHEA, JE; GLEESON, C; JONES, MD; DALTON, E; HOLDEN, DW			SIMULTANEOUS IDENTIFICATION OF BACTERIAL VIRULENCE GENES BY NEGATIVE SELECTION	SCIENCE			English	Article							SALMONELLA-TYPHIMURIUM; MUTANTS; AVIRULENT; CELLS; MICE	An insertional mutagenesis system that uses transposons carrying unique DNA sequence tags was developed for the isolation of bacterial virulence genes. The tags from a mixed population of bacterial mutants representing the inoculum and bacteria recovered from infected hosts were detected by amplification, radiolabeling, and hybridization analysis. When applied to a murine model of typhoid fever caused by Salmonella typhimurium, mutants with attenuated virulence were revealed by use of tags that were present in the inoculum but not in bacteria recovered from infected mice. This approach resulted in the identification of new virulence genes, some of which are related to, but functionally distinct from, the inv/spa family of S. typhimurium.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT INFECT DIS & BACTERIOL,LONDON W12 0NN,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT VIROL,LONDON W12 0NN,ENGLAND	Imperial College London; Imperial College London				Dalton, Emma/0000-0002-3517-0742; Hensel, Michael/0000-0001-6604-6253				BAUMLER AJ, 1994, INFECT IMMUN, V62, P1623; BUCHMEIER NA, 1993, MOL MICROBIOL, V7, P933, DOI 10.1111/j.1365-2958.1993.tb01184.x; CARTER PB, 1974, J EXP MED, V139, P1189, DOI 10.1084/jem.139.5.1189; Davis R., 1980, ADV BACTERIAL GENETI; DELORENZO V, 1994, METHOD ENZYMOL, V264, P386; FIELDS PI, 1986, P NATL ACAD SCI USA, V83, P5189, DOI 10.1073/pnas.83.14.5189; FINLAY BB, 1988, MOL MICROBIOL, V2, P757, DOI 10.1111/j.1365-2958.1988.tb00087.x; GALAN JE, 1989, P NATL ACAD SCI USA, V86, P6383, DOI 10.1073/pnas.86.16.6383; GINOCCHIO CC, 1994, CELL, V76, P717, DOI 10.1016/0092-8674(94)90510-X; GROISMAN EA, 1990, TRENDS BIOCHEM SCI, V15, P30, DOI 10.1016/0968-0004(90)90128-X; GROISMAN EA, 1993, EMBO J, V12, P3779, DOI 10.1002/j.1460-2075.1993.tb06056.x; Groisman Eduardo A., 1994, Trends in Microbiology, V2, P289, DOI 10.1016/0966-842X(94)90006-X; HENSEL M, UNPUB; HOLDEN DW, 1989, EMBO J, V8, P1927, DOI 10.1002/j.1460-2075.1989.tb03596.x; LEE JC, 1987, J INFECT DIS, V156, P741, DOI 10.1093/infdis/156.5.741; LU SW, 1994, P NATL ACAD SCI USA, V91, P12649, DOI 10.1073/pnas.91.26.12649; MAURIZI MR, 1990, J BIOL CHEM, V265, P12536; MILLER I, 1989, INFECT IMMUN, V57, P2758, DOI 10.1128/IAI.57.9.2758-2763.1989; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; REED L. J., 1938, AMER JOUR HYG, V27, P493; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Van Gijsegem F, 1993, Trends Microbiol, V1, P175, DOI 10.1016/0966-842X(93)90087-8	22	955	1135	1	78	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 21	1995	269	5222					400	403		10.1126/science.7618105	http://dx.doi.org/10.1126/science.7618105			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK427	7618105				2022-12-24	WOS:A1995RK42700048
J	HORN, D; CROSS, GAM				HORN, D; CROSS, GAM			A DEVELOPMENTALLY-REGULATED POSITION EFFECT AT A TELOMERIC LOCUS IN TRYPANOSOMA-BRUCEI	CELL			English	Article							GENE-EXPRESSION SITE; BLOOD-STREAM FORMS; TRANSCRIPTION UNIT; ANTIGENIC VARIATION; REPETITIVE PROTEIN; II TRANSCRIPTION; SURFACE-ANTIGEN; VSG GENE; PROMOTER; DNA	Trypanosoma brucei undergoes antigenic variation in the mammalian host. This can be achieved by activation and inactivation of telomeric variant-specific surface glycoprotein genes (vsg). In procyclic (insect midgut stage) cells, Vsg is not expressed. The mechanisms that regulate transcription of vsg expression sites (ESs) are unknown. Here we demonstrate that transcription from three different promoters was repressed when they were inserted at a transcriptionally silent telomere-proximal locus in bloodstream-form cells. This position effect was stable and heritable. Only transcription from an ES promoter was repressed in procyclic cells. The observed position effect and the promoter-specific developmental regulation suggest that these phenomena reflect the mechanisms that regulate vsg expression.			HORN, D (corresponding author), ROCKEFELLER UNIV,MOLEC PARASITOL LAB,NEW YORK,NY 10021, USA.		Cross, George A M/B-7444-2011	Cross, George A M/0000-0003-1374-6955; Horn, David/0000-0001-5173-9284	NIAID NIH HHS [AI21729] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI021729, R01AI021729] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALARCON CM, 1994, MOL CELL BIOL, V14, P5579, DOI 10.1128/MCB.14.8.5579; BERNARDS A, 1984, NUCLEIC ACIDS RES, V12, P4153, DOI 10.1093/nar/12.10.4153; BERNARDS A, 1984, CELL, V36, P163, DOI 10.1016/0092-8674(84)90085-0; BORST P, 1993, COLD SPRING HARB SYM, V58, P105, DOI 10.1101/SQB.1993.058.01.014; BROWN SD, 1992, MOL CELL BIOL, V12, P2644, DOI 10.1128/MCB.12.6.2644; CARRUTHERS VB, 1992, P NATL ACAD SCI USA, V89, P8818, DOI 10.1073/pnas.89.18.8818; CARRUTHERS VB, 1993, NUCLEIC ACIDS RES, V21, P2537, DOI 10.1093/nar/21.10.2537; CHUNG HM, 1992, PARASITOL TODAY, V8, P414, DOI 10.1016/0169-4758(92)90194-7; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; DROCOURT D, 1990, NUCLEIC ACIDS RES, V18, P4009, DOI 10.1093/nar/18.13.4009; GOMMERSAMPT JH, 1993, CELL, V75, P1129, DOI 10.1016/0092-8674(93)90322-H; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; HAJDUK SL, 1981, PARASITOLOGY, V83, P609, DOI 10.1017/S0031182000080574; HARTREE D, 1995, MOL BIOCHEM PARASIT, V71, P27, DOI 10.1016/0166-6851(95)00034-X; HEHL A, 1994, PARASITOL TODAY, V10, P442, DOI 10.1016/0169-4758(94)90180-5; HIRUMI H, 1994, PARASITOL TODAY, V10, P80, DOI 10.1016/0169-4758(94)90402-2; HUG M, 1993, MOL BIOCHEM PARASIT, V61, P87, DOI 10.1016/0166-6851(93)90161-P; JANZ L, 1994, MOL CELL BIOL, V14, P5804, DOI 10.1128/MCB.14.9.5804; JEFFERIES D, 1993, NUCLEIC ACIDS RES, V21, P191, DOI 10.1093/nar/21.2.191; JOHNSON JG, 1979, BIOCHEM J, V178, P689, DOI 10.1042/bj1780689; JOHNSON PJ, 1987, CELL, V51, P273, DOI 10.1016/0092-8674(87)90154-1; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; LEE MGS, 1995, MOL BIOCHEM PARASIT, V69, P223, DOI 10.1016/0166-6851(94)00186-Q; LENARDO MJ, 1986, MOL CELL BIOL, V6, P1991, DOI 10.1128/MCB.6.6.1991; MOWATT MR, 1987, MOL CELL BIOL, V7, P2838, DOI 10.1128/MCB.7.8.2838; NASMYTH KA, 1981, NATURE, V289, P244, DOI 10.1038/289244a0; OVERATH P, 1986, EUR J BIOCHEM, V160, P175, DOI 10.1111/j.1432-1033.1986.tb09955.x; PATNAIK PK, 1993, EMBO J, V12, P2529, DOI 10.1002/j.1460-2075.1993.tb05908.x; PAYS E, 1984, NUCLEIC ACIDS RES, V12, P5235, DOI 10.1093/nar/12.13.5235; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; RICHARDSON JP, 1988, MOL BIOCHEM PARASIT, V31, P203, DOI 10.1016/0166-6851(88)90150-8; RUDENKO G, 1994, EMBO J, V13, P5470, DOI 10.1002/j.1460-2075.1994.tb06882.x; Sambrook J., 1989, MOL CLONING LAB MANU; SCHLIMME W, 1993, PARASITOLOGY, V107, P237, DOI 10.1017/S003118200007921X; SHERMAN DR, 1991, EMBO J, V10, P3379, DOI 10.1002/j.1460-2075.1991.tb04902.x; URMENYI TP, 1995, NUCLEIC ACIDS RES, V23, P1010, DOI 10.1093/nar/23.6.1010; VANHAMME L, 1995, MICROBIOL REV, V59, P223, DOI 10.1128/MMBR.59.2.223-240.1995; VIJAYASARATHY S, 1990, NUCLEIC ACIDS RES, V18, P2967, DOI 10.1093/nar/18.10.2967; WHITE TC, 1986, NUCLEIC ACIDS RES, V14, P9471, DOI 10.1093/nar/14.23.9471; ZOMERDIJK JCBM, 1991, NUCLEIC ACIDS RES, V19, P5153, DOI 10.1093/nar/19.19.5153; ZOMERDIJK JCBM, 1993, MOL BIOCHEM PARASIT, V57, P295, DOI 10.1016/0166-6851(93)90205-C; ZOMERDIJK JCBM, 1992, NUCLEIC ACIDS RES, V20, P2725, DOI 10.1093/nar/20.11.2725; ZOMERDIJK JCBM, 1990, EMBO J, V9, P2791, DOI 10.1002/j.1460-2075.1990.tb07467.x	43	123	123	0	0	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 17	1995	83	4					555	561		10.1016/0092-8674(95)90095-0	http://dx.doi.org/10.1016/0092-8674(95)90095-0			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TF248	7585958	Bronze			2022-12-24	WOS:A1995TF24800008
J	VANDERPUT, NMJ; STEEGERSTHEUNISSEN, RPM; FROSST, P; TRIJBELS, FJM; ESKES, TKAB; VANDENHEUVEL, LP; MARIMAN, ECM; DENHEYER, M; ROZEN, R; BLOM, HJ				VANDERPUT, NMJ; STEEGERSTHEUNISSEN, RPM; FROSST, P; TRIJBELS, FJM; ESKES, TKAB; VANDENHEUVEL, LP; MARIMAN, ECM; DENHEYER, M; ROZEN, R; BLOM, HJ			MUTATED METHYLENETETRAHYDROFOLATE REDUCTASE AS A RISK FACTOR FOR SPINA-BIFIDA	LANCET			English	Note								Periconceptional folate supplementation reduces the risk of neural-tube defects. We studied the frequency of the 677C-->T mutation in the 5,10-methylenetetrahydrofolate reductase (MTHFR) gene in 55 patients with spina bifida and parents of such patients (70 mothers, 60 fathers). 5% of 207 controls were homozygous for the 677C-->T mutation compared with 16% of mothers, 10% of fathers, and 13% of patients. The mutation was associated with decreased MTHFR activity, low plasma folate, and high plasma homocysteine and red-cell folate concentrations. The 677C-->7 mutation should be regarded as a genetic risk factor for spina bifida.	UNIV NIJMEGEN HOSP,DEPT PEDIAT,6500 HB NIJMEGEN,NETHERLANDS; UNIV NIJMEGEN HOSP,DEPT OBSTET & GYNECOL,6500 HB NIJMEGEN,NETHERLANDS; UNIV NIJMEGEN HOSP,DEPT EPIDEMIOL,6500 HB NIJMEGEN,NETHERLANDS; UNIV NIJMEGEN HOSP,DEPT HUMAN GENET,6500 HB NIJMEGEN,NETHERLANDS; MUNICIPAL HOSP LEYENBURG,DEPT HEMATOL,THE HAGUE,NETHERLANDS; MCGILL UNIV,DEPT HUMAN GENET,MONTREAL,PQ,CANADA; MCGILL UNIV,DEPT PEDIAT,MONTREAL,PQ H3A 2T5,CANADA; MCGILL UNIV,DEPT BIOL,MONTREAL,PQ,CANADA	Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; McGill University; McGill University; McGill University			van den Heuvel, L.P.W.J./H-8044-2014; van den Heuvel, Lambertus/AAM-1772-2021; Rozen, Rima/AAE-9294-2020	van den Heuvel, L.P.W.J./0000-0003-3917-6727; van den Heuvel, Lambertus/0000-0003-3917-6727; Blom, Henk/0000-0001-5202-9241				CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; DENHEIJER M, 1995, LANCET, V345, P882, DOI 10.1016/S0140-6736(95)90008-X; ENGBERSEN AMT, 1995, AM J HUM GENET, V56, P142; FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111; GOYETTE P, 1994, NAT GENET, V7, P195, DOI 10.1038/ng0694-195; KANG SS, 1991, AM J HUM GENET, V48, P536; MILLS JL, 1995, LANCET, V345, P149, DOI 10.1016/S0140-6736(95)90165-5; STEEGERSTHEUNIS.RP, 1994, METABOLISM, V43, P1475; Te Poele-Pothoff M. T. W. B., 1995, Annals of Clinical Biochemistry, V32, P218; 1991, LANCET, V338, P131	10	738	756	0	37	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 21	1995	346	8982					1070	1071		10.1016/S0140-6736(95)91743-8	http://dx.doi.org/10.1016/S0140-6736(95)91743-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA697	7564788	Green Submitted, Bronze			2022-12-24	WOS:A1995TA69700012
J	VELCULESCU, VE; ZHANG, L; VOGELSTEIN, B; KINZLER, KW				VELCULESCU, VE; ZHANG, L; VOGELSTEIN, B; KINZLER, KW			SERIAL ANALYSIS OF GENE-EXPRESSION	SCIENCE			English	Article							CDNA CLONES; SEQUENCE; DNA; IDENTIFICATION	The characteristics of an organism are determined by the genes expressed within it. A method was developed, called serial analysis of gene expression (SAGE), that allows the quantitative and simultaneous analysis of a large number of transcripts. To demonstrate this strategy, short diagnostic sequence tags were isolated from pancreas, concatenated, and cloned. Manual sequencing of 1000 tags revealed a gene expression pattern characteristic of pancreatic function. New pancreatic transcripts corresponding to novel tags were identified. SAGE should provide a broadly applicable means for the quantitative cataloging and comparison of expressed genes in a variety of normal, developmental, and disease states.	JOHNS HOPKINS UNIV,CTR ONCOL,HOWARD HUGHES MED INST,BALTIMORE,MD 21231; JOHNS HOPKINS UNIV,PROGRAM HUMAN GENET & MOLEC BIOL,BALTIMORE,MD 21231	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University			Velculescu, Victor/ABF-4846-2020; Zhang, Lin/A-7389-2009	Velculescu, Victor/0000-0003-1195-438X; Zhang, Lin/0000-0003-0018-3903	NCI NIH HHS [CA57345, CA35494] Funding Source: Medline; NIGMS NIH HHS [GM07309] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA057345, R37CA035494, R01CA057345, R01CA035494] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ALWINE JC, 1977, P NATL ACAD SCI USA, V74, P5350, DOI 10.1073/pnas.74.12.5350; DEININGER PL, 1981, J MOL BIOL, V151, P17, DOI 10.1016/0022-2836(81)90219-9; DELSAL G, 1989, BIOTECHNIQUES, V7, P514; FIELDS C, 1994, NAT GENET, V7, P345, DOI 10.1038/ng0794-345; HAN JH, 1986, P NATL ACAD SCI USA, V83, P110, DOI 10.1073/pnas.83.1.110; HEDRICK SM, 1984, NATURE, V308, P149, DOI 10.1038/308149a0; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; OKUBO K, 1992, NAT GENET, V2, P173, DOI 10.1038/ng1192-173; RUPPERT JM, 1988, MOL CELL BIOL, V8, P3104, DOI 10.1128/MCB.8.8.3104; SZYBALSKI W, 1985, GENE, V40, P169, DOI 10.1016/0378-1119(85)90039-3; TAKEDA J, 1993, HUM MOL GENET, V2, P1793, DOI 10.1093/hmg/2.11.1793; VERES G, 1987, SCIENCE, V237, P415, DOI 10.1126/science.3603027; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	16	3211	3836	7	188	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 20	1995	270	5235					484	487		10.1126/science.270.5235.484	http://dx.doi.org/10.1126/science.270.5235.484			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA374	7570003				2022-12-24	WOS:A1995TA37400045
J	REES, MR; MICHALIS, LK				REES, MR; MICHALIS, LK			ACTIVATED-GUIDEWIRE TECHNIQUE FOR TREATING CHRONIC CORONARY-ARTERY OCCLUSION	LANCET			English	Note							ANGIOPLASTY; RECANALIZATION; SYSTEMS	Coronary angioplasty was successfully carried out with an activated guidewire technique in 33 of 47 patients who had undergone a failed attempt at conventional angioplasty for the treatment of chronic coronary artery occlusion. 80% of these occlusions were stump-like occlusions. This technique involves the attachment of a hand-held battery-driven motorised device to standard angioplasty equipment and can be used at any time during the procedure. The device generates complex vibratory movement in the guidewire to facilitate crossing of occluded vessels.	KEELE UNIV,POSTGRAD MED SCH,STOKE ON TRENT,STAFFS,ENGLAND	Keele University			Rees, Michael/Y-4640-2019	Mihalis, Lampros/0000-0001-8834-4462				ABELA GS, 1986, J AM COLL CARDIOL, P184; DANCHIN N, 1995, AM J CARDIOL, V75, P330, DOI 10.1016/S0002-9149(99)80548-7; GRAY DF, 1993, CATHETER CARDIO DIAG, V30, P293, DOI 10.1002/ccd.1810300406; HAMM CW, 1990, AM J CARDIOL, V66, P1459, DOI 10.1016/0002-9149(90)90534-8; MEIER B, 1990, TXB INTERVENTIONAL C, P300; MILKER JP, 1987, AM J CARDIOL, V59, P535; PANDE AK, 1992, AM HEART J, V123, P1182, DOI 10.1016/0002-8703(92)91020-2; SANBORN TA, 1993, CIRCULATION, V88, P504; TIWARI P, 1995, P ROENTGEN CENTURARY, V1, P365	9	21	21	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 7	1995	346	8980					943	944		10.1016/S0140-6736(95)91560-5	http://dx.doi.org/10.1016/S0140-6736(95)91560-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY808	7564731				2022-12-24	WOS:A1995RY80800012
J	KALKSTEIN, LS				KALKSTEIN, LS			LESSONS FROM A VERY HOT SUMMER	LANCET			English	Editorial Material							IMPACTS				KALKSTEIN, LS (corresponding author), UNIV DELAWARE,CTR CLIMAT RES,DEPT GEOG,NEWARK,DE 19711, USA.							HAINES A, 1993, LANCET, V342, P1464, DOI 10.1016/0140-6736(93)92937-O; Kalkstein L.S., 1993, EXPERIENTIA, V49, P469; KALKSTEIN LS, 1993, LANCET, V342, P1397, DOI 10.1016/0140-6736(93)92757-K; MCKENZIE D, 1995, NEW SCI, P4; ROGOT E, 1992, AM J EPIDEMIOL, V136, P106, DOI 10.1093/oxfordjournals.aje.a116413; IN PRESS ASSESSING I; 1994, NATIONAL CLIMATE SUR; IN PRESS HUMAN HLTH; 1995, MMWR-MORBID MORTAL W, V44, P577	9	20	20	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 30	1995	346	8979					857	859						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX196	7564666				2022-12-24	WOS:A1995RX19600004
J	DAVID, M; PETRICOIN, E; BENJAMIN, C; PINE, R; WEBER, MJ; LARNER, AC				DAVID, M; PETRICOIN, E; BENJAMIN, C; PINE, R; WEBER, MJ; LARNER, AC			REQUIREMENT FOR MAP KINASE (ERK2) ACTIVITY IN INTERFERON-ALPHA-STIMULATED AND INTERFERON-BETA-STIMULATED GENE-EXPRESSION THROUGH STAT PROTEINS	SCIENCE			English	Article							ACTIVATION; CELLS	Activation of early response genes by interferons (IFNs) requires tyrosine phosphorylation of STAT (signal transducers and activators of transcription) proteins. It was found that the serine-threonine kinase mitogen-activated protein kinase (MAPK) [specifically, the 42-kilodalton MAPK or extracellular signal-regulated kinase 2 (ERK2)] interacted with the alpha subunit of IFN-alpha/beta receptor in vitro and in vivo. Treatment of cells with IFN-beta induced tyrosine phosphorylation and activation of MAPK and caused MAPK and Stat1 alpha to coimmunoprecipitate. Furthermore, expression of dominant negative MAPK inhibited IFN-beta-induced transcription. Therefore, MAPK appears to regulate IFN-alpha and IFN-beta activation of early response genes by modifying the Jak-STAT signaling cascade.	US FDA,CTR BIOL EVALUAT & RES,DIV CYTOKINE BIOL,BETHESDA,MD 20892; BIOGEN INC,CAMBRIDGE,MA 02142; PUBL HLTH RES INST,NEW YORK,NY 10016; UNIV VIRGINIA,SCH MED,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,SCH MED,CTR CANC,CHARLOTTESVILLE,VA 22908	US Food & Drug Administration (FDA); Biogen; University of Virginia; University of Virginia					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047332] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47332] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; CONSTANTINESCU SN, 1994, P NATL ACAD SCI USA, V91, P9602, DOI 10.1073/pnas.91.20.9602; DAVID M, UNPUB; FINBLOOM DS, UNPUB; HER JH, 1993, BIOCHEM J, V296, P25, DOI 10.1042/bj2960025; IGARASHI K, 1994, J BIOL CHEM, V269, P14333; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; LARNER AC, 1995, BBA-MOL CELL RES, V1266, P278, DOI 10.1016/0167-4889(95)00015-K; PETRICOIN EF, 1992, MOL CELL BIOL, V12, P4486, DOI 10.1128/MCB.12.10.4486; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; REICH NC, 1990, P NATL ACAD SCI USA, V87, P8761, DOI 10.1073/pnas.87.22.8761; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; WANG HCR, 1992, MOL BIOL CELL, V3, P1329, DOI 10.1091/mbc.3.12.1329; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	16	519	536	0	11	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 22	1995	269	5231					1721	1723		10.1126/science.7569900	http://dx.doi.org/10.1126/science.7569900			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV948	7569900				2022-12-24	WOS:A1995RV94800038
J	MORRIS, JG; SHAY, DK; HEBDEN, JN; MCCARTER, RJ; PERDUE, BE; JARVIS, W; JOHNSON, JA; DOWLING, TC; POLISH, LB; SCHWALBE, RS				MORRIS, JG; SHAY, DK; HEBDEN, JN; MCCARTER, RJ; PERDUE, BE; JARVIS, W; JOHNSON, JA; DOWLING, TC; POLISH, LB; SCHWALBE, RS			ENTEROCOCCI RESISTANT TO MULTIPLE ANTIMICROBIAL AGENTS, INCLUDING VANCOMYCIN - ESTABLISHMENT OF ENDEMICITY IN A UNIVERSITY MEDICAL-CENTER	ANNALS OF INTERNAL MEDICINE			English	Article						VANCOMYCIN; ENTEROCOCCUS; ENTEROCOCCUS FAECIUM; DRUG RESISTANCE, MICROBIAL; ORGAN TRANSPLANTATION	HIGH-LEVEL RESISTANCE; ANTIBIOTIC SYNERGISM; FAECIUM; INFECTIONS; GENTAMICIN; TRENDS	Objectives: To determine the distribution of and risk factors for colonization and infection with vancomycin-resistant enterococci; to evaluate the molecular epidemiology of these strains; and to assess the effect of interventions, including 1) strict adherence to infection control procedures and 2) restricted use of vancomycin. Design: Problem identification based on descriptive studies, point-prevalence surveys, and case-control studies and followed by specific interventions and evaluation of the response to these interventions. Setting: University medical center. Participants: All patients hospitalized between May 1992 and June 1994 (59 196 admissions). Main Results: 75 active infections attributed to vancomycin-resistant enterococci were identified. Thirty-one patients (41%) had bloodstream infections and 6 (8%) died. The incidence of active infection was highest in the organ transplantation unit (13.2 infections/1000 admissions). In the point-prevalence studies, vancomycin-resistant enterococci were isolated from 20% of a random sample of hospitalized patients in July, August, and September 1993 (adjusted prevalence, 16.9%). Case-control studies showed significant associations between colonization and infection and 1) receipt of antimicrobial agents, particularly vancomycin, and 2) severity of illness. Although several small case clusters had isolates with identical banding patterns on pulsed-field gel electrophoresis, at least 45 different banding patterns were noted among medical center isolates. Interventions took place in November and December 1993. Vancomycin restriction policies resulted in a 59% decrease in intravenous vancomycin use and an 85% decrease in oral vancomycin use. Point-prevalence surveys done in April, May, and June 1994 showed a consistent 20% level of colonization with vancomycin-resistant enterococci strains (adjusted prevalence, 18.7%). No significant changes were seen in rates of vancomycin-resistant enterococci infection. Conclusions: Vancomycin-resistant enterococci are an important cause of illness and death in the study institution, particularly among organ transplant recipients and other seriously ill persons; they have also become a common intestinal colonizer among hospitalized patients. The diversity of isolates (based on molecular typing studies) suggests that resistant organisms have been introduced from multiple sources. Interventions that effectively lower the overall level of colonization with vancomycin-resistant enterococci must still be identified.	CTR DIS CONTROL & PREVENT, ATLANTA, GA 30341 USA; UNIV MARYLAND, MED CTR, BALTIMORE, MD 21201 USA; UNIV MARYLAND, SCH MED, BALTIMORE, MD 21201 USA	Centers for Disease Control & Prevention - USA; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	MORRIS, JG (corresponding author), VET AFFAIRS MED CTR, INFECT DIS SECT, 10 N GREENE ST, BALTIMORE, MD 21201 USA.		Dowling, Thomas/D-2147-2013	Dowling, Thomas/0000-0003-3214-9283; Shay, David/0000-0001-9619-4820				[Anonymous], 1993, METHODS DILUTION ANT; [Anonymous], 1993, PERFORMANCE STANDARD; ARDUINO RC, 1994, PRINCIPLES PRACTICE; BANERJEE SN, 1991, AM J MED, V91, pS86, DOI 10.1016/0002-9343(91)90349-3; BATES J, 1993, LANCET, V342, P490, DOI 10.1016/0140-6736(93)91613-Q; BATES J, 1994, J ANTIMICROB CHEMOTH, V34, P507, DOI 10.1093/jac/34.4.507; BOYCE JM, 1994, J CLIN MICROBIOL, V32, P1148, DOI 10.1128/JCM.32.5.1148-1153.1994; CHADWICK PR, 1994, LANCET, V344, P685, DOI 10.1016/S0140-6736(94)92119-9; DEAN AG, 1991, EPIINFO VERSION 5 WO; DEAN J, 1994, 94TH GEN M AM SOC MI; DONABEDIAN SM, 1992, J CLIN MICROBIOL, V30, P2757, DOI 10.1128/JCM.30.11.2757-2761.1992; FACKLAM RR, 1989, J CLIN MICROBIOL, V27, P731, DOI 10.1128/JCM.27.4.731-734.1989; FRIEDEN TR, 1993, LANCET, V342, P76, DOI 10.1016/0140-6736(93)91285-T; GARNER JS, 1983, INFECT CONT HOSP EP, V4, P245; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; GOERING RV, 1994, 3RD INT M BACT EP MA; GREEN M, 1993, 33RD INT C ANT AG CH; HARIHARAN R, 1993, 33RD INT C ANT AG CH; HERDEN J, 1994, 34TH INT C ANT AG CH; JETT BD, 1994, CLIN MICROBIOL REV, V7, P462, DOI 10.1128/CMR.7.4.462-478.1994; JONES R, 1993, 33RD INT C ANT AG CH; JORDENS JZ, 1994, J ANTIMICROB CHEMOTH, V34, P515, DOI 10.1093/jac/34.4.515; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LECLERCQ R, 1988, NEW ENGL J MED, V319, P157, DOI 10.1056/NEJM198807213190307; LINDEN P, 1993, 33RD INT C ANT AG CH; LIVORNESE LL, 1992, ANN INTERN MED, V117, P112, DOI 10.7326/0003-4819-117-2-112; MEDERSKISAMORAJ BD, 1983, J INFECT DIS, V147, P751, DOI 10.1093/infdis/147.4.751; MOELLERI.RC, 1971, J CLIN INVEST, V50, P2580, DOI 10.1172/JCI106758; MOELLERING RC, 1971, J INFECT DIS, V124, pS207, DOI 10.1093/infdis/124.Supplement_1.S207; MONTECALVO MA, 1994, ANTIMICROB AGENTS CH, V38, P1363, DOI 10.1128/AAC.38.6.1363; PETERSEN NJ, 1973, HEALTH LAB SCI, V10, P18; PRATTRIPIN K, 1992, CLIN MICROBIOLOGY PR; SCHABERG DR, 1991, AM J MED, V91, pS72, DOI 10.1016/0002-9343(91)90346-Y; SCHWALBE RE, 1991, 91ST ANN M AM SOC MI; SMITH SM, 1994, 34TH INT C ANT AG CH; SPERA RV, 1992, JAMA-J AM MED ASSOC, V268, P2563, DOI 10.1001/jama.268.18.2563; STANDIFORD HD, 1970, ARCH INTERN MED, V126, P255, DOI 10.1001/archinte.126.2.255; STROUD L, 1993, SOC HOSPITAL EPIDEMI; UTTLEY AHC, 1988, LANCET, V1, P57; VENUTI E, 1994, 94TH GEN M AM SOC MI; VERMA P, 1994, 94TH GEN M AM SOC MI; ZERVOS MJ, 1986, J INFECT DIS, V153, P1075, DOI 10.1093/infdis/153.6.1075; 1995, INFECT CONT HOSP EP, V16, P105; 1993, MMWR-MORBID MORTAL W, V42, P5947; 1992, STANDARD METHODS EXA, P69	45	395	404	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1995	123	4					250	259		10.7326/0003-4819-123-4-199508150-00002	http://dx.doi.org/10.7326/0003-4819-123-4-199508150-00002			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN665	7611590				2022-12-24	WOS:A1995RN66500002
J	PAGANO, M; TAM, SW; THEODORAS, AM; BEERROMERO, P; DELSAL, G; CHAU, V; YEW, PR; DRAETTA, GF; ROLFE, M				PAGANO, M; TAM, SW; THEODORAS, AM; BEERROMERO, P; DELSAL, G; CHAU, V; YEW, PR; DRAETTA, GF; ROLFE, M			ROLE OF THE UBIQUITIN-PROTEASOME PATHWAY IN REGULATING ABUNDANCE OF THE CYCLIN-DEPENDENT KINASE INHIBITOR P27	SCIENCE			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; DEGRADATION; ASSOCIATION; PROTEIN; CLONING; SYSTEM; YEAST; GENE; P53	The p27 mammalian cell cycle protein is an inhibitor of cyclin-dependent kinases. Both in vivo and in vitro, p27 was found to be degraded by the ubiquitin-proteasome pathway. The human ubiquitin-conjugating enzymes Ubc2 and Ubc3 were specifically involved in the ubiquitination of p27. Compared with proliferating cells, quiescent cells exhibited a smaller amount of p27 ubiquitinating activity, which accounted for the marked increase of p27 half-life measured in these cells. Thus, the abundance of p27 in cells is regulated by degradation. The specific proteolysis of p27 may represent a mechanism for regulating the activity of cyclin-dependent kinases.	WAYNE STATE UNIV, DEPT PHARMACOL, DETROIT, MI 48201 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA	Wayne State University; Harvard University; Harvard Medical School	PAGANO, M (corresponding author), MITOTIX INC, 1 KENDALL SQ, BLDG 600, CAMBRIDGE, MA 02139 USA.			pagano, michele/0000-0003-3210-2442; DEL SAL, GIANNINO/0000-0003-2185-6003				CHAU V, UNPUB; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GUARINO LA, 1995, CELL, V80, P301, DOI 10.1016/0092-8674(95)90413-1; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HEGDE AN, 1993, P NATL ACAD SCI USA, V90, P7436, DOI 10.1073/pnas.90.16.7436; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HUNT T, 1972, J MOL BIOL, V66, P471, DOI 10.1016/0022-2836(72)90427-5; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; KAISER P, 1994, J BIOL CHEM, V269, P8797; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KOKEN MHM, 1991, P NATL ACAD SCI USA, V88, P8865, DOI 10.1073/pnas.88.20.8865; LIU Z, 1992, J BIOL CHEM, V267, P15829; LUCA FC, 1989, J CELL BIOL, V109, P1895, DOI 10.1083/jcb.109.5.1895; Murray A, 1993, CELL CYCLE INTRO; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1995, CELL CYCLE MATERIALS, pCH24; PAGANO M, UNPUB; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PLON SE, 1993, P NATL ACAD SCI USA, V90, P10484, DOI 10.1073/pnas.90.22.10484; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROLFE M, 1995, P NATL ACAD SCI USA, V92, P3264, DOI 10.1073/pnas.92.8.3264; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; TAM SC, UNPUB; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	34	1723	1771	3	67	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 4	1995	269	5224					682	685		10.1126/science.7624798	http://dx.doi.org/10.1126/science.7624798			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM702	7624798				2022-12-24	WOS:A1995RM70200031
J	BAKER, SM; BRONNER, CE; ZHANG, L; PLUG, AW; ROBATZEK, M; WARREN, G; ELLIOTT, EA; YU, JA; ASHLEY, T; ARNHEIM, N; FLAVELL, RA; LISKAY, RM				BAKER, SM; BRONNER, CE; ZHANG, L; PLUG, AW; ROBATZEK, M; WARREN, G; ELLIOTT, EA; YU, JA; ASHLEY, T; ARNHEIM, N; FLAVELL, RA; LISKAY, RM			MALE-MICE DEFECTIVE IN THE DNA MISMATCH REPAIR GENE PMS2 EXHIBIT ABNORMAL CHROMOSOME SYNAPSIS IN MEIOSIS	CELL			English	Article							NONPOLYPOSIS COLORECTAL-CANCER; SACCHAROMYCES-CEREVISIAE; MEIOTIC SYNAPSIS; ESCHERICHIA-COLI; RECOMBINATION; CONVERSION; YEAST; INITIATION; MUTATIONS; SEQUENCE	Using gene targeting in embryonic stem cells, we have derived mice with a null mutation in a DNA mismatch repair gene homolog, PMS2. We observed microsatellite instability in the male germline, in tail, and in tumor DNA of PMS2-deficient animals. We therefore conclude that PMS2 is involved in DNA mismatch repair in a variety of tissues. PMS2-deficient animals appear prone to sarcomas and lymphomas, PMS2-deficient males are infertile, producing only abnormal spermatozoa. Analysis of axial element and synaptonemal complex formation during prophase of meiosis I indicates abnormalities in chromosome synapsis. These observations suggest links among mismatch repair, genetic recombination, and chromosome synapsis in meiosis.	OREGON HLTH SCI UNIV, DEPT MOLEC MICROBIOL & IMMUNOL, PORTLAND, OR 97201 USA; UNIV SO CALIF, PROGRAM MOLEC BIOL, LOS ANGELES, CA 90089 USA; YALE UNIV, SCH MED, DEPT GENET, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, HOWARD HUGHES MED INST, IMMUNOBIOL SECT, NEW HAVEN, CT 06510 USA; AGR UNIV WAGENINGEN, DEPT GENET, 6703 HA WAGENINGEN, NETHERLANDS	Oregon Health & Science University; University of Southern California; Yale University; Howard Hughes Medical Institute; Yale University; Wageningen University & Research	BAKER, SM (corresponding author), OREGON HLTH SCI UNIV, DEPT MED & MOLEC GENET, PORTLAND, OR 97201 USA.		Yu, Jian/A-8301-2009; Zhang, Lin/A-7389-2009	Yu, Jian/0000-0002-4021-1000; Zhang, Lin/0000-0003-0018-3903; Arnheim, Norman/0000-0003-1247-1347	NIGMS NIH HHS [GM45413-05, GM32741-14, GM49779] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049779, R01GM045413, R01GM032741, R37GM032741] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ALANI E, 1994, GENETICS, V137, P19; ASHLEY T, 1988, GENETICS, V118, P307; ASHLEY T, 1990, GENETICA, V83, P1; AU KG, 1992, J BIOL CHEM, V267, P12142; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; Boer P. de, 1989, Fertility and chromosome pairing: recent studies in plants and animals., P37; BRAUN RE, 1990, BIOL REPROD, V43, P684, DOI 10.1095/biolreprod43.4.684; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CARPENTER ATC, 1987, BIOESSAYS, V6, P232, DOI 10.1002/bies.950060510; DETLOFF P, 1992, GENETICS, V132, P113; DIETRICH W, 1992, GENETICS, V131, P423; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELLIOTT EA, 1994, J EXP MED, V179, P681, DOI 10.1084/jem.179.2.681; FISHEL R, 1994, CANCER RES, V54, P5539; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FOREJT J, 1985, EXP CLIN IMMUNOGENET, V2, P106; GOETZ P, 1984, J CELL SCI, V65, P249; HAWLEY RS, 1993, CELL, V72, P301, DOI 10.1016/0092-8674(93)90108-3; HOEKSTRA MF, 1991, METHOD ENZYMOL, V194, P329; KLECKNER N, 1993, COLD SPRING HARB SYM, V58, P553, DOI 10.1101/SQB.1993.058.01.062; Kolodner Richard D., 1994, Current Opinion in Biotechnology, V5, P585, DOI 10.1016/0958-1669(94)90079-5; KRAMER W, 1989, J BACTERIOL, V171, P5339, DOI 10.1128/jb.171.10.5339-5346.1989; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEEFLANG PE, 1994, CURRENT PROTOCOLS HU, V1; LI FP, 1988, CANCER RES, V48, P5358; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; MIKLOS GLG, 1974, CYTOGENET CELL GENET, V13, P558, DOI 10.1159/000130307; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Moses MJ, 1980, ANIMAL MODELS HUMAN, P169; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; PETES TD, 1991, MOL CELLULAR BIOL YE, V1, P407; PETIT MA, 1991, GENETICS, V129, P327; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; PROLLA TA, 1994, MOL CELL BIOL, V14, P407, DOI 10.1128/MCB.14.1.407; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; REENAN RAG, 1992, GENETICS, V132, P963; ROEDER GS, 1990, TRENDS GENET, V6, P385, DOI 10.1016/0168-9525(90)90297-J; ROSSMACDONALD P, 1994, CELL, V79, P1069, DOI 10.1016/0092-8674(94)90037-X; Russell L. D., 1990, HISTOLOGICAL HISTOPA; SANCAR A, 1993, SCIENCE, V259, P1415, DOI 10.1126/science.8451638; SELVA EM, 1995, GENETICS, V139, P1175; SHERMAN JD, 1992, GENOME, V35, P907, DOI 10.1139/g92-140; SMITHIES O, 1986, PHILOS T ROY SOC B, V312, P291, DOI 10.1098/rstb.1986.0008; Speed R.M., 1989, FERTILITY CHROMOSOME, P1; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; WILLIAMSON MS, 1985, GENETICS, V110, P609; WORTH L, 1994, P NATL ACAD SCI USA, V91, P3238, DOI 10.1073/pnas.91.8.3238	52	469	494	0	11	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 28	1995	82	2					309	319		10.1016/0092-8674(95)90318-6	http://dx.doi.org/10.1016/0092-8674(95)90318-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RL760	7628019	hybrid			2022-12-24	WOS:A1995RL76000018
J	SILBER, JH; ROSENBAUM, PR; SCHWARTZ, JS; ROSS, RN; WILLIAMS, SV				SILBER, JH; ROSENBAUM, PR; SCHWARTZ, JS; ROSS, RN; WILLIAMS, SV			EVALUATION OF THE COMPLICATION RATE AS A MEASURE OF QUALITY OF CARE IN CORONARY-ARTERY BYPASS GRAFT-SURGERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IN-HOSPITAL MORTALITY; SURGICAL-PROCEDURES; ADMISSION SEVERITY; ADVERSE EVENTS; DATA-BASES; ILLNESS; MEDISGROUPS; DEATH; RISK; VOLUME	Objective.-To determine whether hospital rankings based on complication rates provide the same information as hospital rankings based on mortality rates. Design.-A retrospective study of in-hospital death, complication, and death following complication (failure to rescue). Hospitals were ranked using residuals based on the difference between the observed and the expected number of events (from logistic regression models); rankings were compared using Spearman rank correlations. Setting.-Hospitals performing coronary artery bypass graft (CABG) surgery in the 1991 and 1992 MedisGroups National Comparative Data Bases. Patients and Data Sets,-Record abstraction data for 16 673 patients who underwent CABG procedures at 57 hospitals, linked with data from the 1991 American Hospital Association Annual Survey. Results.-After adjusting for patient admission severity of illness, there were low correlations between hospital rankings based on death or failure to rescue and those rankings based on complication (death vs complication, r=0.07, P=.58; failure to rescue vs complication, r=-0.22, P=.11). In addition, many hospital characteristics that are generally associated with a higher quality of care were associated with higher complication rates but with expected or lower-than-expected mortality rates. Conclusions.-HospitaI rankings based on complication rates provide different information than those based on mortality rates. Until more is known about these differences, complication rates should not be used to judge hospital quality of care in CABG surgery.	UNIV PENN, SCH MED, LEONARD DAVIS INST HLTH ECON, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DIV ONCOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DIV GEN INTERNAL MED, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT PEDIAT, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT MED, PHILADELPHIA, PA 19104 USA; UNIV PENN, WHARTON SCH, DEPT STAT, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania			Rosenbaum, Paul R/H-8687-2012		AHRQ HHS [R01-HS06560] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BLUMBERG MS, 1991, JAMA-J AM MED ASSOC, V265, P2965; BRENNAN TA, 1991, JAMA-J AM MED ASSOC, V265, P3265, DOI 10.1001/jama.265.24.3265; BREWSTER AC, 1985, INQUIRY-J HEALTH CAR, V22, P377; BURSTIN HR, 1993, JAMA-J AM MED ASSOC, V270, P845, DOI 10.1001/jama.270.7.845; DESHARNAIS S, 1991, HEALTH SERV RES, V26, P425; FLOOD AF, 1987, HOSPITAL STRUCTURE P, P174; HABERMAN SJ, 1976, 9TH P INT BIOM C BOS, P104; HABERMAN SJ, 1974, ANAL FREQUENCY DATA, P138; HAMMERMEISTER KE, 1990, CIRCULATION, V82, P380; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HANNAN EL, 1992, MED CARE, V30, P892, DOI 10.1097/00005650-199210000-00002; HANNAN EL, 1989, JAMA-J AM MED ASSOC, V262, P503, DOI 10.1001/jama.262.4.503; HANNAN EL, 1994, JAMA-J AM MED ASSOC, V271, P761, DOI 10.1001/jama.271.10.761; HANNAN EL, 1989, AM J PUBLIC HEALTH, V79, P430, DOI 10.2105/AJPH.79.4.430; Hartz A J, 1992, Int J Technol Assess Health Care, V8, P524; HARTZ AJ, 1994, AM J PUBLIC HEALTH, V84, P1609, DOI 10.2105/AJPH.84.10.1609; HARTZ AJ, 1989, NEW ENGL J MED, V321, P1720, DOI 10.1056/NEJM198912213212506; HARTZ AJ, 1992, AM J PUBLIC HEALTH, V82, P1631, DOI 10.2105/AJPH.82.12.1631; HARTZ AJ, 1993, HEALTH SERV RES, V27, P765; Hosmer DW, 1989, APPL LOGISTIC REGRES, P140; IEZZONI LI, 1993, MED CARE, V31, P277, DOI 10.1097/00005650-199303000-00009; IEZZONI LI, 1994, INQUIRY-J HEALTH CAR, V31, P40; IEZZONI LI, 1988, JAMA-J AM MED ASSOC, V260, P3159, DOI 10.1001/jama.260.21.3159; KRAKAUER H, 1993, INQUIRY-J HEALTH CAR, V30, P115; KUHN EM, 1991, MED CARE, V29, P1028, DOI 10.1097/00005650-199110000-00008; LUFT HS, 1993, JAMA-J AM MED ASSOC, V270, P331, DOI 10.1001/jama.270.3.331; LUFT HS, 1986, JAMA-J AM MED ASSOC, V255, P2780, DOI 10.1001/jama.255.20.2780; Mosteller F, 1977, DATA ANAL REGRESSION, P299; OCONNOR GT, 1991, JAMA-J AM MED ASSOC, V266, P803, DOI 10.1001/jama.266.6.803; PARK RE, 1990, JAMA-J AM MED ASSOC, V264, P484; ROSEN AK, 1992, MED CARE, V30, P753, DOI 10.1097/00005650-199209000-00001; SHORTELL SM, 1988, NEW ENGL J MED, V318, P1100, DOI 10.1056/NEJM198804283181705; SHOWSTACK JA, 1987, JAMA-J AM MED ASSOC, V257, P785, DOI 10.1001/jama.257.6.785; SILBER JH, 1992, MED CARE, V30, P615, DOI 10.1097/00005650-199207000-00004; SILBER JH, 1995, J AM STAT ASSOC, V90, P7, DOI 10.2307/2291124; SILBER JH, 1993, CLIN RES, V41, pA181; STEEN PM, 1993, INQUIRY-J HEALTH CAR, V30, P128; THOMAS JW, 1989, INQUIRY-J HEALTH CAR, V26, P483; THOMAS JW, 1991, INQUIRY-J HEALTH CAR, V28, P39; WEISBERG S, 1985, APPL LINEAR REGRESSI, P179; WRIGHT JG, 1987, CHEST, V91, P394, DOI 10.1378/chest.91.3.394	41	250	252	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 26	1995	274	4					317	323		10.1001/jama.274.4.317	http://dx.doi.org/10.1001/jama.274.4.317			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RJ898	7609261				2022-12-24	WOS:A1995RJ89800034
J	COCKERELL, OC; JOHNSON, AL; SANDER, JWAS; HART, YM; SHORVON, SD				COCKERELL, OC; JOHNSON, AL; SANDER, JWAS; HART, YM; SHORVON, SD			REMISSION OF EPILEPSY - RESULTS FROM THE NATIONAL GENERAL-PRACTICE STUDY OF EPILEPSY	LANCET			English	Article							1ST SEIZURE; PROGNOSIS; POPULATION; ROCHESTER; MINNESOTA; NGPSE	Remission of seizures is a crucial measure of outcome in epilepsy. The National General Practice Study of Epilepsy (NGPSE) aimed to investigate the remission of patients with epilepsy and the effect of various factors on the likelihood of remission. The NGPSE is a prospective population-based study free from major selection bias. We enrolled 1091 patients with newly diagnosed or suspected epilepsy who attended one of 275 general practices throughout the UK between 1984 and 1987, Remission was analysed in those patients who were classified after 6 months as having definite epilepsy (n=564) or possible epilepsy (n=228). After 9 years from the index seizure, 86% (95% CI 81-90) of patients with definite epilepsy had achieved a remission of 3 years and 68% (61-75) a remission of 5 years. For the complete cohort, including those with possible epilepsy, the remission rates at 9 years were 87% (83-91) for 3-year remission and 71% (65-77) for 5-year remission. The proportion of patients with definite epilepsy who were still in remission at 9 years' follow-up (terminal remission) was 68% (62-74) for 3-year and 54% (48-60) for 5-year remission. 61% (56-68) of patients with idiopathic seizures and 61% (46-75) of those with remote symptomatic epilepsy had achieved 5-year remission by 9 years. Overall, age and seizure type had little effect on the chances of achieving remission, This study confirms the good outcome for seizure control in the majority of patients.	CHALFONT CTR EPILEPSY, CHALFONT ST PETER, BUCKS, ENGLAND; INST PUBL HLTH, MRC, BIOSTAT UNIT, CAMBRIDGE, ENGLAND	MRC Biostatistics Unit; University of Cambridge	COCKERELL, OC (corresponding author), UCL NATL HOSP NEUROL & NEUROSURG, EPILEPSY RES GRP, QUEEN SQ, LONDON WC1N 3BG, ENGLAND.		Sander, Josemir W/C-1576-2008; Shorvon, Simon D/A-2019-2009	Sander, Josemir W/0000-0001-6041-9661; 				ANNEGERS JF, 1979, EPILEPSIA, V20, P729, DOI 10.1111/j.1528-1157.1979.tb04857.x; BEGHI E, 1992, EPILEPSIA, V33, P45; CHADWICK D, 1991, LANCET, V337, P1175; CHADWICK D, 1993, BRIT MED J, V306, P1374; COCKERELL OC, 1994, LANCET, V344, P918, DOI 10.1016/S0140-6736(94)92270-5; COCKERELL OC, 1995, J NEUROL NEUROSUR PS, V58, P570, DOI 10.1136/jnnp.58.5.570; CROMBIE DL, 1960, BRIT MED J, V2, P416; ELWES RDC, 1984, NEW ENGL J MED, V311, P944, DOI 10.1056/NEJM198410113111503; GOODRIDGE DMG, 1983, BRIT MED J, V287, P645, DOI 10.1136/bmj.287.6393.645; HART YM, 1989, NEUROEPIDEMIOLOGY, V8, P221; HART YM, 1990, LANCET, V336, P1271, DOI 10.1016/0140-6736(90)92960-P; HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/j.1528-1157.1993.tb02586.x; HAUSER WA, 1975, EPILEPSIA, V16, P1, DOI 10.1111/j.1528-1157.1975.tb04721.x; JANZ D, 1990, COMPREHENSIVE EPILEP, P171; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MANFORD M, 1992, NEUROLOGY, V42, P1911; RAMSAY RE, 1983, NEUROLOGY, V33, P904, DOI 10.1212/WNL.33.7.904; RODIN EA, 1968, PROGNOSIS PATIENTS E; SANDER JWAS, 1993, LANCET, V342, P874, DOI 10.1016/0140-6736(93)92737-E; SANDER JWAS, 1993, EPILEPSIA, V34, P1007, DOI 10.1111/j.1528-1157.1993.tb02126.x; SHAFER SQ, 1988, EPILEPSIA, V29, P590, DOI 10.1111/j.1528-1157.1988.tb03767.x; SHORVON SD, 1984, J NEUROL NEUROSUR PS, V47, P1157, DOI 10.1136/jnnp.47.11.1157; VANDONSELAAR CA, 1989, NEUROLOGY, V39, P267, DOI 10.1212/WNL.39.2.267	23	291	295	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 15	1995	346	8968					140	144		10.1016/S0140-6736(95)91208-8	http://dx.doi.org/10.1016/S0140-6736(95)91208-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ031	7603228				2022-12-24	WOS:A1995RJ03100008
J	ZHENG, XF; FIORENTINO, D; CHEN, J; CRABTREE, GR; SCHREIBER, SL				ZHENG, XF; FIORENTINO, D; CHEN, J; CRABTREE, GR; SCHREIBER, SL			TOR KINASE DOMAINS ARE REQUIRED FOR 2 DISTINCT FUNCTIONS, ONLY ONE OF WHICH IS INHIBITED BY RAPAMYCIN	CELL			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN PHOSPHATASE; YEAST; MUTATIONS; VECTORS; TARGET	The rapamycin-sensitive signaling pathway is required to transduce specific mitogenic signals to the cell cycle machinery responsible for G1 progression. Genetic studies in yeast identified two related genes on this pathway, TOR1 and TOR2, thought to encode novel phosphatidylinositol kinases. We now show that an intact kinase domain is required for the G1 cell cycle functions of both proteins, for the ability of a mutation in a neighboring FKBP12-rapamycin-binding domain of the TOR1 protein to inhibit the growth of yeast cells when overexpressed, and for the essential function of the TOR2 protein. The G1 function of both TOR proteins is sensitive to rapamycin, but the essential function of TOR2 is not. Thus, FKBP12-rapamycin does not appear to inhibit the kinase activity of TOR proteins in a general way; instead, it may interfere selectively with TOR protein binding to or phosphorylation of G1 effecters.	HARVARD UNIV, DEPT CHEM, CAMBRIDGE, MA 02138 USA; HARVARD UNIV, DEPT MOLEC & CELLULAR BIOL, CAMBRIDGE, MA 02138 USA; STANFORD UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT DEV BIOL, STANFORD, CA 94305 USA; STANFORD UNIV, SCH MED, DEPT PATHOL, STANFORD, CA 94305 USA	Harvard University; Harvard University; Howard Hughes Medical Institute; Stanford University; Stanford University	ZHENG, XF (corresponding author), HARVARD UNIV, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02138 USA.			Chen, Jie/0000-0002-7887-3747; Fiorentino, David/0000-0001-7951-3674	NATIONAL CANCER INSTITUTE [R37CA039612, R01CA039612] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038627, R01GM038627] Funding Source: NIH RePORTER; NCI NIH HHS [CA-39612] Funding Source: Medline; NIGMS NIH HHS [GM-38627] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRIZUELA L, 1991, MOL CELL BIOL, V11, P4616, DOI 10.1128/MCB.11.9.4616; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BUECHLER YJ, 1991, J BIOL CHEM, V266, P3491; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11149; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; GUTHRIE C, 1991, METH ENZYMOL, V194; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARLOW E, 1988, ANTIBODIES; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SCHENA M, 1991, METHOD ENZYMOL, V194, P389; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SIKORSKI RS, 1989, GENETICS, V122, P19; STACK JH, 1994, J BIOL CHEM, V269, P31552; STAN R, 1994, J BIOL CHEM, V269, P32027	22	244	254	0	13	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 14	1995	82	1					121	130		10.1016/0092-8674(95)90058-6	http://dx.doi.org/10.1016/0092-8674(95)90058-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RK424	7606777	Bronze			2022-12-24	WOS:A1995RK42400015
J	BEG, AA; SHA, WC; BRONSON, RT; GHOSH, S; BALTIMORE, D				BEG, AA; SHA, WC; BRONSON, RT; GHOSH, S; BALTIMORE, D			EMBRYONIC LETHALITY AND LIVER DEGENERATION IN MICE LACKING THE RELA COMPONENT OF NF-KAPPA-B	NATURE			English	Article								NF-kappa B, which consists of two polypeptides, p50 (M, 50K) and p65/RelA (M(r) 65K), is thought to be a key regulator of genes involved in responses to infection, inflammation and stress(1). Indeed, although developmentally normal, mice deficient in p50 display functional defects in immune responses(2). Here we describe the generation of mice deficient in the RelA subunit of NF-kappa B. Disruption of the relA locus leads to embryonic lethality at 15-16 days of gestation, concomitant with a massive degeneration of the liver by programmed cell death or apoptosis. Embryonic fibroblasts from RelA-deficient mice are defective in the tumour necrosis factor (TNF)-mediated induction of messenger RNAs for I kappa B alpha and granulocyte/macrophage colony stimulating factor (GM-CSF), although basal levels of these transcripts are unaltered. These results indicate that RelA controls inducible, but not basal, transcription in NF-kappa B-regulated pathways.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; TUFTS UNIV,SCH MED & VET MED,DEPT PATHOL,BOSTON,MA 02111; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06520; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,IMMUNOBIOL SECT,NEW HAVEN,CT 06520	Massachusetts Institute of Technology (MIT); Tufts University; Howard Hughes Medical Institute; Yale University; Howard Hughes Medical Institute; Yale University								ABBADIE C, 1993, CELL, V75, P889; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BURKLY L, 1995, NATURE, V373, P531, DOI 10.1038/373531a0; CRESSMANDE, 1994, J BIOL CHEM, V269, P30429; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GRILLI M, 1991, INT REV CYTOL, V143, P1; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; MONTGOMERY RA, 1991, J IMMUNOL, V147, P554; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; STEIN B, 1993, EMBO J, V10, P3879; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WEIH F, 1994, CELL, V80, P331; WYLLIE AH, 1994, J PATHOL, V142, P67	23	1584	1644	0	28	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 13	1995	376	6536					167	170		10.1038/376167a0	http://dx.doi.org/10.1038/376167a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ028	7603567				2022-12-24	WOS:A1995RJ02800059
J	FONG, GH; ROSSANT, J; GERTSENSTEIN, M; BREITMAN, ML				FONG, GH; ROSSANT, J; GERTSENSTEIN, M; BREITMAN, ML			ROLE OF THE FLT-1 RECEPTOR TYROSINE KINASE IN REGULATING THE ASSEMBLY OF VASCULAR ENDOTHELIUM	NATURE			English	Article							GROWTH-FACTOR; MOLECULAR-CLONING; STEM-CELLS; EXPRESSION; VASCULOGENESIS; ANGIOGENESIS; FLK-1; MICE; TEK	THE vascular endothelial growth factor (VEGF) and its high-affinity binding receptors, the tyrosine kinases Flt-1 and Flk-1, are thought to be important for the development of embryonic vasculature(1-8). Here we report that Flt-1 is essential for the organization of embryonic vasculature, but is not essential for endothelial cell differentiation. Mouse embryos homozygous for a targeted mutation in the flt-1 locus, flt-1(lcz), formed endothelial cells in both embryonic and extra-embryonic regions, but assembled these cells into abnormal vascular channels and died in utero at mid-somite stages. At earlier stages, the blood islands of flt-1(lcz) homozygotes were abnormal, with angioblasts in the interior as well as on the periphery. We suggest that the Flt-1 signalling pathway may regulate normal endothelial cell-cell or cell-matrix interactions during vascular development.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,TORONTO,ON M5G 1X5,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO,ON M5S 1A8,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto								BALDWIN HS, 1994, DEVELOPMENT, V120, P2539; BRELER G, 1992, DEVELOPMENT, V114, P521; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DUMONT DJ, 1993, ONCOGENE, V8, P1293; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; FINNERTY H, 1993, ONCOGENE, V8, P2293; Hogan B, 1994, MANIPULATING MOUSE E; IWAMA A, 1993, BIOCHEM BIOPH RES CO, V195, P301, DOI 10.1006/bbrc.1993.2045; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; KORHNONEN J, 1994, ONCOGENE, V9, P995; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NODEN DM, 1989, AM REV RESPIR DIS, V149, P1097; PAJUSOLA K, 1992, CANCER RES, V52, P5738; PARK JE, 1994, J BIOL CHEM, V269, P25646; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; PATAN S, 1993, ANAT EMBRYOL, V187, P121; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; RISAU W, 1988, DEVELOPMENT, V102, P471; Risau W., 1991, DEV VASCULAR SYSTEM, P58; SEETHARAM L, 1995, ONCOGENE, V10, P135; SHALABY F, 1995, NATURE, V376, P622; SHIBUYA M, 1990, ONCOGENE, V5, P519; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489	27	2055	2159	2	69	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 6	1995	376	6535					66	70		10.1038/376066a0	http://dx.doi.org/10.1038/376066a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH111	7596436				2022-12-24	WOS:A1995RH11100063
J	BELL, SP; MITCHELL, J; LEBER, J; KOBAYASHI, R; STILLMAN, B				BELL, SP; MITCHELL, J; LEBER, J; KOBAYASHI, R; STILLMAN, B			THE MULTIDOMAIN STRUCTURE OF ORC1P REVEALS SIMILARITY TO REGULATORS OF DNA-REPLICATION AND TRANSCRIPTIONAL SILENCING	CELL			English	Article							ORIGIN RECOGNITION COMPLEX; SACCHAROMYCES-CEREVISIAE; YEAST; LOCI; REPRESSION; DIVISION; MUTANTS; MITOSIS; CDC6	The origin recognition complex (ORC) is a six protein assembly that binds S. cerevisiae origins of replication and directs DNA replication throughout the genome and transcriptional silencing at the yeast mating-type loci. Here we report the cloning of the genes encoding the 120 kDa (ORC1), 62 kDa (ORC3), and 56 kDa (ORC4) subunits of ORC and the reconstitution of the complete complex after expression of all six subunits in insect cells. Orc1p is related to Cdc6p and Cdc18p, which regulate DNA replication and mitosis, and to Sir3p, a regulator of transcriptional silencing. The N-terminal region of Orc1p is highly related to Sir3p, and studies of Orc1p/Sir3p chimeric proteins indicate that this domain is dedicated to the transcriptional silencing function of ORC.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	BELL, SP (corresponding author), COLD SPRING HARBOR LAB,POB 100,COLD SPRING HARBOR,NY 11724, USA.			Bell, Stephen/0000-0002-2876-610X; Stillman, Bruce/0000-0002-9453-4091	PHS HHS [A120460] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BUENO A, 1992, EMBO J, V11, P2167, DOI 10.1002/j.1460-2075.1992.tb05276.x; CHIEN CT, 1993, CELL, V75, P531, DOI 10.1016/0092-8674(93)90387-6; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; HOGAN E, 1992, P NATL ACAD SCI USA, V89, P3098, DOI 10.1073/pnas.89.7.3098; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P2541, DOI 10.1093/nar/21.11.2541; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MCNALLY FJ, 1991, MOL CELL BIOL, V11, P5648, DOI 10.1128/MCB.11.11.5648; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; MILLER AM, 1984, NATURE, V312, P247, DOI 10.1038/312247a0; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; NASMYTH K, 1981, MOL GEN GENET, V182, P119, DOI 10.1007/BF00422777; NEWTON CS, 1993, CURR OPIN GENE DEV, V3, P752; PLATTI S, 1995, EMBO J, V14, P3788; RAO H, 1995, P NATL ACAD SCI USA, V92, P2224, DOI 10.1073/pnas.92.6.2224; ROWLEY A, 1995, EMBO J, V14, P2631, DOI 10.1002/j.1460-2075.1995.tb07261.x; ZWERSCHKE W, 1994, J BIOL CHEM, V269, P23351	28	216	221	0	4	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 17	1995	83	4					563	568		10.1016/0092-8674(95)90096-9	http://dx.doi.org/10.1016/0092-8674(95)90096-9			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TF248	7585959	Bronze			2022-12-24	WOS:A1995TF24800009
J	SUBRAMANIAN, V; MEYER, BI; GRUSS, P				SUBRAMANIAN, V; MEYER, BI; GRUSS, P			DISRUPTION OF THE MURINE HOMEOBOX GENE CDX1 AFFECTS AXIAL SKELETAL IDENTITIES BY ALTERING THE MESODERMAL EXPRESSION DOMAINS OF HOX GENES	CELL			English	Article							EMBRYONIC STEM-CELLS; CAUDAL GENE; C-ELEGANS; HOMEOTIC TRANSFORMATION; CERVICAL-VERTEBRAE; ECTOPIC EXPRESSION; DROSOPHILA; MOUSE; MICE; GRADIENT	Cdx1 is expressed along the embryonic axis from day 7.5 postcoitum until day 12, by which time the anterior limit of expression has regressed from the hindbrain level to the forelimb bud region. To assign a functional role for Cdx1 in murine embryonic development, we have inactivated the gene via homologous recombination. Viable fertile homozygous mutant mice were obtained that show anterior homeotic transformations of vertebrae. These abnormalities were concomitant with posterior shifts of Hox gene expression domains in the semitic mesoderm. The presence of putative Cdx1-binding sites in Hox gene control regions as well as in vitro transactivation of Hoxa-7 indicates a direct regulation.	UNIV BATH,SCH BIOL & BIOCHEM,BATH BA2 7AY,AVON,ENGLAND	University of Bath	SUBRAMANIAN, V (corresponding author), MAX PLANCK INST BIOPHYS CHEM,DEPT MOLEC CELL BIOL,D-37077 GOTTINGEN,GERMANY.							BELLAIRS R, 1986, ANAT EMBRYOL, V174, P1, DOI 10.1007/BF00318331; BLUMBERG B, 1991, SCIENCE, V253, P194, DOI 10.1126/science.1677215; BREIER G, 1986, EMBO J, V5, P2209, DOI 10.1002/j.1460-2075.1986.tb04486.x; BURGLIN TR, 1989, NATURE, V341, P239, DOI 10.1038/341239a0; CAPECCHI MR, 1974, P NATL ACAD SCI USA, V71, P4732, DOI 10.1073/pnas.71.12.4732; CONDIE BG, 1993, DEVELOPMENT, V119, P579; CONDIE BG, 1994, NATURE, V370, P304, DOI 10.1038/370304a0; DAWES B, 1930, PHILOS T ROY SOC B, V218, P155; DEAROLF CR, 1989, NATURE, V341, P340, DOI 10.1038/341340a0; DUPREY P, 1988, GENE DEV, V2, P1647, DOI 10.1101/gad.2.12a.1647; FLINT OP, 1977, CELL INTERACTIONS DE; FRUMKIN A, 1991, DEVELOPMENT, V112, P207; GAMER LW, 1993, MECH DEVELOP, V43, P71, DOI 10.1016/0925-4773(93)90024-R; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; Hogan B., 1986, MANIPULATING MOUSE E; HUNT P, 1992, ANNU REV CELL BIOL, V8, P227, DOI 10.1146/annurev.cb.08.110192.001303; JAMES R, 1991, J BIOL CHEM, V266, P3246; JEANNOTTE L, 1993, GENE DEV, V7, P2085, DOI 10.1101/gad.7.11.2085; JOLY JS, 1992, DIFFERENTIATION, V50, P75, DOI 10.1111/j.1432-0436.1992.tb00488.x; Joyner AL, 1993, GENE TARGETING PRACT; JURGENS G, 1985, NATURE, V316, P153, DOI 10.1038/316153a0; KENYON C, 1986, CELL, V46, P477, DOI 10.1016/0092-8674(86)90668-9; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KIENY M, 1972, DEV BIOL, V28, P142, DOI 10.1016/0012-1606(72)90133-9; KNITTEL T, 1995, DEVELOPMENT, V121, P1077; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LUFKIN T, 1992, NATURE, V359, P835, DOI 10.1038/359835a0; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARGALIT Y, 1993, NUCLEIC ACIDS RES, V21, P4915, DOI 10.1093/nar/21.21.4915; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; MAVILIO F, 1993, EUR J BIOCHEM, V212, P273, DOI 10.1111/j.1432-1033.1993.tb17660.x; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MEYER BI, 1993, DEVELOPMENT, V117, P191; Miller J.H., 1972, EXPT MOL GENETICS; MLODZIK M, 1990, DEVELOPMENT, V109, P271; MLODZIK M, 1987, CELL, V48, P465, DOI 10.1016/0092-8674(87)90197-8; MLODZIK M, 1985, EMBO J, V4, P2961, DOI 10.1002/j.1460-2075.1985.tb04030.x; NAGY A, 1990, DEVELOPMENT, V110, P815; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NORTHROP JL, 1994, DEV BIOL, V161, P490, DOI 10.1006/dbio.1994.1047; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; PUSCHEL AW, 1991, DEVELOPMENT, V112, P279; PUSCHEL AW, 1990, DEVELOPMENT, V106, P435; RAMIREZSOLIS R, 1993, CELL, V73, P279, DOI 10.1016/0092-8674(93)90229-J; RECHSTEINER M, 1987, ANNU REV CELL BIOL, V3, P1, DOI 10.1146/annurev.cb.03.110187.000245; SERRANO J, 1993, BIOCHEM BIOPH RES CO, V190, P270, DOI 10.1006/bbrc.1993.1041; SHARPE PT, 1988, DEVELOPMENT, V102, P397; SUH E, 1995, MOL CELL BIOL, V14, P7340; TAM PPL, 1986, SOMITES DEV EMBRYOS, P17; TREMBLAY P, 1995, IN PRESS DEV BIOL; VANDERLUGT N, 1994, THESIS U AMSTERDAM A; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0; WARING DA, 1991, NATURE, V350, P712, DOI 10.1038/350712a0; WARING DA, 1990, CELL, V60, P123, DOI 10.1016/0092-8674(90)90722-Q; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO; XU X, 1994, DEVELOPMENT, V120, P277	61	289	295	0	5	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 17	1995	83	4					641	653		10.1016/0092-8674(95)90104-3	http://dx.doi.org/10.1016/0092-8674(95)90104-3			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TF248	7585967	Bronze			2022-12-24	WOS:A1995TF24800017
J	JANSEN, ASP; NGUYEN, XV; KARPITSKIY, V; METTENLEITER, TC; LOEWY, AD				JANSEN, ASP; NGUYEN, XV; KARPITSKIY, V; METTENLEITER, TC; LOEWY, AD			CENTRAL COMMAND NEURONS OF THE SYMPATHETIC NERVOUS-SYSTEM - BASIS OF THE FIGHT-OR-FLIGHT RESPONSE	SCIENCE			English	Article							PSEUDORABIES VIRUS; PREGANGLIONIC NEURONS; CHEMICAL-STIMULATION; RAT; MARKER; CATECHOLAMINES; INNERVATION; HEART	During stress, the activity of the sympathetic nervous system is changed in a global fashion, leading to an increase in cardiovascular function and a release of adrenal catecholamines. This response is thought to be regulated by a common set of brain neurons that provide a dual input to the sympathetic preganglionic neurons regulating cardiac and adrenal medullary functions. By using a double-virus transneuronal labeling technique, the existence of such a set of central autonomic neurons in the hypothalamus and brainstem was demonstrated. These neurons innervate both of the sympathetic outflow systems and likely function in circumstances where parallel sympathetic processing occurs, such as in the fight-or-flight response.	WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110; FED RES CTR VIRUS DIS ANIM,FRIEDRICH LOEFFLER INST,INST MOLEC & CELLULAR VIROL,D-17498 INSEL RIEMS,GERMANY	Washington University (WUSTL); Friedrich Loeffler Institute			Mettenleiter, h. c. Thomas C./U-1016-2019		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL025449, R01HL025449] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-25449] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEREITER DA, 1990, PAIN, V42, P81, DOI 10.1016/0304-3959(90)91094-Y; Cannon WB, 1930, LANCET, V1, P1109; Cannon WB., BODILY CHANGES PAIN, DOI [10.1037/10013-000, DOI 10.1037/10013-000]; CARD JP, 1993, J NEUROSCI, V13, P2515, DOI 10.1523/JNEUROSCI.13-06-02515.1993; DIAMANT M, 1992, NEUROENDOCRINOLOGY, V56, P750, DOI 10.1159/000126303; JANSEN ASP, 1995, BRAIN RES, V683, P1, DOI 10.1016/0006-8993(95)00276-V; JANSEN ASP, 1993, BRAIN RES, V617, P103, DOI 10.1016/0006-8993(93)90619-X; KATAFUCHI T, 1988, NEUROSCI LETT, V86, P195, DOI 10.1016/0304-3940(88)90570-8; METTENLEITER TC, 1990, J VIROL METHODS, V30, P55, DOI 10.1016/0166-0934(90)90043-F; METTENLEITER TC, 1988, J VIROL, V62, P2712, DOI 10.1128/JVI.62.8.2712-2717.1988; MINSON JB, 1987, J AUTONOM NERV SYST, V13, P39; PARDINI BJ, 1989, J AUTONOM NERV SYST, V28, P193, DOI 10.1016/0165-1838(89)90146-X; PARDINI BJ, 1990, NEUROSCI LETT, V117, P300, DOI 10.1016/0304-3940(90)90681-X; RINAMAN L, 1993, J NEUROSCI, V13, P684; ROSS CA, 1984, J NEUROSCI, V4, P474; SAMS JM, 1995, BRAIN RES, V687, P182, DOI 10.1016/0006-8993(95)00484-8; STANEK KA, 1984, AM J PHYSIOL, V246, pH44, DOI 10.1152/ajpheart.1984.246.1.H44; STRACK AM, 1990, J NEUROSCI, V10, P2139; STRACK AM, 1989, BRAIN RES, V491, P274, DOI 10.1016/0006-8993(89)90063-2; STRACK AM, 1988, BRAIN RES, V455, P187, DOI 10.1016/0006-8993(88)90132-1; SWANSON LW, 1992, BRAINMAPS	21	493	503	4	113	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 27	1995	270	5236					644	646		10.1126/science.270.5236.644	http://dx.doi.org/10.1126/science.270.5236.644			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TB557	7570024				2022-12-24	WOS:A1995TB55700043
J	SAARINEN, UM; KAJOSAARI, M				SAARINEN, UM; KAJOSAARI, M			BREAST-FEEDING AS PROPHYLAXIS AGAINST ATOPIC DISEASE - PROSPECTIVE FOLLOW-UP-STUDY UNTIL 17 YEARS OLD	LANCET			English	Article							ALLERGIC DISEASES; NATURAL-HISTORY; CHILDHOOD; CHILDREN; ASTHMA; BREAST; MILK; INFANTS; ECZEMA; DIET	Atopic diseases constitute a common health problem. For infants at hereditary risk, prophylaxis of atopy has been sought in elimination diets and other preventive measures. We followed up healthy infants during their first year, and then at ages 1, 3, 5, 10, and 17 years to determine the effect on atopic disease of breastfeeding. Of the initial 236 infants, 150 completed the follow-up, which included history taking, physical examination, and laboratory tests for allergy. The subjects were divided into three groups: prolonged (>6 months), intermediate (1-6 months), and short or no (<1 month) breastfeeding. The prevalence of manifest atopy throughout follow-up was highest in the group who had little or no breastfeeding (p<0.05, analysis of variance and covariance with repeated measures [ANOVA]), Prevalence of eczema at ages 1 and 3 years was lowest (p=0.03, ANOVA) in the prolonged breastfeeding group, prevalence of food allery was highest in the little or no groups (p=0.02, ANOVA) at 1-3 years, and respiratory allergy was also most prevalent in the latter group (p=0.01, ANOVA) having risen to 65% at 17 years of age, Prevalences in the prolonged, intermediate, and little or no groups at age 17 were 42 (95% CI 31-52)%, 36 (28-44)%, and 65 (56-74)% (p=0.02, trend test) for atopy, respectively, and 8 (6-10)%, 23 (21-25)%, and 54 (52-56)% (p=0.0001, trend test) for substantial atopy. We conclude that breastfeeding is prophylactic against atopic disease-including atopic eczema, food allergy, and respiratory allergy-throughout childhood and adolescence.	UNIV HELSINKI,HOSP ALLERG DIS,HELSINKI,FINLAND	University of Helsinki	SAARINEN, UM (corresponding author), UNIV HELSINKI,CHILDRENS HOSP,STENBACKINKATU 11,SF-00290 HELSINKI,FINLAND.							AAS K, 1980, ALLERGY, V35, P250, DOI 10.1111/j.1398-9995.1980.tb01763.x; ABERG N, 1990, ACTA PAEDIATR SCAND, V79, P206, DOI 10.1111/j.1651-2227.1990.tb11440.x; ARSHAD SH, 1992, LANCET, V339, P1493, DOI 10.1016/0140-6736(92)91260-F; BJORKSTEN F, 1976, CLIN ALLERGY, V6, P165, DOI 10.1111/j.1365-2222.1976.tb01894.x; BLAIR H, 1977, ARCH DIS CHILD, V52, P613, DOI 10.1136/adc.52.8.613; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; BUSINCO L, 1987, ANN ALLERGY, V59, P183; COGSWELL JJ, 1987, ARCH DIS CHILD, V62, P338, DOI 10.1136/adc.62.4.338; COHEN GA, 1985, ANN ALLERGY, V4, P112; CRONER S, 1990, PEDIATR ALLERGY IMMU, V1, P14, DOI DOI 10.1111/J.1399-3038.1990.TB00003.X; FERGUSSON DM, 1990, PEDIATRICS, V86, P541; FRICK OL, 1979, J ALLERGY CLIN IMMUN, V63, P228, DOI 10.1016/0091-6749(79)90106-4; GORDON RR, 1982, LANCET, V1, P910; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HIDE DW, 1981, ARCH DIS CHILD, V56, P172, DOI 10.1136/adc.56.3.172; JACKSON PG, 1981, LANCET, V1, P1285; Kajosaari M, 1994, Pediatr Allergy Immunol, V5, P26, DOI 10.1111/j.1399-3038.1994.tb00344.x; LILJA G, 1989, CLIN EXP ALLERGY, V19, P473, DOI 10.1111/j.1365-2222.1989.tb02416.x; OWNBY DR, 1990, J ALLERGY CLIN IMMUN, V86, P279, DOI 10.1016/S0091-6749(05)80088-0; SAARINEN UM, 1979, LANCET, V2, P163; SAARINEN UM, 1979, CLIN ALLERGY, V9, P339, DOI 10.1111/j.1365-2222.1979.tb02492.x; SAARINEN UM, 1980, LANCET, V1, P166; SAARINEN UM, 1982, ALLERGY, V37, P345, DOI 10.1111/j.1398-9995.1982.tb01920.x; SARFATI M, 1986, EUR J IMMUNOL, V16, P1005, DOI 10.1002/eji.1830160822; SAVILAHTI E, 1981, ALLERGY, V36, P73, DOI 10.1111/j.1398-9995.1981.tb04101.x; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; STRANGERT K, 1976, PEDIATRICS, V57, P191; VANASPEREN PP, 1984, CLIN ALLERGY, V14, P525; VONMUTIUS E, 1994, BRIT MED J, V308, P692, DOI 10.1136/bmj.308.6930.692; WALKER WA, 1977, M JOHNSON S PERINAT, V2, P111; WARNER JO, 1989, ARCH DIS CHILD, V64, P1065, DOI 10.1136/adc.64.7.1065; WICKMAN M, 1992, PEDIATRIC ALLERGY IM, V3, P128; Zeiger R, 1992, PEDIAT ALLERG IMM-UK, V3, P110, DOI [DOI 10.1111/J.1399-3038.1992.TB00035.X, 10.1111/j.1399-3038.1992.tb00035.x]	33	489	514	1	28	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 21	1995	346	8982					1065	1069		10.1016/S0140-6736(95)91742-X	http://dx.doi.org/10.1016/S0140-6736(95)91742-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA697	7564787				2022-12-24	WOS:A1995TA69700011
J	SUNDARESAN, M; YU, ZX; FERRANS, VJ; IRANI, K; FINKEL, T				SUNDARESAN, M; YU, ZX; FERRANS, VJ; IRANI, K; FINKEL, T			REQUIREMENT FOR GENERATION OF H2O2 FOR PLATELET-DERIVED GROWTH-FACTOR SIGNAL-TRANSDUCTION	SCIENCE			English	Article							VITAMIN-E CONSUMPTION; CELLS; PROTEIN; DISEASE; PHOSPHORYLATION; INHIBITION; EXPRESSION; APOPTOSIS; RECEPTOR; RISK	Stimulation of rat vascular smooth muscle cells (VSMCs) by platelet-derived growth factor (PDGF) transiently increased the intracellular concentration of hydrogen peroxide (H2O2). This increase could be blunted by increasing the intracellular concentration of the scavenging enzyme catalase or by the chemical antioxidant N-acetylcysteine. The response of VSMCs to PDGF, which includes tyrosine phosphorylation, mitogen-activated protein kinase stimulation, DNA synthesis, and chemotaxis, was inhibited when the growth factor-stimulated rise in H2O2 concentration was blocked. These results suggest that H2O2 may act as a signal-transducing molecule, and they suggest a potential mechanism for the cardioprotective effects of antioxidants.	NHLBI, CARDIOL BRANCH, BETHESDA, MD 20892 USA; NHLBI, PATHOL SECT, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)				Irani, Kaikobad/0000-0001-9194-7387				ABEDI H, 1995, J BIOL CHEM, V270, P11367, DOI 10.1074/jbc.270.19.11367; Aebi H, 1994, METHOD ENZYMOL, V105, P121; BIRO S, 1993, P NATL ACAD SCI USA, V90, P654, DOI 10.1073/pnas.90.2.654; CAMPBELL JH, 1987, VASCULAR SMOOTH MUSC, P15; CHEN ZX, 1993, SCIENCE, V262, P1883, DOI 10.1126/science.8266079; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; ERZURUM SC, 1993, NUCLEIC ACIDS RES, V21, P1607, DOI 10.1093/nar/21.7.1607; GAZIANO JM, 1992, ANN NY ACAD SCI, V669, P249; HAECKER G, 1994, TRENDS BIOCHEM SCI, V19, P99, DOI 10.1016/0968-0004(94)90197-X; HECHT D, 1992, BIOCHEM BIOPH RES CO, V188, P773, DOI 10.1016/0006-291X(92)91123-8; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KRIEGERBRAUER HI, 1992, J CLIN INVEST, V89, P1006, DOI 10.1172/JCI115641; LEFF JA, 1992, FREE RADICAL BIO MED, V13, P143, DOI 10.1016/0891-5849(92)90076-S; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; OFFERMANNS S, 1994, J IMMUNOL, V152, P250; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; RANKIN S, 1994, J BIOL CHEM, V269, P704; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SANDSTROM PA, 1993, P NATL ACAD SCI USA, V90, P4708, DOI 10.1073/pnas.90.10.4708; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Schreck R, 1991, Trends Cell Biol, V1, P39, DOI 10.1016/0962-8924(91)90072-H; SHIBANUMA M, 1990, ONCOGENE, V5, P1025; STAAL FJT, 1994, P NATL ACAD SCI USA, V91, P3619, DOI 10.1073/pnas.91.9.3619; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; SUNDARESAN M, UNPUB; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922	31	2223	2297	2	147	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 13	1995	270	5234					296	299		10.1126/science.270.5234.296	http://dx.doi.org/10.1126/science.270.5234.296			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ342	7569979	Green Submitted			2022-12-24	WOS:A1995RZ34200038
J	LEWIS, C; NEIDHART, S; HOLY, C; NORTH, RA; BUELL, G; SURPRENANT, A				LEWIS, C; NEIDHART, S; HOLY, C; NORTH, RA; BUELL, G; SURPRENANT, A			COEXPRESSION OF P2X(2) AND P2X(3) RECEPTOR SUBUNITS CAN ACCOUNT FOR ATP-GATED CURRENTS IN SENSORY NEURONS	NATURE			English	Article							RAT	Cation-selective P2X receptor channels were first described in sensory neurons(1-4) where they are important for primary afferent neurotransmission and nociception(5,6). Here we report the cloning of a complementary DNA (P2X(3)) from rat dorsal root ganglia that had properties dissimilar to those of sensory neurons. We also found RNA for (P2X(1)) (ref. 7), (P2X(2)) (ref. 8) and P2X(4) (ref. 9) in sensory neurons; channels expressed from individual cDNAs did not reproduce those of sensory ganglia. Coexpression of P2X(3) with P2X(2), but not other combinations, yielded ATP-activated currents that closely resembled those in sensory neurons. These properties could not be accounted for by addition of the two sets of channels, indicating that a new channel had formed by subunit heteropolymerization. Although in some tissues responses to ATP can be accounted for by homomeric channels(1,7-10), our results indicate that ATP-gated channels of sensory neurons may form by a specific heteropolymerization of P2X receptor subunits.			LEWIS, C (corresponding author), GLAXO INST MOLEC BIOL SA,CH-1228 GENEVA,SWITZERLAND.		North, Richard/GQA-6156-2022					ABBRACCHIO MP, 1995, PHARMACOL THERAPEUT, V64, P445; BEAN BP, 1990, J NEUROSCI, V10, P1; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; BUELL G, IN PRESS SOC NEUR AB; COVARRUBIAS M, 1991, NEURON, V7, P763, DOI 10.1016/0896-6273(91)90279-9; EVANS RJ, 1995, MOL PHARMACOL, V48, P178; FRIEL DD, 1988, J PHYSIOL-LONDON, V401, P361, DOI 10.1113/jphysiol.1988.sp017167; FYFFE REW, 1984, P NATL ACAD SCI-BIOL, V81, P6890, DOI 10.1073/pnas.81.21.6890; HOLTON FA, 1954, J PHYSIOL-LONDON, V126, P124, DOI 10.1113/jphysiol.1954.sp005198; JAHR CE, 1983, NATURE, V304, P730, DOI 10.1038/304730a0; KHAKH BS, 1995, J PHYSIOL-LONDON, V484, P385, DOI 10.1113/jphysiol.1995.sp020672; KHAKH BS, 1995, J PHARM, V115, P117; KRISHTAL OA, 1988, BRIT J PHARMACOL, V95, P1057, DOI 10.1111/j.1476-5381.1988.tb11739.x; KRISHTAL OA, NEUROSCI LETT, V35, P41; LEWIS C, IN PRESS SOC NEUR AB; LINDSTROM JM, 1995, LIGAND VOLTAGE GATED, P153; SPRENGEL R, 1995, LIGAND VOLTAGE GATED, P213; SURPRENANT A, 1995, TRENDS NEUROSCI, V18, P224, DOI 10.1016/0166-2236(95)93907-F; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; VULCANOVA L, IN PRESS SOC NEUR AB	20	881	906	0	21	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 5	1995	377	6548					432	435		10.1038/377432a0	http://dx.doi.org/10.1038/377432a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY190	7566120				2022-12-24	WOS:A1995RY19000050
J	PALLARES, R; LINARES, J; VADILLO, M; CABELLOS, C; MANRESA, F; VILADRICH, PF; MARTIN, R; GUDIOL, F				PALLARES, R; LINARES, J; VADILLO, M; CABELLOS, C; MANRESA, F; VILADRICH, PF; MARTIN, R; GUDIOL, F			RESISTANCE TO PENICILLIN AND CEPHALOSPORIN AND MORTALITY FROM SEVERE PNEUMOCOCCAL PNEUMONIA IN BARCELONA, SPAIN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							STREPTOCOCCUS-PNEUMONIAE; ANTIMICROBIAL RESISTANCE; ANTIBIOTIC-RESISTANCE; SYSTEMIC INFECTIONS; BACTEREMIA; CHLORAMPHENICOL; SUSCEPTIBILITY; DIAGNOSIS; DISEASE; THERAPY	Background. Penicillin-resistant strains of Streptococcus pneumoniae are now found worldwide, and strains with resistance to cephalosporin are being reported. The appropriate antibiotic therapy for pneumococcal pneumonia due to resistant strains remains controversial. Methods. To examine the effect of resistance to penicillin and cephalosporin on mortality, we conducted a 10-year, prospective study in Barcelona of 504 adults with culture-proved pneumococcal pneumonia. Results. Among the 504 patients, 145 (29 percent) had penicillin-resistant strains of S. pneumoniae (minimal inhibitory concentration [MIG] of penicillin G, 0.12 to 4.0 mu g per milliliter), and 31 patients (6 percent) had cephalosporin-resistant strains (MIG of ceftriaxone or cefotaxime, 1.0 to 4.0 mu g per milliliter). Mortality was 38 percent in patients with penicillin-resistant strains, as compared with 24 percent in patients with penicillin-sensitive strains (P = 0.001). However, after the exclusion of patients with polymicrobial pneumonia and adjustment for other predictors of mortality, the odds ratio for mortality in patients with penicillin-resistant strains was 1.0 (95 percent confidence interval, 0.5 to 1.9; P = 0.84). Among patients treated with penicillin G or ampicillin, the mortality was 25 percent in the 24 with penicillin-resistant strains and 19 percent in the 126 with penicillin-sensitive strains (P = 0.51). Among patients treated with ceftriaxone or cefotaxime, the mortality was 22 percent in the 59 with penicillin-resistant strains and 25 percent in the 127 with penicillin-sensitive strains (P = 0.64), The frequency of resistance to cephalosporin increased from 2 percent in 1984-1988 to 9 percent in 1989-1993 (P = 0.002). Mortality was 26 percent in patients with cephalosporin-resistant S. pneumoniae and 28 percent in patients with susceptible organisms (P = 0.89), Among patients treated with ceftriaxone or cefotaxime, mortality was 22 percent in the 18 with cephalosporin-resistant strains and 24 percent in the 168 with cephalosporin-sensitive organisms (P = 0.64). Conclusions. Current levels of resistance to penicillin and cephalosporin by S. pneumoniae are not associated with increased mortality in patients with pneumococcal pneumonia, Hence, these antibiotics remain the therapy of choice for this disease.	HOSP BELLVITGE PRINCEPS ESPANYA, INFECT DIS SERV, BARCELONA, SPAIN; HOSP BELLVITGE PRINCEPS ESPANYA, MICROBIOL SERV, BARCELONA, SPAIN; HOSP BELLVITGE PRINCEPS ESPANYA, INTERNAL MED SERV, BARCELONA, SPAIN; HOSP BELLVITGE PRINCEPS ESPANYA, PULM DIS SERV, BARCELONA, SPAIN; UNIV BARCELONA, BARCELONA, SPAIN	University of Barcelona			PALLARES, Roman/B-5710-2008; Liñares, Josefina/N-9450-2014; Cabellos, Carmen/AAO-3784-2021	PALLARES, Roman/0000-0003-3262-8508; Cabellos, Carmen/0000-0001-7392-7382				AMSDEN GW, 1995, PRINCIPLES PRACTICE, P492; APPELBAUM PC, 1977, LANCET, V2, P995; APPELBAUM PC, 1992, CLIN INFECT DIS, V15, P77, DOI 10.1093/clinids/15.1.77; AUSTRIAN R, 1964, ANN INTERN MED, V60, P759, DOI 10.7326/0003-4819-60-5-759; AUSTRIAN R, 1994, ANN INTERN MED, V121, P807, DOI 10.7326/0003-4819-121-10-199411150-00013; BAQUERO F, 1991, J ANTIMICROB CHEMOTH, V28, P31, DOI 10.1093/jac/28.suppl_C.31; BREIMAN RF, 1994, JAMA-J AM MED ASSOC, V271, P1831, DOI 10.1001/jama.271.23.1831; CAPUTO GM, 1993, ARCH INTERN MED, V153, P1301, DOI 10.1001/archinte.153.11.1301; FENOLL A, 1991, REV INFECT DIS, V13, P56; FINKELSTEIN MS, 1983, J AM GERIATR SOC, V31, P19, DOI 10.1111/j.1532-5415.1983.tb06283.x; FRIEDLAND IR, 1992, AM J DIS CHILD, V146, P920, DOI 10.1001/archpedi.1992.02160200042023; FRIEDLAND IR, 1994, NEW ENGL J MED, V331, P377, DOI 10.1056/NEJM199408113310607; GARCIALEONI ME, 1992, CLIN INFECT DIS, V14, P427, DOI 10.1093/clinids/14.2.427; GARCIALEONI ME, 1992, ARCH INTERN MED, V152, P1808, DOI 10.1001/archinte.152.9.1808; GRANSDEN WR, 1985, BRIT MED J, V290, P505, DOI 10.1136/bmj.290.6467.505; GRUER LD, 1984, Q J MED, V53, P259; HANSMAN D, 1971, NEW ENGL J MED, V284, P175, DOI 10.1056/NEJM197101282840403; HOGE CW, 1994, NEW ENGL J MED, V331, P643, DOI 10.1056/NEJM199409083311004; HOOK EW, 1983, JAMA-J AM MED ASSOC, V249, P1055, DOI 10.1001/jama.249.8.1055; JACOBS MR, 1979, ANTIMICROB AGENTS CH, V16, P190, DOI 10.1128/AAC.16.2.190; JACOBS MR, 1992, CLIN INFECT DIS, V15, P119, DOI 10.1093/clinids/15.1.119; JACOBS MR, 1978, NEW ENGL J MED, V299, P735, DOI 10.1056/NEJM197810052991402; JANOFF EN, 1992, ANN INTERN MED, V117, P314, DOI 10.7326/0003-4819-117-4-314; JOHN CC, 1994, CLIN INFECT DIS, V18, P188, DOI 10.1093/clinids/18.2.188; KLUGMAN KP, 1990, CLIN MICROBIOL REV, V3, P171, DOI 10.1128/CMR.3.2.171-196.1990; KRAMER MR, 1987, ISRAEL J MED SCI, V23, P174; LINARES J, 1992, CLIN INFECT DIS, V15, P99, DOI 10.1093/clinids/15.1.99; MANRESA F, 1991, THORAX, V46, P601, DOI 10.1136/thx.46.8.601; MARTON A, 1991, J INFECT DIS, V163, P542, DOI 10.1093/infdis/163.3.542; MUNOZ R, 1992, MOL MICROBIOL, V6, P2461; MYLOTTE JM, 1981, AM REV RESPIR DIS, V123, P265; NAVA JM, 1994, CLIN INFECT DIS, V19, P884, DOI 10.1093/clinids/19.5.884; PALLARES R, 1987, NEW ENGL J MED, V317, P18, DOI 10.1056/NEJM198707023170104; SANCHEZ C, 1992, LANCET, V339, P988, DOI 10.1016/0140-6736(92)91560-U; SCHLESSELMAN JJ, 1982, CASE CONTROL STUDIES, P227; TAN TQ, 1992, PEDIATRICS, V90, P928; TOMASZ A, 1994, NEW ENGL J MED, V330, P1247, DOI 10.1056/NEJM199404283301725; VILADRICH PF, 1988, AM J MED, V84, P839, DOI 10.1016/0002-9343(88)90061-7; WATANAKUNAKORN C, 1993, CHEST, V103, P1152, DOI 10.1378/chest.103.4.1152; 1994, NCCLS M100S5 NAT COM	40	628	642	0	31	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 24	1995	333	8					474	480		10.1056/NEJM199508243330802	http://dx.doi.org/10.1056/NEJM199508243330802			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP759	7623879	Green Submitted, Bronze, Green Published			2022-12-24	WOS:A1995RP75900002
J	MAEDA, T; TAKEKAWA, M; SAITO, H				MAEDA, T; TAKEKAWA, M; SAITO, H			ACTIVATION OF YEAST PBS2 MAPKK BY MAPKKKS OR BY BINDING OF AN SH3-CONTAINING OSMOSENSOR	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; PATHWAY; ALLELE	The role of mitogen-activated protein (MAP) kinase cascades in integrating distinct upstream signals was studied in yeast. Mutants that were not able to activate PBS2 MAP kinase kinase (MAPKK; Pbs2p) at high osmolarity were characterized. Pbs2p was activated by two independent signals that emanated from distinct cell-surface osmosensors. Pbs2p was activated by MAP kinase kinase kinases (MAPKKKs) Ssk2p and Ssk22p that are under the control of the SLN1-SSK1 two-component osmosensor. Alternatively, Pbs2p was activated by a mechanism that involves the binding of its amino terminal proline-rich motif to the Src homology 3 (SH3) domain of a putative transmembrane osmosensor Sho1p.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV TUMOR IMMUNOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School			Saito, Haruo/AAF-6113-2019; Maeda, Tatsuya/L-5540-2019	Saito, Haruo/0000-0001-7891-1689; Takekawa, Mutsuhiro/0000-0002-8027-3847				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BOGUSLAWSKI G, 1992, J GEN MICROBIOL, V138, P2425, DOI 10.1099/00221287-138-11-2425; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; CAIRNS BR, 1992, GENE DEV, V6, P1305, DOI 10.1101/gad.6.7.1305; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COOPER JA, 1994, CURR BIOL, V4, P1118, DOI 10.1016/S0960-9822(00)00251-7; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MAEDA T, UNPUB; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; VOFTEK AB, 1993, CELL, V74, P205	23	537	565	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 28	1995	269	5223					554	558		10.1126/science.7624781	http://dx.doi.org/10.1126/science.7624781			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL495	7624781				2022-12-24	WOS:A1995RL49500033
J	HIRSCH, DR; INGENITO, EP; GOLDHABER, SZ				HIRSCH, DR; INGENITO, EP; GOLDHABER, SZ			PREVALENCE OF DEEP VENOUS THROMBOSIS AMONG PATIENTS IN MEDICAL INTENSIVE GALE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							VEIN-THROMBOSIS	Objective.-To determine the frequency of deep venous thrombosis (DVT) in medical intensive care unit (MICU) patients. Design.-Prospective ultrasound case series. Setting.-An MICU in a large tertiary care hospital in Boston, Mass. Subjects.-Patients older than 18 years of age admitted to the MICU with an anticipated stay of more than 48 hours. Main Outcome Measure.-Deep venous thrombosis as detected by ultrasonography with color Doppler imaging performed twice weekly in the MICU and once within 1 week of discharge from the MICU. Results.-Deep venous thrombosis was detected in 33% (95% confidence interval, 24% to 43%) of 100 eligible patients during the 8-month study period. Forty-eight percent (16/33) were proximal lower extremity DVT, and 15% (5/33) were upper extremity DVT associated with central venous catheters, with one patient having both upper and proximal lower extremity DVT. Ultrasound examination results led to inferior vena cava filter placement in three patients, initiation of full-dose anticoagulation in four patients, initiation or continuation of low-dose subcutaneous heparin in 10 patients, follow-up ultrasound studies in three patients, central line removal in one patient, and no intervention in 10 patients due to active bleeding, prior filter, or heparin-induced thrombocytopenia. Two patients remained anticoagulated for other reasons. In this series, there was no difference in age, gender, body mass index, diagnosis of cancer, recent surgery, duration of hospitalization prior to DVT detection, and DVT prophylaxis between patients with DVT and those without. Conclusions.-An unexpectedly high rate of DVT was detected by ultrasound in these MICU patients despite prophylaxis in 61%. Traditionally recognized DVT risk factors failed to identify patients who developed DVT. Routine ultrasound surveillance or more intensive prophylaxis regimens may be warranted in this patient population if these DVT rates are confirmed in other settings.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002635] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1 RR02635] Funding Source: Medline; NHLBI NIH HHS [HL 02663] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON FA, 1992, ARCH INTERN MED, V152, P1660, DOI 10.1001/archinte.152.8.1660; BARNES RW, 1989, J VASC SURG, V9, P251, DOI 10.1067/mva.1989.vs0090251; BICK RL, 1992, SEMIN THROMB HEMOST, V18, P267, DOI 10.1055/s-2007-1002434; DAVIDSON BL, 1992, ANN INTERN MED, V117, P735, DOI 10.7326/0003-4819-117-9-735; DIEBOLD J, 1991, PATHOL RES PRACT, V187, P260; GARDNER MJ, 1989, BRIT MED J CONFIDENC; Hirst D., 1993, PREVENTION VENOUS TH, P51; IBARRAPEREZ C, 1988, ANGIOLOGY, V39, P505, DOI 10.1177/000331978803900603; KEANE MG, 1994, CHEST, V106, P13, DOI 10.1378/chest.106.1.13; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; MATTOS MA, 1992, J VASC SURG, V15, P366, DOI 10.1016/0741-5214(92)90258-A; POLAK JF, 1992, PERIPHERAL VASCULAR, P162; SIMONS GR, 1995, AM J MED, V99, P1; SIOSON ER, 1988, ARCH PHYS MED REHAB, V69, P183; 1991, EPI INFO VERSION 5 0	15	223	238	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 26	1995	274	4					335	337		10.1001/jama.274.4.335	http://dx.doi.org/10.1001/jama.274.4.335			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ898	7609264				2022-12-24	WOS:A1995RJ89800037
J	METZ, T; HARRIS, AW; ADAMS, JM				METZ, T; HARRIS, AW; ADAMS, JM			ABSENCE OF P53 ALLOWS DIRECT IMMORTALIZATION OF HEMATOPOIETIC-CELLS BY THE MYC AND RAF ONCOGENES	CELL			English	Article							WILD-TYPE P53; RECOMBINANT MURINE RETROVIRUS; EMBRYO FIBROBLASTS; P53-DEFICIENT MICE; GENE AMPLIFICATION; BONE-MARROW; ERB-B; V-RAF; TRANSFORMATION; INVITRO	The p53 tumor suppressor is implicated here as a crucial barrier to unlimited cell proliferation. Its role in transformation of hematopoietic cells was studied by infecting fetal liver cells from wild-type or p53(-/-) mice with oncogenic retroviruses. Transformed colonies arose with a raf and a myc-raf virus. Absence of p53 did not affect their frequency but proved critical for their continued propagation. Colonies of p53(-/-) cells bearing both myc and raf readily yielded continuous cell lines without apparent requirement for genetic alteration. The lines, mainly of erythroid or myelomonocytic origin, were diploid but highly tumorigenic from their inception. These findings imply that p53 loss contributes directly to immortalization and tumorigenesis, probably by abrogating an intrinsic senescence program.	ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PARKVILLE,VIC 3050,AUSTRALIA	Royal Melbourne Hospital; Walter & Eliza Hall Institute			Adams, Jerry M/E-1199-2013	Adams, Jerry/0000-0002-4360-8628	NATIONAL CANCER INSTITUTE [R01CA012421] Funding Source: NIH RePORTER; NCI NIH HHS [CA12421] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON SM, 1985, MOL CELL BIOL, V5, P3369, DOI 10.1128/MCB.5.12.3369; BEUG H, 1977, EXP CELL RES, V107, P417, DOI 10.1016/0014-4827(77)90363-9; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BLASI E, 1985, NATURE, V318, P667, DOI 10.1038/318667a0; BOND JA, 1994, ONCOGENE, V9, P1885; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; COOPER MC, 1974, P NATL ACAD SCI USA, V71, P1677, DOI 10.1073/pnas.71.5.1677; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CORY S, 1991, CELL GROWTH DIFFER, V2, P165; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DANDREA AD, 1994, CURR OPIN CELL BIOL, V6, P804, DOI 10.1016/0955-0674(94)90048-5; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GRAF T, 1981, EXP CELL RES, V131, P331, DOI 10.1016/0014-4827(81)90236-6; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; HARPER JW, 1993, CELL, V75, P805; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HARVEY M, 1993, ONCOGENE, V8, P2457; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HOLLIDAY R, 1989, TRENDS GENET, V5, P42, DOI 10.1016/0168-9525(89)90020-6; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KARNOVSKY MJ, 1964, J HISTOCHEM CYTOCHEM, V12, P219, DOI 10.1177/12.3.219; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KLINKEN SP, 1988, ONCOGENE RES, V3, P187; KLINKEN SP, 1988, P NATL ACAD SCI USA, V85, P8506, DOI 10.1073/pnas.85.22.8506; KLINKEN SP, 1989, J VIROL, V63, P1489, DOI 10.1128/JVI.63.3.1489-1492.1989; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; METCALF D, 1984, CLONAL CULTURES HAEM; METZ T, 1994, SEMIN CANCER BIOL, V5, P125; MILLER M, 1990, ONCOGENE, V5, P1125; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; PRINCIPATO M, 1990, MOL CELL BIOL, V10, P3562, DOI 10.1128/MCB.10.7.3562; PROKOCIMER M, 1994, BLOOD, V84, P2391; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RITTLING SR, 1992, ONCOGENE, V7, P935; ROHME D, 1981, P NATL ACAD SCI-BIOL, V78, P5009, DOI 10.1073/pnas.78.8.5009; ROTTER V, 1993, P NATL ACAD SCI USA, V90, P9075, DOI 10.1073/pnas.90.19.9075; ROVINSKI B, 1988, ONCOGENE, V2, P445; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TSUKADA T, 1993, ONCOGENE, V8, P3313; ULRICH E, 1992, GENE DEV, V6, P876, DOI 10.1101/gad.6.5.876; WANECK GL, 1981, CELL, V26, P79, DOI 10.1016/0092-8674(81)90035-0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	51	114	115	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 14	1995	82	1					29	36		10.1016/0092-8674(95)90049-7	http://dx.doi.org/10.1016/0092-8674(95)90049-7			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RK424	7606782	Bronze			2022-12-24	WOS:A1995RK42400006
J	FORSTER, A; YOUNG, J				FORSTER, A; YOUNG, J			INCIDENCE AND CONSEQUENCES OF FALLS DUE TO STROKE - A SYSTEMATIC INQUIRY	BRITISH MEDICAL JOURNAL			English	Article							ELDERLY PEOPLE; NUMBER; HOME; RISK	Objective-To undertake a systematic inquiry into the incidence and consequences of falls in a cohort of elderly patients with stroke after discharge from hospital. Design-Administration of a questionnaire to patients and main carers at discharge from hospital and eight weeks and six months later. Setting-Bradford Metropolitan District. Subjects-108 patients recruited to the Bradford community stroke trial. Patients were recruited to the trial if they were 60 years or over and resident at home with some residual disability. Main outcome measures-Number of falls, motor club assessment, Barthel index, Frenchay activities index, and Nottingham health profile. Stress in carers was indicated by the general health questionnaire. Results-Of 108 patients, 79 (73%) fell in the six months after discharge from hospital with a total of 270 falls reported. Patients who fell in hospital were significantly more likely to fall at least twice at home after discharge (chi(2)=8.16; P=0.004). ''Fallers'' (two or more falls) were less socially active at six months and more had depressed mood. Carers of these patients were significantly more stressed at six months (53% v 18%; chi(2)=8.5; P=0.003). Conclusion-Stroke is associated with a risk of falling at home and affects the lives of patients with stroke and their carers. Falling and fear of falling is an important issue which needs to be dealt with by the multidisciplinary team.			FORSTER, A (corresponding author), ST LUKES HOSP,DEPT HLTH CARE ELDERLY,BRADFORD BD5 0NA,W YORKSHIRE,ENGLAND.			young, john/0000-0003-4085-9306; Forster, Anne/0000-0001-7466-4414				Ashburn A, 1982, Physiotherapy, V68, P109; Askham J, 1990, HOME LEISURE ACCIDEN; BLAKE AJ, 1988, AGE AGEING, V17, P365, DOI 10.1093/ageing/17.6.365; CAMPBELL AJ, 1990, AGE AGEING, V19, P136, DOI 10.1093/ageing/19.2.136; CUMMINGS SR, 1988, J AM GERIATR SOC, V36, P613, DOI 10.1111/j.1532-5415.1988.tb06155.x; EBRAHIM S, 1986, J EPIDEMIOL COMMUN H, V40, P166, DOI 10.1136/jech.40.2.166; EVANS JG, 1990, AGE AGEING, V19, P268, DOI 10.1093/ageing/19.4.268; FULLERTON KJ, 1986, LANCET, V1, P430; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; HODKINSON H M, 1972, Age and Ageing, V1, P233, DOI 10.1093/ageing/1.4.233; Hunt SM, 1986, MEASURING HLTH STATU; Isaacs B, 1985, Clin Geriatr Med, V1, P513; MAHONEY F I, 1965, Md State Med J, V14, P61; Obonyo T, 1983, Int Rehabil Med, V5, P157; OVERSTALL PW, 1992, REV CLIN GERONTOLOGY, V2, P31; SIMPSON JM, 1993, AGE AGEING, V22, P294, DOI 10.1093/ageing/22.4.294; TINETTI ME, 1986, AM J MED, V80, P429, DOI 10.1016/0002-9343(86)90717-5; TINETTI ME, 1989, NEW ENGL J MED, V320, P1055; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; TUTUARIMA JA, 1993, J ADV NURS, V18, P1101, DOI 10.1046/j.1365-2648.1993.18071101.x; VLAVHOV D, 1990, ARCH PHYS MED REHAB, V71, P8; Wade D T, 1985, Int Rehabil Med, V7, P176; WADE DT, 1992, BRIT MED J, V304, P609, DOI 10.1136/bmj.304.6827.609; WILD D, 1981, J EPIDEMIOL COMMUN H, V35, P200, DOI 10.1136/jech.35.3.200; WOODHOUSE P, 1983, J CLIN EXPT GERONTOL, V54, P309; YOUNG JB, 1992, BRIT MED J, V304, P1085, DOI 10.1136/bmj.304.6834.1085	26	411	426	0	18	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 8	1995	311	6997					83	86		10.1136/bmj.311.6997.83	http://dx.doi.org/10.1136/bmj.311.6997.83			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ030	7613406	Green Published			2022-12-24	WOS:A1995RJ03000018
J	TEMMERMAN, M; NDINYAACHOLA, J; AMBANI, J; PLOT, P				TEMMERMAN, M; NDINYAACHOLA, J; AMBANI, J; PLOT, P			THE RIGHT NOT TO KNOW HIV-TEST RESULTS	LANCET			English	Article							WOMEN; ZAIRE	Large numbers of pregnant women in Africa have been invited to participate in studies on HIV infection. Study protocols adhere to guidelines on voluntary participation after pre-test and post-test counselling and informed consent; nevertheless, women may consent because they have been asked to do so without fully understanding the implications of being tested for HIV. Our studies in Nairobi, Kenya, show that most women informed consent did not actively results, less than one third informed their partner, and violence against women because of a positive HIV-antibody test was common. It is important to have carefully designed protocols weighing the benefits against the potential harms for women participating in a study. Even after having consented to HIV testing, women should have the right not to be told their result.	UNIV NAIROBI,DEPT MED MICROBIOL,NAIROBI,KENYA; INST TROP MED,DEPT MED MICROBIOL,ANTWERP,BELGIUM	University of Nairobi; Institute of Tropical Medicine (ITM)								ALLEN S, 1993, AM J PUBLIC HEALTH, V83, P705, DOI 10.2105/AJPH.83.5.705; HEYWARD WL, 1993, AIDS, V7, P1633, DOI 10.1097/00002030-199312000-00014; RYDER RW, 1991, AIDS, V5, P1521, DOI 10.1097/00002030-199112000-00016; TEMMERMAN M, 1992, AIDS, V6, P1181, DOI 10.1097/00002030-199210000-00019; TEMMERMAN M, 1990, AIDS Care, V2, P247, DOI 10.1080/09540129008257737; TEMMERMAN M, 1994, OBSTET GYNECOL, V83, P495, DOI 10.1097/00006250-199404000-00002; TEMMERMAN M, IN PRESS AM J OBSTET; 1989, WHOGPAESR892; 1990, WHO AIDS SERIES, V8	9	164	167	0	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 15	1995	345	8955					969	970						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QT919	7619122				2022-12-24	WOS:A1995QT91900017
J	RIUNITI, O; BARBUI, T; FINAZZI, G; NEGRI, M; SUD, CMN; DEGAETANO, G; MARCHIOLI, R; TOGNONI, G; PATRONO, C; LANDOLFI, R; DITORRETTE, ON; LEONI, P; RUPOLI, S; CORTELAZZO, S; VESTRI, O; TURA, S; FINELLI, C; NOCENTINI, F; ANGELI, G; DIPASQUALE, A; KRAMER, V; MARFISI, R; OLIVIERI, M; SCIULLI, L; SPOLTORE, R; CAREGGI, P; FERRINI, PR; GROSSI, A; LONGO, G; NIGUARDA, O; DECATALDO, F; GARGANTINI, L; BAUDO, F; GERARDO, S; POGLIANI, EM; MICCOLIS, IR; BIZZI, B; ROCCA, B; TARTAGLIONE, R; MANDELLI, F; MONTEFUSCO, E; SPADEA, A; GIOVANNI, S; CAROTENUTO, M; NOBILE, M; MORELLI, R; MOLINETTE, O; RESEGOTTI, L; VASINO, MAC; BARTOLO, OS; RODEGHIERO, F; RUGGERI, M; ROSSIFERRINI, P				RIUNITI, O; BARBUI, T; FINAZZI, G; NEGRI, M; SUD, CMN; DEGAETANO, G; MARCHIOLI, R; TOGNONI, G; PATRONO, C; LANDOLFI, R; DITORRETTE, ON; LEONI, P; RUPOLI, S; CORTELAZZO, S; VESTRI, O; TURA, S; FINELLI, C; NOCENTINI, F; ANGELI, G; DIPASQUALE, A; KRAMER, V; MARFISI, R; OLIVIERI, M; SCIULLI, L; SPOLTORE, R; CAREGGI, P; FERRINI, PR; GROSSI, A; LONGO, G; NIGUARDA, O; DECATALDO, F; GARGANTINI, L; BAUDO, F; GERARDO, S; POGLIANI, EM; MICCOLIS, IR; BIZZI, B; ROCCA, B; TARTAGLIONE, R; MANDELLI, F; MONTEFUSCO, E; SPADEA, A; GIOVANNI, S; CAROTENUTO, M; NOBILE, M; MORELLI, R; MOLINETTE, O; RESEGOTTI, L; VASINO, MAC; BARTOLO, OS; RODEGHIERO, F; RUGGERI, M; ROSSIFERRINI, P			POLYCYTHEMIA-VERA - THE NATURAL-HISTORY OF 1213 PATIENTS FOLLOWED FOR 20 YEARS	ANNALS OF INTERNAL MEDICINE			English	Article						POLYCYTHEMIA VERA; THROMBOSIS; MYOCARDIAL INFARCTION; CEREBROVASCULAR DISORDERS; ASPIRIN	PORTAL-VEIN THROMBOSIS; CEREBRAL BLOOD-FLOW; MYELOPROLIFERATIVE DISORDERS; PRIMARY THROMBOCYTHEMIA; VASCULAR COMPLICATIONS; VENOUS THROMBOSIS; YOUNG-PEOPLE; RISK-FACTORS; ERYTHROMELALGIA; INVITRO	Objective: To reassess the natural history of polycythemia vera and to obtain reliable estimates of both incidence of thrombosis and survival for use in defining the sample size for therapeutic clinical trials. Study Design: Retrospective cohort study of patients with polycythemia who had been followed for 20 years. Setting: 11 Italian hematology institutions. Patients: 1213 patients with polycythemia vera, which was diagnosed according to criteria established by the Polycythemia Vera Study Group and commonly used in clinical practice. Main Outcome Measures: All-cause mortality, venous and arterial thrombosis, and hematologic and nonhematologic neoplastic disease. Myocardial infarction and stroke were classified as major thrombotic events, and venous and peripheral arterial thrombosis were considered minor thrombotic events. The number of patients who died and the number of those who had major thrombotic events (combined end point) were used as a comprehensive measure of the benefit-risk ratio associated with the use of myelosuppressive agents. Results: 634 fatal and nonfatal arterial and venous thromboses were recorded in 485 patients (41%); 36% of these episodes occurred during follow-up in 230 patients (19%), and 64% occurred either at presentation or before diagnosis. Thrombotic events occurred more frequently in the 2 years preceding diagnosis, suggesting a causal relation between the latent myeloproliferative disorder and the vascular event. The incidence of thrombosis during follow-up was 3.4%/y; older patients or those with a history of thrombosis had a higher risk for thrombosis. Overall mortality was 2.9/100 patients per year; thrombotic events and hematologic or nonhematologic cancers had similar effects on mortality. Patients receiving chemotherapy died three to four times more frequently than those not receiving chemotherapy. The increased risk for cancer in patients receiving myelosuppressive agents was seen approximately 6 years after diagnosis. In addition, the combined end point, computed as the sum of the hardest available events (death, nonfatal myocardial infarction, or stroke), suggests that myelosuppressive agents have an overall unfavorable effect. Conclusions: Cytoreduction favorably affects the incidence of thrombotic events, but aggressive treatment seems to be associated with increased risk for neoplasm. These results provide a basis for reevaluating the therapeutic strategy in patients with polycythemia vera and for estimating the size of clinical trials aimed at testing new therapeutic approaches.	CONSORZIO MARIO NEGRI SUD, CLIN PHARMACOL & EPIDEMIOL LAB, I-66030 SANTA MARIA IMBARO, ITALY; OSPED RIUNITI BERGAMO, BERGAMO, ITALY; CONSORZIO MARIO NEGRI SUD, IST RIC FARMACOL MARIO NEGRI, I-66030 SANTA MARIA IMBARO, ITALY; UNIV GABRIELE DANNUNZIO, CHIETI, ITALY; UNIV CATTOLICA SACRO CUORE, ROME, ITALY; OSPED NUOVO TORRETTE, ANCONA, ITALY; UNIV BOLOGNA, BOLOGNA, ITALY; POLICLIN CAREGGI, FLORENCE, ITALY; OSPED NIGUARDA CA GRANDA, MILAN, ITALY; OSPED SAN GERARDO, MONZA, ITALY; UNIV ROMA LA SAPIENZA, ROME, ITALY; CASA SOLLIEVO SOFFERENZA, SAN GIOVANNI ROTONDO, ITALY; OSPED MOLINETTE, TURIN, ITALY; OSPED SAN BARTOLO, VICENZA, ITALY	Consorzio Mario Negri Sud; Ospedali Riuniti di Bergamo; Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; G d'Annunzio University of Chieti-Pescara; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Bologna; University of Florence; Azienda Ospedaliero Universitaria Careggi; IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda; San Gerardo Hospital; Sapienza University Rome; IRCCS Casa Sollievo Della Sofferenza; A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette; ULSS 8 Berica; Ospedale San Bortolo di Vicenza			Finelli, Carlo/AAB-9686-2019; rocca, bianca/K-3922-2018; Landolfi, Raffaele/AAL-4496-2020	Finelli, Carlo/0000-0001-9372-1197; Landolfi, Raffaele/0000-0002-7913-8576; Patrono, Carlo/0000-0002-6447-2424				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1991, Lancet, V338, P1345; BARBUI T, 1983, EUR J CANCER CLIN ON, V19, P1593, DOI 10.1016/0277-5379(83)90091-3; BAROSI G, 1991, CANCER, V68, P2310, DOI 10.1002/1097-0142(19911115)68:10<2310::AID-CNCR2820681034>3.0.CO;2-2; BERK PD, 1981, NEW ENGL J MED, V304, P441, DOI 10.1056/NEJM198102193040801; BERK PD, 1986, SEMIN HEMATOL, V23, P132; CARDIN F, 1992, DIGEST DIS SCI, V37, P335, DOI 10.1007/BF01307724; CORTELAZZO S, 1990, J CLIN ONCOL, V8, P556, DOI 10.1200/JCO.1990.8.3.556; DRENOU B, 1992, NOUV REV FR HEMATOL, V34, P399; EGLI F, 1988, SCHWEIZ MED WSCHR, V118, P1969; FROHLI P, 1983, SCHWEIZ MED WSCHR, V113, P1622; HOFFMAN R, 1991, HEMATOLOGY BASIC PRI, P834; LANDOLFI R, 1992, BLOOD, V80, P1965; MCCARTHY DM, 1985, BRIT J HAEMATOL, V59, P1, DOI 10.1111/j.1365-2141.1985.tb02956.x; MICHIELS JJ, 1993, MEDIAT INFLAMM, V2, P385, DOI 10.1155/S0962935193000547; MICHIELS JJ, 1992, AM J HEMATOL, V39, P131, DOI 10.1002/ajh.2830390211; MICHIELS JJ, 1985, ANN INTERN MED, V102, P466, DOI 10.7326/0003-4819-102-4-466; MICHIELS JJ, 1993, NEUROLOGY, V43, P1107, DOI 10.1212/WNL.43.6.1107; NAJEAN Y, 1987, BRIT J HAEMATOL, V67, P285, DOI 10.1111/j.1365-2141.1987.tb02349.x; NAJEAN Y, 1994, BRIT J HAEMATOL, V86, P233, DOI 10.1111/j.1365-2141.1994.tb03289.x; NAJEAN Y, 1983, ANN MED INTERNE, V134, P390; PAGLIUCA A, 1990, Q J MED, V76, P981; PATRONO C, 1994, NEW ENGL J MED, V330, P1287; PEARCE JMS, 1983, BRIT MED J, V287, P935, DOI 10.1136/bmj.287.6397.935; PEARSON TC, 1978, LANCET, V2, P1219; Pearson TC, 1981, CLIN ASPECTS BLOOD V; PEETERMANS N, 1981, BRIT J CANCER, V44, P75; RANDI ML, 1991, J MED, V22, P213; REID CD, 1982, LANCET, V1, P14; ROZMAN C, 1991, CANCER, V67, P2658, DOI 10.1002/1097-0142(19910515)67:10<2658::AID-CNCR2820671042>3.0.CO;2-C; TARTAGLIA AP, 1986, SEMIN HEMATOL, V23, P172; TEOFILI L, 1992, THROMB HAEMOSTASIS, V67, P297; THOMAS DJ, 1977, LANCET, V2, P161; THOMAS DJ, 1977, LANCET, V2, P941, DOI 10.1016/S0140-6736(77)90885-6; TOSSOU H, 1991, J CLIN GASTROENTEROL, V13, P597; VALLA D, 1985, ANN INTERN MED, V103, P329, DOI 10.7326/0003-4819-103-3-329; VALLA D, 1988, GASTROENTEROLOGY, V94, P1063, DOI 10.1016/0016-5085(88)90567-7; VANGIJN J, 1991, NEW ENGL J MED, V325, P1261, DOI 10.1056/NEJM199110313251801; WALLENTIN L, 1990, LANCET, V336, P827; WEHMEIER A, 1991, ANN HEMATOL, V63, P101, DOI 10.1007/BF01707281; WESTWOOD N, 1993, EUR J HAEMATOL, V51, P228; ZANKOVICH R, 1987, MED KLIN, V82, P889	42	378	390	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1995	123	9					656	+		10.7326/0003-4819-123-9-199511010-00003	http://dx.doi.org/10.7326/0003-4819-123-9-199511010-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA696	7574220				2022-12-24	WOS:A1995TA69600003
J	BERRY, GT; NISSIM, I; LIN, ZP; MAZUR, AT; GIBSON, JB; SEGAL, S				BERRY, GT; NISSIM, I; LIN, ZP; MAZUR, AT; GIBSON, JB; SEGAL, S			ENDOGENOUS SYNTHESIS OF GALACTOSE IN NORMAL MEN AND PATIENTS WITH HEREDITARY GALACTOSEMIA	LANCET			English	Note							VEGETABLES; FRUITS	Despite restricted ingestion of lactose, patients with galactose-1-phosphate uridyltransferase deficiency have raised concentrations of galactose metabolites in blood and urine. Endogenous production of galactose may underlie this phenomenon. Using isotopically labelled galactose in a continuous intravenous infusion, we employed the steady-state flux method to calculate endogenous galactose production rate in three normal men and three patients with classic galactosaemia. We found that galactosaemic patients and normal subjects synthesise gram quantities of galactose per day. The rate of synthesis ranged from 0.53-1.05 mg/kg per h. Endogenous production of galactose may be an important factor in the pathogenesis of the complications of the brain and ovary, and could explain the persistent elevation of galactose metabolites in patients despite dietary restriction of galactose.			BERRY, GT (corresponding author), UNIV PENN,CHILDRENS HOSP PHILADELPHIA,SCH MED,DEPT PEDIAT,DIV BIOCHEM DEV & MOLEC DIS,PHILADELPHIA,PA 19104, USA.			Berry, Gerard/0000-0001-5299-3313	NCRR NIH HHS [MO1-RR-00240] Funding Source: Medline; NICHD NIH HHS [P01-HD-29847] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD029847] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000240] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BERRY GT, 1993, J INHERIT METAB DIS, V16, P91, DOI 10.1007/BF00711320; Elsas LJ, 1993, INT PEDIATR, V8, P101; Gitzelmann R, 1975, NORMAL PATHOLOGICAL, P25; GROSS KC, 1991, J INHERIT METAB DIS, V14, P253, DOI 10.1007/BF01800599; HOLTON JB, 1994, LANCET, V344, P1242, DOI 10.1016/S0140-6736(94)90745-5; SCHWEITZER S, 1993, EUR J PEDIATR, V152, P36, DOI 10.1007/BF02072514; Segal S, 1995, METABOLIC MOL BASES, P967; WAGGONER DD, 1990, J INHERIT METAB DIS, V13, P802, DOI 10.1007/BF01800204; WIECKO J, 1976, J AM CHEM SOC, V98, P7631, DOI 10.1021/ja00440a030; YUDKOFF M, 1995, CLIN PERINATOL, V22, P97	10	112	115	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 21	1995	346	8982					1073	1074		10.1016/S0140-6736(95)91745-4	http://dx.doi.org/10.1016/S0140-6736(95)91745-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA697	7564790	hybrid			2022-12-24	WOS:A1995TA69700014
J	SCHENA, M; SHALON, D; DAVIS, RW; BROWN, PO				SCHENA, M; SHALON, D; DAVIS, RW; BROWN, PO			QUANTITATIVE MONITORING OF GENE-EXPRESSION PATTERNS WITH A COMPLEMENTARY-DNA MICROARRAY	SCIENCE			English	Article							ARABIDOPSIS-THALIANA; HUMAN GENOME	A high-capacity system was developed to monitor the expression of many genes in parallel. Microarrays prepared by high-speed robotic printing of complementary DNAs on glass were used for quantitative expression measurements of the corresponding genes. Because of the small format and high density of the arrays, hybridization volumes of 2 microliters could be used that enabled detection of rare transcripts in probe mixtures derived from 2 micrograms of total cellular messenger RNA. Differential expression measurements of 45 Arabidopsis genes were made by means of simultaneous, two-color fluorescence hybridization.	STANFORD UNIV,MED CTR,BECKMAN CTR,DEPT BIOCHEM,STANFORD,CA 94305; STANFORD UNIV,MED CTR,BECKMAN CTR,HOWARD HUGHES MED INST,STANFORD,CA 94305	Stanford University; Howard Hughes Medical Institute; Stanford University			Rosa, Bruce/F-6393-2010	Shalon, Tidhar Dari/0000-0003-2646-6215	NHGRI NIH HHS [R21HG00450] Funding Source: Medline; NIA NIH HHS [R37AG00198] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R21HG000450] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; BELLANNECHANTEL.C, 1992, CELL, V70, P1059; COX DR, 1994, SCIENCE, V265, P2031, DOI 10.1126/science.8091223; GREEN ED, 1991, JAMA-J AM MED ASSOC, V266, P1966, DOI 10.1001/jama.266.14.1966; HOFTE H, 1993, PLANT J, V4, P1051, DOI 10.1046/j.1365-313X.1993.04061051.x; HWANG I, 1991, PLANT J, V1, P367, DOI 10.1046/j.1365-313X.1991.t01-5-00999.x; JARVIS P, 1994, PLANT MOL BIOL, V24, P685, DOI 10.1007/BF00023565; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; LEGUEN L, 1994, MOL GEN GENET, V245, P390, DOI 10.1007/BF00290120; MEYEROWITZ EM, 1985, SCIENCE, V229, P1214, DOI 10.1126/science.229.4719.1214; MORTON NE, 1991, P NATL ACAD SCI USA, V88, P7474, DOI 10.1073/pnas.88.17.7474; NEWMAN T, 1994, PLANT PHYSIOL, V106, P1241, DOI 10.1104/pp.106.4.1241; PRUITT RE, 1986, J MOL BIOL, V187, P169, DOI 10.1016/0022-2836(86)90226-3; SCHENA M, 1994, P NATL ACAD SCI USA, V91, P8393, DOI 10.1073/pnas.91.18.8393; SCHENA M, 1992, P NATL ACAD SCI USA, V89, P3894, DOI 10.1073/pnas.89.9.3894; SCHENA M, 1993, GENE DEV, V7, P367, DOI 10.1101/gad.7.3.367; SHALON D, 1995, THESIS STANFORD U; SHALON D, UNPUB	18	6689	7874	27	949	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 20	1995	270	5235					467	470		10.1126/science.270.5235.467	http://dx.doi.org/10.1126/science.270.5235.467			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA374	7569999				2022-12-24	WOS:A1995TA37400041
J	PARADISO, AM; MASON, SJ; LAZAROWSKI, ER; BOUCHER, RC				PARADISO, AM; MASON, SJ; LAZAROWSKI, ER; BOUCHER, RC			MEMBRANE-RESTRICTED REGULATION OF CA2+ RELEASE AND INFLUX IN POLARIZED EPITHELIA	NATURE			English	Article							PAROTID ACINAR-CELLS; INOSITOL 1,4,5-TRISPHOSPHATE; INTRACELLULAR CALCIUM; EXTRACELLULAR ATP; AIRWAY EPITHELIUM; OSCILLATIONS; METABOLISM; TRANSPORT; MESSENGER; CULTURE	EPITHELIAL cells exist in a complex setting in which responses to mucosal or serosal environments are mediated by receptors expressed on specialized cellular domains, such as apical versus basolateral cell membranes, We investigated whether airway epithelia can react selectively through G-protein-coupled receptors to stimuli in the mucosal or serosal environments by measuring inositol phosphate and intracellular Ca2+ responses in polarized human nasal epithelial monolayers, We report here that unilateral ATP (10(-4) M) administration stimulated P-2 purinoceptors and tapped pools of intracellular Ca2+ associated with the plasma membrane ipsilateral but not contralateral to stimulated receptors. Similarly, activation of plasma membrane Ca2+ influx by ATP was confined to the membrane ipsilateral to receptor stimulation. These findings demonstrate that polarized epithelia restrict P-2 receptor-mediated responses to a single domain of the cell, reflecting membrane-specific generation and catabolism of inositol phosphates and confinement of calcium influx regulation to the membrane ipsilateral to the stimulated receptors.	UNIV N CAROLINA,CTR CYST FIBROSIS PULM RES & TREATMENT,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill	PARADISO, AM (corresponding author), UNIV N CAROLINA,DEPT MED,DIV PULM DIS,CHAPEL HILL,NC 27599, USA.							ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; BROWN HA, 1991, MOL PHARMACOL, V40, P648; CLAPHAM DE, 1995, NATURE, V375, P634, DOI 10.1038/375634a0; CLARKE LL, 1992, AM J PHYSIOL, V263, pC348, DOI 10.1152/ajpcell.1992.263.2.C348; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; HANSEN M, 1993, J CELL SCI, V106, P995; HUGHES AR, 1988, J BIOL CHEM, V263, P10314; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; LARSEN EH, 1990, J PHYSIOL-LONDON, V424, P109, DOI 10.1113/jphysiol.1990.sp018058; LAZAROWSKI ER, 1990, J BIOL CHEM, V265, P13118; MASON SJ, 1991, BRIT J PHARMACOL, V103, P1649, DOI 10.1111/j.1476-5381.1991.tb09842.x; PARADISO AM, 1991, AM J PHYSIOL, V261, pL63, DOI 10.1152/ajplung.1991.261.2.L63; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; TAKEMURA H, 1989, BIOCHEM J, V258, P409, DOI 10.1042/bj2580409; THORN P, 1993, CELL CALCIUM, V14, P746, DOI 10.1016/0143-4160(93)90100-K; WU R, 1985, AM REV RESPIR DIS, V132, P311	16	102	103	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 19	1995	377	6550					643	646		10.1038/377643a0	http://dx.doi.org/10.1038/377643a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA275	7566178				2022-12-24	WOS:A1995TA27500056
J	LI, T; STARK, MR; JOHNSON, AD; WOLBERGER, C				LI, T; STARK, MR; JOHNSON, AD; WOLBERGER, C			CRYSTAL-STRUCTURE OF THE MATA1/MAT-ALPHA-2 HOMEODOMAIN HETERODIMER BOUND TO DNA	SCIENCE			English	Article							HUMAN PROTOONCOGENE PBX1; HOMEO DOMAIN PROTEIN; SINGLE AMINO-ACID; ANTENNAPEDIA HOMEODOMAIN; BINDING SPECIFICITY; TRANSCRIPTION FACTOR; TRANSACTIVATOR VP16; ALPHA-2 REPRESSOR; NMR-SPECTROSCOPY; OPERATOR COMPLEX	The Saccharomyces cerevisiae MATa1 and MAT alpha 2 homeodomain proteins, which play a role in determining yeast cell type, form a heterodimer that binds DNA and represses transcription in a cell type-specific manner. Whereas the alpha 2 and a1 proteins on their own have only modest affinity for DNA, the a1/alpha 2 heterodimer binds DNA with high specificity and affinity. The three-dimensional crystal structure of the a1/alpha 2 homeodomain heterodimer bound to DNA was determined at a resolution of 2.5 Angstrom. The a1 and alpha 2 homeodomains bind in a head-to-tail orientation, with heterodimer contacts mediated by a 16-residue tail located carboxyl-terminal to the alpha 2 homeodomain. This tail becomes ordered in the presence of a1, part of it forming a short amphipathic helix that packs against the a1 homeodomain between helices 1 and 2. A pronounced 60 degrees bend is induced in the DNA, which makes possible protein-protein and protein-DNA contacts that could not take place in a straight DNA fragment. Complex formation mediated by flexible protein-recognition peptides attached to stably folded DNA binding domains may prove to be a general feature of the architecture of other classes of eukaryotic transcriptional regulators.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOPHYS & BIOPHYS CHEM,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; University of California System; University of California San Francisco				Wolberger, Cynthia/0000-0001-8578-2969	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037049] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-37049] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AFFOLTER M, 1990, P NATL ACAD SCI USA, V87, P4093, DOI 10.1073/pnas.87.11.4093; AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; ANDERSON JE, 1987, NATURE, V326, P846, DOI 10.1038/326846a0; BAXTER SM, 1994, BIOCHEMISTRY-US, V33, P15309, DOI 10.1021/bi00255a012; BILLETER M, 1993, J MOL BIOL, V234, P1084, DOI 10.1006/jmbi.1993.1661; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; DRANGINIS AM, 1990, NATURE, V347, P682, DOI 10.1038/347682a0; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FENG JA, 1994, SCIENCE, V263, P348, DOI 10.1126/science.8278807; FLEGEL WA, 1993, MECH DEVELOP, V41, P155, DOI 10.1016/0925-4773(93)90045-Y; FUREY W, 1990, AM CRYSTALLOGRAPHIC; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GLOVER M, UNPUB; GOUTTE C, 1994, EMBO J, V13, P1434, DOI 10.1002/j.1460-2075.1994.tb06397.x; GOUTTE C, 1988, CELL, V52, P875, DOI 10.1016/0092-8674(88)90429-1; GOUTTE C, 1993, J MOL BIOL, V233, P359, DOI 10.1006/jmbi.1993.1517; GREAVES RF, 1990, J VIROL, V64, P2716, DOI 10.1128/JVI.64.6.2716-2724.1990; HANES SD, 1991, SCIENCE, V251, P426, DOI 10.1126/science.1671176; HO CY, 1994, EMBO J, V13, P1403, DOI 10.1002/j.1460-2075.1994.tb06394.x; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; JIN YS, 1995, SCIENCE, V270, P290, DOI 10.1126/science.270.5234.290; JOHNSON A, 1992, TRANSCRIPTIONAL REGU, V2, P975; JOHNSON FB, 1995, P NATL ACAD SCI USA, V92, P739, DOI 10.1073/pnas.92.3.739; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; LAI JS, 1992, GENE DEV, V6, P2058, DOI 10.1101/gad.6.11.2058; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; LI T, 1995, PROTEINS, V21, P161, DOI 10.1002/prot.340210210; MA H, 1991, GENE DEV, V5, P484, DOI 10.1101/gad.5.3.484; MAK A, 1993, GENE DEV, V7, P1862, DOI 10.1101/gad.7.10.1862; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; PERCIVALSMITH A, 1990, EMBO J, V9, P3967, DOI 10.1002/j.1460-2075.1990.tb07617.x; PHILLIPS CL, 1994, BIOCHEMISTRY-US, V33, P9294, DOI 10.1021/bi00197a033; PHILLIPS CL, 1991, GENE DEV, V5, P764, DOI 10.1101/gad.5.5.764; POMERANTZ JL, 1992, GENE DEV, V6, P2047, DOI 10.1101/gad.6.11.2047; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; READ RJ, 1990, ACTA CRYSTALLOGR A, V46, P900, DOI 10.1107/S0108767390005529; SAUER RT, 1988, GENE DEV, V2, P807, DOI 10.1101/gad.2.7.807; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SHEPHERD JCW, 1984, NATURE, V310, P70, DOI 10.1038/310070a0; SMITH DL, 1995, NUCLEIC ACIDS RES, V23, P1239, DOI 10.1093/nar/23.7.1239; STARK MR, 1994, NATURE, V371, P429, DOI 10.1038/371429a0; STERN S, 1991, GENE DEV, V5, P2555, DOI 10.1101/gad.5.12b.2555; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STRATHERN J, 1988, GENETICS, V120, P75; TREISMAN J, 1989, CELL, V59, P553; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; VERSHON AK, 1993, CELL, V72, P105, DOI 10.1016/0092-8674(93)90054-T; VERSHON AK, 1995, GENE DEV, V9, P182, DOI 10.1101/gad.9.2.182; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WOLBERGER C, 1988, NATURE, V335, P789, DOI 10.1038/335789a0; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239	64	234	239	0	4	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 13	1995	270	5234					262	269		10.1126/science.270.5234.262	http://dx.doi.org/10.1126/science.270.5234.262			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ342	7569974				2022-12-24	WOS:A1995RZ34200028
J	AKOULITCHEV, S; MAKELA, TP; WEINBERG, RA; REINBERG, D				AKOULITCHEV, S; MAKELA, TP; WEINBERG, RA; REINBERG, D			REQUIREMENT FOR TFIIH KINASE-ACTIVITY IN TRANSCRIPTION BY RNA-POLYMERASE-II	NATURE			English	Article							C-TERMINAL DOMAIN; LARGEST SUBUNIT; PROMOTER; REPEAT	AN array of tandem heptapeptide repeats at the carboxy-terminal domain (CTD) of the largest subunit of RNA polymerase II constitute a highly conserved structure essential for viability(1-3). Studies have established that the CTD is phosphorylated at different stages of the transcription cycle(4-7), and that it may be involved in transcriptional regulation(8-12). The exact role of the CTD remains elusive, as in vitro reconstituted transcription using the adenovirus major late promoter does not require the CTD13,14. Previous studies(7,15,16) showed that transcription from the murine dihydrofolate reductase (DHFR) promoter can be only accomplished by the form of RNA polymerase II that contains the hypophosphorylated CTD (RNAPIIA), but not by the form that lacks it (RNAPIIB)(7). Here we show that the CTD, but not its phosphorylation, is required for initiation of transcription. We also show that transcription requires CTD kinase activity provided by the CDK7 subunit of TFIIH17-19.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,HOWARD HUGHES MED INST,PISCATAWAY,NJ 08854; MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02142	Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)			makela, tomi/B-3734-2009	makela, tomi/0000-0002-4869-8044; Reinberg, Danny/0000-0003-4288-2016				ALLISON LA, 1988, MOL CELL BIOL, V8, P321, DOI 10.1128/MCB.8.1.321; ALLISON LA, 1989, P NATL ACAD SCI USA, V86, P2794, DOI 10.1073/pnas.86.8.2794; BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; BUERMEYER AB, 1992, MOL CELL BIOL, V12, P2250, DOI 10.1128/MCB.12.5.2250; DAHMUS ME, 1992, TRANSCRIPTIONAL REGU, V1, P109; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; DRAPKIN R, 1994, TRENDS BIOCHEM SCI, V19, P504, DOI 10.1016/0968-0004(94)90139-2; FLORES O, 1992, J BIOL CHEM, V267, P2786; GERBER HP, 1995, NATURE, V374, P660, DOI 10.1038/374660a0; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; KANG ME, 1993, J BIOL CHEM, V268, P25033; KIM WY, 1989, J BIOL CHEM, V264, P3169; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MAKELA TP, 1995, P NATL ACAD SCI USA, V92, P5174, DOI 10.1073/pnas.92.11.5174; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; THOMPSON NE, 1989, J BIOL CHEM, V264, P11511; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.bi.60.070191.003353	27	161	164	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 12	1995	377	6549					557	560		10.1038/377557a0	http://dx.doi.org/10.1038/377557a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ336	7566158				2022-12-24	WOS:A1995RZ33600070
J	KNUDSON, CM; TUNG, KSK; TOURTELLOTTE, WG; BROWN, GAJ; KORSMEYER, SJ				KNUDSON, CM; TUNG, KSK; TOURTELLOTTE, WG; BROWN, GAJ; KORSMEYER, SJ			BAX-DEFICIENT MICE WITH LYMPHOID HYPERPLASIA AND MALE GERM-CELL DEATH	SCIENCE			English	Article							APOPTOSIS; BCL-2; PROTEIN; SURVIVAL; GENE; P53	BAX, a heterodimeric partner of BCL2, counters BCL2 and promotes apoptosis in gain-of-function experiments, A Bax knockout mouse was generated that proved viable but displayed lineage-specific aberrations in cell death, Thymocytes and B cells in this mouse displayed hyperplasia, and Bax-deficient ovaries contained unusual atretic follicles with excess granulosa cells. In contrast, Bax-deficient males were infertile as a result of disordered seminiferous tubules with an accumulation of atypical premeiotic germ cells, but no mature haploid sperm, Multinucleated giant cells and dysplastic cells accompanied massive cell death. Thus, the loss of Bax results in hyperplasia or hypoplasia, depending on the cellular context.	WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,DIV MOLEC ONCOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; UNIV VIRGINIA,HLTH SCI CTR,DEPT PATHOL,CHARLOTTESVILLE,VA 22908	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University of Virginia				Knudson, Charles Michael/0000-0003-3964-5466	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027500, P30HD028934] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA049712] Funding Source: NIH RePORTER; NCI NIH HHS [CA49712] Funding Source: Medline; NICHD NIH HHS [HD27500, P30-HD28934] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARINAGA M, 1994, SCIENCE, V263, P754, DOI 10.1126/science.8303290; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOLSE LS, 1995, IMMUNITY, V3, P87; CHAO DT, 1995, J EXP MED, V182, P821, DOI 10.1084/jem.182.3.821; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DYM M, 1994, P NATL ACAD SCI USA, V91, P11287, DOI 10.1073/pnas.91.24.11287; ENDERS GC, 1994, DEV BIOL, V163, P331, DOI 10.1006/dbio.1994.1152; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; GAURIELI Y, 1992, J CELL BIOL, V119, P493; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; HINTZ M, 1977, DEV BIOL, V57, P375, DOI 10.1016/0012-1606(77)90222-6; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; HUCKINS C, 1978, ANAT REC, V190, P905, DOI 10.1002/ar.1091900410; KAMADA S, 1995, CANCER RES, V55, P354; KRAJEWSKI S, 1994, AM J PATHOL, V145, P515; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; LINETTE GP, 1994, IMMUNITY, V1, P197, DOI 10.1016/1074-7613(94)90098-1; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MERRY DE, 1994, DEVELOPMENT, V120, P301; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; NAKAYAMA K, 1993, SCIENCE, V261, P1584, DOI 10.1126/science.8372353; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; ROTTER V, 1993, P NATL ACAD SCI USA, V90, P9075, DOI 10.1073/pnas.90.19.9075; RUSSELL L, 1977, AM J ANAT, V148, P313, DOI 10.1002/aja.1001480303; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TILLY JL, 1995, ENDOCRINOLOGY, V136, P232, DOI 10.1210/en.136.1.232; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	40	1276	1305	0	23	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 6	1995	270	5233					96	99		10.1126/science.270.5233.96	http://dx.doi.org/10.1126/science.270.5233.96			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY302	7569956				2022-12-24	WOS:A1995RY30200041
J	KUROKAWA, R; SODERSTROM, M; HORLEIN, A; HALACHMI, S; BROWN, M; ROSENFELD, MG; GLASS, CK				KUROKAWA, R; SODERSTROM, M; HORLEIN, A; HALACHMI, S; BROWN, M; ROSENFELD, MG; GLASS, CK			POLARITY-SPECIFIC ACTIVITIES OF RETINOIC ACID RECEPTORS DETERMINED BY A CO-REPRESSOR	NATURE			English	Article							BINDING PROTEIN; DIRECT REPEAT; HORMONE; RAR	RETINOIC acid receptors (RARs) and retinoid-X receptors (RXRs) activate or repress transcription by binding as heterodimers to DNA-response elements that generally consist of two direct repeat half-sites of consensus sequence AGGTCA (reviewed in ref. 1). On response elements consisting of direct repeats spaced by five base pairs (DR + 5 elements), RAR/RXR heterodimers activate transcription in response to RAR-specific ligands, such as all-trans-retinoic acid (RA)(2). In contrast, on elements consisting of direct repeats spaced by one base pair (DR + 1 elements), RAR/RXR heterodimers exhibit little or no response to activating ligands and repress RXR-dependent transcription(3). Here we show that ligand-dependent transactivation by RAR on DR + 5 elements requires the dissociation of a new nuclear receptor co-repressor, N-CoR, and recruitment of the putative co-activators p140 and p160 (refs 4, 5). Surprisingly, on DR + 1 elements, N-CoR remains associated with RAR/RXR heterodimers even in the presence of RAR ligands, resulting in constitutive repression. These observations indicate that DNA-response elements can allosterically regulate RAR-co-repressor interactions to determine positive or negative regulation of gene expression.	UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DIV ENDOCRINOL & METAB,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DIV CELLULAR & MOLEC MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093; DANA FARBER CANC INST,DIV NEOPLAST DIS MECHANISMS,BOSTON,MA 02115	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; Harvard University; Dana-Farber Cancer Institute			Brown, Myles/AAX-5332-2021; Brown, Myles/B-6906-2008; Söderström, Mats/C-4005-2009; Glass, Christopher/AAI-3933-2021	Brown, Myles/0000-0002-8213-1658; Söderström, Mats/0000-0003-3927-4394; Glass, Christopher/0000-0003-4344-3592; Halachmi, Shlomit/0000-0001-5921-9515				BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; CASANOVA J, 1995, MOL CELL BIOL, V14, P5756; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; FOREMAN BM, 1995, CELL, V81, P541; GLASS C. K., 1994, ENDOCR REV, V15, P1503; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KEIDEL S, 1994, MOL CELL BIOL, V14, P287, DOI 10.1128/MCB.14.1.287; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; TONE Y, 1994, J BIOL CHEM, V269, P31157; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x	21	475	481	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 5	1995	377	6548					451	454		10.1038/377451a0	http://dx.doi.org/10.1038/377451a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY190	7566126				2022-12-24	WOS:A1995RY19000056
J	LAU, JYN; SIMMONDS, P; URDEA, MS				LAU, JYN; SIMMONDS, P; URDEA, MS			IMPLICATIONS OF VARIATIONS OF CONSERVED REGIONS OF HEPATITIS-C VIRUS GENOME	LANCET			English	Editorial Material									UNIV EDINBURGH,SCH MED,DEPT MED MICROBIOL,EDINBURGH,MIDLOTHIAN,SCOTLAND; CHIRON CORP,EMERYVILLE,CA	University of Edinburgh; Novartis	LAU, JYN (corresponding author), UNIV FLORIDA,DEPT MED,DIV GASTROENTEROL HEPATOL & NUTR,HEPATOBILIARY DIS SECT,GAINESVILLE,FL 32610, USA.			Simmonds, Peter/0000-0002-7964-4700				BROWN EA, 1992, NUCLEIC ACIDS RES, V20, P5041, DOI 10.1093/nar/20.19.5041; CHEMELLO L, 1994, NEW ENGL J MED, V330, P143, DOI 10.1056/NEJM199401133300215; COLLINS ML, 1995, ANAL BIOCHEM, V226, P120, DOI 10.1006/abio.1995.1199; DAVIS GL, 1994, HEPATOLOGY, V19, P1337, DOI 10.1002/hep.1840190603; HAYASHI J, 1995, J INFECTION, V30, P235, DOI 10.1016/S0163-4453(95)90785-8; LAU JYN, 1993, LANCET, V341, P1501, DOI 10.1016/0140-6736(93)90635-T; LAU JYN, IN PRESS ANN INTERN; ORITO E, 1994, J MED VIROL, V44, P410, DOI 10.1002/jmv.1890440418; POZZATO G, 1995, J MED VIROL, V45, P445, DOI 10.1002/jmv.1890450416; SIMMONDS P, 1994, HEPATOLOGY, V19, P1321, DOI 10.1016/0270-9139(94)90887-7; TKOHARA K, 1992, J VIROL, V66, P1476; TSUBOTA A, 1994, HEPATOLOGY, V19, P1088, DOI 10.1016/0270-9139(94)90854-0; Urdea M S, 1991, Nucleic Acids Symp Ser, P197; YAMADA G, IN PRESS HEPATOLOGY	14	96	96	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 12	1995	346	8972					425	426		10.1016/S0140-6736(95)92786-7	http://dx.doi.org/10.1016/S0140-6736(95)92786-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN656	7623576				2022-12-24	WOS:A1995RN65600015
J	SIVARAJASINGAM, V; LASZLO, J; OGDEN, GR				SIVARAJASINGAM, V; LASZLO, J; OGDEN, GR			EXTENT OF HEPATITIS-B IMMUNIZATION AMONG MEDICAL AND DENTAL STUDENTS	BRITISH MEDICAL JOURNAL			English	Article									UNIV DUNDEE,DEPT DENT SURG & PERIODONTOL,DUNDEE DD1 4HR,SCOTLAND	University of Dundee			Ogden, Graham/U-6774-2019	Ogden, Graham/0000-0003-3394-4537				KINGMAN S, 1994, BRIT MED J, V308, P876, DOI 10.1136/bmj.308.6933.876; OATES BC, 1993, BRIT MED J, V307, P301, DOI 10.1136/bmj.307.6899.301; TONKS A, 1993, BRIT MED J, V307, P522; 1992, IMMUNISATION INFECTI, P110	4	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 22	1995	311	6999					231	231		10.1136/bmj.311.6999.231	http://dx.doi.org/10.1136/bmj.311.6999.231			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL441	7627037	Green Published			2022-12-24	WOS:A1995RL44100020
J	COCKS, BG; CHANG, CCJ; CARBALLIDO, JM; YSSEL, H; DEVRIES, JE; AVERSA, G				COCKS, BG; CHANG, CCJ; CARBALLIDO, JM; YSSEL, H; DEVRIES, JE; AVERSA, G			A NOVEL RECEPTOR INVOLVED IN T-CELL ACTIVATION	NATURE			English	Article							MONOCLONAL-ANTIBODIES; B-CELLS; PROLIFERATION; CLONES; CD28; CD4+; ANTIGEN; CLONING; CTLA-4; GAMMA	OPTIMAL T-cell activation and T-cell expansion require triggering by T-cell antigen receptors and co-stimulatory signals provided by accessory cells(1-3). A major co-stimulatory pathway involves crosslinking the CD28 molecule on T cells by its ligands CD80 or CD86 expressed on antigen-presenting cells(4-7). But recent studies(8,9) on CD28-deficient mice have indicated that CD28 is not required for all T-cell responses and that additional T-cell costimulatory pathways exist. Here we describe a novel glycoprotein, of relative molecular mass 70,000 (M(r) 70K), designated SLAM, that belongs to the immunoglobulin gene superfamily, which is involved in T-cell stimulation. SLAM is constitutively expressed on peripheral-blood CD45RO(high) memory T cells, T-cell clones, immature thymocytes, and a proportion of B cells, and is rapidly induced on naive T cells after activation. Engagement of SLAM enhances antigen-specific proliferation and cytokine production by T cells carrying the CD4 antigen (CD4(+)). Particularly, the production of interferon-gamma (IFN-gamma) is strongly upregulated, even in T helper type 2 (Th2) CD4(+) T-cell clones, whereas no induction of interleukin(IL)-4 or IL-5 production was observed in Th1 clones. In addition, the engagement of SLAM induces directly the proliferation of CD4(+) T-cell clones and preactivated T cells, in the absence of any other stimuli, and without CD28 involvement. Thus SLAM is a novel receptor on T cells that, when engaged, potentiates T-cell expansion in a CD28-independent manner and induces a Th0/Th1 cytokine production profile.	DNAX RES INST MOLEC & CELLULAR BIOL INC,DEPT HUMAN IMMUNOL,PALO ALTO,CA 94304	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.			Yssel, Hans/AFV-2907-2022; Yssel, Hans/C-6406-2009	Yssel, Hans/0000-0001-7454-1836; Yssel, Hans/0000-0001-7454-1836				AVERSA G, 1993, J EXP MED, V177, P1575, DOI 10.1084/jem.177.6.1575; AZUMA M, 1993, NATURE, V366, P76, DOI 10.1038/366076a0; AZUMA M, 1909, J EXP MED, V177, P845; BACCHETTA R, 1990, J IMMUNOL, V144, P902; Bierer B E, 1993, Semin Immunol, V5, P249, DOI 10.1006/smim.1993.1029; CHRETIEN I, 1989, J IMMUNOL METHODS, V117, P67, DOI 10.1016/0022-1759(89)90120-8; COCKS BG, 1993, INT IMMUNOL, V5, P657, DOI 10.1093/intimm/5.6.657; FAVRE C, 1989, MOL IMMUNOL, V26, P17, DOI 10.1016/0161-5890(89)90015-1; FREEMAN GJ, 1993, SCIENCE, V262, P909, DOI 10.1126/science.7694363; GREEN JM, 1994, IMMUNITY, V1, P501, DOI 10.1016/1074-7613(94)90092-2; HAANEN JBAG, 1991, J EXP MED, V174, P583, DOI 10.1084/jem.174.3.583; JENKINS MK, 1994, IMMUNITY, V1, P443, DOI 10.1016/1074-7613(94)90086-8; JENKINS MK, 1993, CURR OPIN IMMUNOL, V5, P361, DOI 10.1016/0952-7915(93)90054-V; JUNE CH, 1990, IMMUNOL TODAY, V11, P211, DOI 10.1016/0167-5699(90)90085-N; LINSLEY PS, 1990, P NATL ACAD SCI USA, V87, P5031, DOI 10.1073/pnas.87.13.5031; MATHEW PA, 1993, J IMMUNOL, V151, P5328; MCKINNEY MM, 1987, J IMMUNOL METHODS, V96, P271, DOI 10.1016/0022-1759(87)90324-3; Sambrook J., 1989, MOL CLONING; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; STAUNTON DE, 1989, J EXP MED, V169, P187; YSSEL H, 1992, J IMMUNOL, V148, P738; YSSEL H, 1984, J IMMUNOL METHODS, V72, P21; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	24	416	448	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 20	1995	376	6537					260	263		10.1038/376260a0	http://dx.doi.org/10.1038/376260a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK331	7617038				2022-12-24	WOS:A1995RK33100048
J	COLLINS, JJ; CHOW, CC; IMHOFF, TT				COLLINS, JJ; CHOW, CC; IMHOFF, TT			STOCHASTIC RESONANCE WITHOUT TUNING	NATURE			English	Article							BISTABLE SYSTEMS; NOISE; INFORMATION; SIMULATION; DYNAMICS; NEURONS	STOCHASTIC resonance(1-4) (SR) is a phenomenon wherein the response of a nonlinear system to a weak periodic input signal is optimized by the presence of a particular, non-zero level of noises(5-7). SR has been proposed as a means for improving signal detection in a wide variety of systems, including superconducting quantum interference devices(8), and may be used in some natural systems such as sensory neurons(9-15). But for SR to be effective in a single-unit system (such as a sensory neuron or a single ion channel), the optimal intensity of the noise must be adjusted as the nature of the signal to be detected changes(15). This has been thought to impose a limitation on the practical and natural uses of SR. Here we show that the ability of a summing network of excitable units to detect a range of weak (sub-threshold) signals (either periodic or aperiodic) can be optimized by a fixed level of noise, irrespective of the nature of the input signal. We also show that this noise does not significantly degrade the ability of the network to detect suprathreshold signals. Thus, large nonlinear networks do not suffer from the limitations of SR in single units, and might be able to use a single noise level, such as that provided by the intrinsic noise of the individual components, to enhance the system's sensitivity to weak inputs. This suggests a functional role for neuronal noise(14,16-18) in sensory systems.	BOSTON UNIV, DEPT BIOMED ENGN, BOSTON, MA 02215 USA	Boston University	COLLINS, JJ (corresponding author), BOSTON UNIV, NEUROMUSCULAR RES CTR, 44 CUMMINGTON ST, BOSTON, MA 02215 USA.		Chow, Carson C/A-7970-2009					BENZI R, 1982, TELLUS, V34, P10, DOI 10.1111/j.2153-3490.1982.tb01787.x; BENZI R, 1981, J PHYS A-MATH GEN, V14, pL453, DOI 10.1088/0305-4470/14/11/006; BRAUN HA, 1994, NATURE, V367, P270, DOI 10.1038/367270a0; BULSARA A, 1991, J THEOR BIOL, V152, P531, DOI 10.1016/S0022-5193(05)80396-0; BULSARA AR, 1993, PHYS REV E, V47, P3734, DOI 10.1103/PhysRevE.47.3734; CHIALVO DR, 1993, J STAT PHYS, V70, P375, DOI 10.1007/BF01053974; COLLINS JJ, UNPUB PHYS REV LETT; CRONER LJ, 1993, P NATL ACAD SCI USA, V90, P8128, DOI 10.1073/pnas.90.17.8128; DE LUCA CJ, 1982, J PHYSIOL-LONDON, V329, P113, DOI 10.1113/jphysiol.1982.sp014293; DENK W, 1989, PHYS REV LETT, V63, P207, DOI 10.1103/PhysRevLett.63.207; DOUGLASS JK, 1993, NATURE, V365, P337, DOI 10.1038/365337a0; FAUVE S, 1983, PHYS LETT A, V97, P5, DOI 10.1016/0375-9601(83)90086-5; GINGL Z, 1995, EUROPHYS LETT, V29, P191, DOI 10.1209/0295-5075/29/3/001; HIBBS AD, 1995, J APPL PHYS, V77, P2582, DOI 10.1063/1.358720; INCHIOSA ME, 1995, PHYS LETT A, V200, P283, DOI 10.1016/0375-9601(95)00198-C; INCHIOSA ME, IN PRESS 3RD P TECHN; INCHIOSA ME, IN PRESS PHYS REV E; JUNG P, 1992, PHYS REV A, V46, pR1709, DOI 10.1103/PhysRevA.46.R1709; JUNG P, 1993, PHYS REP, V234, P175, DOI 10.1016/0370-1573(93)90022-6; KISS LB, 1993, J STAT PHYS, V70, P451, DOI 10.1007/BF01053981; KISS LB, 3RD P TECHN C NONL D; KNIGHT BW, 1972, J GEN PHYSIOL, V59, P734, DOI 10.1085/jgp.59.6.734; Kramers HA, 1940, PHYSICA, V7, P284, DOI 10.1016/S0031-8914(40)90098-2; LINDNER JF, IN PRESS PHYS REV LE; LONGTIN A, 1991, PHYS REV LETT, V67, P656, DOI 10.1103/PhysRevLett.67.656; LONGTIN A, 1993, J STAT PHYS, V70, P309, DOI 10.1007/BF01053970; MANNELLA R, 1989, PHYS REV A, V40, P3381, DOI 10.1103/PhysRevA.40.3381; MOSS F, 1993, ANN NY ACAD SCI, V706, P26, DOI 10.1111/j.1749-6632.1993.tb24679.x; MOSS F, 1994, INT J BIFURCAT CHAOS, V4, P1383, DOI 10.1142/S0218127494001118; NEIMAN A, 1995, PHYS LETT A, V197, P379, DOI 10.1016/0375-9601(94)01008-I; NICOLIS C, 1982, TELLUS, V34, P1, DOI 10.1111/j.2153-3490.1982.tb01786.x; PANTAZELOU E, 1993, AIP CONF PROC, P549, DOI 10.1063/1.44658; SHEPHERD GM, 1988, NEUROBIOLOGHY; WIESENFELD K, 1994, PHYS REV LETT, V72, P2125, DOI 10.1103/PhysRevLett.72.2125; WIESENFELD K, 1995, NATURE, V373, P33, DOI 10.1038/373033a0	35	670	693	0	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 20	1995	376	6537					236	238		10.1038/376236a0	http://dx.doi.org/10.1038/376236a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK331	7617033				2022-12-24	WOS:A1995RK33100040
J	VANNOORT, JM; VANSECHEL, AC; BAJRAMOVIC, JJ; ELOUAGMIRI, M; POLMAN, CH; LASSMANN, H; RAVID, R				VANNOORT, JM; VANSECHEL, AC; BAJRAMOVIC, JJ; ELOUAGMIRI, M; POLMAN, CH; LASSMANN, H; RAVID, R			THE SMALL HEAT-SHOCK PROTEIN ALPHA-B-CRYSTALLIN AS CANDIDATE AUTOANTIGEN IN MULTIPLE-SCLEROSIS	NATURE			English	Article							INDIRECT FLIGHT MUSCLES; T-CELL RECEPTOR; DROSOPHILA; TISSUES; DISEASE	THE identification of key antigens in human autoimmune diseases is a crucial step towards the development of specific intervention. The autoantigen(s) relevant to multiple sclerosis (MS) probably reside in myelin of the central nervous system, the target of the disease(1). Here we examine proliferative responses of human peripheral blood T cells to the complete collection of myelin proteins fractionated by reversed-phase high-performance liquid chromatography. Myelin isolated from MS-affected brain contained a single protein fraction to which T cells from MS patients and from healthy controls showed dominant responses. This highly immunogenic protein was identified as alpha B-crystallin, a small heat-shock protein. Immunohistochemical examination of MS lesions revealed the presence of oligodendrocytes and astrocytes with raised alpha B- crystallin expression, which were not found in unaffected myelin. Our findings indicate that alpha B-crystallin serves as immunodominant myelin antigen to human T cells when expressed at the elevated levels found in active MS lesions.	FREE UNIV AMSTERDAM HOSP,DEPT NEUROL,1007 MB AMSTERDAM,NETHERLANDS; AUSTRIAN ACAD SCI,EXPTL NEUROPATHOL RES UNIT,A-1090 VIENNA,AUSTRIA; NETHERLANDS INST BRAIN RES,NETHERLANDS BRAIN BANK,1105 AZ AMSTERDAM,NETHERLANDS	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Austrian Academy of Sciences; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW)	VANNOORT, JM (corresponding author), TNO,PREVENT & HLTH,DIV INFECT DIS & IMMUNOL,POB 2215,2301 CE LEIDEN,NETHERLANDS.		Lassmann, Hans/Z-2269-2019; Bajramovic, Jeffrey/AAF-6695-2020	Lassmann, Hans/0000-0001-8617-5052; Bajramovic, Jeffrey/0000-0002-6504-3437; van Noort, Johannes/0000-0002-9060-5921				BRUCK W, 1994, ANN NEUROL, V35, P65, DOI 10.1002/ana.410350111; DEJONG WW, 1994, PROG RETIN EYE RES, V13, P391, DOI 10.1016/1350-9462(94)90018-3; HEAD MW, 1994, J CELL PHYSIOL, V159, P41, DOI 10.1002/jcp.1041590107; HIROMI Y, 1985, EMBO J, V4, P1681, DOI 10.1002/j.1460-2075.1985.tb03837.x; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; IWAKI T, 1992, AM J PATHOL, V140, P345; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; KARLIK CC, 1984, CELL, V38, P711, DOI 10.1016/0092-8674(84)90266-6; KATO K, 1992, J BIOL CHEM, V167, P7718; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; LOWE J, 1992, J PATHOL, V166, P61, DOI 10.1002/path.1711660110; MARTIN R, 1992, ANNU REV IMMUNOL, V10, P153, DOI 10.1146/annurev.iy.10.040192.001101; NORTON WT, 1973, J NEUROCHEM, V31, P749; OZAWA K, 1994, BRAIN, V117, P1311, DOI 10.1093/brain/117.6.1311; PETTE M, 1990, NEUROLOGY, V40, P1770, DOI 10.1212/WNL.40.11.1770; SALVETTI M, 1992, J AUTOIMMUN, V5, P691, DOI 10.1016/0896-8411(92)90186-T; SELMAJ K, 1991, P NATL ACAD SCI USA, V88, P6452, DOI 10.1073/pnas.88.15.6452; VANNOORT JM, 1993, J NEUROIMMUNOL, V46, P67, DOI 10.1016/0165-5728(93)90234-P; VANNOORT JM, 1994, J CHROMATOGR B, V653, P155, DOI 10.1016/0378-4347(93)E0433-Q; WUCHERPFENNIG KW, 1992, P NATL ACAD SCI USA, V89, P4588, DOI 10.1073/pnas.89.10.4588; ZANTEMA A, 1992, J BIOL CHEM, V267, P12936	21	348	353	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 29	1995	375	6534					798	801		10.1038/375798a0	http://dx.doi.org/10.1038/375798a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF989	7596414				2022-12-24	WOS:A1995RF98900081
J	ADAMES, N; BLUNDELL, K; ASHBY, MN; BOONE, C				ADAMES, N; BLUNDELL, K; ASHBY, MN; BOONE, C			ROLE OF YEAST INSULIN-DEGRADING ENZYME HOMOLOGS IN PROPHEROMONE PROCESSING AND BUD SITE SELECTION	SCIENCE			English	Article							FACTOR MATING PHEROMONE; STE6 GENE-PRODUCT; SACCHAROMYCES-CEREVISIAE; A-FACTOR; FARNESYL CYSTEINE; RAS PROTEINS; TERMINAL METHYLATION; SHUTTLE VECTORS; ACTIVE-SITE; METHYLTRANSFERASE	The Saccharomyces cerevisiae AXL1 gene product Axl1p shares homology with the insulin-degrading enzyme family of endoproteases. Yeast axl1 mutants showed a defect in a-factor pheromone secretion, and a probable site of processing by Axl1p was identified within the a-factor precursor. In addition, Axl1p appears to function as a morphogenetic determinant for axial bud site selection. Amino acid substitutions within the presumptive active site of Axl1p caused defects in propheromone processing but failed to perturb bud site selection. Thus, Axl1p has been shown to participate in the dual regulation of distinct signaling pathways, and a member of the insulinase family has been implicated in propeptide processing.	SIMON FRASER UNIV, INST BIOCHEM & MOLEC BIOL, BURNABY, BC V5A 1S6, CANADA; UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA	Simon Fraser University; University of California System; University of California Berkeley			Adames, Neil/AAO-7913-2020; Adames, Neil/S-1460-2017; Adames, Neil/C-8863-2012	Adames, Neil/0000-0003-4331-9348; Adames, Neil/0000-0003-4331-9348; Adames, Neil/0000-0003-4331-9348				AFFHOLTER JA, 1988, SCIENCE, V242, P1415, DOI 10.1126/science.3059494; ANASTASI A, 1993, BIOCHEM J, V290, P601, DOI 10.1042/bj2900601; ANDEREGG RJ, 1988, J BIOL CHEM, V263, P18236; ASHBY MN, 1992, P NATL ACAD SCI USA, V89, P4613, DOI 10.1073/pnas.89.10.4613; ASHBY MN, 1995, METHOD ENZYMOL, V250, P235; ASHBY MN, 1993, YEAST, V9, P907, DOI 10.1002/yea.320090810; BECKER AB, 1992, P NATL ACAD SCI USA, V89, P3835, DOI 10.1073/pnas.89.9.3835; BECKER AB, 1993, BIOCHEM J, V292, P137, DOI 10.1042/bj2920137; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; BERKOWER C, 1994, MOL BIOL CELL, V5, P1185, DOI 10.1091/mbc.5.11.1185; BOONE C, 1992, NUCLEIC ACIDS RES, V20, P4661, DOI 10.1093/nar/20.17.4661; CALDWELL GA, 1994, J BIOL CHEM, V269, P19817; CHANT J, 1995, J CELL BIOL, V129, P751, DOI 10.1083/jcb.129.3.751; CHANT J, 1994, TRENDS GENET, V10, P328, DOI 10.1016/0168-9525(94)90036-1; CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; CHANT J, 1995, J CELL BIOL, V129, P767, DOI 10.1083/jcb.129.3.767; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; CHEN P, 1993, THESIS J HOPKINS U S; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; CVRCKOVA F, 1993, EMBO J, V12, P5277, DOI 10.1002/j.1460-2075.1993.tb06223.x; DUCKWORTH WC, 1989, BIOCHEMISTRY-US, V28, P2471, DOI 10.1021/bi00432a018; FUJITA A, 1994, NATURE, V372, P567, DOI 10.1038/372567a0; Gething M, 1985, PROTEIN TRANSPORT SE, P103; GOODMAN LE, 1990, P NATL ACAD SCI USA, V87, P9665, DOI 10.1073/pnas.87.24.9665; HE B, 1991, P NATL ACAD SCI USA, V88, P11373, DOI 10.1073/pnas.88.24.11373; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HRYCYNA CA, 1990, MOL CELL BIOL, V10, P5071, DOI 10.1128/MCB.10.10.5071; HRYCYNA CA, 1991, EMBO J, V10, P1699, DOI 10.1002/j.1460-2075.1991.tb07694.x; KOLLING R, 1994, EMBO J, V13, P3261, DOI 10.1002/j.1460-2075.1994.tb06627.x; KUCHLER K, 1993, J CELL BIOL, V120, P1203, DOI 10.1083/jcb.120.5.1203; KUCHLER K, 1992, ENDOCR REV, V13, P499, DOI 10.1210/er.13.3.499; KUCHLER K, 1989, EMBO J, V8, P3973, DOI 10.1002/j.1460-2075.1989.tb08580.x; LI D, 1992, J BIOL CHEM, V267, P2414; MARCUS S, 1991, MOL CELL BIOL, V11, P3603, DOI 10.1128/MCB.11.7.3603; MARR RS, 1990, J BIOL CHEM, V265, P20057; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MATTHEWS BW, 1988, ACCOUNTS CHEM RES, V21, P333, DOI 10.1021/ar00153a003; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MICHAELIS S, 1988, MOL CELL BIOL, V8, P1309, DOI 10.1128/MCB.8.3.1309; PARK HO, 1993, NATURE, V365, P269, DOI 10.1038/365269a0; PERLMAN RK, 1994, J BIOL CHEM, V269, P33140; PERLMAN RK, 1993, J BIOL CHEM, V268, P21538; PIEROTTI AR, 1994, P NATL ACAD SCI USA, V91, P6078, DOI 10.1073/pnas.91.13.6078; POWERS S, 1991, CELL, V65, P1225, DOI 10.1016/0092-8674(91)90017-S; SAPPERSTEIN S, 1994, MOL CELL BIOL, V14, P1438, DOI 10.1128/MCB.14.2.1438; SCHAFER WR, 1992, ANNU REV GENET, V26, P209, DOI 10.1146/annurev.ge.26.120192.001233; SIKORSKI RS, 1989, GENETICS, V122, P19; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; Sprague GF, 1992, MOL CELLULAR BIOL YE, V2, P657; STEINER DF, 1992, J BIOL CHEM, V267, P23435	50	113	114	2	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 20	1995	270	5235					464	467		10.1126/science.270.5235.464	http://dx.doi.org/10.1126/science.270.5235.464			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA374	7569998				2022-12-24	WOS:A1995TA37400040
J	RETALLACK, DM; FRIEDMAN, DI				RETALLACK, DM; FRIEDMAN, DI			A ROLE FOR A SMALL STABLE RNA IN MODULATING THE ACTIVITY OF DNA-BINDING PROTEINS	CELL			English	Article							ESCHERICHIA-COLI; 10SA RNA; PHAGE-LAMBDA; RIBONUCLEASE-P; GENE; TRANSCRIPTION; MECHANISM; ANTITERMINATION; IDENTIFICATION; EXPRESSION	The 10Sa RNA, encoded by the E. coli ssrA gene, appears to modulate action of some DNA-binding proteins. When ssrA is inactivated, lacZ expression from the lac operon, as well as galK from a gal operon fused to a phage lambda promoter, is reduced from that observed in bacteria wild-type for ssrA. These differences are not observed if the relevant repressor is inactive, suggesting that in the absence of 10Sa RNA binding of Lad and lambda cl repressors is enhanced. Gel mobility shifts show that 10Sa RNA binds these repressors and that an excess of 10Sa RNA competes for binding of lambda cl with a DNA fragment containing the O(R)2 repressor-binding sequence. Similar observations were made in studies of the E. coli LexA repressor and phage P22 C1 transcription activator proteins. These results suggest that direct interaction with 10Sa RNA may explain this modulation of protein-DNA interactions.			RETALLACK, DM (corresponding author), UNIV MICHIGAN, SCH MED, DEPT MICROBIOL & IMMUNOL, ANN ARBOR, MI 48109 USA.		Friedman, David/G-3198-2015	Friedman, David/0000-0002-2741-4671	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007544] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1-RR00042] Funding Source: Medline; NIGMS NIH HHS [5T32GM07544-14] Funding Source: Medline; PHS HHS [AL1459-10] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADHYA S, 1974, P NATL ACAD SCI USA, V71, P2534, DOI 10.1073/pnas.71.6.2534; ADHYA S, 1990, J BIOL CHEM, V265, P10797; ADHYA S, 1979, NATURE, V279, P492, DOI 10.1038/279492a0; ALTMAN S, 1993, FASEB J, V7, P7, DOI 10.1096/fasebj.7.1.7916700; AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; Beckwith J.R., 1987, ESCHERICHIA COLI SAL, V2, P1444; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN JW, 1990, NUCLEIC ACIDS RES, V18, P2820, DOI 10.1093/nar/18.9.2820; BRUNKOW ME, 1991, GENE DEV, V5, P1092, DOI 10.1101/gad.5.6.1092; CHAUHAN AK, 1989, MOL MICROBIOL, V3, P1481, DOI 10.1111/j.1365-2958.1989.tb00133.x; COURT D, 1993, CONTROL MRNA STABILI, V3, P71; DAMBLY-CHAUDIERE C, 1983, Journal of Molecular and Applied Genetics, V2, P45; DARR SC, 1992, BIOCHEMISTRY-US, V31, P328, DOI 10.1021/bi00117a003; DECROMBR.B, 1973, NATURE-NEW BIOL, V241, P260, DOI 10.1038/newbio241260a0; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; FRIEDMAN DI, 1990, GENE DEV, V4, P2210, DOI 10.1101/gad.4.12a.2210; FRIEDMAN DI, 1973, VIROLOGY, V51, P216, DOI 10.1016/0042-6822(73)90381-4; GUO QB, 1992, GENE DEV, V6, P1357, DOI 10.1101/gad.6.8.1357; HARRISON SC, 1992, TRANSCRIPTIONAL REGU, P449; HUISMAN O, 1981, NATURE, V290, P797, DOI 10.1038/290797a0; INOUYE M, 1988, CELL, V53, P5, DOI 10.1016/0092-8674(88)90480-1; JENSEN CG, 1994, J BACTERIOL, V176, P2502, DOI 10.1128/JB.176.9.2502-2506.1994; KAMBEROV ES, 1994, PHOSPHATE IN MICROORGANISMS, P302; KAOHUANG Y, 1977, P NATL ACAD SCI USA, V74, P4228, DOI 10.1073/pnas.74.10.4228; KIRBY JE, 1994, J BACTERIOL, V176, P2068, DOI 10.1128/jb.176.7.2068-2081.1994; KOMINE Y, 1994, P NATL ACAD SCI USA, V91, P9223, DOI 10.1073/pnas.91.20.9223; LAMBOWITZ AM, 1990, TRENDS BIOCHEM SCI, V15, P440, DOI 10.1016/0968-0004(90)90283-H; LIN LL, 1988, J BACTERIOL, V170, P2163, DOI 10.1128/jb.170.5.2163-2173.1988; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MOHR G, 1994, NATURE, V370, P147, DOI 10.1038/370147a0; NOVICK RP, 1993, EMBO J, V12, P3967, DOI 10.1002/j.1460-2075.1993.tb06074.x; OH BK, 1991, MOL GEN GENET, V229, P52, DOI 10.1007/BF00264212; PIELER T, 1993, TRENDS BIOCHEM SCI, V18, P226, DOI 10.1016/0968-0004(93)90194-R; RETALLACK DM, 1994, J BACTERIOL, V176, P2082, DOI 10.1128/jb.176.7.2082-2089.1994; RETALLACK DM, 1993, P NATL ACAD SCI USA, V90, P9562, DOI 10.1073/pnas.90.20.9562; REYES O, 1979, VIROLOGY, V94, P400, DOI 10.1016/0042-6822(79)90470-7; Sambrook J., 1989, MOL CLONING LAB MANU; SLEDJESKI D, 1995, P NATL ACAD SCI USA, V92, P2003, DOI 10.1073/pnas.92.6.2003; STRAUCH MA, 1986, J BACTERIOL, V167, P191, DOI 10.1128/jb.167.1.191-200.1986; SUBBARAO MN, 1989, MOL GEN GENET, V217, P499, DOI 10.1007/BF02464923; SUSSKIND MM, 1975, J MOL BIOL, V98, P413, DOI 10.1016/S0022-2836(75)80127-6; SUSSMAN R, 1962, CR HEBD ACAD SCI, V254, P1517; TAKAYAMA KM, 1990, CRIT REV BIOCHEM MOL, V25, P155, DOI 10.3109/10409239009090608; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; TYAGI JS, 1992, NUCLEIC ACIDS RES, V20, P138, DOI 10.1093/nar/20.1.138; USHIDA C, 1994, NUCLEIC ACIDS RES, V22, P3392, DOI 10.1093/nar/22.16.3392; von Hippel P H, 1974, Proc Natl Acad Sci U S A, V71, P4808; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5; ZEILSTRARYALLS J, 1991, ANNU REV MICROBIOL, V45, P301, DOI 10.1146/annurev.mi.45.100191.001505	51	46	48	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 20	1995	83	2					227	235		10.1016/0092-8674(95)90164-7	http://dx.doi.org/10.1016/0092-8674(95)90164-7			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TA965	7585940	Bronze			2022-12-24	WOS:A1995TA96500009
J	BORIES, JC; WILLERFORD, DM; GREVIN, D; DAVIDSON, L; CAMUS, A; MARTIN, P; STEHELIN, D; ALT, FW				BORIES, JC; WILLERFORD, DM; GREVIN, D; DAVIDSON, L; CAMUS, A; MARTIN, P; STEHELIN, D; ALT, FW			INCREASED T-CELL APOPTOSIS AND TERMINAL B-CELL DIFFERENTIATION-INDUCED BY INACTIVATION OF THE ETS-1 PROTOONCOGENE	NATURE			English	Article							DNA-BINDING; TRANSCRIPTION FACTORS; GENE ENHANCER; MICE; ACTIVATION; THYMOCYTES; SEQUENCE	THE Ets-1 proto-oncogene is a member of a transcription factor family characterized by homology to the v-ets oncogene(1-4). In adult mice, Ets-1 is expressed predominantly in lymphoid cells where it has been implicated in regulating transcription of lymphocyte-specific genes(5-7). Following T-cell activation, the specific DNA binding activity of Ets-1 is inactivated by transient phosphorylation, suggesting a function in the transition from the resting to activated state(8,9). Ets-1 has also been suggested to cooperate with the AP-1 transcription factor complex to mediate cellular growth factor responses(4). Here we show, by using RAG-2-deficient blastocyst complementation(10), that Ets-1 deficiency has dramatic, but different, effects on development and function of T- and B-lineage cells, Ets-1-deficient T cells were present in reduced numbers and were highly susceptible to cell death in vitro. In contrast, Ets-1-deficient B cells were present in normal numbers but a large proportion were IgM plasma cells, Our data demonstrate that Ets-1 is essential for maintenance of the normal pool of resting T- and B-lineage cells.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; CTR BLOOD RES,BOSTON,MA 02115; HOP ST LOUIS,INSERM,U93,F-75475 PARIS,FRANCE; INST PASTEUR,MOLEC ONCOL LAB,CNRS,URA 1160,F-59019 LILLE,FRANCE; INST PASTEUR,UNITE BIOL DEV,CNRS,URA 1960,F-75724 PARIS,FRANCE	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	BORIES, JC (corresponding author), CHILDRENS HOSP,HOWARD HUGHES MED INST,BOSTON,MA 02115, USA.		Bories, Jean-Christophe/L-6952-2017; Camus, Anne/P-1515-2014	Camus, Anne/0000-0002-8820-0407				BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BOTTARO A, 1994, EMBO J, V13, P665, DOI 10.1002/j.1460-2075.1994.tb06305.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; CHEN J, 1992, P NATL ACAD SCI USA, V90, P4528; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HARDY RR, 1983, NATURE, V306, P270, DOI 10.1038/306270a0; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; JAKOBOVITS A, 1993, P NATL ACAD SCI USA, V90, P2551, DOI 10.1073/pnas.90.6.2551; JORCYK CL, 1991, ONCOGENE, V6, P523; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; RABAULT B, 1994, J BIOL CHEM, V269, P28143; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SIDMAN CL, 1986, SCIENCE, V232, P1423, DOI 10.1126/science.3487115; SWAT W, 1991, J IMMUNOL METHODS, V137, P79, DOI 10.1016/0022-1759(91)90396-W; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0	24	269	276	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 19	1995	377	6550					635	638		10.1038/377635a0	http://dx.doi.org/10.1038/377635a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA275	7566176				2022-12-24	WOS:A1995TA27500054
J	GRANDEA, AG; ANDROLEWICZ, MJ; ATHWAL, RS; GERAGHTY, DE; SPIES, T				GRANDEA, AG; ANDROLEWICZ, MJ; ATHWAL, RS; GERAGHTY, DE; SPIES, T			DEPENDENCE OF PEPTIDE BINDING BY MHC CLASS-I MOLECULES ON THEIR INTERACTION WITH TAP	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; ENDOPLASMIC-RETICULUM; CELL BIOLOGY; HLA-A; ANTIGEN; TRANSPORTER; TRANSLOCATION; PROTEIN; GENE; EXPRESSION	Major histocompatibility complex (MHC) class I molecules bind peptides that are delivered from the cytosol into the endoplasmic reticulum by the MHC-encoded transporter associated with antigen processing (TAP). Peptide capture by immature heterodimers of class I heavy chains and beta(2)-microglobulin may be facilitated by their physical association with TAP. A genetic defect in a human mutant cell line causes the complete failure of diverse class I heterodimers to associate with TAP. This deficiency impairs the ability of the class I heterodimers to efficiently capture peptides and results from loss of function of an unidentified gene or genes linked to the MHC.	FRED HUTCHINSON CANC RES CTR,DIV CLIN RES,SEATTLE,WA 98104; UNIV S FLORIDA,COLL MED,DEPT BIOCHEM & MOLEC BIOL,TAMPA,FL 33612; UNIV S FLORIDA,COLL MED,H LEE MOFFITT CANC CTR,PROGRAM IMMUNOL,TAMPA,FL 33612; TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19104	Fred Hutchinson Cancer Center; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University					NIAID NIH HHS [AI38508, AI30581] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI030581, R01AI038508, R01AI030581] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALEXANDER J, 1990, IMMUNOGENETICS, V31, P169; ANDERSON K, 1991, J EXP MED, V174, P489, DOI 10.1084/jem.174.2.489; ANDROLEWICZ MJ, 1994, P NATL ACAD SCI USA, V91, P12716, DOI 10.1073/pnas.91.26.12716; ANDROLEWICZ MJ, 1994, IMMUNITY, V1, P7, DOI 10.1016/1074-7613(94)90004-3; ANDROLEWICZ MJ, 1993, P NATL ACAD SCI USA, V90, P9130, DOI 10.1073/pnas.90.19.9130; ARNOLD D, 1992, NATURE, V360, P171, DOI 10.1038/360171a0; ATTAYA M, 1992, NATURE, V355, P647, DOI 10.1038/355647a0; BARBER LD, 1993, ANNU REV CELL BIOL, V9, P163; BURROWS SR, 1992, EUR J IMMUNOL, V22, P191, DOI 10.1002/eji.1830220128; CEMAN S, 1994, J IMMUNOL, V152, P2865; CROMME FV, 1994, J EXP MED, V179, P335, DOI 10.1084/jem.179.1.335; DEMARS R, 1985, P NATL ACAD SCI USA, V82, P8183, DOI 10.1073/pnas.82.23.8183; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.iy.11.040193.002155; GREENWOOD R, 1994, J IMMUNOL, V153, P5525; HAYNES BF, 1982, HUM IMMUNOL, V4, P273, DOI 10.1016/0198-8859(82)90001-5; HEEMELS MT, 1993, SCIENCE, V262, P2059, DOI 10.1126/science.8266106; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; KLEIJMEER MJ, 1992, NATURE, V357, P342, DOI 10.1038/357342a0; MELLINS E, 1991, J EXP MED, V174, P1607, DOI 10.1084/jem.174.6.1607; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; Nelson K, 1989, IMMUNOBIOLOGY HLA, P292; NOSSNER E, 1995, J EXP MED, V181, P327, DOI 10.1084/jem.181.1.327; ORTMANN B, 1994, NATURE, V368, P864, DOI 10.1038/368864a0; SANDHU AK, 1994, P NATL ACAD SCI USA, V91, P5498, DOI 10.1073/pnas.91.12.5498; SHEPHERD JC, 1993, CELL, V74, P577, DOI 10.1016/0092-8674(93)80058-M; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; STAM NJ, 1990, INT IMMUNOL, V2, P113, DOI 10.1093/intimm/2.2.113; STUBBLEFIELD E, 1992, SOMAT CELL MOLEC GEN, V18, P485, DOI 10.1007/BF01232645; SUGITA M, 1994, J EXP MED, V180, P2163, DOI 10.1084/jem.180.6.2163; SUH WK, 1994, SCIENCE, V264, P1322, DOI 10.1126/science.8191286; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; WILLIAMS DB, 1995, CURR OPIN IMMUNOL, V7, P77, DOI 10.1016/0952-7915(95)80032-8; YEWDELL JW, 1992, ADV IMMUNOL, V52, P1, DOI 10.1016/S0065-2776(08)60875-5	38	177	177	1	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 6	1995	270	5233					105	108		10.1126/science.270.5233.105	http://dx.doi.org/10.1126/science.270.5233.105			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY302	7569935				2022-12-24	WOS:A1995RY30200044
J	YAN, H; NEWPORT, J				YAN, H; NEWPORT, J			FFA-1, A PROTEIN THAT PROMOTES THE FORMATION OF REPLICATION CENTERS WITHIN NUCLEI	SCIENCE			English	Article							DNA-REPLICATION; EGG EXTRACTS; INVITRO; OCCURS; SITES	In the nuclei of eukaryotic cells, initiation of DNA replication occurs at a discrete number of foci. One component of these foci is the DNA replication factor RP-A. Here, the process leading to the association of RP-A with foci was reconstituted with cytosolic fractions derived from Xenopus eggs. With the use of this fractionated system, a 170-kilodalton protein required for the assembly of RP-A into foci was identified and purified. The protein appears to be an integral component of the foci at which replication of DNA is initiated in eukaryotic nuclei.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033523, R37GM033523] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33523] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI Y, 1992, J CELL BIOL, V119, P1, DOI 10.1083/jcb.119.1.1; ADACHI Y, 1994, EMBO J, V13, P4153, DOI 10.1002/j.1460-2075.1994.tb06733.x; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BENEDETTI P, 1983, EMBO J, V2, P1303, DOI 10.1002/j.1460-2075.1983.tb01585.x; COX LS, 1991, CELL, V66, P271, DOI 10.1016/0092-8674(91)90617-8; FANG F, 1993, J CELL SCI, V106, P983; MILLS AD, 1989, J CELL SCI, V94, P471; NAKAMURA H, 1986, EXP CELL RES, V165, P291, DOI 10.1016/0014-4827(86)90583-5; NAKAYASU H, 1989, J CELL BIOL, V108, P1, DOI 10.1083/jcb.108.1.1; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; SHEEHAN MA, 1988, J CELL BIOL, V106, P1, DOI 10.1083/jcb.106.1.1; SHIODA M, 1982, P NATL ACAD SCI-BIOL, V79, P7209, DOI 10.1073/pnas.79.23.7209; SMYTHE C, 1991, METHOD CELL BIOL, V35, P449; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; YAN H, 1995, J CELL BIOL, V129, P1, DOI 10.1083/jcb.129.1.1; YAN H, UNPUB	18	36	37	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 29	1995	269	5232					1883	1885		10.1126/science.7569932	http://dx.doi.org/10.1126/science.7569932			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX194	7569932				2022-12-24	WOS:A1995RX19400042
J	WALLEY, T; BARTON, S				WALLEY, T; BARTON, S			A PURCHASER PERSPECTIVE OF MANAGING NEW DRUGS - INTERFERON-BETA AS A CASE-STUDY	BRITISH MEDICAL JOURNAL			English	Article								Many new drugs in the future will be very expensive and have major resource implications. Given current structures and legislation covering the prescribing of drugs, there are no clear means of controlling the use of these drugs to avoid diverting money away from other health care services and into drug treatment. This paper considers what mechanisms might be used by a purchaser to manage the introduction of an expensive new drug and uses interferon beta-1b for treating multiple sclerosis as an example. The most likely mechanism is the prescribing of the drug by a general practitioner on the advice of a neurologist. This would achieve a good benefit for the resources invested but would not control total expenditure. Devolving a limited budget for the drug to a specialist centre so that neurologists may prescribe it directly would be preferable, as this would link clinical, prescribing, and budgetary responsibility. These issues need to be addressed urgently by purchasers if major disruptions of services are to be avoided.			WALLEY, T (corresponding author), UNIV LIVERPOOL,DEPT PHARMACOL & THERAPEUT,POB 147,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND.							[Anonymous], 1994, KEY ISSUES HLTH EC; BOCHNER F, 1994, BRIT MED J, V308, P901, DOI 10.1136/bmj.308.6933.901; CRUMP BJ, 1995, BRIT MED J, V310, P509, DOI 10.1136/bmj.310.6978.509; GOODKIN DE, 1994, LANCET, V344, P1702, DOI 10.1016/S0140-6736(94)90484-7; GOODKIN DE, 1994, LANCET, V344, P1057, DOI 10.1016/S0140-6736(94)91713-2; GOULD J, 1994, BRIT MED J, V309, P1657, DOI 10.1136/bmj.309.6969.1657b; HAYCOX A, 1995, PURCHASER DECISION M; JONES R, 1992, BRIT MED J, V304, P4, DOI 10.1136/bmj.304.6818.4; LEUFKENS H, 1994, BRIT MED J, V309, P1137, DOI 10.1136/bmj.309.6962.1137; NISHIMURA LY, 1994, PHARMACOECONOMICS, V6, P498, DOI 10.2165/00019053-199406060-00003; ORME M, 1991, BRIT MED J, V303, P593, DOI 10.1136/bmj.303.6803.593; PATY DW, 1993, NEUROLOGY, V43, P662, DOI 10.1212/WNL.43.4.662; The IFNB Multiple Sclerosis Study Group, 1993, NEUROLOGY, V43, P655; WALLEY T, 1994, PHARMACOECONOMICS, V5, P93, DOI 10.2165/00019053-199405020-00003; 1994, GUIDELLINES CONDUCT; 1994, BETA INTERFERON 1B P; 1995, EL955 NHS EX DEP HLT; 1994, PRIORITY SETTING NHS, V1; 1994, NEW TREATMENTS MULTI; 1991, EL91127 NHS MAN EX D; 1994, EL9472 NHS EX DEP HL; 1994, NEUROLOGY, V44, P1537; 1944, GUIDELINES TREATMENT	23	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 23	1995	311	7008					796	799		10.1136/bmj.311.7008.796	http://dx.doi.org/10.1136/bmj.311.7008.796			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX107	7580445	Green Published			2022-12-24	WOS:A1995RX10700027
J	STUMVOLL, M; NURJHAN, N; PERRIELLO, G; DAILEY, G; GERICH, JE				STUMVOLL, M; NURJHAN, N; PERRIELLO, G; DAILEY, G; GERICH, JE			METABOLIC EFFECTS OF METFORMIN IN NON-INSULIN-DEPENDENT DIABETES-MELLITUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RAT HEPATOCYTES; SKELETAL-MUSCLE; MECHANISM; GLUCONEOGENESIS; OXIDATION; TURNOVER; LACTATE; BIGUANIDES; THERAPY; ALANINE	Background. The metabolic effects and mechanism of action of metformin are still poorly understood, despite the fact that it has been used to treat patients with non-insulin-dependent diabetes mellitus (NIDDM) for more than 30 years. Methods. In 10 obese patients with NIDDM, we used a combination of isotope dilution, indirect calorimetry, bioimpedance, and tissue-balance techniques to assess the effects of metformin on systemic lactate, glucose, and free-fatty-acid turnover, lactate oxidation and the conversion of lactate to glucose; skeletal-muscle glucose and lactate metabolism; body composition; and energy expenditure before and after four months of treatment. Results. Metformin treatment decreased the mean (+/-SD) glycosylated hemoglobin value from 13.2+/-2.2 percent to 10.5+/-1.6 percent (P<0.001) and reduced fasting plasma glucose concentrations from 220+/-41 to 155+/-28 mg per deciliter (12.2+/-0.7 to 8.6+/-0.5 mmol per liter) (P<0.001). Although resting energy expenditure did not change, the patients lost 2.7+/-1.3 kg of weight (P<0.001:), 88 percent of which was adipose tissue. The mean (+/-SE) rate of plasma glucose turnover (hepatic glucose output and systemic glucose disposal) decreased from 2.8+/-0.2 to 2.0+/-0.2 mg per kilogram of body weight per minute (15.3+/-0.9 to 10.8+/-0.9 mu mol per kilogram per minute) (P<0.001), as a result of a decrease in hepatic glucose output; systemic glucose clearance did not change. The rate of conversion of lactate to glucose (gluconeogenesis) decreased by 37 percent (P<0.001), whereas lactate oxidation increased by 25 percent (P<0.001). There were no changes in the plasma lactate concentration, plasma lactate turnover, muscle lactate release, plasma free-fatty-acid turnover or uptake of glucose by muscle. Conclusions. Metformin acts primarily by decreasing hepatic glucose output, largely by inhibiting gluconeogenesis, It also seems to induce weight toss, preferentially involving adipose tissue.	UNIV ROCHESTER,SCH MED,ROCHESTER,NY 14642; SCRIPPS CLIN & RES FDN,DIV ENDOCRINOL & METAB,LA JOLLA,CA	University of Rochester; Scripps Research Institute			Stumvoll, Michael/ABE-1121-2021	Stumvoll, Michael/0000-0001-6225-8240	NCRR NIH HHS [5MO1-RR 000954, 5MO1-RR 00044] Funding Source: Medline; NIDDK NIH HHS [DK-20411] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000044, P41RR000954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK020411, R01DK020411] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALENGRIN F, 1987, DIABETES METAB, V13, P591; ARGAUD D, 1993, EUR J BIOCHEM, V213, P1341, DOI 10.1111/j.1432-1033.1993.tb17886.x; BAILEY CJ, 1992, DIABETES CARE, V15, P755, DOI 10.2337/diacare.15.6.755; CIGOLINI M, 1984, DIABETES METAB, V10, P311; CONSOLI A, 1990, J CLIN INVEST, V86, P2038, DOI 10.1172/JCI114940; CONSOLI A, 1987, J CLIN INVEST, V80, P1303, DOI 10.1172/JCI113206; CONSOLI A, 1990, AM J PHYSIOL, V259, pE677, DOI 10.1152/ajpendo.1990.259.5.E677; DEFRONZO RA, 1991, J CLIN ENDOCR METAB, V73, P1294, DOI 10.1210/jcem-73-6-1294; DINNEEN S, 1992, NEW ENGL J MED, V327, P707, DOI 10.1056/NEJM199209033271007; FERRANNINI E, 1988, METABOLISM, V37, P287, DOI 10.1016/0026-0495(88)90110-2; GERICH JE, 1989, NEW ENGL J MED, V321, P1231; GERICH JE, 1993, BAILLIERE CLIN ENDOC, V7, P551, DOI 10.1016/S0950-351X(05)80207-1; HENDLER R, 1990, INT J OBESITY, V14, P927; HEYMSFIELD SB, 1982, AM J CLIN NUTR, V35, P1192, DOI 10.1093/ajcn/35.5.1192; JACKSON RA, 1987, DIABETES, V36, P632, DOI 10.2337/diabetes.36.5.632; KELLEY D, 1988, J CLIN INVEST, V81, P1563, DOI 10.1172/JCI113489; KLIP A, 1990, DIABETES CARE, V13, P696, DOI 10.2337/diacare.13.6.696; KREISBERG RA, 1970, DIABETES, V19, P64, DOI 10.2337/diab.19.1.64; LESLIE P, 1987, CLIN SCI, V73, P41, DOI 10.1042/cs0730041; LUKASKI HC, 1987, AM J CLIN NUTR, V46, P537, DOI 10.1093/ajcn/46.4.537; LUKE A, 1992, METABOLISM, V41, P450, DOI 10.1016/0026-0495(92)90083-M; MILES JM, 1987, AM J PHYSIOL, V252, pE431, DOI 10.1152/ajpendo.1987.252.3.E431; NOSADINI R, 1987, DIABETES CARE, V10, P62, DOI 10.2337/diacare.10.1.62; PERRIELLO G, 1994, DIABETES, V43, P920, DOI 10.2337/diabetes.43.7.920; SCHAFER G, 1980, PHARMACOL THERAPEUT, V8, P275, DOI 10.1016/0163-7258(80)90049-2; SEARLE GL, 1975, DIABETES, V24, P741, DOI 10.2337/diabetes.24.8.741; SHIMIZU S, 1980, ANAL BIOCHEM, V107, P193, DOI 10.1016/0003-2697(80)90511-4; VIGNERI R, 1987, DIABETES CARE, V10, P118, DOI 10.2337/diacare.10.1.118; WILLIAMS RH, 1959, METABOLISM, V8, P548; WILLIAMS RH, 1975, ANN INTERN MED, V83, P567, DOI 10.7326/0003-4819-83-4-567; WING RR, 1994, DIABETES CARE, V17, P30, DOI 10.2337/diacare.17.1.30; Wolfe R. R., 1992, RADIOACTIVE STABLE I; WOLLEN N, 1988, BIOCHEM PHARMACOL, V37, P4353, DOI 10.1016/0006-2952(88)90617-X; YKIJARVINEN H, 1992, ENDOCR REV, V13, P415	34	884	901	0	34	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 31	1995	333	9					550	554		10.1056/NEJM199508313330903	http://dx.doi.org/10.1056/NEJM199508313330903			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ751	7623903				2022-12-24	WOS:A1995RQ75100003
J	MEJIA, RE; POLLACK, MM				MEJIA, RE; POLLACK, MM			VARIABILITY IN BRAIN-DEATH DETERMINATION PRACTICES IN CHILDREN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GUIDELINES	Objective.-To investigate variability in practices for determining brain death and organ procurement results in pediatric intensive care units (PICUs). Design.-Prospective cohort study. Setting.-Pediatric ICUs. Patients.-Children undergoing brain death evaluations selected from 5415 consecutive PICU admissions. Main Outcome Measures.-Data from children undergoing brain death evaluations including number of coma examinations, number and duration of apnea tests, Pco(2) measurements at the end of the apnea test, ancillary tests used to confirm brain death, organ procurement, and reasons for nonprocurement. Results.-A total of 93 (37%) of 248 deaths were brain deaths. Compared with the other deaths, children who were classified as brain dead were sicker on admission (mean Pediatric Risk of Mortality [PRISM] score+/-SD: 31+/-11 vs 23+/-12, P<,001; pre-ICU cardiopulmonary resuscitation, 72% vs 40%, P<.001), and had more traumatic injuries (42% vs 12%, P<.001). Variability in apnea testing included lack of apnea testing in 23 patients (25%) and controversial apnea testing practices in 20 patients (22%). Three patients (3%) had brain death evaluations within hours of discontinuing barbiturate infusions, and four of 30 patients younger than 1 year did not have a confirmatory test, Solid organ procurement was successful in 32%, Reasons for nonprocurement included parental refusal (12%), disease state (12%), and medical examiner's case (22%). Conclusions.-Substantial variability exists in the criteria used by clinicians for the diagnosis of brain death. Some practices are contradictory to the Guidelines for the Determination of Brain Death in Children and to recommendations for apnea testing. Organ procurement could be improved by increased medical examiner cooperation.	CHILDRENS NATL MED CTR,DEPT CRIT CARE MED,WASHINGTON,DC 20010; CHILDRENS NATL MED CTR,CHILRENS RES INST,CTR HLTH SERV & CLIN RES,WASHINGTON,DC 20010; GEORGE WASHINGTON UNIV,SCH MED,DEPT PEDIAT,WASHINGTON,DC	Children's National Health System; Children's National Health System; George Washington University					PHS HHS [MCH-110584] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALJUMAH M, 1992, CRIT CARE MED, V20, P1564; ASHWAL S, 1993, J HEART LUNG TRANSPL, V12, pS176; Ashwal S, 1991, Adv Pediatr, V38, P181; DRAKE B, 1986, PEDIATRICS, V78, P107; EDMONDS JF, 1989, PEDIAT BRAIN DEATH O, P89; FACKLER JC, 1988, AM J DIS CHILD, V142, P999, DOI 10.1001/archpedi.1988.02150090097034; FREEMAN JM, 1988, PEDIATRICS, V81, P301; GONNELLA JS, 1986, DISEASE STAGING CLIN; Hauser J E, 1969, J Forensic Sci, V14, P501; KAUFMAN HH, 1989, NEUROSURGERY, V25, P275, DOI 10.1227/00006123-198908000-00019; KOHRMAN MH, 1990, PEDIATR NEUROL, V6, P47, DOI 10.1016/0887-8994(90)90078-F; LEVETOWN M, 1994, JAMA-J AM MED ASSOC, V272, P1271, DOI 10.1001/jama.272.16.1271; NARKEWICZ RM, 1989, PEDIATRICS, V83, P629; POLLACK MM, 1993, CRIT CARE MED, V21, P607, DOI 10.1097/00003246-199304000-00023; POLLACK MM, 1994, JAMA-J AM MED ASSOC, V272, P941, DOI 10.1001/jama.272.12.941; POLLACK MM, 1988, CRIT CARE MED, V16, P1110, DOI 10.1097/00003246-198811000-00006; POWNER DJ, 1976, JAMA-J AM MED ASSOC, V236, P1123, DOI 10.1001/jama.236.10.1123; RIVIELLO JJ, 1988, PEDIATR NEUROL, V4, P213, DOI 10.1016/0887-8994(88)90033-1; SCHAFER JA, 1984, CRIT CARE MED, V12, P357; SHAFER T, 1994, JAMA-J AM MED ASSOC, V272, P1607, DOI 10.1001/jama.272.20.1607; SHERIDAN F, 1993, J HEART LUNG TRANSPL, V12, pS179; SHEWMON DA, 1988, ANN NEUROL, V24, P789; SHEWMON DA, 1988, NEUROLOGY, V38, P1813, DOI 10.1212/WNL.38.11.1813-b; SQUIRES S, 1993, WASHINGTON POST 1118; SQUIRES S, 1994, WASHINGTON POST 0729; STAWORN D, 1994, CRIT CARE MED, V22, P1301, DOI 10.1097/00003246-199408000-00014; 1984, PEDIATRICS, V74, P505; 1981, JAMA-J AM MED ASSOC, V246, P2184	28	61	63	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 16	1995	274	7					550	553		10.1001/jama.274.7.550	http://dx.doi.org/10.1001/jama.274.7.550			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN466	7629983				2022-12-24	WOS:A1995RN46600025
J	PELLIZZER, G; SARGENT, P; GEORGOPOULOS, AP				PELLIZZER, G; SARGENT, P; GEORGOPOULOS, AP			MOTOR CORTICAL ACTIVITY IN A CONTEXT-RECALL TASK	SCIENCE			English	Article							SINGLE CELL; DIRECTION; CORTEX; VISUOMOTOR; MOVEMENTS	A monkey was trained to respond on the basis of the serial position of a test stimulus in a sequence. First, three stimuli were presented successively on a circle. Then one of them (except the last) changed color (test stimulus) and served as the go signal: The monkey was required to produce a motor response in the direction of the stimulus that followed the test stimulus. When the test stimulus was the second in the sequence, there was a change in motor cortical activity from a pattern reflecting the direction of this stimulus to the pattern associated with the direction of the motor response. This change was abrupt, occurred 100 to 150 milliseconds after the go signal, and was evident both in the activity of single cells and in the time-varying neuronal population vector. These findings identify the neural correlates of a switching process that is different from a mental rotation described previously.	VET AFFAIRS MED CTR,CTR BRAIN SCI,MINNEAPOLIS,MN 55417; UNIV MINNESOTA,SCH MED,DEPT PHYSIOL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH MED,DEPT NEUROL,MINNEAPOLIS,MN 55455	US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities			Pellizzer, Giuseppe/B-7540-2017	Pellizzer, Giuseppe/0000-0002-9254-5555	NINDS NIH HHS [NS17413] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017413] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CHELAZZI L, 1993, NATURE, V363, P345, DOI 10.1038/363345a0; GAZZANIGA MS, 1995, COGNITIVE NEUROSCLEN; GEORGOPOULOS AP, 1991, EXP BRAIN RES, V83, P453; GEORGOPOULOS AP, 1989, SCIENCE, V243, P234, DOI 10.1126/science.2911737; GEORGOPOULOS AP, 1986, SCIENCE, V233, P1416, DOI 10.1126/science.3749885; GEORGOPOULOS AP, 1993, SCIENCE, V260, P47, DOI 10.1126/science.8465199; Kosslyn S. M., 1992, FRONTIERS COGNITIVE; LURITO JT, 1991, EXP BRAIN RES, V87, P562; MARDIA KV, 1972, STATISTICS DIRECTION; PELLIZZER G, 1993, EXP BRAIN RES, V93, P165; SCHWARTZ AB, 1988, J NEUROSCI, V8, P2913; Snedecor G. W, 1989, STAT METHODS, V8th; STERNBERG S, 1969, AM SCI, V57, P421; STERNBERG S, 1966, SCIENCE, V153, P652, DOI 10.1126/science.153.3736.652; STERNBERG S, 1975, Q J EXP PSYCHOL, V27, P1, DOI 10.1080/14640747508400459; Zar JH., 1999, BIOSTAT ANAL	16	55	55	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 4	1995	269	5224					702	705		10.1126/science.7624802	http://dx.doi.org/10.1126/science.7624802			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM702	7624802				2022-12-24	WOS:A1995RM70200038
J	JOHNSON, RE; KOVVALI, GK; PRAKASH, L; PRAKASH, S				JOHNSON, RE; KOVVALI, GK; PRAKASH, L; PRAKASH, S			REQUIREMENT OF THE YEAST RTH1 5' TO 3' EXONUCLEASE FOR THE STABILITY OF SIMPLE REPETITIVE DNA	SCIENCE			English	Article							NONPOLYPOSIS COLORECTAL-CANCER; MISMATCH REPAIR; SACCHAROMYCES-CEREVISIAE; INSTABILITY; MUTATIONS; REPLICATION; MECHANISM; PROTEINS; HOMOLOG; HISTORY	Simple repetitive DNA sequences are unstable in human colorectal cancers and a variety of other cancers. Mutations in the DNA mismatch repair genes MSH2, MLH1, and PMS1 result in elevated rates of spontaneous mutation and cause a marked increase in the instability of simple repeats. Compared with the wild type, a null mutation in the yeast RTH1 gene, which encodes a 5' to 3' exonuclease, was shown to increase the rate of instability of simple repetitive DNA by as much as 280 times and to increase the spontaneous mutation rate by 30 times. Epistasis analyses were consistent with the hypothesis that this RTH1-encoded nuclease has a role in the MSH2-MLH1-PMS1 mismatch repair pathway.	UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston			Prakash, Satya/C-6420-2013; Prakash, Louise/C-7891-2012	Prakash, Louise/0000-0001-9143-6261; Prakash, Satya/0000-0001-7228-1444	NATIONAL CANCER INSTITUTE [R01CA041261, R37CA041261] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019261] Funding Source: NIH RePORTER; NCI NIH HHS [CA 41261] Funding Source: Medline; NIGMS NIH HHS [GM 19261] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; FANG WH, 1993, J BIOL CHEM, V268, P11838; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GLEBOV OK, 1994, CANCER RES, V54, P3703; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; HAMADA H, 1982, P NATL ACAD SCI-BIOL, V79, P6465, DOI 10.1073/pnas.79.21.6465; HAN HJ, 1993, CANCER RES, V53, P5087; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HENDERSON ST, 1992, MOL CELL BIOL, V12, P2749, DOI 10.1128/MCB.12.6.2749; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; KIM HG, 1994, AM J PATHOL, V145, P148; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEVINSON G, 1987, NUCLEIC ACIDS RES, V15, P5323, DOI 10.1093/nar/15.13.5323; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; LOTHE RA, 1993, CANCER RES, V53, P5849; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; MERLO A, 1994, CANCER RES, V54, P2098; MIRONOV NM, 1994, CANCER RES, V54, P41; MORRISON A, 1993, PROG NUCLEIC ACID RE, V46, P93, DOI 10.1016/S0079-6603(08)61019-3; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PROLLA TA, 1994, MOL CELL BIOL, V14, P407, DOI 10.1128/MCB.14.1.407; REENAN RAG, 1992, GENETICS, V132, P975; RICH A, 1984, ANNU REV BIOCHEM, V53, P791, DOI 10.1146/annurev.bi.53.070184.004043; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; TURCHI JJ, 1993, J BIOL CHEM, V268, P15136; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; UMAR A, 1994, J BIOL CHEM, V269, P14367; UMAR A, 1994, SCIENCE, V266, P814, DOI 10.1126/science.7973637; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; WAGA S, 1994, J BIOL CHEM, V269, P10923; WALMSLEY RM, 1983, NATURE, V302, P84, DOI 10.1038/302084a0	38	172	181	1	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 14	1995	269	5221					238	240		10.1126/science.7618086	http://dx.doi.org/10.1126/science.7618086			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ029	7618086				2022-12-24	WOS:A1995RJ02900044
J	ROBERGE, JY; BEEBE, X; DANISHEFSKY, SJ				ROBERGE, JY; BEEBE, X; DANISHEFSKY, SJ			A STRATEGY FOR A CONVERGENT SYNTHESIS OF N-LINKED GLYCOPEPTIDES ON A SOLID SUPPORT	SCIENCE			English	Article							OLIGOSACCHARIDES; GLYCOBIOLOGY; GLYCALS; ROUTE	Oligosaccharides and glycopeptides are of considerable importance in molecular biology and pharmacology. However, their synthesis is complicated by the large number of different linking sites between each saccharide unit, the need for stereochemical control, the chemical sensitivity of the glycopeptide bonds, and the need to harmonize diverse protecting groups. Here, an efficient solid-phase synthesis of three N-linked glycopeptides based on glycal assembly is presented. The peptide domain can be extended while the ensemble remains bound to the polymer. The glycopeptides synthesized here are among the largest M-linked glycopeptides ever accessed by either solution- or solid-phase synthesis.	COLUMBIA UNIV,DEPT CHEM,NEW YORK,NY 10027	Columbia University	ROBERGE, JY (corresponding author), SLOAN KETTERING INST CANC RES,BIOORGAN CHEM LAB,1275 YORK AVE,BOX 106,NEW YORK,NY 10021, USA.		Roberge, Jacques Y./B-2412-2013	Roberge, Jacques Y./0000-0002-7810-4139	NCI NIH HHS [T32 CA62948] Funding Source: Medline; NIAID NIH HHS [AI 16943] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA062948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016943] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANISFELD ST, 1990, J ORG CHEM, V55, P5560, DOI 10.1021/jo00308a009; BAHL OP, 1992, GLYCOCONJUGATES COMP, P1; BERKOWITZ DB, 1992, J AM CHEM SOC, V114, P4518, DOI 10.1021/ja00038a011; BLACKBURN GM, 1990, NUCLEIC ACIDS CHEM B; BRAY AM, 1994, J ORG CHEM, V59, P2197, DOI 10.1021/jo00087a041; COHENANISFELD ST, 1993, J AM CHEM SOC, V115, P10531, DOI 10.1021/ja00076a010; DANISHEFSKY J, IN PRESS GLYCOPEPTID; Danishefsky S.J., 1989, CHEMTRACTS ORG CHEM, P273; DANISHEFSKY SJ, 1993, SCIENCE, V260, P1307, DOI 10.1126/science.8493573; DANISHEFSKY SJ, 1995, SCHERING LECTURE SER; DANISHEFSKY SJ, 1994, POLYM PREPR, V35, P977; DELL A, 1993, CURR OPIN STRUC BIOL, V3, P687, DOI 10.1016/0959-440X(93)90051-L; DWEK RA, 1993, ANNU REV BIOCHEM, V62, P65, DOI 10.1146/annurev.bi.62.070193.000433; FEIZI T, 1994, CURR OPIN STRUC BIOL, V4, P673, DOI 10.1016/S0959-440X(94)90164-3; GALLOP MA, 1994, J MED CHEM, V37, P1233, DOI 10.1021/jm00035a001; JONES D A JR, 1977, Tetrahedron Letters, V33, P2853; JUNG G, 1992, ANGEW CHEM INT EDIT, V31, P367, DOI 10.1002/anie.199203673; KOBATA A, 1993, ACCOUNTS CHEM RES, V26, P319, DOI 10.1021/ar00030a004; KUNZ H, 1992, SYNLETT, P591; Lee Y. C., 1994, NEOGLYCOCONJUGATES P; LEHRMAN MA, 1993, Patent No. 5272070; LEMIEUX RU, 1964, CAN J CHEM, V42, P1473, DOI 10.1139/v64-222; MATSUURA S, 1976, J CHEM SOC CHEM COMM, P451, DOI 10.1039/c39760000451; MCDONALD FE, 1992, J ORG CHEM, V57, P7001, DOI 10.1021/jo00052a001; McPherson M. J., 1991, PCR PRACTICAL APPROA; MELDAL M, 1994, CURR OPIN STRUC BIOL, V4, P710, DOI 10.1016/S0959-440X(94)90169-4; Meldal Morten, 1994, P145; NESTLER HP, 1994, J ORG CHEM, V59, P4723, DOI 10.1021/jo00096a008; OPDENAKKER G, 1993, FASEB J, V7, P1330, DOI 10.1096/fasebj.7.14.8224606; PAULSEN H, 1985, LIEBIGS ANN CHEM, P2028; RANDOLPH JT, 1994, ANGEW CHEM INT EDIT, V33, P1470, DOI 10.1002/anie.199414701; ROBINSON AJ, 1993, TETRAHEDRON, V49, P11329, DOI 10.1016/S0040-4020(01)81815-9; SCHUSTER M, 1994, J AM CHEM SOC, V116, P1135, DOI 10.1021/ja00082a047; UNVERZAGT C, 1993, BIOORGAN MED CHEM, V3, P197; VETTER D, 1995, ANGEW CHEM INT EDIT, V34, P60, DOI 10.1002/anie.199500601; WATSON E, 1994, GLYCOBIOLOGY, V4, P227, DOI 10.1093/glycob/4.2.227	36	84	188	0	16	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 14	1995	269	5221					202	204		10.1126/science.7618080	http://dx.doi.org/10.1126/science.7618080			3	Multidisciplinary Sciences	Index Chemicus (IC); Current Chemical Reactions (CCR-EXPANDED); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ029	7618080				2022-12-24	WOS:A1995RJ02900032
J	WARRELL, MJ				WARRELL, MJ			HUMAN DEATHS FROM CRYPTIC BAT RABIES IN THE USA	LANCET			English	Editorial Material							VIRUS				WARRELL, MJ (corresponding author), CTR TROP MED, OXFORD, ENGLAND.							BOURHY H, 1993, VIROLOGY, V194, P70, DOI 10.1006/viro.1993.1236; BRASS DA, 1994, RABIES BATS NATURAL; Campbell J B, 1994, Curr Top Microbiol Immunol, V187, P245; Centers for Disease Control and Prevention (CDC), 1994, MMWR Morb Mortal Wkly Rep, V43, P455; Centers for Disease Control and Prevention (CDC), 1994, MMWR Morb Mortal Wkly Rep, V43, P93; Centers for Disease Control (CDC), 1991, MMWR Morb Mortal Wkly Rep, V40, P132; Centers for Disease Control (CDC), 1991, MMWR Morb Mortal Wkly Rep, V40, P765; CHILDS JE, 1994, EPIDEMIOL INFECT, V113, P501, DOI 10.1017/S0950268800068515; COE CL, 1995, MMWR-MORBID MORTAL W, V44, P269; Constantine DG, 1970, BIOLOGY BATS, VII, P319; Debbie J. G., 1993, Morbidity and Mortality Weekly Report, V42, P799; DEBBIE JG, 1993, MMWR-MORBID MORTAL W, V42, P805; HARDMAN MS, 1995, MMWR-MORBID MORTAL W, V44, P93; HARDMAN MS, 1995, MMWR-MORBID MORTAL W, V44, P86; HOUFF SA, 1979, NEW ENGL J MED, V300, P603, DOI 10.1056/NEJM197903153001105; LUMIO J, 1986, LANCET, V1, P378; SELIMOV MA, 1989, ACTA VIROL, V33, P542; Smith J.S., 1988, P267; SMITH JS, 1992, J INFECT DIS, V166, P296, DOI 10.1093/infdis/166.2.296; WINKLER WG, 1975, NATURAL HIST RABIES, V2, P115	20	15	15	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 8	1995	346	8967					65	66		10.1016/S0140-6736(95)92106-0	http://dx.doi.org/10.1016/S0140-6736(95)92106-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH220	7603211	Bronze			2022-12-24	WOS:A1995RH22000004
J	SATO, TN; TOZAWA, Y; DEUTSCH, U; WOLBURGBUCHHOLZ, K; FUJIWARA, Y; GENDRONMAGUIRE, M; GRIDLEY, T; WOLBURG, H; RISAU, W; QIN, Y				SATO, TN; TOZAWA, Y; DEUTSCH, U; WOLBURGBUCHHOLZ, K; FUJIWARA, Y; GENDRONMAGUIRE, M; GRIDLEY, T; WOLBURG, H; RISAU, W; QIN, Y			DISTINCT ROLES OF THE RECEPTOR TYROSINE KINASES TIE-1 AND TIE-2 IN BLOOD-VESSEL FORMATION	NATURE			English	Article							ENDOTHELIAL GROWTH-FACTOR; MOLECULAR-CLONING; ANGIOGENESIS; EXPRESSION; GENES; CELLS; VASCULOGENESIS; MEMBER; DEFINE; FAMILY	TIE-1 and Tie-2 define a new class of receptor tyrosine kinases that are specifically expressed in developing vascular endothelial cells. To study the functions of Tie-1 and Tie-2 during vascular endothelial cell growth and differentiation in vivo, targeted mutations of the genes in mice were introduced by homologous recombination. Embryos deficient in Tie-1 failed to establish structural integrity of vascular endothelial cells, resulting in oedema and subsequently localized haemorrhage. However, analyses of embryos deficient in Tie-2 showed that it is important in angiogenesis, particularly for vascular network formation in endothelial cells. This result contrasts with previous reports on Tie-2 function in vasculogenesis and/or endothelial cen survival. Our in vivo analyses indicate that the structurally related receptor tyrosine kinases Tie-1 and Tie-2 have important hut distinct roles in the formation of blood vessels.	MAX PLANCK INST PHYSIOL & CLIN RES,WG KERCHOFF INST,MOLEK ZELLBIOL ABT,D-61231 BAD NAUHEIM,GERMANY; UNIV TUBINGEN,INST PATHOL,D-72076 TUBINGEN,GERMANY	Max Planck Society; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	SATO, TN (corresponding author), ROCHE INST MOLEC BIOL,ROCHE RES CTR,NUTLEY,NJ 07110, USA.		Tozawa, Yuzuru/AAM-9620-2020; Tozawa, Yuzuru/G-2657-2013	Tozawa, Yuzuru/0000-0002-3885-1105; Deutsch, Urban/0000-0003-4265-6262				DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DUMONT DJ, 1993, ONCOGENE, V8, P1293; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Folkman J, 1992, Semin Cancer Biol, V3, P65; IWAMA A, 1993, BIOCHEM BIOPH RES CO, V195, P301, DOI 10.1006/bbrc.1993.2045; KALPAINEN A, 1994, CANCER RES, V54, P6571; KASTNER P, 1994, CELL, V78, P987, DOI 10.1016/0092-8674(94)90274-7; MAISONPIERRE PC, 1993, ONCOGENE, V8, P1631; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; OELRICHS RB, 1993, ONCOGENE, V8, P11; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PLATE KH, 1994, INT J CANCER, V59, P520, DOI 10.1002/ijc.2910590415; QIN Y, 1995, DEV DYNAM, V202, P172, DOI 10.1002/aja.1002020209; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; RISAU W, 1988, DEVELOPMENT, V102, P471; Risau W., 1991, DEV VASCULAR SYSTEM, P58; SATO TN, 1993, P NATL ACAD SCI USA, V90, P9355, DOI 10.1073/pnas.90.20.9355; SCHLAEGER TM, 1995, DEVELOPMENT, V121, P1089; SCHNURCH H, 1993, DEVELOPMENT, V119, P957; SUCOV HM, 1994, GENE DEV, V3, P1007; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; VECCHI A, 1994, EUR J CELL BIOL, V63, P247; VIRAGH S, 1981, ANAT REC, V201, P157, DOI 10.1002/ar.1092010117; WAGNER EF, 1994, SEMIN CANCER BIOL, V5, P137; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489; ZIEGLER SF, 1993, ONCOGENE, V8, P663	30	1408	1500	2	35	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 6	1995	376	6535					70	74		10.1038/376070a0	http://dx.doi.org/10.1038/376070a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH111	7596437				2022-12-24	WOS:A1995RH11100064
J	VERRIJZER, CP; CHEN, JL; YOKOMORI, K; TJIAN, R				VERRIJZER, CP; CHEN, JL; YOKOMORI, K; TJIAN, R			BINDING OF TAFS TO CORE ELEMENTS DIRECTS PROMOTER SELECTIVITY BY RNA-POLYMERASE-II	CELL			English	Article							TRANSCRIPTION FACTOR; TATA BOX; DNA-SEQUENCES; MINIMAL SET; INITIATION; GENE; COMPLEXES; PROTEIN; DOWNSTREAM	The mechanisms that govern core promoter recognition and basal transcription efficiency remain poorly understood. Here, we have assessed the potential role of TAFs and the TFIID complex in directing basal promoter function. Reconstituted transcription reactions revealed the ability of TFIID versus TBP to discriminate between distinct core promoters. A comparison of different partial TBP-TAF assemblages established that a trimeric TBP-TAF(II)250-TAF(II)150 complex is minimally required for efficient utilization of the initiator and downstream promoter elements. Depending on the promoter structure, TAFs can increase or decrease the stability of TFIID-promoter interactions. These findings suggest that TAFs play a critical role in promoter selectivity and transcription regulation through direct contacts with core promoter elements.			VERRIJZER, CP (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720, USA.							BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CARCAMO J, 1991, P NATL ACAD SCI USA, V88, P8052, DOI 10.1073/pnas.88.18.8052; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; COULOMBE B, 1994, J BIOL CHEM, V269, P19962; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; DYNLACHT BD, 1991, CELL, V55, P563; EMANUEL PA, 1993, P NATL ACAD SCI USA, V90, P8449, DOI 10.1073/pnas.90.18.8449; GILMOUR DS, 1990, MOL CELL BIOL, V10, P4233, DOI 10.1128/MCB.10.8.4233; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HOLSTEGE FCP, 1995, EMBO J, V14, P810, DOI 10.1002/j.1460-2075.1995.tb07059.x; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KADONAGA JT, 1990, J BIOL CHEM, V265, P2624; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; KLUG A, 1993, NATURE, V365, P486, DOI 10.1038/365486a0; KOKUBO T, 1994, P NATL ACAD SCI USA, V91, P3520, DOI 10.1073/pnas.91.9.3520; MALDONADO E, 1990, MOL CELL BIOL, V10, P653; MARTINEZ E, 1994, EMBO J, V13, P3115, DOI 10.1002/j.1460-2075.1994.tb06610.x; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PARVIN JD, 1992, CELL, V68, P1153; PURNELL BA, 1994, GENE DEV, V8, P830, DOI 10.1101/gad.8.7.830; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SMALE S.T., 1994, TRANSCRIPTION MECHAN, P63; SMALE ST, 1990, P NATL ACAD SCI USA, V81, P4509; SYPES MA, 1994, NUCLEIC ACIDS RES, V22, P807, DOI 10.1093/nar/22.5.807; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TYREE CM, 1993, GENE DEV, V7, P1254, DOI 10.1101/gad.7.7a.1254; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; WAMPLER SL, 1990, J BIOL CHEM, V265, P21223; WANG JC, 1993, BIOCHIM BIOPHYS ACTA, V1216, P73, DOI 10.1016/0167-4781(93)90039-G; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; YOKOMORI K, 1994, GENE DEV, V8, P2313, DOI 10.1101/gad.8.19.2313; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	45	258	259	0	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 30	1995	81	7					1115	1125		10.1016/S0092-8674(05)80016-9	http://dx.doi.org/10.1016/S0092-8674(05)80016-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RG910	7600579	Bronze			2022-12-24	WOS:A1995RG91000016
J	BELLGRAU, D; GOLD, D; SELAWRY, H; MOORE, J; FRANZUSOFF, A; DUKE, RC				BELLGRAU, D; GOLD, D; SELAWRY, H; MOORE, J; FRANZUSOFF, A; DUKE, RC			A ROLE FOR CD95 LIGAND IN PREVENTING GRAFT-REJECTION	NATURE			English	Article							FAS ANTIGEN; TRANSPLANTATION; SURVIVAL; AUTOIMMUNITY; EXPRESSION; APOPTOSIS; TESTIS; DEATH; CELLS; MICE	TESTIS is a remarkable immune-privileged site, long known for its ability to support allogeneic and xenogeneic tissue transplants(1-4). Here we have investigated the molecular basis for testis immune privilege. Testis grafts derived from mice that can express functional CD95 (Fas or Ape-1) ligand(5-8) survived indefinitely when transplanted under the kidney capsule of allogeneic animals, whereas testis grafts derived from mutant gld mice, which express non-functional ligands(8,9), were rejected. Further analysis of testis showed that CD95 ligand messenger RNA is constitutively expressed by testicular Sertoli cells, and that Sertoli cells from normal mice, but not gld mice, were accepted when transplanted into allogeneic recipients. CD95 ligand expression in the testis probably acts by inducing apoptotic cell death of CD95-expressing, recipient T cells activated in response to graft antigens. These findings indicate that CD95 ligand could be used to create immune-privileged tissue for a variety of transplant uses.	UNIV COLORADO,SCH MED,DEPT IMMUNOL,DENVER,CO 80262; UNIV COLORADO,SCH MED,BARBARA DAVIS CTR CHILDHOOD DIABET,DENVER,CO 80262; UNIV COLORADO,SCH MED,DEPT CELLULAR & STRUCT BIOL,DENVER,CO 80262; UNIV COLORADO,SCH MED,DEPT MED,DIV MED ONCOL,DENVER,CO 80262; SIDNEY KIMMEL CANC CTR,SAN DIEGO,CA 92121; VET ADM MED CTR,MEMPHIS,TN 38104	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center								BARKER CF, 1977, ADV IMMUNOL, V25, P1; BOBZIEN B, 1983, DIABETES, V32, P213, DOI 10.2337/diabetes.32.3.213; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CAMERON DF, 1990, TRANSPLANTATION, V50, P649, DOI 10.1097/00007890-199010000-00024; COHEN PL, 1992, IMMUNOL TODAY, V13, P427, DOI 10.1016/0167-5699(92)90066-G; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; HAO LM, 1990, TRANSPLANTATION, V49, P609, DOI 10.1097/00007890-199003000-00025; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; JU ST, 1994, P NATL ACAD SCI USA, V91, P4185, DOI 10.1073/pnas.91.10.4185; LUCIANI MF, 1994, PHILOS T R SOC B, V345, P303, DOI 10.1098/rstb.1994.0110; MIYAWAKI T, 1992, J IMMUNOL, V149, P3753; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OWENSCHAUB LB, 1992, CELL IMMUNOL, V140, P197, DOI 10.1016/0008-8749(92)90187-T; RAMSDELL F, 1994, INT IMMUNOL, V6, P1545, DOI 10.1093/intimm/6.10.1545; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; RUSSELL JH, 1993, P NATL ACAD SCI USA, V90, P4409, DOI 10.1073/pnas.90.10.4409; SELAWRY HP, 1984, DIABETES, V33, P405, DOI 10.2337/diabetes.33.4.405; SELAWRY HP, 1991, TRANSPLANTATION, V52, P846, DOI 10.1097/00007890-199111000-00018; SELAWRY HP, 1993, CELL TRANSPLANT, V2, P123, DOI 10.1177/096368979300200206; SELAWRY HP, 1989, DIABETES, V38, P220, DOI 10.2337/diab.38.1.S220; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SOBEL ES, 1993, INT IMMUNOL, V5, P1275, DOI 10.1093/intimm/5.10.1275; STALDER T, 1994, J IMMUNOL, V152, P1127; STRASSER A, 1995, NATURE, V373, P385, DOI 10.1038/373385a0; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TAKAHASHI T, 1994, INT IMMUNOL, V6, P1567, DOI 10.1093/intimm/6.10.1567; VIGNAUX F, 1994, EUR J IMMUNOL, V24, P923, DOI 10.1002/eji.1830240421; VIGNAUX F, 1995, J EXP MED, V181, P781, DOI 10.1084/jem.181.2.781; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WHITMORE WF, 1985, J UROLOGY, V134, P782, DOI 10.1016/S0022-5347(17)47438-6	30	1056	1111	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 19	1995	377	6550					630	632		10.1038/377630a0	http://dx.doi.org/10.1038/377630a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA275	7566174				2022-12-24	WOS:A1995TA27500052
J	AUSTIN, D; SLEIGH, J				AUSTIN, D; SLEIGH, J			PREDICTION OF ACUTE MOUNTAIN-SICKNESS	BRITISH MEDICAL JOURNAL			English	Article											AUSTIN, D (corresponding author), WAIKATO HOSP,DEPT ANAESTHESIA,HAMILTON,NEW ZEALAND.		Austin, David/A-5703-2012	Austin, David/0000-0001-6829-7937				GUZ A, 1957, CLIN SCI, V30, P161; Houston C. S., 1985, AM ALPINE J, V27, P162; SAMPSON JB, 1983, AVIAT SPACE ENVIR MD, V54, P1063; WRIGHT AD, 1985, AVIAT SPACE ENVIR MD, V56, P572; 1981, LANCET, V1, P180	5	14	16	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 14	1995	311	7011					989	990						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA079	7580641				2022-12-24	WOS:A1995TA07900024
J	DROBNIEWSKI, F				DROBNIEWSKI, F			TUBERCULOSIS IN PRISONS - FORGOTTEN PLAGUE	LANCET			English	Editorial Material											DROBNIEWSKI, F (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,HOWARD HUGHES MED INST,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10461, USA.							BELLIN E, 1993, JAMA-J AM MED ASSOC, V270, P940, DOI 10.1001/jama.1993.03510080044026; CHAVES F, 1993, MED CLIN-BARCELONA, V101, P525; DROBNIEWSKI F, IN PRESS TUBERCLE; DROBNIEWSKI FA, 1995, J MED MICROBIOL, V43, P85, DOI 10.1099/00222615-43-2-85; DROBNIEWSKI FA, 1994, J HOSP INFECT, V28, P249, DOI 10.1016/0195-6701(94)90089-2; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; MARTIN V, 1994, TUBERCLE LUNG DIS, V75, P49, DOI 10.1016/0962-8479(94)90102-3; SPENCE DPS, 1993, BRIT MED J, V307, P759, DOI 10.1136/bmj.307.6907.759; VALWAY SE, 1994, J INFECT DIS, V170, P151, DOI 10.1093/infdis/170.1.151; VALWAY SE, 1994, AM J EPIDEMIOL, V140, P113, DOI 10.1093/oxfordjournals.aje.a117222; 1995, BRIDGING GAP; 1994, TUBERCULOSIS RUSSIA	12	54	57	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 7	1995	346	8980					948	949		10.1016/S0140-6736(95)91562-1	http://dx.doi.org/10.1016/S0140-6736(95)91562-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY808	7564733				2022-12-24	WOS:A1995RY80800014
J	HACKNEY, DD				HACKNEY, DD			HIGHLY PROCESSIVE MICROTUBULE-STIMULATED ATP HYDROLYSIS BY DIMERIC KINESIN HEAD DOMAINS	NATURE			English	Article							MOLECULES; MOVEMENT	STUDIES of immobilized kinesin have shown that a single dimeric molecule can maintain contact with and drive sliding of a microtubule(1,2). In solution, however, native kinesin binds microtubules too weakly(3) and hydrolyses ATP too slowly to produce the high sliding velocities seen in motility assays(4). This apparent inhibition in solution appears to be caused by the binding of kinesin's tail domains to its motor (head) domains in a folded conformation(5). DKH392, a construct containing two heads but no tails, has been shown to display both tight binding to microtubules and high ATPase rates(6). Furthermore, it retains one molecule of ADP per dimer when bound to microtubules(7), which could facilitate a 'hand-over-hand' mechanism for processive motion. Here we show that DKH392 hydrolyses more than 100 ATP molecules per diffusional encounter with a microtubule, even in the high-salt conditions encountered physiologically. This provides direct evidence that kinesin's activity is highly processive, with the motor remaining attached to a microtubule through many cycles of ATP hydrolysis.			HACKNEY, DD (corresponding author), CARNEGIE MELLON UNIV,DEPT BIOL SCI,4400 5TH AVE,PITTSBURGH,PA 15213, USA.							BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; Hackney D. D., 1995, Biophysical Journal, V68, pA286; HACKNEY DD, 1992, J BIOL CHEM, V267, P8696; HACKNEY DD, 1995, BIOPHYS J, V68, pS267; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HACKNEY DD, 1988, P NATL ACAD SCI USA, V85, P6314, DOI 10.1073/pnas.85.17.6314; HACKNEY DD, 1994, J BIOL CHEM, V269, P16508; HACKNEY DD, 1989, J BIOL CHEM, V264, P15943; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HUANG TG, 1994, J BIOL CHEM, V269, P16493; HUANG TG, 1994, J BIOL CHEM, V269, P16502; SADHU A, 1992, J BIOL CHEM, V267, P11352; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4	15	159	159	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 5	1995	377	6548					448	450		10.1038/377448a0	http://dx.doi.org/10.1038/377448a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY190	7566125				2022-12-24	WOS:A1995RY19000055
J	CLEMESSY, JL; FAVIER, C; BORRON, SW; HANTSON, PE; VICAUT, E; BAUD, FJ				CLEMESSY, JL; FAVIER, C; BORRON, SW; HANTSON, PE; VICAUT, E; BAUD, FJ			HYPOKALEMIA RELATED TO ACUTE CHLOROQUINE INGESTION	LANCET			English	Article							HEART	Large doses of chloroquine can cause poisoning. Our aim was to determine the possible relation between the plasma potassium concentration on admission with the severity of acute chloroquine poisoning and to assess the mechanism of chloroquine-induced hypokalaemia. We conducted a retrospective study of 191 consecutive cases. The main data included the occurrence of vomiting before admission, plasma, and urinary potassium concentration at admission, whole blood chloroquine concentration on admission, haemodynamic parameters and EGG, administration of catecholamines and outcome. Mean blood chloroquine level was 20.1 mu mol/L (SD 14.3) (therapeutic level less than or equal to 6 mu mol/L). Mean plasma potassium concentration was 3.0 mmol/L (0.8) and was lower in the subjects who died than in those who survived (p=0.0003). Plasma potassium varied directly with the systolic blood pressure and inversely with the QRS and QT. Plasma potassium varied inversely with the blood chloroquine (p=0.0001; tau=-0.42). Acute chloroquine intoxication is responsible for a hypokalaemia which correlates with the gravity of the intoxication and may be due to a transport-dependent mechanism. Plasma potassium concentrations should be carefully observed, particularly among patients who also receive catecholamine infusions. We should keep in mind, however, that overzealous repletion invokes the risk of subsequent hyperkalaemia and thus should be avoided.	HOP ST ROCHE,DEPT ANESTHESE REANIMAT,F-06000 NICE,FRANCE; UNIV NICE,HOP ST ROCH,F-06000 NICE,FRANCE; CLIN UNIV ST LUC,B-1200 BRUSSELS,BELGIUM; HOP FERNAND WIDAL,DEPT BIOPHYS,F-75010 PARIS,FRANCE	CHU Nice; CHU Nice; UDICE-French Research Universities; Universite Cote d'Azur; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite	CLEMESSY, JL (corresponding author), UNIV PARIS 07,HOP FERNAND WIDAL,200 RUE FAUBOURG ST DENIS,F-75010 PARIS,FRANCE.							AGARWAL SL, 1960, ARCH INT PHARMACOD T, V123, P305; ARMITAGE AK, 1957, BRIT J PHARM CHEMOTH, V12, P74, DOI 10.1111/j.1476-5381.1957.tb01365.x; BAUER P, 1991, J TOXICOL-CLIN TOXIC, V29, P23, DOI 10.3109/15563659109038594; BONDURAND A, 1980, AF MED, V179, P239; BRANDFONBRENER M, 1966, J PHARMACOL EXP THER, V154, P250; BRIVET F, 1987, PRESSE MED, V16, P1433; BROWN MJ, 1983, NEW ENGL J MED, V309, P1414, DOI 10.1056/NEJM198312083092303; ENSINGER H, 1992, EUR J ANAESTH, V9, P435; HOLLAND WC, 1957, AM J PHYSIOL, V190, P492, DOI 10.1152/ajplegacy.1957.190.3.492; JAEGER A, 1987, MED TOXICOL ADV DRUG, V2, P242, DOI 10.1007/BF03259868; LECHAT P, 1988, REAN SOINS INTENS ME, V4, P51; LOFASO F, 1987, PRESSE MED, V16, P22; MICHAEL TAD, 1970, AM HEART J, V79, P831, DOI 10.1016/0002-8703(70)90371-6; MONNET R, 1964, Ann Biol Clin (Paris), V22, P429; RAKOTOSON L, 1973, J EUR TOXICOL, V2, P85; RIOU B, 1988, NEW ENGL J MED, V318, P1, DOI 10.1056/NEJM198801073180101; SOFOLA OA, 1983, CLIN PHYSIOL, V3, P75, DOI 10.1111/j.1475-097X.1983.tb00701.x; SOFOLA OA, 1979, CAN J PHARM, V58, P836; Vitris M, 1983, Dakar Med, V28, P593; 1988, REAN SOINS INTENS ME, V4, P43	20	54	57	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 30	1995	346	8979					877	880		10.1016/S0140-6736(95)92711-5	http://dx.doi.org/10.1016/S0140-6736(95)92711-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX196	7564673				2022-12-24	WOS:A1995RX19600011
J	SIMONICH, SL; HITES, RA				SIMONICH, SL; HITES, RA			GLOBAL DISTRIBUTION OF PERSISTENT ORGANOCHLORINE COMPOUNDS	SCIENCE			English	Article							AIR	The global distribution of 22 potentially harmful organochlorine compounds was investigated in more than 200 tree bark samples from 90 sites worldwide. High concentrations of organochlorines were found not only in some developing countries but also in industrialized countries, which continue to be highly contaminated even though the use of many of these compounds is restricted. The distribution of relatively volatile organochlorine compounds (such as hexachlorobenzene) is dependent on latitude and demonstrates the global distillation effect, whereas less volatile organochlorine compounds (such as endosulfan) are not as effectively distilled and tend to remain in the region of use.	INDIANA UNIV,SCH PUBL & ENVIRONM AFFAIRS,BLOOMINGTON,IN 47405; INDIANA UNIV,DEPT CHEM,BLOOMINGTON,IN 47405	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington								ANDERSON DJ, 1989, ATMOS ENVIRON, V23, P2063, DOI 10.1016/0004-6981(89)90532-5; BUSER HR, 1993, ENVIRON SCI TECHNOL, V27, P1211, DOI 10.1021/es00043a023; CALAMARI D, 1991, ENVIRON SCI TECHNOL, V25, P1489, DOI 10.1021/es00020a020; CALAMARI D, 1994, ENVIRON SCI TECHNOL, V28, P429, DOI 10.1021/es00052a014; CHERNYAK SM, 1995, SCI TOTAL ENVIRON, V160-61, P75, DOI 10.1016/0048-9697(95)04346-3; HERMANSON MH, 1990, ENVIRON SCI TECHNOL, V24, P666, DOI 10.1021/es00075a008; HILEMAN B, 1994, CHEM ENG NEWS, V72, P19, DOI 10.1021/cen-v072n005.p019; HINCKLEY DA, 1990, J CHEM ENG DATA, V35, P232, DOI 10.1021/je00061a003; IWATA H, 1993, ENVIRON SCI TECHNOL, V27, P1080, DOI 10.1021/es00043a007; KELCE WR, 1995, NATURE, V375, P581, DOI 10.1038/375581a0; MACKAY D, 1995, SCI TOTAL ENVIRON, V160-61, P25, DOI 10.1016/0048-9697(95)04342-X; MACKAY D, 1995, SCI TOTAL ENVIRON, V160, P211; MUIR DCG, 1995, SCI TOTAL ENVIRON, V160-61, P447, DOI 10.1016/0048-9697(95)04378-E; SIMONICH SL, 1994, NATURE, V370, P49, DOI 10.1038/370049a0; SIMONICH SL, 1994, ENVIRON SCI TECHNOL, V28, P939, DOI 10.1021/es00054a028; SIMONICH SL, 1995, THESIS INDIANA U; TREMOLADA P, 1993, CHEMOSPHERE, V27, P2235, DOI 10.1016/0045-6535(93)90135-R; VOLDNER EC, 1995, SCI TOTAL ENVIRON, V160-61, P201, DOI 10.1016/0048-9697(95)04357-7; WANIA F, 1993, AMBIO, V22, P10; 1990, PUBLIC HLTH IMPACT P, P24; 1995, INSECT CONTROL GUIDE	21	526	550	6	188	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 29	1995	269	5232					1851	1854		10.1126/science.7569923	http://dx.doi.org/10.1126/science.7569923			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX194	7569923				2022-12-24	WOS:A1995RX19400031
J	MORRISON, RS; OLSON, E; MERTZ, KR; MEIER, DE				MORRISON, RS; OLSON, E; MERTZ, KR; MEIER, DE			THE INACCESSIBILITY OF ADVANCE DIRECTIVES ON TRANSFER FROM AMBULATORY TO ACUTE-CARE SETTINGS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ATTITUDES	Objective.-To investigate the accessibility of patients' previously executed advance directives during an acute hospitalization. Design.-Retrospective chart review. Setting.-A large metropolitan teaching hospital, a 514-bed skilled nursing facility, a geriatrics ambulatory care clinic, and a geriatrics group practice office. Patients.-One hundred fourteen geriatric patients who had previously executed an advance directive. Main Outcome Measures.-The medical records of 180 admissions over 3 years, 1991 through 1993, were reviewed for documentation of patients' advance directive status. Results.-Twenty-six percent of patients who had previously executed advance directives had their directives recognized during their hospitalization. Of the subgroup of patients who were judged not to have the capacity to make medical decisions during their admissions, 26% (14/53) had their directives recognized. When the advance directive was recognized, it appeared to influence treatment decisions in 12 (86%) of 14 cases. Conclusions.-Previously executed advance directives are not accessible when patients are admitted to hospitals for acute illness. When such directives are recognized, they are used to influence medical treatment decisions. Further research is needed to define and overcome barriers to this inaccessibility.	JEWISH HOME & HOSP AGED NEW YORK,NEW YORK,NY		MORRISON, RS (corresponding author), MT SINAI MED CTR,DEPT GERIATR & ADULT DEV,BOX 1070,1 GUSTAVE L LEVY PL,NEW YORK,NY 10029, USA.							DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; DAVIDSON KW, 1989, JAMA-J AM MED ASSOC, V262, P2415, DOI 10.1001/jama.262.17.2415; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; FINUCANE TE, 1988, J GEN INTERN MED, V3, P322, DOI 10.1007/BF02595788; GHUSIN HF, 1993, J AM GERIATR SOC S, V41; HIGH DM, 1994, GERONTOLOGIST, V24, P409; LIBOW LS, 1978, GERIATRICS, V33, P92; LO B, 1986, ARCH INTERN MED, V146, P1613, DOI 10.1001/archinte.146.8.1613; LYNN J, 1993, HASTINGS CENT REP, V23, P20, DOI 10.2307/3562275; MILLER MB, 1976, J AM GERIATR SOC, V24, P108, DOI 10.1111/j.1532-5415.1976.tb04281.x; MORRISON RS, 1994, ARCH INTERN MED, V154, P2311, DOI 10.1001/archinte.154.20.2311; OUSLANDER J, 1990, PRINCIPLES GERIATRIC, P331; PARIS B, 1992, J AM GERIATR SOC, V40, pA129; PARIS BEC, 1993, ARCH INTERN MED, V153, P1689, DOI 10.1001/archinte.153.14.1689; PFEIFER MP, 1994, J GEN INTERN MED, V9, P82, DOI 10.1007/BF02600206; RUBIN SM, 1994, JAMA-J AM MED ASSOC, V271, P209, DOI 10.1001/jama.271.3.209; SCHMERLING RH, 1988, J GEN INTERN MED, V3, P317; SUGARMAN J, 1994, J CLIN ETHIC, V5, P60; TENO JM, 1994, J CLIN ETHIC, V5, P23; 1992, Q PROGR REPORT ADV D	20	139	139	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 9	1995	274	6					478	482		10.1001/jama.274.6.478	http://dx.doi.org/10.1001/jama.274.6.478			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RM699	7629957				2022-12-24	WOS:A1995RM69900028
J	CAMPFIELD, LA; SMITH, FJ; GUISEZ, Y; DEVOS, R; BURN, P				CAMPFIELD, LA; SMITH, FJ; GUISEZ, Y; DEVOS, R; BURN, P			RECOMBINANT MOUSE OB PROTEIN - EVIDENCE FOR A PERIPHERAL SIGNAL LINKING ADIPOSITY AND CENTRAL NEURAL NETWORKS	SCIENCE			English	Article							DIABETES-OBESITY SYNDROMES; MICE; RODENTS; ANIMALS	The recent positional cloning of the mouse ob gene and its human homolog has provided the basis to investigate the potential role of the ob gene product in body weight regulation. A biologically active form of recombinant mouse OB protein was overexpressed and purified to near homogeneity from a bacterial expression system. Peripheral and central administration of microgram doses of OB protein reduced food intake and body weight of ob/ob and diet-induced obese mice but not in db/db obese mice. The behavioral effects after brain administration suggest that OB protein can act directly on neuronal networks that control feeding and energy balance.	ROCHE RES GENT,B-9000 GHENT,BELGIUM		CAMPFIELD, LA (corresponding author), HOFFMANN LA ROCHE INC,DEPT METAB DIS,NUTLEY,NJ 07110, USA.							BJORNTORP P, 1992, OBESITY; BOGARDUS C, 1986, NEW ENGL J MED, V315, P96, DOI 10.1056/NEJM198607103150205; BOUCHARD C, 1993, ANNU REV NUTR, V13, P337, DOI 10.1146/annurev.nu.13.070193.002005; BRAY GA, 1979, PHYSIOL REV, V59, P719, DOI 10.1152/physrev.1979.59.3.719; BRAY GA, 1975, METABOLISM, V24, P99, DOI 10.1016/0026-0495(75)90011-6; BRAY GA, 1971, PHYSIOL REV, V51, P598, DOI 10.1152/physrev.1971.51.3.598; Coleman D L, 1981, Prog Clin Biol Res, V45, P145; COLEMAN DL, 1973, DIABETOLOGIA, V9, P287, DOI 10.1007/BF01221856; COLEMAN DL, 1973, DIABETOLOGIA, V9, P294, DOI 10.1007/BF01221857; COLEMAN DL, 1982, DIABETES, V31, P1; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; COLEMAN DL, 1982, DIABETES, V31, P24, DOI 10.2337/diab.31.1.S24; CONSIDINE RV, 1995, J CLIN INVEST, V95, P2986, DOI 10.1172/JCI118007; FRIEDMAN JM, 1991, GENOMICS, V11, P1054, DOI 10.1016/0888-7543(91)90032-A; FRIEDMAN JM, 1992, CELL, V69, P217, DOI 10.1016/0092-8674(92)90402-X; GUISEZ Y, UNPUB; HALEY TJ, 1957, BRIT J PHARM CHEMOTH, V12, P12, DOI 10.1111/j.1476-5381.1957.tb01354.x; HERBERG L, 1977, METABOLISM, V26, P59, DOI 10.1016/0026-0495(77)90128-7; INGALS AM, 1950, J HERED, V17, P317; KEESEY RE, 1989, MED CLIN N AM, V73, P15, DOI 10.1016/S0025-7125(16)30689-7; Le Magnen J, 1992, NEUROBIOLOGY FEEDING; LEIBEL RL, 1993, CRIT REV FOOD SCI, V33, P351, DOI 10.1080/10408399309527632; LEIBEL RL, 1995, NEW ENGL J MED, V232, P621; MOKHTARIAN A, 1993, PHYSIOL BEHAV, V54, P895, DOI 10.1016/0031-9384(93)90298-T; MORLEY JE, 1987, AM J PHYSIOL, V253, pR516, DOI 10.1152/ajpregu.1987.253.3.R516; MURAKAMI T, 1995, BIOCHEM BIOPH RES CO, V209, P944, DOI 10.1006/bbrc.1995.1589; SCHWARTZ MW, 1992, ENDOCR REV, V13, P387, DOI 10.1210/er.13.3.387; Schwartz MW, 1994, ENDOCR REV, V2, P109; Snedecor G. W, 1989, STAT METHODS, V8th; Thomas PR, 1995, WEIGHING OPTIONS CRI; WEST DB, 1994, MAMM GENOME, V5, P546, DOI 10.1007/BF00354928; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	32	2907	3047	4	136	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 28	1995	269	5223					546	549		10.1126/science.7624778	http://dx.doi.org/10.1126/science.7624778			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL495	7624778				2022-12-24	WOS:A1995RL49500030
J	HOENGER, A; SABLIN, EP; VALE, RD; FLETTERICK, RJ; MILLIGAN, RA				HOENGER, A; SABLIN, EP; VALE, RD; FLETTERICK, RJ; MILLIGAN, RA			3-DIMENSIONAL STRUCTURE OF A TUBULIN-MOTOR-PROTEIN COMPLEX	NATURE			English	Article							ELECTRON-MICROSCOPY; 3-DIMENSIONAL STRUCTURE; MICROTUBULE DYNAMICS; SURFACE LATTICE; DROSOPHILA; KINESIN; RECONSTRUCTION; SEGREGATION; MOLECULE; CRYSTALS	THE kinesin superfamily is a class of microtubule-based mechanoenzymes involved in intracellular transport and chromosome movements. Molecules that move towards either the plus end or the minus end of microtubules are represented within the family. The motor domains of these molecules exhibit considerable sequence homology and contain both the ATP- and microtubule-binding sites (reviewed in refs 1, 2). Here we focus on non-claret disjunctional (ncd), a minus-end-directed motor involved in chromosome segregation in meiosis and early mitosis in Drosophila(3-6). We have calculated a three-dimensional map of tubulin sheets decorated with monomeric recombinant ncd motor domains(7) by negative-stain electron microscopy and image analysis. Comparisons with a control structure of tubulin alone reveal that each motor domain binds to the crest of a single protofilament, making extensive contacts with both the alpha and beta tubulin monomers. Binding of the motor domain results in significant conformational changes in both of the tubulin monomers.	UNIV CALIF SAN FRANCISCO, DEPT BIOPHYS & BIOCHEM, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	HOENGER, A (corresponding author), SCRIPPS RES INST, DEPT CELL BIOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.			Hoenger, Andreas/0000-0001-9176-6658				AGARD DA, 1983, J MOL BIOL, V167, P849, DOI 10.1016/S0022-2836(83)80114-4; AMOS LA, 1983, PROG BIOPHYS MOL BIO, V39, P183, DOI 10.1016/0079-6107(83)90017-2; AMOS LA, 1979, NATURE, V279, P607, DOI 10.1038/279607a0; CHANDRA R, 1993, J BIOL CHEM, V268, P9005; CREPEAU RH, 1978, P NATL ACAD SCI USA, V75, P5006, DOI 10.1073/pnas.75.10.5006; CREPEAU RH, 1977, J MOL BIOL, V116, P301, DOI 10.1016/0022-2836(77)90218-2; ENDOW SA, 1990, NATURE, V345, P81, DOI 10.1038/345081a0; ERICKSON HP, 1974, J CELL BIOL, V60, P153, DOI 10.1083/jcb.60.1.153; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; GOLDSTEIN LSB, 1993, ANNU REV GENET, V27, P319; HENDERSON R, 1986, ULTRAMICROSCOPY, V19, P147, DOI 10.1016/0304-3991(86)90203-2; HEUSER JE, 1986, J CELL BIOL, V103, P2209, DOI 10.1083/jcb.103.6.2209; HYMAN AA, 1992, MOL BIOL CELL, V3, P1155, DOI 10.1091/mbc.3.10.1155; HYMAN AA, 1995, J CELL BIOL, V128, P117, DOI 10.1083/jcb.128.1.117; MANDELKOW EM, 1991, J CELL BIOL, V114, P977, DOI 10.1083/jcb.114.5.977; MCDONALD HB, 1990, CELL, V63, P1159, DOI 10.1016/0092-8674(90)90412-8; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; ROMBERG L, 1993, NATURE, V361, P168, DOI 10.1038/361168a0; SABLIN EP, 1995, PROTEINS, V21, P68, DOI 10.1002/prot.340210108; SCHMID MF, 1993, ULTRAMICROSCOPY, V48, P251, DOI 10.1016/0304-3991(93)90099-J; SHIMIZU T, 1993, METHOD CELL BIOL, V39, P167, DOI 10.1016/S0091-679X(08)60169-7; SIMON JR, 1990, J CELL SCI, V96, P571; SONG YH, 1995, J CELL BIOL, V128, P81, DOI 10.1083/jcb.128.1.81; SONG YH, 1993, P NATL ACAD SCI USA, V90, P1671, DOI 10.1073/pnas.90.5.1671; TAMM LK, 1979, J MOL BIOL, V130, P473, DOI 10.1016/0022-2836(79)90435-2; VALLEE RB, 1990, ANNU REV BIOCHEM, V59, P909, DOI 10.1146/annurev.biochem.59.1.909; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0	27	100	100	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 20	1995	376	6537					271	274		10.1038/376271a0	http://dx.doi.org/10.1038/376271a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK331	7617040				2022-12-24	WOS:A1995RK33100051
J	VALLANCE, P; PATTON, S; BHAGAT, K; MACALLISTER, R; RADOMSKI, M; MONCADA, S; MALINSKI, T				VALLANCE, P; PATTON, S; BHAGAT, K; MACALLISTER, R; RADOMSKI, M; MONCADA, S; MALINSKI, T			DIRECT MEASUREMENT OF NITRIC-OXIDE IN HUMAN-BEINGS	LANCET			English	Note							HUMAN VEINS INVIVO; ENDOTHELIUM; ACETYLCHOLINE; RELEASE	Nitric oxide is a short-lived radical involved in various biological processes. We have used an electrochemical microsensor to detect nitric oxide signals in blood vessels of healthy volunteers. The sensor was inserted into a hand vein, and the vessel was stimulated with acetylcholine or bradykinin. Dose-dependent signals were detected and were attenuated by an inhibitor of nitric oxide synthase. The results provide further evidence that endothelium-derived relaxing factor is nitric oxide and demonstrate a method for monitoring the L-arginjne/nitric-oxide pathway in human beings.	OAKLAND UNIV, DEPT PHARMACOL, ROCHESTER, MI 48309 USA; UNIV LONDON ST GEORGES HOSP, SCH MED, DEPT PHARMACOL & CLIN PHARMACOL, LONDON SW17 0RE, ENGLAND; WELLCOME RES LABS, BECKENHAM BR3 3BS, KENT, ENGLAND	Oakland University; St Georges University London; GlaxoSmithKline; Wellcome Research Laboratories			Radomski, Marek W/C-5195-2014					COLLIER J, 1990, CLIN SCI, V78, P101, DOI 10.1042/cs0780101; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; KIECHLE FL, 1993, AM J CLIN PATHOL, V100, P567, DOI 10.1093/ajcp/100.5.567; MALINSKI T, 1994, INT CONGR SER, V1058, P207; MALINSKI T, 1992, NATURE, V358, P676, DOI 10.1038/358676a0; SHIBUKI K, 1990, NEUROSCI RES, V9, P69, DOI 10.1016/0168-0102(90)90048-J; VALLANCE P, 1989, CARDIOVASC RES, V23, P1053, DOI 10.1093/cvr/23.12.1053; VALLANCE P, 1994, J ROY COLL PHYS LOND, V28, P209; VALLANCE P, 1989, LANCET, V2, P997	9	131	137	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 15	1995	346	8968					153	154		10.1016/S0140-6736(95)91211-8	http://dx.doi.org/10.1016/S0140-6736(95)91211-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ031	7603231				2022-12-24	WOS:A1995RJ03100011
J	DENZIN, LK; CRESSWELL, P				DENZIN, LK; CRESSWELL, P			HLA-DM INDUCES CLIP DISSOCIATION FROM MHC CLASS-II ALPHA-BETA DIMERS AND FACILITATES PEPTIDE LOADING	CELL			English	Article							ANTIGEN-PROCESSING MUTANT; INVARIANT CHAIN PEPTIDES; DR MOLECULES; CELL LINE; BINDING; COMPLEX; EXPRESSION; TRANSPORT; GENES; COMPARTMENTS	Human leukocyte antigen DM (HLA-DM) molecules are structurally related to classical MHC class II molecules and reside in the lysosome-like compartment where class II-restricted antigen processing is thought to occur. Mutant cell lines lacking HLA-DM are defective in antigen processing and accumulate class II molecules associated with a nested set of invariant chain-derived peptides (class II-associated invariant chain peptides, CLIP). Here we show that HLA-DM catalyzes the dissociation of CLIP from MHC class II-CLIP complexes in vitro and facilitates the binding of antigenic peptides. The reaction has an acidic pH optimum, consistent with its occurrence in a lysosome-like compartment in vivo. Antibody blocking experiments suggest that a transient interaction between HLA-DM and the MHC class II-CLIP complex is required.			DENZIN, LK (corresponding author), YALE UNIV,SCH MED,HOWARD HUGHES MED INST,IMMUNOBIOL SECT,NEW HAVEN,CT 06510, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023081, R37AI023081] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 23081] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMIGORENA S, 1995, J EXP MED, V181, P1729, DOI 10.1084/jem.181.5.1729; AVVA RR, 1994, IMMUNITY, V1, P763, DOI 10.1016/S1074-7613(94)80018-9; BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BERGER AE, 1982, HYBRIDOMA, V1, P87, DOI 10.1089/hyb.1.1982.1.87; BLUM JS, 1988, P NATL ACAD SCI USA, V85, P3975, DOI 10.1073/pnas.85.11.3975; CEMAN S, 1992, J IMMUNOL, V149, P754; CHERVONSKY AV, 1994, INT IMMUNOL, V6, P1973; CRESSWELL P, 1994, CURR BIOL, V4, P541, DOI 10.1016/S0960-9822(00)00119-6; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; DENZIN LK, 1994, IMMUNITY, V1, P595, DOI 10.1016/1074-7613(94)90049-3; FLING SP, 1994, NATURE, V368, P554, DOI 10.1038/368554a0; GELUK A, 1992, EUR J IMMUNOL, V22, P107, DOI 10.1002/eji.1830220117; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; GUY K, 1982, EUR J IMMUNOL, V12, P942, DOI 10.1002/eji.1830121109; KARLSSON L, 1994, SCIENCE, V266, P1569, DOI 10.1126/science.7985028; KELLY AP, 1991, NATURE, V353, P571, DOI 10.1038/353571a0; LAMPSON LA, 1980, J IMMUNOL, V125, P293; MACHAMER CE, 1984, P NATL ACAD SCI-BIOL, V81, P1287, DOI 10.1073/pnas.81.5.1287; MALCHEREK G, 1995, J EXP MED, V181, P527, DOI 10.1084/jem.181.2.527; MARIC MA, 1994, P NATL ACAD SCI USA, V91, P2171, DOI 10.1073/pnas.91.6.2171; MELLINS E, 1994, J EXP MED, V179, P541, DOI 10.1084/jem.179.2.541; MELLINS E, 1990, NATURE, V343, P71, DOI 10.1038/343071a0; MORRIS P, 1994, NATURE, V368, P551, DOI 10.1038/368551a0; NEWCOMB JR, 1993, J IMMUNOL, V151, P4153; NEWCOMB JR, 1993, J IMMUNOL, V151, P499; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; PIETERS J, 1991, J CELL BIOL, V115, P1213, DOI 10.1083/jcb.115.5.1213; RIBERDY JM, 1992, J IMMUNOL, V148, P2586; RIBERDY JM, 1992, NATURE, V360, P474, DOI 10.1038/360474a0; RIBERDY JM, 1994, J CELL BIOL, V1125, P1225; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; ROCHE PA, 1991, NATURE, V354, P392, DOI 10.1038/354392a0; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; SALTER RD, 1985, IMMUNOGENETICS, V21, P235, DOI 10.1007/BF00375376; SANDERSON F, 1994, SCIENCE, V266, P1566, DOI 10.1126/science.7985027; SETTE A, 1992, SCIENCE, V258, P1801, DOI 10.1126/science.1465617; SETTE A, 1995, J EXP MED, V181, P677, DOI 10.1084/jem.181.2.677	39	612	616	0	16	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 14	1995	82	1					155	165		10.1016/0092-8674(95)90061-6	http://dx.doi.org/10.1016/0092-8674(95)90061-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RK424	7606781	Bronze			2022-12-24	WOS:A1995RK42400018
J	PERNIS, A; GUPTA, S; GOLLOB, KJ; GARFEIN, E; COFFMAN, RL; SCHINDLER, C; ROTHMAN, P				PERNIS, A; GUPTA, S; GOLLOB, KJ; GARFEIN, E; COFFMAN, RL; SCHINDLER, C; ROTHMAN, P			LACK OF INTERFERON-GAMMA RECEPTOR-BETA CHAIN AND THE PREVENTION OF INTERFERON-GAMMA SIGNALING IN T(H)1 CELLS	SCIENCE			English	Article							PROTEIN-TYROSINE KINASE; LYMPHOCYTE-T CLONES; IFN-GAMMA; TRANSCRIPTION FACTOR; IMMUNE REGULATION; TH1; PHOSPHORYLATION; ACTIVATION; SUBSETS; ANTIBODIES	The ability of interferon gamma (IFN-gamma) to inhibit the proliferation of type 2 T helper cells (T(H)2), but not that of type 1 (T(H)1) cells, suggests that helper cell subsets might differ in their activation of the IFN-gamma signaling pathway. The IFN-gamma-inducible signal transducing factor (STF-IFN gamma) was activated in murine T(H)2 but not in T(H)1 cell clones, because in the latter the second chain of the IFN-gamma receptor (accessory factor 1 or IFN-gamma R beta) was absent. Thus, T(H)1 cells use receptor modification to prevent the activation of STF-IFN gamma and achieve an IFN-gamma-resistant state.	COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT MICROBIOL,NEW YORK,NY 10032; DNAX RES INST MOLEC & CELLULAR BIOL INC,PALO ALTO,CA 94304	Columbia University; Columbia University; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.			Gollob, Kenneth J/C-1341-2008; Gollob, Kenneth J/GPX-8434-2022	Gollob, Kenneth J/0000-0003-4184-3867; 				BOTTOMLY K, 1988, IMMUNOL TODAY, V9, P268, DOI 10.1016/0167-5699(88)91308-4; CHERWINSKI HM, 1987, J EXP MED, V166, P1229, DOI 10.1084/jem.166.5.1229; COFFMAN RL, 1988, IMMUNOL REV, V102, P5, DOI 10.1111/j.1600-065X.1988.tb00739.x; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; COOK JR, 1994, J BIOL CHEM, V269, P7013; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; FITCH FW, 1993, ANNU REV IMMUNOL, V11, P29, DOI 10.1146/annurev.immunol.11.1.29; GAJEWSKI TF, 1988, J IMMUNOL, V140, P4245; GAJEWSKI TF, 1989, J IMMUNOL, V143, P15; HEMMI S, 1994, CELL, V76, P803, DOI 10.1016/0092-8674(94)90355-7; HEMMI S, 1992, P NATL ACAD SCI USA, V89, P2737, DOI 10.1073/pnas.89.7.2737; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KAYE J, 1983, J EXP MED, V158, P836, DOI 10.1084/jem.158.3.836; KOHLER I, 1993, EUR J IMMUNOL, V23, P3066, DOI 10.1002/eji.1830231204; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; KURTJONES EA, 1987, J EXP MED, V166, P1774, DOI 10.1084/jem.166.6.1774; LECLAIRE RD, 1992, J LEUKOCYTE BIOL, V51, P507, DOI 10.1002/jlb.51.5.507; LEDERER JA, 1994, J IMMUNOL, V152, P77; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; PERNIS A, UNPUB; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; ROTHMAN P, 1994, IMMUNITY, V1, P457, DOI 10.1016/1074-7613(94)90088-4; SCHINDLER C, 1994, EMBO J, V13, P1350, DOI 10.1002/j.1460-2075.1994.tb06388.x; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; SWAIN SL, 1991, IMMUNOL REV, V123, P115, DOI 10.1111/j.1600-065X.1991.tb00608.x; TONY HP, 1985, J EXP MED, V161, P223, DOI 10.1084/jem.161.1.223; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; YANG XJ, 1993, J NEUROSCI, V13, P3006	42	265	269	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 14	1995	269	5221					245	247		10.1126/science.7618088	http://dx.doi.org/10.1126/science.7618088			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ029	7618088				2022-12-24	WOS:A1995RJ02900047
J	SU, XZ; HEATWOLE, VM; WERTHEIMER, SP; GUINET, F; HERRFELDT, JA; PETERSON, DS; RAVETCH, JA; WELLEMS, TE				SU, XZ; HEATWOLE, VM; WERTHEIMER, SP; GUINET, F; HERRFELDT, JA; PETERSON, DS; RAVETCH, JA; WELLEMS, TE			THE LARGE DIVERSE GENE FAMILY VAR ENCODES PROTEINS INVOLVED IN CYTOADHERENCE AND ANTIGENIC VARIATION OF PLASMODIUM-FALCIPARUM-INFECTED ERYTHROCYTES	CELL			English	Article							HISTIDINE-RICH PROTEIN; PARASITIZED ERYTHROCYTES; MALARIA PARASITES; HOMOLOGOUS RECOMBINATION; ADHESION MOLECULE-1; MELANOMA-CELLS; P-FALCIPARUM; EXPRESSION; SEQUESTRATION; MEMBRANE	The human malaria parasite Plasmodium falciparum evades host immunity by varying the antigenic and adhesive character of infected erythrocytes. We describe a large and extremely diverse family of P. falciparum genes (var) that encode 200-350 kDa proteins having the expected properties of antigenically variant adhesion molecules. Predicted amino acid sequences of var genes show a variable extracellular segment with domains having receptor-binding features, a transmembrane sequence, and a terminal segment that is a probable submembrane anchor. There are 50-150 var genes on multiple parasite chromosomes, and some are in clustered arrangements. var probes detect two classes of transcripts in steady-state RNA: 7-9 kb var transcripts, and an unusual family of 1.8-2.4 kb transcripts that may be involved in expression or rearrangements of var genes.	SLOAN KETTERING INST, DEWITT WALLACE RES LAB, PROGRAM MOLEC BIOL, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center	SU, XZ (corresponding author), NIAID, PARASIT DIS LAB, BETHESDA, MD 20892 USA.		Ravetch, Jeffrey/Z-1596-2019	Ravetch, Jeffrey/0000-0003-2024-9041; Su, Xinzhuan/0000-0003-3246-3248				ADAMS JH, 1992, P NATL ACAD SCI USA, V89, P7085, DOI 10.1073/pnas.89.15.7085; ALT FW, 1987, SCIENCE, V238, P1079, DOI 10.1126/science.3317825; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARDESHIR F, 1987, EMBO J, V6, P1421, DOI 10.1002/j.1460-2075.1987.tb02383.x; BABIKER HA, 1994, PARASITOLOGY, V109, P413, DOI 10.1017/S0031182000080665; BARNWELL JW, 1985, J IMMUNOL, V135, P3494; BARNWELL JW, 1983, INFECT IMMUN, V40, P985, DOI 10.1128/IAI.40.3.985-994.1983; BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3; BERENDT AR, 1989, NATURE, V341, P57, DOI 10.1038/341057a0; BIGGS BA, 1991, P NATL ACAD SCI USA, V88, P9171, DOI 10.1073/pnas.88.20.9171; BIGGS BA, 1992, J IMMUNOL, V149, P2047; BLOOM BR, 1979, NATURE, V279, P21, DOI 10.1038/279021a0; BLUM ML, 1993, NATURE, V362, P603, DOI 10.1038/362603a0; BORST P, 1987, SCIENCE, V235, P658, DOI 10.1126/science.3544215; BROWN KN, 1965, NATURE, V208, P1286, DOI 10.1038/2081286a0; BROWN KN, 1973, NATURE, V242, P49, DOI 10.1038/242049a0; CARCY B, 1994, MOL BIOCHEM PARASIT, V68, P221, DOI 10.1016/0166-6851(94)90167-8; CHAIYAROJ SC, 1994, MOL BIOCHEM PARASIT, V67, P21, DOI 10.1016/0166-6851(94)90092-2; CHITNIS CE, 1994, J EXP MED, V180, P497, DOI 10.1084/jem.180.2.497; CORCORAN LM, 1988, CELL, V53, P807, DOI 10.1016/0092-8674(88)90097-9; CREEDON KA, 1994, J BIOL CHEM, V269, P16364; DAY KP, 1993, P NATL ACAD SCI USA, V90, P8292, DOI 10.1073/pnas.90.17.8292; DEBRUIN D, 1992, GENOMICS, V14, P332, DOI 10.1016/S0888-7543(05)80223-X; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOLAN SA, 1993, MOL BIOCHEM PARASIT, V61, P137, DOI 10.1016/0166-6851(93)90166-U; DOLAN SA, 1990, J CLIN INVEST, V86, P618, DOI 10.1172/JCI114753; ELLIS J, 1987, MOL BIOCHEM PARASIT, V26, P203, DOI 10.1016/0166-6851(87)90144-7; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; HANDUNNETTI SM, 1987, J EXP MED, V165, P1269, DOI 10.1084/jem.165.5.1269; HAYNES RO, 1992, CELL, V69, P11; HOMMEL M, 1983, J EXP MED, V157, P1137, DOI 10.1084/jem.157.4.1137; HOMMEL M, 1985, IMMUNOL TODAY, V6, P28, DOI 10.1016/0167-5699(85)90165-3; HOWARD RJ, 1988, MOL BIOCHEM PARASIT, V27, P207, DOI 10.1016/0166-6851(88)90040-0; HYNES RO, 1994, BIOESSAYS, V16, P663, DOI 10.1002/bies.950160912; LANGRETH SG, 1979, J EXP MED, V150, P1241, DOI 10.1084/jem.150.5.1241; LANZER M, 1993, NATURE, V361, P654, DOI 10.1038/361654a0; LEECH JH, 1984, J EXP MED, V159, P1567, DOI 10.1084/jem.159.6.1567; LUSCINSKAS FW, 1994, FASEB J, V8, P929, DOI 10.1096/fasebj.8.12.7522194; LUSE SA, 1971, AM J TROP MED HYG, V20, P655, DOI 10.4269/ajtmh.1971.20.655; MACPHERSON GG, 1985, AM J PATHOL, V119, P385; MAGOWAN C, 1988, J EXP MED, V168, P1307, DOI 10.1084/jem.168.4.1307; MARSH K, 1986, SCIENCE, V231, P150, DOI 10.1126/science.2417315; MILLER LH, 1994, SCIENCE, V264, P1878, DOI 10.1126/science.8009217; NICKOLOFF JA, 1990, MOL CELL BIOL, V10, P4837, DOI 10.1128/MCB.10.9.4837; OCKENHOUSE CF, 1991, J INFECT DIS, V164, P163, DOI 10.1093/infdis/164.1.163; OCKENHOUSE CF, 1992, J EXP MED, V176, P1183, DOI 10.1084/jem.176.4.1183; OCKENHOUSE CF, 1989, SCIENCE, V243, P1469, DOI 10.1126/science.2467377; Okada A, 1994, Semin Immunol, V6, P185, DOI 10.1006/smim.1994.1024; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; OVERDUIN M, 1995, SCIENCE, V267, P386, DOI 10.1126/science.7824937; PETERSON DS, 1988, P NATL ACAD SCI USA, V85, P9114, DOI 10.1073/pnas.85.23.9114; PETERSON DS, 1995, IN PRESS P NATL ACAD, V92; POLOGE LG, 1987, P NATL ACAD SCI USA, V84, P7139, DOI 10.1073/pnas.84.20.7139; PONGPONRATN E, 1991, AM J TROP MED HYG, V44, P168, DOI 10.4269/ajtmh.1991.44.168; ROBERTS DD, 1985, NATURE, V318, P64, DOI 10.1038/318064a0; ROBERTS DJ, 1992, NATURE, V357, P689, DOI 10.1038/357689a0; SAUL A, 1988, MOL BIOCHEM PARASIT, V27, P35, DOI 10.1016/0166-6851(88)90022-9; SEIFERT HS, 1988, MICROBIOL REV, V52, P327, DOI 10.1128/MMBR.52.3.327-336.1988; SHAPIRO MB, 1986, NUCLEIC ACIDS RES, V14, P65, DOI 10.1093/nar/14.1.65; SHARMA YD, 1987, MOL BIOCHEM PARASIT, V26, P11, DOI 10.1016/0166-6851(87)90124-1; SIM BKL, 1994, SCIENCE, V264, P1941, DOI 10.1126/science.8009226; SINNIS P, 1988, GENOMICS, V3, P287, DOI 10.1016/0888-7543(88)90117-6; SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X; SU XZ, 1994, GENE, V151, P225, DOI 10.1016/0378-1119(94)90661-0; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; TRIGLIA T, 1987, EMBO J, V6, P1413, DOI 10.1002/j.1460-2075.1987.tb02382.x; UDEINYA IJ, 1983, NATURE, V303, P429, DOI 10.1038/303429a0; WEBER JL, 1988, MOL BIOCHEM PARASIT, V29, P117, DOI 10.1016/0166-6851(88)90066-7; WELLEMS TE, 1987, CELL, V49, P633, DOI 10.1016/0092-8674(87)90539-3; WELLEMS TE, 1991, P NATL ACAD SCI USA, V88, P3382, DOI 10.1073/pnas.88.8.3382	71	957	977	0	32	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 14	1995	82	1					89	100		10.1016/0092-8674(95)90055-1	http://dx.doi.org/10.1016/0092-8674(95)90055-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RK424	7606788	Bronze			2022-12-24	WOS:A1995RK42400012
J	CALLAHAN, CA; MURALIDHAR, MG; LUNDGREN, SE; SCULLY, AL; THOMAS, JB				CALLAHAN, CA; MURALIDHAR, MG; LUNDGREN, SE; SCULLY, AL; THOMAS, JB			CONTROL OF NEURONAL PATHWAY SELECTION BY A DROSOPHILA RECEPTOR PROTEIN-TYROSINE KINASE FAMILY MEMBER	NATURE			English	Article							CELL-ADHESION MOLECULE; GENE; DOMAIN; ELEGANS; EMBRYOS; MUSCLES; ENCODES; HOMOLOG; SUBSET; RYK	DURING development, neurons are capable of selecting specific pathways that lead them to their appropriate target areas. A variety of molecular mechanisms are thought to be involved in pathway recognition, including cell adhesion(1), repulsion(2,3) and chemotropism(4). However, apart from a few genes whose involvement has been shown genetically(5-8), the mechanisms underlying neuronal pathway selection are largely unknown. Here we report the isolation of the Drosophila derailed (drl) gene, which encodes a novel member of the receptor protein-tyrosine kinase family. Using a newly developed axon-targeted reporter gene(9) we find that drl is expressed by a small subset of embryonic interneurons whose growth cones choose common pathways during development. In drl mutant embryos these neurons fail to make the correct pathway choices. Our results provide evidence for receptor protein-tyrosine kinase involvement in key aspects of neuronal pathway recognition.	SALK INST BIOL STUDIES,MOLEC NEUROBIOL LAB,SAN DIEGO,CA 92186; UNIV CALIF SAN DIEGO,DEPT NEUROSCI,LA JOLLA,CA 92093	Salk Institute; University of California System; University of California San Diego								AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BOURGOUIN C, 1992, NEURON, V9, P549, DOI 10.1016/0896-6273(92)90192-G; CALLAHAN CA, 1994, P NATL ACAD SCI USA, V91, P5972, DOI 10.1073/pnas.91.13.5972; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; DOE CQ, 1993, DEV DROSOPHILA MELAN, P1131; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; GAY P, 1993, MOL GEN GENET, V239, P361, DOI 10.1007/BF00276934; GILBERT D, 1984, GENETICS, V106, P679; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HOVENS CM, 1992, P NATL ACAD SCI USA, V89, P11818, DOI 10.1073/pnas.89.24.11818; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; JIANG J, 1991, GENE DEV, V5, P1881, DOI 10.1101/gad.5.10.1881; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; KLAMBT C, 1992, GENE DEV, V6, P1668, DOI 10.1101/gad.6.9.1668; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; LIN DM, 1994, NEURON, V13, P1055, DOI 10.1016/0896-6273(94)90045-0; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MAMINTA MLD, 1992, BIOCHEM BIOPH RES CO, V189, P1077; NOSE A, 1992, CELL, V70, P553, DOI 10.1016/0092-8674(92)90426-D; NOSE A, 1994, NEURON, V13, P525, DOI 10.1016/0896-6273(94)90023-X; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; Rutishauser U, 1993, Curr Opin Neurobiol, V3, P709, DOI 10.1016/0959-4388(93)90142-L; SMITH HK, 1991, ROUX ARCH DEV BIOL, V200, P306, DOI 10.1007/BF00665525; STACKER SA, 1993, ONCOGENE, V8, P1347; THOMAS JB, 1982, NATURE, V298, P650, DOI 10.1038/298650a0; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VANVACTOR D, 1993, CELL, V73, P1155; WRIGHT TRF, 1981, CHROMOSOMA, V83, P45, DOI 10.1007/BF00286015	30	153	158	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 13	1995	376	6536					171	174		10.1038/376171a0	http://dx.doi.org/10.1038/376171a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ028	7603568				2022-12-24	WOS:A1995RJ02800060
J	PROUDLER, AJ; AHMED, AIH; CROOK, D; FOGELMAN, I; RYMER, JM; STEVENSON, JC				PROUDLER, AJ; AHMED, AIH; CROOK, D; FOGELMAN, I; RYMER, JM; STEVENSON, JC			HORMONE REPLACEMENT THERAPY AND SERUM ANGIOTENSIN CONVERTING-ENZYME ACTIVITY IN POSTMENOPAUSAL WOMEN	LANCET			English	Note							DELETION POLYMORPHISM; HYPERTENSION; PLASMA; GENE	The mechanisms by which hormone replacement therapy (HRT) reduces the risk of coronary heart disease (CHD) are incompletely understood, but may include direct arterial effects. We examined the effect of oestrogen/progestagen HRT on serum angiotensin-converting-enzyme (ACE) activity in postmenopausal women. After 6 months, ACE activity was reduced by 20% (p<0.001) on average in 28 treated women but remained unchanged in 16 controls. Serum ACE activity is modifiable by gonadal steroids and changes in serum ACE may represent a novel mechanism by which HRT reduces CHD risk in women.	GUYS HOSP,DEPT NUCL MED,LONDON SE1 9RT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust	PROUDLER, AJ (corresponding author), NATL HEART & LUNG INST,WYNN DEPT METAB MED,LONDON NW8 9SQ,ENGLAND.			Crook, David/0000-0002-9587-3730				ALHENCGELAS F, 1991, J LAB CLIN MED, V117, P33; BUTTERY JE, 1993, CLIN CHEM, V39, P312; CAMBIEN F, 1994, CIRCULATION, V90, P669, DOI 10.1161/01.CIR.90.2.669; CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; DUX S, 1984, ISRAEL J MED SCI, V20, P1138; RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844; SASSANO P, 1987, AM J MED, V83, P227, DOI 10.1016/0002-9343(87)90690-5; STAMPFER MJ, 1991, PREV MED, V28, P47; STEVENSON JC, 1994, DRUGS, V47, P35, DOI 10.2165/00003495-199400472-00007	9	166	168	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 8	1995	346	8967					89	90		10.1016/S0140-6736(95)92114-1	http://dx.doi.org/10.1016/S0140-6736(95)92114-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH220	7603219				2022-12-24	WOS:A1995RH22000012
J	WANG, Y; PRIVES, C				WANG, Y; PRIVES, C			INCREASED AND ALTERED DNA-BINDING OF HUMAN P53 BY S AND G2/M BUT NOT G1 CYCLIN-DEPENDENT KINASES	NATURE			English	Article							PHOSPHORYLATION; PROTEIN; MUTANT; PROLIFERATION; REPLICATION; INHIBIT; ANTIGEN; GENES	CENTRAL to the role of p53 in cell regulation are its sequence-specific interactions with genes that control the cell cycle and apoptosis(1,2). p53 response elements contain two or more copies of a somewhat promiscuous consensus sequence: 5'-XXXC(A,T)(T, A)GYYY-3' (where X is a purine and Y is a pyrimidine) (ref, 3), The sequence-specific DNA-binding region of p53 resides in its central conserved region(4). Although this region itself is not known to he phosphorylated, the amino and carboxy termini of human p53 contain sites for phosphorylation by several protein kinases.			WANG, Y (corresponding author), COLUMBIA UNIV, DEPT BIOL SCI, NEW YORK, NY 10027 USA.							BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FISCELLA M, 1994, ONCOGENE, V9, P3249; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MARSTON NJ, 1994, ONCOGENE, V9, P2707; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; NIGRO JM, 1992, MOL CELL BIOL, V12, P1357, DOI 10.1128/MCB.12.3.1357; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; STEWART N, 1995, ONCOGENE, V10, P109; STURZBECHER HW, 1990, ONCOGENE, V5, P795; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	30	326	331	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 6	1995	376	6535					88	91		10.1038/376088a0	http://dx.doi.org/10.1038/376088a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH111	7596441				2022-12-24	WOS:A1995RH11100068
J	AIGNER, L; ARBER, S; KAPFHAMMER, JP; LAUX, T; SCHNEIDER, C; BOTTERI, F; BRENNER, HR; CARONI, P				AIGNER, L; ARBER, S; KAPFHAMMER, JP; LAUX, T; SCHNEIDER, C; BOTTERI, F; BRENNER, HR; CARONI, P			OVEREXPRESSION OF THE NEURAL GROWTH-ASSOCIATED PROTEIN GAP-43 INDUCES NERVE SPROUTING IN THE ADULT NERVOUS-SYSTEM OF TRANSGENIC MICE	CELL			English	Article							RETINAL GANGLION-CELLS; NEUROMUSCULAR-JUNCTIONS; TRANSPORTED PROTEINS; NEURITE OUTGROWTH; AXON REGENERATION; PC12 CELLS; EXPRESSION; INJURY; NEURONS; MUSCLE	Regulation of neurite outgrowth and structural plasticity may involve the expression of intrinsic determinants controlling growth competence. We have tested this concept by targeting constitutive expression of the growth-associated protein GAP-43 to the neurons of adult transgenic mice. Such mice showed striking spontaneous nerve sprouting at the neuromuscular junction and in the terminal field of hippocampal messy fibers. In control mice, these nerve fibers did not express GAP-43, and did not sprout spontaneously. Lesion-induced nerve sprouting and terminal arborization during reinnervation were greatly potentiated in GAP-43-overexpressing mice. A mutant GAP-43 that cannot be phosphorylated by PKC had reduced sprout-promoting activity. The results establish GAP-43 as an intrinsic presynaptic determinant for neurite outgrowth and plasticity.	UNIV ZURICH,BRAIN RES INST,CH-8029 ZURICH,SWITZERLAND; UNIV BASEL,DEPT PHYSIOL,CH-4000 BASEL,SWITZERLAND	University of Zurich; University of Basel	AIGNER, L (corresponding author), FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND.			Aigner, Ludwig/0000-0002-1653-8046; Arber, Silvia/0000-0002-6261-250X				AIGNER L, 1993, J CELL BIOL, V123, P417, DOI 10.1083/jcb.123.2.417; AIGNER L, 1995, J CELL BIOL, V128, P647, DOI 10.1083/jcb.128.4.647; ARBER S, 1994, CELL, V79, P221, DOI 10.1016/0092-8674(94)90192-9; BAETGE EE, 1991, NEURON, V6, P21, DOI 10.1016/0896-6273(91)90118-J; BALICEGORDON RJ, 1994, NATURE, V372, P519, DOI 10.1038/372519a0; BENARI Y, 1990, TRENDS NEUROSCI, V13, P312, DOI 10.1016/0166-2236(90)90135-W; BENOWITZ LI, 1987, TRENDS NEUROSCI, V10, P527, DOI 10.1016/0166-2236(87)90135-4; BISBY MA, 1992, MOL NEUROBIOL, V6, P107, DOI 10.1007/BF02780547; BISBY MA, 1993, SOC NEUROSCI, V23; BROWN MC, 1984, TRENDS NEUROSCI, V7, P10, DOI 10.1016/S0166-2236(84)80180-0; CARONI P, 1994, J CELL BIOL, V125, P893, DOI 10.1083/jcb.125.4.893; CARONI P, 1992, J NEUROSCI, V12, P3849; CHAPMAN ER, 1991, J BIOL CHEM, V266, P207; CHONG MS, 1994, J NEUROSCI, V14, P4375; DOSTER SK, 1991, NEURON, V6, P635, DOI 10.1016/0896-6273(91)90066-9; LAUFER R, 1989, MOL NEUROBIOL, V3, P1, DOI 10.1007/BF02935587; LIU YC, 1990, TRENDS PHARMACOL SCI, V11, P107; MCKERRACHER L, 1993, J NEUROSCI, V13, P5294, DOI 10.1523/JNEUROSCI.13-12-05294.1993; MEIRI KF, 1990, J NEUROSCI, V10, P256; MOYA KL, 1988, J NEUROSCI, V8, P4445; PESTRONK A, 1978, MUSCLE NERVE, V1, P70, DOI 10.1002/mus.880010110; REYNOLDS ML, 1991, NEUROSCIENCE, V41, P201, DOI 10.1016/0306-4522(91)90210-F; REYNOLDS ML, 1992, J NEUROCYTOL, V21, P50, DOI 10.1007/BF01206897; ROBBINS N, 1988, J NEUROCYTOL, V17, P545, DOI 10.1007/BF01189809; SANES JR, 1989, ANNU REV NEUROSCI, V12, P491, DOI 10.1146/annurev.ne.12.030189.002423; SCHREYER DJ, 1991, J NEUROSCI, V11, P3738; SHEA TB, 1991, J NEUROSCI, V11, P1685; SHWEGLER G, 1995, J NEUROSCI, V15, P2756; SKENE JHP, 1989, ANNU REV NEUROSCI, V12, P127, DOI 10.1146/annurev.ne.12.030189.001015; SKENE JHP, 1981, J CELL BIOL, V89, P86, DOI 10.1083/jcb.89.1.86; SLOVITER RS, 1982, BRAIN RES BULL, V8, P771, DOI 10.1016/0361-9230(82)90104-6; SMALL SJ, 1987, J CELL BIOL, V105, P2335, DOI 10.1083/jcb.105.5.2335; SON YJ, 1995, NEURON, V114, P133; STRITTMATTER SM, 1995, CELL, V80, P445, DOI 10.1016/0092-8674(95)90495-6; TETZLAFF W, 1991, J NEUROSCI, V11, P2528; THESLEFF S, 1989, Q J EXP PHYSIOL CMS, V74, P1003, DOI 10.1113/expphysiol.1989.sp003329; VIDAL M, 1990, EMBO J, V9, P833, DOI 10.1002/j.1460-2075.1990.tb08180.x; WIDMER F, 1993, J CELL BIOL, V120, P503, DOI 10.1083/jcb.120.2.503; WIDMER F, 1990, J CELL BIOL, V111, P3035, DOI 10.1083/jcb.111.6.3035; WOOLF CJ, 1992, NATURE, V355, P75, DOI 10.1038/355075a0; YANKNER BA, 1990, MOL BRAIN RES, V7, P39, DOI 10.1016/0169-328X(90)90071-K	41	527	550	0	11	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 20	1995	83	2					269	278		10.1016/0092-8674(95)90168-X	http://dx.doi.org/10.1016/0092-8674(95)90168-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TA965	7585944	Bronze			2022-12-24	WOS:A1995TA96500013
J	MANJUNATH, N; CORREA, M; ARDMAN, M; ARDMAN, B				MANJUNATH, N; CORREA, M; ARDMAN, M; ARDMAN, B			NEGATIVE REGULATION OF T-CELL ADHESION AND ACTIVATION BY CD43	NATURE			English	Article							WISKOTT-ALDRICH SYNDROME; LYMPHOCYTE SURFACE SIALOGLYCOPROTEIN; MONOCLONAL-ANTIBODY; EXPRESSION; DIFFERENTIATION; MOLECULE; IDENTIFICATION; LEUKOSIALIN; SIALOPHORIN; ENHANCEMENT	CD43 is a cell-surface sialoglycoprotein expressed by a variety of haematopoietically derived cells, including T lymphocytes(1-9). Earlier observations of defective CD43 expression by T lymphocytes from boys with the X-chromosome-linked Wiskott-Aldrich syndrome suggested the importance of CD43 in lymphocyte function(10,11). Subsequent studies have suggested that CD43 facilitates leukocyte adhesion(12-14) and has a co-stimulatory role during T-cell activation(15). To define the physiologically relevant functions(s) of CD43, we have generated CD43-knockout mice. We report here that CD43-deficient T cells from such mice show a marked increase in their in vitro proliferative response to concanavalin A, anti-CD3, the superantigen SEB and allostimulation. Additionally, CD43-deficient T cells show a substantial enhancement in homotypic adhesion and in their ability to bind different ligands, including fibronectin and the intercellular adhesion molecule ICAM-1. Vaccinia-virus-infected CD43-knockout mice mounted an augmented anti-vaccinia, cytotoxic T-cell response compared with their wild-type littermates, yet developed an increased virus load. We conclude that CD43 negatively regulates T-cell activation and adhesion and is important for viral clearance.			MANJUNATH, N (corresponding author), TUFTS UNIV,NEW ENGLAND MED CTR HOSP,DEPT MED,DIV HAEMATOL ONCOL,750 WASHINGTON ST,BOSTON,MA 02111, USA.		Correa, Mariangela/K-8700-2019; Correa, Mariangela/A-6666-2010; Correa, Mariangela/B-3426-2019	Correa, Mariangela/0000-0003-4856-7578				ARDMAN B, 1992, P NATL ACAD SCI USA, V89, P5001, DOI 10.1073/pnas.89.11.5001; AXELSSON B, 1985, EUR J IMMUNOL, V15, P427, DOI 10.1002/eji.1830150503; AXELSSON B, 1988, J IMMUNOL, V141, P2912; BETTAIEB A, 1988, BLOOD, V71, P1226; BIERER BE, 1989, ANNU REV IMMUNOL, V7, P579, DOI 10.1146/annurev.immunol.7.1.579; BORCHE L, 1987, EUR J IMMUNOL, V17, P1623; BROWN WRA, 1981, NATURE, V289, P456, DOI 10.1038/289456a0; CARLSSON SR, 1986, J BIOL CHEM, V261, P2779; CYSTER JG, 1991, EMBO J, V4, P893; DEFOUGEROLLES AR, 1994, J EXP MED, V179, P619, DOI 10.1084/jem.179.2.619; DUSTIN ML, 1991, ANNU REV IMMUNOL, V9, P27, DOI 10.1146/annurev.iy.09.040191.000331; GAHMBERG CG, 1976, J CELL BIOL, V68, P642, DOI 10.1083/jcb.68.3.642; GAHMBERG CG, 1977, J BIOL CHEM, V252, P5888; GULLEY ML, 1988, J IMMUNOL, V140, P3751; GUNJI Y, 1992, BLOOD, V80, P429; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; KUHLMAN P, 1991, J IMMUNOL, V146, P1773; MANJUNATH N, 1994, J IMMUNOL, V151, P1528; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MENTZER SJ, 1987, J EXP MED, V165, P1382; MOORE T, 1994, J IMMUNOL, V153, P4978; NONG YH, 1989, J EXP MED, V170, P259, DOI 10.1084/jem.170.1.259; PARK JK, 1991, NATURE, V350, P706, DOI 10.1038/350706a0; PARKMAN R, 1981, LANCET, V2, P1387; REMOLDODONNELL E, 1984, J EXP MED, V159, P1705, DOI 10.1084/jem.159.6.1705; REMOLDODONNELL E, 1987, BLOOD, V70, P104; REMOLDODONNELL E, 1986, J BIOL CHEM, V261, P7526; ROSENSTEIN Y, 1991, NATURE, V354, P233, DOI 10.1038/354233a0; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; WIKEN M, 1988, SCAND J IMMUNOL, V28, P457, DOI 10.1111/j.1365-3083.1988.tb01476.x	30	187	190	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 12	1995	377	6549					535	538		10.1038/377535a0	http://dx.doi.org/10.1038/377535a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ336	7566153				2022-12-24	WOS:A1995RZ33600065
J	MASISON, DC; WICKNER, RB				MASISON, DC; WICKNER, RB			PRION-INDUCING DOMAIN OF YEAST URE2P AND PROTEASE RESISTANCE OF URE2P PRION-CONTAINING CELLS	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; PSI	The genetic properties of the [URE3] non-Mendelian element of Saccharomyces cerevisiae suggest that it is a prion (infectious protein) form of Ure2p, a regulator of nitrogen catabolism. In extracts from [URE3] strains, Ure2p was partially resistant to proteinase K compared with Ure2p from wild-type extracts. Overexpression of Ure2p in wild-type strains induced a 20- to 200-fold increase in the frequency with which [URE3] arose, Overexpression of just the amino-terminal 65 residues of Ure2p increased the frequency of [URE3] induction 6000-fold. Without this ''prion-inducing domain'' the carboxyl-terminal domain performed the nitrogen regulation function of Ure2p, but could not be changed to the [URE3] prion state. Thus, this domain induced the prion state in trans, whereas in cis it conferred susceptibility of the adjoining nitrogen regulatory domain to prion infections.	NIDDKD, BIOCHEM PHARMACOL LAB, GENET SIMPLE EUKARYOTES SECT, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								AIGLE M, 1975, MOL GEN GENET, V136, P327, DOI 10.1007/BF00341717; ALPER T, 1967, NATURE, V214, P764, DOI 10.1038/214764a0; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; CHERNOFF YO, 1993, CURR GENET, V24, P268, DOI 10.1007/BF00351802; COSCHIGANO PW, 1991, MOL CELL BIOL, V11, P822, DOI 10.1128/MCB.11.2.822; COX B, 1994, CURR BIOL, V4, P744, DOI 10.1016/S0960-9822(00)00167-6; Cox Brian, 1993, P219; COX BS, 1988, YEAST, V4, P159, DOI 10.1002/yea.320040302; COX BS, 1965, HEREDITY, V20, P505, DOI 10.1038/hdy.1965.65; DIRINGER H, 1983, NATURE, V306, P476, DOI 10.1038/306476a0; DOEL SM, 1994, GENETICS, V137, P659; GAJDUSEK DC, 1991, EUR J EPIDEMIOL, V7, P567, DOI 10.1007/BF00143141; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LACROUTE F, 1971, J BACTERIOL, V106, P519, DOI 10.1128/JB.106.2.519-522.1971; MAGASANIK B, 1992, MOL CELLULAR BIOL YE, V2, P283; PRUSINER SB, 1994, ANNU REV MICROBIOL, V48, P655, DOI 10.1146/annurev.mi.48.100194.003255; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGH A, 1979, P NATL ACAD SCI USA, V76, P1952, DOI 10.1073/pnas.76.4.1952; STANSFIELD I, 1994, CURR GENET, V25, P385, DOI 10.1007/BF00351776; TERAVANESYAN MD, 1994, GENETICS, V137, P671; TUITE MF, 1994, NATURE, V370, P327, DOI 10.1038/370327a0; TUITE MF, 1981, GENETICS, V98, P691; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170	26	319	324	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 6	1995	270	5233					93	95		10.1126/science.270.5233.93	http://dx.doi.org/10.1126/science.270.5233.93			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY302	7569955	Green Submitted			2022-12-24	WOS:A1995RY30200040
J	OHNO, H; STEWART, J; FOURNIER, MC; BOSSHART, H; RHEE, I; MIYATAKE, S; SAITO, T; GALLUSSER, A; KIRCHHAUSEN, T; BONIFACINO, JS				OHNO, H; STEWART, J; FOURNIER, MC; BOSSHART, H; RHEE, I; MIYATAKE, S; SAITO, T; GALLUSSER, A; KIRCHHAUSEN, T; BONIFACINO, JS			INTERACTION OF TYROSINE-BASED SORTING SIGNALS WITH CLATHRIN-ASSOCIATED PROTEINS	SCIENCE			English	Article							TRANS-GOLGI NETWORK; PLASMA-MEMBRANE; COATED VESICLES; CYTOPLASMIC DOMAIN; INVITRO BINDING; RECEPTOR; SEQUENCE; CLONING; TGN38; MOTIF	Tyrosine-based signals within the cytoplasmic domain of integral membrane proteins mediate clathrin-dependent protein sorting in the endocytic and secretory pathways. A yeast two-hybrid system was used to identify proteins that bind to tyrosine-based signals. The medium chains (mu(1) and mu(2)) of two clathrin-associated protein complexes (AP-1 and AP-2, respectively) specifically interacted with tyrosine-based signals of several integral membrane proteins. The interaction was confirmed by in vitro binding assays. Thus, it is likely that the medium chains serve as signal-binding components of the clathrin-dependent sorting machinery.	NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115; CHIBA UNIV,SCH MED,CTR BIOMED SCI,DIV MOLEC GENET,CHIBA 260,JAPAN	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Chiba University			Yang, Chen/G-1379-2010; Ohno, Hiroshi/L-7899-2014; Saito, Takashi/C-9684-2009; Bosshart, Herbert/N-1367-2016	Ohno, Hiroshi/0000-0001-8776-9661; Saito, Takashi/0000-0001-9495-3547; Bonifacino, Juan S./0000-0002-5673-6370; Bosshart, Herbert/0000-0002-9315-9592				BELTZER JP, 1991, EMBO J, V10, P3735, DOI 10.1002/j.1460-2075.1991.tb04942.x; BOS K, 1993, EMBO J, V12, P2219, DOI 10.1002/j.1460-2075.1993.tb05870.x; CHANG MP, 1993, EMBO J, V12, P2169, DOI 10.1002/j.1460-2075.1993.tb05865.x; CHO SG, 1991, NATURE, V353, P573, DOI 10.1038/353573a0; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FUKUDA M, 1988, J BIOL CHEM, V263, P18920; GILBOA L, 1995, J BIOL CHEM, V270, P7061, DOI 10.1074/jbc.270.13.7061; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; HOLNESS CL, 1993, J BIOL CHEM, V268, P9661; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KELLY AP, 1991, NATURE, V353, P571, DOI 10.1038/353571a0; KIRCHHAUSEN T, 1993, CURR OPIN STRUC BIOL, V3, P182, DOI 10.1016/S0959-440X(05)80150-2; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; MARKS MS, IN PRESS J CELL BIOL; MATSUI W, 1990, BIOCHEMISTRY-US, V29, P10791, DOI 10.1021/bi00500a011; NAKAYAMA Y, 1991, EUR J BIOCHEM, V202, P569, DOI 10.1111/j.1432-1033.1991.tb16409.x; NESTEROV A, 1995, J BIOL CHEM, V270, P6320, DOI 10.1074/jbc.270.11.6320; OHNO H, UNPUB; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; ROBINSON MS, 1989, J CELL BIOL, V108, P833, DOI 10.1083/jcb.108.3.833; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SORKIN A, 1995, J BIOL CHEM, V270, P619, DOI 10.1074/jbc.270.2.619; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SOSA MA, 1993, J BIOL CHEM, V268, P12537; THURIEAU C, 1988, DNA-J MOLEC CELL BIO, V7, P663, DOI 10.1089/dna.1988.7.663; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955; WONG SH, 1993, J BIOL CHEM, V2368, P22853	35	812	822	2	32	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 29	1995	269	5232					1872	1875		10.1126/science.7569928	http://dx.doi.org/10.1126/science.7569928			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX194	7569928				2022-12-24	WOS:A1995RX19400038
J	EHLERS, MD; TINGLEY, WG; HUGANIR, RL				EHLERS, MD; TINGLEY, WG; HUGANIR, RL			REGULATED SUBCELLULAR-DISTRIBUTION OF THE NR1 SUBUNIT OF THE NMDA RECEPTOR	SCIENCE			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; CULTURED HIPPOCAMPAL-NEURONS; GLUTAMATE RECEPTORS; RAT-BRAIN; PROTEIN-KINASE; CHANNEL; SYNAPSES; PHOSPHORYLATION; LOCALIZATION; POLYAMINES	NMDA (N-methyl-D-aspartate) receptors are selectively localized at the postsynaptic membrane of excitatory synapses in the mammalian brain. The molecular mechanisms underlying this localization were investigated by expressing the NR1 subunit of the NMDA receptor in fibroblasts. NR1 splice variants containing the first COOH-terminal exon cassette (NR1A and NR1D) were located in discrete, receptor-rich domains associated with the plasma membrane. NR1 splice variants lacking this exon cassette (NR1C and NR1E) were distributed throughout the cell, with large amounts of NR1 protein present in the cell interior. Insertion of this exon cassette into the COOH-terminus of the GluR1 AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate) receptor was sufficient to cause GluR1 to be localized to discrete, receptor-rich domains. Furthermore, protein kinase C phosphorylation of specific serines within this exon disrupted the receptor-rich domains. These results demonstrate that amino acid sequences contained within the NR1 molecule serve to localize this receptor subunit to discrete membrane domains in a manner that is regulated by alternative splicing and protein phosphorylation.	JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT NEUROSCI,BALTIMORE,MD 21205	Howard Hughes Medical Institute; Johns Hopkins University								BENVENISTE M, 1993, J PHYSIOL-LONDON, V464, P131, DOI 10.1113/jphysiol.1993.sp019627; BLACKSTONE CD, 1992, J NEUROCHEM, V58, P1118, DOI 10.1111/j.1471-4159.1992.tb09370.x; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; CONSTANTINEPATO.M, 1990, ANN REV NEUROSCI, V13, P129; CRAIG AM, 1993, NEURON, V10, P1055, DOI 10.1016/0896-6273(93)90054-U; DURAND GM, 1992, P NATL ACAD SCI USA, V89, P9359, DOI 10.1073/pnas.89.19.9359; ESHHAR N, 1993, NEUROSCIENCE, V57, P943, DOI 10.1016/0306-4522(93)90040-M; FROEHNER SC, 1991, J CELL BIOL, V114, P1, DOI 10.1083/jcb.114.1.1; FROEHNER SC, 1993, ANNU REV NEUROSCI, V16, P347, DOI 10.1146/annurev.ne.16.030193.002023; HOLLMANN M, 1993, NEURON, V10, P943, DOI 10.1016/0896-6273(93)90209-A; HUNTLEY GW, 1993, J NEUROSCI, V13, P2965; HUNTLEY GW, 1994, J NEUROSCI, V14, P3603; JONES KA, 1991, NEURON, V7, P593, DOI 10.1016/0896-6273(91)90372-7; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LAURIE DJ, 1994, J NEUROSCI, V14, P3180; MAIMONE MM, 1993, NEURON, V11, P53, DOI 10.1016/0896-6273(93)90270-2; MARTIN LJ, 1993, NEUROSCIENCE, V53, P327, DOI 10.1016/0306-4522(93)90199-P; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; PAOLETTI P, 1994, NEURON, V13, P645, DOI 10.1016/0896-6273(94)90032-9; PETRALIA RS, 1992, J COMP NEUROL, V318, P329, DOI 10.1002/cne.903180309; PETRALIA RS, 1994, J NEUROSCI, V14, P6102; PETRALIA RS, 1994, J NEUROSCI, V14, P667; PHILLIPS WD, 1993, J CELL BIOL, V123, P729, DOI 10.1083/jcb.123.3.729; PHILLIPS WD, 1991, SCIENCE, V251, P568, DOI 10.1126/science.1703661; RAYMOND LA, 1993, NATURE, V361, P637, DOI 10.1038/361637a0; ROCK DM, 1992, MOL PHARMACOL, V42, P157; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; TINGLEY WG, 1993, NATURE, V364, P70, DOI 10.1038/364070a0; TRILLER A, 1985, J CELL BIOL, V101, P683, DOI 10.1083/jcb.101.2.683; ZHANG L, 1994, P NATL ACAD SCI USA, V91, P10883, DOI 10.1073/pnas.91.23.10883	36	250	254	0	4	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 22	1995	269	5231					1734	1737		10.1126/science.7569904	http://dx.doi.org/10.1126/science.7569904			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV948	7569904				2022-12-24	WOS:A1995RV94800042
J	LAND, CE				LAND, CE			STUDIES OF CANCER AND RADIATION-DOSE AMONG ATOMIC-BOMB SURVIVORS - THE EXAMPLE OF BREAST-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IONIZING-RADIATION; MORTALITY; THERAPY; WOMEN; RISK	A comprehensive program of medical follow-up of survivors of the atomic bombings of Hiroshima and Nagasaki, Japan, by the Radiation Effects Research Foundation (RERF) has produced quantitative estimates of cancer risk from exposure to ionizing radiation. For breast cancer in women, in particular, the strength of the radiation dose response and the generally low level of population risk in the absence of radiation exposure have led to a clear description of excess risk and its variation by age at exposure and over time following exposure. Comparisons of RERF data with data from medically irradiated populations have yielded additional information on the influence of population and underlying breast cancer rates on radiation-related risk. Epidemiological investigations of breast cancer cases and matched controls among atomic bomb survivors have clarified the role of reproductive history as a modifier of the carcinogenic effects of radiation exposure. Finally, a pattern of radiation-related risk by attained age among the survivors exposed during childhood or adolescence suggests the possible existence of a radiation-susceptible subgroup. The hypothetical existence of such a group is lent plausibility by the results of recent family studies suggesting that heritable mutations in certain genes are associated with familial aggregations of breast cancer. The recent isolation and cloning of one such gene, BRCA1, makes it likely that the hypothesis can be tested using molecular assays of archival and other tissue obtained from atomic bomb survivor cases and controls.			LAND, CE (corresponding author), NCI,RADIAT EPIDEMIOL BRANCH,EPN 408,6130 EXECUT BLVD,MS 7362,BETHESDA,MD 20892, USA.							BOICE JD, 1990, RADIAT RES, V125, P214; CLIFTON KH, 1975, J NATL CANCER I, V55, P485; CLIFTON KH, 1978, CANCER RES, V38, P1507; ENG C, 1993, JNCI-J NATL CANCER I, V85, P1121, DOI 10.1093/jnci/85.14.1121; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; HANCOCK SL, 1993, J NATL CANCER I, V181, P25; HILDRETH NG, 1989, NEW ENGL J MED, V321, P1281, DOI 10.1056/NEJM198911093211901; KELSEY JL, 1993, EPIDEMIOL REV, V15, P36, DOI 10.1093/oxfordjournals.epirev.a036115; LAND CE, 1993, LANCET, V342, P237, DOI 10.1016/0140-6736(93)92324-M; LAND CE, 1980, SCIENCE, V209, P1197, DOI 10.1126/science.7403879; LAND CE, 1994, CANCER CAUSE CONTROL, V5, P167, DOI 10.1007/BF01830263; LAND CE, 1994, CANCER CAUSE CONTROL, V5, P157, DOI 10.1007/BF01830262; LAND CE, 1980, J NATL CANCER I, V65, P353; MABUCHI K, 1994, RADIAT RES, V137, P51; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; MATTSSON A, 1993, J NATL CANCER I, V85, P1679, DOI 10.1093/jnci/85.20.1679; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Neel J V, 1991, CHILDREN ATOMIC BOMB; PARKIN DM, 1992, IARC SCI PUBLICATION, V120; PUTNAM FW, 1994, PERSPECT BIOL MED, V37, P515; RALL JE, 1985, NIH852748 PUBL; Roesch WC, 1987, US JAPAN JOINT REASS; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; SHIMIZU Y, 1990, RADIAT RES, V121, P120, DOI 10.2307/3577495; SHORE RE, 1986, J NATL CANCER I, V77, P689, DOI 10.1093/jnci/77.3.689; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; THOMPSON DE, 1994, RADIAT RES, V137, P517; TOKUNAGA M, 1987, RADIAT RES, V112, P243, DOI 10.2307/3577254; TOKUNAGA M, 1994, RADIAT RES, V138, P209, DOI 10.2307/3578591; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; ZIEGLER RG, 1993, J NATL CANCER I, V22, P1819; 1994, SOURCES EFFECTS IONI, P115	33	92	97	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 2	1995	274	5					402	407						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL416	7616636				2022-12-24	WOS:A1995RL41600026
J	WAGNER, JE; KERNAN, NA; STEINBUCH, M; BROXMEYER, HE; GLUCKMAN, E				WAGNER, JE; KERNAN, NA; STEINBUCH, M; BROXMEYER, HE; GLUCKMAN, E			ALLOGENEIC SIBLING UMBILICAL-CORD-BLOOD TRANSPLANTATION IN CHILDREN WITH MALIGNANT AND NONMALIGNANT DISEASE	LANCET			English	Article							BONE-MARROW TRANSPLANTATION; VERSUS-HOST DISEASE; HEMATOPOIETIC STEM; RISK-FACTORS; APLASTIC-ANEMIA; CELLS; LEUKEMIA; PATIENT; RECONSTITUTION; ENGRAFTMENT	Allogeneic bone marrow transplantation is limited by the availability of suitable marrow donors and risk of graft-versus-host disease (GVHD) and opportunistic infection. In an attempt to ameliorate these limitations, umbilical cord blood has been postulated as an alternative source of allogeneic haemopoietic stem cells for transplantation. From September, 1994, umbilical cord blood from sibling donors has been used to reconstitute haemapoiesis in 44 children with acquired or congenital lympho-haemapoietic disorders, neuroblastoma, or metabolic diseases. Patients who had HLA-identical and HLA-1 antigen disparate grafts, had a probability of engraftment at 50 days after transplantation of 85%. No patient had late graft failure. The probability of grade II-IV GVHD at 100 days was 3% and the probability of chronic GVHD at one year was 6%. With a median follow-up of 1.6 years, the probability of survival for recipients of HLA-identical or HLA-1 antigen disparate grafts is 72%. We conclude that umbilical cord blood is a sufficient source of transplantable haemopoietic stem cells for children with HLA-identical or HLA-1 antigen disparate sibling donors with very low risk of acute or extensive chronic GVHD. The feasibility of umbilical-cord-blood transplantation with HLA-2 and HLA-3 antigen disparate sibling donors remains to be determined.	UNIV MINNESOTA,SCH MED,DIV EPIDEMIOL & CLIN RES,MINNEAPOLIS,MN 55455; MEM SLOAN KETTERING CANC CTR,DEPT PEDIAT,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,BONE MARROW TRANSPLANTAT SERV,NEW YORK,NY 10021; INDIANA UNIV,SCH MED,DEPT MED HEMATOL ONCOL,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT MICROBIOL,INDIANAPOLIS,IN; INDIANA UNIV,SCH MED,DEPT IMMUNOL,INDIANAPOLIS,IN; INDIANA UNIV,SCH MED,WALTHER ONCOL CTR,INDIANAPOLIS,IN 46202; HOP ST LOUIS,SERV GREFE MOELLE,FEDERAT HEMATOL,PARIS,FRANCE	University of Minnesota System; University of Minnesota Twin Cities; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	WAGNER, JE (corresponding author), UNIV MINNESOTA,SCH MED,DEPT PEDIAT,DIV BONE MARROW TRANSPLANTAT,MINNEAPOLIS,MN 55455, USA.				NATIONAL CANCER INSTITUTE [P01CA021737, P01CA023766] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI032918] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA21737, P01-CA23766] Funding Source: Medline; NIAID NIH HHS [P01-AI32918] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANASETTI C, 1989, NEW ENGL J MED, V320, P197, DOI 10.1056/NEJM198901263200401; BENSUSSAN A, 1994, P NATL ACAD SCI USA, V91, P9136, DOI 10.1073/pnas.91.19.9136; Bertolini F, 1995, J Hematother, V4, P29, DOI 10.1089/scd.1.1995.4.29; BOGDANIC V, 1993, TRANSPLANTATION, V56, P477; BROXMEYER HE, 1992, P NATL ACAD SCI USA, V89, P4109, DOI 10.1073/pnas.89.9.4109; BROXMEYER HE, 1989, P NATL ACAD SCI USA, V86, P3828, DOI 10.1073/pnas.86.10.3828; BROXMEYER HE, 1991, BLOOD CELLS, V17, P313; CHAMPLIN RE, 1989, BLOOD, V73, P606; CHANG RS, 1979, LANCET, V2, P201; CLAAS FHJ, 1988, SCIENCE, V241, P1815, DOI 10.1126/science.3051377; DEACOCK SJ, 1992, TRANSPLANTATION, V53, P1128, DOI 10.1097/00007890-199205000-00028; GALE RP, 1987, BRIT J HAEMATOL, V67, P397, DOI 10.1111/j.1365-2141.1987.tb06160.x; GLUCKMAN E, 1989, NEW ENGL J MED, V321, P1174, DOI 10.1056/NEJM198910263211707; GLUCKMAN E, 1993, BONE MARROW TRANSPL, V11, P199; HALL J, 1994, BLOOD, V84, pA97; ISSARAGRISIL S, 1995, NEW ENGL J MED, V332, P367, DOI 10.1056/NEJM199502093320605; KALIA A, 1988, TRANSPLANTATION, V46, P70, DOI 10.1097/00007890-198807000-00012; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOHLIKUMAR M, 1993, BRIT J HAEMATOL, V85, P419, DOI 10.1111/j.1365-2141.1993.tb03192.x; LINCH DC, 1989, NATURE, V340, P676, DOI 10.1038/340676a0; LUCARELLI G, 1990, NEW ENGL J MED, V322, P417, DOI 10.1056/NEJM199002153220701; NATHAN DG, 1989, NEW ENGL J MED, V321, P1190, DOI 10.1056/NEJM198910263211710; PAHWA RN, 1994, P NATL ACAD SCI USA, V91, P4485, DOI 10.1073/pnas.91.10.4485; RISDON G, 1994, CELL IMMUNOL, V154, P14, DOI 10.1006/cimm.1994.1053; RONCAROLO MG, 1994, BLOOD CELLS, V20, P573; RUBINSTEIN P, 1993, BLOOD, V81, P1679; SOCIE G, 1994, BLOOD, V83, P340; STAGNO S, 1986, JAMA-J AM MED ASSOC, V256, P1904, DOI 10.1001/jama.256.14.1904; STORB R, 1983, BRIT J HAEMATOL, V55, P573, DOI 10.1111/j.1365-2141.1983.tb02839.x; THIERRY D, 1992, BONE MARROW TRANSPL, V9, P101; Traineau R, 1993, J Hematother, V2, P231, DOI 10.1089/scd.1.1993.2.231; VANROOD JJ, 1990, SCIENCE, V248, P1388, DOI 10.1126/science.1972596; VILMER E, 1992, TRANSPLANTATION, V53, P1155; VOWELS MR, 1993, NEW ENGL J MED, V329, P1623, DOI 10.1056/NEJM199311253292205; Wagner J E, 1992, J Hematother, V1, P167, DOI 10.1089/scd.1.1992.1.167; WAGNER JE, 1992, BLOOD, V79, P1874; WEISDORF D, 1991, TRANSPLANTATION, V51, P1197, DOI 10.1097/00007890-199106000-00010	37	511	524	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 22	1995	346	8969					214	219		10.1016/S0140-6736(95)91268-1	http://dx.doi.org/10.1016/S0140-6736(95)91268-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK419	7616801				2022-12-24	WOS:A1995RK41900010
J	FLAHAULT, A; GARNERIN, P; CHAUVIN, P; FARRAN, N; SAIDI, Y; DIAZ, C; TOUBIANA, L; DRUCKER, J; VALLERON, AJ				FLAHAULT, A; GARNERIN, P; CHAUVIN, P; FARRAN, N; SAIDI, Y; DIAZ, C; TOUBIANA, L; DRUCKER, J; VALLERON, AJ			SENTINELLE TRACES OF AN EPIDEMIC OF ACUTE GASTROENTERITIS IN FRANCE	LANCET			English	Article									HOP NATL ST MAURICE,RESEAU NATL SANTE PUBL,F-75571 PARIS 12,FRANCE		FLAHAULT, A (corresponding author), INSERM,U263,F-75571 PARIS 12,FRANCE.		Chauvin, Pierre/G-1095-2015; Toubiana, Laurent/L-6840-2017; Chauvin, Pierre/S-2981-2019	Chauvin, Pierre/0000-0002-9183-6406; Toubiana, Laurent/0000-0002-1849-9829; Chauvin, Pierre/0000-0002-9183-6406				COSTAGLIOLA D, 1994, EUR J EPIDEMIOL, V10, P475, DOI 10.1007/BF01719680; Valleron A.-J., 1992, Morbidity and Mortality Weekly Report, V41, P101	2	20	20	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 15	1995	346	8968					162	163		10.1016/S0140-6736(95)91214-2	http://dx.doi.org/10.1016/S0140-6736(95)91214-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ031	7603234				2022-12-24	WOS:A1995RJ03100014
J	ROSENBERG, J				ROSENBERG, J			METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS (MRSA) IN THE COMMUNITY - WHOS WATCHING	LANCET			English	Editorial Material							MICROBIOLOGY; INFECTIONS				ROSENBERG, J (corresponding author), CALIF DEPT HLTH SERV,DIV COMMUNICABLE DIS CONTROL,INFECT CONTROL PROGRAM,BERKELEY,CA 94704, USA.							BERMAN DS, 1994, NEW ENGL J MED, V330, P1247; DECKER MD, 1992, HOSP INFECT, P221; EMBIL J, 1994, INFECT CONT HOSP EP, V15, P646; EMORI TG, 1993, CLIN MICROBIOL REV, V6, P428, DOI 10.1128/CMR.6.4.428-442.1993; LAYTON MC, 1995, INFECT CONT HOSP EP, V16, P12; LINNEMANN CC, 1991, AM J MED, V91, pS238, DOI 10.1016/0002-9343(91)90375-8; MCGOWAN JE, 1995, INFECT CONT HOSP EP, V16, P67, DOI 10.1086/647058; MULLIGAN ME, 1993, AM J MED, V94, P313, DOI 10.1016/0002-9343(93)90063-U; MURRAY BE, 1994, NEW ENGL J MED, V330, P1229, DOI 10.1056/NEJM199404283301710; NETTLEMAN MD, 1991, AM J MED S3B, V1, pS228; SARAVOLATZ LD, 1982, ANN INTERN MED, V97, P325, DOI 10.7326/0003-4819-97-3-325; TOMASZ A, 1994, NEW ENGL J MED, V330, P1247, DOI 10.1056/NEJM199404283301725	12	54	55	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 15	1995	346	8968					132	133		10.1016/S0140-6736(95)91203-7	http://dx.doi.org/10.1016/S0140-6736(95)91203-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ031	7603224				2022-12-24	WOS:A1995RJ03100002
J	TEDDER, RS; ZUCKERMAN, MA; GOLDSTONE, AH; HAWKINS, AE; FIELDING, A; BRIGGS, EM; IRWIN, D; BLAIR, S; GORMAN, AM; PATTERSON, KG; LINCH, DC; HEPTONSTALL, J; BRINK, NS				TEDDER, RS; ZUCKERMAN, MA; GOLDSTONE, AH; HAWKINS, AE; FIELDING, A; BRIGGS, EM; IRWIN, D; BLAIR, S; GORMAN, AM; PATTERSON, KG; LINCH, DC; HEPTONSTALL, J; BRINK, NS			HEPATITIS-B TRANSMISSION FROM CONTAMINATED CRYOPRESERVATION TANK	LANCET			English	Article								Over a 25-month period, six multiply transfused patients undergoing cytotoxic treatment for haematological or other malignant disorders developed icteric acute hepatitis B virus (HBV) infection. Bone marrow or peripheral-blood stem cells had been harvested from all six patients and stored in the same cryopreservation tank for possible future transplantation. Human DNA, HBsAg, and HBV DNA with sequences identical to those from four patients with related infections were subsequently found in the liquid nitrogen. Leakage of the cryopreservation bags used to store bone marrow harvested from the first patient when acutely infected with HBV led to contamination of the tank and its contents with HBV and subsequent transmission to patients after transplantation. This incident emphasises the continuing need to screen donors of tissue to be cryopreserved for bloodborne virus infections. It also reinforces the requirement for primary containers used to cryopreserve human tissue to be sealed in a way which prevents exchange of material between the specimen and the liquid nitrogen.	UCL HOSP, DEPT HAEMATOL, LONDON, ENGLAND; ACAD DEPT GENITOURINARY MED, LONDON, ENGLAND; NE THAMES REG TRANSFUS CTR, BRENTWOOD, ESSEX, ENGLAND; PUBL HLTH LAB SERV, LONDON, ENGLAND	University College London Hospitals NHS Foundation Trust; University of London; University College London; Public Health England	TEDDER, RS (corresponding author), UCL, SCH MED, DIV VIROL, WINDEYER BLDG, 46 CLEVELAND ST, LONDON W1P 6DB, ENGLAND.			Tedder, Richard/0000-0002-9672-5721				ALLANDER T, 1995, LANCET, V345, P603, DOI 10.1016/S0140-6736(95)90518-9; HAWKINS AE, 1994, J MED VIROL, V44, P13, DOI 10.1002/jmv.1890440105; KOIKE K, 1992, UNPUB PCR CLIN DIAGN; TEDDER RS, 1980, J MED VIROL, V6, P323, DOI 10.1002/jmv.1890060407; VOAK D, 1994, TRANSFUSION MED, V4, P165; ZUCKERMAN MA, 1994, OCT MO LBIOL HEP B V	6	327	338	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 15	1995	346	8968					137	140		10.1016/S0140-6736(95)91207-X	http://dx.doi.org/10.1016/S0140-6736(95)91207-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ031	7603227				2022-12-24	WOS:A1995RJ03100007
J	RAO, Z; HANDFORD, P; MAYHEW, M; KNOTT, V; BROWNLEE, GG; STUART, D				RAO, Z; HANDFORD, P; MAYHEW, M; KNOTT, V; BROWNLEE, GG; STUART, D			THE STRUCTURE OF A CA2+-BINDING EPIDERMAL GROWTH FACTOR-LIKE DOMAIN - ITS ROLE IN PROTEIN-PROTEIN INTERACTIONS	CELL			English	Article							HUMAN FACTOR-IX; FACTOR HOMOLOGY REGION; COAGULATION FACTOR-X; FACTOR-LIKE MODULE; EGF-LIKE DOMAINS; CALCIUM-BINDING; CRYSTAL-STRUCTURE; DROSOPHILA-NOTCH; SECONDARY STRUCTURE; MARFAN-SYNDROME	Various diverse extracellular proteins possess Ca2+-binding epidermal growth factor (EGF)-like domains, the function of which remains uncertain. We have determined, at high resolution (1.5 Angstrom), the crystal structure of such a domain, from human clotting factor IX, as a complex with Ca2+. The Ca2+ ligands form a classic pentagonal bipyramid with six ligands contributed by one polypeptide chain and the seventh supplied by a neighboring EGF-like domain. The crystal structure identifies the role of Ca2+ in maintaining the conformation of the N-terminal region of the domain, but more importantly demonstrates that Ca2+ can directly mediate protein-protein contacts. The observed crystal packing of the domains provides a plausible model for the association of multiple tandemly linked EGF-like domains in proteins such as fibrillin-1, Notch, and protein S. This model is consistent with the known functional data and suggests a general biological role for these domains.	UNIV OXFORD, SIR WILLIAM DUNN SCH PATHOL, OXFORD OX1 3RE, ENGLAND; UNIV OXFORD, OXFORD CTR MOLEC SCI, NEW CHEM LAB, OXFORD OX1 3QT, ENGLAND	University of Oxford; University of Oxford	RAO, Z (corresponding author), UNIV OXFORD, MOLEC BIOPHYS LAB, REX RICHARDS BLDG, OXFORD OX1 3QU, ENGLAND.		Rao, Zihe/HCH-6944-2022					ACHARYA KR, 1991, J MOL BIOL, V221, P571; ARLAUD GJ, 1989, BEHRING I MITT, V84, P56; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARON M, 1992, PROTEIN SCI, V1, P81; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BODIAN DL, 1994, STRUCTURE, V2, P755, DOI 10.1016/S0969-2126(94)00076-X; BRUNGER AT, 1992, XPLOR VERSION 31 SYS; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; CORSON GM, 1993, GENOMICS, V17, P476, DOI 10.1006/geno.1993.1350; DAHLBACK B, 1990, J BIOL CHEM, V265, P18481; DAY AJ, 1993, BEHRING I MITT, V93, P31; DIETZ HC, 1993, GENOMICS, V17, P468, DOI 10.1006/geno.1993.1349; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; GIANNELLI F, 1994, NUCLEIC ACIDS RES, V22, P3534, DOI 10.1093/nar/22.17.3534; GLANVILLE RW, 1994, J BIOL CHEM, V269, P26630; HANDFORD P, 1995, J BIOL CHEM, V270, P6751, DOI 10.1074/jbc.270.12.6751; HANDFORD PA, 1990, EMBO J, V9, P475, DOI 10.1002/j.1460-2075.1990.tb08133.x; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; HASE S, 1988, J BIOCHEM-TOKYO, V104, P867, DOI 10.1093/oxfordjournals.jbchem.a122571; HEWETT DR, 1993, HUM MOL GENET, V2, P475, DOI 10.1093/hmg/2.4.475; HUANG LH, 1989, BIOCHEM BIOPH RES CO, V160, P133, DOI 10.1016/0006-291X(89)91631-8; HUGHES PE, 1993, J BIOL CHEM, V268, P17727; JONES EY, 1991, ACTA CRYSTALLOGR A, V47, P753, DOI 10.1107/S0108767391006839; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KAINULAINEN K, 1994, NAT GENET, V6, P64, DOI 10.1038/ng0194-64; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; MAYHEW M, 1992, PROTEIN ENG, V5, P489, DOI 10.1093/protein/5.6.489; MCCALDON P, 1988, PROTEINS, V4, P99, DOI 10.1002/prot.340040204; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NISHIMURA H, 1989, J BIOL CHEM, V264, P20320; OHLIN AK, 1988, J BIOL CHEM, V263, P7411; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; PEREIRA L, 1993, HUM MOL GENET, V2, P961, DOI 10.1093/hmg/2.7.961; PERSSON E, 1989, J BIOL CHEM, V264, P16897; RAO Z, 1995, ACTA CRYSTALLOGR D, V51, P402, DOI 10.1107/S0907444994009881; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; REES DC, 1983, J MOL BIOL, V168, P367, DOI 10.1016/S0022-2836(83)80024-2; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; SAKAI LY, 1991, J BIOL CHEM, V266, P14763; SAVAGE CR, 1972, J BIOL CHEM, V247, P7612; SELANDER M, 1990, BIOCHEMISTRY-US, V29, P8111, DOI 10.1021/bi00487a018; SELANDERSUNNERH.M, 1994, THESIS U LUND SWEDEN; SELANDERSUNNERHAGEN M, 1992, J BIOL CHEM, V267, P19642; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; STENFLO J, 1991, BLOOD, V78, P1637; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; STUART DI, 1979, J MOL BIOL, V134, P109, DOI 10.1016/0022-2836(79)90416-9; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; THIELENS NM, 1990, BIOCHEMISTRY-US, V29, P3570, DOI 10.1021/bi00466a021; THIELENS NM, 1990, J BIOL CHEM, V265, P14469; VALCARCE C, 1993, J BIOL CHEM, V268, P26673; VANDERMERWE PA, 1995, CURR BIOL, V5, P74; WILKINSON HA, 1994, CELL, V79, P1187, DOI 10.1016/0092-8674(94)90010-8; WINSHIP PR, 1991, BRIT J HAEMATOL, V77, P102, DOI 10.1111/j.1365-2141.1991.tb07955.x; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	64	309	316	1	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 14	1995	82	1					131	141		10.1016/0092-8674(95)90059-4	http://dx.doi.org/10.1016/0092-8674(95)90059-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RK424	7606779	Bronze			2022-12-24	WOS:A1995RK42400016
J	DURING, MJ; RYDER, KM; SPENCER, DD				DURING, MJ; RYDER, KM; SPENCER, DD			HIPPOCAMPAL GABA TRANSPORTER FUNCTION IN TEMPORAL-LOBE EPILEPSY	NATURE			English	Article							GAMMA-AMINOBUTYRIC ACID; EXCITATORY AMINO-ACIDS; PRIMARY CULTURE; RELEASE; NEURONS; RECEPTORS; BRAIN; GLUTAMATE; INVITRO; SEIZURE	ELECTROPHYSIOLOGICAL studies of human temporal-lobe epilepsy suggest that a loss of hippocampal GABA-mediated inhibition may underlie the neuronal hyperexcitability(1-3). However, GABA (gamma-aminobutyric acid)-containing cells are preserved(4) and GABA receptors are maintained in the surviving hippocampal neurons(5). Diminished GABA release may therefore mediate the loss of inhibition. Here we show that, in the human brain, potassium-stimulated release of GABA was increased, and glutamate-induced, calcium-independent release of GABA was markedly decreased, in epileptogenic hippocampi, in contrast with contralateral, non-epileptogenic hippocampi. The glutamate-induced GABA release in vivo was transporter-mediated in rats. Furthermore, in amygdala-kindled rats, a model for human epilepsy, a decease in glutamate-induced GABA release was associated with a 48% decrease in tbe number of GABA transporters. These data suggest that temporal-lobe epilepsy is characterized in part by a loss of glutamate-stimulated GABA release that is secondary to a reduction in the number of GABA transporters.	YALE UNIV,SCH MED,DEPT SURG,ENDOCRINOL SECT,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT INTERNAL MED,NEW HAVEN,CT 06510	Yale University; Yale University	DURING, MJ (corresponding author), YALE UNIV,SCH MED,DEPT SURG,NEUROSURG SECT,MOLEC PHARMACOL & NEUROGENET LAB,333 CEDAR ST,NEW HAVEN,CT 06510, USA.		During, Matthew/AAC-1388-2020					ALGER BE, 1982, J PHYSIOL-LONDON, V328, P125, DOI 10.1113/jphysiol.1982.sp014256; BABB TL, 1989, J NEUROSCI, V9, P2562; BRAESTRUP C, 1990, J NEUROCHEM, V54, P639, DOI 10.1111/j.1471-4159.1990.tb01919.x; DELANEROLLE NC, 1991, DENTATE GYRUS ITS RO, P235; DREJER J, 1987, J NEUROSCI, V7, P2910; During M., 1992, Epilepsia, V33, P83; DURING MJ, 1993, LANCET, V341, P1607; DURING MJ, 1992, BRAIN RES, V584, P36, DOI 10.1016/0006-8993(92)90875-A; GALLO V, 1991, GLIA, V4, P245, DOI 10.1002/glia.440040302; GEDDES JW, 1990, EXP NEUROL, V108, P214, DOI 10.1016/0014-4886(90)90125-C; GONSALVES SF, 1989, EPILEPSY RES, V4, P34, DOI 10.1016/0920-1211(89)90056-9; HARRIS KM, 1989, BRAIN RES, V482, P23, DOI 10.1016/0006-8993(89)90538-6; HORTON RW, 1979, EUR J PHARMACOL, V59, P75, DOI 10.1016/0014-2999(79)90026-8; ISOKAWA M, 1991, EPILEPSY RES, V9, P242, DOI 10.1016/0920-1211(91)90058-N; JOHNSON EW, 1992, NEUROLOGY, V42, P811, DOI 10.1212/WNL.42.4.811; KNOWLES WD, 1992, EPILEPSIA, V33, P601, DOI 10.1111/j.1528-1157.1992.tb02335.x; MANGANO RM, 1983, BRAIN RES BULL, V10, P47, DOI 10.1016/0361-9230(83)90073-4; MCDONALD JW, 1991, ANN NEUROL, V29, P325; MCNAMARA JO, 1980, PROG NEUROBIOL, V15, P139, DOI 10.1016/0301-0082(80)90006-4; MORRISON PF, 1991, MONITORING MOLECULES IN NEUROSCIENCE, P47; PIN JP, 1989, J NEUROSCI, V9, P648; RADIAN R, 1990, J NEUROSCI, V10, P1319; SIMPSON MD, 1988, NEUROSCI LETT, V107, P211; SZERB JC, 1982, J NEUROCHEM, V39, P850, DOI 10.1111/j.1471-4159.1982.tb07970.x; WILLIAMSON A, 1994, CLIN NEUROSCI, V2, P47; WILLIAMSON A, IN PRESS J NEUROPHYS	26	298	304	0	16	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 13	1995	376	6536					174	177		10.1038/376174a0	http://dx.doi.org/10.1038/376174a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ028	7603569				2022-12-24	WOS:A1995RJ02800061
J	GOLDIE, AS; FEARON, KCH; ROSS, JA; BARCLAY, GR; JACKSON, RE; GRANT, IS; RAMSAY, G; BLYTH, AS; HOWIE, JC				GOLDIE, AS; FEARON, KCH; ROSS, JA; BARCLAY, GR; JACKSON, RE; GRANT, IS; RAMSAY, G; BLYTH, AS; HOWIE, JC			NATURAL CYTOKINE ANTAGONISTS AND ENDOGENOUS ANTIENDOTOXIN CORE ANTIBODIES IN SEPSIS SYNDROME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TUMOR-NECROSIS-FACTOR; CONTROLLED CLINICAL-TRIAL; NEGATIVE SEPTIC SHOCK; ORGAN FAILURE; FACTOR TNF; ENDOTOXIN; RECEPTORS; SERUM; INTERLEUKIN-6; SURVIVAL	Objective.-To assess the value of measuring circulating concentrations of mediators (endotoxin, tumor necrosis factor-alpha [TNF-alpha], interleukin-1 beta [IL-1 beta], and interleukin-6 [IL-6]) and their endogenous antagonists (antiendotoxin core antibody [EndoCAb], interleukin-1 receptor antagonist [lL-1ra], and soluble TNF receptors [sTNF-R]) in predicting mortality and organ failure in sepsis syndrome. Design.-Cohort study with a follow-up period of 30 days. Setting.-Intensive therapy units of five tertiary referral centers in Scotland. Subjects.-A total of 146 intensive therapy unit patients with sepsis syndrome underwent repeated sampling during a 10-day period following admission to an intensive therapy unit. Main Outcome Measures.-Circulating concentrations of mediators and antagonists were compared in survivors and nonsurvivors. Results.-Median Acute Physiology and Chronic Health Evaluation II score was 23 (range, 8 to 40). Mortality at 30 days was 49%. On entry to the study, circulating endotoxin was detected in 66% of patients, TNF-alpha in 14%, and IL-1 beta in 29%. Levels did not predict mortality or organ failure. Patients with IL-6 concentrations in excess of 3000 pg/mL had an increased mortality rate (64% vs 40%, P=.02). The incidence of IgG EndoCAb depletion on entry to the study was 26% in nonsurvivors and 10% in survivors (P=.02). Initial concentrations of both type I and type II sTNF-R were significantly higher in nonsurvivors (P<.01). Initial circulating IL-1ra concentrations were not of value in predicting mortality, Cytokine antagonists were present in concentrations 30- to 100 000-fold greater than their corresponding cytokine. Conclusion.-The observed high circulating levels of the cytokine antagonists IL-1ra and sTNF-R and the relatively small proportion of patients developing EndoCAb depletion may contribute to the limitations of therapies that aim to augment natural defenses against endotoxin or the proinflammatory cytokines.	UNIV EDINBURGH, ROYAL INFIRM, DEPT SURG, EDINBURGH EH3 9YW, MIDLOTHIAN, SCOTLAND; SCOTTISH NATL BLOOD TRANSFUS SERV, EDINBURGH, MIDLOTHIAN, SCOTLAND; WESTERN GEN HOSP, INTENS THERAPY UNIT, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND; WESTERN INFIRM & ASSOCIATED HOSP, DEPT ANAESTHET, GLASGOW, LANARK, SCOTLAND; VICTORIA INFIRM, DEPT ANAESTHET, GLASGOW G42 9TY, LANARK, SCOTLAND; ACAD ZEIKENHUIS, MAASTRICHT, NETHERLANDS	Royal Infirmary of Edinburgh; University of Edinburgh; University of Edinburgh; Maastricht University; Maastricht University Medical Centre (MUMC)								BARCLAY GR, 1989, CIRC SHOCK, V29, P93; BONE RC, 1987, NEW ENGL J MED, V317, P653, DOI 10.1056/NEJM198709103171101; BONE RC, 1989, CRIT CARE MED, V17, P389, DOI 10.1097/00003246-198905000-00002; CALANDRA T, 1991, AM J MED, V91, P23, DOI 10.1016/0002-9343(91)90069-A; CALANDRA T, 1990, J INFECT DIS, V161, P982, DOI 10.1093/infdis/161.5.982; CASEY LC, 1993, ANN INTERN MED, V119, P771, DOI 10.7326/0003-4819-119-8-199310150-00001; CERRA FB, 1987, SURGERY, V101, P1; COYLE SM, 1993, CLIN NUTR S2, V12, P29; DAMAS P, 1989, CRIT CARE MED, V17, P975, DOI 10.1097/00003246-198910000-00001; DANNER RL, 1991, CHEST, V99, P169, DOI 10.1378/chest.99.1.169; DEGROOTE MA, 1989, JAMA-J AM MED ASSOC, V262, P249, DOI 10.1001/jama.262.2.249; DHAINAUT JF, 1993, AUG INT C END AMST; DING AH, 1989, J BIOL CHEM, V264, P3924; DOFFERHOFF ASM, 1992, CRIT CARE MED, V20, P185, DOI 10.1097/00003246-199202000-00007; FISHER CJ, 1994, JAMA-J AM MED ASSOC, V271, P1836, DOI 10.1001/jama.271.23.1836; FROON AHM, IN PRESS CRIT CARE M; GILBERT ROBERT P., 1960, PHYSIOL REVS, V40, P245; GLAUSER MP, 1991, LANCET, V338, P732, DOI 10.1016/0140-6736(91)91452-Z; GORIS RJA, 1985, ARCH SURG-CHICAGO, V120, P1109; GRANOWITZ EV, 1991, LANCET, V338, P1423, DOI 10.1016/0140-6736(91)92725-H; GREENMAN RL, 1991, JAMA-J AM MED ASSOC, V266, P1097, DOI 10.1001/jama.266.8.1097; HACK CE, 1989, BLOOD, V74, P1704; HURLEY JC, 1992, CLIN INFECT DIS, V15, P840, DOI 10.1093/clind/15.5.840; ISPAHANI P, 1987, Q J MED, V63, P427; KISHIMOTO T, 1993, 8TH P INT C IMM BUD, P887; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; MOHLER KM, 1993, J IMMUNOL, V151, P1548; NYS M, 1993, ANN SURG, V217, P300, DOI 10.1097/00000658-199303000-00013; PINSKY MR, 1993, CHEST, V103, P565, DOI 10.1378/chest.103.2.565; POLLACK M, 1983, J CLIN INVEST, V72, P1874, DOI 10.1172/JCI111150; SCHEDEL I, 1991, CRIT CARE MED, V19, P1104, DOI 10.1097/00003246-199109000-00003; SPINAS GA, 1992, J CLIN INVEST, V90, P533, DOI 10.1172/JCI115891; WAAGE A, 1987, LANCET, V1, P355; WHICHER JT, 1978, ANN CLIN BIOCHEM, V15, P77, DOI 10.1177/000456327801500117; WORTEL CH, 1992, J INFECT DIS, V166, P1367, DOI 10.1093/infdis/166.6.1367; WRIGHT SD, 1991, CURR OPIN IMMUNOL, V3, P83, DOI 10.1016/0952-7915(91)90082-C; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701	37	224	229	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 12	1995	274	2					172	177		10.1001/jama.274.2.172	http://dx.doi.org/10.1001/jama.274.2.172			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH222	7596007				2022-12-24	WOS:A1995RH22200032
J	NUYTS, GD; VANVLEM, E; THYS, J; DELEERSNIJDER, D; DHAESE, PC; ELSEVIERS, MM; DEBROE, ME				NUYTS, GD; VANVLEM, E; THYS, J; DELEERSNIJDER, D; DHAESE, PC; ELSEVIERS, MM; DEBROE, ME			NEW OCCUPATIONAL RISK-FACTORS FOR CHRONIC-RENAL-FAILURE	LANCET			English	Article							LEAD WORKERS; BODY BURDEN; CADMIUM; DISEASE; EXPOSURE; BLOOD; GLOMERULONEPHRITIS; DYSFUNCTION; POPULATION; CREATININE	Occupational pollutants may have a role in development of chronic renal failure (CRF). Most epidemiological studies have been cross-sectional, limited to certain renal diagnoses, or concentrated on early transient renal effects. In a case-control study, we examined the association between CRF and occupational exposure. Occupational histories of 272 men and women with CRF (of all types) were compared with those of 272 controls matched for age, sex, and region of residence. Exposures were assessed and degree and frequency were scored independently by three industrial hygienists unaware of case/control status, Significantly increased risk of CRF were found for exposure to lead (odds ratio 2.11 [95% CI 1.23-4.36]), copper (2.54 [1.16-5.53]), chromium (2.77 [1.21-6.33]), tin (3.72 [1.22-11.3]), mercury (5.13 [1.02-25.7]), welding fumes (2.06 [1.05-4.04]), silicon-containing compounds (2.51 [1.37-4.60]), grain dust (2.96 [1.24-7.04]), and oxygenated hydrocarbons (5.45 [1.84-16.2]). The frequencies of various occupational exposures were high among patients with diabetic nephropathy. This epidemiological study confirms previously identified risk factors and suggests that additional occupational exposures, for which there is some other experimental evidence, may be important in the development of CRF. The role of grain dust and the association between occupational exposure and diabetic nephropathy merit further investigation.	UNIV ANTWERP HOSP,DEPT NEPHROL HYPERTENS,B-2650 EDEGEM,BELGIUM; OPEL BELGIUM NV,ANTWERP,BELGIUM; APRIM,ANTWERP,BELGIUM; BRUSSELS NATL AIRPORT,SABENA SAFETY,BRUSSELS,BELGIUM	University of Antwerp			D'Haese, Patrick C/C-9599-2019	Elseviers, Monique/0000-0001-9415-6900				BOMBASSEI GJ, 1992, AM J IND MED, V21, P141, DOI 10.1002/ajim.4700210204; BROCKHAUS A, 1983, INT ARCH OCC ENV HEA, V52, P167, DOI 10.1007/BF00405420; BROWN WD, 1987, J OCCUP ENVIRON MED, V29, P877; BUCHET JP, 1990, LANCET, V336, P699, DOI 10.1016/0140-6736(90)92201-R; DECASTO M, 1994, SCHWEIZ ARCH TIERH, V136, P111; DHAESE PC, 1991, CLIN CHEM, V37, P1583; DIEPERINK HH, 1991, TOXICOL LETT, V46, P257; DIEPERINK HH, 1991, TOXICOL LETT, V46, P1; ELSEVIERS MM, 1987, LANCET, V1, P457; EPSTEIN E, 1994, P NATL ACAD SCI USA, V96, P11; GEERLINGS W, 1991, NEPHROL DIAL TRANSPL, V6, P5; GOLDSMITH JR, 1993, AM J IND MED, V23, P873, DOI 10.1002/ajim.4700230605; HEBERT CD, 1993, FUND APPL TOXICOL, V21, P461, DOI 10.1006/faat.1993.1122; KIDO T, 1990, ARCH ENVIRON HEALTH, V45, P35, DOI 10.1080/00039896.1990.9935922; LINDER MC, 1985, NUTRITIONAL BIOCH ME, P246; NELSON NA, 1990, AM J NEPHROL, V10, P10, DOI 10.1159/000168048; NUYTS GD, 1991, NEPHROL DIAL TRANSPL, V6, P307, DOI 10.1093/ndt/6.5.307; NUYTS GD, 1993, J OCCUP ENVIRON MED, V35, P387; NUYTS GD, IN PRESS NEPHROL DIA; NYE L. J. J., 1929, Medical Journal of Australia, V2, P145; OSORIO AM, 1987, AM J KIDNEY DIS, V9, P224, DOI 10.1016/S0272-6386(87)80059-8; PORRO A, 1992, BRIT J IND MED, V49, P738; ROELS H, 1993, BRIT J IND MED, V50, P37; ROELS HA, 1989, BRIT J IND MED, V46, P755; SCHUTZ A, 1987, ARCH ENVIRON HEALTH, V42, P340, DOI 10.1080/00039896.1987.9934356; SPEIZER FE, HARRISONS PRINCIPLES, P1167; STEENLAND NK, 1990, AM J PUBLIC HEALTH, V80, P153, DOI 10.2105/AJPH.80.2.153; STENGEL B, 1992, DEC INT S PATH PATH, P24; VANDEVYVER FL, 1988, KIDNEY INT, V33, P601, DOI 10.1038/ki.1988.39; WANG XR, 1994, TOXICOLOGY, V90, P93, DOI 10.1016/0300-483X(94)90208-9; YAQOOB M, IN PRESS DIABETIC ME	31	73	76	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 1	1995	346	8966					7	11		10.1016/S0140-6736(95)92648-8	http://dx.doi.org/10.1016/S0140-6736(95)92648-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RF985	7603180				2022-12-24	WOS:A1995RF98500006
J	WRIGHT, CJ; MUELLER, CB				WRIGHT, CJ; MUELLER, CB			SCREENING MAMMOGRAPHY AND PUBLIC-HEALTH POLICY - THE NEED FOR PERSPECTIVE	LANCET			English	Article							BREAST-CANCER DETECTION; CARCINOMA INSITU; DEATH RATES; FOLLOW-UP; MORTALITY; TRIAL; WOMEN; DURATION; GROWTH	The early trials of screening mammography, reporting 30% relative reduction in mortality from breast cancer in women over 50 years of age, led to strong professional and public demand for screening programmes. There has been little publicity about the subsequent trials showing no Significant benefit in any age group, or about the harm and costs associated with screening mammography, For women under 50, there is a reluctant consensus that screening is not beneficial, but there is increasing pressure for publicly funded programmes for older women. When analysed in terms of population benefit, the randomised controlled prospective trials showed that the numbers of women screened to achieve one less death per year ranged from 7086 (Health Insurance Plan of New York), to 63 264 (Malmo), to infinity (Canadian National Breast Screening Study). About 5% of screening mammograms are positive or suspicious, and of these 80-93% are false positives that cause much unnecessary anxiety and further procedures including surgery. False reassurance by negative mammography occurs in 10-15% of women with breast cancer that will manifest clinically within a year. Our calculations confirm others that the mean annual cost per life ''saved'' is around $1.2 million (pound 558 000). In the allocation of limited resources, public health policy on a proposed mass population intervention must be based on a critical analysis of benefits, harm, and cost. Since the benefit achieved is marginal, the harm caused is substantial, and the costs incurred are enormous, we suggest that public funding for breast cancer screening in any age group is not justifiable.	UNIV BRITISH COLUMBIA,DEPT HLTH CARE & EPIDEMIOL,VANCOUVER,BC V6T 1W5,CANADA; MCMASTER UNIV,DEPT SURG,HAMILTON,ON L8S 4L8,CANADA	University of British Columbia; McMaster University								ANDERSSON I, 1988, BRIT MED J, V297, P943, DOI 10.1136/bmj.297.6654.943; BAINES CJ, 1988, J CAN ASSOC RADIOL, V39, P273; BAKER LH, 1982, CA-CANCER J CLIN, V32, P194, DOI 10.3322/canjclin.32.4.194; EDDY DM, 1988, JAMA-J AM MED ASSOC, V259, P1512, DOI 10.1001/jama.259.10.1512; ELWOOD JM, 1993, ONLINE J CURR C 0225; FRISELL J, 1991, BREAST CANCER RES TR, V18, P49, DOI 10.1007/BF01975443; KATTLOVE H, 1995, JAMA-J AM MED ASSOC, V273, P142, DOI 10.1001/jama.273.2.142; MARTEAU TM, 1989, BRIT MED J, V299, P527, DOI 10.1136/bmj.299.6698.527; MILLER AB, 1992, CAN MED ASSOC J, V147, P1477; MILLER AB, 1992, CAN MED ASSOC J, V147, P1459; MUELLER CB, 1994, AM J CLIN ONCOL-CANC, V17, P86; MUELLER CB, 1975, ANN SURG, V182, P334, DOI 10.1097/00000658-197509000-00016; NORTON LW, 1988, ARCH SURG-CHICAGO, V123, P947; NYSTROM L, 1993, LANCET, V341, P973, DOI 10.1016/0140-6736(93)91067-V; PAGE DL, 1982, CANCER, V49, P751, DOI 10.1002/1097-0142(19820215)49:4<751::AID-CNCR2820490426>3.0.CO;2-Y; ROBERTS MM, 1990, LANCET, V335, P241; ROSEN PP, 1978, AM J SURG PATHOL, V2, P225, DOI 10.1097/00000478-197809000-00001; SCHMIDT JG, 1990, J CLIN EPIDEMIOL, V43, P215, DOI 10.1016/0895-4356(90)90002-7; SHAPIRO S, 1982, JNCI-J NATL CANCER I, V69, P349; SHAPIRO S, 1989, CANCER, V63, P1873, DOI 10.1002/1097-0142(19890515)63:10<1873::AID-CNCR2820631002>3.0.CO;2-6; SKRABANEK P, 1985, LANCET, V2, P316; SPRATT JA, 1993, CANCER-AM CANCER SOC, V71, P2020, DOI 10.1002/1097-0142(19930315)71:6<2020::AID-CNCR2820710616>3.0.CO;2-#; SPRATT JS, 1986, CANCER RES, V46, P970; STRAX P, 1989, CANCER, V63, P1881, DOI 10.1002/1097-0142(19890515)63:10<1881::AID-CNCR2820631003>3.0.CO;2-8; TABAR L, 1985, LANCET, V1, P829, DOI 10.1016/S0140-6736(85)92204-4; WRIGHT CJ, 1986, SURGERY, V100, P594; 1986, PAMPHLET 86 30 MM NO	27	71	72	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 1	1995	346	8966					29	32		10.1016/S0140-6736(95)92655-0	http://dx.doi.org/10.1016/S0140-6736(95)92655-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RF985	7603143				2022-12-24	WOS:A1995RF98500013
J	PALOMBO, F; GALLINARI, P; IACCARINO, I; LETTIERI, T; HUGHES, M; DARRIGO, A; TRUONG, O; HSUAN, JJ; JIRICNY, J				PALOMBO, F; GALLINARI, P; IACCARINO, I; LETTIERI, T; HUGHES, M; DARRIGO, A; TRUONG, O; HSUAN, JJ; JIRICNY, J			GTBP, A 160-KILODALTON PROTEIN ESSENTIAL FOR MISMATCH-BINDING ACTIVITY IN HUMAN-CELLS	SCIENCE			English	Article							COLORECTAL-CANCER; GENE; MUTATIONS; CLONING; HOMOLOG; COLON	DNA mismatch recognition and binding in human cells has been thought to be mediated by the hMSH2 protein. Here it is shown that the mismatch-binding factor consists of two distinct proteins, the 100-kilodalton hMSH2 and a 160-kilodalton polypeptide, GTBP (for G/T binding protein). Sequence analysis identified GTBP as a new member of the MutS homolog family. Both proteins are required for mismatch-specific binding, a result consistent with the finding that tumor-derived cell lines devoid of either protein are also devoid of mismatch-binding activity.	IST RIC BIOL MOLEC P ANGELETTI, I-00040 POMEZIA, ITALY; UCL, SCH MED, LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND	Ludwig Institute for Cancer Research; University of London; University College London; UCL Medical School			Hsuan, Justin/C-8825-2009; Iaccarino, Ingram/B-9086-2015; Gallinari, Paola/ABE-8238-2021	Hsuan, Justin/0000-0001-6083-7564; Iaccarino, Ingram/0000-0001-7324-993X; Palombo, Fabio/0000-0003-0473-4901; Lettieri, Teresa/0000-0002-3363-9666				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ALANI E, 1995, GENE DEV, V9, P234, DOI 10.1101/gad.9.2.234; AQUILINA G, 1994, P NATL ACAD SCI USA, V91, P8905, DOI 10.1073/pnas.91.19.8905; CHI NW, 1994, J BIOL CHEM, V269, P29984; COSTA LT, 1995, NAT GENET, V9, P10; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; FISHEL R, 1994, CANCER RES, V54, P5539; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FUJII H, 1989, J BIOL CHEM, V264, P10057; HUGHES MJ, 1992, J BIOL CHEM, V267, P23876; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JIRICNY J, 1988, P NATL ACAD SCI USA, V85, P8860, DOI 10.1073/pnas.85.23.8860; KAWASAKI H, 1990, ANAL BIOCHEM, V186, P264, DOI 10.1016/0003-2697(90)90077-M; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LINGNER J, 1991, NATURE, V354, P496, DOI 10.1038/354496a0; LINTON JP, 1989, MOL CELL BIOL, V9, P3058, DOI 10.1128/MCB.9.7.3058; MERLO A, 1994, CANCER RES, V54, P2098; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; NEW L, 1993, MOL GEN GENET, V239, P97, DOI 10.1007/BF00281607; PALOMBO F, 1994, NATURE, V367, P417, DOI 10.1038/367417a0; PAPADOPOULOUS N, SCIENCE, V268, P1915; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; TOTTY NF, 1992, PROTEIN SCI, V1, P1215, DOI 10.1002/pro.5560010914; UMAR A, 1994, J BIOL CHEM, V269, P14367; VOGELSTEIN B, COMMUNICATION; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152	30	481	489	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 30	1995	268	5219					1912	1914		10.1126/science.7604265	http://dx.doi.org/10.1126/science.7604265			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF990	7604265				2022-12-24	WOS:A1995RF99000042
J	DEVORE, DL; HORVITZ, HR; STERN, MJ				DEVORE, DL; HORVITZ, HR; STERN, MJ			AN FGF RECEPTOR SIGNALING PATHWAY IS REQUIRED FOR THE NORMAL-CELL MIGRATIONS OF THE SEX MYOBLASTS IN C-ELEGANS HERMAPHRODITES	CELL			English	Article							FIBROBLAST GROWTH-FACTOR; CAENORHABDITIS-ELEGANS; VULVAR INDUCTION; POINT MUTATION; GENE SEM-5; MESODERM; PROTEIN; MITOGENESIS; NEMATODE; ENCODES	The sex myoblasts (SMs) in C. elegans hermaphrodites undergo anteriorly directed cell migrations that allow for the proper localization of the egg-laying muscles. These migrations are controlled in part by a signal emanating from gonadal cells that allows the SMs to be attracted to their precise final positions flanking the center of the go nad. Mutations in egl-15 alter the nature of the interaction between the gonad and the SMs, resulting in the posterior displacement of the SMs. Here we show that egl-15 encodes a receptor tyrosine kinase of the fibroblast growth factor receptor (FGFR) subfamily with multiple roles in development. Three genes were identified that behave genetically as activators or mediators of egl-15 activity. One of these genes, sem-5, encodes an adaptor molecule that transduces signals from a variety of receptor tyrosine kinases. Like egl-15 and sem-5, the other two genes may similarly act in FGFR signaling pathways in C, elegans.	MIT,HOWARD HUGHES MED INST,DEPT BIOL,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	DEVORE, DL (corresponding author), YALE UNIV,SCH MED,DEPT GENET,333 CEDAR ST,NEW HAVEN,CT 06520, USA.							ADNANE J, 1991, ONCOGENE, V6, P659; ALTSCHUL SF, 1990, P NATL ACAD SCI USA, V87, P5509, DOI 10.1073/pnas.87.14.5509; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; AROIAN RV, 1991, GENETICS, V128, P251; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BRENNER S, 1974, GENETICS, V77, P71; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CLIFFORD RJ, 1989, GENETICS, V123, P771; CORNELL RA, 1994, DEVELOPMENT, V120, P453; CORNELL RA, 1995, DEVELOPMENT, V121, P2429; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; Fodor A., 1985, Journal of Genetics, V64, P143, DOI 10.1007/BF02931143; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HERMAN RK, 1988, NEMATODE CAENORHABDI, P17; HODGKIN J, 1979, GENETICS, V91, P67; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KLAMBT C, 1992, GENE DEV, V6, P1668, DOI 10.1101/gad.6.9.1668; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; LABONNE C, 1994, DEVELOPMENT, V120, P463; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MOERMAN DG, 1986, P NATL ACAD SCI USA, V83, P2579, DOI 10.1073/pnas.83.8.2579; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; NUSBAUM C, 1989, GENETICS, V122, P579; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; REICHMANFRIED M, 1994, GENE DEV, V8, P428, DOI 10.1101/gad.8.4.428; RUVKUN G, 1989, GENETICS, V121, P501; Sambrook J., 1989, MOL CLONING LAB MANU; STERN MJ, 1993, MOL BIOL CELL, V4, P1175, DOI 10.1091/mbc.4.11.1175; STERN MJ, 1991, DEVELOPMENT, V113, P797; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; THOMAS JH, 1990, CELL, V62, P1041, DOI 10.1016/0092-8674(90)90382-O; UMBHAUER M, 1995, NATURE, V376, P58, DOI 10.1038/376058a0; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; Wood WB, 1988, NEMATODE CAENORHABDI	43	147	156	3	6	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 17	1995	83	4					611	620		10.1016/0092-8674(95)90101-9	http://dx.doi.org/10.1016/0092-8674(95)90101-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TF248	7585964	hybrid			2022-12-24	WOS:A1995TF24800014
J	BUTLER, VP; ODEL, JG; RATH, E; WOLIN, MJ; BEHRENS, MM; MARTIN, TJ; KARDON, RH; GOURAS, P				BUTLER, VP; ODEL, JG; RATH, E; WOLIN, MJ; BEHRENS, MM; MARTIN, TJ; KARDON, RH; GOURAS, P			DIGITALIS-INDUCED VISUAL DISTURBANCES WITH THERAPEUTIC SERUM DIGITALIS CONCENTRATIONS	ANNALS OF INTERNAL MEDICINE			English	Note							RAT RETINA; DIGOXIN; INTOXICATION; LOCALIZATION; DEGENERATION; CELLS	Objective: To assess the role of digitalis in the development of visual symptoms severe enough to warrant ophthalmologic consultation in patients who received digitalis and who had no other clinical or laboratory evidence of digitalis toxicity. Design: Clinical case study. Setting: Neuro-ophthalmology referral practice. Patients: Six elderly patients (aged 66 to 85 years) who received digitalis were referred to ophthalmologists for evaluation of photopsia (five patients) or decreased visual acuity (one patient). No patient had chromatopsia or nonvisual clinical manifestations of digitalis intoxication at the time of examination. Measurements: All patients had serum digitalis concentrations within or below the therapeutic range. In most patients, the electroretinographic cone b-wave implicit time was longer than normal. Results: Discontinuation of digitalis therapy, which was possible in five patients, was followed by resolution of visual symptoms and by shortening of the b-wave implicit time. Characteristic features of digitalis-induced photopsia were its dependence on illumination and its tendency to be localized in peripheral visual fields. Conclusions: In an elderly patient receiving digitalis, the development of photopsia characterized by innumerable points of light in the peripheral visual fields or a decrease in visual acuity raises the possibility that the patient's visual disturbance may have been digitalis induced. Digitalis-induced visual disturbances other than chromatopsia or disturbances of color vision may occur in elderly patients who have no other clinical manifestations of digitalis intoxication and who have a serum digitalis concentration within or below the therapeutic range.	UNIV IOWA, DEPT OPHTHALMOL, IOWA CITY, IA 52242 USA; COLUMBIA PRESBYTERIAN MED CTR, NEW YORK, NY 10032 USA; VET AFFAIRS HOSP, IOWA CITY, IA USA	University of Iowa; Columbia University; NewYork-Presbyterian Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System				Kardon, Randy/0000-0002-3173-7123	NEI NIH HHS [R01 EY 04138-10] Funding Source: Medline; NHLBI NIH HHS [R01 HL 10608-27] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY004138] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL010608] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BURKE JM, 1993, EXP EYE RES, V57, P51, DOI 10.1006/exer.1993.1098; BUTLER V P JR, 1972, Progress in Cardiovascular Diseases, V14, P571, DOI 10.1016/0033-0620(72)90009-6; CARROLL FD, 1945, AM J OPHTHALMOL, V28, P373, DOI 10.1016/0002-9394(45)90940-8; DENDEN A, 1962, GRAEFE ARCH OPHTHAL, V165, P185; DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691; FISHER CM, 1981, NEUROLOGY, V31, P1569, DOI 10.1212/WNL.31.12.1569; GARTNER S, 1981, BRIT J OPHTHALMOL, V65, P23, DOI 10.1136/bjo.65.1.23; GIBSON HC, 1965, ARCH OPHTHALMOL-CHIC, V74, P154, DOI 10.1001/archopht.1965.00970040156004; GILLETTE DF, 1946, T AM OPHTHAL SOC, V44, P156; GOURAS P, 1989, INVEST OPHTH VIS SCI, V30, P619; HOFFMAN B F, 1990, P814; LEAHEY EB, 1978, JAMA-J AM MED ASSOC, V240, P533, DOI 10.1001/jama.240.6.533; LELY AH, 1970, BRIT MED J, V3, P737, DOI 10.1136/bmj.3.5725.737; MADREPERLA SA, 1994, ARCH OPHTHALMOL-CHIC, V112, P807, DOI 10.1001/archopht.1994.01090180105044; MASSARO FJ, 1983, DRUG INTEL CLIN PHAR, V17, P368, DOI 10.1177/106002808301700509; MCGRAIL KM, 1986, J NEUROSCI, V6, P1272; MCGRAIL KM, 1990, EUR J NEUROSCI, V2, P170, DOI 10.1111/j.1460-9568.1990.tb00409.x; Moore C E, 1973, Aust J Ophthalmol, V1, P76, DOI 10.1111/j.1442-9071.1973.tb01413.x; OAKLEY B, 1992, EXP EYE RES, V55, P539, DOI 10.1016/S0014-4835(05)80166-6; REICHENBACH A, 1992, CAN J PHYSIOL PHARM, V70, pS239, DOI 10.1139/y92-267; ROBERTSON DM, 1966, ARCH OPHTHALMOL-CHIC, V76, P640, DOI 10.1001/archopht.1966.03850010642004; ROBERTSON DM, 1966, ARCH OPHTHALMOL-CHIC, V76, P852; SMITH TW, 1972, CIRCULATION, V46, P188; SMITH TW, 1970, J CLIN INVEST, V49, P2377, DOI 10.1172/JCI106457; Sprague HB, 1925, J AMER MED ASSOC, V85, P716, DOI 10.1001/jama.1925.02670100004002; STAHL WL, 1984, J HISTOCHEM CYTOCHEM, V32, P248, DOI 10.1177/32.2.6319483; WAGENER HP, 1946, ARCH OPHTHALMOL-CHIC, V36, P478, DOI 10.1001/archopht.1946.00890210486003; WELEBER RG, 1981, ARCH OPHTHALMOL-CHIC, V99, P1568, DOI 10.1001/archopht.1981.03930020442007; WHITE PD, 1965, NEW ENGL J MED, V272, P904, DOI 10.1056/NEJM196504292721709; Withering W, 1785, ACCOUNT FOXGLOVE SOM	30	21	21	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1995	123	9					676	680		10.7326/0003-4819-123-9-199511010-00006	http://dx.doi.org/10.7326/0003-4819-123-9-199511010-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA696	7574223				2022-12-24	WOS:A1995TA69600006
J	SAKSELA, K; STEVENS, CE; RUBINSTEIN, P; TAYLOR, PE; BALTIMORE, D				SAKSELA, K; STEVENS, CE; RUBINSTEIN, P; TAYLOR, PE; BALTIMORE, D			HIV-1 MESSENGER-RNA IN PERIPHERAL-BLOOD MONONUCLEAR-CELLS AS AN EARLY MARKER OF RISK FOR PROGRESSION TO AIDS	ANNALS OF INTERNAL MEDICINE			English	Article						HUMAN IMMUNODEFICIENCY VIRUS; ACQUIRED IMMUNODEFICIENCY SYNDROME; RNA, MESSENGER; LEUKOCYTES, MONONUCLEAR; BIOLOGICAL MARKER	HUMAN-IMMUNODEFICIENCY-VIRUS; CD4 LYMPHOCYTE COUNTS; ANTIGEN CAPTURE ASSAY; NEW-YORK-CITY; HOMOSEXUAL MEN; TYPE-1 INFECTION; VIRAL BURDEN; SERUM BETA-2-MICROGLOBULIN; DISEASE PROGRESSION; PROGNOSTIC VALUE	Objective: To establish human immunodeficiency virus type 1 (HIV-1) messenger RNA (mRNA) expression in peripheral blood mononuclear cells as a marker of risk for progression to the acquired immunodeficiency syndrome (AIDS) in a large cohort of HIV-infected persons followed for a prolonged period. Design: Retrospective testing of cryopreserved, coded specimens. Setting: Research laboratories at the New York Blood Center and the Rockefeller University. Patients: 150 homosexual men infected with HIV-I who did not have an AIDS diagnosis at the time of testing. Measurements: Multiply spliced and unspliced HIV-I mRNAs in total peripheral blood mononuclear cell RNA were quantitated using reverse transcriptase-initiated polymerase chain reaction (PCR) and compared with other laboratory data and clinical outcome during the subsequent 8 years. Results: Although HIV-1 mRNA expression generally correlated with immunologic status, it was associated with future disease progression independently of CD4(+) cell counts or their rate of decrease at the time of sampling. The association of HIV-1 mRNA with disease progression in persons with CD4(+) cell counts higher than the median (>624 cells/mm(3)) was particularly noteworthy; further variation in the CD4(+) cell counts within this group was not prognostically significant. Conclusions: The expression of HIV-1 mRNA in peripheral blood mononuclear cells is a strong independent marker for future HIV disease progression, even in persons with normal T-cell subsets.	NEW YORK BLOOD CTR, NEW YORK, NY 10021 USA; MIT, CAMBRIDGE, MA 02139 USA	New York Blood Center; Massachusetts Institute of Technology (MIT)	SAKSELA, K (corresponding author), ROCKEFELLER UNIV, BOX 285, 1230 YORK AVE, NEW YORK, NY 10021 USA.				PHS HHS [A122346] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALLAIN JP, 1987, NEW ENGL J MED, V317, P1114, DOI 10.1056/NEJM198710293171804; ASCHER DP, 1992, J ACQ IMMUN DEF SYND, V5, P1080; ASJO B, 1986, LANCET, V2, P660; BAGNARELLI P, 1994, J VIROL, V68, P2495, DOI 10.1128/JVI.68.4.2495-2502.1994; BAGNARELLI P, 1992, J VIROL, V66, P7328, DOI 10.1128/JVI.66.12.7328-7335.1992; BRIGGS NC, 1993, AIDS RES HUM RETROV, V9, P811, DOI 10.1089/aid.1993.9.811; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; CONNOR RI, 1994, J VIROL, V68, P4400, DOI 10.1128/JVI.68.7.4400-4408.1994; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; Cox D. R., 1984, ANAL SURVIVAL DATA; DAILEY PJ, 1994, 34TH INT C ANT AG CH; DETELS R, 1988, J ACQ IMMUN DEF SYND, V1, P390; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; FERRE F, 1992, AIDS RES HUM RETROV, V8, P269, DOI 10.1089/aid.1992.8.269; FURTADO MR, 1995, J VIROL, V69, P2092, DOI 10.1128/JVI.69.4.2092-2100.1995; GODFRIED MH, 1994, J INFECT DIS, V169, P739, DOI 10.1093/infdis/169.4.739; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; GUPTA P, 1993, VIROLOGY, V196, P586, DOI 10.1006/viro.1993.1514; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HOFMANN B, 1990, AIDS, V4, P207, DOI 10.1097/00002030-199003000-00005; HOGERVORST E, 1995, J INFECT DIS, V171, P811, DOI 10.1093/infdis/171.4.811; HOLODNIY M, 1991, J INFECT DIS, V163, P862, DOI 10.1093/infdis/163.4.862; HOOVER DR, 1992, J ACQ IMMUN DEF SYND, V5, P794; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; KOBLIN BA, 1992, AM J EPIDEMIOL, V136, P646, DOI 10.1093/oxfordjournals.aje.a116544; KOOT M, 1993, ANN INTERN MED, V118, P681, DOI 10.7326/0003-4819-118-9-199305010-00004; KRAMER A, 1990, NEW ENGL J MED, V322, P1886; LEARMONT J, 1992, LANCET, V340, P863, DOI 10.1016/0140-6736(92)93281-Q; LEE TH, 1994, J ACQ IMMUN DEF SYND, V7, P381; LEFRERE JJ, 1992, BRIT J HAEMATOL, V82, P467, DOI 10.1111/j.1365-2141.1992.tb06446.x; LEVY JA, 1993, MICROBIOL REV, V57, P183, DOI 10.1128/MMBR.57.1.183-289.1993; LIFSON AR, 1992, LANCET, V339, P1436, DOI 10.1016/0140-6736(92)92030-J; LU W, 1993, J INFECT DIS, V168, P1165, DOI 10.1093/infdis/168.5.1165; MACDONELL KB, 1990, AM J MED, V89, P706, DOI 10.1016/0002-9343(90)90210-5; MATHEZ D, 1990, P NATL ACAD SCI USA, V87, P7438, DOI 10.1073/pnas.87.19.7438; MCNEARNEY T, 1992, P NATL ACAD SCI USA, V89, P10247, DOI 10.1073/pnas.89.21.10247; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; MELMED RN, 1989, J ACQ IMMUN DEF SYND, V2, P70; MICHAEL NL, 1992, J VIROL, V66, P310, DOI 10.1128/JVI.66.1.310-316.1992; MICHAEL NL, 1995, J VIROL, V69, P1868, DOI 10.1128/JVI.69.3.1868-1877.1995; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; MULDER JW, 1992, J INFECT DIS, V165, P413, DOI 10.1093/infdis/165.3.413; MUNOZ A, 1988, J ACQ IMMUN DEF SYND, V1, P396; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PHILLIPS AN, 1991, LANCET, V337, P389; PHILLIPS AN, 1993, AIDS, V7, P975, DOI 10.1097/00002030-199307000-00011; PHILLIPS AN, 1991, AIDS, V5, P1217, DOI 10.1097/00002030-199110000-00010; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; POLK BF, 1987, NEW ENGL J MED, V316, P61, DOI 10.1056/NEJM198701083160201; SABIN CA, 1994, BRIT J HAEMATOL, V86, P366, DOI 10.1111/j.1365-2141.1994.tb04741.x; SAKSELA K, 1994, P NATL ACAD SCI USA, V91, P1104, DOI 10.1073/pnas.91.3.1104; SAKSELA K, 1993, J VIROL, V67, P7423, DOI 10.1128/JVI.67.12.7423-7427.1993; SCHNITTMAN SM, 1990, ANN INTERN MED, V113, P438, DOI 10.7326/0003-4819-113-6-438; SCHNITTMAN SM, 1991, AIDS RES HUM RETROV, V7, P361, DOI 10.1089/aid.1991.7.361; SELWYN PA, 1992, NEW ENGL J MED, V327, P1697, DOI 10.1056/NEJM199212103272401; SEMPLE M, 1991, J MED VIROL, V35, P38, DOI 10.1002/jmv.1890350109; STEIN DS, 1992, J INFECT DIS, V165, P352, DOI 10.1093/infdis/165.2.352; STEVENS CE, 1986, JAMA-J AM MED ASSOC, V255, P2167, DOI 10.1001/jama.255.16.2167; SZMUNESS W, 1980, NEW ENGL J MED, V303, P833, DOI 10.1056/NEJM198010093031501; TERSMETTE M, 1989, LANCET, V1, P983; VASUDEVACHARI MB, 1993, J CLIN IMMUNOL, V13, P185, DOI 10.1007/BF00919971; VENET A, 1991, AIDS, V5, P283, DOI 10.1097/00002030-199103000-00006; WOOD R, 1993, J ACQ IMMUN DEF SYND, V6, P237; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453; 1989, MMWR MORB MORTAL S7, V38, P1; 1987, MMWR MORB MORTAL S1, V36, pS1	70	73	73	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1995	123	9					641	+		10.7326/0003-4819-123-9-199511010-00001	http://dx.doi.org/10.7326/0003-4819-123-9-199511010-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA696	7574218				2022-12-24	WOS:A1995TA69600001
J	SISCOVICK, DS; RAGHUNATHAN, TE; KING, I; WEINMANN, S; WICKLUND, KG; ALBRIGHT, J; BOVBJERG, V; ARBOGAST, P; SMITH, H; KUSHI, LH; COBB, LA; COPASS, MK; PSATY, BM; LEMAITRE, R; RETZLAFF, B; CHILDS, M; KNOPP, RH				SISCOVICK, DS; RAGHUNATHAN, TE; KING, I; WEINMANN, S; WICKLUND, KG; ALBRIGHT, J; BOVBJERG, V; ARBOGAST, P; SMITH, H; KUSHI, LH; COBB, LA; COPASS, MK; PSATY, BM; LEMAITRE, R; RETZLAFF, B; CHILDS, M; KNOPP, RH			DIETARY-INTAKE AND CELL-MEMBRANE LEVELS OF LONG-CHAIN N-3 POLYUNSATURATED FATTY-ACIDS AND THE RISK OF PRIMARY CARDIAC-ARREST	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VENTRICULAR-FIBRILLATION THRESHOLD; CORONARY HEART-DISEASE; FISH CONSUMPTION; MARMOSET MONKEY; MODULATION; MORTALITY	Objective.-To assess whether the dietary intake of long-chain n-3 polyunsaturated fatty acids from seafood, assessed both directly and indirectly through a biomarker, is associated with a reduced risk of primary cardiac arrest. Design.-Population-based case-control study. Setting.-Seattle and suburban King County, Washington, Participants.-A total of 334 case patients with primary cardiac arrest, aged 25 to 74 years, attended by paramedics during 1988 to 1994 and 493 population-based control cases and controls, matched for age and sex, randomly identified from the community. All cases and controls were free of prior clinical heart disease, major comorbidity, and use of fish oil supplements. Measures of Exposure.-Spouses of case patients and control subjects were interviewed to quantify dietary n-3 polyunsaturated fatty acid intake from seafood during the prior month and other clinical characteristics. Blood specimens from 82 cases (collected in the field) and 108 controls were analyzed to determine red blood cell membrane fatty acid composition, a biomarker of dietary n-3 polyunsaturated fatty acid intake. Results.-Compared with no dietary intake of eicosapentaenoic acid (C-20:5n-3) and docosahexaenoic acid (C-22:6n-3), an intake of 5.5 g of n-3 fatty acids per month (the mean of the third quartile and the equivalent of one fatty fish meal per week) was associated with a 50% reduction in the risk of primary cardiac arrest (odds ratio [OR], 0.5; 95% confidence interval [CI], 0.4 to 0.8), after adjustment for potential confounding factors. Compared with a red blood cell membrane n-3 polyunsaturated fatty acid level of 3.3% of total fatty acids (the mean of the lowest quartile), a red blood cell n-3 polyunsaturated fatty acid level of 5.0% of total fatty acids (the mean of the third quartile) was associated with a 70% reduction in the risk of primary cardiac arrest (OR, 0.3; 95% CI, 0.2 to 0.6). Conclusion.-Dietary intake of n-3 polyunsaturated fatty acids from seafood is associated with a reduced risk of primary cardiac arrest.	WASHINGTON UNIV,DEPT EPIDEMIOL,SEATTLE,WA 98101; WASHINGTON UNIV,DEPT BIOSTAT,SEATTLE,WA 98101; FRED HUTCHINSON CANC RES CTR,DIV PUBL HLTH SCI,SEATTLE,WA 98104; UNIV MICHIGAN,INST SOCIAL RES,ANN ARBOR,MI; UNIV MINNESOTA,SCH PUBL HLTH,DIV EPIDEMIOL,MINNEAPOLIS,MN 55455	Fred Hutchinson Cancer Center; University of Michigan System; University of Michigan; University of Minnesota System; University of Minnesota Twin Cities	SISCOVICK, DS (corresponding author), WASHINGTON UNIV,DEPT MED,CARDIOVASC HLTH RES UNIT,METROPOLITAN PK 2 BLDG,SUITE 1360,SEATTLE,WA 98101, USA.			Kushi, Lawrence/0000-0001-9136-1175	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041993] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK035816] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41993] Funding Source: Medline; NIDDK NIH HHS [DK-35816] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASCHERIO A, 1995, NEW ENGL J MED, V332, P977, DOI 10.1056/NEJM199504133321501; BANG HO, 1980, AM J CLIN NUTR, V33, P2657, DOI 10.1093/ajcn/33.12.2657; BILLMAN GE, 1994, P NATL ACAD SCI USA, V91, P4427, DOI 10.1073/pnas.91.10.4427; BURR ML, 1989, LANCET, V9, P757; CHARNOCK JS, 1992, COMP BIOCHEM PHYS A, V101, P387, DOI 10.1016/0300-9629(92)90551-Z; CHARNOCK JS, 1994, NUTRITION, V10, P161; CUMMINGS KM, 1979, PUBLIC OPIN QUART, V43, P233, DOI 10.1086/268514; CURB JD, 1985, NEW ENGL J MED, V313, P821; DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; DOWDY A, 1993, J AM DIET ASSOC, V93, pA65; FARQUHAR JW, 1963, J CLIN INVEST, V42, P675, DOI 10.1172/JCI104759; GLOMSET JA, 1985, NEW ENGL J MED, V312, P1253, DOI 10.1056/NEJM198505093121909; HALLAQ H, 1992, P NATL ACAD SCI USA, V89, P1760, DOI 10.1073/pnas.89.5.1760; KANG JX, 1994, P NATL ACAD SCI USA, V91, P9886, DOI 10.1073/pnas.91.21.9886; KROMHOUT D, 1985, NEW ENGL J MED, V312, P1205, DOI 10.1056/NEJM198505093121901; LEAF A, 1988, NEW ENGL J MED, V318, P549, DOI 10.1056/NEJM198803033180905; LEE TH, 1985, NEW ENGL J MED, V312, P1217, DOI 10.1056/NEJM198505093121903; LEPAGE G, 1986, J LIPID RES, V27, P114; MCLENNAN PL, 1992, AM HEART J, V123, P1555, DOI 10.1016/0002-8703(92)90809-A; MCLENNAN PL, 1993, AM J CLIN NUTR, V58, P666, DOI 10.1093/ajcn/58.5.666; MCLENNAN PL, 1989, AUST NZ J MED, V19, P1, DOI 10.1111/j.1445-5994.1989.tb01662.x; Nomenclature and criteria for diagnosis of ischemic heart disease, 1979, CIRCULATION, V59, P607; NORDOY A, 1971, ACTA MED SCAND, V190, P27; NORDOY A, 1987, BIBL NUTR DIET, V40, P33; PEPE S, 1994, P NATL ACAD SCI USA, V91, P8832, DOI 10.1073/pnas.91.19.8832; ROSE HG, 1965, J LIPID RES, V6, P428; SHEKELLE RB, 1985, NEW ENGL J MED, V313, P820; SISCOVICK DS, 1993, ANN EMERG MED, V22, P92, DOI 10.1016/S0196-0644(05)80258-6; VOLLSET SE, 1985, NEW ENGL J MED, V313, P820; 1991, USDA NUTRITION MONIT, V815	30	728	777	0	29	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 1	1995	274	17					1363	1367		10.1001/jama.274.17.1363	http://dx.doi.org/10.1001/jama.274.17.1363			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB278	7563561				2022-12-24	WOS:A1995TB27800027
J	LABARRERE, CA; PITTS, D; NELSON, DR; FAULK, WP				LABARRERE, CA; PITTS, D; NELSON, DR; FAULK, WP			VASCULAR TISSUE-PLASMINOGEN ACTIVATOR AND THE DEVELOPMENT OF CORONARY-ARTERY DISEASE IN HEART-TRANSPLANT RECIPIENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN CARDIAC ALLOGRAFTS; ENDOTHELIAL-CELLS; PROCOAGULANT ACTIVITY; MESSENGER-RNA; VESSEL WALL; ATHEROSCLEROSIS; IMMUNOPATHOLOGY; INTERLEUKIN-1; LOCALIZATION; EXPRESSION	Background. An aggressive and potentially fatal form of coronary artery disease may develop after cardiac transplantation. We studied the role of vascular tissue plasminogen activator (t-PA), the primary mediator of fibrinolysis, in the development of this problem. Methods. We studied 78 consecutive recipients of cardiac allografts over a five-year period, and we collected follow-up data over a mean (+/-SE) of 32.5+/-2.0 months. The patients were studied with ventricular function tests, serial endomyocardial biopsies (16.6+/-0.5 per patient), and annual coronary angiography. Measurements of t-PA and its inhibitor were performed immunocytochemically on unfixed cryostat sections of endomyocardial-biopsy specimens with the use of monoclonal antibodies to t-PA and its inhibitor. Results. In biopsy specimens obtained during the first three months of follow-up, 38 allografts had a normal distribution of t-PA in arteriolar smooth-muscle cells, whereas in 40 allografts there was depletion of t-PA that persisted in subsequent follow-up. Coronary artery disease developed during follow-up in 31 of 40 allografts (78 percent) with depletion of t-PA, but the disease developed in only 9 of the 38 allografts (24 percent) with normal t-PA levels (P<0.001). Allografts with depletion of tPA also had the t-PA inhibitor and were at greater risk for earlier and more severe disease than were allografts with normal arteriolar t-PA levels. Twelve patients whose allografts were depleted of t-PA either received a second transplant or died, whereas only one of the patients whose allografts had persistently normal t-PA levels died (P<0.001). Conclusions. These findings reveal an association between the depletion of t-PA from arteriolar smooth-muscle cells and the subsequent development of coronary artery disease and decreased graft survival. Although we cannot be certain about a cause-and-effect relation, our data suggest a possible role for deficient fibrinolysis in the development of coronary artery disease in transplanted human hearts.	METHODIST HOSP INDIANA,CTR REPROD & TRANSPLANTAT IMMUNOL,INDIANAPOLIS,IN 46202; METHODIST HOSP INDIANA,DEPT TRANSPLANTAT,INDIANAPOLIS,IN 46202; METHODIST HOSP INDIANA,CTR HLTH SERV RES,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University System; Indiana University System				Nelson, David/0000-0002-3240-0725				BAJAJ S, 1993, CIRCULATION, V88, P263; BEVILACQUA MP, 1986, P NATL ACAD SCI USA, V83, P4533, DOI 10.1073/pnas.83.12.4533; BEVILACQUA MP, 1984, J EXP MED, V160, P618, DOI 10.1084/jem.160.2.618; Billingham M E, 1990, J Heart Transplant, V9, P587; BILLINGHAM ME, 1987, TRANSPLANT P, V19, P19; BRAUNWALD E, 1992, HEART DISEASE TXB CA, P1; DICHEK D, 1989, BLOOD, V74, P222; FAULK WP, 1993, HAEMOSTASIS, V23, P194; FAULK WP, 1993, J HEART LUNG TRANSPL, V12, P219; FAULK WP, 1995, TRANSPLANT P, V27, P1944; FAULK WP, 1993, J HEART LUNG TRANSPL, V12, pS125; FAULK WP, 1994, SEMIN HEMATOL, V31, P26; FAULK WP, 1992, ARCH PATHOL LAB MED, V116, P1337; FAULK WP, 1994, MAJOR PROBL PATHOL, V30, P49; GAO SZ, 1988, J AM COLL CARDIOL, V12, P334, DOI 10.1016/0735-1097(88)90402-0; HAMSTEN A, 1994, FIBRINOLYSIS, V8, P253, DOI 10.1016/0268-9499(94)90723-4; HASUI Y, 1988, THROMB RES, V51, P453, DOI 10.1016/0049-3848(88)90381-7; HUNT BJ, 1993, TRANSPLANTATION, V55, P309, DOI 10.1097/00007890-199302000-00016; IP JH, 1990, J AM COLL CARDIOL, V15, P1667, DOI 10.1016/0735-1097(90)92845-S; JAMIESON SW, 1992, CIRCULATION, V85, P1211, DOI 10.1161/01.CIR.85.3.1211; JANSSON JH, 1993, CIRCULATION, V88, P2030, DOI 10.1161/01.CIR.88.5.2030; JOHNSON DE, 1989, J HEART TRANSPLANT, V8, P349; KERMAN RH, 1994, TRANSPLANTATION, V57, P884, DOI 10.1097/00007890-199403270-00020; KOOISTRA T, 1991, THROMB HAEMOSTASIS, V65, P565; LABARRERE CA, 1993, TRANSPLANTATION, V55, P1056, DOI 10.1097/00007890-199305000-00021; LABARRERE CA, 1994, CIRCULATION, V89, P1599, DOI 10.1161/01.CIR.89.4.1599; LABARRERE CA, 1995, TRANSPLANT P, V27, P1941; LABARRERE CA, 1995, TRANSPLANT P, V27, P1939; LARSSON A, 1985, J CLIN PATHOL, V38, P140, DOI 10.1136/jcp.38.2.140; Meade TW, 1992, THROMBOSIS CARDIOVAS, P79; RIDKER PM, 1993, LANCET, V341, P1165, DOI 10.1016/0140-6736(93)90998-V; RIDKER PM, 1994, LANCET, V343, P940, DOI 10.1016/S0140-6736(94)90064-7; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SALOMON RN, 1991, AM J PATHOL, V138, P791; SCHROEDER JS, 1991, NEW ENGL J MED, V324, P1805, DOI 10.1056/NEJM199106203242509; SMITH EB, 1994, THROMB RES, V73, P1, DOI 10.1016/0049-3848(94)90049-3; STOVIN PGI, 1993, J HEART LUNG TRANSPL, V12, P110; TAYLOR PM, 1992, TRANSPLANTATION, V54, P451, DOI 10.1097/00007890-199209000-00013; VANZONNEVELD AJ, 1986, BIOCHEM J, V235, P385, DOI 10.1042/bj2350385; WILCOX JN, 1989, P NATL ACAD SCI USA, V86, P2839, DOI 10.1073/pnas.86.8.2839; WOJTA J, 1993, THROMB HAEMOSTASIS, V70, P469	41	87	87	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 26	1995	333	17					1111	1116		10.1056/NEJM199510263331704	http://dx.doi.org/10.1056/NEJM199510263331704			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA372	7565949				2022-12-24	WOS:A1995TA37200004
J	BUCKBINDER, L; TALBOTT, R; VELASCOMIGUEL, S; TAKENAKA, I; FAHA, B; SEIZINGER, BR; KLEY, N				BUCKBINDER, L; TALBOTT, R; VELASCOMIGUEL, S; TAKENAKA, I; FAHA, B; SEIZINGER, BR; KLEY, N			INDUCTION OF THE GROWTH INHIBITOR IGF-BINDING PROTEIN-3 BY P53	NATURE			English	Article							KINASES; P21	TRANSCRIPTIONAL activation of target genes represents an important component of the tumour-suppressor function of p53 and provides a functional link between p53 and various growth-regulatory processes, including cell cycle progression (p21/WAF1)(1-3), DNA repair (GADD45)(4) and apoptosis (bax)(5). Here we use a differential cloning approach to identify the gene encoding insulin-like growth factor binding protein 3 (IGF-BP3) as a novel p53-regulated target gene. Induction of IGF-BP3 gene expression by wild-type but not mutant p53 is associated with enhanced secretion of an active form of IGF-BP3 capable of inhibiting mitogenic signalling by the insulin-like growth factor IGF-1, Our results indicate that ICF-BP3 may link p53 to potential novel autocrine/paracrine signalling pathways and to processes regulated by or dependent on IGF(s), such as cellular growth, transformation and survival.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC GENET,PRINCETON,NJ 08543	Bristol-Myers Squibb								BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; BUCKBINDER L, 1994, P NATL ACAD SCI USA, V91, P10640, DOI 10.1073/pnas.91.22.10640; COHEN P, 1994, J ENDOCRINOL, V142, P407, DOI 10.1677/joe.0.1420407; CUBBAGE ML, 1990, J BIOL CHEM, V265, P12642; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GRIGORIEV VG, 1994, J CELL PHYSIOL, V160, P203, DOI 10.1002/jcp.1041600123; HARPER JW, 1993, CELL, V75, P805; HARVEY M, 1993, ONCOGENE, V8, P2457; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; MIYASHITA T, 1994, ONCOGENE, V9, P1799; RESNICOFF M, 1995, CANCER RES, V55, P2463; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHIMASAKI S, 1992, PROG GROWTH FACTOR R, V3, P243; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SWISSHELM K, 1995, P NATL ACAD SCI USA, V92, P4472, DOI 10.1073/pnas.92.10.4472; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YU H, 1995, CANCER RES, V55, P1603; YU H, 1995, CANCER RES, V55, P2104	21	736	759	0	16	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 19	1995	377	6550					646	649		10.1038/377646a0	http://dx.doi.org/10.1038/377646a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA275	7566179				2022-12-24	WOS:A1995TA27500057
J	MULDER, D; NUNN, A; KAMALI, A; KENGEYAKAYONDO, J				MULDER, D; NUNN, A; KAMALI, A; KENGEYAKAYONDO, J			DECREASING HIV-1 SEROPREVALENCE IN YOUNG-ADULTS IN A RURAL UGANDAN COHORT	BRITISH MEDICAL JOURNAL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PREGNANT-WOMEN; INFECTION; ZAIRE	Objective-To assess the trend in HIV-1 seroprevalence in an adult population in Uganda. Design-An observational cohort study with four year follow up. Setting-A cluster of 15 villages in rural Uganda. Subjects-All residents of the 15 villages-about 10 000 people. Main outcome measure-Prevalence of HIV-1 infection as assessed by enzyme immunoassay. Results-During the five year period the overall standardised seroprevalence of HIV-1 showed little change; 8.2% in 1990, 7.6% in 1994. Among males aged 13-24 years the prevalence decreased from 3.4% to 1.0% (P for trend < 0.001); among females of the same age the corresponding values were 9.9% and 7.3%. The decrease was greatest in males aged 20-24 years and females aged 13-19 years. Conclusion-This is the first report of a decline in HIV-1 prevalence among young adults in a general population in sub-Saharan Africa with high overall HIV-1 prevalence. It is too early to conclude that the epidemic in this population is in decline, but the results of this study should be reason for some cautious optimism and encourage the vigorous pursuit of AIDS control measures.	MRC PROGRAMME AIDS UGANDA,ENTEBBE,UGANDA; UGANDA VIRUS RES INST,ENTEBBE,UGANDA	Uganda Virus Research Institute				Nunn, Andrew/0000-0002-9158-4595				ALLEN S, 1992, BRIT MED J, V304, P1605, DOI 10.1136/bmj.304.6842.1605; BATTER V, 1994, AIDS, V8, P811, DOI 10.1097/00002030-199406000-00014; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; HEYWARD WL, 1994, AIDS, V8, P1285, DOI 10.1097/00002030-199409000-00011; KARITA E, 1993, INT J STD AIDS, V4, P211, DOI 10.1177/095646249300400406; KENGEYAKAYONDO JF, 1995, ANN TROP PAEDIATR, V15, P115, DOI 10.1080/02724936.1995.11747758; LAGA M, 1994, LANCET, V344, P246, DOI 10.1016/S0140-6736(94)93005-8; MAGAZANI K, 1993, J ACQ IMMUN DEF SYND, V6, P419; MALAMBA SS, 1994, AIDS, V8, P253, DOI 10.1097/00002030-199402000-00014; MULDER DW, 1994, LANCET, V343, P1021, DOI 10.1016/S0140-6736(94)90133-3; MULDER DW, 1994, AIDS, V8, P87, DOI 10.1097/00002030-199401000-00013; NUNN AJ, 1994, AIDS, V8, P81, DOI 10.1097/00002030-199401000-00012; NUNN AJ, 1994, METHOD INFORM MED, V33, P170; NUNN AJ, 1993, AIDS, V7, P1057, DOI 10.1097/00002030-199308000-00005; NUNN AJ, 1995, AIDS, V9, P503, DOI 10.1097/00002030-199509050-00013; NZILAMBI N, 1988, NEW ENGL J MED, V318, P276, DOI 10.1056/NEJM198802043180503; SEELEY J, 1991, AIDS Care, V3, P207, DOI 10.1080/09540129108253064; SOKAL DC, 1993, AIDS, V7, P1481, DOI 10.1097/00002030-199311000-00012; WAGNER HU, 1994, INT J STD AIDS, V5, P332, DOI 10.1177/095646249400500509; WAGNER HU, 1993, AIDS, V7, P1461, DOI 10.1097/00002030-199311000-00009; WILLERFORD DM, 1993, J INFECT DIS, V167, P1414, DOI 10.1093/infdis/167.6.1414; 1994, WHOGPATCOSEF944; 1995, 1995 MIN HLTH SURV R	23	93	93	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 30	1995	311	7009					833	836		10.1136/bmj.311.7009.833	http://dx.doi.org/10.1136/bmj.311.7009.833			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY191	7580488	Green Published			2022-12-24	WOS:A1995RY19100018
J	DANIAL, NN; PERNIS, A; ROTHMAN, PB				DANIAL, NN; PERNIS, A; ROTHMAN, PB			JAK-STAT SIGNALING INDUCED BY THE V-ABL ONCOGENE	SCIENCE			English	Article							PROTEIN-TYROSINE KINASE; MURINE LEUKEMIA-VIRUS; ABELSON VIRUS; BONE-MARROW; CELL-LINE; MYELOID CELLS; TRANSFORMATION; GROWTH; DEPENDENCE; MECHANISM	The effect of the v-abl oncogene of the Abelson murine leukemia virus (A-MuLV) on the Jak-STAT pathway of cytokine signal transduction was investigated. In murine pre-B lymphocytes transformed with A-MuLV, the Janus kinases (Jaks) Jak1 and Jak3 exhibited constitutive tyrosine kinase activity, acid the STAT proteins (signal transducers and activators of transcription) normally activated by interleukin-4, and interleukin-7 were tyrosine-phosphorylated in the absence of these cytokines. Coimmunoprecipitation experiments revealed that in these cells v-Abl was physically associated with Jak1 and Jak3. Inactivation of v-Abl tyrosine kinase in a pre-B cell line transformed with a temperature-sensitive mutant of v-abl resulted in abrogation of constitutive Jak-STAT signaling. A direct link may exist between transformation by v-abl and cytokine signal transduction.	COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,INTEGRATED PROGRAM MOLEC CELLULAR & BIOPHYS STUD,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT MICROBIOL,NEW YORK,NY 10032	Columbia University; Columbia University					NIAID NIH HHS [AI 33540-02] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033540] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALT F, 1981, CELL, V27, P381, DOI 10.1016/0092-8674(81)90421-9; CHEN YY, 1994, GENE DEV, V8, P688, DOI 10.1101/gad.8.6.688; CHEN YY, 1992, P NATL ACAD SCI USA, V89, P6683, DOI 10.1073/pnas.89.15.6683; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; COOK WD, 1987, MOL CELL BIOL, V7, P2631, DOI 10.1128/MCB.7.7.2631; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; DANIAL NN, UNPUB; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; ENGELMAN A, 1990, J VIROL, V64, P4242, DOI 10.1128/JVI.64.9.4242-4251.1990; ENGELMAN A, 1990, MOL CELL BIOL, V10, P4365, DOI 10.1128/MCB.10.8.4365; Hariharan I K, 1988, Oncogene Res, V3, P387; HOU JZ, 1995, IMMUNITY, V2, P321, DOI 10.1016/1074-7613(95)90140-X; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HUNT P, 1987, CELL, V48, P997, DOI 10.1016/0092-8674(87)90708-2; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; KINCADE PW, 1989, ANNU REV IMMUNOL, V7, P111, DOI 10.1146/annurev.iy.07.040189.000551; KIPREOS ET, 1988, ONCOGENE RES, V2, P277; KONOPKA JB, 1985, BIOCHIM BIOPHYS ACTA, V823, P1, DOI 10.1016/0304-419X(85)90012-5; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; PERNIS A, 1995, J BIOL CHEM, V270, P14517, DOI 10.1074/jbc.270.24.14517; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; PRYWES R, 1985, J VIROL, V54, P114, DOI 10.1128/JVI.54.1.114-122.1985; QUELLE FW, 1995, MOL CELL BIOL, V15, P336; ROSENBERG N, 1994, SEMIN CANCER BIOL, V5, P95; ROTHMAN P, 1994, IMMUNITY, V1, P457, DOI 10.1016/1074-7613(94)90088-4; SCHINDLER C, 1994, EMBO J, V13, P1350, DOI 10.1002/j.1460-2075.1994.tb06388.x; SHIELDS A, 1979, CELL, V18, P955, DOI 10.1016/0092-8674(79)90208-3; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; WHITLOCK CA, 1983, CELL, V32, P903, DOI 10.1016/0092-8674(83)90075-2; WHITLOCK CA, 1987, CELL, V48, P1009, DOI 10.1016/0092-8674(87)90709-4; YOUNG JC, 1991, MOL CELL BIOL, V11, P854, DOI 10.1128/MCB.11.2.854	36	314	319	1	7	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 29	1995	269	5232					1875	1877		10.1126/science.7569929	http://dx.doi.org/10.1126/science.7569929			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX194	7569929				2022-12-24	WOS:A1995RX19400039
J	DESCOTEAUX, A; LUO, Y; TURCO, SJ; BEVERLEY, SM				DESCOTEAUX, A; LUO, Y; TURCO, SJ; BEVERLEY, SM			A SPECIALIZED PATHWAY AFFECTING VIRULENCE GLYCOCONJUGATES OF LEISHMANIA	SCIENCE			English	Article							SECRETED ACID-PHOSPHATASE; MONOCLONAL-ANTIBODIES; DONOVANI PROMASTIGOTES; LIPOPHOSPHOGLYCAN; BIOSYNTHESIS; PROTEINS; EXPRESSION; EPITOPES; MUTANT	For virulence and transmission, the protozoan Leishmania must assemble a complex glycolipid on the cell surface, the lipophosphoglycan (LPG). Functional complementation identified the gene LPG2, which encodes an integral Golgi membrane protein implicated in intracellular compartmentalization of LPG biosynthesis. Ipg2(-) mutants lack only characteristic disaccharide-phosphate repeats, normally present on both LPG and other surface or secreted molecules considered critical for infectivity. In contrast, a related yeast gene, VAN2/VRG4, is essential and required for general Golgi function. These results suggest that LPG2 participates in a specialized virulence pathway, which may offer an attractive target for chemotherapy.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; UNIV KENTUCKY,MED CTR,DEPT BIOCHEM,LEXINGTON,KY 40546	Harvard University; Harvard Medical School; University of Kentucky				Beverley, Stephen/0000-0001-5319-0811	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031078] Funding Source: NIH RePORTER; NIAID NIH HHS [AI31078] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BATES PA, 1989, EXP PARASITOL, V68, P335, DOI 10.1016/0014-4894(89)90115-X; BATES PA, 1990, MOL BIOCHEM PARASIT, V39, P247, DOI 10.1016/0166-6851(90)90063-R; BELLO AR, 1994, P NATL ACAD SCI USA, V91, P11442, DOI 10.1073/pnas.91.24.11442; CALLAHAN HL, 1991, J BIOL CHEM, V266, P18427; CAPPAI R, 1994, PARASITOLOGY, V108, P397, DOI 10.1017/S0031182000075946; CARVER MA, 1992, ARCH BIOCHEM BIOPHYS, V295, P309, DOI 10.1016/0003-9861(92)90523-Y; CARVER MA, 1991, J BIOL CHEM, V266, P10974; CRUZ A, 1991, P NATL ACAD SCI USA, V88, P7170, DOI 10.1073/pnas.88.16.7170; DESCOTEAUX A, 1993, METHODS MOL GENETICS, V1, P22; DESCOTEAUX A, UNPUB; ELHAY M, 1990, MOL BIOCHEM PARASIT, V40, P255, DOI 10.1016/0166-6851(90)90047-P; FLINN HM, 1994, MOL BIOCHEM PARASIT, V65, P259, DOI 10.1016/0166-6851(94)90077-9; GUEIROSFILHO FJ, UNPUB; HANDMAN E, 1986, J IMMUNOL, V137, P3608; HUANG CC, 1993, J BIOL CHEM, V268, P24060; ILG T, 1993, EUR J BIOCHEM, V217, P603, DOI 10.1111/j.1432-1033.1993.tb18283.x; ILG T, 1991, J CELL SCI, V99, P175; ILG T, 1994, PARASITOLOGY, V108, pS63, DOI 10.1017/S0031182000075739; JAFFE CL, 1990, J IMMUNOL, V144, P699; JARDIM A, 1991, J IMMUNOL, V147, P3538; JARDIM A, 1995, BIOCHEM J, V305, P305; KANIKENNULAT C, 1995, GENETICS, V140, P933; KATAKURA K, 1988, INFECT IMMUN, V56, P2856, DOI 10.1128/IAI.56.11.2856-2860.1988; KING DL, 1988, MOL BIOCHEM PARASIT, V28, P285, DOI 10.1016/0166-6851(88)90013-8; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOVELACE JK, 1987, MOL BIOCHEM PARASIT, V22, P19, DOI 10.1016/0166-6851(87)90065-X; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MCNEELY T B, 1990, Glycobiology, V1, P63, DOI 10.1093/glycob/1.1.63; MCNEELY TB, 1990, J IMMUNOL, V144, P2475; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; NG K, 1994, GLYCOBIOLOGY, V4, P845, DOI 10.1093/glycob/4.6.845; POSTER JB, UNPUB; REEVES P, 1994, BACTERIAL CELL WALL, P281; REINER SL, 1994, J EXP MED, V179, P447, DOI 10.1084/jem.179.2.447; RYAN KA, 1993, P NATL ACAD SCI USA, V90, P8609, DOI 10.1073/pnas.90.18.8609; SACKS DL, 1994, PARASITOLOGY, V108, pS55, DOI 10.1017/S0031182000075727; SMITH DF, 1995, GLYCOBIOLOGY, V5, P161, DOI 10.1093/glycob/5.2.161; TOLSON DL, 1989, MOL BIOCHEM PARASIT, V35, P109, DOI 10.1016/0166-6851(89)90113-8; TURCO SJ, 1984, J BIOL CHEM, V259, P3883; TURCO SJ, 1992, ANNU REV MICROBIOL, V46, P65, DOI 10.1146/annurev.mi.46.100192.000433; WHITFIELD C, 1993, ADV MICROB PHYSIOL, V35, P135, DOI 10.1016/S0065-2911(08)60099-5	43	138	143	0	2	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 29	1995	269	5232					1869	1872		10.1126/science.7569927	http://dx.doi.org/10.1126/science.7569927			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX194	7569927				2022-12-24	WOS:A1995RX19400037
J	DOGGETT, NA; GOODWIN, LA; TESMER, JG; MEINCKE, LJ; BRUCE, DC; CLARK, LM; ALTHERR, MR; FORD, AA; CHI, HC; MARRONE, BL; LONGMIRE, JL; LANE, SA; WHITMORE, SA; LOWENSTEIN, MG; SUTHERLAND, RD; MUNDT, MO; KNILL, EH; BRUNO, WJ; MACKEN, CA; TORNEY, DC; WU, JR; GRIFFITH, J; SUTHERLAND, GR; DEAVEN, LL; CALLEN, DF; MOYZIS, RK				DOGGETT, NA; GOODWIN, LA; TESMER, JG; MEINCKE, LJ; BRUCE, DC; CLARK, LM; ALTHERR, MR; FORD, AA; CHI, HC; MARRONE, BL; LONGMIRE, JL; LANE, SA; WHITMORE, SA; LOWENSTEIN, MG; SUTHERLAND, RD; MUNDT, MO; KNILL, EH; BRUNO, WJ; MACKEN, CA; TORNEY, DC; WU, JR; GRIFFITH, J; SUTHERLAND, GR; DEAVEN, LL; CALLEN, DF; MOYZIS, RK			AN INTEGRATED PHYSICAL MAP OF HUMAN-CHROMOSOME-16	NATURE			English	Article							DINUCLEOTIDE REPEAT POLYMORPHISMS; REPETITIVE DNA-SEQUENCES; HUMAN GENOME; CLONES; CLONING; FRAGMENTS; REGIONS; VECTOR	We describe an integrated physical, genetic and cytogenetic map of human chromosome 16 comprising both a low-resolution megaYAC map and a high-resolution cosmid contig/miniYAC map, which provides nearly complete coverage of the euchromatic arms of the chromosome. The physical map is anchored to a high-resolution cytogenetic breakpoint map and is integrated with genetic and gene transcript maps of the chromosome by sequence-tagged sites and clone hybridizations.	LOS ALAMOS NATL LAB,DIV LIFE SCI,LOS ALAMOS,NM 87545; LOS ALAMOS NATL LAB,THEORET BIOL & BIOPHYS GRP,LOS ALAMOS,NM 87545; LOS ALAMOS NATL LAB,APPLICAT PROGRAMMING GRP,LOS ALAMOS,NM 87545; LOS ALAMOS NATL LAB,COMP RES & APPLICAT GRP,LOS ALAMOS,NM 87545; ADELAIDE CHILDRENS HOSP INC,DEPT CYTOGENET & MOLEC GENET,ADELAIDE,SA 5006,AUSTRALIA; UNIV NEW MEXICO,DEPT CELL BIOL,ALBUQUERQUE,NM 87131	United States Department of Energy (DOE); Los Alamos National Laboratory; United States Department of Energy (DOE); Los Alamos National Laboratory; United States Department of Energy (DOE); Los Alamos National Laboratory; United States Department of Energy (DOE); Los Alamos National Laboratory; University of New Mexico	DOGGETT, NA (corresponding author), LOS ALAMOS NATL LAB,CTR HUMAN GENOME STUDIES,LOS ALAMOS,NM 87545, USA.		Callen, David F/G-1975-2012; Sutherland, Grant Robert/D-2606-2012					ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; ASLANIDIS C, 1991, P NATL ACAD SCI USA, V88, P6765, DOI 10.1073/pnas.88.15.6765; AUFFRAY C, 1995, CR ACAD SCI III-VIE, V318, P263; BELLANNECHANTEL.C, 1992, CELL, V70, P1059; BOTSTEIN D, 1990, DOEER0452P; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; CALLEN DF, 1992, GENOMICS, V13, P1178, DOI 10.1016/0888-7543(92)90035-Q; CALLEN DF, 1990, ANN GENET-PARIS, V33, P190; CALLEN DF, IN PRESS GENOMICS, V29; CHUMAKOV I, 1992, NATURE, V359, P380, DOI 10.1038/359380a0; CINKOSKY MJ, 1992, LOS ALAMOS SCI, V20, P267; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; DOGGETT NA, 1995, CYTOGENET CELL GENET, V68, P165; FOOTE S, 1992, SCIENCE, V258, P60, DOI 10.1126/science.1359640; Green E D, 1991, PCR Methods Appl, V1, P77; GREEN ED, 1991, GENOMICS, V11, P658, DOI 10.1016/0888-7543(91)90073-N; HARRIS PC, 1994, GENOMICS, V23, P321, DOI 10.1006/geno.1994.1507; JURKA J, 1992, J MOL EVOL, V35, P286, DOI 10.1007/BF00161166; KAHN AS, 1992, NAT GENET, V2, P180; KOZMAN HM, 1995, GENOMICS, V25, P44, DOI 10.1016/0888-7543(95)80108-X; LIU P, 1993, CANCER GENET CYTOGEN, V65, P92; LOVETT M, 1991, P NATL ACAD SCI USA, V88, P9628, DOI 10.1073/pnas.88.21.9628; MARRONE BL, 1994, GENOMICS, V21, P202, DOI 10.1006/geno.1994.1243; MCCORMICK MK, 1993, P NATL ACAD SCI USA, V90, P1063, DOI 10.1073/pnas.90.3.1063; MORTON NE, 1991, P NATL ACAD SCI USA, V88, P7474, DOI 10.1073/pnas.88.17.7474; MOYZIS RK, 1987, CHROMOSOMA, V95, P375, DOI 10.1007/BF00333988; OKUMURA K, 1994, CYTOGENET CELL GENET, V67, P61, DOI 10.1159/000133799; OLSON MV, 1993, COLD SPRING HARB SYM, V57, P349; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAPPAPORT B, 1994, AUTOMATED DNA SEQUEN, P289; RIETHMAN HC, 1989, P NATL ACAD SCI USA, V86, P6240, DOI 10.1073/pnas.86.16.6240; SELLERI L, 1992, GENOMICS, V14, P536, DOI 10.1016/S0888-7543(05)80263-0; SHEN Y, 1993, HUM MOL GENET, V2, P1745, DOI 10.1093/hmg/2.10.1745; SHEN Y, 1994, GENOMICS, V22, P68, DOI 10.1006/geno.1994.1346; SHEN Y, 1994, HUM MOL GENET, V3, P210, DOI 10.1093/hmg/3.1.210; SHEN Y, 1993, HUM MOL GENET, V2, P1505, DOI 10.1093/hmg/2.9.1505; SHEN Y, 1993, HUM MOL GENET, V2, P1504, DOI 10.1093/hmg/2.9.1504; SHEPHERD NS, 1994, P NATL ACAD SCI USA, V91, P2629, DOI 10.1073/pnas.91.7.2629; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; STALLINGS RL, 1990, P NATL ACAD SCI USA, V87, P6218, DOI 10.1073/pnas.87.16.6218; STALLINGS RL, 1993, CYTOGENET CELL GENET, V63, P97, DOI 10.1159/000133509; STALLINGS RL, 1992, GENOMICS, V13, P332, DOI 10.1016/0888-7543(92)90249-R; STALLINGS RL, 1992, GENOMICS, V13, P1031, DOI 10.1016/0888-7543(92)90016-L; WHITMORE SA, 1994, GENOMICS, V20, P169, DOI 10.1006/geno.1994.1150; 1995, HUM MOL GENET, V4, P575	46	99	100	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 28	1995	377			S			335	365						31	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA343	7566100				2022-12-24	WOS:A1995TA34300006
J	LONDON, NJ; FARMERY, SM; WILL, EJ; DAVISON, AM; LODGE, JPA				LONDON, NJ; FARMERY, SM; WILL, EJ; DAVISON, AM; LODGE, JPA			RISK OF NEOPLASIA IN RENAL-TRANSPLANT PATIENTS	LANCET			English	Article							MALIGNANT-TUMORS; RECIPIENTS; CANCER; CYCLOSPORINE; FAILURE	Renal allograft recipients are at an increased risk of neoplasia, although the extent of the problem has not been established in a typical European transplant population. To assess this risk we did a comprehensive, retrospective study of 918 patients transplanted at one centre over 24 years. The centre (Leeds) serves Yorkshire and Humberside, a region in northern England with a population of 3.6 million. The search, which made use of six sources of information, revealed 70 patients (7.6%) who had developed a neoplastic lesion, 10 patients having more than one type. More than half (42) were cutaneous lesions (mostly squamous cell carcinomas). The risk of developing neoplasia in the first 10 years after transplantation was calculated to be 14%. By 20 years this had risen to 40% compared with a 6% cumulative risk of neoplasia in an age-matched control population (p<0.005). The full extent of this problem in the European transplant population has been underestimated and, now that recipients are surviving longer, there is a clear need for both lifelong surveillance and closer investigation of these patients.	ST JAMES UNIV HOSP, ACAD SURG UNIT, LEEDS LS9 7TF, W YORKSHIRE, ENGLAND; ST JAMES UNIV HOSP, DEPT RENAL MED, LEEDS LS9 7TF, W YORKSHIRE, ENGLAND	Saint James's University Hospital; Saint James's University Hospital								ARMITAGE P, 1971, STATISTICAL METHODS, P414; BIRKELAND SA, 1983, CANCER, V51, P1571, DOI 10.1002/1097-0142(19830501)51:9<1571::AID-CNCR2820510903>3.0.CO;2-S; BLOHME I, 1984, TRANSPLANTATION, V37, P165, DOI 10.1097/00007890-198402000-00010; BROYER M, 1985, P EUR DIAL TRANS, V21, P2; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LIDDINGTON M, 1989, BRIT J SURG, V76, P1002, DOI 10.1002/bjs.1800761005; LONDON NJ, 1994, THESIS U CAMBRIDGE C; MATAS AJ, 1975, LANCET, V1, P883; PECQUEUX JC, 1990, UROL INT, V45, P290, DOI 10.1159/000281722; PENN I, 1991, TRANSPLANT P, V23, P1101; PENN I, 1987, TRANSPLANTATION, V43, P32, DOI 10.1097/00007890-198701000-00008; PENN I, 1994, TRANSPLANT P, V26, P1; PENN I, 1969, TRANSPLANT P, V1, P106; SHEIL AGR, 1977, TRANSPLANT P, V9, P1133; SHEIL AGR, 1993, TRANSPLANT P, V25, P1383; VILARDELL J, 1992, TRANSPLANT P, V24, P1948; WALZ MK, 1992, DTS MED WSCHR, V119, P927	17	297	307	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 12	1995	346	8972					403	406		10.1016/S0140-6736(95)92780-8	http://dx.doi.org/10.1016/S0140-6736(95)92780-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN656	7623570				2022-12-24	WOS:A1995RN65600009
J	SALINAS, F; KODADEK, T				SALINAS, F; KODADEK, T			PHAGE-T4 HOMOLOGOUS STRAND EXCHANGE - A DNA HELICASE, NOT THE STRAND TRANSFERASE, DRIVES POLAR BRANCH MIGRATION	CELL			English	Article							ESCHERICHIA-COLI RECA; PROTEIN-PROTEIN INTERACTIONS; BINDING-PROTEIN; RUVB PROTEINS; BACTERIOPHAGE-T4 UVSX; HOLLIDAY JUNCTIONS; SACCHAROMYCES-CEREVISIAE; GENETIC-RECOMBINATION; GENE-32 PROTEINS; PURIFICATION	Homologous strand exchange is a central step in general genetic recombination. A multiprotein complex composed of five purified bacteriophage T4 proteins (the products of the uvsX, uvsY, 32, 41, and 59 genes) that mediates strand exchange under physiologically relevant conditions has been reconstituted. One of these proteins, the product of the uvsY gene, is required for homologous pairing but strongly inhibits branch migration catalyzed by UvsX protein, the phage RecA analog. Branch migration is completely dependent on the gene 41 protein, a DNA helicase that also functions in phage replication. The helicase is delivered to the strand exchange complex by the gene 59 accessory protein in a strand-specific fashion through direct interactions between the gene 59 and gene 32 proteins. These data suggest that strand transferases such as UvsX protein are essential for homologous pairing in vivo, but that a DNA helicase drives polar branch migration.	UNIV TEXAS, INST MOLEC BIOL, AUSTIN, TX 78712 USA	University of Texas System; University of Texas Austin	SALINAS, F (corresponding author), UNIV TEXAS, DEPT CHEM & BIOCHEM, AUSTIN, TX 78712 USA.				NIGMS NIH HHS [GM-39393] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS BM, 1984, COLD SPRING HARB SYM, V49, P1; BARRY J, 1994, J BIOL CHEM, V269, P33063; BARRY J, 1994, J BIOL CHEM, V269, P33049; BEZZUBOVA O, 1993, NUCLEIC ACIDS RES, V21, P1577, DOI 10.1093/nar/21.7.1577; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; Challberg M D, 1980, Methods Enzymol, V65, P39; CONKLING MA, 1984, GENETICS, V107, P505; COX MM, 1983, J BIOL CHEM, V258, P2577; COX MM, 1987, ANNU REV BIOCHEM, V56, P229, DOI 10.1146/annurev.bi.56.070187.001305; EGGLESTON AK, 1991, BIOCHIMIE, V73, P163, DOI 10.1016/0300-9084(91)90199-B; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; FORMOSA T, 1984, COLD SPRING HARB SYM, V49, P363, DOI 10.1101/SQB.1984.049.01.043; FORMOSA T, 1986, J BIOL CHEM, V261, P6107; FORMOSA T, 1985, THESIS SAN FRANCISCO; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; HARRIS LD, 1989, J MOL BIOL, V206, P19, DOI 10.1016/0022-2836(89)90520-2; HASHIMOTO K, 1991, J BIOL CHEM, V266, P4883; HINTON DM, 1986, J BIOL CHEM, V261, P5663; IWASAKI H, 1992, GENE DEV, V6, P2214, DOI 10.1101/gad.6.11.2214; JIANG H, 1993, J BIOL CHEM, V268, P7904; KODADEK T, 1989, J BIOL CHEM, V264, P16451; KODADEK T, 1991, J BIOL CHEM, V266, P9712; KODADEK T, 1990, BIOCHEM BIOPH RES CO, V172, P804, DOI 10.1016/0006-291X(90)90746-A; KODADEK T, 1987, NATURE, V326, P312, DOI 10.1038/326312a0; KODADEK T, 1988, J BIOL CHEM, V263, P9427; KODADEK T, 1990, J BIOL CHEM, V265, P20966; KRASSA KB, 1991, P NATL ACAD SCI USA, V88, P4010, DOI 10.1073/pnas.88.9.4010; Kreuzer K. N., 1994, MOL BIOL BACTERIOP T, P28; LAVERY PE, 1992, J BIOL CHEM, V267, P9315; LIU CC, 1981, J BIOL CHEM, V256, P2813; LLOYD RG, 1993, NUCLEIC ACIDS RES, V21, P1719, DOI 10.1093/nar/21.8.1719; MADIRAJU MVVS, 1992, BIOCHEMISTRY-US, V31, P10529, DOI 10.1021/bi00158a016; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P21, DOI 10.1073/pnas.87.1.21; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MORITA T, 1993, P NATL ACAD SCI USA, V90, P6577, DOI 10.1073/pnas.90.14.6577; MORRICAL SW, 1994, J BIOL CHEM, V269, P33069; MORRICAL SW, 1990, J BIOL CHEM, V265, P15096; Mosig G, 1983, BACTERIOPHAGE, V4, P120; MULLER B, 1993, J BIOL CHEM, V268, P17185; MULLER B, 1994, EXPERIENTIA, V50, P216; MUNIYAPPA K, 1984, P NATL ACAD SCI-BIOL, V81, P2757, DOI 10.1073/pnas.81.9.2757; PARSONS CA, 1993, J MOL BIOL, V232, P397, DOI 10.1006/jmbi.1993.1399; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; SHAH DB, 1976, J VIROL, V17, P175, DOI 10.1128/JVI.17.1.175-182.1976; SHAMOO Y, 1986, P NATL ACAD SCI USA, V83, P8844, DOI 10.1073/pnas.83.23.8844; SHINAGAWA H, 1991, BIOCHIMIE, V73, P505, DOI 10.1016/0300-9084(91)90120-P; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SPACCIAPOLI P, 1994, J BIOL CHEM, V269, P447; SPICER EK, 1979, J BIOL CHEM, V254, P6433; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; TSANEVA IR, 1992, CELL, V69, P1171, DOI 10.1016/0092-8674(92)90638-S; TSANEVA IR, 1993, P NATL ACAD SCI USA, V90, P1315, DOI 10.1073/pnas.90.4.1315; UMEZU K, 1993, P NATL ACAD SCI USA, V90, P3875, DOI 10.1073/pnas.90.9.3875; UMEZU K, 1994, J BIOL CHEM, V269, P30005; VENKATESAN M, 1982, J BIOL CHEM, V257, P2426; WU R, 1975, J VIROL, V16, P5, DOI 10.1128/JVI.16.1.5-16.1975; YAMAMOTO KR, 1970, VIROLOGY, V40, P734, DOI 10.1016/0042-6822(70)90218-7; YONESAKI T, 1994, GENETICS, V138, P247; YONESAKI T, 1985, EUR J BIOCHEM, V148, P127, DOI 10.1111/j.1432-1033.1985.tb08816.x; YONESAKI T, 1989, J BIOL CHEM, V264, P7814; YONESAKI T, 1985, EMBO J, V4, P3321, DOI 10.1002/j.1460-2075.1985.tb04083.x; YONESAKI T, 1994, J BIOL CHEM, V269, P1284	63	57	57	2	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 14	1995	82	1					111	119		10.1016/0092-8674(95)90057-8	http://dx.doi.org/10.1016/0092-8674(95)90057-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RK424	7606776	Bronze			2022-12-24	WOS:A1995RK42400014
J	FRIEDRICH, M; TAUTZ, D				FRIEDRICH, M; TAUTZ, D			RIBOSOMAL DNA PHYLOGENY OF THE MAJOR EXTANT ARTHROPOD CLASSES AND THE EVOLUTION OF MYRIAPODS	NATURE			English	Article								THE evolutionary relationships among arthropods are of particular interest because the best-studied model system for ontogenetic pattern formation, the insect Drosophila, is a member of this phylum. Evolutionary inferences about the developmental mechanisms that have led to the various designs of the arthropod body plan depend on a knowledge of the phylogenetic framework of arthropod evolution, Based on morphological evidence(1-3), but also on palaeontological considerations(4), the sister group of the insects is believed to be found among the myriapods. Using nuclear ribosomal gene sequences for constructing a molecular phylogeny, we provide strong evidence that the crustaceans and not the myriapods should be considered to be the sister group of the insects. Moreover, the degree of sequence divergence suggests that the diversification of the myriapods occurred during the Cambrian. Our findings have general implications for the course of land colonization by the different arthropod groups, as well as for the interpretation of primitive and derived features of arthropod morphology.			FRIEDRICH, M (corresponding author), UNIV MUNICH,INST ZOOL,LUISENSTR 14,D-80333 MUNICH,GERMANY.		Tautz, Diethard/H-8436-2014; Tautz, Diethard/D-4304-2011	Tautz, Diethard/0000-0002-0460-5344; 				Anderson D. T., 1973, EMBRYOLOGY PHYLOGENY; [Anonymous], 1993, MEGA MOL EVOLUTIONAR; AVEROF M, 1995, PHILOS T R SOC B, V347, P293, DOI 10.1098/rstb.1995.0028; Boudreaux H.B., 1979, P551; Brusca C.R., 1990, INVERTEBRATES; Dohle W, 1980, ABHANDLUNGEN NATURWI, V23, P45; FELSENSTEIN J, 1985, EVOLUTION, V39, P791; FELSENSTEIN J, 1989, PHYLOGENETIC INFEREN; GAUT BS, 1995, MOL BIOL EVOL, V12, P152, DOI 10.1093/oxfordjournals.molbev.a040183; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HILLIS DM, 1994, NATURE, V369, P363, DOI 10.1038/369363a0; HUELSENBECK JP, 1993, SYST BIOL, V42, P247, DOI 10.2307/2992463; JERAM AJ, 1990, SCIENCE, V250, P685; Kristensen N.P., 1991, P125; Kukalova-Peck J., 1991, P141; Lauterbach K.-E., 1980, Abhandlungen des Naturwissenschaftlichen Vereins Wuerzburg, V23, P105; MANTON SM, 1964, PHILOS T ROY SOC B, V247, P1, DOI 10.1098/rstb.1964.0001; PANGANIBAN G, 1994, CURR BIOL, V4, P671, DOI 10.1016/S0960-9822(00)00151-2; Paulus H.F., 1979, P299; ROBISON R, 1987, FOSSIL INVERTEBRATES, P206; ROBISON RA, 1990, NATURE, V343, P163, DOI 10.1038/343163a0; STYS P, 1994, EUR J ENTOMOL, V91, P257; Swofford D, 1993, PHYLOGENETIC ANAL US; TAUTZ D, 1988, MOL BIOL EVOL, V5, P366; Weir BS, 1990, GENETIC DATA ANAL; WEYGOLDT P, 1986, Z ZOOL SYST EVOL, V24, P19; Weygoldt P., 1985, P20; WHITINGTON PM, 1993, DEVELOPMENT, V118, P449; WHITINGTON PM, 1991, ROUX ARCH DEV BIOL, V199, P349, DOI 10.1007/BF01705928; WU CI, 1985, P NATL ACAD SCI USA, V82, P1741, DOI 10.1073/pnas.82.6.1741	30	297	320	0	28	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 13	1995	376	6536					165	167		10.1038/376165a0	http://dx.doi.org/10.1038/376165a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ028	7603566				2022-12-24	WOS:A1995RJ02800058
J	OKADA, F; KINOSHITA, S				OKADA, F; KINOSHITA, S			SHINSHINSHO - CLINICAL ENTITY OR PSEUDOSCIENCE	LANCET			English	Editorial Material											OKADA, F (corresponding author), HOKKAIDO UNIV,CTR HLTH ADM,SAPPORO,HOKKAIDO 060,JAPAN.							Alexander F, 1950, PSYCHOSOMATIC MED IT; IKEMI Y, 1975, SEISHIN IGAKU JITEN, P331; IKEMI Y, 1962, THEORY PRACTICE PSYC; Okada F, 1994, Clin Auton Res, V4, P189, DOI 10.1007/BF01826185; SIMOSAKA K, 1979, SERIES MODERN PSYC A, V7, P3	5	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 8	1995	346	8967					66	67		10.1016/S0140-6736(95)92107-9	http://dx.doi.org/10.1016/S0140-6736(95)92107-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH220	7603212				2022-12-24	WOS:A1995RH22000005
J	RUIZAVILA, L; MCLAUGHLIN, SK; WILDMAN, D; MCKINNON, PJ; ROBICHON, A; SPICKOFSKY, N; MARGOLSKEE, RF				RUIZAVILA, L; MCLAUGHLIN, SK; WILDMAN, D; MCKINNON, PJ; ROBICHON, A; SPICKOFSKY, N; MARGOLSKEE, RF			COUPLING OF BITTER RECEPTOR TO PHOSPHODIESTERASE THROUGH TRANSDUCIN IN TASTE RECEPTOR-CELLS	NATURE			English	Article							AMINO-ACID SEQUENCE; GTP-BINDING PROTEIN; ROD OUTER SEGMENTS; ALPHA-SUBUNIT; CONFORMATIONAL-CHANGES; ADENOSINE RECEPTOR; CDNA SEQUENCE; RHODOPSIN; PROTEOLYSIS; ACTIVATION	THE rod and cone transducins rue specific G proteins originally thought to be present only in photoreceptor cells of the vertebrate retina(1-4). Transducins convert light stimulation of photoreceptor opsins into activation of cyclic GMP phosphodiesterase (reviewed in refs. 5-7). A transducin-like G protein, gustducin, has been identified and cloned from rat taste cells(8). We report here that rod transducin is also present in vertebrate taste cells, where it specifically activates a phosphodiesterase isolated from taste tissue. Furthermore, the bitter compound denatonium in the presence of taste-ceh membranes activates transducin but not G(i). A peptide that competitively inhibits rhodopsin activation of transducing also blocks taste-cell membrane activation of transducin, arguing for the involvement of a seven-transmembrane-helix G-protein-coupled receptor. These results suggest that rod transducin tranduces bitter taste by coupling taste receptor(s) to taste-cell phosphodiesterase. Phosphodiesterase-mediated degradation of cyclic nucleotides may lead to taste-cell depolarization through the recently identified cyclic-nucleotide-suppressible conductance(10).	HOFFMANN LA ROCHE INC, ROCHE RES CTR, ROCHE INST MOLEC BIOL, NUTLEY, NJ 07110 USA	Roche Holding				Margolskee, Robert/0000-0002-9572-2887; Ruiz-Avila, Luis/0000-0001-8777-1083; robichon, alain/0000-0003-1075-9646				ABE K, 1993, FEBS LETT, V316, P253, DOI 10.1016/0014-5793(93)81302-G; ABE K, 1993, J BIOL CHEM, V268, P12033; ALVAREZ R, 1992, ANAL BIOCHEM, V203, P76, DOI 10.1016/0003-2697(92)90045-9; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; FAWZI AB, 1990, BIOCHEMISTRY-US, V29, P3804, DOI 10.1021/bi00467a030; FUNG BKK, 1983, J BIOL CHEM, V258, P503; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; HALLIDAY KR, 1984, J BIOL CHEM, V259, P516; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; HWANG PM, 1990, P NATL ACAD SCI USA, V87, P7395, DOI 10.1073/pnas.87.19.7395; KOLESNIKOV SS, 1995, NATURE, V376, P85, DOI 10.1038/376085a0; KOPF GS, 1991, METHOD ENZYMOL, V195, P257; LOCHRIE MA, 1985, SCIENCE, V228, P96, DOI 10.1126/science.3856323; MATSUOKA I, 1993, BIOCHEM BIOPH RES CO, V194, P504, DOI 10.1006/bbrc.1993.1848; MCLAUGHLIN SK, 1992, NATURE, V357, P563, DOI 10.1038/357563a0; MEDYNSKI DC, 1985, P NATL ACAD SCI USA, V82, P4311, DOI 10.1073/pnas.82.13.4311; NAIM M, 1991, COMP BIOCHEM PHYS B, V100, P455, DOI 10.1016/0305-0491(91)90203-P; PRICE S, 1973, NATURE, V241, P54, DOI 10.1038/241054a0; RARICK HM, 1992, SCIENCE, V256, P1031, DOI 10.1126/science.1317058; SCHIFFMAN SS, 1985, PHARMACOL BIOCHEM BE, V22, P195, DOI 10.1016/0091-3057(85)90377-6; SCHIFFMAN SS, 1986, PHARMACOL BIOCHEM BE, V24, P429, DOI 10.1016/0091-3057(86)90536-8; SPICKOFSKY N, 1994, NAT STRUCT BIOL, V1, P771, DOI 10.1038/nsb1194-771; Spickofsky Nancy, 1992, Chemical Senses, V17, P701; STRIEM B J, 1991, Cellular Physiology and Biochemistry, V1, P46, DOI 10.1159/000154592; STRIEM BJ, 1989, BIOCHEM J, V260, P121, DOI 10.1042/bj2600121; STRYER L, 1991, J BIOL CHEM, V266, P10711; TANABE T, 1985, NATURE, V315, P242, DOI 10.1038/315242a0; Whiteside B, 1926, J COMP NEUROL, V40, P33, DOI 10.1002/cne.900400105; YATSUNAMI K, 1985, P NATL ACAD SCI USA, V82, P4316, DOI 10.1073/pnas.82.13.4316	30	176	189	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 6	1995	376	6535					80	85		10.1038/376080a0	http://dx.doi.org/10.1038/376080a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH111	7596440				2022-12-24	WOS:A1995RH11100066
J	GOWDA, R; RAZVI, FM; SUMMERFIELD, GP				GOWDA, R; RAZVI, FM; SUMMERFIELD, GP			RISK OF PNEUMOCOCCAL SEPTICEMIA IN PATIENTS WITH CHRONIC LYMPHOPROLIFERATIVE MALIGNANCIES	BRITISH MEDICAL JOURNAL			English	Article									MIDDLESBROUGH GEN HOSP,DEPT HAEMATOL,MIDDLESBROUGH TS5 5AZ,CLEVELAND,ENGLAND									CONE L, 1964, J CLIN INVEST, V43, P2241, DOI 10.1172/JCI105098; FRIEDEN TR, 1990, JAMA-J AM MED ASSOC, V264, P1438, DOI 10.1001/jama.264.11.1438; RICE P, 1994, BRIT MED J, V309, P1069, DOI 10.1136/bmj.309.6961.1069; IN PRESS GUIDELINES; 1988, NEW ENGL J MED, V319, P902	5	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 1	1995	311	6996					26	27		10.1136/bmj.311.6996.26	http://dx.doi.org/10.1136/bmj.311.6996.26			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG975	7613318	Green Published			2022-12-24	WOS:A1995RG97500021
J	DRUMMOND, JT; LI, GM; LONGLEY, MJ; MODRICH, P				DRUMMOND, JT; LI, GM; LONGLEY, MJ; MODRICH, P			ISOLATION OF AN HMSH2-P160 HETERODIMER THAT RESTORES DNA MISMATCH REPAIR TO TUMOR-CELLS	SCIENCE			English	Article							EXTRACTS; HOMOLOG; CANCER	A mismatch-binding heterodimer of hMSH2 and a 160-kilodalton polypeptide has been isolated from Hela cells by virtue of its ability to restore mismatch repair to nuclear extracts of hMSH2-deficient LoVo colorectal tumor cells. This heterodimer, designated hMutS alpha; also restores mismatch repair to extracts of alkylation-tolerant MT1 lymphoblastoid cells and HCT-15 colorectal tumor cells, which are selectively defective in the repair of base-base and single-nucleotide insertion-deletion mismatches. Because HCT-15 cells appear to be free of hMSH2 mutations, this selective repair defect is likely a result of a deficiency of the hMutS alpha 160-kilodalton subunit, and mutations in the corresponding gene may confer hypermutability and cancer predisposition.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Howard Hughes Medical Institute; Duke University			Li, Guo-Min/I-5016-2014	Li, Guo-Min/0000-0002-9842-4578; Modrich, Paul/0000-0001-8708-9885	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045190] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45190] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1995, GENE DEV, V9, P234, DOI 10.1101/gad.9.2.234; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CHI NW, 1994, J BIOL CHEM, V269, P29984; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; DACOSTA LT, 1995, NAT GENET, V9, P10, DOI 10.1038/ng0195-10; ESHLEMAN JR, 1994, ONCOGENE, V10, P33; FANG WH, 1993, J BIOL CHEM, V268, P11838; FISHEL R, 1994, CANCER RES, V54, P5539; FISHEL R, 1994, SCIENCE, V266, P1403, DOI 10.1126/science.7973733; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GOLDMACHER VS, 1986, J BIOL CHEM, V261, P2462; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; HUGHES MJ, 1992, J BIOL CHEM, V267, P23876; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Li G., UNPUB; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; LOEB LA, 1994, CANCER RES, V54, P5059; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PALOMBO F, 1994, NATURE, V367, P417, DOI 10.1038/367417a0; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SU SS, 1988, J BIOL CHEM, V263, P6829; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; UMAR A, 1994, J BIOL CHEM, V269, P14367; UMAR A, 1994, SCIENCE, V266, P814, DOI 10.1126/science.7973637	33	534	555	0	38	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 30	1995	268	5219					1909	1912		10.1126/science.7604264	http://dx.doi.org/10.1126/science.7604264			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF990	7604264				2022-12-24	WOS:A1995RF99000041
J	FARRINGTON, P; PUGH, S; COLVILLE, A; FLOWER, A; NASH, J; MORGANCAPNER, P; RUSH, M; MILLER, E				FARRINGTON, P; PUGH, S; COLVILLE, A; FLOWER, A; NASH, J; MORGANCAPNER, P; RUSH, M; MILLER, E			A NEW METHOD FOR ACTIVE SURVEILLANCE OF ADVERSE EVENTS FROM DIPHTHERIA-TETANUS-PERTUSSIS AND MEASLES MUMPS RUBELLA VACCINES	LANCET			English	Article							IMMUNIZATION; RISK; VACCINATION; CHILDREN; SEIZURES	We describe a new method for active post-marketing surveillance of vaccine safety based on patient records. We studied the association between diphtheria/tetanus/pertussis (DTP) vaccination and febrile convulsion, and between measles/mumps/rubella (MMR) vaccination and febrile convulsion and idiopathic thrombocytopenic purpura (ITP) in five district health authorities in England by linking vaccination records with computerised hospital admission records. We found an increased relative incidence for convulsions 0-3 days after DTP vaccination. The effect was limited to the third dose of vaccine for which the attributable risk (all ages) was 1 in 12 500 doses. Completion of vaccination by 4 months instead of 10 months after the change in the UK to an accelerated immunisation schedule may have resulted in a 4-fold decrease in febrile convulsions attributable to DTP vaccine. 67% of admissions for a convulsion 6-11 days after MMR vaccination were attributable to the measles component of the vaccine (risk 1 in 3000 doses). An excess of admissions for a convulsion 15-35 days after MMR vaccination was found only for vaccines containing the Urabe mumps strain (1 in 2600 Urabe doses). There was a causal association between MMR vaccination and ITP resulting in admission 15-35 days subsequently; there was no evidence of a mumps strain-specific effect. The estimated absolute risk of 1 in 24 000 doses was 5 times that calculated from cases passively reported by clinicians. This finding emphasises the need for active surveillance of adverse events. The record linkage method that we used is an effective way to identify vaccine-attributable adverse events.	PUBL HLTH LAB SERV,CTR COMMUNICABLE DIS SURVEILLANCE,STAT UNIT,LONDON NW9 5EQ,ENGLAND; PUBL HLTH LAB SERV,CTR COMMUNICABLE DIS SURVEILLANCE,DIV IMMUNISAT,LONDON NW9 5EQ,ENGLAND; UNIV NOTTINGHAM HOSP,QUEENS MED CTR,PUBL HLTH LAB,NOTTINGHAM NG7 2UH,ENGLAND; LEICESTER ROYAL INFIRM,PUBL HLTH LAB,LEICESTER,LEICS,ENGLAND; WILLIAM HARVEY HOSP,PUBL HLTH LAB,ASHFORD,KENT,ENGLAND; ROYAL PRESTON HOSP,PUBL HLTH LAB,PRESTON,LANCS,ENGLAND	Public Health England; Public Health England; University of Nottingham; University of Leicester; Royal Preston Hospital				Farrington, Conor Patrick/0000-0002-7148-2612				BEGG NT, 1989, PUBLIC HEALTH, V103, P81, DOI 10.1016/S0033-3506(89)80021-6; FARRINGTON CP, IN PRESS BIOMETRICS; FINE PEM, 1992, AM J EPIDEMIOL, V136, P121, DOI 10.1093/oxfordjournals.aje.a116479; GRIFFIN MR, 1990, JAMA-J AM MED ASSOC, V263, P1641, DOI 10.1001/jama.263.12.1641; GRIFFIN MR, 1991, PEDIATRICS, V88, P881; MILLER DL, 1981, BRIT MED J, V282, P1595, DOI 10.1136/bmj.282.6276.1595; MILLER E, 1993, LANCET, V341, P979, DOI 10.1016/0140-6736(93)91069-X; NEIMINEN U, 1993, ACTA PAEDIATR, V82, P267; POLLOCK TM, 1983, LANCET, V1, P753; SCHMITT HJ, 1993, EUR J PEDIATR, V152, P387, DOI 10.1007/BF01955892; WEIRSBITZKY S, 1993, LANCET, V341, P379	11	240	243	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 4	1995	345	8949					567	569		10.1016/S0140-6736(95)90471-9	http://dx.doi.org/10.1016/S0140-6736(95)90471-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK444	7619183	Bronze			2022-12-24	WOS:A1995QK44400016
J	LIU, SH; WONG, ML; CRAIK, CS; BRODSKY, FM				LIU, SH; WONG, ML; CRAIK, CS; BRODSKY, FM			REGULATION OF CLATHRIN ASSEMBLY AND TRIMERIZATION DEFINED USING RECOMBINANT TRISKELION HUBS	CELL			English	Article							HEAVY-CHAIN; LIGHT-CHAINS; MOLECULAR-CLONING; SECONDARY-STRUCTURE; COATED VESICLES; PROTEINS; SEQUENCE; GENE; BINDING; TRIMERS	Clathrin polymerization into a polyhedral vesicle coat drives receptor sorting at cellular membranes during endocytosis and organelle biogenesis. To study clathrin self-assembly, we expressed the C-terminal third of the clathrin heavy chain in bacteria. The recombinant fragment trimerized, bound clathrin light chains, and morphologically resembled the hub domain of the triskelion-shaped clathrin molecule. Self-assembly of recombinant hubs demonstrated a regulatory role for clathrin light chains and for the distal portions of triskelion legs in clathrin coat formation. Deletion mutagenesis of the hub localized a domain mediating light chain binding and clathrin self-assembly and mapped a transferable trimerization domain. These studies define molecular interactions controlling clathrin self-assembly and establish a recombinant system for future analysis.	UNIV CALIF SAN FRANCISCO,SCH PHARM,DEPT PHARM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH PHARM,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT MICROBIOL & IMMUNOL,GW HOOPER FDN,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,HOWARD HUGHES MED INST,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH PHARM,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Brodsky, Frances/0000-0002-1334-9258	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM026691, R01GM038093] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26691, GM38093] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACTON SL, 1990, J CELL BIOL, V111, P1419, DOI 10.1083/jcb.111.4.1419; ADAMS MD, 1993, NAT GENET, V4, P373, DOI 10.1038/ng0893-373; BAZINET C, 1993, GENETICS, V134, P1119; BLANK GS, 1986, EMBO J, V5, P2087, DOI 10.1002/j.1460-2075.1986.tb04470.x; BLANK GS, 1987, J CELL BIOL, V105, P2011, DOI 10.1083/jcb.105.5.2011; BRODSKY FM, 1988, SCIENCE, V242, P1396, DOI 10.1126/science.2904698; BRODSKY FM, 1983, J CELL BIOL, V96, P911, DOI 10.1083/jcb.96.3.911; BRODSKY FM, 1987, NATURE, V326, P203, DOI 10.1038/326203a0; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DODGE GR, 1991, GENOMICS, V11, P174, DOI 10.1016/0888-7543(91)90115-U; ENNIS PD, 1988, J IMMUNOL, V141, P642; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; JACKSON AP, 1987, NATURE, V326, P154, DOI 10.1038/326154a0; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KEEN JH, 1991, J BIOL CHEM, V266, P7950; KIRCHHAUSEN T, 1987, SCIENCE, V236, P320, DOI 10.1126/science.3563513; KIRCHHAUSEN T, 1986, J ULTRA MOL STRUCT R, V94, P199, DOI 10.1016/0889-1605(86)90067-4; KIRCHHAUSEN T, 1983, P NATL ACAD SCI-BIOL, V80, P2481, DOI 10.1073/pnas.80.9.2481; KIRCHHAUSEN T, 1993, J BIOL CHEM, V268, P10268; KIRCHHAUSEN T, 1984, J CELL BIOL, V99, P1725, DOI 10.1083/jcb.99.5.1725; KIRCHHAUSEN T, 1987, P NATL ACAD SCI USA, V84, P8805, DOI 10.1073/pnas.84.24.8805; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMMON SK, 1991, J CELL BIOL, V112, P65, DOI 10.1083/jcb.112.1.65; LISANTI MP, 1982, EUR J BIOCHEM, V125, P463, DOI 10.1111/j.1432-1033.1982.tb06706.x; MANFREDI JJ, 1987, J BIOL CHEM, V262, P12182; MOOLBROEK MJ, 1987, J BIOL CHEM, V262, P25; NATHANS J, 1983, CELL, V34, P807, DOI 10.1016/0092-8674(83)90537-8; NATHKE IS, 1992, CELL, V68, P899, DOI 10.1016/0092-8674(92)90033-9; OHALLORAN TJ, 1992, DNA CELL BIOL, V11, P321, DOI 10.1089/dna.1992.11.321; PEARSE BMF, 1987, ANNU REV BIOPHYS BIO, V16, P49, DOI 10.1146/annurev.bb.16.060187.000405; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PETERANDERL R, 1992, BIOCHEMISTRY-US, V31, P12272, DOI 10.1021/bi00163a042; PLEY U, 1993, CRIT REV BIOCHEM MOL, V28, P431, DOI 10.3109/10409239309078441; PONNAMBALAM S, 1994, GENOMICS, V24, P440, DOI 10.1006/geno.1994.1650; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STAMM S, 1992, NUCLEIC ACIDS RES, V20, P5097, DOI 10.1093/nar/20.19.5097; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UNGEWICKELL E, 1981, NATURE, V289, P420, DOI 10.1038/289420a0; UNGEWICKELL E, 1991, J BIOL CHEM, V266, P12710; UNGEWICKELL E, 1983, EMBO J, V2, P1401, DOI 10.1002/j.1460-2075.1983.tb01598.x; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WINKLER FK, 1983, EMBO J, V2, P1393, DOI 10.1002/j.1460-2075.1983.tb01597.x; WONG DH, 1990, J NEUROSCI, V10, P3025	45	130	134	0	15	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 20	1995	83	2					257	267		10.1016/0092-8674(95)90167-1	http://dx.doi.org/10.1016/0092-8674(95)90167-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TA965	7585943	Bronze			2022-12-24	WOS:A1995TA96500012
J	KUH, D; STIRLING, S				KUH, D; STIRLING, S			SOCIOECONOMIC VARIATION IN ADMISSION FOR DISEASES OF FEMALE GENITAL SYSTEM AND BREAST IN A NATIONAL COHORT AGED 15-43	BRITISH MEDICAL JOURNAL			English	Article							HYSTERECTOMY; WOMEN; EPIDEMIOLOGY; MENORRHAGIA	Objective-To investigate socioeconomic variation among young women in the risk of hospital admission for diseases (including neoplasms) of the female genital system and breast and for the common surgical procedures of dilatation and curettage and hysterectomy. Design-Large nationally representative cohort study with individual records of confirmed admissions to NHS and private hospitals since birth and data on occupational and educational experience. Setting-England, Scotland, and Wales. Patients-General population sample of 1628 women, 1549 of whom had a complete admissions record for the ages of 15-43 years. Main outcome measures-The percentage of women admitted for neoplasms or other diseases of the female genital system and breast or who had dilatation and curettage or hysterectomy between the ages of 15 and 43 years. Results-By the age of 43, 35% of women had been admitted, 17% had undergone dilatation and curettage at least once, and 10% had had a hysterectomy. There were significant inverse educational gradients, the risk of admission increasing more than twofold between the most and least educated women. The differential risk was most striking for disorders of menstruation, in which only 1% of those with the highest educational qualifications and 19% of those with minimal qualifications had been admitted to hospital. There was a significant educational gradient in the hysterectomy rate (from 1% to 15%) and a twofold difference in the risk of dilatation and curettage. There were also significant gradients in risk of admission and of hysterectomy according to partner's social class. Conclusions-Socioeconomic variations in the risk of dilatation and curettage and of hysterectomy were large. Lessening the socioeconomic gradient in risks of admissions and surgery for diseases of the female genital system. and breast, particularly for menstrual disorders, could have important resource implications.			KUH, D (corresponding author), UNIV LONDON UNIV COLL,SCH MED,DEPT EPIDEMIOL & PUBL HLTH,MED RES COUNCIL NATL SURVEY HLTH DEV,LONDON WC1E 6BT,ENGLAND.		Kuh, Diana/L-6019-2014	Kuh, Diana/0000-0001-7386-2857				BAYER LM, 1981, PRESENT PAST MIDDLE, P55, DOI DOI 10.1016/B978-0-12-233680-5.50009-5; BLAXTER M, 1987, LANCET, V2, P30; BLAXTER N, 1987, HLTH LIFESTYLE SURVE, P5; BOTO TCA, 1990, BRIT J HOSP MED, V44, P93; BRINTON LA, 1986, J CHRON DIS, V39, P1051, DOI 10.1016/0021-9681(86)90139-6; Buchan IC, 1973, TIME STUDY CONSULTAT; CARTWRIGHT A, 1976, SOCIOL REV MONOGR, V22, P77; CENTERWALL BS, 1981, AM J OBSTET GYNECOL, V139, P58, DOI 10.1016/0002-9378(81)90412-9; COLE SK, 1971, J OBSTET GYN BR COMM, V78, P933; COULTER A, 1993, BRIT MED J, V306, P236, DOI 10.1136/bmj.306.6872.236; COULTER A, 1994, FAM PRACT, V11, P67, DOI 10.1093/fampra/11.1.67; COULTER A, 1986, Q J SOC AFF, V2, P379; COULTER A, 1985, BRIT MED J, V291, P183, DOI 10.1136/bmj.291.6489.183; COULTER A, 1995, EUROPEAN J PUBLIC HL, V5, P123; GATH D, 1987, BMJ-BRIT MED J, V294, P213, DOI 10.1136/bmj.294.6566.213; GOLDBLATT P, 1990, 1971 1981 LONGITUDIN, P163; KJERULFF K, 1993, AM J PUBLIC HEALTH, V83, P106, DOI 10.2105/AJPH.83.1.106; MAGOS AL, 1991, LANCET, V337, P1074, DOI 10.1016/0140-6736(91)91718-A; MEILAHN EN, 1989, MATURITAS, V11, P319, DOI 10.1016/0378-5122(89)90028-5; Moser K., 1990, LONGITUDINAL STUDY M, P145; PENDLETON DA, 1980, SOC SCI MED, V36, P669; SIDDLE N, 1987, FERTIL STERIL, V47, P94; VESSEY MP, 1992, BRIT J OBSTET GYNAEC, V99, P402, DOI 10.1111/j.1471-0528.1992.tb13758.x; Wadsworth M E, 1987, Paediatr Perinat Epidemiol, V1, P95, DOI 10.1111/j.1365-3016.1987.tb00093.x; Wadsworth M. E. J., 1991, IMPRINT TIME CHILDHO; WADSWORTH MEJ, 1992, J EPIDEMIOL COMMUN H, V46, P300, DOI 10.1136/jech.46.3.300; 1977, MB4 DEP HLTH SOC SEC; 1972, 1968 1972 DEP HLTH S; 1986, MB5 OFF POP CENS SUR; 1994, INPATIENT TREATMENT; 1982, MB1 OFF POP CENS SUR; 1964, 1961 1966 MIN HLTH G; 1972, BURNHAM FURTHER ED C; 1977, 1973 DEP HLTH SOC SE; 1983, MB4 OFF POP CENS SUR	35	32	33	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 30	1995	311	7009					840	843		10.1136/bmj.311.7009.840	http://dx.doi.org/10.1136/bmj.311.7009.840			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY191	7580490	Green Published			2022-12-24	WOS:A1995RY19100021
J	SHEPHERD, RM; DENT, THS; ALEXANDER, GJM; LONDON, M				SHEPHERD, RM; DENT, THS; ALEXANDER, GJM; LONDON, M			PREVALENCE OF ALCOHOL HISTORIES IN MEDICAL AND NURSING NOTES OF PATIENTS ADMITTED WITH SELF-POISONING	BRITISH MEDICAL JOURNAL			English	Article									FULBOURNE HOSP,CAMBRIDGE & HUNTINGDON HLTH COMMISS,DEPT HLTH POLICY & PUBL HLTH,CAMBRIDGE CB1 5EF,ENGLAND; DRINKING PROBLEMS SERV,CAMBRIDGE CB1 3DF,ENGLAND; ADDENBROOKES HOSP,DEPT MED,CAMBRIDGE CB2 2QQ,ENGLAND	Addenbrooke's Hospital; University of Cambridge								DALY M, 1988, CURRENT RES SUICIDE; FREEMANTLE N, 1993, BRIEF INTERVENTIONS; GROOTENHUIS M, 1994, BRIT J PSYCHIAT, V165, P73, DOI 10.1192/bjp.165.1.73; PATEL AR, 1975, BRIT MED J, V2, P426, DOI 10.1136/bmj.2.5968.426; 1992, HLTH NATION STRATEGY	5	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 30	1995	311	7009					847	847		10.1136/bmj.311.7009.847	http://dx.doi.org/10.1136/bmj.311.7009.847			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY191	7580493	Green Published			2022-12-24	WOS:A1995RY19100024
J	GRAY, DWR				GRAY, DWR			MYCOPHENOLATE MOFETIL FOR TRANSPLANTATION - NEW DRUG, OLD PROBLEMS	LANCET			English	Editorial Material											GRAY, DWR (corresponding author), OXFORD RADCLIFFE HOSP,OXFORD TRANSPLANT CTR,NUFFIELD DEPT SURG,OXFORD,ENGLAND.							AZUMA H, 1995, TRANSPLANTATION, V59, P460; 1995, LANCET, V345, P1321	2	9	9	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 12	1995	346	8972					390	390		10.1016/S0140-6736(95)92775-1	http://dx.doi.org/10.1016/S0140-6736(95)92775-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN656	7623565				2022-12-24	WOS:A1995RN65600004
J	NEWMAN, M; STRZELECKA, T; DORNER, LF; SCHILDKRAUT, I; AGGARWAL, AK				NEWMAN, M; STRZELECKA, T; DORNER, LF; SCHILDKRAUT, I; AGGARWAL, AK			STRUCTURE OF BAM-HI ENDONUCLEASE BOUND TO DNA - PARTIAL FOLDING AND UNFOLDING ON DNA-BINDING	SCIENCE			English	Article							REPRESSOR OPERATOR COMPLEX; CRYSTAL-STRUCTURE; RESTRICTION ENDONUCLEASE; WEISSENBERG CAMERA; DIFFRACTION DATA; RESOLUTION; CRYSTALLOGRAPHY; RECOGNITION; REFINEMENT; ECORI	The crystal structure of restriction endonuclease Bam HI complexed to DNA has been determined at 2.2 angstrom resolution. The DNA binds in the cleft and retains a B-DNA type of conformation. The enzyme, however, undergoes a series of conformational changes, including rotation of subunits and folding of disordered regions. The most striking conformational change is the unraveling of carboxyl-terminal alpha helices to form partially disordered ''arms.'' The arm from one subunit fits into the minor groove while the arm from the symmetry related subunit follows the DNA sugar-phosphate backbone. Recognition of DNA base pairs occurs primarily in the major groove, with a few interactions occurring in the minor groove. Tightly bound water molecules play an equally important role as side chain and main chain atoms in the recognition of base pairs. The complex also provides new insights into the mechanism by which the enzyme catalyzes the hydrolysis of DNA phosphodiester groups.	COLUMBIA UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032; NEW ENGLAND BIOLABS INC,BEVERLY,MA 01915	Columbia University					NIGMS NIH HHS [GM-44006] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044006] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; ANDERSON JE, 1987, NATURE, V326, P846, DOI 10.1038/326846a0; ATHANASIADIS A, 1994, NAT STRUCT BIOL, V1, P469, DOI 10.1038/nsb0794-469; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BRENNAN RG, 1990, P NATL ACAD SCI USA, V87, P8165, DOI 10.1073/pnas.87.20.8165; BRUNGER AT, 1992, XPLOR V3 0 MANUAL; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CHENG XD, 1994, EMBO J, V13, P3927, DOI 10.1002/j.1460-2075.1994.tb06708.x; CONNOLLY BA, 1984, J BIOL CHEM, V259, P760; Creighton T. E., 1993, PROTEINS STRUCTURES; ELLENBERGER T, 1994, CURR OPIN STRUC BIOL, V4, P12, DOI 10.1016/S0959-440X(94)90054-X; FITAGERALD PMD, 1988, J APPL CRYSTALLOGR, V20, P383; FRANKEL AD, 1991, CELL, V65, P717, DOI 10.1016/0092-8674(91)90378-C; GRASBY JA, 1992, BIOCHEMISTRY-US, V31, P7855, DOI 10.1021/bi00149a016; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P993; HIGASHI T, 1989, J APPL CRYSTALLOGR, V22, P9, DOI 10.1107/S0021889888009562; JELTSCH A, 1993, P NATL ACAD SCI USA, V90, P8499, DOI 10.1073/pnas.90.18.8499; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; LAVERY R, 1989, J BIOMOL STRUCT DYN, V6, P655, DOI 10.1080/07391102.1989.10507728; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; NEWMAN M, 1994, STRUCTURE, V2, P439, DOI 10.1016/S0969-2126(00)00045-9; NEWMAN M, 1994, NATURE, V368, P660, DOI 10.1038/368660a0; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; Roberts R, 1993, NUCLEASES, P35; Rosenberg JM, 1991, CURR OPIN STRUC BIOL, V1, P104, DOI 10.1016/0959-440X(91)90018-O; SAKABE N, 1991, NUCL INSTRUM METH A, V303, P448, DOI 10.1016/0168-9002(91)90282-U; SARAI A, 1989, P NATL ACAD SCI USA, V86, P6513, DOI 10.1073/pnas.86.17.6513; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; STEITZ T, NIH GM44006 GRAN; STRZELECKA T, 1994, J MOL BIOL, V239, P430, DOI 10.1006/jmbi.1994.1383; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; Winkler F. K., 1992, CURR OPIN STRUC BIOL, V2, P93; WINKLER FK, 1993, EMBO J, V12, P1781, DOI 10.1002/j.1460-2075.1993.tb05826.x; XUONG NH, 1978, ACTA CRYSTALLOGR A, V34, P289, DOI 10.1107/S0567739478000546	38	295	297	1	22	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 4	1995	269	5224					656	663		10.1126/science.7624794	http://dx.doi.org/10.1126/science.7624794			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM702	7624794				2022-12-24	WOS:A1995RM70200023
J	HALAAS, JL; GAJIWALA, KS; MAFFEI, M; COHEN, SL; CHAIT, BT; RABINOWITZ, D; LALLONE, RL; BURLEY, SK; FRIEDMAN, JM				HALAAS, JL; GAJIWALA, KS; MAFFEI, M; COHEN, SL; CHAIT, BT; RABINOWITZ, D; LALLONE, RL; BURLEY, SK; FRIEDMAN, JM			WEIGHT-REDUCING EFFECTS OF THE PLASMA-PROTEIN ENCODED BY THE OBESE GENE	SCIENCE			English	Article							RATS	The gene product of the ob locus is important in the regulation of body weight. The ob product was shown to be present as a 16-kilodalton protein in mouse and human plasma but was undetectable in plasma from C57BL/6J ob/ob mice. Plasma levels of this protein were increased in diabetic (db) mice, a mutant thought to be resistant to the effects of ab. Daily intraperitoneal injections of either mouse or human recombinant OB protein reduced the body weight of ob/ob mice by 30 percent after 2 weeks of treatment with no apparent toxicity but had no effect on db/db mice. The protein reduced food intake and increased energy expenditure in ob/ob mice. Injections of wild-type mice twice daily with the mouse protein resulted in a sustained 12 percent weight loss, decreased food intake, and a reduction of body fat from 12.2 to 0.7 percent. These data suggest that the OB protein serves an endocrine function to regulate body fat stores.	ROCKEFELLER UNIV,HOWARD HUGHES MED INST,GENET MOLEC LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,MOLEC BIOPHYS LABS,NEW YORK,NY 10021; ROCKEFELLER UNIV,MASS SPECTROMETRY LAB,NEW YORK,NY 10021; COLUMBIA UNIV,DEPT STAT,NEW YORK,NY 10027; BROOKWOOD BIOMED CTR,BIRMINGHAM,AL 35209	Howard Hughes Medical Institute; Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; Rockefeller University; Columbia University				Burley, Stephen K./0000-0002-2487-9713	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000862] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041096] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00862] Funding Source: Medline; NIDDK NIH HHS [DK41096] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEAVIS RC, 1990, P NATL ACAD SCI USA, V87, P6873, DOI 10.1073/pnas.87.17.6873; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; DAWSONSAUNDERS B, 1990, BASIC CLIN BIOSTTIST; HALAAS JL, UNPUB; HARLOW E, 1988, ANTIBODIES LABORATOR; HARRIS RBS, 1987, INT J OBESITY, V11, P275; HERVEY GR, 1959, J PHYSIOL-LONDON, V145, P336, DOI 10.1113/jphysiol.1959.sp006145; HERVEY GR, 1976, P PHYSL SOC, V266, pP65; KEESEY RC, 1984, ASS RES NERVOUS MENT, V62, P87; KENNEDY GC, 1953, PROC R SOC SER B-BIO, V140, P578, DOI 10.1098/rspb.1953.0009; LEIBEL RL, 1995, NEW ENGL J MED, V332, P621, DOI 10.1056/NEJM199503093321001; LEIBELT RA, 1965, ANN NY ACAD SCI, V131, P559; PARAMESWARAN SV, 1977, AM J PHYSIOL, V232, pR150, DOI 10.1152/ajpregu.1977.232.5.R150; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	15	3945	4169	7	239	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 28	1995	269	5223					543	546		10.1126/science.7624777	http://dx.doi.org/10.1126/science.7624777			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL495	7624777				2022-12-24	WOS:A1995RL49500029
J	TOWERS, CV				TOWERS, CV			GROUP-B STREPTOCOCCUS - THE US CONTROVERSY	LANCET			English	Editorial Material							SELECTIVE INTRAPARTUM CHEMOPROPHYLAXIS; EARLY-ONSET DISEASE; PREGNANCY; CARRIAGE				TOWERS, CV (corresponding author), LONG BEACH MEM WOMENS HOSP,CTR PERINATAL,LONG BEACH,CA, USA.							BOYER KM, 1986, NEW ENGL J MED, V314, P1665, DOI 10.1056/NEJM198606263142603; BOYER KM, 1983, J INFECT DIS, V148, P802, DOI 10.1093/infdis/148.5.802; BOYER KM, 1983, J INFECT DIS, V148, P795, DOI 10.1093/infdis/148.5.795; DILLON HC, 1982, J INFECT DIS, V145, P794, DOI 10.1093/infdis/145.6.794; LEWIN EB, 1981, AM J OBSTET GYNECOL, V139, P512, DOI 10.1016/0002-9378(81)90509-3; ROUSE DJ, 1994, OBSTET GYNECOL, V83, P483, DOI 10.1097/00006250-199404000-00001; TOWERS CV, 1990, AM J OBSTET GYNECOL, V163, P965, DOI 10.1016/0002-9378(90)91105-L; YANCEY MK, 1992, OBSTET GYNECOL, V80, P1038; 1992, ACOG TECH B, V170, P1; 1993, ACOG NEWSL, V37, P2; 1992, PEDIATRICS, V90, P775	11	16	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 22	1995	346	8969					197	199		10.1016/S0140-6736(95)91262-2	http://dx.doi.org/10.1016/S0140-6736(95)91262-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK419	7616795				2022-12-24	WOS:A1995RK41900004
J	SMITH, WC; MCKENDRY, R; RIBISI, S; HARLAND, RM				SMITH, WC; MCKENDRY, R; RIBISI, S; HARLAND, RM			A NODAL-RELATED GENE DEFINES A PHYSICAL AND FUNCTIONAL DOMAIN WITHIN THE SPEMANN ORGANIZER	CELL			English	Article							XENOPUS-LAEVIS; NEURAL INDUCTION; MESODERM INDUCTION; DORSAL MESODERM; INJECTED XWNT-8; EARLY RESPONSE; CELL MOTILITY; ACTIVIN; EMBRYOS; EXPRESSION	A functional screen for gene products that rescue dorsal development in ventralized Xenopus embryos has yielded Xenopus nodal-related 3 (Xnr3), a diverged member of the TGF beta superfamily. Xnr3 is specifically expressed in the Spemann organizer and is only expressed in the epithelial layer of the organizer immediately preceding and extending through gastrulation, Like noggin, Xnr3 can induce muscle in ventral mesoderm explants, consistent with a role in patterning the gastrula, In other ways, the activity of Xnr3 is different from noggin. Embryos receiving injections of Xnr3, particularly in the animal pole, send out tube-like extensions of tissue from the site of injection. These protrusions usually contain no axial mesoderm and only occasionally are positive for neural markers. It has previously been proposed that the epithelial layer of the organizer initiates and coordinates the morphogenetic movements at gastrulation. The protrusions observed may reflect an activity of Xnr3 in promoting morphogenesis.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley								AMAYA E, 1993, DEVELOPMENT, V118, P477; BOLCE ME, 1992, DEVELOPMENT, V115, P681; BOLCE ME, 1993, DEV BIOL, V160, P413, DOI 10.1006/dbio.1993.1317; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CHRISTIAN JL, 1992, EMBO J, V11, P33, DOI 10.1002/j.1460-2075.1992.tb05024.x; CHRISTIAN JL, 1993, GENE DEV, V7, P13, DOI 10.1101/gad.7.1.13; CONLON FL, 1994, DEVELOPMENT, V120, P1919; CONLON FL, 1991, DEVELOPMENT, V118, P969; Faber J., 1994, NORMAL TABLE XENOPUS, P2; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREEN JBA, 1990, DEVELOPMENT, V108, P173; HARLAND R, 1988, DEVELOPMENT, V102, P837; HARLAND RM, 1994, P NATL ACAD SCI USA, V91, P10243, DOI 10.1073/pnas.91.22.10243; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; HEMMATIBRIVANLOU A, 1990, SCIENCE, V250, P800, DOI 10.1126/science.1978411; IANNACCONE PM, 1992, DEV DYNAM, V194, P198, DOI 10.1002/aja.1001940305; JOHNSON AD, 1994, GENE, V147, P233; JONES EA, 1989, DEVELOPMENT, V107, P785; KAO KR, 1989, DEV BIOL, V132, P81, DOI 10.1016/0012-1606(89)90207-8; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KELLER R, 1991, METHOD CELL BIOL, V36, P61; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KINTNER CR, 1984, NATURE, V308, P67, DOI 10.1038/308067a0; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KNECHT AK, 1995, DEVELOPMENT, V121, P1911; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; LEMAIRE P, 1995, CELL, V81, P85, DOI 10.1016/0092-8674(95)90373-9; LETTICE LA, 1993, DEVELOPMENT, V117, P263; PIERCE SB, 1995, DEVELOPMENT, V121, P755; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SHIH J, 1992, DEVELOPMENT, V116, P887; SHIH J, 1992, DEVELOPMENT, V116, P901; SHIH J, 1992, DEVELOPMENT, V116, P915; SLACK JMW, 1988, DEVELOPMENT, V103, P581; SLACK JMW, 1994, CURR BIOL, V4, P116, DOI 10.1016/S0960-9822(94)00027-8; SMITH JC, 1983, J EMBRYOL EXP MORPH, V78, P299; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH WC, 1993, NATURE, V361, P547, DOI 10.1038/361547a0; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL SY, 1992, DEV BIOL, V154, P348, DOI 10.1016/0012-1606(92)90073-P; STEINBEISSER H, 1993, DEVELOPMENT, V118, P499; WILSON P, 1991, DEVELOPMENT, V112, P289; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0	46	290	295	0	5	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 14	1995	82	1					37	46		10.1016/0092-8674(95)90050-0	http://dx.doi.org/10.1016/0092-8674(95)90050-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RK424	7606783	Bronze			2022-12-24	WOS:A1995RK42400007
J	CLARKE, A				CLARKE, A			POPULATION SCREENING FOR GENETIC SUSCEPTIBILITY TO DISEASE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CHOLESTEROL CONCENTRATION; HEALTH; HYPERCHOLESTEROLEMIA; PREVENTION	Genetic screening for susceptibility to common diseases, such as the common cancers, cardiovascular disease, and diabetes, may soon be technically feasible. Commercial interests should not be allowed to introduce such screening before proper evaluation or without adequate counselling and support. The evaluation of such testing should include psychosocial and medical outcomes and outcomes for those given low risks as well as high risks. These tests may distract attention away from environmental factors contributing to disease, for which social and political measures may be more appropriate than individualised susceptibility screening and lifestyle modification.			CLARKE, A (corresponding author), UNIV WALES COLL CARDIFF, COLL MED, DEPT MED GENET, CARDIFF CF4 4XW, S GLAM, WALES.							BACHMAN RP, 1993, AM J DIS CHILD, V147, P382, DOI 10.1001/archpedi.1993.02160280032013; BAIRD PA, 1990, PERSPECT BIOL MED, V33, P203; BERGMAN AB, 1967, NEW ENGL J MED, V276, P1008, DOI 10.1056/NEJM196705042761804; BRETT AS, 1991, AM J MED, V91, P642, DOI 10.1016/0002-9343(91)90218-M; CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276; CLARKE A, 1994, J MED GENET, V31, P785, DOI 10.1136/jmg.31.10.785; COULTER A, 1994, BRIT MED J, V308, P308; DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; DAVISON C, 1989, Health Education Research, V4, P329, DOI 10.1093/her/4.3.329; DAVISON C, 1992, SOC SCI MED, V34, P675, DOI 10.1016/0277-9536(92)90195-V; GREEN J, 1993, J MED GENET, V30, P575, DOI 10.1136/jmg.30.7.575; GUSTAVSON KH, 1989, CLIN GENET, V36, P327; HARPER PS, 1993, LANCET, V341, P224, DOI 10.1016/0140-6736(93)90080-Z; HARPER PS, 1990, LANCET, V335, P1205, DOI 10.1016/0140-6736(90)92713-R; HASHIMOTO L, 1994, NATURE, V371, P161, DOI 10.1038/371161a0; HOLTZMAN NA, 1992, FASEB J, V6, P2806, DOI 10.1096/fasebj.6.10.1634043; KINLAY S, 1990, BRIT MED J, V300, P1545, DOI 10.1136/bmj.300.6739.1545; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; LAW MR, 1994, BRIT MED J, V308, P373, DOI 10.1136/bmj.308.6925.373; LEFEBVRE RC, 1988, ARCH INTERN MED, V148, P1993, DOI 10.1001/archinte.148.9.1993; LIFSHITZ F, 1989, AM J DIS CHILD, V143, P537, DOI 10.1001/archpedi.1989.02150170035015; LIPMANN A, 1993, MISCONCEPTIONS, V1, P39; MANT D, 1994, LANCET, V344, P1343, DOI 10.1016/S0140-6736(94)90698-X; MCCORMICK J, 1994, LANCET, V344, P390; MULLERHILL B, 1993, NATURE, V362, P491, DOI 10.1038/362491a0; NEWMAN TB, 1990, JAMA-J AM MED ASSOC, V264, P3039, DOI 10.1001/jama.264.23.3039; PHILLIMORE P, 1994, BRIT MED J, V308, P1125, DOI 10.1136/bmj.308.6937.1125; PLOMIN R, 1994, BEHAV GENET, V24, P107, DOI 10.1007/BF01067815; RAMSEY M, 1994, GENETIC COUNSELLING, P241; STOTT N, 1994, BRIT MED J, V308, P285, DOI 10.1136/bmj.308.6924.285; TOWNSEND P, 1990, INT J HEALTH SERV, V20, P373, DOI 10.2190/9Q6H-2KE7-X6FN-3DK8; Townsend P., 1988, INEQUALITIES HLTH BL; VANDERSTEENSTRATEN IM, 1994, AM J HUM GENET, V55, P618; WALD NJ, 1994, LANCET, V343, P75, DOI 10.1016/S0140-6736(94)90814-1; WEBER JL, 1994, NAT GENET, V7, P343, DOI 10.1038/ng0794-343; WILLIAMS RR, 1988, NEW ENGL J MED, V318, P769, DOI 10.1056/NEJM198803243181208; WOOD DA, 1994, BRIT MED J, V308, P313, DOI 10.1136/bmj.308.6924.313; 1990, REPRODUCTION GENETIC, V3, P287	38	33	33	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 1	1995	311	6996					35	38		10.1136/bmj.311.6996.35	http://dx.doi.org/10.1136/bmj.311.6996.35			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RG975	7613325	Green Published			2022-12-24	WOS:A1995RG97500026
J	BARRY, MA; LAI, WC; JOHNSTON, SA				BARRY, MA; LAI, WC; JOHNSTON, SA			PROTECTION AGAINST MYCOPLASMA-INFECTION USING EXPRESSION-LIBRARY IMMUNIZATION	NATURE			English	Article							IMMUNE-RESPONSES; GENETIC IMMUNIZATION; DNA; TRYPTOPHAN; UBIQUITIN; PULMONIS; ANTIGEN; CELLS; READ; UGA	As is evident from the human immunodeficiency virus epidemic, there is no systematic method for producing a vaccine, Genetic immunization(1) is a new approach to vaccine production that has many of the advantages of live/attenuated pathogens but no risk of infection. It involves introducing DNA encoding a pathogen protein into host cells and has shown promise in several disease models(2-13) Here we describe a new method for vaccine development, expression-library immunization, which makes use of the technique of genetic immunization and the fact that all the antigens of a pathogen are encoded in its DNA. An expression library of pathogen DNA is used to immunize a host thereby producing the effects of antigen presentation of a live vaccine without the risk. We show that even partial expression libraries made from the DNA of Mycoplasma pulmonis, a natural pathogen in rodents, provide protection against challenge from the pathogen. Expression library immunization may prove to be a general method for vaccination against any pathogen.	UNIV TEXAS,SW MED CTR,DEPT MED,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PATHOL,DIV COMPARAT MED,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BARRY MA, 1994, BIOTECHNIQUES, V16, P616; CASSELL GH, 1982, REV INFECT DIS, V4, P518; CONEY L, 1994, VACCINE, V12, P1545, DOI 10.1016/0264-410X(94)90082-5; CONRY RM, 1994, CANCER RES, V54, P1164; COX GJM, 1993, J VIROL, V67, P5664, DOI 10.1128/JVI.67.9.5664-5667.1993; DAVIDSON MK, 1982, REV INFECT DIS, V4, pS243; DAVIS HL, 1993, HUM MOL GENET, V2, P1847, DOI 10.1093/hmg/2.11.1847; ECKER DJ, 1989, J BIOL CHEM, V264, P7715; EISENBRAUN MD, 1993, DNA CELL BIOL, V12, P791, DOI 10.1089/dna.1993.12.791; FYNAN EF, 1993, P NATL ACAD SCI USA, V90, P11478, DOI 10.1073/pnas.90.24.11478; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; INAMINE JM, 1990, J BACTERIOL, V172, P504, DOI 10.1128/JB.172.1.504-506.1990; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; KATSUMI A, 1994, HUM GENE THER, V5, P1335, DOI 10.1089/hum.1994.5.11-1335; Lai Wayne C., 1995, P469, DOI 10.1016/B978-012583805-4/50050-9; LAI WC, 1991, INFECT IMMUN, V59, P346, DOI 10.1128/IAI.59.1.346-350.1991; LAI WC, 1990, J INFECT DIS, V161, P1269, DOI 10.1093/infdis/161.6.1269; LINDSEY JR, 1978, PATHOLOGY LABORATORY, P1482; NEIMARK HC, 1990, NUCLEIC ACIDS RES, V18, P5443, DOI 10.1093/nar/18.18.5443; RAZ E, 1994, P NATL ACAD SCI USA, V91, P9519, DOI 10.1073/pnas.91.20.9519; SEDEGAH M, 1994, P NATL ACAD SCI USA, V91, P9866, DOI 10.1073/pnas.91.21.9866; TANG DC, 1992, NATURE, V356, P152, DOI 10.1038/356152a0; TAYLOR G, 1976, IMMUNOLOGY, V30, P611; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; WANG B, 1993, P NATL ACAD SCI USA, V90, P4156, DOI 10.1073/pnas.90.9.4156; XIANG ZQ, 1994, VIROLOGY, V199, P132, DOI 10.1006/viro.1994.1105; XU D, 1994, VACCINE, V12, P1534, DOI 10.1016/0264-410X(94)90079-5; YAMAO F, 1985, P NATL ACAD SCI USA, V82, P2306, DOI 10.1073/pnas.82.8.2306	29	255	297	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 19	1995	377	6550					632	635		10.1038/377632a0	http://dx.doi.org/10.1038/377632a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA275	7566175				2022-12-24	WOS:A1995TA27500053
J	HEITMANN, BL; LISSNER, L				HEITMANN, BL; LISSNER, L			DIETARY UNDERREPORTING BY OBESE INDIVIDUALS - IS IT SPECIFIC OR NONSPECIFIC	BRITISH MEDICAL JOURNAL			English	Article							AGED 35-65 YEARS; ENERGY-EXPENDITURE; BODY-COMPOSITION; DANISH POPULATION; URINE NITROGEN; WOMEN; PREDICTION; FAT; MEN	Objective-To examine the distribution of patterns of macronutrient density in relation to obesity. Design-Cross sectional. Setting-Denmark. Subjects-323 men and women aged 35-65 years, selected randomly from a larger population sample of Danish adults. Main outcome measure-Bias in dietary reporting of energy and protein intake in relation to percentage body fat, assessed by comparison of data from an interview on dietary intake with data estimated from 24 hour nitrogen output, validated by administering p-aminobenzoic acid, and estimated 24 hour energy expenditure. Results-Degree of obesity was positively associated with underreporting of total energy and protein, whereas compared with total energy reported, protein was overreported by the obese subjects. Conclusion-Errors in dietary reporting of protein seem to occur disproportionately with respect to total energy, suggesting a differential reporting pattern of different foods. Although, on average, all subjects showed a greater underreporting of energy than of protein, this was most common in the obese subjects. Snack-type foods may be preferentially forgotten when obese people omit food items in dietary reporting. These results seem to agree with the general assumption that obese people tend to underreport fatty foods and foods rich in carbohydrates rather than underreport their total dietary intake. These results may have implications for the interpretation of studies of diet and comorbidities related to obesity.	DANISH EPIDEMIOL SCI CTR,INST PREVENT MED,COPENHAGEN,DENMARK; GLOSTRUP CTY HOSP,DEPT MED C,GLOSTRUP,DENMARK; GOTHENBURG UNIV,DEPT INTERNAL MED & PRIMARY HLTH CARE,GOTHENBURG,SWEDEN	Aarhus University; University of Copenhagen; University of Gothenburg				Heitmann, Berit Lilienthal/0000-0002-6809-4504				ASTRUP A, 1990, AM J CLIN NUTR, V52, P777, DOI 10.1093/ajcn/52.5.777; BINGHAM S, 1983, CLIN SCI, V64, P629, DOI 10.1042/cs0640629; BINGHAM SA, 1985, AM J CLIN NUTR, V42, P1276, DOI 10.1093/ajcn/42.6.1276; BINGHAM SA, 1991, BIOMARKERS DIETARY E, P41; BLACK AE, 1991, EUR J CLIN NUTR, V45, P583; BLACK AE, 1991, P NUTR SOC, V50, pA108; CUNNINGHAM JJ, 1991, AM J CLIN NUTR, V54, P963, DOI 10.1093/ajcn/54.6.963; DREWNOWSKI A, 1992, APPETITE, V18, P207, DOI 10.1016/0195-6663(92)90198-F; GARBY L, 1988, EUR J CLIN NUTR, V42, P301; HEITMANN BL, 1992, J CLIN EPIDEMIOL, V45, P693, DOI 10.1016/0895-4356(92)90046-P; HEITMANN BL, 1993, INT J OBESITY, V17, P329; HEITMANN BL, 1991, INT J OBESITY, V15, P535; HEITMANN BL, 1990, INT J OBESITY, V14, P789; HULTEN B, 1990, EUR J CLIN NUTR, V44, P169; ISAKSSON B, 1980, AM J CLIN NUTR, V33, P4, DOI 10.1093/ajcn/33.1.4; JENSEN KH, 1991, GASTROENTEROLOGY, V100, P790, DOI 10.1016/0016-5085(91)80027-7; LICHTMAN SW, 1992, NEW ENGL J MED, V327, P1893, DOI 10.1056/NEJM199212313272701; LISSNER L, 1994, EUR J CLIN NUTR, V48, P453; LISSNER L, 1989, AM J CLIN NUTR, V49, P320, DOI 10.1093/ajcn/49.2.320; LIVINGSTONE MBE, 1990, BRIT MED J, V300, P708, DOI 10.1136/bmj.300.6726.708; MOLLER A, 1986, PUBLICATION MINISTRY, V75; PRENTICE AM, 1986, BRIT MED J, V292, P983, DOI 10.1136/bmj.292.6526.983; RUTISHAUSER IHE, 1995, EUR J CLIN NUTR, V49, P219; SCHOELLER DA, 1990, NUTR REV, V48, P373, DOI 10.1111/j.1753-4887.1990.tb02882.x; SUMMERBELL CD, 1995, EUR J CLIN NUTR, V49, P33; 1989, WHO EUR ICP NUT125 N	26	510	512	1	19	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 14	1995	311	7011					986	989						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA079	7580640				2022-12-24	WOS:A1995TA07900023
J	WU, JC; CHOO, KB; CHEN, CM; CHEN, TZ; HUE, TL; LEE, SD				WU, JC; CHOO, KB; CHEN, CM; CHEN, TZ; HUE, TL; LEE, SD			GENOTYPING OF HEPATITIS-D VIRUS BY RESTRICTION-FRAGMENT-LENGTH-POLYMORPHISM AND RELATION TO OUTCOME OF HEPATITIS-D	LANCET			English	Article							DELTA-VIRUS; MOLECULAR-CLONING; RNA; SEQUENCE; EXPRESSION; LIVER	The outcome of hepatitis D virus (HDV) superinfection varies among patients and in different geographical areas. To find out whether HDV genotype affects outcome, we used a simple genotyping method based on restriction-fragment length polymorphism with enzymes Xhol and SacII for cleavage of PCR products of the HDV genome. Of samples from 88 patients studied, the genotypes of 61 were confirmed by two methods-analysis with both enzymes or by combined restriction-enzyme and direct sequencing analyses-with consistent results. No genotype III HDV was detected among these patients. The majority of patients with acute HDV infection (35/41 [85%]) had genotype II HDV. Among the 41 patients with acute infection, four of six with genotype I had fulminant disease compared with two of 35 with genotype II. Among patients in chronic stage, cirrhosis or hepatocellular carcinoma were found in 12 of 18 with genotype I HDV and eight of 29 with genotype II. Thus genotype II was the predominant HDV genotype in this study in Taiwan. Genotype II HDV was less frequently associated with fulminant hepatitis at the acute stage or with an unfavourable long-term clinical outcome at the chronic stage than was genotype I.	NATL YANG MING UNIV,SCH MED,DEPT MED,TAIPEI,TAIWAN; NATL YANG MING UNIV,SCH MED,GRAD INST CLIN MED,TAIPEI,TAIWAN; VET GEN HOSP,DEPT MED RES,TAIPEI 112,TAIWAN	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University	WU, JC (corresponding author), VET GEN HOSP,DEPT MED,DIV GASTROENTEROL,TAIPEI 112,TAIWAN.		Chen, Chuan-Mu/K-7049-2013	Chen, Chuan-Mu/0000-0003-2461-9150				CASEY JL, 1993, P NATL ACAD SCI USA, V90, P9016, DOI 10.1073/pnas.90.19.9016; CHAO YC, 1991, HEPATOLOGY, V13, P345, DOI 10.1016/0270-9139(91)92451-D; CHAO YC, 1990, VIROLOGY, V178, P384; GOVINDARAJAN S, 1986, HEPATOLOGY, V6, P640, DOI 10.1002/hep.1840060415; GOVINDARAJAN S, 1984, GASTROENTEROLOGY, V86, P1417; HADLER SC, 1984, ANN INTERN MED, V100, P339, DOI 10.7326/0003-4819-100-3-339; IMAZEKI F, 1990, J VIROL, V64, P5594, DOI 10.1128/JVI.64.11.5594-5599.1990; KUO MYP, 1988, J VIROL, V62, P1855, DOI 10.1128/JVI.62.6.1855-1861.1988; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; LEE CM, 1992, VIROLOGY, V188, P266; LEE HH, 1992, ANAL BIOCHEM, V205, P289, DOI 10.1016/0003-2697(92)90437-C; MAKINO S, 1987, NATURE, V329, P343, DOI 10.1038/329343a0; RIZZETTO M, 1983, ANN INTERN MED, V98, P437, DOI 10.7326/0003-4819-98-4-437; SALDANHA JA, 1990, J GEN VIROL, V71, P1603, DOI 10.1099/0022-1317-71-7-1603; WANG KS, 1986, NATURE, V323, P508, DOI 10.1038/323508a0; WU JC, 1995, GASTROENTEROLOGY, V108, P796, DOI 10.1016/0016-5085(95)90453-0; WU JC, 1994, HEPATOLOGY, V19, P836, DOI 10.1002/hep.1840190406	17	120	124	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 7	1995	346	8980					939	941		10.1016/S0140-6736(95)91558-3	http://dx.doi.org/10.1016/S0140-6736(95)91558-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY808	7564729				2022-12-24	WOS:A1995RY80800010
J	BROWN, EJ; BEAL, PA; KEITH, CT; CHEN, J; SHIN, TB; SCHREIBER, SL				BROWN, EJ; BEAL, PA; KEITH, CT; CHEN, J; SHIN, TB; SCHREIBER, SL			CONTROL OF P70 S6 KINASE BY KINASE-ACTIVITY OF FRAP IN-VIVO	NATURE			English	Article							RAPAMYCIN-INDUCED INHIBITION; PROTEIN-KINASE; LYMPHOCYTES-T; RAT-LIVER; ACTIVATION; IDENTIFICATION; ENZYME; VPS34	WHEN complexed with the inh acellular protein FKBP12, rapamycin is a potent immunosuppressant(1,2) and an inhibitor of a mitogen-stimulated signalling pathway that leads to activation of p70 S6 kinase(3-6) (p70(S6k)) and cyclin-dependent kinases(7-10) (CDKs). A recently cloned FKBP12-rapamycin-associated protein (FRAP/RAFT) is the likely mediator of these effects(11,12). Using FRAP variants that do not bind FKBP12-rapamycin, we demonstrate here that FRAP is a rapamycin-sensitive regulator of p70(S6k) in vivo and that the kinase activity of FRAP is required for this regulation. In addition, we show that FRAP autophosphorylates in vitro. Consistent with an essential role for FRAP kinase activity in vivo, autophosphorylation of FRAP is inhibited by FKBP12-rapamycin. Deletion studies indicate that the kinase activity of FRAP alone is not sufficient for control of p70(S6k) and that an amino-terminal domain in FRAP is also required.	HARVARD UNIV, HOWARD HUGHES MED INST, DEPT CHEM, CAMBRIDGE, MA 02138 USA; HARVARD UNIV, PROGRAM IMMUNOL, CAMBRIDGE, MA 02138 USA	Harvard University; Howard Hughes Medical Institute; Harvard University				Chen, Jie/0000-0002-7887-3747				ALBERS MW, 1993, J BIOL CHEM, V268, P22825; BALLOU LM, 1988, P NATL ACAD SCI USA, V85, P7154, DOI 10.1073/pnas.85.19.7154; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CALVO V, 1992, P NATL ACAD SCI USA, V89, P7571, DOI 10.1073/pnas.89.16.7571; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; DUMONT FJ, 1990, J IMMUNOL, V144, P251; FLOTOW H, 1992, J BIOL CHEM, V267, P3074; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; MORICE WG, 1993, J BIOL CHEM, V268, P22737; MORICE WG, 1993, J BIOL CHEM, V268, P3734; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6	26	604	614	2	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 5	1995	377	6548					441	446		10.1038/377441a0	http://dx.doi.org/10.1038/377441a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY190	7566123				2022-12-24	WOS:A1995RY19000053
J	TSUGORKA, A; RIOS, E; BLATTER, LA				TSUGORKA, A; RIOS, E; BLATTER, LA			IMAGING ELEMENTARY EVENTS OF CALCIUM-RELEASE IN SKELETAL-MUSCLE CELLS	SCIENCE			English	Article							SARCOPLASMIC-RETICULUM; CARDIAC-MUSCLE; RYANODINE; FIBERS; CHANNEL; RECEPTORS; CHARGE; BRAIN	In skeletal muscle cells, calcium release to trigger contraction occurs at triads, specialized junctions where sarcoplasmic reticulum channels are opened by voltage sensors in the transverse tubule. Scanning confocal microscopy was used in cells under voltage clamp to measure the concentration of intracellular calcium, [Ca2+](i), at individual triads and [Ca2+](i) gradients that were proportional to calcium release. In cells stimulated with small depolarizations, the [Ca2+](i) gradients broke down into elementary events, corresponding to sing le-chan net currents of about 0.1 picoampere. Because these events were one-tenth to one-fifth the size of calcium sparks (elementary release events of cardiac muscle), skeletal muscle control mechanisms appear to be fundamentally different.	RUSH UNIV,DEPT MOLEC BIOPHYS & PHYSIOL,CHICAGO,IL 60612; LOYOLA UNIV,DEPT PHYSIOL,MAYWOOD,IL 60153; AA BOGOMOLETS PHYSIOL INST,KIEV 252601,UKRAINE	Rush University; Loyola University Chicago; National Academy of Sciences Ukraine; A.A. Bogomoletz Institute of Physiology			Blatter, Lothar/AAC-8431-2020					ASHLEY RH, 1989, J MEMBRANE BIOL, V111, P179, DOI 10.1007/BF01871781; BERS DM, 1993, AM J PHYSIOL, V264, pC1587, DOI 10.1152/ajpcell.1993.264.6.C1587; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; BRUM G, 1988, J PHYSIOL-LONDON, V398, P441, DOI 10.1113/jphysiol.1988.sp017052; CANNELL MB, 1995, SCIENCE, V268, P1045, DOI 10.1126/science.7754384; CANNELL MB, 1994, BIOPHYS J, V67, P1942, DOI 10.1016/S0006-3495(94)80677-0; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; ESCOBAR AL, 1994, NATURE, V367, P739, DOI 10.1038/367739a0; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; GIANNINI G, 1992, SCIENCE, V257, P91, DOI 10.1126/science.1320290; GONZALEZ A, 1993, J GEN PHYSIOL, V102, P272; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; HARKINS AB, 1993, BIOPHYS J, V65, P865, DOI 10.1016/S0006-3495(93)81112-3; KOVACS L, 1979, NATURE, V279, P391, DOI 10.1038/279391a0; LESH RE, 1993, CIRC RES, V72, P481, DOI 10.1161/01.RES.72.2.481; LIPP P, 1994, CIRC RES, V74, P979, DOI 10.1161/01.RES.74.5.979; LOPEZLOPEZ JR, 1994, J PHYSIOL-LONDON, V480, P21, DOI 10.1113/jphysiol.1994.sp020337; LOPEZLOPEZ JR, 1995, SCIENCE, V268, P1042, DOI 10.1126/science.7754383; MEISSNER G, 1994, ANN REV PHYSL, V76, P485; MELZER W, 1984, BIOPHYS J, V45, P637, DOI 10.1016/S0006-3495(84)84203-4; MELZER W, 1987, BIOPHYS J, V51, P849, DOI 10.1016/S0006-3495(87)83413-6; NABAUER M, 1989, SCIENCE, V244, P800, DOI 10.1126/science.2543067; NEHER E, 1992, J PHYSIOL-LONDON, V450, P273, DOI 10.1113/jphysiol.1992.sp019127; OGAWA Y, 1994, CRIT REV BIOCHEM MOL, V29, P229, DOI 10.3109/10409239409083482; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; RIOS E, 1988, NEWS PHYSIOL SCI, V3, P223, DOI 10.1152/physiologyonline.1988.3.6.223; SATOH H, UNPUB; SCHNEIDER MF, 1994, ANNU REV PHYSIOL, V56, P463, DOI 10.1146/annurev.ph.56.030194.002335; SHIROKOVA N, IN PRESS J GEN PHYSL; SORRENTINO V, 1993, TRENDS PHARMACOL SCI, V14, P98, DOI 10.1016/0165-6147(93)90072-R; STERN MD, 1992, CELL CALCIUM, V13, P183, DOI 10.1016/0143-4160(92)90046-U; STERN MD, 1992, BIOPHYS J, V63, P497, DOI 10.1016/S0006-3495(92)81615-6; SUN XH, 1995, J CELL BIOL, V129, P979; TINKER A, 1992, J GEN PHYSIOL, V100, P495, DOI 10.1085/jgp.100.3.495	34	251	257	1	12	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 22	1995	269	5231					1723	1726		10.1126/science.7569901	http://dx.doi.org/10.1126/science.7569901			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV948	7569901				2022-12-24	WOS:A1995RV94800039
J	MCADAMS, HH; SHAPIRO, L				MCADAMS, HH; SHAPIRO, L			CIRCUIT SIMULATION OF GENETIC NETWORKS	SCIENCE			English	Article							SITE-SPECIFIC RECOMBINATION; BACTERIOPHAGE-LAMBDA; PHAGE-LAMBDA; ESCHERICHIA-COLI; TRANSCRIPTION TERMINATION; LOGICAL ANALYSIS; RIGHT OPERATOR; ANTISENSE RNA; REPRESSOR; INFECTION	Genetic networks with tens to hundreds of genes are difficult to analyze with currently available techniques. Because of the many parallels in the function of these biochemically based genetic circuits and electrical circuits, a hybrid modeling approach is proposed that integrates conventional biochemical kinetic modeling within the framework of a circuit simulation. The circuit diagram of the bacteriophage lambda lysis-lysogeny decision circuit represents connectivity in signal paths of the biochemical components. A key feature of the lambda genetic circuit is that operons function as active integrated logic components and introduce signal time delays essential for the in vivo behavior of phage lambda.			MCADAMS, HH (corresponding author), STANFORD UNIV, BECKMAN CTR, SCH MED, DEPT DEV BIOL, STANFORD, CA 94305 USA.							ARKIN A, 1994, BIOPHYS J, V67, P560, DOI 10.1016/S0006-3495(94)80516-8; BRAY D, 1993, MOL BIOL CELL, V4, P469, DOI 10.1091/mbc.4.5.469; BRUN YV, 1994, ANNU REV BIOCHEM, V63, P419, DOI 10.1146/annurev.bi.63.070194.002223; CAMPBELL A, 1983, LAMBDA, V2, P365; Casjens S, 1992, SEMINARS VIROLOGY, V3, P383; DAS A, 1992, J BACTERIOL, V174, P6711, DOI 10.1128/JB.174.21.6711-6716.1992; DEVARGAS LM, 1991, P NATL ACAD SCI USA, V88, P588, DOI 10.1073/pnas.88.2.588; ECHOLS H, 1983, LAMBDA, V2, P75; Friedman DI, 1992, CURR OPIN GENET DEV, V2, P727, DOI 10.1016/S0959-437X(05)80133-9; GLASS L, 1973, J THEOR BIOL, V39, P103, DOI 10.1016/0022-5193(73)90208-7; GOTTA SL, 1991, J BACTERIOL, V173, P6647, DOI 10.1128/jb.173.20.6647-6649.1991; GREENBLATT J, 1993, NATURE, V364, P401, DOI 10.1038/364401a0; HARTWELL LH, 1991, GENETICS, V129, P975; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HAURI DC, 1995, BIOPHYS J, V68, P708, DOI 10.1016/S0006-3495(95)80232-8; Hendrix R. W, 1983, LAMBDA, VII; HERMAN C, 1993, P NATL ACAD SCI USA, V90, P10861, DOI 10.1073/pnas.90.22.10861; HERSKOWITZ I, 1980, ANNU REV GENET, V14, P399, DOI 10.1146/annurev.ge.14.120180.002151; HO YS, 1985, J BIOL CHEM, V260, P1838; HOOPES BC, 1985, P NATL ACAD SCI USA, V82, P3134, DOI 10.1073/pnas.82.10.3134; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; HOYT MA, 1982, CELL, V31, P565, DOI 10.1016/0092-8674(82)90312-9; KAUFMAN M, 1985, J THEOR BIOL, V114, P527, DOI 10.1016/S0022-5193(85)80042-4; KIM SK, 1992, ANNU REV MICROBIOL, V46, P117, DOI 10.1146/annurev.mi.46.100192.001001; KORNBERG A, 1992, DNA REPLICATION, P246; KOURILSKY P, 1973, MOL GEN GENET, V122, P183, DOI 10.1007/BF00435190; KRINKE L, 1987, GENE DEV, V1, P1005, DOI 10.1101/gad.1.9.1005; KRINKE L, 1990, GENE DEV, V4, P2223, DOI 10.1101/gad.4.12a.2223; LANDY A, 1993, CURR OPIN GENET DEV, V3, P699, DOI 10.1016/S0959-437X(05)80086-3; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; LEONG JM, 1986, J MOL BIOL, V189, P603, DOI 10.1016/0022-2836(86)90491-2; LEVINE A, 1979, J MOL BIOL, V131, P655, DOI 10.1016/0022-2836(79)90014-7; LONG SR, 1993, CELL, V73, P921, DOI 10.1016/0092-8674(93)90271-Q; LUK KC, 1983, J GEN VIROL, V64, P183, DOI 10.1099/0022-1317-64-1-183; MASON SW, 1992, J BIOL CHEM, V267, P19418; MCFALLNGAI MJ, 1991, SCIENCE, V254, P1491, DOI 10.1126/science.1962208; MEYER BJ, 1980, J MOL BIOL, V139, P163, DOI 10.1016/0022-2836(80)90303-4; MEYER BJ, 1980, J MOL BIOL, V139, P195, DOI 10.1016/0022-2836(80)90304-6; MONOD J, 1961, COLD SPRING HARB SYM, V26, P389, DOI 10.1101/SQB.1961.026.01.048; NOBLE JA, 1993, P NATL ACAD SCI USA, V90, P10866, DOI 10.1073/pnas.90.22.10866; PTASHNE M, 1992, GENETIC SWITCH GENE; ROBERTS JW, 1988, CELL, V52, P5, DOI 10.1016/0092-8674(88)90523-5; ROBERTS JW, 1983, LAMBDA, V2, P123; SCHMEISSNER U, 1980, P NATL ACAD SCI-BIOL, V77, P3191, DOI 10.1073/pnas.77.6.3191; SHEA MA, 1985, J MOL BIOL, V181, P211, DOI 10.1016/0022-2836(85)90086-5; SIMONS RW, 1988, ANNU REV GENET, V22, P567, DOI 10.1146/annurev.ge.22.120188.003031; THOMAS R, 1991, J THEOR BIOL, V153, P1, DOI 10.1016/S0022-5193(05)80350-9; VOGEL U, 1994, J BACTERIOL, V176, P2807, DOI 10.1128/JB.176.10.2807-2813.1994; Wulff DL, 1983, LAMBDA, VII, P53; YARCHUK O, 1992, J MOL BIOL, V226, P581, DOI 10.1016/0022-2836(92)90617-S; ZAMBETTI GP, 1984, MOL GEN GENET, V193, P322, DOI 10.1007/BF00330688	51	366	389	2	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 4	1995	269	5224					650	656		10.1126/science.7624793	http://dx.doi.org/10.1126/science.7624793			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM702	7624793				2022-12-24	WOS:A1995RM70200022
J	NAKAO, S; TAKENAKA, T; MAEDA, M; KODAMA, C; TANAKA, A; TAHARA, M; YOSHIDA, A; KURIYAMA, M; HAYASHIBE, H; SAKURABA, H; TANAKA, H				NAKAO, S; TAKENAKA, T; MAEDA, M; KODAMA, C; TANAKA, A; TAHARA, M; YOSHIDA, A; KURIYAMA, M; HAYASHIBE, H; SAKURABA, H; TANAKA, H			AN ATYPICAL VARIANT OF FABRYS-DISEASE IN MEN WITH LEFT-VENTRICULAR HYPERTROPHY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ALPHA-GALACTOSIDASE-A; POINT MUTATIONS; CARDIOMYOPATHY; GENE; MANIFESTATIONS; HEMIZYGOTES; IDENTIFICATION; HETEROZYGOTES; REGION	Background. Fabry's disease is an x-linked recessive disorder that results from a deficiency of alpha-galactosidase. Left ventricular hypertrophy is one of the common manifestations in men with classic hemizygous disease. Recently, several cases of an atypical variant of hemizygous Fabry's disease, with manifestations limited to the heart, have been reported. Therefore, we assessed the incidence of hemizygosity for Fabry's disease among male patients with left ventricular hypertrophy. Methods. We measured plasma alpha-galactosidase activity in 230 consecutive male patients with left ventricular hypertrophy. Clinical manifestations were assessed, endomyocardial biopsies were performed, and the patients were screened for mutations in the alpha-galactosidase gene. Results. Seven of the 230 patients with left ventricular hypertrophy (3 percent) had low plasma alpha-galactosidase activity (4 to 14 percent of the mean value in normal controls). These seven unrelated patients, ranging in age from 55 to 72 years, did not have angiokeratoma, acroparesthesias, hypohidrosis, or corneal opacities, which are typical manifestations of Fabry's disease. Endomyocardial biopsy was performed in five patients and revealed marked sarcoplasmic vacuolization in all five. Samples from four patients were examined by electron microscopy and revealed typical lysosomal inclusions with a concentric lamellar configuration in all four. Two patients had novel missense mutations in exon 1 and exon 6. The remaining five had no mutations in the coding region of the alpha-galactosidase gene, but the amounts of the alpha-galactosidase messenger RNA were markedly lower than normal. Conclusions. Seven unrelated patients with atypical variants of hemizygous Fabry's disease were found among 230 men with left ventricular hypertrophy. Fabry's disease should be considered as a cause of unexplained left ventricular hypertrophy.	KAGOSHIMA UNIV, FAC MED, DEPT INTERNAL MED 1, KAGOSHIMA 890, JAPAN; KAGOSHIMA UNIV, FAC MED, DEPT PATHOL 1, KAGOSHIMA 890, JAPAN; KAGOSHIMA UNIV, FAC MED, DEPT INTERNAL MED 3, KAGOSHIMA 890, JAPAN; TOKYO METROPOLITAN INST MED SCI, DEPT CLIN GENET, TOKYO 113, JAPAN	Kagoshima University; Kagoshima University; Kagoshima University; Tokyo Metropolitan Institute of Medical Science								ANDERSON MA, 1984, IN VITRO CELL DEV B, V20, P856; BASS JL, 1980, AM HEART J, V100, P807, DOI 10.1016/0002-8703(80)90060-5; BECKER AE, 1975, AM J CARDIOL, V36, P829, DOI 10.1016/0002-9149(75)90468-3; BISHOP DF, 1988, P NATL ACAD SCI USA, V85, P3903, DOI 10.1073/pnas.85.11.3903; BRADY RO, 1967, NEW ENGL J MED, V276, P1163, DOI 10.1056/NEJM196705252762101; COLUCCI WS, 1982, NEW ENGL J MED, V307, P926, DOI 10.1056/NEJM198210073071505; DAVIS LG, 1986, BASIC METHODS MOL BI, P130; DESNICK RJ, 1973, J LAB CLIN MED, V81, P157; DESNICK RJ, 1976, CIRCULATION, V54, P818, DOI 10.1161/01.CIR.54.5.818; DESNICK RJ, 1995, METABOLIC MOL BASIS, V2, P2741; ELLEDER M, 1990, VIRCHOWS ARCH A, V417, P449, DOI 10.1007/BF01606034; ENG CM, 1993, AM J HUM GENET, V53, P1186; FELNER JM, 1990, HEART, P1990; FERRANS VJ, 1969, AM J CARDIOL, V24, P95, DOI 10.1016/0002-9149(69)90055-1; FISHER EA, 1992, ANN INTERN MED, V117, P221, DOI 10.7326/0003-4819-117-3-221; GOLDMAN ME, 1986, J AM COLL CARDIOL, V7, P1157, DOI 10.1016/S0735-1097(86)80238-8; HENRY WL, 1973, CIRCULATION, V47, P225, DOI 10.1161/01.CIR.47.2.225; IKARI Y, 1992, BRIT HEART J, V68, P323; ISHII S, 1992, HUM GENET, V89, P29, DOI 10.1007/BF00207037; ISHII S, 1994, BBA-PROTEIN STRUCT M, V1204, P265, DOI 10.1016/0167-4838(94)90017-5; KOIDE T, 1990, FEBS LETT, V259, P353, DOI 10.1016/0014-5793(90)80046-L; KUHN H, 1982, CIRCULATION, V66, P117; MATSUI S, 1977, JPN CIRC J, V41, P1023, DOI 10.1253/jcj.41.1023; MAYES JS, 1981, CLIN CHIM ACTA, V112, P247, DOI 10.1016/0009-8981(81)90384-3; MEHTA J, 1977, AM HEART J, V93, P699, DOI 10.1016/S0002-8703(77)80064-1; NAGAO Y, 1991, CLIN GENET, V39, P233; OGAWA K, 1990, HUM PATHOL, V21, P1067, DOI 10.1016/0046-8177(90)90258-7; ROUDEBUSH CP, 1973, NEW ENGL J MED, V289, P357, DOI 10.1056/NEJM197308162890709; SAKURABA H, 1986, CLIN GENET, V29, P276; SAKURABA H, 1990, AM J HUM GENET, V47, P784; Sambrook J., 1989, MOL CLONING LAB MANU; VONSCHEIDT W, 1991, NEW ENGL J MED, V324, P395, DOI 10.1056/NEJM199102073240607; WEBB JG, 1990, J AM COLL CARDIOL, V15, P83, DOI 10.1016/0735-1097(90)90180-W; YANAGAWA Y, 1988, Acta Paediatrica Japonica, V30, P38	34	571	612	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 3	1995	333	5					288	293		10.1056/NEJM199508033330504	http://dx.doi.org/10.1056/NEJM199508033330504			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL694	7596372	Bronze			2022-12-24	WOS:A1995RL69400004
J	PELES, E; NATIV, M; CAMPBELL, PL; SAKURAI, T; MARTINEZ, R; LEV, S; CLARY, DO; SCHILLING, J; BARNEA, G; PLOWMAN, GD; GRUMET, M; SCHLESSINGER, J				PELES, E; NATIV, M; CAMPBELL, PL; SAKURAI, T; MARTINEZ, R; LEV, S; CLARY, DO; SCHILLING, J; BARNEA, G; PLOWMAN, GD; GRUMET, M; SCHLESSINGER, J			THE CARBONIC-ANHYDRASE DOMAIN OF RECEPTOR TYROSINE PHOSPHATASE-BETA IS A FUNCTIONAL LIGAND FOR THE AXONAL CELL RECOGNITION MOLECULE CONTACTIN	CELL			English	Article							ADHESION MOLECULE; NERVOUS-SYSTEM; NEURONAL DIFFERENTIATION; MULTIFUNCTIONAL PROTEIN; NEUROTROPHIN RECEPTORS; GLYCOPROTEIN; EXPRESSION; IMMUNOGLOBULIN; BINDING; GROWTH	Receptor-type protein tyrosine phosphatase beta (RPTP beta) is expressed in the developing nervous system and contains a carbonic anhydrase (CAH) domain as well as a fibronectin type III repeat in its extracellular domain. Fusion proteins containing these domains were used to search for ligands of RPTP beta. The CAH domain bound specifically to a 140 kDa protein expressed on the surface of neuronal cells. Expression cloning in COS7 cells revealed that this protein is contactin, a GPI membrane-anchored neuronal cell recognition molecule. The CAH domain of RPTP beta induced cell adhesion and neurite growth of primary tectal neurons, and differentiation of neuroblastoma cells. These responses were blocked by antibodies against contactin, demonstrating that contactin is a neuronal receptor for RPTP beta. These experiments show that an individual domain of RPTP beta acts as a functional ligand for the neuronal receptor contactin. The Interaction between contactin and RPTP beta may generate unidirectional or bidirectional signals during neural development.	NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	New York University	PELES, E (corresponding author), SUGEN INC,515 GALVESTON DR,REDWOOD CITY,CA 94063, USA.		Lev, Sima/AAP-7880-2020; grumet, martin/ABC-6462-2020	Lev, Sima/0000-0002-2108-3330; Peles, Elior/0000-0002-3325-0597	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021629] Funding Source: NIH RePORTER; NINDS NIH HHS [NS21629] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARNEA G, 1994, J BIOL CHEM, V269, P14349; BARNEA G, 1993, MOL CELL BIOL, V13, P1497, DOI 10.1128/MCB.13.3.1497; BARNEA G, 1994, CELL, V76, P205, DOI 10.1016/0092-8674(94)90328-X; BERGLUND EO, 1994, GENOMICS, V21, P571, DOI 10.1006/geno.1994.1316; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; BRUMMENDORF T, 1993, J NEUROCHEM, V61, P1207, DOI 10.1111/j.1471-4159.1993.tb13611.x; BRUMMENDORF T, 1993, NEURON, V10, P711; CANOLL PD, 1993, DEV BRAIN RES, V75, P293, DOI 10.1016/0165-3806(93)90035-9; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; Doherty Patrick, 1994, Current Opinion in Neurobiology, V4, P49, DOI 10.1016/0959-4388(94)90031-0; DURBEC P, 1992, J CELL BIOL, V117, P877, DOI 10.1083/jcb.117.4.877; FAIVRESARRAILH C, 1992, J NEUROSCI, V12, P257; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; GENNARINI G, 1989, J CELL BIOL, V109, P755; GLOOR S, 1990, J CELL BIOL, V110, P165, DOI 10.1083/jcb.110.1.165; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GRUMET M, 1993, J CELL BIOL, V120, P815, DOI 10.1083/jcb.120.3.815; GRUMET M, 1994, J BIOL CHEM, V269, P12142; HAWROT E, 1979, METHOD ENZYMOL, V58, P547; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; IGNELZI MA, 1994, NEURON, V12, P873, DOI 10.1016/0896-6273(94)90339-5; Keynes R J, 1992, Curr Opin Neurobiol, V2, P55, DOI 10.1016/0959-4388(92)90162-E; KRUEGER NX, 1992, P NATL ACAD SCI USA, V89, P7417, DOI 10.1073/pnas.89.16.7417; LAMMERS R, 1993, J BIOL CHEM, V168, P24456; LEVY JB, 1993, J BIOL CHEM, V268, P10573; LUDECKE G, 1990, CANCER, V65, P2270, DOI 10.1002/1097-0142(19900515)65:10<2270::AID-CNCR2820651019>3.0.CO;2-4; MAA JS, 1990, J BIOL CHEM, V265, P1569; MAUREL P, 1994, P NATL ACAD SCI USA, V91, P2512, DOI 10.1073/pnas.91.7.2512; MILEV P, 1994, J CELL BIOL, V127, P1703, DOI 10.1083/jcb.127.6.1703; MORALES G, 1993, NEURON, V11, P1113, DOI 10.1016/0896-6273(93)90224-F; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PESHEVA P, 1993, NEURON, V10, P69, DOI 10.1016/0896-6273(93)90243-K; PLOWMAN GD, 1992, J BIOL CHEM, V267, P13073; PULIDO D, 1992, EMBO J, V11, P391, DOI 10.1002/j.1460-2075.1992.tb05067.x; RANSCHT B, 1988, J CELL BIOL, V107, P1561, DOI 10.1083/jcb.107.4.1561; RAO ASMK, 1993, P NATL ACAD SCI USA, V90, P2950, DOI 10.1073/pnas.90.7.2950; REID RA, 1994, MOL BRAIN RES, V21, P1, DOI 10.1016/0169-328X(94)90372-7; ROUGON G, 1994, J MED BIOL RES, V2, P409; SAHIN M, 1995, J COMP NEUROL, V351, P617, DOI 10.1002/cne.903510410; SAP J, 1994, MOL CELL BIOL, V14, P1; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHARMA E, 1995, J BIOL CHEM, V270, P49, DOI 10.1074/jbc.270.1.49; SHITARA K, 1994, J BIOL CHEM, V269, P20189; SHOCK LP, 1995, MOL BRAIN RES, V28, P110, DOI 10.1016/0169-328X(94)00190-P; THEVENIAU M, 1992, J CELL BIOCHEM, V48, P61, DOI 10.1002/jcb.240480110; UMEMORI H, 1994, NATURE, V367, P572, DOI 10.1038/367572a0; WALSH FS, 1991, CELL BIOL INT REP, V15, P1151, DOI 10.1016/0309-1651(91)90061-M; WALTON KM, 1993, NEURON, V11, P387, DOI 10.1016/0896-6273(93)90193-U; ZHANG JS, 1995, J CELL BIOL, V128, P415, DOI 10.1083/jcb.128.3.415; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373; ZISCH AH, 1992, J CELL BIOL, V119, P203, DOI 10.1083/jcb.119.1.203	56	353	363	0	6	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 28	1995	82	2					251	260		10.1016/0092-8674(95)90312-7	http://dx.doi.org/10.1016/0092-8674(95)90312-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RL760	7628014	Bronze			2022-12-24	WOS:A1995RL76000012
J	HANSEN, JG; SCHMIDT, H; ROSBORG, J; LUND, E				HANSEN, JG; SCHMIDT, H; ROSBORG, J; LUND, E			PREDICTING ACUTE MAXILLARY SINUSITIS IN A GENERAL-PRACTICE POPULATION	BRITISH MEDICAL JOURNAL			English	Article							PHYSICAL-EXAMINATION; DIAGNOSIS; HISTORY; ULTRASONOGRAPHY; SYMPTOMS; SIGNS; NASAL	Objective-To evaluate the diagnostic value of symptoms, signs, erythrocyte sedimentation rate, and C reactive protein for acute maxillary sinusitis. Design-Prospective cohort study. Setting-Danish general practice in cooperation with the otorhinolaryngology and neuroradiology department at Aalborg County Hospital. Subjects-174 patients aged 18-65 years who were suspected by the general practitioner of having acute maxillary sinusitis. Main outcome measure-The independent association of symptoms, signs, erythrocyte sedimentation rate, and concentration of C reactive protein in patients with acute maxillary sinusitis defined as purulent or mucopurulent antral aspirate. Results-Only raised erythrocyte sedimentation rate (P=0.01) and raised C reactive protein (P=0.007) were found to be independently associated with a diagnosis of acute maxillary sinusitis. The combination of the two variables had a sensitivity of 0.82 and a specificity of 0.57. Conclusion-Erythrocyte sedimentation rate and C reactive protein are useful diagnostic criteria for acute maxillary sinusitis.	AALBORG CTY HOSP,DEPT OTORHINOLARYNGOL,AALBORG,DENMARK; AALBORG CTY HOSP,DEPT NEURORADIOL,AALBORG,DENMARK	Aalborg University; Aalborg University Hospital; Aalborg University; Aalborg University Hospital								Antila J., 1993, Rhinology (Utrecht), V31, P145; AXELSSON A, 1976, ORL J OTO-RHINO-LARY, V38, P298, DOI 10.1159/000275288; BERG O, 1988, ACTA OTO-LARYNGOL, V105, P343, DOI 10.3109/00016488809097017; BERG O, 1985, LARYNGOSCOPE, V95, P851; BERG O, 1981, ANN OTO RHINOL LARYN, V90, P272, DOI 10.1177/000348948109000316; Bro F, 1986, Ugeskr Laeger, V148, P2540; DRUCE HM, 1992, J ALLERGY CLIN IMMUN, V90, P436, DOI 10.1016/0091-6749(92)90165-X; FLINN J, 1994, CLIN OTOLARYNGOL, V19, P287, DOI 10.1111/j.1365-2273.1994.tb01232.x; Hansen J G, 1994, Ugeskr Laeger, V156, P1934; HJORTDAHL P, 1991, Scandinavian Journal of Primary Health Care, V9, P3, DOI 10.3109/02813439109026574; Hovelius B, 1986, INFEKTIONER PRIMARVA, P75; JANNERT M, 1982, ACTA OTOLARYNGOL S, V389, P29; KATHOLM M, 1984, ACTA OTOLARYNGOL S S, V412, P88; KAY NJ, 1984, ANN OTO RHINOL LARYN, V93, P37, DOI 10.1177/000348948409300109; Lindbaek Morten, 1993, Tidsskrift for den Norske Laegeforening, V113, P700; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; UNGER JM, 1984, LARYNGOSCOPE, V94, P1319; VANDUIJN NP, 1992, BRIT MED J, V305, P684, DOI 10.1136/bmj.305.6855.684; WILLIAMS JW, 1993, JAMA-J AM MED ASSOC, V270, P1242, DOI 10.1001/jama.270.10.1242; WILLIAMS JW, 1992, ANN INTERN MED, V117, P705, DOI 10.7326/0003-4819-117-9-705	20	132	138	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 22	1995	311	6999					233	236		10.1136/bmj.311.6999.233	http://dx.doi.org/10.1136/bmj.311.6999.233			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL441	7627042	Green Published			2022-12-24	WOS:A1995RL44100025
J	ANDERSON, NE; BROAD, JB; BONITA, R				ANDERSON, NE; BROAD, JB; BONITA, R			DELAYS IN-HOSPITAL ADMISSION AND INVESTIGATION IN ACUTE STROKE	BRITISH MEDICAL JOURNAL			English	Article							TIME		AUCKLAND HOSP,AUCKLAND,NEW ZEALAND; SCH MED AUCKLAND,GERIATR MED SECT,AUCKLAND,NEW ZEALAND	Auckland City Hospital; University of Auckland			Broad, Joanna B/D-1194-2010	Broad, Joanna B/0000-0003-0157-7031				ALBERTS MJ, 1990, JAMA-J AM MED ASSOC, V263, P65, DOI 10.1001/jama.263.1.65; BARSAN WG, 1993, ARCH INTERN MED, V153, P2558, DOI 10.1001/archinte.153.22.2558; BONITA R, 1995, INT J EPIDEMIOL, V24, P535, DOI 10.1093/ije/24.3.535; BONITA R, 1993, LANCET, V342, P470; HARPER GD, 1992, STROKE, V23, P835, DOI 10.1161/01.STR.23.6.835	5	51	53	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 15	1995	311	6998					162	162		10.1136/bmj.311.6998.162	http://dx.doi.org/10.1136/bmj.311.6998.162			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK159	7613428	Green Published			2022-12-24	WOS:A1995RK15900022
J	FOREYT, J; GOODRICK, K				FOREYT, J; GOODRICK, K			THE ULTIMATE TRIUMPH OF OBESITY	LANCET			English	Editorial Material											FOREYT, J (corresponding author), BAYLOR COLL MED,DEPT MED,NUTR RES CLIN,HOUSTON,TX 77030, USA.							BENNETT WI, 1995, NEW ENGL J MED, V332, P673, DOI 10.1056/NEJM199503093321009; Foreyt J P, 1994, Obes Res, V2, P378; FOREYT JP, 1994, LIVING DIETING; KIRSCHENBAUM DS, 1995, BEHAV THER, V26, P43, DOI 10.1016/S0005-7894(05)80082-6; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; LISSNER L, 1994, PHARMACOECONOMICS, V5, P8, DOI 10.2165/00019053-199400051-00004; Logue A. W., 2014, PSYCHOL EATING DRINK; POWELL KE, 1994, MED SCI SPORT EXER, V26, P851; RESNICOW K, 1993, ANN NY ACAD SCI, V699, P154, DOI 10.1111/j.1749-6632.1993.tb18847.x; Seligman, 1994, WHAT YOU CAN CHANGE; THOMAS PR, 1995, WEIGHTING OPTIONS CR; VANITALLIE TB, 1994, PHARMACOECONOMICS, V5, P1, DOI 10.2165/00019053-199400051-00003; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P642, DOI 10.1038/clpt.1992.76; WOLF AM, 1994, PHARMACOECONOMICS, V5, P34, DOI 10.2165/00019053-199400051-00007; 1994, MMWR-MORBID MORTAL W, V43, P116; 1994, SHAPE UP AM EXECUTIV	16	58	60	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 15	1995	346	8968					134	135		10.1016/S0140-6736(95)91205-3	http://dx.doi.org/10.1016/S0140-6736(95)91205-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ031	7603226				2022-12-24	WOS:A1995RJ03100005
J	YOKOYAMA, N; HAYASHI, N; SEKI, T; PANTE, N; OHBA, T; NISHII, K; KUMA, K; HAYASHIDA, T; MIYATA, T; AEBI, U; FUKUI, M; NISHIMOTO, T				YOKOYAMA, N; HAYASHI, N; SEKI, T; PANTE, N; OHBA, T; NISHII, K; KUMA, K; HAYASHIDA, T; MIYATA, T; AEBI, U; FUKUI, M; NISHIMOTO, T			A GIANT NUCLEOPORE PROTEIN THAT BINDS RAN/TC4	NATURE			English	Article							NUCLEAR-PORE COMPLEX; CELL-CYCLE; CHROMOSOME CONDENSATION; MESSENGER-RNA; RCC1; IMPORT; GENES; DNA	RAN/TC4 is a small nuclear G protein(1) that forms a complex with the chromatin-bound guanine nucleotide release factor RCC1 (ref. 2). Loss of RCC1 causes defects in cell-cycle progression(3,4), RNA export(5-7) and nuclear protein import(8). Some of these can be suppressed by overexpression of Ran/TC4 (ref. 1), suggesting that Ran/TC4 functions downstream of RCC1. We have searched for proteins that bind Ran/TC4 by using a two-hybrid screen, and here we report the identification of RanBP2, a novel protein of 3,224 residues. This giant protein comprises an amino-terminal 700-residue leucine-rich region, four RanBP1-homologous (refs 9, 10) domains, eight zinc-finger motifs similar to those of NUP153 (refs 11, 12), and a carboxy terminus with high homology to cyclophilin(13). The molecule contains the XFXFG pentapeptide motif characteristic of nuclear pore complex (NPC) proteins(14), and immunolocalization suggests that RanBP2 is a constituent of the NPC. The fact that NLS-mediated nuclear import can be inhibited by an antibody directed against RanBP2 supports a functional role in protein import through the NPC.	KYUSHU UNIV,GRAD SCH MED SCI,DEPT NEUROSURG,HIGASHI KU,FUKUOKA 81282,JAPAN; KYUSHU UNIV,GRAD SCH MED SCI,DEPT ANAT,HIGASHI KU,FUKUOKA 81282,JAPAN; KYOTO UNIV,FAC SCI,DEPT BIOPHYS,SAKYO KU,KYOTO 606,JAPAN; UNIV BASEL,BIOZENTRUM,ME MULLER INST MICROSCOPY,CH-4056 BASEL,SWITZERLAND; JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL & ANAT,BALTIMORE,MD 21205	Kyushu University; Kyushu University; Kyoto University; University of Basel; Johns Hopkins University	YOKOYAMA, N (corresponding author), KYUSHU UNIV,GRAD SCH MED SCI,DEPT MOLEC BIOL,HIGASHI KU,MAIDASHI 3-1-1,FUKUOKA 81282,JAPAN.		Oba, Tomoyuki/ABT-2152-2022; Pante, Nelly/GVR-8478-2022	Oba, Tomoyuki/0000-0002-6715-7892; Hayashi, Naoyuki/0000-0001-9626-3689				ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; AMBERG DC, 1993, EMBO J, V12, P233, DOI 10.1002/j.1460-2075.1993.tb05649.x; BISCHOFF FR, 1990, P NATL ACAD SCI USA, V87, P8617, DOI 10.1073/pnas.87.21.8617; BYRD DA, 1994, J CELL BIOL, V127, P1515, DOI 10.1083/jcb.127.6.1515; CHENG Y, 1995, SCIENCE, V267, P1807, DOI 10.1126/science.7534442; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; DASSO M, 1993, TRENDS BIOCHEM SCI, V18, P96, DOI 10.1016/0968-0004(93)90161-F; DASSO M, 1994, EMBO J, V13, P5732, DOI 10.1002/j.1460-2075.1994.tb06911.x; DAVIS LI, 1990, CELL, V61, P965, DOI 10.1016/0092-8674(90)90062-J; GALAT A, 1993, EUR J BIOCHEM, V216, P689, DOI 10.1111/j.1432-1033.1993.tb18189.x; GERACE L, 1984, J CELL SCI S, V1, P137; HARPER JW, 1993, CELL, V75, P805; HAYASHI N, IN PRESS MOL GEN GEN; KADOWAKI T, 1993, EMBO J, V12, P2929, DOI 10.1002/j.1460-2075.1993.tb05955.x; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KRAEMER D, 1994, P NATL ACAD SCI USA, V91, P1519, DOI 10.1073/pnas.91.4.1519; LOUNSBURY KM, 1994, J BIOL CHEM, V269, P11285; MCMORROW I, 1994, BBA-GENE STRUCT EXPR, V1217, P219, DOI 10.1016/0167-4781(94)90040-X; MELCHIOR F, 1993, J CELL BIOL 2, V123, P1649; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; NISHITANI H, 1991, EMBO J, V10, P1555, DOI 10.1002/j.1460-2075.1991.tb07675.x; OHTSUBO M, 1991, EMBO J, V10, P1265, DOI 10.1002/j.1460-2075.1991.tb08068.x; PANTE N, 1994, J STRUCT BIOL, V113, P179, DOI 10.1006/jsbi.1994.1052; PANTE N, 1994, J CELL BIOL, V126, P603, DOI 10.1083/jcb.126.3.603; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; RADU A, 1994, J BIOL CHEM, V269, P17600; SAZER S, 1994, EMBO J, V13, P606, DOI 10.1002/j.1460-2075.1994.tb06298.x; Schwartz RM, 1978, ATLAS PROTEIN SEQ S3, P353; SUKEGAWA J, 1993, CELL, V72, P29, DOI 10.1016/0092-8674(93)90047-T; TACHIBANA T, 1994, J BIOL CHEM, V269, P24542; TOH H, 1983, NATURE, V305, P827, DOI 10.1038/305827a0; VONLINDERN M, 1992, MOL CELL BIOL, V12, P1687	32	425	431	1	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 13	1995	376	6536					184	188		10.1038/376184a0	http://dx.doi.org/10.1038/376184a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ028	7603572				2022-12-24	WOS:A1995RJ02800064
J	BOYD, JW; HIMMELSTEIN, DU; WOOLHANDLER, S				BOYD, JW; HIMMELSTEIN, DU; WOOLHANDLER, S			THE TOBACCO HEALTH-INSURANCE CONNECTION	LANCET			English	Editorial Material									HARVARD UNIV,CAMBRIDGE HOSP,SCH MED,DEPT MED,CAMBRIDGE,MA; HARVARD UNIV,SCH MED,DEPT SOCIAL MED,CAMBRIDGE,MA 02138	Harvard University; Cambridge Health Alliance; Cambridge Hospital; Harvard University	BOYD, JW (corresponding author), HARVARD UNIV,CAMBRIDGE HOSP,SCH MED,DEPT PSYCHIAT,CAMBRIDGE,MA 02138, USA.							ANDERS G, 1994, WALL STREET J   1221, P1; DAVIS RM, 1991, JAMA-J AM MED ASSOC, V266, P3186, DOI 10.1001/jama.266.22.3186; Friedman M., 1962, CAPITALISM FREEDOM, DOI DOI 10.2307/825316; MACKAY J, 1992, NATL CANCER I MONOGR, V12, P25; PIERCE JP, 1991, JAMA-J AM MED ASSOC, V266, P3154, DOI 10.1001/jama.266.22.3154; SALMON J, 1994, CORPORATE TRANSFORMA; Taylor Peter, 1984, SMOKE RING TOBACCO M; Tudor Hart J, 1994, FEASIBLE SOCIALISM N; 1995, COMPACT DISCLOSURE D	9	12	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 8	1995	346	8967					64	64		10.1016/S0140-6736(95)92104-4	http://dx.doi.org/10.1016/S0140-6736(95)92104-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH220	7603209				2022-12-24	WOS:A1995RH22000002
J	NICHOLSON, DW; ALI, A; THORNBERRY, NA; VAILLANCOURT, JP; DING, CK; GALLANT, M; GAREAU, Y; GRIFFIN, PR; LABELLE, M; LAZEBNIK, YA; MUNDAY, NA; RAJU, SM; SMULSON, ME; YAMIN, TT; YU, VL; MILLER, DK				NICHOLSON, DW; ALI, A; THORNBERRY, NA; VAILLANCOURT, JP; DING, CK; GALLANT, M; GAREAU, Y; GRIFFIN, PR; LABELLE, M; LAZEBNIK, YA; MUNDAY, NA; RAJU, SM; SMULSON, ME; YAMIN, TT; YU, VL; MILLER, DK			IDENTIFICATION AND INHIBITION OF THE ICE/CED-3 PROTEASE NECESSARY FOR MAMMALIAN APOPTOSIS	NATURE			English	Article							INTERLEUKIN-1-BETA CONVERTING ENZYME; POLY(ADP-RIBOSE) POLYMERASE; ENDONUCLEASE; CELLS; RIBOSYLATION; SEQUENCE; ENCODES; VIRUS; GENE	The protease responsible for the cleavage of poly(ADP-ribose) polymerase and necessary for apoptosis has been purified and characterized. This enzyme, named apopain, is composed of two subunits of relative molecular mass (M(r)) 17K and 12K that are derived from a common proenzyme identified as CPP32. This proenzyme is related to interleukin-1 beta-converting enzyme (ICE) and CED-3, the product of a gene required for programmed cell death in Caenorhabditis elegans. A potent peptide aldehyde inhibitor has been developed and shown to prevent apoptotic events In vitro, suggesting that apopain/CPP32 is important for the initiation of apoptotic cell death.	MERCK FROSST CANADA INC,MERCK FROSST CTR THERAPEUT RES,DEPT MED CHEM,POINTE CLAIRE,PQ H9R 4P8,CANADA; MERCK & CO INC,RES LABS,DEPT BIOCHEM,RAHWAY,NJ 07065; MERCK & CO INC,RES LABS,DEPT INFLAMMAT RES,RAHWAY,NJ 07065; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724; GEORGETOWN UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,WASHINGTON,DC	Merck & Company; Merck & Company; Merck & Company; Cold Spring Harbor Laboratory; Georgetown University	NICHOLSON, DW (corresponding author), MERCK FROSST CANADA INC,MERCK FROSST CTR THERAPEUT RES,DEPT BIOCHEM & MOLEC BIOL,POB 1005,POINTE CLAIRE,PQ H9R 4P8,CANADA.							AYALA JM, 1994, J IMMUNOL, V153, P2592; BARR PJ, 1994, BIO-TECHNOL, V12, P487, DOI 10.1038/nbt0594-487; BERGER NA, 1980, BIOCHEMISTRY-US, V19, P289, DOI 10.1021/bi00543a006; BURKLE A, 1992, EXP CLIN IMMUNOGENET, V9, P230; CARSON DA, 1994, LANCET, V341, P1251; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHAPMAN KT, 1992, BIOORG MED CHEM LETT, V2, P613, DOI 10.1016/S0960-894X(01)81209-9; CHERNEY BW, 1987, P NATL ACAD SCI USA, V84, P8370, DOI 10.1073/pnas.84.23.8370; DEMURCIA G, 1991, BIOESSAYS, V13, P455, DOI 10.1002/bies.950130905; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DING RC, 1994, CANCER RES, V54, P4627; DING RC, 1992, J BIOL CHEM, V267, P12804; ELLIS RE, 1991, REV CELL BIOL, V7, P663; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; HOWARD AD, 1995, J IMMUNOL, V154, P2321; JUAREZSALINAS H, 1979, NATURE, V282, P740, DOI 10.1038/282740a0; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LANGLOIS AJ, 1974, CANCER RES, V34, P1457; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARTIN SJ, 1994, TRENDS BIOCHEM SCI, V19, P26, DOI 10.1016/0968-0004(94)90170-8; MILLER DK, 1993, J BIOL CHEM, V268, P18062; MIURA M, 1993, CELL, V76, P653; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SMULSON M, 1994, BIOCHEMISTRY-US, V33, P6186, DOI 10.1021/bi00186a018; SOLARY E, 1993, BLOOD, V81, P1359; TANAKA Y, 1984, J BIOL CHEM, V259, P6579; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; WESTERIK JO, 1972, J BIOL CHEM, V247, P8195; WILLIAMS MS, 1994, J IMMUNOL, V153, P4247; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; YOSHIHAR.K, 1974, BIOCHEM BIOPH RES CO, V59, P658, DOI 10.1016/S0006-291X(74)80030-6; YOSHIHARA K, 1975, P NATL ACAD SCI USA, V72, P289, DOI 10.1073/pnas.72.1.289; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	48	3711	3861	1	91	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 6	1995	376	6535					37	43		10.1038/376037a0	http://dx.doi.org/10.1038/376037a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH111	7596430				2022-12-24	WOS:A1995RH11100055
J	ELLIS, NA; GRODEN, J; YE, TZ; STRAUGHEN, J; LENNON, DJ; CIOCCI, S; PROYTCHEVA, M; GERMAN, J				ELLIS, NA; GRODEN, J; YE, TZ; STRAUGHEN, J; LENNON, DJ; CIOCCI, S; PROYTCHEVA, M; GERMAN, J			THE BLOOMS-SYNDROME GENE-PRODUCT IS HOMOLOGOUS TO RECQ HELICASES	CELL			English	Article							SYNDROME FIBROBLASTS; SYNDROME CELLS; ADENOMATOUS POLYPOSIS; PUTATIVE HELICASES; DNA GLYCOSYLASE; RECOMBINATION; REPAIR; IDENTIFICATION; REPLICATION; SENSITIVITY	The Bloom's syndrome (BS) gene, BLM, plays an important role in the maintenance of genomic stability in somatic cells. A candidate for BLM was identified by direct selection of a cDNA derived from a 250 kb segment of the genome to which BLM had been assigned by somatic crossover point mapping. In this novel mapping method, cells were used from persons with BS that had undergone intragenic recombination within BLM. cDNA analysis of the candidate gene identified a 4437 bp cDNA that encodes a 1417 amino acid peptide with homology to the RecQ helicases, a subfamily of DExH box-containing DNA and RNA helicases. The presence of chain-terminating mutations in the candidate gene in persons with BS proved that it was BLM.	UNIV CINCINNATI, COLL MED, DEPT MOLEC GENET BIOCHEM & MICROBIOL, CINCINNATI, OH 45267 USA	University System of Ohio; University of Cincinnati	ELLIS, NA (corresponding author), NEW YORK BLOOD CTR, HUMAN GENET LAB, NEW YORK, NY 10021 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD004134] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA050897] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006096] Funding Source: NIH RePORTER; NCI NIH HHS [CA-50897] Funding Source: Medline; NICHD NIH HHS [HD-04134] Funding Source: Medline; NIEHS NIH HHS [ES-06096] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BECKMANN JS, 1993, HUM MOL GENET, V2, P2019, DOI 10.1093/hmg/2.12.2019; CHAN JYH, 1987, NATURE, V325, P357, DOI 10.1038/325357a0; COLLINS FS, 1995, NAT GENET, V9, P347, DOI 10.1038/ng0495-347; DEHAZYA P, 1986, CANCER RES, V46, P3756; ELLIS NA, 1994, AM J HUM GENET, V55, P453; ELLIS NA, 1994, NAT GENET, V6, P394, DOI 10.1038/ng0494-394; ELLIS NA, 1995, AM J HUM GENET, V57, P1019; FREJTER WL, 1992, P NATL ACAD SCI USA, V89, P261; FRIEDBERG EC, 1979, ADV RADIAT BIOL, V8, P85; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GERMAN J, 1989, CLIN GENET, V35, P57; GERMAN J, 1994, P NATL ACAD SCI USA, V91, P6669, DOI 10.1073/pnas.91.14.6669; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; GERMAN J, IN PRESS CLIN GENET; GERMAN J, 1980, GENETIC ENV FACTORS, P175; GLANNELLI F, 1977, NATURE, V265, P466; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GRODEN J, 1993, AM J HUM GENET, V52, P263; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HAND R, 1975, P NATL ACAD SCI USA, V72, P758, DOI 10.1073/pnas.72.2.758; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; HEARTLEIN MW, 1987, EXP CELL RES, V169, P245; Heddle J.A., 1983, CHROMOSOME MUTATION, P203; HORII ZI, 1973, J MOL BIOL, V80, P327, DOI 10.1016/0022-2836(73)90176-9; ISHIZAKI K, 1981, MUTAT RES, V80, P213, DOI 10.1016/0027-5107(81)90189-5; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KIM S, 1986, MUTAT RES, V173, P141, DOI 10.1016/0165-7992(86)90092-8; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KREPINSKY AB, 1979, HUM GENET, V50, P151, DOI 10.1007/BF00390236; KREPINSKY AB, 1980, MUTAT RES, V69, P357, DOI 10.1016/0027-5107(80)90100-1; KURIHARA T, 1987, MUTAT RES, V184, P147, DOI 10.1016/0167-8817(87)90071-X; KUSANO K, 1994, P NATL ACAD SCI USA, V91, P1173, DOI 10.1073/pnas.91.3.1173; LEHESJOKI AE, 1993, HUM MOL GENET, V2, P1229, DOI 10.1093/hmg/2.8.1229; LONN U, 1990, CANCER RES, V50, P3141; LUISIDELUCA C, 1989, GENETICS, V122, P269; MA LB, 1994, MOL CELL BIOL, V14, P4126, DOI 10.1128/MCB.14.6.4126; MATHEW S, 1993, CYTOGENET CELL GENET, V63, P33, DOI 10.1159/000133496; MCDANIEL LD, 1992, P NATL ACAD SCI USA, V89, P7968, DOI 10.1073/pnas.89.17.7968; NAKAYAMA H, 1984, MOL GEN GENET, V195, P474, DOI 10.1007/BF00341449; NICOTERA TM, 1989, CANCER RES, V49, P5239; PARIMOO S, 1991, P NATL ACAD SCI USA, V88, P9623, DOI 10.1073/pnas.88.21.9623; PURANAM KL, 1994, J BIOL CHEM, V269, P29838; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEAL G, 1988, P NATL ACAD SCI USA, V85, P2339, DOI 10.1073/pnas.85.7.2339; SEKI M, 1994, NUCLEIC ACIDS RES, V22, P4566, DOI 10.1093/nar/22.22.4566; SHIRAISHI Y, 1989, MUTAT RES, V211, P273, DOI 10.1016/0027-5107(89)90010-9; SIRUGO G, 1992, AM J HUM GENET, V50, P559; STRATHDEE CA, 1992, NATURE, V356, P763, DOI 10.1038/356763a0; SUNG P, 1993, NATURE, V365, P852, DOI 10.1038/365852a0; SURDEJ P, 1994, ANNU REV GENET, V28, P263; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; TSENG YC, 1994, MUTAT RES, V315, P1; UMEZU K, 1990, P NATL ACAD SCI USA, V87, P5363, DOI 10.1073/pnas.87.14.5363; WARBURTON D, 1990, GENOMICS, V6, P358, DOI 10.1016/0888-7543(90)90577-H; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; WEBER CA, 1990, EMBO J, V9, P1437, DOI 10.1002/j.1460-2075.1990.tb08260.x; WILLIS AE, 1987, NATURE, V325, P355, DOI 10.1038/325355a0	61	1153	1186	1	33	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 17	1995	83	4					655	666		10.1016/0092-8674(95)90105-1	http://dx.doi.org/10.1016/0092-8674(95)90105-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TF248	7585968	Bronze			2022-12-24	WOS:A1995TF24800018
J	HEALE, SM; PETES, TD				HEALE, SM; PETES, TD			THE STABILIZATION OF REPETITIVE TRACTS OF DNA BY VARIANT REPEATS REQUIRES A FUNCTIONAL DNA MISMATCH REPAIR SYSTEM	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; CAG REPEAT; YEAST; INSTABILITY; GENE; SEQUENCE; MUTANTS; RECOMBINATION; MUTATIONS	Simple repetitive tracts of DNA are unstable in all organisms thus far examined. In the yeast S. cerevisiae, we show that a 51 bp poly(GT) tract alters length at a rate of about 10(-5) per cell division. Insertion of a single variant repeat (either AT or CT) into the middle of the poly(GT) tract results in 100-fold stabilization. This stabilization requires the DNA mismatch repair system. Alterations within tracts with variant repeats occur more frequently on one side of the interruption than on the other. The stabilizing effects of variant repeats and polarity of repeat alterations have also been observed in trinucleotide repeats associated with certain human diseases.			HEALE, SM (corresponding author), UNIV N CAROLINA,DEPT BIOL,CB 3280,CHAPEL HILL,NC 27599, USA.				NIGMS NIH HHS [GM50892] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1994, GENETICS, V137, P19; ALANI E, 1987, GENETICS, V117, P5; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BICHARA M, 1992, GENETICS, V140, P897; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; CHONG SS, 1995, NAT GENET, V10, P344, DOI 10.1038/ng0795-344; CHUNG MY, 1993, NAT GENET, V5, P254, DOI 10.1038/ng1193-254; DETLOFF P, 1992, MOL CELL BIOL, V12, P1805, DOI 10.1128/MCB.12.4.1805; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; EICHLER EE, 1994, NAT GENET, V8, P88, DOI 10.1038/ng0994-88; FARBER RA, 1994, HUM MOL GENET, V3, P253, DOI 10.1093/hmg/3.2.253; FREUND AM, 1989, P NATL ACAD SCI USA, V86, P7465, DOI 10.1073/pnas.86.19.7465; GACY AM, 1995, CELL, V81, P533; GORDENIN DA, 1992, P NATL ACAD SCI USA, V89, P3785, DOI 10.1073/pnas.89.9.3785; HAMADA H, 1982, P NATL ACAD SCI-BIOL, V79, P6465, DOI 10.1073/pnas.79.21.6465; HENDERSON ST, 1992, MOL CELL BIOL, V12, P2749, DOI 10.1128/MCB.12.6.2749; HIRST MC, 1994, HUM MOL GENET, V3, P1553, DOI 10.1093/hmg/3.9.1553; JEFFREYS AJ, 1994, NAT GENET, V6, P136, DOI 10.1038/ng0294-136; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; KARRAN P, 1994, BIOESSAYS, V16, P833, DOI 10.1002/bies.950161110; KRAMER W, 1989, J BACTERIOL, V171, P5339, DOI 10.1128/jb.171.10.5339-5346.1989; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; KUNST CB, 1994, CELL, V77, P853, DOI 10.1016/0092-8674(94)90134-1; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; LEVINSON G, 1987, NUCLEIC ACIDS RES, V15, P5323, DOI 10.1093/nar/15.13.5323; NANCARROW JK, 1995, HUM MOL GENET, V4, P367, DOI 10.1093/hmg/4.3.367; NELSON DL, 1993, NAT GENET, V4, P107, DOI 10.1038/ng0693-107; NEW L, 1993, MOL GEN GENET, V239, P97, DOI 10.1007/BF00281607; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; REENAN RAG, 1992, GENETICS, V132, P963; REENAN RAG, 1992, GENETICS, V132, P975; RICHARDS RI, 1994, NAT GENET, V6, P114, DOI 10.1038/ng0294-114; Sambrook J., 1989, MOL CLONING LAB MANU; SELVA EM, 1995, GENETICS, V139, P1175; Sherman F., 1983, METHODS YEAST GENETI; SMITH GP, 1973, COLD SPRING HARB SYM, V38, P507, DOI 10.1101/SQB.1974.038.01.055; SNOW K, 1994, HUM MOL GENET, V3, P1543, DOI 10.1093/hmg/3.9.1543; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; STRAND MK, 1995, IN PRESS P NATL ACAD; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; TRINH TQ, 1991, NATURE, V352, P544, DOI 10.1038/352544a0; WALMSLEY RM, 1983, NATURE, V302, P84, DOI 10.1038/302084a0; WARD AC, 1990, NUCLEIC ACIDS RES, V18, P5345; WILLIAMSON MS, 1985, GENETICS, V110, P609; WORTH L, 1994, P NATL ACAD SCI USA, V91, P3238, DOI 10.1073/pnas.91.8.3238	47	59	74	0	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 17	1995	83	4					539	545		10.1016/0092-8674(95)90093-4	http://dx.doi.org/10.1016/0092-8674(95)90093-4			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TF248	7585956	Bronze, Green Submitted			2022-12-24	WOS:A1995TF24800006
J	HILLMEN, P; LEWIS, SM; BESSLER, M; LUZZATTO, L; DACIE, JV				HILLMEN, P; LEWIS, SM; BESSLER, M; LUZZATTO, L; DACIE, JV			NATURAL-HISTORY OF PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CELL-LINES; MARROW TRANSPLANTATION; ANCHOR BIOSYNTHESIS; APLASTIC-ANEMIA; RED-CELLS; PIG-A; PHOSPHATIDYLINOSITOL; DEFICIENCY; DEFECT; PROTEIN	Background. Paroxysmal nocturnal hemoglobinuria (PNH), which is characterized by intravascular hemolysis and venous thrombosis, is an acquired clonal disorder associated with a somatic mutation in a totipotent hematopoietic stem cell, An understanding of the natural history of PNH is essential to improve therapy. Methods. We have followed a group of 80 consecutive patients with PNH who were referred to Hammersmith Hospital, London, between 1940 and 1970. They were treated with supportive measures, such as oral anticoagulant therapy after established thromboses, and transfusions. Results. The median age of the patients at the time of diagnosis was 42 years (range, 16 to 75), and the median survival after diagnosis was 10 years, with 22 patients (28 percent) surviving for 25 years. Sixty patients have died; 28 of the 48 patients for whom the cause of death is known died from either venous thrombosis or hemorrhage. Thirty-one patients (39 percent) had one or more episodes of venous thrombosis during their illness. Of the 35 patients who survived for 10 years or more, 12 had a spontaneous clinical recovery, No PNH-affected cells were found among the erythrocytes or neutrophils of the patients in prolonged remission, but a few PNH-affected lymphocytes were detectable in three of the four patients tested. Leukemia did not develop in any of the patients. Conclusions. PNH is a chronic disorder that curtails life, A spontaneous long-term remission can occur, which must be taken into account when considering potentially dangerous treatments, such as bone marrow transplantation. Platelet transfusions should be given, as appropriate, and long-term anticoagulation therapy should be considered for all patients.	ROYAL POSTGRAD MED SCH,DEPT HAEMATOL,LONDON W12 0HS,ENGLAND; HAMMERSMITH HOSP,LONDON,ENGLAND; MEM SLOAN KETTERING CANC CTR,DEPT HUMAN GENET,NEW YORK,NY 10021	Imperial College London; Imperial College London; Memorial Sloan Kettering Cancer Center	HILLMEN, P (corresponding author), GEN INFIRM,INST PATHOL,HAEMATOL MALIGNANCY DIAGNOST SERV,GREAT GEORGE ST,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARMITAGE JO, 1994, NEW ENGL J MED, V330, P827, DOI 10.1056/NEJM199403243301206; ARMSTRONG C, 1992, J BIOL CHEM, V267, P25347; BESSLER M, 1994, EMBO J, V13, P110, DOI 10.1002/j.1460-2075.1994.tb06240.x; BESSLER M, 1994, LANCET, V343, P951, DOI 10.1016/S0140-6736(94)90068-X; CHARACHE S, 1969, BLOOD-J HEMATOL, V33, P877, DOI 10.1182/blood.V33.6.877.877; CROSBY WH, 1951, BLOOD, V6, P270, DOI 10.1182/blood.V6.3.270.270; CROSBY WH, 1953, BLOOD, V8, P769, DOI 10.1182/blood.V8.9.769.769; Dacie J, 1980, Sangre (Barc), V25, P890; DACIE J V, 1972, Series Haematologica, V5, P3; Dacie J V, 1944, Arch Dis Child, V19, P155; DACIE JV, 1961, BRIT J HAEMATOL, V7, P442, DOI 10.1111/j.1365-2141.1961.tb00354.x; DACIE JV, 1963, P ROY SOC MED, V56, P587, DOI 10.1177/003591576305600723; DACIE JV, 1954, HAEMOLYTIC ANAEMIA, P412; DEVINE DV, 1987, J CLIN INVEST, V79, P314, DOI 10.1172/JCI112802; FERGUSON MAJ, 1992, BIOCHEM SOC T, V20, P243, DOI 10.1042/bst0200243; HILLMEN P, 1993, BLOOD, V81, P193; HILLMEN P, 1993, P NATL ACAD SCI USA, V90, P5272, DOI 10.1073/pnas.90.11.5272; HILLMEN P, 1992, BRIT J HAEMATOL, V80, P399, DOI 10.1111/j.1365-2141.1992.tb08151.x; HOLGUIN MH, 1989, J CLIN INVEST, V84, P7, DOI 10.1172/JCI114172; KAWAHARA K, 1992, AM J HEMATOL, V39, P283, DOI 10.1002/ajh.2830390409; KURNICK JE, 1971, P SOC EXP BIOL MED, V137, P917; LETMAN H, 1952, BLOOD, V7, P842, DOI 10.1182/blood.V7.8.842.842; LONGO L, 1994, BRIT J HAEMATOL, V87, P401, DOI 10.1111/j.1365-2141.1994.tb04930.x; LUZZATTO L, 1995, PRACTICAL HAEMATOLOG, P287; MCMULLIN MF, 1994, J INTERN MED, V235, P85, DOI 10.1111/j.1365-2796.1994.tb01037.x; MIYATA T, 1994, NEW ENGL J MED, V330, P249, DOI 10.1056/NEJM199401273300404; MIYATA T, 1993, SCIENCE, V259, P1318, DOI 10.1126/science.7680492; MOORE JG, 1986, EXP HEMATOL, V14, P222; ONI SB, 1970, BLOOD-J HEMATOL, V36, P145, DOI 10.1182/blood.V36.2.145.145; ROSSE WF, 1991, BLOOD, V78, P547, DOI 10.1182/blood.V78.3.547.bloodjournal783547; ROSSE WF, 1990, BLOOD, V75, P1595; ROTOLI B, 1989, SEMIN HEMATOL, V26, P201; Rotoli B, 1989, Baillieres Clin Haematol, V2, P113, DOI 10.1016/S0950-3536(89)80010-1; ROTOLI B, 1982, BLOOD, V60, P157; STORB R, 1973, BRIT J HAEMATOL, V24, P743, DOI 10.1111/j.1365-2141.1973.tb01701.x; TAKAHASHI M, 1993, J EXP MED, V177, P517, DOI 10.1084/jem.177.2.517; TAKEDA J, 1993, CELL, V73, P703, DOI 10.1016/0092-8674(93)90250-T; TICHELLI A, 1988, BRIT J HAEMATOL, V69, P413, DOI 10.1111/j.1365-2141.1988.tb02382.x; VANKAMP H, 1994, BRIT J HAEMATOL, V87, P399, DOI 10.1111/j.1365-2141.1994.tb04929.x; YAMASHINA M, 1990, NEW ENGL J MED, V323, P1184, DOI 10.1056/NEJM199010253231707	40	601	630	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 9	1995	333	19					1253	1258		10.1056/NEJM199511093331904	http://dx.doi.org/10.1056/NEJM199511093331904			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC715	7566002				2022-12-24	WOS:A1995TC71500004
J	JIN, YS; MEAD, J; LI, T; WOLBERGER, C; VERSHON, AK				JIN, YS; MEAD, J; LI, T; WOLBERGER, C; VERSHON, AK			ALTERED DNA RECOGNITION AND BENDING BY INSERTIONS IN THE ALPHA-2 TAIL OF THE YEAST A1/ALPHA-2 HOMEODOMAIN HETERODIMER	SCIENCE			English	Article							PROTEIN; BINDING; SPECIFICITY; DROSOPHILA; REPRESSOR; ORIENTATION; RECEPTORS; GENE; MCM1; A1	The yeast MAT alpha 2 and MATa1 homeodomain proteins bind cooperatively as a heterodimer to sites upstream of haploid-specific genes, repressing their transcription. In the crystal structure of alpha 2 and a1 bound to DNA, each homeodomain makes independent base-specific contacts with the DNA and the two proteins contact each other through an extended tail region of alpha 2 that tethers the two homeodomains to one another. Because this extended region may be flexible, the ability of the heterodimer to discriminate among DNA sites with altered spacing between alpha 2 and a1 binding sites was examined. Spacing between the half sites was critical for specific DNA binding and transcriptional repression by the complex. However, amino acid insertions in the tail region of alpha 2 suppressed the effect of altering an a1/alpha 2 site by increasing the spacing between the half sites. Insertions in the tail also decreased DNA bending by a1/alpha 2. Thus tethering the two homeodomains contributes to DNA bending by a1/alpha 2, but the precise nature of the resulting bend is not essential for repression.	RUTGERS STATE UNIV,WAKSMAN INST,PISCATAWAY,NJ 08855; RUTGERS STATE UNIV,DEPT MOLEC BIOL & BIOCHEM,PISCATAWAY,NJ 08855; JOHNS HOPKINS UNIV,SCH MED,DEPT BIOPHYS & BIOPHYS CHEM,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University				Wolberger, Cynthia/0000-0001-8578-2969	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049265] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49265] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; DRANGINIS AM, 1990, NATURE, V347, P682, DOI 10.1038/347682a0; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.bi.63.070194.002415; GOUTTE C, 1994, EMBO J, V13, P1434, DOI 10.1002/j.1460-2075.1994.tb06397.x; GOUTTE C, 1988, CELL, V52, P875, DOI 10.1016/0092-8674(88)90429-1; GOUTTE C, 1993, J MOL BIOL, V233, P359, DOI 10.1006/jmbi.1993.1517; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; JIN Y, UNPUB; Johnson A. A, 1992, TRANSCRIPTIONAL REGU, P975; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KELEHER CA, 1989, MOL CELL BIOL, V9, P5228, DOI 10.1128/MCB.9.11.5228; KORNFELD K, 1989, GENE DEV, V3, P243, DOI 10.1101/gad.3.2.243; LAWRENCE PA, 1994, CELL, V78, P181, DOI 10.1016/0092-8674(94)90289-5; LI T, 1995, SCIENCE, V270, P262, DOI 10.1126/science.270.5234.262; MAK A, 1993, GENE DEV, V7, P1862, DOI 10.1101/gad.7.10.1862; MEAD J, UNPUB; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; PHILLIPS CL, 1994, BIOCHEMISTRY-US, V33, P9294, DOI 10.1021/bi00197a033; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SMITH DL, 1995, NUCLEIC ACIDS RES, V23, P1239, DOI 10.1093/nar/23.7.1239; SMITH DL, 1992, CELL, V68, P133, DOI 10.1016/0092-8674(92)90212-U; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; VERSHON AK, 1992, MOL CELL BIOL, V12, P3706, DOI 10.1128/MCB.12.9.3706; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239	31	20	21	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 13	1995	270	5234					290	293		10.1126/science.270.5234.290	http://dx.doi.org/10.1126/science.270.5234.290			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ342	7569977				2022-12-24	WOS:A1995RZ34200036
J	SIZEMORE, DR; BRANSTROM, AA; SADOFF, JC				SIZEMORE, DR; BRANSTROM, AA; SADOFF, JC			ATTENUATED SHIGELLA AS A DNA DELIVERY VEHICLE FOR DNA-MEDIATED IMMUNIZATION	SCIENCE			English	Article							GRAM-NEGATIVE BACTERIA; ESCHERICHIA-COLI; FLEXNERI; CONSTRUCTION; SELECTION; PLASMID; VECTOR; CELLS; GENES	Direct inoculation of DNA, in the form of purified bacterial plasmids that are unable to replicate in mammalian cells but are able to direct cell synthesis of foreign proteins, is being explored as an approach to vaccine development. Here, a highly attenuated Shigella vector invaded mammalian cells and delivered such plasmids into the cytoplasm of cells, and subsequent production of functional foreign protein was measured. Because this Shigella vector was designed to deliver DNA to colonic mucosa, the method is a potential basis for oral and other mucosal DNA immunization and gene therapy strategies.			SIZEMORE, DR (corresponding author), WALTER REED ARMY INST RES,DEPT BACTERIAL DIS,DIV COMMUNICABLE DIS & IMMUNOL,WASHINGTON,DC 20307, USA.							Bethesda MD, 1985, NIH PUBLICATION, V86-23; DONNELLY JJ, 1994, J IMMUNOL METHODS, V176, P145, DOI 10.1016/0022-1759(94)90308-5; DONNENBERG MS, 1991, INFECT IMMUN, V59, P4310, DOI 10.1128/IAI.59.12.4310-4317.1991; HARTMAN AB, 1991, INFECT IMMUN, V59, P4075, DOI 10.1128/IAI.59.11.4075-4083.1991; HAZIZA C, 1982, EMBO J, V1, P379, DOI 10.1002/j.1460-2075.1982.tb01178.x; HIGH N, 1992, EMBO J, V11, P1991, DOI 10.1002/j.1460-2075.1992.tb05253.x; Macgregor G R, 1991, Methods Mol Biol, V7, P217, DOI 10.1385/0-89603-178-0:217; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MALOY SR, 1981, J BACTERIOL, V145, P1110, DOI 10.1128/JB.145.2.1110-1111.1981; MILLS JA, 1988, INFECT IMMUN, V56, P2933, DOI 10.1128/IAI.56.11.2933-2941.1988; NAKAYAMA K, 1988, BIO-TECHNOL, V6, P693, DOI 10.1038/nbt0688-693; OAKS EV, 1985, INFECT IMMUN, V48, P124, DOI 10.1128/IAI.48.1.124-129.1985; PORTNOY DA, 1994, ANN NY ACAD SCI, V730, P15, DOI 10.1111/j.1749-6632.1994.tb44235.x; QUANDT J, 1993, GENE, V127, P15, DOI 10.1016/0378-1119(93)90611-6; SANDER B, 1993, J IMMUNOL METHODS, V166, P201, DOI 10.1016/0022-1759(93)90361-A; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SANSONETTI PJ, 1983, INFECT IMMUN, V39, P1392, DOI 10.1128/IAI.39.3.1392-1402.1983; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; SIZEMORE DR, UNPUB; SUN JB, 1994, P NATL ACAD SCI USA, V91, P10795, DOI 10.1073/pnas.91.23.10795; VANDEVERG LL, 1995, INFECT IMMUN, V63, P1947, DOI 10.1128/IAI.63.5.1947-1954.1995; ZYCHLINSKY A, 1992, NATURE, V358, P167, DOI 10.1038/358167a0	22	237	308	0	5	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 13	1995	270	5234					299	302		10.1126/science.270.5234.299	http://dx.doi.org/10.1126/science.270.5234.299			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ342	7569980	Green Submitted			2022-12-24	WOS:A1995RZ34200039
J	OHASHI, M; DEVRIES, KJ; FRANK, R; SNOEK, G; BANKAITIS, V; WIRTZ, K; HUTTNER, WB				OHASHI, M; DEVRIES, KJ; FRANK, R; SNOEK, G; BANKAITIS, V; WIRTZ, K; HUTTNER, WB			A ROLE FOR PHOSPHATIDYLINOSITOL TRANSFER PROTEIN IN SECRETORY VESICLE FORMATION	NATURE			English	Article							PHOSPHOLIPID TRANSFER PROTEIN; SACCHAROMYCES-CEREVISIAE; REQUIREMENT	VESICULAR traffic in eukaryotic cells is characterized by two steps of membrane rearrangement: the formation of vesicles from donor membranes and their fusion with acceptor membranes. With respect to vesicle formation, several of the cytosolic proteins implicated in budding and fission have been identified. A feature common to all these proteins is that their targets, when known, are other proteins rather than lipids. Here we report, using a previously established cell-free system(1,2) derived from a neuroendocrine cell line, the purification of cytosolic factors that stimulate the formation of constitutive secretory vesicles and immature secretory granules from the trans-Golgi network. One such factor, referred to as CAST1, was identified as the alpha and beta isoforms of the mammalian phosphatidylinositol transfer protein (PtdIns-TP) (refs 3-5). The yeast PtdIns-TP, SEC14p (ref. 6), which has no sequence homology to mammalian PtdIns-TP (refs 7,8), was able to substitute for the mammalian PtdIns-TP in secretory vesicle formation. Our results suggest a highly conserved role for phosphoinositides in vesicle formation.	UNIV HEIDELBERG,DEPT NEUROBIOL,D-69120 HEIDELBERG,GERMANY; UNIV HEIDELBERG,CTR BIOL MOLEC,D-69120 HEIDELBERG,GERMANY; UNIV UTRECHT,CTR BIOMEMBRANES & LIPID ENZYMOL,3584 CH UTRECHT,NETHERLANDS; UNIV ALABAMA,DEPT CELL BIOL,BIRMINGHAM,AL 35294	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Utrecht University; University of Alabama System; University of Alabama Birmingham			Huttner, Wieland B./P-4080-2018					BANKAITIS VA, 1989, J CELL BIOL, V108, P1271, DOI 10.1083/jcb.108.4.1271; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; BECK KA, 1991, J BIOL CHEM, V266, P4442; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; CUNNINGHAM E, 1995, CURR BIOL, V5, P775, DOI 10.1016/S0960-9822(95)00154-0; DEVRIES KJ, 1995, BIOCHEM J, V310, P643, DOI 10.1042/bj3100643; DICKESON SK, 1989, J BIOL CHEM, V294, P16557; FRANZUSOFF A, 1989, EMBO J, V8, P2695, DOI 10.1002/j.1460-2075.1989.tb08410.x; GEITENBEEK TB, 1994, BIOCHIM BIOPHYS ACTA, V1213, P309; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; JANSENDURR P, 1992, NUCLEIC ACIDS RES, V20, P1243, DOI 10.1093/nar/20.6.1243; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NIEHRS C, 1990, EMBO J, V9, P35, DOI 10.1002/j.1460-2075.1990.tb08077.x; NORRIS FA, 1995, J BIOL CHEM, V270, P214, DOI 10.1074/jbc.270.1.214; OHASHI M, 1994, J BIOL CHEM, V269, P24897; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SKINNER HB, 1995, P NATL ACAD SCI USA, V92, P112, DOI 10.1073/pnas.92.1.112; SKINNER HB, 1993, EMBO J, V12, P4775, DOI 10.1002/j.1460-2075.1993.tb06166.x; SNOEK GT, 1992, J CELL BIOCHEM, V49, P339, DOI 10.1002/jcb.240490404; STENBECK G, 1993, EMBO J, V12, P2841, DOI 10.1002/j.1460-2075.1993.tb05945.x; TANAKA S, 1994, J BIOCHEM-TOKYO, V115, P981, DOI 10.1093/oxfordjournals.jbchem.a124448; TOOZE SA, 1990, NATURE, V347, P207, DOI 10.1038/347207a0; TOOZE SA, 1990, CELL, V60, P837, DOI 10.1016/0092-8674(90)90097-X; VANDENAKKER WMR, 1990, FEBS LETT, V276, P123, DOI 10.1016/0014-5793(90)80523-L; VATER CA, 1992, J CELL BIOL, V119, P773, DOI 10.1083/jcb.119.4.773; WIRTZ KWA, 1991, ANNU REV BIOCHEM, V60, P73, DOI 10.1146/annurev.bi.60.070191.000445; YE WL, 1995, J BIOL CHEM, V270, P1564, DOI 10.1074/jbc.270.4.1564	30	166	173	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 12	1995	377	6549					544	547		10.1038/377544a0	http://dx.doi.org/10.1038/377544a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ336	7566155				2022-12-24	WOS:A1995RZ33600067
J	BOLSHAKOV, VY; SIEGELBAUM, SA				BOLSHAKOV, VY; SIEGELBAUM, SA			REGULATION OF HIPPOCAMPAL TRANSMITTER RELEASE DURING DEVELOPMENT AND LONG-TERM POTENTIATION	SCIENCE			English	Article							MINIATURE SYNAPTIC CURRENTS; QUANTAL ANALYSIS; PYRAMIDAL CELLS; NEURONS; PROBABILITY; AMPLITUDE; SLICES; TRANSMISSION; SYNAPSES; PAIRS	Developmental changes in rat hippocampal transmitter release and synaptic plasticity were investigated. Recordings from pairs of pyramidal neurons in slices showed that an action potential in a CA3 neuron released only a single quantum of transmitter onto a CAI neuron. Failures of synaptic transmission reflected probabilistic transmitter release. The probability of release (P-r) was 0.9 in 4- to 8-day-old rats and decreased to less than 0.5 at 2 to 3 weeks. Long-term potentiation (LTP) in 2- to 3-week-old rats was associated with an increase in P-r from a single synaptic site. The high initial P-r in 4- to 8-day-old rats normally occludes the expression of LTP at this stage.	COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,NEW YORK,NY 10032	Columbia University; Howard Hughes Medical Institute	BOLSHAKOV, VY (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,DEPT PHARMACOL,722 W 168TH ST,NEW YORK,NY 10032, USA.							ARANCIO O, 1994, J PHYSIOL-LONDON, V481, P395, DOI 10.1113/jphysiol.1994.sp020448; BAUDRY M, 1981, DEV BRAIN RES, V1, P37, DOI 10.1016/0165-3806(81)90092-4; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOLSHAKOV VY, 1994, SCIENCE, V264, P1148, DOI 10.1126/science.7909958; CONSTANTINEPATO.M, 1990, ANN REV NEUROSCI, V13, P1229; CRAIR MC, 1995, NATURE, V375, P325, DOI 10.1038/375325a0; DAVIES SN, 1989, NATURE, V338, P500, DOI 10.1038/338500a0; DODGE FA, 1967, J PHYSIOL-LONDON, V193, P419, DOI 10.1113/jphysiol.1967.sp008367; DUDEK SM, 1993, J NEUROSCI, V13, P2910; EDWARDS F, 1991, NATURE, V350, P271, DOI 10.1038/350271a0; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; GULYAS AI, 1993, NATURE, V366, P683, DOI 10.1038/366683a0; HESSLER NA, 1993, NATURE, V366, P569, DOI 10.1038/366569a0; JESSELL TM, 1993, NEURON S, V10, P1; JONAS P, 1993, J PHYSIOL-LONDON, V472, P615, DOI 10.1113/jphysiol.1993.sp019965; Katz B., 1969, RELEASE NEURAL TRANS; KIRKWOOD A, 1995, NATURE, V375, P328, DOI 10.1038/375328a0; KORN H, 1991, TRENDS NEUROSCI, V14, P439, DOI 10.1016/0166-2236(91)90042-S; KULLMANN DM, 1994, NEURON, V12, P1111, DOI 10.1016/0896-6273(94)90318-2; KULLMANN DM, 1992, NATURE, V357, P240, DOI 10.1038/357240a0; LARKMAN A, 1992, NATURE, V360, P70, DOI 10.1038/360070a0; LIAO D, 1992, NEURON, V9, P1089, DOI 10.1016/0896-6273(92)90068-O; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; LINDEN DJ, 1995, ANNU REV NEUROSCI, V18, P319, DOI 10.1146/annurev.ne.18.030195.001535; MALENKA RC, 1993, P NATL ACAD SCI USA, V90, P3121, DOI 10.1073/pnas.90.8.3121; MALGAROLI A, 1995, SCIENCE, V268, P1624, DOI 10.1126/science.7777862; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; MALINOW R, 1994, SCIENCE, V266, P1195, DOI 10.1126/science.7973700; MALINOW R, 1991, SCIENCE, V252, P722, DOI 10.1126/science.1850871; MALLART A, 1968, J PHYSIOL-LONDON, V196, P593, DOI 10.1113/jphysiol.1968.sp008525; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MULLER D, 1989, DEV BRAIN RES, V49, P105, DOI 10.1016/0165-3806(89)90063-1; PURVES D, 1985, PRINCIPLES NEURAL DE; RAASTAD M, 1992, EUR J NEUROSCI, V4, P113, DOI 10.1111/j.1460-9568.1992.tb00114.x; ROSENMUND C, 1993, SCIENCE, V262, P754, DOI 10.1126/science.7901909; SAYER RJ, 1990, J NEUROSCI, V10, P826; SORRA KE, 1993, J NEUROSCI, V13, P3736; STEVENS CF, 1995, P NATL ACAD SCI USA, V92, P846, DOI 10.1073/pnas.92.3.846; STEVENS CF, 1995, NEURON, V14, P795, DOI 10.1016/0896-6273(95)90223-6; STEVENS CF, 1994, NATURE, V371, P704, DOI 10.1038/371704a0; ZENGEL JE, 1980, J GEN PHYSIOL, V76, P175, DOI 10.1085/jgp.76.2.175; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	43	300	303	0	7	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 22	1995	269	5231					1730	1734		10.1126/science.7569903	http://dx.doi.org/10.1126/science.7569903			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV948	7569903				2022-12-24	WOS:A1995RV94800041
J	GUILLOT, T				GUILLOT, T			CONDENSATION OF METHANE, AMMONIA, AND WATER AND THE INHIBITION OF CONVECTION IN GIANT PLANETS	SCIENCE			English	Article							RADIO OCCULTATION MEASUREMENTS; MOIST CONVECTION; JUPITERS ATMOSPHERE; VERTICAL STRUCTURE; PARA-HYDROGEN; TROPOSPHERE; ABUNDANCE; NEPTUNE; URANUS; VOYAGER-2	The condensation of chemical species of high molecular mass such as methane, ammonia, and water can inhibit convection in the hydrogen-helium atmospheres of the giant planets. Convection is inhibited in Uranus and Neptune when methane reaches an abundance of about 15 times the solar value and in Jupiter and Saturn if the abundance of water is more than about five times the solar value. The temperature gradient consequently becomes superadiabatic, which is observed in temperature profiles inferred from radio-occultation measurements. The planetary heat flux is then likely to be transported by another mechanism, possibly radiation in Uranus, or diffusive convection.			GUILLOT, T (corresponding author), UNIV ARIZONA,LUNAR & PLANETARY LAB,TUCSON,AZ 85721, USA.			Guillot, Tristan/0000-0002-7188-8428				ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; BAINES KH, 1995, ICARUS, V114, P328, DOI 10.1006/icar.1995.1065; BAINES KH, 1994, ICARUS, V109, P20, DOI 10.1006/icar.1994.1075; BJORAKER GL, 1986, ICARUS, V66, P579, DOI 10.1016/0019-1035(86)90093-X; CARLSON BE, 1992, ASTROPHYS J, V388, P648, DOI 10.1086/171182; CARLSON BE, 1988, J ATMOS RES, V45, P2067; CONRATH BJ, 1984, ICARUS, V57, P184, DOI 10.1016/0019-1035(84)90065-4; DELGENIO AD, 1990, ICARUS, V84, P29, DOI 10.1016/0019-1035(90)90156-4; Emanuel K. A., 1994, ATMOSPHERIC CONVECTI; FLASAR FM, 1988, JUN UR C PAS; FLASAR FM, COMMUNICATION; GAUTIER D, IN PRESS NEPTUNE; GIERASCH PJ, 1987, J GEOPHYS RES, V92, P15019, DOI 10.1029/JA092iA13p15019; GUILLOT T, 1994, ICARUS, V112, P37; GUILLOT T, 1994, ICARUS, V112, P57; GUILLOTEAU S, 1993, ASTRON ASTROPHYS, V279, P661; HAMMEL HB, 1995, SCIENCE, V267, P1288, DOI 10.1126/science.7871425; INGERSOLL AP, 1995, NATURE, V374, P706, DOI 10.1038/374706a0; Kippenhahn R., 1990, STELLAR STRUCTURE EV; LEDOUX P, 1947, ASTROPHYS J, V125, P242; LEWIS JS, 1969, ICARUS, V10, P365, DOI 10.1016/0019-1035(69)90091-8; LINDAL GF, 1992, ASTRON J, V103, P967, DOI 10.1086/116119; LINDAL GF, 1985, ASTRON J, V90, P1136, DOI 10.1086/113820; LINDAL GF, 1987, J GEOPHYS RES, V92, P14987, DOI 10.1029/JA092iA13p14987; LODDERS K, 1994, ICARUS, V112, P368, DOI 10.1006/icar.1994.1190; LUNINE JI, 1989, PLANET SPACE SCI, V37, P151, DOI 10.1016/0032-0633(89)90003-2; LUNINE JI, 1987, ICARUS, V69, P566, DOI 10.1016/0019-1035(87)90025-X; MARTEN A, 1981, ICARUS, V46, P233, DOI 10.1016/0019-1035(81)90211-6; MARTEN A, 1993, ASTROPHYS J, V406, P285, DOI 10.1086/172440; MASSIE ST, 1982, ICARUS, V49, P213, DOI 10.1016/0019-1035(82)90073-2; NEAL VT, 1969, SCIENCE, V166, P373, DOI 10.1126/science.166.3903.373; RAGES K, 1991, ICARUS, V89, P359, DOI 10.1016/0019-1035(91)90183-T; ROSSOW WB, 1978, ICARUS, V36, P1, DOI 10.1016/0019-1035(78)90072-6; SCHMITT RW, 1994, ANNU REV FLUID MECH, V26, P255, DOI 10.1146/annurev.fl.26.010194.001351; SHIRTCLIFFE TG, 1967, NATURE, V213, P489, DOI 10.1038/213489a0; STEVENSON DJ, 1979, MON NOT R ASTRON SOC, V187, P129, DOI 10.1093/mnras/187.2.129; STOKER CR, 1989, GEOPHYS RES LETT, V16, P929, DOI 10.1029/GL016i008p00929; STOKER CR, 1986, ICARUS, V67, P106, DOI 10.1016/0019-1035(86)90179-X; Turner J. S., 1973, BUOYANCY EFFECTS FLU; VERONIS G, 1968, J FLUID MECH, V34, P315, DOI 10.1017/S0022112068001916; YAIR Y, 1992, ICARUS, V98, P72, DOI 10.1016/0019-1035(92)90208-O; [No title captured]	42	61	61	1	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 22	1995	269	5231					1697	1699		10.1126/science.7569896	http://dx.doi.org/10.1126/science.7569896			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV948	7569896				2022-12-24	WOS:A1995RV94800029
J	VISWANATHAN, R; MADSEN, LL; ZASADZINSKI, JA; SCHWARTZ, DK				VISWANATHAN, R; MADSEN, LL; ZASADZINSKI, JA; SCHWARTZ, DK			LIQUID TO HEXATIC TO CRYSTALLINE ORDER IN LANGMUIR-BLODGETT-FILMS	SCIENCE			English	Article							ATOMIC-FORCE MICROSCOPY; BOND-ORIENTATIONAL ORDER; NORMAL-ALKANES; ELECTRON-DIFFRACTION; ROTATOR PHASES; VORTEX GLASS; MONOLAYERS; RESOLUTION; LATTICE; SUPERSTRUCTURES	Atomic force microscope images of zinc arachidate (ZnA(2)) Langmuir-Blodgett films show that three- and five-layer films are ''hexatic,'' with long-range bond-orientational order and short-range positional correlations of three to five lattice repeats. The monolayer in contact with the substrate is disordered. Films of seven or more layers of ZnA(2) are crystalline. A population of dislocations, most likely originating at the substrate, disrupts the positional but not the orientational order of the lattice, leading to hexatic layers intermediate between crystal and liquid. The influence of the substrate propagates farther into ZnA(2) films than into cadmium arachidate films because the molecular cohesion is much weaker in ZnA(2) than in cadmium arachidate, as evidenced by a less dense molecular packing.	UNIV CALIF SANTA BARBARA,DEPT CHEM ENGN,SANTA BARBARA,CA 93106; TULANE UNIV,DEPT CHEM,NEW ORLEANS,LA 70118	University of California System; University of California Santa Barbara; Tulane University			Schwartz, Daniel K/H-5153-2012	Schwartz, Daniel K/0000-0001-5397-7200	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051177] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047334] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL51177] Funding Source: Medline; NIGMS NIH HHS [GM47334] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; BIRGENEAU RJ, 1978, J PHYS LETT-PARIS, V39, pL399; BISHOP DJ, 1992, SCIENCE, V255, P165, DOI 10.1126/science.255.5041.165; BONNEROT A, 1985, CHEM PHYS, V97, P365, DOI 10.1016/0301-0104(85)87045-2; BOURDIEU L, 1991, PHYS REV LETT, V67, P2029, DOI 10.1103/PhysRevLett.67.2029; BROCK JD, 1986, PHYS REV LETT, V57, P98, DOI 10.1103/PhysRevLett.57.98; CHENG M, 1987, PHYS REV LETT, V59, P1112, DOI 10.1103/PhysRevLett.59.1112; CHUDNOVSKY EM, 1989, PHYS REV B, V40, P11355, DOI 10.1103/PhysRevB.40.11355; DAI HJ, 1992, PHYS REV LETT, V69, P1576, DOI 10.1103/PhysRevLett.69.1576; DAI HJ, 1991, PHYS REV LETT, V66, P3183, DOI 10.1103/PhysRevLett.66.3183; DAI HJ, 1993, J PHYS CHEM-US, V97, P2362, DOI 10.1021/j100112a042; ECKHARDT CJ, 1993, NATURE, V362, P614, DOI 10.1038/362614a0; EGGER M, 1990, J STRUCT BIOL, V103, P89, DOI 10.1016/1047-8477(90)90089-U; FROMMER J, 1992, ANGEW CHEM INT EDIT, V31, P1298, DOI 10.1002/anie.199212981; GARNAES J, 1992, NATURE, V357, P54, DOI 10.1038/357054a0; HALPERIN BI, 1978, PHYS REV LETT, V41, P121, DOI 10.1103/PhysRevLett.41.121; HALPERIN BI, 1978, PHYS REV LETT, V41, P519, DOI 10.1103/PhysRevLett.41.519; HELM CA, 1987, BIOPHYS J, V52, P381, DOI 10.1016/S0006-3495(87)83226-5; JOSEFOWICZ JY, 1993, SCIENCE, V260, P323, DOI 10.1126/science.260.5106.323; KIMURA F, 1986, LANGMUIR, V2, P96, DOI 10.1021/la00067a017; Kitaigorodskii A.I., 1961, ORGANIC CHEM CRYSTAL; KJAER K, 1987, PHYS REV LETT, V58, P2224, DOI 10.1103/PhysRevLett.58.2224; KOSTERLI.JM, 1972, J PHYS PART C SOLID, V5, pL124, DOI 10.1088/0022-3719/5/11/002; Kosterlitz JM, 1973, J PHYS C SOLID STATE, V6, P1181, DOI 10.1088/0022-3719/6/7/010; MACLENNAN J, 1992, PHYS REV LETT, V69, P2082, DOI 10.1103/PhysRevLett.69.2082; MARCHETTI MC, 1990, PHYS REV B, V41, P1910, DOI 10.1103/PhysRevB.41.1910; MARTI O, 1988, SCIENCE, V239, P50, DOI 10.1126/science.3336773; MEYER E, 1991, NATURE, V349, P398, DOI 10.1038/349398a0; MURRAY CA, 1987, PHYS REV LETT, V58, P1200, DOI 10.1103/PhysRevLett.58.1200; MURRAY CA, 1989, PHYS REV LETT, V62, P1643, DOI 10.1103/PhysRevLett.62.1643; MURRAY CA, 1990, PHYS REV LETT, V64, P2312, DOI 10.1103/PhysRevLett.64.2312; NELSON DR, 1979, PHYS REV B, V19, P2457, DOI 10.1103/PhysRevB.19.2457; NELSON DR, 1982, PHILOS MAG A, V46, P105, DOI 10.1080/01418618208236211; OHNESORGE F, 1993, SCIENCE, V260, P1451, DOI 10.1126/science.260.5113.1451; PINDAK R, 1981, PHYS REV LETT, V46, P1135, DOI 10.1103/PhysRevLett.46.1135; PRAKASH M, 1986, CHEM PHYS LETT, V128, P354, DOI 10.1016/0009-2614(86)80376-1; QIU X, 1991, PHYS REV LETT, V67, P703, DOI 10.1103/PhysRevLett.67.703; SCHWARTZ DK, 1993, J AM CHEM SOC, V115, P7374, DOI 10.1021/ja00069a040; SCHWARTZ DK, 1993, LANGMUIR, V9, P1384, DOI 10.1021/la00029a036; SCHWARTZ DK, 1993, PHYS REV E, V47, P452, DOI 10.1103/PhysRevE.47.452; SCHWARTZ DK, 1992, SCIENCE, V257, P508, DOI 10.1126/science.257.5069.508; SCHWARTZ DK, 1993, PHYS REV LETT, V70, P1267, DOI 10.1103/PhysRevLett.70.1267; SELINGER JV, 1993, PHYS REV LETT, V70, P1139, DOI 10.1103/PhysRevLett.70.1139; SIROTA EB, 1993, J CHEM PHYS, V98, P5809, DOI 10.1063/1.464874; SIROTA EB, 1992, PHYS REV LETT, V68, P492, DOI 10.1103/PhysRevLett.68.492; Strandburg KJ., 1992, BOND ORIENTATIONAL O, DOI 10.1007/978-1-4612-2812-7; UNGAR G, 1983, J PHYS CHEM-US, V87, P689, DOI 10.1021/j100227a032; VISWANATHAN R, 1994, NATURE, V368, P440, DOI 10.1038/368440a0; VISWANATHAN R, 1993, SCIENCE, V261, P449, DOI 10.1126/science.8392751; ZASADZINSKI JA, 1994, SCIENCE, V263, P1726, DOI 10.1126/science.8134836	50	53	54	0	9	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 7	1995	269	5220					51	54		10.1126/science.7604278	http://dx.doi.org/10.1126/science.7604278			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RG980	7604278				2022-12-24	WOS:A1995RG98000027
J	ARANCIO, O; KANDEL, ER; HAWKINS, RD				ARANCIO, O; KANDEL, ER; HAWKINS, RD			ACTIVITY-DEPENDENT LONG-TERM ENHANCEMENT OF TRANSMITTER RELEASE BY PRESYNAPTIC 3',5'-CYCLIC GMP IN CULTURED HIPPOCAMPAL-NEURONS	NATURE			English	Article							NITRIC-OXIDE; RAT HIPPOCAMPUS; SYNAPTIC TRANSMISSION; POTENTIATION; MESSENGER; PLASTICITY; INDUCTION; CURRENTS; PATHWAY; AREA	LONG-TERM potentiation (LTP) in hippocampus is a type of synaptic plasticity that is thought to be involved in learning and memory(1). Several lines of evidence suggest that LTP involves 3',5'-cyclic GMP (cGMP), perhaps as an activity-dependent presynaptic effector of one or more retrograde messengers (refs 2-12, but see ref, 13). However, previous results are also consistent with postsynaptic effects of cGMP. This is difficult to test in hippocampal slices, but more rigorous tests are possible in dissociated cell culture(14-17). We have therefore developed a reliable method for producing N-methyl-D-aspartate (NMDA) receptor-dependent LTP at synapses between individual hippocampal pyramidal neurons in culture, We report that inhibitors of guanylyl cyclase or of cGMP-dependent protein kinase block potentiation by either tetanic stimulation or low-frequency stimulation paired with postsynaptic depolarization. Conversely, application of 8-Br-cGMP to the bath or injection of cGMP into the presynaptic neuron produces activity-dependent long-lasting potentiation, The potentiation by cGMP involves an increase in transmitter release that is in part independent of changes in the presynaptic action potential. These results support a presynaptic role for cGMP in LTP.	HOWARD HUGHES MED INST,NEW YORK,NY 10032	Howard Hughes Medical Institute	ARANCIO, O (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,NEW YORK STATE PSYCHIAT INST,CTR NEUROBIOL & BEHAV,722 W 168TH ST,NEW YORK,NY 10032, USA.		arancio, ottavio/AAB-7959-2019	arancio, ottavio/0000-0001-6335-164X				Arancio O., 1994, Society for Neuroscience Abstracts, V20, P1713; Arancio O., 1993, Society for Neuroscience Abstracts, V19, P241; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; CHETKOVICH DM, 1993, NEUROREPORT, V4, P919, DOI 10.1097/00001756-199307000-00020; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P560, DOI 10.1113/jphysiol.1954.sp005129; DEVENTE J, 1988, BRAIN RES, V446, P387, DOI 10.1016/0006-8993(88)90900-6; EAST SJ, 1991, NEUROSCI LETT, V123, P17, DOI 10.1016/0304-3940(91)90147-L; FABER DS, 1991, BIOPHYS J, V60, P1288, DOI 10.1016/S0006-3495(91)82162-2; FORSYTHE ID, 1988, J PHYSIOL-LONDON, V396, P515, DOI 10.1113/jphysiol.1988.sp016975; HALEY JE, 1992, NEURON, V8, P211, DOI 10.1016/0896-6273(92)90288-O; HAWKINS RD, 1994, J NEUROBIOL, V25, P652, DOI 10.1002/neu.480250607; HAWKINS RD, 1993, ANNU REV NEUROSCI, V16, P625, DOI 10.1146/annurev.ne.16.030193.003205; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; MALINOW R, 1986, NATURE, V320, P529, DOI 10.1038/320529a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MATSUOKA I, 1992, J NEUROSCI, V12, P3350; MCNAUGHTON BL, 1978, BRAIN RES, V157, P277, DOI 10.1016/0006-8993(78)90030-6; NEHER E, 1988, CALCIUM ION CHANNEL, P371; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; SCHUMAN EM, 1994, P NATL ACAD SCI USA, V91, P11958, DOI 10.1073/pnas.91.25.11958; SCHWARTZKROIN PA, 1975, BRAIN RES, V89, P107, DOI 10.1016/0006-8993(75)90138-9; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; WIGSTROM H, 1986, ACTA PHYSIOL SCAND, V126, P317, DOI 10.1111/j.1748-1716.1986.tb07822.x; ZHUO M, 1994, NATURE, V368, P635, DOI 10.1038/368635a0; ZHUO M, 1994, NEUROREPORT, V5, P1033, DOI 10.1097/00001756-199405000-00004	28	264	275	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 6	1995	376	6535					74	80		10.1038/376074a0	http://dx.doi.org/10.1038/376074a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH111	7596438				2022-12-24	WOS:A1995RH11100065
J	HAMPTON, HL				HAMPTON, HL			CURRENT CONCEPTS - CARE OF THE WOMAN WHO HAS BEEN RAPED	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SEXUAL ASSAULT; VICTIMS; WOMEN				HAMPTON, HL (corresponding author), UNIV MISSISSIPPI,MED CTR,DEPT OBSTET & GYNECOL,2500 N STATE ST,JACKSON,MS 39216, USA.							Burgess AW, 1974, RAPE VICTIMS CRISIS, P37; CHAKRABORTY R, 1991, SCIENCE, V254, P1735, DOI 10.1126/science.1763323; DAVIS TC, 1993, J ADOLESCENT HEALTH, V14, P220, DOI 10.1016/1054-139X(93)90009-E; DEMING JE, 1983, J FORENSIC SCI, V28, P572; Geist R F, 1988, Emerg Med Clin North Am, V6, P439; GRAVES HCB, 1985, NEW ENGL J MED, V312, P338, DOI 10.1056/NEJM198502073120603; JENNY C, 1990, NEW ENGL J MED, V322, P713, DOI 10.1056/NEJM199003153221101; MARCHBANKS PA, 1990, AM J EPIDEMIOL, V132, P540, DOI 10.1093/oxfordjournals.aje.a115690; MCCAULEY J, 1986, PEDIATRICS, V78, P1039; MIRABILE PJ, 1980, TULANE LAW REV, V54, P456; RAMBOW B, 1992, ANN EMERG MED, V21, P727, DOI 10.1016/S0196-0644(05)82788-X; RAMIN SM, 1992, OBSTET GYNECOL, V80, P860; SCHWARCZ SK, 1990, REV INFECT DIS, V12, pS682; SCHWARTZ IL, 1991, AM J PREV MED, V7, P363, DOI 10.1016/S0749-3797(18)30873-0; SLAUGHTER L, 1992, AM J OBSTET GYNECOL, V166, P83, DOI 10.1016/0002-9378(92)91834-W; WARNER CG, 1980, RAPE SEXUAL ASSAULT, P47; YOUNG WW, 1992, OBSTET GYNECOL, V80, P878; YUZPE AA, 1982, FERTIL STERIL, V37, P508; 1993, MMWR-MORBID MORTAL W, V42, P8; 1988, UNIFORM CRIME REPORT, P46; 1993, MMWR-MORBID MORTAL W, V42, P1	21	45	46	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 26	1995	332	4					234	237		10.1056/NEJM199501263320407	http://dx.doi.org/10.1056/NEJM199501263320407			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC270	7619112				2022-12-24	WOS:A1995QC27000007
J	FLEGAL, KM; TROIANO, RP; PAMUK, ER; KUCZMARSKI, RJ; CAMPBELL, SM				FLEGAL, KM; TROIANO, RP; PAMUK, ER; KUCZMARSKI, RJ; CAMPBELL, SM			THE INFLUENCE OF SMOKING CESSATION ON THE PREVALENCE OF OVERWEIGHT IN THE UNITED-STATES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							QUITTING CIGARETTE-SMOKING; BODY-WEIGHT; GENDER DIFFERENCES; HIGH-SCHOOL; GAIN; POPULATION; MORTALITY; CONSUMPTION; PREVENTION; FRAMINGHAM	Background. The proportion of U.S. adults, 35 to 74 years of age who were overweight increased by 9.6 percent for men and 8.0 percent for women between 1978 and 1990. Since the prevalence of smoking declined over the same period, smoking cessation has been suggested as a factor contributing to the increasing prevalence of overweight. Methods. To estimate the influence of smoking cessation on the increase in the prevalence of overweight, we analyzed data on current and past weight and smoking status for a national sample of 5247 adults 35 years of age or older who participated in the third National Health and Nutrition Examination Survey, conducted from 1988 through 1998. The results were adjusted for age, sociodemographic characteristics, level of physical activity, alcohol consumption, and (for women) parity. Results. The weight gain over a 10-year period that was associated with the cessation of smoking (i.e., the gain among smokers who quit that was in excess of the gain among continuing smokers) was 4.4 kg for men and 5.0 kg for women. Smokers who had quit within the past 10 years were significantly more likely than respondents who had never smoked to become overweight (odds ratios, 2.4 for men and 2.0 for women). For men, about a quarter (2.3 of 9.6 percentage points) and for women, about a sixth (1.3 of 8.0 percentage points) of the increase in the prevalence of overweight could be attributed to smoking cessation within the past 10 years. Conclusions. Although its health benefits are undeniable, smoking cessation may nevertheless be associated with a small increase in the prevalence of overweight.			FLEGAL, KM (corresponding author), CTR DIS CONTROL & PREVENT, NATL CTR HLTH STAT, 6525 BELCREST RD, RM 900, HYATTSVILLE, MD 20782 USA.		Troiano, Richard/AAK-3540-2021; Flegal, Katherine M/A-4608-2013	Troiano, Richard/0000-0002-6807-989X; Flegal, Katherine/0000-0002-0838-469X				AINSWORTH BE, 1993, MED SCI SPORT EXER, V25, P71, DOI 10.1249/00005768-199301000-00011; BIENER L, 1992, HEALTH PSYCHOL, V11, P52; BOYLE CA, 1994, INT J OBESITY, V18, P55; CAMP DE, 1993, HEALTH PSYCHOL, V12, P24, DOI 10.1037/0278-6133.12.1.24; CASEY VA, 1991, AM J CLIN NUTR, V53, P1493, DOI 10.1093/ajcn/53.6.1493; DYER AR, 1975, J CHRON DIS, V28, P109, DOI 10.1016/0021-9681(75)90067-3; FISHER M, 1991, J ADOLESCENT HEALTH, V12, P377, DOI 10.1016/0197-0070(91)90051-M; FRENCH SA, 1994, AM J PUBLIC HEALTH, V84, P1818, DOI 10.2105/AJPH.84.11.1818; FRIEDMAN GD, 1980, CIRCULATION, V61, P716, DOI 10.1161/01.CIR.61.4.716; GARRISON RJ, 1985, ANN INTERN MED, V103, P1006, DOI 10.7326/0003-4819-103-6-1006; GORDON T, 1975, AM HEART J, V90, P322, DOI 10.1016/0002-8703(75)90320-8; GRITZ ER, 1992, HEALTH PSYCHOL, V11, P17, DOI 10.1037/h0090341; GRITZ ER, 1991, HEALTH PSYCHOL, V10, P330, DOI 10.1037/0278-6133.10.5.330; GROSS J, 1989, J CONSULT CLIN PSYCH, V57, P87, DOI 10.1037/0022-006X.57.1.87; HALL SM, 1989, J CONSULT CLIN PSYCH, V57, P81, DOI 10.1037/0022-006X.57.1.81; HALL SM, 1992, AM J PUBLIC HEALTH, V82, P799, DOI 10.2105/AJPH.82.6.799; Higgins M, 1988, ACTA MED SCAND, V723, P23; KLESGES RC, 1989, PSYCHOL BULL, V106, P204, DOI 10.1037/0033-2909.106.2.204; KLESGES RC, 1988, INT J EAT DISORDER, V7, P413, DOI 10.1002/1098-108X(198805)7:3<413::AID-EAT2260070314>3.0.CO;2-D; KLESGES RC, 1987, INT J EAT DISORDER, V6, P409, DOI 10.1002/1098-108X(198705)6:3<409::AID-EAT2260060311>3.0.CO;2-O; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; MOFFATT RJ, 1991, METABOLISM, V40, P465, DOI 10.1016/0026-0495(91)90225-L; MUST A, 1993, AM J EPIDEMIOL, V138, P56, DOI 10.1093/oxfordjournals.aje.a116777; NOPPA H, 1980, PREV MED, V9, P534, DOI 10.1016/0091-7435(80)90048-1; PERKINS KA, 1993, J CONSULT CLIN PSYCH, V61, P768, DOI 10.1037/0022-006X.61.5.768; PERKINS KA, 1992, J APPL PHYSIOL, V72, P401, DOI 10.1152/jappl.1992.72.2.401; PIRIE PL, 1991, AM J PUBLIC HEALTH, V81, P324, DOI 10.2105/AJPH.81.3.324; PIRIE PL, 1992, AM J PUBLIC HEALTH, V82, P1238, DOI 10.2105/AJPH.82.9.1238; PISUNYER FX, 1994, JAMA-J AM MED ASSOC, V272, P238; SHAH BV, 1991, SUDAAN USERS MANUAL; STAMFORD BA, 1986, AM J CLIN NUTR, V43, P486, DOI 10.1093/ajcn/43.4.486; STEVENS J, 1990, AM J EPIDEMIOL, V132, P1156, DOI 10.1093/oxfordjournals.aje.a115758; TUOMILEHTO J, 1987, BRIT MED J, V295, P623, DOI 10.1136/bmj.295.6599.623; WALDRON I, 1991, SOC SCI MED, V32, P989, DOI 10.1016/0277-9536(91)90157-8; WANNAMETHEE G, 1989, BRIT MED J, V299, P1497, DOI 10.1136/bmj.299.6714.1497; WILLIAMSON DF, 1991, NEW ENGL J MED, V324, P739, DOI 10.1056/NEJM199103143241106; 1990, DHHS CDC908416 DEP H; 1994, VITAL HLTH STATIST 1, V32; 1990, SAS PROCEDURES GUIDE; 1993, JAMA-J AM MED ASSOC, V269, P1931; 1987, VITAL HLTH STATIS 11, V238; 1993, JAMA-J AM MED ASSOC, V269, P2198	42	344	355	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 2	1995	333	18					1165	1170		10.1056/NEJM199511023331801	http://dx.doi.org/10.1056/NEJM199511023331801			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TB560	7565970				2022-12-24	WOS:A1995TB56000001
J	GIANAKOS, D				GIANAKOS, D			UMANA	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											GIANAKOS, D (corresponding author), LYNCHBURG FAMILY PRACTICE RESIDENCY, 2097 LANGHORNE RD, LYNCHBURG, VA 24501 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1995	123	9					730	730		10.7326/0003-4819-123-9-199511010-00016	http://dx.doi.org/10.7326/0003-4819-123-9-199511010-00016			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA696	7574233				2022-12-24	WOS:A1995TA69600016
J	GODDARD, AD; COVELLO, R; LUOH, SM; CLACKSON, T; ATTIE, KM; GESUNDHEIT, N; RUNDLE, AC; WELLS, JA; CARLSSON, LMS				GODDARD, AD; COVELLO, R; LUOH, SM; CLACKSON, T; ATTIE, KM; GESUNDHEIT, N; RUNDLE, AC; WELLS, JA; CARLSSON, LMS			MUTATIONS OF THE GROWTH-HORMONE RECEPTOR IN CHILDREN WITH IDIOPATHIC SHORT STATURE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LARON-TYPE DWARFISM; SERUM BINDING-PROTEIN; EXTRACELLULAR DOMAIN; PURIFICATION; ASSAY	Background. Short stature in children who are not deficient in growth hormone (GH) is probably caused by a variety of defects. Some children with idiopathic short stature have low serum concentrations of GH-binding protein, which is derived from the GH receptor. The possibility that low serum concentrations of GH-binding protein might indicate partial insensitivity to GH led us to investigate possible defects in the gene for the GH receptor in children with idiopathic short stature and low serum concentrations of GH-binding protein. Methods. We studied 14 children with idiopathic short stature who were selected on the basis of normal GH secretion and low serum concentrations of GH-binding protein. Analysis of single-strand conformation polymorphisms and DNA sequencing were both used to identify mutations in the GH-receptor gene. Results. Mutations in the region of the GH-receptor gene that codes for the extracellular domain of the receptor were found in 4 of the 14 children, but in none of 24 normal subjects. One of the four children with mutations was a compound heterozygote, with one mutation that reduced the affinity of the receptor for GH and a second mutation that may affect a function other than ligand binding. The remaining three children had single mutations in one allele of the gene. One mutation introduced a premature termination codon, and two caused substitutions of single amino acids in a structurally conserved domain of the receptor. Conclusions. Some children with idiopathic short stature may have partial insensitivity to GH due to mutations in the GH-receptor gene.	GENENTECH INC,DEPT ENDOCRINE RES,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT PROT ENGN,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT MED AFFAIRS,S SAN FRANCISCO,CA 94080; GOTHENBURG UNIV,DEPT INTERNAL MED,ENDOCRINOL & METAB RES CTR,GOTHENBURG,SWEDEN; GENENTECH INC,DEPT MOLEC BIOL,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; University of Gothenburg; Roche Holding; Genentech			Wells, Jim A/O-9854-2016; Carlsson, Lena/F-7570-2018	Carlsson, Lena/0000-0003-4145-6242				AGUIRRE A, 1990, HORM RES, V34, P4, DOI 10.1159/000181786; AMIT T, 1990, J CLIN ENDOCR METAB, V71, P474, DOI 10.1210/jcem-71-2-474; AMSELEM S, 1993, HUM MOL GENET, V2, P355, DOI 10.1093/hmg/2.4.355; ATTIE KM, 1995, J PEDIATR-US, V127, P244, DOI 10.1016/S0022-3476(95)70302-0; BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BAUMGARTNER JW, 1994, J BIOL CHEM, V269, P29094; CARLSSON LMS, 1994, J CLIN ENDOCR METAB, V78, P1325, DOI 10.1210/jc.78.6.1325; CARLSSON LMS, 1991, J CLIN ENDOCR METAB, V73, P1216, DOI 10.1210/jcem-73-6-1216; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FUH G, 1990, J BIOL CHEM, V265, P3111; GODOWSKI PJ, 1989, P NATL ACAD SCI USA, V86, P8083, DOI 10.1073/pnas.86.20.8083; HAMILL PVV, 1979, AM J CLIN NUTR, V32, P607, DOI 10.1093/ajcn/32.3.607; HOPWOOD NJ, 1993, J PEDIATR-US, V123, P215, DOI 10.1016/S0022-3476(05)81691-9; KATZ BZ, 1989, J INFECT DIS, V160, P589, DOI 10.1093/infdis/160.4.589; LARON Z, 1989, ACTA ENDOCRINOL-COP, V121, P603, DOI 10.1530/acta.0.1210603; LARON Z, 1993, ENDOCRINOLOGIST, V3, P21; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LIPPE BM, 1993, RECENT PROG HORM RES, V48, P179; MAURAS N, 1994, METABOLISM, V43, P357, DOI 10.1016/0026-0495(94)90104-X; RAVNIKGLAVAC M, 1994, HUM MOL GENET, V3, P801, DOI 10.1093/hmg/3.5.801; ROSENBLOOM AL, 1994, ACTA PAEDIATR S, V399, P125; ROSENFELD RG, 1994, ENDOCR REV, V15, P369, DOI 10.1210/er.15.3.369; SPENCER SA, 1988, J BIOL CHEM, V263, P7862; VIDALPUIG A, 1994, BIOTECHNIQUES, V17, P490	27	227	238	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 26	1995	333	17					1093	1098		10.1056/NEJM199510263331701	http://dx.doi.org/10.1056/NEJM199510263331701			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA372	7565946				2022-12-24	WOS:A1995TA37200001
J	STRACHAN, DP; CAREY, IM				STRACHAN, DP; CAREY, IM			HOME-ENVIRONMENT AND SEVERE ASTHMA IN ADOLESCENCE - A POPULATION-BASED CASE-CONTROL STUDY	BRITISH MEDICAL JOURNAL			English	Article							RESPIRATORY SYMPTOMS; CHILDHOOD ASTHMA; RISK-FACTORS; CHILDREN; PETS; SENSITIZATION; ALLERGY	Objective-To investigate the effects of the home environment on the risk of severe asthma during adolescence. Design-A questionnaire based case-control study drawn from a cross sectional survey of allergic diseases among secondary school pupils in Sheffield in 1991. Subjects-763 children whose parents had reported that over the previous 12 months they had suffered either 12 or more wheezing attacks or a speech limiting attack of wheeze. A further 763 children were frequency matched for age and school class to act as controls. Analysis was restricted to 486 affected children and 475 others born between 1975 and 1980 who had lived at their present address for more than three years. Results-Independent associations with severe wheeze were seen for non-feather bedding, especially foam pillows (odds ratio 2.78; 95% confidence interval 1.89 to 4.17), and the ownership of furry pets now (1.51; 1.04 to 2.20) and at birth (1.70; 1.20 to 2.40). These estimates were derived from subjects whose parents denied making changes in the bedroom or avoiding having a pet because of allergy. Parental smoking, use of gas for cooking, age of mattress, and mould growth in the child's bedroom were not significantly associated with wheezing. Conclusions-Either our study questionnaire failed to detect the avoidance or removal of feather bedding by allergic families or there is some undetermined hazard related to foam pillows. Synthetic bedding and furry pets were both widespread in this population and may represent remediable causes of childhood asthma.			STRACHAN, DP (corresponding author), ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND.		Carey, Iain/O-6973-2014	Carey, Iain/0000-0003-1099-8460				ARSHAD SH, 1991, BRIT J CLIN PRACT, V45, P88; BRUNEKREEF B, 1992, INT J EPIDEMIOL, V21, P338, DOI 10.1093/ije/21.2.338; CLIFFORD RD, 1989, ARCH DIS CHILD, V64, P1118, DOI 10.1136/adc.64.8.1118; DEKKER C, 1991, CHEST, V100, P922, DOI 10.1378/chest.100.4.922; Francis B., 1993, GLIM SYSTEM RELEASE; HONG CY, 1994, Q J MED, V87, P639; HOSEIN HR, 1989, INT J EPIDEMIOL, V18, P390, DOI 10.1093/ije/18.2.390; INFANTERIVARD C, 1993, AM J EPIDEMIOL, V137, P834, DOI 10.1093/oxfordjournals.aje.a116745; KUEHR J, 1992, J ALLERGY CLIN IMMUN, V90, P358, DOI 10.1016/S0091-6749(05)80015-6; LINNA O, 1983, ALLERGY, V38, P513, DOI 10.1111/j.1398-9995.1983.tb02360.x; MURRAY AB, 1983, J ALLERGY CLIN IMMUN, V72, P145, DOI 10.1016/0091-6749(83)90522-5; PEARCE N, 1993, EUR RESPIR J, V6, P1455; POPP W, 1990, ALLERGY, V45, P75, DOI 10.1111/j.1398-9995.1990.tb01087.x; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; SHATZ G, 1982, ANN ALLERGY, V48, P59; STRACHAN DP, 1994, ARCH DIS CHILD, V70, P174, DOI 10.1136/adc.70.3.174; WARDLAW AJ, 1992, J ALLERGY CLIN IMMUN, V90, P358	17	137	142	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 21	1995	311	7012					1053	1056		10.1136/bmj.311.7012.1053	http://dx.doi.org/10.1136/bmj.311.7012.1053			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB354	7580660	Green Published			2022-12-24	WOS:A1995TB35400018
J	NEWTON, JN; HENDERSON, J; GOLDACRE, MJ				NEWTON, JN; HENDERSON, J; GOLDACRE, MJ			WAITING LIST DYNAMICS AND THE IMPACT OF EARMARKED FUNDING	BRITISH MEDICAL JOURNAL			English	Article							MANAGEMENT	Objective-To determine how changes in the number of admissions from waiting lists and changes in the number of additions to the lists are related to list size and waiting times, in the context of local waiting list initiatives. Design-Review of national and Korner statistics. Setting-England (1987-94) and districts of the former Oxford region (1987-91). Main outcome measures-Correlation of quarterly changes in the number of admissions from waiting Lists in England with changes in total list size, numbers of patients waiting one to two, or over two years, and number of additions to the lists; examination of changes in waiting list statistics for individual district specialties in one region in relation to funding for waiting list initiatives. Results-Nationally, changes in the number of admissions to hospital from lists closely correlated with changes in the number of additions to lists (r=0.84; P<0.01). After adjusting for changes in the number of additions to lists, changes in the number of admissions correlated inversely with changes in List size (r=-0.62; P<0.001), Decreases in the number of patients waiting from one to two years were significantly associated with increases in the number of admissions (r=-0.52; P<0.01); locally, only six of 44 waiting list initiatives were followed by an increase in admissions and a fall in list size, although a further 11 were followed by a fall in list size without a corresponding increase in admissions. Conclusions-An increase in admissions improved waiting times but did not reduce list size because additions to the list tended to increase at the same time. The appropriateness of waiting list initiatives as a method of funding elective surgery should be reviewed.			NEWTON, JN (corresponding author), UNIV OXFORD,HLTH CARE EPIDEMIOL UNIT,OXFORD OX3 7LF,ENGLAND.		Newton, John/HCH-8693-2022	Newton, John/0000-0002-5641-6457; Henderson, Jane/0000-0001-7527-694X				Arnstein P M, 1991, Br J Plast Surg, V44, P553, DOI 10.1016/0007-1226(91)90029-J; Frankel S, 1989, Health Trends, V21, P56; GOLDACRE MJ, 1987, BRIT MED J, V295, P1105, DOI 10.1136/bmj.295.6606.1105; HEMINGWAY H, 1995, BRIT MED J, V310, P818, DOI 10.1136/bmj.310.6983.818; MILLS RP, 1991, J ROY SOC MED, V84, P405, DOI 10.1177/014107689108400709; Naylor C D, 1994, Qual Health Care, V3, P221, DOI 10.1136/qshc.3.4.221; PARMAR JR, 1993, ANN ROY COLL SURG, V75, P4; POPE C, 1991, SOCIOL HEALTH ILL, V13, P193, DOI 10.1111/1467-9566.ep11340798; POPE C, 1992, BRIT MED J, V305, P577, DOI 10.1136/bmj.305.6853.577; Umeh H N, 1994, Ann R Coll Surg Engl, V76, P4; WILLIAMS M, 1992, EPIDEMIOLOGICALLY BA; 1992, HLTH SERVICE CHARTER; 1994, EL9490 NHS EX; 1992, 4TH REPORT PROGR NHS; 1987, HOSPITAL WAITING STA; 1909, REVISED EXPANDED PAT; 1995, BRIT MED J, V310, P1045	17	27	27	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 23	1995	311	7008					783	785		10.1136/bmj.311.7008.783	http://dx.doi.org/10.1136/bmj.311.7008.783			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX107	7580440	Green Published			2022-12-24	WOS:A1995RX10700021
J	JONES, C; PENNY, L; MATTINA, T; YU, S; BAKER, E; VOULLAIRE, L; LANGDON, WY; SUTHERLAND, GR; RICHARDS, RI; TUNNACLIFFE, A				JONES, C; PENNY, L; MATTINA, T; YU, S; BAKER, E; VOULLAIRE, L; LANGDON, WY; SUTHERLAND, GR; RICHARDS, RI; TUNNACLIFFE, A			ASSOCIATION OF A CHROMOSOME DELETION SYNDROME WITH A FRAGILE SITE WITHIN THE PROTOONCOGENE CBL2	NATURE			English	Article							LINKED MENTAL-RETARDATION; SOMATIC-CELL HYBRIDS; X-SYNDROME; MICROSATELLITE INSTABILITY; CGG REPEAT; DNA; REGION; CANCER; FMR-1; 11Q23	The fragile site FRA11B has been localized to the p(CCG)(n) repeat of the CBL2 proto-oncogene. A proportion of Jacobsen (11q(-)) syndrome patients inherited a chromosome carrying a CBL2 p(CCG)(n) expansion, which was truncated close to FRA11B. These results have broad implications for the role of p(CCG)(n) repeat expansion in the aetiology of genetic disease involving chromosome rearrangements.	UNIV CALIF SAN DIEGO,DEPT MED,DIV MED GENET,LA JOLLA,CA 92093; UNIV CATANIA 1,PEDIAT CLIN,CATANIA,ITALY; ADELAIDE WOMENS & CHILDRENS HOSP,CTR MED GENET,DEPT CYTOGENET & MOLEC GENET,ADELAIDE,SA 5006,AUSTRALIA; ROYAL CHILDRENS HOSP,MURDOCH INST,MELBOURNE,VIC 3052,AUSTRALIA; UNIV WESTERN AUSTRALIA,DEPT BIOCHEM,NEDLANDS,WA 6009,AUSTRALIA; QUADRANT RES FDN,CAMBRIDGE CB2 2SY,ENGLAND	University of California System; University of California San Diego; University of Catania; Womens & Childrens Hospital Australia; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Western Australia	JONES, C (corresponding author), UNIV CAMBRIDGE,DEPT PATHOL,TENNIS COURT RD,CAMBRIDGE CB2 1QP,ENGLAND.		Richards, Robert/ABE-6423-2020; Sutherland, Grant Robert/D-2606-2012; Mattina, Teresa/AGB-4604-2022	Tunnacliffe, Alan/0000-0001-8570-125X; Mattina, Teresa/0000-0001-6143-6682; Richards, Robert Ian/0000-0002-5978-6453				ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BELL MV, 1991, CELL, V64, P861, DOI 10.1016/0092-8674(91)90514-Y; BLAKE TJ, 1991, ONCOGENE, V6, P653; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Brown W T, 1992, Mol Genet Med, V2, P39; DEVYS D, 1993, NAT GENET, V4, P335, DOI 10.1038/ng0893-335; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FLYNN GA, 1993, J MED GENET, V30, P97, DOI 10.1136/jmg.30.2.97; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; GIRAUD F, 1976, HUM GENET, V34, P125, DOI 10.1007/BF00278880; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HARVEY J, 1977, J MED GENET, V14, P46, DOI 10.1136/jmg.14.1.46; HUMMERICH H, 1994, HUM MOL GENET, V3, P73, DOI 10.1093/hmg/3.1.73; JACOBSEN P, 1973, HUM HERED, V23, P568, DOI 10.1159/000152624; JONES C, 1994, HUM MOL GENET, V3, P2123, DOI 10.1093/hmg/3.12.2123; KNIGHT SJL, 1993, CELL, V74, P127, DOI 10.1016/0092-8674(93)90300-F; Knudson A. G., 1973, ADV CANCER RES, V17, P317; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; MAO L, 1994, P NATL ACAD SCI USA, V91, P9871, DOI 10.1073/pnas.91.21.9871; MULLEY JC, 1995, J MED GENET, V32, P162, DOI 10.1136/jmg.32.3.162; NANCARROW JK, 1994, SCIENCE, V264, P1938, DOI 10.1126/science.8009225; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARRISH JE, 1994, NAT GENET, V8, P229, DOI 10.1038/ng1194-229; PELTOMAKI P, 1993, CANCER RES, V53, P5853; PENNY LA, 1995, AM J HUM GENET, V56, P676; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; RICHARDS RI, 1992, CELL, V70, P709, DOI 10.1016/0092-8674(92)90302-S; ROUSSEAU F, 1991, NEW ENGL J MED, V325, P1673, DOI 10.1056/NEJM199112123252401; Sambrook J., 1989, MOL CLONING LAB MANU; SAVAGE PD, 1991, CYTOGENET CELL GENET, V56, P112, DOI 10.1159/000133062; SCHINZEL A, 1977, J MED GENET, V14, P438, DOI 10.1136/jmg.14.6.438; Sutherland G, 1985, FRAGILE SITES HUMAN; SUTHERLAND GR, 1983, AM J HUM GENET, V35, P432; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; TUNNACLIFFE A, 1990, GENOMICS, V8, P447, DOI 10.1016/0888-7543(90)90030-X; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VINCENT A, 1991, NATURE, V349, P624, DOI 10.1038/349624a0; VOULLAIRE LE, 1987, HUM GENET, V76, P202, DOI 10.1007/BF00284923; WARREN ST, 1990, P NATL ACAD SCI USA, V87, P3856, DOI 10.1073/pnas.87.10.3856; WARREN ST, 1987, SCIENCE, V237, P420, DOI 10.1126/science.3603029; WILLEMS PJ, 1994, NAT GENET, V8, P213, DOI 10.1038/ng1194-213; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179; YUNIS JJ, 1983, SCIENCE, V221, P227, DOI 10.1126/science.6336310	46	130	131	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 13	1995	376	6536					145	149		10.1038/376145a0	http://dx.doi.org/10.1038/376145a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ028	7603564				2022-12-24	WOS:A1995RJ02800052
J	HANIF, M; MOBARAK, MR; RONAN, A; RAHMAN, D; DONOVAN, JJ; BENNISH, ML				HANIF, M; MOBARAK, MR; RONAN, A; RAHMAN, D; DONOVAN, JJ; BENNISH, ML			FATAL RENAL-FAILURE CAUSED BY DIETHYLENE GLYCOL IN PARACETAMOL ELIXIR - THE BANGLADESH EPIDEMIC	BRITISH MEDICAL JOURNAL			English	Article							CHILDREN	Objective-To determine the cause of a large increase in the number of children with unexplained renal failure. Design-Case-control study. Setting-Children's hospital in Dhaka, Bangladesh. Subjects-Cases were all 339 children with initially unexplained renal failure; controls were 90 children with cause of renal failure identified; all were admitted to hospital during 35 months after January 1990. Main outcome measures-Differences between the case and control patients in clinical and histological features and outcome; toxicological examination of 69 bottles of paracetamol from patients and pharmacies. Results-Compared with children with an identified cause for their renal failure, children with initially unexplained renal failure were significantly (P < 0 . 05) more likely to have hepatomegaly (58% v 33%), oedema (37% v 20%), and hypertension (58% v 23%); to have a higher serum creatinine concentration (mean 519 mu mol/l v 347 mu mol/l) and lower serum bicarbonate concentration (10 . 1 mmol/l v 12 . 4 mmol/l); to have been given a drug for fever (91% v 31%); to have ingested a brand of paracetamol shown to contain diethylene glycol (20% v 0%); and to have died in hospital (70% v 33%). Diethylene glycol was identified in 19 bottles of paracetamol, from 7 of 28 brands tested. In the 12 months after a government ban on the sale of paracetamol elixir, new cases of renal failure decreased by 54%, and cases of unexplained renal failure decreased by 84%. Conclusion-Paracetamol elixirs with diethylene glycol as a diluent were responsible for a large outbreak of fatal renal failure in Bangladesh.	TUFTS UNIV NEW ENGLAND MED CTR,DIV GEOG MED & INFECT DIS,BOSTON,MA 02111; DHAKA SHISHU HOSP,DEPT NEPHROL,DHAKA,BANGLADESH; INT CTR DIARRHOEAL DIS RES,DHAKA,BANGLADESH; MASSACHUSETTS DEPT PUBL HLTH,STATE LAB INST,BOSTON,MA 02116	Tufts Medical Center; International Centre for Diarrhoeal Disease Research (ICDDR); Massachusetts Department of Public Health								ANDREWS LS, 1991, CASARETT DOULLS TOXI, P704; BOWIE MD, 1972, S AFR MED J, V46, P931; CANTARELL MC, 1987, ANN INTERN MED, V106, P478, DOI 10.7326/0003-4819-106-3-478_2; Castelo A, 1991, J Clin Epidemiol, V44 Suppl 2, p21S; CHETLEY A, 1992, POLICY PRACTICE FUTU, P53; Geiling EMK., 1938, J AM MED ASS, V111, P919, DOI [10.1001/jama.1938.72790360005007, DOI 10.1001/JAMA.1938.72790360005007]; GRANT JP, 1994, STATE WORLDS CHILDRE, P64; MASLAND T, 1990, NEWSWEEK        1105, P22; OKUONGHAE HO, 1992, ANN TROP PAEDIATR, V12, P235, DOI 10.1080/02724936.1992.11747577; PANDYA SK, 1988, BRIT MED J, V297, P117, DOI 10.1136/bmj.297.6641.117; REICH MR, 1994, HEALTH POLICY PLANN, V9, P130, DOI 10.1093/heapol/9.2.130; ROY SK, 1993, WHO SEA98 DRUGS DRUG; SILVERMAN M, 1992, BAD MED PRESCRIPTION, P209; TIRANTI DJ, 1986, ESSENTIAL DRUGS BANG, P11; van Leusen R, 1987, Ned Tijdschr Geneeskd, V131, P768; VANDERLINDENCRE.PM, 1985, NED TIJDSCHR GENEESK, V129, P1890; WINDHOLZ M, 1983, MERCK INDEX, P453; 1977, PEDIATR S, V59, P803; 1985, LANCET, V2, P254; 1992, WHO TECHNICAL REPORT, V825, P22; 1981, TREATMENT MANAGEMENT	21	103	109	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 8	1995	311	6997					88	91		10.1136/bmj.311.6997.88	http://dx.doi.org/10.1136/bmj.311.6997.88			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ030	7613408	Green Published			2022-12-24	WOS:A1995RJ03000020
J	MEYER, HE; TVERDAL, A; FALCH, JA				MEYER, HE; TVERDAL, A; FALCH, JA			CHANGES IN BODY-WEIGHT AND INCIDENCE OF HIP FRACTURE AMONG MIDDLE-AGED NORWEGIANS	BRITISH MEDICAL JOURNAL			English	Article									AKER HOSP,DEPT INTERNAL MED,N-0514 OSLO,NORWAY	University of Oslo	MEYER, HE (corresponding author), NATL HLTH SCREENING SERV,POB 8155,N-0033 OSLO,NORWAY.		Meyer, Haakon E./AAH-9333-2019	Tverdal, Aage/0000-0002-2909-5678				CUMMING RG, 1994, AM J EPIDEMIOL, V139, P493, DOI 10.1093/oxfordjournals.aje.a117032; LISSNER L, 1991, NEW ENGL J MED, V324, P1839, DOI 10.1056/NEJM199106273242602; MEYER HE, 1993, AM J EPIDEMIOL, V137, P1203, DOI 10.1093/oxfordjournals.aje.a116622; REID IR, 1994, J CLIN ENDOCR METAB, V79, P950, DOI 10.1210/jc.79.4.950; 1988, CARDIOVASCULAR DISEA	5	23	23	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 8	1995	311	6997					91	92		10.1136/bmj.311.6997.91	http://dx.doi.org/10.1136/bmj.311.6997.91			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ030	7613409	Green Published			2022-12-24	WOS:A1995RJ03000021
J	JANG, JK; MESSINA, L; ERDMAN, MB; ARBEL, T; HAWLEY, RS				JANG, JK; MESSINA, L; ERDMAN, MB; ARBEL, T; HAWLEY, RS			INDUCTION OF METAPHASE ARREST IN DROSOPHILA OOCYTES BY CHIASMA-BASED KINETOCHORE TENSION	SCIENCE			English	Article							CHROMOSOMES	In normal Drosophila melanogaster oocytes, meiosis arrests at metaphase I and resumes after oocyte passage through the oviduct. Thus, metaphase arrest defines a control point in the meiotic cell cycle. Metaphase arrest only occurs in oocytes that have undergone at least one meiotic exchange. Here it Is shown that crossovers between homologs attached to the same centromere do not induce metaphase arrest. Hence, exchanges induce metaphase arrest only when they physically conjoin two separate kinetochores. Thus, the signal that mediates metaphase arrest is not the exchange event per se but the resulting tension on homologous kinetochores.	UNIV CALIF DAVIS,DEPT GENET,MOLEC & CELLULAR BIOL SECT,DAVIS,CA 95616	University of California System; University of California Davis				Hawley, R. Scott/0000-0002-6478-0494	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD023144] Funding Source: NIH RePORTER; NICHD NIH HHS [N01-HD-2-3144] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		COURTOT C, 1992, DEVELOPMENT, V116, P405; GORBSKY GJ, 1993, J CELL BIOL, V122, P1311, DOI 10.1083/jcb.122.6.1311; HAWLEY RS, 1993, DEV GENET, V13, P440; HOLM DG, 1976, GENET BIOL DROSOPHIL, P529; JANG J, UNPUB; King R. C., 1970, OVARIAN DEV DROSOPHI; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MCINTOSH JR, 1991, COLD SH Q B, V56, P613; MCKIM KS, 1993, NATURE, V362, P364, DOI 10.1038/362364a0; MIYAZAKI WY, 1994, ANNU REV GENET, V28, P167, DOI 10.1146/annurev.ge.28.120194.001123; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; REIDER CL, 1994, J CELL BIOL, V127, P1301; Sonnenblick BP, 1965, BIOLOGY DROSOPHILA, P62; THEURKAUF WE, 1992, J CELL BIOL, V116, P1167, DOI 10.1083/jcb.116.5.1167; WHITECOOPER H, 1993, J CELL SCI, V106, P1035	16	48	48	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 30	1995	268	5219					1917	1919		10.1126/science.7604267	http://dx.doi.org/10.1126/science.7604267			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF990	7604267				2022-12-24	WOS:A1995RF99000044
J	LIN, JJ; ZAKIAN, VA				LIN, JJ; ZAKIAN, VA			AN IN-VITRO ASSAY FOR SACCHAROMYCES TELOMERASE REQUIRES EST1	CELL			English	Article							TERMINAL TRANSFERASE-ACTIVITY; YEAST TELOMERES; PHOSPHOGLYCERATE KINASE; BINDING-PROTEIN; DNA; IDENTIFICATION; CLONING; RNA; TETRAHYMENA; CEREVISIAE	Telomerase activity was demonstrated in cell-free extracts from S. cerevisiae through the use of a PCR-based assay. As expected, this activity was eliminated by RNase or phenol treatment of the extract and was dependent on dGTP and dTTP. Telomerase was not detected in extracts prepared from cells grown far similar to 30 or more cell divisions in the absence of the EST1 product, Est1p. TLC1 RNA, which determines the sequence of telomeric DNA in vivo, was present in normal amounts in est1 Delta cells. Moreover, TLC1 RNA specifically precipitated with epitope-tagged Est1p. These data indicate that Est1p is either a subunit of yeast telomerase or an accessory protein associated with telomerase that is essential in vitro for its activity.	UNIV WASHINGTON, DEPT GENET, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT PATHOL, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	LIN, JJ (corresponding author), FRED HUTCHINSON CANC RES CTR, 1124 COLUMBIA ST, SEATTLE, WA 98104 USA.		Lin, Jing-Jer/G-8068-2015	LIN, JING-JER/0000-0001-8250-7398	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026938, R01GM026938] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26938] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BROWN WRA, 1989, NATURE, V338, P774, DOI 10.1038/338774a0; COLLINS K, 1995, CELL, V81, P677, DOI 10.1016/0092-8674(95)90529-4; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; CROSS SH, 1989, NATURE, V338, P771, DOI 10.1038/338771a0; DANI GM, 1983, P NATL ACAD SCI-BIOL, V80, P3406, DOI 10.1073/pnas.80.11.3406; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; DOBSON MJ, 1982, NUCLEIC ACIDS RES, V10, P2625, DOI 10.1093/nar/10.8.2625; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HOLLAND MJ, 1978, BIOCHEMISTRY-US, V17, P4900, DOI 10.1021/bi00616a007; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; LIN JJ, 1994, NUCLEIC ACIDS RES, V22, P4906, DOI 10.1093/nar/22.23.4906; LINGNER J, 1994, GENE DEV, V8, P1984, DOI 10.1101/gad.8.16.1984; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; LUNDBLAD V, 1990, CELL, V60, P529; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; LUSTIG AJ, 1990, SCIENCE, V250, P549, DOI 10.1126/science.2237406; LUSTIG AJ, 1986, P NATL ACAD SCI USA, V83, P1398, DOI 10.1073/pnas.83.5.1398; MANTELL LL, 1994, EMBO J, V13, P3211, DOI 10.1002/j.1460-2075.1994.tb06620.x; MELEK M, 1994, MOL CELL BIOL, V14, P7827, DOI 10.1128/MCB.14.12.7827; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; NG R, 1980, P NATL ACAD SCI-BIOL, V77, P3912, DOI 10.1073/pnas.77.7.3912; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; PERKINS RE, 1983, BIOCHEM J, V211, P199, DOI 10.1042/bj2110199; PLUTA AF, 1984, P NATL ACAD SCI-BIOL, V81, P1475, DOI 10.1073/pnas.81.5.1475; PROWSE KR, 1993, P NATL ACAD SCI USA, V90, P1493, DOI 10.1073/pnas.90.4.1493; RIETHMAN HC, 1989, P NATL ACAD SCI USA, V86, P6240, DOI 10.1073/pnas.86.16.6240; ROMERO DP, 1991, CELL, V67, P343, DOI 10.1016/0092-8674(91)90186-3; SAKAKIBARA Y, 1974, P NATL ACAD SCI USA, V71, P802, DOI 10.1073/pnas.71.3.802; Sambrook J., 1989, MOL CLONING LAB MANU; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SCHATZ PJ, 1986, MOL CELL BIOL, V6, P3711, DOI 10.1128/MCB.6.11.3711; SCHULZ VP, 1994, CELL, V76, P145, DOI 10.1016/0092-8674(94)90179-1; SHAMPAY J, 1984, NATURE, V310, P154, DOI 10.1038/310154a0; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; SHIPPENLENTZ D, 1989, MOL CELL BIOL, V9, P2761, DOI 10.1128/MCB.9.6.2761; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; SINGER MS, 1994, SCIENCE, V266, P387; SZOSTAK JW, 1982, CELL, V29, P245, DOI 10.1016/0092-8674(82)90109-X; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; WANG SS, 1990, MOL CELL BIOL, V10, P4415, DOI 10.1128/MCB.10.8.4415; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WRIGHT JH, 1995, NUCLEIC ACIDS RES, V23, P1454, DOI 10.1093/nar/23.9.1454; YU GL, 1991, CELL, V67, P823, DOI 10.1016/0092-8674(91)90077-C; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; ZAHLER AM, 1988, NUCLEIC ACIDS RES, V16, P6953, DOI 10.1093/nar/16.14.6953	52	96	99	0	6	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 30	1995	81	7					1127	1135		10.1016/S0092-8674(05)80017-0	http://dx.doi.org/10.1016/S0092-8674(05)80017-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RG910	7600580	Bronze			2022-12-24	WOS:A1995RG91000017
J	HUGHES, CH; BAUMER, JH				HUGHES, CH; BAUMER, JH			MOVING HOUSE - A RISK FACTOR FOR THE DEVELOPMENT OF CHILDHOOD ASTHMA	BRITISH MEDICAL JOURNAL			English	Article							SMOKING; ILLNESS		DERRIFORD HOSP,DEPT CHILD HLTH,PLYMOUTH PL6 8DH,DEVON,ENGLAND	Derriford Hospital	HUGHES, CH (corresponding author), CTR HLTH,ESTOVER,PLYMOUTH PL6 8UE,DEVON,ENGLAND.							ANDERSON HR, 1983, ARCH DIS CHILD, V58, P777, DOI 10.1136/adc.58.10.777; COGSWELL JJ, 1987, ARCH DIS CHILD, V62, P338, DOI 10.1136/adc.62.4.338; KAPLAN BA, 1985, J EPIDEMIOL COMMUN H, V39, P152, DOI 10.1136/jech.39.2.152; TAYLOR B, 1987, ARCH DIS CHILD, V62, P786, DOI 10.1136/adc.62.8.786; VONMUTIUS E, 1994, BRIT MED J, V308, P692, DOI 10.1136/bmj.308.6930.692	5	13	13	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 21	1995	311	7012					1069	1070		10.1136/bmj.311.7012.1069	http://dx.doi.org/10.1136/bmj.311.7012.1069			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB354	7580667	Green Published			2022-12-24	WOS:A1995TB35400026
J	MANDEL, MA; YANOFSKY, MF				MANDEL, MA; YANOFSKY, MF			A GENE TRIGGERING FLOWER FORMATION IN ARABIDOPSIS	NATURE			English	Article							INFLORESCENCE DEVELOPMENT; FLORAL DEVELOPMENT; THALIANA; LEAFY	IN Arabidopsis, the apical shoot meristem produces lateral meristems that develop into either shoots or flowers. The decision to form flowers instead of shoots is mediated by the action of floral-meristem-identity genes, such as APETALA1 (API) and LEAFY (LFY), which specify meristem fate(1-7). Here we show that transgenic plants which constitutively express the AP1 gene show transformations of apical and lateral shoots into flowers, and that these plants flower much earlier than wild-type plants. These results indicate that AP1 alone can convert infloresence shoot meristems into floral meristems, and that ectopic AP1 expression can dramatically reduce the time to flowering.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR GENET MOLEC,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego								ALVAREZ J, 1992, PLANT J, V2, P103, DOI 10.1111/j.1365-313X.1992.00103.x; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BOWMAN JL, 1993, DEVELOPMENT, V119, P721; CHUNG YY, PL MOL BIOL, V26, P657; GUSTAFSONBROWN C, 1994, CELL, V76, P131, DOI 10.1016/0092-8674(94)90178-3; HUALA E, 1992, PLANT CELL, V4, P901, DOI 10.1105/tpc.4.8.901; IRISH VF, 1990, PLANT CELL, V2, P741, DOI 10.1105/tpc.2.8.741; JACK T, 1994, CELL, V76, P703, DOI 10.1016/0092-8674(94)90509-6; JOFUKU KD, 1994, PLANT CELL, V6, P1211, DOI 10.1105/tpc.6.9.1211; KEMPIN SA, 1995, SCIENCE, V267, P522, DOI 10.1126/science.7824951; LEVIN J, 1995, CELL, V7, P529; MANDEL MA, 1992, NATURE, V380, P273; ODELL JT, 1985, NATURE, V313, P810, DOI 10.1038/313810a0; SCHULTZ EA, 1991, PLANT CELL, V3, P771, DOI 10.1105/tpc.3.8.771; SHANNON S, 1991, PLANT CELL, V3, P877, DOI 10.1105/tpc.3.9.877; SHANNON S, 1993, PLANT CELL, V5, P639, DOI 10.1105/tpc.5.6.639; Weigel D, 1995, ANNU REV GENET, V29, P19, DOI 10.1146/annurev.ge.29.120195.000315; WEIGEL D, 1992, CELL, V89, P843; WEIGEL D, IN PRESS NATURE; YANOFSKY MF, 1995, ANNU REV PLANT PHYS, V46, P167, DOI 10.1146/annurev.pp.46.060195.001123	20	408	474	3	34	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 12	1995	377	6549					522	524		10.1038/377522a0	http://dx.doi.org/10.1038/377522a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ336	7566148				2022-12-24	WOS:A1995RZ33600060
J	SALADIN, R; DEVOS, P; GUERREMILLO, M; LETURQUE, A; GIRARD, J; STAELS, B; AUWERX, J				SALADIN, R; DEVOS, P; GUERREMILLO, M; LETURQUE, A; GIRARD, J; STAELS, B; AUWERX, J			TRANSIENT INCREASE IN OBESE GENE-EXPRESSION AFTER FOOD-INTAKE OR INSULIN ADMINISTRATION	NATURE			English	Article							PROTEIN	OBESITY is a disorder of energy balance, indicating a chronic disequilibrium between energy intake and expenditure(1). Recently, the mouse ob gene(2), and subsequently its human and rat homologues(2-6), have been cloned. The ob gene product, leptin(7), is expressed exclusively in adipose tissue, and appears to be a signalling factor regulating body-weight homeostasis and energy balance(2,7-9). Because the level of ob gene expression might indicate the size of the adipose depot, we suggest that it is regulated by factors modulating adipose tissue size. Here we show that ob gene exhibits diurnal variation, increasing during the night, after rats start eating. This variation was linked to changes in food intake, as fasting prevented the cyclic variation and decreased ob messenger RNA. Furthermore, refeeding fasted rats restored ob mRNA within 4 hours to levels of fed animals. A single insulin injection in fasted animals increased ob mRNA to levels of fed controls. Experiments to control glucose and insulin independently in animals, and studies in primary adipocytes, showed that insulin regulates ob gene expression directly in rats, regardless of its glucose-lowering effects. Whereas the ob gene product, leptin, has been shown to reduce food intake and increase energy expenditure(7-9) our data demonstrate that ob gene expression is increased after food ingestion in rats, perhaps through a direct action of insulin on the adipocyte.	INST BIOMED CORDELIERS,INSERM,U177,F-75006 PARIS,FRANCE; CNRS,UPR 1511,CEREMOD,F-92190 MEUDON,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS)	SALADIN, R (corresponding author), INST PASTEUR,BIOL REGULAT CHEZ EUCARYOTES LAB,INSERM,U325,1 RUE CALMETTE,F-59019 LILLE,FRANCE.		Auwerx, Johan/ABE-9307-2021; Staels, Bart/N-9497-2016; Leturque, Armelle/Q-9437-2017	Staels, Bart/0000-0002-3784-1503; Leturque, Armelle/0000-0001-6570-6387; Auwerx, Johan/0000-0002-5065-5393				CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; DEVOS P, 1995, J BIOL CHEM, V270, P15958, DOI 10.1074/jbc.270.27.15958; FUNAHASHI T, 1995, BIOCHEM BIOPH RES CO, V211, P469, DOI 10.1006/bbrc.1995.1837; GAZDAR AF, 1990, CANCER RES, V50, P5488; GEFFROY S, 1995, GENOMICS, V28, P603, DOI 10.1006/geno.1995.1201; GRUNDY SM, 1990, DM-DIS MON, V36, P641; HAJDUCH EJ, 1992, J CELL BIOCHEM, V49, P251, DOI 10.1002/jcb.240490307; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; MAFFEI M, 1995, P NATL ACAD SCI USA, V92, P6957, DOI 10.1073/pnas.92.15.6957; MASUZAKI H, 1995, DIABETES, V44, P855, DOI 10.2337/diabetes.44.7.855; MURAKAMI T, 1995, BIOCHEM BIOPH RES CO, V209, P944, DOI 10.1006/bbrc.1995.1589; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; PERET J, 1973, J NUTR, V103, P866, DOI 10.1093/jn/103.6.866; POSTIC C, 1993, DIABETES, V42, P922, DOI 10.2337/diabetes.42.6.922; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; [No title captured]	17	1037	1064	0	39	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 12	1995	377	6549					527	529		10.1038/377527a0	http://dx.doi.org/10.1038/377527a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ336	7566150				2022-12-24	WOS:A1995RZ33600062
J	OMAHONY, D				OMAHONY, D			PATHOPHYSIOLOGY OF CAROTID-SINUS HYPERSENSITIVITY IN ELDERLY PATIENTS	LANCET			English	Note							BLOOD-PRESSURE; CLINICAL CHARACTERISTICS; BAROREFLEX SENSITIVITY; AGE; SYNCOPE	Carotid sinus hypersensitivity (CSH) is recognised in up to 45% of elderly patients with syncope, falls, and dizziness that may not be attributed to specific myocardial sinus node dysfunction, various diseases that affect pacemaker activity, cardiac output and blood supply to the brain. The pathophysiology of CSH is unclear but it is associated with ageing, hypertension, and ischaemic heart disease. CSH is potentially treatable with dual chamber pacing for prolonged sinus arrest (cardio-inhibitory CSH) but therapy for the more prevalent hypotension (vasodepressor CSH) is unsatisfactory. However, hypersensitivity of the carotid sinus is not consistent with the known blunting effects of senescence and hypertension on baroreflex sensitivity. The present hypothesis proposes that CSH patients results from up-regulation of postsynaptic alpha-2 adrenoceptors. Reduced carotid sinus compliance in elderly arteriosclerotic hypertensive patients will reduce afferent impulse traffic in the baroreflex pathway. Such relative deafferentation may be expected to cause baroreflex postsynaptic hypersensitivity, mediated by up-regulation of the dominant postsynaptic receptor population in the baroreflex pathway, ie, alpha-2 adrenoceptors. Vigorous carotid sinus stimulation, eg, massage, could thus cause an overshoot baroreflex efferent response, resulting in profound hypotension and bradycardia. Hypotension and bradycardia are compounded by the effects of age, hypertension, ischaemic heart disease and arteriosclerosis on rapid cardiovascular compensation, resulting in cerebral hypoperfusion and syncope. Thus, CSH in elderly patients should be considered as a clinical marker of widespread arteriosclerotic disease, rather than as a distinct disease entity. If correct, this hypothesis has potentially important implications for the pharmacotherapy of hypotension-related symptoms in elderly arteriosclerotic patients.			OMAHONY, D (corresponding author), UNIV BIRMINGHAM,DEPT GERIATR MED,BIRMINGHAM B29 6JD,W MIDLANDS,ENGLAND.							BRIGNOLE M, 1992, AM J CARDIOL, V69, P1039, DOI 10.1016/0002-9149(92)90860-2; CLIFFORD JM, 1989, BRIT J CLIN PHARMACO, V28, pP224; DEHN TCB, 1984, J PHYSL, V49, P37; GILLIS RA, 1985, J CARDIOVASC PHARM, V7, pS38; GRIBBIN B, 1971, CIRC RES, V29, P424, DOI 10.1161/01.RES.29.4.424; HAEUSLER G, 1974, N-S ARCH PHARMACOL, V286, P97, DOI 10.1007/BF00499107; HALLIDAY CA, 1991, BRIT J PHARMACOL, V102, P887, DOI 10.1111/j.1476-5381.1991.tb12272.x; HYLAND L, 1985, EUR J PHARMACOL, V114, P361, DOI 10.1016/0014-2999(85)90381-4; KANNEL WB, 1985, HDB BIOL AGING, P859; KAPOOR WN, 1994, J AM GERIATR SOC, V42, P426, DOI 10.1111/j.1532-5415.1994.tb07493.x; KENNY RA, 1991, AGE AGEING, V20, P449, DOI 10.1093/ageing/20.6.449; KOBINGER W, 1976, EUR J PHARMACOL, V40, P311, DOI 10.1016/0014-2999(76)90068-6; LIPSITZ LA, 1985, CLIN SCI, V69, P337, DOI 10.1042/cs0690337; MCGARRY K, 1983, HYPERTENSION, V5, P8763; MCINTOSH S, 1993, AGE AGEING, V22, P53, DOI 10.1093/ageing/22.1.53; MCINTOSH SJ, 1993, AM J MED, V95, P203, DOI 10.1016/0002-9343(93)90261-M; MINAKER KL, 1980, GERONTOLOGIST, V20, P163; MORLEY CA, 1984, INT J CARDIOL, V6, P287, DOI 10.1016/0167-5273(84)90188-8; REIFFEL JA, 1983, PACE, V6, P1143, DOI 10.1111/j.1540-8159.1983.tb04451.x; ROBERTSON HA, 1985, CAN J PHYSIOL PHARM, V63, P1190, DOI 10.1139/y85-195; ROSS RT, 1988, MAJOR PROBLEMS NEURO, V18, P107; RUFFOLO RR, 1994, PHARMACOL THERAPEUT, V61, P1, DOI 10.1016/0163-7258(94)90058-2; Schmitt H, 1971, Actual Pharmacol (Paris), V24, P93; SHIMADA K, 1986, CLIN SCI, V70, P489, DOI 10.1042/cs0700489; SMYTH HS, 1969, CIRC RES, V24, P109, DOI 10.1161/01.RES.24.1.109; STRASBERG B, 1989, PROG CARDIOVASC DIS, V31, P379, DOI 10.1016/0033-0620(89)90032-7; Wallin B.G., 1992, AUTONOMIC FAILURE TX, P359; WIEDEMANN G, 1985, J NEUROL, V232, P318, DOI 10.1007/BF00313874	29	56	57	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 7	1995	346	8980					950	952		10.1016/S0140-6736(95)91563-X	http://dx.doi.org/10.1016/S0140-6736(95)91563-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY808	7564734				2022-12-24	WOS:A1995RY80800015
J	IWASA, Y; POMIANKOWSKI, A				IWASA, Y; POMIANKOWSKI, A			CONTINUAL CHANGE IN MATE PREFERENCES	NATURE			English	Article							SEXUAL SELECTION; EVOLUTION; FISHER; SPECIATION; PRINCIPLE; MUTATION	SECONDARY sexual characters are highly variable both within(1) and between species(2-6). Closely related species often differ markedly in sexual morphology but hardly at all In non-sexual traits(2-5). Here we show that Fisher's runaway process of sexual selection is intrinsically unstable and naturally leads to continual change in sexual traits. Runaway leads to semi-stable exaggeration of female preference for a malt sexual character, followed by a slow decay of both traits until runaway is triggered again In a different direction. The process then repeats itself resulting in continual change in male sexual traits through time. Allopatric populations are thus expected to diverge without drift or substantial changes in selective pressures. If there is significant mutation bias acting on the male trait, continual change stops and a stable equilibrium appears. Such an outcome is more likely when exaggeration of the male sexual trait signals good genes.	UNIV LONDON UNIV COLL, DEPT GENET & BIOMETRY, LONDON NW1 2HE, ENGLAND; KYUSHU UNIV, FAC SCI, DEPT BIOL, FUKUOKA 81281, JAPAN	University of London; University College London; Kyushu University			Pomiankowski, Andrew/X-3888-2019; Iwasa, Yoh/G-5368-2010	Pomiankowski, Andrew/0000-0002-5171-8755; Iwasa, Yoh/0000-0003-0691-1852				Andersson Malte, 1994; Charlesworth B, 1987, SEXUAL SELECTION TES, P21; Darwin C., 1871, P423; Eberhard W. G., 1985, SEXUAL SELECTION ANI; Fisher R. A., 1930, GENETICAL THEORY NAT, DOI 10.5962/bhl.title.27468; FRYER G, 1980, CICHLID FISHES GREAT; Hirsch M., 1974, DIFFERENTIAL EQUATIO; IWASA Y, 1994, EVOLUTION, V48, P853, DOI 10.1111/j.1558-5646.1994.tb01367.x; IWASA Y, 1991, EVOLUTION, V45, P1431, DOI 10.1111/j.1558-5646.1991.tb02646.x; KARLIN S, 1990, THEOR POPUL BIOL, V38, P306, DOI 10.1016/0040-5809(90)90017-P; KIRKPATRICK M, 1990, EVOLUTION, V44, P180, DOI 10.1111/j.1558-5646.1990.tb04288.x; LANDE R, 1981, P NATL ACAD SCI-BIOL, V78, P3721, DOI 10.1073/pnas.78.6.3721; LANDE R, 1982, EVOLUTION, V36, P213, DOI 10.1111/j.1558-5646.1982.tb05034.x; MUKAI T, 1977, P NATL ACAD SCI USA, V74, P2514, DOI 10.1073/pnas.74.6.2514; POMIANKOWSKI A, 1995, P ROY SOC B-BIOL SCI, V260, P21, DOI 10.1098/rspb.1995.0054; POMIANKOWSKI A, 1991, EVOLUTION, V45, P1422, DOI 10.1111/j.1558-5646.1991.tb02645.x; POMIANKOWSKI A, 1993, P ROY SOC B-BIOL SCI, V253, P173, DOI 10.1098/rspb.1993.0099; TEMPLETON AR, 1980, GENETICS, V94, P1011; YOUNG JR, 1994, ANIM BEHAV, V47, P1353, DOI 10.1006/anbe.1994.1183	19	168	170	2	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 5	1995	377	6548					420	422		10.1038/377420a0	http://dx.doi.org/10.1038/377420a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY190	7566117				2022-12-24	WOS:A1995RY19000046
J	RUIZ, J; BLANCHE, H; JAMES, RW; GARIN, MCB; VAISSE, C; CHARPENTIER, G; COHEN, N; MORABIA, A; PASSA, P; FROGUEL, P				RUIZ, J; BLANCHE, H; JAMES, RW; GARIN, MCB; VAISSE, C; CHARPENTIER, G; COHEN, N; MORABIA, A; PASSA, P; FROGUEL, P			GLN-ARG192 POLYMORPHISM OF PARAOXONASE AND CORONARY HEART-DISEASE IN TYPE-2 DIABETES	LANCET			English	Article							LOW-DENSITY-LIPOPROTEIN; SERUM; MELLITUS	Paraoxonase is a high-density-lipoprotein-associated enzyme capable of hydrolysing lipid peroxides. Thus it might protect lipoproteins from oxidation. It has two isoforms, which arise from a glutamine (A isoform) to arginine (B isoform) interchange at position 199. The relevance of this polymorphism to coronary heart disease (CHD) in non-insulin-dependent diabetic patients was investigated in case-control study. Of the 434 patients, 171 had confirmed coronary artery disease; the other 263 had no history of such disease. The B allele and AB+BB genotypes were associated with an increased risk of coronary heart disease. Compared with subjects homozygous for the A allele (AA genotype), the odds ratio of CHD for subjects homozygous for the B allele was 2.5 (95% CI 1.2-5.3) and that for those heterozygous for the B allele was 1.6 (95% CI 1.1-2.4), suggesting a codominant effect on cardiovascular risk. When subjected to multivariate analysis, the B allele remained significantly associated with CHD (odds ratio 1.94, p=0.03). The paraoxonase gene polymorphism is thus an independent cardiovascular risk factor in non-insulin-dependent diabetic patients. A possible explanation for this finding is that activity of the paraoxonase B isotype does not protect well against lipid oxidation, a major atherogenic pathway.	UNIV HOSP GENEVA, DIV CLIN EPIDEMIOL, GENEVA, SWITZERLAND; FDN JEAN DAUSSET, CEPH, PARIS, FRANCE; UNIV HOSP GENEVA, DIV ENDOCRINOL & DIABETOL, GENEVA, SWITZERLAND; HOP CORBEIL, CORBEIL ESSONNES, FRANCE; ST LOUIS HOSP, SERV DIABETOL, PARIS, FRANCE; INST PASTEUR, CNRS, EP 10, LILLE, FRANCE	University of Geneva; Foundation Jean Dausset-CEPH; University of Geneva; Centre Hospitalier Sud Francilien; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille			Vaisse, Christian/F-1067-2011; FROGUEL, Philippe/O-6799-2017	FROGUEL, Philippe/0000-0003-2972-0784				ASSMANN G, 1988, AM HEART J, V116, P1713, DOI 10.1016/0002-8703(88)90220-7; BELLOMO G, 1995, DIABETES, V44, P60, DOI 10.2337/diabetes.44.1.60; BLATTER MC, 1993, EUR J BIOCHEM, V211, P871, DOI 10.1111/j.1432-1033.1993.tb17620.x; BUCALA R, 1993, P NATL ACAD SCI USA, V90, P6434, DOI 10.1073/pnas.90.14.6434; CHISOLM GM, 1992, DIABETES, V41, P61, DOI 10.2337/diab.41.2.S61; GARIN MCB, 1994, BIOCHEM J, V304, P549, DOI 10.1042/bj3040549; HAFFNER SM, 1995, DIABETES CARE, V18, P646, DOI 10.2337/diacare.18.5.646; HEGELE RA, 1995, ARTERIOSCL THROM VAS, V15, P89, DOI 10.1161/01.ATV.15.1.89; HUMBERT R, 1993, NAT GENET, V3, P73, DOI 10.1038/ng0193-73; HUNT JV, 1990, DIABETES, V39, P1420, DOI 10.2337/diabetes.39.11.1420; LORENTZ K, 1979, CLIN CHEM, V25, P1714; LYONS TJ, 1991, DIABETIC MED, V8, P411, DOI 10.1111/j.1464-5491.1991.tb01624.x; MACKNESS MI, 1991, FEBS LETT, V286, P152, DOI 10.1016/0014-5793(91)80962-3; MACKNESS MI, 1991, ATHEROSCLEROSIS, V86, P193, DOI 10.1016/0021-9150(91)90215-O; MACKNESS MI, 1993, ATHEROSCLEROSIS, V104, P129, DOI 10.1016/0021-9150(93)90183-U; MARRE M, 1994, DIABETES, V43, P384, DOI 10.2337/diabetes.43.3.384; NISHIGAKI I, 1981, BIOCHEM MED METAB B, V25, P373, DOI 10.1016/0006-2944(81)90096-X; PARTHASARATHY S, 1990, BIOCHIM BIOPHYS ACTA, V1044, P275, DOI 10.1016/0005-2760(90)90314-N; RUIZ J, 1994, P NATL ACAD SCI USA, V91, P3662, DOI 10.1073/pnas.91.9.3662; Sambrook J., 1989, MOL CLONING LAB MANU; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; STEINBERG D, 1990, JAMA-J AM MED ASSOC, V264, P3047, DOI 10.1001/jama.264.23.3047; TAS S, 1994, LANCET, V343, P1194, DOI 10.1016/S0140-6736(94)92402-3; WALTER SD, 1978, INT J EPIDEMIOL, V7, P175, DOI 10.1093/ije/7.2.175; WATSON AD, 1994, CIRCULATION, V90, P353; 1985, WHO TECH REP SER, V727	26	326	344	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 30	1995	346	8979					869	872		10.1016/S0140-6736(95)92709-3	http://dx.doi.org/10.1016/S0140-6736(95)92709-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX196	7564671				2022-12-24	WOS:A1995RX19600009
J	CHUMAKOV, IM; RIGAULT, P; LEGALL, I; BELLANNECHANTELOT, C; BILLAULT, A; GUILLOU, S; SOULARUE, P; GUASCONI, G; POULLIER, E; GROS, I; BELOVA, M; SAMBUCY, JL; SUSINI, L; GERVY, P; GLIBERT, F; BEAUFILS, S; BUI, H; MASSART, C; DETAND, MF; DUKASZ, F; LECOULANT, S; OUGEN, P; PERROT, V; SAUMLER, M; SORAVITO, C; BAHOUAYILA, R; COHENAKENINE, A; BARILLOT, E; BERTRAND, S; CODANI, JJ; CATERINA, D; GEORGES, I; LACROIX, B; LUCOTTE, G; SAHBATOU, M; SCHMIT, C; SANGOUARD, M; TUBACHER, E; DIB, C; FAURE, S; FIZAMES, C; GYAPAY, G; MILLASSEAU, P; NGUYEN, S; MUSELET, D; VIGNAL, A; MORISSETTE, J; MENNINGER, J; LIEMAN, J; DESAI, T; BANKS, A; BRAYWARD, P; WARD, D; HUDSON, T; GERETY, S; FOOTE, S; STEIN, L; PAGE, DC; LANDER, ES; WEISSENBACH, J; LEPASLIER, D; COHEN, D				CHUMAKOV, IM; RIGAULT, P; LEGALL, I; BELLANNECHANTELOT, C; BILLAULT, A; GUILLOU, S; SOULARUE, P; GUASCONI, G; POULLIER, E; GROS, I; BELOVA, M; SAMBUCY, JL; SUSINI, L; GERVY, P; GLIBERT, F; BEAUFILS, S; BUI, H; MASSART, C; DETAND, MF; DUKASZ, F; LECOULANT, S; OUGEN, P; PERROT, V; SAUMLER, M; SORAVITO, C; BAHOUAYILA, R; COHENAKENINE, A; BARILLOT, E; BERTRAND, S; CODANI, JJ; CATERINA, D; GEORGES, I; LACROIX, B; LUCOTTE, G; SAHBATOU, M; SCHMIT, C; SANGOUARD, M; TUBACHER, E; DIB, C; FAURE, S; FIZAMES, C; GYAPAY, G; MILLASSEAU, P; NGUYEN, S; MUSELET, D; VIGNAL, A; MORISSETTE, J; MENNINGER, J; LIEMAN, J; DESAI, T; BANKS, A; BRAYWARD, P; WARD, D; HUDSON, T; GERETY, S; FOOTE, S; STEIN, L; PAGE, DC; LANDER, ES; WEISSENBACH, J; LEPASLIER, D; COHEN, D			A YAC CONTIG MAP OF THE HUMAN GENOME	NATURE			English	Article							YEAST ARTIFICIAL CHROMOSOMES; POLYMERASE CHAIN-REACTION; DNA; CLONES; SEQUENCES; CLONING; VECTORS; LIBRARY; REPEATS; GENES	A yeast artificial chromosome library containing 33,000 clones with an average insert size of one megabase of human genomic DNA was extensively analysed by several different procedures for detecting overlaps and positional information. We developed an analysis strategy that resulted, after confirmatory tests, in a YAC contig map reliably covering about 75% of the human genome in 225 contigs having an average size of about ten megabases.	GENETHON SA,F-91000 EVRY,FRANCE; YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510; MIT,WHITEHEAD INST BIOMED RES,CTR GENOME RES,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; UNIV LAVAL,CTR HOSP,CTR RECH,QUEBEC CITY,PQ G1V 4G2,CANADA	Yale University; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Laval University	CHUMAKOV, IM (corresponding author), FDN JEAN DAUSSET,CTR ETUD POLYMORPHISME HUMAIN,27 RUE JULIETTE DODU,F-75010 PARIS,FRANCE.		Vignal, Alain/I-6253-2017; susini, laurent/N-7913-2019; Susini, Laurent/O-4227-2016; Foote, Simon J/F-2802-2013	Vignal, Alain/0000-0002-6797-2125; Susini, Laurent/0000-0002-5164-2770; Fizames, Cecile/0000-0002-0551-8250; BARILLOT, Emmanuel/0000-0003-2724-2002; Le Paslier, Denis/0000-0003-4335-9956; Hudson, Thomas/0000-0002-1376-4849; Foote, Simon/0000-0002-9142-2107				ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; ARATIA R, 1991, GENOMICS, V11, P806; BELL CJ, 1995, HUM MOL GENET, V4, P59; BELLANNECHANTEL.C, 1992, CELL, V70, P1059; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; CARLE GF, 1986, SCIENCE, V232, P65, DOI 10.1126/science.3952500; CHUMAKOV I, 1992, NATURE, V359, P380, DOI 10.1038/359380a0; CHUMAKOV IM, 1992, NAT GENET, V1, P222, DOI 10.1038/ng0692-222; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; COLLINS FS, 1992, NAT GENET, V1, P3, DOI 10.1038/ng0492-3; DEJONG PJ, 1989, CYTOGENET CELL GENET, V51, P985; FIELDS CA, 1992, GENOMICS, V13, P431, DOI 10.1016/0888-7543(92)90264-S; FOOTE S, 1992, SCIENCE, V258, P60, DOI 10.1126/science.1359640; FRANCKE U, 1994, CYTOGENET CELL GENET, V65, P206, DOI 10.1159/000133633; GREEN ED, 1991, GENOMICS, V11, P658, DOI 10.1016/0888-7543(91)90073-N; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HAIDI M, 1994, GENOMICS, V24, P478; JURKA J, 1991, J MOL EVOL, V32, P105, DOI 10.1007/BF02515383; KAPLAN DJ, 1991, NUCLEIC ACIDS RES, V19, P4731, DOI 10.1093/nar/19.17.4731; LITT M, 1989, AM J HUM GENET, V44, P397; MATERA AG, 1990, NUCLEIC ACIDS RES, V18, P6019, DOI 10.1093/nar/18.20.6019; McKusick V.A., 1978, MENDELIAN INHERITANC; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MULLIVOR RA, 1991, AM J HUM GENET S, V49, P370; MURRAY JC, 1994, SCIENCE, V265, P2049, DOI 10.1126/science.8091227; NELSON DL, 1989, P NATL ACAD SCI USA, V86, P6686, DOI 10.1073/pnas.86.17.6686; OLSON M, 1989, SCIENCE, V245, P1434, DOI 10.1126/science.2781285; SHAFITZAGARDO B, 1982, NUCLEIC ACIDS RES, V10, P3175, DOI 10.1093/nar/10.10.3175; WEBER JL, 1989, AM J HUM GENET, V44, P388; YANG SY, 1989, IMMUNOBIOLOGY HLA, V1; 1993, HUNTINGTON DISEASE C, V72, P971	31	320	325	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 28	1995	377			S			175	&						0	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA343	7566096				2022-12-24	WOS:A1995TA34300003
J	GIUGLIANO, D; MARFELLA, R; VERRAZZO, G; ACAMPORA, R; DONZELLA, C; QUATRARO, A; COPPOLA, L; DONOFRIO, F				GIUGLIANO, D; MARFELLA, R; VERRAZZO, G; ACAMPORA, R; DONZELLA, C; QUATRARO, A; COPPOLA, L; DONOFRIO, F			ABNORMAL RHEOLOGIC EFFECTS OF GLYCERYL TRINITRATE IN PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES-MELLITUS AND REVERSAL BY ANTIOXIDANTS	ANNALS OF INTERNAL MEDICINE			English	Article						DIABETES MELLITUS, NON-INSULIN-DEPENDENT; ANTIOXIDANTS; NITRATES; RHEOLOGY; HEMODYNAMICS	GLYCEMIC CONTROL; NITRIC-OXIDE; RISK-FACTORS; VISCOSITY; NITRATES; DISEASE	Objective: io evaluate 1) the hemorrheologic and hemodynamic effects of glyceryl trinitrate in patients with non-insulin-dependent diabetes mellitus and 2) the influence of antioxidants on these effects. Design: Case-control study. Setting: University hospital clinic. Patients: 40 patients with diabetes and no evidence of cardiovascular complications and 40 controls matched for demographic variables and body habitus. Interventions: Sublingual glyceryl trinitrate (0.3 mg) and transdermal glyceryl trinitrate patches (10 mg/d). Vitamin E, 300 mg/d orally for 7 days, and glutathione, 600 mg intravenously or intramuscularly, were given to test the effects of antioxidant supplementation. Measurements: Systolic, diastolic, and mean arterial pressure and heart rate; left ventricular ejection fraction; platelet aggregation, blood viscosity, and blood filterability in vitro and ex vivo. Results: Compared with controls, patients with diabetes had increased platelet aggregation to adenosine diphosphate (P < 0.005), increased blood viscosity (P < 0.001), and decreased blood filterability (P = 0.041) at baseline; blood pressure, heart rate, and ejection fraction were similar in the two groups. In controls, both sublingual glyceryl trinitrate and transdermal glyceryl trinitrate patches significantly reduced platelet aggregation (-38%; 95% CI, -49% to -27%) and blood viscosity (-8%; CI, -11% to -5%) and increased blood filterability (10%; CI, 7.0% to 13.1%). Slight but significant decreases in blood pressure and ejection fraction and an increase in heart rate were also seen in controls after administration of glyceryl trinitrate (both preparations). In patients with diabetes, glyceryl trinitrate paradoxically increased platelet aggregation (24%; CI, 15% to 33%) and blood viscosity (6%; CI, 2.9% to 8.8%) and decreased blood filterability (-7%; CI, -9.5% to -4.4%); hemodynamic values did not change significantly. In both groups, theologic responses to glyceryl trinitrate (end concentration, 100 and 200 ng/mL) in vitro were similar to those seen in ex vivo studies. Vitamin E and glutathione normalized theologic responses to glyceryl trinitrate in patients with diabetes. Conclusions: Organic nitrates have beneficial effects on blood theology in controls but not in patients with diabetes, in whom a paradoxical deterioration is seen. Antioxidant supplementation can normalize primary tolerance to the theologic effects of nitrates in diabetes.	UNIV NAPLES 2, NAPLES, ITALY; DIABET CLIN LEPANTO, NAPLES, ITALY; DIABET CLIN SANTA RITA, TARANTO, ITALY	Universita della Campania Vanvitelli			Marfella, Raffaele/C-6899-2012	Marfella, Raffaele/0000-0003-3960-9270; Giugliano, Dario/0000-0002-9377-873X				ABRAIRA C, 1992, DIABETES CARE, V15, P1560, DOI 10.2337/diacare.15.11.1560; BEKS PJ, 1995, DIABETOLOGIA, V38, P86, DOI 10.1007/s001250050257; BORN GVR, 1962, NATURE, V194, P927, DOI 10.1038/194927b0; BROWNLEE M, 1994, DIABETES, V43, P836, DOI 10.2337/diab.43.6.836; CERIELLO A, 1993, DIABETOLOGIA, V36, P265, DOI 10.1007/BF00399961; COLLIER A, 1989, DIABETES METAB, V15, P420; COLWELL JA, 1993, DIABETES, V42, P8, DOI 10.2337/diab.42.1.8; COOKE JP, 1993, CIRCULATION, V88, P2451, DOI 10.1161/01.CIR.88.5.2451; DENT M T, 1991, Diabetologia, V34, pA74; DESIMONE G, 1990, CIRCULATION, V81, P107, DOI 10.1161/01.CIR.81.1.107; FITZGERALD DJ, 1984, CIRCULATION, V70, P297, DOI 10.1161/01.CIR.70.2.297; FUNG HL, 1992, AM J CARDIOL, V70, pB4, DOI 10.1016/0002-9149(92)90588-P; GIUGLIANO D, 1995, METABOLISM, V44, P363, DOI 10.1016/0026-0495(95)90167-1; GRYGLEWSKI RJ, 1986, NATURE, V320, P454, DOI 10.1038/320454a0; HAMPTON J. R., 1967, CARDIOVASC RES, V1, P101, DOI 10.1093/cvr/1.2.101; HUNT JV, 1988, BIOCHEM J, V256, P205, DOI 10.1042/bj2560205; KOENIG W, 1994, LANCET, V344, P711, DOI 10.1016/S0140-6736(94)92207-1; KUNISAKI M, 1993, DIABETES, V42, P1138, DOI 10.2337/diabetes.42.8.1138; KUUSISTO J, 1994, DIABETES, V43, P960, DOI 10.2337/diabetes.43.8.960; MALMBERG K, 1988, EUR HEART J, V9, P259, DOI 10.1093/oxfordjournals.eurheartj.a062494; MALMBERG KA, 1994, DIABETES CARE, V17, P1007, DOI 10.2337/diacare.17.9.1007; MARFELLA R, 1994, DIABETES, V43, P607, DOI 10.2337/diabetes.43.4.607; MCMILLAN DE, 1988, MAYO CLIN PROC, V63, P517, DOI 10.1016/S0025-6196(12)65652-3; MCVEIGH G, 1994, DIABETOLOGIA, V37, P115, DOI 10.1007/BF00428787; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; MOSS SE, 1992, ARCH INTERN MED, V152, P610, DOI 10.1001/archinte.152.3.610; PARATI G, 1989, HYPERTENSION, V13, P647, DOI 10.1161/01.HYP.13.6.647; REID HL, 1976, J CLIN PATHOL, V29, P855, DOI 10.1136/jcp.29.9.855; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; TESFAMARIAM B, 1994, FREE RADICAL BIO MED, V16, P383, DOI 10.1016/0891-5849(94)90040-X; UZEL N, 1987, HORM METAB RES, V19, P89, DOI 10.1055/s-2007-1011748; WILBRANDT W, 1956, EXP CELL RES, V11, P59, DOI 10.1016/0014-4827(56)90190-2; YARNELL JWG, 1991, CIRCULATION, V83, P836, DOI 10.1161/01.CIR.83.3.836; YUSUF S, 1988, LANCET, V1, P1088	34	34	34	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1995	123	5					338	343		10.7326/0003-4819-123-5-199509010-00003	http://dx.doi.org/10.7326/0003-4819-123-5-199509010-00003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ988	7625621				2022-12-24	WOS:A1995RQ98800003
J	MCDANIEL, DO; ALARCON, GS; PRATT, PW; REVEILLE, JD				MCDANIEL, DO; ALARCON, GS; PRATT, PW; REVEILLE, JD			MOST AFRICAN-AMERICAN PATIENTS WITH RHEUMATOID-ARTHRITIS DO NOT HAVE THE RHEUMATOID ANTIGENIC DETERMINANT (EPITOPE)	ANNALS OF INTERNAL MEDICINE			English	Article						ARTHRITIS, RHEUMATOID; BLACKS; HLA-DR ANTIGENS; ANTIGENIC DETERMINANTS	HLA-DR ANTIGENS; DISEASE SEVERITY; D REGION; ASSOCIATION; SUSCEPTIBILITY; GENES; BLACKS; HYPOTHESIS; POPULATION; SEQUENCE	Objective: To evaluate the relation between the presence of the ''rheumatoid epitope,'' defined by a sequence motif in the HLA-DRB1 alleles, and disease severity in African-American patients with rheumatoid arthritis. Design: Cross-sectional study. Setting: Rheumatology outpatient clinics at two university medical centers. Patients: 86 African-American patients with rheumatoid arthritis (66 seropositive and 20 seronegative for the rheumatoid factor) attending the clinics and 88 healthy African-American persons. Measurements: HLA-DRB1 alleles were determined by restriction fragment length polymorphism and by allele-specific oligonucleotide typing of polymerase chain reaction-amplified HLA-DRB1 second exons. Results: With the exception of an increased frequency of HLA-DRB1*04 alleles in seropositive patients with rheumatoid arthritis (27.3%) compared with controls (13.1%) (P = 0.02), the frequencies of HLA-DRB1 alleles were similar in patients and controls. Most seropositive (48 of 66) and seronegative (15 of 20) patients were HLA-DR4 negative, but some (7 of 48 seropositive patients and 3 of 15 seronegative persons) inherited the rheumatoid epitope on a non-DR4 allele. Disease features, including severity, were similar for patients without the epitope and for those with either a single or a double dose of an epitope-positive allele. Positivity for rheumatoid factor, but not for the rheumatoid epitope, was weakly associated with severity in these patients. Conclusion: Most African-American patients with rheumatoid arthritis did not express the rheumatoid epitope. The predisposition to and severity of rheumatoid arthritis in African-Americans appears to be independent of the presence and dose of the shared rheumatoid epitope.	UNIV TEXAS, HLTH SCI CTR, DIV RHEUMATOL & CLIN IMMUNOGENET, HOUSTON, TX 77225 USA; UNIV ALABAMA, DIV CLIN IMMUNOL & RHEUMATOL, BIRMINGHAM, AL 35294 USA	University of Texas System; University of Texas Health Science Center Houston; University of Alabama System; University of Alabama Birmingham					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR039325, P60AR020614] Funding Source: NIH RePORTER; NIAMS NIH HHS [P0-AR 20614, AR39325] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALARCON GS, 1983, J RHEUMATOL, V10, P579; ALARCON GS, 1982, ARTHRITIS RHEUM, V25, P502, DOI 10.1002/art.1780250503; ALARIF LI, 1983, J RHEUMATOL, V10, P297; ANGELINI G, 1992, HUM IMMUNOL, V34, P135, DOI 10.1016/0198-8859(92)90039-P; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; BOKI KA, 1992, ARTHRITIS RHEUM, V35, P749, DOI 10.1002/art.1780350706; CASTRO F, 1994, B ASS PERUAN RHEUM, V13, P14; DEJUAN MD, 1994, TISSUE ANTIGENS, V43, P320; DEVRIES N, 1993, TISSUE ANTIGENS, V41, P26; GAO XJ, 1991, ARTHRITIS RHEUM, V34, P1310, DOI 10.1002/art.1780341016; GAO XJ, 1990, ARTHRITIS RHEUM, V33, P939, DOI 10.1002/art.1780330704; GORONZY J, 1986, J CLIN INVEST, V77, P1042, DOI 10.1172/JCI112358; GOUGH A, 1994, ARTHRITIS RHEUM, V37, P1166, DOI 10.1002/art.1780370809; GREGERSEN PK, 1987, ARTHRITIS RHEUM, V30, P1205, DOI 10.1002/art.1780301102; KARR RW, 1980, ARTHRITIS RHEUM-US, V23, P1241, DOI 10.1002/art.1780231102; LONG EO, 1983, EMBO J, V2, P389, DOI 10.1002/j.1460-2075.1983.tb01435.x; LOPEZMENDEZ A, 1989, J RHEUMATOL, V16, P1197; MARSAL S, 1994, ARTHRITIS RHEUM, V37, P504, DOI 10.1002/art.1780370410; MARTELL RW, 1989, TISSUE ANTIGENS, V36, P1326; MCDANIEL DO, 1989, TISSUE ANTIGENS, V34, P299, DOI 10.1111/j.1399-0039.1989.tb01746.x; MCDANIEL DO, 1993, BIOTECHNIQUES, V15, P140; MODY GM, 1989, J RHEUMATOL, V16, P1326; NELSON JL, 1991, TISSUE ANTIGENS, V38, P145, DOI 10.1111/j.1399-0039.1991.tb01888.x; NELSON JL, 1994, ARTHRITIS RHEUM, V37, P673; NEPOM GT, 1986, LANCET, V2, P1002; OHTA N, 1982, HUM IMMUNOL, V5, P123, DOI 10.1016/0198-8859(82)90057-X; PERDRIGER A, 1992, TISSUE ANTIGENS, V39, P14, DOI 10.1111/j.1399-0039.1992.tb02149.x; PILE KD, 1992, TISSUE ANTIGENS, V39, P138, DOI 10.1111/j.1399-0039.1992.tb01924.x; RENNINGEN KS, 1990, TISSUE ANTIGENS, V36, P235, DOI 10.1111/j.1399-0039.1990.tb01834.x; Reveille J. D., 1994, Arthritis and Rheumatism, V37, pS359; SILMAN AJ, 1993, J RHEUMATOL, V20, P618; SINGAL DP, 1994, CLIN EXP RHEUMATOL, V12, P29; SINGAL DP, 1987, LANCET, V2, P1118; STASTNY P, 1976, J CLIN INVEST, V57, P1148, DOI 10.1172/JCI108382; STEPHENS HAF, 1989, IMMUNOGENETICS, V30, P119, DOI 10.1007/BF02421540; TAN PLJ, 1993, ARTHRITIS RHEUM, V36, P15, DOI 10.1002/art.1780360104; TANEJA V, 1993, ARTHRITIS RHEUM, V36, P1380, DOI 10.1002/art.1780361009; VANDERHEIJDE DMFM, 1992, BRIT J RHEUMATOL, V31, P519; WATANABE Y, 1989, J EXP MED, V169, P2263, DOI 10.1084/jem.169.6.2263; WEYAND CM, 1994, B RHEUM DIS, V43, P5; WEYAND CM, 1992, J CLIN INVEST, V89, P2033, DOI 10.1172/JCI115814; WEYAND CM, 1992, ANN INTERN MED, V117, P801, DOI 10.7326/0003-4819-117-10-801; WEYAND CM, 1989, IMMUNOBIOLOGY HLA IM, P422; WILLKENS RF, 1991, ARTHRITIS RHEUM, V34, P43, DOI 10.1002/art.1780340107; WORDSWORTH BP, 1989, P NATL ACAD SCI USA, V86, P10049, DOI 10.1073/pnas.86.24.10049; YELAMOS J, 1993, ARTHRITIS RHEUM-US, V36, P811, DOI 10.1002/art.1780360611; ZOSCHKE D, 1986, HUM IMMUNOL, V15, P118, DOI 10.1016/0198-8859(86)90322-8; [No title captured]	48	72	73	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1995	123	3					181	187		10.7326/0003-4819-123-3-199508010-00004	http://dx.doi.org/10.7326/0003-4819-123-3-199508010-00004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL104	7598299				2022-12-24	WOS:A1995RL10400004
J	BOCZKO, EM; BROOKS, CL				BOCZKO, EM; BROOKS, CL			FIRST-PRINCIPLES CALCULATION OF THE FOLDING FREE-ENERGY OF A 3-HELIX BUNDLE PROTEIN	SCIENCE			English	Article							MOLTEN GLOBULE STATE; THERMODYNAMIC ANALYSIS; STAPHYLOCOCCUS-AUREUS; MOLECULAR-DYNAMICS; SIMULATIONS; DENATURATION; SEQUENCE; PEPTIDE	The folding and unfolding of a three-helix bundle protein were explored with molecular-dynamics simulations, cluster analysis, and weighted-histogram techniques. The folding-unfolding process occurs by means of a ''folding funnel,'' in which a uniform and broad distribution of conformational states is accessible outside of the native manifold. This distribution narrows near a transition region and becomes compact within the native manifold. Key thermodynamic steps in folding include initial interactions around the amino-terminal helix-turn-helix motif, interactions between helices I and II, and, finally, the docking of helix III onto the helix I-II subdomain. A metastable minimum in the calculated free-energy surface is observed at approximately 1.5 times the native volume. Folding-unfolding thermodynamics are dominated by the opposing influences of protein-solvent energy, which favors unfolding, and the overall entropy, which favors folding by means of the hydrophobic effect.			BOCZKO, EM (corresponding author), Scripps Res Inst, RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA.				NIGMS NIH HHS [GM48807] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048807] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDER P, 1992, BIOCHEMISTRY-US, V31, P3597, DOI 10.1021/bi00129a007; Allen M. P., 1989, COMPUTER SIMULATION, DOI DOI 10.1093/OSO/9780198803195.001.0001; BALDWIN RL, 1989, TRENDS BIOCHEM SCI, V14, P291, DOI 10.1016/0968-0004(89)90067-4; BOCZKO EM, 1993, J PHYS CHEM-US, V97, P4509, DOI 10.1021/j100119a043; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BROOKS CL, 1993, CURR OPIN STRUC BIOL, V3, P92, DOI 10.1016/0959-440X(93)90207-2; BROOKS CL, 1985, J CHEM PHYS, V83, P5897, DOI 10.1063/1.449621; BROOKS CL, 1993, CHEM REV, V93, P2487, DOI 10.1021/cr00023a008; BROOKS CL, 1992, J MOL BIOL, V227, P375, DOI 10.1016/0022-2836(92)90893-O; BRYNGELSON JD, 1995, PROTEINS, V21, P167, DOI 10.1002/prot.340210302; DAGGETT V, 1994, CURR OPIN STRUC BIOL, V4, P291, DOI 10.1016/S0959-440X(94)90322-0; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; DILL KA, 1995, PROTEIN SCI, V4, P561; GILL SJ, 1988, ADV PROTEIN CHEM, V39, P191; GORDON AD, 1987, J ROY STAT SOC A STA, V150, P119, DOI 10.2307/2981629; GOUDA H, 1992, BIOCHEMISTRY-US, V31, P9665, DOI 10.1021/bi00155a020; HONIG B, 1994, OCT COLD SPRING HARB; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; KARPLUS M, 1995, CURR OPIN STRUC BIOL, V5, P58, DOI 10.1016/0959-440X(95)80010-X; KARPLUS M, 1994, PROTEIN SCI, V3, P650; KOLINSKI A, 1994, PROTEINS, V18, P353, DOI 10.1002/prot.340180406; KUMAR S, 1992, J COMPUT CHEM, V13, P169; KURITA T, 1991, PATTERN RECOGN, V24, P205, DOI 10.1016/0031-3203(91)90062-A; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LAZARIDIS T, 1992, J PHYS CHEM-US, V96, P3847, DOI 10.1021/j100188a051; LEOPOLD PE, 1992, P NATL ACAD SCI USA, V89, P8721, DOI 10.1073/pnas.89.18.8721; LIEBERMAN M, 1994, J AM CHEM SOC, V116, P5035, DOI 10.1021/ja00091a002; LUTHEYSCHULTEN Z, 1995, J PHYS CHEM-US, V99, P2177, DOI 10.1021/j100007a057; PTITSYN OB, 1987, J PROTEIN CHEM, V6, P273; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; SHAKHNOVICH EI, 1989, BIOPOLYMERS, V28, P1667, DOI 10.1002/bip.360281003; SJODAHL J, 1977, EUR J BIOCHEM, V78, P471, DOI 10.1111/j.1432-1033.1977.tb11760.x; SKOLNICK J, 1991, J MOL BIOL, V221, P499, DOI 10.1016/0022-2836(91)80070-B; SKOLNICK J, 1993, CURR BIOL, V3, P414, DOI 10.1016/0960-9822(93)90348-R; TADDEI N, 1994, EUR J BIOCHEM, V225, P811, DOI 10.1111/j.1432-1033.1994.0811b.x; UVERSKY VN, 1993, BIOCHEMISTRY-US, V32, P13288, DOI 10.1021/bi00211a042; UVERSKY VN, 1994, FEBS LETT, V321, P15; VALLEAU JP, 1977, GUIDE MONTE CARLO ST, V2, P169; VEITH M, 1994, J MOL BIOL, V237, P361; VERLET L, 1967, PHYS REV, V159, P98, DOI 10.1103/PhysRev.159.98; WOLYNES PG, 1995, SCIENCE, V267, P1619, DOI 10.1126/science.7886447; XU S, 1993, PATTERN RECOGN LETT, V14, P7, DOI 10.1016/0167-8655(93)90127-Y; YU HA, 1988, J CHEM PHYS, V89, P2366, DOI 10.1063/1.455080	45	358	361	1	30	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 21	1995	269	5222					393	396		10.1126/science.7618103	http://dx.doi.org/10.1126/science.7618103			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK427	7618103				2022-12-24	WOS:A1995RK42700046
J	MARTIN, PT; ETTINGER, AJ; SANES, JR				MARTIN, PT; ETTINGER, AJ; SANES, JR			A SYNAPTIC LOCALIZATION DOMAIN IN THE SYNAPTIC CLEFT PROTEIN LAMININ BETA-2 (S-LAMININ)	SCIENCE			English	Article							BASAL LAMINA; NEUROMUSCULAR-JUNCTION; ACETYLCHOLINE-RECEPTORS; MOUSE MUSCLE; ADHESION; CELLS; DIFFERENTIATION; EXPRESSION; VARIANTS; SEQUENCE	The basal lamina that ensheaths skeletal muscle fibers traverses the synaptic cleft at the neuromuscular junction. Synaptic and extrasynaptic portions of the basal lamina contain different laminin beta chains: beta 2 (or s) at synapses and beta 1 (or beta 1) extrasynaptically. Laminin beta 2 is also confined to synapselike parches on myotube surfaces in vitro, whereas beta 1 is present throughout the extracellular matrix. This differential localization of laminin beta chains was analyzed by expression of chimeric beta 1-beta 2 molecules in cultured mouse myotubes. A 16-amino acid carboxyl-terminal sequence in beta 2 was necessary for synaptic localization, and an amino-terminal domain in beta 1 promoted association with extracellular fibrils. The synaptic targeting sequence of beta 2 contains a site previously shown to be adhesive for motor neurons.	WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110	Washington University (WUSTL)				Martin, Paul/0000-0002-0674-6191				ABRAHAMSON DR, 1989, J CELL BIOL, V109, P3477, DOI 10.1083/jcb.109.6.3477; Apel Elizabeth D., 1995, Current Opinion in Neurobiology, V5, P62, DOI 10.1016/0959-4388(95)80088-3; BLOCH RJ, 1988, AM J PHYSIOL, V254, pC345, DOI 10.1152/ajpcell.1988.254.3.C345; BOWE MA, 1995, ANNU REV NEUROSCI, V18, P443; BURDEN SJ, 1993, TRENDS GENET, V9, P12, DOI 10.1016/0168-9525(93)90066-Q; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; CHIU AY, 1984, DEV BIOL, V103, P4556; COHEN MW, 1980, J EXP BIOL, V89, P43; COOPER DNW, 1991, J CELL BIOL, V115, P1437, DOI 10.1083/jcb.115.5.1437; ENGVALL E, 1990, CELL REGUL, V1, P731, DOI 10.1091/mbc.1.10.731; FAMBROUGH DM, 1979, PHYSIOL REV, V59, P165, DOI 10.1152/physrev.1979.59.1.165; GREEN TL, 1992, J BIOL CHEM, V267, P2014; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HUNTER DD, 1989, CELL, V59, P905, DOI 10.1016/0092-8674(89)90613-2; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; HUNTER DD, 1991, J NEUROSCI, V11, P3960; INESTROSA NC, 1983, EXP CELL RES, V147, P393, DOI 10.1016/0014-4827(83)90221-5; LINDBLOM A, 1994, EUR J BIOCHEM, V219, P383, DOI 10.1111/j.1432-1033.1994.tb19950.x; MARTIN PT, 1995, NEURON, V14, P743, DOI 10.1016/0896-6273(95)90218-X; MECHAM RP, 1991, FASEB J, V5, P2538, DOI 10.1096/fasebj.5.11.1651264; MOSCOSO LM, 1995, MOL CELL NEUROSCI, V6, P80, DOI 10.1006/mcne.1995.1008; NOAKES PG, 1995, NATURE, V374, P258, DOI 10.1038/374258a0; PAULSSON M, 1991, J BIOL CHEM, V266, P17545; PHILLIPS WD, 1991, J CELL BIOL, V115, P1713, DOI 10.1083/jcb.115.6.1713; PORTER BE, 1995, NEURON, V14, P549, DOI 10.1016/0896-6273(95)90311-9; REING J, 1992, J BIOL CHEM, V267, P23143; SANES JR, 1983, DEV BIOL, V97, P123, DOI 10.1016/0012-1606(83)90070-2; SANES JR, 1984, J NEUROSCI, V4, P464; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SCHITTNY JC, 1993, EUR J BIOCHEM, V216, P437, DOI 10.1111/j.1432-1033.1993.tb18161.x; SILBERSTEIN L, 1982, NATURE, V295, P143, DOI 10.1038/295143a0; Sonnenberg A, 1993, Curr Top Microbiol Immunol, V184, P7; UTANI A, 1994, J BIOL CHEM, V269, P19167; WEWER UM, 1994, LAB INVEST, V71, P719; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YURCHENCO PD, 1993, J BIOL CHEM, V268, P17286; YURCHENCO PD, 1994, CURR OPIN CELL BIOL, V6, P674, DOI 10.1016/0955-0674(94)90093-0	38	84	84	0	2	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 21	1995	269	5222					413	416		10.1126/science.7618109	http://dx.doi.org/10.1126/science.7618109			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK427	7618109				2022-12-24	WOS:A1995RK42700052
J	MALES, MA				MALES, MA			ADULT INVOLVEMENT IN TEENAGE CHILDBEARING AND STD	LANCET			English	Editorial Material							PREGNANCY				MALES, MA (corresponding author), UNIV CALIF IRVINE,SCH SOCIAL ECOL,IRVINE,CA 92717, USA.							BOYER D, 1992, FAM PLANN PERSPECT, V24, P4, DOI 10.2307/2135718; BOYER D, 1992, FAMILY PLANNING PERS, V24, P19; DEAN M, 1994, LANCET, V343, P1149, DOI 10.1016/S0140-6736(94)90243-7; GERSHENSON H, 1989, J INTERPERS VIOLENCE, V4, P204; JONES EF, 1985, FAM PLANN PERSPECT, V17, P53, DOI 10.2307/2135261; MALES M, 1994, APR ANN M POP ASS AM; 1994, SEX AM TEENAGERS; 1994, IV AIDS SURVEILLANCE; 1994, LANCET, V344, P899; 1994, CALIFORNIA RESIDENT; 1994, BRITHS TEEN MOMS AGE	11	19	19	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 8	1995	346	8967					64	65		10.1016/S0140-6736(95)92105-2	http://dx.doi.org/10.1016/S0140-6736(95)92105-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH220	7603210				2022-12-24	WOS:A1995RH22000003
J	SASAKI, J; BROWN, LS; CHON, YS; KANDORI, H; MAEDA, A; NEEDLEMAN, R; LANYI, JK				SASAKI, J; BROWN, LS; CHON, YS; KANDORI, H; MAEDA, A; NEEDLEMAN, R; LANYI, JK			CONVERSION OF BACTERIORHODOPSIN INTO A CHLORIDE-ION PUMP	SCIENCE			English	Article							X-RAY-DIFFRACTION; NATRONOBACTERIUM-PHARAONIS; BACTERIAL RHODOPSINS; PROTON TRANSLOCATION; STRUCTURAL-CHANGES; HALORHODOPSIN; PHOTOCYCLE; IDENTIFICATION; INTERMEDIATE; TRANSPORT	In the light-driven proton pump bacteriorhodopsin, proton transfer from the retinal Schiff base to aspartate-85 is the crucial reaction of the transport cycle. In halorhodopsin, a light-driven chloride ion pump, the equivalent of residue 85 is threonine. When aspartate-85 was replaced with threonine, the mutated bacteriorhodopsin became a chloride ion pump when expressed in Halobacterium salinarium and, like halorhodopsin, actively transported chloride ions in the direction opposite from the proton pump. Chloride was bound to it, as revealed by large shifts of the absorption maximum of the chromophore, and its photointermediates included a red-shifted state in the millisecond time domain, with its amplitude and decay rate dependent on chloride concentration. Bacteriorhodopsin and halorhodopsin thus share a common transport mechanism, and the interaction of residue 85 with the retinal Schiff base determines the ionic specificity.	UNIV CALIF IRVINE,DEPT PHYSIOL & BIOPHYS,IRVINE,CA 92717; KYOTO UNIV,FAC SCI,DEPT BIOPHYS,KYOTO 60601,JAPAN; WAYNE STATE UNIV,DEPT BIOCHEM,DETROIT,MI 48201	University of California System; University of California Irvine; Kyoto University; Wayne State University			Lanyi, Janos/C-3808-2011; Brown, Leonid/A-1050-2008; Brown, Leonid/X-7445-2019	Brown, Leonid/0000-0002-5614-8317; Brown, Leonid/0000-0002-5614-8317	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029498, R37GM029498] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM29498] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLANCK A, 1987, EMBO J, V6, P265, DOI 10.1002/j.1460-2075.1987.tb04749.x; BROWN LO, UNPUB; DUSCHL A, 1990, J BIOL CHEM, V265, P1261; HENDERSON R, 1990, J MOL BIOL, V213, P899, DOI 10.1016/S0022-2836(05)80271-2; KATAOKA M, 1994, J MOL BIOL, V243, P621, DOI 10.1016/0022-2836(94)90037-X; KOCH MHJ, 1991, EMBO J, V10, P521, DOI 10.1002/j.1460-2075.1991.tb07978.x; KOUYAMA T, 1988, BIOCHEMISTRY-US, V27, P5855, DOI 10.1021/bi00416a006; Lanyi J K, 1979, Methods Enzymol, V56, P398; LANYI JK, 1982, J BIOL CHEM, V257, P2674; LANYI JK, 1990, J BIOL CHEM, V265, P1253; LANYI JK, 1990, PHYSIOL REV, V70, P319, DOI 10.1152/physrev.1990.70.2.319; LANYI JK, 1993, BIOCHIM BIOPHYS ACTA, V1183, P241, DOI 10.1016/0005-2728(93)90226-6; LANYI JK, 1986, BIOCHEMISTRY-US, V25, P1465, DOI 10.1021/bi00354a042; MATHIES RA, 1991, ANNU REV BIOPHYS BIO, V20, P491, DOI 10.1146/annurev.bb.20.060191.002423; MATSUNOYAGI A, 1977, BIOCHEM BIOPH RES CO, V78, P237, DOI 10.1016/0006-291X(77)91245-1; MOGI T, 1988, P NATL ACAD SCI USA, V85, P4148, DOI 10.1073/pnas.85.12.4148; NAKASAKO M, 1991, FEBS LETT, V292, P73, DOI 10.1016/0014-5793(91)80837-S; OESTERHELT D, 1992, J BIOENERG BIOMEMBR, V24, P181, DOI 10.1007/BF00762676; OESTERHELT D, 1989, TRENDS BIOCHEM SCI, V14, P57, DOI 10.1016/0968-0004(89)90044-3; OGURUSU T, 1984, J BIOCHEM-TOKYO, V95, P1073, DOI 10.1093/oxfordjournals.jbchem.a134695; OTOMO J, 1992, BIOCHIM BIOPHYS ACTA, V1112, P7, DOI 10.1016/0005-2736(92)90246-I; OTTO H, 1989, P NATL ACAD SCI USA, V86, P9228, DOI 10.1073/pnas.86.23.9228; SASAKI J, UNPUB; SCHARF B, 1994, BIOCHEMISTRY-US, V33, P6387, DOI 10.1021/bi00187a002; SCHOBERT B, 1986, J BIOL CHEM, V261, P2690; SCHOBERT B, 1982, J BIOL CHEM, V257, P306; SOPPA J, 1993, J BACTERIOL, V175, P2720, DOI 10.1128/JB.175.9.2720-2726.1993; SPUDICH JL, 1994, CELL, V79, P747, DOI 10.1016/0092-8674(94)90064-7; SUBRAMANIAM S, 1990, P NATL ACAD SCI USA, V87, P1013, DOI 10.1073/pnas.87.3.1013; SUBRAMANIAM S, 1993, EMBO J, V12, P1; SUNDBERG SA, 1990, J BACTERIOL, V172, P2328, DOI 10.1128/jb.172.5.2328-2335.1990; TITTOR J, 1994, BIOPHYS J, V67, P1682, DOI 10.1016/S0006-3495(94)80642-3; TITTOR J, 1987, BIOPHYS J, V52, P999, DOI 10.1016/S0006-3495(87)83292-7; VARO G, 1995, BIOPHYS J, V68, P2062, DOI 10.1016/S0006-3495(95)80385-1; VARO G, UNPUB; ZIMANYI L, 1989, BIOCHEMISTRY-US, V28, P5165, DOI 10.1021/bi00438a038; ZIMANYI L, 1993, BIOCHEMISTRY-US, V32, P7669, DOI 10.1021/bi00081a010	37	211	216	0	20	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 7	1995	269	5220					73	75		10.1126/science.7604281	http://dx.doi.org/10.1126/science.7604281			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RG980	7604281				2022-12-24	WOS:A1995RG98000035
J	JULIUSSON, G; VITOLS, S; LILIEMARK, J				JULIUSSON, G; VITOLS, S; LILIEMARK, J			MECHANISMS BEHIND HYPOCHOLESTEROLEMIA IN HAIRY-CELL LEUKEMIA	BRITISH MEDICAL JOURNAL			English	Article							LOW-DENSITY-LIPOPROTEIN; LEUKEMIA		HUDDINGE HOSP,DEPT MED,DIV CLIN HAEMATOL & ONCOL,HUDDINGE,SWEDEN; KAROLINSKA HOSP,DEPT CLIN PHARMACOL,S-10401 STOCKHOLM,SWEDEN; KAROLINSKA HOSP,DEPT ONCOL,S-10401 STOCKHOLM,SWEDEN	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital								HAKIMIAN D, 1991, BLOOD S1, V78, pA454; JULIUSSON G, 1992, BLOOD, V79, P888; JULIUSSON G, IN PRESS CANCER; VITOLS S, 1985, LANCET, V2, P1150; VITOLS S, 1991, CANCER CELL-MON REV, V3, P488	5	5	6	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 1	1995	311	6996					27	27		10.1136/bmj.311.6996.27	http://dx.doi.org/10.1136/bmj.311.6996.27			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG975	7613319	Green Published			2022-12-24	WOS:A1995RG97500022
J	FEHLING, HJ; KROTKOVA, A; SAINTRUF, C; VONBOEHMER, H				FEHLING, HJ; KROTKOVA, A; SAINTRUF, C; VONBOEHMER, H			CRUCIAL ROLE OF THE PRE-T-CELL RECEPTOR-ALPHA GENE IN DEVELOPMENT OF ALPHA-BETA BUT NOT GAMMA-DELTA T-CELLS	NATURE			English	Article							DEFICIENT MICE; EXPRESSION; SURFACE; CHAIN; TCR; GENERATION; THYMOCYTES; IMMATURE; ANTIGENS	T-cell precursors, the T-cell-receptor B chain is expressed before the T-cell-receptor alpha chain(1,2) and is sufficient to advance T-cell development in the absence of T-cell receptor a chains(3-7). In immature T cells, the T-cell-receptor beta protein can form disulphide-linked heterodimers with the pre-T-cell-receptor alpha chain(8,9) and associate with signal-transducing CD3 molecules(5). The recently cloned pre-T-cell-receptor alpha gene encodes a transmembrane protein that is expressed in immature but not mature T cells(9,10). Here we show that alpha beta, but not gamma delta, cell development is severely hampered in pre-T-cell-receptor alpha-gene-deficient mice, which establishes a crucial role for the pre-T-cell receptor in early thymocyte development.	INST NECKER,INSERM,U373,F-75730 PARIS 15,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	FEHLING, HJ (corresponding author), BASEL INST IMMUNOL,GRENZACHERSTR 487,CH-4005 BASEL,SWITZERLAND.			Fehling, Hans Joerg/0000-0002-4580-1990				ALLISON JP, 1987, UCLA S MOL CELLULAR; BRUNO LEA, IN PRESS EUR J IMMUN; DUDLEY EC, 1994, IMMUNITY, V1, P83, DOI 10.1016/1074-7613(94)90102-3; FEHLING HJ, IN PRESS IMMUNOGENET; GROETTRUP M, 1992, EMBO J, V11, P2735, DOI 10.1002/j.1460-2075.1992.tb05339.x; GROETTRUP M, 1993, CELL, V75, P283, DOI 10.1016/0092-8674(93)80070-U; KISHI H, 1991, EMBO J, V10, P93, DOI 10.1002/j.1460-2075.1991.tb07924.x; KISIELOW P, 1995, ADV IMMUNOL, V58, P87, DOI 10.1016/S0065-2776(08)60620-3; KUBO RT, 1989, J IMMUNOL, V142, P2736; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LYNCH F, 1993, INT IMMUNOL, V5, P991, DOI 10.1093/intimm/5.8.991; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; RAULET DH, 1985, NATURE, V314, P103, DOI 10.1038/314103a0; ROTHENBERG EV, 1992, ADV IMMUNOL, V51, P85, DOI 10.1016/S0065-2776(08)60487-3; SAINTRUF C, 1994, SCIENCE, V266, P1208, DOI 10.1126/science.7973703; SCOTT B, 1989, NATURE, V338, P591, DOI 10.1038/338591a0; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; SHORES EW, 1990, EUR J IMMUNOL, V20, P69, DOI 10.1002/eji.1830200111; SNODGRASS HR, 1985, NATURE, V315, P232, DOI 10.1038/315232a0; SPRINGER T, 1978, EUR J IMMUNOL, V8, P539, DOI 10.1002/eji.1830080802; VONBOEHMER H, 1993, J EXP MED, V177, P891, DOI 10.1084/jem.177.4.891; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531	22	455	458	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 29	1995	375	6534					795	798		10.1038/375795a0	http://dx.doi.org/10.1038/375795a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF989	7596413	Green Submitted			2022-12-24	WOS:A1995RF98900080
J	RIDDLE, RD; ENSINI, M; NELSON, C; TSUCHIDA, T; JESSELL, TM; TABIN, C				RIDDLE, RD; ENSINI, M; NELSON, C; TSUCHIDA, T; JESSELL, TM; TABIN, C			INDUCTION OF THE LIM HOMEOBOX GENE LMX1 BY WNT7A ESTABLISHES DORSOVENTRAL PATTERN IN THE VERTEBRATE LIMB	CELL			English	Article							ECTODERMAL CONTROL; WINGLESS PROTEIN; IMAGINAL DISKS; INSULIN GENE; CHICK-EMBRYO; DROSOPHILA; EXPRESSION; BUD; DIFFERENTIATION; HOMEODOMAIN	During vertebrate limb development, the ectoderm directs the dorsoventral patterning of the underlying mesoderm. To define the molecular events involved in this process, we have analyzed the function of WNT7a, a secreted factor expressed in the dorsal ectoderm, and LMX1, a LIM homeodomain transcription factor expressed in the dorsal mesenchyme. Ectopic expression of Wnt7a is sufficient to induce and maintain Lmx1 expression in limb mesenchyme, both in vivo and in vitro. Ectopic expression of Lmx1 in the ventral mesenchyme is sufficient to generate double-dorsal limbs. Thus, the dorsalization of limb mesoderm appears to involve the WNT7a-mediated induction of Lmx1 in limb mesenchymal cells.	COLUMBIA UNIV,HOWARD HUGHES MED INST,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032	Columbia University; Howard Hughes Medical Institute	RIDDLE, RD (corresponding author), HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115, USA.							BAKER NE, 1988, DEVELOPMENT, V102, P489; BLAIR SS, 1995, BIOESSAYS, V17, P299, DOI 10.1002/bies.950170406; BLAIR SS, 1994, DEVELOPMENT, V120, P1805; CHUONG CM, 1993, BIOESSAYS, V15, P513, DOI 10.1002/bies.950150804; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; DAWID IB, 1995, CR ACAD SCI III-VIE, V318, P295; DEALY CN, 1993, MECH DEVELOP, V43, P175, DOI 10.1016/0925-4773(93)90034-U; DENT JA, 1989, DEVELOPMENT, V105, P61; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; FALLON JF, 1994, SCIENCE, V264, P104, DOI 10.1126/science.7908145; FEKETE DM, 1993, P NATL ACAD SCI USA, V90, P2350, DOI 10.1073/pnas.90.6.2350; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GAVIN BJ, 1991, GENE DEV, V4, P2319; GEDUSPAN JS, 1987, DEV BIOL, V124, P398, DOI 10.1016/0012-1606(87)90492-1; GEDUSPAN JS, 1989, ANAT REC, V224, P79, DOI 10.1002/ar.1092240110; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; HUMASON GL, 1972, ANIMAL TISSUE TECHNI, P173; JOHNSON RL, 1994, CURR OPIN GENET DEV, V4, P535, DOI 10.1016/0959-437X(94)90069-F; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; LUNDGREN FE, 1995, DEVELOPMENT, V121, P1769; MACCABE JA, 1974, DEV BIOL, V39, P69, DOI 10.1016/S0012-1606(74)80009-6; MORGAN BA, 1992, NATURE, V358, P236, DOI 10.1038/358236a0; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; NUSSE R, 1992, CELL, V75, P1073; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; PARR BA, 1993, DEVELOPMENT, V119, P247; PAUTOU MP, 1977, J EMBRYOL EXP MORPH, V42, P177; PERRIMON N, 1995, CELL, V80, P517, DOI 10.1016/0092-8674(95)90503-0; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; Saunders J. W., 1968, EPITHELIAL MESENCHYM, P78; SHAWLOT W, 1995, NATURE, V374, P425, DOI 10.1038/374425a0; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TABIN C, 1995, CELL, V80, P671, DOI 10.1016/0092-8674(95)90343-7; TAIRA M, 1994, NATURE, V372, P677, DOI 10.1038/372677a0; TESSAROLLO L, 1992, DEVELOPMENT, V115, P11; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WILDER EL, 1995, DEVELOPMENT, V121, P477; WILLIAMS JA, 1993, DEVELOPMENT, V117, P571; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O; YANG YZ, 1995, CELL, V80, P939, DOI 10.1016/0092-8674(95)90297-X; ZAKANY J, 1993, NATURE, V362, P546, DOI 10.1038/362546a0	49	386	397	1	13	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 17	1995	83	4					631	640		10.1016/0092-8674(95)90103-5	http://dx.doi.org/10.1016/0092-8674(95)90103-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TF248	7585966	Bronze			2022-12-24	WOS:A1995TF24800016
J	PAAUW, DS; WENRICH, MD; CURTIS, JR; CARLINE, JD; RAMSEY, PG				PAAUW, DS; WENRICH, MD; CURTIS, JR; CARLINE, JD; RAMSEY, PG			ABILITY OF PRIMARY-CARE PHYSICIANS TO RECOGNIZE PHYSICAL FINDINGS ASSOCIATED WITH HIV-INFECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							ORAL HAIRY LEUKOPLAKIA; KAPOSIS SARCOMA; AIDS; VIRUS	Objective.-To assess the ability of primary care physicians to identify physical findings associated with human immunodeficiency virus (HIV) infection. Design.-Standardized patient examination. Participants.-A total of 134 general internists and family practitioners were randomly selected after stratifying by year of medical school graduation, specialty, and experience caring for patients with HIV infection. Main Outcome Measures.-Recognition of physical findings of Kaposi's sarcoma, oral hairy leukoplakia, and diffuse lymphadenopathy. Results.-Despite being directed by presenting histories to sites of prominent physical abnormalities, only 23 (25.8%) of 89 physicians evaluating a patient with Kaposi's sarcoma and 22 (22.7%) of 97 physicians evaluating a patient with oral hairy leukoplakia detected and correctly diagnosed the abnormalities. Twenty-th ree (17%) of 133 physicians detected diffuse lymphadenopathy in a patient complaining of fatigue, fever, and arthralgias. Physicians with the most experience treating patients with HIV infection more frequently identified oral hairy leukoplakia, but HIV experience did not influence identification of Kaposi's sarcoma or detection of lymphadenopathy. There were no differences between general internists and family practitioners or among physicians by year of medical school graduation in identifying the three physical findings associated with HIV infection. Conclusions.-Primary care physicians may frequently miss important physical findings related to HIV infection during patient examinations,	UNIV WASHINGTON,SCH MED,DEPT MED,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT MED EDUCAT,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					AHRQ HHS [HS-06454-03] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ABRAMS JE, 1993, 1ST NAT C HUM RETR W; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; CALABRESE LH, 1991, ARCH INTERN MED, V151, P1157, DOI 10.1001/archinte.151.6.1157; COONEY TG, 1991, J GEN INTERN MED, V6, pS12, DOI 10.1007/BF02599252; CURTIS JR, 1995, J GEN INTERN MED, V10, P395, DOI 10.1007/BF02599841; GALLANT JE, 1995, CHEST, V107, P1018, DOI 10.1378/chest.107.4.1018; GREENSPAN D, 1987, J INFECT DIS, V155, P475, DOI 10.1093/infdis/155.3.475; GREENSPAN D, 1984, LANCET, V2, P831; GREENSPAN JS, 1989, ORAL SURG ORAL MED O, V67, P396, DOI 10.1016/0030-4220(89)90381-2; HUTCHINSON CM, 1991, JAMA-J AM MED ASSOC, V266, P253, DOI 10.1001/jama.266.2.253; KROWN SE, 1987, B NEW YORK ACAD MED, V63, P679; MANTEL N, 1959, J NATL CANCER I, V22, P719; MCCANCE KL, 1991, AM J PREV MED, V7, P141, DOI 10.1016/S0749-3797(18)30929-2; RAMSEY PG, 1994, FINAL REPORT AGENCY; SAFAI B, 1985, ANN INTERN MED, V103, P744, DOI 10.7326/0003-4819-103-5-744; STILLMAN P, 1991, ANN INTERN MED, V114, P393, DOI 10.7326/0003-4819-114-5-393; Van der Vleuten CPM, 1990, TEACH LEARN MED, V2, P58, DOI DOI 10.1080/10401339009539432; WENRICH MD, IN PRESS AM J PREV M	18	92	94	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 1	1995	274	17					1380	1382		10.1001/jama.274.17.1380	http://dx.doi.org/10.1001/jama.274.17.1380			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB278	7563564				2022-12-24	WOS:A1995TB27800030
J	HOFMEISTER, AEM; LONDONOVALLEJO, A; HARRY, E; STRAGIER, P; LOSICK, R				HOFMEISTER, AEM; LONDONOVALLEJO, A; HARRY, E; STRAGIER, P; LOSICK, R			EXTRACELLULAR SIGNAL PROTEIN TRIGGERING THE PROTEOLYTIC ACTIVATION OF A DEVELOPMENTAL TRANSCRIPTION FACTOR IN BACILLUS-SUBTILIS	CELL			English	Article							CONTROL GENE-EXPRESSION; ENCODING SIGMA-FACTORS; BACILLUS-SUBTILIS; RNA-POLYMERASE; ESCHERICHIA-COLI; ENDOSPORE FORMATION; CELL-TYPE; SPORULATION; DNA; FORESPORE	We present biochemical evidence for an intercellular signal transduction pathway in B. subtilis. This pathway governs the conversion of the proprotein pro-sigma(E) to the mature transcription factor rho(E). Proteolytic processing is mediated by the membrane protein SpoIIGA and is triggered by the inferred extracellular signal protein SpoIIR. A factor in conditioned medium from B. subtilis cells engineered to produce SpoIIR during growth triggered processing in protoplasts of B. subtilis cells that had been engineered to produce SpoIIGA and pro-sigma(E). The factor was also detected in, and partially purified from, extracts of SpoIIR-producing cells of E. coli. We speculate that SpoIIGA is both a receptor and a protease and that SpoIIR interacts with SpoIIGA on the outside of the cytoplasmic membrane, activating the intracellular protease domain of SpoIIGA.	INST BIOL PHYSICOCHIM,F-75005 PARIS,FRANCE		HOFMEISTER, AEM (corresponding author), HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,BIOL LABS,CAMBRIDGE,MA 02138, USA.		Harry, Elizabeth/G-8123-2017; Londono-Vallejo, Arturo/ABH-5555-2020; Harry, Liz/AAT-9396-2020	Londono-Vallejo, Arturo/0000-0003-3535-7563; STRAGIER, Patrick/0000-0003-0849-3025; Harry, Elizabeth/0000-0003-0858-9473	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018568, R01GM018568] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM18568] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS LF, 1991, J BACTERIOL, V173, P3846, DOI 10.1128/JB.173.12.3846-3854.1991; BEALL B, 1991, GENE DEV, V5, P447, DOI 10.1101/gad.5.3.447; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; CUTTING S, 1991, GENE DEV, V5, P456, DOI 10.1101/gad.5.3.456; CUTTING S, 1990, CELL, V62, P239, DOI 10.1016/0092-8674(90)90362-I; Cutting SM, 1990, MOL BIOL METHODS BAC, P65; DRIKS A, 1991, P NATL ACAD SCI USA, V88, P9934, DOI 10.1073/pnas.88.22.9934; DUBNAU D, 1971, J MOL BIOL, V56, P209, DOI 10.1016/0022-2836(71)90460-8; ERRLNGTON J, 1993, MICROBIOL REV, V57, P1; HARRY EJ, 1995, J BACTERIOL, V177, P3386, DOI 10.1128/jb.177.12.3386-3393.1995; ISHHOROWICZ D, 1981, NUCLEIC ACIDS RES, V9, P2989, DOI 10.1093/nar/9.13.2989; JONAS RM, 1988, J BACTERIOL, V170, P507, DOI 10.1128/jb.170.2.507-511.1988; KARMAZYNCAMPELL.C, 1989, GENES DEV, V3, P150, DOI 10.1101/gad.3.2.150; KAROW LM, 1995, P NATL ACAD SCI USA, V92, P2012; KROOS L, 1989, SCIENCE, V243, P526, DOI 10.1126/science.2492118; LABELL TL, 1987, P NATL ACAD SCI USA, V84, P1784, DOI 10.1073/pnas.84.7.1784; LONDONOVALLEJO JA, 1995, GENE DEV, V9, P503, DOI 10.1101/gad.9.4.503; LOSICK R, 1986, ANNU REV GENET, V20, P625, DOI 10.1146/annurev.ge.20.120186.003205; LOSICK R, 1992, NATURE, V355, P601, DOI 10.1038/355601a0; LU SJ, 1990, P NATL ACAD SCI USA, V87, P9722, DOI 10.1073/pnas.87.24.9722; MARGOLIS P, 1991, SCIENCE, V254, P562, DOI 10.1126/science.1948031; MASUDA ES, 1988, P NATL ACAD SCI USA, V85, P7637, DOI 10.1073/pnas.85.20.7637; MIYAO A, 1993, J BACTERIOL, V175, P4081, DOI 10.1128/JB.175.13.4081-4086.1993; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PETERS HK, 1991, J BACTERIOL, V173, P7821, DOI 10.1128/jb.173.24.7821-7827.1991; PETERS HK, 1994, J BACTERIOL, V176, P7763, DOI 10.1128/JB.176.24.7763-7766.1994; PIGGOT PJ, 1976, BACTERIOL REV, V40, P908, DOI 10.1128/MMBR.40.4.908-962.1976; RICCA E, 1992, J BACTERIOL, V174, P3177, DOI 10.1128/jb.174.10.3177-3184.1992; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHMIDT R, 1990, P NATL ACAD SCI USA, V87, P9221, DOI 10.1073/pnas.87.23.9221; SHAZAND K, 1995, EMBO J, V14, P1439, DOI 10.1002/j.1460-2075.1995.tb07130.x; STRAGIER P, 1984, NATURE, V312, P376, DOI 10.1038/312376a0; STRAGIER P, 1988, CELL, V52, P697, DOI 10.1016/0092-8674(88)90407-2; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TREMPY JE, 1985, P NATL ACAD SCI USA, V82, P4189, DOI 10.1073/pnas.82.12.4189; TREMPY JE, 1985, J BACTERIOL, V161, P340, DOI 10.1128/JB.161.1.340-346.1985; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; YANSURA DG, 1984, P NATL ACAD SCI-BIOL, V81, P439, DOI 10.1073/pnas.81.2.439; YOUNGMAN P, 1984, MOL GEN GENET, V195, P424, DOI 10.1007/BF00341443	39	93	94	0	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 20	1995	83	2					219	226		10.1016/0092-8674(95)90163-9	http://dx.doi.org/10.1016/0092-8674(95)90163-9			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TA965	7585939	Bronze			2022-12-24	WOS:A1995TA96500008
J	TURNER, GM; COULTHARD, MG				TURNER, GM; COULTHARD, MG			FEVER CAN CAUSE PYURIA IN CHILDREN	BRITISH MEDICAL JOURNAL			English	Article							URINARY-TRACT INFECTION		ROYAL VICTORIA INFIRM,PAEDIAT NEPHROL UNIT,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND	Newcastle University - UK								BUYS H, 1994, BRIT MED J, V308, P690, DOI 10.1136/bmj.308.6930.690; DOGUNRO AS, 1991, TROP DOCT, V21, P26, DOI 10.1177/004947559102100111; HOGG RJ, 1987, PEDIATR INFECT DIS J, V6, P233, DOI 10.1097/00006454-198703000-00002; VICKERS D, 1991, LANCET, V338, P767, DOI 10.1016/0140-6736(91)90662-9	4	24	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 7	1995	311	7010					924	924						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ237	7580553				2022-12-24	WOS:A1995RZ23700024
J	CHEN, JD; EVANS, RM				CHEN, JD; EVANS, RM			A TRANSCRIPTIONAL CO-REPRESSOR THAT INTERACTS WITH NUCLEAR HORMONE RECEPTORS	NATURE			English	Article							RETINOIC ACID RECEPTOR; A ONCOGENE PRODUCT; THYROID-HORMONE; V-ERBA; PROTEIN; BINDING; SILENCER; ALPHA; BETA	TRANSCRIPTIONAL silencing mediated by nuclear receptors is important in development, differentiation and oncogenesis(1-3). The mechanism underlying this effect is unknown but is one key to understanding the molecular basis of hormone action. Here we identify a receptor-interacting factor, SMRT, as a silencing mediator (co-repressor) for retinoid and thyroid-hormone receptors. SMRT is a previously undiscovered protein whose association with receptors both in solution and bound to DNA-response elements is destabilized by ligand. The interaction with mutant receptors correlates with their transcriptional silencing activities. In vivo, SMRT functions as a potent co-repressor, and a GAL4 DNA-binding domain fusion of SMRT behaves as a frank repressor of a GALA-dependent reporter. Together, our results identify a new class of cofactors which may be important mediators of hormone action.			CHEN, JD (corresponding author), SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,GENE EXPRESS LAB,10010 N TORREY PINES RD,LA JOLLA,CA 92037, USA.		Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965				AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; BANIAHMAD A, 1992, P NATL ACAD SCI USA, V89, P10633, DOI 10.1073/pnas.89.22.10633; BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BARLOW C, 1994, EMBO J, V13, P4241, DOI 10.1002/j.1460-2075.1994.tb06744.x; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CASANOVA J, 1994, MOL CELL BIOL, V14, P5756, DOI 10.1128/MCB.14.9.5756; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; DAMM K, 1987, EMBO J, V6, P375, DOI 10.1002/j.1460-2075.1987.tb04765.x; DAMM K, 1993, P NATL ACAD SCI USA, V90, P10668, DOI 10.1073/pnas.90.22.10668; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DAMM K, 1993, P NATL ACAD SCI USA, V90, P2989, DOI 10.1073/pnas.90.7.2989; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; SAITOU M, 1995, NATURE, V374, P159, DOI 10.1038/374159a0; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SEOL WG, 1995, MOL ENDOCRINOL, V9, P72, DOI 10.1210/me.9.1.72; TONG GX, 1995, J BIOL CHEM, V270, P10601, DOI 10.1074/jbc.270.18.10601; TSAI S, 1993, P NATL ACAD SCI USA, V90, P7153, DOI 10.1073/pnas.90.15.7153; TZAMARIAS D, 1994, NATURE, V369, P758, DOI 10.1038/369758a0; WEINBERGER C, 1985, NATURE, V318, P670, DOI 10.1038/318670a0; YANG N, 1991, P NATL ACAD SCI USA, V88, P3559, DOI 10.1073/pnas.88.9.3559; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E	31	1637	1675	0	36	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 5	1995	377	6548					454	457		10.1038/377454a0	http://dx.doi.org/10.1038/377454a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY190	7566127				2022-12-24	WOS:A1995RY19000057
J	LOCKWOOD, DNJ; SAUNDERSON, PR				LOCKWOOD, DNJ; SAUNDERSON, PR			HARNESSING THE STRENGTHS OF THE LEPROSY PROGRAM TO CONTROL TUBERCULOSIS	BRITISH MEDICAL JOURNAL			English	Article								Tuberculosis remains a leading cause of death in Ethiopia but there is no effective national tuberculosis control programme, By contrast, the leprosy control programme has been very successful, with a 10-fold reduction in the number of leprosy cases requiring antibacterial treatment, though patients with nerve damage require continuing care. The paradox of rising numbers of tuberculosis cases and declining numbers of leprosy cases may be solved by joint leprosy-tuberculosis clinics. The strengths of leprosy fieldworkers in control management, case holding, and compliance can be harnessed in developing an effective tuberculosis control programme. Implementing a joint programme in Ethiopia may be beneficial not only for tuberculosis patients but also for leprosy patients, who are thus brought closer to general medical services.	ALERT,LEPROSY & TB CONTROL PROGRAMME,ADDIS ABABA,ETHIOPIA				Saunderson, Paul/AAH-8770-2021					1994, HLTH INDICATORS 1994	1	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 30	1995	311	7009					862	863		10.1136/bmj.311.7009.862	http://dx.doi.org/10.1136/bmj.311.7009.862			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY191	7580498	Green Published			2022-12-24	WOS:A1995RY19100031
J	GARDNER, KA; MAYER, JM				GARDNER, KA; MAYER, JM			UNDERSTANDING C-H BOND OXIDATIONS - H-CENTER-DOT AND H- TRANSFER IN THE OXIDATION OF TOLUENE BY PERMANGANATE	SCIENCE			English	Article							AQUEOUS-SOLUTION; RATE CONSTANTS; METAL-OXIDES; RADICALS; HYDROXYLASE; MECHANISM; REDUCTION; ACID	The oxidation of toluene by permanganate has been studied as a model for the oxidation of C-H bonds by metal reagents, metalloenzymes, and metal oxide surfaces. In water, the reaction proceeds by hydride (H-) transfer from toluene to a permanganate oxygen, whereas in toluene solution, permanganate abstracts a hydrogen atom (H-.). The ability of permanganate to abstract a hydrogen atom is rationalized on the basis of the strong O-H bond formed on H addition to permanganate. This approach allows understanding and prediction of the rates of hydrogen atom transfer from substrates to metal active sites.	UNIV WASHINGTON,DEPT CHEM,SEATTLE,WA 98195	University of Washington; University of Washington Seattle								AVILA DV, 1993, J AM CHEM SOC, V115, P466, DOI 10.1021/ja00055a015; BERKOWITZ J, 1994, J PHYS CHEM-US, V98, P2744, DOI 10.1021/j100062a009; BORDWELL FG, 1994, J AM CHEM SOC, V116, P6605, DOI 10.1021/ja00094a015; BOYINGTON JC, 1993, SCIENCE, V260, P1482, DOI 10.1126/science.8502991; BRAUMAN JI, 1970, J AM CHEM SOC, V92, P329, DOI 10.1021/ja00705a642; BUXTON GV, 1988, J PHYS CHEM REF DATA, V17, P513, DOI 10.1063/1.555805; CENTI G, 1988, CHEM REV, V88, P55, DOI 10.1021/cr00083a003; COLUSSI AJ, 1988, CHEM KINETICS SMALL, P33; COOK GK, 1994, J AM CHEM SOC, V116, P8859, DOI 10.1021/ja00098a077; COOK GK, 1994, J AM CHEM SOC, V116, P1855, DOI 10.1021/ja00084a029; CULLIS CF, 1955, J CHEM SOC, P555, DOI 10.1039/jr9550000555; DEMONTELLANO PRO, 1985, CYTOCHROME P450 STRU; Exner O., 1978, CORRELATION ANAL CHE, P439; GARDNER KA, UNPUB; HOWARD JA, 1984, LANDOLTBORNSTEIN D, V13; INGOLD KU, 1973, FREE RADICALS, V1, P67; JONSSON M, 1994, J AM CHEM SOC, V116, P1423, DOI 10.1021/ja00083a030; KARAMAN H, 1984, J ORG CHEM, V49, P4509, DOI 10.1021/jo00197a037; Knox J. H., 1968, OXIDATION ORGANIC CO, P1; Kochi J.K., 1973, FREE RADICALS; Latimer W. M., 1952, OXIDATION STATES ELE, V2nd; LEE DG, 1993, J AM CHEM SOC, V115, P11231, DOI 10.1021/ja00077a023; LIND J, 1990, J AM CHEM SOC, V112, P479, DOI 10.1021/ja00158a002; MAILLARD B, 1983, J AM CHEM SOC, V105, P5095, DOI 10.1021/ja00353a039; PEREZBENITO JF, 1992, J COLLOID INTERF SCI, V152, P70, DOI 10.1016/0021-9797(92)90009-B; PEREZBENITO JF, 1985, CAN J CHEM, V63, P1275; PEREZBENITO JF, 1979, J CHEM SOC CHEM COMM, V18, P69; ROSENZWEIG AC, 1993, NATURE, V366, P537, DOI 10.1038/366537a0; ROSS SD, 1975, ANODIC OXYDATION, P83; RUCHARDT C, 1992, ANGEW CHEM INT EDIT, V31, P1523, DOI 10.1002/anie.199215231; RUSSELL GA, 1973, FREE RADICALS, V1, P275; SCHMIDT HJ, 1979, ANGEW CHEM INT EDIT, V18, P68, DOI 10.1002/anie.197900681; STEENKEN S, 1982, J AM CHEM SOC, V104, P1244, DOI 10.1021/ja00369a017; STEWART LC, 1988, ANNU REV BIOCHEM, V57, P551; STEWART R, 1964, OXIDATION MECHANISMS; THOMPSON MS, 1982, J AM CHEM SOC, V104, P5070, DOI 10.1021/ja00383a013; TONG YD, 1991, J AM CHEM SOC, V113, P4741, DOI 10.1021/ja00013a005; WATANABE Y, 1992, ENZYMES, V20, P405; WIBERG KB, 1963, J AM CHEM SOC, V85, P3487, DOI 10.1021/ja00904a040	39	218	221	2	104	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 29	1995	269	5232					1849	1851		10.1126/science.7569922	http://dx.doi.org/10.1126/science.7569922			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX194	7569922				2022-12-24	WOS:A1995RX19400030
J	VERSCHUREN, WMM; KROMHOUT, D				VERSCHUREN, WMM; KROMHOUT, D			TOTAL CHOLESTEROL CONCENTRATION AND MORTALITY AT A RELATIVELY YOUNG AGE - DO MEN AND WOMEN DIFFER	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; SERUM-CHOLESTEROL; FOLLOW-UP; PLASMA-CHOLESTEROL; PAISLEY SURVEY; CANCER; POPULATION; RENFREW; COHORT; RISK	Objective-To investigate the relation between total cholesterol concentration and mortality from coronary heart disease, cardiovascular diseases, non-cardiovascular causes, and all causes. Design-Population based cohort study. Subjects-23000 men and 26000 women aged 30-51 years examined between 1974 and 1980. Main outcome measures-Mortality for the above mentioned end points for fifths of cholesterol distribution, and relative risks estimated by using Cox's proportional hazard (survival) analysis. Adjustment was made for age, smoking, systolic blood pressure, and body mass index. Results-Mortality from coronary heart disease in men was five times higher than that in women. A strong positive association between total cholesterol concentration and mortality from coronary heart disease and cardiovascular diseases was observed in both men and women, The relative risk for the highest compared with the lowest fifth of the cholesterol distribution was for mortality from coronary heart disease (3.0 (95% confidence interval 1.8 to 5.1) in men and 3.8 (1.1 to 13.1) in women) and for mortality from cardiovascular disease (2.8 (1.8 to 4.2) in men and 2.9 (1.4 to 6.0) in women). No increase of non-cardiovascular mortality at low cholesterol concentration was observed. All cause mortality was significantly higher in the highest compared with the lowest fifth of the cholesterol distribution: relative risk 1.6 (1.3 to 2.0) in men and 1.5 (1.1 to 1.9) in women. Conclusion-Total cholesterol concentration is a strong predictor of mortality from coronary heart disease, cardiovascular diseases, and all causes in women as well as in men. Low cholesterol concentrations are not associated with increased mortality from non-cardiovascular causes,			VERSCHUREN, WMM (corresponding author), NATL INST PUBL HLTH & ENVIRONM PROTECT,DEPT CHRON DIS & ENVIRONM EPIDEMIOL,POB 1,3720 BA BILTHOVEN,NETHERLANDS.		Kromhout, Daan/A-8566-2014					ANDERSON KM, 1987, JAMA-J AM MED ASSOC, V257, P2176, DOI 10.1001/jama.257.16.2176; [Anonymous], 1993, NETH J CARDIOL; [Anonymous], 1989, SAS STAT USERS GUIDE, V2; CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276; HARRIS T, 1992, J CLIN EPIDEMIOL, V45, P595, DOI 10.1016/0895-4356(92)90131-6; HIATT RA, 1986, J CHRON DIS, V39, P861, DOI 10.1016/0021-9681(86)90034-2; HUANG TC, 1961, ANAL CHEM, V33, P1405, DOI 10.1021/ac60178a040; ISLES CG, 1992, LANCET, V339, P702, DOI 10.1016/0140-6736(92)90599-X; ISLES CG, 1989, BMJ-BRIT MED J, V298, P920, DOI 10.1136/bmj.298.6678.920; JACOBS D, 1992, CIRCULATION, V86, P1046, DOI 10.1161/01.CIR.86.3.1046; KARK JD, 1980, J CHRON DIS, V33, P311, DOI 10.1016/0021-9681(80)90026-0; KLAG MJ, 1993, NEW ENGL J MED, V328, P313, DOI 10.1056/NEJM199302043280504; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; LAW MR, 1994, BMJ-BRIT MED J, V308, P363, DOI 10.1136/bmj.308.6925.363; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; Manolio T A, 1992, Ann Epidemiol, V2, P161, DOI 10.1016/1047-2797(92)90051-Q; MEIJER J, 1976, HART B, V7, P42; NEATON JD, 1992, ARCH INTERN MED, V152, P1480; PERSSON B, 1984, ACTA MED SCAND, V216, P485; RUWAARD D, 1993, PUBLIC HLTH STATUS F, P377; SCHATZKIN A, 1988, CANCER RES, V48, P452; SMITH GD, 1992, JAMA-J AM MED ASSOC, V267, P70, DOI 10.1001/jama.267.1.70; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; VERSCHUREN WMM, 1991, AM J EPIDEMIOL, V134, P1290, DOI 10.1093/oxfordjournals.aje.a116032; 1989, SAS STAT USERS GUIDE, V1; 1994, WOMEN CARDIOVASCULAR; 1982, JAMA-J AM MED ASSOC, V248, P2853; 1990, HART B S, V23, P9	28	34	34	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 23	1995	311	7008					779	783		10.1136/bmj.311.7008.779	http://dx.doi.org/10.1136/bmj.311.7008.779			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX107	7580439	Green Published, Green Accepted			2022-12-24	WOS:A1995RX10700020
J	STANDAERT, SM; DAWSON, JE; SCHAFFNER, W; CHILDS, JE; BIGGIE, KL; SINGLETON, BS; GERHARDT, RR; KNIGHT, ML; HUTCHESON, RH				STANDAERT, SM; DAWSON, JE; SCHAFFNER, W; CHILDS, JE; BIGGIE, KL; SINGLETON, BS; GERHARDT, RR; KNIGHT, ML; HUTCHESON, RH			EHRLICHIOSIS IN A GOLF-ORIENTED RETIREMENT COMMUNITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN INFECTION; TICKS; CANIS	Background. Ehrlichiosis due to Ehrlichia chaffeensis usually occurs sporadically or in small clusters, with an annual incidence estimated at 3 to 5 cases per 100,000 population in areas of endemic disease. The putative principal vector is the Lone Star tick (Amblyomma americanum). We investigated an outbreak of ehrlichiosis that occurred in June 1993 among members of a golf-oriented retirement community (community A) in Tenessee. The community is densely wooded and borders a wildlife-management area where deer are numerous. Methods. We conducted a case-control study, using medical-history reviews, serologic testing, and testing with the polymerase chain reaction for E. chaffeensis infection. We also surveyed a sample of 10 percent of the households in community A and in another golf-oriented community (community B) more than 20 miles (32 km) from the wildlife-management area. Survey participants completed a questionnaire and provided specimens for serologic testing. In both communities, searches for ticks were undertaken. Results. Eleven cases of symptomatic ehrlichiosis were identified in the case-control study, 10 of which were in community A (attack rate, 330 per 100,000). Of 311 surveyed residents of community-A, 12.5 percent had serologic evidence of past E. chaffeensis infection, as compared with 3.3 percent of 92 in community B (relative risk in community A as compared with community B, 3.9; 95 percent confidence interval, 1.2 to 12.2). The risk of infection was associated with tick bites, exposure to wildlife, golfing, and among golfers, retrieving lost golf balls from the rough. Persons who never used insect repellent were more likely to have had infection than persons who did. In community A, thousands of Lone Star ticks were found; in community B, only three ticks were found. Conclusions. The high rate of E. chaffeensis infection in community A resulted from its proximity to a wildlife reserve. When outdoor recreational activities are common and concentrations of ticks are high, outbreaks of arthropod-borne zoonoses can be anticipated.	VANDERBILT UNIV,SCH MED,DEPT PREVENT MED,NASHVILLE,TN 37232; NATL CTR INFECT DIS,DIV FIELD EPIDEMIOL,EPIDEM INTELLIGENCE SERV,EPIDEMIOL PROGRAM OFF,ATLANTA,GA; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV VIRAL & RICKETTSIAL DIS,ATLANTA,GA; TENNESSEE DEPT HLTH,NASHVILLE,TN; UNIV TENNESSEE,DEPT ENTOMOL & PLANT PATHOL,KNOXVILLE,TN; TENNESSEE VALLEY AUTHOR,GOLDEN POND,KY	Vanderbilt University; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Tennessee Department Health; University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture; Tennessee Valley Authority			Childs, James E/B-4002-2012					ANDERSON BE, 1992, J CLIN MICROBIOL, V30, P775, DOI 10.1128/JCM.30.4.775-780.1992; ANDERSON BE, 1993, AM J TROP MED HYG, V49, P239, DOI 10.4269/ajtmh.1993.49.239; ANDERSON BE, 1991, J CLIN MICROBIOL, V29, P2838, DOI 10.1128/JCM.29.12.2838-2842.1991; DAWSON JE, 1991, J CLIN MICROBIOL, V29, P2741, DOI 10.1128/JCM.29.12.2741-2745.1991; DAWSON JE, 1994, J CLIN MICROBIOL, V32, P2725, DOI 10.1128/JCM.32.11.2725-2728.1994; Dean A. G., 1990, EPI INFO VERSION 5 W; ENG TR, 1990, JAMA-J AM MED ASSOC, V264, P2251, DOI 10.1001/jama.264.17.2251; EVERETT ED, 1994, ANN INTERN MED, V120, P730, DOI 10.7326/0003-4819-120-9-199405010-00002; FISHBEIN DB, 1994, ANN INTERN MED, V120, P736, DOI 10.7326/0003-4819-120-9-199405010-00003; FISHBEIN DB, 1989, J INFECT DIS, V160, P803, DOI 10.1093/infdis/160.5.803; FISHBEIN DB, 1987, JAMA-J AM MED ASSOC, V257, P3100, DOI 10.1001/jama.257.22.3100; Hair J.A., 1986, P406; Harkess J R, 1991, Infect Dis Clin North Am, V5, P37; HARKESS JR, 1989, J INFECT DIS, V159, P576, DOI 10.1093/infdis/159.3.576; KARDATZKE JT, 1992, J MED ENTOMOL, V29, P669, DOI 10.1093/jmedent/29.4.669; LEDERBERG J, 1992, EMERGING INFECTIONS, P206; MAEDA K, 1987, NEW ENGL J MED, V316, P853, DOI 10.1056/NEJM198704023161406; PETERSEN LR, 1989, J INFECT DIS, V159, P562, DOI 10.1093/infdis/159.3.562; ROHRBACH BW, 1990, AM J PUBLIC HEALTH, V80, P442, DOI 10.2105/AJPH.80.4.442; SCHWARTZ BS, 1990, AM J EPIDEMIOL, V131, P877, DOI 10.1093/oxfordjournals.aje.a115578; TAYLOR JP, 1988, J INFECT DIS, V158, P217, DOI 10.1093/infdis/158.1.217; Telford S R 3rd, 1991, Infect Dis Clin North Am, V5, P7; TOPPING NH, 1947, NEW YORK STATE J MED, V47, P1585; WALKER DH, 1994, NEW ENGL J MED, V331, P1651, DOI 10.1056/NEJM199412153312410; YEVICH SJ, 1995, J INFECT DIS, V171, P1266, DOI 10.1093/infdis/171.5.1266; 1988, MMWR-MORBID MORTAL W, V37, P270; 1988, MMWR-MORBID MORTAL W, V37, P275	27	94	99	0	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 17	1995	333	7					420	425		10.1056/NEJM199508173330704	http://dx.doi.org/10.1056/NEJM199508173330704			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP243	7616991				2022-12-24	WOS:A1995RP24300004
J	CLEMENT, K; VAISSE, C; MANNING, BS; BASDEVANT, A; GUYGRAND, B; RUIZ, J; SILVER, KD; SHULDINER, AR; FROGUEL, P; STROSBERG, AD				CLEMENT, K; VAISSE, C; MANNING, BS; BASDEVANT, A; GUYGRAND, B; RUIZ, J; SILVER, KD; SHULDINER, AR; FROGUEL, P; STROSBERG, AD			GENETIC-VARIATION IN THE BETA(3)-ADRENERGIC RECEPTOR AND AN INCREASED CAPACITY TO GAIN WEIGHT IN PATIENTS WITH MORBID-OBESITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BETA-3-ADRENERGIC RECEPTOR; MOLECULAR CHARACTERIZATION	Background. The beta(3)-adrenergic receptor, located mainly in adipose tissue, is involved in the regulation of lipolysis and thermogenesis, The potential relevance of this receptor to obesity in humans led us to screen obese French patients for a recently identified mutation in the gene for the receptor. Methods. We used the polymerase chain reaction to amplify a region of the gene for the beta(3)-adrenergic receptor encoding amino acid residues 27 to 110 in genomic DNA extracted from leukocytes from 185 patients with morbid obesity (body-mass index [the weight in kilograms divided by the square of the height in meters], >40) and 94 normal subjects. A mutation resulting in the replacement of tryptophan by arginine at position 64 (Trp64Arg) was detected by an analysis of restriction-fragment-length polymorphisms with the use of the endonuclease BstNI, which discriminates between the normal and mutant sequences. Results. The frequency of the Trp64Arg allele was similar in the morbidly obese patients and the normal subjects (0.08 and 0.10, respectively), However, the patients with morbid obesity who were heterozygous for the Trp64Arg mutation had an increased capacity to gain weight; the mean weight in the 14 heterozygous patients was 140 kg, as compared with 126 kg in the 171 patients without the mutation (P=0.03), There were no homozygotes in this sample, The cumulative 25-year change in weight (from the age of 20 years) was 67 kg in the Trp64Arg heterozygotes, as compared with 51 kg in those without the mutation. The maximal weight differential (the maximal lifetime weight minus the weight at 20 years of age) in the Trp64Arg heterozygotes was 74 kg, as compared with 59 kg in the patients without the mutation (P=0.02), Conclusions. People with the Trp64Arg mutation of the gene for the beta(3)-adrenergic receptor may have an increased capacity to gain weight.	INST PASTEUR,CNRS,UNITE EP10,F-59019 LILLE,FRANCE; UNIV HOSP LILLE,LILLE,FRANCE; HOP HOTEL DIEU,DEPT NUTR,F-75181 PARIS,FRANCE; INST COCHIN GENET MOLEC,IMMUNOPHARMACOL MOLEC LAB,CNRS,UNITE UPR 0415,F-75014 PARIS,FRANCE; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille - ISITE; CHU Lille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Johns Hopkins University			Clément, karine/R-1120-2017; FROGUEL, Philippe/O-6799-2017; Vaisse, Christian/F-1067-2011	FROGUEL, Philippe/0000-0003-2972-0784; Shuldiner, Alan/0000-0001-9921-4305				Adams T D, 1993, Obes Res, V1, P261; Arbeeny C. M., 1994, International Journal of Obesity, V18, P4; ARCH JRS, 1993, MED RES REV, V13, P663, DOI 10.1002/med.2610130604; BOUCHARD C, 1988, ANNU REV NUTR, V8, P259, DOI 10.1146/annurev.nu.08.070188.001355; COLLINS S, 1994, MOL ENDOCRINOL, V8, P518, DOI 10.1210/me.8.4.518; EMORINE L, 1994, TRENDS PHARMACOL SCI, V15, P3, DOI 10.1016/0165-6147(94)90118-X; EMORINE LJ, 1989, SCIENCE, V245, P1118, DOI 10.1126/science.2570461; KRIEF S, 1993, J CLIN INVEST, V91, P344, DOI 10.1172/JCI116191; NAHMIAS C, 1991, EMBO J, V10, P3721, DOI 10.1002/j.1460-2075.1991.tb04940.x; PRICE RA, 1990, HUM BIOL, V62, P747; RAVUSSIN E, 1988, NEW ENGL J MED, V318, P467, DOI 10.1056/NEJM198802253180802; ROLLANDCACHERA MF, 1991, EUR J CLIN NUTR, V45, P13; Sambrook J., 1989, MOL CLONING LAB MANU; Susulic V. S., 1994, International Journal of Obesity, V18, P5; WALSTON J, 1995, NEW ENGL J MED, V333, P343, DOI 10.1056/NEJM199508103330603	15	581	600	0	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 10	1995	333	6					352	354		10.1056/NEJM199508103330605	http://dx.doi.org/10.1056/NEJM199508103330605			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN082	7609752				2022-12-24	WOS:A1995RN08200005
J	BELL, TW; HOU, Z; LUO, Y; DREW, MGB; CHAPOTEAU, E; CZECH, BP; KUMAR, A				BELL, TW; HOU, Z; LUO, Y; DREW, MGB; CHAPOTEAU, E; CZECH, BP; KUMAR, A			DETECTION OF CREATININE BY A DESIGNED RECEPTOR	SCIENCE			English	Article							TORANDS; ASSAY	An artificial receptor has been designed to bind creatinine with a color change (chromogenic response) caused by proton transfer from one end of the receptor to the other. The receptor was synthesized and found to extract creatinine from water into chlorocarbon solvents. The color change in the organic layer is specific for creatinine relative to other organic solutes, and it is selective far creatinine relative to sodium, potassium, and ammonium ions. The chromogenic mechanism is revealed by x-ray crystal structures of creatinine, the free receptor, and the complex, showing ''induced fit'' binding resulting from electronic complementarity between host and guest.	SUNY STONY BROOK,DEPT CHEM,STONY BROOK,NY 11794; UNIV READING,DEPT CHEM,READING RG6 2AD,BERKS,ENGLAND; BAYER CORP,DIV DIAGNOST,TARRYTOWN,NY 10591	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Reading; Bayer AG								BALL P, 1994, NATURE, V371, P202, DOI 10.1038/371202a0; BECKLES DL, 1995, TETRAHEDRON, V51, P363, DOI 10.1016/0040-4020(94)00902-7; BELL TW, 1993, PURE APPL CHEM, V65, P361, DOI 10.1351/pac199365030361; BELL TW, 1994, NATURE, V367, P441, DOI 10.1038/367441a0; BELL TW, 1986, J AM CHEM SOC, V108, P8109, DOI 10.1021/ja00285a049; BELL TW, 1993, FLUORESCENT CHEMOSEN, P85; BELL TW, 1993, ORG SYNTH, V8, P87; BUHLMANN P, 1993, TETRAHEDRON, V49, P7627, DOI 10.1016/S0040-4020(01)87238-0; BUTLER AR, 1985, J CHEM SOC PERK T 2, P1465, DOI 10.1039/p29850001465; CALABRESE GS, 1988, TOP CURR CHEM, V143, P49; CRAM DJ, 1986, ANGEW CHEM INT EDIT, V25, P1039, DOI 10.1002/anie.198610393; DUPRE S, 1955, ACTA CRYSTALLOGR, V8, P311, DOI 10.1107/S0365110X55000972; FOSSATI P, 1983, CLIN CHEM, V29, P1494; FREE HM, 1991, MODERN URINE CHEM; HIRSHFELD FL, 1980, ACTA CRYSTALLOGR B, V36, P406, DOI 10.1107/S0567740880003366; JAYNES PK, 1982, CLIN CHEM, V28, P114; Jencks W. P., 1987, CATALYSIS CHEM ENZYM; Johnson D., 1989, CLIN CHEM, P55; KENYON GL, 1971, J AM CHEM SOC, V93, P5552, DOI 10.1021/ja00750a039; KOSHLAND DE, 1958, P NATL ACAD SCI USA, V44, P98, DOI 10.1073/pnas.44.2.98; LEHN JM, 1993, SCIENCE, V260, P1762, DOI 10.1126/science.8511582; MAJEWICZ TG, 1974, J ORG CHEM, V39, P720, DOI 10.1021/jo00919a033; NARAYANAN S, 1980, CLIN CHEM, V26, P1119; SHELDRICK GM, 1993, SHELXI PROGRAM CRYST; Stewart J. J. P., 1993, MOPAC93; VANLENTE F, 1990, CLIN CHEM NEWS   OCT, P8	26	101	106	2	19	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 4	1995	269	5224					671	674		10.1126/science.7624796	http://dx.doi.org/10.1126/science.7624796			4	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM702	7624796				2022-12-24	WOS:A1995RM70200027
J	LEE, SL; WESSELSCHMIDT, RL; LINETTE, GP; KANAGAWA, O; RUSSELL, JH; MILBRANDT, J				LEE, SL; WESSELSCHMIDT, RL; LINETTE, GP; KANAGAWA, O; RUSSELL, JH; MILBRANDT, J			UNIMPAIRED THYMIC AND PERIPHERAL T-CELL DEATH IN MICE LACKING THE NUCLEAR RECEPTOR NGFI-B (NUR77)	SCIENCE			English	Article							CLONAL DELETION; THYMOCYTES; APOPTOSIS; ANTIBODIES; HYBRIDOMAS; INVIVO; GENE	T cell hybridomas require the immediate-early gene NGFI-B (nur77) for T cell receptor (TCR)-mediated apoptosis, a model for negative selection of self-reactive T cells. TCR-mediated death was examined in mice bearing an NGFI-B loss-of-function mutation, either by administration of antibodies to CD3 (anti-CD3) or in two well-characterized transgenic models expressing self-reactive TCRs. Both the extent and the rate of thymocyte death were unimpaired. Anti-CD3-induced death was normal in CD4+ peripheral T cells, in which death is mediated predominantly by the Fas signaling pathway. Thus, no unique requirement for NGFI-B is observed for thymic or peripheral T cell death.	WASHINGTON UNIV, SCH MED, DEPT PATHOL, HOWARD HUGHES MED INST, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT INTERNAL MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, JEWISH HOSP ST LOUIS, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, JEWISH HOSP ST LOUIS, SCH MED, DEPT GENET, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MOLEC BIOL & PHARMACOL, ST LOUIS, MO 63110 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)				Russell, John/0000-0002-3680-9587; Milbrandt, Jeffrey/0000-0002-5477-7689	NATIONAL CANCER INSTITUTE [P01CA049712] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA49712] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HENGARTNER H, 1988, NATURE, V336, P388, DOI 10.1038/336388a0; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KISLELOW P, 1988, NATURE, V333, P742; LAW SW, 1992, MOL ENDOCRINOL, V6, P2129, DOI 10.1210/me.6.12.2129; Lee S. A., UNPUB; LEE SL, 1995, J BIOL CHEM, V270, P9971, DOI 10.1074/jbc.270.17.9971; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; ROBERTSON E, 1987, TERATOCARCINOMA EMBR; RUSSELL JH, 1993, P NATL ACAD SCI USA, V90, P4409, DOI 10.1073/pnas.90.10.4409; SCEARCE LM, 1993, J BIOL CHEM, V268, P8855; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SHI YF, 1990, J IMMUNOL, V144, P3326; SHI YF, 1991, J IMMUNOL, V146, P3340; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; SWAT W, 1991, NATURE, V351, P150, DOI 10.1038/351150a0; VASQUEZ NJ, 1992, J EXP MED, V175, P1307, DOI 10.1084/jem.175.5.1307; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WATSON MA, UNPUB; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0	28	222	225	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 28	1995	269	5223					532	535		10.1126/science.7624775	http://dx.doi.org/10.1126/science.7624775			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL495	7624775				2022-12-24	WOS:A1995RL49500025
J	WEEKS, KM; CECH, TR				WEEKS, KM; CECH, TR			PROTEIN FACILITATION OF GROUP-I INTRON SPLICING BY ASSEMBLY OF THE CATALYTIC CORE AND THE 5'-SPLICE-SITE DOMAIN	CELL			English	Article							BASE-PAIRING INTERACTION; GUANOSINE-BINDING-SITE; TETRAHYMENA RIBOZYME; INTERVENING SEQUENCE; RIBONUCLEASE-P; RIBOSOMAL-RNA; SECONDARY STRUCTURE; GUIDE SEQUENCE; MESSENGER-RNA; CBP2 PROTEIN	The yeast mitochondrial group 1 intron b15 undergoes self-splicing at high Mg2+ concentrations, but requires the splicing factor CBP2 for reaction under physiological conditions. Chemical accessibility and UV crosslinking experiments now reveal that self-processing is slow because functional elements are not properly positioned in an active tertiary structure. Folding anergy provided by CBP2 drives assembly of two RNA domains that comprise the catalytic core and meditates association of an similar to 100 nt 5' domain that contains the 5' splice site. Thus, the protein assembles RNA secondary structure elements into a specific three-dimensional array while the RNA provides the catalytic center. The division of labor between RNA and protein illustrated by this simple system reveals principles applicable to complex ribonucleoprotein assemblies such as the spliceosome and ribosome.			WEEKS, KM (corresponding author), UNIV COLORADO,HOWARD HUGHES MED INST,DEPT CHEM & BIOCHEM,BOULDER,CO 80309, USA.							BEVILACQUA PC, 1992, SCIENCE, V258, P1355, DOI 10.1126/science.1455230; BURGESS SM, 1993, CELL, V73, P1377, DOI 10.1016/0092-8674(93)90363-U; BURKE JM, 1990, NATURE, V344, P80, DOI 10.1038/344080a0; CECH TR, 1994, NAT STRUCT BIOL, V1, P273, DOI 10.1038/nsb0594-273; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CELANDER DW, 1990, BIOCHEMISTRY-US, V29, P1355, DOI 10.1021/bi00458a001; DAVIES RW, 1982, NATURE, V300, P719, DOI 10.1038/300719a0; FERSHT A, 1985, ENZYME STRUCTURE MEC, P102; GAMPEL A, 1987, MOL CELL BIOL, V7, P2545, DOI 10.1128/MCB.7.7.2545; GAMPEL A, 1989, MOL CELL BIOL, V9, P5424, DOI 10.1128/MCB.9.12.5424; GAMPEL A, 1991, GENE DEV, V5, P1870, DOI 10.1101/gad.5.10.1870; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; GUO QB, 1992, GENE DEV, V6, P1357, DOI 10.1101/gad.6.8.1357; GUO QB, 1991, J BIOL CHEM, V266, P1809; HERSCHLAG D, 1992, BIOCHEMISTRY-US, V31, P1386, DOI 10.1021/bi00120a015; HERTZBERG RP, 1984, BIOCHEMISTRY-US, V23, P3934, DOI 10.1021/bi00312a022; HEUER TS, 1988, P NATL ACAD SCI USA, V88, P11105; INOUE T, 1985, P NATL ACAD SCI USA, V82, P648, DOI 10.1073/pnas.82.3.648; JAEGER L, 1991, J MOL BIOL, V221, P1153, DOI 10.1016/0022-2836(91)90925-V; JANDROSITZ A, 1995, EMBO J, V14, P820, DOI 10.1002/j.1460-2075.1995.tb07060.x; LATHAM JA, 1989, SCIENCE, V245, P276, DOI 10.1126/science.2501870; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MICHEL F, 1990, GENE DEV, V4, P777, DOI 10.1101/gad.4.5.777; MICHEL F, 1982, BIOCHIMIE, V64, P867, DOI 10.1016/S0300-9084(82)80349-0; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MOAZED D, 1986, J MOL BIOL, V187, P399, DOI 10.1016/0022-2836(86)90441-9; MOHR G, 1992, CELL, V69, P483, DOI 10.1016/0092-8674(92)90449-M; MOHR G, 1991, NATURE, V347, P578; MURPHY FL, 1994, SCIENCE, V265, P1709, DOI 10.1126/science.8085157; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; PAN T, 1995, BIOCHEMISTRY-US, V34, P902, DOI 10.1021/bi00003a024; PARTONO S, 1990, P NATL ACAD SCI USA, V87, P8192, DOI 10.1073/pnas.87.21.8192; PARTONO S, 1988, MOL CELL BIOL, V8, P2562, DOI 10.1128/MCB.8.6.2562; PEATTIE DA, 1979, P NATL ACAD SCI USA, V76, P1760, DOI 10.1073/pnas.76.4.1760; PYLE AM, 1992, NATURE, V358, P123, DOI 10.1038/358123a0; REICH C, 1988, SCIENCE, V239, P178, DOI 10.1126/science.3122322; RITCHINGS BW, 1992, NUCLEIC ACIDS RES, V20, P2349, DOI 10.1093/nar/20.9.2349; SCHATZ D, 1991, P NATL ACAD SCI USA, V88, P6132, DOI 10.1073/pnas.88.14.6132; SMITH D, 1993, BIOCHEMISTRY-US, V32, P5273, DOI 10.1021/bi00071a001; TALBOT SJ, 1994, BIOCHEMISTRY-US, V33, P1399, DOI 10.1021/bi00172a016; TALBOT SJ, 1994, BIOCHEMISTRY-US, V33, P1406, DOI 10.1021/bi00172a017; TULLIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469, DOI 10.1073/pnas.83.15.5469; WANG JF, 1992, SCIENCE, V256, P526, DOI 10.1126/science.1315076; WANG JF, 1993, SCIENCE, V260, P504, DOI 10.1126/science.7682726; WEEKS KM, 1995, BIOCHEMISTRY-US, V34, P7728, DOI 10.1021/bi00023a020; WOLLENZIEN PL, 1983, CELL, V32, P397, DOI 10.1016/0092-8674(83)90459-2; YOUNG B, 1991, CELL, V67, P1007, DOI 10.1016/0092-8674(91)90373-7; ZAUG AJ, 1984, SCIENCE, V224, P574, DOI 10.1126/science.6200938	49	103	106	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 28	1995	82	2					221	230		10.1016/0092-8674(95)90309-7	http://dx.doi.org/10.1016/0092-8674(95)90309-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RL760	7628013	Bronze			2022-12-24	WOS:A1995RL76000009
J	GREENBERGER, P				GREENBERGER, P			ALLERGIC RHINITIS IN AN ALLERGY CLINIC NURSE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											GREENBERGER, P (corresponding author), NORTHWESTERN UNIV,SCH MED,CHICAGO,IL 60611, USA.		Greenberger, Paul/L-2770-2019	Greenberger, Paul/0000-0003-3882-8498					0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 26	1995	274	4					358	358						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ898	7609269				2022-12-24	WOS:A1995RJ89800042
J	GLANTZ, SA; BARNES, DE; BERO, L; HANAUER, P; SLADE, J				GLANTZ, SA; BARNES, DE; BERO, L; HANAUER, P; SLADE, J			LOOKING THROUGH A KEYHOLE AT THE TOBACCO INDUSTRY - THE BROWN-AND-WILLIAMSON DOCUMENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To introduce a series of papers discussing previously undocumented tobacco industry activities regarding strategies to avoid products liability litigation, understand nicotine addiction, and manipulate both internal and external scientific research on the effects of both active and passive smoking. Data Sources.-Documents from Brown and Williamson Tobacco Corporation (B&W), the British American Tobacco Company (BAT), and other tobacco interests provided by an anonymous source, obtained from Congress, and received from the private papers of a former BAT officer. Study Selection.-All available materials, including confidential reports regarding research and internal memoranda exchanged between tobacco industry lawyers. Conclusions.-These documents provide our first look at the inner workings of the tobacco industry during the crucial period in which the scientific case that smoking is addictive and kills smokers solidified. The documents show a sophisticated legal and public relations strategy to avoid liability for the diseases induced by tobacco use. The documents show that lawyers steered scientists away from particular research avenues, which is inconsistent with the company's purported disbelief in the causation and addiction claims; if the company had been genuinely unconvinced by the causation and addiction hypotheses, then it should have had no concern that new research would provide ammunition for the enemy. Quite the contrary, the documents show that B&W and BAT recognized more than 30 years ago that nicotine is addictive and that tobacco smoke is ''biologically active'' (leg, carcinogenic).	UNIV CALIF SAN FRANCISCO,DIV CLIN PHARM,SAN FRANCISCO,CA 94143; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,ST PETERS MED CTR,DEPT MED,NEW BRUNSWICK,NJ 08903	University of California System; University of California San Francisco; Rutgers State University New Brunswick; Rutgers State University Medical Center	GLANTZ, SA (corresponding author), UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,DEPT MED,DIV CARDIOL,BOX 0124,SAN FRANCISCO,CA 94143, USA.				NATIONAL CANCER INSTITUTE [R01CA061021] Funding Source: NIH RePORTER; NCI NIH HHS [CA-61021] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARNES DE, 1995, JAMA-J AM MED ASSOC, V274, P248, DOI 10.1001/jama.274.3.248; BERO L, 1995, JAMA-J AM MED ASSOC, V274, P241, DOI 10.1001/jama.274.3.241; HANAUER P, 1995, JAMA-J AM MED ASSOC, V274, P234; HILTS P, 1994, NY TIMES        0310, pA10; HILTS PJ, 1994, NY TIMES        0507, pA1; KING W, 1976, NY TIMES        1030, pA8; MAXWELL JJ, 1993, HIST SALES TRENDS CI; MAXWELL JJ, 1993, MAXWELL CONSUMER REP; MILLHISER RR, 1978, NY TIMES        0112, pA19; SLADE J, 1995, JAMA-J AM MED ASSOC, V274, P225, DOI 10.1001/jama.274.3.225; WEISZ P, 1995, BRANDWEEK       0606, P20; WOLINSKY H, 1985, NEW YORK STATE J MED, V85, P451; 1964, US DHEW PHS1103 PUBL; 1988, PHS CDC888406 US DEP; 1989, PHS DHHS CDC898411 U; 1981, DHHS PHS8150156 US D; 1982, DHHS PHS8550179 US D; 1979, NY TIMES        0922, pA6; 1972, PHS DHEW HSM727516 H; 1979, DHEW PHS7950066 OFF; 1985, ORG POLICY STATEMENT; 1986, PHS DHHS CDC878398 U; 1986, TOBACCO SMOKE NONSMO	23	91	92	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 19	1995	274	3					219	224		10.1001/jama.274.3.219	http://dx.doi.org/10.1001/jama.274.3.219			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH937	7609230				2022-12-24	WOS:A1995RH93700027
J	LICINIO, J; GOLD, PW; WONG, ML				LICINIO, J; GOLD, PW; WONG, ML			A MOLECULAR MECHANISM FOR STRESS-INDUCED ALTERATIONS IN SUSCEPTIBILITY TO DISEASE	LANCET			English	Note							CORTICOTROPIN-RELEASING-FACTOR; HUMAN-IMMUNODEFICIENCY-VIRUS; BLOOD IMMUNOCYTES; INTERLEUKIN-1; REPLICATION; EXPRESSION; SEQUENCE; HORMONE; CLONING; GENE	Corticotropin-releasing hormone (CRH) is a 41-aminoacid peptide which mediates behavioural and physiological responses to stress. A major target of CRH is the proopiomelanocortin (POMC) gene. Three transcription factors have been identified that affect transcription of the POMC gene by binding to two different sites within the CRH-responsive element of that promoter. We searched Genbank and found that nucleotide sequences in the POMC promoter which bind POMC-transcription factors are also contained in the genome of HIV-1 and cytomegalovirus, in c-fes and human MAT-1 breast cancer oncogenes, and in proinflammatory molecules, such as the interleukin-1 beta converting enzyme. We hypothesise a mechanism of hormone action by which a peptide hormone, such as CRH, might affect disease susceptibility by eliciting the production of transcription factors which may bind to unexpected intracellular targets, such as viruses, oncogenes, or the genes encoding for inflammatory mediators, infection, inflammation, and neoplastic transformation would thus be facilitated. This hypothesis can be tested, if confirmed. CRH antagonists may prove useful in the treatment of disorders whose pathophysiology involves molecules that respond to CRH-regulated POMC transcription factors.			LICINIO, J (corresponding author), NIMH, CLIN NEUROENDOCRINOL BRANCH, BETHESDA, MD 20892 USA.		Licinio, Julio/L-4244-2013; Wong, Ma-Li/D-7903-2011; Wong, Ma-Li/ABD-5525-2020	Licinio, Julio/0000-0001-6905-5884; Wong, Ma-Li/0000-0003-1512-3073; 				ADER R, 1995, LANCET, V345, P99, DOI 10.1016/S0140-6736(95)90066-7; ALCALAY M, 1990, ONCOGENE, V5, P267; BERA TK, 1994, P NATL ACAD SCI USA, V91, P9789, DOI 10.1073/pnas.91.21.9789; BERKENBOSCH F, 1987, SCIENCE, V238, P524, DOI 10.1126/science.2443979; BURBELO PD, 1993, P NATL ACAD SCI USA, V90, P11543, DOI 10.1073/pnas.90.24.11543; CHEE MS, 1990, CURR TOP MICROBIOL, V154, P125; CHEN RP, 1993, P NATL ACAD SCI USA, V90, P8967, DOI 10.1073/pnas.90.19.8967; CULLEN BR, 1989, CELL, V58, P423, DOI 10.1016/0092-8674(89)90420-0; DEBELLIS MD, 1993, AM J PSYCHIAT, V150, P656; DINARELLO CA, 1993, NEW ENGL J MED, V328, P106; GAGNER JP, 1985, MOL CELL ENDOCRINOL, V40, P25, DOI 10.1016/0303-7207(85)90154-6; GOLD PW, 1986, NEW ENGL J MED, V314, P1335, DOI 10.1056/NEJM198605223142102; GOLD PW, 1986, NEW ENGL J MED, V314, P1329, DOI 10.1056/NEJM198605223142101; JIN WD, 1994, MOL ENDOCRINOL, V8, P1377, DOI 10.1210/me.8.10.1377; JOHNSON EO, 1992, NEUROSCI BIOBEHAV R, V16, P115, DOI 10.1016/S0149-7634(05)80175-7; JUCKER M, 1992, ONCOGENE, V7, P943; KARALIS K, 1991, SCIENCE, V254, P421, DOI 10.1126/science.1925600; Lee KAW, 1991, CURR OPIN CELL BIOL, V3, P953, DOI 10.1016/0955-0674(91)90113-D; LU Y, 1993, BIOCHEM BIOPH RES CO, V193, P779, DOI 10.1006/bbrc.1993.1693; POTTER E, 1994, P NATL ACAD SCI USA, V91, P8777, DOI 10.1073/pnas.91.19.8777; RIEGEL AT, 1990, NUCLEIC ACIDS RES, V18, P4513, DOI 10.1093/nar/18.15.4513; SAPOLSKY R, 1987, SCIENCE, V238, P522, DOI 10.1126/science.2821621; SINGH VK, 1988, IMMUNOL LETT, V18, P5, DOI 10.1016/0165-2478(88)90061-2; SINGH VK, 1993, IMMUNOL LETT, V35, P239, DOI 10.1016/0165-2478(93)90189-9; SPIEGEL D, 1989, LANCET, V2, P888; SPIRE B, 1989, GENE, V81, P275, DOI 10.1016/0378-1119(89)90188-1; STRAYER DS, 1991, VIROLOGY, V185, P585, DOI 10.1016/0042-6822(91)90529-K; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TORNATORE C, 1991, J VIROL, V65, P6094, DOI 10.1128/JVI.65.11.6094-6100.1991; WONG ML, 1994, ENDOCRINOLOGY, V135, P2275, DOI 10.1210/en.135.5.2275	30	27	27	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 8	1995	346	8967					104	106		10.1016/S0140-6736(95)92119-2	http://dx.doi.org/10.1016/S0140-6736(95)92119-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH220	7626147				2022-12-24	WOS:A1995RH22000017
J	EVANS, JMM; MCMAHON, AD; MCGILCHRIST, MM; WHITE, G; MURRAY, FE; MCDEVITT, DG; MACDONALD, TM				EVANS, JMM; MCMAHON, AD; MCGILCHRIST, MM; WHITE, G; MURRAY, FE; MCDEVITT, DG; MACDONALD, TM			TOPICAL NONSTEROIDAL ANTIINFLAMMATORY DRUGS AND ADMISSION TO HOSPITAL FOR UPPER GASTROINTESTINAL-BLEEDING AND PERFORATION - A RECORD LINKAGE CASE-CONTROL STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective-To evaluate the relation between topically applied non-steroidal anti-inflammatory drugs and upper gastrointestinal bleeding and perforation. Design-A case-control study with 1103 patients admitted to hospital for upper gastrointestinal bleeding or perforation between January 1990 and December 1992 (cases). Two different control groups were used, with six community controls and with two hospital controls for each case. Previous exposure to topical and oral non-steroidal antiinflammatory drugs and ulcer healing drugs was assessed. Study population-The population of 319465 people who were resident in Tayside and were registered with a Tayside general practitioner between January 1989 and October 1994. A record linkage database containing all data on hospital events and dispensed drugs between 1989 and 1992 was used for this population. Main outcome measures-Unadjusted and adjusted odds ratios of exposure in those admitted to hospital compared with controls. Results-Significant unadjusted associations were detected between all three classes of drug and upper gastrointestinal complications. The significant association detected for topical non-steroidal anti-inflammatory drugs was no longer evident in analyses which adjusted for the confounding effect of concomitant exposure to oral anti-inflammatories and ulcer healing drugs (odds ratio=1.45; 95% confidence interval 0.84 to 2.50 with community controls; 1.06; 0.60 to 1.88 with hospital controls). Conclusion-In this study topical non-steroidal anti-inflammatory drugs were not significantly associated with upper gastrointestinal bleeding and perforation after adjustment for the confounding effects of concomitant use of oral anti-inflammatories and ulcer healing drugs.	UNIV DUNDEE, NINEWELLS HOSP & MED SCH, DEPT CLIN PHARMACOL, MED MONITORING UNIT, DUNDEE DD1 9SY, SCOTLAND	University of Dundee			McMahon, Alex D/C-4304-2008	MacDonald, Thomas/0000-0001-5189-6669				BEARDON PHG, 1993, BRIT MED J, V307, P846, DOI 10.1136/bmj.307.6908.846; BOLLINI P, 1992, ARCH INTERN MED, V152, P1289, DOI 10.1001/archinte.152.6.1289; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; DEAN AD, 1990, EPI INFO DATA PROCES; HAWKEY CJ, 1990, BMJ-BRIT MED J, V300, P278, DOI 10.1136/bmj.300.6720.278; KOHLI H S, 1992, Health Bulletin (Edinburgh), V50, P14; LANGMAN MJS, 1994, LANCET, V343, P1075, DOI 10.1016/S0140-6736(94)90185-6; MACDONALD TM, 1994, PHARMACOEPIDEM DR S, P245; Morgenstern H, 1982, EPIDEMIOLOGIC RES PR, P223; NEWBERY R, 1992, EUR J CLIN RES, V3, P139; RODRIGUEZ LAG, 1994, LANCET, V343, P769, DOI 10.1016/S0140-6736(94)91843-0; Wood S. M., 1993, Pharmaceutical Medicine (London), V7, P203; 1991, SAS P217 TECHN REP	13	125	128	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 1	1995	311	6996					22	26		10.1136/bmj.311.6996.22	http://dx.doi.org/10.1136/bmj.311.6996.22			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG975	7613317	Green Accepted, Green Published			2022-12-24	WOS:A1995RG97500020
J	SHERRINGTON, R; ROGAEV, EI; LIANG, Y; ROGAEVA, EA; LEVESQUE, G; IKEDA, M; CHI, H; LIN, C; LI, G; HOLMAN, K; TSUDA, T; MAR, L; FONCIN, JF; BRUNI, AC; MONTESI, MP; SORBI, S; RAINERO, I; PINESSI, L; NEE, L; CHUMAKOV, I; POLLEN, D; BROOKES, A; SANSEAU, P; POLINSKY, RJ; WASCO, W; DASILVA, HAR; HAINES, JL; PERICAKVANCE, MA; TANZI, RE; ROSES, AD; FRASER, PE; ROMMENS, JM; STGEORGEHYSLOP, PH				SHERRINGTON, R; ROGAEV, EI; LIANG, Y; ROGAEVA, EA; LEVESQUE, G; IKEDA, M; CHI, H; LIN, C; LI, G; HOLMAN, K; TSUDA, T; MAR, L; FONCIN, JF; BRUNI, AC; MONTESI, MP; SORBI, S; RAINERO, I; PINESSI, L; NEE, L; CHUMAKOV, I; POLLEN, D; BROOKES, A; SANSEAU, P; POLINSKY, RJ; WASCO, W; DASILVA, HAR; HAINES, JL; PERICAKVANCE, MA; TANZI, RE; ROSES, AD; FRASER, PE; ROMMENS, JM; STGEORGEHYSLOP, PH			CLONING OF A GENE BEARING MISSENSE MUTATIONS IN EARLY-ONSET FAMILIAL ALZHEIMERS-DISEASE	NATURE			English	Article							PRECURSOR PROTEIN GENE; CAENORHABDITIS-ELEGANS; HUMAN GENOME; APOLIPOPROTEIN-E; CHROMOSOME-14; IDENTIFICATION; LINKAGE; LIBRARY; ALLELE; CLONES	Some cases of Alzheimer's disease are inherited as an autosomal dominant trait. Genetic linkage studies have mapped a locus (AD3) associated with susceptibility to a very aggressive form of Alzheimer's disease to chromosome 14q24.3. We have defined a minimal cosegregating region containing the AD3 gene, and isolated at least 19 different transcripts encoded within this region. One of these transcripts (S182) corresponds to a novel gene whose product is predicted to contain multiple transmembrane domains and resembles an integral membrane protein. Five different missense mutations have been found that cosegregate with early-onset familial Alzheimer's disease. Because these changes occurred In conserved domains of this gene, and are not present in normal controls, they are likely to be causative of AD3.	UNIV TORONTO,DEPT MED NEUROL,CTR RES NEURODEGENERAT DIS,TORONTO,ON,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON,CANADA; UNIV TORONTO,DEPT MED,DIV NEUROL,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,HOSP SICK CHILDREN,RES INST,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,DEPT MED & MOLEC GENET,TORONTO,ON M5S 1A8,CANADA; ECOLE PRAT HAUTES ETUD,NEUROHIST LAB,F-75651 PARIS 13,FRANCE; INSERM LA SALPETRIERE,U106,F-75651 PARIS 13,FRANCE; USL 6,I-88046 LAMEZIA TERME,ITALY; CNR,UO,I-88046 LAMEZIA TERME,ITALY; UNIV FLORENCE,DEPT NEUROL & PSYCHIAT,FLORENCE,ITALY; UNIV TURIN,DEPT NEUROL,I-10126 TURIN,ITALY; NINCDS,CLIN NEUROPHARMACOL SECT,BETHESDA,MD 20892; CTR ETUD POLYMORPHISME HUMAIN,F-75010 PARIS,FRANCE; UNIV MASSACHUSETTS,MED CTR,DEPT NEUROL,WORCESTER,MA 01655; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,MOLEC NEUROGENET LAB,BOSTON,MA 02114; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT NEUROL,GENET & AGING LAB,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02114; DUKE UNIV,MED CTR,BRYAN ALZHEIMERS DIS RES CTR,DURHAM,NC 27710; GLAXO GRP RES LTD,RES & DEV,MOLEC PATHOL,GREENFORD UB6 0HE,MIDDX,ENGLAND; SANDOZ PHARMACEUT CORP,SANDOZ RES INST,E HANOVER,NJ 07936; WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,EDINBURGH,MIDLOTHIAN,SCOTLAND	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; UDICE-French Research Universities; PSL Research University Paris; Ecole Pratique des Hautes Etudes (EPHE); Institut National de la Sante et de la Recherche Medicale (Inserm); Consiglio Nazionale delle Ricerche (CNR); University of Florence; University of Turin; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Duke University; GlaxoSmithKline; Novartis; Sandoz; University of Edinburgh			Tanzi, Rudolph/AAE-9622-2019; Haines, Jonathan/C-3374-2012; Rogaev, Evgeny/AAN-7662-2020; de Silva, Rohan/C-1734-2008; Bruni, Amalia/K-5038-2016	Tanzi, Rudolph/0000-0002-7032-1454; Haines, Jonathan/0000-0002-4351-4728; de Silva, Rohan/0000-0002-5052-5775; sorbi, sandro/0000-0002-0380-6670; Bruni, Amalia/0000-0003-3471-3343	CIHR [64309] Funding Source: Medline; Telethon [E.0010] Funding Source: Medline	CIHR(Canadian Institutes of Health Research (CIHR)); Telethon(Fondazione Telethon)		ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bergamini L, 1991, Acta Neurol (Napoli), V13, P534; CHALFIE M, 1990, NATURE, V345, P410, DOI 10.1038/345410a0; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; CHUMAKOV I, 1992, NATURE, V359, P380, DOI 10.1038/359380a0; CHUMAKOV IM, 1992, NAT GENET, V1, P222, DOI 10.1038/ng0692-222; CRUTS M, 1994, NEUROBIOL AGING, V15, pS129; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; ETCHEBERRIGARAY R, 1994, P NATL ACAD SCI USA, V90, P8209; FONCIN JF, 1985, REV NEUROL, V141, P194; FROMMELT P, 1991, ALZ DIS ASSOC DIS, V5, P36, DOI 10.1097/00002093-199100510-00005; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOUDSMIT J, 1981, J NEUROL SCI, V49, P78; GUSELLA JF, 1993, CELL, V72, P971; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; H/CEPH Collaborative Mapping Group, 1992, SCIENCE, V258, P67; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; KARLINSKY H, 1992, NEUROLOGY, V42, P1445, DOI 10.1212/WNL.42.8.1445; KATZMAN R, 1986, NEW ENGL J MED, V314, P964, DOI 10.1056/NEJM198604103141506; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; Kosik Kenneth S., 1994, P335; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LHERNAULT SW, 1992, J CELL BIOL, V119, P55, DOI 10.1083/jcb.119.1.55; LIU Q, 1995, BIOTECHNIQUES, V18, P470; MACLENNAN DH, 1990, NATURE, V343, P559, DOI 10.1038/343559a0; MATTSON MP, 1993, TRENDS NEUROSCI, V16, P409, DOI 10.1016/0166-2236(93)90009-B; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; NEE LE, 1983, ARCH NEUROL-CHICAGO, V40, P203, DOI 10.1001/archneur.1983.04050040033004; PERICAKVANCE MA, 1988, EXP NEUROL, V102, P271, DOI 10.1016/0014-4886(88)90220-8; Pollen D. A., 1993, HANNAHS HEIRS QUEST; PTACEK LJ, 1991, CELL, V67, P1021; QUERFURTH HW, 1994, BIOCHEMISTRY-US, V33, P4550, DOI 10.1021/bi00181a016; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; ROGAEV EI, 1993, NEUROLOGY, V43, P2275, DOI 10.1212/WNL.43.11.2275; ROMMENS JM, 1993, HUM MOL GENET, V2, P901, DOI 10.1093/hmg/2.7.901; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; SALEEBA JA, 1993, METHOD ENZYMOL, V217, P285; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCHELLENBERG GD, 1993, AM J HUM GENET, V53, P619; SCHELLENBERG GD, 1992, SCIENCE, V258, P668, DOI 10.1126/science.1411576; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; STGEORGEHYSLOP P, 1992, NAT GENET, V2, P330, DOI 10.1038/ng1292-330; STGEORGEHYSLOP PH, 1994, SCIENCE, V263, P536; STGEORGEHYSLOP PH, 1991, NATURE, V347, P194; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; VAN BROECKHOVEN C, 1992, NAT GENET, V2, P335, DOI 10.1038/ng1292-335; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WONG L, 1993, NEUROSCI LETT, V152, P96, DOI 10.1016/0304-3940(93)90492-4	50	3364	3526	1	179	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 29	1995	375	6534					754	760		10.1038/375754a0	http://dx.doi.org/10.1038/375754a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF989	7596406				2022-12-24	WOS:A1995RF98900069
